

Anhang 4-G – Analyseergebnisse und Abbildungen, BALATON (GR41984), COMINO (GR41986)

Das Dokument ist nach folgender Struktur aufgebaut:

Die Daten aller Endpunkte werden zu Teil 1 (Woche 24) und zu Teil 2 (Woche 72) getrennt gezeigt. Die Ergebnisse werden entlang der Ergebnisdarstellung im Modul 4 dargestellt. Hierbei werden immer zunächst die Ergebnisse zu BALATON dargestellt gefolgt von den Ergebnissen zu COMINO. Zu jedem Endpunkt ist die Hauptauswertung mit den zugehörigen Subgruppen zuerst dargestellt.

Inhaltsverzeichnis

Teil 1 - Woche 24

Bestkorrigierte Sehschärfe.....	8
BALATON.....	8
Veränderung der BCVA.....	8
Anteil der Patienten mit einem Gewinn von ≥ 10 oder ≥ 15 Buchstaben in der BCVA.....	13
Anteil der Patienten, bei denen ein Verlust von ≥ 10 oder ≥ 15 Buchstaben in der BCVA vermieden werden kann	15
COMINO.....	17
Veränderung der BCVA.....	17
Anteil der Patienten mit einem Gewinn von ≥ 10 oder ≥ 15 Buchstaben in der BCVA.....	22
Anteil der Patienten, bei denen ein Verlust von ≥ 10 oder ≥ 15 Buchstaben in der BCVA vermieden werden kann	24
Zentrale Subfelddicke	26
BALATON.....	26
Veränderung der CST	26
Anteil der Patienten mit Abwesenheit des Makulaödems.....	30
COMINO.....	31
Veränderung der CST	31
Anteil der Patienten mit Abwesenheit des Makulaödems.....	36
Gesundheitsbezogene Lebensqualität	37
BALATON.....	37
NEI VFQ-25 Composite Score	37
NEI VFQ-25 Subskala allgemeiner Gesundheitszustand	39
NEI VFQ-25 Subskala allgemeine Sehkraft	41
NEI VFQ-25 Subskala Augenschmerzen.....	43
NEI VFQ-25 Subskala Nahsicht	45
NEI VFQ-25 Subskala Fernsicht	47
NEI VFQ-25 Subskala sehbedingte soziale Funktionsfähigkeit.....	49
NEI VFQ-25 Subskala sehbedingtes psychisches Befinden.....	51
NEI VFQ-25 Subskala sehbedingte Ausübung sozialer Rollen.....	53
NEI VFQ-25 Subskala sehbedingte Abhängigkeit von anderen	55
NEI VFQ-25 Subskala Probleme mit dem Autofahren.....	57
NEI VFQ-25 Subskala peripheres Sehen.....	59
NEI VFQ-25 Subskala Farbsehen	61
COMINO.....	63
NEI VFQ-25 Composite Score	63
NEI VFQ-25 Subskala allgemeiner Gesundheitszustand	65
NEI VFQ-25 Subskala allgemeine Sehkraft	67
NEI VFQ-25 Subskala Augenschmerzen.....	69
NEI VFQ-25 Subskala Nahsicht	71
NEI VFQ-25 Subskala Fernsicht	73
NEI VFQ-25 Subskala sehbedingte soziale Funktionsfähigkeit.....	75

NEI VFQ-25 Subskala sehbedingtes psychisches Befinden.....	77
NEI VFQ-25 Subskala sehbedingte Ausübung sozialer Rollen.....	79
NEI VFQ-25 Subskala sehbedingte Abhängigkeit von anderen.....	81
NEI VFQ-25 Subskala Probleme mit dem Autofahren.....	83
NEI VFQ-25 Subskala peripheres Sehen.....	85
NEI VFQ-25 Subskala Farbsehen.....	87
Verträglichkeit.....	89
Generelle Verträglichkeit.....	89
BALATON.....	89
Jegliche unerwünschte Ereignisse (UE).....	89
Okulare UE (Studienauge).....	90
Okulare UE (Nicht-Studienauge).....	91
Moderate UE.....	92
Schwere UE.....	93
Jegliche schwerwiegende UE (SUE).....	94
Okulare SUE (Studienauge).....	95
Okulare SUE (Nicht-Studienauge).....	96
UE, die zum Behandlungsabbruch führten.....	97
UE mit Todesfolge.....	98
Jegliche UE nach SOC und PT.....	99
Moderate UE nach SOC und PT.....	127
Schwere UE nach SOC und PT.....	141
Jegliche SUE nach SOC und PT.....	148
UE, die zum Behandlungsabbruch führten nach SOC und PT (deskriptiv).....	155
UE mit Todesfolge nach SOC und PT.....	161
COMINO.....	167
Jegliche UE.....	167
Okulare UE (Studienauge).....	168
Okulare UE (Nicht-Studienauge).....	169
Moderate UE.....	170
Schwere UE.....	171
Jegliche SUE.....	172
Okulare SUE (Studienauge).....	173
Okulare SUE (Nicht-Studienauge).....	174
UE, die zum Behandlungsabbruch führten.....	175
UE mit Todesfolge.....	176
Jegliche UE nach SOC und PT.....	177
Moderate UE nach SOC und PT.....	252
Schwere UE nach SOC und PT.....	287
Jegliche SUE nach SOC und PT.....	306
UE, die zum Behandlungsabbruch führten nach SOC und PT (deskriptiv).....	326
UE mit Todesfolge nach SOC und PT.....	334
Spezifische Verträglichkeit.....	342
BALATON.....	342
Ausgewählte okulare UE (Studienauge).....	342
Ausgewählte okulare UE (Nicht-Studienauge).....	345
Ausgewählte okulare UE (Studienauge, schwer).....	348

Ausgewählte okuläre UE (Nicht-Studienauge, schwer).....	351
Ausgewählte okuläre UE (Studienauge, schwerwiegend).....	354
Ausgewählte okuläre UE (Nicht-Studienauge, schwerwiegend)	357
Unerwünschte Ergebnisse von besonderem Interesse (AESI)	360
Schwere AESI	370
Schwerwiegende AESI.....	380
COMINO.....	390
Ausgewählte okuläre UE (Studienauge)	390
Ausgewählte okuläre UE (Nicht-Studienauge)	393
Ausgewählte okuläre UE (Studienauge, schwer).....	396
Ausgewählte okuläre UE (Nicht-Studienauge, schwer).....	399
Ausgewählte okuläre UE (Studienauge, schwerwiegend)	402
Ausgewählte okuläre UE (Nicht-Studienauge, schwerwiegend)	405
AESI	408
Schwere AESI	418
Schwerwiegende AESI.....	428
Weitere Analysen.....	438
BALATON	438
Anzahl der Zentren/Länder/geografischen Regionen mit <10, ≥10 Patienten pro Arm (ITT-Population)	438
Zeit, in der PRO erhoben wurden	439
Exposition mit dem Studienmedikament	440
Zusammenfassung Patientendisposition und Abbruchgründe	441
Demografie und Baseline Charakteristika	442
Okuläre Baseline Charakteristika des Studienauges	443
Nicht-okuläre Baseline Charakteristika	444
Okuläre medizinische Vorgeschichte des Studienauges	445
Frühere gezielte nicht-okuläre medizinische Vorgeschichte	446
Frühere gezielte okuläre Therapien/Behandlung am Studienauge.....	447
Begleitende nicht-okuläre Medikamente nach Medikamentenklasse und Wirkstoff (preferred name)	448
COMINO.....	466
Anzahl der Zentren/Länder/geographischen Regionen mit <10, ≥10 Patienten pro Arm (ITT-Population).....	466
Zeit, in der PRO erhoben wurden	467
Exposition mit dem Studienmedikament	468
Zusammenfassung Patientendisposition und Abbruchgründe	469
Demografie und Baseline Charakteristika	470
Okuläre Baseline Charakteristika des Studienauges	471
Nicht-okuläre Baseline Charakteristika	472
Okuläre medizinische Vorgeschichte des Studienauges	473
Frühere gezielte nicht-okuläre medizinische Vorgeschichte	474
Frühere gezielte okuläre Therapien/Behandlung am Studienauge.....	475
Begleitende nicht-okuläre Medikamente nach Medikamentenklasse und Wirkstoff (preferred name)	476

Teil 2 - Woche 72

Bestkorrigierte Sehschärfe.....	496
BALATON	496
Veränderung der BCVA.....	496
Anteil der Patienten mit einem Gewinn von ≥ 10 oder ≥ 15 Buchstaben in der BCVA.....	502
Anteil der Patienten, bei denen ein Verlust von ≥ 10 oder ≥ 15 Buchstaben in der BCVA vermieden werden kann	504
COMINO.....	506
Veränderung der BCVA.....	506
Anteil der Patienten mit einem Gewinn von ≥ 10 oder ≥ 15 Buchstaben in der BCVA.....	513
Anteil der Patienten, bei denen ein Verlust von ≥ 10 oder ≥ 15 Buchstaben in der BCVA vermieden werden kann	515
Zentrale Subfelddicke	517
BALATON.....	517
Veränderung der CST	517
Anteil der Patienten mit Abwesenheit des Makulaödems.....	522
COMINO.....	523
Veränderung der CST	523
Anteil der Patienten mit Abwesenheit des Makulaödems.....	530
Gesundheitsbezogene Lebensqualität	531
BALATON.....	531
NEI VFQ-25 Composite Score	531
NEI VFQ-25 Subskala allgemeiner Gesundheitszustand	534
NEI VFQ-25 Subskala allgemeine Sehkraft	537
NEI VFQ-25 Subskala Augenschmerzen.....	540
NEI VFQ-25 Subskala Nahsicht	543
NEI VFQ-25 Subskala Fernsicht	546
NEI VFQ-25 Subskala sehbedingte soziale Funktionsfähigkeit.....	549
NEI VFQ-25 Subskala sehbedingtes psychisches Befinden.....	552
NEI VFQ-25 Subskala sehbedingte Ausübung sozialer Rollen.....	555
NEI VFQ-25 Subskala sehbedingte Abhängigkeit von anderen	558
NEI VFQ-25 Subskala Probleme mit dem Autofahren.....	561
NEI VFQ-25 Subskala peripheres Sehen.....	564
NEI VFQ-25 Subskala Farbsehen.....	567
COMINO.....	570
NEI VFQ-25 Composite Score	570
NEI VFQ-25 Subskala allgemeiner Gesundheitszustand	573
NEI VFQ-25 Subskala allgemeine Sehkraft	576
NEI VFQ-25 Subskala Augenschmerzen.....	579
NEI VFQ-25 Subskala Nahsicht	582
NEI VFQ-25 Subskala Fernsicht	585
NEI VFQ-25 Subskala sehbedingte soziale Funktionsfähigkeit.....	588
NEI VFQ-25 Subskala sehbedingtes psychisches Befinden.....	591
NEI VFQ-25 Subskala sehbedingte Ausübung sozialer Rollen.....	594
NEI VFQ-25 Subskala sehbedingte Abhängigkeit von anderen.....	597

NEI VFQ-25 Subskala Probleme mit dem Autofahren.....	600
NEI VFQ-25 Subskala peripheres Sehen.....	603
NEI VFQ-25 Subskala Farbsehen.....	606
Verträglichkeit.....	609
Generelle Verträglichkeit.....	609
BALATON.....	609
Jegliche UE.....	609
Okulare UE (Studienauge)	610
Okulare UE (Nicht-Studienauge)	611
Moderate UE	612
Schwere UE.....	613
Jegliche SUE	614
Okulare SUE (Studienauge)	615
Okulare SUE (Nicht-Studienauge).....	616
UE, die zum Behandlungsabbruch führten.....	617
UE mit Todesfolge	618
Jegliche UE nach SOC und PT.....	619
Moderate UE nach SOC und PT	684
Schwere UE nach SOC und PT.....	726
Jegliche SUE nach SOC und PT	746
UE, die zum Behandlungsabbruch führten nach SOC und PT (deskriptiv).....	767
UE mit Todesfolge nach SOC und PT	773
COMINO.....	779
Jegliche UE.....	779
Okulare UE (Studienauge)	780
Okulare UE (Nicht-Studienauge)	781
Moderate UE	782
Schwere UE.....	783
Jegliche SUE	784
Okulare SUE (Studienauge)	785
Okulare SUE (Nicht-Studienauge).....	786
UE, die zum Behandlungsabbruch führten.....	787
UE mit Todesfolge	788
Jegliche UE nach SOC und PT.....	789
Moderate UE nach SOC und PT	928
Schwere UE nach SOC und PT.....	1008
Jegliche SUE nach SOC und PT	1051
UE, die zum Behandlungsabbruch führten nach SOC und PT (deskriptiv).....	1100
UE mit Todesfolge nach SOC und PT	1112
Spezifische Verträglichkeit	1120
BALATON.....	1120
Ausgewählte okulare UE (Studienauge)	1120
Ausgewählte okulare UE (Nicht-Studienauge)	1123
Ausgewählte okulare UE (Studienauge, schwer).....	1126
Ausgewählte okulare UE (Nicht-Studienauge, schwer).....	1129
Ausgewählte okulare UE (Studienauge, schwerwiegend)	1132
Ausgewählte okulare UE (Nicht-Studienauge, schwerwiegend)	1135

AESI	1138
Schwere AESI	1148
Schwerwiegende AESI.....	1158
COMINO.....	1168
Ausgewählte okuläre UE (Studienauge)	1168
Ausgewählte okuläre UE (Nicht-Studienauge)	1171
Ausgewählte okuläre UE (Studienauge, schwer)	1174
Ausgewählte okuläre UE (Nicht-Studienauge, schwer).....	1177
Ausgewählte okuläre UE (Studienauge, schwerwiegend)	1180
Ausgewählte okuläre UE (Nicht-Studienauge, schwerwiegend)	1183
AESI	1186
Schwere AESI	1196
Schwerwiegende AESI.....	1206
Behandlungsintervalle.....	1216
BALATON.....	1216
Anteil der Patienten auf einem Q4W-Behandlungsintervall.....	1216
Anteil der Patienten auf einem Q8W-Behandlungsintervall.....	1217
Anteil der Patienten auf einem Q12W-Behandlungsintervall.....	1218
Anteil der Patienten auf einem Q16W-Behandlungsintervall.....	1219
COMINO.....	1220
Anteil der Patienten auf einem Q4W-Behandlungsintervall.....	1220
Anteil der Patienten auf einem Q8W-Behandlungsintervall.....	1221
Anteil der Patienten auf einem Q12W-Behandlungsintervall.....	1222
Anteil der Patienten auf einem Q16W-Behandlungsintervall.....	1223
Weitere Analysen.....	1224
BALATON.....	1224
Zeit, in der PRO erhoben wurden	1224
Exposition mit dem Studienmedikament	1225
Zusammenfassung Patientendisposition und Abbruchgründe	1226
Begleitende nicht-okuläre Medikamente nach Medikamentenklasse und Wirkstoff (preferred name)	1227
COMINO.....	1248
Zeit, in der PRO erhoben wurden	1248
Exposition mit dem Studienmedikament	1249
Zusammenfassung Patientendisposition und Abbruchgründe	1250
Begleitende nicht-okuläre Medikamente nach Medikamentenklasse und Wirkstoff (preferred name)	1251


POPULATION: Intent-To-Treat Population
 ENDPOINT: Best Corrected Visual Acuity in Study Eye at Week 24
 MODEL: Adjusted Analysis for Baseline BCVA ETRS Letter score, Geographic region
 STUDY: GR41984
 Change from Baseline (Analysis of MMRM)

Visit	Name	Level	Faricimab (N=276)					Aflibercept (N=277)					Difference between Treatments (Faricimab - Aflibercept)									Effects			
			N			Statistics		N			Statistics		Statistics									p-value (treatment)	p-value (visit)	p-value (subgroup* treatment)	
			With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at Week 24	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at Week 24	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Hedges g	95% CI Hedges g (LL)	95% CI Hedges g (UL)	Population	Method				
Week 24	All	n/a	276	274	254	16.90	0.60	277	274	247	17.47	0.60	-0.57	0.84	-2.23	1.09	-0.06	-0.23	0.11	Intent-To-Treat Population	adjusted	0.1752	<.0001		
	Gender																								
		Male	143	143	133	17.89	0.79	130	127	119	18.76	0.83	-0.87	1.15	-3.13	1.39	-0.09	-0.33	0.15	Intent-To-Treat Population	adjusted	0.1646	<.0001	0.8931	
		Female	133	131	121	15.82	0.89	147	147	128	16.32	0.85	-0.49	1.23	-2.92	1.93	-0.05	-0.28	0.19	Intent-To-Treat Population	adjusted	0.2402	<.0001		
	Age																								
		<65 years	133	132	121	19.46	0.83	144	143	128	19.05	0.80	0.42	1.15	-1.85	2.69	0.04	-0.19	0.28	Intent-To-Treat Population	adjusted	0.6711	<.0001	0.4815	
		>=65 years	143	142	133	14.40	0.78	133	131	119	15.88	0.81	-1.48	1.13	-3.70	0.74	-0.16	-0.40	0.08	Intent-To-Treat Population	adjusted	0.1197	<.0001		
	Baseline BCVA ETRS letter score																								
		<=54 letters	89	89	84	22.12	1.31	90	90	80	23.72	1.31	-1.60	1.86	-5.27	2.07	-0.13	-0.42	0.16	Intent-To-Treat Population	adjusted	0.3337	<.0001	0.4101	
		>=55 letters	187	185	170	14.37	0.61	187	184	167	14.44	0.62	-0.07	0.87	-1.78	1.64	-0.01	-0.21	0.19	Intent-To-Treat Population	adjusted	0.3393	<.0001		
	Geographic Region																								
		Europe	82	81	79	17.05	1.10	70	70	61	18.30	1.20	-1.26	1.63	-4.48	1.97	-0.13	-0.44	0.19	Intent-To-Treat Population	adjusted	0.1644	<.0001	0.5170	
		America	97	96	90	17.40	1.16	105	103	98	17.03	1.11	0.36	1.61	-2.81	3.54	0.03	-0.25	0.31	Intent-To-Treat Population	adjusted	0.9504	<.0001		
		Asia Pacific (inc. Australia)	97	97	85	16.23	0.81	102	101	88	17.31	0.80	-1.07	1.14	-3.32	1.18	-0.13	-0.41	0.14	Intent-To-Treat Population	adjusted	0.2695	<.0001		
	Race/ethnicity																								
		White	172	170	162	17.38	0.83	172	170	155	17.10	0.83	0.28	1.18	-2.04	2.60	0.03	-0.19	0.24	Intent-To-Treat Population	adjusted	0.5032	<.0001	0.5664	
		Asian	90	90	79	16.47	0.81	94	93	81	17.68	0.80	-1.21	1.14	-3.46	1.04	-0.16	-0.45	0.13	Intent-To-Treat Population	adjusted	0.2831	<.0001		
		Other	10	10	9	10.90	2.43	7	7	7	13.97	2.94	-3.07	3.90	-11.49	5.36	-0.37	-1.29	0.56	Intent-To-Treat Population	adjusted	0.8485	<.0001		
		Unknown	4	4	4	NE	NE	4	4	4	NE	NE	NE	NE	NE	NE	NE	NE	NE	Intent-To-Treat Population	adjusted	NE	NE		

[1] Patients included in the analysis: with a value at baseline and at least one post-baseline value at the selected visits.
 [2] LSMeans of change from baseline from MMRM (including all available records from all selected visits). Selected visits: every 4 weeks from Week 4 to 24. Early Termination (ET) visit was mapped to closest regular visit.
 [3] Contrasts from MMRM: Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition adjusted for randomization stratification factors. The stratification factor is excluded if it is the subgroup.
 Units: letters. Data as observed (no imputation of missing values). Covariance matrix: unstructured. Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACR_data_analysis/prod/program/t_eff_mrm_sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACR_CSR_Primary/prod/output/t_eff_mrm_adj_PREST_tW24_SBCVA_IT_06JUL2022_41984.xls
 09JUL2024 12:18

POPULATION: Intent-To-Treat Population
ENDPOINT: Best Corrected Visual Acuity in Study Eye over Time through Week 24
STUDY: GR41984



Units: letters.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: ..al_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/g_mean_plot.sas
 Output: ..sis/ACE_CSR_Primary/prod/output/g_mean_plot_PREST_tW24_SBCVA_IT_06JUL2022_41984.pdf
 18MAR2024 8:32

POPULATION: Intent-To-Treat Population

ENDPOINT: Best Corrected Visual Acuity in Study Eye over Time through Week 24

MODEL: --

STUDY: GR41984

Compliance/Mean

		Faricimab (N=276)						Aflibercept (N=277)					
		Patients				Statistics		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
Visit													
All													
Baseline	n/a	276	100,0	276	100,0	57,50	13,04	277	100,0	277	100,0	57,64	12,15
Week 1	n/a	276	100,0	269	97,5	65,29	12,82	275	99,3	267	97,1	66,00	11,81
Week 4	n/a	274	99,3	269	98,2	69,06	12,71	274	98,9	272	99,3	69,97	11,32
Week 8	n/a	274	99,3	267	97,4	71,10	12,67	274	98,9	269	98,2	72,50	11,65
Week 12	n/a	274	99,3	264	96,4	72,70	12,11	274	98,9	268	97,8	73,53	11,76
Week 16	n/a	274	99,3	261	95,3	73,08	12,28	274	98,9	262	95,6	74,17	12,00
Week 20	n/a	272	98,6	257	94,5	74,25	11,77	274	98,9	257	93,8	74,78	12,11
Week 24	n/a	272	98,6	254	93,4	74,46	12,35	274	98,9	247	90,1	75,12	12,06
Gender													
Baseline	Male	143	100,0	143	100,0	56,85	13,48	130	100,0	130	100,0	58,42	11,47
Week 1	Male	143	100,0	139	97,2	65,39	13,62	128	98,5	122	95,3	66,96	11,22
Week 4	Male	143	100,0	140	97,9	69,04	13,28	127	97,7	126	99,2	70,72	10,94
Week 8	Male	143	100,0	138	96,5	71,86	12,87	127	97,7	125	98,4	73,81	10,89
Week 12	Male	143	100,0	137	95,8	73,10	12,34	127	97,7	125	98,4	74,52	10,91
Week 16	Male	143	100,0	134	93,7	74,07	12,71	127	97,7	121	95,3	75,13	11,34
Week 20	Male	141	98,6	132	93,6	74,46	12,74	127	97,7	122	96,1	76,09	10,71
Week 24	Male	141	98,6	133	94,3	75,24	12,64	127	97,7	119	93,7	76,82	10,62
Baseline	Female	133	100,0	133	100,0	58,20	12,56	147	100,0	147	100,0	56,95	12,72
Week 1	Female	133	100,0	130	97,7	65,18	11,95	147	100,0	145	98,6	65,19	12,26
Week 4	Female	131	98,5	129	98,5	69,09	12,11	147	100,0	146	99,3	69,33	11,64
Week 8	Female	131	98,5	129	98,5	70,28	12,46	147	100,0	144	98,0	71,37	12,20
Week 12	Female	131	98,5	127	96,9	72,26	11,88	147	100,0	143	97,3	72,67	12,42
Week 16	Female	131	98,5	127	96,9	72,05	11,78	147	100,0	141	95,9	73,34	12,53
Week 20	Female	131	98,5	125	95,4	74,02	10,70	147	100,0	135	91,8	73,60	13,18
Week 24	Female	131	98,5	121	92,4	73,60	12,03	147	100,0	128	87,1	73,53	13,10
Age													
Baseline	<65 years	133	100,0	133	100,0	58,19	12,65	144	100,0	144	100,0	59,75	11,34
Week 1	<65 years	133	100,0	131	98,5	67,59	11,86	144	100,0	140	97,2	68,62	10,89
Week 4	<65 years	132	99,2	127	96,2	71,72	11,85	143	99,3	142	99,3	72,76	10,65
Week 8	<65 years	132	99,2	127	96,2	74,09	10,84	143	99,3	140	97,9	75,69	10,11
Week 12	<65 years	132	99,2	125	94,7	75,98	10,27	143	99,3	139	97,2	76,87	10,41
Week 16	<65 years	132	99,2	122	92,4	76,70	9,80	143	99,3	136	95,1	77,61	10,97
Week 20	<65 years	131	98,5	123	93,9	77,44	9,94	143	99,3	132	92,3	77,87	11,98
Week 24	<65 years	131	98,5	121	92,4	78,39	9,86	143	99,3	128	89,5	78,02	12,01

Baseline	>=65 years	143	100,0	143	100,0	56,87	13,41	133	100,0	133	100,0	55,35	12,61
Week 1	>=65 years	143	100,0	138	96,5	63,10	13,34	131	98,5	127	96,9	63,11	12,14
Week 4	>=65 years	142	99,3	142	100,0	66,68	13,02	131	98,5	130	99,2	66,93	11,29
Week 8	>=65 years	142	99,3	140	98,6	68,38	13,61	131	98,5	129	98,5	69,04	12,25
Week 12	>=65 years	142	99,3	139	97,9	69,75	12,89	131	98,5	129	98,5	69,94	12,10
Week 16	>=65 years	142	99,3	139	97,9	69,91	13,35	131	98,5	126	96,2	70,45	12,00
Week 20	>=65 years	141	98,6	134	95,0	71,31	12,57	131	98,5	125	95,4	71,52	11,42
Week 24	>=65 years	141	98,6	133	94,3	70,88	13,31	131	98,5	119	90,8	71,99	11,35
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	41,91	10,18	90	100,0	90	100,0	43,47	9,98
Week 1	<=54 letters	89	100,0	89	100,0	52,90	12,35	90	100,0	85	94,4	54,53	12,14
Week 4	<=54 letters	89	100,0	86	96,6	57,45	12,53	90	100,0	90	100,0	60,13	11,92
Week 8	<=54 letters	89	100,0	87	97,8	60,28	13,38	90	100,0	90	100,0	62,90	13,03
Week 12	<=54 letters	89	100,0	83	93,3	61,96	12,49	90	100,0	87	96,7	64,30	13,18
Week 16	<=54 letters	89	100,0	83	93,3	62,94	13,44	90	100,0	85	94,4	65,42	13,52
Week 20	<=54 letters	89	100,0	80	89,9	63,80	12,50	90	100,0	84	93,3	66,23	12,60
Week 24	<=54 letters	89	100,0	84	94,4	64,54	13,89	90	100,0	80	88,9	67,56	12,72
Baseline BCVA ETDRS letter score													
Baseline	>=55 letters	187	100,0	187	100,0	64,93	5,54	187	100,0	187	100,0	64,46	5,23
Week 1	>=55 letters	187	100,0	180	96,3	71,41	7,55	185	98,9	182	98,4	71,36	6,77
Week 4	>=55 letters	185	98,9	183	98,9	74,52	8,41	184	98,4	182	98,9	74,84	7,08
Week 8	>=55 letters	185	98,9	180	97,3	76,33	8,26	184	98,4	179	97,3	77,33	7,03
Week 12	>=55 letters	185	98,9	181	97,8	77,62	8,10	184	98,4	181	98,4	77,97	7,81
Week 16	>=55 letters	185	98,9	178	96,2	77,81	8,20	184	98,4	177	96,2	78,37	8,47
Week 20	>=55 letters	183	97,9	177	96,7	78,97	7,70	184	98,4	173	94,0	78,94	9,41
Week 24	>=55 letters	183	97,9	170	92,9	79,36	7,79	184	98,4	167	90,8	78,74	9,89
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	59,07	13,02	70	100,0	70	100,0	58,59	12,85
Week 1	Europe	82	100,0	82	100,0	66,00	12,95	70	100,0	70	100,0	68,17	12,78
Week 4	Europe	81	98,8	79	97,5	70,22	13,96	70	100,0	70	100,0	72,70	10,45
Week 8	Europe	81	98,8	78	96,3	72,87	13,22	70	100,0	68	97,1	74,19	12,88
Week 12	Europe	81	98,8	76	93,8	74,16	13,72	70	100,0	67	95,7	75,27	12,67
Week 16	Europe	81	98,8	77	95,1	73,38	14,69	70	100,0	69	98,6	76,14	12,18
Week 20	Europe	80	97,6	76	95,0	75,12	13,30	70	100,0	67	95,7	76,91	12,24
Week 24	Europe	80	97,6	79	98,8	75,84	13,98	70	100,0	61	87,1	77,87	10,88
Baseline BCVA ETDRS letter score													
Baseline	America	97	100,0	97	100,0	57,04	13,42	105	100,0	105	100,0	57,01	12,50
Week 1	America	97	100,0	91	93,8	66,10	13,92	104	99,0	97	93,3	64,99	12,20
Week 4	America	96	99,0	94	97,9	69,68	13,20	103	98,1	102	99,0	69,31	12,62
Week 8	America	96	99,0	92	95,8	71,43	13,27	103	98,1	103	100,0	72,27	12,23
Week 12	America	96	99,0	93	96,9	72,75	11,85	103	98,1	101	98,1	72,95	12,57
Week 16	America	96	99,0	93	96,9	73,61	11,31	103	98,1	98	95,1	72,68	13,63
Week 20	America	96	99,0	90	93,8	74,49	11,32	103	98,1	100	97,1	73,27	13,84
Week 24	America	96	99,0	90	93,8	74,60	11,52	103	98,1	98	95,1	73,51	14,27
Baseline BCVA ETDRS letter score													
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	56,64	12,68	102	100,0	102	100,0	57,64	11,34
Week 1	Asia Pacific (inc. Australia)	97	100,0	96	99,0	63,91	11,57	101	99,0	100	99,0	65,46	10,56
Week 4	Asia Pacific (inc. Australia)	97	100,0	96	99,0	67,51	11,01	101	99,0	100	99,0	68,74	10,24
Week 8	Asia Pacific (inc. Australia)	97	100,0	97	100,0	69,35	11,49	101	99,0	98	97,0	71,57	10,01
Week 12	Asia Pacific (inc. Australia)	97	100,0	95	97,9	71,47	10,92	101	99,0	100	99,0	72,96	10,18

Week 16	Asia Pacific (inc. Australia)	97	100,0	91	93,8	72,30	11,05	101	99,0	95	94,1	74,26	9,78
Week 20	Asia Pacific (inc. Australia)	96	99,0	91	94,8	73,27	10,87	101	99,0	90	89,1	74,88	9,57
Week 24	Asia Pacific (inc. Australia)	96	99,0	85	88,5	73,02	11,56	101	99,0	88	87,1	75,00	9,72
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	57,86	13,36	172	100,0	172	100,0	57,80	12,57
Week 1	White	172	100,0	167	97,1	66,07	13,16	171	99,4	165	96,5	66,08	12,76
Week 4	White	170	98,8	166	97,6	69,96	13,57	170	98,8	170	100,0	70,58	12,03
Week 8	White	170	98,8	164	96,5	72,18	13,28	170	98,8	167	98,2	73,02	13,11
Week 12	White	170	98,8	162	95,3	73,31	13,05	170	98,8	165	97,1	74,02	12,95
Week 16	White	170	98,8	164	96,5	73,45	13,30	170	98,8	166	97,6	74,14	13,45
Week 20	White	169	98,3	160	94,7	74,73	12,55	170	98,8	165	97,1	74,58	13,75
Week 24	White	169	98,3	162	95,9	75,20	13,04	170	98,8	155	91,2	74,95	13,88
Baseline	Asian	90	100,0	90	100,0	56,63	12,64	94	100,0	94	100,0	57,60	11,43
Week 1	Asian	90	100,0	89	98,9	64,00	12,21	93	98,9	92	98,9	65,64	10,24
Week 4	Asian	90	100,0	89	98,9	67,67	11,26	93	98,9	92	98,9	68,88	9,74
Week 8	Asian	90	100,0	90	100,0	69,34	11,86	93	98,9	91	97,8	71,66	8,87
Week 12	Asian	90	100,0	88	97,8	71,83	10,94	93	98,9	92	98,9	72,83	9,65
Week 16	Asian	90	100,0	84	93,3	72,77	10,74	93	98,9	86	92,5	74,43	8,89
Week 20	Asian	89	98,9	83	93,3	73,29	10,87	93	98,9	82	88,2	75,15	8,37
Week 24	Asian	89	98,9	79	88,8	73,29	11,51	93	98,9	81	87,1	75,19	8,23
Baseline	Other	10	100,0	10	100,0	61,60	8,73	7	100,0	7	100,0	59,29	5,19
Week 1	Other	10	100,0	9	90,0	65,11	10,01	7	100,0	6	85,7	69,00	7,54
Week 4	Other	10	100,0	10	100,0	67,10	10,13	7	100,0	7	100,0	70,43	12,01
Week 8	Other	10	100,0	10	100,0	69,50	9,37	7	100,0	7	100,0	71,57	7,37
Week 12	Other	10	100,0	10	100,0	69,90	5,26	7	100,0	7	100,0	72,14	9,37
Week 16	Other	10	100,0	10	100,0	70,10	7,52	7	100,0	6	85,7	73,17	11,02
Week 20	Other	10	100,0	10	100,0	73,90	5,88	7	100,0	7	100,0	76,43	7,63
Week 24	Other	10	100,0	9	90,0	70,56	5,55	7	100,0	7	100,0	75,71	10,01
Baseline	Unknown	4	100,0	4	100,0	51,50	17,60	4	100,0	4	100,0	48,75	18,80
Week 1	Unknown	4	100,0	4	100,0	61,50	18,48	4	100,0	4	100,0	66,50	12,79
Week 4	Unknown	4	100,0	4	100,0	67,75	12,20	4	100,0	3	75,0	68,00	17,32
Week 8	Unknown	4	100,0	3	75,0	70,00	9,00	4	100,0	4	100,0	71,50	10,15
Week 12	Unknown	4	100,0	4	100,0	74,00	9,20	4	100,0	4	100,0	72,25	10,14
Week 16	Unknown	4	100,0	3	75,0	71,67	9,81	4	100,0	4	100,0	71,25	11,50
Week 20	Unknown	4	100,0	4	100,0	75,75	9,95	4	100,0	3	75,0	72,00	15,13
Week 24	Unknown	4	100,0	4	100,0	76,00	9,83	4	100,0	4	100,0	79,00	3,56

¹ in study: number of subjects in study at respective visit; % based on baseline

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Units: letters.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_SBCVA_IT_06JUL2022_41984.xls

18MAR2024 8:26

POPULATION: Intent-To-Treat Population
 ENDPOINT: Study Bye - Proportion of Patients Avoiding a Loss of >=10 in BCVA at Week 24
 NOME: Stratified Analysis by Baseline BCVA ETDRS Letter score, Geographic region
 STUDY: GR41984
 Dichotomous Analysis by Subgroups (Efficacy)

Name	Level	Faricimab (N=276)				Aflibercept (N=277)				Faricimab vs. Aflibercept										Aflibercept vs. Faricimab				
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Absolute Risk		Absolute Risk Difference		Relative Risk		Relative Risk		Relative Risk		Relative Risk		
		n	%	n	%	n	%	n	%	Odds Ratio	95% Lower CI	95% Upper CI	Absolute Risk	95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI	95% Upper CI	p-value (Cochran-Mantel-Haenszel)	Interaction Test p-value	Relative Risk	95% Lower CI	95% Upper CI	
All	n/a	254	92.0	254	100.0	247	89.2	245	99.2	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Gender	Male	133	48.0	133	100.0	119	43.0	118	99.2	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Gender	Female	121	43.8	121	100.0	128	46.2	127	99.2	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Age	<65 years	121	43.8	121	100.0	128	46.2	127	99.2	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Age	>=65 years	133	48.0	133	100.0	119	43.0	118	99.2	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Baseline BCVA ETDRS Letter score	<=54 letters	84	30.4	84	100.0	80	28.9	80	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Baseline BCVA ETDRS Letter score	>=55 letters	170	61.6	170	100.0	167	60.3	165	98.8	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Geographic Region	Europe	79	28.6	79	100.0	61	22.0	61	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Geographic Region	America	90	32.0	90	100.0	98	35.4	96	98.0	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Geographic Region	Asia Pacific (inc. Australia)	85	30.8	85	100.0	88	31.8	88	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Race/ethnicity	White	162	58.7	162	100.0	155	56.0	153	98.7	>999.99	(GCONV=1E-8) satisfied.	0.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Race/ethnicity	Asian	79	28.6	79	100.0	81	29.2	81	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Race/ethnicity	Other	9	3.3	9	100.0	7	2.5	7	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Race/ethnicity	Unknown	4	1.4	4	100.0	4	1.4	4	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE

Test for interaction based on RR (Log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 0.0002022

Program: root/clinical_studies/RO6867461/CPT30303/GR41984/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
 Output: root/clinical_studies/RO6867461/CPT30303/GR41984/data_analysis/ACE_CUR_Primary/prod/output/t_eff_resp_sq_str_SBCVAN010_PRES1_W24_IT_06JUL2022_41984.xls
 16AUG2023 9:30

POPULATION: Intent-To-Treat Population
 ENDPOINT: Study Bye - Proportion of Patients Avoiding a Loss of >=15 in BCVA at Week 24
 MOE: Stratified Analysis by baseline BCVA ETDRS letter score, Geographic region
 STUDY: GR41984
 Dichotomous Analysis by Subgroups (Efficacy)

Name	Level	Faricimab (N=276)				Aflibercept (N=277)				Faricimab vs. Aflibercept										Aflibercept vs. Faricimab					
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Absolute Risk		Absolute Risk Difference		Relative Risk		Relative Risk		Interaction		Relative Risk			
		n	%	n	%	n	%	n	%	Odds Ratio	95% Lower CL	95% Upper CL	Absolute Risk	95% Lower CL	95% Upper CL	Relative Risk	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Interaction Test p-value	Relative Risk	95% Lower CL	95% Upper CL		
All	n/a	254	92.0	214	100.0	247	89.2	216	99.5	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	WARNING: The relative Hessian convergence criterion of	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Gender	Male	133	48.2	133	100.0	139	43.0	119	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Female	121	43.8	121	100.0	128	46.2	121	99.2	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	WARNING: The relative Hessian convergence criterion of	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Age	<=5 years	121	43.8	121	100.0	128	46.2	121	99.2	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	WARNING: The relative Hessian convergence criterion of	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	>=5 years	133	48.2	133	100.0	119	43.0	119	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE		
Baseline BCVA ETDRS letter score	<=54 letters	84	30.4	84	100.0	80	28.9	80	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	>=55 letters	170	61.6	170	100.0	167	60.3	166	99.4	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	WARNING: The relative Hessian convergence criterion of	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Geographic Region	Europe	79	28.6	79	100.0	61	22.0	61	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	America	90	32.6	90	100.0	98	35.4	97	99.0	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	WARNING: The relative Hessian convergence criterion of	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Asia Pacific (inc. Australia)	85	30.8	85	100.0	88	31.8	88	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE		
Race/ethnicity	White	162	58.7	162	100.0	155	56.0	154	99.4	>999.99	Convergence criterion (GCONV=1E-8) satisfied.	0.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Asian	79	28.6	79	100.0	81	29.2	81	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE		
	Other	9	3.3	9	100.0	7	2.5	7	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE		
	Unknown	4	1.4	4	100.0	4	1.4	4	100.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE		

Test for interaction based on RR (Log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Endpoints).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDF30303/GR41984/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
 Output: root/clinical_studies/RO6867461/CDF30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_resp_sq_str_SBCVAN0115_PREST_W24_IT_06JUL2022_41984.xls
 10AUG2023 9:27


POPULATION: Intent-To-Treat Population
 ENDPOINT: Best Corrected Visual Acuity in Study Eye at Week 24
 MODEL: Adjusted Analysis for Baseline BCVA ETDRS letter score, Geographic region
 STUDY: GR41986
 Change from Baseline (Analysis of MMRM)

Visit	Name	Level	Faricimab (N=366)						Aflibercept (N=363)						Difference between Treatments (Faricimab - Aflibercept)									Effects		
			N			Statistics			N			Statistics			Statistics									p-value (treatment)	p-value (visit)	p-value (subgroup treatment)
			With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at Week 24	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at Week 24	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Hedges g	95% CI Hedges g (LL)	95% CI Hedges g (UL)	Population	Method					
Week 24	All	n/a	366	364	340	16.87	0.73	363	360	331	17.31	0.74	-0.44	1.04	-2.49	1.60	-0.03	-0.18	0.11	Intent-To-Treat Population	adjusted	0.4984	<.0001			
	Gender																									
		Male	193	191	176	18.16	0.93	200	198	178	17.53	0.92	0.63	1.31	-1.94	1.20	0.05	-0.15	0.25	Intent-To-Treat Population	adjusted	0.9217	<.0001	0.9774		
		Female	173	173	164	15.51	1.15	163	162	153	17.04	1.19	-1.53	1.66	-4.72	1.73	-0.10	-0.31	0.11	Intent-To-Treat Population	adjusted	0.4368	<.0001			
	Age																									
		<65 years	162	160	151	21.96	0.90	158	155	141	22.09	0.92	-0.12	1.29	-2.66	2.41	-0.01	-0.23	0.21	Intent-To-Treat Population	adjusted	0.7258	<.0001	0.7039		
		>=65 years	204	204	189	12.85	1.00	205	205	190	13.78	1.00	-0.93	1.42	-3.72	1.86	-0.06	-0.26	0.13	Intent-To-Treat Population	adjusted	0.4124	<.0001			
	Baseline BCVA ETDRS letter score																									
		<=34 letters	79	79	72	26.68	1.82	80	80	76	26.17	1.80	0.53	2.56	-4.54	5.56	0.03	-0.28	0.34	Intent-To-Treat Population	adjusted	0.7288	<.0001	0.5377		
		35 - 54 letters	106	106	100	19.11	1.27	105	105	96	21.04	1.29	-1.93	1.81	-5.51	1.64	-0.15	-0.42	0.12	Intent-To-Treat Population	adjusted	0.1204	<.0001			
		>=55 letters	181	179	168	11.02	0.97	178	175	159	11.17	0.99	-0.15	1.38	-2.88	2.57	-0.01	-0.22	0.20	Intent-To-Treat Population	adjusted	0.7811	<.0001			
	Baseline BCVA ETDRS letter score																									
		<=23 letters	35	35	32	23.29	2.84	36	36	33	24.01	2.80	-0.72	3.99	-8.69	7.25	-0.04	-0.50	0.42	Intent-To-Treat Population	adjusted	0.7373	0.0007	0.3125		
		>=24 letters	331	329	308	16.15	0.74	327	324	298	16.62	0.75	-0.47	1.06	-2.54	1.60	-0.03	-0.19	0.12	Intent-To-Treat Population	adjusted	0.4827	<.0001			
	Geographic Region																									
		Europe	111	111	101	16.09	1.23	114	112	104	18.59	1.23	-2.50	1.74	-5.93	0.94	-0.19	-0.45	0.07	Intent-To-Treat Population	adjusted	0.0727	<.0001	0.3785		
		America	147	145	137	17.59	1.23	146	145	133	16.73	1.23	0.86	1.74	-2.57	4.29	0.06	-0.17	0.29	Intent-To-Treat Population	adjusted	0.6214	<.0001			
		Asia Pacific (inc. Australia)	108	108	102	16.61	1.31	103	103	94	16.87	1.35	-0.26	1.88	-3.97	3.46	-0.02	-0.29	0.25	Intent-To-Treat Population	adjusted	0.8781	<.0001			
	Race/ethnicity																									
		White	243	241	225	16.21	0.94	253	250	232	17.17	0.93	-0.96	1.32	-3.56	1.64	-0.07	-0.24	0.11	Intent-To-Treat Population	adjusted	0.2661	<.0001	0.3850		
		Asian	89	89	85	17.21	1.29	88	88	79	17.05	1.31	0.16	1.84	-3.48	3.79	0.01	-0.28	0.31	Intent-To-Treat Population	adjusted	0.7628	<.0001			
		Other	13	13	13	30.03	2.41	17	17	15	23.11	2.12	6.92	3.23	0.29	13.55	0.77	0.04	1.50	Intent-To-Treat Population	adjusted	0.0070	0.0029			
		Unknown	21	21	17	14.40	3.12	5	5	5	10.35	6.56	4.05	7.43	-11.32	19.41	0.26	-0.68	1.21	Intent-To-Treat Population	adjusted	0.7498	0.6083			
	Baseline RVO status																									
		CRVO	302	301	278	16.37	0.84	293	290	269	16.12	0.85	0.26	1.20	-2.09	2.61	0.02	-0.14	0.18	Intent-To-Treat Population	adjusted	0.8415	<.0001	0.8026		
		HRVO	61	60	59	18.61	1.26	64	64	58	22.28	1.24	-3.67	1.77	-7.18	-0.16	-0.37	-0.72	-0.02	Intent-To-Treat Population	adjusted	0.1086	<.0001			
		Missing	3	3	3	NE	NE	6	6	4	NE	NE	NE	NE	NE	NE	NE	NE	NE	Intent-To-Treat Population	adjusted	NE	NE			

[1] Patients included in the analysis: with a value at baseline and at least one post-baseline value at the selected visits.
 [2] LSMeans of change from baseline from MMRM (including all available records from all selected visits). Selected visits: every 4 weeks from Week 4 to 24. Early Termination (ET) visit was mapped to closest regular visit.
 [3] Contrasts from MMRM: Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition adjusted for randomization stratification factors. The stratification factor is excluded if the variable is involved in the subgroup.
 Units: letters. Data as observed (no imputation of missing values). Covariance matrix: unstructured. Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09A02022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mrm.sas
 Output: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mrm_adj_PREST_tW24_SBCVA_IT_09A02022_41986.xls
 09JUL2024 12:19

POPULATION: Intent-To-Treat Population
ENDPOINT: Best Corrected Visual Acuity in Study Eye over Time through Week 24
STUDY: GR41986



Units: letters.
Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
Clinical cut-off: 09AUG2022

Program: ..al_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/g_mean_plot.sas
Output: ..sis/ACE_CSR_Primary/prod/output/g_mean_plot_PREST_tW24_SBCVA_IT_09AUG2022_41986.pdf
18MAR2024 8:41

POPULATION: Intent-To-Treat Population
 ENDPOINT: Best Corrected Visual Acuity in Study Eye over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=366)						Aflibercept (N=363)					
Name Visit	Level	Patients				Statistics		Patients				Statistics	
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100,0	366	100,0	50,25	16,25	363	100,0	363	100,0	50,71	16,34
Week 1	n/a	365	99,7	355	97,3	59,91	15,83	362	99,7	346	95,6	60,32	15,86
Week 4	n/a	365	99,7	356	97,5	63,67	15,98	362	99,7	352	97,2	64,86	14,92
Week 8	n/a	365	99,7	360	98,6	65,63	15,75	360	99,2	348	96,7	67,14	15,83
Week 12	n/a	364	99,5	349	95,9	67,19	15,53	360	99,2	342	95,0	67,75	16,05
Week 16	n/a	364	99,5	347	95,3	67,00	16,11	358	98,6	337	94,1	68,55	16,06
Week 20	n/a	364	99,5	347	95,3	67,09	16,28	355	97,8	332	93,5	68,02	16,28
Week 24	n/a	359	98,1	340	94,7	67,67	16,12	352	97,0	331	94,0	68,19	16,82
Gender													
Baseline	Male	193	100,0	193	100,0	50,88	16,74	200	100,0	200	100,0	51,84	15,86
Week 1	Male	192	99,5	185	96,4	60,46	16,07	200	100,0	186	93,0	62,22	15,25
Week 4	Male	192	99,5	190	99,0	64,55	16,12	200	100,0	193	96,5	66,30	14,85
Week 8	Male	192	99,5	190	99,0	66,68	15,36	198	99,0	190	96,0	67,98	15,70
Week 12	Male	191	99,0	182	95,3	68,26	15,55	198	99,0	186	93,9	68,93	15,37
Week 16	Male	191	99,0	183	95,8	68,01	15,18	196	98,0	186	94,9	69,96	15,21
Week 20	Male	191	99,0	182	95,3	67,83	15,83	194	97,0	182	93,8	70,03	14,58
Week 24	Male	188	97,4	176	93,6	69,53	15,32	193	96,5	178	92,2	69,58	15,47
Baseline	Female	173	100,0	173	100,0	49,54	15,70	163	100,0	163	100,0	49,33	16,86
Week 1	Female	173	100,0	170	98,3	59,32	15,58	162	99,4	160	98,8	58,13	16,31
Week 4	Female	173	100,0	166	96,0	62,67	15,81	162	99,4	159	98,1	63,12	14,86
Week 8	Female	173	100,0	170	98,3	64,46	16,15	162	99,4	158	97,5	66,14	15,97
Week 12	Female	173	100,0	167	96,5	66,01	15,46	162	99,4	156	96,3	66,35	16,76
Week 16	Female	173	100,0	164	94,8	65,88	17,07	162	99,4	151	93,2	66,81	16,94
Week 20	Female	173	100,0	165	95,4	66,27	16,77	161	98,8	150	93,2	65,58	17,88
Week 24	Female	171	98,8	164	95,9	65,68	16,74	159	97,5	153	96,2	66,58	18,19
Age													
Baseline	<65 years	162	100,0	162	100,0	51,01	16,34	158	100,0	158	100,0	51,66	16,58
Week 1	<65 years	161	99,4	157	97,5	62,56	15,73	157	99,4	148	94,3	62,18	15,90
Week 4	<65 years	161	99,4	156	96,9	67,22	14,17	157	99,4	153	97,5	67,78	13,93
Week 8	<65 years	161	99,4	160	99,4	70,24	13,43	155	98,1	150	96,8	71,03	14,82
Week 12	<65 years	161	99,4	150	93,2	72,01	12,04	155	98,1	147	94,8	72,53	13,58
Week 16	<65 years	161	99,4	154	95,7	71,68	14,54	155	98,1	145	93,5	73,57	13,50
Week 20	<65 years	161	99,4	152	94,4	72,07	14,56	154	97,5	143	92,9	72,88	14,00
Week 24	<65 years	160	98,8	151	94,4	73,52	13,16	152	96,2	141	92,8	73,14	13,86
Baseline	>=65 years	204	100,0	204	100,0	49,64	16,20	205	100,0	205	100,0	49,98	16,16
Week 1	>=65 years	204	100,0	198	97,1	57,81	15,63	205	100,0	198	96,6	58,93	15,72
Week 4	>=65 years	204	100,0	200	98,0	60,91	16,78	205	100,0	199	97,1	62,62	15,29
Week 8	>=65 years	204	100,0	200	98,0	61,94	16,52	205	100,0	198	96,6	64,20	15,97
Week 12	>=65 years	203	99,5	199	98,0	63,55	16,84	205	100,0	195	95,1	64,15	16,83
Week 16	>=65 years	203	99,5	193	95,1	63,26	16,36	203	99,0	192	94,6	64,76	16,81
Week 20	>=65 years	203	99,5	195	96,1	63,21	16,52	201	98,0	189	94,0	64,34	16,95
Week 24	>=65 years	199	97,5	189	95,0	62,99	16,75	200	97,6	190	95,0	64,52	17,89
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100,0	106	100,0	45,70	6,17	105	100,0	105	100,0	46,83	5,97
Week 1	35 - 54 letters	106	100,0	102	96,2	57,33	8,89	105	100,0	100	95,2	59,20	9,70
Week 4	35 - 54 letters	106	100,0	103	97,2	61,37	11,72	105	100,0	103	98,1	64,33	9,68
Week 8	35 - 54 letters	106	100,0	105	99,1	63,70	11,70	105	100,0	102	97,1	66,67	10,72
Week 12	35 - 54 letters	106	100,0	104	98,1	65,22	12,46	105	100,0	102	97,1	67,31	11,77
Week 16	35 - 54 letters	106	100,0	100	94,3	63,55	13,16	104	99,0	100	96,2	67,37	12,77
Week 20	35 - 54 letters	106	100,0	102	96,2	64,76	12,87	103	98,1	95	92,2	68,43	11,98
Week 24	35 - 54 letters	106	100,0	100	94,3	65,39	11,75	102	97,1	96	94,1	68,01	14,09
Baseline	<=34 letters	79	100,0	79	100,0	25,30	4,84	80	100,0	80	100,0	25,45	4,90

Week 1	<=34 letters	79	100,0	78	98,7	39,21	14,29	80	100,0	79	98,8	39,13	13,19
Week 4	<=34 letters	79	100,0	78	98,7	45,12	15,28	80	100,0	79	98,8	46,29	13,86
Week 8	<=34 letters	79	100,0	79	100,0	49,09	15,65	80	100,0	76	95,0	48,53	15,68
Week 12	<=34 letters	79	100,0	74	93,7	51,45	16,44	80	100,0	75	93,8	49,97	15,95
Week 16	<=34 letters	79	100,0	75	94,9	52,52	17,21	80	100,0	76	95,0	51,71	16,29
Week 20	<=34 letters	79	100,0	78	98,7	52,14	17,74	80	100,0	76	95,0	50,50	16,34
Week 24	<=34 letters	77	97,5	72	93,5	53,38	16,62	80	100,0	76	95,0	52,04	17,69
Baseline	>=55 letters	181	100,0	181	100,0	63,80	5,77	178	100,0	178	100,0	64,35	5,48
Week 1	>=55 letters	180	99,4	175	97,2	70,65	7,84	177	99,4	167	94,4	71,02	7,42
Week 4	>=55 letters	180	99,4	175	97,2	73,30	9,29	177	99,4	170	96,0	73,81	8,65
Week 8	>=55 letters	180	99,4	176	97,8	74,20	10,91	175	98,3	170	97,1	75,75	10,30
Week 12	>=55 letters	179	98,9	171	95,5	75,19	10,42	175	98,3	165	94,3	76,11	10,97
Week 16	>=55 letters	179	98,9	172	96,1	75,32	11,32	174	97,8	161	92,5	77,23	10,23
Week 20	>=55 letters	179	98,9	167	93,3	75,49	11,23	172	96,6	161	93,6	76,05	11,33
Week 24	>=55 letters	176	97,2	168	95,5	75,15	13,43	170	95,5	159	93,5	76,02	11,67
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	35	100,0	20,66	1,33	36	100,0	36	100,0	20,72	1,37
Week 1	<=23 letters	35	100,0	34	97,1	29,91	10,48	36	100,0	35	97,2	33,86	14,25
Week 4	<=23 letters	35	100,0	35	100,0	36,17	11,96	36	100,0	36	100,0	40,36	14,44
Week 8	<=23 letters	35	100,0	35	100,0	40,09	13,29	36	100,0	35	97,2	42,06	17,15
Week 12	<=23 letters	35	100,0	34	97,1	42,50	15,05	36	100,0	32	88,9	41,66	16,34
Week 16	<=23 letters	35	100,0	34	97,1	44,38	15,52	36	100,0	33	91,7	43,88	17,92
Week 20	<=23 letters	35	100,0	34	97,1	42,85	15,29	36	100,0	35	97,2	44,20	17,19
Week 24	<=23 letters	34	97,1	32	94,1	45,16	14,47	36	100,0	33	91,7	45,21	18,80
Baseline	>=24 letters	331	100,0	331	100,0	53,37	13,76	327	100,0	327	100,0	54,01	13,64
Week 1	>=24 letters	330	99,7	321	97,3	63,09	12,65	326	99,7	311	95,4	63,30	13,02
Week 4	>=24 letters	330	99,7	321	97,3	66,67	13,28	326	99,7	316	96,9	67,65	12,18
Week 8	>=24 letters	330	99,7	325	98,5	68,38	13,36	324	99,1	313	96,6	69,95	12,97
Week 12	>=24 letters	329	99,4	315	95,7	69,85	13,05	324	99,1	310	95,7	70,45	13,40
Week 16	>=24 letters	329	99,4	313	95,1	69,46	14,16	322	98,5	304	94,4	71,23	13,36
Week 20	>=24 letters	329	99,4	313	95,1	69,72	14,07	319	97,6	297	93,1	70,83	13,69
Week 24	>=24 letters	325	98,2	308	94,8	70,01	14,40	316	96,6	298	94,3	70,73	14,54
Geographic Region													
Baseline	Europe	111	100,0	111	100,0	50,29	16,31	114	100,0	114	100,0	50,63	17,20
Week 1	Europe	111	100,0	107	96,4	60,55	14,92	114	100,0	109	95,6	61,22	16,48
Week 4	Europe	111	100,0	107	96,4	63,03	16,14	114	100,0	111	97,4	65,39	16,44
Week 8	Europe	111	100,0	110	99,1	64,69	17,35	112	98,2	108	96,4	67,19	17,22
Week 12	Europe	110	99,1	106	96,4	66,50	16,78	112	98,2	109	97,3	68,63	17,27
Week 16	Europe	110	99,1	104	94,5	66,30	17,59	111	97,4	105	94,6	69,69	17,36
Week 20	Europe	110	99,1	107	97,3	66,28	18,08	110	96,5	104	94,5	68,75	16,99
Week 24	Europe	108	97,3	101	93,5	66,89	17,43	109	95,6	104	95,4	69,63	16,71
Baseline	America	147	100,0	147	100,0	49,44	17,24	146	100,0	146	100,0	50,16	16,67
Week 1	America	146	99,3	143	97,9	58,55	16,87	145	99,3	138	95,2	59,54	16,56
Week 4	America	146	99,3	143	97,9	63,49	17,02	145	99,3	140	96,6	64,26	14,94
Week 8	America	146	99,3	143	97,9	65,51	16,18	145	99,3	139	95,9	66,94	15,76
Week 12	America	146	99,3	137	93,8	67,33	15,84	145	99,3	135	93,1	66,87	16,70
Week 16	America	146	99,3	138	94,5	67,29	15,33	145	99,3	136	93,8	67,35	16,57
Week 20	America	146	99,3	136	93,2	67,29	16,11	143	97,9	136	95,1	66,80	17,64
Week 24	America	143	97,3	137	95,8	68,06	16,13	141	96,6	133	94,3	66,53	18,20
Baseline	Asia Pacific (inc. Australia)	108	100,0	108	100,0	51,31	14,83	103	100,0	103	100,0	51,58	14,97
Week 1	Asia Pacific (inc. Australia)	108	100,0	105	97,2	61,11	15,26	103	100,0	99	96,1	60,43	14,17
Week 4	Asia Pacific (inc. Australia)	108	100,0	106	98,1	64,58	14,40	103	100,0	101	98,1	65,12	13,12
Week 8	Asia Pacific (inc. Australia)	108	100,0	107	99,1	66,76	13,34	103	100,0	101	98,1	67,38	14,47
Week 12	Asia Pacific (inc. Australia)	108	100,0	106	98,1	67,69	13,84	103	100,0	98	95,1	68,00	13,64
Week 16	Asia Pacific (inc. Australia)	108	100,0	105	97,2	67,31	15,70	102	99,0	96	94,1	69,01	13,73
Week 20	Asia Pacific (inc. Australia)	108	100,0	104	96,3	67,66	14,57	102	99,0	92	90,2	69,00	13,13
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	67,92	14,82	102	99,0	94	92,2	68,96	14,77
Race/ethnicity													
Baseline	White	243	100,0	243	100,0	49,88	16,77	253	100,0	253	100,0	51,10	16,73
Week 1	White	242	99,6	235	97,1	59,59	16,30	252	99,6	239	94,8	61,34	16,21
Week 4	White	242	99,6	234	96,7	63,35	16,98	252	99,6	243	96,4	65,49	15,32
Week 8	White	242	99,6	237	97,9	65,08	16,95	250	98,8	240	96,0	67,73	16,01
Week 12	White	241	99,2	230	95,4	66,54	16,70	250	98,8	238	95,2	67,96	17,05
Week 16	White	241	99,2	229	95,0	66,26	17,08	249	98,4	232	93,2	68,84	16,75
Week 20	White	241	99,2	231	95,9	65,82	17,35	246	97,2	232	94,3	68,17	17,27

Week 24	White	238	97,9	225	94,5	67,01	16,97	243	96,0	232	95,5	68,32	17,75
Baseline	Asian	89	100,0	89	100,0	51,12	15,45	88	100,0	88	100,0	50,74	15,18
Week 1	Asian	89	100,0	88	98,9	60,15	15,76	88	100,0	85	96,6	59,00	14,47
Week 4	Asian	89	100,0	88	98,9	63,81	14,74	88	100,0	87	98,9	64,08	13,50
Week 8	Asian	89	100,0	89	100,0	66,34	13,60	88	100,0	86	97,7	66,31	15,04
Week 12	Asian	89	100,0	87	97,8	67,87	13,09	88	100,0	83	94,3	67,40	14,04
Week 16	Asian	89	100,0	87	97,8	68,18	14,30	87	98,9	83	95,4	68,49	13,96
Week 20	Asian	89	100,0	85	95,5	68,68	14,10	87	98,9	80	92,0	68,33	13,17
Week 24	Asian	89	100,0	85	95,5	67,82	14,76	87	98,9	79	90,8	68,51	14,12
Baseline	Other	13	100,0	13	100,0	44,23	17,34	17	100,0	17	100,0	46,06	16,35
Week 1	Other	13	100,0	13	100,0	59,46	11,62	17	100,0	17	100,0	54,76	15,30
Week 4	Other	13	100,0	13	100,0	64,54	11,52	17	100,0	17	100,0	61,94	14,80
Week 8	Other	13	100,0	13	100,0	67,85	9,79	17	100,0	17	100,0	65,76	13,65
Week 12	Other	13	100,0	12	92,3	71,00	10,15	17	100,0	17	100,0	66,12	12,24
Week 16	Other	13	100,0	11	84,6	71,36	9,65	17	100,0	17	100,0	67,53	13,67
Week 20	Other	13	100,0	13	100,0	75,23	7,90	17	100,0	15	88,2	68,00	12,54
Week 24	Other	13	100,0	13	100,0	74,31	8,87	17	100,0	15	88,2	68,33	13,09
Baseline	Unknown	21	100,0	21	100,0	54,48	11,78	5	100,0	5	100,0	46,20	18,16
Week 1	Unknown	21	100,0	19	90,5	63,16	12,90	5	100,0	5	100,0	53,00	20,60
Week 4	Unknown	21	100,0	21	100,0	66,19	11,79	5	100,0	5	100,0	58,00	19,79
Week 8	Unknown	21	100,0	21	100,0	67,52	13,37	5	100,0	5	100,0	57,80	26,68
Week 12	Unknown	21	100,0	20	95,2	69,35	14,08	5	100,0	4	80,0	70,00	9,42
Week 16	Unknown	21	100,0	20	95,2	67,90	15,09	5	100,0	5	100,0	59,40	24,47
Week 20	Unknown	21	100,0	18	85,7	69,94	14,01	5	100,0	5	100,0	56,20	23,89
Week 24	Unknown	19	90,5	17	89,5	70,59	14,74	5	100,0	5	100,0	56,60	22,21
Baseline RVO status													
Baseline	CRVO	302	100,0	302	100,0	49,96	16,46	293	100,0	293	100,0	50,41	16,62
Week 1	CRVO	301	99,7	293	97,3	59,79	16,18	292	99,7	279	95,5	60,27	16,04
Week 4	CRVO	301	99,7	293	97,3	63,39	16,42	292	99,7	283	96,9	64,53	15,47
Week 8	CRVO	301	99,7	297	98,7	65,13	16,36	290	99,0	281	96,9	66,54	16,53
Week 12	CRVO	300	99,3	287	95,7	66,70	16,06	290	99,0	276	95,2	66,68	16,69
Week 16	CRVO	300	99,3	286	95,3	66,29	16,85	289	98,6	275	95,2	67,69	16,60
Week 20	CRVO	300	99,3	285	95,0	66,52	17,01	287	98,0	269	93,7	66,81	16,79
Week 24	CRVO	295	97,7	278	94,2	66,94	16,92	285	97,3	269	94,4	66,75	17,44
Baseline	HRVO	61	100,0	61	100,0	52,25	14,87	64	100,0	64	100,0	52,16	14,92
Week 1	HRVO	61	100,0	59	96,7	60,46	14,30	64	100,0	61	95,3	60,77	15,18
Week 4	HRVO	61	100,0	60	98,4	65,05	13,78	64	100,0	63	98,4	66,27	11,88
Week 8	HRVO	61	100,0	60	98,4	68,05	12,58	64	100,0	61	95,3	69,87	11,86
Week 12	HRVO	61	100,0	59	96,7	69,31	12,79	64	100,0	61	95,3	72,15	12,03
Week 16	HRVO	61	100,0	58	95,1	70,24	11,79	63	98,4	57	90,5	71,81	12,80
Week 20	HRVO	61	100,0	59	96,7	69,58	12,40	62	96,9	57	91,9	73,39	12,45
Week 24	HRVO	61	100,0	59	96,7	70,93	11,68	62	96,9	58	93,5	74,09	12,03
Baseline	Missing	3	100,0	3	100,0	38,00	20,81	6	100,0	6	100,0	50,00	19,21
Week 1	Missing	3	100,0	3	100,0	61,00	13,89	6	100,0	6	100,0	58,33	16,21
Week 4	Missing	3	100,0	3	100,0	64,33	16,92	6	100,0	6	100,0	65,83	18,50
Week 8	Missing	3	100,0	3	100,0	66,67	6,43	6	100,0	6	100,0	67,50	16,93
Week 12	Missing	3	100,0	3	100,0	72,33	11,68	6	100,0	5	83,3	73,20	14,45
Week 16	Missing	3	100,0	3	100,0	72,00	7,00	6	100,0	5	83,3	78,80	12,15
Week 20	Missing	3	100,0	3	100,0	72,00	3,61	6	100,0	6	100,0	71,50	17,05
Week 24	Missing	3	100,0	3	100,0	71,00	2,65	5	83,3	4	80,0	79,75	13,23

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Units: letters.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_SBCVA_IT_09AUG2022_41986.xls

18MAR2024 8:30


POPULATION: Intent-To-Treat Population
 ENDPOINT: Center Subfield Thickness ILM-BW in Study Eye at Week 24
 MODEL: Adjusted Analysis for Baseline BCVA ETRS Letter score, Geographic region
 STUDY: GR41984
 Change from Baseline (Analysis of MMRM)

Visit	Name	Level	Faricimab (N=276)					Aflibercept (N=277)					Difference between Treatments (Faricimab - Aflibercept)							Effects				
			N		Statistics			N		Statistics			Statistics							Population	Method	p-value (treatment)	p-value (visit)	p-value (subgroup* treatment)
			With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and at least one a value at Week 24	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one a value at Week 24	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Hedges g	95% CI Hedges g (LL)	95% CI Hedges g (UL)						
Week 24	All	n/a	275	273	252	-311.39	2.53	275	274	243	-304.35	2.53	-7.03	3.57	-14.05	-0.01	-0.17	-0.34	0.00	Intent-To-Treat Population	adjusted	0.1734	<.0001	
	Gender	Male	142	142	132	-328.42	3.65	128	127	118	-322.43	3.83	-5.99	5.29	-16.41	4.44	-0.14	-0.38	0.10	Intent-To-Treat Population	adjusted	0.2307	<.0001	0.9855
		Female	133	131	120	-285.22	3.42	147	147	125	-285.96	3.26	-9.26	4.73	-18.58	0.06	-0.23	-0.47	0.00	Intent-To-Treat Population	adjusted	0.3778	<.0001	
	Age	<65 years	132	131	120	-312.07	3.54	144	143	126	-304.96	3.38	-7.11	4.89	-16.75	2.53	-0.18	-0.41	0.06	Intent-To-Treat Population	adjusted	0.1415	<.0001	0.8305
		>=65 years	143	142	132	-310.68	3.63	131	131	117	-303.55	3.79	-7.14	5.25	-17.48	3.20	-0.16	-0.40	0.07	Intent-To-Treat Population	adjusted	0.4970	<.0001	
	Baseline BCVA ETRS letter score	<=54 letters	89	89	84	-411.82	4.44	90	90	78	-396.06	4.39	-15.76	6.25	-28.00	-3.43	-0.38	-0.67	-0.08	Intent-To-Treat Population	adjusted	0.0553	<.0001	0.1475
		>=55 letters	186	184	168	-263.24	3.04	185	184	165	-260.20	3.05	-3.04	4.31	-13.52	5.43	-0.07	-0.28	0.13	Intent-To-Treat Population	adjusted	0.7508	<.0001	
	Geographic Region	Europe	82	81	79	-311.25	4.65	70	70	60	-299.18	5.02	-12.07	6.85	-25.62	1.48	-0.29	-0.61	0.03	Intent-To-Treat Population	adjusted	0.1442	<.0001	0.8275
		America	97	96	90	-302.39	4.86	104	103	96	-296.49	4.66	-5.89	6.73	-19.17	7.39	-0.12	-0.40	0.15	Intent-To-Treat Population	adjusted	0.7315	<.0001	
		Asia Pacific (inc. Australia)	96	96	83	-320.93	3.68	101	101	87	-316.27	3.58	-4.66	5.14	-14.80	5.48	-0.13	-0.41	0.15	Intent-To-Treat Population	adjusted	0.4331	<.0001	
	Race/ethnicity	White	172	170	162	-307.66	3.26	171	170	152	-302.41	3.26	-5.26	4.61	-14.34	3.82	-0.12	-0.34	0.09	Intent-To-Treat Population	adjusted	0.5469	<.0001	0.4012
		Asian	89	89	77	-319.31	4.40	93	93	80	-313.35	4.30	-5.96	6.16	-18.13	6.21	-0.14	-0.43	0.15	Intent-To-Treat Population	adjusted	0.2310	<.0001	
		Other	10	10	9	-262.48	11.32	7	7	7	-223.79	13.69	-38.69	18.21	-77.37	-0.01	-0.99	-1.97	-0.02	Intent-To-Treat Population	adjusted	0.1318	0.0173	
		Unknown	4	4	4	NE	NE	4	4	4	NE	NE	NE	NE	NE	NE	NE	NE	NE	Intent-To-Treat Population	adjusted	NE	NE	NE

[1] Patients included in the analysis: with a value at baseline and at least one post-baseline value at the selected visits.
 [2] LSMeans of change from baseline from MMRM (including all available records from all selected visits). Selected visits: every 4 weeks from Week 4 to 24. Early Termination (ET) visit was mapped to closest regular visit.
 [3] Contrasts from MMRM: Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition adjusted for randomization stratification factors. The stratification factor is excluded if it is the subgroup.
 Units: microns. Data as observed (no imputation of missing values). Covariance matrix: unstructured. Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACR_data_analysis/prod/program/t_eff_mrm_sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACR_CSR_Primary/prod/output/t_eff_mrm_adj_PREST_tW24_SBCST_IT_06JUL2022_41984.xls
 09JUL2024 12:22

POPULATION: Intent-To-Treat Population
ENDPOINT: Center Subfield Thickness ILM-BM in Study Eye over Time through Week 24
STUDY: GR41984



Treatment Group —○— Faricimab (N=276) -x- Aflibercept (N=277)

Units: microns.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: ..al_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/g_mean_plot.sas
 Output: ..sis/ACE_CSR_Primary/prod/output/g_mean_plot_PREST_tW24_SBCST_IT_06JUL2022_41984.pdf
 18MAR2024 8:33

POPULATION: Intent-To-Treat Population
 ENDPOINT: Center Subfield Thickness ILM-BM in Study Eye over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients			Statistics			Patients			Statistics		
		in study ¹	%	with value ¹	%	Mean ²	SD (Mean)	in study ¹	%	with value ¹	%	Mean ²	SD (Mean)
All													
Baseline	n/a	276	100,0	275	99,6	558,32	177,03	277	100,0	275	99,3	558,12	180,26
Week 1	n/a	276	100,0	269	97,5	329,10	84,06	275	99,3	267	97,1	330,76	69,31
Week 4	n/a	274	99,3	268	97,8	273,67	54,06	274	98,9	272	99,3	276,46	50,94
Week 8	n/a	274	99,3	266	97,1	258,08	52,64	274	98,9	269	98,2	260,88	45,75
Week 12	n/a	274	99,3	263	96,0	251,95	42,74	274	98,9	267	97,4	259,12	44,31
Week 16	n/a	274	99,3	260	94,9	251,85	50,74	274	98,9	261	95,3	256,42	41,65
Week 20	n/a	272	98,6	257	94,5	249,33	43,24	274	98,9	256	93,4	255,82	41,79
Week 24	n/a	272	98,6	253	93,0	246,48	46,69	274	98,9	243	88,7	254,09	40,27
Gender													
Baseline	Male	143	100,0	142	99,3	597,39	180,32	130	100,0	128	98,5	576,80	183,60
Week 1	Male	143	100,0	140	97,9	338,28	87,03	128	98,5	122	95,3	334,02	72,12
Week 4	Male	143	100,0	139	97,2	279,37	53,83	127	97,7	126	99,2	281,57	55,46
Week 8	Male	143	100,0	137	95,8	262,01	47,85	127	97,7	125	98,4	265,16	43,66
Week 12	Male	143	100,0	137	95,8	256,43	44,73	127	97,7	125	98,4	264,81	43,87
Week 16	Male	143	100,0	133	93,0	255,88	47,50	127	97,7	121	95,3	262,23	42,68
Week 20	Male	141	98,6	132	93,6	254,64	46,43	127	97,7	122	96,1	265,34	42,75
Week 24	Male	141	98,6	133	94,3	253,65	51,25	127	97,7	118	92,9	259,86	40,88
Baseline	Female	133	100,0	133	100,0	527,28	168,64	147	100,0	147	100,0	541,85	176,31
Week 1	Female	133	100,0	129	97,0	319,13	79,86	147	100,0	145	98,6	328,02	66,98
Week 4	Female	131	98,5	129	98,5	267,53	53,84	147	100,0	146	99,3	272,04	46,43
Week 8	Female	131	98,5	129	98,5	253,91	57,19	147	100,0	144	98,0	257,16	47,32
Week 12	Female	131	98,5	126	96,2	247,07	40,07	147	100,0	142	96,6	254,11	44,25
Week 16	Female	131	98,5	127	96,9	247,62	53,79	147	100,0	140	95,2	251,39	40,23
Week 20	Female	131	98,5	125	95,4	243,73	39,00	147	100,0	134	91,2	247,15	39,08
Week 24	Female	131	98,5	120	91,6	238,54	39,76	147	100,0	125	85,0	248,66	39,07
Age													
Baseline	<65 years	133	100,0	132	99,2	560,20	179,89	144	100,0	144	100,0	555,03	188,93
Week 1	<65 years	133	100,0	131	98,5	328,21	84,77	144	100,0	140	97,2	334,44	74,81
Week 4	<65 years	132	99,2	127	96,2	267,83	45,29	143	99,3	142	99,3	273,91	50,37
Week 8	<65 years	132	99,2	127	96,2	252,73	38,48	143	99,3	140	97,9	257,21	35,37
Week 12	<65 years	132	99,2	125	94,7	249,57	34,63	143	99,3	139	97,2	256,25	34,40
Week 16	<65 years	132	99,2	121	91,7	250,46	39,32	143	99,3	135	94,4	255,10	33,17
Week 20	<65 years	131	98,5	123	93,9	246,64	35,82	143	99,3	131	91,6	255,44	34,27
Week 24	<65 years	131	98,5	121	92,4	246,68	46,76	143	99,3	126	88,1	254,01	36,88
Baseline	>=65 years	143	100,0	143	100,0	556,58	174,96	133	100,0	131	98,5	561,51	170,87
Week 1	>=65 years	143	100,0	138	96,5	329,93	83,69	131	98,5	127	96,9	326,70	62,73
Week 4	>=65 years	142	99,3	141	99,3	278,93	60,58	131	98,5	130	99,2	279,24	51,60
Week 8	>=65 years	142	99,3	139	97,9	262,97	62,61	131	98,5	129	98,5	264,85	54,71
Week 12	>=65 years	142	99,3	138	97,2	254,10	48,97	131	98,5	128	97,7	262,23	52,99
Week 16	>=65 years	142	99,3	139	97,9	253,05	59,03	131	98,5	126	96,2	257,83	49,25
Week 20	>=65 years	141	98,6	134	95,0	251,80	49,08	131	98,5	125	95,4	256,22	48,59
Week 24	>=65 years	141	98,6	132	93,6	246,30	46,80	131	98,5	117	89,3	254,19	43,79
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	642,49	193,33	90	100,0	90	100,0	635,80	202,21
Week 1	<=54 letters	89	100,0	89	100,0	337,94	102,40	90	100,0	85	94,4	341,20	86,09
Week 4	<=54 letters	89	100,0	86	96,6	268,92	67,03	90	100,0	90	100,0	275,96	67,96
Week 8	<=54 letters	89	100,0	87	97,8	241,91	53,77	90	100,0	90	100,0	252,43	54,86
Week 12	<=54 letters	89	100,0	83	93,3	233,12	36,59	90	100,0	86	95,6	248,10	47,00
Week 16	<=54 letters	89	100,0	82	92,1	231,96	43,09	90	100,0	85	94,4	244,94	43,38
Week 20	<=54 letters	89	100,0	80	89,9	230,83	39,67	90	100,0	84	93,3	246,60	43,58
Week 24	<=54 letters	89	100,0	84	94,4	226,68	40,03	90	100,0	78	86,7	245,85	43,87
Baseline	>=55 letters	187	100,0	186	99,5	518,04	153,61	187	100,0	185	98,9	520,33	155,63
Week 1	>=55 letters	187	100,0	180	96,3	324,72	73,26	185	98,9	182	98,4	325,88	59,54
Week 4	>=55 letters	185	98,9	182	98,4	275,91	46,75	184	98,4	182	98,9	276,70	40,17
Week 8	>=55 letters	185	98,9	179	96,8	265,94	50,39	184	98,4	179	97,3	265,12	39,90
Week 12	>=55 letters	185	98,9	180	97,3	260,63	42,66	184	98,4	181	98,4	264,35	42,11
Week 16	>=55 letters	185	98,9	178	96,2	261,01	51,48	184	98,4	176	95,7	261,96	39,74
Week 20	>=55 letters	183	97,9	177	96,7	257,69	42,28	184	98,4	172	93,5	260,33	40,26
Week 24	>=55 letters	183	97,9	169	92,3	256,33	46,73	184	98,4	165	89,7	257,99	37,97

Geographic Region													
Baseline	Europe	82	100,0	82	100,0	564,26	180,89	70	100,0	70	100,0	545,89	179,86
Week 1	Europe	82	100,0	81	98,8	328,89	81,33	70	100,0	70	100,0	326,79	72,12
Week 4	Europe	81	98,8	78	96,3	276,27	55,83	70	100,0	70	100,0	280,61	52,79
Week 8	Europe	81	98,8	77	95,1	257,38	49,93	70	100,0	68	97,1	268,50	52,09
Week 12	Europe	81	98,8	75	92,6	253,05	48,29	70	100,0	67	95,7	264,99	42,38
Week 16	Europe	81	98,8	77	95,1	253,32	50,87	70	100,0	69	98,6	262,07	37,97
Week 20	Europe	80	97,6	76	95,0	250,14	45,15	70	100,0	67	95,7	261,19	29,75
Week 24	Europe	80	97,6	79	98,8	245,34	47,38	70	100,0	60	85,7	257,80	36,62
Baseline	America	97	100,0	97	100,0	560,00	179,02	105	100,0	104	99,0	558,98	199,61
Week 1	America	97	100,0	91	93,8	335,43	89,86	104	99,0	97	93,3	331,55	66,94
Week 4	America	96	99,0	94	97,9	282,35	55,37	103	98,1	102	99,0	287,38	55,68
Week 8	America	96	99,0	92	95,8	271,30	64,35	103	98,1	103	100,0	268,57	46,58
Week 12	America	96	99,0	93	96,9	260,25	41,94	103	98,1	101	98,1	262,73	44,88
Week 16	America	96	99,0	92	95,8	262,39	60,77	103	98,1	97	94,2	261,31	44,52
Week 20	America	96	99,0	90	93,8	257,69	46,24	103	98,1	99	96,1	258,59	52,01
Week 24	America	96	99,0	90	93,8	257,18	52,24	103	98,1	96	93,2	260,73	44,54
Baseline	Asia Pacific (inc. Australia)	97	100,0	96	99,0	551,54	173,28	102	100,0	101	99,0	565,71	159,70
Week 1	Asia Pacific (inc. Australia)	97	100,0	97	100,0	323,33	81,08	101	99,0	100	99,0	332,78	70,15
Week 4	Asia Pacific (inc. Australia)	97	100,0	96	99,0	263,05	49,93	101	99,0	100	99,0	262,40	40,78
Week 8	Asia Pacific (inc. Australia)	97	100,0	97	100,0	246,10	37,93	101	99,0	98	97,0	247,50	36,64
Week 12	Asia Pacific (inc. Australia)	97	100,0	95	97,9	242,95	37,20	101	99,0	99	98,0	251,45	44,37
Week 16	Asia Pacific (inc. Australia)	97	100,0	91	93,8	239,93	35,08	101	99,0	95	94,1	247,32	39,99
Week 20	Asia Pacific (inc. Australia)	96	99,0	91	94,8	240,38	36,80	101	99,0	90	89,1	248,78	35,91
Week 24	Asia Pacific (inc. Australia)	96	99,0	84	87,5	236,10	36,71	101	99,0	87	86,1	244,22	35,97
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	563,99	179,62	172	100,0	171	99,4	556,75	186,84
Week 1	White	172	100,0	165	95,9	330,07	79,80	171	99,4	165	96,5	329,29	68,76
Week 4	White	170	98,8	165	97,1	279,93	56,70	170	98,8	170	100,0	282,71	53,20
Week 8	White	170	98,8	163	95,9	266,23	59,56	170	98,8	167	98,2	266,32	45,96
Week 12	White	170	98,8	161	94,7	259,57	46,72	170	98,8	165	97,1	263,50	45,33
Week 16	White	170	98,8	163	95,9	260,56	58,27	170	98,8	165	97,1	260,76	41,59
Week 20	White	169	98,3	160	94,7	257,41	48,12	170	98,8	164	96,5	260,72	39,76
Week 24	White	169	98,3	162	95,9	252,64	46,54	170	98,8	152	89,4	257,28	41,33
Baseline	Asian	90	100,0	89	98,9	551,52	171,22	94	100,0	93	98,9	562,87	168,67
Week 1	Asian	90	100,0	90	100,0	327,67	92,91	93	98,9	92	98,9	336,75	71,52
Week 4	Asian	90	100,0	89	98,9	261,54	47,29	93	98,9	92	98,9	263,95	42,65
Week 8	Asian	90	100,0	90	100,0	244,24	36,80	93	98,9	91	97,8	248,29	39,89
Week 12	Asian	90	100,0	88	97,8	239,82	33,46	93	98,9	91	97,8	250,48	40,82
Week 16	Asian	90	100,0	84	93,3	236,85	30,51	93	98,9	86	92,5	248,94	42,30
Week 20	Asian	89	98,9	83	93,3	236,00	30,18	93	98,9	82	88,2	246,01	44,94
Week 24	Asian	89	98,9	78	87,6	235,65	47,34	93	98,9	80	86,0	245,45	35,09
Baseline	Other	10	100,0	10	100,0	462,80	151,15	7	100,0	7	100,0	545,71	168,65
Week 1	Other	10	100,0	10	100,0	308,60	51,06	7	100,0	6	85,7	314,17	51,33
Week 4	Other	10	100,0	10	100,0	271,70	41,89	7	100,0	7	100,0	301,00	66,01
Week 8	Other	10	100,0	10	100,0	244,10	29,35	7	100,0	7	100,0	286,00	61,97
Week 12	Other	10	100,0	10	100,0	238,60	22,33	7	100,0	7	100,0	276,00	53,68
Week 16	Other	10	100,0	10	100,0	235,20	22,80	7	100,0	6	85,7	253,33	18,12
Week 20	Other	10	100,0	10	100,0	235,50	23,16	7	100,0	7	100,0	264,57	31,40
Week 24	Other	10	100,0	9	90,0	236,22	31,26	7	100,0	7	100,0	276,71	35,86
Baseline	Unknown	4	100,0	4	100,0	704,50	180,70	4	100,0	4	100,0	528,00	240,17
Week 1	Unknown	4	100,0	4	100,0	372,25	123,55	4	100,0	4	100,0	278,50	50,22
Week 4	Unknown	4	100,0	4	100,0	290,25	81,43	4	100,0	3	75,0	248,33	52,54
Week 8	Unknown	4	100,0	3	75,0	277,33	13,43	4	100,0	4	100,0	276,25	80,05
Week 12	Unknown	4	100,0	4	100,0	245,25	32,43	4	100,0	4	100,0	245,25	42,17
Week 16	Unknown	4	100,0	3	75,0	254,00	18,25	4	100,0	4	100,0	242,75	40,56
Week 20	Unknown	4	100,0	4	100,0	237,25	32,65	4	100,0	3	75,0	235,67	48,23
Week 24	Unknown	4	100,0	4	100,0	231,50	32,05	4	100,0	4	100,0	266,25	76,96

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Units: microns.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_SBCST_IT_06JUL2022_41984.xls

18MAR2024 8:28

POPULATION: Intent-To-Treat Population
 ENDPOINT: Study Eye - Proportion of Patients with Absence of Macular Edema at Week 24
 MODEL: Stratified Analysis by Baseline BCVA ETDRS Letter score, Geographic region
 STUDY: GR41984
 Dichotomous Analysis by Subgroups (Efficacy)

Name	Level	Faricimab (N=276)				Aflibercept (N=277)				Faricimab vs. Aflibercept										Aflibercept vs. Faricimab									
		n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CI	95% Upper CI	Absolute Risk	Absolute Risk Difference	Convergence Reason	95% Lower CI	95% Upper CI	Relative Risk	Convergence Reason	95% Lower CI	95% Upper CI	p-value (Cochran Mantel-Haenszel)	Interaction Test p-value (likelihood)	Relative Risk	Convergence Reason	95% Lower CI	95% Upper CI	
All	n/a	253	91.7	242	95.7	243	87.7	231	95.1	1.13	Convergence criterion (GCONV+18-8) satisfied.	0.49	2.62	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of			*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of
Gender	Male	133	48.2	127	95.5	118	42.6	109	92.4	1.91	Convergence criterion (GCONV+18-8) satisfied.	0.64	5.68	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	0.4332		*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of
	Female	120	43.1	115	95.8	125	45.1	122	97.6	0.59	Convergence criterion (GCONV+18-8) satisfied.	0.14	2.51	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of			*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of
Age	<65 years	121	43.8	117	96.7	126	45.5	122	96.8	0.97	Convergence criterion (GCONV+18-8) satisfied.	0.24	4.01	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	0.4692		*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of
	>=65 years	132	47.8	125	94.7	117	42.2	109	92.5	1.30	Convergence criterion (GCONV+18-8) satisfied.	0.46	3.70	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of			*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of
Baseline BCVA ETDRS Letter score	<=54 letters	84	30.4	83	98.8	78	28.2	74	94.5	4.36	Convergence criterion (GCONV+18-8) satisfied.	0.47	40.70	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: Negative of Hessian not positive definite.	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	1.0000		*	WARNING: Negative of Hessian not positive definite.	*	WARNING: Negative of Hessian not positive definite.
	>=55 letters	169	61.2	159	94.1	165	59.6	157	95.2	*	NE			0.021	Algorithm converged.	-0.049	0.091	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of			*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of
Geographic Region	Europe	79	28.6	75	94.9	60	21.7	59	98.3	0.34	(GCONV+18-8) satisfied.	0.04	3.06	-0.032	Algorithm converged.	-0.103	0.040	0.97	Algorithm converged.	0.90	1.04	0.3102	0.3753	1.03	Algorithm converged.	0.96	1.12		
	America	90	32.6	84	93.3	96	34.7	88	92.7	1.30	Convergence criterion (GCONV+18-8) satisfied.	0.43	3.90	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of			*	WARNING: The relative Hessian convergence criterion of	*	WARNING: The relative Hessian convergence criterion of
	Asia Pacific (inc. Australia)	84	30.4	83	98.8	87	31.4	84	96.6	2.67	Convergence criterion (GCONV+18-8) satisfied.	0.27	26.29	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: Negative of Hessian not positive definite.	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: Negative of Hessian not positive definite.	*	WARNING: The relative Hessian convergence criterion of			*	WARNING: Negative of Hessian not positive definite.	*	WARNING: Negative of Hessian not positive definite.
Race/ethnicity	White	162	58.7	152	93.8	152	54.9	148	95.4	0.74	Convergence criterion (GCONV+18-8) satisfied.	0.28	3.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	0.5564	NE	NE	NE	NE	NE	
	Asian	78	28.3	77	98.7	80	28.9	77	96.3	2.65	Convergence criterion (GCONV+18-8) satisfied.	0.25	28.13	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: Negative of Hessian not positive definite.	*	WARNING: The relative Hessian convergence criterion of	*	WARNING: Negative of Hessian not positive definite.	*	WARNING: The relative Hessian convergence criterion of			*	WARNING: Negative of Hessian not positive definite.	*	WARNING: Negative of Hessian not positive definite.
	Other	9	3.3	9	100.0	7	2.5	6	85.7	>999.99	Convergence criterion (GCONV+18-8) satisfied.	0.00	NE	NE	NE	NE	NE	NE	NE	NE	NE	0.3173	NE	NE	NE	NE	NE		
	Unknown	4	1.4	4	100.0	4	1.4	3	75.0	NE	(ABS(GCONV+)) satisfied.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	

Test for interaction based on RR (Log-binomial regression).
 * indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_resp_sq_str_SNOACED_PRES2_W24_IT_06JUL2022_41984.xls
 10AUG2023 9:37


POPULATION: Intent-To-Treat Population
 ENDPOINT: Center Subfield Thickness ILM-BW in Study Eye at Week 24
 MODEL: Adjusted Analysis for Baseline BCVA ETDRS letter score, Geographic region
 STUDY: GR41986
 Change from Baseline (Analysis of MMRM)

Visit	Name	Level	Faricimab (N=366)					Aflibercept (N=363)					Difference between Treatments (Faricimab - Aflibercept)							Effects					
			N		Statistics			N		Statistics			Statistics							p-value (treatment)	p-value (visit)	p-value (subgroup treatment)			
			With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at Week 24	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at Week 24	LSMeans[3]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Hedges g	95% CI Hedges g (LL)	95% CI Hedges g (UL)						
Week 24	All	n/a	359	358	329	-461.64	4.96	359	357	326	-448.80	4.99	-12.84	7.04	-26.66	0.97	-0.14	-0.28	0.01	Intent-To-Treat Population	adjusted	0.0790	<.0001		
	Gender																								
		Male	187	186	171	-460.20	7.88	198	196	176	-441.73	7.73	-18.47	11.05	-40.21	3.26	-0.17	-0.37	0.03	Intent-To-Treat Population	adjusted	0.1697	<.0001	0.8135	
		Female	172	172	158	-462.35	5.94	161	161	150	-456.93	6.12	-5.43	8.54	-22.22	11.39	-0.07	-0.28	0.15	Intent-To-Treat Population	adjusted	0.4488	<.0001		
	Age																								
		<65 years	159	158	145	-477.19	8.49	155	153	137	-462.87	8.67	-14.32	12.16	-38.26	9.62	-0.13	-0.36	0.09	Intent-To-Treat Population	adjusted	0.5323	<.0001	0.5812	
		>=65 years	200	200	184	-449.74	5.88	204	204	189	-437.92	5.81	-11.82	8.27	-28.09	4.45	-0.14	-0.34	0.05	Intent-To-Treat Population	adjusted	0.0710	<.0001		
	Baseline BCVA ETDRS letter score																								
		<=34 letters	76	76	67	-670.43	9.02	78	75	75	-674.96	8.73	4.53	12.57	-20.34	29.40	0.06	-0.26	0.37	Intent-To-Treat Population	adjusted	0.5734	<.0001	0.1494	
		35 - 54 letters	104	104	98	-514.80	9.34	103	103	94	-489.60	9.50	-25.20	13.33	-53.47	3.08	-0.26	-0.53	0.01	Intent-To-Treat Population	adjusted	0.1013	<.0001		
		>=55 letters	179	178	164	-336.99	7.50	177	175	157	-324.80	7.61	-12.19	10.68	-33.22	8.83	-0.12	-0.33	0.09	Intent-To-Treat Population	adjusted	0.0987	<.0001		
	Baseline BCVA ETDRS letter score																								
		<=23 letters	34	34	31	-719.08	12.50	36	36	33	-734.35	12.09	15.28	17.40	-19.48	50.03	0.21	-0.26	0.87	Intent-To-Treat Population	adjusted	0.3949	<.0001	0.0659	
		>=24 letters	325	324	298	-433.70	5.36	323	323	293	-437.37	5.41	-16.53	7.61	-33.48	-1.58	-0.17	-0.33	-0.02	Intent-To-Treat Population	adjusted	0.0261	<.0001		
	Geographic Region																								
		Europe	111	111	97	-452.72	9.07	114	112	103	-444.58	8.94	-8.14	12.74	-33.26	16.98	-0.09	-0.35	0.18	Intent-To-Treat Population	adjusted	0.8812	<.0001	0.4079	
		America	140	139	130	-459.86	6.37	142	142	129	-453.33	6.38	-6.53	9.02	-24.29	11.24	-0.09	-0.32	0.15	Intent-To-Treat Population	adjusted	0.0427	<.0001		
		Asia Pacific (inc. Australia)	108	108	102	-472.85	10.11	103	103	94	-452.76	10.44	-20.09	14.54	-48.78	8.57	-0.19	-0.46	0.08	Intent-To-Treat Population	adjusted	0.1949	0.0005		
	Race/ethnicity																								
		White	236	235	216	-459.03	6.46	249	247	228	-448.61	6.32	-10.43	9.04	-28.20	7.34	-0.10	-0.28	0.07	Intent-To-Treat Population	adjusted	0.2275	<.0001	0.2150	
		Asian	89	89	84	-471.51	9.42	88	88	78	-451.76	9.57	-19.74	13.43	-46.26	6.77	-0.22	-0.51	0.07	Intent-To-Treat Population	adjusted	0.0653	<.0001		
		Other	13	13	13	-479.72	9.01	17	17	15	-506.65	7.89	26.93	12.10	1.99	51.88	0.80	0.07	1.53	Intent-To-Treat Population	adjusted	0.0386	0.0003		
		Unknown	21	21	16	-405.55	12.46	5	5	5	-388.37	25.24	-17.38	28.38	-81.59	46.83	-0.30	-1.24	0.65	Intent-To-Treat Population	adjusted	0.5201	0.5056		
	Baseline RVO status																								
		CRVO	298	297	270	-479.18	5.55	290	288	265	-461.31	5.62	-17.87	7.90	-33.40	-2.34	-0.19	-0.35	-0.02	Intent-To-Treat Population	adjusted	0.0094	<.0001	0.1098	
		HRVO	58	58	56	-366.82	11.70	63	63	57	-375.56	11.29	8.74	16.28	-23.51	40.99	0.10	-0.26	0.45	Intent-To-Treat Population	adjusted	0.4732	<.0001		
		Missing	3	3	3	NE	NE	6	6	4	NE	NE	NE	NE	NE	NE	NE	NE	NE	Intent-To-Treat Population	adjusted	NE	NE		

[1] Patients included in the analysis: with a value at baseline and at least one post-baseline value at the selected visits.
 [2] LSMeans of change from baseline from MMRM (including all available records from all selected visits). Selected visits: every 4 weeks from Week 4 to 24. Early Termination (ET) visit was mapped to closest regular visit.
 [3] Contrasts from MMRM: Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition adjusted for randomization stratification factors. The stratification factor is excluded if the variable is involved in the subgroup.
 Units: microns. Data as observed (no imputation of missing values). Covariance matrix: unstructured. Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09A02022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mrm.sas
 Output: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mrm_adj_PREST_tW24_SBCST_IT_09A02022_41986.xls
 09JUL2024 12:24

POPULATION: Intent-To-Treat Population
ENDPOINT: Center Subfield Thickness ILM-BM in Study Eye over Time through Week 24
STUDY: GR41986



Units: microns.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: ..al_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/g_mean_plot.sas
 Output: ..sis/ACE_CSR_Primary/prod/output/g_mean_plot_PREST_tW24_SBCST_IT_09AUG2022_41986.pdf
 18MAR2024 8:43

POPULATION: Intent-To-Treat Population
 ENDPOINT: Center Subfield Thickness ILM-EM in Study Eye over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=366)						Aflibercept (N=363)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All														
Baseline		n/a	366	100,0	359	98,1	702,21	244,00	363	100,0	359	98,9	721,07	242,86
Week 1		n/a	365	99,7	351	96,2	346,16	88,55	362	99,7	346	95,6	354,84	87,88
Week 4		n/a	365	99,7	355	97,3	292,57	79,79	362	99,7	352	97,2	295,39	71,86
Week 8		n/a	365	99,7	358	98,1	269,39	80,47	360	99,2	348	96,7	275,83	80,65
Week 12		n/a	364	99,5	348	95,6	262,38	86,38	360	99,2	341	94,7	269,48	83,63
Week 16		n/a	364	99,5	346	95,1	260,72	93,27	358	98,6	336	93,9	265,55	74,72
Week 20		n/a	364	99,5	345	94,8	253,93	69,31	355	97,8	330	93,0	263,37	72,67
Week 24		n/a	359	98,1	335	93,3	252,74	84,06	352	97,0	329	93,5	265,14	95,58
Gender														
Baseline		Male	193	100,0	187	96,9	703,99	246,53	200	100,0	198	99,0	727,21	242,69
Week 1		Male	192	99,5	184	95,8	350,74	89,18	200	100,0	187	93,5	352,66	86,04
Week 4		Male	192	99,5	189	98,4	299,53	87,28	200	100,0	193	96,5	298,18	80,06
Week 8		Male	192	99,5	190	99,0	270,68	73,08	198	99,0	190	96,0	281,37	95,92
Week 12		Male	191	99,0	182	95,3	266,69	97,79	198	99,0	186	93,9	278,15	103,15
Week 16		Male	191	99,0	183	95,8	268,89	108,02	196	98,0	186	94,9	271,82	88,45
Week 20		Male	191	99,0	181	94,8	259,25	77,53	194	97,0	180	92,8	265,79	72,12
Week 24		Male	188	97,4	176	93,6	259,70	87,30	193	96,5	178	92,2	273,96	114,03
Baseline		Female	173	100,0	172	99,4	700,28	241,92	163	100,0	161	98,8	713,51	243,62
Week 1		Female	173	100,0	167	96,5	341,11	87,84	162	99,4	159	98,1	357,41	90,21
Week 4		Female	173	100,0	166	96,0	284,64	69,72	162	99,4	159	98,1	292,01	60,51
Week 8		Female	173	100,0	168	97,1	267,93	88,28	162	99,4	158	97,5	269,17	56,73
Week 12		Female	173	100,0	166	96,0	257,64	71,84	162	99,4	155	95,7	259,08	49,61
Week 16		Female	173	100,0	163	94,2	251,55	72,51	162	99,4	150	92,6	257,77	52,24
Week 20		Female	173	100,0	164	94,8	248,06	58,60	161	98,8	150	93,2	260,45	73,47
Week 24		Female	171	98,8	159	93,0	245,04	79,89	159	97,5	151	95,0	254,75	66,58
Age														
Baseline		<65 years	162	100,0	159	98,1	708,68	266,19	158	100,0	155	98,1	762,40	261,73
Week 1		<65 years	161	99,4	156	96,9	351,87	82,33	157	99,4	147	93,6	363,55	95,89
Week 4		<65 years	161	99,4	155	96,3	294,50	77,44	157	99,4	153	97,5	297,87	75,65
Week 8		<65 years	161	99,4	160	99,4	277,34	91,94	155	98,1	150	96,8	277,46	92,20
Week 12		<65 years	161	99,4	149	92,5	267,89	77,50	155	98,1	146	94,2	271,49	79,71
Week 16		<65 years	161	99,4	154	95,7	268,51	91,93	155	98,1	145	93,5	270,11	84,49
Week 20		<65 years	161	99,4	150	93,2	262,97	76,14	154	97,5	142	92,2	268,11	83,02
Week 24		<65 years	160	98,8	147	91,9	260,61	84,92	152	96,2	139	91,4	275,94	115,07
Baseline		>=65 years	204	100,0	200	98,0	697,08	225,36	205	100,0	204	99,5	689,66	223,06
Week 1		>=65 years	204	100,0	195	95,6	341,60	93,19	205	100,0	199	97,1	348,41	81,12
Week 4		>=65 years	204	100,0	200	98,0	291,08	81,72	205	100,0	199	97,1	293,49	68,94
Week 8		>=65 years	204	100,0	198	97,1	262,97	69,42	205	100,0	198	96,6	274,60	70,87
Week 12		>=65 years	203	99,5	199	98,0	258,25	92,46	205	100,0	195	95,1	267,97	86,63
Week 16		>=65 years	203	99,5	192	94,6	254,47	94,10	203	99,0	191	94,1	262,08	66,38
Week 20		>=65 years	203	99,5	195	96,1	246,97	62,87	201	98,0	188	93,5	259,79	63,76
Week 24		>=65 years	199	97,5	188	94,5	246,60	83,08	200	97,6	190	95,0	257,24	77,71
Baseline BCVA ETDRS letter score														
Baseline		35 - 54 letters	106	100,0	104	98,1	763,96	238,10	105	100,0	103	98,1	748,35	217,06
Week 1		35 - 54 letters	106	100,0	101	95,3	348,40	70,10	105	100,0	101	96,2	360,64	91,56
Week 4		35 - 54 letters	106	100,0	102	96,2	285,55	75,08	105	100,0	104	99,0	290,82	60,08
Week 8		35 - 54 letters	106	100,0	104	98,1	257,53	43,51	105	100,0	102	97,1	270,12	89,54
Week 12		35 - 54 letters	106	100,0	104	98,1	258,65	102,02	105	100,0	102	97,1	263,14	97,53
Week 16		35 - 54 letters	106	100,0	99	93,4	248,74	55,13	104	99,0	100	96,2	259,06	60,97
Week 20		35 - 54 letters	106	100,0	101	95,3	254,01	76,77	103	98,1	95	92,2	251,51	33,35
Week 24		35 - 54 letters	106	100,0	100	94,3	244,99	62,20	102	97,1	96	94,1	269,67	119,97
Baseline		<=34 letters	79	100,0	76	96,2	881,76	258,43	80	100,0	79	98,8	926,96	253,23

Week 1	<=34 letters	79	100,0	77	97,5	395,43	127,25	80	100,0	78	97,5	388,90	113,77
Week 4	<=34 letters	79	100,0	78	98,7	311,27	111,85	80	100,0	79	98,8	289,90	61,95
Week 8	<=34 letters	79	100,0	78	98,7	268,83	120,61	80	100,0	76	95,0	253,17	51,67
Week 12	<=34 letters	79	100,0	74	93,7	243,15	61,50	80	100,0	75	93,8	253,68	83,35
Week 16	<=34 letters	79	100,0	75	94,9	248,08	106,31	80	100,0	76	95,0	247,21	82,20
Week 20	<=34 letters	79	100,0	77	97,5	240,83	73,94	80	100,0	75	93,8	246,05	85,46
Week 24	<=34 letters	77	97,5	70	90,9	235,03	75,55	80	100,0	76	95,0	235,47	70,19
Baseline	>=55 letters	181	100,0	179	98,9	590,11	173,67	178	100,0	177	99,4	613,29	181,94
Week 1	>=55 letters	180	99,4	173	96,1	322,93	65,66	177	99,4	167	94,4	335,43	63,67
Week 4	>=55 letters	180	99,4	175	97,2	288,33	62,77	177	99,4	169	95,5	300,78	82,08
Week 8	>=55 letters	180	99,4	176	97,8	276,65	74,55	175	98,3	170	97,1	289,39	83,33
Week 12	>=55 letters	179	98,9	170	95,0	273,02	84,03	175	98,3	164	93,7	280,65	72,64
Week 16	>=55 letters	179	98,9	172	96,1	273,12	103,01	174	97,8	160	92,0	278,31	76,88
Week 20	>=55 letters	179	98,9	167	93,3	259,92	61,53	172	96,6	160	93,0	278,53	80,10
Week 24	>=55 letters	176	97,2	165	93,8	264,96	96,61	170	95,5	157	92,4	276,74	86,59
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	34	97,1	936,26	252,19	36	100,0	36	100,0	958,19	280,91
Week 1	<=23 letters	35	100,0	34	97,1	399,29	133,02	36	100,0	34	94,4	404,09	122,17
Week 4	<=23 letters	35	100,0	35	100,0	317,09	120,48	36	100,0	36	100,0	284,56	53,07
Week 8	<=23 letters	35	100,0	35	100,0	272,20	114,73	36	100,0	35	97,2	247,23	51,26
Week 12	<=23 letters	35	100,0	34	97,1	245,65	79,63	36	100,0	32	88,9	240,63	68,17
Week 16	<=23 letters	35	100,0	34	97,1	243,35	97,55	36	100,0	33	91,7	247,82	116,33
Week 20	<=23 letters	35	100,0	33	94,3	235,24	93,02	36	100,0	35	97,2	224,11	38,36
Week 24	<=23 letters	34	97,1	32	94,1	234,13	95,10	36	100,0	33	91,7	221,67	43,62
Baseline	>=24 letters	331	100,0	325	98,2	677,73	230,12	327	100,0	323	98,8	694,64	223,63
Week 1	>=24 letters	330	99,7	317	96,1	340,46	80,63	326	99,7	312	95,7	349,48	81,80
Week 4	>=24 letters	330	99,7	320	97,0	289,89	73,79	326	99,7	316	96,9	296,63	73,66
Week 8	>=24 letters	330	99,7	323	97,9	269,09	76,08	324	99,1	313	96,6	279,03	82,74
Week 12	>=24 letters	329	99,4	314	95,4	324,19	87,01	324	99,1	309	95,4	272,47	84,61
Week 16	>=24 letters	329	99,4	312	94,8	262,61	92,76	322	98,5	303	94,1	267,48	68,71
Week 20	>=24 letters	329	99,4	312	94,8	255,91	66,20	319	97,6	295	92,5	268,02	74,40
Week 24	>=24 letters	325	98,2	303	93,2	254,71	82,74	316	96,6	296	93,7	269,99	98,57
Geographic Region													
Baseline	Europe	111	100,0	111	100,0	693,60	224,10	114	100,0	114	100,0	716,37	240,17
Week 1	Europe	111	100,0	103	92,8	351,50	97,98	114	100,0	108	94,7	355,81	89,32
Week 4	Europe	111	100,0	107	96,4	305,62	107,61	114	100,0	111	97,4	297,56	67,33
Week 8	Europe	111	100,0	108	97,3	285,83	127,71	112	98,2	108	96,4	277,96	81,66
Week 12	Europe	110	99,1	105	95,5	270,27	99,75	112	98,2	109	97,3	270,15	68,51
Week 16	Europe	110	99,1	104	94,5	272,90	120,39	111	97,4	105	94,6	272,04	71,49
Week 20	Europe	110	99,1	106	96,4	259,75	88,78	110	96,5	104	94,5	265,00	67,56
Week 24	Europe	108	97,3	97	89,8	252,59	94,64	109	95,6	103	94,5	268,19	96,81
Baseline	America	147	100,0	140	95,2	695,77	239,17	146	100,0	142	97,3	725,13	253,17
Week 1	America	146	99,3	143	97,9	350,88	87,76	145	99,3	139	95,9	358,91	87,96
Week 4	America	146	99,3	142	97,3	295,72	73,38	145	99,3	139	95,9	298,43	73,71
Week 8	America	146	99,3	143	97,9	265,64	48,63	145	99,3	139	95,9	274,32	67,57
Week 12	America	146	99,3	137	93,8	255,04	41,07	145	99,3	134	92,4	270,45	97,75
Week 16	America	146	99,3	137	93,8	252,46	56,11	145	99,3	135	93,1	266,87	94,36
Week 20	America	146	99,3	136	93,2	250,42	53,35	143	97,9	135	94,4	267,11	90,02
Week 24	America	143	97,3	136	95,1	254,57	78,65	141	96,6	132	93,6	257,77	63,90
Baseline	Asia Pacific (inc. Australia)	108	100,0	108	100,0	719,42	269,85	103	100,0	103	100,0	720,66	233,38
Week 1	Asia Pacific (inc. Australia)	108	100,0	105	97,2	334,50	79,13	103	100,0	99	96,1	348,08	86,68
Week 4	Asia Pacific (inc. Australia)	108	100,0	106	98,1	275,18	45,28	103	100,0	102	99,0	288,89	74,34
Week 8	Asia Pacific (inc. Australia)	108	100,0	107	99,1	257,80	41,78	103	100,0	101	98,1	275,62	95,54
Week 12	Asia Pacific (inc. Australia)	108	100,0	106	98,1	264,04	111,74	103	100,0	98	95,1	267,42	78,64
Week 16	Asia Pacific (inc. Australia)	108	100,0	105	97,2	259,42	100,74	102	99,0	96	94,1	256,59	37,49
Week 20	Asia Pacific (inc. Australia)	108	100,0	103	95,4	252,58	65,32	102	99,0	91	89,2	255,95	44,01
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	250,46	81,09	102	99,0	94	92,2	272,15	126,69
Race/ethnicity													
Baseline	White	243	100,0	236	97,1	707,57	237,66	253	100,0	249	98,4	719,54	241,41
Week 1	White	242	99,6	233	96,3	349,42	86,95	252	99,6	239	94,8	357,28	84,42
Week 4	White	242	99,6	233	96,3	296,50	82,25	252	99,6	243	96,4	301,20	77,14
Week 8	White	242	99,6	235	97,1	274,01	86,60	250	98,8	240	96,0	277,59	73,84
Week 12	White	241	99,2	229	95,0	266,32	97,73	250	98,8	237	94,8	273,67	90,89
Week 16	White	241	99,2	228	94,6	265,86	107,75	249	98,4	232	93,2	270,85	85,33
Week 20	White	241	99,2	230	95,4	257,40	79,35	246	97,2	232	94,3	267,16	80,03

Week 24	White	238	97,9	222	93,3	256,88	93,40	243	96,0	231	95,1	266,92	95,42
Baseline	Asian	89	100,0	89	100,0	699,06	265,80	88	100,0	88	100,0	732,57	241,22
Week 1	Asian	89	100,0	88	98,9	335,49	84,28	88	100,0	85	96,6	346,00	88,10
Week 4	Asian	89	100,0	88	98,9	275,52	46,68	88	100,0	87	98,9	282,53	60,53
Week 8	Asian	89	100,0	89	100,0	254,99	44,17	88	100,0	86	97,7	277,63	103,61
Week 12	Asian	89	100,0	87	97,8	248,06	34,58	88	100,0	83	94,3	263,46	68,14
Week 16	Asian	89	100,0	87	97,8	243,99	33,80	87	98,9	82	94,3	257,45	41,05
Week 20	Asian	89	100,0	84	94,4	243,25	32,84	87	98,9	79	90,8	258,34	51,43
Week 24	Asian	89	100,0	84	94,4	245,67	68,23	87	98,9	78	89,7	268,23	105,96
Baseline	Other	13	100,0	13	100,0	771,46	304,75	17	100,0	17	100,0	702,71	285,43
Week 1	Other	13	100,0	13	100,0	348,62	69,52	17	100,0	17	100,0	372,00	135,38
Week 4	Other	13	100,0	13	100,0	315,54	111,15	17	100,0	17	100,0	283,06	40,70
Week 8	Other	13	100,0	13	100,0	265,00	37,01	17	100,0	17	100,0	245,94	35,95
Week 12	Other	13	100,0	12	92,3	268,17	47,36	17	100,0	17	100,0	240,94	39,25
Week 16	Other	13	100,0	11	84,6	262,73	35,72	17	100,0	17	100,0	236,47	36,55
Week 20	Other	13	100,0	13	100,0	268,69	64,47	17	100,0	15	88,2	236,00	46,83
Week 24	Other	13	100,0	13	100,0	250,46	37,36	17	100,0	15	88,2	228,40	27,31
Baseline	Unknown	21	100,0	21	100,0	612,52	153,27	5	100,0	5	100,0	657,00	254,29
Week 1	Unknown	21	100,0	17	81,0	354,88	137,02	5	100,0	5	100,0	330,20	42,19
Week 4	Unknown	21	100,0	21	100,0	306,14	123,81	5	100,0	5	100,0	278,80	33,59
Week 8	Unknown	21	100,0	21	100,0	281,48	130,71	5	100,0	5	100,0	262,20	30,44
Week 12	Unknown	21	100,0	20	95,2	276,05	116,66	5	100,0	4	80,0	267,50	26,25
Week 16	Unknown	21	100,0	20	95,2	273,70	107,86	5	100,0	5	100,0	251,00	29,14
Week 20	Unknown	21	100,0	18	85,7	248,72	57,10	5	100,0	4	80,0	245,00	32,81
Week 24	Unknown	19	90,5	16	84,2	234,38	32,13	5	100,0	5	100,0	245,20	29,41
Baseline RVO status													
Baseline	CRVO	302	100,0	298	98,7	713,55	246,19	293	100,0	290	99,0	739,01	243,24
Week 1	CRVO	301	99,7	289	96,0	346,68	86,88	292	99,7	279	95,5	354,48	87,57
Week 4	CRVO	301	99,7	292	97,0	291,16	73,69	292	99,7	283	96,9	297,72	72,74
Week 8	CRVO	301	99,7	295	98,0	268,30	78,33	290	99,0	281	96,9	278,71	83,71
Week 12	CRVO	300	99,3	286	95,3	260,49	82,65	290	99,0	275	94,8	271,50	86,35
Week 16	CRVO	300	99,3	285	95,0	257,49	86,85	289	98,6	274	94,8	268,20	79,96
Week 20	CRVO	300	99,3	283	94,3	249,41	55,76	287	98,0	267	93,0	265,10	76,60
Week 24	CRVO	295	97,7	274	92,9	249,74	77,14	285	97,3	267	93,7	267,23	102,21
Baseline	HRVO	61	100,0	58	95,1	636,45	214,72	64	100,0	63	98,4	627,60	220,47
Week 1	HRVO	61	100,0	59	96,7	346,15	98,44	64	100,0	61	95,3	353,93	89,87
Week 4	HRVO	61	100,0	60	98,4	294,58	96,15	64	100,0	63	98,4	287,59	70,01
Week 8	HRVO	61	100,0	60	98,4	275,43	91,97	64	100,0	61	95,3	267,10	67,06
Week 12	HRVO	61	100,0	59	96,7	271,93	104,32	64	100,0	61	95,3	263,70	73,09
Week 16	HRVO	61	100,0	58	95,1	277,19	121,02	63	98,4	57	90,5	256,84	42,92
Week 20	HRVO	61	100,0	59	96,7	272,81	110,75	62	96,9	57	91,9	259,51	53,45
Week 24	HRVO	61	100,0	58	95,1	267,21	112,16	62	96,9	58	93,5	258,28	59,90
Baseline	Missing	3	100,0	3	100,0	848,00	406,77	6	100,0	6	100,0	835,17	237,21
Week 1	Missing	3	100,0	3	100,0	296,67	22,28	6	100,0	6	100,0	381,00	93,84
Week 4	Missing	3	100,0	3	100,0	389,00	222,64	6	100,0	6	100,0	267,50	36,85
Week 8	Missing	3	100,0	3	100,0	255,67	52,27	6	100,0	6	100,0	229,83	32,47
Week 12	Missing	3	100,0	3	100,0	254,00	48,54	6	100,0	5	83,3	229,00	28,97
Week 16	Missing	3	100,0	3	100,0	248,33	51,60	6	100,0	5	83,3	219,20	34,36
Week 20	Missing	3	100,0	3	100,0	309,00	119,03	6	100,0	6	100,0	222,83	32,69
Week 24	Missing	3	100,0	3	100,0	247,33	44,61	5	83,3	4	80,0	225,25	31,06

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Units: microns.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_SBCST_IT_09AUG2022_41986.xls

18MAR2024 8:33

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Composite Score over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics				Patients		Statistics			
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	276	100,0	80,24	13,74	277	100,0	274	98,9	79,62	14,76
Week 24	n/a	276	100,0	253	91,7	85,90	12,30	275	99,3	246	89,5	86,17	11,94
Gender													
Baseline	Male	143	100,0	143	100,0	81,51	14,00	130	100,0	128	98,5	83,19	12,01
Week 24	Male	143	100,0	133	93,0	87,39	11,14	128	98,5	118	92,2	88,48	9,29
Baseline	Female	133	100,0	133	100,0	78,87	13,37	147	100,0	146	99,3	76,50	16,22
Week 24	Female	133	100,0	120	90,2	84,25	13,32	147	100,0	128	87,1	84,05	13,65
Age													
Baseline	<65 years	133	100,0	133	100,0	80,44	14,11	144	100,0	143	99,3	80,12	14,03
Week 24	<65 years	133	100,0	121	91,0	86,91	10,88	144	100,0	127	88,2	86,90	11,11
Baseline	>=65 years	143	100,0	143	100,0	80,05	13,43	133	100,0	131	98,5	79,08	15,56
Week 24	>=65 years	143	100,0	132	92,3	84,98	13,45	131	98,5	119	90,8	85,40	12,78
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	77,02	15,83	90	100,0	90	100,0	76,53	16,64
Week 24	<=54 letters	89	100,0	83	93,3	85,30	13,49	90	100,0	79	87,8	82,87	13,87
Baseline	>=55 letters	187	100,0	187	100,0	81,77	12,38	187	100,0	184	98,4	81,14	13,54
Week 24	>=55 letters	187	100,0	170	90,9	86,19	11,71	185	98,9	167	90,3	87,74	10,61
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	78,86	13,67	70	100,0	68	97,1	79,05	14,77
Week 24	Europe	82	100,0	79	96,3	83,53	15,30	70	100,0	61	87,1	85,81	12,01
Baseline	America	97	100,0	97	100,0	79,98	14,30	105	100,0	105	100,0	80,66	14,17
Week 24	America	97	100,0	89	91,8	86,50	11,40	104	99,0	97	93,3	87,20	10,93
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	81,66	13,22	102	100,0	101	99,0	78,93	15,43
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	87,48	9,60	101	99,0	88	87,1	85,29	12,97
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	80,18	13,96	172	100,0	170	98,8	80,52	13,90
Week 24	White	172	100,0	161	93,6	85,82	13,38	171	99,4	155	90,6	86,54	11,73
Baseline	Asian	90	100,0	90	100,0	80,68	13,82	94	100,0	93	98,9	78,22	15,66
Week 24	Asian	90	100,0	79	87,8	86,44	9,52	93	98,9	80	86,0	84,91	12,75
Baseline	Other	10	100,0	10	100,0	81,57	8,96	7	100,0	7	100,0	75,83	20,60
Week 24	Other	10	100,0	9	90,0	82,14	16,41	7	100,0	7	100,0	88,48	8,92
Baseline	Unknown	4	100,0	4	100,0	69,30	11,28	4	100,0	4	100,0	80,84	20,66
Week 24	Unknown	4	100,0	4	100,0	87,08	5,48	4	100,0	4	100,0	92,95	5,37

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

POPULATION: Intent-To-Treat Population
 ENDPOINT: Proportion of Patients with a >= 15-point Improvement from Baseline in NEI VPG-23 Composite Score at Week 24
 MODEL: Stratified Analysis by Baseline BCVA EDRS Letter score, Geographic region
 STUDY: GR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Base	Level	Par (104) (N=216)				All (99) (N=217)				Odds Ratio		Par (104) vs. All (99)						All (99) vs. Par (104)										
		Patients		Patients with Event		Patients		Patients with Event		OR	95% CI	Absolute Risk Difference		Relative Risk		Relative Risk		p-value (Cochran-Mantel-Haenszel)	Interaction Test p-value (likelihood)	Relative Risk	Relative Risk							
		n	k	n	k	n	k	n	k			Lower CI	Upper CI	Lower CI	Upper CI	Lower CI	Upper CI				Lower CI	Upper CI						
Site	Site	153	11	11	11	244	81	16	149	1.00	Convergence criterion (GCONV=1E-8) satisfied.	0.65	0.73	-0.082	Algorithm converged.	-0.04	0.061	1.00	Algorithm converged.	0.70	0.61	0.816	0.14	Algorithm converged.	0.92	1.42		
Gender	Male	113	48.2	20	16.5	113	42.3	11	9.4	1.80	Convergence criterion (GCONV=1E-8) satisfied.	0.81	1.89	0.044	Algorithm converged.	-0.030	0.130	0.70	Algorithm converged.	0.89	1.44	0.130	0.048	0.57	Algorithm converged.	0.99	1.15	
	Female	100	43.3	11	15.2	100	45.8	25	19.7	0.48	Convergence criterion (GCONV=1E-8) satisfied.	0.35	0.34	-0.083	Algorithm converged.	-0.153	0.021	0.70	Algorithm converged.	0.42	0.29	0.878	0.16	Algorithm converged.	0.78	0.38		
Age	<=65 years	121	43.8	21	17.4	121	44.4	16	12.7	1.44	Convergence criterion (GCONV=1E-8) satisfied.	0.71	0.21	0.047	Algorithm converged.	-0.031	0.144	1.33	Algorithm converged.	0.70	0.48	0.374	0.23	Algorithm converged.	0.40	1.12		
	>65 years	112	47.8	18	13.6	118	42.6	20	16.9	0.80	Convergence criterion (GCONV=1E-8) satisfied.	0.40	1.61	-0.044	Algorithm converged.	-0.127	0.040	0.84	Algorithm converged.	0.40	1.53	0.634	0.17	Algorithm converged.	0.65	2.08		
Baseline BCVA EDRS letter score	>=4 letters	81	30.1	20	24.1	79	28.5	12	15.2	1.78	Convergence criterion (GCONV=1E-8) satisfied.	0.81	0.93	0.102	Algorithm converged.	-0.019	0.221	1.60	Algorithm converged.	0.84	1.04	0.1486	0.082	0.43	Algorithm converged.	0.91	1.19	
	<=3 letters	170	61.4	18	11.3	165	59.4	24	14.3	0.78	Convergence criterion (GCONV=1E-8) satisfied.	0.38	1.63	-0.028	Algorithm converged.	-0.097	0.041	0.73	Algorithm converged.	0.44	1.36	0.1843	0.29	Algorithm converged.	0.74	2.24		
Geographic Region	Europe	79	28.5	10	12.7	59	21.0	11	18.1	0.62	Convergence criterion (GCONV=1E-8) satisfied.	0.24	1.54	-0.054	Algorithm converged.	-0.174	0.070	0.65	Algorithm converged.	0.50	1.42	0.4041	0.64	Algorithm converged.	0.71	1.99		
	Asia	89	32.3	14	15.2	81	35.4	13	13.4	1.00	Convergence criterion (GCONV=1E-8) satisfied.	0.24	1.38	0.020	Algorithm converged.	-0.080	0.121	0.45	Algorithm converged.	0.74	0.84	0.9211	0.68	Algorithm converged.	0.85	1.24		
	Asia Pacific (inc. Australia)	85	30.8	13	15.3	88	31.8	12	13.6	1.14	Convergence criterion (GCONV=1E-8) satisfied.	0.50	2.70	0.032	Algorithm converged.	-0.082	0.145	1.12	Algorithm converged.	0.54	2.32	0.7339	0.89	Algorithm converged.	0.43	1.84		
Sex/ethnicity	White	141	58.2	24	17.1	143	55.3	21	13.7	0.98	Convergence criterion (GCONV=1E-8) satisfied.	0.51	1.87	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Other	79	28.4	14	17.0	81	28.8	12	15.1	1.00	Convergence criterion (GCONV=1E-8) satisfied.	0.51	0.71	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Other	9	3.3	1	11.1	1	2.1	2	14.3	1.58	Convergence criterion (GCONV=1E-8) satisfied.	0.04	25.19	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Unknown	4	1.4	2	50.0	4	1.4	2	50.0	NE	Convergence criterion (ABSRCOV=0) satisfied.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (primary failure).
 Clinical cut-off: 06JUL2022

Program: /root/clinical_studies/205867461/CDT30303/GR4194/data_analysis/ACT_BASE/prod/program/t_eff_resp.sas
 Output: /root/clinical_studies/205867461/CDT30303/GR4194/data_analysis/ACT_CD_Primery/prod/output/t_eff_resp_wt_str_PBEST_W4_QACDORRIS_IT_06JUL2022_4194.sls
 10AM2023 9:42

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 General Health subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Paricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics				Patients		Statistics			
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	276	100,0	50,91	21,51	277	100,0	274	98,9	52,83	22,82
Week 24	n/a	276	100,0	253	91,7	54,25	21,58	275	99,3	246	89,5	53,46	21,51
Gender													
Baseline	Male	143	100,0	143	100,0	51,92	21,82	130	100,0	128	98,5	55,86	20,92
Week 24	Male	143	100,0	133	93,0	55,64	21,68	128	98,5	118	92,2	54,87	21,00
Baseline	Female	133	100,0	133	100,0	49,81	21,21	147	100,0	146	99,3	50,17	24,12
Week 24	Female	133	100,0	120	90,2	52,71	21,45	147	100,0	128	87,1	52,15	21,97
Age													
Baseline	<65 years	133	100,0	133	100,0	50,56	21,64	144	100,0	143	99,3	53,85	21,46
Week 24	<65 years	133	100,0	121	91,0	55,37	20,21	144	100,0	127	88,2	55,51	21,11
Baseline	>=65 years	143	100,0	143	100,0	51,22	21,46	133	100,0	131	98,5	51,72	24,26
Week 24	>=65 years	143	100,0	132	92,3	53,22	22,78	131	98,5	119	90,8	51,26	21,80
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	50,84	23,06	90	100,0	90	100,0	49,44	22,48
Week 24	<=54 letters	89	100,0	83	93,3	53,01	21,88	90	100,0	79	87,8	52,53	21,41
Baseline	>=55 letters	187	100,0	187	100,0	50,94	20,80	187	100,0	184	98,4	54,48	22,87
Week 24	>=55 letters	187	100,0	170	90,9	54,85	21,47	185	98,9	167	90,3	53,89	21,60
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	42,68	20,97	70	100,0	68	97,1	43,38	23,11
Week 24	Europe	82	100,0	79	96,3	49,68	22,11	70	100,0	61	87,1	49,18	21,39
Baseline	America	97	100,0	97	100,0	57,47	21,09	105	100,0	105	100,0	61,43	20,52
Week 24	America	97	100,0	89	91,8	59,83	21,19	104	99,0	97	93,3	59,54	21,18
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	51,29	20,21	102	100,0	101	99,0	50,25	21,94
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	52,65	20,42	101	99,0	88	87,1	49,72	20,59
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	50,15	22,54	172	100,0	170	98,8	53,97	22,81
Week 24	White	172	100,0	161	93,6	55,43	22,48	171	99,4	155	90,6	54,52	21,22
Baseline	Asian	90	100,0	90	100,0	51,39	19,96	94	100,0	93	98,9	49,73	22,57
Week 24	Asian	90	100,0	79	87,8	50,95	20,19	93	98,9	80	86,0	49,38	21,41
Baseline	Other	10	100,0	10	100,0	62,50	13,18	7	100,0	7	100,0	64,29	24,40
Week 24	Other	10	100,0	9	90,0	61,11	18,16	7	100,0	7	100,0	67,86	23,78
Baseline	Unknown	4	100,0	4	100,0	43,75	23,94	4	100,0	4	100,0	56,25	23,94
Week 24	Unknown	4	100,0	4	100,0	56,25	12,50	4	100,0	4	100,0	68,75	12,50

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

POPULATION: Intent-To-Treat Population
 ENDPOINT: Proportion of Patients with a >= 15-point Improvement from Baseline in NEI VPG-23 General Health subscale at Week 24
 MODEL: Stratified Analysis by Baseline BCVA Letter score, Geographic region
 STUDY: GR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Base	Level	Patients (N=276)				Allpatients (N=377)				Patients vs. Allpatients																	
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio				Absolute Risk Difference				Relative Risk									
		n	%	n	%	n	%	n	%	Odds Ratio	95% Lower CI	95% Upper CI	Absolute Risk	95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI	95% Upper CI	p-value (Cochran-Mantel-Haenszel)	Interaction Test p-value (likelihood)	Relative Risk	95% Lower CI	95% Upper CI				
Sex	Sex	253	91.7	24	23.2	244	64.1	18	21.8	1.1	Convergence criterion (SCORV=12.8) satisfied	0.43	1.39	0.41	Algorithm converged	-0.010	0.124	1.24	Algorithm converged	0.32	1.04	0.182	0.81	Algorithm converged	0.41	1.03	
Gender	Male	133	48.2	38	29.0	137	42.2	22	18.8	1.70	Convergence criterion (SCORV=12.8) satisfied	0.43	1.31	0.485	Algorithm converged	-0.018	0.188	1.10	Algorithm converged	0.40	1.10	0.0810	0.2165	0.67	Algorithm converged	0.42	1.03
	Female	120	43.5	34	27.0	127	45.8	36	28.3	1.00	Convergence criterion (SCORV=12.8) satisfied	0.39	1.07	0.53	Algorithm converged	-0.001	0.128	1.24	Algorithm converged	0.21	1.04	0.2488	0.36	Algorithm converged	0.43	1.11	
Age	<65 years	122	43.8	40	31.1	124	45.4	32	25.4	1.40	Convergence criterion (SCORV=12.8) satisfied	0.42	1.45	0.405	Algorithm converged	-0.045	0.182	1.18	Algorithm converged	0.41	1.05	0.2145	0.4035	0.78	Algorithm converged	0.41	1.05
	>=65 years	112	47.8	34	25.8	118	42.6	26	22.0	1.21	Convergence criterion (SCORV=12.8) satisfied	0.49	1.21	0.514	Algorithm converged	-0.071	0.140	1.18	Algorithm converged	0.26	1.05	0.4877	0.45	Algorithm converged	0.44	1.12	
Baseline BCVA Letter score	<=4 letters	81	30.1	22	26.5	79	28.5	21	26.6	0.99	Convergence criterion (SCORV=12.8) satisfied	0.50	1.09	0.000	Algorithm converged	-0.117	0.138	0.99	Algorithm converged	0.59	1.07	0.9883	0.3491	1.01	Algorithm converged	0.40	1.08
	>=5 letters	170	61.4	62	36.4	165	58.4	17	22.4	0.50	Convergence criterion (SCORV=12.8) satisfied	0.32	0.48	0.267	Algorithm converged	-0.024	0.160	1.36	Algorithm converged	0.35	1.04	0.1064	0.71	Algorithm converged	0.41	1.05	
Geographic Region	Europe	79	28.5	30	38.0	59	21.0	17	28.0	1.58	Convergence criterion (SCORV=12.8) satisfied	0.45	1.17	0.088	Algorithm converged	-0.088	0.145	1.10	Algorithm converged	0.43	1.02	0.2422	0.5515	0.74	Algorithm converged	0.43	1.03
	Asia Pacific (inc. Australia)	85	30.8	19	22.4	88	31.8	21	23.9	0.90	Convergence criterion (SCORV=12.8) satisfied	0.45	1.03	-0.014	Algorithm converged	-0.141	0.110	0.92	Algorithm converged	0.43	1.04	0.7748	1.09	Algorithm converged	0.43	1.08	
Baseline BCVA Letter score	<=4 letters	101	36.5	34	34.0	103	35.3	36	32.0	1.01	Convergence criterion (SCORV=12.8) satisfied	1.12	1.02	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	>=5 letters	170	61.4	62	36.4	165	58.4	17	22.4	0.78	Convergence criterion (SCORV=12.8) satisfied	0.44	1.08	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Geographic Region	Europe	79	28.5	30	38.0	59	21.0	17	28.0	1.58	Convergence criterion (SCORV=12.8) satisfied	0.45	1.17	0.088	Algorithm converged	-0.088	0.145	1.10	Algorithm converged	0.43	1.02	0.2422	0.5515	0.74	Algorithm converged	0.43	1.03
	Asia Pacific (inc. Australia)	85	30.8	19	22.4	88	31.8	21	23.9	0.90	Convergence criterion (SCORV=12.8) satisfied	0.45	1.03	-0.014	Algorithm converged	-0.141	0.110	0.92	Algorithm converged	0.43	1.04	0.7748	1.09	Algorithm converged	0.43	1.08	
Baseline BCVA Letter score	<=4 letters	101	36.5	34	34.0	103	35.3	36	32.0	1.01	Convergence criterion (SCORV=12.8) satisfied	1.12	1.02	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	>=5 letters	170	61.4	62	36.4	165	58.4	17	22.4	0.78	Convergence criterion (SCORV=12.8) satisfied	0.44	1.08	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Geographic Region	Europe	79	28.5	30	38.0	59	21.0	17	28.0	1.58	Convergence criterion (SCORV=12.8) satisfied	0.45	1.17	0.088	Algorithm converged	-0.088	0.145	1.10	Algorithm converged	0.43	1.02	0.2422	0.5515	0.74	Algorithm converged	0.43	1.03
	Asia Pacific (inc. Australia)	85	30.8	19	22.4	88	31.8	21	23.9	0.90	Convergence criterion (SCORV=12.8) satisfied	0.45	1.03	-0.014	Algorithm converged	-0.141	0.110	0.92	Algorithm converged	0.43	1.04	0.7748	1.09	Algorithm converged	0.43	1.08	
Baseline BCVA Letter score	<=4 letters	101	36.5	34	34.0	103	35.3	36	32.0	1.01	Convergence criterion (SCORV=12.8) satisfied	1.12	1.02	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	>=5 letters	170	61.4	62	36.4	165	58.4	17	22.4	0.78	Convergence criterion (SCORV=12.8) satisfied	0.44	1.08	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Geographic Region	Europe	79	28.5	30	38.0	59	21.0	17	28.0	1.58	Convergence criterion (SCORV=12.8) satisfied	0.45	1.17	0.088	Algorithm converged	-0.088	0.145	1.10	Algorithm converged	0.43	1.02	0.2422	0.5515	0.74	Algorithm converged	0.43	1.03
	Asia Pacific (inc. Australia)	85	30.8	19	22.4	88	31.8	21	23.9	0.90	Convergence criterion (SCORV=12.8) satisfied	0.45	1.03	-0.014	Algorithm converged	-0.141	0.110	0.92	Algorithm converged	0.43	1.04	0.7748	1.09	Algorithm converged	0.43	1.08	
Baseline BCVA Letter score	<=4 letters	101	36.5	34	34.0	103	35.3	36	32.0	1.01	Convergence criterion (SCORV=12.8) satisfied	1.12	1.02	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	>=5 letters	170	61.4	62	36.4	165	58.4	17	22.4	0.78	Convergence criterion (SCORV=12.8) satisfied	0.44	1.08	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Geographic Region	Europe	79	28.5	30	38.0	59	21.0	17	28.0	1.58	Convergence criterion (SCORV=12.8) satisfied	0.45	1.17	0.088	Algorithm converged	-0.088	0.145	1.10	Algorithm converged	0.43	1.02	0.2422	0.5515	0.74	Algorithm converged	0.43	1.03
	Asia Pacific (inc. Australia)	85	30.8	19	22.4	88	31.8	21	23.9	0.90	Convergence criterion (SCORV=12.8) satisfied	0.45	1.03	-0.014	Algorithm converged	-0.141	0.110	0.92	Algorithm converged	0.43	1.04	0.7748	1.09	Algorithm converged	0.43	1.08	
Baseline BCVA Letter score	<=4 letters	101	36.5	34	34.0	103	35.3	36	32.0	1.01	Convergence criterion (SCORV=12.8) satisfied	1.12	1.02	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	>=5 letters	170	61.4	62	36.4	165	58.4	17	22.4	0.78	Convergence criterion (SCORV=12.8) satisfied	0.44	1.08	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Geographic Region	Europe	79	28.5	30	38.0	59	21.0	17	28.0	1.58	Convergence criterion (SCORV=12.8) satisfied	0.45	1.17	0.088	Algorithm converged	-0.088	0.145	1.10	Algorithm converged	0.43	1.02	0.2422	0.5515	0.74	Algorithm converged	0.43	1.03
	Asia Pacific (inc. Australia)	85	30.8	19	22.4	88	31.8	21	23.9	0.90	Convergence criterion (SCORV=12.8) satisfied	0.45	1.03	-0.014	Algorithm converged	-0.141	0.110	0.92	Algorithm converged	0.43	1.04	0.7748	1.09	Algorithm converged	0.43	1.08	
Baseline BCVA Letter score	<=4 letters	101	36.5	34	34.0	103	35.3	36	32.0	1.01	Convergence criterion (SCORV=12.8) satisfied	1.12	1.02	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	>=5 letters	170	61.4	62	36.4	165	58.4	17	22.4	0.78	Convergence criterion (SCORV=12.8) satisfied	0.44	1.08	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Geographic Region	Europe	79	28.5	30	38.0	59	21.0	17	28.0	1.58	Convergence criterion (SCORV=12.8) satisfied	0.45	1.17	0.088	Algorithm converged	-0.088	0.145	1.10	Algorithm converged	0.43	1.02	0.2422	0.5515	0.74	Algorithm converged	0.43	1.03
	Asia Pacific (inc. Australia)	85	30.8	19	22.4	88	31.8	21	23.9	0.90	Convergence criterion (SCORV=12.8) satisfied	0.45	1.03	-0.014	Algorithm converged	-0.141	0.110	0.92	Algorithm converged	0.43	1.04	0.7748	1.09	Algorithm converged	0.43	1.08	
Baseline BCVA Letter score	<=4 letters	101	36.5	34	34.0	103	35.3	36	32.0	1.01	Convergence criterion (SCORV=12.8) satisfied	1.12	1.02	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	>=5 letters	170	61.4	62	36.4	165	58.4	17	22.4	0.78	Convergence criterion (SCORV=12.8) satisfied	0.44	1.08	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Geographic Region	Europe	79	28.5	30	38.0	59	21.0	17	28.0	1.58	Convergence criterion (SCORV=12.8) satisfied	0.45	1.17	0.088	Algorithm converged	-0.088	0.145	1.10	Algorithm converged	0.43	1.02	0.2422	0.5515	0.74	Algorithm converged	0.43	1.03
	Asia Pacific (inc. Australia)	85	30.8	19	22.4	88	31.8	21	23.9	0.90	Convergence criterion (SCORV=12.8) satisfied	0.45	1.03	-0.014	Algorithm converged	-0.141	0.110	0.92	Algorithm converged	0.43	1.04	0.7748	1.09	Algorithm converged	0.43	1.08	
Baseline BCVA Letter score	<=4 letters	101	36.5	34	34.0	103	35.3	36	32.0	1.01	Convergence criterion (SCORV=12.8) satisfied	1.12	1.02	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	>=5 letters	170	61.4	62	36.4	165	58.4	17	22.4	0.78	Convergence criterion (SCORV=12.8) satisfied	0.44	1.08	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Geographic Region	Europe	79	28.5	30	38.0	59	21.0	17	28.0	1.58	Convergence criterion (SCORV=12.8) satisfied	0.45	1.17	0.088	Algorithm converged	-0.088	0.145	1.10	Algorithm converged	0.43	1.02	0.2422	0.5515	0.74	Algorithm converged	0.43	1.03
	Asia Pacific (inc. Australia)	85	30.8	19	22.4	88	31.8	21	23.9	0.90	Convergence criterion (SCORV=12.8) satisfied	0.45	1.03	-0.014	Algorithm converged	-0.141	0.110	0.92	Algorithm converged	0.43	1.04	0.7748	1.09	Algorithm converged	0.43	1.08	
Baseline BCVA Letter score	<=4 letters	101	36.5	34	34.0	103	35.3	36	32.0	1.01	Convergence criterion (SCORV=12.8) satisfied	1.12	1.02	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	>=5 letters	170	61.4	62	36.4	165	58.4	17	22.4	0.78	Convergence criterion (SCORV=12.8) satisfied	0.44	1.08	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Geographic Region	Europe	79	28.5	30	38.0	59	21.0	17	28.0	1.58	Convergence criterion (SCORV=12.8) satisfied	0.45	1.17	0.088	Algorithm converged	-0.088	0.145	1.10	Algorithm converged	0.43	1.02	0.2422	0.5515	0.74	Algorithm converged	0.43	1.03
	Asia Pacific (inc. Australia)	85	30.8	19	22.4	88	31.8	21</																			

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 General Vision subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics		Patients		Statistics		Patients		Statistics	
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	276	100,0	61,30	15,48	277	100,0	274	98,9	61,24	16,33
Week 24	n/a	276	100,0	253	91,7	70,36	14,10	275	99,3	246	89,5	71,06	14,16
Gender													
Baseline	Male	143	100,0	143	100,0	62,38	15,65	130	100,0	128	98,5	62,97	15,49
Week 24	Male	143	100,0	133	93,0	70,83	12,19	128	98,5	118	92,2	71,36	14,20
Baseline	Female	133	100,0	133	100,0	60,15	15,27	147	100,0	146	99,3	59,73	16,94
Week 24	Female	133	100,0	120	90,2	69,83	15,98	147	100,0	128	87,1	70,78	14,18
Age													
Baseline	<65 years	133	100,0	133	100,0	61,20	15,91	144	100,0	143	99,3	60,84	16,25
Week 24	<65 years	133	100,0	121	91,0	71,74	12,29	144	100,0	127	88,2	71,97	13,86
Baseline	>=65 years	143	100,0	143	100,0	61,40	15,13	133	100,0	131	98,5	61,68	16,46
Week 24	>=65 years	143	100,0	132	92,3	69,09	15,50	131	98,5	119	90,8	70,08	14,47
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	60,45	16,78	90	100,0	90	100,0	59,78	16,56
Week 24	<=54 letters	89	100,0	83	93,3	67,71	14,26	90	100,0	79	87,8	68,35	13,81
Baseline	>=55 letters	187	100,0	187	100,0	61,71	14,86	187	100,0	184	98,4	61,96	16,21
Week 24	>=55 letters	187	100,0	170	90,9	71,65	13,88	185	98,9	167	90,3	72,34	14,18
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	59,51	14,73	70	100,0	68	97,1	59,41	16,92
Week 24	Europe	82	100,0	79	96,3	69,11	14,25	70	100,0	61	87,1	72,79	13,68
Baseline	America	97	100,0	97	100,0	67,42	16,16	105	100,0	105	100,0	65,52	15,81
Week 24	America	97	100,0	89	91,8	75,28	12,07	104	99,0	97	93,3	73,81	13,34
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	56,70	13,44	102	100,0	101	99,0	58,02	15,62
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	66,35	14,54	101	99,0	88	87,1	66,82	14,51
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	64,07	16,03	172	100,0	170	98,8	63,06	16,14
Week 24	White	172	100,0	161	93,6	72,67	13,91	171	99,4	155	90,6	73,29	12,54
Baseline	Asian	90	100,0	90	100,0	55,56	12,99	94	100,0	93	98,9	57,63	15,84
Week 24	Asian	90	100,0	79	87,8	65,06	13,76	93	98,9	80	86,0	66,00	15,06
Baseline	Other	10	100,0	10	100,0	68,00	13,98	7	100,0	7	100,0	60,00	16,33
Week 24	Other	10	100,0	9	90,0	73,33	10,00	7	100,0	7	100,0	71,43	22,68
Baseline	Unknown	4	100,0	4	100,0	55,00	10,00	4	100,0	4	100,0	70,00	25,82
Week 24	Unknown	4	100,0	4	100,0	75,00	10,00	4	100,0	4	100,0	85,00	10,00

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Ocular Pain subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Paricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics		Patients		Statistics		Patients		Statistics	
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	276	100,0	84,83	19,40	277	100,0	274	98,9	85,36	19,57
Week 24	n/a	276	100,0	253	91,7	86,22	18,32	275	99,3	246	89,5	88,31	16,31
Gender													
Baseline	Male	143	100,0	143	100,0	86,45	19,60	130	100,0	128	98,5	89,26	16,21
Week 24	Male	143	100,0	133	93,0	87,59	16,82	128	98,5	118	92,2	92,16	12,64
Baseline	Female	133	100,0	133	100,0	83,08	19,11	147	100,0	146	99,3	81,93	21,58
Week 24	Female	133	100,0	120	90,2	84,69	19,81	147	100,0	128	87,1	84,77	18,42
Age													
Baseline	<65 years	133	100,0	133	100,0	85,15	19,53	144	100,0	143	99,3	85,75	19,99
Week 24	<65 years	133	100,0	121	91,0	85,95	18,72	144	100,0	127	88,2	89,37	15,11
Baseline	>=65 years	143	100,0	143	100,0	84,53	19,34	133	100,0	131	98,5	84,92	19,16
Week 24	>=65 years	143	100,0	132	92,3	86,46	18,01	131	98,5	119	90,8	87,18	17,49
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	82,02	23,76	90	100,0	90	100,0	82,64	22,70
Week 24	<=54 letters	89	100,0	83	93,3	87,35	18,47	90	100,0	79	87,8	87,18	16,98
Baseline	>=55 letters	187	100,0	187	100,0	86,16	16,85	187	100,0	184	98,4	86,68	17,76
Week 24	>=55 letters	187	100,0	170	90,9	85,66	18,28	185	98,9	167	90,3	88,85	16,00
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	83,54	20,31	70	100,0	68	97,1	81,99	20,42
Week 24	Europe	82	100,0	79	96,3	82,44	19,66	70	100,0	61	87,1	85,45	17,26
Baseline	America	97	100,0	97	100,0	85,18	19,38	105	100,0	105	100,0	86,31	18,71
Week 24	America	97	100,0	89	91,8	88,90	16,58	104	99,0	97	93,3	89,30	15,31
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	85,57	18,78	102	100,0	101	99,0	86,63	19,78
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	86,91	18,39	101	99,0	88	87,1	89,20	16,65
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	84,30	19,75	172	100,0	170	98,8	85,22	18,63
Week 24	White	172	100,0	161	93,6	86,65	18,17	171	99,4	155	90,6	87,42	16,64
Baseline	Asian	90	100,0	90	100,0	86,11	18,87	94	100,0	93	98,9	85,08	21,36
Week 24	Asian	90	100,0	79	87,8	86,87	17,78	93	98,9	80	86,0	89,22	16,37
Baseline	Other	10	100,0	10	100,0	78,75	20,45	7	100,0	7	100,0	92,86	9,83
Week 24	Other	10	100,0	9	90,0	70,83	21,65	7	100,0	7	100,0	92,86	9,83
Baseline	Unknown	4	100,0	4	100,0	93,75	12,50	4	100,0	4	100,0	84,38	31,25
Week 24	Unknown	4	100,0	4	100,0	90,63	18,75	4	100,0	4	100,0	96,88	6,25

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_QSBOP_IT_06JUL2022_41984.xls
 03JUN2024 17:16

POPULATION: Intent-To-Treat Population
 ENDPOINT: Proportion of Patients with a >= 15-point Improvement from Baseline in NEZ VPG-23 Ocular Pain subscale at Week 24
 MODEL: Stratified Analysis by Baseline BCVA EDRS Letter score, Geographic region
 STUDY: GR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Base	Level	Patients (N=216)				Allpatients (N=217)				Odds Ratio	Patients vs. Allpatients																
		Patients with Event		Patients with Event		Patients with Event		Patients with Event			Odds Ratio					Relative Risk											
		n	%	n	%	n	%	n	%		95% Lower CI	95% Upper CI	Absolute Risk	Convergence Reason	95% Lower CI	95% Upper CI	Relative Risk	Convergence Reason	95% Lower CI	95% Upper CI	p-value (Cochran-Mantel-Haenszel)	Interaction Test p-value (likelihood)	Relative Risk	Convergence Reason	95% Lower CI	95% Upper CI	
Sex	Sex	253	91.7	17	14.4	244	89.1	16	14.8	0.98	Convergence criterion (SCRMV+12-E) satisfied	0.93	1.41	<0.001	Algorithm converged	-0.064	0.982	0.98	Algorithm converged	0.64	1.41	0.977			0.61	1.14	
Gender	Male	113	48.2	18	12.0	113	42.2	17	14.0	0.85	Convergence criterion (SCRMV+12-E) satisfied	0.89	1.65	<0.001	Algorithm converged	-0.114	0.076	0.81	Algorithm converged	0.43	1.51	0.440	0.4167	1.23	Algorithm converged	0.43	2.12
	Female	120	43.3	21	17.5	127	45.8	19	15.0	1.15	Convergence criterion (SCRMV+12-E) satisfied	0.98	2.04	0.002	Algorithm converged	-0.091	0.114	0.98	Algorithm converged	0.60	2.04	0.645			0.60	1.22	
Age	<65 years	122	43.8	20	16.0	124	44.4	20	16.4	1.03	Convergence criterion (SCRMV+12-E) satisfied	0.92	2.02	0.004	Algorithm converged	-0.044	0.024	1.02	Algorithm converged	0.58	1.70	0.445	0.8218	0.98	Algorithm converged	0.58	1.33
	>=65 years	112	47.8	17	12.9	118	42.6	16	13.4	0.96	Convergence criterion (SCRMV+12-E) satisfied	0.46	1.98	<0.001	Algorithm converged	-0.105	0.076	0.96	Algorithm converged	0.61	1.83	0.6021			0.61	1.94	
Baseline BCVA EDRS letter score	>=54 letters	81	30.1	15	18.1	79	28.5	14	17.7	1.02	Convergence criterion (SCRMV+12-E) satisfied	0.46	2.25	0.007	Algorithm converged	-0.112	0.127	1.01	Algorithm converged	0.52	1.94	0.7613	0.9250	0.99	Algorithm converged	0.51	1.21
	<=53 letters	120	43.4	22	12.9	145	58.4	22	13.3	0.80	Convergence criterion (SCRMV+12-E) satisfied	0.90	1.78	<0.001	Algorithm converged	-0.084	0.068	0.94	Algorithm converged	0.50	1.87	0.8718	1.04	1.04	Algorithm converged	0.50	1.10
Geographic Region	Europe	79	28.5	12	15.2	59	21.0	8	11.4	1.13	Convergence criterion (SCRMV+12-E) satisfied	0.43	2.93	0.001	Algorithm converged	-0.101	0.143	1.11	Algorithm converged	0.48	2.55	0.780	0.1073	0.93	Algorithm converged	0.48	2.57
	Asia Pacific (inc. Australia)	85	30.8	9	10.6	88	31.8	17	19.3	0.48	Convergence criterion (SCRMV+12-E) satisfied	0.20	1.15	<0.001	Algorithm converged	-0.208	-0.055	0.55	Algorithm converged	0.28	1.15	0.0993			0.47	3.47	
Smoker/Smoker	Smoker	161	58.3	24	14.1	163	55.3	23	13.1	1.24	Convergence criterion (SCRMV+12-E) satisfied	0.65	3.11	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	Non-smoker	79	28.4	11	11.4	81	28.8	14	12.4	0.91	Convergence criterion (SCRMV+12-E) satisfied	0.43	1.98	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
	Unknown	4	1.4	0	0.0	4	1.4	1	25.0	NS	Convergence criterion (ABSOROV+1) satisfied	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and RD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (primary endpoint).
 Clinical cut-off: 0.625/2.022

Program: /root/clinical_studies/202407461/CDT30303/GR4194/data_analysis/ACT_BASE/prod/program/t_eff_resp.exe
 Output: /root/clinical_studies/202407461/CDT30303/GR4194/data_analysis/ACT_CD_Primery/prod/output/t_eff_resp_exe_str_PREST_W4_QBR015_IT_06JUL2022_4194.xlsx
 15AUG2023 10:10

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Near Activities Subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics		Patients		Statistics		Patients		Statistics	
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	276	100,0	75,69	19,85	277	100,0	274	98,9	73,27	21,35
Week 24	n/a	276	100,0	253	91,7	82,91	17,66	275	99,3	246	89,5	82,57	18,33
Gender													
Baseline	Male	143	100,0	143	100,0	76,63	21,06	130	100,0	128	98,5	74,71	20,41
Week 24	Male	143	100,0	133	93,0	84,30	16,86	128	98,5	118	92,2	84,46	17,22
Baseline	Female	133	100,0	133	100,0	74,69	18,48	147	100,0	146	99,3	72,00	22,13
Week 24	Female	133	100,0	120	90,2	81,35	18,44	147	100,0	128	87,1	80,83	19,21
Age													
Baseline	<65 years	133	100,0	133	100,0	76,47	21,11	144	100,0	143	99,3	72,79	21,95
Week 24	<65 years	133	100,0	121	91,0	84,19	16,46	144	100,0	127	88,2	83,56	17,38
Baseline	>=65 years	143	100,0	143	100,0	74,97	18,64	133	100,0	131	98,5	73,79	20,75
Week 24	>=65 years	143	100,0	132	92,3	81,72	18,67	131	98,5	119	90,8	81,51	19,31
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	72,85	20,59	90	100,0	90	100,0	71,94	22,13
Week 24	<=54 letters	89	100,0	83	93,3	83,18	20,38	90	100,0	79	87,8	79,59	20,64
Baseline	>=55 letters	187	100,0	187	100,0	77,05	19,39	187	100,0	184	98,4	73,91	20,99
Week 24	>=55 letters	187	100,0	170	90,9	82,77	16,23	185	98,9	167	90,3	83,98	17,02
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	73,98	21,01	70	100,0	68	97,1	73,53	21,50
Week 24	Europe	82	100,0	79	96,3	80,06	20,34	70	100,0	61	87,1	80,33	20,92
Baseline	America	97	100,0	97	100,0	72,98	20,70	105	100,0	105	100,0	72,14	21,62
Week 24	America	97	100,0	89	91,8	80,06	18,31	104	99,0	97	93,3	82,77	18,10
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	79,85	17,31	102	100,0	101	99,0	74,26	21,13
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	88,53	12,32	101	99,0	88	87,1	83,90	16,67
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	74,06	20,67	172	100,0	170	98,8	73,19	20,86
Week 24	White	172	100,0	161	93,6	81,08	19,28	171	99,4	155	90,6	82,10	19,03
Baseline	Asian	90	100,0	90	100,0	79,21	18,47	94	100,0	93	98,9	74,01	21,88
Week 24	Asian	90	100,0	79	87,8	87,39	13,06	93	98,9	80	86,0	83,59	17,32
Baseline	Other	10	100,0	10	100,0	75,00	11,79	7	100,0	7	100,0	64,29	26,23
Week 24	Other	10	100,0	9	90,0	78,70	18,69	7	100,0	7	100,0	77,38	19,07
Baseline	Unknown	4	100,0	4	100,0	68,75	24,88	4	100,0	4	100,0	75,00	26,35
Week 24	Unknown	4	100,0	4	100,0	77,08	14,23	4	100,0	4	100,0	89,58	7,98

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_QSBN_IT_06JUL2022_41984.xls
 03JUN2024 17:05

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Distance Activities Subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Paricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics		Patients		Statistics		Patients		Statistics	
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	276	100,0	81,46	18,77	277	100,0	274	98,9	80,38	20,45
Week 24	n/a	276	100,0	253	91,7	87,99	16,67	275	99,3	246	89,5	87,48	15,92
Gender													
Baseline	Male	143	100,0	143	100,0	83,89	17,97	130	100,0	128	98,5	84,93	16,90
Week 24	Male	143	100,0	133	93,0	90,91	13,13	128	98,5	118	92,2	91,24	12,69
Baseline	Female	133	100,0	133	100,0	78,85	19,32	147	100,0	146	99,3	76,40	22,43
Week 24	Female	133	100,0	120	90,2	84,76	19,42	147	100,0	128	87,1	84,02	17,75
Age													
Baseline	<65 years	133	100,0	133	100,0	83,58	17,20	144	100,0	143	99,3	82,84	19,09
Week 24	<65 years	133	100,0	121	91,0	89,98	14,27	144	100,0	127	88,2	89,80	14,22
Baseline	>=65 years	143	100,0	143	100,0	79,49	19,98	133	100,0	131	98,5	77,70	21,59
Week 24	>=65 years	143	100,0	132	92,3	86,17	18,47	131	98,5	119	90,8	85,01	17,27
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	78,56	20,20	90	100,0	90	100,0	76,71	24,01
Week 24	<=54 letters	89	100,0	83	93,3	88,55	17,26	90	100,0	79	87,8	85,50	18,46
Baseline	>=55 letters	187	100,0	187	100,0	82,84	17,94	187	100,0	184	98,4	82,18	18,26
Week 24	>=55 letters	187	100,0	170	90,9	87,72	16,42	185	98,9	167	90,3	88,42	14,52
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	80,28	21,52	70	100,0	68	97,1	80,39	20,53
Week 24	Europe	82	100,0	79	96,3	84,97	20,34	70	100,0	61	87,1	86,00	15,76
Baseline	America	97	100,0	97	100,0	77,96	19,49	105	100,0	105	100,0	80,00	21,69
Week 24	America	97	100,0	89	91,8	86,89	17,49	104	99,0	97	93,3	87,63	16,27
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	85,95	14,31	102	100,0	101	99,0	80,78	19,22
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	91,96	10,16	101	99,0	88	87,1	88,35	15,75
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	80,11	20,20	172	100,0	170	98,8	80,42	20,84
Week 24	White	172	100,0	161	93,6	86,67	18,94	171	99,4	155	90,6	86,85	16,33
Baseline	Asian	90	100,0	90	100,0	85,23	14,50	94	100,0	93	98,9	80,56	19,41
Week 24	Asian	90	100,0	79	87,8	91,03	10,82	93	98,9	80	86,0	88,28	15,24
Baseline	Other	10	100,0	10	100,0	77,08	17,49	7	100,0	7	100,0	77,98	26,65
Week 24	Other	10	100,0	9	90,0	84,26	16,37	7	100,0	7	100,0	89,88	18,30
Baseline	Unknown	4	100,0	4	100,0	65,63	30,88	4	100,0	4	100,0	79,17	24,06
Week 24	Unknown	4	100,0	4	100,0	89,58	7,98	4	100,0	4	100,0	91,67	11,79

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

POPULATION: Intent-To-Treat Population
 ENDPOINT: Proportion of Patients with ≥ 15 -point Improvement from Baseline in NEI VPG-23 Distance Activities Subscale at Week 24
 MODEL: Stratified Analysis by Baseline BCVA ETRS Letter score, Geographic region
 STUDY: GR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Base	Level	Pavlovsk (N=216)				Aflibercept (N=217)				Pavlovsk vs. Aflibercept																		
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference					Relative Risk								
		n	%	n	%	n	%	n	%	OR	95% Lower CI	95% Upper CI	Absolute Risk	95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI	95% Upper CI	Convergence Reason	Lower CI	Upper CI	p-value (Cochran-Mantel-Haenszel)	Interaction Test p-value (likelihood)	Relative Risk	95% Lower CI	95% Upper CI		
Sex	Sex	113	51.9	61	28.1	244	89.1	44	20.2	0.93	Convergence criterion (GCONV+IR-8) satisfied.	0.62	1.43	-0.008	Algorithm converged.	-0.082	0.064	0.98	Algorithm converged.	0.72	1.23	0.7223		1.04	Algorithm converged.	0.79	1.40	
Gender	Male	113	48.2	33	29.1	113	42.3	27	23.1	1.05	Convergence criterion (GCONV+IR-8) satisfied.	0.59	1.89	0.005	Algorithm converged.	-0.105	0.104	0.98	Algorithm converged.	0.68	1.48	0.4641	0.5251	0.94	Algorithm converged.	0.60	1.44	
	Female	100	45.8	31	29.8	100	45.8	37	37.1	0.83	Convergence criterion (GCONV+IR-8) satisfied.	0.48	1.50	-0.008	Algorithm converged.	-0.113	0.101	0.88	Algorithm converged.	0.60	1.30	0.5878		1.14	Algorithm converged.	0.77	1.07	
Age	<65 years	122	43.8	28	23.1	122	44.4	30	24.6	0.86	Convergence criterion (GCONV+IR-8) satisfied.	0.41	1.22	-0.012	Algorithm converged.	-0.118	0.084	0.97	Algorithm converged.	0.62	1.42	0.4842	0.2122	1.03	Algorithm converged.	0.66	1.42	
	≥65 years	112	47.8	33	29.5	118	42.6	34	28.8	0.91	Convergence criterion (GCONV+IR-8) satisfied.	0.51	1.63	0.029	Algorithm converged.	-0.077	0.110	0.97	Algorithm converged.	0.67	1.41	0.7615		1.03	Algorithm converged.	0.71	1.50	
Baseline BCVA ETRS letter score	≥54 letters	81	30.1	29	34.9	79	28.5	29	36.7	0.92	Convergence criterion (GCONV+IR-8) satisfied.	0.48	1.76	-0.029	Algorithm converged.	-0.174	0.110	0.98	Algorithm converged.	0.65	1.47	0.7989	0.8835	1.02	Algorithm converged.	0.68	1.51	
	<54 letters	130	61.4	34	26.0	140	59.6	15	11.0	0.94	Convergence criterion (GCONV+IR-8) satisfied.	0.55	1.53	-0.006	Algorithm converged.	-0.093	0.081	0.84	Algorithm converged.	0.62	1.43	0.6088		1.04	Algorithm converged.	0.70	1.45	
Geographic Region	Europe	79	28.0	18	17.7	59	21.0	15	25.4	0.82	Convergence criterion (GCONV+IR-8) satisfied.	0.27	1.41	-0.049	Algorithm converged.	-0.010	0.073	0.84	Algorithm converged.	0.44	1.27	0.4534	0.2611	1.01	Algorithm converged.	0.79	2.00	
	Asia	89	32.0	28	31.5	89	35.0	25	28.0	1.03	Convergence criterion (GCONV+IR-8) satisfied.	0.58	1.43	0.041	Algorithm converged.	-0.086	0.171	1.22	Algorithm converged.	0.74	1.31	0.5778		0.84	Algorithm converged.	0.82	1.28	
	Asia Pacific (inc. Australia)	85	30.8	21	24.7	89	31.8	23	26.1	0.87	Convergence criterion (GCONV+IR-8) satisfied.	0.43	1.74	-0.032	Algorithm converged.	-0.156	0.092	0.92	Algorithm converged.	0.56	1.51	0.6877		1.09	Algorithm converged.	0.68	1.78	
Sex*Geographic Region	Male	113	58.0	38	34.0	103	35.0	38	34.0	0.94	Convergence criterion (GCONV+IR-8) satisfied.	0.50	1.58	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Female	79	28.0	18	24.0	80	28.0	22	27.0	0.97	Convergence criterion (GCONV+IR-8) satisfied.	0.40	1.59	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Other	3	1.3	1	33.3	2	66.7	2	66.7	0.57	Convergence criterion (GCONV+IR-8) satisfied.	0.01	0.57	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Unknown	4	1.8	3	50.0	4	100.0	2	50.0	NE	Convergence criterion (ABSIGNV+0) satisfied.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (primary failure).
 Clinical cut-off: 0.62UL2022

Program: /root/clinical_studies/202867461/CDT30303/GR4194/data_analysis/ACT_BASE/prod/program/t_eff_resp.sas
 Output: /root/clinical_studies/202867461/CDT30303/GR4194/data_analysis/ACT_CD_Primery/prod/output/t_eff_resp_wg_str_PREST_W4_QBRDA15_IT_06JUL2022_4194.xls
 15AUG2023 9:48

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Vision Specific Social Functioning subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics				Patients		Statistics			
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	275	99,6	92,09	12,86	277	100,0	273	98,6	91,67	14,90
Week 24	n/a	276	100,0	251	90,9	94,42	12,20	275	99,3	246	89,5	95,33	10,52
Gender													
Baseline	Male	143	100,0	142	99,3	93,05	12,85	130	100,0	127	97,7	94,39	12,67
Week 24	Male	143	100,0	132	92,3	96,12	9,78	128	98,5	118	92,2	96,93	8,48
Baseline	Female	133	100,0	133	100,0	91,07	12,83	147	100,0	146	99,3	89,30	16,28
Week 24	Female	133	100,0	119	89,5	92,54	14,22	147	100,0	128	87,1	93,85	11,95
Age													
Baseline	<65 years	133	100,0	132	99,2	92,90	12,57	144	100,0	142	98,6	92,87	13,10
Week 24	<65 years	133	100,0	120	90,2	95,52	10,72	144	100,0	127	88,2	96,06	9,14
Baseline	>=65 years	143	100,0	143	100,0	91,35	13,12	133	100,0	131	98,5	90,36	16,60
Week 24	>=65 years	143	100,0	131	91,6	93,42	13,37	131	98,5	119	90,8	94,54	11,81
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	88,90	14,77	90	100,0	89	98,9	87,50	19,76
Week 24	<=54 letters	89	100,0	81	91,0	93,52	12,67	90	100,0	79	87,8	93,04	13,24
Baseline	>=55 letters	187	100,0	186	99,5	93,62	11,57	187	100,0	184	98,4	93,68	11,39
Week 24	>=55 letters	187	100,0	170	90,9	94,85	11,98	185	98,9	167	90,3	96,41	8,80
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	91,77	14,19	70	100,0	68	97,1	91,36	14,20
Week 24	Europe	82	100,0	78	95,1	93,11	14,62	70	100,0	61	87,1	94,47	11,97
Baseline	America	97	100,0	96	99,0	90,10	14,04	105	100,0	104	99,0	92,67	14,43
Week 24	America	97	100,0	88	90,7	93,75	12,85	104	99,0	97	93,3	95,75	9,70
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	94,33	9,89	102	100,0	101	99,0	90,84	15,90
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	96,32	8,37	101	99,0	88	87,1	95,45	10,41
Race/ethnicity													
Baseline	White	172	100,0	171	99,4	91,01	14,24	172	100,0	169	98,3	92,75	13,68
Week 24	White	172	100,0	160	93,0	94,14	13,00	171	99,4	155	90,6	95,08	10,99
Baseline	Asian	90	100,0	90	100,0	93,89	10,13	94	100,0	93	98,9	89,52	16,82
Week 24	Asian	90	100,0	78	86,7	95,03	10,14	93	98,9	80	86,0	95,31	10,21
Baseline	Other	10	100,0	10	100,0	96,25	6,04	7	100,0	7	100,0	91,07	18,70
Week 24	Other	10	100,0	9	90,0	93,06	16,67	7	100,0	7	100,0	98,21	4,72
Baseline	Unknown	4	100,0	4	100,0	87,50	14,43	4	100,0	4	100,0	96,88	6,25
Week 24	Unknown	4	100,0	4	100,0	96,88	6,25	4	100,0	4	100,0	100,00	0,00

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_QSBSF_IT_06JUL2022_41984.xls
 03JUN2024 17:21

POPULATION: Intent-To-Treat Population
 ENDPOINTS: Proportion of Patients with a >= 15-point Improvement from Baseline in NEI VFG-25 Social Functioning subscale at Week 24
 MODEL: Stratified Analysis by Baseline BCVA ETDRS Letter score, Geographic region
 STUDY: OR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Base	Level	Parimab (N=216)				Allimrecept (N=217)				Parimab vs. Allimrecept																	
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Absolute Risk		Absolute Risk Difference		Relative Risk		Relative Risk		Interaction Test		Relative Risk					
		n	%	n	%	n	%	n	%	OR	Lower CI	Upper CI	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI	p-value (Cochran-Mantel-Haenszel)	p-value (Likelihood)	Relative Risk	Lower CI	Upper CI					
Sex	Sex	250	92.4	27	12.4	243	87.7	20	8.2	1.13	Convergence criterion (GCMV+12-E) satisfied	0.74	2.49	0.413	Algorithm converged.	-0.413	0.972	1.43	Algorithm converged.	0.77	2.14	0.1214	0.75	Algorithm converged.	0.41	1.13	
Gender	Male	111	47.5	11	9.9	116	43.9	8	6.9	1.43	Convergence criterion (GCMV+12-E) satisfied	0.47	3.97	0.624	Algorithm converged.	-0.045	0.498	1.43	Algorithm converged.	0.42	1.13	0.4441	0.8724	0.70	Algorithm converged.	0.30	1.42
	Female	139	53.1	14	11.4	127	45.8	12	9.4	1.29	Convergence criterion (GCMV+12-E) satisfied	0.97	2.93	0.953	Algorithm converged.	0.42	0.96	1.28	Algorithm converged.	0.62	2.01	0.5549	0.78	Algorithm converged.	0.78	1.62	
Age	<65 years	110	43.1	14	12.6	124	44.1	11	8.8	1.43	Convergence criterion (GCMV+12-E) satisfied	0.48	3.10	0.461	Algorithm converged.	-0.045	0.122	1.42	Algorithm converged.	0.48	2.05	0.3845	0.7914	0.71	Algorithm converged.	0.38	1.48
	>=65 years	111	47.5	12	10.2	118	42.6	9	7.4	1.25	Convergence criterion (GCMV+12-E) satisfied	0.50	3.10	0.509	Algorithm converged.	-0.02	0.469	1.28	Algorithm converged.	0.57	2.88	0.6287	0.98	Algorithm converged.	0.35	1.27	
Baseline BCVA ETDRS letter score	>=4 letters	81	29.3	12	14.6	78	28.2	7	9.0	1.77	Convergence criterion (GCMV+12-E) satisfied	0.45	4.74	0.004	Algorithm converged.	-0.045	0.154	1.68	Algorithm converged.	0.70	4.02	0.2540	0.5191	0.40	Algorithm converged.	0.20	1.41
	<=3 letters	169	61.2	14	8.3	165	59.4	13	7.8	1.10	Convergence criterion (GCMV+12-E) satisfied	0.13	2.48	0.268	Algorithm converged.	0.263	0.306	1.44	Algorithm converged.	0.18	2.11	0.7277	0.47	Algorithm converged.	0.41	1.14	
Geographic Region	Europe	78	28.3	14	17.9	59	21.9	4	6.8	1.91	Convergence criterion (GCMV+12-E) satisfied	0.48	4.97	0.021	Algorithm converged.	-0.052	0.189	1.27	Algorithm converged.	0.49	4.10	0.6838	0.8821	0.49	Algorithm converged.	0.24	2.53
	North America	87	31.5	14	15.9	84	30.7	6	7.1	1.29	Convergence criterion (GCMV+12-E) satisfied	1.07	2.94	0.362	Algorithm converged.	0.302	0.187	2.44	Algorithm converged.	1.04	3.19	0.0348	0.18	Algorithm converged.	0.34	2.54	
	Asia Pacific (inc. Australia)	85	30.8	4	4.7	89	31.8	10	11.4	0.60	Convergence criterion (GCMV+12-E) satisfied	0.21	1.71	-0.243	Algorithm converged.	-0.129	0.483	0.62	Algorithm converged.	0.24	1.64	0.3335	1.41	Algorithm converged.	0.61	4.24	
Smoking status	Smoker	159	57.6	21	13.2	152	54.9	16	10.5	1.11	Convergence criterion (GCMV+12-E) satisfied	0.20	4.46	NR	NR	NR	NR	NR	NR	NR	NR	NR	0.0931	0.0938	NR	NR	NR
	Non-smoker	78	28.3	5	6.4	81	29.1	4	4.9	0.92	Convergence criterion (GCMV+12-E) satisfied	0.41	1.64	NR	NR	NR	NR	NR	NR	NR	NR	NR	0.5271	NR	NR	NR	NR
	Other	3	1.1	1	12.5	1	3.7	1	14.3	0.20	Convergence criterion (GCMV+12-E) satisfied	0.10	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Unknown	4	1.4	1	25.0	4	1.4	0	0.0	NR	Convergence criterion (ABSOROV+1) satisfied	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

Test for interaction based on RR (log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Endpoint).
 Clinical cut-off: 06JUL2022

Program: /root/clinical_studies/202407461/CDF30303/OR4194/data_analysis/ACT_BASE/prod/program/t_eff_resp.sas
 Output: /root/clinical_studies/202407461/CDF30303/OR4194/data_analysis/ACT_CDR_Primary/prod/output/t_eff_resp_sas_str_PREST_W4_QBRP15_IT_06JUL2022_4194.sls
 15AUG2023 10:20

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Vision Specific Mental Health subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Paricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics		Patients		Statistics		Patients		Statistics	
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	276	100,0	69,50	22,87	277	100,0	274	98,9	69,02	21,96
Week 24	n/a	276	100,0	253	91,7	79,22	19,43	275	99,3	246	89,5	79,62	18,24
Gender													
Baseline	Male	143	100,0	143	100,0	70,80	22,70	130	100,0	128	98,5	73,68	19,01
Week 24	Male	143	100,0	133	93,0	80,78	18,20	128	98,5	118	92,2	82,10	15,78
Baseline	Female	133	100,0	133	100,0	68,09	23,04	147	100,0	146	99,3	64,94	23,57
Week 24	Female	133	100,0	120	90,2	77,50	20,65	147	100,0	128	87,1	77,34	20,04
Age													
Baseline	<65 years	133	100,0	133	100,0	67,58	24,75	144	100,0	143	99,3	67,79	20,60
Week 24	<65 years	133	100,0	121	91,0	79,44	18,79	144	100,0	127	88,2	78,40	18,17
Baseline	>=65 years	143	100,0	143	100,0	71,28	20,89	133	100,0	131	98,5	70,37	23,37
Week 24	>=65 years	143	100,0	132	92,3	79,02	20,07	131	98,5	119	90,8	80,93	18,30
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	65,03	24,35	90	100,0	90	100,0	66,11	22,23
Week 24	<=54 letters	89	100,0	83	93,3	76,88	21,04	90	100,0	79	87,8	74,29	21,25
Baseline	>=55 letters	187	100,0	187	100,0	71,62	21,87	187	100,0	184	98,4	70,45	21,75
Week 24	>=55 letters	187	100,0	170	90,9	80,37	18,55	185	98,9	167	90,3	82,15	16,09
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	66,62	22,29	70	100,0	68	97,1	66,45	22,18
Week 24	Europe	82	100,0	79	96,3	76,74	21,95	70	100,0	61	87,1	78,07	18,35
Baseline	America	97	100,0	97	100,0	71,01	22,97	105	100,0	105	100,0	69,05	20,65
Week 24	America	97	100,0	89	91,8	80,06	19,49	104	99,0	97	93,3	80,67	17,35
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	70,43	23,25	102	100,0	101	99,0	70,73	23,17
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	80,66	16,69	101	99,0	88	87,1	79,55	19,23
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	69,88	22,75	172	100,0	170	98,8	68,42	20,80
Week 24	White	172	100,0	161	93,6	79,35	20,49	171	99,4	155	90,6	80,20	17,70
Baseline	Asian	90	100,0	90	100,0	68,68	24,04	94	100,0	93	98,9	70,16	23,66
Week 24	Asian	90	100,0	79	87,8	79,43	16,66	93	98,9	80	86,0	78,44	19,61
Baseline	Other	10	100,0	10	100,0	74,38	12,99	7	100,0	7	100,0	67,86	24,85
Week 24	Other	10	100,0	9	90,0	73,61	27,02	7	100,0	7	100,0	77,68	17,99
Baseline	Unknown	4	100,0	4	100,0	59,38	23,11	4	100,0	4	100,0	70,31	32,43
Week 24	Unknown	4	100,0	4	100,0	82,81	5,98	4	100,0	4	100,0	84,38	14,88

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

POPULATION: Intent-To-Treat Population
 ENDPOINT: Proportion of Patients with a >= 15-point Improvement from Baseline in NEI VPG-25 Mental Health subscale at Week 24
 MODEL: Stratified Analysis by Baseline BOVA ETRS Letter score, Geographic region
 STUDY: GR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Base	Level	Pavlovsk (N=276)				Aflibercept (N=277)				Pavlovsk vs. Aflibercept												
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Absolute Risk Difference			Relative Risk			INTERACTION TEST		Relative Risk		
		n	%	n	%	n	%	n	%	Lower CI	Upper CI	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI	p-value (Cochran-Mantel-Haenszel)	p-value (likelihood)	Relative Risk	Lower CI	Upper CI	
Sex	Sex	253	91.7	62	11.4	244	88.1	82	13.4	0.92	0.61	1.33	-0.23	0.14	0.92	0.71	1.21	0.4871	1.07	0.81	1.37	
Gender	Male	133	48.2	40	10.1	133	48.2	33	8.2	1.08	0.62	1.87	0.24	0.06	0.92	0.72	1.56	0.7824	0.4219	0.95	0.64	1.39
	Female	120	43.3	22	5.7	111	40.0	49	14.4	0.81	0.48	1.37	-0.25	0.06	0.92	0.21	0.45	0.4545	1.15	0.83	1.52	
Age	<65 years	122	43.8	43	11.4	124	45.1	44	14.4	1.02	0.60	1.70	-0.20	0.03	0.92	0.71	1.44	0.8620	0.5182	0.94	0.70	1.17
	>=65 years	112	40.8	19	5.0	118	42.9	38	12.2	0.82	0.48	1.42	-0.21	0.07	0.92	0.60	1.27	0.4863	1.15	0.83	1.48	
Baseline BOVA ETRS Letter Score	<=4 letters	8	3.0	3	0.8	7	2.5	2	2.6	1.60	0.82	1.15	0.11	0.12	0.92	0.84	2.09	0.1699	0.2656	0.76	0.48	1.19
	>=5 letters	170	61.6	59	16.4	165	59.6	61	17.0	0.79	0.45	1.11	-0.27	0.19	0.92	0.59	1.08	0.1347	1.25	0.93	1.71	
Geographic Region	Europe	79	28.6	31	8.2	79	28.6	23	19.0	1.01	0.51	2.01	0.03	0.01	0.92	0.64	1.54	0.9733	0.8773	0.93	0.65	1.51
	America	89	32.2	26	6.7	87	31.0	32	19.0	0.85	0.46	1.59	-0.28	0.04	0.91	0.59	1.39	0.6145	1.10	0.83	1.70	
	Asia Pacific Inc.	85	30.8	23	6.1	88	31.8	27	19.7	0.87	0.45	1.69	0.01	0.06	0.92	0.54	1.37	0.6789	1.16	0.83	1.84	
	Australia																					
Responsibility	White	161	58.3	54	13.5	161	58.3	55	15.9	0.91	0.57	1.44	NE	NE	NE	NE	NE	0.4330	NE	NE	NE	NE
	Asian	79	28.6	21	5.5	80	28.9	24	10.0	0.88	0.41	1.79	-0.22	0.08	0.92	0.51	1.44	0.1256	1.14	0.83	1.88	
	Other	9	3.3	2	0.5	7	2.5	1	1.4	1.58	0.08	23.28	NE	NE	NE	NE	NE	0.7525	NE	NE	NE	NE
	Unknown	4	1.4	1	0.3	4	1.4	2	50.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value were used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Status).
 Clinical cut-off: 0.625/2022

Program: root/clinical_studies/RO6867461/CDT3030/GR4194/data_analysis/ACK_BASE/prod/program/t_eff_rwp.exe
 Output: root/clinical_studies/RO6867461/CDT3030/GR4194/data_analysis/ACK_CDR_Primary/prod/output/t_eff_rwp_exe_mtr_PRESOT_W4_Q28M15_T1_06JUL2022_41944.xls
 10/06/2023 10:06

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Vision Specific Role Difficulties subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics		Patients		Statistics		Patients		Statistics	
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	276	100,0	75,14	25,19	277	100,0	273	98,6	73,90	27,01
Week 24	n/a	276	100,0	253	91,7	82,02	22,66	275	99,3	246	89,5	82,98	22,60
Gender													
Baseline	Male	143	100,0	143	100,0	74,48	25,52	130	100,0	128	98,5	79,79	24,05
Week 24	Male	143	100,0	133	93,0	83,93	22,17	128	98,5	118	92,2	84,75	21,25
Baseline	Female	133	100,0	133	100,0	75,85	24,91	147	100,0	145	98,6	68,71	28,46
Week 24	Female	133	100,0	120	90,2	79,90	23,11	147	100,0	128	87,1	81,35	23,74
Age													
Baseline	<65 years	133	100,0	133	100,0	74,72	26,89	144	100,0	143	99,3	74,74	26,22
Week 24	<65 years	133	100,0	121	91,0	82,95	22,07	144	100,0	127	88,2	83,17	22,46
Baseline	>=65 years	143	100,0	143	100,0	75,52	23,59	133	100,0	130	97,7	72,98	27,92
Week 24	>=65 years	143	100,0	132	92,3	81,16	23,24	131	98,5	119	90,8	82,77	22,84
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	72,19	27,29	90	100,0	90	100,0	68,06	28,61
Week 24	<=54 letters	89	100,0	83	93,3	81,63	25,40	90	100,0	79	87,8	77,22	25,30
Baseline	>=55 letters	187	100,0	187	100,0	76,54	24,08	187	100,0	183	97,9	76,78	25,78
Week 24	>=55 letters	187	100,0	170	90,9	82,21	21,27	185	98,9	167	90,3	85,70	20,73
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	72,56	23,36	70	100,0	68	97,1	74,08	26,30
Week 24	Europe	82	100,0	79	96,3	79,59	26,03	70	100,0	61	87,1	84,84	19,91
Baseline	America	97	100,0	97	100,0	76,42	26,51	105	100,0	105	100,0	77,50	25,97
Week 24	America	97	100,0	89	91,8	84,55	21,15	104	99,0	97	93,3	87,11	20,92
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	76,03	25,43	102	100,0	100	98,0	70,00	28,26
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	81,62	20,74	101	99,0	88	87,1	77,13	25,02
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	76,53	24,93	172	100,0	170	98,8	77,57	25,90
Week 24	White	172	100,0	161	93,6	83,23	23,56	171	99,4	155	90,6	85,65	20,83
Baseline	Asian	90	100,0	90	100,0	73,06	26,09	94	100,0	92	97,9	67,53	27,92
Week 24	Asian	90	100,0	79	87,8	79,75	20,83	93	98,9	80	86,0	76,25	25,28
Baseline	Other	10	100,0	10	100,0	76,25	18,11	7	100,0	7	100,0	66,07	30,37
Week 24	Other	10	100,0	9	90,0	77,78	25,60	7	100,0	7	100,0	91,07	15,67
Baseline	Unknown	4	100,0	4	100,0	59,38	31,25	4	100,0	4	100,0	78,13	25,77
Week 24	Unknown	4	100,0	4	100,0	87,50	14,43	4	100,0	4	100,0	100,00	0,00

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_QSBRD_IT_06JUL2022_41984.xls
 03JUN2024 17:19

POPULATION: Intent-To-Treat Population
 ENDPOINT: Proportion of Patients with a >= 15-point Improvement from Baseline in NEI VPG-25 Role Difficulties subscale at Week 24
 MODEL: Stratified Analysis by Baseline BCVA ETRS Letter score, Geographic region
 STUDY: GR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Stratification Factor	Level	Paralimab (N=216)				Aflibercept (N=217)				Odds Ratio	Paralimab vs Aflibercept				Aflibercept vs Paralimab														
		Patients		Patients with Event		Patients		Patients with Event			Absolute Risk Difference		Relative Risk		Interaction Test		Relative Risk												
		n	%	n	%	n	%	n	%		Lower CI	Upper CI	Lower CI	Upper CI	p-value (Cochran-Mantel-Haenszel)	p-value (likelihood)	Lower CI	Upper CI											
Sex	Sex	113	51.9	42	27.1	124	57.1	43	33.9	0.88	Convergence criterion (GCONV+IR-8) satisfied.	0.62	0.23	-0.027	Algorithm converged.	-0.104	0.051	0.31	Algorithm converged.	0.63	0.20	0.311	0.0548	0.45	Algorithm converged.	0.81	0.45		
Gender	Male	113	48.2	33	29.3	117	42.2	28	23.9	1.12	Convergence criterion (GCONV+IR-8) satisfied.	0.75	0.31	0.052	Algorithm converged.	-0.039	0.163	1.24	Algorithm converged.	0.82	1.88	0.133	0.0548	0.81	Algorithm converged.	0.51	1.24		
	Female	100	45.8	32	29.0	100	45.0	45	35.7	0.81	Convergence criterion (GCONV+IR-8) satisfied.	0.35	0.28	-0.102	Algorithm converged.	-0.221	0.053	0.75	Algorithm converged.	0.48	0.28	0.293	0.0548	0.45	Algorithm converged.	0.25	0.21		
Age	<65 years	112	43.4	34	29.4	124	45.1	38	30.6	1.00	Convergence criterion (GCONV+IR-8) satisfied.	0.48	0.22	0.000	Algorithm converged.	-0.116	0.118	0.28	Algorithm converged.	0.42	1.43	0.3938	0.0548	0.72	1.43				
	>=65 years	112	47.8	33	29.0	117	42.2	35	29.9	0.78	Convergence criterion (GCONV+IR-8) satisfied.	0.45	1.16	-0.050	Algorithm converged.	-0.161	0.064	0.83	Algorithm converged.	0.55	1.25	0.1855	0.0548	1.20	Algorithm converged.	0.80	1.80		
Baseline BCVA ETRS Letter score	<=4 letters	85	39.1	25	30.1	79	28.5	24	30.4	0.99	Convergence criterion (GCONV+IR-8) satisfied.	0.51	1.93	-0.001	Algorithm converged.	-0.143	0.140	0.99	Algorithm converged.	0.62	1.59	0.2813	0.0548	1.01	Algorithm converged.	0.81	1.60		
	>=5 letters	130	61.4	44	29.9	144	59.2	45	29.9	0.82	Convergence criterion (GCONV+IR-8) satisfied.	0.51	1.33	-0.031	Algorithm converged.	-0.134	0.063	0.84	Algorithm converged.	0.61	1.22	0.4278	0.0548	1.35	Algorithm converged.	0.82	1.63		
Geographic Region	Europe	79	28.5	23	31.6	59	21.0	20	33.9	0.91	Convergence criterion (GCONV+IR-8) satisfied.	0.45	1.84	-0.024	Algorithm converged.	-0.180	0.131	0.94	Algorithm converged.	0.58	1.52	0.2918	0.0548	1.01	Algorithm converged.	0.84	1.74		
	Asia	85	32.3	24	27.9	89	35.0	28	28.9	0.93	Convergence criterion (GCONV+IR-8) satisfied.	0.34	0.76	-0.039	Algorithm converged.	-0.187	0.103	0.95	Algorithm converged.	0.55	1.52	0.1655	0.0548	1.20	Algorithm converged.	0.85	1.65		
	Asia Pacific (inc. Australia)	85	30.8	20	23.5	87	31.4	25	28.7	0.77	Convergence criterion (GCONV+IR-8) satisfied.	0.39	1.53	-0.048	Algorithm converged.	-0.180	0.083	0.82	Algorithm converged.	0.50	1.37	0.4598	0.0548	1.21	Algorithm converged.	0.73	2.01		
Baseline/visit	Baseline	112	58.3	41	26.7	107	55.3	43	28.1	0.74	Convergence criterion (GCONV+IR-8) satisfied.	0.51	1.23	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Baseline	79	28.4	22	27.6	79	28.5	24	30.4	0.87	Convergence criterion (GCONV+IR-8) satisfied.	0.44	0.72	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Other	3	1.3	1	22.2	1	2.1	4	37.1	0.51	Convergence criterion (GCONV+IR-8) satisfied.	0.05	0.23	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Unknown	4	1.4	2	50.0	4	1.4	2	50.0	NE	Convergence criterion (ABSCONV=0) satisfied.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (primary endpoint).
 Clinical cut-off: 06JUL2022

Program: /root/clinical_studies/202867461/CDT30303/GR4194/data_analysis/ACT_BASE/prod/program/t_eff_resp.sas
 Output: /root/clinical_studies/202867461/CDT30303/GR4194/data_analysis/ACT_CD_Primery/prod/output/t_eff_resp_wg_str_PRESST_W4_Q88RD15_IT_06JUL2022_41944.xls
 15AUG2023 10:16

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Vision Specific Dependency subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=276)						Aflibercept (N=277)						
		Patients			Statistics			Patients			Statistics			
Name	Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All														
Baseline		n/a	276	100,0	276	100,0	86,50	23,20	277	100,0	274	98,9	85,31	22,97
Week 24		n/a	276	100,0	253	91,7	91,50	18,05	275	99,3	246	89,5	91,57	17,54
Gender														
Baseline		Male	143	100,0	143	100,0	88,17	21,17	130	100,0	128	98,5	88,87	19,85
Week 24		Male	143	100,0	133	93,0	92,98	16,02	128	98,5	118	92,2	94,49	13,53
Baseline		Female	133	100,0	133	100,0	84,71	25,15	147	100,0	146	99,3	82,19	25,04
Week 24		Female	133	100,0	120	90,2	89,86	20,01	147	100,0	128	87,1	88,87	20,23
Age														
Baseline		<65 years	133	100,0	133	100,0	86,78	24,79	144	100,0	143	99,3	85,26	25,01
Week 24		<65 years	133	100,0	121	91,0	92,91	16,23	144	100,0	127	88,2	92,59	16,24
Baseline		>=65 years	143	100,0	143	100,0	86,25	21,70	133	100,0	131	98,5	85,37	20,60
Week 24		>=65 years	143	100,0	132	92,3	90,21	19,55	131	98,5	119	90,8	90,48	18,83
Baseline BCVA ETDRS letter score														
Baseline		<=54 letters	89	100,0	89	100,0	83,61	24,98	90	100,0	90	100,0	81,02	25,33
Week 24		<=54 letters	89	100,0	83	93,3	90,26	18,44	90	100,0	79	87,8	85,97	21,99
Baseline		>=55 letters	187	100,0	187	100,0	87,88	22,24	187	100,0	184	98,4	87,41	21,48
Week 24		>=55 letters	187	100,0	170	90,9	92,11	17,89	185	98,9	167	90,3	94,21	14,31
Geographic Region														
Baseline		Europe	82	100,0	82	100,0	89,53	18,42	70	100,0	68	97,1	87,01	19,71
Week 24		Europe	82	100,0	79	96,3	91,03	17,44	70	100,0	61	87,1	92,76	17,11
Baseline		America	97	100,0	97	100,0	87,80	20,84	105	100,0	105	100,0	87,54	20,77
Week 24		America	97	100,0	89	91,8	92,51	18,21	104	99,0	97	93,3	92,53	14,56
Baseline		Asia Pacific (inc. Australia)	97	100,0	97	100,0	82,65	28,23	102	100,0	101	99,0	81,85	26,68
Week 24		Asia Pacific (inc. Australia)	97	100,0	85	87,6	90,88	18,62	101	99,0	88	87,1	89,68	20,61
Race/ethnicity														
Baseline		White	172	100,0	172	100,0	89,53	19,34	172	100,0	170	98,8	87,84	20,63
Week 24		White	172	100,0	161	93,6	92,13	17,68	171	99,4	155	90,6	92,74	16,55
Baseline		Asian	90	100,0	90	100,0	80,65	29,16	94	100,0	93	98,9	80,47	26,79
Week 24		Asian	90	100,0	79	87,8	90,40	18,73	93	98,9	80	86,0	88,65	19,81
Baseline		Other	10	100,0	10	100,0	94,17	11,15	7	100,0	7	100,0	86,90	17,91
Week 24		Other	10	100,0	9	90,0	88,89	22,44	7	100,0	7	100,0	94,05	12,47
Baseline		Unknown	4	100,0	4	100,0	68,75	15,77	4	100,0	4	100,0	87,50	15,96
Week 24		Unknown	4	100,0	4	100,0	93,75	12,50	4	100,0	4	100,0	100,00	0,00

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_QSBDP_IT_06JUL2022_41984.xls
 03JUN2024 17:22

POPULATION: Intent-To-Treat Population
 ENDPOINT: Proportion of Patients with a >= 15-point Improvement from Baseline in NEZ YPO-23 Dependency subscale at Week 24
 MODEL: Stratified Analysis by Baseline BCVA ETRS Letter score, Geographic region
 STUDY: OR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Base	Level	Parimab (N=216)				Alliparab (N=217)				Odds Ratio	Parimab vs. Alliparab				Relative Risk				Alliparab vs. Parimab				
		Patients		Patients with Event		Patients		Patients with Event			Odds Ratio		Relative Risk		Relative Risk		Interaction Test		Relative Risk		Relative Risk		
		n	%	n	%	n	%	n	%		95% Lower CI	95% Upper CI	95% Lower CI	95% Upper CI	95% Lower CI	95% Upper CI	p-value (Cochran-Mantel-Haenszel)	p-value (Likelihood)	95% Lower CI	95% Upper CI	95% Lower CI	95% Upper CI	
Sex	Sex	153	71.0	44	18.2	244	89.1	52	21.1	0.81	Convergence criterion (GCMV<12-E) satisfied	0.33	1.29	<0.011	Algorithm converged	0.40	1.29	0.4578		1.18	Algorithm converged	0.81	1.45
Gender	Male	113	48.2	21	10.8	173	42.2	21	19.7	0.70	Convergence criterion (GCMV<12-E) satisfied	0.40	1.45	<0.010	Algorithm converged	0.47	1.38	0.4188	0.6981	1.04	Algorithm converged	0.70	2.13
	Female	120	43.8	23	20.8	177	45.8	29	22.8	0.90	Convergence criterion (GCMV<12-E) satisfied	0.30	1.08	<0.028	Algorithm converged	0.38	1.49	0.7764		1.07	Algorithm converged	0.67	1.32
Age	<65 years	122	43.8	18	15.7	124	44.4	10	23.4	0.41	Convergence criterion (GCMV<12-E) satisfied	0.22	1.15	<0.016	Algorithm converged	0.40	1.11	0.1201	0.1824	1.03	Algorithm converged	0.80	2.38
	>=65 years	112	47.8	27	20.5	118	42.6	22	18.4	1.11	Convergence criterion (GCMV<12-E) satisfied	0.40	2.11	0.513	Algorithm converged	0.47	1.84	0.7084		0.90	Algorithm converged	0.54	1.48
Baseline BCVA ETRS letter score	<=4 letters	81	30.1	17	20.5	79	28.5	16	20.3	1.02	Convergence criterion (GCMV<12-E) satisfied	0.48	2.18	<0.002	Algorithm converged	0.26	1.88	0.3601	0.5111	0.98	Algorithm converged	0.63	1.79
	>=5 letters	170	61.4	27	17.1	165	59.6	16	21.8	0.70	Convergence criterion (GCMV<12-E) satisfied	0.41	1.29	<0.044	Algorithm converged	0.41	1.29	0.2963		1.18	Algorithm converged	0.82	1.85
Geographic Region	Europe	79	28.5	10	10.2	89	21.0	14	21.7	0.51	Convergence criterion (GCMV<12-E) satisfied	0.44	1.33	<0.088	Algorithm converged	0.42	1.22	0.2007	0.4088	1.17	Algorithm converged	0.78	1.43
	North America	85	32.0	14	15.2	81	35.1	18	18.5	1.25	Convergence criterion (GCMV<12-E) satisfied	0.30	2.48	0.027	Algorithm converged	0.48	2.09	0.8521		0.85	Algorithm converged	0.48	1.43
	Asia Pacific (inc. Australia)	85	30.8	15	17.6	88	31.8	20	22.7	0.75	Convergence criterion (GCMV<12-E) satisfied	0.35	1.37	<0.043	Algorithm converged	0.43	1.43	0.4339		1.27	Algorithm converged	0.70	2.32
Sex*Geographic Region	Male	113	58.2	24	16.1	107	35.3	16	19.4	0.70	Convergence criterion (GCMV<12-E) satisfied	0.44	1.49	NS	NS	NS	NS	0.3816	0.9943	NS	NS	NS	NS
	Female	79	28.4	10	10.2	81	28.1	14	21.4	0.88	Convergence criterion (GCMV<12-E) satisfied	0.48	1.69	NS	NS	NS	NS	0.4585	1.21	NS	NS	NS	NS
	Other	0	0.0	0	0.0	0	0.0	0	0.0	1.00	Convergence criterion (GCMV<12-E) satisfied	0.00	0.00	NS	NS	NS	NS	0.7500		NS	NS	NS	NS
	Unknown	4	1.4	3	7.5	4	1.4	2	50.0	NS	Convergence criterion (ABSOROW<1) satisfied	NS	NS	NS	NS	NS	NS	NS		NS	NS	NS	NS

Test for interaction based on RR (log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and RD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Retained).
 Clinical cut-off: 06JUL2022

Program: /root/clinical_studies/202867461/CDT30303/OR4194/data_analysis/ACT_BASE/prod/program/t_eff_resp.sas
 Output: /root/clinical_studies/202867461/CDT30303/OR4194/data_analysis/ACT_CD_Primery/prod/output/t_eff_resp_sas_PREST_W4_Q8RD15_IT_06JUL2022_4194.sas
 15AUG2023 10:24

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Driving subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Paricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics				Patients		Statistics			
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	191	69,2	74,67	26,08	277	100,0	172	62,1	74,54	26,39
Week 24	n/a	276	100,0	170	61,6	82,38	22,40	275	99,3	157	57,1	81,74	21,12
Gender													
Baseline	Male	143	100,0	120	83,9	78,13	24,68	130	100,0	101	77,7	79,70	21,90
Week 24	Male	143	100,0	109	76,2	84,71	21,94	128	98,5	99	77,3	85,27	17,97
Baseline	Female	133	100,0	71	53,4	68,84	27,50	147	100,0	71	48,3	67,19	30,39
Week 24	Female	133	100,0	61	45,9	78,21	22,80	147	100,0	58	39,5	75,72	24,65
Age													
Baseline	<65 years	133	100,0	107	80,5	74,96	26,51	144	100,0	103	71,5	74,76	26,39
Week 24	<65 years	133	100,0	93	69,9	84,90	20,67	144	100,0	94	65,3	81,56	22,79
Baseline	>=65 years	143	100,0	84	58,7	74,31	25,68	133	100,0	69	51,9	74,21	26,59
Week 24	>=65 years	143	100,0	77	53,8	79,33	24,12	131	98,5	63	48,1	82,01	18,53
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	60	67,4	70,83	25,20	90	100,0	50	55,6	68,58	28,09
Week 24	<=54 letters	89	100,0	57	64,0	80,85	23,52	90	100,0	48	53,3	74,65	25,73
Baseline	>=55 letters	187	100,0	131	70,1	76,43	26,39	187	100,0	122	65,2	76,98	25,38
Week 24	>=55 letters	187	100,0	113	60,4	83,15	21,89	185	98,9	109	58,9	84,86	18,01
Geographic Region													
Baseline	Europe	82	100,0	53	64,6	70,52	31,24	70	100,0	43	61,4	77,42	26,40
Week 24	Europe	82	100,0	47	57,3	74,73	31,26	70	100,0	41	58,6	86,79	13,30
Baseline	America	97	100,0	84	86,6	74,65	22,20	105	100,0	82	78,1	73,58	26,48
Week 24	America	97	100,0	79	81,4	83,12	16,92	104	99,0	73	70,2	78,20	23,56
Baseline	Asia Pacific (inc. Australia)	97	100,0	54	55,7	78,78	25,98	102	100,0	47	46,1	73,58	26,60
Week 24	Asia Pacific (inc. Australia)	97	100,0	44	45,4	89,20	17,20	101	99,0	43	42,6	82,95	22,12
Race/ethnicity													
Baseline	White	172	100,0	127	73,8	74,15	26,34	172	100,0	121	70,3	76,14	25,52
Week 24	White	172	100,0	119	69,2	80,85	23,48	171	99,4	109	63,7	81,42	21,80
Baseline	Asian	90	100,0	52	57,8	77,64	24,62	94	100,0	42	44,7	71,83	24,76
Week 24	Asian	90	100,0	42	46,7	85,71	20,10	93	98,9	38	40,9	82,46	20,58
Baseline	Other	10	100,0	8	80,0	83,33	14,09	7	100,0	5	71,4	70,00	44,72
Week 24	Other	10	100,0	7	70,0	92,86	10,12	7	100,0	6	85,7	83,33	18,26
Baseline	Unknown	4	100,0	4	100,0	35,42	27,53	4	100,0	4	100,0	60,42	45,83
Week 24	Unknown	4	100,0	2	50,0	66,67	23,57	4	100,0	4	100,0	81,25	17,18

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_QSBDR_IT_06JUL2022_41984.xls
 03JUN2024 17:08

POPULATION: Intent-To-Treat Population
 ENDPOINT: Proportion of Patients with a >= 15-point Improvement from Baseline in NEZ VPG-23 Driving subscale at Week 24
 MODEL: Stratified Analysis by Baseline BCVA ETRS Letter score, Geographic region
 STUDY: GR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Base	Level	Pavlovsk (N=216)				Aflibercept (N=217)				Pavlovsk vs. Aflibercept																
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Absolute Risk Difference		Relative Risk		p-value (Cochran-Mantel-Haenszel)		Interaction Test p-value (Likelihood)		Relative Risk						
		n	%	n	%	n	%	n	%	Lower CI	Upper CI	Lower CI	Upper CI	Lower CI	Upper CI	Lower CI	Upper CI	Lower CI	Upper CI							
Sex	Sex	155	71.8	47	28.1	153	70.5	42	27.5	1.05	0.62	1.64	0.004	Algorithm converged.	-0.034	0.102	1.11	Algorithm converged.	0.71	1.44	0.553	0.93	Algorithm converged.	0.70	1.40	
Gender	Male	109	50.4	29	17.4	103	47.5	24	15.8	1.05	0.55	1.99	0.031	Algorithm converged.	-0.118	0.129	1.07	Algorithm converged.	0.47	1.49	0.485	0.75	Algorithm converged.	0.59	1.48	
	Female	56	25.8	18	10.6	57	26.5	18	11.0	0.97	0.64	1.45	0.358	Algorithm converged.	-0.150	0.184	0.94	Algorithm converged.	0.51	1.57	0.935	1.15	Algorithm converged.	0.64	1.38	
Age	<65 years	81	37.5	24	14.3	81	37.3	23	14.1	1.17	0.61	2.25	0.028	Algorithm converged.	-0.103	0.158	1.12	Algorithm converged.	0.43	1.42	0.432	0.84	Algorithm converged.	0.56	1.44	
	>=65 years	74	34.2	23	13.6	72	33.2	19	11.4	0.84	0.40	1.85	0.031	Algorithm converged.	-0.186	0.120	0.82	Algorithm converged.	0.48	1.39	0.495	1.22	Algorithm converged.	0.72	2.08	
Baseline BCVA ETRS letter score	<=4 letters	56	25.8	19	10.9	55	25.3	16	9.2	1.02	0.44	2.34	0.001	Algorithm converged.	-0.182	0.378	1.00	Algorithm converged.	0.59	1.74	0.979	0.942	1.05	Algorithm converged.	0.58	1.72
	>=5 letters	109	50.4	28	13.7	103	47.5	27	12.7	1.03	0.55	1.84	0.002	Algorithm converged.	-0.135	0.118	1.03	Algorithm converged.	0.64	1.58	0.853	0.93	Algorithm converged.	0.61	1.57	
Geographic Region	Europe	47	21.8	19	10.1	50	23.0	9	4.3	0.71	0.25	2.04	0.004	Algorithm converged.	-0.231	0.124	0.75	Algorithm converged.	0.31	1.74	0.501	0.1459	1.31	Algorithm converged.	0.58	1.68
	North America	56	25.8	24	13.5	57	26.3	19	10.5	1.05	0.54	2.08	0.008	Algorithm converged.	-0.061	0.058	1.02	Algorithm converged.	0.48	1.39	0.572	0.78	Algorithm converged.	0.63	1.64	
	Asia Pacific (inc. Australia)	43	19.8	10	23.3	41	18.8	14	34.1	0.57	0.22	1.48	0.112	Algorithm converged.	-0.303	0.078	0.66	Algorithm converged.	0.31	1.31	0.2458	1.51	Algorithm converged.	0.76	2.89	
Smoker/Smoker	Smoker	119	55.1	33	10.4	104	47.9	28	14.0	1.17	0.55	2.58	0.004	Algorithm converged.	-0.105	0.158	1.00	Algorithm converged.	0.59	1.64	0.104	0.163	1.05	Algorithm converged.	0.58	1.62
	Non-smoker	41	18.9	14	14.4	27	12.5	11	15.1	0.84	0.45	1.64	0.004	Algorithm converged.	-0.125	0.124	1.00	Algorithm converged.	0.59	1.74	0.979	0.942	1.05	Algorithm converged.	0.58	1.72
	Unknown	2	0.9	1	50.0	4	1.8	2	50.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (primary analysis).
 Clinical cut-off: 0.625/2.022

Program: /root/clinical_studies/205867461/CDT30303/GR4194/data_analysis/ACT_BASE/prod/program/t_eff_resp.sas
 Output: /root/clinical_studies/205867461/CDT30303/GR4194/data_analysis/ACT_CD_Primery/prod/output/t_eff_resp_wt_str_PREST_W4_QBRD15_IT_06JUL2022_4194.xls
 15AUG2023 9:52

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Peripheral Vision subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients		Statistics				Patients		Statistics			
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	273	98,9	85,62	20,60	277	100,0	272	98,2	85,29	20,25
Week 24	n/a	276	100,0	253	91,7	90,32	16,67	275	99,3	245	89,1	89,90	17,31
Gender													
Baseline	Male	143	100,0	142	99,3	86,97	19,69	130	100,0	126	96,9	89,29	17,73
Week 24	Male	143	100,0	133	93,0	92,11	13,54	128	98,5	117	91,4	92,09	14,92
Baseline	Female	133	100,0	131	98,5	84,16	21,53	147	100,0	146	99,3	81,85	21,68
Week 24	Female	133	100,0	120	90,2	88,33	19,43	147	100,0	128	87,1	87,89	19,08
Age													
Baseline	<65 years	133	100,0	132	99,2	85,61	20,75	144	100,0	142	98,6	87,68	18,77
Week 24	<65 years	133	100,0	121	91,0	90,50	15,90	144	100,0	127	88,2	90,94	16,27
Baseline	>=65 years	143	100,0	141	98,6	85,64	20,54	133	100,0	130	97,7	82,69	21,53
Week 24	>=65 years	143	100,0	132	92,3	90,15	17,41	131	98,5	118	90,1	88,77	18,37
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	88	98,9	79,55	23,84	90	100,0	90	100,0	81,67	22,73
Week 24	<=54 letters	89	100,0	83	93,3	91,57	18,01	90	100,0	79	87,8	87,34	20,36
Baseline	>=55 letters	187	100,0	185	98,9	88,51	18,24	187	100,0	182	97,3	87,09	18,72
Week 24	>=55 letters	187	100,0	170	90,9	89,71	15,99	185	98,9	166	89,7	91,11	15,57
Geographic Region													
Baseline	Europe	82	100,0	80	97,6	82,50	21,93	70	100,0	66	94,3	84,09	21,32
Week 24	Europe	82	100,0	79	96,3	87,03	21,13	70	100,0	60	85,7	88,33	17,51
Baseline	America	97	100,0	97	100,0	82,73	22,64	105	100,0	105	100,0	86,67	19,01
Week 24	America	97	100,0	89	91,8	90,17	15,82	104	99,0	97	93,3	92,01	15,12
Baseline	Asia Pacific (inc. Australia)	97	100,0	96	99,0	91,15	15,80	102	100,0	101	99,0	84,65	20,91
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	93,53	11,67	101	99,0	88	87,1	88,64	19,29
Race/ethnicity													
Baseline	White	172	100,0	169	98,3	83,28	22,11	172	100,0	168	97,7	85,42	20,37
Week 24	White	172	100,0	161	93,6	89,91	18,20	171	99,4	154	90,1	90,10	17,25
Baseline	Asian	90	100,0	90	100,0	91,39	15,07	94	100,0	93	98,9	85,75	19,29
Week 24	Asian	90	100,0	79	87,8	92,41	12,24	93	98,9	80	86,0	88,44	18,20
Baseline	Other	10	100,0	10	100,0	80,00	25,82	7	100,0	7	100,0	75,00	28,87
Week 24	Other	10	100,0	9	90,0	80,56	20,83	7	100,0	7	100,0	100,00	0,00
Baseline	Unknown	4	100,0	4	100,0	68,75	23,94	4	100,0	4	100,0	87,50	25,00
Week 24	Unknown	4	100,0	4	100,0	87,50	14,43	4	100,0	4	100,0	93,75	12,50

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

POPULATION: Intent-To-Treat Population
 ENDPOINT: Proportion of Patients with a >= 15-point Improvement from Baseline in NEI VFQ-25 Peripheral Vision subscale at Week 24
 MODEL: Stratified Analysis by Baseline BCVA ETDRS Letter score, Geographic region
 STUDY: OR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Base	Level	Paralimab (N=216)				Allibronop (N=217)				Odds Ratio	Paralimab vs Allibronop					Allibronop vs Paralimab											
		Patients		Patients with Event		Patients		Patients with Event			Odds Ratio		Absolute Risk Difference			Relative Risk			p-value (Cochran-Mantel-Haenszel)		Interaction Test (Likelihood)		Relative Risk				
		n	%	n	%	n	%	n	%		Lower CI	Upper CI	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI	p-value	p-value	Relative Risk	Lower CI	Upper CI					
Sex	Sex	252	92.0	11	21.0	242	87.4	15	24.4	0.82	Convergence criterion (GCMV+12-E) satisfied	0.17	1.12	-0.241	Algorithm converged	0.112	0.133	0.424	Algorithm converged	0.48	1.29	0.5003	1.23	Algorithm converged	0.78	1.42	
Gender	Male	112	47.8	20	20.0	113	43.3	21	18.3	1.11	Convergence criterion (GCMV+12-E) satisfied	0.48	2.10	-0.614	Algorithm converged	-0.110	0.482	1.13	Algorithm converged	0.48	1.61	0.7847	0.48	Algorithm converged	0.46	1.45	
Female	Female	112	43.1	28	23.5	127	45.8	38	29.9	0.76	Convergence criterion (GCMV+12-E) satisfied	0.22	1.30	-0.287	Algorithm converged	0.258	0.282	0.82	Algorithm converged	0.54	1.29	0.2277	1.22	Algorithm converged	0.85	1.81	
Age	<65 years	110	43.4	20	21.0	128	44.1	25	20.0	1.08	Convergence criterion (GCMV+12-E) satisfied	0.18	2.02	-0.202	Algorithm converged	-0.104	0.102	1.12	Algorithm converged	0.28	1.45	0.7918	0.48	Algorithm converged	0.44	1.44	
>=65 years	>=65 years	111	47.5	28	21.4	117	42.2	34	29.1	0.68	Convergence criterion (GCMV+12-E) satisfied	0.38	1.22	-0.579	Algorithm converged	-0.181	0.224	0.81	Algorithm converged	0.51	1.25	0.1961	1.23	Algorithm converged	0.80	1.80	
Baseline BCVA ETDRS letter score	<=4 letters	82	29.7	29	35.4	79	28.5	24	30.4	1.20	Convergence criterion (GCMV+12-E) satisfied	0.05	2.42	0.049	Algorithm converged	-0.097	0.194	1.18	Algorithm converged	0.76	1.84	0.4944	0.115	0.85	Algorithm converged	0.54	1.32
>=5 letters	>=5 letters	168	61.2	24	11.4	163	58.9	15	21.3	0.67	Convergence criterion (GCMV+12-E) satisfied	0.18	1.17	-0.263	Algorithm converged	0.149	0.118	0.71	Algorithm converged	0.46	1.18	0.1384	1.18	Algorithm converged	0.87	2.12	
Geographic Region	Europe	77	27.9	18	20.8	67	20.8	15	26.1	0.70	Convergence criterion (GCMV+12-E) satisfied	0.11	1.59	-0.04	Algorithm converged	-0.201	0.076	0.79	Algorithm converged	0.43	1.41	0.1845	1.48	Algorithm converged	0.71	2.13	
North America	North America	88	32.0	24	26.5	87	35.1	22	25.1	1.33	Convergence criterion (GCMV+12-E) satisfied	0.28	2.66	0.343	Algorithm converged	0.298	1.22	1.23	Algorithm converged	0.78	2.11	0.1563	2.11	Algorithm converged	0.45	1.24	
Asia Pacific (inc. Australia)	Asia Pacific (inc. Australia)	85	30.8	14	16.5	89	31.8	22	25.0	0.54	Convergence criterion (GCMV+12-E) satisfied	0.27	1.20	-0.299	Algorithm converged	-0.215	0.017	0.65	Algorithm converged	0.26	1.18	0.1348	1.54	Algorithm converged	0.85	2.71	
Sex*Geographic Region	Male	112	51.0	38	24.5	103	24.3	36	23.8	1.02	Convergence criterion (GCMV+12-E) satisfied	0.10	1.13	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Female	Female	79	28.4	12	11.0	80	28.8	14	22.1	0.61	Convergence criterion (GCMV+12-E) satisfied	0.22	1.18	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Other	Other	3	1.3	22.2	72.1	2	1.1	4	37.1	0.23	Convergence criterion (GCMV+12-E) satisfied	0.12	1.58	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Unknown	Unknown	4	1.4	1	7.5	4	1.4	1	25.0	NR	Convergence criterion (ABSOROV+1) satisfied	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

Test for interaction based on RR (log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (primary treatment).
 Clinical cut-off: 06JUL2022

Program: /root/clinical_studies/202867461/CDT30303/OR4194/data_analysis/ACT_BASE/prod/program/t_eff_resp.sas
 Output: /root/clinical_studies/202867461/CDT30303/OR4194/data_analysis/ACT_CD_Primery/prod/output/t_eff_resp_sas_str_PREST_W4_QBRPV15_IT_06JUL2022_4194.sas
 15AUG2023 10:11

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Color Vision subscale over Time through Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=276)						Aflibercept (N=277)					
Name Visit	Level	Patients				Statistics		Patients				Statistics	
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
Baseline	n/a	276	100,0	276	100,0	94,84	13,59	277	100,0	272	98,2	95,40	13,14
Week 24	n/a	276	100,0	253	91,7	97,43	9,36	275	99,3	245	89,1	96,94	10,16
Gender													
Baseline	Male	143	100,0	143	100,0	95,45	12,46	130	100,0	127	97,7	97,44	9,36
Week 24	Male	143	100,0	133	93,0	96,99	10,22	128	98,5	118	92,2	98,31	6,31
Baseline	Female	133	100,0	133	100,0	94,17	14,72	147	100,0	145	98,6	93,62	15,53
Week 24	Female	133	100,0	120	90,2	97,92	8,32	147	100,0	127	86,4	95,67	12,64
Age													
Baseline	<65 years	133	100,0	133	100,0	95,49	11,45	144	100,0	141	97,9	95,92	12,90
Week 24	<65 years	133	100,0	121	91,0	97,93	8,89	144	100,0	126	87,5	98,02	8,13
Baseline	>=65 years	143	100,0	143	100,0	94,23	15,33	133	100,0	131	98,5	94,85	13,42
Week 24	>=65 years	143	100,0	132	92,3	96,97	9,78	131	98,5	119	90,8	95,80	11,88
Baseline BCVA ETDRS letter score													
Baseline	<=54 letters	89	100,0	89	100,0	92,13	15,81	90	100,0	90	100,0	95,00	14,12
Week 24	<=54 letters	89	100,0	83	93,3	96,39	11,13	90	100,0	79	87,8	95,57	11,15
Baseline	>=55 letters	187	100,0	187	100,0	96,12	12,23	187	100,0	182	97,3	95,60	12,65
Week 24	>=55 letters	187	100,0	170	90,9	97,94	8,35	185	98,9	166	89,7	97,59	9,63
Geographic Region													
Baseline	Europe	82	100,0	82	100,0	94,21	13,20	70	100,0	67	95,7	95,52	11,45
Week 24	Europe	82	100,0	79	96,3	96,84	10,87	70	100,0	61	87,1	96,72	9,66
Baseline	America	97	100,0	97	100,0	93,30	17,12	105	100,0	105	100,0	95,24	13,91
Week 24	America	97	100,0	89	91,8	97,19	10,28	104	99,0	97	93,3	97,68	8,13
Baseline	Asia Pacific (inc. Australia)	97	100,0	97	100,0	96,91	9,03	102	100,0	100	98,0	95,50	13,47
Week 24	Asia Pacific (inc. Australia)	97	100,0	85	87,6	98,24	6,44	101	99,0	87	86,1	96,26	12,37
Race/ethnicity													
Baseline	White	172	100,0	172	100,0	94,19	14,89	172	100,0	169	98,3	95,86	11,79
Week 24	White	172	100,0	161	93,6	97,05	10,22	171	99,4	155	90,6	96,94	10,40
Baseline	Asian	90	100,0	90	100,0	95,83	10,76	94	100,0	92	97,9	95,38	13,83
Week 24	Asian	90	100,0	79	87,8	98,42	6,13	93	98,9	79	84,9	96,84	10,10
Baseline	Other	10	100,0	10	100,0	95,00	15,81	7	100,0	7	100,0	82,14	27,82
Week 24	Other	10	100,0	9	90,0	94,44	16,67	7	100,0	7	100,0	96,43	9,45
Baseline	Unknown	4	100,0	4	100,0	100,00	0,00	4	100,0	4	100,0	100,00	0,00
Week 24	Unknown	4	100,0	4	100,0	100,00	0,00	4	100,0	4	100,0	100,00	0,00

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tW24_QSBCV_IT_06JUL2022_41984.xls
 03JUN2024 17:10

POPULATION: Intent-To-Treat Population
 ENDPOINT: Proportion of Patients with a >= 15-point Improvement from Baseline in NEI VFIQ-25 Color Vision subscale at Week 24
 MODEL: Stratified Analysis by Baseline BCVA EOTDR Letter score, Geographic region
 STUDY: GR4194
 Dichotomous Analysis by Subgroups (Efficacy)

Base	Level	Patients (N=276)				All-Events (N=277)				Odds Ratio	Patients vs. All-Events																	
		Patients		Patients with Event		Patients		Patients with Event			Odds Ratio					Relative Risk												
		n	%	n	%	n	%	n	%		95% Lower CI	95% Upper CI	Absolute Risk	Convergence Reason	95% Lower CI	95% Upper CI	Relative Risk	Convergence Reason	95% Lower CI	95% Upper CI	p-value (Cochran-Mantel-Haenszel)	Interaction Test p-value (likelihood)	Relative Risk	Convergence Reason	95% Lower CI	95% Upper CI		
Sex	Sex	253	91.7	24	11.1	242	87.4	19	7.0	1.40	Convergence criterion (SCORV12-S) satisfied	0.41	2.76	0.214	Algorithm converged	-0.41	0.985	1.41	Algorithm converged	0.41	2.44	0.197		0.41	Algorithm converged	0.41	1.21	
Gender	Male	133	48.2	13	9.3	116	43.0	4	3.2	1.40	Convergence criterion (SCORV12-S) satisfied	0.40	4.55	0.403	Algorithm converged	-0.014	0.493	1.40	Algorithm converged	0.40	4.14	0.338	0.818	0.41	Algorithm converged	0.44	1.41	
	Female	120	43.5	11	9.2	109	40.1	15	12.3	1.40	Convergence criterion (SCORV12-S) satisfied	0.47	3.18	0.264	Algorithm converged	-0.241	0.189	1.40	Algorithm converged	0.21	2.74	0.157		0.21	Algorithm converged	0.38	1.41	
Sex	<=5 years	121	43.8	14	11.5	104	38.0	11	8.9	1.40	Convergence criterion (SCORV12-S) satisfied	0.27	3.40	0.248	Algorithm converged	-0.207	0.233	1.41	Algorithm converged	0.28	3.45	0.230	0.810	0.41	Algorithm converged	0.35	1.41	
	>=6 years	132	47.8	10	7.1	118	43.0	8	6.8	1.40	Convergence criterion (SCORV12-S) satisfied	0.54	3.47	*	WARNING: The relative hazard convergence criterion of			1.39	Algorithm converged	0.49	3.25	0.454		0.72	Algorithm converged	0.41	1.41	
Baseline BCVA EOTDR Letter Score	<=4 letters	81	30.1	12	14.8	79	28.1	4	5.1	1.33	Convergence criterion (SCORV12-S) satisfied	1.02	11.31	0.030	Algorithm converged	-0.024	0.144	2.94	Algorithm converged	1.02	8.44	0.030	0.052	0.14	Algorithm converged	0.12	0.38	
	>=5 letters	170	61.6	16	9.4	163	58.8	15	9.2	1.02	Convergence criterion (SCORV12-S) satisfied	0.49	2.14	0.001	Algorithm converged	-0.063	0.066	1.02	Algorithm converged	0.52	2.08	0.948		0.98	Algorithm converged	0.50	1.01	
Geographic Region	Europe	79	28.6	8	10.1	68	25.0	7	5.2	2.11	Convergence criterion (SCORV12-S) satisfied	0.54	8.10	0.041	Algorithm converged	-0.040	0.115	2.02	Algorithm converged	0.46	7.09	0.274	0.322	0.49	Algorithm converged	0.24	1.08	
	America	89	32.2	14	15.7	87	31.0	8	8.2	2.11	Convergence criterion (SCORV12-S) satisfied	0.84	5.29	0.009	Algorithm converged	-0.029	0.166	1.88	Algorithm converged	0.87	4.80	0.106		0.22	Algorithm converged	0.22	1.13	
	Asia Pacific (incl. Australia)	85	30.8	4	7.1	87	31.4	8	9.2	0.76	Convergence criterion (SCORV12-S) satisfied	0.25	2.28	-0.019	Algorithm converged	-0.107	0.070	0.77	Algorithm converged	0.28	2.13	0.621	1.10	Algorithm converged	0.47	3.58		
Race/ethnicity	White	161	58.3	19	11.8	142	51.9	8	5.9	2.17	Convergence criterion (SCORV12-S) satisfied	0.45	4.89	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	Asian	79	28.6	8	11.4	79	28.1	7	8.9	1.31	Convergence criterion (SCORV12-S) satisfied	0.47	3.78	*	convergence criterion of			1.57	Algorithm converged	0.41	4.09	0.590		0.64	Algorithm converged	0.24	1.03	
	Other	9	3.3	0	0.0	7	2.5	3	42.9	0.00	Convergence criterion (SCORV12-S) satisfied	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
Unknown	6	2.2	0	0.0	4	1.4	0	0.0	NS		NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	

Test for interaction based on RR (Log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Only patients with at least one value are used for analysis. The stratification factor is excluded if it is the subgroup. OR is computed by stratified analysis, RR and ARD by adjusted analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Endpoint).
 Clinical non-eff: SCORV12

Program: root/clinical_studies/206867461/CDT30303/GR4194/data_analysis/ACR_BASE/prod/program/t_eff_rwp.sas
 Output: root/clinical_studies/206867461/CDT30303/GR4194/data_analysis/ACR_CSR_Primary/prod/output/t_eff_rwp_sas_str_PRRST_W4_GBRV15_17_06JUL2022_41984.klx
 10A02023 9:58

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Composite Score over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients			Statistics			Patients			Statistics		
		in study ¹	%	with value ²	%	Mean ²	SD(Mean)	in study ¹	%	with value ²	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100,0	364	99,5	76,06	16,75	363	100,0	362	99,7	76,49	16,31
Week 24	n/a	365	99,7	341	93,4	83,50	13,79	362	99,7	331	91,4	84,68	12,80
Gender													
Baseline	Male	193	100,0	192	99,5	77,50	16,37	200	100,0	199	99,5	78,95	15,40
Week 24	Male	192	99,5	177	92,2	85,60	12,01	200	100,0	180	90,0	86,55	11,44
Baseline	Female	173	100,0	172	99,4	74,46	17,06	163	100,0	163	100,0	73,48	16,91
Week 24	Female	173	100,0	164	94,8	81,24	15,19	162	99,4	151	93,2	82,45	13,97
Age													
Baseline	<65 years	162	100,0	162	100,0	78,19	15,76	158	100,0	157	99,4	74,69	16,91
Week 24	<65 years	161	99,4	151	93,8	85,16	12,14	157	99,4	139	88,5	84,77	12,64
Baseline	>=65 years	204	100,0	202	99,0	74,35	17,35	205	100,0	205	100,0	77,87	15,73
Week 24	>=65 years	204	100,0	190	93,1	82,18	14,87	205	100,0	192	93,7	84,61	12,95
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100,0	105	99,1	73,41	18,25	105	100,0	105	100,0	76,94	16,34
Week 24	35 - 54 letters	106	100,0	101	95,3	81,63	14,52	105	100,0	97	92,4	85,93	11,16
Baseline	<=34 letters	79	100,0	78	98,7	68,93	17,35	80	100,0	80	100,0	72,19	19,02
Week 24	<=34 letters	79	100,0	71	89,9	77,87	16,11	80	100,0	74	92,5	81,00	14,54
Baseline	>=55 letters	181	100,0	181	100,0	80,67	14,03	178	100,0	177	99,4	78,17	14,62
Week 24	>=55 letters	180	99,4	169	93,9	86,99	11,10	177	99,4	160	90,4	85,63	12,64
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	34	97,1	70,47	15,37	36	100,0	36	100,0	70,33	18,29
Week 24	<=23 letters	35	100,0	32	91,4	75,54	17,10	36	100,0	32	88,9	79,94	14,56
Baseline	>=24 letters	331	100,0	330	99,7	76,64	16,80	327	100,0	326	99,7	77,17	15,96
Week 24	>=24 letters	330	99,7	309	93,6	84,33	13,16	326	99,7	299	91,7	85,19	12,52
Geographic Region													
Baseline	Europe	111	100,0	110	99,1	74,13	18,70	114	100,0	113	99,1	77,27	15,57
Week 24	Europe	111	100,0	102	91,9	80,18	17,65	114	100,0	103	90,4	83,02	13,09
Baseline	America	147	100,0	146	99,3	76,72	16,31	146	100,0	146	100,0	73,92	17,79
Week 24	America	146	99,3	137	93,8	85,12	11,58	145	99,3	133	91,7	85,12	13,55
Baseline	Asia Pacific (inc. Australia)	108	100,0	108	100,0	77,12	15,13	103	100,0	103	100,0	79,27	14,38
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	84,65	11,47	103	100,0	95	92,2	85,87	11,27
Race/ethnicity													
Baseline	White	243	100,0	241	99,2	76,19	17,52	253	100,0	252	99,6	76,28	16,37
Week 24	White	242	99,6	227	93,8	83,04	15,02	252	99,6	231	91,7	84,88	12,89
Baseline	Asian	89	100,0	89	100,0	77,23	14,54	88	100,0	88	100,0	78,25	15,65
Week 24	Asian	89	100,0	85	95,5	84,95	10,49	88	100,0	80	90,9	84,79	12,89
Baseline	Other	13	100,0	13	100,0	67,03	15,34	17	100,0	17	100,0	71,19	18,18
Week 24	Other	13	100,0	13	100,0	83,35	8,87	17	100,0	15	88,2	82,09	11,34
Baseline	Unknown	21	100,0	21	100,0	75,20	16,64	5	100,0	5	100,0	74,17	18,29
Week 24	Unknown	21	100,0	16	76,2	82,58	14,60	5	100,0	5	100,0	81,66	13,88
Baseline RVO status													
Baseline	CRVO	302	100,0	300	99,3	76,03	16,76	293	100,0	292	99,7	77,29	15,69
Week 24	CRVO	301	99,7	279	92,7	83,39	13,90	292	99,7	269	92,1	85,14	12,94
Baseline	HRVO	61	100,0	61	100,0	76,38	16,81	64	100,0	64	100,0	74,22	17,53
Week 24	HRVO	61	100,0	59	96,7	84,07	13,45	64	100,0	58	90,6	82,30	12,26
Baseline	Missing	3	100,0	3	100,0	72,72	19,77	6	100,0	6	100,0	61,77	25,07
Week 24	Missing	3	100,0	3	100,0	83,07	13,95	6	100,0	4	66,7	87,99	8,86

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_primary/prod/output/t_eff_mean_sg_PREST_TW24_QBCSCORE_IT_09AUG2022_41986.xls
 03JUN2024 17:15

Name	Letter	Placebo (N=161)				Active (N=161)				N of Events	N of Patients	Relative Risk Difference	Relative Risk				Relative Risk			
		Patients with Event		Patients with Event		95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI				95% Upper CI	P-value (Odds Ratio - Mean)	Interaction Test P-value (Stratified)	Relative Risk	95% Lower CI	95% Upper CI		
		n	%	n	%															
All	n/a	109	67.4	10	22	119	74.6	12	21.1	1.13	0.000	0.72	1.55	0.000	0.74	1.57	0.000	0.75	1.57	
Gender	Male	119	81.1	41	25	279	49.2	33	20.1	1.11	0.000	0.73	1.13	0.000	0.49	1.47	0.000	0.49	1.47	
Region	Europe	100	64.6	10	20	101	61.2	20	22.0	0.87	0.000	0.72	1.04	0.000	0.62	1.12	0.000	0.62	1.12	
Age	< 65 years	113	71.4	21	22	124	76.2	40	29.0	0.75	0.000	0.61	0.90	0.000	0.44	1.11	0.000	0.44	1.11	
	>= 65 years	100	63.4	40	31	100	63.4	18	18.0	1.00	0.000	0.93	1.08	0.000	0.93	1.08	0.000	0.93	1.08	
Baseline MVA WPI21	n/a letters	100	63.4	20	19	100	63.4	10	10.0	1.00	0.000	0.62	0.91	0.000	0.62	0.91	0.000	0.62	0.91	
Letter score	15-18 letters	100	63.4	20	20	100	63.4	20	20.0	1.00	0.000	0.62	0.91	0.000	0.62	0.91	0.000	0.62	0.91	
	< 15 letters	100	63.4	10	17	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Geographic region	Europe	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	Asia	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Sex	Female (inc.)	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	Male	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Non-responders	None	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	None	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
	< 15 letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Baseline MVA WPI21	n/a letters	100	63.4	10	10	100	63.4	10	10.0	1.00	0.000	0.64	0.95	0.000	0.64	0.95	0.000	0.64	0.95	
Letter score	15-18 letters	100	63.4	10	10															

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 General Health subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients		Statistics		Patients		Statistics					
		in study ¹	%	with value ²	%	Mean ²	SD(Mean)	in study ¹	%	with value ²	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100,0	364	99,5	53,43	22,47	363	100,0	362	99,7	52,83	23,55
Week 24	n/a	365	99,7	341	93,4	54,62	21,83	362	99,7	331	91,4	53,93	22,35
Gender													
Baseline	Male	193	100,0	192	99,5	54,69	21,04	200	100,0	199	99,5	55,65	22,53
Week 24	Male	192	99,5	177	92,2	56,92	21,60	200	100,0	180	90,0	56,06	21,74
Baseline	Female	173	100,0	172	99,4	52,03	23,94	163	100,0	163	100,0	49,39	24,37
Week 24	Female	173	100,0	164	94,8	52,13	21,88	162	99,4	151	93,2	49,01	22,15
Age													
Baseline	<65 years	162	100,0	162	100,0	53,24	19,73	158	100,0	157	99,4	53,03	23,74
Week 24	<65 years	161	99,4	151	93,8	54,64	20,90	157	99,4	139	88,5	54,14	22,03
Baseline	>=65 years	204	100,0	202	99,0	53,59	24,49	205	100,0	205	100,0	52,68	23,46
Week 24	>=65 years	204	100,0	190	93,1	54,61	22,61	205	100,0	192	93,7	53,78	22,64
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100,0	105	99,1	54,05	21,68	105	100,0	105	100,0	54,29	22,32
Week 24	35 - 54 letters	106	100,0	101	95,3	51,73	21,87	105	100,0	97	92,4	56,19	22,25
Baseline	<=34 letters	79	100,0	78	98,7	50,00	21,70	80	100,0	80	100,0	50,00	23,19
Week 24	<=34 letters	79	100,0	71	89,9	51,06	21,73	80	100,0	74	92,5	50,00	21,50
Baseline	>=55 letters	181	100,0	181	100,0	54,56	23,20	178	100,0	177	99,4	53,25	24,43
Week 24	>=55 letters	180	99,4	169	93,9	57,84	21,51	177	99,4	160	90,4	54,38	22,70
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	34	97,1	48,53	19,41	36	100,0	36	100,0	49,31	21,12
Week 24	<=23 letters	35	100,0	32	91,4	50,00	24,59	36	100,0	32	88,9	49,22	19,56
Baseline	>=24 letters	331	100,0	330	99,7	53,94	22,72	327	100,0	326	99,7	53,22	23,80
Week 24	>=24 letters	330	99,7	309	93,6	55,10	21,52	326	99,7	299	91,7	54,43	22,60
Geographic Region													
Baseline	Europe	111	100,0	110	99,1	50,23	21,81	114	100,0	113	99,1	51,77	22,59
Week 24	Europe	111	100,0	102	91,9	50,49	22,52	114	100,0	103	90,4	53,40	22,70
Baseline	America	147	100,0	146	99,3	57,19	22,54	146	100,0	146	100,0	58,56	22,64
Week 24	America	146	99,3	137	93,8	59,49	19,44	145	99,3	133	91,7	58,27	20,81
Baseline	Asia Pacific (inc. Australia)	108	100,0	108	100,0	51,62	22,48	103	100,0	103	100,0	45,87	24,02
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	52,21	23,10	103	100,0	95	92,2	48,42	23,01
Race/ethnicity													
Baseline	White	243	100,0	241	99,2	55,71	22,62	253	100,0	252	99,6	56,45	22,88
Week 24	White	242	99,6	227	93,8	56,50	21,79	252	99,6	231	91,7	56,82	22,47
Baseline	Asian	89	100,0	89	100,0	46,35	20,14	88	100,0	88	100,0	43,47	23,21
Week 24	Asian	89	100,0	85	95,5	49,12	21,97	88	100,0	80	90,9	46,88	21,56
Baseline	Other	13	100,0	13	100,0	51,92	23,85	17	100,0	17	100,0	47,06	24,82
Week 24	Other	13	100,0	13	100,0	55,77	25,32	17	100,0	15	88,2	51,67	17,59
Baseline	Unknown	21	100,0	21	100,0	58,33	24,15	5	100,0	5	100,0	55,00	11,18
Week 24	Unknown	21	100,0	16	76,2	56,25	14,43	5	100,0	5	100,0	40,00	13,69
Baseline RVO status													
Baseline	CRVO	302	100,0	300	99,3	53,00	23,12	293	100,0	292	99,7	53,94	23,85
Week 24	CRVO	301	99,7	279	92,7	54,39	22,56	292	99,7	269	92,1	54,37	22,59
Baseline	HRVO	61	100,0	61	100,0	54,92	19,27	64	100,0	64	100,0	49,22	21,81
Week 24	HRVO	61	100,0	59	96,7	55,08	18,44	64	100,0	58	90,6	52,16	21,60
Baseline	Missing	3	100,0	3	100,0	66,67	14,43	6	100,0	6	100,0	37,50	20,92
Week 24	Missing	3	100,0	3	100,0	66,67	14,43	6	100,0	4	66,7	50,00	20,41

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tw24_QSBGH_IT_09AUG2022_41986.xls
 03JUN2024 17:30

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 General Vision subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients		Statistics		Patients		Statistics					
		in study ¹	%	with value ²	%	Mean ²	SD(Mean)	in study ¹	%	with value ²	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100,0	364	99,5	60,33	18,36	363	100,0	362	99,7	60,28	16,54
Week 24	n/a	365	99,7	341	93,4	68,74	14,79	362	99,7	331	91,4	69,91	15,60
Gender													
Baseline	Male	193	100,0	192	99,5	62,08	18,75	200	100,0	199	99,5	61,31	17,87
Week 24	Male	192	99,5	177	92,2	70,62	13,49	200	100,0	180	90,0	71,33	16,11
Baseline	Female	173	100,0	172	99,4	58,37	17,76	163	100,0	163	100,0	59,02	14,71
Week 24	Female	173	100,0	164	94,8	66,71	15,86	162	99,4	151	93,2	68,21	14,84
Age													
Baseline	<65 years	162	100,0	162	100,0	62,47	18,35	158	100,0	157	99,4	59,36	17,31
Week 24	<65 years	161	99,4	151	93,8	70,46	13,82	157	99,4	139	88,5	70,36	15,67
Baseline	>=65 years	204	100,0	202	99,0	58,61	18,23	205	100,0	205	100,0	60,98	15,94
Week 24	>=65 years	204	100,0	190	93,1	67,37	15,41	205	100,0	192	93,7	69,58	15,58
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100,0	105	99,1	57,52	19,35	105	100,0	105	100,0	60,95	16,26
Week 24	35 - 54 letters	106	100,0	101	95,3	67,52	14,10	105	100,0	97	92,4	70,93	16,08
Baseline	<=34 letters	79	100,0	78	98,7	55,64	19,24	80	100,0	80	100,0	58,25	17,77
Week 24	<=34 letters	79	100,0	71	89,9	63,10	15,73	80	100,0	74	92,5	67,84	13,17
Baseline	>=55 letters	181	100,0	181	100,0	63,98	16,66	178	100,0	177	99,4	60,79	16,15
Week 24	>=55 letters	180	99,4	169	93,9	71,83	14,04	177	99,4	160	90,4	70,25	16,33
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	34	97,1	55,88	20,17	36	100,0	36	100,0	58,33	15,40
Week 24	<=23 letters	35	100,0	32	91,4	58,75	18,97	36	100,0	32	88,9	69,38	11,34
Baseline	>=24 letters	331	100,0	330	99,7	60,79	18,13	327	100,0	326	99,7	60,49	16,67
Week 24	>=24 letters	330	99,7	309	93,6	69,77	13,92	326	99,7	299	91,7	69,97	16,00
Geographic Region													
Baseline	Europe	111	100,0	110	99,1	57,64	17,29	114	100,0	113	99,1	60,35	15,81
Week 24	Europe	111	100,0	102	91,9	66,86	17,00	114	100,0	103	90,4	71,26	13,63
Baseline	America	147	100,0	146	99,3	65,62	17,85	146	100,0	146	100,0	63,15	17,37
Week 24	America	146	99,3	137	93,8	72,99	12,51	145	99,3	133	91,7	73,08	13,94
Baseline	Asia Pacific (inc. Australia)	108	100,0	108	100,0	55,93	18,50	103	100,0	103	100,0	56,12	15,35
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	64,90	13,91	103	100,0	95	92,2	64,00	18,12
Race/ethnicity													
Baseline	White	243	100,0	241	99,2	62,99	18,29	253	100,0	252	99,6	62,14	16,27
Week 24	White	242	99,6	227	93,8	70,40	15,21	252	99,6	231	91,7	72,64	14,43
Baseline	Asian	89	100,0	89	100,0	53,93	16,90	88	100,0	88	100,0	54,32	16,03
Week 24	Asian	89	100,0	85	95,5	63,29	13,04	88	100,0	80	90,9	60,75	16,05
Baseline	Other	13	100,0	13	100,0	55,38	14,50	17	100,0	17	100,0	62,35	17,15
Week 24	Other	13	100,0	13	100,0	72,31	13,01	17	100,0	15	88,2	76,00	13,52
Baseline	Unknown	21	100,0	21	100,0	60,00	20,98	5	100,0	5	100,0	64,00	16,73
Week 24	Unknown	21	100,0	16	76,2	71,25	12,58	5	100,0	5	100,0	72,00	10,95
Baseline RVO status													
Baseline	CRVO	302	100,0	300	99,3	59,87	18,58	293	100,0	292	99,7	60,75	16,69
Week 24	CRVO	301	99,7	279	92,7	68,39	15,07	292	99,7	269	92,1	69,89	15,61
Baseline	HRVO	61	100,0	61	100,0	62,62	17,31	64	100,0	64	100,0	60,00	15,12
Week 24	HRVO	61	100,0	59	96,7	70,17	13,58	64	100,0	58	90,6	69,31	15,54
Baseline	Missing	3	100,0	3	100,0	60,00	20,00	6	100,0	6	100,0	40,00	12,65
Week 24	Missing	3	100,0	3	100,0	73,33	11,55	6	100,0	4	66,7	80,00	16,33

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CUT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CUT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tw24_QSBGV_IT_09AUG2022_41986.xls
 03JUN2024 17:32

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Ocular Pain subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients			Statistics			Patients			Statistics		
		in study ¹	%	with value ²	%	Mean ²	SD(Mean)	in study ¹	%	with value ²	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100.0	364	99.5	82.42	19.98	363	100.0	362	99.7	85.95	18.62
Week 24	n/a	365	99.7	341	93.4	87.28	16.91	362	99.7	331	91.4	88.29	16.77
Gender													
Baseline	Male	193	100.0	192	99.5	82.62	19.89	200	100.0	199	99.5	88.69	17.25
Week 24	Male	192	99.5	177	92.2	89.48	14.09	200	100.0	180	90.0	90.90	14.58
Baseline	Female	173	100.0	172	99.4	82.19	20.14	163	100.0	163	100.0	82.59	19.71
Week 24	Female	173	100.0	164	94.8	84.91	19.26	162	99.4	151	93.2	85.18	18.62
Age													
Baseline	<65 years	162	100.0	162	100.0	82.95	19.44	158	100.0	157	99.4	85.03	18.96
Week 24	<65 years	161	99.4	151	93.8	87.67	16.96	157	99.4	139	88.5	88.04	16.20
Baseline	>=65 years	204	100.0	202	99.0	81.99	20.45	205	100.0	205	100.0	86.65	18.38
Week 24	>=65 years	204	100.0	190	93.1	86.97	16.90	205	100.0	192	93.7	88.48	17.20
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100.0	105	99.1	82.50	21.06	105	100.0	105	100.0	88.21	16.52
Week 24	35 - 54 letters	106	100.0	101	95.3	85.77	18.79	105	100.0	97	92.4	89.43	16.67
Baseline	<=34 letters	79	100.0	78	98.7	78.37	21.38	80	100.0	80	100.0	85.00	18.59
Week 24	<=34 letters	79	100.0	71	89.9	85.74	17.33	80	100.0	74	92.5	89.36	13.98
Baseline	>=55 letters	181	100.0	181	100.0	84.12	18.53	178	100.0	177	99.4	85.03	19.77
Week 24	>=55 letters	180	99.4	169	93.9	88.83	15.43	177	99.4	160	90.4	87.11	17.98
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100.0	34	97.1	79.78	20.87	36	100.0	36	100.0	85.42	19.25
Week 24	<=23 letters	35	100.0	32	91.4	85.94	17.32	36	100.0	32	88.9	93.36	10.52
Baseline	>=24 letters	331	100.0	330	99.7	82.69	19.90	327	100.0	326	99.7	86.00	18.58
Week 24	>=24 letters	330	99.7	309	93.6	87.42	16.88	326	99.7	299	91.7	87.75	17.23
Geographic Region													
Baseline	Europe	111	100.0	110	99.1	81.93	22.05	114	100.0	113	99.1	84.96	20.06
Week 24	Europe	111	100.0	102	91.9	84.93	21.06	114	100.0	103	90.4	83.25	20.30
Baseline	America	147	100.0	146	99.3	83.73	18.88	146	100.0	146	100.0	85.10	18.30
Week 24	America	146	99.3	137	93.8	88.69	14.77	145	99.3	133	91.7	90.32	15.20
Baseline	Asia Pacific (inc. Australia)	108	100.0	108	100.0	81.13	19.30	103	100.0	103	100.0	88.23	17.40
Week 24	Asia Pacific (inc. Australia)	108	100.0	102	94.4	87.75	14.71	103	100.0	95	92.2	90.92	13.20
Race/ethnicity													
Baseline	White	243	100.0	241	99.2	83.61	19.79	253	100.0	252	99.6	85.37	18.80
Week 24	White	242	99.6	227	93.8	86.89	17.53	252	99.6	231	91.7	87.45	17.96
Baseline	Asian	89	100.0	89	100.0	81.46	19.23	88	100.0	88	100.0	88.64	17.44
Week 24	Asian	89	100.0	85	95.5	90.15	13.24	88	100.0	80	90.9	92.03	11.97
Baseline	Other	13	100.0	13	100.0	73.08	22.15	17	100.0	17	100.0	83.09	22.07
Week 24	Other	13	100.0	13	100.0	86.54	17.28	17	100.0	15	88.2	85.00	16.50
Baseline	Unknown	21	100.0	21	100.0	78.57	23.10	5	100.0	5	100.0	77.50	16.30
Week 24	Unknown	21	100.0	16	76.2	78.13	22.13	5	100.0	5	100.0	77.50	18.54
Baseline RVO status													
Baseline	CRVO	302	100.0	300	99.3	81.63	20.35	293	100.0	292	99.7	87.37	16.98
Week 24	CRVO	301	99.7	279	92.7	86.56	17.38	292	99.7	269	92.1	88.75	16.66
Baseline	HRVO	61	100.0	61	100.0	86.07	18.13	64	100.0	64	100.0	80.86	23.78
Week 24	HRVO	61	100.0	59	96.7	90.25	14.51	64	100.0	58	90.6	85.99	17.53
Baseline	Missing	3	100.0	3	100.0	87.50	12.50	6	100.0	6	100.0	70.83	20.41
Week 24	Missing	3	100.0	3	100.0	95.83	7.22	6	100.0	4	66.7	90.63	11.97

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tw24_QSBOP_IT_09AUG2022_41986.xls
 03JUN2024 17:38

POPULATION: Intent-To-Treat Population
 ENDPPOINT: NEI VFQ-25 Near Activities Subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients		Statistics		Patients		Statistics					
		in study ¹	%	with value ²	%	Mean ²	SD(Mean) ²	in study ¹	%	with value ²	%	Mean ²	SD(Mean) ²
All													
Baseline	n/a	366	100,0	364	99,5	70,65	23,46	363	100,0	362	99,7	70,65	21,59
Week 24	n/a	365	99,7	341	93,4	79,28	19,68	362	99,7	331	91,4	79,91	19,06
Gender													
Baseline	Male	193	100,0	192	99,5	71,61	23,25	200	100,0	199	99,5	73,26	20,67
Week 24	Male	192	99,5	177	92,2	80,23	18,98	200	100,0	180	90,0	81,34	17,75
Baseline	Female	173	100,0	172	99,4	69,57	23,71	163	100,0	163	100,0	67,46	22,32
Week 24	Female	173	100,0	164	94,8	78,25	20,42	162	99,4	151	93,2	78,20	20,43
Age													
Baseline	<65 years	162	100,0	162	100,0	73,41	23,53	158	100,0	157	99,4	68,58	22,28
Week 24	<65 years	161	99,4	151	93,8	82,26	18,00	157	99,4	139	88,5	79,65	19,15
Baseline	>=65 years	204	100,0	202	99,0	68,44	23,23	205	100,0	205	100,0	72,24	20,96
Week 24	>=65 years	204	100,0	190	93,1	76,91	20,67	205	100,0	192	93,7	80,10	19,03
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100,0	105	99,1	69,29	25,01	105	100,0	105	100,0	71,07	22,70
Week 24	35 - 54 letters	106	100,0	101	95,3	77,15	19,24	105	100,0	97	92,4	80,28	17,74
Baseline	<=34 letters	79	100,0	78	98,7	61,00	23,93	80	100,0	80	100,0	66,82	24,76
Week 24	<=34 letters	79	100,0	71	89,9	72,07	22,45	80	100,0	74	92,5	75,90	20,53
Baseline	>=55 letters	181	100,0	181	100,0	75,60	20,91	178	100,0	177	99,4	72,13	19,17
Week 24	>=55 letters	180	99,4	169	93,9	83,58	17,61	177	99,4	160	90,4	81,54	18,97
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	34	97,1	61,27	23,83	36	100,0	36	100,0	65,28	23,61
Week 24	<=23 letters	35	100,0	32	91,4	65,10	23,13	36	100,0	32	88,9	72,66	20,98
Baseline	>=24 letters	331	100,0	330	99,7	71,62	23,24	327	100,0	326	99,7	71,24	21,31
Week 24	>=24 letters	330	99,7	309	93,6	80,74	18,73	326	99,7	299	91,7	80,69	18,71
Geographic Region													
Baseline	Europe	111	100,0	110	99,1	68,41	24,00	114	100,0	113	99,1	72,31	19,96
Week 24	Europe	111	100,0	102	91,9	74,18	22,23	114	100,0	103	90,4	78,80	19,80
Baseline	America	147	100,0	146	99,3	70,18	23,15	146	100,0	146	100,0	66,95	23,54
Week 24	America	146	99,3	137	93,8	80,72	17,84	145	99,3	133	91,7	79,67	19,37
Baseline	Asia Pacific (inc. Australia)	108	100,0	108	100,0	73,57	23,22	103	100,0	103	100,0	74,07	19,76
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	82,43	18,50	103	100,0	95	92,2	81,45	17,85
Race/ethnicity													
Baseline	White	243	100,0	241	99,2	70,06	23,17	253	100,0	252	99,6	69,87	22,04
Week 24	White	242	99,6	227	93,8	77,72	20,47	252	99,6	231	91,7	79,83	19,30
Baseline	Asian	89	100,0	89	100,0	73,97	22,95	88	100,0	88	100,0	73,77	20,89
Week 24	Asian	89	100,0	85	95,5	82,94	18,23	88	100,0	80	90,9	80,99	19,14
Baseline	Other	13	100,0	13	100,0	64,10	22,41	17	100,0	17	100,0	64,71	19,88
Week 24	Other	13	100,0	13	100,0	80,13	15,04	17	100,0	15	88,2	76,11	18,06
Baseline	Unknown	21	100,0	21	100,0	67,46	28,86	5	100,0	5	100,0	75,00	10,21
Week 24	Unknown	21	100,0	16	76,2	81,25	17,61	5	100,0	5	100,0	77,50	8,12
Baseline RVO status													
Baseline	CRVO	302	100,0	300	99,3	70,35	24,11	293	100,0	292	99,7	71,35	21,10
Week 24	CRVO	301	99,7	279	92,7	79,30	19,74	292	99,7	269	92,1	81,10	18,44
Baseline	HRVO	61	100,0	61	100,0	72,34	20,61	64	100,0	64	100,0	68,23	23,47
Week 24	HRVO	61	100,0	59	96,7	78,67	19,95	64	100,0	58	90,6	74,14	20,81
Baseline	Missing	3	100,0	3	100,0	66,67	8,33	6	100,0	6	100,0	62,50	25,14
Week 24	Missing	3	100,0	3	100,0	88,89	4,81	6	100,0	4	66,7	83,33	23,57

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CUT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CUT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_TW24_QSBNB_IT_09AUG2022_41986.xls
 03JUN2024 17:19

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Distance Activities Subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients		Statistics		Patients		Statistics					
		in study ¹	%	with value ²	%	Mean ²	SD(Mean)	in study ¹	%	with value ²	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100,0	362	98,9	75,48	22,61	363	100,0	362	99,7	76,37	21,69
Week 24	n/a	365	99,7	340	93,2	84,64	18,06	362	99,7	331	91,4	84,78	17,24
Gender													
Baseline	Male	193	100,0	191	99,0	78,66	21,12	200	100,0	199	99,5	80,00	20,25
Week 24	Male	192	99,5	177	92,2	88,16	14,89	200	100,0	180	90,0	86,83	14,96
Baseline	Female	173	100,0	171	98,8	71,93	23,72	163	100,0	163	100,0	71,93	22,61
Week 24	Female	173	100,0	163	94,2	80,83	20,34	162	99,4	151	93,2	82,34	19,39
Age													
Baseline	<65 years	162	100,0	162	100,0	80,61	20,30	158	100,0	157	99,4	75,77	21,67
Week 24	<65 years	161	99,4	151	93,8	88,25	14,60	157	99,4	139	88,5	85,04	17,64
Baseline	>=65 years	204	100,0	200	98,0	71,33	23,56	205	100,0	205	100,0	76,83	21,75
Week 24	>=65 years	204	100,0	189	92,6	81,77	19,99	205	100,0	192	93,7	84,59	16,99
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100,0	104	98,1	73,56	24,27	105	100,0	105	100,0	76,83	22,12
Week 24	35 - 54 letters	106	100,0	101	95,3	84,08	19,31	105	100,0	97	92,4	87,50	13,59
Baseline	<=34 letters	79	100,0	78	98,7	66,88	23,68	80	100,0	80	100,0	71,46	24,25
Week 24	<=34 letters	79	100,0	71	89,9	77,99	21,45	80	100,0	74	92,5	78,27	21,05
Baseline	>=55 letters	181	100,0	180	99,4	80,32	19,81	178	100,0	177	99,4	78,32	19,92
Week 24	>=55 letters	180	99,4	168	93,3	87,80	14,74	177	99,4	160	90,4	86,15	16,61
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	34	97,1	70,59	22,57	36	100,0	36	100,0	67,94	21,86
Week 24	<=23 letters	35	100,0	32	91,4	75,65	22,00	36	100,0	32	88,9	77,34	18,48
Baseline	>=24 letters	331	100,0	328	99,1	75,99	22,58	327	100,0	326	99,7	77,30	21,50
Week 24	>=24 letters	330	99,7	308	93,3	85,58	17,38	326	99,7	299	91,7	85,58	16,94
Geographic Region													
Baseline	Europe	111	100,0	109	98,2	75,04	25,28	114	100,0	113	99,1	79,20	20,54
Week 24	Europe	111	100,0	101	91,0	82,10	23,32	114	100,0	103	90,4	84,51	17,02
Baseline	America	147	100,0	146	99,3	74,37	21,89	146	100,0	146	100,0	72,40	23,44
Week 24	America	146	99,3	137	93,8	85,77	15,65	145	99,3	133	91,7	83,83	18,94
Baseline	Asia Pacific (inc. Australia)	108	100,0	107	99,1	77,45	20,69	103	100,0	103	100,0	78,88	19,58
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	85,66	14,75	103	100,0	95	92,2	86,40	14,89
Race/ethnicity													
Baseline	White	243	100,0	240	98,8	74,93	23,55	253	100,0	252	99,6	76,21	22,07
Week 24	White	242	99,6	226	93,4	84,20	19,64	252	99,6	231	91,7	84,88	16,57
Baseline	Asian	89	100,0	88	98,9	78,31	20,74	88	100,0	88	100,0	78,08	19,87
Week 24	Asian	89	100,0	85	95,5	86,18	13,79	88	100,0	80	90,9	85,52	17,41
Baseline	Other	13	100,0	13	100,0	66,67	18,63	17	100,0	17	100,0	68,63	26,52
Week 24	Other	13	100,0	13	100,0	86,54	12,52	17	100,0	15	88,2	76,94	26,06
Baseline	Unknown	21	100,0	21	100,0	75,40	20,62	5	100,0	5	100,0	80,83	12,36
Week 24	Unknown	21	100,0	16	76,2	81,25	19,18	5	100,0	5	100,0	91,67	8,33
Baseline RVO status													
Baseline	CRVO	302	100,0	298	98,7	75,78	22,71	293	100,0	292	99,7	77,28	20,91
Week 24	CRVO	301	99,7	278	92,4	84,67	17,92	292	99,7	269	92,1	85,35	16,95
Baseline	HRVO	61	100,0	61	100,0	74,93	21,01	64	100,0	64	100,0	73,63	23,39
Week 24	HRVO	61	100,0	59	96,7	84,82	18,68	64	100,0	58	90,6	81,68	18,75
Baseline	Missing	3	100,0	3	100,0	56,94	43,77	6	100,0	6	100,0	61,11	34,83
Week 24	Missing	3	100,0	3	100,0	79,17	26,02	6	100,0	4	66,7	91,67	9,62

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_TW24_QSBDL_IT_09AUG2022_41986.xls
 03JUN2024 17:22

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Vision Specific Social Functioning subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients			Statistics			Patients			Statistics		
		in study ¹	%	with value ²	%	Mean ²	SD(Mean)	in study ¹	%	with value ²	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100,0	364	99,5	87,98	18,01	363	100,0	362	99,7	88,98	17,85
Week 24	n/a	365	99,7	341	93,4	92,93	14,28	362	99,7	331	91,4	94,60	11,42
Gender													
Baseline	Male	193	100,0	192	99,5	88,09	18,06	200	100,0	199	99,5	89,70	17,34
Week 24	Male	192	99,5	177	92,2	94,07	11,47	200	100,0	180	90,0	95,28	9,72
Baseline	Female	173	100,0	172	99,4	87,86	18,01	163	100,0	163	100,0	88,11	18,47
Week 24	Female	173	100,0	164	94,8	91,69	16,75	162	99,4	151	93,2	93,79	13,14
Age													
Baseline	<65 years	162	100,0	162	100,0	90,43	15,98	158	100,0	157	99,4	87,18	17,96
Week 24	<65 years	161	99,4	151	93,8	93,87	12,90	157	99,4	139	88,5	95,14	10,80
Baseline	>=65 years	204	100,0	202	99,0	86,01	19,30	205	100,0	205	100,0	90,37	17,68
Week 24	>=65 years	204	100,0	190	93,1	92,17	15,28	205	100,0	192	93,7	94,21	11,85
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100,0	105	99,1	85,83	19,69	105	100,0	105	100,0	88,69	19,03
Week 24	35 - 54 letters	106	100,0	101	95,3	91,46	16,00	105	100,0	97	92,4	95,10	10,14
Baseline	<=34 letters	79	100,0	78	98,7	82,05	20,40	80	100,0	80	100,0	84,69	21,14
Week 24	<=34 letters	79	100,0	71	89,9	88,03	18,47	80	100,0	74	92,5	90,71	16,43
Baseline	>=55 letters	181	100,0	181	100,0	91,78	14,81	178	100,0	177	99,4	91,10	15,03
Week 24	>=55 letters	180	99,4	169	93,9	95,86	9,90	177	99,4	160	90,4	96,09	8,66
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	34	97,1	85,29	15,83	36	100,0	36	100,0	82,64	18,49
Week 24	<=23 letters	35	100,0	32	91,4	84,38	20,08	36	100,0	32	88,9	89,84	16,33
Baseline	>=24 letters	331	100,0	330	99,7	88,26	18,22	327	100,0	326	99,7	89,69	17,66
Week 24	>=24 letters	330	99,7	309	93,6	93,81	13,27	326	99,7	299	91,7	95,11	10,67
Geographic Region													
Baseline	Europe	111	100,0	110	99,1	87,27	19,74	114	100,0	113	99,1	88,83	17,94
Week 24	Europe	111	100,0	102	91,9	89,71	19,62	114	100,0	103	90,4	93,45	12,84
Baseline	America	147	100,0	146	99,3	87,67	18,45	146	100,0	146	100,0	85,87	19,87
Week 24	America	146	99,3	137	93,8	93,98	11,85	145	99,3	133	91,7	94,17	11,67
Baseline	Asia Pacific (inc. Australia)	108	100,0	108	100,0	89,12	15,48	103	100,0	103	100,0	93,57	13,31
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	94,73	9,86	103	100,0	95	92,2	96,45	9,05
Race/ethnicity													
Baseline	White	243	100,0	241	99,2	88,80	17,94	253	100,0	252	99,6	88,14	18,31
Week 24	White	242	99,6	227	93,8	92,46	15,52	252	99,6	231	91,7	94,37	11,57
Baseline	Asian	89	100,0	89	100,0	87,78	16,32	88	100,0	88	100,0	91,48	16,36
Week 24	Asian	89	100,0	85	95,5	94,12	10,31	88	100,0	80	90,9	95,31	11,14
Baseline	Other	13	100,0	13	100,0	77,88	24,02	17	100,0	17	100,0	87,50	19,76
Week 24	Other	13	100,0	13	100,0	95,19	9,60	17	100,0	15	88,2	94,17	11,44
Baseline	Unknown	21	100,0	21	100,0	85,71	20,65	5	100,0	5	100,0	92,50	11,18
Week 24	Unknown	21	100,0	16	76,2	91,41	17,51	5	100,0	5	100,0	95,00	11,18
Baseline RVO status													
Baseline	CRVO	302	100,0	300	99,3	87,96	17,48	293	100,0	292	99,7	89,43	17,09
Week 24	CRVO	301	99,7	279	92,7	92,88	14,11	292	99,7	269	92,1	94,89	10,88
Baseline	HRVO	61	100,0	61	100,0	88,32	20,78	64	100,0	64	100,0	88,87	18,38
Week 24	HRVO	61	100,0	59	96,7	93,22	15,28	64	100,0	58	90,6	93,10	13,89
Baseline	Missing	3	100,0	3	100,0	83,33	14,43	6	100,0	6	100,0	68,75	35,13
Week 24	Missing	3	100,0	3	100,0	91,67	14,43	6	100,0	4	66,7	96,88	6,25

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tw24_QSBSF_IT_09AUG2022_41986.xls
 03JUN2024 17:44

POPULATION: Indian-Tribes Population
 HYPOTHESIS: proportion of incidence with a >= 10-point improvement from baseline in HSE VQ-01 social functioning subscale at week 14
 MODEL: stratified analysis by baseline SMD WPM letter score, geographic region
 STUDY: WATSON
 Substratification Analysis by Subgroup (Efficiency)

Name	Label	Population (N=166)				At-Risk (N=162)				Observed Incidence	Population vs. At-Risk			Relative Risk			At-Risk vs. Population		
		Participants		Participants with Event		Participants		Participants with Event			Relative Risk	95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI	95% Upper CI
		N	%	N	%	N	%	N	%										
All	n/a	129	78.4	41	25.4	129	80.4	41	31.7	0.22	0.15	0.32	0.22	0.15	0.32	0.22	0.15	0.32	
Gender	Male	179	89.1	22	12.3	179	89.1	22	12.3	0.13	0.08	0.21	0.13	0.08	0.21	0.13	0.08	0.21	
	Female	128	64.8	20	15.6	128	64.8	20	15.6	0.24	0.17	0.34	0.24	0.17	0.34	0.24	0.17	0.34	
Race	US White	113	56.1	13	11.5	113	56.1	13	11.5	0.11	0.07	0.17	0.11	0.07	0.17	0.11	0.07	0.17	
	US Black	113	56.1	13	11.5	113	56.1	13	11.5	0.24	0.17	0.34	0.24	0.17	0.34	0.24	0.17	0.34	
Baseline SMD WPM	<28 letters	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	28-34 letters	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	>=35 letters	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
Baseline SMD WPM	<12 letters	10	5.0	0	0.0	10	5.0	0	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	12-18 letters	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	>=19 letters	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
Baseline SMD WPM	<12 letters	10	5.0	0	0.0	10	5.0	0	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	12-18 letters	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	>=19 letters	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
Age (years)	18-24	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	25-34	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	35-44	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	45-54	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	55-64	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	65-74	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	75-84	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	85-94	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	95-104	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	105-114	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	115-124	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	125-134	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	135-144	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	145-154	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	155-164	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	165-174	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	175-184	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	185-194	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	195-204	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	205-214	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	215-224	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	225-234	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	235-244	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	245-254	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	255-264	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	265-274	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	275-284	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	285-294	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	295-304	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	305-314	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	315-324	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	325-334	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	335-344	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	345-354	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	355-364	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	365-374	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	375-384	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	385-394	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	395-404	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	405-414	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	415-424	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	425-434	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	435-444	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	445-454	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	455-464	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	465-474	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	475-484	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	485-494	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	
	495-504	100	50.0	10	10.0	100	50.0	10	10.0	0.21	0.15	0.29	0.21	0.15	0.29	0.21	0.15	0.29	

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Vision Specific Mental Health subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients				Statistics		Patients				Statistics	
		in study ¹	%	with value ²	%	Mean ²	SD(Mean) ²	in study ¹	%	with value ²	%	Mean ²	SD(Mean) ²
All													
Baseline	n/a	366	100,0	364	99,5	64,87	24,86	363	100,0	362	99,7	64,36	24,02
Week 24	n/a	365	99,7	341	93,4	75,57	21,97	362	99,7	331	91,4	77,55	19,97
Gender													
Baseline	Male	193	100,0	192	99,5	66,44	23,74	200	100,0	199	99,5	67,09	23,28
Week 24	Male	192	99,5	177	92,2	77,75	19,85	200	100,0	180	90,0	79,44	18,29
Baseline	Female	173	100,0	172	99,4	63,12	26,01	163	100,0	163	100,0	61,04	24,57
Week 24	Female	173	100,0	164	94,8	73,21	23,88	162	99,4	151	93,2	75,29	21,65
Age													
Baseline	<65 years	162	100,0	162	100,0	65,05	24,93	158	100,0	157	99,4	60,71	24,71
Week 24	<65 years	161	99,4	151	93,8	76,45	21,38	157	99,4	139	88,5	76,03	20,04
Baseline	>=65 years	204	100,0	202	99,0	64,73	24,87	205	100,0	205	100,0	67,16	23,16
Week 24	>=65 years	204	100,0	190	93,1	74,87	22,46	205	100,0	192	93,7	78,65	19,90
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100,0	105	99,1	60,89	27,38	105	100,0	105	100,0	63,27	25,63
Week 24	35 - 54 letters	106	100,0	101	95,3	70,67	22,72	105	100,0	97	92,4	78,48	19,62
Baseline	<=34 letters	79	100,0	78	98,7	54,57	25,28	80	100,0	80	100,0	59,38	25,29
Week 24	<=34 letters	79	100,0	71	89,9	70,16	24,19	80	100,0	74	92,5	74,07	21,24
Baseline	>=55 letters	181	100,0	181	100,0	71,62	20,95	178	100,0	177	99,4	67,27	22,09
Week 24	>=55 letters	180	99,4	169	93,9	80,77	19,28	177	99,4	160	90,4	78,59	19,52
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	34	97,1	56,43	22,06	36	100,0	36	100,0	58,85	25,72
Week 24	<=23 letters	35	100,0	32	91,4	68,95	24,57	36	100,0	32	88,9	74,02	22,29
Baseline	>=24 letters	331	100,0	330	99,7	65,74	25,00	327	100,0	326	99,7	64,97	23,79
Week 24	>=24 letters	330	99,7	309	93,6	76,25	21,61	326	99,7	299	91,7	77,93	19,71
Geographic Region													
Baseline	Europe	111	100,0	110	99,1	61,36	25,97	114	100,0	113	99,1	65,49	21,60
Week 24	Europe	111	100,0	102	91,9	72,18	24,95	114	100,0	103	90,4	75,36	19,76
Baseline	America	147	100,0	146	99,3	65,03	25,40	146	100,0	146	100,0	60,92	26,55
Week 24	America	146	99,3	137	93,8	76,73	20,52	145	99,3	133	91,7	78,24	21,25
Baseline	Asia Pacific (inc. Australia)	108	100,0	108	100,0	68,23	22,61	103	100,0	103	100,0	68,02	22,28
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	77,39	20,46	103	100,0	95	92,2	78,95	18,30
Race/ethnicity													
Baseline	White	243	100,0	241	99,2	64,60	25,01	253	100,0	252	99,6	64,26	23,90
Week 24	White	242	99,6	227	93,8	75,47	22,66	252	99,6	231	91,7	77,60	20,32
Baseline	Asian	89	100,0	89	100,0	68,75	22,61	88	100,0	88	100,0	67,33	24,30
Week 24	Asian	89	100,0	85	95,5	76,99	20,58	88	100,0	80	90,9	77,89	19,71
Baseline	Other	13	100,0	13	100,0	58,17	25,69	17	100,0	17	100,0	52,57	20,97
Week 24	Other	13	100,0	13	100,0	73,08	18,11	17	100,0	15	88,2	76,25	17,39
Baseline	Unknown	21	100,0	21	100,0	55,65	29,64	5	100,0	5	100,0	57,50	28,44
Week 24	Unknown	21	100,0	16	76,2	71,48	23,16	5	100,0	5	100,0	73,75	20,44
Baseline RVO status													
Baseline	CRVO	302	100,0	300	99,3	65,15	24,70	293	100,0	292	99,7	65,30	23,60
Week 24	CRVO	301	99,7	279	92,7	75,87	21,54	292	99,7	269	92,1	78,11	19,84
Baseline	HRVO	61	100,0	61	100,0	63,83	25,57	64	100,0	64	100,0	61,33	25,63
Week 24	HRVO	61	100,0	59	96,7	74,58	23,81	64	100,0	58	90,6	74,89	20,93
Baseline	Missing	3	100,0	3	100,0	58,33	35,54	6	100,0	6	100,0	51,04	24,18
Week 24	Missing	3	100,0	3	100,0	66,67	30,83	6	100,0	4	66,7	78,13	14,88

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tw24_QSBMM_IT_09AUG2022_41986.xls
 03JUN2024 17:35

POPULATION: ISRAELI-TOYOTA Population
 HIERARCHY: Projection of incidence with a >= 10-point improvement from baseline in the WHO-6 mental health subscale at week 14
 MODEL: Stratified Analysis by Baseline MVA MVA Letter score, Geographic region
 EVENT: WASHIN
 Substratum Analysis by Subgroup (Efficiency)

Name	Letter	Placebo (N=164)				Active (N=164)				ORR Ratio	Stratified vs. Reference				Relative Risk				Interaction Test			
		Patients with Event		Patients with Event		Patients with Event		Patients with Event			ORR Ratio	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI	p-value (Odds-Ratio-based)	Interaction Test p-value (Likelihood Ratio)	Relative Risk	Lower CI	Upper CI	
		N	%	N	%	N	%	N	%													
All	1-4	120	52.4	124	51.1	120	51.1	124	51.4	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
Gender	Male	179	48.1	173	49.1	179	48.1	173	49.1	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	Female	120	44.2	124	51.1	120	44.2	124	51.1	0.68	0.54	0.83	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
Age	18-34 years	113	41.1	113	41.1	113	41.1	113	41.1	0.68	0.54	0.83	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	>=35 years	120	51.4	124	51.4	120	51.4	124	51.4	0.75	0.61	0.91	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
Baseline MVA MVA Letter score	1-36 letters	100	19.1	100	19.1	100	19.1	100	19.1	0.65	0.48	0.82	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	37-48 letters	120	51.4	124	51.4	120	51.4	124	51.4	0.75	0.61	0.91	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	>=49 letters	120	48.2	124	43.4	120	48.2	124	43.4	0.62	0.48	0.76	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
Baseline MVA MVA Letter score	<=22 letters	113	8.4	113	41.1	113	8.4	113	41.1	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	>=23 letters	120	48.2	124	51.4	120	48.2	124	51.4	0.62	0.48	0.76	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
Geographic Region	Asia	120	48.2	124	51.4	120	48.2	124	51.4	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	Europe	120	48.2	124	51.4	120	48.2	124	51.4	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	Latin America	120	48.2	124	51.4	120	48.2	124	51.4	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	North America	120	48.2	124	51.4	120	48.2	124	51.4	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	Oceania	120	48.2	124	51.4	120	48.2	124	51.4	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	South America	120	48.2	124	51.4	120	48.2	124	51.4	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	Unknown	120	48.2	124	51.4	120	48.2	124	51.4	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
Baseline WHO status	None	103	16.1	103	16.1	103	16.1	103	16.1	0.62	0.48	0.76	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	Mild	120	41.4	124	42.0	120	41.4	124	42.0	0.72	0.58	0.87	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17
	Severe	120	48.2	124	51.4	120	48.2	124	51.4	0.62	0.48	0.76	0.14	0.11	0.17	0.14	0.14	0.11	0.17	0.14	0.11	0.17

Test for interaction based on RR (Log-Binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Only patients with at least one event are used for analysis. The stratification factor is included if the variable is involved in the subgroup. OR is computed by stratified analysis. RR and RD by adjusted analysis.
 Observed counts were used regardless of the occurrence of treatment events (Primary Analysis).
 CI: 95% confidence interval
 Program: mva_analysis_000007401_0070303_0041586_data_analysis_ACR_RMR_Toyota_T02_T04_T06_T08_T10_T12_T14_T16_T18_T20_T22_T24_T26_T28_T30_T32_T34_T36_T38_T40_T42_T44_T46_T48_T50_T52_T54_T56_T58_T60_T62_T64_T66_T68_T70_T72_T74_T76_T78_T80_T82_T84_T86_T88_T90_T92_T94_T96_T98_T100
 Output: /mnt/c/Users/robert/OneDrive/Documents/mva_analysis_ACR_RMR_Toyota_T02_T04_T06_T08_T10_T12_T14_T16_T18_T20_T22_T24_T26_T28_T30_T32_T34_T36_T38_T40_T42_T44_T46_T48_T50_T52_T54_T56_T58_T60_T62_T64_T66_T68_T70_T72_T74_T76_T78_T80_T82_T84_T86_T88_T90_T92_T94_T96_T98_T100_010

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Vision Specific Role Difficulties subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients		Statistics				Patients		Statistics			
		in study ¹	%	with value ²	%	Mean ²	SD(Mean)	in study ¹	%	with value ²	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100.0	364	99.5	68.03	29.82	363	100.0	362	99.7	68.82	28.42
Week 24	n/a	365	99.7	340	93.2	79.41	24.13	362	99.7	331	91.4	80.59	24.69
Gender													
Baseline	Male	193	100.0	192	99.5	69.53	30.10	200	100.0	199	99.5	72.05	28.34
Week 24	Male	192	99.5	176	91.7	82.74	21.08	200	100.0	180	90.0	84.24	22.24
Baseline	Female	173	100.0	172	99.4	66.35	29.50	163	100.0	163	100.0	64.88	28.11
Week 24	Female	173	100.0	164	94.8	75.84	26.64	162	99.4	151	93.2	76.24	26.76
Age													
Baseline	<65 years	162	100.0	162	100.0	68.52	30.94	158	100.0	157	99.4	63.38	30.75
Week 24	<65 years	161	99.4	151	93.8	80.22	23.29	157	99.4	139	88.5	81.56	21.72
Baseline	>=65 years	204	100.0	202	99.0	67.64	28.96	205	100.0	205	100.0	72.99	25.81
Week 24	>=65 years	204	100.0	189	92.6	78.77	24.83	205	100.0	192	93.7	79.88	26.67
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100.0	105	99.1	63.81	31.00	105	100.0	105	100.0	68.33	27.95
Week 24	35 - 54 letters	106	100.0	100	94.3	76.38	26.17	105	100.0	97	92.4	80.93	25.52
Baseline	<=34 letters	79	100.0	78	98.7	59.29	31.63	80	100.0	80	100.0	66.41	30.40
Week 24	<=34 letters	79	100.0	71	89.9	71.65	24.73	80	100.0	74	92.5	76.52	25.67
Baseline	>=55 letters	181	100.0	181	100.0	74.24	26.98	178	100.0	177	99.4	70.20	27.85
Week 24	>=55 letters	180	99.4	169	93.9	84.47	21.46	177	99.4	160	90.4	82.27	23.65
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100.0	34	97.1	61.76	28.86	36	100.0	36	100.0	65.63	30.09
Week 24	<=23 letters	35	100.0	32	91.4	71.48	23.17	36	100.0	32	88.9	76.56	26.89
Baseline	>=24 letters	331	100.0	330	99.7	68.67	29.88	327	100.0	326	99.7	69.17	28.26
Week 24	>=24 letters	330	99.7	308	93.3	80.24	24.12	326	99.7	299	91.7	81.02	24.46
Geographic Region													
Baseline	Europe	111	100.0	110	99.1	64.09	32.57	114	100.0	113	99.1	67.26	28.26
Week 24	Europe	111	100.0	102	91.9	73.77	28.17	114	100.0	103	90.4	76.70	25.37
Baseline	America	147	100.0	146	99.3	70.03	30.17	146	100.0	146	100.0	67.12	29.83
Week 24	America	146	99.3	136	93.2	82.35	22.28	145	99.3	133	91.7	82.71	24.89
Baseline	Asia Pacific (inc. Australia)	108	100.0	108	100.0	69.33	26.05	103	100.0	103	100.0	72.94	26.32
Week 24	Asia Pacific (inc. Australia)	108	100.0	102	94.4	81.13	21.24	103	100.0	95	92.2	81.84	23.40
Race/ethnicity													
Baseline	White	243	100.0	241	99.2	67.74	31.53	253	100.0	252	99.6	67.96	28.95
Week 24	White	242	99.6	226	93.4	77.99	25.65	252	99.6	231	91.7	80.41	25.20
Baseline	Asian	89	100.0	89	100.0	70.37	25.80	88	100.0	88	100.0	72.73	26.71
Week 24	Asian	89	100.0	85	95.5	81.76	20.91	88	100.0	80	90.9	82.03	23.94
Baseline	Other	13	100.0	13	100.0	59.62	21.74	17	100.0	17	100.0	62.50	28.30
Week 24	Other	13	100.0	13	100.0	81.73	17.39	17	100.0	15	88.2	76.67	19.97
Baseline	Unknown	21	100.0	21	100.0	66.67	30.45	5	100.0	5	100.0	65.00	32.36
Week 24	Unknown	21	100.0	16	76.2	85.16	22.46	5	100.0	5	100.0	77.50	31.12
Baseline RVO status													
Baseline	CRVO	302	100.0	300	99.3	68.21	29.35	293	100.0	292	99.7	69.73	28.05
Week 24	CRVO	301	99.7	278	92.4	79.45	23.53	292	99.7	269	92.1	80.99	25.22
Baseline	HRVO	61	100.0	61	100.0	67.62	32.39	64	100.0	64	100.0	66.02	28.99
Week 24	HRVO	61	100.0	59	96.7	80.08	25.96	64	100.0	58	90.6	79.09	21.64
Baseline	Missing	3	100.0	3	100.0	58.33	31.46	6	100.0	6	100.0	54.17	39.26
Week 24	Missing	3	100.0	3	100.0	62.50	45.07	6	100.0	4	66.7	75.00	35.36

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tw24_QSBRD_IT_09AUG2022_41986.xls
 03JUN2024 17:42

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Vision Specific Dependency subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients			Statistics			Patients			Statistics		
		in study ¹	%	with value ²	%	Mean ²	SD(Mean)	in study ¹	%	with value ²	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100,0	364	99,5	80,68	26,16	363	100,0	362	99,7	83,68	24,78
Week 24	n/a	365	99,7	341	93,4	87,95	19,89	362	99,7	331	91,4	91,24	18,19
Gender													
Baseline	Male	193	100,0	192	99,5	83,03	23,99	200	100,0	199	99,5	86,85	22,21
Week 24	Male	192	99,5	177	92,2	90,87	17,26	200	100,0	180	90,0	93,70	14,83
Baseline	Female	173	100,0	172	99,4	78,05	28,23	163	100,0	163	100,0	79,81	27,17
Week 24	Female	173	100,0	164	94,8	84,81	22,00	162	99,4	151	93,2	88,30	21,20
Age													
Baseline	<65 years	162	100,0	162	100,0	82,92	24,50	158	100,0	157	99,4	82,59	25,50
Week 24	<65 years	161	99,4	151	93,8	89,68	18,02	157	99,4	139	88,5	91,97	18,86
Baseline	>=65 years	204	100,0	202	99,0	78,88	27,34	205	100,0	205	100,0	84,51	24,25
Week 24	>=65 years	204	100,0	190	93,1	86,58	21,20	205	100,0	192	93,7	90,71	17,72
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100,0	105	99,1	76,75	29,04	105	100,0	105	100,0	84,29	24,55
Week 24	35 - 54 letters	106	100,0	101	95,3	85,73	21,81	105	100,0	97	92,4	92,61	16,13
Baseline	<=34 letters	79	100,0	78	98,7	69,66	28,07	80	100,0	80	100,0	76,98	28,35
Week 24	<=34 letters	79	100,0	71	89,9	80,05	22,65	80	100,0	74	92,5	87,84	20,33
Baseline	>=55 letters	181	100,0	181	100,0	87,71	21,07	178	100,0	177	99,4	86,35	22,69
Week 24	>=55 letters	180	99,4	169	93,9	92,60	15,89	177	99,4	160	90,4	91,98	18,24
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	34	97,1	74,26	25,65	36	100,0	36	100,0	74,07	27,44
Week 24	<=23 letters	35	100,0	32	91,4	79,95	22,29	36	100,0	32	88,9	86,98	19,62
Baseline	>=24 letters	331	100,0	330	99,7	81,34	26,16	327	100,0	326	99,7	84,74	24,28
Week 24	>=24 letters	330	99,7	309	93,6	88,78	19,47	326	99,7	299	91,7	91,69	18,00
Geographic Region													
Baseline	Europe	111	100,0	110	99,1	78,11	29,41	114	100,0	113	99,1	89,09	19,19
Week 24	Europe	111	100,0	102	91,9	84,80	24,16	114	100,0	103	90,4	92,39	14,20
Baseline	America	147	100,0	146	99,3	82,65	24,96	146	100,0	146	100,0	79,00	28,72
Week 24	America	146	99,3	137	93,8	89,72	17,22	145	99,3	133	91,7	90,60	20,03
Baseline	Asia Pacific (inc. Australia)	108	100,0	108	100,0	80,63	24,16	103	100,0	103	100,0	84,39	23,06
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	88,73	18,27	103	100,0	95	92,2	90,88	19,41
Race/ethnicity													
Baseline	White	243	100,0	241	99,2	81,09	26,94	253	100,0	252	99,6	84,69	24,25
Week 24	White	242	99,6	227	93,8	88,11	20,17	252	99,6	231	91,7	92,14	16,67
Baseline	Asian	89	100,0	89	100,0	80,62	23,63	88	100,0	88	100,0	82,20	25,34
Week 24	Asian	89	100,0	85	95,5	88,43	17,96	88	100,0	80	90,9	88,85	21,62
Baseline	Other	13	100,0	13	100,0	70,51	20,87	17	100,0	17	100,0	78,92	27,81
Week 24	Other	13	100,0	13	100,0	80,77	20,24	17	100,0	15	88,2	92,22	17,10
Baseline	Unknown	21	100,0	21	100,0	82,54	30,38	5	100,0	5	100,0	75,00	33,85
Week 24	Unknown	21	100,0	16	76,2	89,06	25,59	5	100,0	5	100,0	85,00	29,11
Baseline RVO status													
Baseline	CRVO	302	100,0	300	99,3	80,78	26,00	293	100,0	292	99,7	84,79	23,32
Week 24	CRVO	301	99,7	279	92,7	87,63	20,36	292	99,7	269	92,1	91,51	18,10
Baseline	HRVO	61	100,0	61	100,0	80,33	27,18	64	100,0	64	100,0	80,08	28,16
Week 24	HRVO	61	100,0	59	96,7	89,69	17,26	64	100,0	58	90,6	90,09	19,21
Baseline	Missing	3	100,0	3	100,0	77,78	31,55	6	100,0	6	100,0	68,06	46,67
Week 24	Missing	3	100,0	3	100,0	83,33	28,87	6	100,0	4	66,7	89,58	7,98

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CUT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CUT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tw24_QSBDP_IT_09AUG2022_41986.xls
 03JUN2024 17:47

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Driving subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients		Statistics				Patients		Statistics			
		in study ¹	%	with value ²	%	Mean ³	SD (Mean)	in study ¹	%	with value ²	%	Mean ³	SD (Mean)
All													
Baseline	n/a	366	100.0	236	64.5	70.06	30.24	363	100.0	246	67.8	66.79	31.73
Week 24	n/a	365	99.7	217	59.5	76.50	26.92	362	99.7	226	62.4	78.85	25.35
Gender													
Baseline	Male	193	100.0	154	79.8	74.57	26.09	200	100.0	166	83.0	74.02	25.96
Week 24	Male	192	99.5	139	72.4	81.62	22.17	200	100.0	149	74.5	84.26	20.30
Baseline	Female	173	100.0	82	47.4	61.59	35.44	163	100.0	80	49.1	51.77	37.10
Week 24	Female	173	100.0	78	45.1	67.36	31.94	162	99.4	77	47.5	68.40	30.52
Age													
Baseline	<65 years	162	100.0	113	69.8	72.90	26.46	158	100.0	119	75.3	65.37	30.96
Week 24	<65 years	161	99.4	104	64.6	80.53	20.19	157	99.4	105	66.9	79.25	24.46
Baseline	>=65 years	204	100.0	123	60.3	67.45	33.23	205	100.0	127	62.0	68.11	32.50
Week 24	>=65 years	204	100.0	113	55.4	72.79	31.52	205	100.0	121	59.0	78.51	26.19
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100.0	68	64.2	62.07	32.09	105	100.0	72	68.6	61.28	35.47
Week 24	35 - 54 letters	106	100.0	65	61.3	72.24	27.06	105	100.0	65	61.9	82.37	23.65
Baseline	<=34 letters	79	100.0	43	54.4	63.18	34.13	80	100.0	48	60.0	62.93	32.17
Week 24	<=34 letters	79	100.0	41	51.9	65.85	33.74	80	100.0	45	56.3	70.83	28.32
Baseline	>=55 letters	181	100.0	125	69.1	76.77	26.18	178	100.0	126	70.8	71.40	28.72
Week 24	>=55 letters	180	99.4	111	61.7	82.92	22.10	177	99.4	116	65.5	79.99	24.61
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100.0	18	51.4	66.20	31.50	36	100.0	20	55.6	45.83	34.78
Week 24	<=23 letters	35	100.0	19	54.3	66.23	31.36	36	100.0	20	55.6	63.75	32.70
Baseline	>=24 letters	331	100.0	218	65.9	70.37	30.19	327	100.0	226	69.1	68.64	30.85
Week 24	>=24 letters	330	99.7	198	60.0	77.48	26.34	326	99.7	206	63.2	80.32	24.12
Geographic Region													
Baseline	Europe	111	100.0	62	55.9	70.36	32.52	114	100.0	77	67.5	67.91	31.26
Week 24	Europe	111	100.0	59	53.2	73.09	34.16	114	100.0	70	61.4	74.94	28.06
Baseline	America	147	100.0	112	76.2	68.94	29.10	146	100.0	111	76.0	63.51	31.39
Week 24	America	146	99.3	104	71.2	76.96	23.90	145	99.3	104	71.7	78.29	26.06
Baseline	Asia Pacific (inc. Australia)	108	100.0	62	57.4	71.77	30.30	103	100.0	58	56.3	71.55	32.82
Week 24	Asia Pacific (inc. Australia)	108	100.0	54	50.0	79.32	23.33	103	100.0	52	50.5	85.26	18.27
Race/ethnicity													
Baseline	White	243	100.0	164	67.5	69.82	30.49	253	100.0	187	73.9	66.56	31.62
Week 24	White	242	99.6	154	63.6	76.08	27.74	252	99.6	172	68.3	78.29	26.48
Baseline	Asian	89	100.0	47	52.8	71.45	30.78	88	100.0	45	51.1	67.59	33.95
Week 24	Asian	89	100.0	42	47.2	80.75	21.42	88	100.0	40	45.5	84.06	19.06
Baseline	Other	13	100.0	10	76.9	65.00	18.76	17	100.0	11	64.7	61.36	27.96
Week 24	Other	13	100.0	10	76.9	73.33	22.50	17	100.0	11	64.7	67.42	27.75
Baseline	Unknown	21	100.0	15	71.4	71.67	34.04	5	100.0	3	60.0	88.89	12.73
Week 24	Unknown	21	100.0	11	52.4	68.94	37.28	5	100.0	3	60.0	83.33	8.33
Baseline RVO status													
Baseline	CRVO	302	100.0	195	64.6	70.64	29.97	293	100.0	206	70.3	67.88	31.51
Week 24	CRVO	301	99.7	177	58.8	76.72	27.12	292	99.7	187	64.0	79.68	25.13
Baseline	HRVO	61	100.0	39	63.9	66.24	32.09	64	100.0	39	60.9	62.07	32.57
Week 24	HRVO	61	100.0	38	62.3	74.89	26.87	64	100.0	38	59.4	74.67	26.64
Baseline	Missing	3	100.0	2	66.7	87.50	17.68	6	100.0	1	16.7	25.00	NE
Week 24	Missing	3	100.0	2	66.7	87.50	5.89	6	100.0	1	16.7	83.33	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tw24_QSBDL_IT_09AUG2022_41986.xls
 03JUN2024 17:25

POPULATION: 2014-2024 Population
IMPURITY: Proportion of patients with a > 15-point improvement from baseline in MCQ WP-02 writing subscale at Week 24
NOTE: Stratified Analysis by Baseline MCQ WF06 Letter score, Geographic region
EVENT: WATERS
Substratum Analysis by Subgroup (Efficiency)

		Population (0.05)				At-Risk (0.05)				Population 0 - At-Risk											Population 0 - Population										
		Patients				Events				N		N		N		N		N		N		N		N		N		N		N	
		C	S	Q	N	C	S	Q	N	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE	SE		
		Patients				Events				N		N		N		N		N		N		N		N		N		N		N	
All	All	227	58.4	42	31.4	218	60.1	41	29.1	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	
Gender	Male	122	58.2	43	32.3	247	60.0	33	24.2	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	
	Female	105	58.7	22	20.7	151	59.9	28	24.2	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	
Race	Hispanic	110	57.8	23	21.4	212	61.0	42	29.8	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	
	Non-Hispanic	117	58.9	19	16.2	197	60.2	29	23.0	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	
Baseline MCQ WF06 Letter score	≥28 Letters	101	59.4	13	13.2	214	60.1	33	24.2	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.85	
	16-27 Letters	126	58.4	29	23.4	204	60.2	38	24.2	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	
	15-16 Letters	100	59.2	11	11.2	203	60.4	48	24.2	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	
Baseline MCQ WF06 Letter score	≥28 Letters	112	60.4	12	11.2	219	61.6	28	25.6	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	
	16-27 Letters	100	58.4	41	39.4	214	60.2	38	24.2	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	
	15-16 Letters	109	59.2	11	11.2	209	60.6	48	24.2	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	
Geographic region	Asia	22	60.4	3	14.4	10	60.0	1	10.0	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	
	Europe	108	57.8	28	28.4	212	60.8	37	24.2	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	
	North America	100	58.4	21	21.4	209	60.2	44	24.2	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	
	South America	10	60.4	2	20.4	21	60.0	1	10.0	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	0.74	
Year of birth	≤1964	108	59.2	12	14.4	208	60.6	41	24.2	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	
	1965-1979	119	58.4	30	28.4	210	60.4	44	24.2	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	
	≥1980	100	58.4	10	10.4	203	60.2	37	24.2	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	
Baseline MCQ WF06 Letter score	≥28 Letters	104	60.2	12	12.4	211	61.0	41	24.2	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	
	16-27 Letters	126	58.4	28	28.4	209	60.2	37	24.2	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	0.73	
	15-16 Letters	100	59.2	11	11.2	203	60.6	48	24.2	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	0.72	
MCQ WF06	MCQ	12	60.4	11	41.4	14	60.0	11	44.4	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87		
	WP06	10	60.4	11	41.4	14	60.0	11	44.4	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	
	WP07	10	60.4	11	41.4	14	60.0	11	44.4	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	0.87	

Test for interaction based on RR (Log-Binomial regression)
* Indicates convergence problem. Result is uninterpretable.
Only patients with at least one value are used for analysis. The stratification factor is excluded if the variable is involved in the subgroup. OR is computed by stratified analysis. RR and RR0 are adjusted relative.
Observed outcomes were used regardless of the occurrence of intercurrent events (Primary Intention).
Clinical use only (NDA000022)

Program: `cont/clinical_utilities/ROBERT421/DF010001/041586/data_analysis/ACR_SMB/primary/prop/prop_rr_eff_west_ag_mff_PROD_MCQ_Q08001_07_09/RO000022_41996.xlsx`
(Output: `cont/clinical_utilities/ROBERT421/DF010001/041586/data_analysis/ACR_SMB/primary/prop/prop_rr_eff_west_ag_mff_PROD_MCQ_Q08001_07_09/RO000022_41996.xlsx`)
04/09/2022 14:46

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Peripheral Vision subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients				Statistics		Patients				Statistics	
		in study ¹	%	with value ²	%	Mean ²	SD(Mean)	in study ¹	%	with value ²	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100,0	364	99,5	81,52	23,33	363	100,0	362	99,7	79,01	24,07
Week 24	n/a	365	99,7	341	93,4	88,56	18,52	362	99,7	331	91,4	87,54	18,71
Gender													
Baseline	Male	193	100,0	192	99,5	82,16	22,54	200	100,0	199	99,5	81,53	23,60
Week 24	Male	192	99,5	177	92,2	89,12	17,43	200	100,0	180	90,0	88,06	17,62
Baseline	Female	173	100,0	172	99,4	80,81	24,24	163	100,0	163	100,0	75,92	24,36
Week 24	Female	173	100,0	164	94,8	87,96	19,67	162	99,4	151	93,2	86,92	19,97
Age													
Baseline	<65 years	162	100,0	162	100,0	83,49	21,79	158	100,0	157	99,4	77,39	24,31
Week 24	<65 years	161	99,4	151	93,8	88,58	17,50	157	99,4	139	88,5	87,59	18,89
Baseline	>=65 years	204	100,0	202	99,0	79,95	24,44	205	100,0	205	100,0	80,24	23,87
Week 24	>=65 years	204	100,0	190	93,1	88,55	19,34	205	100,0	192	93,7	87,50	18,62
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100,0	105	99,1	79,76	25,73	105	100,0	105	100,0	83,33	21,83
Week 24	35 - 54 letters	106	100,0	101	95,3	87,62	20,50	105	100,0	97	92,4	87,89	18,44
Baseline	<=34 letters	79	100,0	78	98,7	74,68	24,34	80	100,0	80	100,0	70,94	26,82
Week 24	<=34 letters	79	100,0	71	89,9	84,51	20,43	80	100,0	74	92,5	82,77	23,01
Baseline	>=55 letters	181	100,0	181	100,0	85,50	20,59	178	100,0	177	99,4	80,08	23,28
Week 24	>=55 letters	180	99,4	169	93,9	90,83	16,05	177	99,4	160	90,4	89,53	16,22
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100,0	34	97,1	73,53	23,79	36	100,0	36	100,0	70,83	25,00
Week 24	<=23 letters	35	100,0	32	91,4	82,03	22,21	36	100,0	32	88,9	78,13	24,39
Baseline	>=24 letters	331	100,0	330	99,7	82,35	23,17	327	100,0	326	99,7	79,91	23,84
Week 24	>=24 letters	330	99,7	309	93,6	89,24	18,00	326	99,7	299	91,7	88,55	17,75
Geographic Region													
Baseline	Europe	111	100,0	110	99,1	79,77	23,09	114	100,0	113	99,1	78,32	24,44
Week 24	Europe	111	100,0	102	91,9	87,01	20,13	114	100,0	103	90,4	85,44	18,70
Baseline	America	147	100,0	146	99,3	80,31	24,95	146	100,0	146	100,0	74,49	25,51
Week 24	America	146	99,3	137	93,8	89,23	18,39	145	99,3	133	91,7	86,65	21,22
Baseline	Asia Pacific (inc. Australia)	108	100,0	108	100,0	84,95	21,05	103	100,0	103	100,0	86,17	19,72
Week 24	Asia Pacific (inc. Australia)	108	100,0	102	94,4	89,22	17,06	103	100,0	95	92,2	91,05	14,08
Race/ethnicity													
Baseline	White	243	100,0	241	99,2	80,08	24,10	253	100,0	252	99,6	77,68	24,45
Week 24	White	242	99,6	227	93,8	88,22	19,43	252	99,6	231	91,7	87,45	19,49
Baseline	Asian	89	100,0	89	100,0	86,52	18,49	88	100,0	88	100,0	85,23	20,98
Week 24	Asian	89	100,0	85	95,5	89,71	14,58	88	100,0	80	90,9	89,06	15,83
Baseline	Other	13	100,0	13	100,0	57,69	31,27	17	100,0	17	100,0	67,65	26,17
Week 24	Other	13	100,0	13	100,0	86,54	21,93	17	100,0	15	88,2	83,33	20,41
Baseline	Unknown	21	100,0	21	100,0	91,67	14,43	5	100,0	5	100,0	75,00	30,62
Week 24	Unknown	21	100,0	16	76,2	89,06	22,30	5	100,0	5	100,0	80,00	20,92
Baseline RVO status													
Baseline	CRVO	302	100,0	300	99,3	81,75	23,45	293	100,0	292	99,7	79,71	23,39
Week 24	CRVO	301	99,7	279	92,7	88,44	19,05	292	99,7	269	92,1	88,48	18,25
Baseline	HRVO	61	100,0	61	100,0	80,74	23,00	64	100,0	64	100,0	77,34	26,62
Week 24	HRVO	61	100,0	59	96,7	88,98	16,26	64	100,0	58	90,6	82,76	20,52
Baseline	Missing	3	100,0	3	100,0	75,00	25,00	6	100,0	6	100,0	62,50	26,22
Week 24	Missing	3	100,0	3	100,0	91,67	14,43	6	100,0	4	66,7	93,75	12,50

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tw24_QSBPV_IT_09AUG2022_41986.xls
 03JUN2024 17:40

POPULATION: Intent-To-Treat Population
 ENDPOINT: NEI VFQ-25 Color Vision subscale over Time through Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

Name Visit	Level	Faricimab (N=366)						Aflibercept (N=363)					
		Patients		Statistics				Patients		Statistics			
		in study ¹	%	with value ²	%	Mean ²	SD(Mean)	in study ¹	%	with value ²	%	Mean ²	SD(Mean)
All													
Baseline	n/a	366	100.0	361	98.6	93.84	14.26	363	100.0	361	99.4	93.28	14.96
Week 24	n/a	365	99.7	336	92.1	96.13	11.59	362	99.7	331	91.4	96.90	10.11
Gender													
Baseline	Male	193	100.0	190	98.4	93.68	14.07	200	100.0	198	99.0	93.18	15.66
Week 24	Male	192	99.5	173	90.1	95.95	11.98	200	100.0	180	90.0	97.22	9.85
Baseline	Female	173	100.0	171	98.8	94.01	14.50	163	100.0	163	100.0	93.40	14.12
Week 24	Female	173	100.0	163	94.2	96.32	11.19	162	99.4	151	93.2	96.52	10.42
Age													
Baseline	<65 years	162	100.0	162	100.0	95.99	11.46	158	100.0	157	99.4	93.15	14.04
Week 24	<65 years	161	99.4	151	93.8	97.52	9.02	157	99.4	139	88.5	96.58	10.94
Baseline	>=65 years	204	100.0	199	97.5	92.09	16.00	205	100.0	204	99.5	93.38	15.67
Week 24	>=65 years	204	100.0	185	90.7	95.00	13.24	205	100.0	192	93.7	97.14	9.48
Baseline BCVA ETDRS letter score													
Baseline	35 - 54 letters	106	100.0	105	99.1	92.14	16.01	105	100.0	105	100.0	93.57	14.31
Week 24	35 - 54 letters	106	100.0	99	93.4	96.97	9.63	105	100.0	97	92.4	98.71	5.56
Baseline	<=34 letters	79	100.0	77	97.5	91.56	14.96	80	100.0	80	100.0	88.44	20.65
Week 24	<=34 letters	79	100.0	71	89.9	92.61	16.58	80	100.0	74	92.5	93.24	15.09
Baseline	>=55 letters	181	100.0	179	98.9	95.81	12.57	178	100.0	176	98.9	95.31	11.47
Week 24	>=55 letters	180	99.4	166	92.2	97.14	9.70	177	99.4	160	90.4	97.50	8.95
Baseline BCVA ETDRS letter score													
Baseline	<=23 letters	35	100.0	33	94.3	91.67	13.50	36	100.0	36	100.0	87.50	21.96
Week 24	<=23 letters	35	100.0	32	91.4	89.06	18.98	36	100.0	32	88.9	90.63	18.78
Baseline	>=24 letters	331	100.0	328	99.1	94.05	14.33	327	100.0	325	99.4	93.92	13.87
Week 24	>=24 letters	330	99.7	304	92.1	96.88	10.28	326	99.7	299	91.7	97.58	8.47
Geographic Region													
Baseline	Europe	111	100.0	107	96.4	92.06	15.20	114	100.0	113	99.1	93.58	14.09
Week 24	Europe	111	100.0	100	90.1	93.00	15.92	114	100.0	103	90.4	95.39	12.00
Baseline	America	147	100.0	146	99.3	94.86	13.75	146	100.0	146	100.0	91.95	16.33
Week 24	America	146	99.3	134	91.8	97.95	7.54	145	99.3	133	91.7	97.37	10.33
Baseline	Asia Pacific (inc. Australia)	108	100.0	108	100.0	94.21	13.93	103	100.0	102	99.0	94.85	13.78
Week 24	Asia Pacific (inc. Australia)	108	100.0	102	94.4	96.81	10.36	103	100.0	95	92.2	97.89	6.98
Race/ethnicity													
Baseline	White	243	100.0	238	97.9	94.01	14.28	253	100.0	252	99.6	93.45	13.82
Week 24	White	242	99.6	222	91.7	95.38	13.18	252	99.6	231	91.7	97.19	10.04
Baseline	Asian	89	100.0	89	100.0	93.82	13.73	88	100.0	87	98.9	94.54	13.97
Week 24	Asian	89	100.0	85	95.5	97.35	7.74	88	100.0	80	90.9	96.56	9.53
Baseline	Other	13	100.0	13	100.0	90.38	19.20	17	100.0	17	100.0	89.71	19.88
Week 24	Other	13	100.0	13	100.0	98.08	6.93	17	100.0	15	88.2	96.67	8.80
Baseline	Unknown	21	100.0	21	100.0	94.05	13.47	5	100.0	5	100.0	75.00	43.30
Week 24	Unknown	21	100.0	16	76.2	98.44	6.25	5	100.0	5	100.0	90.00	22.36
Baseline RVO status													
Baseline	CRVO	302	100.0	297	98.3	93.77	14.64	293	100.0	292	99.7	93.66	14.30
Week 24	CRVO	301	99.7	276	91.7	95.92	12.03	292	99.7	269	92.1	96.75	10.63
Baseline	HRVO	61	100.0	61	100.0	93.85	12.63	64	100.0	63	98.4	92.86	15.18
Week 24	HRVO	61	100.0	57	93.4	96.93	9.53	64	100.0	58	90.6	97.41	7.68
Baseline	Missing	3	100.0	3	100.0	100.00	0.00	6	100.0	6	100.0	79.17	33.23
Week 24	Missing	3	100.0	3	100.0	100.00	0.00	6	100.0	4	66.7	100.00	0.00

¹ in study: number of subjects in study at respective visit; % based on baseline
 with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_eff_mean_sg_PREST_tw24_QSBCV_IT_09AUG2022_41986.xls
 03JUN2024 17:27

POPULATION: Safety-Rvaluable Population, BALATON
 ENDPOINTS: Any AEs through Week 24
 MODES: Unstratified analysis
 STUDY: GR4194
 Dichotomous Analysis by Subgroups (Safety)

Base	Level	Favours (B=27)				Favours (B=24)				Favours vs. All Interop										All Interop vs. Favours									
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		95% Lower CI		95% Upper CI		Relative Risk	Convergence Reason		95% Lower CI		95% Upper CI		Relative Risk	Convergence Reason		95% Lower CI		95% Upper CI	
		n	%	n	%	n	%	n	%																				
Sex	Male	274	100.0	125	45.3	274	100.0	128	46.7	0.94	0.48	1.42	-0.014	Algorithm converged	-0.031	0.043	0.97	Algorithm converged	0.81	1.14	0.734								
Gender	Male	141	49.0	64	44.8	137	45.4	55	43.0	1.08	0.46	1.72	-0.014	Convergence criterion (GCONV=1E-8) satisfied	-0.104	0.143	1.03	Algorithm converged	0.79	1.16	0.813	0.546	0.07	Algorithm converged	0.74	1.27			
	Female	133	48.2	61	45.3	147	53.5	73	49.1	0.84	0.34	1.31	-0.038	Convergence criterion (GCONV=1E-8) satisfied	-0.151	0.079	0.92	Algorithm converged	0.72	1.18	0.529								
Age	<65 years	133	48.2	54	40.4	143	52.2	45	46.1	0.82	0.31	1.32	-0.040	Convergence criterion (GCONV=1E-8) satisfied	-0.105	0.088	0.88	Algorithm converged	0.64	1.17	0.438	0.481	1.12	Algorithm converged	0.81	1.47			
	>=65 years	141	51.8	72	49.7	131	47.8	63	48.1	1.09	0.44	1.74	-0.014	Convergence criterion (GCONV=1E-8) satisfied	-0.103	0.134	1.03	Algorithm converged	0.81	1.32	0.787								
Baseline BCVA ETDRS letter score	<=54 letters	89	32.3	41	46.1	95	32.8	41	45.6	1.02	0.37	1.68	-0.005	Convergence criterion (GCONV=1E-8) satisfied	-0.141	0.151	1.01	Algorithm converged	0.74	1.39	0.942	0.720	0.99	Algorithm converged	0.72	1.36			
	>54 letters	187	67.8	84	44.9	184	67.2	87	47.2	0.91	0.40	1.37	-0.024	Convergence criterion (GCONV=1E-8) satisfied	-0.121	0.078	0.93	Algorithm converged	0.76	1.18	0.648								
Geographic Region	Europe	82	29.7	41	50.0	70	25.5	40	57.1	0.71	0.19	1.42	-0.071	Convergence criterion (GCONV=1E-8) satisfied	-0.210	0.087	0.88	Algorithm converged	0.65	1.18	0.377	0.940	1.14	Algorithm converged	0.85	1.54			
	America	97	35.1	42	43.1	103	37.6	43	43.0	1.07	0.41	1.67	-0.016	Convergence criterion (GCONV=1E-8) satisfied	-0.122	0.143	1.04	Algorithm converged	0.75	1.43	0.824								
	Pacific (inc. Australia)	97	35.2	42	43.1	101	35.9	45	44.5	0.91	0.34	1.47	-0.013	Convergence criterion (GCONV=1E-8) satisfied	-0.151	0.129	0.97	Algorithm converged	0.71	1.33	0.858								
Race/Ethnicity	White	178	64.4	84	48.1	178	64.4	84	48.1	1.00	0.47	1.46	-0.002	Convergence criterion (GCONV=1E-8) satisfied	-0.101	0.142	1.01	Algorithm converged	0.81	1.24	0.811	0.745	0.97	Algorithm converged	0.78	1.41			
	Asian	95	34.4	38	40.0	93	33.9	42	45.2	0.81	0.41	1.44	-0.025	Convergence criterion (GCONV=1E-8) satisfied	-0.139	0.081	0.89	Algorithm converged	0.63	1.24	0.481								
	Other	10	3.6	4	40.0	7	2.6	2	28.6	1.67	0.23	13.22	0.114	Convergence criterion (GCONV=1E-8) satisfied	-0.338	0.565	1.40	Algorithm converged	0.35	5.65	0.365								
Unknown	4	1.4	2	50.0	4	1.5	2	50.0	0.91	0.22	6.43	-0.253	Convergence criterion (GCONV=1E-8) satisfied	-0.831	0.188	0.24	Algorithm converged	0.07	0.93	0.482									

Test for interaction based on RR (Log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical post-hoc: 9620292

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_sa_raw.exe
 Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RV0_CSR_Primary/prod/output/t_sa_raw_RR_M24_BALATON_RR_2022_41984_41986.xls
 9/18/2024 17:52

POPULATION: Safety-Evaluable Population, BALATOR
 ENDPOINT: Ocular Ase (Study Eye) through Week 24
 MODEL: Unstratified analysis
 STUDY: 041994
 Dichotomous Analysis by Subgroups (Safety)

Base	Level	Pairwise (B=2/0)				All-against-All (B=2/1)				Pairwise vs. All-against-All															
		Patience		Discontinuation with Event		Patience		Discontinuation with Event		Absolute Risk Difference					Relative Risk										
		n	k	n	k	n	k	n	k	Odds Ratio	95% Lower CI	95% Upper CI	Absolute Risk	95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI	95% Upper CI	Convergence Reason	p-value (Wald)	Interaction Test p-value (likelihood)	Relative Risk	95% Lower CI	95% Upper CI	
Sex	Male	274	100.0	45	16.4	274	100.0	54	20.4	0.74															
Gender	Male	143	61.0	19	13.3	127	56.4	21	16.0	0.70															
	Female	131	59.0	26	19.3	147	63.6	33	25.0	0.74															
Age	<65 years	133	58.0	17	12.8	116	52.2	24	18.0	0.80															
	>=65 years	143	62.0	28	19.6	115	57.8	30	22.9	0.82															
Baseline BCVA ETDRS letter score	<=54 letters	89	32.2	12	13.3	77	32.8	20	22.2	0.53															
	>54 letters	187	67.8	33	17.0	184	67.2	36	19.0	0.83															
Geographic Region	Europe	82	29.7	14	17.1	70	25.3	20	28.0	0.81															
	America	97	35.1	18	18.6	103	37.0	18	17.0	1.00															
	Asia Pacific (Inc. Australia)	97	35.1	13	13.4	101	36.9	18	17.0	0.71															
Race/Ethnicity	White	128	56.0	18	18.0	110	52.0	26	20.0	0.89															
	Asian	95	32.0	11	12.3	83	33.9	19	20.4	0.54															
	Other	10	3.0	1	10.0	7	2.6	1	14.0	0.67															
	Unknown	4	1.0	0	0.0	4	1.5	1	25.0																

Test for interaction based on BR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.62/0.2022

Program: /root/clinical_studies/20240741/CDT30303/share/ACR_data_analysis/prod/program/1_ee_7aw.exe
 Output: /root/clinical_studies/20240741/CDT30303/share/ACR_data_analysis/prod/output/1_ee_7aw_04_SOC24_BALATOR_02_2022_01994_0186.klm
 04202024 18:05

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: Ocular AEs (Fellow Eye) through Week 24
 MOSE: Unstratified analysis
 STUDY: GR41984
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Faricimab (N=276)				Aflibercept (N=274)				Faricimab vs. Aflibercept																
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio				Absolute Risk Difference				Relative Risk				Aflibercept vs. Faricimab				
		n	%	n	%	n	%	n	%	Odds Ratio	95% Lower CI	95% Upper CI	Absolute Risk	95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI	95% Upper CI	p-value (Wald)	Interaction Test p-value (likelihood)	Relative Risk	95% Lower CI	95% Upper CI			
All	n/a	276	100.0	26	9.4	274	100.0	20	7.3	1.32	0.72	2.43	0.021	Algorithm converged.	-0.025	0.067	1.25	Algorithm converged.	0.74	2.26	0.3705		0.72	Algorithm converged.	0.44	1.35
Gender	Male	143	51.8	12	8.4	127	46.4	5	3.9	2.24	0.77	6.53	0.045	Algorithm converged.	-0.012	0.101	2.13	Algorithm converged.	0.77	5.88	0.1441	0.2362	0.47	Algorithm converged.	0.17	1.30
	Female	133	48.2	14	10.5	147	53.6	15	10.2	1.04	0.48	2.23	0.003	Algorithm converged.	-0.068	0.071	1.03	Algorithm converged.	0.52	2.06	0.9296		0.97	Algorithm converged.	0.49	1.93
Age	<65 years	133	48.2	9	6.8	143	52.2	10	7.0	0.97	0.38	2.45	-0.002	Algorithm converged.	-0.062	0.057	0.97	Algorithm converged.	0.41	2.31	0.9409	0.4129	1.03	Algorithm converged.	0.43	2.46
	≥65 years	143	51.8	17	11.9	131	47.8	10	7.6	1.63	0.72	3.71	0.045	Algorithm converged.	-0.027	0.112	1.56	Algorithm converged.	0.76	3.29	0.2434		0.64	Algorithm converged.	0.21	1.35
Baseline BCVA STDRS letter score	<=54 letters	85	32.2	7	7.9	80	29.8	7	7.8	1.03	0.34	3.01	0.001	Algorithm converged.	-0.076	0.080	1.03	Algorithm converged.	0.37	2.76	0.9826	0.5669	0.99	Algorithm converged.	0.16	2.70
	>=55 letters	187	67.8	19	10.2	184	67.2	13	7.1	1.49	0.71	3.11	0.031	Algorithm converged.	-0.026	0.088	1.44	Algorithm converged.	0.73	2.83	0.2918		0.70	Algorithm converged.	0.35	1.97
Geographic Region	Europe	82	29.7	8	9.8	70	25.5	5	7.1	1.41	0.44	4.51	0.026	Algorithm converged.	-0.062	0.114	1.37	Algorithm converged.	0.47	3.99	0.5682	0.9489	0.73	Algorithm converged.	0.25	2.14
	America	97	35.1	8	8.2	103	37.6	6	5.8	1.45	0.49	4.35	0.024	Algorithm converged.	-0.047	0.095	1.42	Algorithm converged.	0.51	3.93	0.5047		0.71	Algorithm converged.	0.25	1.96
	Asia Pacific (inc. Australia)	97	35.1	10	10.3	101	36.9	9	8.9	1.17	0.46	3.03	0.014	Algorithm converged.	-0.068	0.096	1.16	Algorithm converged.	0.49	2.72	0.7387		0.86	Algorithm converged.	0.17	2.04
Race/ethnicity	White	172	62.3	16	9.3	170	62.0	10	5.9	1.64	0.72	3.73	0.034	Algorithm converged.	-0.022	0.090	1.58	Algorithm converged.	0.76	3.39	0.2379	0.6934	0.63	Algorithm converged.	0.30	1.35
	Asian	90	32.6	9	10.0	93	33.9	9	9.7	1.04	0.39	2.74	0.003	Algorithm converged.	-0.083	0.090	1.03	Algorithm converged.	0.43	2.48	0.9416		0.97	Algorithm converged.	0.40	2.33
	Other	10	3.6	1	10.0	7	2.6	1	14.3	0.67	0.03	12.84	-0.043	Algorithm converged.	-0.362	0.276	0.70	Algorithm converged.	0.05	9.41	0.7879		1.43	Algorithm converged.	0.11	19.20
	Unknown	4	1.4	0	0.0	4	1.5	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE

Test for interaction based on RR (Log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDF30303/share/ACR_data_analysis/prod/program/t_se_raw.sas
 Output: root/clinical_studies/R06867461/CDF30303/share/ACR_pool_RVO_CDR_Primary/prod/output/t_se_raw_sq_FOCAR_WK24_BALATON_SE_2022_41984_41986.xls
 04JUN2024 18:11

POPULATION: Safety-Evaluable Population, BALATOR
 ENDPOINT: Moderate AEs through Week 24
 MODEL: Stratified Analysis
 STUDY: 041984
 Dichotomous Analysis by Subgroups (Safety)

Stratum	Stratum Label	Favours (a/b)				Disfavours (a/b)				Favours vs. Disfavours										Attributed vs. Favours												
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Convergence Reason		95% Lower CI	95% Upper CI	Absolute Risk	Absolute Risk Difference		95% Lower CI	95% Upper CI	Relative Risk	Convergence Reason		95% Lower CI	95% Upper CI	p-value	Interaction p-value	Relative Risk	Convergence Reason		95% Lower CI	95% Upper CI
		n	N	n	%	n	N	n	%	Odds Ratio	Convergence Reason	95% Lower CI	95% Upper CI				Absolute Risk	95% Lower CI				95% Upper CI	Relative Risk						95% Lower CI	95% Upper CI		
Sex	Male	274	100.0	23	10.3	274	100.0	18	13.1	0.71	Convergence criterion (OCOMP-18-B) satisfied.	0.46	1.11	-0.026			Algorithm converged.	-0.030	0.028	0.41	Algorithm converged.	0.51	1.27	0.1805			1.20	Algorithm converged.	0.79	1.91		
	Female	143	51.8	15	10.5	143	100.0	24	16.8	1.24	Convergence criterion (OCOMP-18-B) satisfied.	0.53	1.64	0.011			Algorithm converged.	-0.031	0.009	1.18	Algorithm converged.	0.51	2.41	0.6403	0.1543	0.04	Algorithm converged.	0.42	1.72			
Gender	Male	137	49.2	15	10.9	147	56.4	22	15.0	0.51	Convergence criterion (OCOMP-18-B) satisfied.	0.27	0.74	-0.065			Algorithm converged.	-0.144	0.013	0.62	Algorithm converged.	0.32	1.13	0.1121			1.43	Algorithm converged.	0.89	3.15		
	Female	133	48.2	14	10.5	143	52.2	18	12.6	0.82	Convergence criterion (OCOMP-18-B) satisfied.	0.39	1.72	-0.021			Algorithm converged.	-0.036	0.055	0.84	Algorithm converged.	0.41	1.61	0.5919	0.8460	1.20	Algorithm converged.	0.62	2.31			
Age	<=65 years	143	51.8	15	10.5	131	47.8	18	13.7	0.74	Convergence criterion (OCOMP-18-B) satisfied.	0.35	1.51	-0.031			Algorithm converged.	-0.110	0.043	0.78	Algorithm converged.	0.40	1.45	0.4105			1.31	Algorithm converged.	0.69	2.40		
	>=65 years	89	32.2	10	11.2	95	32.8	11	12.3	0.91	Convergence criterion (OCOMP-18-B) satisfied.	0.37	2.26	-0.010			Algorithm converged.	-0.104	0.084	0.92	Algorithm converged.	0.41	2.06	0.8376	0.6801	1.09	Algorithm converged.	0.49	2.41			
Baseline BOVA ETOED Letter score	<=4 letters	187	67.8	19	10.2	184	67.2	25	13.6	0.72	Convergence criterion (OCOMP-18-B) satisfied.	0.38	1.16	-0.014			Algorithm converged.	-0.100	0.013	0.75	Algorithm converged.	0.41	1.31	0.1093			1.14	Algorithm converged.	0.76	2.34		
	>=5 letters	82	29.7	10	12.2	70	25.5	15	21.4	0.51	Convergence criterion (OCOMP-18-B) satisfied.	0.21	1.22	-0.092			Algorithm converged.	-0.212	0.047	0.57	Algorithm converged.	0.27	1.19	0.1122	0.3448	1.76	Algorithm converged.	0.84	3.64			
Geographic Region	Europe	97	35.1	13	13.0	103	37.6	14	13.6	1.00	Convergence criterion (OCOMP-18-B) satisfied.	0.51	2.54	0.019			Algorithm converged.	-0.079	0.148	1.18	Algorithm converged.	0.53	2.23	0.7073			1.68	Algorithm converged.	0.45	1.70		
	Asia Pacific (Inc. Australia)	172	62.6	23	13.4	170	62.0	20	11.7	0.82	Convergence criterion (OCOMP-18-B) satisfied.	0.35	2.04	-0.028			Algorithm converged.	-0.091	0.033	0.91	Algorithm converged.	0.38	1.97	0.3950			1.43	Algorithm converged.	0.51	2.55		
Race/ethnicity	White	30	10.9	3	10.0	31	11.2	3	9.7	0.91	Convergence criterion (OCOMP-18-B) satisfied.	0.45	1.45	-0.025			Algorithm converged.	-0.100	0.058	0.84	Algorithm converged.	0.51	1.41	0.5120	0.4160	1.18	Algorithm converged.	0.71	1.81			
	Asian	10	3.6	0	0.0	7	2.5	1	14.3	0.00	Qual-complete separation of data points detected.	0.22	2.31	-0.020			Algorithm converged.	-0.081	0.052	0.74	Algorithm converged.	0.24	0.24	0.5920			1.05	Algorithm converged.	0.45	4.11		
	Other	4	1.4	1	25.0	4	1.5	1	25.0	1.00	Convergence criterion (OCOMP-18-B) satisfied.	0.04	24.55	0.000			Algorithm converged.	-0.600	0.600	1.00	Algorithm converged.	0.00	99	1.0000	>99.99	99	Algorithm converged.	0.00	99			
	Unknown	4	1.4	1	25.0	4	1.5	1	25.0	1.00	Convergence criterion (OCOMP-18-B) satisfied.	0.04	24.55	0.000			Algorithm converged.	-0.600	0.600	1.00	Algorithm converged.	0.00	11.03	1.0000			1.00	Algorithm converged.	0.00	11.03		

Only AEs of highest severity are counted.
 Test for interaction based on SE (Log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.025/0.025

Program: root/clinical_studies/RO6867461/CD730303/ahare/ACE_data_analysis/prod/program/t_w_raw.exe
 Output: root/clinical_studies/RO6867461/CD730303/ahare/ACE_pool_RVD_CSR_Primary/prod/output/t_w_raw_sg_MOCDAE_WK24_BALATOR_SE_2022_41984_41986.xlsx
 04/20/2024 17:54

POPULATION: Safety-Evaluable Population, BALATOR
 ENDPOINTS: Sarsc AEs through Week 24
 MODEL: Unstratified Analysis
 STUDY: 041984
 Dichotomous Analysis by Subgroups (Safety)

Name	Sex	Patients (n/N)				Milestones (n/N)				Odds Ratio	Convergence Reason	95% Lower CI	95% Upper CI	Absolute Risk	Patients vs. Milestones				Milestones vs. Patients								
		Patients		Patients with Event		Patients		Patients with Event							Absolute Risk Difference				Relative Risk								
		n	N	n	N	n	N	n	N						95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI	95% Upper CI	p-value	contraction max (likelihood)	Relative Risk	95% Lower CI	95% Upper CI			
All	Male	274	100.0	4	2.9	274	100.0	14	5.1	0.21	Convergence criterion (GCMW-IR-B) satisfied.	0.21	1.14	-0.022	Algorithm converged.	-0.051	0.011	0.57	Algorithm converged.	0.24	1.11	0.1924	1.76	Algorithm converged.	0.71	4.11	
Gender	Male	143	51.8	5	3.5	143	51.8	4	2.8	1.38	Convergence criterion (GCMW-IR-B) satisfied.	0.27	1.48	0.010	Algorithm converged.	-0.034	0.015	0.47	Algorithm converged.	0.48	1.41	0.6529	5.056	0.78	Algorithm converged.	0.21	2.02
	Female	131	48.2	2	1.5	131	48.2	10	8.3	0.21	Convergence criterion (GCMW-IR-B) satisfied.	0.04	0.97	-0.051	Algorithm converged.	-0.099	-0.007	0.22	Algorithm converged.	0.05	0.93	0.5486	4.52	Algorithm converged.	1.01	20.27	
Age	<65 years	133	48.2	4	3.0	133	48.2	6	4.5	0.71	Convergence criterion (GCMW-IR-B) satisfied.	0.20	1.07	-0.012	Algorithm converged.	-0.054	0.012	0.72	Algorithm converged.	0.21	1.48	0.5995	0.6080	1.40	Algorithm converged.	0.43	4.84
	>=65 years	141	51.8	4	2.8	141	51.8	8	5.7	0.44	Convergence criterion (GCMW-IR-B) satisfied.	0.11	1.51	-0.031	Algorithm converged.	-0.082	0.016	0.44	Algorithm converged.	0.14	1.49	0.1934	2.18	Algorithm converged.	0.67	7.08	
Baseline BOVA ETOB Letter score	<=4 letters	89	32.2	1	1.1	89	32.2	5	5.6	0.19	Convergence criterion (GCMW-IR-B) satisfied.	0.02	1.69	-0.044	Algorithm converged.	-0.094	0.009	0.20	Algorithm converged.	0.04	1.70	0.1408	0.2228	4.94	Algorithm converged.	0.59	41.48
	>=5 letters	187	67.8	3	1.7	187	67.8	9	4.8	0.78	Convergence criterion (GCMW-IR-B) satisfied.	0.28	2.07	-0.011	Algorithm converged.	-0.051	0.010	0.72	Algorithm converged.	0.28	2.01	0.4875	1.31	Algorithm converged.	0.80	3.44	
Geographic Region	Europe	82	29.7	1	1.2	70	25.5	2	2.9	0.40	Convergence criterion (GCMW-IR-B) satisfied.	0.04	1.73	-0.016	Algorithm converged.	-0.060	0.029	0.43	Algorithm converged.	0.04	1.61	0.4811	0.7799	2.94	Algorithm converged.	0.02	25.29
	America	97	35.1	3	3.0	103	37.6	3	3.0	0.40	Convergence criterion (GCMW-IR-B) satisfied.	0.11	1.74	-0.037	Algorithm converged.	-0.099	0.023	0.45	Algorithm converged.	0.14	1.70	0.2438	2.20	Algorithm converged.	0.03	8.20	
	Asia Pacific (Inc. Australia)	97	35.1	4	4.1	105	38.9	3	2.9	0.81	Convergence criterion (GCMW-IR-B) satisfied.	0.22	1.57	-0.008	Algorithm converged.	-0.064	0.000	0.43	Algorithm converged.	0.23	1.50	0.1804	1.20	Algorithm converged.	0.31	4.14	
Race/ethnicity	White	172	62.0	4	2.3	178	62.0	6	3.3	0.41	Convergence criterion (GCMW-IR-B) satisfied.	0.13	1.41	-0.030	Algorithm converged.	-0.028	0.011	0.44	Algorithm converged.	0.14	1.40	0.1640	0.1870	2.28	Algorithm converged.	0.71	7.25
	Asian	90	32.6	1	1.1	93	33.9	2	2.1	0.61	Convergence criterion (GCMW-IR-B) satisfied.	0.14	2.42	-0.020	Algorithm converged.	-0.079	0.019	0.42	Algorithm converged.	0.15	2.50	0.4039	1.61	Algorithm converged.	0.40	6.52	
	Other	10	3.6	1	10.0	7	2.5	0	0.0	0.0	Qual-complete separation of data points detected.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Unknown	4	1.4	0	0.0	4	1.5	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	

Only AEs of highest severity are counted.
 Test for interaction based on SE (Log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.025/0.022

Program: root/clinical_studies/R06867461/CD730303/ahare/ACE_data_analysis/prod/program/t_w_raw.exe
 Output: root/clinical_studies/R06867461/CD730303/ahare/ACE_pool_RVD_CSR_Primary/prod/output/t_w_raw_sg_MSEVA_WK24_BALATOR_SE_2022_41984_41986.xlsx
 04/20/2024 17:16

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: Any SAE through Week 24
 MODEL: Unstratified analysis
 STUDY: 041994
 Dichotomous Analysis by Subgroups (Safety)

Base	Level	Favortek (N=276)				Allibersept (N=214)				Odds Ratio	Favortek vs. Allibersept				Allibersept vs. Favortek												
		Patients		Patients with Event		Patients		Patients with Event			Lower CI	Upper CI	Absolute Risk	Convergence		Relative Risk	Convergence		p-value (Wald)	Interaction Test p-value (Likelihood)	Relative Risk	Convergence					
		n	%	n	%	n	%	n	%					Reason	Reason		Reason	Reason									
Sex	Sex	276	100.0	12	4.3	276	100.0	17	6.2	0.43	0.32	1.47	-0.012	Algorithm converged.	0.32	0.34	0.133	0.70	Algorithm converged.	0.14	1.44	0.133	0.43	2.31			
Gender	Male	143	51.8	0	0.0	127	58.4	4	3.1	2.00	0.62	0.88	0.031	Algorithm converged.	-0.019	0.082	2.00	Algorithm converged.	0.61	0.13	0.2134	0.0098	0.53	Algorithm converged.	0.14	1.44	
	Female	133	48.2	12	9.0	87	41.6	13	8.9	0.24	0.07	0.49	-0.151	Algorithm converged.	-0.071	0.39	0.0299	0.29	Algorithm converged.	0.071	0.89	0.0299	0.32	Algorithm converged.	1.14	13.41	
Age	<65 years	133	48.2	7	5.2	143	67.0	7	4.9	1.00	0.37	1.18	0.024	Algorithm converged.	-0.044	0.084	1.00	Algorithm converged.	0.10	3.28	0.4882	0.1484	0.21	Algorithm converged.	0.14	2.18	
	>=65 years	143	51.8	5	3.5	71	33.0	10	7.0	0.44	0.15	1.32	-0.041	Algorithm converged.	-0.094	0.013	0.44	Algorithm converged.	0.16	1.31	0.1439	0.18	Algorithm converged.	0.27	6.22		
Baseline BCVA ETDRS letter score	<=4 letters	89	32.2	3	3.4	99	46.3	6	6.7	0.49	0.12	2.02	-0.033	Algorithm converged.	-0.097	0.031	0.51	Algorithm converged.	0.13	1.95	0.1239	0.1650	1.99	Algorithm converged.	0.51	7.16	
	>=5 letters	187	67.8	9	4.8	115	53.7	11	6.0	0.80	0.32	1.97	-0.012	Algorithm converged.	-0.053	0.014	0.81	Algorithm converged.	0.34	1.90	0.4220	0.124	Algorithm converged.	0.51	2.33		
Geographic Region	Europe	82	29.7	0	0.0	76	35.5	4	5.3					WARNING: The relative Bayesian convergence criterion of 5.3026643887 is greater than the limit of 0.0001. The convergence is questionable.	0.00	Algorithm converged.	0.50	NR	0.9999	0.0521	>>>99.99	0.00	NR	Algorithm converged.	0.00	NR	
	America	97	35.1	5	5.2	103	48.1	8	7.8	0.78	0.26	2.34	-0.016	Algorithm converged.	-0.084	0.055	0.80	Algorithm converged.	0.29	2.23	0.4523	0.25	Algorithm converged.	0.49	3.49		
	Asia Pacific (inc. Australia)	97	35.1	5	5.2	101	46.3	5	5.0	1.27	0.37	4.29	0.012	Algorithm converged.	-0.052	0.076	1.22	Algorithm converged.	0.38	3.80	0.7951	0.80	Algorithm converged.	0.25	2.84		
Responsibility	India	172	62.0	5	2.9	170	79.0	13	7.6	0.38	0.19	1.04	-0.047	Algorithm converged.	-0.093	0.000	0.38	Algorithm converged.	0.14	1.04	0.0604	0.0388	0.63	Algorithm converged.	0.46	7.02	
	Russia	90	32.0	5	5.7	93	43.5	4	4.3	1.59	0.43	5.83	0.024	Algorithm converged.	-0.042	0.090	1.55	Algorithm converged.	0.45	5.31	0.4855	0.65	Algorithm converged.	0.19	2.21		
	Other	10	3.6	1	10.0	7	3.4	0	0.0					ERROR: Error in computing the link function, its derivatives, or the variance function.	NR	NR	NR	Algorithm converged.	NR	NR	NR	NR	Algorithm converged.	NR	NR		
	Unknown	4	1.4	0	0.0	4	1.9	0	0.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

Test for interaction based on BR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.6202022

Program: /mnt/clinical_studies/205867461/CDT30303/share/ACR_data_analysis/prod/program/1_as_1aw.exe
 Output: /mnt/clinical_studies/205867461/CDT30303/share/ACR_pool_170_CDR_Primary/prod/output/1_as_1aw_041994_BALATON_SE_2022_41984_41986.xls
 04/20/2024 18:00

POPULATION: Safety-Evaluable Population, BALATOR
 ENDPOINT: Ocular Side (Study Eye) through Week 14
 MODEL: Unstratified analysis
 STUDY: 084194
 Dichotomous Analysis by Subgroups (Safety)

Base	Level	Patients (N=276)				All-cause (N=274)				Patients vs. All-cause										All-cause vs. Patients							
		Patients with Event		Patients with Event		Patients with Event		Patients with Event		Odds Ratio		Absolute Risk Difference		Relative Risk		Interaction TEST		Relative Risk		Interaction TEST							
		n	%	n	%	n	%	n	%	Lower CI	Upper CI	Lower CI	Upper CI	Lower CI	Upper CI	p-value (Wald)	p-value (Likelihood Ratio)	Lower CI	Upper CI	p-value (Wald)	p-value (Likelihood Ratio)						
Sex	Male	141	51.0	2	1.4	137	49.6	1	0.8	1.70	0.16	10.9%	0.004	Algorithm converged.	-0.014	0.031	1.70	Algorithm converged.	0.10	19.30	0.610	0.798	0.55	Algorithm converged.	0.00	6.14	
	Female	133	48.2	1	0.8	127	46.4	1	0.9	1.11	0.07	5.8%	0.001	Algorithm converged.	-0.011	0.021	1.11	Algorithm converged.	0.01	17.50	0.944	0.95	Algorithm converged.	0.00	14.12		
Age	<65 years	133	48.2	2	1.5	127	46.4	1	0.8	2.13	0.19	14.1%	0.008	Algorithm converged.	-0.011	0.031	2.13	Algorithm converged.	0.00	21.44	0.529	0.445	0.43	Algorithm converged.	0.00	5.00	
	>=65 years	143	51.8	1	0.7	131	47.8	1	0.8	0.82	0.06	4.7%	<0.001	Algorithm converged.	-0.021	0.020	0.92	Algorithm converged.	0.06	14.50	0.950	1.09	Algorithm converged.	0.07	17.21		
Baseline BCVA ETDRS letter score	<=54 letters	89	32.2	2	2.2	87	32.8	0	0.0					Quasi-complete separation of data points detected.			NE	Algorithm converged.	NE	NE	NE	0.0845	NE	Algorithm converged.	NE	NE	
	>54 letters	187	67.8	1	0.5	184	67.2	2	1.1	0.48	0.04	3.4%	<0.001	Algorithm converged.	-0.024	0.011	0.48	Algorithm converged.	0.04	9.38	0.561	0.93	Algorithm converged.	0.10	22.25		
Geographic Region	Europe	82	29.7	0	0.0	78	28.5	0	0.0	NE	NE	NE	NE	Algorithm converged.	NE	NE	NE	Algorithm converged.	NE	NE	NE	NE	NE	NE	NE	NE	NE
	America	97	35.1	1	0.8	101	36.9	2	1.9	1.08	0.25	18.5%	0.012	Algorithm converged.	-0.015	0.058	1.08	Algorithm converged.	0.01	9.10	0.605	0.93	Algorithm converged.	0.11	3.01		
	Asia Pacific (inc. Australia)	97	35.1	0	0.0	96	35.0	0	0.0	NE	NE	NE	NE	Algorithm converged.	NE	NE	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	0.11	3.01		
Race/Ethnicity	White	172	62.3	2	1.5	170	62.0	2	1.0	0.99	0.14	7.1%	0.000	Algorithm converged.	-0.001	0.021	0.99	Algorithm converged.	0.14	6.84	0.990	NE	1.01	Algorithm converged.	0.14	7.10	
	Asian	90	32.6	1	1.1	83	30.3	0	0.0					Quasi-complete separation of data points detected.			NE	Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE	
	Other	10	3.6	0	0.0	7	2.6	0	0.0	NE	NE	NE	NE	Algorithm converged.	NE	NE	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		
	Unknown	4	1.4	0	0.0	4	1.5	0	0.0	NE	NE	NE	NE	Algorithm converged.	NE	NE	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		

Test for interaction based on RR (Log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.025,0.022

Program: root/clinical_studies/006867461/CDT0303/share/ACR_data_analysis/prod/program/t_m_rw.exe
 Output: root/clinical_studies/006867461/CDT0303/share/ACR_pool_RVO_CSR_Primary/prod/output/t_m_rw_02_SOCRAC_W24_BALATOR_SE_2022_41984_41986.xls
 04/20/2024 18:08

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Ocular SAEs (Fellow Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_FOCSAE_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:13

POPULATION: Safety-Rvaluable Population, BALATOR
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: 084194
 Dichotomous Analysis by Subgroups (Safety)

Base	Level	Paritimb (N=276)				Millsberg (N=214)				Odds Ratio	Paritimb vs. Millsberg				Relative Risk				Interaction Test							
		n	%	n	%	n	%	n	%		Lower CI	Upper CI	Absolute Risk	Convergence Reason	Lower CI	Upper CI	Relative Risk	Convergence Reason	Lower CI	Upper CI	p-value (Wald)	Interaction Test p-value (Likelihood)	Relative Risk	Convergence Reason	Lower CI	Upper CI
Sex	Male	276	100.0	1	0.4	276	100.0	1	0.4	0.38	Convergence criterion (GCONV=1E-6) satisfied.	0.06	15.93	0.000	Algorithm converged.	-0.010	0.010	0.93	Algorithm converged.	0.00	15.10	0.3950	0.01	Algorithm converged.	0.00	16.00
Gender	Male	143	51.8	1	0.7	137	64.4	0	0.0	Quasi-complete separation of data points detected.				WARNING: The mean parameter is either invalid or at a limit of its range. WARNING: The relative Bayesian convergence criterion of 14.49249593 is greater than the limit of 0.0001. The convergence is				Algorithm converged.	NE	NE	NE	0.1092	NE	Algorithm converged.	NE	NE
	Female	133	48.2	0	0.0	147	63.6	1	0.7	Quasi-complete separation of data points detected.								Algorithm converged.	0.00	NE	0.3999	>999.99	Algorithm converged.	0.00	NE	
Age	<=55 years	133	48.2	0	0.0	143	67.2	0	0.0	NE	NE	NE	NE	WARNING: The mean parameter is either invalid or at a limit of its range. WARNING: The relative Bayesian convergence criterion of 14.49249593 is greater than the limit of 0.0001. The convergence is				Algorithm converged.	NE	NE	NE	1.0000	NE	Algorithm converged.	NE	NE
	>55 years	143	51.8	1	0.7	131	67.4	1	0.8	0.42	Convergence criterion (GCONV=1E-6) satisfied.	0.04	14.70	-0.001	Algorithm converged.	-0.021	0.020	0.93	Algorithm converged.	0.00	14.10	0.4504	1.04	Algorithm converged.	0.00	17.00
Baseline BCVA ETDRS letter score	<=54 letters	89	32.2	0	0.0	90	32.8	1	1.1	Quasi-complete separation of data points detected.				WARNING: The relative Bayesian convergence criterion of 14.431279355 is greater than the limit of 0.0001. The convergence is				Algorithm converged.	0.00	NE	0.3999	0.0970	>999.99	Algorithm converged.	0.00	NE
	>54 letters	187	67.8	1	0.5	184	87.2	0	0.0	Quasi-complete separation of data points detected.								Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Geographic Region	Europe	82	29.7	0	0.0	70	32.8	0	0.0	NE	NE	NE	NE	WARNING: The relative Bayesian convergence criterion of 23.07168004 is greater than the limit of 0.0001. The convergence is				Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE
	Asia Pacific (inc. Australia)	97	35.3	1	1.0	101	47.6	1	1.1	Quasi-complete separation of data points detected.								Algorithm converged.	0.00	NE	0.3999	>999.99	Algorithm converged.	0.00	NE	
Race/Ethnicity	White	172	62.0	0	0.0	170	62.0	1	0.6	Quasi-complete separation of data points detected.				WARNING: The relative Bayesian convergence criterion of 22.182657441 is greater than the limit of 0.0001. The convergence is				Algorithm converged.	0.00	NE	0.3999	NE	>999.99	Algorithm converged.	0.00	NE
	Other	104	37.8	1	1.1	91	41.9	0	0.0	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.				Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE
Unknown	Unknown	10	3.6	0	0.0	7	2.6	0	0.0	NE	NE	NE	NE	WARNING: Negative of Hessian not positive definite.				Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE
	Unknown	4	1.4	0	0.0	4	1.9	0	0.0	NE	NE	NE	NE				Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE	

Test for interaction based on RR (Log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Clinical not-off! 06/02/2022

Program: root/clinical_studies/066857461/CDT30303/share/ACR_data_analysis/prod/program/t_am_rvw.exe
 Output: root/clinical_studies/066857461/CDT30303/share/ACR_pool_rvw_CDR_Primary/prod/output/t_am_rvw_sg_MOSTAR_W24_BALATOR_08_2022_41984_41986_xls
 04/06/2024 18:03

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: AE leading to Death through Week 24
 MODEL: Unstratified analysis
 STUDY: 041984
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Favoured (B=276)				At Risk (B=274)				Odds Ratio	Favoured vs. At Risk				At Risk vs. Favoured					
		Patients		Patients with Event		Patients		Patients with Event			Absolute Risk Difference		Relative Risk		Relative Risk		Interaction Test		Relative Risk	
		n	%	n	%	n	%	n	%		Lower CI	Upper CI	Lower CI	Upper CI	Lower CI	Upper CI	p-value (Wald)	p-value (Likelihood)	Lower CI	Upper CI
All	n/a	276	100.0	1	0.4	274	100.0	0	0											
Gender	Male	143	51.8	0	0.0	142	49.4	0	0	NE										
	Female	133	48.2	1	0.8	147	53.4	0	0											
Age	<=55 years	133	48.2	0	0.0	143	52.2	0	0	NE										
	>55 years	143	51.8	1	0.7	131	47.8	0	0											
Baseline BCVA ETDRS letter score	<=54 letters	89	32.2	0	0.0	95	34.6	0	0	NE										
	>54 letters	187	67.8	1	0.5	179	65.4	0	0											
Geographic Region	Europe	82	29.7	0	0.0	70	25.5	0	0	NE										
	America	97	35.1	0	0.0	103	37.6	0	0	NE										
	Asia Pacific (inc. Australia)	97	35.1	1	1.0	101	36.9	0	0											
Race/ethnicity	White	172	62.0	1	0.6	170	62.0	0	0											
	Asian	92	33.3	0	0.0	93	33.9	0	0	NE										
	Other	10	3.6	0	0.0	7	2.6	0	0	NE										
	Unknown	4	1.4	0	0.0	4	1.5	0	0	NE										

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.6251022

Program: root/clinical_studies/208867461/CCT030303/ahaw/ACT_data_analysis/prod/program/1_w_r_w.exe
 Output: root/clinical_studies/208867461/CCT030303/ahaw/ACT_data_analysis/prod/output/1_w_r_w_030303_BALATON_05_2022_41984_41986.xls
 04/02/2024 17:58

Base activity	APPLICABLE CODES										APPLICABLE CODES										APPLICABLE CODES																			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40
Los Angeles County	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40
Los Angeles County	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40

Geographic Region	Population (Index)	Population (Index)		Population (Index)		Population (Index)		Population (Index)		Population (Index)		Population (Index)		Population (Index)		Population (Index)		Population (Index)		Population (Index)	
		Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year
Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy	Italy/Italy/Italy

Only data of highest available resolution is included.
 Data for population based on UN World Population Prospects.
 * Indicates convergence problem. Result is uninterpretable.
 (Global and other) (Worldwide)

Characteristic	Univariate Analysis				All-Response Analysis				Cohen's Kappa	Cohen's Weighted Kappa	Univariate Analysis				All-Response Analysis				Cohen's Kappa	Cohen's Weighted Kappa														
	Percent	Mean	SD	Min-Max	Percent	Mean	SD	Min-Max			Percent	Mean	SD	Min-Max	Percent	Mean	SD	Min-Max																
Overall Response Rate	41.4	110.4	20.0	70-150	41.4	110.4	20.0	70-150	0.94	0.93	31.8	108.8	18.8	70-150	41.4	110.4	20.0	70-150	0.94	0.93	31.8	108.8	18.8	70-150	41.4	110.4	20.0	70-150	0.94	0.93	31.8	108.8	18.8	70-150

Note: For information based on the univariate analysis:
 * indicates non-response problem. Result is uninterpretable.
 # indicates non-response problem.
 Program: /srm/csl/csl_utils/RCM8785/000001/obsm/ACT_Data_Analysis/program/1_44_2m_000.mxd
 Output: /srm/csl/csl_utils/RCM8785/000001/obsm/ACT_data_2m_000_2m_000_2m_000_2m_000_BIA40B_M021_2100_2100.mxd
 04/28/2015 10:15

Item	Financial Ratios												Performance Ratios												Operational Ratios											
	Debt to Equity				Debt to Capitalization				Debt to Assets				Return on Assets				Return on Equity				Return on Assets				Return on Equity											
	Ratio	Value	Limit	Unit	Ratio	Value	Limit	Unit	Ratio	Value	Limit	Unit	Ratio	Value	Limit	Unit	Ratio	Value	Limit	Unit	Ratio	Value	Limit	Unit	Ratio	Value	Limit	Unit	Ratio	Value	Limit	Unit				
Debt to Equity	2.34	2.00	%	1.00	1.00	%	1.00	1.00	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%				
Debt to Capitalization	0.95	1.00	%	1.00	1.00	%	1.00	1.00	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%				
Debt to Assets	0.78	1.00	%	1.00	1.00	%	1.00	1.00	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%	1.00	1.00	%				
Return on Assets	0.05	0.05	%	0.05	0.05	%	0.05	0.05	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%				
Return on Equity	0.10	0.10	%	0.10	0.10	%	0.10	0.10	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%				
Return on Assets	0.05	0.05	%	0.05	0.05	%	0.05	0.05	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%	0.05	0.05	%				
Return on Equity	0.10	0.10	%	0.10	0.10	%	0.10	0.10	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%	0.10	0.10	%				

For information based on the latest financial information available to the registrant, the registrant has determined that the information presented in this report is not materially different from the information presented in its most recent financial statements.

No.	Name of the organization	Address	Phone number	E-mail address	Website	2017		2018		2019		2020		2021		2022		Total
						2017	2018	2019	2020	2021	2022	2017	2018	2019	2020	2021	2022	
1																		
2																		
3																		
4																		
5																		
6																		
7																		
8																		
9																		
10																		
11																		
12																		
13																		
14																		
15																		
16																		
17																		
18																		
19																		
20																		
21																		
22																		
23																		
24																		
25																		
26																		
27																		
28																		
29																		
30																		
31																		
32																		
33																		
34																		
35																		
36																		
37																		
38																		
39																		
40																		
41																		
42																		
43																		
44																		
45																		
46																		
47																		
48																		
49																		
50																		
51																		
52																		
53																		
54																		
55																		
56																		
57																		
58																		
59																		
60																		
61																		
62																		
63																		
64																		
65																		
66																		
67																		
68																		
69																		
70																		
71																		
72																		
73																		
74																		
75																		
76																		
77																		
78																		
79																		
80																		
81																		
82																		
83																		
84																		
85																		
86																		
87																		
88																		
89																		
90																		
91																		
92																		
93																		
94																		
95																		
96																		
97																		
98																		
99																		
100																		

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41984
 Dichotomous Analysis by Subgroups (Safety)

All

			Faricimab (N=276)				Aflibercept (N=274)			
			Patients		Patients with Event		Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%
Nervous system disorders		n/a	276	100,0	1	0,4	274	100,0	1	0,4
Nervous system disorders	Cerebral infarction	n/a	276	100,0	1	0,4	274	100,0	0	0,0
Nervous system disorders	Multiple sclerosis	n/a	276	100,0	0	0,0	274	100,0	1	0,4

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 22:24

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41984
 Dichotomous Analysis by Subgroups (Safety)

Gender

			Faricimab (N=276)				Aflibercept (N=274)			
			Patients		Patients with Event		Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%
Nervous system disorders		Male	143	51,8	1	0,7	127	46,4	0	0,0
Nervous system disorders		Female	133	48,2	0	0,0	147	53,6	1	0,7
Nervous system disorders	Cerebral infarction	Male	143	51,8	1	0,7	127	46,4	0	0,0
Nervous system disorders	Cerebral infarction	Female	133	48,2	0	0,0	147	53,6	0	0,0
Nervous system disorders	Multiple sclerosis	Male	143	51,8	0	0,0	127	46,4	0	0,0
Nervous system disorders	Multiple sclerosis	Female	133	48,2	0	0,0	147	53,6	1	0,7

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_BALATON_SE_2022_41984_41986.xls
 04JUN2024 22:24

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41984
 Dichotomous Analysis by Subgroups (Safety)

Age

			Faricimab (N=276)				Aflibercept (N=274)			
			Patients		Patients with Event		Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%
Nervous system disorders		<65 years	133	48,2	0	0,0	143	52,2	0	0,0
Nervous system disorders		>=65 years	143	51,8	1	0,7	131	47,8	1	0,8
Nervous system disorders	Cerebral infarction	<65 years	133	48,2	0	0,0	143	52,2	0	0,0
Nervous system disorders	Cerebral infarction	>=65 years	143	51,8	1	0,7	131	47,8	0	0,0
Nervous system disorders	Multiple sclerosis	<65 years	133	48,2	0	0,0	143	52,2	0	0,0
Nervous system disorders	Multiple sclerosis	>=65 years	143	51,8	0	0,0	131	47,8	1	0,8

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_BALATON_SE_2022_41984_41986.xls
 04JUN2024 22:24

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41984
 Dichotomous Analysis by Subgroups (Safety)

Baseline BCVA ETDRS letter score

			Faricimab (N=276)				Aflibercept (N=274)			
			Patients		Patients with Event		Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%
Nervous system disorders		<=54 letters	89	32,2	0	0,0	90	32,8	1	1,1
Nervous system disorders		>=55 letters	187	67,8	1	0,5	184	67,2	0	0,0
Nervous system disorders	Cerebral infarction	<=54 letters	89	32,2	0	0,0	90	32,8	0	0,0
Nervous system disorders	Cerebral infarction	>=55 letters	187	67,8	1	0,5	184	67,2	0	0,0
Nervous system disorders	Multiple sclerosis	<=54 letters	89	32,2	0	0,0	90	32,8	1	1,1
Nervous system disorders	Multiple sclerosis	>=55 letters	187	67,8	0	0,0	184	67,2	0	0,0

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_BALATON_SE_2022_41984_41986.xls
 04JUN2024 22:24

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41984
 Dichotomous Analysis by Subgroups (Safety)

Geographic Region

			Faricimab (N=276)				Aflibercept (N=274)			
			Patients		Patients with Event		Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%
Nervous system disorders		Europe	82	29,7	0	0,0	70	25,5	0	0,0
Nervous system disorders		America	97	35,1	0	0,0	103	37,6	1	1,0
Nervous system disorders		Asia Pacific (inc. Australia)	97	35,1	1	1,0	101	36,9	0	0,0
Nervous system disorders	Cerebral infarction	Europe	82	29,7	0	0,0	70	25,5	0	0,0
Nervous system disorders	Cerebral infarction	America	97	35,1	0	0,0	103	37,6	0	0,0
Nervous system disorders	Cerebral infarction	Asia Pacific (inc. Australia)	97	35,1	1	1,0	101	36,9	0	0,0
Nervous system disorders	Multiple sclerosis	Europe	82	29,7	0	0,0	70	25,5	0	0,0
Nervous system disorders	Multiple sclerosis	America	97	35,1	0	0,0	103	37,6	1	1,0
Nervous system disorders	Multiple sclerosis	Asia Pacific (inc. Australia)	97	35,1	0	0,0	101	36,9	0	0,0

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_BALATON_SE_2022_41984_41986.xls
 04JUN2024 22:24

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41984
 Dichotomous Analysis by Subgroups (Safety)

Race/ethnicity

			Faricimab (N=276)				Aflibercept (N=274)			
			Patients		Patients with Event		Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%
Nervous system disorders		White	172	62,3	0	0,0	170	62,0	1	0,6
Nervous system disorders		Asian	90	32,6	1	1,1	93	33,9	0	0,0
Nervous system disorders		Other	10	3,6	0	0,0	7	2,6	0	0,0
Nervous system disorders		Unknown	4	1,4	0	0,0	4	1,5	0	0,0
Nervous system disorders	Cerebral infarction	White	172	62,3	0	0,0	170	62,0	0	0,0
Nervous system disorders	Cerebral infarction	Asian	90	32,6	1	1,1	93	33,9	0	0,0
Nervous system disorders	Cerebral infarction	Other	10	3,6	0	0,0	7	2,6	0	0,0
Nervous system disorders	Cerebral infarction	Unknown	4	1,4	0	0,0	4	1,5	0	0,0
Nervous system disorders	Multiple sclerosis	White	172	62,3	0	0,0	170	62,0	1	0,6
Nervous system disorders	Multiple sclerosis	Asian	90	32,6	0	0,0	93	33,9	0	0,0
Nervous system disorders	Multiple sclerosis	Other	10	3,6	0	0,0	7	2,6	0	0,0
Nervous system disorders	Multiple sclerosis	Unknown	4	1,4	0	0,0	4	1,5	0	0,0

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 22:24

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: Moderate AEs through Week 24
 NOTE: Unstratified analysis
 STUDY: GR41986
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Fascinab (N=365)				Afibercept (N=361)				Fascinab vs. Afibercept												Afibercept vs. Fascinab					
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Absolute Risk		Absolute Risk Difference		Relative Risk		Interaction Test		Relative Risk							
		n	%	n	%	n	%	n	%	Odds Ratio	95% Lower CI	95% Upper CI	Absolute Risk	95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI	95% Upper CI	p-value (Wald)	p-value (likelihood ratio)	Relative Risk	95% Lower CI	95% Upper CI				
All	Overall	365	100.0	52	14.2	361	100.0	58	16.1	0.87	Convergence criterion (GCOMV+18-8) satisfied.	0.58	1.30	-0.018	Algorithm converged.	-0.070	0.034	0.89	Algorithm converged.	0.63	1.21	0.4941	1.13	Algorithm converged.	0.80	1.19	
Gender	Male	192	52.6	29	15.1	199	55.1	32	16.1	0.93	Convergence criterion (GCOMV+18-8) satisfied.	0.54	1.60	-0.010	Algorithm converged.	-0.082	0.062	0.94	Algorithm converged.	0.59	1.49	0.7904	0.7227	1.06	Algorithm converged.	0.67	1.69
	Female	173	47.4	23	13.3	162	44.9	26	16.0	0.80	Convergence criterion (GCOMV+18-8) satisfied.	0.44	1.47	-0.028	Algorithm converged.	-0.103	0.048	0.83	Algorithm converged.	0.49	1.39	0.4764	1.21	Algorithm converged.	0.72	2.03	
Age	<65 years	161	44.1	22	13.7	156	43.2	25	16.0	0.83	Convergence criterion (GCOMV+18-8) satisfied.	0.45	1.84	-0.024	Algorithm converged.	-0.102	0.055	0.85	Algorithm converged.	0.50	1.45	0.5548	0.8463	1.17	Algorithm converged.	0.69	1.99
	>=65 years	204	55.9	30	14.7	205	56.8	33	16.1	0.90	Convergence criterion (GCOMV+18-8) satisfied.	0.53	1.54	-0.014	Algorithm converged.	-0.084	0.056	0.93	Algorithm converged.	0.58	1.44	0.6968	1.09	Algorithm converged.	0.69	1.73	
Baseline BCVA ETDRS letter score	<=34 letters	79	21.6	11	13.9	80	22.2	17	21.3	0.60	Convergence criterion (GCOMV+18-8) satisfied.	0.26	1.38	-0.073	Algorithm converged.	-0.193	0.044	0.66	Algorithm converged.	0.33	1.31	0.2310	0.2010	1.43	Algorithm converged.	0.76	3.03
	35 - 54 letters	106	29.0	11	10.4	105	29.1	17	16.2	0.60	Convergence criterion (GCOMV+18-8) satisfied.	0.27	1.35	-0.058	Algorithm converged.	-0.149	0.033	0.64	Algorithm converged.	0.32	1.30	0.2187	1.56	Algorithm converged.	0.77	3.17	
	>=55 letters	180	49.3	30	16.7	176	48.8	24	13.6	1.27	Convergence criterion (GCOMV+18-8) satisfied.	0.74	2.22	0.050	Algorithm converged.	-0.044	0.105	1.22	Algorithm converged.	0.75	2.00	0.4268	0.82	Algorithm converged.	0.50	1.24	
Baseline BCVA ETDRS letter score	<=23 letters	35	9.6	3	8.6	36	10.0	6	16.7	0.47	Convergence criterion (GCOMV+18-8) satisfied.	0.11	2.04	-0.081	Algorithm converged.	-0.234	0.072	0.81	Algorithm converged.	0.14	1.80	0.3181	0.3792	1.94	Algorithm converged.	0.53	7.17
	>=24 letters	330	90.4	49	14.8	325	90.0	52	16.0	0.92	Convergence criterion (GCOMV+18-8) satisfied.	0.60	1.40	-0.012	Algorithm converged.	-0.067	0.044	0.93	Algorithm converged.	0.65	1.33	0.6834	1.08	Algorithm converged.	0.75	1.54	
Geographic Region	Europe	111	30.4	22	19.8	113	31.3	21	18.6	1.08	Convergence criterion (GCOMV+18-8) satisfied.	0.56	2.11	0.012	Algorithm converged.	-0.091	0.116	1.07	Algorithm converged.	0.62	1.83	0.8144	0.1338	0.94	Algorithm converged.	0.55	1.61
	America	146	40.0	22	15.1	145	40.2	20	13.8	1.11	Convergence criterion (GCOMV+18-8) satisfied.	0.58	2.13	0.013	Algorithm converged.	-0.068	0.093	1.09	Algorithm converged.	0.62	1.91	0.7570	0.92	Algorithm converged.	0.52	1.60	
	Asia Pacific (inc. Australia)	108	29.6	8	7.4	103	28.5	17	16.5	0.40	Convergence criterion (GCOMV+18-8) satisfied.	0.17	0.98	-0.091	Algorithm converged.	-0.178	-0.004	0.45	Algorithm converged.	0.20	0.99	0.0485	2.23	Algorithm converged.	1.01	4.84	
Baseline RVO status	CRVO	301	82.5	43	14.3	291	80.6	42	14.4	0.99	Convergence criterion (GCOMV+18-8) satisfied.	0.62	1.96	-0.001	Algorithm converged.	-0.058	0.055	0.99	Algorithm converged.	0.67	1.47	0.9593	0.2171	1.01	Algorithm converged.	0.68	1.60
	HRVO	61	16.7	9	14.8	64	17.7	16	25.0	0.52	Convergence criterion (GCOMV+18-8) satisfied.	0.21	1.28	-0.102	Algorithm converged.	-0.241	0.036	0.59	Algorithm converged.	0.28	1.23	0.1611	1.69	Algorithm converged.	0.81	3.84	
	Missing	3	0.8	0	0.0	6	1.7	0	0.0	NE		NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Race/ethnicity	White	242	66.3	37	15.3	251	69.5	40	15.9	0.95	Convergence criterion (GCOMV+18-8) satisfied.	0.59	1.55	-0.006	Algorithm converged.	-0.071	0.058	0.96	Algorithm converged.	0.64	1.45	0.8432	0.5006	1.04	Algorithm converged.	0.69	1.57
	Asian	89	24.4	9	10.1	88	24.4	15	17.0	0.55	Convergence criterion (GCOMV+18-8) satisfied.	0.23	1.33	-0.049	Algorithm converged.	-0.170	0.031	0.59	Algorithm converged.	0.27	1.28	0.1850	1.69	Algorithm converged.	0.78	3.65	
	Other	113	31.0	2	1.8	117	32.7	2	1.7	1.36	Convergence criterion (GCOMV+18-8) satisfied.	0.17	1.22	0.036	Algorithm converged.	-0.212	0.284	1.31	Algorithm converged.	0.21	0.99	0.7739	0.76	Algorithm converged.	0.12	4.73	
	Unknown	21	5.8	4	19.0	5	1.4	1	20.0	0.94	Convergence criterion (GCOMV+18-8) satisfied.	0.08	10.87	-0.010	Algorithm converged.	-0.398	0.379	0.95	Algorithm converged.	0.13	6.78	0.9611	1.05	Algorithm converged.	0.15	7.47	

Only AEs of highest severity are counted.
 Test for interaction based on RR (Log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 clinical cut-off: 0.9402022

Program: /root/clinical_studies/RO6867461/CPT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
 Output: /root/clinical_studies/RO6867461/CPT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_MM00AR_WK24_COMINO_SE_2022_41984_41986.xls
 04JUN2024 17:53

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: Severe AEs through Week 24
 NOTE: Unstratified analysis
 STUDY: GR41986
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Fascinab (N=365)				Afibercept (N=361)				Fascinab vs. Afibercept										Afibercept vs. Fascinab							
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Absolute Risk		Absolute Risk Difference		Relative Risk		Interaction Test		Relative Risk		Relative Risk					
		n	%	n	%	n	%	n	%	Odds Ratio	95% Lower CI	95% Upper CI	Absolute Risk	95% Lower CI	95% Upper CI	Relative Risk	95% Lower CI	95% Upper CI	p-value (Wald)	p-value (likelihood ratio)	Relative Risk	95% Lower CI	95% Upper CI				
All	Overall	365	100.0	19	5.2	361	100.0	25	6.9	0.74	Convergence criterion (GCOMV+18-8) satisfied.	0.40	0.37	-0.017	Algorithm converged.	-0.052	0.018	0.78	Algorithm converged.	0.42	0.34	0.3191	1.33	Algorithm converged.	0.73	0.17	
Gender	Male	192	52.6	9	4.7	199	55.1	17	8.5	0.53	Convergence criterion (GCOMV+18-8) satisfied.	0.21	0.21	-0.039	Algorithm converged.	-0.088	0.010	0.55	Algorithm converged.	0.25	0.20	0.1331	0.2101	1.82	Algorithm converged.	0.83	0.89
Gender	Female	173	47.4	10	5.8	162	44.9	8	4.9	1.18	Convergence criterion (GCOMV+18-8) satisfied.	0.48	0.07	0.098	Algorithm converged.	-0.040	0.087	1.17	Algorithm converged.	0.47	0.89	0.7330	0.88	Algorithm converged.	0.19	2.11	
Age	<65 years	161	44.1	5	3.1	156	43.2	7	4.5	0.68	Convergence criterion (GCOMV+18-8) satisfied.	0.21	0.20	-0.014	Algorithm converged.	-0.056	0.028	0.69	Algorithm converged.	0.22	0.13	0.5219	0.8555	1.44	Algorithm converged.	0.47	4.48
Age	>=65 years	204	55.9	14	6.9	205	56.8	18	8.8	0.77	Convergence criterion (GCOMV+18-8) satisfied.	0.37	1.58	-0.019	Algorithm converged.	-0.071	0.033	0.78	Algorithm converged.	0.40	1.53	0.4716	1.28	Algorithm converged.	0.65	2.50	
Baseline BCVA ETDRS letter score	<=34 letters	79	21.6	2	2.5	80	22.2	6	7.5	0.32	Convergence criterion (GCOMV+18-8) satisfied.	0.06	1.84	-0.050	Algorithm converged.	-0.117	0.018	0.34	Algorithm converged.	0.07	1.82	0.1751	0.0522	2.86	Algorithm converged.	0.62	14.24
Baseline BCVA ETDRS letter score	35 - 54 letters	106	29.0	8	7.5	105	29.1	3	2.8	2.78	Convergence criterion (GCOMV+18-8) satisfied.	0.72	10.77	0.047	Algorithm converged.	-0.013	0.106	2.64	Algorithm converged.	0.72	9.68	0.1428	0.38	Algorithm converged.	0.10	1.39	
Baseline BCVA ETDRS letter score	>=55 letters	180	49.3	9	5.0	178	48.8	16	9.1	0.54	Convergence criterion (GCOMV+18-8) satisfied.	0.23	1.22	-0.041	Algorithm converged.	-0.094	0.012	0.55	Algorithm converged.	0.25	1.21	0.1279	1.82	Algorithm converged.	0.84	4.01	
Baseline BCVA ETDRS letter score	<=23 letters	35	9.6	1	2.9	38	10.6	5	13.3	0.18	Convergence criterion (GCOMV+18-8) satisfied.	0.02	1.85	-0.110	Algorithm converged.	-0.236	0.015	0.21	Algorithm converged.	0.03	1.67	0.1392	0.1363	4.86	Algorithm converged.	0.60	39.54
Baseline BCVA ETDRS letter score	>=24 letters	330	90.4	18	5.5	325	90.0	20	6.2	0.88	Convergence criterion (GCOMV+18-8) satisfied.	0.46	1.70	-0.007	Algorithm converged.	-0.043	0.029	0.89	Algorithm converged.	0.48	1.64	0.7021	1.13	Algorithm converged.	0.61	2.09	
Geographic Region	Europe	111	30.4	3	2.7	113	31.3	9	8.0	0.32	Convergence criterion (GCOMV+18-8) satisfied.	0.08	1.22	-0.053	Algorithm converged.	-0.111	0.006	0.34	Algorithm converged.	0.09	1.22	0.0980	0.1005	2.95	Algorithm converged.	0.82	10.60
Geographic Region	America	146	40.0	9	6.2	143	40.2	13	9.0	0.67	Convergence criterion (GCOMV+18-8) satisfied.	0.28	1.61	-0.028	Algorithm converged.	-0.089	0.033	0.69	Algorithm converged.	0.30	1.56	0.3696	1.45	Algorithm converged.	0.64	3.30	
Geographic Region	Asia Pacific (inc. Australia)	108	29.6	7	6.5	103	28.5	3	2.9	2.31	Convergence criterion (GCOMV+18-8) satisfied.	0.58	9.19	0.036	Algorithm converged.	-0.021	0.092	2.23	Algorithm converged.	0.59	8.37	0.2368	0.45	Algorithm converged.	0.12	1.69	
Baseline RVO status	CRVO	301	82.5	15	5.0	291	80.6	22	7.6	0.64	Convergence criterion (GCOMV+18-8) satisfied.	0.33	1.26	-0.026	Algorithm converged.	-0.065	0.011	0.66	Algorithm converged.	0.35	1.25	0.1991	0.3499	1.82	Algorithm converged.	0.80	2.87
Baseline RVO status	HRVO	61	16.7	4	6.6	64	17.7	3	4.7	1.43	Convergence criterion (GCOMV+18-8) satisfied.	0.31	6.65	0.019	Algorithm converged.	-0.062	0.100	1.40	Algorithm converged.	0.33	6.00	0.6512	0.71	Algorithm converged.	0.17	3.06	
Baseline RVO status	Missing	3	0.8	0	0.0	6	1.7	0	0.0	NR		NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Race/ethnicity	White	242	66.3	15	6.2	251	69.5	21	8.4	0.72	Convergence criterion (GCOMV+18-8) satisfied.	0.36	1.44	-0.022	Algorithm converged.	-0.067	0.024	0.74	Algorithm converged.	0.39	1.40	0.3573	0.7126	1.35	Algorithm converged.	0.71	2.58
Race/ethnicity	Asian	89	24.4	2	2.2	88	24.4	1	1.1	2.00	Convergence criterion (GCOMV+18-8) satisfied.	0.18	22.46	0.011	Algorithm converged.	-0.027	0.049	1.98	Algorithm converged.	0.18	21.42	0.5748	0.61	Algorithm converged.	0.05	5.48	
Race/ethnicity	Other	113	31.0	1	0.9	117	32.4	3	2.6	0.63	Convergence criterion (GCOMV+18-8) satisfied.	0.01	7.78	-0.041	Algorithm converged.	-0.252	0.170	0.46	Algorithm converged.	0.07	6.45	0.7140	1.43	Algorithm converged.	0.15	15.08	
Race/ethnicity	Unknown	21	5.8	1	4.8	5	1.4	1	20.0	0.20	Convergence criterion (GCOMV+18-8) satisfied.	0.01	3.91	-0.152	Algorithm converged.	-0.515	0.210	0.24	Algorithm converged.	0.02	3.19	0.2783	4.20	Algorithm converged.	0.11	56.24	

Only AEs of highest severity are counted.
 Test for interaction based on RR (Log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.9402022

Program: /root/clinical_studies/RO6867461/CPT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
 Output: /root/clinical_studies/RO6867461/CPT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_MSEVAR_WK24_COMINO_SE_2022_41984_41986.xls
 04JUN2024 17:55

Substratum	Event	Observed (95% CI)						Attributed (95% CI)						Population vs. Attributed											
		Patients with Event			Patients with Event			Patients with Event			Patients with Event			Absolute Risk Difference						Relative Risk					
		n	%	95% CI	n	%	95% CI	n	%	95% CI	n	%	95% CI	Lower	Upper	Relative Risk	Lower	Upper	Relative Risk	Lower	Upper	Relative Risk	Lower	Upper	
All	All	301	100.0		301	100.0		301	100.0		301	100.0		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
Gender	Male	133	44.2		140	46.5		133	44.2		140	46.5		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	Female	170	55.8		161	53.5		170	55.8		161	53.5		-0.00	-0.00	0.00	-0.00	-0.00	0.00	-0.00	-0.00	0.00	-0.00	-0.00	
Age	18-64 years	148	49.2		154	51.2		148	49.2		154	51.2		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	65-74 years	104	34.5		97	32.2		104	34.5		97	32.2		-0.00	-0.00	0.00	-0.00	-0.00	0.00	-0.00	-0.00	0.00	-0.00	-0.00	
	75-84 years	104	34.5		104	34.5		104	34.5		104	34.5		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	85+ years	45	14.8		46	15.1		45	14.8		46	15.1		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
Baseline WHO EDSS Letter score	0-14 letters	70	23.3		67	22.3		70	23.3		67	22.3		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	15-14 letters	105	34.9		105	34.9		105	34.9		105	34.9		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	15-14 letters	126	41.8		128	42.4		126	41.8		128	42.4		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
Baseline WHO EDSS Letter score	0-14 letters	28	9.3		28	9.3		28	9.3		28	9.3		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	15-14 letters	102	33.8		102	33.8		102	33.8		102	33.8		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	15-14 letters	170	55.9		171	56.1		170	55.9		171	56.1		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
Disability Region	Europe	111	36.9		111	36.9		111	36.9		111	36.9		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	North America	148	49.2		148	49.2		148	49.2		148	49.2		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	Asia Pacific (incl. Australia)	142	47.1		142	47.1		142	47.1		142	47.1		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
Baseline WHO EDSS score	0-14	111	36.9		111	36.9		111	36.9		111	36.9		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	15-14	102	33.8		102	33.8		102	33.8		102	33.8		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	15-14	170	55.9		170	55.9		170	55.9		170	55.9		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
Gender	Male	51	16.9		51	16.9		51	16.9		51	16.9		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	Female	150	49.5		150	49.5		150	49.5		150	49.5		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
Age	18-64 years	94	31.2		97	32.2		94	31.2		97	32.2		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	65-74 years	76	25.2		70	23.0		76	25.2		70	23.0		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	75-84 years	15	4.9		15	4.9		15	4.9		15	4.9		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	
	85+ years	11	3.6		11	3.6		11	3.6		11	3.6		0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00	0.00	0.00	

Note for interpretation based on RR (log-binomial regression):
 * indicates convergence problem. Result is uninterpretable.
 Clinical not-est: UNCONVERG

Program: /root/.cvsroot/analysis/04047441/0203033/ohsu_vtkr_analysis/psd/program_r_m_fm_ohs
 Output: /root/.cvsroot/analysis/04047441/0203033/ohsu_vtkr_fm_fm_ohs/psd/program_r_m_fm_ohs_000004_MDR_OHSHR_08_2022_4184_4184_vtkr
 04/20/24 10:06

Exp. Standart	Component	Unit	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050																																																																																												
Exp. Standart	Accounting element	Rate	0.28	0.32	0.38	0.44	0.50	0.57	0.64	0.72	0.80	0.88	0.96	1.04	1.12	1.20	1.28	1.36	1.44	1.52	1.60	1.68	1.76	1.84	1.92	2.00	2.08	2.16	2.24	2.32	2.40	2.48	2.56	2.64	2.72	2.80	2.88	2.96	3.04	3.12	3.20	3.28	3.36	3.44	3.52	3.60	3.68	3.76	3.84	3.92	4.00	4.08	4.16	4.24	4.32	4.40	4.48	4.56	4.64	4.72	4.80	4.88	4.96	5.04	5.12	5.20	5.28	5.36	5.44	5.52	5.60	5.68	5.76	5.84	5.92	6.00	6.08	6.16	6.24	6.32	6.40	6.48	6.56	6.64	6.72	6.80	6.88	6.96	7.04	7.12	7.20	7.28	7.36	7.44	7.52	7.60	7.68	7.76	7.84	7.92	8.00	8.08	8.16	8.24	8.32	8.40	8.48	8.56	8.64	8.72	8.80	8.88	8.96	9.04	9.12	9.20	9.28	9.36	9.44	9.52	9.60	9.68	9.76	9.84	9.92	10.00

Table with columns: Description, Unit, Value, Error, Status, Notes, and Performance metrics. Rows include various mathematical functions like arctan, cos, exp, gamma, and gamma_inc, along with special functions like digamma and zeta. Each row provides a detailed summary of the function's behavior and performance across different platforms and data points.

Table with multiple columns containing identifiers (e.g., Hepatitis B surface antigen), values (e.g., 10, 5.0), and notes (e.g., 'Error in computing the Link Function...').

POKROKOV: Matematičeskaya Populatsiya, OSNO				MEMOIR: my am through time 14				MEMOIR: unclassified analysis				FROM: MEMOIR				MEMOIR: Analysis by subgroup (Infery)			
MEMOIR: WGS 600k Error Rate				MEMOIR: WGS 600k Error Rate				MEMOIR: WGS 600k Error Rate				MEMOIR: WGS 600k Error Rate				MEMOIR: WGS 600k Error Rate			
Subgroup		Subgroup		Subgroup		Subgroup		Subgroup		Subgroup		Subgroup		Subgroup		Subgroup		Subgroup	
Category	Subgroup	Category	Subgroup	Category	Subgroup	Category	Subgroup	Category	Subgroup	Category	Subgroup	Category	Subgroup	Category	Subgroup	Category	Subgroup	Category	Subgroup
MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate
	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate	MEMOIR: WGS 600k Error Rate

Baseline MCO: 87000 Error: None

Module Name	Module Type	Module Version	Performance (MCO)				Reliability (MCO)				MCO Metric	MCO Value	MCO Unit	MCO Status	MCO Reason	MCO Error	MCO Action	MCO Impact	MCO Severity	MCO Category
			Min	Max	Avg	Std	Min	Max	Avg	Std										
Module A	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module B	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module C	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module D	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module E	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module F	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module G	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module H	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module I	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module J	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module K	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module L	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module M	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module N	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module O	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module P	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module Q	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module R	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module S	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module T	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module U	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module V	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module W	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module X	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module Y	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Module Z	System	1.0.0	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10

Run ID	Run Name	Run Type	Run Location	Run Date	Run Time	Run Status	Run Description	Run Parameters	Run Results	Run Metrics	Run Notes
Run 00000000000000000000	Run 00000000000000000000	Run 00000000000000000000	Run 00000000000000000000	Run 00000000000000000000	Run 00000000000000000000	Run 00000000000000000000	Run 00000000000000000000	Run 00000000000000000000	Run 00000000000000000000	Run 00000000000000000000	Run 00000000000000000000

POPULATION: Italy - Roma
 MEMORY: 48M / 1024M / 1024M
 MODEL: Unlabeled Analysis
 EVENT: RAIN

Baseline MSB status		Parameter (MSB)				Baseline (MSB)				Parameter (MSB)				Baseline (MSB)				Parameter (MSB)				Baseline (MSB)																									
		a	b	c	d	a	b	c	d	beta	gamma	delta	epsilon	eta	theta	phi	psi	omega	lambda	mu	nu	xi	eta	theta	phi	psi	omega	lambda	mu	nu	xi	eta	theta	phi	psi	omega	lambda	mu	nu	xi	eta	theta	phi	psi	omega		
Model	MSB	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	
Model	MSB	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1

Item/Component	Item Name / Description	Model	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC	CI	LC											
Electronics	Electronics	Mean & var Gaussian	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table with columns for System Name, Type, Component, Value, Units, Description, Status, and various Performance Indicators. The table lists various systems such as 'Revenue system standard', 'Payment system standard', and 'Reporting system standard', each with associated numerical values and descriptive text.

Symbol	Company	Country	Market	Industry	Market Cap (USD)	Revenue (USD)	Profit (USD)	EPS (USD)	Dividend (USD)	P/E Ratio	Dividend Yield (%)	ROIC (%)	Debt/Equity	Current Ratio	Operating Margin (%)	Net Profit Margin (%)	EBITDA Margin (%)	Free Cash Flow Margin (%)	Capital Expenditure/Revenue (%)	Research and Development/Revenue (%)	SG&A/Revenue (%)	Interest Expense/Revenue (%)	Income Tax Expense/Revenue (%)	Effective Tax Rate (%)	Return on Assets (%)	Return on Equity (%)	Return on Capital Employed (%)	Return on Invested Capital (%)
AMZN	Amazon.com Inc	USA	Market	Internet Retailer	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
GOOGL	Alphabet Inc Class A	USA	Market	Internet Content & Information	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
MSFT	Microsoft Corporation	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
FB	Meta Platforms Inc	USA	Market	Internet Content & Information	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
BRK.A	Berkshire Hathaway Inc Class A	USA	Market	Financial Services	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
APPL	Apple Inc	USA	Market	Consumer Electronics	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
ADBE	Adobe Inc	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
CRM	Salesforce Inc	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
ORCL	Oracle Corporation	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
IBM	International Business Machines Corporation	USA	Market	Information Technology	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
INTC	Intel Corporation	USA	Market	Semiconductors	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
QCOM	Qualcomm Inc	USA	Market	Semiconductors	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
TXN	Transacta Group Inc	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
NET	Cloudflare Inc	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
SHOP	Shopify Inc	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
PLTR	Palantir Technologies Inc	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
COIN	Coinbase Global Inc	USA	Market	Financial Services	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
HOLO	Hologram Inc	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
NETSC	NetScout Systems Inc	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
NETS	NetScout Systems Inc	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00
NETS	NetScout Systems Inc	USA	Market	Software	1,000,000,000,000	1,000,000,000,000	100,000,000,000	10.00	0.00	100.00	0.00	10.00	0.50	1.50	10.00	5.00	15.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00	10.00	20.00	15.00	10.00

Account Name	Account Type	Account Category	Account Sub-Category	Account Description	Account Balance	Account Debit	Account Credit	Account Net	Account Status	Account Location	Account Date	Account Time	Account User	Account Password	Account IP	Account Port	Account Protocol	Account Action	Account Result	Account Error	Account Message
Account Name	Account Type	Account Category	Account Sub-Category	Account Description	Account Balance	Account Debit	Account Credit	Account Net	Account Status	Account Location	Account Date	Account Time	Account User	Account Password	Account IP	Account Port	Account Protocol	Account Action	Account Result	Account Error	Account Message
Account Name	Account Type	Account Category	Account Sub-Category	Account Description	Account Balance	Account Debit	Account Credit	Account Net	Account Status	Account Location	Account Date	Account Time	Account User	Account Password	Account IP	Account Port	Account Protocol	Account Action	Account Result	Account Error	Account Message

63

SR#	Subsystem/Component	Subsystem/Component Class	Subsystem/Component Description	Level	Passive (SR#)						Active (SR#)						Failure Mode Difference						Failure Mode					
					Passive With Event		Passive With Event		Passive With Event		Active With Event		Active With Event		Active With Event		Failure Mode		Failure Mode		Failure Mode		Failure Mode					
					F	S	F	S	F	S	F	S	F	S	F	S	F	S	F	S	F	S	F	S				
100	Human Error	Human Error	Operator Error	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1						

Baseline MMR: OSMO Error State		Population W. MMR										Population W. MMR: Difference										Population W. Population									
MMR Subgroup Error Class	MMR Unresolved Type	Population (MMR)					Population (MMR)					MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	Population W. MMR: Difference					Population W. Population							
		0	1	2	3	4	0	1	2	3	4								0	1	2	3	4	0	1	2	3	4	0	1	2
MMR Subgroup Error Class	MMR Unresolved Type	0	1	2	3	4	0	1	2	3	4	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	0	1	2	3	4	0	1	2	3	4		
MMR Subgroup Error Class	MMR Unresolved Type	0	1	2	3	4	0	1	2	3	4	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	0	1	2	3	4	0	1	2	3	4		
MMR Subgroup Error Class	MMR Unresolved Type	0	1	2	3	4	0	1	2	3	4	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	0	1	2	3	4	0	1	2	3	4		
MMR Subgroup Error Class	MMR Unresolved Type	0	1	2	3	4	0	1	2	3	4	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	0	1	2	3	4	0	1	2	3	4		
MMR Subgroup Error Class	MMR Unresolved Type	0	1	2	3	4	0	1	2	3	4	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	MMR State	0	1	2	3	4	0	1	2	3	4		

Study, platform and research organization	SN	Year	Age	Sex	Outcome	SN	Year	Age	Sex	Outcome	SN	Year	Age	Sex	Outcome	SN	Year	Age	Sex	Outcome	SN	Year	Age	Sex	Outcome	SN	Year	Age	Sex	Outcome	SN	Year	Age	Sex	Outcome	SN	Year	Age	Sex	Outcome					
PROY, platform and research organization	PROY	2018	9.4	M	Convergence criterion (G000101-8) satisfied.	PROY	2018	9.4	M	Convergence criterion (G000101-8) satisfied.	PROY	2018	9.4	M	Convergence criterion (G000101-8) satisfied.	PROY	2018	9.4	M	Convergence criterion (G000101-8) satisfied.	PROY	2018	9.4	M	Convergence criterion (G000101-8) satisfied.	PROY	2018	9.4	M	Convergence criterion (G000101-8) satisfied.	PROY	2018	9.4	M	Convergence criterion (G000101-8) satisfied.	PROY	2018	9.4	M	Convergence criterion (G000101-8) satisfied.	PROY	2018	9.4	M	Convergence criterion (G000101-8) satisfied.

Product Name	Product Code	Performance (Safety)				Performance (Healthcare)				Performance (OHSW)										Performance (Business)																			
		Score	Weight	Score	Weight	Score	Weight	Score	Weight	Score	Weight	Score	Weight	Score	Weight	Score	Weight	Score	Weight	Score	Weight	Score	Weight																
Product A	101	95	1.0	90	0.5	85	0.5	80	0.5	75	0.5	70	0.5	65	0.5	60	0.5	55	0.5	50	0.5	45	0.5	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5
Product B	102	90	1.0	85	0.5	80	0.5	75	0.5	70	0.5	65	0.5	60	0.5	55	0.5	50	0.5	45	0.5	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5		
Product C	103	85	1.0	80	0.5	75	0.5	70	0.5	65	0.5	60	0.5	55	0.5	50	0.5	45	0.5	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5				
Product D	104	80	1.0	75	0.5	70	0.5	65	0.5	60	0.5	55	0.5	50	0.5	45	0.5	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5						
Product E	105	75	1.0	70	0.5	65	0.5	60	0.5	55	0.5	50	0.5	45	0.5	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5				
Product F	106	70	1.0	65	0.5	60	0.5	55	0.5	50	0.5	45	0.5	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5				
Product G	107	65	1.0	60	0.5	55	0.5	50	0.5	45	0.5	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5				
Product H	108	60	1.0	55	0.5	50	0.5	45	0.5	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5				
Product I	109	55	1.0	50	0.5	45	0.5	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5				
Product J	110	50	1.0	45	0.5	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		
Product K	111	45	1.0	40	0.5	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		
Product L	112	40	1.0	35	0.5	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		
Product M	113	35	1.0	30	0.5	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		
Product N	114	30	1.0	25	0.5	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		
Product O	115	25	1.0	20	0.5	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		
Product P	116	20	1.0	15	0.5	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		
Product Q	117	15	1.0	10	0.5	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		
Product R	118	10	1.0	5	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		
Product S	119	5	1.0	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		
Product T	120	0	1.0	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5	0	0.5		

Table with columns for Model, Variable, Method, and various statistical metrics (Mean, Std. Dev., Skewness, Kurtosis, etc.). The table is organized into multiple groups of rows, each representing a different model or variable type. It includes headers for 'Model' and 'Variable', and columns for 'Method', 'Mean', 'Std. Dev.', 'Skewness', 'Kurtosis', 'Normality Test', 'Linearity Test', and 'Non-normality Test'. The data is presented in a grid format with numerical values and categorical labels like 'Normality test passed' or 'Linearity test passed'.

Method	Variable	Mean	Std. Dev.	Skewness	Kurtosis	Normality	Linearity	Homoscedasticity	Normality of Residuals	Linearity of Residuals	Homoscedasticity of Residuals	Normality of Residuals	Linearity of Residuals	Homoscedasticity of Residuals	Normality of Residuals	Linearity of Residuals	Homoscedasticity of Residuals	Normality of Residuals	Linearity of Residuals	Homoscedasticity of Residuals	
Linear regression	Heavy metal concentration	15.0	4.0	0.2	3.2	0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Linear regression	Heavy metal concentration	15.0	4.0	0.2	3.2	0.15	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Linear regression	Heavy metal concentration	15.0	4.0	0.2	3.2	0.15	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
Linear regression	Heavy metal concentration	15.0	4.0	0.2	3.2	0.15	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
Linear regression	Heavy metal concentration	15.0	4.0	0.2	3.2	0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Linear regression	Heavy metal concentration	15.0	4.0	0.2	3.2	0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Linear regression	Heavy metal concentration	15.0	4.0	0.2	3.2	0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Linear regression	Heavy metal concentration	15.0	4.0	0.2	3.2	0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Linear regression	Heavy metal concentration	15.0	4.0	0.2	3.2	0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Linear regression	Heavy metal concentration	15.0	4.0	0.2	3.2	0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Only one of highest severity was counted.
Test for heteroscedasticity based on EN (log likelihood regression).
+ indicates heteroscedastic problem, - results in homoscedasticity.
Skewness and kurtosis values are in brackets.
Normality test results are in brackets.
+ indicates normality, - indicates non-normality.
Linearity test results are in brackets.
+ indicates linearity, - indicates non-linearity.
Homoscedasticity test results are in brackets.
+ indicates homoscedasticity, - indicates heteroscedasticity.

Table with columns: Test Name, Test ID, Test Type, Test Category, Test Frequency, Test Duration, Test Complexity, Test Priority, Test Status, Test Results, Test Description, Test Parameters, Test Values, Test Metrics, Test Conclusions, Test Recommendations.

Only AEs of highest severity were counted.
Test for interaction based on log-logit-linear regression
* indicates convergence problem. Result is nonrepresentative.
clinical out-off: 00000002
Program: root:\clinical_data\00047461\00000002\raw\AEX_AEA_data_analysis\prod\program_fm_fm_mmc_mmc
Output: root:\clinical_data\00047461\00000002\raw\AEX_AEA_data_analysis\prod\output_fm_fm_mmc_mmc_00047461_00000002_0002_4194_4284_434
04780024 14-40

Year	Subgroup				Subgroup				Year			Year			Year						Year						Year								
	Population		Energy		Population		Energy		Year	Year	Year	Year	Year	Year	Year		Year		Year		Year		Year		Year		Year		Year		Year		Year		Year
Year	Population	Energy	Population	Energy	Year	Population	Energy	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year		
1980	1.0	1.0	1.0	1.0	1980	1.0	1.0	1980	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	
1981	1.0	1.0	1.0	1.0	1981	1.0	1.0	1981	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	
1982	1.0	1.0	1.0	1.0	1982	1.0	1.0	1982	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	

ID	Personal - Demographic												Economic - Administrative												Education - Services											
	Age			Sex			Marital Status			Religion			Nationality			Migration			Employment			Income			Assets			Occupation			Services					
Variable	Unit	Min	Max	Mean	Std Dev	Skewness	Kurtosis	Min	Max	Mean	Std Dev	Skewness	Kurtosis	Min	Max	Mean	Std Dev	Skewness	Kurtosis	Min	Max	Mean	Std Dev	Skewness	Kurtosis	Min	Max	Mean	Std Dev	Skewness	Kurtosis					
Age	Years	0	100	31.5	10.2	0.15	0.10	0	100	31.5	10.2	0.15	0.10	0	100	31.5	10.2	0.15	0.10	0	100	31.5	10.2	0.15	0.10	0	100	31.5	10.2	0.15	0.10					
Sex	Category	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0					
Marital Status	Category	1	5	2.5	1.5	0.0	0.0	1	5	2.5	1.5	0.0	0.0	1	5	2.5	1.5	0.0	0.0	1	5	2.5	1.5	0.0	0.0	1	5	2.5	1.5	0.0	0.0					
Religion	Category	1	5	2.5	1.5	0.0	0.0	1	5	2.5	1.5	0.0	0.0	1	5	2.5	1.5	0.0	0.0	1	5	2.5	1.5	0.0	0.0	1	5	2.5	1.5	0.0	0.0					
Nationality	Category	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0					
Migration	Category	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0					
Employment	Category	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0					
Income	Rs	0	100000	25000	40000	1.0	0.5	0	100000	25000	40000	1.0	0.5	0	100000	25000	40000	1.0	0.5	0	100000	25000	40000	1.0	0.5	0	100000	25000	40000	1.0	0.5					
Assets	Rs	0	1000000	50000	100000	1.0	0.5	0	1000000	50000	100000	1.0	0.5	0	1000000	50000	100000	1.0	0.5	0	1000000	50000	100000	1.0	0.5	0	1000000	50000	100000	1.0	0.5					
Occupation	Category	1	10	5.0	3.0	0.0	0.0	1	10	5.0	3.0	0.0	0.0	1	10	5.0	3.0	0.0	0.0	1	10	5.0	3.0	0.0	0.0	1	10	5.0	3.0	0.0	0.0					
Services	Category	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0	1	2	1.5	0.5	0.0	0.0					

Table with columns: Population (Normal, Multinomial), Repetition (1st, 2nd), and various statistical measures (Mean, Variance, Covariance, etc.). Rows list variables like 'Hypertension', 'Diabetes Mellitus', 'Asthma', etc., under different estimation methods and subgroup labels. The table contains numerical data for means, variances, and covariances across different groups and estimations.

Information and Information	Administrative	18 - 64 letters	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63	66	69	72	75	78	81	84	87	90	93	96	99	102	105	108	111	114	117	120	123	126	129	132	135	138	141	144	147	150	153	156	159	162	165	168	171	174	177	180	183	186	189	192	195	198	201	204	207	210	213	216	219	222	225	228	231	234	237	240	243	246	249	252	255	258	261	264	267	270	273	276	279	282	285	288	291	294	297	300	303	306	309	312	315	318	321	324	327	330	333	336	339	342	345	348	351	354	357	360	363	366	369	372	375	378	381	384	387	390	393	396	399	402	405	408	411	414	417	420	423	426	429	432	435	438	441	444	447	450	453	456	459	462	465	468	471	474	477	480	483	486	489	492	495	498	501	504	507	510	513	516	519	522	525	528	531	534	537	540	543	546	549	552	555	558	561	564	567	570	573	576	579	582	585	588	591	594	597	600	603	606	609	612	615	618	621	624	627	630	633	636	639	642	645	648	651	654	657	660	663	666	669	672	675	678	681	684	687	690	693	696	699	702	705	708	711	714	717	720	723	726	729	732	735	738	741	744	747	750	753	756	759	762	765	768	771	774	777	780	783	786	789	792	795	798	801	804	807	810	813	816	819	822	825	828	831	834	837	840	843	846	849	852	855	858	861	864	867	870	873	876	879	882	885	888	891	894	897	900	903	906	909	912	915	918	921	924	927	930	933	936	939	942	945	948	951	954	957	960	963	966	969	972	975	978	981	984	987	990	993	996	999
Information and Information	Administrative	18 - 64 letters	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63	66	69	72	75	78	81	84	87	90	93	96	99	102	105	108	111	114	117	120	123	126	129	132	135	138	141	144	147	150	153	156	159	162	165	168	171	174	177	180	183	186	189	192	195	198	201	204	207	210	213	216	219	222	225	228	231	234	237	240	243	246	249	252	255	258	261	264	267	270	273	276	279	282	285	288	291	294	297	300	303	306	309	312	315	318	321	324	327	330	333	336	339	342	345	348	351	354	357	360	363	366	369	372	375	378	381	384	387	390	393	396	399	402	405	408	411	414	417	420	423	426	429	432	435	438	441	444	447	450	453	456	459	462	465	468	471	474	477	480	483	486	489	492	495	498	501	504	507	510	513	516	519	522	525	528	531	534	537	540	543	546	549	552	555	558	561	564	567	570	573	576	579	582	585	588	591	594	597	600	603	606	609	612	615	618	621	624	627	630	633	636	639	642	645	648	651	654	657	660	663	666	669	672	675	678	681	684	687	690	693	696	699	702	705	708	711	714	717	720	723	726	729	732	735	738	741	744	747	750	753	756	759	762	765	768	771	774	777	780	783	786	789	792	795	798	801	804	807	810	813	816	819	822	825	828	831	834	837	840	843	846	849	852	855	858	861	864	867	870	873	876	879	882	885	888	891	894	897	900	903	906	909	912	915	918	921	924	927	930	933	936	939	942	945	948	951	954	957	960	963	966	969	972	975	978	981	984	987	990	993	996	999
Information and Information	Administrative	18 - 64 letters	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63	66	69	72	75	78	81	84	87	90	93	96	99	102	105	108	111	114	117	120	123	126	129	132	135	138	141	144	147	150	153	156	159	162	165	168	171	174	177	180	183	186	189	192	195	198	201	204	207	210	213	216	219	222	225	228	231	234	237	240	243	246	249	252	255	258	261	264	267	270	273	276	279	282	285	288	291	294	297	300	303	306	309	312	315	318	321	324	327	330	333	336	339	342	345	348	351	354	357	360	363	366	369	372	375	378	381	384	387	390	393	396	399	402	405	408	411	414	417	420	423	426	429	432	435	438	441	444	447	450	453	456	459	462	465	468	471	474	477	480	483	486	489	492	495	498	501	504	507	510	513	516	519	522	525	528	531	534	537	540	543	546	549	552	555	558	561	564	567	570	573	576	579	582	585	588	591	594	597	600	603	606	609	612	615	618	621	624	627	630	633	636	639	642	645	648	651	654	657	660	663	666	669	672	675	678	681	684	687	690	693	696	699	702	705	708	711	714	717	720	723	726	729	732	735	738	741	744	747	750	753	756	759	762	765	768	771	774	777	780	783	786	789	792	795	798	801	804	807	810	813	816	819	822	825	828	831	834	837	840	843	846	849	852	855	858	861	864	867	870	873	876	879	882	885	888	891	894	897	900	903	906	909	912	915	918	921	924	927	930	933	936	939	942	945	948	951	954	957	960	963	966	969	972	975	978	981	984	987	990	993	996	999

Model Name (Index)	Model Description	Predictor (X)										Response (Y)										R ²	F	P	T-Test	S.E.					
		X1					X2					Y1					Y2														
		B	S	M	A	W	B	S	M	A	W	B	S	M	A	W	B	S	M	A	W										
Model 00000	Baseline Model	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.00	0.00	0.00	0.00	0.00

Country	City	Year	Value	Unit	Category	Notes	Value	Unit	Category	Notes	Value	Unit	Category	Notes
Spain	Spain	2012	14.0	kg	Quasi-complete separation of data points detected									
Spain	Spain	2013	14.0	kg										
Spain	Spain	2014	14.0	kg										
Spain	Spain	2015	14.0	kg										
Spain	Spain	2016	14.0	kg										
Spain	Spain	2017	14.0	kg										
Spain	Spain	2018	14.0	kg										
Spain	Spain	2019	14.0	kg										
Spain	Spain	2020	14.0	kg										
Spain	Spain	2021	14.0	kg										
Spain	Spain	2022	14.0	kg										
Spain	Spain	2023	14.0	kg										
Spain	Spain	2024	14.0	kg										
Spain	Spain	2025	14.0	kg										
Spain	Spain	2026	14.0	kg										
Spain	Spain	2027	14.0	kg										
Spain	Spain	2028	14.0	kg										
Spain	Spain	2029	14.0	kg										
Spain	Spain	2030	14.0	kg										
Spain	Spain	2031	14.0	kg										
Spain	Spain	2032	14.0	kg										
Spain	Spain	2033	14.0	kg										
Spain	Spain	2034	14.0	kg										
Spain	Spain	2035	14.0	kg										
Spain	Spain	2036	14.0	kg										
Spain	Spain	2037	14.0	kg										
Spain	Spain	2038	14.0	kg										
Spain	Spain	2039	14.0	kg										
Spain	Spain	2040	14.0	kg										
Spain	Spain	2041	14.0	kg										
Spain	Spain	2042	14.0	kg										
Spain	Spain	2043	14.0	kg										
Spain	Spain	2044	14.0	kg										
Spain	Spain	2045	14.0	kg										
Spain	Spain	2046	14.0	kg										
Spain	Spain	2047	14.0	kg										
Spain	Spain	2048	14.0	kg										
Spain	Spain	2049	14.0	kg										
Spain	Spain	2050	14.0	kg										
Spain	Spain	2051	14.0	kg										
Spain	Spain	2052	14.0	kg										
Spain	Spain	2053	14.0	kg										
Spain	Spain	2054	14.0	kg										
Spain	Spain	2055	14.0	kg										
Spain	Spain	2056	14.0	kg										
Spain	Spain	2057	14.0	kg										
Spain	Spain	2058	14.0	kg										
Spain	Spain	2059	14.0	kg										
Spain	Spain	2060	14.0	kg										
Spain	Spain	2061	14.0	kg										
Spain	Spain	2062	14.0	kg										
Spain	Spain	2063	14.0	kg										
Spain	Spain	2064	14.0	kg										
Spain	Spain	2065	14.0	kg										
Spain	Spain	2066	14.0	kg										
Spain	Spain	2067	14.0	kg										
Spain	Spain	2068	14.0	kg										
Spain	Spain	2069	14.0	kg										
Spain	Spain	2070	14.0	kg										
Spain	Spain	2071	14.0	kg										
Spain	Spain	2072	14.0	kg										
Spain	Spain	2073	14.0	kg										
Spain	Spain	2074	14.0	kg										
Spain	Spain	2075	14.0	kg										
Spain	Spain	2076	14.0	kg										
Spain	Spain	2077	14.0	kg										
Spain	Spain	2078	14.0	kg										
Spain	Spain	2079	14.0	kg										
Spain	Spain	2080	14.0	kg										
Spain	Spain	2081	14.0	kg										
Spain	Spain	2082	14.0	kg										
Spain	Spain	2083	14.0	kg										
Spain	Spain	2084	14.0	kg										
Spain	Spain	2085	14.0	kg										
Spain	Spain	2086	14.0	kg										
Spain	Spain	2087	14.0	kg										
Spain	Spain	2088	14.0	kg										
Spain	Spain	2089	14.0	kg										
Spain	Spain	2090	14.0	kg										
Spain	Spain	2091	14.0	kg										
Spain	Spain	2092	14.0	kg										
Spain	Spain	2093	14.0	kg										
Spain	Spain	2094	14.0	kg										
Spain	Spain	2095	14.0	kg										
Spain	Spain	2096	14.0	kg										
Spain	Spain	2097	14.0	kg										
Spain	Spain	2098	14.0	kg										
Spain	Spain	2099	14.0	kg										
Spain	Spain	2100	14.0	kg										

For the information based on the following information:
 - Indicates convergence problem. Result is undetermined.
 - Indicates not converged.
 - Indicates convergence problem. Result is undetermined.
 - Indicates not converged.
 - Indicates convergence problem. Result is undetermined.
 - Indicates not converged.

POPULATION: Andhra Pradesh Population, DMOs
 SUBJECT: Age and Sex Structure
 UNIT: Standardized Analysis
 DATE: 08/2024
 Estimated Analysis by Software (Auto)

Indicator Code	Indicator Name	Indicator Unit	Population (DMOs)			Age Structure (DMOs)			Sex Ratio (DMOs)			Total (DMOs)			Age Structure (DMOs)			Sex Ratio (DMOs)			Total (DMOs)			Age Structure (DMOs)			Sex Ratio (DMOs)																									
			Age	Sex	Total	Age	Sex	Total	Age	Sex	Total	Age	Sex	Total	Age	Sex	Total	Age	Sex	Total	Age	Sex	Total	Age	Sex	Total																										
DMO001	DMO001	

Age-Subgroup	Performance - (R) (L)				Performance - (R) (L)				Performance - (R) (L)										Performance - (R) (L)				
	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative	Relative
Adoptive - Adoptive	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Adoptive - Non-Adoptive	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Adoptive - Adoptive	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Adoptive - Adoptive	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Adoptive - Adoptive	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41986
 Dichotomous Analysis by Subgroups (Safety)

All

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=365)				Aflibercept (N=361)			
			Patients		Patients with Event		Patients		Patients with Event	
			n	%	n	%	n	%	n	%
Eye disorders		n/a	365	100,0	3	0,8	361	100,0	1	0,3
Eye disorders	Retinal vein occlusion	n/a	365	100,0	0	0,0	361	100,0	1	0,3
Eye disorders	Rhegmatogenous retinal detachment	n/a	365	100,0	1	0,3	361	100,0	0	0,0
Eye disorders	Uveitis	n/a	365	100,0	2	0,5	361	100,0	0	0,0
Infections and infestations		n/a	365	100,0	0	0,0	361	100,0	1	0,3
Infections and infestations	Endophthalmitis	n/a	365	100,0	0	0,0	361	100,0	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	365	100,0	0	0,0	361	100,0	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	n/a	365	100,0	0	0,0	361	100,0	1	0,3

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_COMINO_SE_2022_41984_41986.xls
 05JUN2024 0:49

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41986
 Dichotomous Analysis by Subgroups (Safety)

Gender

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=365)				Aflibercept (N=361)			
			Patients		Patients with Event		Patients		Patients with Event	
			n	%	n	%	n	%	n	%
Eye disorders		Male	192	52,6	1	0,5	199	55,1	1	0,5
Eye disorders		Female	173	47,4	2	1,2	162	44,9	0	0,0
Eye disorders	Retinal vein occlusion	Male	192	52,6	0	0,0	199	55,1	1	0,5
Eye disorders	Retinal vein occlusion	Female	173	47,4	0	0,0	162	44,9	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Male	192	52,6	1	0,5	199	55,1	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Female	173	47,4	0	0,0	162	44,9	0	0,0
Eye disorders	Uveitis	Male	192	52,6	0	0,0	199	55,1	0	0,0
Eye disorders	Uveitis	Female	173	47,4	2	1,2	162	44,9	0	0,0
Infections and infestations		Male	192	52,6	0	0,0	199	55,1	1	0,5
Infections and infestations		Female	173	47,4	0	0,0	162	44,9	0	0,0
Infections and infestations	Endophthalmitis	Male	192	52,6	0	0,0	199	55,1	1	0,5
Infections and infestations	Endophthalmitis	Female	173	47,4	0	0,0	162	44,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Male	192	52,6	0	0,0	199	55,1	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Female	173	47,4	0	0,0	162	44,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	Male	192	52,6	0	0,0	199	55,1	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	Female	173	47,4	0	0,0	162	44,9	0	0,0

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_COMINO_SE_2022_41984_41986.xls
 05JUN2024 0:49

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41986
 Dichotomous Analysis by Subgroups (Safety)

Age			Faricimab (N=365)				Aflibercept (N=361)			
			Patients		Patients with Event		Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%
Eye disorders		<65 years	161	44,1	2	1,2	156	43,2	0	0,0
Eye disorders		>=65 years	204	55,9	1	0,5	205	56,8	1	0,5
Eye disorders	Retinal vein occlusion	<65 years	161	44,1	0	0,0	156	43,2	0	0,0
Eye disorders	Retinal vein occlusion	>=65 years	204	55,9	0	0,0	205	56,8	1	0,5
Eye disorders	Rhegmatogenous retinal detachment	<65 years	161	44,1	0	0,0	156	43,2	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	>=65 years	204	55,9	1	0,5	205	56,8	0	0,0
Eye disorders	Uveitis	<65 years	161	44,1	2	1,2	156	43,2	0	0,0
Eye disorders	Uveitis	>=65 years	204	55,9	0	0,0	205	56,8	0	0,0
Infections and infestations		<65 years	161	44,1	0	0,0	156	43,2	0	0,0
Infections and infestations		>=65 years	204	55,9	0	0,0	205	56,8	1	0,5
Infections and infestations	Endophthalmitis	<65 years	161	44,1	0	0,0	156	43,2	0	0,0
Infections and infestations	Endophthalmitis	>=65 years	204	55,9	0	0,0	205	56,8	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<65 years	161	44,1	0	0,0	156	43,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=65 years	204	55,9	0	0,0	205	56,8	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	<65 years	161	44,1	0	0,0	156	43,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	>=65 years	204	55,9	0	0,0	205	56,8	1	0,5

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_COMINO_SE_2022_41984_41986.xls
 05JUN2024 0:49

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41986
 Dichotomous Analysis by Subgroups (Safety)

Baseline BCVA ETRS letter score

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=365)				Aflibercept (N=361)			
			Patients		Patients with Event		Patients		Patients with Event	
			n	%	n	%	n	%	n	%
Eye disorders		<=34 letters	79	21,6	0	0,0	80	22,2	0	0,0
Eye disorders		35 - 54 letters	106	29,0	2	1,9	105	29,1	0	0,0
Eye disorders		>=55 letters	180	49,3	1	0,6	176	48,8	1	0,6
Eye disorders	Retinal vein occlusion	<=34 letters	79	21,6	0	0,0	80	22,2	0	0,0
Eye disorders	Retinal vein occlusion	35 - 54 letters	106	29,0	0	0,0	105	29,1	0	0,0
Eye disorders	Retinal vein occlusion	>=55 letters	180	49,3	0	0,0	176	48,8	1	0,6
Eye disorders	Rhegmatogenous retinal detachment	<=34 letters	79	21,6	0	0,0	80	22,2	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	35 - 54 letters	106	29,0	0	0,0	105	29,1	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	>=55 letters	180	49,3	1	0,6	176	48,8	0	0,0
Eye disorders	Uveitis	<=34 letters	79	21,6	0	0,0	80	22,2	0	0,0
Eye disorders	Uveitis	35 - 54 letters	106	29,0	2	1,9	105	29,1	0	0,0
Eye disorders	Uveitis	>=55 letters	180	49,3	0	0,0	176	48,8	0	0,0
Infections and infestations		<=34 letters	79	21,6	0	0,0	80	22,2	0	0,0
Infections and infestations		35 - 54 letters	106	29,0	0	0,0	105	29,1	0	0,0
Infections and infestations		>=55 letters	180	49,3	0	0,0	176	48,8	1	0,6
Infections and infestations	Endophthalmitis	<=34 letters	79	21,6	0	0,0	80	22,2	0	0,0
Infections and infestations	Endophthalmitis	35 - 54 letters	106	29,0	0	0,0	105	29,1	0	0,0
Infections and infestations	Endophthalmitis	>=55 letters	180	49,3	0	0,0	176	48,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=34 letters	79	21,6	0	0,0	80	22,2	1	1,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		35 - 54 letters	106	29,0	0	0,0	105	29,1	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=55 letters	180	49,3	0	0,0	176	48,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	<=34 letters	79	21,6	0	0,0	80	22,2	1	1,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	35 - 54 letters	106	29,0	0	0,0	105	29,1	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	>=55 letters	180	49,3	0	0,0	176	48,8	0	0,0

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_COMINO_SE_2022_41984_41986.xls
 05JUN2024 0:49

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41986
 Dichotomous Analysis by Subgroups (Safety)

Baseline BCVA ETRS letter score

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=365)				Aflibercept (N=361)			
			Patients		Patients with Event		Patients		Patients with Event	
			n	%	n	%	n	%	n	%
Eye disorders		<=23 letters	35	9,6	0	0,0	36	10,0	0	0,0
Eye disorders		>=24 letters	330	90,4	3	0,9	325	90,0	1	0,3
Eye disorders	Retinal vein occlusion	<=23 letters	35	9,6	0	0,0	36	10,0	0	0,0
Eye disorders	Retinal vein occlusion	>=24 letters	330	90,4	0	0,0	325	90,0	1	0,3
Eye disorders	Rhegmatogenous retinal detachment	<=23 letters	35	9,6	0	0,0	36	10,0	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	>=24 letters	330	90,4	1	0,3	325	90,0	0	0,0
Eye disorders	Uveitis	<=23 letters	35	9,6	0	0,0	36	10,0	0	0,0
Eye disorders	Uveitis	>=24 letters	330	90,4	2	0,6	325	90,0	0	0,0
Infections and infestations		<=23 letters	35	9,6	0	0,0	36	10,0	0	0,0
Infections and infestations		>=24 letters	330	90,4	0	0,0	325	90,0	1	0,3
Infections and infestations	Endophthalmitis	<=23 letters	35	9,6	0	0,0	36	10,0	0	0,0
Infections and infestations	Endophthalmitis	>=24 letters	330	90,4	0	0,0	325	90,0	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=23 letters	35	9,6	0	0,0	36	10,0	1	2,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=24 letters	330	90,4	0	0,0	325	90,0	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	<=23 letters	35	9,6	0	0,0	36	10,0	1	2,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	>=24 letters	330	90,4	0	0,0	325	90,0	0	0,0

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_COMINO_SE_2022_41984_41986.xls
 05JUN2024 0:49

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41986
 Dichotomous Analysis by Subgroups (Safety)

Geographic Region

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=365)				Aflibercept (N=361)			
			Patients		Patients with Event		Patients		Patients with Event	
			n	%	n	%	n	%	n	%
Eye disorders		Europe	111	30,4	2	1,8	113	31,3	0	0,0
Eye disorders		America	146	40,0	0	0,0	145	40,2	0	0,0
Eye disorders		Asia Pacific (inc. Australia)	108	29,6	1	0,9	103	28,5	1	1,0
Eye disorders	Retinal vein occlusion	Europe	111	30,4	0	0,0	113	31,3	0	0,0
Eye disorders	Retinal vein occlusion	America	146	40,0	0	0,0	145	40,2	0	0,0
Eye disorders	Retinal vein occlusion	Asia Pacific (inc. Australia)	108	29,6	0	0,0	103	28,5	1	1,0
Eye disorders	Rhegmatogenous retinal detachment	Europe	111	30,4	1	0,9	113	31,3	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	America	146	40,0	0	0,0	145	40,2	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Asia Pacific (inc. Australia)	108	29,6	0	0,0	103	28,5	0	0,0
Eye disorders	Uveitis	Europe	111	30,4	1	0,9	113	31,3	0	0,0
Eye disorders	Uveitis	America	146	40,0	0	0,0	145	40,2	0	0,0
Eye disorders	Uveitis	Asia Pacific (inc. Australia)	108	29,6	1	0,9	103	28,5	0	0,0
Infections and infestations		Europe	111	30,4	0	0,0	113	31,3	1	0,9
Infections and infestations		America	146	40,0	0	0,0	145	40,2	0	0,0
Infections and infestations		Asia Pacific (inc. Australia)	108	29,6	0	0,0	103	28,5	0	0,0
Infections and infestations	Endophthalmitis	Europe	111	30,4	0	0,0	113	31,3	1	0,9
Infections and infestations	Endophthalmitis	America	146	40,0	0	0,0	145	40,2	0	0,0
Infections and infestations	Endophthalmitis	Asia Pacific (inc. Australia)	108	29,6	0	0,0	103	28,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Europe	111	30,4	0	0,0	113	31,3	1	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		America	146	40,0	0	0,0	145	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asia Pacific (inc. Australia)	108	29,6	0	0,0	103	28,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	Europe	111	30,4	0	0,0	113	31,3	1	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	America	146	40,0	0	0,0	145	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	Asia Pacific (inc. Australia)	108	29,6	0	0,0	103	28,5	0	0,0

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_COMINO_SE_2022_41984_41986.xls
 05JUN2024 0:49

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41986
 Dichotomous Analysis by Subgroups (Safety)

Baseline RVO status

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=365)				Aflibercept (N=361)			
			Patients		Patients with Event		Patients		Patients with Event	
			n	%	n	%	n	%	n	%
Eye disorders		CRVO	301	82,5	3	1,0	291	80,6	1	0,3
Eye disorders		HRVO	61	16,7	0	0,0	64	17,7	0	0,0
Eye disorders		Missing	3	0,8	0	0,0	6	1,7	0	0,0
Eye disorders	Retinal vein occlusion	CRVO	301	82,5	0	0,0	291	80,6	1	0,3
Eye disorders	Retinal vein occlusion	HRVO	61	16,7	0	0,0	64	17,7	0	0,0
Eye disorders	Retinal vein occlusion	Missing	3	0,8	0	0,0	6	1,7	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	CRVO	301	82,5	1	0,3	291	80,6	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	HRVO	61	16,7	0	0,0	64	17,7	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Missing	3	0,8	0	0,0	6	1,7	0	0,0
Eye disorders	Uveitis	CRVO	301	82,5	2	0,7	291	80,6	0	0,0
Eye disorders	Uveitis	HRVO	61	16,7	0	0,0	64	17,7	0	0,0
Eye disorders	Uveitis	Missing	3	0,8	0	0,0	6	1,7	0	0,0
Infections and infestations		CRVO	301	82,5	0	0,0	291	80,6	1	0,3
Infections and infestations		HRVO	61	16,7	0	0,0	64	17,7	0	0,0
Infections and infestations		Missing	3	0,8	0	0,0	6	1,7	0	0,0
Infections and infestations	Endophthalmitis	CRVO	301	82,5	0	0,0	291	80,6	1	0,3
Infections and infestations	Endophthalmitis	HRVO	61	16,7	0	0,0	64	17,7	0	0,0
Infections and infestations	Endophthalmitis	Missing	3	0,8	0	0,0	6	1,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		CRVO	301	82,5	0	0,0	291	80,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		HRVO	61	16,7	0	0,0	64	17,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Missing	3	0,8	0	0,0	6	1,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	CRVO	301	82,5	0	0,0	291	80,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	HRVO	61	16,7	0	0,0	64	17,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	Missing	3	0,8	0	0,0	6	1,7	0	0,0

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_COMINO_SE_2022_41984_41986.xls
 05JUN2024 0:49

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: AEs leading to Study Treatment Discontinuation through Week 24
 MODEL: Unstratified analysis
 STUDY: GR41986
 Dichotomous Analysis by Subgroups (Safety)

Race/ethnicity

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=365)				Aflibercept (N=361)			
			Patients		Patients with Event		Patients		Patients with Event	
			n	%	n	%	n	%	n	%
Eye disorders		White	242	66,3	3	1,2	251	69,5	0	0,0
Eye disorders		Asian	89	24,4	0	0,0	88	24,4	1	1,1
Eye disorders		Other	13	3,6	0	0,0	17	4,7	0	0,0
Eye disorders		Unknown	21	5,8	0	0,0	5	1,4	0	0,0
Eye disorders	Retinal vein occlusion	White	242	66,3	0	0,0	251	69,5	0	0,0
Eye disorders	Retinal vein occlusion	Asian	89	24,4	0	0,0	88	24,4	1	1,1
Eye disorders	Retinal vein occlusion	Other	13	3,6	0	0,0	17	4,7	0	0,0
Eye disorders	Retinal vein occlusion	Unknown	21	5,8	0	0,0	5	1,4	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	White	242	66,3	1	0,4	251	69,5	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Asian	89	24,4	0	0,0	88	24,4	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Other	13	3,6	0	0,0	17	4,7	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Unknown	21	5,8	0	0,0	5	1,4	0	0,0
Eye disorders	Uveitis	White	242	66,3	2	0,8	251	69,5	0	0,0
Eye disorders	Uveitis	Asian	89	24,4	0	0,0	88	24,4	0	0,0
Eye disorders	Uveitis	Other	13	3,6	0	0,0	17	4,7	0	0,0
Eye disorders	Uveitis	Unknown	21	5,8	0	0,0	5	1,4	0	0,0
Infections and infestations		White	242	66,3	0	0,0	251	69,5	1	0,4
Infections and infestations		Asian	89	24,4	0	0,0	88	24,4	0	0,0
Infections and infestations		Other	13	3,6	0	0,0	17	4,7	0	0,0
Infections and infestations		Unknown	21	5,8	0	0,0	5	1,4	0	0,0
Infections and infestations	Endophthalmitis	White	242	66,3	0	0,0	251	69,5	1	0,4
Infections and infestations	Endophthalmitis	Asian	89	24,4	0	0,0	88	24,4	0	0,0
Infections and infestations	Endophthalmitis	Other	13	3,6	0	0,0	17	4,7	0	0,0
Infections and infestations	Endophthalmitis	Unknown	21	5,8	0	0,0	5	1,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		White	242	66,3	0	0,0	251	69,5	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asian	89	24,4	0	0,0	88	24,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Other	13	3,6	0	0,0	17	4,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Unknown	21	5,8	0	0,0	5	1,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	White	242	66,3	0	0,0	251	69,5	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	Asian	89	24,4	0	0,0	88	24,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	Other	13	3,6	0	0,0	17	4,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of the oral cavity	Unknown	21	5,8	0	0,0	5	1,4	0	0,0

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive.sas
 Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_soc_descriptive_sg_WDSTAE_WK24_COMINO_SE_2022_41984_41986.xls
 05JUN2024 0:49

POPULATION: Infected/Infected Population, 0.0000
 IMPORTED: Not loaded in batch through menu #4
 MODEL: Unstratified Analysis
 EVENT: 0.0000
 Distance Analysis by Subgroup (Infected)

Model		Parameters (0.0001)				Estimate(s) (0.0001)				Estimate vs. Maximum Absolute Bias (0.0000)				Estimate vs. Percent Relative Bias			
Model	Parameter	Value	SE	CI	SE	CI	SE	CI	SE	CI	SE	CI	SE	CI	SE	CI	
Infected and Infected	Relative	52.4	0.0	52.4	0.0	52.4	0.0	52.4	0.0	52.4	0.0	52.4	0.0	52.4	0.0	52.4	
Infected and Infected	Relative	47.4	0.0	47.4	0.0	47.4	0.0	47.4	0.0	47.4	0.0	47.4	0.0	47.4	0.0	47.4	
Infected and Infected	Relative	52.4	0.0	52.4	0.0	52.4	0.0	52.4	0.0	52.4	0.0	52.4	0.0	52.4	0.0	52.4	
Infected and Infected	Relative	47.4	0.0	47.4	0.0	47.4	0.0	47.4	0.0	47.4	0.0	47.4	0.0	47.4	0.0	47.4	

Test for interaction based on RR (Log-Binomial regression)
 * indicates convergence problem. Results in white/grey/red.
 Clinical cut-off: 0.90000000
 Program: userclinical_analysis (04/07/16) (07/10/16) where: ANZ_Data_Analysis (prod) program: r_an_rm_ana.exe
 Output: userclinical_analysis (04/07/16) (07/10/16) where: ANZ_Data_Analysis (prod) output: r_an_rm_ana_04_170AK_0414_2012_41994_41996.txt
 04/20/16 18:10

POPULATION: Safety/Pharmacovigilance Population, OND09
 REPORTING: Raw results to be read through view at
 NAME: Unqualified Analysis
 EVENT: 000106
 Risk/RiskScore Analysis by Subgroup (Safety)

Study	Population (N=261)				At-Risk (N=261)				Event	Event Rate	95% Lower CI	95% Upper CI	Relative Risk	Population vs. At-Risk											
	Parameters		Parameters		Parameters		Parameters							Absolute Risk Difference		Relative Risk		Relative Risk		Relative Risk		Relative Risk		Relative Risk	
	D	S	D	S	D	S	D	S						Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper
Initial diagnosis	11	44	0	0	11	42	0	0						WARNING: The relative hazard convergence criterion of 21.46742298 is greater than the limit of 5.000. The convergence is questionable.											
Initial diagnosis	204	51	0	0	201	56	0	0						WARNING: Error in computing the likelihood function. Its derivatives or the variance function.											
Initial diagnosis	11	44	0	0	11	42	0	0						WARNING: The relative hazard convergence criterion of 21.46742298 is greater than the limit of 5.000. The convergence is questionable.											
Initial diagnosis	204	51	0	0	201	56	0	0						WARNING: Error in computing the likelihood function. Its derivatives or the variance function.											
Infections and Infestations	11	44	0	0	11	42	0	0	NO					NO											
Infections and Infestations	204	51	0	0	201	56	0	0						WARNING: The mean parameter is either invalid or at a limit of its range for some observation.											
Infections and Infestations	11	44	0	0	11	42	0	0	NO					NO											
Infections and Infestations	204	51	0	0	201	56	0	0						WARNING: The mean parameter is either invalid or at a limit of its range for some observation.											

Note for generation based on SR Log-Binomial Regression
 * indicate convergence problem. Result is non-interpretable.
 Clinical out-off: 0.00000022

Program: non-clinical_analysis\NONCLIN\00701001\ANALYSIS\prod\program_tsm_fm_001.mn
 Output: non-clinical_analysis\NONCLIN\00701001\ANALYSIS\prod\output_tsm_fm_001.mn_0504N_MCH_C00000_2012_4194_4196.xls
 04/20/2014 18:10

Baseline WHO ATC 030A Letter codes	Population 02000									All-Treatment 02001									Population vs. All-Treatment												All-Treatment vs. Population			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients With Event			Patients With Event			Rate	95% CI			CI Lower	CI Upper	Relative Risk	95% CI			CI Lower	CI Upper	Relative Risk	95% CI			CI Lower	CI Upper								
			n	%	95% CI	n	%	95% CI		Lower	Upper	Lower				Upper	Lower	Upper				Lower	Upper	Lower			Upper	Lower	Upper					
			Absolute Risk Difference																															
Ear disorders	Otitis interna	034	21	0	0.0	10	22.2	0	0.0	30	0	0.0	30	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				
Ear disorders	Otitis externa	034	29	0	0.0	138	29.1	0	0.0	36	0	0.0	36	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				
Ear disorders	Otitis media with effusion	034	43	0	0.0	133	48.4	0	0.0	63	0	0.0	63	0	0.0	-	Quasi-complete separation of data points detected	-	-	-	-	-	-	-	-	-	-	-	-	-				
Ear disorders	Suppurative otitis media	034	19	0	0.0	64	22.2	0	0.0	36	0	0.0	36	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				
Ear disorders	Suppurative otitis externa	034	29	0	0.0	138	29.1	0	0.0	36	0	0.0	36	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Ear disorders	Suppurative otitis media	034	49	0	0.0	133	48.4	0	0.0	63	0	0.0	63	0	0.0	-	Quasi-complete separation of data points detected	-	-	-	-	-	-	-	-	-	-	-	-	-				
Infectious and infestations	Otitis interna	034	21	0	0.0	6	22.2	0	0.0	30	0	0.0	30	0	0.0	-	Quasi-complete separation of data points detected	-	-	-	-	-	-	-	-	-	-	-	-	-				
Infectious and infestations	Otitis externa	034	29	0	0.0	138	29.1	0	0.0	36	0	0.0	36	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Infectious and infestations	Otitis media with effusion	034	43	0	0.0	133	48.4	0	0.0	63	0	0.0	63	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Infectious and infestations	Suppurative otitis media	034	19	0	0.0	64	22.2	0	0.0	36	0	0.0	36	0	0.0	-	Quasi-complete separation of data points detected	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
Infectious and infestations	Suppurative otitis externa	034	29	0	0.0	138	29.1	0	0.0	36	0	0.0	36	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Infectious and infestations	Otitis interna	034	49	0	0.0	133	48.4	0	0.0	63	0	0.0	63	0	0.0	-	Quasi-complete separation of data points detected	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
Infectious and infestations	Otitis externa	034	29	0	0.0	138	29.1	0	0.0	36	0	0.0	36	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Infectious and infestations	Otitis media with effusion	034	43	0	0.0	133	48.4	0	0.0	63	0	0.0	63	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			

Note for interaction based on RR (Log-Binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.9600000

Program: sasr/cf/rt/rt_utilities/B0487461_02010303.xlsx;NCL_data_analyze;prodprog;rt_rm_fm_000_sas
 Output: sasr/cf/rt/rt_utilities/B0487461_02010303.xlsx;NCL_data_analyze;prodprog;rt_rm_fm_000_sas;SPLAT_NCL2_C00001_00_2012_4194_4196.vls
 04/29/2014 18:10

POPULATION: Infected/Infected Population, COVID
 REPORTING: Are leading to death through mean at
 MODEL: Unstratified Analysis
 PLOT: NONE
 Distance Analysis by Subgroup (Infected)

Baseline W/O EPID Extra Score

Model System Organ Class				Parameter (IC50)				Milestone (IC50)				Favism vs. Allfavism												Milestone vs. Favism			
				Parameter With Event				Parameter With Event				Absolute Bias Difference				Relative Bias				Relative Bias							
				IC50	Lower	Upper	Median	IC50	Lower	Upper	Median	Lower	Upper	Relative	Lower	Upper	Relative	Lower	Upper	Relative	Lower	Upper					
Infected	IC23	Infected	Infected	2.0	9.0	0	2.0	10.0	0	0.0	90																
				2.0	9.0	0	2.0	10.0	0	0.0	90																
Infected	IC23	Infected	Infected	Quasi-complete separation of data points detected.																							
				WARNING: The mean parameter is either outside or at a limit of the range for some observations.																							
Infected	IC23	Infected	Infected	2.0	9.0	0	2.0	10.0	0	0.0	90																
				2.0	9.0	0	2.0	10.0	0	0.0	90																
Infected	IC23	Infected	Infected	Quasi-complete separation of data points detected.																							
				WARNING: The mean parameter is either outside or at a limit of the range for some observations.																							
Infected and Infected	IC23	Infected	Infected	2.0	9.0	0	2.0	10.0	0	0.0																	
				2.0	9.0	0	2.0	10.0	0	0.0																	
Infected and Infected	IC23	Infected	Infected	Quasi-complete separation of data points detected.																							
				WARNING: The relative Pearson convergence criterion of 7.68901166 is greater than the limit of 3.0001. The convergence is questionable.																							
Infected and Infected	IC23	Infected	Infected	2.0	9.0	0	2.0	10.0	0	0.0																	
				2.0	9.0	0	2.0	10.0	0	0.0																	
Infected and Infected	IC23	Infected	Infected	Quasi-complete separation of data points detected.																							
				WARNING: The relative Pearson convergence criterion of 7.68901166 is greater than the limit of 3.0001. The convergence is questionable.																							

Test for interaction based on RR (Log-Binomial regression)
 * indicates convergence problem. Results in uninterpretable.
 Clinical cut-off: 0.98000002

Program: user/cliclinn_arctifera/04087461/0270303/where/ANZ_data_analysis/prod/program_rsm_rsm_ana_ana
 Output: user/cliclinn_arctifera/04087461/0270303/where/ANZ_data_ana/0270303/summary/prod/output_rsm_rsm_ana_04_1294K_MH4_03CNDR_08_2022_4394_4196_1ca
 04700214 18:10

POPULATION: safety-analysis-population: OMSD
 REPORTING: case loading to track through time: 14
 MODEL: Unstratified Analysis
 STUDY: H41954
 Risk-based Analysis by subgroup (Safety)

Population Segment		Population: (N=181)				Missedness: (N=181)				Population vs. Missedness														
		Patients With Event		Patients Without Event		Patients		Patients With Event		Absolute Bias: Difference														
		n	%	n	%	n	%	n	%	OR	95% CI	OR	95% CI	Relative Bias	95% Lower CI	95% Upper CI	Median	Relative Bias	95% Lower CI	95% Upper CI	Median	Relative Bias	95% Lower CI	95% Upper CI
WebDAV System Organ Class	WebDAV Protocol Term	Level																						
Cardiac disorders	Europe	Europe	111	28.4	0	0.0	111	28.4	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Cardiac disorders	America	America	134	40.0	0	0.0	134	40.0	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Cardiac disorders	Asia Pacific (incl. Australia)	Asia Pacific (incl. Australia)	104	29.0	0	0.0	104	29.0	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Cardiac disorders	Myocardial infarction	Myocardial infarction	113	29.8	0	0.0	113	29.8	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Cardiac disorders	Myocardial infarction	Asia Pacific (incl. Australia)	104	29.0	0	0.0	104	29.0	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Infectious and infestations	Europe	Europe	111	29.0	0	0.0	111	29.0	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Infectious and infestations	America	America	134	40.0	0	0.0	134	40.0	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Infectious and infestations	Asia Pacific (incl. Australia)	Asia Pacific (incl. Australia)	104	29.0	0	0.0	104	29.0	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Infectious and infestations	Rememba	Rememba	111	29.0	0	0.0	111	29.0	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Infectious and infestations	Rememba	America	134	40.0	0	0.0	134	40.0	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Infectious and infestations	Rememba	Asia Pacific (incl. Australia)	104	29.0	0	0.0	104	29.0	0	0.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

Test for interaction based on RR (Log-Binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.80000022

Program: /root/c010101_arutils/04081741/0070303/obave_ADR_data_analysis/prod/program_t_m_fm_001_000
 Output: /root/c010101_arutils/04081741/0070303/obave_ADR_data_analysis/prod/output_t_m_fm_001_001_000K_MCH_CFMOM_06_2012_4194_4196.v1a
 04/28/2014 14:10

Baseline R03 status	Population (B01)						Milestone (B01)						Population vs. Milestone										Milestone vs. Population			
	N	n	p	s	p	s	OR	95% Lower	95% Upper	95% Lower	95% Upper	Relative Risk	CI	CI	95% Lower	95% Upper	95% Lower	95% Upper	Relative Risk	CI	CI	95% Lower	95% Upper	95% Lower	95% Upper	
																										CI
MedSA System Organ Class	MedSA Preferred Term	Level																								
Cardiac disorders	2020	21	23	0	0.0	0.0	0.0	0.0	0.0	0.0	-															
Cardiac disorders	AFIB	21	16	0	0.0	0.0	0.0	0.0	0.0	0.0																
Cardiac disorders	Bradycardia	21	0	0	0.0	0.0	0.0	0.0	0.0	0.0																
Cardiac disorders	Myocardial infarction	21	21	0	0.0	0.0	0.0	0.0	0.0	0.0																
Cardiac disorders	Myocardial infarction	21	16	0	0.0	0.0	0.0	0.0	0.0	0.0																
Cardiac disorders	Myocardial infarction	21	0	0	0.0	0.0	0.0	0.0	0.0	0.0																
Infectious and infestations	2020	11	23	0	0.0	0.0	0.0	0.0	0.0	0.0																
Infectious and infestations	ABO	11	16	0	0.0	0.0	0.0	0.0	0.0	0.0																
Infectious and infestations	Histamine	11	0	0	0.0	0.0	0.0	0.0	0.0	0.0																
Infectious and infestations	Herpesvirus	21	23	0	0.0	0.0	0.0	0.0	0.0	0.0																
Infectious and infestations	Herpesvirus	21	16	0	0.0	0.0	0.0	0.0	0.0	0.0																
Infectious and infestations	Herpesvirus	11	0	0	0.0	0.0	0.0	0.0	0.0	0.0																

Test: For interaction based on RR (Log-Binomial regression)
 * Indicates convergence problem. Result is unreferenced.
 Clinical out-off: 0.0000022

Program: root\clinical_analysis\04087461\00701010\deltabwa_AZL_data_analysis\procd\program_t_m_fm_m01.exe
 Report: root\clinical_analysis\04087461\00701010\deltabwa_AZL_data_analysis\procd\output\t_m_fm_m01_02194_K1966.xls
 04/28/2024 14:10

Run #45164

Population (045164)		All-Events (045164)								Population vs. All-Events																All-Events vs. Population																								
Model System Origin Class	Model Preferral Term	Level	Primary VTE Event				Secondary VTE Event				IC90 Metric	Convergence Reason				VTE Lower CI	VTE Upper CI	Relative Bias	Convergence Reason				Relative Bias				Relative Bias	Convergence Reason																						
			n	h	a	r	n	h	a	r		SE	SE	SE	SE				SE	SE	SE	SE	SE	SE	SE	SE		SE	SE	SE	SE	SE	SE	SE																
Baseline (Reference)	Baseline	Model	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0
Baseline (Reference)	Baseline	Model	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0
Baseline (Reference)	Other	Model	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Other	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Model	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0	242	62	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0
Baseline (Reference)	Secondary (Reference)	Other	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0	11	3	0	0.0

Test for interaction based on LR (Log-Binomial regression).
 * Indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.0000022
 Program: root:clinical_studies:ROK48743:0070303:rdmc_ACR_data_analysis:prod:program_r_m_yml_040_044
 Output: root:clinical_studies:ROK48743:0070303:rdmc_ACR_data_analysis:prod:program_r_m_yml_040_044_007048_ACR_040_2022_0104_01040_044
 04/06/2024 10:50

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: Intraocular Inflammation Events (Study Eye) through Week 24
 MODEL: Unstratified analysis
 STUDY: 04194
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Pavlovsk (N=276)				Alliberg (N=274)				Odds Ratio	Pavlovsk vs. Alliberg				Alliberg vs. Pavlovsk			
		Patients		Patients with Event		Patients		Patients with Event			Odds Ratio		Relative Risk		Interaction Test		Relative Risk	
		n	%	n	%	n	%	n	%		Lower	Upper	Lower	Upper	p-value	p-value (likelihood ratio)	Lower	Upper
All	n/a	276	100.0	1	0.4	274	100.0	0	0									
										Quasi-complete separation of data points detected.				ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				
Gender	Male	143	51.8	0	0.0	127	46.4	0	0	NI	NI	NI	NI	NI	NI	NI	NI	NI
	Female	133	48.2	1	0.8	147	53.6	0	0					Quasi-complete separation of data points detected.				
										NI	NI	NI	NI	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				
Age	<=5 years	133	48.2	0	0.0	143	52.2	0	0	NI	NI	NI	NI	NI	NI	NI	NI	NI
	>=5 years	143	51.8	1	0.7	131	47.8	0	0					Quasi-complete separation of data points detected.				
										NI	NI	NI	NI	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				
Baseline BCVA ETDRS letter score	<=54 letters	89	32.2	0	0.0	90	32.8	0	0	NI	NI	NI	NI	NI	NI	NI	NI	NI
	>=55 letters	187	67.8	1	0.5	184	67.2	0	0					Quasi-complete separation of data points detected.				
										NI	NI	NI	NI	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				
Geographic Region	Europe	82	29.7	0	0.0	70	25.5	0	0	NI	NI	NI	NI	NI	NI	NI	NI	NI
	America	97	35.1	0	0.0	103	37.6	0	0	NI	NI	NI	NI	NI	NI	NI	NI	NI
	Asia Pacific (inc. Australia)	97	35.1	1	1.0	101	36.9	0	0					Quasi-complete separation of data points detected.				
										NI	NI	NI	NI	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				
Race/ethnicity	White	172	62.3	0	0.0	170	62.0	0	0	NI	NI	NI	NI	NI	NI	NI	NI	NI
	Other	86	30.9	1	1.1	83	30.3	0	0					Quasi-complete separation of data points detected.				
	Unknown	18	6.5	0	0.0	21	7.6	0	0	NI	NI	NI	NI	WARNING: Relative of Negative and positive definite.				
										NI	NI	NI	NI	NI	NI	NI	NI	NI
										NI	NI	NI	NI	NI	NI	NI	NI	NI

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Intraocular inflammation events include Anterior chamber flare, Anterior chamber inflammation, Choroiderinitis, Choroiditis, Cyclitis, Eye inflammation, Iridocyclitis, Iritis, Keratic precipitates, Keratoconjunctivitis, Noninfective choroiderinitis, Non-infective endophthalmitis, Ocular vasculitis, Post procedural inflammation, Retinal vasculitis, Uveitis, and Vitritis.
 Clinical cut-off: 0.620202

Program: /mnt/clinical_studies/204867461/CDT30303/share/ACK_data_analysis/prod/program/1_sw_raw.sas
 Output: /mnt/clinical_studies/204867461/CDT30303/share/ACK_pool_001_CD3_Primary/prod/output/1_sw_raw_04194_W24_BALATON_SW_2022_41984_41986.xls
 04/10/2024 18:24

POPULATION: Ischemic-Minimal Population, ANCATM
 HYPOTHESIS: Minimal Vascular Occlusive Disease (Study Eye) through Week 24
 MODEL: Unstratified Analysis
 STUDY: IMBUSA
 ESTIMATION: Analysis by Subgroup (Safety)

Name	Enrollment (n/N)		At-Risk (n/N)		Censoring (n/N)		Primary vs. Alternative Absolute Risk Difference					Relative Risk				Interaction Test											
	n	N	n	N	n	N	95% Lower	95% Upper	Relative Risk	95% Lower	95% Upper	95% Lower	95% Upper	95% Lower	95% Upper	95% Lower	95% Upper	95% Lower	95% Upper								
	Control	Treatment	Control	Treatment	Control	Treatment	ORR Ratio	Convergence Status	Convergence Status	Relative Risk	Convergence Status	Convergence Status	Interaction Test p-value (1-sided)	Interaction Test p-value (2-sided)	Convergence Status	Convergence Status	Relative Risk	Convergence Status	Relative Risk	Convergence Status							
All	100	100	0	0	274	274	1	1	0.13	Convergence criteria (0.0001) satisfied	0.01	2.14	-0.07	Algorithm converged	0.12	0.10	0.12	Algorithm converged	0.13	0.10	0.14	3.15	Algorithm converged	0.12	0.14		
Gender										**	Quasi-complete separation of data points detected			**	WARNING: The relative residual convergence criterion of 1E-07 (0.0001) is greater than the limit of 0.001. The convergence is questionable.	0.01	Algorithm converged	0.10	0.09	0.09	0.09	0.10	0.09	0.09	0.09	0.09	0.09
	Male	51	51	0	127	127	1	1	0.11	Convergence criteria (0.0001) satisfied	0.02	17.84	0.02	Algorithm converged	0.12	0.12	1.12	Algorithm converged	0.07	0.10	0.09	0.09	0.09	0.09	0.09		
	Female	49	49	0	147	147	1	1	0.11	Convergence criteria (0.0001) satisfied	0.01	17.84	0.02	Algorithm converged	0.12	0.12	1.12	Algorithm converged	0.07	0.10	0.09	0.09	0.09	0.09	0.09		
Age																											
	18-45 years	117	117	0	143	143	1	1	0.12	Convergence criteria (0.0001) satisfied	0.03	1.94	-0.04	Algorithm converged	0.12	0.12	0.12	Algorithm converged	0.05	0.10	0.10	0.10	0.10	0.10	0.10	0.10	
	46-64 years	14	14	0	131	131	1	1	0.0	Quasi-complete separation of data points detected	**		**	WARNING: The relative residual convergence criterion of 1E-07 (0.0001) is greater than the limit of 0.001. The convergence is questionable.	0.01	Algorithm converged	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	
Baseline VLDL (mg/dL) (Latter Score)																											
	<100 mg/dL	59	59	0	91	91	1	1	0.10	Convergence criteria (0.0001) satisfied	0.03	1.61	-0.01	Algorithm converged	0.12	0.11	0.11	Algorithm converged	0.05	0.10	0.10	0.10	0.10	0.10	0.10	0.10	
	100-149 mg/dL	16	16	0	124	124	1	1	0.10	Convergence criteria (0.0001) satisfied	0.03	1.61	-0.01	Algorithm converged	0.12	0.11	0.11	Algorithm converged	0.05	0.10	0.10	0.10	0.10	0.10	0.10	0.10	
	≥150 mg/dL	15	15	0	144	144	1	1	0.10	Quasi-complete separation of data points detected	**		**	WARNING: Error in computing the likelihood function. Its derivatives, or the variance function.	0.01	Algorithm converged	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Broadbody Region																											
	Europe	16	16	0	23	23	1	1	0.38	Convergence criteria (0.0001) satisfied	0.04	2.42	-0.03	Algorithm converged	0.10	0.11	0.10	Algorithm converged	0.04	0.10	0.10	0.10	0.10	0.10	0.10	0.10	
	Australia	6	6	0	10	10	1	1	0.28	Convergence criteria (0.0001) satisfied	0.04	2.42	-0.03	Algorithm converged	0.10	0.11	0.10	Algorithm converged	0.04	0.10	0.10	0.10	0.10	0.10	0.10	0.10	
	North Pacific (incl. South Korea)	4	4	0	10	10	1	1	0.08	Convergence criteria (0.0001) satisfied	0.04	2.42	-0.03	Algorithm converged	0.10	0.11	0.10	Algorithm converged	0.04	0.10	0.10	0.10	0.10	0.10	0.10	0.10	
Body Mass Index																											
	18.5-24.9	110	110	0	135	135	1	1	0.10	Convergence criteria (0.0001) satisfied	0.01	1.61	-0.01	Algorithm converged	0.12	0.12	0.12	Algorithm converged	0.05	0.10	0.10	0.10	0.10	0.10	0.10	0.10	
	25.0-29.9	4	4	0	24	24	1	1	0.0	Quasi-complete separation of data points detected	**		**	WARNING: The relative residual convergence criterion of 1E-07 (0.0001) is greater than the limit of 0.001. The convergence is questionable.	0.01	Algorithm converged	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	
	≥30.0	1	1	0	19	19	1	1	0.0	Quasi-complete separation of data points detected	**		**	WARNING: Relative of missing for derivative function.	0.01	Algorithm converged	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
	Missing	1	1	0	4	4	1	1	0.0	Quasi-complete separation of data points detected	**		**	WARNING: Error in computing the likelihood function. Its derivatives, or the variance function.	0.01	Algorithm converged	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05

Note: For interaction based on RR (Log-Binomial regression)
 * indicates convergence problem, result is uninterpretable.
 Relative Residual Convergence criteria include: Relative residual convergence criteria, Relative residual convergence, Relative residual convergence, and Relative residual convergence.
 Clinical use only: (0.0001)

Program: sncr-clinical_utilities\06082741\070203\obv-ack_data_analysis\prod\prod\output_r_m_wm_ig_ABITM_M24_ANCATM_RR_2021_4184_4186.sls
 Output: sncr-clinical_utilities\06082741\070203\obv-ack_data_analysis\prod\prod\output_r_m_wm_ig_ABITM_M24_ANCATM_RR_2021_4184_4186.sls
 04/08/2024 10:31

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: PT: Endophthalmitis (Study Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI10a_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:31

POPULATION: Safety-Evaluable Population, BALAFON
 ENDPOINTS: Intraocular Inflammation Events (Yellow Eye) through Week 24
 MODES: Unstratified analysis
 STUDY: 041944
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Paritameb (N=276)				Aflibercept (N=274)				Odds Ratio	Paritameb vs. Aflibercept				Aflibercept vs. Paritameb						
		Patients		Patients with Event		Patients		Patients with Event			Absolute Risk Difference		Relative Risk		Relative Risk		Interaction Test		Relative Risk		
		n	%	n	%	n	%	n	%		Lower CL	Upper CL	Lower CL	Upper CL	Lower CL	Upper CL	p-value (Wald)	p-value (likelihood ratio)	Lower CL	Upper CL	
All	n/a	276	100.0	1	0.4	274	100.0	0	0												
										Quasi-complete separation of data points detected.						ERROR: The mean parameter is either invalid or at a limit of its range for some observations.					
Gender	Male	143	51.8	0	0.0	137	46.4	0	0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Female	133	48.2	1	0.8	147	53.6	0	0							ERROR: Error in computing the link function, its derivative, or the variance function.					
										Quasi-complete separation of data points detected.						Algorithm converged.	NE	NE	NE	NE	Algorithm converged.
Age	<=5 years	133	48.2	0	0.0	143	52.2	0	0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	>=5 years	143	51.8	1	0.7	131	47.8	0	0							ERROR: The mean parameter is either invalid or at a limit of its range for some observations.					
										Quasi-complete separation of data points detected.						Algorithm converged.	NE	NE	NE	NE	Algorithm converged.
Baseline BCVA ETDRS letter score	>=54 letters	89	32.2	0	0.0	90	32.8	0	0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	<=53 letters	187	67.8	1	0.5	184	67.2	0	0							WARNING: Negative of Hessian not positive definite.					
										Quasi-complete separation of data points detected.						Algorithm converged.	NE	NE	NE	NE	Algorithm converged.
Geographic Region	Europe	82	29.7	1	1.2	78	28.5	0	0							WARNING: The relative Hessian convergence criterion of 11.770916295 is greater than the limit of 0.0001. The convergence is questionable.					
	America	97	35.1	0	0.0	107	39.1	0	0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Asia Pacific (inc. Australia)	97	35.1	0	0.0	101	36.9	0	0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
										Quasi-complete separation of data points detected.						WARNING: Negative of Hessian not positive definite.					
										NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Race/ethnicity	White	172	62.0	1	0.6	170	62.0	0	0							WARNING: Negative of Hessian not positive definite.					
	Black	90	32.6	0	0.0	93	33.9	0	0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Other	110	39.4	0	0.0	111	40.1	0	0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Unknown	4	1.4	0	0.0	4	1.5	0	0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Intraocular inflammation events include Anterior chamber flare, Anterior Chamber inflammation, Choroiderinitis, Choroiditis, Cystitis, Eye inflammation, Iridocyclitis, Iritis, Keratic precipitates, Retinitis, Multifocal choroiderinitis, Non-infectious endophthalmitis, Ocular vasculitis, Post-procedural inflammation, Retinal vasculitis, Vitritis and Vitreitis.
 Clinical cut-off: 04202022

Program: /root/clinical_studies/005867461/CDT30303/share/ACE_data_analysis/prod/program/t_w_e_w.sas
 Output: /root/clinical_studies/005867461/CDT30303/share/ACE_pool_RVO_CDV_Primary/prod/output/t_w_e_w_pg_A0517b_W24_BALAFON_SE_1022_41944_41946.rtf
 04202024 18:25

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: Retinal Vascular Occlusive Disease (Yellow Eye) through Week 24
 MODEL: Stratified Analysis
 STUDY: 064194
 Dichotomous Analysis by Subgroups (Safety)

Stratum	Sex	Patients (n/N%)				Milligrams (mg/24)				Odds Ratio	95% Lower CI	95% Upper CI	Absolute Risk	Patients vs. Milligrams					Milligrams vs. Patients							
		Patients with Event		Patients without Event		Patients with Event		Patients without Event						Convergence Reason		Relative Risk	Convergence Reason		p-value (95% CI)	Interaction Test p-value (likelihood ratio)	Relative Risk		Convergence Reason		95% Lower	95% Upper
		n	N	n	N	n	N	n	N					Lower	Upper		Lower	Upper			Lower	Upper	Lower	Upper		
All	Male	274	100.0	1	0.4	274	100.0	0	0				-	WARNING! Negative of Hessian not positive definite.												
	Female	143	51.8	2	1.4	143	51.4	0	0				-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE						
Gender	Male	143	51.8	2	1.4	143	51.4	0	0				-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE						
	Female	137	49.2	1	0.7	147	53.5	0	0				-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE	1.0000	NE	Algorithm converged.	NE	NE	
Age	<65 years	133	48.2	1	0.8	143	52.2	0	0				-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE						
	>=65 years	143	51.8	2	1.4	131	47.8	0	0				-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE						
Baseline BCVA ETDRS letter score	<=54 letters	89	32.2	1	1.1	90	32.8	0	0				-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE						
	>=55 letters	187	67.8	2	1.1	184	67.2	0	0				-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE	1.0000	NE	Algorithm converged.	NE	NE	
Geographic Region	Europe	82	29.7	1	1.2	70	25.5	0	0				-	WARNING! The relative Hessian convergence criterion of 1.779910295 is greater than the limit of 0.001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE						
	Asia Pacific (inc. Australia)	97	35.1	0	0.0	103	36.9	0	0	NE		NE	-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE						
Race/ethnicity	White	172	62.3	1	1.7	170	62.0	0	0				-	WARNING! The relative Hessian convergence criterion of 10.55959129 is greater than the limit of 0.001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE						
	Asian	40	14.6	0	0.0	41	14.9	0	0	NE		NE	-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE						
	Other	10	3.6	0	0.0	9	3.2	0	0	NE		NE	-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE						
	Unknown	4	1.4	0	0.0	4	1.4	0	0	NE		NE	-	WARNING! Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE						

Test for interaction based on SP (Log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Retinal Vascular Occlusive events include Arterial occlusive disease, Retinal artery embolism, Retinal artery occlusion, Retinal vein occlusion, and Venous occlusion.
 Clinical cut-off: 06702022
 Program root/clinical_studies/R06867461/CPT30303/above/ACE_data_analysis/prod/program/1_w_1_w_1_w.exe
 Output: root/clinical_studies/R06867461/CPT30303/above/ACE_post_BOV_CDR.Primary/prod/output/1_w_1_w_1_w_02_AES19h_WK24_BALATON_SR_2022_41984_41986.v1x
 04/28/2024 18:29

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: PT: Endophthalmitis (Fellow Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI10b_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:32

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Intraocular Inflammation Events (Study Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Intraocular Inflammation events include Anterior chamber flare, Anterior Chamber inflammation, Chorioretinitis, Choroiditis, Cyclitis, Eye inflammation, Iridocyclitis, Iritis, Keratic
Keratouveitis, Noninfective chorioretinitis, Non-infectious endophthalmitis, Ocular vasculitis, Post procedural inflammation, Retinal vasculitis, Uveitis, and Vitritis.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI7aSEV_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:59

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Retinal Vascular Occlusive Disease (Study Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Retinal Vascular Occlusive events include Arterial occlusive disease, Retinal artery embolism, Retinal artery occlusion, Retinal vein occlusion, and Venous occlusion
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI8aSEV_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 19:00

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: PT: Endophthalmitis (Study Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI10aSEV_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 19:02

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Intraocular Inflammation Events (Fellow Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Intraocular Inflammation events include Anterior chamber flare, Anterior Chamber inflammation, Chorioretinitis, Choroiditis, Cyclitis, Eye inflammation, Iridocyclitis, Iritis, Keratic
Keratouveitis, Noninfective chorioretinitis, Non-infectious endophthalmitis, Ocular vasculitis, Post procedural inflammation, Retinal vasculitis, Uveitis, and Vitritis.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI7bSEV_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:59

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Retinal Vascular Occlusive Disease (Fellow Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Retinal Vascular Occlusive events include Arterial occlusive disease, Retinal artery embolism, Retinal artery occlusion, Retinal vein occlusion, and Venous occlusion

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI8bSEV_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 19:01

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: PT: Endophthalmitis (Fellow Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI10bSEV_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 19:02

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Intraocular Inflammation Events (Study Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Intraocular Inflammation events include Anterior chamber flare, Anterior Chamber inflammation, Chorioretinitis, Choroiditis, Cyclitis, Eye inflammation, Iridocyclitis, Iritis, Keratic precipitat
Keratouveitis, Noninfective chorioretinitis, Non-infectious endophthalmitis, Ocular vasculitis, Post procedural inflammation, Retinal vasculitis, Uveitis, and Vitritis.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI7aSER_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:42

POPULATION Safety-Individual Population, ANA10M
 IMPROVED: Retinal Vein/Artery Occlusive Disease (Study Eye, Retinal) through Week 24
 MODEL: Unstratified Analysis
 EVENT: VASO10A

Subpopulation Analysis by Subgroup (Safety)

		Population (Event)				At-Risk/Event (Event)				Population vs. Alternative														Attribution to Population				
Name	Level	Observed		Relative Risk Event		Relative Risk Event		Relative Risk Event		ORR Ratio	Convergence Status	95% Lower CI	95% Upper CI	Relative Risk	Convergence Status	95% Lower CI	95% Upper CI	Relative Risk	Convergence Status	95% Lower CI	95% Upper CI	p-value (1-sided)	p-value (2-sided)	Relative Risk	Convergence Status	95% Lower CI	95% Upper CI	
		n	k	n	k	n	k	n	k																			
ALL	ALL	270	100	1	0.4	274	102	1	0.4	0.99	Convergence criteria (COV=10) satisfied	0.02	15.55	0.02	Algorithm converged	-0.02	0.12	0.15	Algorithm converged	0.04	15.72	0.186	1.02	Algorithm converged	0.58	11.02	0.58	11.02
Gender	Male	145	51	0	0.0	127	41	1	0.8	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
	Female	125	49	1	0.8	147	61	0	0.0	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
Race	ASD white	117	40	1	0.8	143	52	0	0.0	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
	ASD black	153	60	1	0.7	131	47	1	0.8	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
	ASD other	50	19	0	0.0	40	15	0	0.0	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
Baseline BYO BYO30 Later Score	<34 (score)	109	32	0	0.0	91	31	0	0.0	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
	>=34 (score)	161	68	0	0.0	183	71	1	0.5	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
Baseline BYO BYO30 Later Score	<34 (score)	109	32	0	0.0	91	31	0	0.0	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
	>=34 (score)	161	68	0	0.0	183	71	1	0.5	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
Baseline BYO BYO30 Later Score	<34 (score)	109	32	0	0.0	91	31	0	0.0	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
	>=34 (score)	161	68	0	0.0	183	71	1	0.5	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
Baseline BYO BYO30 Later Score	<34 (score)	109	32	0	0.0	91	31	0	0.0	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
	>=34 (score)	161	68	0	0.0	183	71	1	0.5	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
Baseline BYO BYO30 Later Score	<34 (score)	109	32	0	0.0	91	31	0	0.0	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
	>=34 (score)	161	68	0	0.0	183	71	1	0.5	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
Baseline BYO BYO30 Later Score	<34 (score)	109	32	0	0.0	91	31	0	0.0	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89
	>=34 (score)	161	68	0	0.0	183	71	1	0.5	**	Quasi-complete separation of data points detected.													0.89	0.89	0.89	0.89	0.89

Note: For interaction based on RR (Log-Binomial regression)
 * Indicates convergence problem. Model is unconverged.
 Retinal Vein/Artery Occlusive events include Retinal Vein/Artery Occlusive Disease, Retinal Vein Occlusion, Retinal Artery Occlusion, Retinal Vein Occlusion, and Venous Occlusion.
 CI=95% (0.05)

Program: /usr/cclinical_utilities/00467461/0050303/obsrv_ACR_pool_1/ANALYSIS/pool_output/1_m_fm_ag_ABT0008_M02_SAR008_R0_2022_41464_41464_41464_41464_19-14

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: PT: Endophthalmitis (Study Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI10aSER_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:46

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Intraocular Inflammation Events (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.

Intraocular Inflammation events include Anterior chamber flare, Anterior Chamber inflammation, Chorioretinitis, Choroiditis, Cyclitis, Eye inflammation, Iridocyclitis, Iritis, Keratic
Keratouveitis, Noninfective chorioretinitis, Non-infectious endophthalmitis, Ocular vasculitis, Post procedural inflammation, Retinal vasculitis, Uveitis, and Vitritis.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI7bSER_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:43

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Retinal Vascular Occlusive Disease (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Retinal Vascular Occlusive events include Arterial occlusive disease, Retinal artery embolism, Retinal artery occlusion, Retinal vein occlusion, and Veno
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI8bSER_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:45

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: PT: Endophthalmitis (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI10bSER_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:47

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI1_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:13

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2a_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:14

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2b_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:19

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Causes a decrease of ≥ 30 letters in VA Score lasting more than 1 hour (Fellow Eye) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI3b_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:19

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI4a_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:17

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI4b_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:20

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Associated with severe intraocular inflammation (Study Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5a_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:18

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5b_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:21

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINTS: Antiplatelet Treatment Collaboration (APTC) event through Week 24
 MODES: Unstratified analysis
 STUDY: 0841984
 Dichotomous Analysis by Subgroups (Safety)

Base	Level	Paritimb (N=276)				Allhercept (N=214)				Paritimb vs. Allhercept														
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Absolute Risk Difference		Relative Risk		Relative Risk		Interaction Test		Relative Risk		Relative Risk		
		n	%	n	%	n	%	n	%	Lower CI	Upper CI	Lower CI	Upper CI	Lower CI	Upper CI	Lower CI	Upper CI	p-value (Wald)	p-value (Likelihood ratio)	Lower CI	Upper CI	Lower CI	Upper CI	
Sex	Male	276	100.0	3	1.1	276	100.0	4	1.4	0.74														
	Female																							
Gender	Male	143	51.8	3	2.1	137	64.4	2	1.4	1.10														
	Female	133	48.2	0	0.0	77	57.6	2	1.4															
Age	<=65 years	133	48.2	3	2.3	143	67.2	1	0.7	0.98														
	>=65 years	143	51.8	0	0.0	71	52.8	1	0.8															
Baseline NYA ETTSD Letter score	<=4 letters	89	32.2	1	1.1	89	41.6	2	2.2	0.50														
	>=5 letters	187	67.8	2	1.1	125	58.4	2	1.1	0.98														
Geographic Region	Europe	82	29.7	0	0.0	70	32.7	0	0.0	NS														
	America	97	35.1	1	1.0	103	48.1	1	2.0	0.35														
	Asia Pacific (inc. Australia)	97	35.1	2	2.1	102	47.7	2	1.9	0.21														
Race/Ethnicity	White	172	62.3	1	0.6	170	79.4	1	1.1	0.34														
	Asian	90	32.8	2	2.2	81	37.8	1	1.1	0.69														
	Other	10	3.6	0	0.0	7	3.2	0	0.0	NS														
	Unknown	4	1.4	0	0.0	4	1.9	0	0.0	NS														

Test for interaction based on RR (Log-binomial regression)
 * Indicate convergence problem. Result is uninterpretable.
 Clinical cut-off! 0.025,0.025

Program: root/clinical_studies/006867461/CDT0303/share/ACE_data_analysis/prod/program/t_w_rw.exe
 Output: root/clinical_studies/006867461/CDT0303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_w_rw_02_03_2022_41984_41986.xls
 04/08/2024 18:22

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice (Severe) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI1SEV_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:47

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye, Severe) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2aSEV_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:48

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye, Severe) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2bSEV_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:53

POPULATION: Safety-Whistleblowers Population: SAKATHO
 REPORTING: Closure & Successes of 19-20 Initiatives in 16 Hours lasting more than 1 hour (study days, events) through Week 24
 MODEL: Unregularized Analysis
 PLOT: WHISTLE
 SUBSTANCE: Analysis by Subgroups (Safety)

		Factorial (0-17)						Mittlerung (0-17)						Factorial vs. Mittlerung																			
		Relative with Event			Relative with Event			Relative with Event			Relative with Event			Relative Risk Difference																			
name	level	n	k	n	k	n	k	n	k	OR	CI	OR	CI	OR	CI	OR	CI	OR	CI	OR	CI	OR	CI	OR	CI	OR	CI	OR	CI	OR	CI	OR	CI
All	All	270	100	0	0	274	100	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
Gender	Male	143	51.1	0	0	147	51.4	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
	Female	127	46.7	0	0	127	46.4	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
Age	<35 years	110	40.7	0	0	110	40.1	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
	≥35 years	160	58.3	0	0	164	59.6	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
Baseline WHO WHO2 Latest Score	<35 latest	100	37.0	0	0	100	36.6	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
	≥35 latest	170	62.0	0	0	174	63.4	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
Baseline Region	Europe	80	29.6	0	0	75	27.5	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
	America	190	69.4	0	0	199	72.5	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
Meta-Analysis (no. Subgroups)	1	10	3.7	0	0	10	3.6	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
	2	260	96.3	0	0	264	96.4	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
Sub-analytic	Male	110	40.7	0	0	110	40.1	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
	Female	117	43.3	0	0	117	43.3	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
Event	0	190	69.4	0	0	199	72.5	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	
	1	80	29.6	0	0	75	27.5	0	0	0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0		0.0	

Note for interaction based on RR (Log-Binomial regression)
 * Indicate convergence problem. Result is uninterpretable.
 CI: 95% CI
 Program: conf/ci/initial_analysis/00467461/0070303/00467461_analysis/cond/program/1_04_100_004
 Output: 1 conf/ci/initial_analysis/00467461/0070303/00467461_analysis/cond/output/1_04_100_004_001/00467461_0070303_00467461_analysis_10_00

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Causes a decrease of ≥ 30 letters in VA Score lasting more than 1 hour (Fellow Eye, Severe) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI3bSEV_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:54

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye, Severe) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI4aSEV_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:51

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye, Severe) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI4bSEV_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:54

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Associated with severe intraocular inflammation (Study Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5aSEV_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:52

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5bSEV_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:55

POPULATION: Safety-Evaluable Population, BALATON
 ENDPOINT: Antiplatelet Treatment Collaboration (APTC) event (Severe) through Week 24
 MODEL: Unstratified Analysis
 STUDY: 041984
 Dichotomous Analysis by Subgroups (Safety)

Name	Sex	Patients (n/N)				All-cause (n/N)				Odds Ratio	95% Lower CI	95% Upper CI	Absolute Risk	Patients vs. All-cause				All-cause vs. Patients										
		Patients		Patients with Event		Patients		Patients with Event						Convergence		Relative Risk		Convergence		Relative Risk								
		n	%	n	%	n	%	n	%					Lower CI	Upper CI	Lower CI	Upper CI	Lower CI	Upper CI	p-value (95% CI)	p-value (likelihood ratio)	Relative Risk	Convergence	95% Lower CI	95% Upper CI			
All	Male	274	100.0	1	1.1	274	100.0	4	1.4	0.74	0.16	3.15	-0.024	Algorithm converged.	-0.022	0.013	0.74	Algorithm converged.	0.17	3.35	0.0070		1.14	Algorithm converged.	0.10	3.44		
Gender	Male	141	51.8	1	2.1	127	45.4	2	1.6	1.14	0.22	0.15	0.005	Convergence criterion (GCONV-1E-8) satisfied.	-0.022	0.010	1.13	Algorithm converged.	0.23	7.85	0.1525		0.144	0.75	Algorithm converged.	0.13	4.42	
	Female	133	48.2	0	0.0	147	53.6	2	1.4					Quasi-complete separation of data points detected.				WARNING: The relative median convergence criterion of 11.519514016 is greater than the limit of 0.005. The convergence is questionable.	0.00	NR	0.9980		>999.99	Algorithm converged.	0.00	NR		
Age	<=65 years	133	48.2	1	2.3	143	52.2	1	2.1	1.03	0.21	0.43	0.002	Convergence criterion (GCONV-1E-8) satisfied.	-0.033	0.030	1.08	Algorithm converged.	0.22	5.23	0.9281		0.2381	0.93	Algorithm converged.	0.19	4.53	
	>=65 years	143	51.8	0	0.0	131	47.8	1	0.8					Quasi-complete separation of data points detected.				WARNING: The relative median convergence criterion of 30.448103107 is greater than the limit of 0.005. The convergence is questionable.	0.00	NR	0.9999		>999.99	Algorithm converged.	0.00	NR		
Baseline SOVA STORS letter score	<=4 letters	89	32.2	1	1.1	90	32.8	2	2.2	0.50	0.04	0.61	-0.011	Convergence criterion (GCONV-1E-8) satisfied.	-0.048	0.027	0.51	Algorithm converged.	0.05	5.48	0.5748		0.6682	1.99	Algorithm converged.	0.19	21.10	
	>=5 letters	187	67.8	2	1.1	184	67.2	2	1.1	0.98	0.14	0.96	0.000	Convergence criterion (GCONV-1E-8) satisfied.	-0.021	0.021	0.98	Algorithm converged.	0.14	6.91	0.9870		1.02	Algorithm converged.	0.14	7.14		
Geographic Region	Europe	82	29.7	0	0.0	70	25.5	0	0.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	America	97	35.1	1	1.0	101	37.6	1	2.0	0.10	0.04	0.40	-0.019	Convergence criterion (GCONV-1E-8) satisfied.	-0.051	0.048	0.45	Algorithm converged.	0.04	1.35	0.8448		0.81	Algorithm converged.	0.01	26.70		
	Asia Pacific (inc. Australia)	97	35.1	2	2.1	105	38.9	1	1.0	0.11	0.19	0.50	0.011	Convergence criterion (GCONV-1E-8) satisfied.	-0.024	0.024	0.98	Algorithm converged.	0.13	21.00	0.5463		0.45	Algorithm converged.	0.14	5.24		
Race/ethnicity	White	172	62.3	1	0.6	170	62.0	1	1.0	0.11	0.03	0.16	-0.012	Convergence criterion (GCONV-1E-8) satisfied.	-0.035	0.011	0.11	Algorithm converged.	0.03	3.14	0.3343		0.5161	3.04	Algorithm converged.	0.10	28.48	
	Asian	90	32.6	0	0.0	91	33.9	1	1.1	2.09	0.19	23.47	0.011	Convergence criterion (GCONV-1E-8) satisfied.	-0.026	0.048	2.07	Algorithm converged.	0.19	22.19	0.5504		0.04	Algorithm converged.	0.04	5.24		
	Other	10	3.6	0	0.0	7	2.6	0	0.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
	Unknown	4	1.4	0	0.0	4	1.5	0	0.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	

Test for interaction based on RR (Log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.675/2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_w_rev.exe
 Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVD_CDR_Primary/prod/output/t_w_rev_ag_AE165SV_WK24_BALATON_SR_2022_41984_41986.xls
 04/20/24 18:16

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice (Serious) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI1SER_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:33

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye, Serious) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2aSER_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:33

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2bSER_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:37

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Causes a decrease of ≥ 30 letters in VA Score lasting more than 1 hour (Fellow Eye, Serious) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI3bSER_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:38

POPULATION: Safety-Evaluable Population, BALATON

ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye, Serious) through Week 24

MODEL: Unstratified analysis

STUDY: GR41984

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI4aSER_WK24_BALATON_SE_2022_41984_41986.xls

04JUN2024 18:36

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI4bSER_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:39

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Associated with severe intraocular inflammation (Study Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5aSER_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:37

POPULATION: Safety-Evaluable Population, BALATON
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41984
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5bSER_WK24_BALATON_SE_2022_41984_41986.xls
04JUN2024 18:39

POPULATION: Safety-Evaluable Population, BALATOR
 ENDPOINT: Antiplatelet Treatment Collaboration (APTC) event (serious) through Week 24
 MODEL: Unstratified Analysis
 STUDY: GRASP
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Patients (n/N%)				Milestones (n/N%)				Patients vs. Milestones										Milestones vs. Patients																	
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		95% Lower CI		95% Upper CI		Absolute Risk		Convergence		Relative Risk		Convergence		Relative Risk		Convergence		Relative Risk									
		n	N	n	%	n	N	n	%																												
All	All	274	100.0	1	0.4	274	100.0	1	0.4	0.20	0.20	0.20	0.000	0.20	0.20	0.000	0.20	0.20	0.017	0.93	Algorithm converged.	0.20	0.20	0.9324	0.20	0.20	0.017	0.93	Algorithm converged.	0.20	0.20	0.9324	0.20	0.20	0.017	0.93	Algorithm converged.
Gender	Male	143	51.8	1	0.7	143	100.0	1	0.7	1.0	1.0	1.0	0.000	1.0	1.0	0.000	1.0	1.0	0.017	0.93	Algorithm converged.	1.0	1.0	0.9324	1.0	1.0	0.017	0.93	Algorithm converged.	1.0	1.0	0.9324	1.0	1.0	0.017	0.93	Algorithm converged.
	Female	131	48.2	0	0.0	131	100.0	0	0.0	0.0	0.0	0.0	0.000	0.0	0.0	0.000	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.
Age	<=65 years	133	48.2	1	0.7	133	100.0	1	0.7	1.0	1.0	1.0	0.000	1.0	1.0	0.000	1.0	1.0	0.017	0.93	Algorithm converged.	1.0	1.0	0.9324	1.0	1.0	0.017	0.93	Algorithm converged.	1.0	1.0	0.9324	1.0	1.0	0.017	0.93	Algorithm converged.
	>=65 years	143	51.8	0	0.0	143	100.0	0	0.0	0.0	0.0	0.0	0.000	0.0	0.0	0.000	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.
Baseline SOFA STORS letter score	<=4 letters	89	32.5	1	1.1	89	100.0	1	1.1	1.0	1.0	1.0	0.000	1.0	1.0	0.000	1.0	1.0	0.017	0.93	Algorithm converged.	1.0	1.0	0.9324	1.0	1.0	0.017	0.93	Algorithm converged.	1.0	1.0	0.9324	1.0	1.0	0.017	0.93	Algorithm converged.
	>=5 letters	187	67.5	0	0.0	187	100.0	0	0.0	0.0	0.0	0.0	0.000	0.0	0.0	0.000	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.
Geographic Region	Europe	82	29.7	0	0.0	82	100.0	0	0.0	0.0	0.0	0.0	0.000	0.0	0.0	0.000	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.
	America	97	35.1	1	1.0	97	100.0	1	1.0	1.0	1.0	1.0	0.000	1.0	1.0	0.000	1.0	1.0	0.017	0.93	Algorithm converged.	1.0	1.0	0.9324	1.0	1.0	0.017	0.93	Algorithm converged.	1.0	1.0	0.9324	1.0	1.0	0.017	0.93	Algorithm converged.
Race/ethnicity	White	172	62.3	1	0.6	172	100.0	1	0.6	1.0	1.0	1.0	0.000	1.0	1.0	0.000	1.0	1.0	0.017	0.93	Algorithm converged.	1.0	1.0	0.9324	1.0	1.0	0.017	0.93	Algorithm converged.	1.0	1.0	0.9324	1.0	1.0	0.017	0.93	Algorithm converged.
	Asian	90	32.6	0	0.0	90	100.0	0	0.0	0.0	0.0	0.0	0.000	0.0	0.0	0.000	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.
Other	Other	10	3.6	0	0.0	10	100.0	0	0.0	0.0	0.0	0.0	0.000	0.0	0.0	0.000	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.
	Unknown	4	1.4	0	0.0	4	100.0	0	0.0	0.0	0.0	0.0	0.000	0.0	0.0	0.000	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.	0.0	0.0	0.9324	0.0	0.0	0.017	0.93	Algorithm converged.

Test for interaction based on BR (Log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.025/0.025

Program: root/clinical_studies/RO6867461/CDT3030/share/ACE_data_analysis/prod/program/t_w_rev.exe
 Output: root/clinical_studies/RO6867461/CDT3030/share/ACE_pool_RVD_CDR_Primary/prod/output/t_w_rev_wg_AE1658R_WK24_BALATOR_SR_2022_41984_41986.xls
 04/20/2024 18:40

POPULATION: Safety-Evaluable Population, COMING
 ENDPOINTS: Retinal Vascular Occlusive Disease (Study Eye) through Week 24
 MODEL: Stratified Analysis
 STUDY: 04A196
 Dichotomous Analysis by Subgroups (Safety)

Stratum	Stratum Label	Patients (N=24)			All-cause (N=24)			Odds Ratio	Absolute Risk Difference			Relative Risk			Interaction Test			All-cause vs. Retinal									
		n	%	n	n	%	n		Lower CI	Upper CI	Absolute Risk	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI	p-value	Interaction Test	Relative Risk	Lower CI	Upper CI						
Age	Age	355	100.0	4	1.1	351	100.0	1.0	0.00	Convergence criterion (GCMW-IR-B) satisfied.	0.14	1.43	-0.004	Algorithm converged.	0.00	0.00	0.00	Algorithm converged.	0.17	1.41	0.192	1.77	Algorithm converged.	0.21	1.47		
Gender	Male	172	52.4	1	0.6	171	51.7	2.0	0.20	Convergence criterion (GCMW-IR-B) satisfied.	0.00	2.00	-0.01	Algorithm converged.	0.00	2.00	0.202	Algorithm converged.	0.00	2.00	0.202	0.322	1.00	Algorithm converged.	0.44	1.44	
Gender	Female	173	47.4	3	1.7	170	48.3	3	1.6	0.14	Convergence criterion (GCMW-IR-B) satisfied.	0.13	4.50	-0.001	Algorithm converged.	0.13	4.50	0.193	Algorithm converged.	0.13	4.50	0.193	1.00	Algorithm converged.	0.21	5.22	
Age	<65 years	161	44.1	0	0.0	161	43.2	2	1.1	+	Quasi-complete separation of data points detected.								WARNING: The relative Hessian convergence criterion of 13.6459773 is greater than the limit of 0.0001. The convergence is questionable.								
Age	≥65 years	324	85.9	4	1.2	320	86.8	1	0.4	+	Convergence criterion (GCMW-IR-B) satisfied.	0.21	3.02	-0.00	Algorithm converged.	0.21	3.02	0.193	Algorithm converged.	0.21	3.02	0.193	0.451	1.26	Algorithm converged.	0.14	4.10
Baseline BCVA STDRS letter score	<34 letters	79	21.6	0	0.0	80	22.2	1	1.1	+	Quasi-complete separation of data points detected.								ERROR: Error in computing the link function, its derivatives, or the variance function.								
Baseline BCVA STDRS letter score	35 - 54 letters	196	59.0	1	0.9	195	59.1	3	2.0	0.02	Convergence criterion (GCMW-IR-B) satisfied.	0.03	3.16	-0.010	Algorithm converged.	0.03	3.16	0.338	Algorithm converged.	0.03	3.16	0.338	0.451	1.00	Algorithm converged.	0.32	28.65
Baseline BCVA STDRS letter score	≥55 letters	180	49.3	3	1.7	176	48.8	3	1.7	0.18	Convergence criterion (GCMW-IR-B) satisfied.	0.19	4.81	0.000	Algorithm converged.	0.19	4.81	0.378	Algorithm converged.	0.19	4.81	0.378	1.00	Algorithm converged.	0.21	5.40	
Baseline BCVA STDRS letter score	<21 letters	35	9.4	0	0.0	35	10.0	0	0.0	NR	Convergence criterion (GCMW-IR-B) satisfied.	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Baseline BCVA STDRS letter score	≥21 letters	310	80.4	4	1.2	305	79.5	4	1.2	0.15	Convergence criterion (GCMW-IR-B) satisfied.	0.15	1.92	-0.00	Algorithm converged.	0.15	1.92	0.193	Algorithm converged.	0.15	1.92	0.193	1.000	NR	Algorithm converged.	NR	NR
Geographic Region	Europe	111	30.4	0	0.0	113	31.1	1	0.9	+	Quasi-complete separation of data points detected.								WARNING: The relative Hessian convergence criterion of 16.69946948 is greater than the limit of 0.0001. The convergence is questionable.								
Geographic Region	Asia Pacific (incl. Australia)	146	40.0	2	1.4	144	40.3	2	1.4	0.16	Convergence criterion (GCMW-IR-B) satisfied.	0.11	3.09	-0.00	Algorithm converged.	0.11	3.09	0.468	Algorithm converged.	0.11	3.09	0.468	0.624	1.21	Algorithm converged.	0.24	8.31
Geographic Region	Asia Pacific (incl. Australia)	106	29.4	2	1.9	103	28.5	1	0.9	0.63	Convergence criterion (GCMW-IR-B) satisfied.	0.10	3.44	-0.01	Algorithm converged.	0.10	3.44	0.418	Algorithm converged.	0.10	3.44	0.418	1.00	Algorithm converged.	0.21	9.24	
Baseline RVO status	RVO	301	82.5	4	1.3	291	80.4	3	2.4	0.15	Convergence criterion (GCMW-IR-B) satisfied.	0.14	1.89	-0.011	Algorithm converged.	0.14	1.89	0.396	Algorithm converged.	0.14	1.89	0.396	1.000	1.81	Algorithm converged.	0.54	6.11
Baseline RVO status	NRVO	61	16.3	0	0.0	64	17.7	0	0.0	NR	Convergence criterion (GCMW-IR-B) satisfied.	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Baseline RVO status	Missing	1	0.3	0	0.0	1	0.3	0	0.0	NR	Convergence criterion (GCMW-IR-B) satisfied.	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Race/ethnicity	White	242	66.1	1	1.2	231	69.5	4	1.6	0.78	Convergence criterion (GCMW-IR-B) satisfied.	0.17	3.50	-0.021	Algorithm converged.	0.17	3.50	0.745	Algorithm converged.	0.17	3.50	0.745	0.613	1.20	Algorithm converged.	0.29	5.61
Race/ethnicity	Asian	89	24.4	1	1.1	88	24.4	0	0.0	0.10	Convergence criterion (GCMW-IR-B) satisfied.	0.01	1.14	-0.021	Algorithm converged.	0.01	1.14	0.123	Algorithm converged.	0.01	1.14	0.123	1.00	Algorithm converged.	0.21	18.41	
Race/ethnicity	Other	13	3.6	0	0.0	17	4.7	0	0.0	NR	Convergence criterion (GCMW-IR-B) satisfied.	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Race/ethnicity	Unknown	21	5.8	0	0.0	1	0.3	0	0.0	NR	Convergence criterion (GCMW-IR-B) satisfied.	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	

Test for interaction based on RR (Log-Binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Retinal Vascular Occlusive events include arterial occlusive disease, Retinal artery embolism, Retinal artery occlusion, Retinal vein occlusion, and Venous occlusion.
 Clinical cut-off: 0.9402022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_w_raw.exe
 Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CDR_Primary/prod/output/t_w_raw_ug_AE218_W24_COMING_SE_2022_41964_41966.xls
 04/20/2024 14:29

POPULATION: Safety-Evaluable Population, COMING
 ENDPOINTS: ST: Demographic (Study Eye) through Week 24
 MODEL: Stratified Analysis
 SDPP: GR4398
 Dichotomous Analysis by Subgroups (Safety)

Stratum	Level	Patients (N=24)				Adverse Events (N=24)				Odds Ratio	Patients vs. Adverse Events														
		Patients		Patients with Event		Patients		Patients with Event			Absolute Risk Difference					Relative Risk									
		n	%	n	%	n	%	n	%		Lower CI	Upper CI	Absolute Risk	Convergence Reason	Lower CI	Upper CI	Relative Risk	Convergence Reason	Lower CI	Upper CI	p-value (95% CI)	Interaction Test (p-value)	Relative Risk	Convergence Reason	Lower CI
All	Eye	355	100.0	0	0	351	100.0	0	0.0	*	Quasi-complete separation of data points					0.00	Algorithm converged	0.00	NE	0.9999		>>>> 99	Algorithm converged	0.00	NE
Gender	Male	172	52.4	0	0	169	55.1	0	0.0	*	Quasi-complete separation of data points					0.00	Algorithm converged	0.00	NE	0.9999	NS	>>>> 99	Algorithm converged	0.00	NE
	Female	173	47.6	0	0	182	44.9	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Age	<65 years	161	44.0	0	0	154	43.2	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	≥65 years	204	55.0	0	0	205	56.8	0	0.0	*	Quasi-complete separation of data points					0.00	Algorithm converged	0.00	NE	1.0000	>>>> 99	Algorithm converged	0.00	NE	
Baseline BCVA ETDRS letter score	<14 letters	79	21.4	0	0	80	22.2	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	15 - 18 letters	166	49.0	0	0	165	49.1	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Baseline BCVA ETDRS letter score	≥19 letters	180	49.2	0	0	174	46.8	0	0.0	*	Quasi-complete separation of data points					0.00	Algorithm converged	0.00	NE	0.9999		>>>> 99	Algorithm converged	0.00	NE
	<21 letters	28	7.4	0	0	28	10.0	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Baseline BCVA ETDRS letter score	<24 letters	130	36.4	0	0	125	35.0	0	0.0	*	Quasi-complete separation of data points					0.00	Algorithm converged	0.00	NE	0.9999		>>>> 99	Algorithm converged	0.00	NE
	≥24 letters	225	63.6	0	0	226	65.0	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Geographic Region	Europe	111	30.4	0	0	113	31.3	0	0.0	*	Quasi-complete separation of data points					0.00	Algorithm converged	0.00	NE	0.9999	NS	>>>> 99	Algorithm converged	0.00	NE
	North America	146	40.0	0	0	145	40.4	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Geographic Region	Asia Pacific (incl. Australia)	108	29.2	0	0	103	28.5	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	Other	10	2.8	0	0	10	2.8	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Baseline RVO status	CRVO	301	82.0	0	0	291	80.6	0	0.0	*	Quasi-complete separation of data points					0.00	Algorithm converged	0.00	NE	0.9999	NS	>>>> 99	Algorithm converged	0.00	NE
	BRVO	61	16.2	0	0	64	17.7	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Baseline RVO status	Other	4	0.4	0	0	4	1.1	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	Unknown	0	0.0	0	0	0	0.0	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Race/ethnicity	White	242	66.3	0	0	241	69.5	0	0.0	*	Quasi-complete separation of data points					0.00	Algorithm converged	0.00	NE	0.9999	NS	>>>> 99	Algorithm converged	0.00	NE
	Asian	89	24.4	0	0	88	24.4	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Race/ethnicity	Other	13	3.0	0	0	17	4.7	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	Unknown	21	4.4	0	0	13	3.4	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS

Test for interaction based on RR (Log-Binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.999999999

Program: root/clinical_studies/RO687461/CD73303/abare/ACT_data_analysis/prod/program/act_ses.exe
 Output: root/clinical_studies/RO687461/CD73303/abare/ACT_pool_RVO_CDR_Primary/prod/output/s_abare_wg_AER10a_WK24_COMING_SR_2022_41984_41986.v1e
 04/20/2024 18:33

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: PT: Endophthalmitis (Fellow Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI10b_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:35

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Intraocular Inflammation Events (Study Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Intraocular Inflammation events include Anterior chamber flare, Anterior Chamber inflammation, Chorioretinitis, Choroiditis, Cyclitis, Eye inflammation, Iridocyclitis, Iritis, Keratic precipitates, Keratouveitis, Noninfective chorioretinitis, Non-infectious endophthalmitis, Ocular vasculitis, Post procedural inflammation, Retinal vasculitis, Uveitis, and Vitritis.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI7aSEV_WK24_COMINO_SE_2022_41984_41986.xls

04JUN2024 19:10

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINTS: ST: Endophthalmitis (Study Eye, Severe) through Week 24
 MODEL: Stratified Analysis
 STUDY: 041984
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Patients (N=24)				At-Risk (N=24)				Odds Ratio	Patients vs. At-Risk																
		Patients		Patients with Event		Patients		Patients with Event			Absolute Risk						Absolute Risk Difference										
		n	%	n	%	n	%	n	%		95% Lower CI	95% Upper CI	Absolute Risk	Convergence Reason	95% Lower CI	95% Upper CI	Relative Risk	Convergence Reason	95% Lower CI	95% Upper CI	p-value (loglik)	Interaction Test (value likelihood ratio)	Relative Risk	Convergence Reason	95% Lower CI	95% Upper CI	
All	Male	395	100.0	0	0	351	100.0	1	0.3	*	Quasi-complete separation of data points						0.00	Algorithm converged	0.00	NE	0.9999		>999.99	Algorithm converged	0.00	NE	
Gender	Male	172	52.4	0	0	159	55.1	0	0.0	*	Quasi-complete separation of data points						0.00	Algorithm converged	0.00	NE	0.9999	NS	>999.99	Algorithm converged	0.00	NE	
	Female	173	47.6	0	0	152	44.9	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Age	<65 years	161	44.1	0	0	154	43.2	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	Algorithm converged	0.00	NE	NS	NS	NS	NS	NS	NS	NS
	≥65 years	204	55.9	0	0	203	56.8	1	0.5	*	Quasi-complete separation of data points						0.00	Algorithm converged	0.00	NE	1.0500		>999.99	Algorithm converged	0.00	NE	
Baseline BCVA ETDRS letter score	≤14 letters	79	21.4	0	0	80	22.2	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	15 - 18 letters	156	49.0	0	0	103	29.1	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	≥19 letters	180	49.0	0	0	174	49.8	0	0.0	*	Quasi-complete separation of data points						0.00	Algorithm converged	0.00	NE	0.9999		>999.99	Algorithm converged	0.00	NE	
Baseline BCVA ETDRS letter score	≤23 letters	35	9.4	0	0	33	10.0	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	≥24 letters	330	90.6	0	0	325	90.0	1	0.3	*	Quasi-complete separation of data points detected						0.00	Algorithm converged	0.00	NE	0.9999		>999.99	Algorithm converged	0.00	NE	
Geographic Region	Europe	111	30.4	0	0	111	31.1	0	0.0	*	Quasi-complete separation of data points detected						0.00	Algorithm converged	0.00	NE	0.9999		>999.99	Algorithm converged	0.00	NE	
	Asia	146	40.0	0	0	145	40.2	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	
	Asia Pacific (inc. Australia)	108	29.6	0	0	103	28.5	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	
Baseline RVO status	SRVO	301	82.5	0	0	291	80.4	1	0.3	*	Quasi-complete separation of data points detected						0.00	Algorithm converged	0.00	NE	0.9999		>999.99	Algorithm converged	0.00	NE	
	NRVO	61	16.3	0	0	64	17.7	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	
Race/ethnicity	Hispanic	1	0.3	0	0	1	0.3	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	White	242	66.1	0	0	231	69.5	1	0.4	*	Quasi-complete separation of data points						0.00	Algorithm converged	0.00	NE	0.9999		>999.99	Algorithm converged	0.00	NE	
Race/ethnicity	Asian	89	24.4	0	0	88	24.4	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	Other	13	3.0	0	0	17	4.7	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	
	Unknown	21	5.4	0	0	1	1.4	0	0.0	NS	NS	NS	NS	NS	NS	NS	0.00	NS	NS	NS	NS	NS	NS	NS	NS	NS	

Test for interaction based on RR (Log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.9000000

Program: root/clinical_studies/S06867461/CD730303/share/ACE_data_analysis/prod/program/t_at_ee.exe
 Output: root/clinical_studies/S06867461/CD730303/share/ACE_pool_RVO_CDR_Primary/prod/output/t_at_ee_raw_sq_AE010aREV_WK24_COMINO_SR_2022_41984_41986_w1_0420M2024_1915

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Intraocular Inflammation Events (Fellow Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Intraocular Inflammation events include Anterior chamber flare, Anterior Chamber inflammation, Chorioretinitis, Choroiditis, Cyclitis, Eye inflammation, Iridocyclitis, Iritis, Keratic precipitates, Keratouveitis, Noninfective chorioretinitis, Non-infectious endophthalmitis, Ocular vasculitis, Post procedural inflammation, Retinal vasculitis, Uveitis, and Vitritis.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI7bSEV_WK24_COMINO_SE_2022_41984_41986.xls

04JUN2024 19:11

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Retinal Vascular Occlusive Disease (Fellow Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.

Retinal Vascular Occlusive events include Arterial occlusive disease, Retinal artery embolism, Retinal artery occlusion, Retinal vein occlusion, and Venous occlusion.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI8bSEV_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 19:14

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: PT: Endophthalmitis (Fellow Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI10bSEV_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 19:17

POPULATION: Safety-Evaluable Population, COMING
 ENDPOINTS: Retinal Vascular Occlusive Disease (Study Eye, Serious) through Week 24
 MODEL: Stratified Analysis
 PDOP: GRA186
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Fixed-effects (N=161)			All-observers (N=161)			Odds Ratio	Absolute Risk			Absolute Risk Difference			Relative Risk			Interaction Test												
		Patients		Patients with Event	Patients		Patients with Event		Lower	Upper	Absolute	Lower	Upper	Relative	Lower	Upper	p-value	Interaction Test	Relative	Lower	Upper									
		n	%	n	n	%	n		%	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI										
All	Overall	395	100.0	1	0.4	351	100.0	0.0	0.00	0.20	4.43	0.000	Convergence criterion (GCMV*1k-8) satisfied.	0.00	5.33	-0.001	Algorithm converged.	-0.013	0.013	0.99	Algorithm converged.	0.20	4.87	0.980	1.01	Algorithm converged.	0.21	4.88		
Gender	Male	172	52.4	2	1.2	159	55.1	2	1.0	0.00	0.00	0.000	Convergence criterion (GCMV*1k-8) satisfied.	-0.000	5.33	-0.001	Algorithm converged.	-0.022	0.012	0.42	Algorithm converged.	0.00	4.41	0.490	0.443	0.20	Algorithm converged.	0.18	4.11	
	Female	173	47.4	1	0.6	162	44.9	1	0.6	1.00	1.00	0.000	Convergence criterion (GCMV*1k-8) satisfied.	0.17	20.97	0.001	Algorithm converged.	-0.010	0.025	1.87	Algorithm converged.	0.17	20.46	0.870	0.51	Algorithm converged.	0.15	5.83		
Age	<65 years	161	44.1	0	0.0	154	43.2	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	≥65 years	204	55.0	1	0.5	205	56.8	1	0.5	1.00	1.00	0.000	Convergence criterion (GCMV*1k-8) satisfied.	0.20	5.04	0.000	Algorithm converged.	-0.023	0.023	1.00	Algorithm converged.	0.21	4.92	0.990	1.00	Algorithm converged.	0.20	4.87		
Baseline BCVA ETDRS letter score	≥14 letters	79	21.4	0	0.0	80	22.2	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	<14 letters	106	29.0	1	0.9	105	29.1	0	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Baseline BCVA ETDRS letter score	≥24 letters	180	49.2	2	1.1	176	48.8	2	1.1	0.83	0.83	0.000	Convergence criterion (GCMV*1k-8) satisfied.	0.11	3.03	-0.000	Algorithm converged.	-0.030	0.010	0.65	Algorithm converged.	0.11	3.85	0.630	1.53	Algorithm converged.	0.26	9.07		
	<24 letters	35	9.4	0	0.0	34	10.0	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Baseline BCVA ETDRS letter score	≥24 letters	330	90.4	3	0.9	325	90.0	3	0.9	0.88	0.88	0.000	Convergence criterion (GCMV*1k-8) satisfied.	0.20	4.81	0.000	Algorithm converged.	-0.010	0.014	0.98	Algorithm converged.	0.20	4.84	0.980	1.00	Algorithm converged.	0.21	4.99		
	<24 letters	111	30.4	0	0.0	113	31.1	0	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Geographic Region	Europe	146	40.4	2	1.4	145	40.2	2	1.0	0.83	0.83	0.000	Convergence criterion (GCMV*1k-8) satisfied.	0.18	21.30	0.000	Algorithm converged.	-0.027	0.026	0.95	Algorithm converged.	0.04	10.05	0.970	1.05	Algorithm converged.	0.07	16.54		
	Asia Pacific (inc. Australia)	108	29.6	1	0.9	103	28.5	1	1.0	0.83	0.83	0.000	Convergence criterion (GCMV*1k-8) satisfied.	0.00	15.44	0.000	Algorithm converged.	-0.027	0.026	0.95	Algorithm converged.	0.04	10.05	0.970	1.05	Algorithm converged.	0.07	16.54		
Baseline RVO status	RVO	301	82.0	3	1.0	291	80.4	3	1.0	0.97	0.97	0.000	Convergence criterion (GCMV*1k-8) satisfied.	0.10	4.83	0.000	Algorithm converged.	-0.016	0.016	0.97	Algorithm converged.	0.20	4.70	0.960	1.00	Algorithm converged.	0.21	5.08		
	NOVO	62	16.2	0	0.0	64	17.7	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Race/ethnicity	White	242	66.3	3	1.2	231	69.5	3	1.3	0.83	0.83	0.000	Convergence criterion (GCMV*1k-8) satisfied.	0.26	9.44	0.000	Algorithm converged.	-0.010	0.022	1.55	Algorithm converged.	0.26	9.23	0.620	NE	0.64	Algorithm converged.	0.11	3.81	
	Other	13	3.0	0	0.0	17	4.7	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Baseline RVO status	Asian	89	24.4	0	0.0	84	24.4	1	1.1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Other	13	3.0	0	0.0	17	4.7	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Baseline RVO status	Unknown	21	5.4	0	0.0	5	1.4	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Other	13	3.0	0	0.0	17	4.7	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	

Test for interaction based on RR (Log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Retinal Vascular Occlusive events include arterial occlusive disease, Retinal artery embolism, Retinal artery occlusion, Retinal vein occlusion, and Venous occlusion.
 Clinical cut-off: GRA186222

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_w_raw.exe
 Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_NOV_CDR_Primary/prod/output/t_w_raw_ag_AE186222_W24_COMING_SE_2022_41984_41986.xls
 04/20/2024 18:51

POPULATION: Safety-Evaluable Population, COMING
 ENDPOINTS: VV: Endophthalmitis (Study Eye, Serious) through Week 24
 MODEL: Stratified Analysis
 STUDY: 04198
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Fas/Ineb (N=24)				Aflibercept (N=24)				Odds Ratio	Fas/Ineb vs. Aflibercept										Aflibercept vs. Fas/Ineb						
		Patients		Patients with Event		Patients		Patients with Event			Absolute Risk					Relative Risk					Relative Risk		Relative Risk				
		n	%	n	%	n	%	n	%		95% Lower CI	95% Upper CI	Absolute Risk	Convergence Reason	95% Lower CI	95% Upper CI	Relative Risk	Convergence Reason	95% Lower CI	95% Upper CI	p-value	Interaction Test	Relative Risk	Convergence Reason	95% Lower CI	95% Upper CI	
All	Eye	395	100.0	0	0	351	100.0	1	0.3	*	Quasi-complete separation of data points																
Gender	Male	172	52.4	0	0	159	55.1	0	0.0	*	Quasi-complete separation of data points																
	Female	173	47.6	0	0	152	44.9	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Age	<65 years	161	44.1	0	0	154	43.7	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	≥65 years	204	55.9	0	0	203	56.8	1	0.5	*	Quasi-complete separation of data points																
Baseline BCVA ETDRS letter score	≥14 letters	79	21.4	0	0	80	22.2	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	15 - 14 letters	156	49.0	0	0	103	29.1	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	<55 letters	180	49.2	0	0	174	49.4	0	0.0	*	Quasi-complete separation of data points																
Baseline BCVA ETDRS letter score	≥23 letters	35	9.4	0	0	33	10.0	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	≥24 letters	330	90.6	0	0	325	90.0	1	0.3	*	Quasi-complete separation of data points detected																
Geographic Region	Europe	111	30.4	0	0	111	31.1	0	0.0	*	Quasi-complete separation of data points detected																
	Asia Pacific	146	40.0	0	0	145	40.2	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Asia Pacific (inc. Australia)	108	29.6	0	0	103	28.5	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Baseline RVO status	RVO	301	82.5	0	0	291	80.4	1	0.3	*	Quasi-complete separation of data points detected																
	NRVO	61	16.2	0	0	64	17.7	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Missing	3	0.8	0	0	3	1.1	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Race/ethnicity	White	242	66.1	0	0	221	69.5	1	0.4	*	Quasi-complete separation of data points																
	Asian	89	24.4	0	0	88	24.4	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Other	13	3.8	0	0	17	4.7	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Unknown	21	5.8	0	0	3	1.4	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE

Test for interaction based on RR (Log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.9000000

Program: root/clinical_studies/S06867461/CD730303/share/ACE_data_analysis/prod/program/t_at_rev.exe
 Output: root/clinical_studies/S06867461/CD730303/share/ACE_pool_RVO_CDR_Primary/prod/output/t_at_rev_sq_AE010aSER_MX24_COMING_IR_2022_41984_41986.xls
 04/20/2024 18:55

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Intraocular Inflammation Events (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Intraocular Inflammation events include Anterior chamber flare, Anterior Chamber inflammation, Chorioretinitis, Choroiditis, Cyclitis, Eye inflammation, Iridocyclitis, Iritis, Keratic precipitates, Keratouveitis, Noninfective chorioretinitis, Non-infectious endophthalmitis, Ocular vasculitis, Post procedural inflammation, Retinal vasculitis, Uveitis, and Vitritis.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI7bSER_WK24_COMINO_SE_2022_41984_41986.xls

04JUN2024 18:50

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINTS: Retinal Vascular Occlusive Disease (Yellow Eye, Serious) through Week 24
 MODEL: Stratified Analysis
 PDOP: 084388
 Dichotomous Analysis by Subgroups (Safety)

Name	Strat	Ferdinab (N=24)				Allibercept (N=24)				Odds Ratio	Ferdinab vs. Allibercept																	
		Patients		Patients with Event		Patients		Patients with Event			Absolute Risk Difference						Relative Risk											
		n	%	n	%	n	%	n	%		OR	Lower CI	Upper CI	Absolute Risk	Convergence Reason	Lower CI	Upper CI	Relative Risk	Convergence Reason	Lower CI	Upper CI	p-value (null)	Interaction Test p-value (likelihood ratio)	Relative Risk	Convergence Reason	Lower CI	Upper CI	
All		355	100.0	0	0	351	100.0	1	0.3	*	Quasi-complete separation of data points detected.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Gender																												
Male		172	48.4	0	0	169	55.1	2	0.9	*	Quasi-complete separation of data points detected.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Female		173	47.6	0	0	182	44.9	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Age																												
<65 years		161	44.1	0	0	154	43.2	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
>=65 years		204	55.0	0	0	205	56.8	1	0.5	*	Quasi-complete separation of data points detected.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Baseline BCVA ETDRS letter score																												
<=14 letters		79	21.6	0	0	80	22.2	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
15 - 54 letters		106	29.0	0	0	105	29.1	1	1.0	*	Quasi-complete separation of data points detected.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
>=55 letters		180	49.2	0	0	176	48.8	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Baseline BCVA ETDRS letter score																												
<=23 letters		35	9.4	0	0	34	10.0	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
>=24 letters		330	85.0	0	0	325	90.0	1	0.3	*	Quasi-complete separation of data points detected.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Geographic Region																												
Europe		111	29.4	0	0	113	30.3	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
America		146	39.0	0	0	135	36.2	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Asia Pacific (inc. Australia)		108	29.0	0	0	102	28.5	1	1.0	*	Quasi-complete separation of data points detected.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Baseline RVO status																												
NOVO		301	82.0	0	0	291	80.4	2	0.3	*	Quasi-complete separation of data points detected.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
NOVO		62	16.2	0	0	64	17.3	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Neovascular		4	0.8	0	0	4	1.1	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Race/ethnicity																												
White		242	66.3	0	0	231	65.5	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Asian		89	24.4	0	0	88	24.4	1	1.1	*	Quasi-complete separation of data points detected.	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Other		13	3.0	0	0	17	4.7	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Unknown		21	5.4	0	0	5	1.4	0	0.0	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Retinal Vascular Occlusive events include arterial occlusive disease, Retinal artery embolism, Retinal artery occlusion, Retinal vein occlusion, and Venous occlusion.

Clinical cut-off: 0.9999999

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_w_raw.exe

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CDR_Primary/prod/output/t_w_raw_ug_AE21808ER_M24_COMINO_SE_2022_41984_41986.xls

04/10/2024 16:53

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: PT: Endophthalmitis (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI10bSER_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:57

POPULATION: Safety-Evaluable Population, COMINO

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice through Week 24

MODEL: Unstratified analysis

STUDY: GR41986

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI1_WK24_COMINO_SE_2022_41984_41986.xls

04JUN2024 18:12

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2a_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:13

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2b_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:19

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: Change in decrease of >= 30 letters in VA Score Lasting more than 1 hour (Study Eye) through Week 24
 MOEBS: Unstratified analysis
 STUDY: 084198
 Dichotomous Analysis by Subgroups (Safety)

Base	Label	Par1 (n=165)				Allibronz (n=141)				Par1 (n=165) vs. Allibronz (n=141)																	
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference					Relative Risk							
		n	%	n	%	n	%	n	%	OR	Lower CI	Upper CI	Absolute Risk	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI	p-value (Wald)	Interaction Test p-value (Likelihood ratio)	Relative Risk	Lower CI	Upper CI	p1	p2		
Gender	Male	193	45.4	1	0.5	151	108.0	4	2.6	0.52	0.03	2.10	-0.013	Algorithm converged.	-0.013	0.000	0.99	Algorithm converged.	0.10	1.04	0.9843	1.01	Algorithm converged.	0.11	1.11		
	Female	173	47.4	5	2.9	152	45.9	5	3.2	2.38	0.66	15.85	0.521	Algorithm converged.	-0.014	0.047	2.14	Algorithm converged.	0.44	11.40	0.1050	0.41	Algorithm converged.	0.29	2.17		
Age	<= 65 years	161	44.1	2	1.2	134	43.2	1	0.4	1.44	0.18	21.22	0.004	Algorithm converged.	-0.015	0.000	1.44	Algorithm converged.	0.18	21.14	0.5871	0.54	Algorithm converged.	0.04	4.43		
	>= 65 years	204	55.9	4	2.0	205	56.8	5	2.4	0.80	0.21	3.02	-0.003	Algorithm converged.	-0.011	0.004	0.80	Algorithm converged.	0.22	2.95	0.7422	1.04	Algorithm converged.	0.14	4.57		
Baseline BCVA ETDRS letter score	>= 34 letters	79	21.4	0	0.0	80	22.2	1	1.3	*				ERROR: Error in computing the risk function, its derivatives, or the variance function.			0.00	Algorithm converged.	0.00	NR	1.0000	0.424	>>> NR	Algorithm converged.	0.00	NR	
	>= 18 letters	106	29.0	2	1.9	105	28.1	1	1.3	2.00	0.18	22.40	0.003	Algorithm converged.	-0.023	0.041	1.98	Algorithm converged.	0.18	21.50	0.5743	0.54	Algorithm converged.	0.01	5.48		
	>= 5 letters	180	49.3	4	2.2	176	48.8	4	2.3	0.88	0.24	3.87	-0.001	Algorithm converged.	-0.011	0.010	0.88	Algorithm converged.	0.25	3.85	0.9744	1.02	Algorithm converged.	0.26	4.03		
Baseline BCVA ETDRS letter score	>= 23 letters	35	9.4	0	0.0	36	10.0	1	2.8	*				ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			0.00	Algorithm converged.	0.00	NR	0.9999	0.2286	>>> NR	Algorithm converged.	0.00	NR	
	>= 18 letters	339	90.6	5	1.8	355	95.0	5	1.5	1.19	0.36	3.92	0.001	Algorithm converged.	-0.015	0.022	1.18	Algorithm converged.	0.16	3.83	0.9059	0.85	Algorithm converged.	0.04	2.05		
Geographic Region	Europe	111	30.4	1	0.9	110	31.7	1	1.4	0.56	0.08	5.48	0.004	Algorithm converged.	-0.016	0.013	0.54	Algorithm converged.	0.08	5.43	0.5781	0.7842	1.44	Algorithm converged.	0.18	21.16	
	Asia Pacific (inc. Australia)	144	40.0	3	1.4	145	40.2	3	1.4	0.99	0.18	7.15	0.003	Algorithm converged.	-0.007	0.007	0.99	Algorithm converged.	0.14	6.84	0.9343	1.01	Algorithm converged.	0.14	7.04		
	Asia Pacific (exc. Australia)	108	29.6	3	2.8	103	28.5	2	1.9	1.44	0.24	6.81	0.008	Algorithm converged.	-0.013	0.049	1.43	Algorithm converged.	0.24	8.19	0.6915	0.70	Algorithm converged.	0.12	4.10		
Baseline RVO status	CRVO	101	27.1	6	2.0	291	80.4	6	2.1	0.97	0.31	3.01	-0.001	Algorithm converged.	-0.021	0.022	0.97	Algorithm converged.	0.12	2.94	0.9529	1.0000	1.01	Algorithm converged.	0.14	3.13	
	BRVO	62	16.7	0	0.0	146	17.7	0	0.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
	Neovascular	4	1.1	0	0.0	4	1.1	0	0.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Race/ethnicity	White	242	66.3	3	1.2	251	69.5	3	2.0	1.04	0.30	3.43	0.001	Algorithm converged.	-0.024	0.026	1.04	Algorithm converged.	0.10	3.54	0.9335	NR	0.94	Algorithm converged.	0.28	3.29	
	Asian	89	24.4	0	0.0	88	24.4	1	1.1	*				WARNING: the relative maximum convergence criterion of 1.1111111111111112 is greater than the limit of 0.001. The convergence is questionable.			0.00	Algorithm converged.	0.00	NR	0.9999	>>> NR	Algorithm converged.	0.00	NR		
	Other	11	3.0	0	0.0	17	4.7	0	0.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
	Unknown	21	5.6	1	4.8	5	1.4	0	0.0	*				WARNING: the relative maximum convergence criterion of 1.1111111111111112 is greater than the limit of 0.001. The convergence is questionable.			NR	Algorithm converged.	NR	NR	NR	NR	NR	NR	NR	NR	NR

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.9402022

Program: root/clinical_studies/06867461/CD330303/share/ACR_data_analysis/prod/program/t_w_rw.exe
 Output: root/clinical_studies/06867461/CD330303/share/ACR_pool_CDR_CD330303/output/t_w_rw_wg_A0213_W24_COMINO_SR_2022_41984_41986.xls
 04/20/2024 18:14

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: Change in decrease of >= 10 letters in VA Score lasting more than 1 hour (Fellow Eye) through Week 24
 MODEL: Stratified Analysis
 PDPID: 064396
 Dichotomous Analysis by Subgroups (Safety)

Stratum	Level	Favosimab (N=241)			Allibresomab (N=241)			Odds Ratio	Absolute Risk Difference			Relative Risk			Interaction Test			Allibresomab vs Favosimab							
		Patients	Patients with Event	Events	Patients	Patients with Event	Events		Lower CI	Upper CI	Absolute Risk	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI	p-value (loglik)	Interaction Test (likelihood ratio)	Relative Risk	Lower CI	Upper CI				
All	All	355	100.0	1	0.3	351	100.0	2	0.6	0.49	0.04	5.45	-0.001	0.01	0.007	0.49	Algorithm converged.	0.03	5.43	0.5441	2.02	Algorithm converged.	0.18	22.02	
Gender	Male	192	52.4	1	0.5	189	51.1	1	0.5	1.03	0.00	16.49	0.00				Algorithm converged.								
	Female	173	47.6	0	0.0	162	44.9	1	0.6	*								WARNING: The relative Bayesian convergence criterion of 21.61659393 is greater than the limit of 0.0001. The convergence is questionable.							
Age	<65 years	161	44.3	0	0.0	156	43.2	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	>=65 years	324	85.7	1	0.3	325	86.8	2	1.0	0.10	0.00	5.18	-0.001				Algorithm converged.	0.03	5.43	0.5723	1.93	Algorithm converged.	0.18	21.76	
Baseline BCVA ETDRS letter score	<=14 letters	79	21.6	1	1.3	80	22.2	0	0.0	*								WARNING: The relative Bayesian convergence criterion of 13.70488764 is greater than the limit of 0.0001. The convergence is questionable.							
	15 - 14 letters	106	29.0	0	0.0	103	27.1	2	1.0	*								WARNING: The relative Bayesian convergence criterion of 10.12558699 is greater than the limit of 0.0001. The convergence is questionable.							
	>=55 letters	180	49.3	0	0.0	176	48.8	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	
Baseline BCVA ETDRS letter score	<=23 letters	30	9.4	0	0.0	34	10.0	0	0.0	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
	>=24 letters	330	89.6	1	0.3	325	90.0	2	0.6	0.49	0.04	5.44	-0.001				Algorithm converged.	0.03	5.43	0.5622	2.01	Algorithm converged.	0.19	22.29	
Geographic Region	Europe	111	30.4	1	0.9	113	31.3	0	0.0	*								ERROR: Error in computing the link function, its derivatives, or the variance function.							
	America	146	40.0	0	0.0	145	40.5	1	0.7	*								WARNING: The relative Bayesian convergence criterion of 19.8922939 is greater than the limit of 0.0001. The convergence is questionable.							
Baseline RVO status	SEVO	301	82.3	1	0.3	291	80.6	1	0.3	0.37	0.00	15.32	0.00				Algorithm converged.	0.05	15.32	0.9809	0.180	1.01	Algorithm converged.	0.07	16.45
	NEVO	62	16.7	0	0.0	64	17.7	0	1.0	*								WARNING: The relative Bayesian convergence criterion of 11.0164339 is greater than the limit of 0.0001. The convergence is questionable.							
Race/ethnicity	White	242	66.3	1	0.4	231	63.5	0	0.0	*								WARNING: Negative of Hessian not positive definite.							
	Asian	89	24.4	0	0.0	88	24.4	1	1.1	*								WARNING: The relative Bayesian convergence criterion of 14.51837582 is greater than the limit of 0.0001. The convergence is questionable.							
Baseline RVO status	Other	13	3.0	0	0.0	17	4.7	0	5.9	*								ERROR: Error in computing the link function, its derivatives, or the variance function.							
	Unknown	21	5.4	0	0.0	3	1.4	0	0.2	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	

Test for interaction based on RR (Log-Binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.90000022

Program: root/clinical_studies/S06867461/CD70303/share/ACE_data_analysis/prd/prd/mf/ct_at_new.exe
 Output: root/clinical_studies/S06867461/CD70303/share/ACE_pool_RVO_CD70303_Primary/prd/output/r_at_new_ag_AE513_WK24_COMINO_SE_2022_41984_41986.xlsx
 04/29/2024 18:20

POPULATION: Safety-Evaluable Population, COMING
 ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye) through Week 24
 MODEL: Stratified Analysis
 STUDY: 044368
 Dichotomous Analysis by Subgroups (Safety)

Subgroup	Level	Patients (N=241)				All-cause (N=241)				Patients vs. All-cause										All-cause vs. Patients					
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Absolute Risk Difference		Relative Risk		Relative Risk		p-value		Interaction Test		Relative Risk		Relative Risk	
		n	%	n	%	n	%	n	%	OR	95% CI	Lower CI	Upper CI	RR	95% CI	Lower CI	Upper CI	p-value	Interaction Test	Relative Risk	95% CI	Lower CI	Upper CI		
Age	≥65 years	395	100.0	2	0.5	351	100.0	0	0.0	1.0	1.43	-0.011	Algorithm converged.	0.07	0.04	0.11	Algorithm converged.	0.07	1.42	0.174	1.01	Algorithm converged.	0.42	14.43	
Gender	Male	172	52.4	1	0.5	159	55.1	1	0.6	0.93	0.49	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	Female	173	47.4	1	0.5	152	44.9	2	1.3	0.94	0.54	0.000	Algorithm converged.	-0.011	0.014	0.04	Algorithm converged.	0.04	14.81	0.923	1.07	Algorithm converged.	0.07	16.51	
Age	≥65 years	161	44.1	0	0.0	156	43.2	2	1.3	0.93	0.49	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
Baseline BCVA ETDRS letter score	≥14 letters	79	21.0	0	0.0	80	22.2	0	0.0	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	35 - 14 letters	106	29.0	0	0.0	105	29.1	2	1.9	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	≤35 letters	182	49.3	2	1.1	174	48.8	4	2.3	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
Baseline BCVA ETDRS letter score	≥21 letters	35	9.4	0	0.0	35	10.0	0	0.0	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	≥15 letters	105	28.4	2	1.9	103	28.5	0	0.0	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
Geographic Region	Europe	111	30.4	1	0.9	113	31.3	4	3.5	0.93	0.49	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	North America	144	40.0	0	0.0	145	40.2	2	1.4	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	Asia Pacific (incl. Australia)	106	29.0	1	0.9	103	28.5	0	0.0	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
Baseline RVO status	RVO	301	82.5	2	0.7	291	80.4	4	1.4	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	NOVO	61	16.7	0	0.0	64	17.7	2	3.1	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	Missing	1	0.3	0	0.0	6	1.7	0	0.0	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
Race/ethnicity	White	242	66.3	1	0.4	251	69.5	4	2.4	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	Asian	89	24.4	1	1.1	88	24.4	0	0.0	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	Other	13	3.6	0	0.0	17	4.7	0	0.0	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81
	Unknown	21	5.8	0	0.0	3	0.8	0	0.0	0.92	0.48	-0.021	Algorithm converged.	-0.015	0.001	0.01	Algorithm converged.	0.02	1.39	1.441	0.394	4.82	Algorithm converged.	0.37	40.81

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 0.9000000

Program: root/clinical_studies/006867461/CD730303/share/ACE_data_analysis/prod/prog/mf/acc_new.exe
 Output: root/clinical_studies/006867461/CD730303/share/ACE_pool_RVO_CDR_Primary/prod/output/r_acc_raw_ag_AE214a_W24_COMING_SE_2022_41984_41986.xls
 04/20/2024 18:16

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI4b_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:22

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Associated with severe intraocular inflammation (Study Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5a_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:18

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5b_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:22

POPULATION: Safety-Evaluable Population, COMINO

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice (Severe) through Week 24

MODEL: Unstratified analysis

STUDY: GR41986

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI1SEV_WK24_COMINO_SE_2022_41984_41986.xls

04JUN2024 18:58

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2aSEV_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:59

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2bSEV_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 19:05

POPULATION: Safety-Evaluable Population, COMINO

ENDPOINT: Causes a decrease of ≥ 30 letters in VA Score lasting more than 1 hour (Fellow Eye, Severe) through Week 24

MODEL: Unstratified analysis

STUDY: GR41986

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI3bSEV_WK24_COMINO_SE_2022_41984_41986.xls

04JUN2024 19:06

POPULATION: Safety-Evaluable Population, COMINO

ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye, Severe) through Week 24

MODEL: Unstratified analysis

STUDY: GR41986

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI4bSEV_WK24_COMINO_SE_2022_41984_41986.xls

04JUN2024 19:07

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Associated with severe intraocular inflammation (Study Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5aSEV_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 19:04

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye, Severe) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5bSEV_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 19:07

POPULATION: Safety-Evaluable Population, COMING
 ENDPOINTS: Antiplatelet Trialists Collaboration (ATC) event (Severe) through Week 24
 MODEL: Stratified Analysis
 PDOP: GRADES
 Dichotomous Analysis by Subgroups (Safety)

Name	Level	Patients (N=24)				Adverse Events (N=24)				Odds Ratio	Patients vs. Adverse Events																
		Patients		Patients with Event		Patients		Patients with Event			Absolute Risk Difference					Relative Risk											
		n	%	n	%	n	%	n	%		Lower CI	Upper CI	Absolute Risk	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI	p-value (95% CI)	Interaction Test (p-value)	Relative Risk	Lower CI	Upper CI				
Sex	Male	365	100.0	3	0.8	361	100.0	0	0.0	0.99	Convergence criterion (GCONV<=1E-8) satisfied.	0.20	4.43	0.000	Algorithm converged.	-0.01	0.01	0.99	Algorithm converged.	0.20	4.47	0.993	1.01	Algorithm converged.	0.21	4.48	
Gender	Male	372	92.4	2	0.5	370	95.1	2	0.5	2.00	Convergence criterion (GCONV<=1E-8) satisfied.	-0.00	0.00	0.000	Algorithm converged.	-0.00	0.00	0.00	Algorithm converged.	0.10	22.43	0.550	0.173	0.48	Algorithm converged.	0.10	22.43
	Female	31	7.6	1	0.3	30	74.3	1	3.3	0.47	Convergence criterion (GCONV<=1E-8) satisfied.	0.04	5.18	-0.000	Algorithm converged.	-0.07	0.04	0.47	Algorithm converged.	0.04	9.11	0.533	2.14	Algorithm converged.	0.20	21.13	
Age	<65 years	161	44.1	0	0.0	161	43.2	1	0.6	1.11	Quasi-complete separation of data points detected.				WARNING: The relative Bayesian convergence criterion of 21.40747529 is greater than the limit of 0.0001. The convergence is questionable.	0.00	0.00	0.00	Algorithm converged.	0.00	0.00	0.999	0.203	>>>> 99	Algorithm converged.	0.00	0.00
	≥65 years	204	55.9	3	1.5	203	56.8	2	1.0	1.11	Convergence criterion (GCONV<=1E-8) satisfied.	0.20	9.14	0.000	Algorithm converged.	-0.00	0.00	1.00	Algorithm converged.	0.20	9.23	0.621	0.66	Algorithm converged.	0.21	9.23	
Baseline BCVA ETDRS letter score	<24 letters	79	21.6	0	0.0	80	22.2	0	1.0	1.00	Quasi-complete separation of data points				ERROR: Error in computing the link function, its derivatives, or the variance			0.00	Algorithm converged.	0.00	0.00	1.000	0.480	>>>> 99	Algorithm converged.	0.00	0.00
	≥24 letters	105	29.0	0	0.0	105	29.1	0	0.0	0.00	Convergence criterion (GCONV<=1E-8) satisfied.				Algorithm converged.			0.00	Algorithm converged.					Algorithm converged.			
	>=55 letters	180	49.2	3	1.7	176	46.8	2	1.1	1.47	Convergence criterion (GCONV<=1E-8) satisfied.	0.24	8.03	0.000	Algorithm converged.	-0.03	0.00	1.47	Algorithm converged.	0.23	8.67	0.672	0.68	Algorithm converged.	0.12	4.03	
Baseline BCVA ETDRS letter score	<23 letters	35	9.6	0	0.0	34	10.0	1	2.9	1.11	Quasi-complete separation of data points				ERROR: The mean parameter is either invalid or at a limit of its range for some			0.00	Algorithm converged.	0.00	0.00	0.999	0.217	>>>> 99	Algorithm converged.	0.00	0.00
	≥24 letters	330	90.4	3	0.9	325	90.0	2	0.6	1.48	Convergence criterion (GCONV<=1E-8) satisfied.	0.25	8.02	0.000	Algorithm converged.	-0.00	0.00	1.48	Algorithm converged.	0.25	8.78	0.667	0.68	Algorithm converged.	0.11	4.02	
Geographic Region	Europe	111	30.4	0	0.0	113	30.3	2	1.8	1.11	Quasi-complete separation of data points				WARNING: The relative Bayesian convergence criterion of 10.38824555 is greater than			0.00	Algorithm converged.	0.00	0.00	0.999	0.109	>>>> 99	Algorithm converged.	0.00	0.00
	North America	146	40.4	1	0.7	145	40.4	0	0.0	0.00	Convergence criterion (GCONV<=1E-8) satisfied.	0.10	25.37	0.000	Algorithm converged.	-0.00	0.00	1.00	Algorithm converged.	0.10	21.47	0.578	0.40	Algorithm converged.	0.22	5.44	
	Asia Pacific (incl. Australia)	108	29.2	1	0.9	103	28.5	0	0.0	0.00	Quasi-complete separation of data points				WARNING: Negative of Bayesian not positive definite.			0.00	Algorithm converged.					Algorithm converged.			
Baseline RVO status	CRVO	301	82.0	3	1.0	293	80.8	3	1.0	0.97	Convergence criterion (GCONV<=1E-8) satisfied.	0.13	4.83	0.000	Algorithm converged.	-0.01	0.01	0.97	Algorithm converged.	0.20	4.75	0.968	1.000	Algorithm converged.	0.21	5.08	
	BRVO	61	16.7	0	0.0	64	17.7	0	0.0	0.00	Convergence criterion (GCONV<=1E-8) satisfied.				Algorithm converged.			0.00	Algorithm converged.					Algorithm converged.			
	Retinal	4	0.8	0	0.0	4	1.1	0	0.0	0.00	Convergence criterion (GCONV<=1E-8) satisfied.				Algorithm converged.			0.00	Algorithm converged.					Algorithm converged.			
Race/ethnicity	Mixed	242	66.1	3	1.2	241	69.5	3	1.2	1.04	Convergence criterion (GCONV<=1E-8) satisfied.	0.21	5.19	0.000	Algorithm converged.	-0.03	0.00	1.04	Algorithm converged.	0.21	5.09	0.941	0.98	Algorithm converged.	0.20	4.73	
	Asian	89	24.4	0	0.0	88	24.4	0	0.0	0.00	Convergence criterion (GCONV<=1E-8) satisfied.				Algorithm converged.			0.00	Algorithm converged.					Algorithm converged.			
	Other	13	3.6	0	0.0	17	4.7	0	0.0	0.00	Convergence criterion (GCONV<=1E-8) satisfied.				Algorithm converged.			0.00	Algorithm converged.					Algorithm converged.			
	Unknown	21	5.8	0	0.0	14	4.4	0	0.0	0.00	Convergence criterion (GCONV<=1E-8) satisfied.				Algorithm converged.			0.00	Algorithm converged.					Algorithm converged.			

Test for interaction based on RR (Log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.9602022

Program: root/clinical_studies/RO687461/CD3333/share/ACT_data_analysis/prod/program/act_ses.exe
 Output: root/clinical_studies/RO687461/CD3333/share/ACT_pool_RVO_CDR_Primary/prod/output/1_ses_res_wg_AE165EV_W24_COMING_SE_2022_41984_41986_x1s
 04/20/2024 19:08

POPULATION: Safety-Evaluable Population, COMINO

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice (Serious) through Week 24

MODEL: Unstratified analysis

STUDY: GR41986

Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas

Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI1SER_WK24_COMINO_SE_2022_41984_41986.xls

04JUN2024 18:36

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2aSER_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:36

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI2bSER_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:42

POPULATION: Safety-Evaluable Population, COMINO
 ENDPOINT: Cases of decrease of >= 30 letters in VA Score lasting more than 1 hour (Fellow Eye, Serious) through Week 24
 MODEL: Unstratified analysis
 STUDY: 044368
 Dichotomous Analysis by Subgroups (Safety)

Name	Strat	Patients (N=241)				All-Events (N=16)				Odds Ratio	Patients vs All-Events				Relative Risk				All-Events vs Patients								
		n	%	n	%	n	%	n	%		Lower CI	Upper CI	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI							
All		355	100.0	1	0.3	351	100.0	1	0.3	0.99	Convergence criterion (GCONV<1E-8) satisfied.	0.04	15.47	0.000	Algorithm converged.	-0.008	0.008	0.99	Algorithm converged.	0.04	15.70	0.999	1.01	Algorithm converged.	0.04	15.43	
Gender											Convergence criterion (GCONV<1E-8) satisfied.	0.04	15.47	0.000	Algorithm converged.	-0.014	0.014	1.01	Algorithm converged.	0.07	15.43	0.979	1.000	0.98	Algorithm converged.	0.04	15.37
	Male	172	52.4	1	0.6	169	55.1	1	0.6	1.04					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
	Female	173	47.6	0	0.0	182	44.9	0	0.0	0.94					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Age											Convergence criterion (GCONV<1E-8) satisfied.	0.04	15.47	0.000	Algorithm converged.	-0.011	0.011	1.00	Algorithm converged.	0.04	15.94	0.997	1.00	Algorithm converged.	0.04	15.80	
	<65 years	161	44.1	0	0.0	154	43.2	0	0.0	0.98					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	>=65 years	204	55.9	1	0.5	205	56.8	1	0.5	1.03					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Baseline BCVA STDRS letter score											Quasi-complete separation of data points detected.				WARNING: The relative Bayesian convergence criterion of 11.51485742 is greater than the limit of 0.0001. The convergence is questionable.			0.00	Algorithm converged.	NE	NE	NE	NE	NE	NE	NE	NE
	35 - 54 letters	196	52.0	0	0.0	105	29.1	1	1.0	*	Quasi-complete separation of data points detected.				WARNING: The relative Bayesian convergence criterion of 15.10988828 is greater than the limit of 0.0001. The convergence is questionable.			0.00	Algorithm converged.	0.00	NE	NE	NE	>>>>99	Algorithm converged.	0.00	NE
	>=55 letters	180	49.1	0	0.0	176	48.9	0	0.0	0.98					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Baseline BCVA STDRS letter score											Quasi-complete separation of data points detected.				WARNING: The relative Bayesian convergence criterion of 11.51485742 is greater than the limit of 0.0001. The convergence is questionable.			0.00	Algorithm converged.	NE	NE	NE	NE	NE	NE	NE	NE
	<=31 letters	26	6.4	0	0.0	101	26.0	0	0.0	0.97					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	>=32 letters	330	86.4	1	0.3	350	93.9	0	0.0	0.99					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Geographic Region											Quasi-complete separation of data points detected.				WARNING: Error in computing the link function, the derivatives, or the variance.			0.00	Algorithm converged.	NE	NE	NE	NE	NE	NE	NE	NE
	Europe	111	30.4	1	0.4	113	31.3	0	0.0	*	Quasi-complete separation of data points detected.				WARNING: The relative Bayesian convergence criterion of 12.99419794 is greater than the limit of 0.0001. The convergence is questionable.			0.00	Algorithm converged.	0.00	NE	NE	NE	>>>>99	Algorithm converged.	0.00	NE
	Asia Pacific (incl. Australia)	146	40.0	0	0.0	145	40.2	0	0.0	0.98					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Baseline RVO status											Convergence criterion (GCONV<1E-8) satisfied.	0.04	15.52	0.000	Algorithm converged.	-0.009	0.009	0.97	Algorithm converged.	0.04	15.18	0.989	1.000	1.03	Algorithm converged.	0.07	14.41
	None	301	82.5	1	0.3	291	80.4	1	0.3	0.97					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	SRVO	61	16.3	0	0.0	64	17.7	0	0.0	0.98					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Neovascular	1	0.3	0	0.0	1	0.3	0	0.0	0.98					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
Race/ethnicity											Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	NE	NE	NE	NE	NE	NE	NE	NE
	White	242	66.3	1	0.4	251	69.5	0	0.0	*	Quasi-complete separation of data points detected.				WARNING: The relative Bayesian convergence criterion of 11.52187362 is greater than the limit of 0.0001. The convergence is questionable.			0.00	Algorithm converged.	0.00	NE	NE	NE	>>>>99	Algorithm converged.	0.00	NE
	Asian	89	24.4	0	0.0	88	24.4	0	0.0	0.98					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Other	13	3.6	0	0.0	17	4.7	0	0.0	0.98					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	
	Unknown	21	5.8	0	0.0	1	0.3	0	0.0	0.98					NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	

Test for interaction based on RR (log-binomial regression)
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.9A02022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_w_raw.exe
 Output: root/clinical_studies/RO6867461/CDT30303/share/ACE_pool_RVO_CDR_Primary/prod/output/t_w_raw_eg_AE3130E8_W24_COMINO_R0_2022_41984_41986.v16
 04/30/2024 16:42

POPULATION: Safety-Evaluable Population, COMBO
 ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye, serious) through Week 24
 MODEL: Unstratified analysis
 STUDY: 041964
 Dichotomous Analysis by Subgroups (Safety)

Base	Level	Paritamb (N=161)				Alifbercept (N=141)				Paritamb vs. Alifbercept															
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio		Absolute Risk Difference		Relative Risk		Relative Bias		Interaction Test		Relative Risk		Convergence			
		n	%	n	%	n	%	n	%	OR	95% Lower CI	95% Upper CI	Absolute Risk	Lower CI	Upper CI	Relative Risk	Lower CI	Upper CI	p-value	Labelled ratio	Relative Risk	Lower CI	Upper CI		
Sex	Male	145	100.0	2	0.0	141	100.0	3	1.4	0.10	0.00	0.04	-0.004	0.00	0.00	0.40	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	Female	173	47.4	1	0.6	192	44.3	1	0.4	0.24	0.00	0.00	-0.001	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
Gender	Male	191	45.4	1	0.4	199	55.1	4	2.0	0.20	0.00	0.00	-0.016	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	Female	173	47.4	1	0.6	192	44.3	1	0.4	0.24	0.00	0.00	-0.001	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
Age	<65 years	161	44.1	0	0.0	156	43.2	1	0.6	0.40	0.00	0.00	-0.004	0.00	0.00	0.40	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	≥65 years	204	55.9	2	1.0	205	54.8	4	2.0	0.20	0.00	0.00	-0.010	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
Baseline BCVA ETDRS letter score	≥14 letters	79	21.6	0	0.0	83	22.2	0	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	10 - 14 letters	106	29.0	0	0.0	105	29.1	2	1.0	0.40	0.00	0.00	-0.004	0.00	0.00	0.40	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	<10 letters	180	49.3	2	1.1	176	48.8	3	1.5	0.40	0.00	0.00	-0.004	0.00	0.00	0.40	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
Baseline BCVA ETDRS letter score	≥23 letters	35	9.5	0	0.0	36	10.0	0	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	≥14 letters	339	90.4	2	0.6	325	90.0	3	1.5	0.40	0.00	0.00	-0.004	0.00	0.00	0.40	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
Geographic Region	Europe	111	30.0	1	0.9	110	30.7	1	1.4	0.40	0.00	0.00	-0.004	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	Asia Pacific (inc. Australia)	144	40.0	1	0.6	145	40.2	1	0.7	0.40	0.00	0.00	-0.004	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	Asia Pacific (excl. Australia)	108	29.0	1	0.9	103	28.5	0	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
Baseline RVO status	CRVO	101	27.3	2	0.3	291	80.4	4	1.4	0.14	0.00	0.00	-0.007	0.00	0.00	0.48	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	BRVO	62	16.7	0	0.0	146	40.7	1	1.4	0.40	0.00	0.00	-0.004	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	None	4	1.1	0	0.0	4	1.1	0	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
Race/ethnicity	White	242	66.1	1	0.4	251	69.3	3	2.0	0.20	0.00	0.00	-0.014	0.00	0.00	0.21	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	Asian	85	24.4	1	1.1	84	24.4	0	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	Other	13	3.6	0	0.0	17	4.7	0	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25
	Unknown	21	5.8	0	0.0	3	1.4	0	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.00	0.00	0.25	0.00	0.20	0.25	0.00	0.40	0.25

Test for interaction based on log (log-binomial regression)
 * Indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 0.94000022

Program root:\clinical_studies\06887461\CTR0303\share\ACT_data_analysis\prod\program\l_w_r_w.exe
 Output: root:\clinical_studies\06887461\CTR0303\share\ACT_data_analysis\prod\output\l_w_r_w_wg_AES144SR_W24_COMBO_SR_2022_41964_41966.xls
 04/20/2024 18:39

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI4bSER_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:44

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Associated with severe intraocular inflammation (Study Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5aSER_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:41

POPULATION: Safety-Evaluable Population, COMINO
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye, Serious) through Week 24
MODEL: Unstratified analysis
STUDY: GR41986
Dichotomous Analysis by Subgroups (Safety)

Null Report: No results could be derived for this output.

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_raw.sas
Output: root/clinical_studies/R06867461/CDT30303/share/ACE_pool_RVO_CSR_Primary/prod/output/t_ae_raw_sg_AESI5bSER_WK24_COMINO_SE_2022_41984_41986.xls
04JUN2024 18:45

POPULATION: Intent-To-Treat Population

ENDPOINT: --

MODEL: descriptive

STUDY: GR41984

Number of Centers/Countries/Geographical Regions with <10, >=10 Patients per Arm

	Center				Country				Geographical region			
	n	%	n of patients randomized	% randomized patients	n	%	n of patients randomized	% randomized patients	n	%	n of patients randomized	% randomized patients
Overall	149	100,0	553	100,0	22	100,0	553	100,0	3	100,0	553	100,0
with <10 patients per arm	149	100,0	553	100,0	16	72,7	167	30,2	0	NE	NE	NE
with >=10 patients per arm	0	NE	NE	NE	6	27,3	386	69,8	3	100,0	553	100,0

'<10 patients' category if at least one treatment arm has <10 patients; '>=10 patients' category if all treatment arms have >=10 patients.

Geographical regions: Europe, America, Asia Pacific

'n': Number of centers/countries/regions; "%": Percent of centers/countries/regions compared to overall number of centers/countries/regions

'n of patients randomized': Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)

'% randomized patients': Percent of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm compared to overall number of randomized patients)

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_center.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_center_IT_06JUL2022_41984.xls

03AUG2023 10:43

POPULATION: Intent-To-Treat Population

ENDPOINT: --

MODEL: descriptive

STUDY: GR41984

Times in which patient reported outcomes were collected through Week 24

	Faricimab (N=276)	Aflibercept (N=277)
PRO (NEI VFQ-25) (weeks)		
n	276	276
Median	24,14	24,14

Times were calculated as:

PRO (NEI VFQ-25): Last Date of answered questionnaire - Randomization Date + 1.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_fu.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_fu_IT_06JUL2022_41984.xls

12JUL2023 16:14

POPULATION: Safety-Evaluable Population

ENDPOINT: --

MODEL: descriptive

STUDY: GR41984

Duration of Exposure to Treatment through Week 24

	Faricimab 6 mg Q4W (N=276)	Aflibercept 2 mg Q4W (N=274)
Treatment duration (weeks)		
n	276	274
Mean (SD)	19.7 (2.63)	20.0 (1.46)
Median	20,1	20,1
Min-max	0 - 21	8 - 21
Number of study drug administrations		
n	276	274
Mean (SD)	5.8 (0.72)	5.8 (0.46)
Median	6	6
Min-max	1 - 6	3 - 6
Dose interruption		
Number of doses interrupted	3	5
At least one interrupted dose	3 (1.1%)	5 (1.8%)
Intraocular inflammation	0	1 (0.4%)
BCVA decrease	0	0
Elevated intraocular pressure	0	0
Rhegmatogenous retinal break	0	0
Rhegmatogenous retinal detachment or macular hole	0	0
Active or suspected infection	0	0
Cataract surgery in the study eye	1 (0.4%)	0
Vitrectomy	0	0
Intraocular surgery in study eye	1 (0.4%)	0
On-study prohibited medications	0	0
Other	2 (0.7%)	5 (1.8%)
Interruptions per patient		
n	3	5
1	3 (1.1%)	5 (1.8%)

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ex.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_ex_SE_06JUL2022_41984.xls

12JUL2023 16:12

POPULATION: Intent-To-Treat Population
 ENDPOINT: Disposition of Patients per Arm through Week 24
 MODEL: descriptive
 STUDY: GR41984

	Faricimab (N=276)	Aflibercept (N=277)
Discontinued Study	4 (1.4%)	3 (1.1%)
Adverse event	1 (0.4%)	0
Lost to follow-up	2 (0.7%)	0
Protocol deviation	0	3 (1.1%)
Withdrawal by subject	1 (0.4%)	0
Discontinued Treatment	9 (3.3%)	3 (1.1%)
Adverse event	1 (0.4%)	0
Death	1 (0.4%)	0
Lost to follow-up	5 (1.8%)	2 (0.7%)
Withdrawal by subject	2 (0.7%)	1 (0.4%)

Includes discontinuation occurring prior to day 154 (first day of week 24 analysis visit window).
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ds.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_ds_IT_06JUL2022_41984.xls
 12JUL2023 16:13

POPULATION: Intent-To-Treat Population

ENDPOINT: --

MODEL: descriptive

STUDY: GR41984

Baseline Demographics

	Faricimab 6 mg Q4W (N=276)	Aflibercept 2 mg Q4W (N=277)	All Patients (N=553)
Region			
n	276	277	553
Rest of the World	129 (46.7%)	128 (46.2%)	257 (46.5%)
Asia	85 (30.8%)	85 (30.7%)	170 (30.7%)
US and Canada	62 (22.5%)	64 (23.1%)	126 (22.8%)
Age (years)			
n	276	277	553
Mean (SD)	64.3 (10.7)	63.8 (10.6)	64.1 (10.7)
Median	65	64	64
Min - Max	35 - 93	28 - 88	28 - 93
Age group (years)			
n	276	277	553
<65	133 (48.2%)	144 (52.0%)	277 (50.1%)
>=65	143 (51.8%)	133 (48.0%)	276 (49.9%)
Sex			
n	276	277	553
Female	133 (48.2%)	147 (53.1%)	280 (50.6%)
Male	143 (51.8%)	130 (46.9%)	273 (49.4%)
Ethnicity			
n	276	277	553
Not Hispanic or Latino	224 (81.2%)	224 (80.9%)	448 (81.0%)
Hispanic or Latino	47 (17.0%)	51 (18.4%)	98 (17.7%)
Unknown	4 (1.4%)	1 (0.4%)	5 (0.9%)
Not Reported	1 (0.4%)	1 (0.4%)	2 (0.4%)
Race			
n	276	277	553
American Indian or Alaska Native	3 (1.1%)	0	3 (0.5%)
Black or African American	6 (2.2%)	7 (2.5%)	13 (2.4%)
Native Hawaiian or other Pacific Islander	1 (0.4%)	0	1 (0.2%)
White	172 (62.3%)	172 (62.1%)	344 (62.2%)
Unknown	4 (1.4%)	4 (1.4%)	8 (1.4%)
Asian	90 (32.6%)	94 (33.9%)	184 (33.3%)
Chinese	41 (45.6%)	44 (46.8%)	85 (46.2%)
Taiwanese	0	0	0
Asian Indian	1 (1.1%)	2 (2.1%)	3 (1.6%)
Korean	29 (32.2%)	21 (22.3%)	50 (27.2%)
Malaysian	0	0	0
Vietnamese	0	0	0
Japanese	14 (15.6%)	22 (23.4%)	36 (19.6%)
Filipino	0	1 (1.1%)	1 (0.5%)
Other Asian	5 (5.6%)	4 (4.3%)	9 (4.9%)

Age at randomization.

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_dm.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_dm_IT_06JUL2022_41984.xls

12JUL2023 16:14

POPULATION: Intent-To-Treat Population

ENDPOINT: --

MODEL: descriptive

STUDY: GR41984

Baseline Ocular Characteristics in the Study Eye

	Faricimab (N=276)	Aflibercept (N=277)
Study Eye		
n	276	277
Left	140 (50.7%)	127 (45.8%)
Right	136 (49.3%)	150 (54.2%)
Bilateral Eligibility		
n	0	0
Eye with worse BCVA selected	0	0
Eye with better BCVA selected	0	0
No difference in BCVA between eyes	0	0
Months since RVO diagnosis in the Study Eye		
n	271	275
Mean (SD)	1.26 (1.88)	1.65 (7.27)
Median	0.82	0.89
Min - Max	0.2 - 27.7	0.1 - 120.6
Unknown	5	2
BCVA (letters)		
n	276	277
Mean (SD)	57.50 (13.04)	57.64 (12.15)
Median	60	60
Min - Max	19.0 - 76.0	21.0 - 73.0
Missing/Invalid	0	0
BCVA (letters) categories		
n	276	277
<= 54 (20/80 or worse)	89 (32.2%)	90 (32.5%)
>= 55 (20/80 or better)	187 (67.8%)	187 (67.5%)
CST (ILM-BM) (microns)		
n	275	275
Mean (SD)	558.32 (177.03)	558.12 (180.26)
Median	518	506
Min - Max	281.0 - 1154.0	290.0 - 1208.0
Missing/Ungradable	1	2
Macular Ischemic Non-Perfusion		
n	276	277
Yes	49 (17.8%)	48 (17.3%)
No	70 (25.4%)	66 (23.8%)
Missing/Ungradable	157 (56.9%)	163 (58.8%)
Intraocular pressure (mmHg)		
n	276	277
Mean (SD)	14.57 (2.88)	14.48 (2.94)
Median	14	14
Min - Max	7.0 - 21.0	7.0 - 22.0
Lens Status		
n	276	276
Phakic	236 (85.5%)	239 (86.3%)
Pseudophakic	40 (14.5%)	36 (13.0%)
Aphakic	0	1 (0.4%)
Other	0	0

BCVA=Best Corrected Visual Acuity; CRC = Central Reading Center; CST=Central Subfield Thickness; ILM = Internal Limiting Membrane.

Baseline is defined as the last available measurement obtained on or prior to randomization. CST(ILM-BM) is defined as the distance between ILM and Bruch's membrane (BM) as assessed by the CRC.

Absence of macular ischemic non perfusion is defined as an area of ischemic non perfusion within the macula of 0 to 0.1 mm2

Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_blc.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_blc_SOCULCH_IT_06JUL2022_41984.xls

12JUL2023 16:08

POPULATION: Intent-To-Treat Population
 ENDPOINT: --
 MODEL: descriptive
 STUDY: GR41984
 Non-Ocular Baseline Characteristics

	Faricimab (N=276)	Aflibercept (N=277)
Weight (kg)		
n	275	273
Mean (SD)	79.42 (21.62)	77.83 (19.57)
Median	77	75
Min - Max	35.0 - 199.5	37.7 - 131.5
Missing/Not Done	1	4
Height (cm)		
n	275	274
Mean (SD)	166.33 (9.84)	164.93 (11.07)
Median	165.1	164.35
Min - Max	140.0 - 193.0	107.2 - 200.0
Missing/Not Done	1	3
BMI (kg/m2)		
n	275	273
Mean (SD)	28.61 (7.42)	28.58 (7.37)
Median	27.45	27.17
Min - Max	16.6 - 77.5	16.6 - 81.8
Missing/Not Done	1	4
BMI (kg/m2) categories		
n	276	277
< 30	187 (67.8%)	184 (66.4%)
>= 30	88 (31.9%)	89 (32.1%)
Missing/Not Done	1 (0.4%)	4 (1.4%)
Systolic blood pressure (mmHg)		
n	276	273
Mean (SD)	137.39 (14.61)	137.22 (14.11)
Median	136	135
Min - Max	103.0 - 177.0	94.0 - 178.0
Missing/Not Done	0	4
Systolic blood pressure (mmHg) categories		
n	276	277
< 140	168 (60.9%)	159 (57.4%)
>= 140 and < 160	87 (31.5%)	93 (33.6%)
>= 160	21 (7.6%)	21 (7.6%)
Missing/Not Done	0	4 (1.4%)
Diastolic blood pressure (mmHg)		
n	276	273
Mean (SD)	83.00 (9.72)	82.19 (9.25)
Median	82	82
Min - Max	53.0 - 109.0	44.0 - 108.0
Missing/Not Done	0	4
Blood pressure (mmHg)		
n	276	273
> 160 systolic or > 90 diastolic	55 (19.9%)	51 (18.7%)
<= 140 systolic and <= 85 diastolic	138 (50.0%)	132 (48.4%)
<= 120 systolic and <= 80 diastolic	24 (8.7%)	23 (8.4%)
Missing/Invalid	0	4

BMI = Body Mass Index.
 Baseline is the last available measurement prior to first exposure to study drug.
 Clinical cut-off: 06JUL2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_blc.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_blc_NOCULCH_IT_06JUL2022_41984.xls
 12JUL2023 16:07

POPULATION: Intent-To-Treat Population
 ENDPOINT: --
 MODEL: descriptive
 STUDY: GR41984
 Ocular Medical History in the Study Eye

Ocular Medical History Description	Faricimab (N=276)	Aflibercept (N=277)
Total Number of patients with at least one condition	151 (54.7%)	156 (56.3%)
Total number of conditions	218	209
CATARACT	115 (41.7%)	112 (40.4%)
RETINAL VEIN OCCLUSION	34 (12.3%)	33 (11.9%)
RETINOPATHY - HYPERTENSIVE	15 (5.4%)	17 (6.1%)
GLAUCOMA	16 (5.8%)	15 (5.4%)
DRY EYE DISEASE	13 (4.7%)	14 (5.1%)
OCULAR HYPERTENSION	2 (0.7%)	3 (1.1%)
CONJUNCTIVITIS	2 (0.7%)	2 (0.7%)
EYELID DISORDERS	3 (1.1%)	1 (0.4%)
PSEUDOEXFOLIATION SYNDROME	1 (0.4%)	3 (1.1%)
BLEPHARITIS/MGD	0	3 (1.1%)
DRY AMD	1 (0.4%)	2 (0.7%)
POSTERIOR CAPSULE OPACIFICATION	3 (1.1%)	0
RETINAL TEAR/HOLE	2 (0.7%)	0
GEOGRAPHIC ATROPHY	1 (0.4%)	0
KERATITIS - NOT SPECIFIED	1 (0.4%)	0
RETINAL DETACHMENT	1 (0.4%)	0
RETINOSCHISIS	0	1 (0.4%)
STRABISMUS	1 (0.4%)	0
TRAUMATIC EYE INJURY: CHEMICAL BURN	0	1 (0.4%)
VITREOUS HAEMORRHAGE	1 (0.4%)	0

Percentages are based on N in the column headings. Includes all diseases and conditions reported as part of ocular medical history at baseline.
 Clinical cut-off: 06JUL2022

Program: ../clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_mh.sas
 Output: ../GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_mh_SOMH_IT_06JUL2022_41984.xls
 12JUL2023 16:05

POPULATION: Intent-To-Treat Population
 ENDPOINT: --
 MODEL: descriptive
 STUDY: GR41984
 Prior Targeted Non-Ocular Medical History

Medical Condition	Faricimab (N=276)	Aflibercept (N=277)
Total number of patients with at least one condition	181 (65.6%)	190 (68.6%)
SYSTEMIC HYPERTENSION	150 (54.3%)	167 (60.3%)
TYPE 2 DIABETES	49 (17.8%)	46 (16.6%)
DIABETES MELLITUS UNCOMPLICATED	28 (10.1%)	20 (7.2%)
ATRIAL FIBRILATION	11 (4.0%)	17 (6.1%)
CORONARY ARTERY DISEASE	15 (5.4%)	10 (3.6%)
SOLID TUMOR	7 (2.5%)	11 (4.0%)
CEREBROVASCULAR ACCIDENTS (STROKE)	8 (2.9%)	6 (2.2%)
PERIPHERAL VASCULAR DISEASE	9 (3.3%)	5 (1.8%)
COPD	8 (2.9%)	5 (1.8%)
ANGINA	2 (0.7%)	9 (3.2%)
MYOCARDIAL INFARCTION	9 (3.3%)	2 (0.7%)
PEPTIC ULCER DISEASE	7 (2.5%)	4 (1.4%)
LIVER DISEASE MILD	6 (2.2%)	4 (1.4%)
RENAL FAILURE	7 (2.5%)	3 (1.1%)
DEEP VENOUS THROMBOSIS	3 (1.1%)	5 (1.8%)
CEREBROVASCULAR DISEASE	5 (1.8%)	2 (0.7%)
CONGESTIVE HEART FAILURE	6 (2.2%)	1 (0.4%)
TRANSIENT ISCHEMIC ATTACK	4 (1.4%)	1 (0.4%)
DIABETES MELLITUS END ORGAN DAMAGE	1 (0.4%)	3 (1.1%)
MODERATE TO SEVERE CKD	3 (1.1%)	1 (0.4%)
DEMENTIA	3 (1.1%)	0
LEUKAEMIA	2 (0.7%)	1 (0.4%)
SOLID TUMOR METASTATIC	3 (1.1%)	0
HEMIPLEGIA	1 (0.4%)	1 (0.4%)
AIDS	1 (0.4%)	0
CONNECTIVE TISSUE DISEASE	1 (0.4%)	0
LIVER DISEASE MODERATE TO SEVERE	1 (0.4%)	0
MALIGNANT LYMPHOMA	1 (0.4%)	0
TYPE 1 DIABETES	1 (0.4%)	0

Clinical cut-off: 06JUL2022

Program: ..nical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_mh_cat.sas
 Output: ..ata_analysis/ACE_CSR_Primary/prod/output/t_mh_cat_TARG_NOCUL_IT_06JUL2022_41984.xls
 12JUL2023 16:05

POPULATION: Intent-To-Treat Population

ENDPOINT: --

MODEL: descriptive

STUDY: GR41984

Prior Targeted Ocular Therapies/Treatment in the Study Eye

Therapy/Treatment Category Therapy/Treatment	Faricimab (N=276)	Aflibercept (N=277)
Total number of patients with at least one applicable therapy or treatment	8 (2.9%)	16 (5.8%)
Total number of applicable therapies or treatments	13	22
Any other prior ocular therapy		
Total number of patients with at least one applicable therapy or treatment	6 (2.2%)	14 (5.1%)
Total number of applicable therapies or treatments	11	19
OTHER	6 (2.2%)	13 (4.7%)
DIETARY SUPPLEMENT	0	1 (0.4%)
Other laser photocoagulation		
Total number of patients with at least one applicable therapy or treatment	2 (0.7%)	1 (0.4%)
Total number of applicable therapies or treatments	2	1
OTHER LASER PHOTOCOAGULATION	2 (0.7%)	1 (0.4%)
Panretinal photocoagulation (PRP) therapy		
Total number of patients with at least one applicable therapy or treatment	0	1 (0.4%)
Total number of applicable therapies or treatments	0	1
PANRETINAL PHOTOCOAGULATION LASER (PRP)	0	1 (0.4%)
Steroid therapy		
Total number of patients with at least one applicable therapy or treatment	0	1 (0.4%)
Total number of applicable therapies or treatments	0	1
TOPICAL STEROIDS	0	1 (0.4%)

PRP = Panretinal Photocoagulation.

Percentages are based on N in the column headings.

For frequency counts by therapy or treatment, multiple occurrences of the same therapy or treatment in an individual are counted only once.

For the total number of therapies or treatments, multiple occurrences of the same therapy or treatment in an individual are counted separately.

Clinical cut-off: 06JUL2022

Program: ../clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_cm.sas

Output: ../84/data_analysis/ACE_CSR_Primary/prod/output/t_cm_POTT_SOCUL_IT_06JUL2022_41984.xls

12JUL2023 16:06

POPULATION: Intent-To-Treat Population
 ENDPOINT: --
 MODEL: descriptive
 STUDY: G41584
 Concomitant Non-Ocular Medications by Medication Class and Preferred Name through Week 24

ATC Class Level 2 Other Treatment	Facitlimab (N=276)	Aflibercept (N=277)
Total number of patients with at least one treatment	237 (85.94)	238 (85.94)
Total number of treatments	1313	1494
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM		
Total number of patients with at least one treatment	111 (40.26)	119 (43.04)
Total number of treatments	128	135
AMLODIPINE BESILATE/AZILSARTAN	0	1 (0.48)
AMLODIPINE BESILATE/FIMASARTAN POTASSIUM TRIHYDRATE	1 (0.48)	0
AMLODIPINE BESILATE/INDAPAMIDE/PERINDOPRIL ARGININE	0	3 (1.14)
AMLODIPINE BESILATE/INDAPAMIDE/PERINDOPRIL ERBUMINE	0	1 (0.48)
AMLODIPINE BESILATE/LOSARTAN POTASSIUM	1 (0.48)	0
AMLODIPINE BESILATE/OLMESARTAN MEDOXOMIL	0	2 (0.78)
AMLODIPINE BESILATE/PERINDOPRIL ARGININE	1 (0.48)	3 (1.14)
AMLODIPINE BESILATE/RAMIPRIL	0	1 (0.48)
AMLODIPINE BESILATE/TELMISARTAN	2 (0.78)	2 (0.78)
AMLODIPINE BESILATE/VALSARTAN	2 (0.78)	1 (0.48)
AMLODIPINE/VALSARTAN	0	1 (0.48)
AZILSARTAN	0	1 (0.48)
BENAZEPRIL	1 (0.48)	0
CANDESARTAN	1 (0.48)	2 (0.78)
CANDESARTAN CILEXETIL	3 (1.14)	1 (0.48)
CAPTOPRIL	1 (0.48)	3 (1.14)
ENALAPRIL	8 (2.98)	9 (3.28)
ENALAPRIL MALEATE	1 (0.48)	3 (1.14)
ENALAPRIL MALEATE/HYDROCHLOROTHIAZIDE	3 (1.14)	0
ENALAPRILAT	1 (0.48)	1 (0.48)
FOLOSINAPRIL	1 (0.48)	0
HYDROCHLOROTHIAZIDE/IRBESARTAN	3 (1.14)	1 (0.48)
HYDROCHLOROTHIAZIDE/LISINAPRIL	1 (0.48)	3 (1.14)
HYDROCHLOROTHIAZIDE/LOSARTAN	1 (0.48)	1 (0.48)
HYDROCHLOROTHIAZIDE/LOSARTAN POTASSIUM	2 (0.78)	2 (0.78)
HYDROCHLOROTHIAZIDE/OLMESARTAN	0	1 (0.48)
HYDROCHLOROTHIAZIDE/TELMISARTAN	1 (0.48)	1 (0.48)
HYDROCHLOROTHIAZIDE/VALSARTAN	1 (0.48)	1 (0.48)
INDAPAMIDE/PERINDOPRIL ARGININE	1 (0.48)	0
INDAPAMIDE/PERINDOPRIL ERBUMINE	2 (0.78)	0
IRBESARTAN	5 (1.88)	4 (1.48)
LISINAPRIL	12 (4.38)	11 (4.08)
LOSARTAN	17 (6.28)	19 (6.98)
LOSARTAN POTASSIUM	4 (1.48)	9 (3.28)
OLMESARTAN	1 (0.48)	1 (0.48)
OLMESARTAN MEDOXOMIL	7 (2.58)	3 (1.14)
PERINDOPRIL	0	2 (0.78)
PERINDOPRIL ARGININE	0	2 (0.78)
PERINDOPRIL ERBUMINE	2 (0.78)	1 (0.48)
QUINAPRIL HYDROCHLORIDE	0	1 (0.48)
RAMIPRIL	9 (3.28)	10 (3.68)
SECURITRIL/VALSARTAN	0	1 (0.48)
TELMISARTAN	11 (4.08)	10 (3.68)
VALSARTAN	12 (4.38)	8 (2.98)
ZOFENOPRIL CALCIUM	1 (0.48)	0
ALL OTHER NON-THERAPEUTIC PRODUCTS		
Total number of patients with at least one treatment	12 (4.38)	12 (4.38)
Total number of treatments	14	16
ALL OTHER NON-THERAPEUTIC PRODUCTS		
ASCORBIC ACID	1 (0.48)	0
ASCORBIC ACID	9 (3.38)	8 (2.98)
METHYL	0	1 (0.48)
SODIUM CHLORIDE	2 (0.78)	3 (1.14)
ALL OTHER THERAPEUTIC PRODUCTS		
Total number of patients with at least one treatment	24 (8.78)	20 (7.28)
Total number of treatments	27	23
ACETYLCHOLINE	2 (0.78)	1 (0.48)
ALL OTHER THERAPEUTIC PRODUCTS		
ASCORBIC ACID	3 (1.14)	0
ASCORBIC ACID	9 (3.38)	8 (2.98)
CALCIUM ACETATE	1 (0.48)	0
CALCIUM CARBONATE	0	3 (1.14)
CALCIUM POLYSTYRENE SULFONATE	1 (0.48)	0
CALCIUM SULFATE DIHYDRATE	0	1 (0.48)
CHONDROITIN	0	1 (0.48)
CHONDROITIN SULFATE SODIUM	1 (0.48)	0
GLUCOPHYRINUM BROMIDE	1 (0.48)	0
HERBAL NOS/MINERALS NOS/VITAMINS NOS	1 (0.48)	0
IRON	1 (0.48)	3 (1.14)
LACTULOSE	1 (0.48)	0
MALONIC	1 (0.48)	1 (0.48)
OXICODONE	0	1 (0.48)
SEVELAMER	1 (0.48)	0
SEVELAMER CARBONATE	1 (0.48)	0
SIBOLIMUS	1 (0.48)	0
SUGAMMADEX SODIUM	0	1 (0.48)
VITAMIN B12 NOS	1 (0.48)	3 (1.14)
ANALGESICS		
Total number of patients with at least one treatment	85 (30.88)	90 (32.58)
Total number of treatments	132	156
ACETYLSALICYLATE IIBINE	1 (0.48)	0
ACETYLSALICYLIC ACID	41 (14.98)	39 (14.18)
ACETYLSALICYLIC ACID/GLYCINE	2 (0.78)	0
ACETYLSALICYLIC ACID/MAGNESIUM HYDROXIDE	1 (0.48)	1 (0.48)
AMANTADINE HYDROCHLORIDE/CAFFEINE/CHLORPHENAMINE MALEATE/COM BEZOAR/PARACETAMOL		
AMANTADINE HYDROCHLORIDE/CAFFEINE/CHLORPHENAMINE MALEATE/COM BEZOAR/PARACETAMOL	0	1 (0.48)
AMBIKOL HYDROCHLORIDE/CARBOCISTEINE/CHLORPHENAMINE MALEATE/DIHYDROCODEINE	1 (0.48)	0
PHOSPHATE/PARACETAMOL/RIBOFLAVIN	1 (0.48)	0
AMTRIPYPTLINE	2 (0.78)	0
AMTRIPYPTLINE HYDROCHLORIDE	1 (0.48)	0
ASCORBIC ACID/CHLORPHENAMINE MALEATE/PARACETAMOL	1 (0.48)	2 (0.78)
ASCORBIC ACID/PARACETAMOL/PHENIRAMINE MALEATE	1 (0.48)	0
ASCORBIC ACID/RUTOXIDE/SALICYLAMIDE	0	1 (0.48)

BUTALBITAL/CAFFEINE/PARACETAMOL	0	1 (0.4%)
CAFFEINE/COCAINE PHOSPHATE/PARACETAMOL	1 (0.4%)	1 (0.4%)
CAFFEINE/PARACETAMOL	0	1 (0.4%)
CALCIUM BROMIDE/CINCHOCANINE HYDROCHLORIDE/SALICYLATE SODIUM	0	1 (0.4%)
CANNABIDIOL	0	1 (0.4%)
CANNABIS SATIVA	1 (0.4%)	0
CLORIPRAMINE HYDROCHLORIDE	1 (0.4%)	0
CLORINDINE	1 (0.4%)	2 (0.7%)
CODEINE	1 (0.4%)	0
CODEINE PHOSPHATE	1 (0.4%)	0
CODEINE PHOSPHATE/PARACETAMOL	0	2 (0.7%)
CODEINE/PARACETAMOL	2 (0.7%)	0
DEKETOPROPEN TRICMETAMOL/TRAMADOL HYDROCHLORIDE	0	1 (0.4%)
DEKTROMETORPHAN HYDROBROMIDE/GUALFENESIN/PARACETAMOL/PHENYLEPHRINE HYDROCHLORIDE	1 (0.4%)	0
DEKTROMETORPHAN HYDROBROMIDE/PARACETAMOL/PEUKODOPIRINE HYDROCHLORIDE	0	1 (0.4%)
DIPHENHYDRAMINE HYDROCHLORIDE/PARACETAMOL	1 (0.4%)	0
DIPHENHYDRAMINE/PARACETAMOL	1 (0.4%)	0
DILOXATINE	4 (1.4%)	4 (1.4%)
DILOXATINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
BUCONIA ULMOIDES	1 (0.4%)	0
FENTANYL	0	1 (0.4%)
FLORAZETINE DIHYDROCHLORIDE	0	1 (0.4%)
GABAPENTIN	5 (1.8%)	3 (1.1%)
GUALFENESIN/PARACETAMOL/PHENYLEPHRINE HYDROCHLORIDE	2 (0.7%)	0
HYDROCODONE BITARTRATE/PARACETAMOL	1 (0.4%)	0
HYDROCODONE/PARACETAMOL	1 (0.4%)	1 (0.4%)
ISATIS TINCTORIA ROOT	0	1 (0.4%)
MENTHOL	0	1 (0.4%)
METAMIZOLE SODIUM	3 (1.1%)	3 (1.1%)
METOPROLOL	10 (3.6%)	8 (2.9%)
METOPROLOL SUCCINATE	3 (1.1%)	6 (2.2%)
METOPROLOL TARTRATE	3 (1.1%)	8 (2.9%)
OXYCODONE HYDROCHLORIDE	0	1 (0.4%)
PAMABSON/PARACETAMOL	0	1 (0.4%)
PARACETAMOL	18 (6.5%)	25 (9.0%)
PARACETAMOL/PHENIRAMINE MALEATE/PHENYLEPHRINE HYDROCHLORIDE	0	1 (0.4%)
PARACETAMOL/PHENYLEPHRINE HYDROCHLORIDE	0	1 (0.4%)
PARACETAMOL/TRAMADOL HYDROCHLORIDE	1 (0.4%)	2 (0.7%)
PETHIDINE	0	1 (0.4%)
PREDAALIN	3 (1.1%)	3 (1.1%)
SOPHORA FLAVESCENS	0	1 (0.4%)
SUMATRIPTAN	0	1 (0.4%)
TORIPRAMATE	1 (0.4%)	2 (0.7%)
TRAMADOL	3 (1.1%)	6 (2.2%)
TRAMADOL HYDROCHLORIDE	0	1 (0.4%)
UNCODED	0	1 (0.4%)
VALPROIC ACID	0	1 (0.4%)
VENLAFAXINE	0	2 (0.7%)
VENLAFAXINE HYDROCHLORIDE	0	2 (0.7%)
VERAPAMIL	2 (0.7%)	1 (0.4%)
VERAPAMIL HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
ANESTHETICS		
Total number of patients with at least one treatment	6 (2.2%)	4 (1.4%)
Total number of treatments	8	10
BUPIVACAINE	0	1 (0.4%)
EPINEPHRINE BITARTRATE/LIDOCAINE HYDROCHLORIDE	1 (0.4%)	0
EPINEPHRINE/LIDOCAINE	0	1 (0.4%)
FENTANYL	0	1 (0.4%)
GLISETH/LIDOCAINE	1 (0.4%)	0
LIDOCAINE	3 (1.1%)	3 (1.1%)
PROPOFOL	1 (0.4%)	1 (0.4%)
REMIFENTANYL	1 (0.4%)	1 (0.4%)
ROPIVACAINE HYDROCHLORIDE	1 (0.4%)	0
SEVOFLURANE	1 (0.4%)	1 (0.4%)
ANTHELMINTICS		
Total number of patients with at least one treatment	0	2 (0.7%)
Total number of treatments	0	2
CUCURBITA PEO SEED OIL	0	1 (0.4%)
SOPHORA FLAVESCENS	0	1 (0.4%)
ANTI-ACNE PREPARATIONS		
Total number of patients with at least one treatment	24 (8.7%)	18 (6.5%)
Total number of treatments	28	28
AZITROMYCIN	4 (1.4%)	2 (0.7%)
CHLORHEXIDINE GLUCONATE	0	1 (0.4%)
CLINDAMYCIN PHOSPHATE	0	1 (0.4%)
DAPSONE	1 (0.4%)	0
DEAMETHASONE	1 (0.4%)	1 (0.4%)
DEAMETHASONE SODIUM PHOSPHATE	0	3 (1.1%)
DIBENEST/ETHINYLESTRADIOL	1 (0.4%)	0
DIMETICONE	2 (0.7%)	0
ERYTHROMYCIN	1 (0.4%)	1 (0.4%)
IBUPROFEN	12 (4.3%)	10 (3.6%)
METHYLPHENIDOLONE	3 (1.1%)	2 (0.7%)
TRETINOIN	1 (0.4%)	0
ANTI-PARKINSON DRUGS		
Total number of patients with at least one treatment	7 (2.5%)	8 (2.9%)
Total number of treatments	8	11
BENSERAZIDE HYDROCHLORIDE/LEVODOPA	0	1 (0.4%)
BENZATROPINE MESILATE	0	1 (0.4%)
CAMBIDOPA/LEVODOPA	1 (0.4%)	1 (0.4%)
DIPHENHYDRAMINE	2 (0.7%)	0
DIPHENHYDRAMINE HYDROCHLORIDE	4 (1.4%)	4 (1.4%)
PRAMIFEXOLE	0	2 (0.7%)
PRAMIFEXOLE DIHYDROCHLORIDE MONOHYDRATE	0	1 (0.4%)
ROPINIROLE	0	1 (0.4%)
SELEGILINE HYDROCHLORIDE	1 (0.4%)	0
ANTI-ANEMIC PREPARATIONS		
Total number of patients with at least one treatment	16 (5.8%)	20 (7.2%)
Total number of treatments	21	23
ASCORBIC ACID/FERROUS SULFATE	1 (0.4%)	0
CYANOCOBALAMIN	5 (1.8%)	2 (0.7%)
DABEPROTIN ALFA	1 (0.4%)	0
FERROUS SODIUM CITRATE	0	1 (0.4%)
FERROUS SULFATE	0	3 (1.1%)
FOLIC ACID	4 (1.4%)	7 (2.5%)
IRON	1 (0.4%)	3 (1.1%)

IRON PREPARATIONS	1 (0.4%)	0
MICOBALAMIN	1 (0.4%)	1 (0.4%)
MINERALS NOS /VITAMINS NOS	2 (0.7%)	1 (0.4%)
VITAMIN B NOS	1 (0.4%)	2 (0.7%)
VITAMIN B12 NOS	1 (0.4%)	3 (1.1%)
ANTIBACTERIALS FOR SYSTEMIC USE		
Total number of patients with at least one treatment	18 (6.5%)	28 (10.1%)
Total number of treatments	22	38
AMOXICILLIN	2 (0.7%)	0
AMOXICILLIN TRIHYDRATE/CLAVULANATE POTASSIUM	3 (1.1%)	2 (0.7%)
AMOXICILLIN/CLAVULANATE POTASSIUM	2 (0.7%)	1 (0.4%)
AMOXICILLIN/CLAVULANIC ACID	0	1 (0.4%)
AZITHROMYCIN	4 (1.4%)	2 (0.7%)
BACAMPICILLIN HYDROCHLORIDE	0	1 (0.4%)
CEFALOXIN SODIUM	1 (0.4%)	1 (0.4%)
CEFDINIR	0	1 (0.4%)
CEFDITOREN PIVOXIL	1 (0.4%)	0
CEFTAZOLIME SODIUM	1 (0.4%)	0
CEFOXITIN SODIUM	1 (0.4%)	0
CEFTURAM PIVOXIL	0	1 (0.4%)
CEFUROXIME AXETIL	1 (0.4%)	0
CIFROFLOXACIN	0	2 (0.7%)
CLARITHROMYCIN	1 (0.4%)	0
CLINDAMYCIN PHOSPHATE	0	1 (0.4%)
ERYTHROMYCIN	1 (0.4%)	1 (0.4%)
ISATIS TINCTORIA ROOT	0	1 (0.4%)
LEVOFLOXACIN	1 (0.4%)	1 (0.4%)
LEVOPLOXACIN LACTATE	0	1 (0.4%)
LINEX USITATISSIMUM SEED	0	2 (0.7%)
MEROPENEM	1 (0.4%)	0
MEROPENEM TRIHYDRATE	1 (0.4%)	0
METHAMINE HIPPIRATE	0	1 (0.4%)
METRONIDAZOLE	0	3 (1.1%)
METRONIDAZOLE/SPIRAMYCIN	0	1 (0.4%)
MOXIFLOXACIN HYDROCHLORIDE	0	1 (0.4%)
NETILMICIN SULFATE	0	1 (0.4%)
NITROURANTOIN	0	1 (0.4%)
PURBONITRIMETHYLPENICILLIN POTASSIUM	0	1 (0.4%)
PIPERACILLIN SODIUM/TAZOBACTAM SODIUM	0	1 (0.4%)
SOPHORA FLAVESCENS	0	1 (0.4%)
SULFAMETHOXAZOLE/TRIMETHOPRIM	0	3 (1.1%)
VACCINIUM MACROCARPON	0	1 (0.4%)
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE		
Total number of patients with at least one treatment	4 (1.4%)	8 (2.9%)
Total number of treatments	4	8
ACICLOVIR	1 (0.4%)	0
CIFROFLOXACIN	0	2 (0.7%)
CLARITHROMYCIN	1 (0.4%)	0
ERYTHROMYCIN	1 (0.4%)	1 (0.4%)
METRONIDAZOLE	0	3 (1.1%)
MUPIROCIN	1 (0.4%)	2 (0.7%)
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS		
Total number of patients with at least one treatment	17 (6.2%)	15 (5.4%)
Total number of treatments	23	19
ARSULINUS HIPPOCASTANUM	1 (0.4%)	0
ATROPINE/DIPHENOXYLATE	1 (0.4%)	0
BACILLUS LICHENIFORMIS	0	1 (0.4%)
BETAMETHASONE	1 (0.4%)	1 (0.4%)
BETAMETHASONE DIPHOSPHATE	1 (0.4%)	0
BETAMETHASONE VALERATE	1 (0.4%)	0
BIFIDOBACTERIUM BIFIDUM/BIFIDOBACTERIUM LONGUM/LACTOBACILLUS GASSERI	0	1 (0.4%)
BIFIDOBACTERIUM INFANTIS	1 (0.4%)	1 (0.4%)
BIFIDOBACTERIUM LONGUM/BIFIDOBACTERIUM PARCALIS/LACTOBACILLUS ACIDOPHILUS	0	1 (0.4%)
BIFIDOBACTERIUM NOS	1 (0.4%)	0
BISMUTH SUBSALICYLATE	1 (0.4%)	0
BUSECONIDE	0	1 (0.4%)
CODEINE	1 (0.4%)	0
CHOLICICLATE SODIUM	1 (0.4%)	0
ELECTROLYTES NOS/GLUCOSE	1 (0.4%)	0
GLUCOSE/POTASSIUM CHLORIDE/SODIUM CHLORIDE	0	1 (0.4%)
GLUCOSE/POTASSIUM CHLORIDE/SODIUM CHLORIDE/SODIUM CITRATE	1 (0.4%)	0
LACTOBACILLUS ACIDOPHILUS	0	1 (0.4%)
LOPERAMIDE HYDROCHLORIDE	0	1 (0.4%)
MENTHOL	0	1 (0.4%)
MONTMORILLONITE	1 (0.4%)	0
NIFUROXAZIDE	1 (0.4%)	0
ORAL REHYDRATION SALT FORMULATIONS	1 (0.4%)	0
PRINISOLONE	1 (0.4%)	1 (0.4%)
PRENISOONE	2 (0.7%)	2 (0.7%)
PROBIOTICS NOS	2 (0.7%)	2 (0.7%)
SACCHAROMYCES BOULARDII	2 (0.7%)	0
SOPHORA FLAVESCENS	0	1 (0.4%)
SUBSALICYLATE	0	1 (0.4%)
VACCINIUM MYRTILLIS	1 (0.4%)	0
ANTIEMETICS AND ANTINAUSEANTS		
Total number of patients with at least one treatment	15 (5.4%)	13 (4.7%)
Total number of treatments	15	18
CANBASSIS SATIVA	1 (0.4%)	0
CYANOCOBALAMIN/PYRIDOXINE HYDROCHLORIDE/THIAMINE HYDROCHLORIDE	3 (1.1%)	0
DIMENHYDRINATE	0	1 (0.4%)
DIPHENHYDRAMINE	2 (0.7%)	0
DIPHENHYDRAMINE HYDROCHLORIDE	4 (1.4%)	4 (1.4%)
DROPERIDOL	0	1 (0.4%)
HYDROXYZINE	3 (1.1%)	0
HYDROXYZINE HYDROCHLORIDE	0	2 (0.7%)
MECLOZINE	1 (0.4%)	0
METOCLOPRAMIDE	0	1 (0.4%)
METOCLOPRAMIDE HYDROCHLORIDE	2 (0.7%)	3 (1.1%)
ONDANSETRON	0	1 (0.4%)
ONDANSETRON HYDROCHLORIDE DIHYDRATE	0	1 (0.4%)
PROCHLOPERAZINE	0	1 (0.4%)
PROMETHAZINE	0	1 (0.4%)
ANTI-EPILEPTICS		
Total number of patients with at least one treatment	16 (5.8%)	23 (8.3%)
Total number of treatments	19	29
ACETAZOLAMIDE	1 (0.4%)	2 (0.7%)

BENZODIAZEPINE DERIVATIVES	0	1 (0.4%)
CANNABIDIOL	0	1 (0.4%)
CANNABIS SATIVA	1 (0.4%)	0
CLONAZEPAM	1 (0.4%)	5 (1.8%)
DIAZEPAM	2 (0.7%)	4 (1.4%)
GABAPENTIN	5 (1.8%)	3 (1.1%)
LAMOTRIGINE	0	2 (0.7%)
LEVETIRACETAM	1 (0.4%)	0
LOXAZEPAM	2 (0.7%)	1 (0.4%)
MIDAZOLAM	0	1 (0.4%)
PHENOBARBITAL	0	1 (0.4%)
PHENYTOIN	1 (0.4%)	0
PRIDIPRALIN	3 (1.1%)	3 (1.1%)
TOPIRAMATE	1 (0.4%)	2 (0.7%)
VALPROIC ACID	0	1 (0.4%)
ANTIFUNGALS FOR DERMATOLOGICAL USE		
Total number of patients with at least one treatment	2 (0.7%)	7 (2.5%)
Total number of treatments	3	8
NETAMETERGONOL DIPHOSPHONATE/CLOTRIMAZOLE	1 (0.4%)	0
CLOTRIMAZOLE	1 (0.4%)	0
PENTICONAZOLE NITRATE	0	1 (0.4%)
FLUCONAZOLE	0	1 (0.4%)
HYDROXYFLUORISONE/IMICONAZOLE NITRATE	0	1 (0.4%)
MYCOSTAZOLE	0	2 (0.7%)
SELENIUM SULFIDE	0	1 (0.4%)
TERBINAFINE HYDROCHLORIDE	0	1 (0.4%)
ANTIGOUT PREPARATIONS		
Total number of patients with at least one treatment	16 (5.8%)	13 (4.7%)
Total number of treatments	18	15
ALLOPURINOL	11 (4.0%)	10 (3.6%)
COLCHICINE	3 (1.1%)	1 (0.4%)
DOCOSEXARIC ACID/EICOSAPENTAENOIC ACID	3 (1.1%)	1 (0.4%)
FERROSTAT	1 (0.4%)	3 (1.1%)
ANTIHEMORRHAGICS		
Total number of patients with at least one treatment	6 (2.2%)	9 (3.2%)
Total number of treatments	6	9
ACHILTON RUSNEZOVII ROOT/HERBAL MEX	1 (0.4%)	0
CHLAMY	2 (0.7%)	1 (0.4%)
DESMOPRESSIN	0	1 (0.4%)
EPINEPHRINE	1 (0.4%)	1 (0.4%)
EUCOMIA ULMOIDES	1 (0.4%)	0
SOPIWA FLAVESCENS	0	1 (0.4%)
TRANSAMIC ACID	1 (0.4%)	2 (0.7%)
UNOVED	0	3 (1.1%)
ANTIHISTAMINES FOR SYSTEMIC USE		
Total number of patients with at least one treatment	25 (9.1%)	23 (8.3%)
Total number of treatments	26	28
AZELASTINE	0	2 (0.7%)
AZELASTINE HYDROCHLORIDE	0	1 (0.4%)
BILASTINE	1 (0.4%)	0
CETIRIZINE	1 (0.4%)	2 (0.7%)
CETIRIZINE HYDROCHLORIDE	5 (1.8%)	2 (0.7%)
CHLORPHENIRAMINE MALEATE	0	2 (0.7%)
DIMENHYDRINATE	0	1 (0.4%)
DIPHENHYDRAMINE	2 (0.7%)	0
DIPHENHYDRAMINE HYDROCHLORIDE	4 (1.4%)	4 (1.4%)
EMASTINE	0	1 (0.4%)
EPINASTINE HYDROCHLORIDE	0	1 (0.4%)
FEKOFENADINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
FEKOFENADINE HYDROCHLORIDE/PSEUDOEPHEDRINE HYDROCHLORIDE	0	1 (0.4%)
HYDROXYZINE	3 (1.1%)	0
HYDROXYZINE HYDROCHLORIDE	0	2 (0.7%)
LEVOCETIRIZINE DIIHYDROCHLORIDE	1 (0.4%)	2 (0.7%)
LORATADINE	6 (2.2%)	5 (1.8%)
MECLOZINE	1 (0.4%)	0
OLOPATADINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
PROMETHAZINE	0	1 (0.4%)
ANTIHYPERTENSIVES		
Total number of patients with at least one treatment	14 (5.1%)	11 (4.0%)
Total number of treatments	17	17
CALCIUM PAROTOMENATE/DIHYDROLAZINE SULFATE/HYDROCHLOROTHIAZIDE/MAGNESIUM		
TRISILLICATE/POTASSIUM CHLORIDE/PROMETHAZINE HYDROCHLORIDE/PYRIDOXINE		
HYDROCHLORIDE/RESERPINE/THIAMINE HYDROCHLORIDE	1 (0.4%)	0
CLONIDINE	1 (0.4%)	2 (0.7%)
DILTIZEMALINE SULFATE/HYDROCHLOROTHIAZIDE/RESERPINE/TRIAMTERENE	0	1 (0.4%)
DOLAZOLIN	3 (1.1%)	3 (1.1%)
DOMAZOSIN MESILATE	2 (0.7%)	1 (0.4%)
EUCOMIA ULMOIDES	1 (0.4%)	0
HYDRALAZINE	0	3 (1.1%)
MIBOXIDIL	0	1 (0.4%)
MONOXIDINE	0	1 (0.4%)
RILMENIDINE	1 (0.4%)	1 (0.4%)
RILMENIDINE PHOSPHATE	3 (1.1%)	0
SILDENAFIL	1 (0.4%)	0
TALALAFIL	2 (0.7%)	1 (0.4%)
URAPIDIL	1 (0.4%)	2 (0.7%)
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS		
Total number of patients with at least one treatment	33 (12.0%)	44 (15.9%)
Total number of treatments	46	65
ACETOPHENAC	2 (0.7%)	0
ANHELICA SINENSIS ROOT/BORNOL/BORHELLIA SACRA BARK RESIN/EUPOLYPHAGA SINENSIS/PANAX		
NOTOGINSENG ROOT WITH RHIZOME/PYRITE	0	1 (0.4%)
BORHELLIA SERRATA/CURCUMA LONGA/DL-PHENYLANILINE/NATTOKINASE	0	1 (0.4%)
CHEBULOH	3 (1.1%)	4 (1.4%)
CHETELIA ASTATICA HERB	0	1 (0.4%)
CHEMNOITIN	0	1 (0.4%)
CHEMNOITIN SULFATE SODIUM	1 (0.4%)	0
CHEMNOITIN SULFATE/GLUCOSAMINE HYDROCHLORIDE	1 (0.4%)	0
COLLAGEN	2 (0.7%)	1 (0.4%)
CURCUMA LONGA	3 (1.1%)	3 (1.1%)
CURCUMIN	1 (0.4%)	0
CYANOCOBALAMIN/DICLOFENAC SODIUM/PYRIDOXINE HYDROCHLORIDE/THIAMINE HYDROCHLORIDE	0	1 (0.4%)
DICLOFENAC	3 (1.1%)	4 (1.4%)
DICLOFENAC SODIUM	0	2 (0.7%)
DICLOFENAC SODIUM/OMEPRAZOLE	1 (0.4%)	0
ETOFENAMATE	0	1 (0.4%)

ETORICOXIB	1 (0.4%)	2 (0.7%)
FAMOTIDINE/IBUPROFEN	0	1 (0.4%)
FLURBIPROFEN AXETIL	1 (0.4%)	1 (0.4%)
GELATIN HYDROLYSATE	1 (0.4%)	0
GLYCOSAMINE	4 (1.4%)	2 (0.7%)
GLUCINE MAX/PERSEA AMERICANA EXTRACT	0	1 (0.4%)
GLYCYRRHIZA SPP. ROOT/PARONIA LACTIFLORA ROOT	1 (0.4%)	0
IBUPROFEN	12 (4.3%)	10 (3.6%)
IBUPROFEN ANGININE	1 (0.4%)	0
IMBEXIN	0	1 (0.4%)
KETOPROFEN	1 (0.4%)	2 (0.7%)
KETOROLAC	0	1 (0.4%)
LOXAPROFEN SODIUM	1 (0.4%)	5 (1.8%)
MELNIXAM	2 (0.7%)	5 (1.8%)
METHYLSULFONYLMETHANE	0	1 (0.4%)
NAFROKEN	1 (0.4%)	3 (1.1%)
NAFROKEN SODIUM	1 (0.4%)	1 (0.4%)
NIMESULIDE	1 (0.4%)	0
PEYVERIA ALLIACEA	0	1 (0.4%)
SILOMINE HYDROCHLORIDE	0	1 (0.4%)
SULFASALAZINE	0	1 (0.4%)
UNDOED	0	3 (1.1%)
VACCINIUM MACROCARPON	0	1 (0.4%)
ANTIMICROBIALS		
Total number of patients with at least one treatment	1 (0.4%)	0
Total number of treatments	1	0
DAPSONE	1 (0.4%)	0
ANTIMYCOTICS FOR SYSTEMIC USE		
Total number of patients with at least one treatment	1 (0.4%)	4 (1.4%)
Total number of treatments	1	5
DAPSONE	1 (0.4%)	0
FLUCONAZOLE	0	1 (0.4%)
KETONAZOLE	0	2 (0.7%)
SOPHORA FLAVESCENS	0	1 (0.4%)
ANTINEOPLASTIC AGENTS		
Total number of patients with at least one treatment	7 (2.5%)	7 (2.5%)
Total number of treatments	8	14
CHEKOCIN	3 (1.1%)	4 (1.4%)
FLUOROURACIL	0	1 (0.4%)
IRINOTECAN	0	1 (0.4%)
ISATIS TINCTORIA ROOT	0	1 (0.4%)
METHOTREXATE	2 (0.7%)	1 (0.4%)
ORAL ELATIN	0	1 (0.4%)
STROLMOS	1 (0.4%)	0
TRETININ	1 (0.4%)	0
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS		
Total number of patients with at least one treatment	4 (1.4%)	4 (1.4%)
Total number of treatments	4	4
AMFETAMINE/DEXAMFETAMINE	0	1 (0.4%)
BUPROPION HYDROCHLORIDE/NALTREXONE HYDROCHLORIDE	0	1 (0.4%)
COLLAGEN	2 (0.7%)	1 (0.4%)
LIRAGLUTIDE	1 (0.4%)	1 (0.4%)
SPIRULLINA SPP.	1 (0.4%)	0
ANTIPROTOZOALS		
Total number of patients with at least one treatment	1 (0.4%)	4 (1.4%)
Total number of treatments	2	5
CLOTIMAZOLE	1 (0.4%)	0
HYDROXYCHLOROQUINE	0	2 (0.7%)
METRONIDAZOLE	0	3 (1.1%)
ANTIPURITICS, INCL. ANTIRHISMATICS, ANESTHETICS, ETC.		
Total number of patients with at least one treatment	24 (8.7%)	23 (8.3%)
Total number of treatments	26	30
CALAMINE/GLYCEROL/ZINC OXIDE	0	1 (0.4%)
CETIRIZINE	1 (0.4%)	2 (0.7%)
CETIRIZINE HYDROCHLORIDE	5 (1.8%)	2 (0.7%)
CHLORPHENIRAMINE MALATE	0	2 (0.7%)
DIPHENHYDRAMINE	2 (0.7%)	0
DIPHENHYDRAMINE HYDROCHLORIDE	4 (1.4%)	4 (1.4%)
DOXEPIN	0	1 (0.4%)
EMALTINE	0	1 (0.4%)
HYDROXYZINE	3 (1.1%)	0
HYDROXYZINE HYDROCHLORIDE	0	2 (0.7%)
LEVOCETIRIZINE DIHYDROCHLORIDE	1 (0.4%)	2 (0.7%)
LIDOCAINE	3 (1.1%)	3 (1.1%)
LEVATADINE	6 (2.2%)	5 (1.8%)
METHUS	0	1 (0.4%)
OLOPATADINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
PROMETHAZINE	0	1 (0.4%)
SOPHORA FLAVESCENS	0	1 (0.4%)
ANTIPROSTATIC		
Total number of patients with at least one treatment	3 (1.1%)	1 (0.4%)
Total number of treatments	3	1
BETAMETHASONE BUTYRATE PROPIONATE/MAXACALCITROL	1 (0.4%)	0
CALCIPTROL	1 (0.4%)	1 (0.4%)
CALCIYTRIGL	1 (0.4%)	0
ANTISEPTICS AND DISINFECTANTS		
Total number of patients with at least one treatment	2 (0.7%)	1 (0.4%)
Total number of treatments	2	1
CHLORHEXIDINE GLUCONATE	0	1 (0.4%)
POVIDONE-IODINE	1 (0.4%)	0
VACCINIUM MYRTILLIS	1 (0.4%)	0
ANTITHROMBOTIC AGENTS		
Total number of patients with at least one treatment	70 (25.4%)	65 (23.5%)
Total number of treatments	80	82
ACENOCUMAROL	2 (0.7%)	3 (1.1%)
ACETYLSALICYLATE LYDINE	1 (0.4%)	0
ACETYLSALICYLIC ACID	41 (14.9%)	39 (14.1%)
ACETYLSALICYLIC ACID/GLYCINE	2 (0.7%)	0
ACETYLSALICYLIC ACID/MAGNESIUM HYDROXIDE	1 (0.4%)	1 (0.4%)
ALPROSTATIL	1 (0.4%)	0
APIXABAN	3 (1.1%)	9 (3.2%)
BEKAPROST SODIUM	1 (0.4%)	0
CILOSTAZOL	1 (0.4%)	1 (0.4%)

CLOPIDOGREL	7 (2.5%)	4 (1.4%)
CLOPIDOGREL BISULFATE	3 (1.1%)	2 (0.7%)
DABIGATRAN ETEXILATE MESYLATE	1 (0.4%)	0
ENOXAPARIN	1 (0.4%)	0
ENOXAPARIN SODIUM	0	1 (0.4%)
FONDAPARINUX SODIUM	1 (0.4%)	0
HEPARIN	1 (0.4%)	3 (1.1%)
RIVAROXANAN	7 (2.5%)	5 (1.8%)
SARICORHELATE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
STREPTODORNASE /STREPTOKINASE	0	1 (0.4%)
SULOXIDINE	1 (0.4%)	4 (1.4%)
TEHCETEPLASE	0	1 (0.4%)
TIROFIBAN	0	1 (0.4%)
WARFARIN	2 (0.7%)	1 (0.4%)
WARFARIN SODIUM	4 (1.4%)	1 (0.4%)
ANTIVIRALS FOR SYSTEMIC USE		
Total number of patients with at least one treatment	6 (2.2%)	4 (1.4%)
Total number of treatments	6	6
ACICLOVIR	1 (0.4%)	0
DOLUTEGRAVIR	1 (0.4%)	0
EMTRICITABINE	0	1 (0.4%)
ENTECAVIR	1 (0.4%)	0
INSIDINE FRANCOBEX	1 (0.4%)	0
MOLNUPREVIR	0	1 (0.4%)
NEVIRAPINE	0	1 (0.4%)
TELEFOVIR	0	1 (0.4%)
TELEFOVIR ALAFENAMIDE FUMARATE	0	1 (0.4%)
UMIFENOVIR	1 (0.4%)	0
VALACICLOVIR	1 (0.4%)	0
VALACICLOVIR HYDROCHLORIDE	0	1 (0.4%)
APPETITE STIMULANTS		
Total number of patients with at least one treatment	1 (0.4%)	1 (0.4%)
Total number of treatments	1	1
CARNISIN ANTYA	1 (0.4%)	0
CARNITINE HYDROCHLORIDE/CYANOCOBALAMIN/CYPROHEPTADINE OKOTATE/LYSINE HYDROCHLORIDE	0	1 (0.4%)
BETA BLOCKING AGENTS		
Total number of patients with at least one treatment	53 (19.2%)	52 (18.8%)
Total number of treatments	54	57
ACETIMOLOL HYDROCHLORIDE	1 (0.4%)	0
ATENOLOL	6 (2.2%)	3 (1.1%)
BETANOLOL HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
BISOPROLOL	4 (1.4%)	6 (2.2%)
BISOPROLOL FUMARATE	11 (4.0%)	8 (2.9%)
CARVEDILOL	9 (3.3%)	8 (2.9%)
HYDROCHLOROTHIAZIDE/METOPROLOL	0	1 (0.4%)
LABETALOL HYDROCHLORIDE	0	1 (0.4%)
METOPROLOL	10 (3.6%)	8 (2.9%)
METOPROLOL SUCCINATE	3 (1.1%)	6 (2.2%)
METOPROLOL TARTRATE	3 (1.1%)	8 (2.9%)
NEBIVOLOL	1 (0.4%)	1 (0.4%)
NEBIVOLOL HYDROCHLORIDE	4 (1.4%)	2 (0.7%)
SOVALG	1 (0.4%)	0
BILE AND LIVER THERAPY		
Total number of patients with at least one treatment	10 (3.6%)	6 (2.2%)
Total number of treatments	11	7
ACTYLTYROSINE	2 (0.7%)	1 (0.4%)
ACHILLEA MILLEFOLIUM/AYURVEDIC PREPARATION NOS/CAPPARIS SPINOSA/CICHORIUM INTYBUS/SENNA OCCIDENTALIS/SOLANUM NIGRUM/TAMARIX GALICA/TERMINALIA ARBUTA	1 (0.4%)	0
ARGININE	1 (0.4%)	0
ASCORBIC ACID/BETA VULGARIS ROOT/LIPASE/PEPTIDASE/PHOSPHOLIPIDS SOYBEAN/SILYBUM MARIANUM SEED/TARAXACUM OFFICINALE ROOT/TAURINE/ZINGIBER OFFICINALE ROOT	1 (0.4%)	0
CHENODEOXYCHOLIC ACID/URSODEOXYCHOLIC ACID	0	1 (0.4%)
CINCHONA LIGNA	3 (1.1%)	2 (0.7%)
EUCOMMIA ULMOIDES	1 (0.4%)	0
GLUCYRRHIZA GLABRA	0	1 (0.4%)
LIVER THERAPY	1 (0.4%)	0
ROSMARINUS OFFICINALIS	1 (0.4%)	0
SONCHUS OLERACEUS	0	1 (0.4%)
URSODEOXYCHOLIC ACID	0	1 (0.4%)
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS		
Total number of patients with at least one treatment	29 (10.5%)	24 (8.7%)
Total number of treatments	31	26
ARGININE	1 (0.4%)	0
ASCORBIC ACID/BIOTIN/CALCIUM PANTOTHENATE/CYANOCOBALAMIN/FOLIC ACID/NICOTINAMIDE/PYRIDOXINE HYDROCHLORIDE/RIBOFLAVIN/THIAMINE HYDROCHLORIDE	1 (0.4%)	0
CALCIUM CHLORIDE	0	1 (0.4%)
CALCIUM CHLORIDE DIHYDRATE/MAGNESIUM CHLORIDE HEXAHYDRATE/POTASSIUM CHLORIDE/SODIUM BICARBONATE/SODIUM CHLORIDE/SODIUM CITRATE DIHYDRATE	0	1 (0.4%)
CALCIUM CHLORIDE DIHYDRATE/POTASSIUM CHLORIDE/SODIUM CHLORIDE/SODIUM LACTATE	0	2 (0.7%)
CALCIUM CHLORIDE/MAGNESIUM CHLORIDE/POTASSIUM CHLORIDE/SODIUM ACETATE/SODIUM CHLORIDE	1 (0.4%)	0
CALCIUM GLUCONATE MONOHYDRATE/GLUCOSE/MAGNESIUM CHLORIDE HEXAHYDRATE/POTASSIUM CHLORIDE/SODIUM ACETATE/SODIUM CHLORIDE/SODIUM CITRATE DIHYDRATE	0	1 (0.4%)
CARBONYLATES NOS/POTASSIUM CHLORIDE/SODIUM CHLORIDE/SODIUM LACTATE	0	1 (0.4%)
CHLORHEXIDINE GLUCONATE	0	1 (0.4%)
ELECTROLYTES NOS/GLUCOSE	1 (0.4%)	0
GLUCOSE	0	2 (0.7%)
GLUCOSE/POTASSIUM CHLORIDE/SODIUM CHLORIDE	0	1 (0.4%)
GLUCOSE/POTASSIUM CHLORIDE/SODIUM CHLORIDE/SODIUM CITRATE	1 (0.4%)	0
HISTIDINE/ISOLEUCINE/LEUCINE/LYSINE ACETATE/METHIONINE/PHENYLALANINE/THREONINE/TRYPTOPHAN, L-VALINE	1 (0.4%)	0
LYSINE	0	1 (0.4%)
MINERALS NOS/VITAMINS NOS	2 (0.7%)	1 (0.4%)
OMEGA-3 FATTY ACIDS	2 (0.7%)	0
POTASSIUM	1 (0.4%)	3 (1.1%)
POTASSIUM CHLORIDE	7 (2.5%)	3 (1.1%)
SERENIM	2 (0.7%)	0
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)
VITAMINS NOS	12 (4.3%)	11 (4.0%)
ZINC	1 (0.4%)	1 (0.4%)
CALCIUM CHANNEL BLOCKERS		
Total number of patients with at least one treatment	63 (22.8%)	58 (20.9%)
Total number of treatments	69	66
AMLODIPINE	20 (7.2%)	26 (9.4%)
AMLODIPINE BESILATE	20 (7.2%)	6 (2.2%)

BENIDIPINE HYDROCHLORIDE	1 (0.4%)	0
DILTIAZEM	1 (0.4%)	5 (1.8%)
DILTIAZEM HYDROCHLORIDE	0	1 (0.4%)
FRISODIPINE	1 (0.4%)	1 (0.4%)
LACIDIPINE	1 (0.4%)	0
LERCANIDIPINE	4 (1.4%)	3 (1.1%)
LERCANIDIPINE HYDROCHLORIDE	5 (1.8%)	5 (1.8%)
LEVAMIZOLE BESILATE	2 (0.7%)	4 (1.4%)
LEVAMIZOLE MESILATE	1 (0.4%)	1 (0.4%)
NIFEDIPINE	7 (2.5%)	5 (1.8%)
NIMODIPINE	0	1 (0.4%)
NITRENDIPINE	0	1 (0.4%)
VERAPAMIL	2 (0.7%)	1 (0.4%)
VERAPAMIL HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
CALCIUM HOMEOSTASIS		
Total number of patients with at least one treatment	0	1 (0.4%)
Total number of treatments	0	1
CALCIFEDIOL	0	1 (0.4%)
CARDIAC THERAPY		
Total number of patients with at least one treatment	31 (11.2%)	34 (12.3%)
Total number of treatments	36	45
ALPROSTADIL	1 (0.4%)	0
AMIODARONE	0	2 (0.7%)
AMIODARONE HYDROCHLORIDE	1 (0.4%)	0
ATROPINE SULFATE	0	1 (0.4%)
BORNICOL/PANAX NOTOGINSENG ROOT WITH RHIZOME/SALVIA MILTIORRHIZA ROOT WITH RHIZOME	1 (0.4%)	1 (0.4%)
DIOSQUIN	1 (0.4%)	1 (0.4%)
EMPAFLIDIZIN	0	2 (0.7%)
EPINEPHRINE HYDROCHLORIDE	0	1 (0.4%)
EPINEPHRINE	1 (0.4%)	1 (0.4%)
FLACANIDIN	0	2 (0.7%)
GLUCOSE/LIDOCAINE	1 (0.4%)	0
GLUCERYL TRINITRATE	3 (1.1%)	5 (1.8%)
IBUPROFEN	12 (4.3%)	10 (3.6%)
IBUPROFEN ARGININE	1 (0.4%)	0
IPRAVOPROFEN	1 (0.4%)	0
ISOSORBIDE MONONITRATE	1 (0.4%)	4 (1.4%)
LIDOCAINE	3 (1.1%)	3 (1.1%)
MAGNESIUM ASPARTATE/POTASSIUM ASPARTATE	0	1 (0.4%)
MIDODRINE HYDROCHLORIDE	0	1 (0.4%)
NICERGOLINE	1 (0.4%)	1 (0.4%)
NICORANDIL	0	1 (0.4%)
PHENYLEPHRINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
SOPHORA FLAVESCENS	0	1 (0.4%)
TRIMETAZIDINE	0	1 (0.4%)
TRIMETAZIDINE HYDROCHLORIDE	1 (0.4%)	0
TRILICANDRONE	4 (1.4%)	3 (1.1%)
UNCODED	1 (0.4%)	0
CONTRAST MEDIA		
Total number of patients with at least one treatment	0	2 (0.7%)
Total number of treatments	0	2
IODIZANOL	0	1 (0.4%)
IOHEXOL	0	1 (0.4%)
CORTICOSTEROIDS FOR SYSTEMIC USE		
Total number of patients with at least one treatment	10 (3.6%)	10 (3.6%)
Total number of treatments	13	18
BETAMETHASONE	1 (0.4%)	1 (0.4%)
BETAMETHASONE DIPHOSPHONATE	1 (0.4%)	0
BETAMETHASONE VALERATE	1 (0.4%)	0
CORTISONE	1 (0.4%)	0
DEXAMETHASONE	1 (0.4%)	1 (0.4%)
DEXAMETHASONE SODIUM PHOSPHATE	0	3 (1.1%)
KETOCONAZOLE	0	2 (0.7%)
METHYLPREDNISOLONE	3 (1.1%)	2 (0.7%)
PRENIDISOLONE	1 (0.4%)	0
PREDNISONE	2 (0.7%)	2 (0.7%)
TRIAMCINOLONE ACETONIDE	2 (0.7%)	0
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS		
Total number of patients with at least one treatment	19 (6.9%)	15 (5.4%)
Total number of treatments	27	23
BETAMETHASONE	1 (0.4%)	1 (0.4%)
BETAMETHASONE DIPHOSPHONATE	1 (0.4%)	0
BETAMETHASONE SODIUM PHOSPHATE/NEOMYCIN SULFATE	1 (0.4%)	0
BETAMETHASONE VALERATE	1 (0.4%)	0
BENDESONIDE	0	1 (0.4%)
CLOBETASOL	0	1 (0.4%)
CLOBETASOL PROPIONATE	1 (0.4%)	0
DESONIDE	0	1 (0.4%)
DEXAMETHASONE	1 (0.4%)	1 (0.4%)
DEXAMETHASONE SODIUM PHOSPHATE	0	3 (1.1%)
DIFLORASONE DIACETATE	1 (0.4%)	0
DIFLUOCORTOLONE VALERATE	1 (0.4%)	0
FLUFICASON	4 (1.4%)	3 (1.1%)
FLUFICASON PROPIONATE	5 (1.8%)	0
METHYLPREDNISOLONE	3 (1.1%)	2 (0.7%)
METHYLPREDNISOLONE ACEPONATE	0	1 (0.4%)
MEMETASONE PROATE	1 (0.4%)	1 (0.4%)
PRENIDISOLONE	1 (0.4%)	0
PREDNISONE	2 (0.7%)	2 (0.7%)
TRIAMCINOLONE ACETONIDE	2 (0.7%)	0
COUGH AND COLD PREPARATIONS		
Total number of patients with at least one treatment	15 (5.4%)	14 (5.1%)
Total number of treatments	21	22
ACETYLCHYTRENE	2 (0.7%)	1 (0.4%)
ARCTIUM HYPOCASTANUM	1 (0.4%)	1 (0.4%)
AMBROKOL HYDROCHLORIDE	1 (0.4%)	0
ATRACYLGOSES MACROCEPHALA, RHIZOMA/CODONOPSIS SPP. ROOT/CULLEN CORYLIFOLIUM		
FRUIT/ GLYCYRRHIZA SPP. ROOT WITH RHIZOME/OPHIPOGON JAPONICUS ROOT TUBER/PORIA COCOS		
SCLEARENIN/SCLEARENIA CHENODRIS FRUIT	1 (0.4%)	0
BENZONATE	1 (0.4%)	1 (0.4%)
BETA VULGARIS	1 (0.4%)	0
CARBOCISTEINE	0	1 (0.4%)
CIMBOL/DIPIVETEN/PIPERINE	1 (0.4%)	0
CITRUS ADAMANTINUM/PELLETIERUS KOTTINENS RHIZOME/GLYCYRRHIZA SPP. ROOT/PERILLA FRUTESCENS		
VAR. CRISPA HERB/ ZINGIBER OFFICINALE RHIZOME	0	1 (0.4%)
CODEINE	1 (0.4%)	0

CODEINE PHOSPHATE	1 (0.4%)	0
CODEINE PHOSPHATE/PROMETHAZINE HYDROCHLORIDE	0	1 (0.4%)
COUGH AND COLD PREPARATIONS	1 (0.4%)	0
DEXTROMETHORPHAN HYDROBROMIDE	1 (0.4%)	0
DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE	0	1 (0.4%)
DEXTROMETHORPHAN HYDROBROMIDE/GUAFENESIN	1 (0.4%)	1 (0.4%)
ERGOSTERINE	1 (0.4%)	0
GLYCYPHERIZA GLABRA	0	1 (0.4%)
GUAFENESIN	2 (0.7%)	0
GUAFENESIN/PSEUDOEPHEDRINE HYDROCHLORIDE	0	1 (0.4%)
LINUM USITATISSIMUM SEED	0	2 (0.7%)
MENTHOL	0	1 (0.4%)
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)
SOPHORA FLAVESCENS	0	1 (0.4%)
STREPTODORASE/STREPTOKINASE	0	1 (0.4%)
ZINC	1 (0.4%)	1 (0.4%)
DIAGNOSTIC AGENTS		
Total number of patients with at least one treatment	5 (1.8%)	9 (3.2%)
Total number of treatments	5	10
FLUORESCIN SODIUM	1 (0.4%)	0
FOLIC ACID	4 (1.4%)	7 (2.5%)
GLUCOSE	0	2 (0.7%)
DIURETICS, INCL. BUFORM		
Total number of patients with at least one treatment	0	2 (0.7%)
Total number of treatments	0	2
MANASCUS PURPUREUS	0	1 (0.4%)
SOPHORA FLAVESCENS	0	1 (0.4%)
DIURETICS		
Total number of patients with at least one treatment	26 (9.4%)	36 (13.0%)
Total number of treatments	31	42
ACETAZOLAMIDE	1 (0.4%)	2 (0.7%)
AMLODINE HYDROCHLORIDE/HYDROCHLOROTHIAZIDE	2 (0.7%)	1 (0.4%)
CHLORZALICONE	0	1 (0.4%)
CLOPAMIDE	0	1 (0.4%)
EPLERENONE	1 (0.4%)	1 (0.4%)
EUCOMMIA ULMOIDES	1 (0.4%)	0
FORSYTHIUM	11 (4.0%)	7 (2.5%)
HYDROCHLOROTHIAZIDE	9 (2.9%)	13 (4.7%)
HYDROCHLOROTHIAZIDE/TRIAMTERENE	1 (0.4%)	2 (0.7%)
HYPERICUM PERFORATUM EXTRACT	0	1 (0.4%)
INDAPAMIDE	1 (0.4%)	3 (1.1%)
ROSMARINUS OFFICINALIS	1 (0.4%)	0
SOPHORA FLAVESCENS	0	1 (0.4%)
SPERONOLACTONE	3 (1.1%)	5 (1.8%)
TORASEMIDE	1 (0.4%)	4 (1.4%)
DRUGS FOR ACID RELATED DISORDERS		
Total number of patients with at least one treatment	46 (16.7%)	43 (15.5%)
Total number of treatments	54	54
ALUMINIUM/MAGNESIUM HYDROXIDE/SIMETICONE	0	1 (0.4%)
BISMUTH SUBSALICYLATE	1 (0.4%)	0
CALCIUM CARBONATE	0	3 (1.1%)
ESOMEPRAZOLE	7 (2.5%)	3 (1.1%)
ESOMEPRAZOLE MAGNESIUM	3 (1.1%)	1 (0.4%)
FAMOTIDINE	4 (1.4%)	4 (1.4%)
GLYCYPHERIZA GLABRA	0	1 (0.4%)
HYDROZALITE	1 (0.4%)	1 (0.4%)
LANSOPRAZOLE	3 (1.1%)	3 (1.1%)
MAGNESIUM HYDROXIDE	0	2 (0.7%)
MAGNESIUM OXIDE	1 (0.4%)	0
MISOPROSTOL	1 (0.4%)	0
MENTHOLILLITE	1 (0.4%)	0
OMEPRAZOLE	15 (5.4%)	15 (5.4%)
OMEPRAZOLE/SODIUM BICARBONATE	0	1 (0.4%)
PANTOPRAZOLE	8 (2.9%)	7 (2.5%)
PANTOPRAZOLE SODIUM SESQUIHYDRATE	4 (1.4%)	3 (1.1%)
RABEPRAZOLE SODIUM	3 (1.1%)	1 (0.4%)
REBAMIPIDE	0	5 (1.8%)
SUCRALFATE	1 (0.4%)	0
UNDODED	0	1 (0.4%)
VONOPRAN FUMARATE	0	1 (0.4%)
DRUGS FOR CONSTIPATION		
Total number of patients with at least one treatment	6 (2.2%)	11 (4.0%)
Total number of treatments	9	25
ASCORBIC ACID/MACROGOL 3350/POTASSIUM CHLORIDE/SODIUM ASCORBATE/SODIUM CHLORIDE/SODIUM SULFATE ANHYDROUS	0	1 (0.4%)
BISACODYL	0	1 (0.4%)
DOCUSATE SODIUM	1 (0.4%)	1 (0.4%)
DOCUSATE/SENNA ALEXANDRINA	0	1 (0.4%)
LINUM USITATISSIMUM SEED	0	2 (0.7%)
LIBROPROSTONE	1 (0.4%)	0
MACROGOL 3350	0	4 (1.4%)
MAGNESIUM HYDROXIDE	0	2 (0.7%)
MAGNESIUM OXIDE	1 (0.4%)	0
NALOXONE	1 (0.4%)	1 (0.4%)
PHOSPHORIC ACID SODIUM/SODIUM PHOSPHATE DIASIC	0	1 (0.4%)
PLANTAGO SP.	0	1 (0.4%)
POLYCARBOPHIL CALCIUM	0	1 (0.4%)
SENNOSEIDE A+B	0	1 (0.4%)
SENNOSEIDE A+B CALCIUM	0	1 (0.4%)
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS		
Total number of patients with at least one treatment	10 (3.6%)	14 (5.1%)
Total number of treatments	11	18
ATROPINE SULFATE	0	1 (0.4%)
CIBICUM LIGNA	3 (1.1%)	2 (0.7%)
DIMETICONE	2 (0.7%)	0
DOMPERIDONE	0	2 (0.7%)
GLUCOPYRCONIUM BROMIDE	1 (0.4%)	0
GLYCYPHERIZA GLABRA	0	1 (0.4%)
HYOSCINE BUTYLBROMIDE	0	1 (0.4%)
LYSINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
METHYLCOPOLAMINE	0	1 (0.4%)
METOCLOPRAMIDE	0	1 (0.4%)
METOCLOPRAMIDE HYDROCHLORIDE	2 (0.7%)	3 (1.1%)
MISAPAMIDE CITRATE	0	1 (0.4%)
ROSMARINUS OFFICINALIS	1 (0.4%)	0

SIMETICONE/TRIMESUTINE MALEATE	1 (0.4%)	0
SOPHORA FLAVESCENS	0	1 (0.4%)
TRIMESUTINE	0	1 (0.4%)
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES		
Total number of patients with at least one treatment	25 (9.1%)	19 (6.9%)
Total number of treatments	39	30
BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE	1 (0.4%)	0
BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRRONIUM BROMIDE	0	1 (0.4%)
BETAMETHASONE	1 (0.4%)	1 (0.4%)
BETAMETHASONE DIPROPIONATE	1 (0.4%)	0
BETAMETHASONE VALERATE	1 (0.4%)	0
BUDESONIDE	0	1 (0.4%)
BUDESONIDE/FORMOTEROL FUMARATE	0	2 (0.7%)
CYCLOSIOLONE	0	1 (0.4%)
CHROMOLICATE SODIUM	1 (0.4%)	0
DEKAMETHASONE	1 (0.4%)	1 (0.4%)
DEKAMETHASONE SODIUM PHOSPHATE	0	3 (1.1%)
EPINEPHRINE HYDROCHLORIDE	0	1 (0.4%)
EPINEPHRINE	1 (0.4%)	1 (0.4%)
FLUTICASONE	4 (1.4%)	3 (1.1%)
FLUTICASONE FUROATE	1 (0.4%)	0
FLUTICASONE PROPIONATE	5 (1.8%)	0
FLUTICASONE PROPIONATE/FORMOTEROL FUMARATE	1 (0.4%)	0
FLUTICASONE PROPIONATE/SALMETEROL XINAFOATE	1 (0.4%)	1 (0.4%)
FLUTICASONE/VILANTEROL	1 (0.4%)	0
GLYCOPYRRONIUM BROMIDE	1 (0.4%)	0
INDACATEROL MALEATE	0	1 (0.4%)
IPRATROPIUM	1 (0.4%)	0
MOMETASONE FUROATE	1 (0.4%)	1 (0.4%)
MONTelukAST	1 (0.4%)	1 (0.4%)
MONTelukAST SODIUM	0	1 (0.4%)
OLIGATEROL HYDROCHLORIDE/TIOTROPIUM BROMIDE	0	1 (0.4%)
SALBUTAMOL	5 (1.8%)	2 (0.7%)
SALBUTAMOL SULFATE	4 (1.4%)	4 (1.4%)
SALMETEROL XINAFOATE	1 (0.4%)	0
THEOPHYLLINE	1 (0.4%)	1 (0.4%)
TIOTROPIUM	1 (0.4%)	0
TRAMCINOLONE ACETONIDE	2 (0.7%)	0
DRUGS FOR TREATMENT OF BONE DISEASES		
Total number of patients with at least one treatment	4 (1.4%)	5 (1.8%)
Total number of treatments	4	5
ALENDRONATE SODIUM	2 (0.7%)	0
ALENDRONATE SODIUM/COLCALSIFEROL	0	1 (0.4%)
ALENDRONIC ACID	0	1 (0.4%)
COLCALSIFEROL/RISERODRONATE SODIUM	0	1 (0.4%)
DEDOSUMAB	1 (0.4%)	1 (0.4%)
MINEDRONIC ACID	0	1 (0.4%)
ZOLEDRONIC ACID	1 (0.4%)	0
DRUGS USED IN DIABETES		
Total number of patients with at least one treatment	38 (13.8%)	47 (17.0%)
Total number of treatments	61	74
ACARBOSSE	1 (0.4%)	1 (0.4%)
AGLISIPTIN BENZOATE	1 (0.4%)	0
CANAGLIFLOZIN	0	1 (0.4%)
DAPAFLIFLOZIN	0	1 (0.4%)
DAPAFLIFLOZIN PROPRANOLOL MONOHYDRATE	3 (1.1%)	0
DAPAFLIFLOZIN PROPRANOLOL MONOHYDRATE/METFORMIN HYDROCHLORIDE	1 (0.4%)	0
DULAGLUTIDE	0	2 (0.7%)
EMPAFLIFLOZIN	0	2 (0.7%)
EMPAFLIFLOZIN/LINAGLIPTIN	0	1 (0.4%)
EMPAFLIFLOZIN/METFORMIN HYDROCHLORIDE	2 (0.7%)	1 (0.4%)
GENMIGLIPTIN TARTRATE/METFORMIN HYDROCHLORIDE	1 (0.4%)	0
GLICAZONE	4 (1.4%)	3 (1.1%)
GLIMEPIRIDE	5 (1.8%)	6 (2.2%)
GLEPIZIDE	4 (1.4%)	0
GYNERMA SYLVESTRE	1 (0.4%)	0
INSULIN	2 (0.7%)	0
INSULIN ASPART/INSULIN ASPART PROTAMINE (CRYSTALLINE)	1 (0.4%)	0
INSULIN DEGLICER	1 (0.4%)	0
INSULIN DETEMIR	0	2 (0.7%)
INSULIN GLARGINE	1 (0.4%)	1 (0.4%)
INSULIN HUMAN	0	1 (0.4%)
INSULIN HUMAN INJECTION, ISOPHANE	0	2 (0.7%)
INSULIN LISPRO	0	2 (0.7%)
LINAGLIPTIN	0	2 (0.7%)
LIRAGLUTIDE	1 (0.4%)	1 (0.4%)
METFORMIN	10 (3.6%)	23 (8.3%)
METFORMIN HYDROCHLORIDE	14 (5.1%)	13 (4.7%)
METFORMIN HYDROCHLORIDE/SITAGLIPTIN PHOSPHATE	0	1 (0.4%)
METFORMIN HYDROCHLORIDE/SITAGLIPTIN PHOSPHATE MONOHYDRATE	1 (0.4%)	1 (0.4%)
METFORMIN HYDROCHLORIDE/VILDAGLIPTIN	0	1 (0.4%)
SAGLIGLIPTIN	1 (0.4%)	0
SEMAGLUTIDE	2 (0.7%)	1 (0.4%)
SITAGLIPTIN	0	1 (0.4%)
SITAGLIPTIN PHOSPHATE	2 (0.7%)	1 (0.4%)
TREGLIOLIPTIN	0	1 (0.4%)
VACCINIUM MYRTILLIS	1 (0.4%)	0
VILAGLIPTIN	0	1 (0.4%)
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS		
Total number of patients with at least one treatment	3 (1.1%)	1 (0.4%)
Total number of treatments	3	1
DIMETICONE	2 (0.7%)	0
ROSMARINI OFFICINALIS	1 (0.4%)	0
SOPHORA FLAVESCENS	0	1 (0.4%)
EMOLLIENTS AND PROTECTIVES		
Total number of patients with at least one treatment	7 (2.5%)	10 (3.6%)
Total number of treatments	7	10
WETACRYLONE	0	1 (0.4%)
DIMETICONE	2 (0.7%)	0
LINUM USITATISSIMUM SEED	0	2 (0.7%)
OTHER EMOLLIENTS AND PROTECTIVES	1 (0.4%)	0
SOPHORA FLAVESCENS	0	1 (0.4%)
THIOCTIC ACID	0	1 (0.4%)
VITAMIN E NOS	2 (0.7%)	4 (1.4%)
WITHANIA SOMNIFERA ROOT	1 (0.4%)	0
ZINC	1 (0.4%)	1 (0.4%)

ENDOCRINE THERAPY		
Total number of patients with at least one treatment	0	8 (2.9%)
Total number of treatments	0	8
ANDROSTENONE	0	2 (0.7%)
ESTRADIOL	0	4 (1.4%)
ESTROGENS CONJUGATED	0	1 (0.4%)
LETROZOLE	0	1 (0.4%)
GENERAL NUTRIENTS		
Total number of patients with at least one treatment	13 (4.7%)	9 (3.2%)
Total number of treatments	14	10
ARGININE	1 (0.4%)	0
ASPARTIC ACID	0	1 (0.4%)
DOCOSAHEXAENOIC ACID/EICOSAPENTAENOIC ACID	3 (1.1%)	1 (0.4%)
FISH OIL	2 (0.7%)	3 (1.1%)
FISH OIL/HERBAL OIL NOS/ORYZA SATIVA/SESAMIN/VITAMIN D NOS	1 (0.4%)	0
GELATINE HYDROLYSATE	1 (0.4%)	0
GLUCOSE	0	2 (0.7%)
HERBAL NOS/MINERALS NOS/VITAMINS NOS	1 (0.4%)	0
METHIONINE ISOLEUCINE LEUCINE LYSINE ACETATE/METHIONINE PHENYLALANINE/THREONINE/TRYPTOPHAN, L-VALINE	1 (0.4%)	0
LYSINE	0	1 (0.4%)
MINERALS NOS/VITAMINS NOS	2 (0.7%)	1 (0.4%)
OMEGA-3 FATTY ACIDS	2 (0.7%)	0
GYNECOLOGICAL ANTINFECTIVES AND ANTISEPTICS		
Total number of patients with at least one treatment	12 (4.3%)	21 (7.6%)
Total number of treatments	13	24
ACROBIC ACID	9 (3.3%)	8 (2.9%)
CHLORHEXIDINE GLUCONATE	0	1 (0.4%)
CIFROFLOXACIN	0	2 (0.7%)
CLINDAMYCIN PHOSPHATE	0	1 (0.4%)
CLOTRIMAZOLE	1 (0.4%)	0
PENTICONSOLE NITRATE	0	1 (0.4%)
SETOCONAZOLE	0	2 (0.7%)
LACTOBACILLUS ACIDOPHILUS	0	1 (0.4%)
METRONIDAZOLE	0	3 (1.1%)
POTASSIUM	1 (0.4%)	3 (1.1%)
POVIDONE-IODINE	1 (0.4%)	0
SOPHORA FLAVESCENS	0	1 (0.4%)
HOMEOPATHIC PREPARATION		
Total number of patients with at least one treatment	31 (11.2%)	25 (9.0%)
Total number of treatments	42	33
ARCTIUM HYPOCASTANUM	1 (0.4%)	0
ASCORBIC ACID	9 (3.3%)	8 (2.9%)
CALCIUM CARBONATE	0	3 (1.1%)
CORTISONE	1 (0.4%)	0
CYANOCOBALAMIN	5 (1.8%)	2 (0.7%)
EPINEPHRINE	1 (0.4%)	1 (0.4%)
ESTRIL	0	1 (0.4%)
GINKGO BILOBA	1 (0.4%)	0
IRON	1 (0.4%)	3 (1.1%)
POTASSIUM	1 (0.4%)	3 (1.1%)
POTASSIUM CHLORIDE	7 (2.5%)	3 (1.1%)
ROSMAFINIS OFFICINALIS	1 (0.4%)	0
SELENIUM	2 (0.7%)	0
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)
THYROID	1 (0.4%)	0
UREICARBONENE	4 (1.4%)	3 (1.1%)
VACCINIUM MYRTILLIS	1 (0.4%)	0
ZINC	1 (0.4%)	1 (0.4%)
IMMUNE SERA AND IMMUNOGLOBULINS		
Total number of patients with at least one treatment	0	1 (0.4%)
Total number of treatments	0	1
SOTROVIMAB	0	1 (0.4%)
IMMUNOSTIMULANTS		
Total number of patients with at least one treatment	2 (0.7%)	2 (0.7%)
Total number of treatments	2	2
ECHINACEA SPP.	1 (0.4%)	0
IMMUNOTHERAPY	1 (0.4%)	0
NAITREXONE HYDROCHLORIDE	0	1 (0.4%)
PETIVERIA ALLIACA	0	1 (0.4%)
IMMENSUPPRESSANTS		
Total number of patients with at least one treatment	5 (1.8%)	7 (2.5%)
Total number of treatments	10	9
ADALIMUMAB	0	1 (0.4%)
GOLIMUMAB	1 (0.4%)	1 (0.4%)
HYDROXYCHLOROQUINE	0	2 (0.7%)
IMMUNOTHERAPY	1 (0.4%)	0
INFLIXIMAB	0	1 (0.4%)
LEFLUNOMIDE	1 (0.4%)	0
METHOTREXATE	2 (0.7%)	1 (0.4%)
MYCOPHENOLATE MOPFILL	1 (0.4%)	0
SIBOLIMIS	1 (0.4%)	0
TACROLIMUS	1 (0.4%)	2 (0.7%)
INJECTIIONAL DRUG		
Total number of patients with at least one treatment	1 (0.4%)	0
Total number of treatments	1	0
SULFORAPHANE	1 (0.4%)	0
LIPID MODIFYING AGENTS		
Total number of patients with at least one treatment	97 (35.1%)	97 (35.0%)
Total number of treatments	111	119
ALLIUM SATIVUM	2 (0.7%)	0
AMLODIPINE BESILATE/ATORVASTATIN L-LYSINE	1 (0.4%)	0
ATORVASTATIN	21 (7.6%)	23 (8.3%)
ATORVASTATIN CALCIUM	17 (6.2%)	13 (4.7%)
ATORVASTATIN CALCIUM TRIHYDRATE	1 (0.4%)	0
ATORVASTATIN CALCIUM TRIHYDRATE/EZETIMIBE	0	1 (0.4%)
ATORVASTATIN CALCIUM/EZETIMIBE	1 (0.4%)	1 (0.4%)
ATORVASTATIN CALCIUM/ERBESARTAN	0	1 (0.4%)
ATORVASTATIN/EZETIMIBE	0	2 (0.7%)
CANDESARTAN CILEXETIL/ROSUVASTATIN CALCIUM	0	1 (0.4%)
CURCUMA LONGA	3 (1.1%)	2 (0.7%)
DOCOSAHEXAENOIC ACID/EICOSAPENTAENOIC ACID	3 (1.1%)	1 (0.4%)
DOCOSAHEXAENOIC ACID/EICOSAPENTAENOIC ACID/FISH OIL	0	1 (0.4%)
DOCOSAHEXAENOIC ACID/EICOSAPENTAENOIC ACID/VITAMIN D NOS/VITAMIN E NOS	1 (0.4%)	0

EICOSAPENTAENOIC ACID ETHYL ESTER	1 (0.4%)	0
EUCOMMIA ULMOIDES	1 (0.4%)	0
EZETIMIBE	5 (1.8%)	4 (1.4%)
EZETIMIBE/ROSUVASTATIN CALCIUM	1 (0.4%)	2 (0.7%)
FENOFIBRATE	2 (0.7%)	3 (1.1%)
FENOFIBRATE/PRAVASTATIN SODIUM	0	1 (0.4%)
FISH OIL	2 (0.7%)	3 (1.1%)
KRILL OIL	1 (0.4%)	2 (0.7%)
LINUM USITATISSIMUM SEED	0	2 (0.7%)
LOXAPATIN	2 (0.7%)	0
MUSCOSCUS PURPUREUS	0	1 (0.4%)
OLMESARTAN MEDOXOMIL/ROSUVASTATIN CALCIUM	1 (0.4%)	0
OMEGA-3 FATTY ACIDS	2 (0.7%)	0
OTHER LIPID MODIFYING AGENTS	1 (0.4%)	0
PHYTOSTEROLS NOS	1 (0.4%)	0
PIVASTATIN CALCIUM	1 (0.4%)	1 (0.4%)
PRAVASTATIN	0	1 (0.4%)
PRAVASTATIN SODIUM	2 (0.7%)	1 (0.4%)
ROSUVASTATIN	9 (3.3%)	13 (4.7%)
ROSUVASTATIN CALCIUM	16 (5.8%)	17 (6.1%)
SIMVASTATIN	13 (4.7%)	18 (6.5%)
MEDICATED DRESSINGS		
Total number of patients with at least one treatment	4 (1.4%)	6 (2.2%)
Total number of treatments	5	10
CALAMINE/GLYCEROL/SILIC OXIDE	0	1 (0.4%)
CHLORHEXIDINE GLUCONATE	0	1 (0.4%)
POVIDONE-IODINE	1 (0.4%)	0
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)
ZINC	1 (0.4%)	1 (0.4%)
MINERAL SUPPLEMENTS		
Total number of patients with at least one treatment	21 (7.6%)	25 (9.0%)
Total number of treatments	28	37
ASCORBIC ACID/CALCIUM CARBONATE/COLECALCIFEROL	1 (0.4%)	0
CALCIUM	2 (0.7%)	4 (1.4%)
CALCIUM ACETATE	1 (0.4%)	0
CALCIUM CARBONATE	0	3 (1.1%)
CALCIUM CARBONATE/COLECALCIFEROL	2 (0.7%)	2 (0.7%)
CALCIUM CHLORIDE	0	1 (0.4%)
CALCIUM CITRATE	1 (0.4%)	1 (0.4%)
CALCIUM/COLECALCIFEROL	1 (0.4%)	1 (0.4%)
MAGNESIUM	1 (0.4%)	4 (1.4%)
MAGNESIUM ASPARTATE/POTASSIUM ASPARTATE	0	1 (0.4%)
MAGNESIUM HYDROXIDE	0	2 (0.7%)
MAGNESIUM LACTATE	0	1 (0.4%)
MAGNESIUM OXIDE	1 (0.4%)	0
MAGNESIUM/PYRIDOXINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
MINERALS NOS/VITAMINS NOS	2 (0.7%)	1 (0.4%)
PHOSPHORIC ACID SODIUM/SODIUM PHOSPHATE DIASIC	0	1 (0.4%)
POTASSIUM	1 (0.4%)	3 (1.1%)
POTASSIUM CHLORIDE	7 (2.5%)	3 (1.1%)
SELENIUM	2 (0.7%)	0
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)
ZINC	1 (0.4%)	1 (0.4%)
MUSCLE RELAXANTS		
Total number of patients with at least one treatment	8 (2.9%)	14 (5.1%)
Total number of treatments	9	17
ACETYLSALICYLIC ACID/METHECARAMOL	0	1 (0.4%)
BACLOFEN	0	3 (1.1%)
CHLORZOXAZONE	1 (0.4%)	0
CYCLOBENZAPRINE	1 (0.4%)	2 (0.7%)
DIAZEPAM	2 (0.7%)	4 (1.4%)
DICLOFENAC/PRIDINOL	1 (0.4%)	0
EPHEDRINE HYDROCHLORIDE	0	1 (0.4%)
LIDOCaine HYDROCHLORIDE/TOLPERISONE HYDROCHLORIDE	1 (0.4%)	0
METHECARAMOL	1 (0.4%)	1 (0.4%)
PARACETAMOL/PHENOLCHLORIDE	0	1 (0.4%)
ROCURONIUM BROMIDE	1 (0.4%)	1 (0.4%)
TIZANIDINE HYDROCHLORIDE	0	1 (0.4%)
N/A		
Total number of patients with at least one treatment	3 (1.1%)	0
Total number of treatments	3	0
ALLIUM SATIVUM	2 (0.7%)	0
ARDININE	1 (0.4%)	0
NASAL PREPARATIONS		
Total number of patients with at least one treatment	25 (9.1%)	21 (7.6%)
Total number of treatments	35	37
ACETILCYSTEINE	2 (0.7%)	1 (0.4%)
ANELICA SARHICA ROOT/ASTRAGALUS MONGOLICUS ROOT/ATRACTYLODES MACROCEPHALA, RHIZOMA/MAGNOLIA SPP. FLOWER BUD/MENTHA CANADENSIS/SAPOSNIKOVIA DIVARICATA ROOT/XANTHUM SIBIRICUM FRUIT	0	1 (0.4%)
ARLEGINE	0	2 (0.7%)
AZELASTINE	0	1 (0.4%)
AZELASTINE HYDROCHLORIDE	0	1 (0.4%)
BETAMETHASONE	1 (0.4%)	1 (0.4%)
BETAMETHASONE DIPROPIONATE	1 (0.4%)	0
BETAMETHASONE VALERATE	1 (0.4%)	0
BENDESONIDE	0	1 (0.4%)
CHLORCICLIZINE HYDROCHLORIDE/PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.4%)	0
CICLESONIDE	0	1 (0.4%)
CRONOLICATE SODIUM	1 (0.4%)	0
DEKAMETHASONE	1 (0.4%)	1 (0.4%)
DEKAMETHASONE SODIUM PHOSPHATE	0	3 (1.1%)
EPHEDRINE HYDROCHLORIDE	0	1 (0.4%)
EPINEPHRINE	1 (0.4%)	1 (0.4%)
PEKOPENADINE HYDROCHLORIDE/PSEUDOEPHEDRINE HYDROCHLORIDE	0	1 (0.4%)
PLATTICARONE	4 (1.4%)	3 (1.1%)
PLATTICARONE FOSFATE	1 (0.4%)	0
PLATTICARONE PROPIONATE	5 (1.8%)	0
HYALURONATE SODIUM	1 (0.4%)	2 (0.7%)
IPRATROPIUM	1 (0.4%)	0
MINTHOL	0	1 (0.4%)
MOMETASONE FUROATE	1 (0.4%)	1 (0.4%)
MILRINCIN	1 (0.4%)	2 (0.7%)
OLOPATADINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
OXMETAZOLINE	0	1 (0.4%)
PHENYLEPHRINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
PERIN SOLICONE	1 (0.4%)	0
PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.4%)	0
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)

TRIAMCINOLONE ACETONIDE	2 (0.7%)	0
ZINC	1 (0.4%)	1 (0.4%)
OPHTHALMOLOGICAL AND OTOLARYNGOLOGICAL PREPARATIONS		
Total number of patients with at least one treatment	5 (1.8%)	8 (2.9%)
Total number of treatments	5	11
BETAMETHASONE	1 (0.4%)	1 (0.4%)
BETAMETHASONE SODIUM PHOSPHATE/NEOMYCIN SULFATE	1 (0.4%)	0
CHLORHEXIDINE GLUCONATE	0	1 (0.4%)
CHLOROFENIRAMINE	0	2 (0.7%)
DEKAMETHASONE	1 (0.4%)	1 (0.4%)
DEKAMETHASONE SODIUM PHOSPHATE	0	3 (1.1%)
LEVOPROXACIN	1 (0.4%)	1 (0.4%)
PRENIZOLONE	1 (0.4%)	0
OPHTHALMOLOGICALS		
Total number of patients with at least one treatment	60 (21.7%)	64 (23.1%)
Total number of treatments	109	125
ACETAZOLAMIDE	1 (0.4%)	2 (0.7%)
ACETYL CYSTEINE	2 (0.7%)	1 (0.4%)
ACICLOVIR	1 (0.4%)	0
ARTIFICIAL TEARS (UMBRELLA TERM)	1 (0.4%)	0
ASCORBIC ACID	9 (3.3%)	8 (2.9%)
ASCORBIC ACID/BETACAROTENE/CUPRIC OXIDE/TOCOPHERYL ACETATE/ZINC OXIDE	1 (0.4%)	0
ASCORBIC ACID/COPPER GLUCONATE/FISH OIL/TOCOPHERYL ACETATE/XANTOPYL/ZEAXANTHIN/ZINC OXIDE	0	1 (0.4%)
ASCORBIC ACID/COPPER/VITAMIN E NOS/XANTOPYL/ZEAXANTHIN/ZINC	0	1 (0.4%)
ASPAGALUS MONGOLICUS ROOT/PANAX NOTOGINSENG ROOT WITH RHIZOME/SALVIA MILTIORRHIZA ROOT WITH RHIZOME/SCHONHILARIA NINGPOENSIS ROOT	0	1 (0.4%)
ATROPINE SULFATE	0	1 (0.4%)
AZELASTINE	0	2 (0.7%)
AZELASTINE HYDROCHLORIDE	0	1 (0.4%)
AZITHROMYCIN	4 (1.4%)	2 (0.7%)
BETAMETHASONE	1 (0.4%)	1 (0.4%)
BETAMETHASONE DIPROPIONATE	1 (0.4%)	0
BETAMETHASONE SODIUM PHOSPHATE/NEOMYCIN SULFATE	1 (0.4%)	0
BETAMETHASONE VALERATE	1 (0.4%)	0
BETAHOLOL HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
BILASTINE	1 (0.4%)	0
BUPIVACAINE	0	1 (0.4%)
CAHOMER	1 (0.4%)	0
CETALONUM CHLORIDE (GLYCEROL/POLOXALCOL/TRIMETAZOL HYDROCHLORIDE/TYLOXAPOL	0	1 (0.4%)
CETIRIZINE	1 (0.4%)	2 (0.7%)
CETIRIZINE HYDROCHLORIDE	5 (1.8%)	2 (0.7%)
CHLORHEXIDINE GLUCONATE	0	1 (0.4%)
CHENODIOLIN	0	1 (0.4%)
CHENODIOLIN SULFATE SODIUM	1 (0.4%)	0
CIPROFLOXACIN	0	2 (0.7%)
CLAMIDINE	1 (0.4%)	2 (0.7%)
CLOTHESMOLE	1 (0.4%)	0
CORTISONE	1 (0.4%)	0
CHROMOLICATE SODIUM	1 (0.4%)	0
CYANOCOBALAMIN	5 (1.8%)	2 (0.7%)
DESONIDE	0	1 (0.4%)
DEKAMETHASONE	1 (0.4%)	1 (0.4%)
DEKAMETHASONE SODIUM PHOSPHATE	0	3 (1.1%)
DICLOFENAC	3 (1.1%)	4 (1.4%)
DICLOFENAC SODIUM	0	2 (0.7%)
DIMETHICONE	2 (0.7%)	0
DORGLAMIDE HYDROCHLORIDE/TIMOLOL MALEATE	2 (0.7%)	0
EPINEPHRINE HYDROCHLORIDE	0	1 (0.4%)
EPINASTINE HYDROCHLORIDE	0	1 (0.4%)
EPINEPHRINE	1 (0.4%)	1 (0.4%)
ERYTHROMYCIN	1 (0.4%)	1 (0.4%)
FLUCONAZOLE	0	1 (0.4%)
FLUORESCIN SODIUM	1 (0.4%)	0
FLURBIPROFEN AXETIL	1 (0.4%)	1 (0.4%)
GLUCOSE/POTASSIUM CHLORIDE/SODIUM CHLORIDE	0	1 (0.4%)
HEPARIN	1 (0.4%)	3 (1.1%)
HYALURONATE SODIUM	1 (0.4%)	2 (0.7%)
HYLAN G-F 20	1 (0.4%)	0
KETOROLAC	0	1 (0.4%)
LEVOPROXACIN	1 (0.4%)	1 (0.4%)
LEVOPROXACIN LACTATE	0	1 (0.4%)
LIDOCaine	3 (1.1%)	3 (1.1%)
MACRODOL 400/PROPYLENE GLYCOL	1 (0.4%)	1 (0.4%)
MELOXICAM	2 (0.7%)	5 (1.8%)
METHYLPREINIZOLONE	3 (1.1%)	2 (0.7%)
MINERALS NOS/VITAMINS NOS	2 (0.7%)	1 (0.4%)
MOLIFLOXACIN HYDROCHLORIDE	0	1 (0.4%)
NAFROXEN	1 (0.4%)	3 (1.1%)
NAFROXEN SODIUM	1 (0.4%)	1 (0.4%)
NEPAFENAC	0	1 (0.4%)
NETILMICIN SULFATE	0	1 (0.4%)
OLAPAGADIS HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
OTHER OPTHALMOLOGICALS	2 (0.7%)	1 (0.4%)
OXOMETAZOLINE	0	1 (0.4%)
PHENYLEPHRINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
PHOSPHORIC ACID SODIUM/SODIUM PHOSPHATE DIASIC	0	1 (0.4%)
PIRENIZINE	1 (0.4%)	0
POTASSIUM	1 (0.4%)	3 (1.1%)
POTASSIUM CHLORIDE	7 (2.5%)	3 (1.1%)
POVIDONE-IODINE	1 (0.4%)	0
PRENIZOLONE	1 (0.4%)	0
PRENIZONE	2 (0.7%)	2 (0.7%)
PROXIMETAINE	1 (0.4%)	0
REBANIPIDE	0	5 (1.8%)
SIBOLIMOS	1 (0.4%)	0
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)
TACROLIMOS	1 (0.4%)	2 (0.7%)
TRIAMCINOLONE ACETONIDE	2 (0.7%)	0
TROPICAMIDE	1 (0.4%)	0
TROXERUTIN	1 (0.4%)	1 (0.4%)
UBIDECARENONE	4 (1.4%)	3 (1.1%)
VACCINIUM MYRTILLIS	1 (0.4%)	0
XANTOPYL	1 (0.4%)	2 (0.7%)
XANTOPYL/ZEAXANTHIN	1 (0.4%)	0
ZINC	1 (0.4%)	1 (0.4%)
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS		
Total number of patients with at least one treatment	13 (4.7%)	10 (3.6%)
Total number of treatments	14	11
ACETYL CYSTEINE	2 (0.7%)	1 (0.4%)

ARGININE	1 (0.4%)	0
BETA VULGARIS ROOT/CRATAEGUS LARVIGATA/POENICULUM VULGARE SEED/GLYCYRRHIZA GLABRA ROOT	0	1 (0.4%)
CLOSTRIDIUM BUTYRICUM	1 (0.4%)	0
LEVOCARNITINE FUMARATE/PINUS PINASTER/THIOCTIC ACID/UBIDECARENONE	1 (0.4%)	0
LYSINE	0	1 (0.4%)
PROBIOTICS NOS	2 (0.7%)	2 (0.7%)
SUCRALFATE	1 (0.4%)	0
THEANINE	1 (0.4%)	0
THIOCTIC ACID	0	1 (0.4%)
UBIDECARENONE	4 (1.4%)	3 (1.1%)
VARIOUS ALIMENTARY TRACT AND METABOLISM PRODUCTS	0	1 (0.4%)
ZINC	1 (0.4%)	1 (0.4%)
OTHER DERMATOLOGICAL PREPARATIONS		
Total number of patients with at least one treatment	43 (15.6%)	40 (14.4%)
Total number of treatments	56	49
ASCORBIC ACID	9 (3.3%)	8 (2.9%)
ASCORBIC ACID/BIOTIN	1 (0.4%)	0
COLLAGEN	2 (0.7%)	1 (0.4%)
CHROMICLICATE SODIUM	1 (0.4%)	0
DAPSONE	1 (0.4%)	0
DICLOFENAC	3 (1.1%)	4 (1.4%)
DICLOFENAC SODIUM	0	2 (0.7%)
ENTASTERIDE	3 (1.1%)	0
ESTRADIOL	0	4 (1.4%)
FINASTERIDE	5 (1.8%)	3 (1.1%)
GELATINE HYDROLYSATE	1 (0.4%)	0
GLYCOPHYLLIN BROMIDE	1 (0.4%)	0
HYALURONATE SODIUM	1 (0.4%)	2 (0.7%)
IBUPROFEN	12 (4.3%)	10 (3.6%)
MINERALS NOS/VITAMINS NOS	2 (0.7%)	1 (0.4%)
MINOXIDIL	0	1 (0.4%)
OTHER DERMATOLOGICALS	1 (0.4%)	0
OXYGEN	0	1 (0.4%)
OXOMETAZOLINE	0	1 (0.4%)
PIMECROLIMUS	0	1 (0.4%)
POVIDONE-IODINE	1 (0.4%)	0
SELENIUM	2 (0.7%)	0
SELENIUM SULFIDE	0	1 (0.4%)
SIROLIMUS	1 (0.4%)	0
SOPHORA FLAVESCENS	0	1 (0.4%)
SUCRALFATE	1 (0.4%)	0
TACROLIMUS	1 (0.4%)	2 (0.7%)
TRANKAMIC ACID	1 (0.4%)	2 (0.7%)
TRETINOIN	1 (0.4%)	0
UBIDECARENONE	4 (1.4%)	3 (1.1%)
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM		
Total number of patients with at least one treatment	3 (1.1%)	3 (1.1%)
Total number of treatments	3	3
ASTRAGALUS MONSOLICUS ROOT/CORYDALIS YANNISUD TUBER/DEER HORN/EUCOMMIA ULMIDIDES	0	1 (0.4%)
BARK/SALVIA MILTIORRHIZA ROOT WITH RHIZOME	1 (0.4%)	0
CLAMIPERANINE HYDROCHLORIDE	1 (0.4%)	0
HYALURONATE SODIUM	1 (0.4%)	2 (0.7%)
HYLAN G-F 20	1 (0.4%)	0
OTHER GYNECOLOGICALS		
Total number of patients with at least one treatment	33 (12.0%)	34 (12.3%)
Total number of treatments	41	36
CARBOMER	1 (0.4%)	0
CLARIDINE	1 (0.4%)	2 (0.7%)
HYALURONATE SODIUM	1 (0.4%)	2 (0.7%)
IBUPROFEN	12 (4.3%)	10 (3.6%)
IBUPROFEN ARGININE	1 (0.4%)	0
METHOTREXATE	2 (0.7%)	1 (0.4%)
MISOPROSTOL	1 (0.4%)	0
NAFROKEN	1 (0.4%)	3 (1.1%)
NAFROKEN SODIUM	1 (0.4%)	1 (0.4%)
NIFEDIPINE	7 (2.5%)	5 (1.8%)
PAROXETINE	1 (0.4%)	2 (0.7%)
PAROXETINE HYDROCHLORIDE	0	1 (0.4%)
PAITIMACA SATIVA	0	1 (0.4%)
PROGESTERONE	0	1 (0.4%)
SALBUTAMOL	5 (1.8%)	2 (0.7%)
SALBUTAMOL SULFATE	4 (1.4%)	4 (1.4%)
STREPTOCOCCINASE/STREPTOKINASE	0	1 (0.4%)
WITAMIA SOMNIFERA ROOT	1 (0.4%)	0
OTHER HEMATOLOGICAL AGENTS		
Total number of patients with at least one treatment	0	1 (0.4%)
Total number of treatments	0	1
STREPTOCOCCINASE/STREPTOKINASE	0	1 (0.4%)
OTHER NERVOUS SYSTEM DRUGS		
Total number of patients with at least one treatment	19 (6.9%)	21 (7.6%)
Total number of treatments	21	24
BETAHISTINE	0	1 (0.4%)
BETAHISTINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
BUPROPION	3 (1.1%)	1 (0.4%)
BUPROPION HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
BUTYLPHENALIDE	1 (0.4%)	0
CHOLINE ALFOSKERATE	0	1 (0.4%)
CLONIDINE	1 (0.4%)	2 (0.7%)
DIPENTHYMINATE	0	1 (0.4%)
FLORAZINE DIBENZOCHLORIDE	0	1 (0.4%)
FLOROXETINE	0	1 (0.4%)
FLOROXETINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
GABAPENTIN	5 (1.8%)	3 (1.1%)
GINKGO BILOBA	1 (0.4%)	0
GINKGO BILOBA EXTRACT	1 (0.4%)	1 (0.4%)
GINKGO BILOBA LEAF	1 (0.4%)	1 (0.4%)
MECLOZINE	1 (0.4%)	0
MECOBALAMIN	1 (0.4%)	1 (0.4%)
NALOXONE	1 (0.4%)	1 (0.4%)
NALTREXONE HYDROCHLORIDE	0	1 (0.4%)
THIOCTIC ACID	0	1 (0.4%)
TRIMETAZIDINE	0	1 (0.4%)
TRIMETAZIDINE HYDROCHLORIDE	1 (0.4%)	0
VITAMIN B12 NOS	1 (0.4%)	3 (1.1%)
OTHER RESPIRATORY SYSTEM PRODUCTS		
Total number of patients with at least one treatment	3 (1.1%)	1 (0.4%)

Total number of treatments	3	1
AMBROGOL HYDROCHLORIDE	1 (0.4%)	0
CITRUS AURANTIUM PEEL/CYPERUS ROTUNDUS RHIZOME/GLYCYRRHIZA SPP. ROOT/PERILLA FRUTESCENS VAR. CRISPA HERB/LEONURUS OFFICINALIS RHIZOME	0	1 (0.4%)
OTHER RESPIRATORY SYSTEM PRODUCTS	2 (0.7%)	0
OTOLGICALS		
Total number of patients with at least one treatment	11 (4.0%)	12 (4.3%)
Total number of treatments	17	23
BETAMETHASONE	1 (0.4%)	1 (0.4%)
BETAMETHASONE DIPROPIONATE	1 (0.4%)	0
BETAMETHASONE VALERATE	1 (0.4%)	0
CHLORHEXIDINE GLUCONATE	0	1 (0.4%)
CITRIFLOXACIN	0	2 (0.7%)
CLOTRIMAZOLE	1 (0.4%)	0
DEKAMETHASONE	1 (0.4%)	1 (0.4%)
DEKAMETHASONE SODIUM PHOSPHATE	0	3 (1.1%)
DOCUSATE SODIUM	1 (0.4%)	1 (0.4%)
LEVOPULGACIN	1 (0.4%)	1 (0.4%)
LIDOCAINE	3 (1.1%)	3 (1.1%)
PRENISKOLONE	1 (0.4%)	0
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)
PERIPHERAL VASODILATORS		
Total number of patients with at least one treatment	5 (1.8%)	5 (1.8%)
Total number of treatments	6	1
EUCOMMIA ULMOIDES	1 (0.4%)	0
GINKGO BILOBA	1 (0.4%)	0
GINKGO BILOBA EXTRACT	1 (0.4%)	1 (0.4%)
GINKGO BILOBA LEAF	1 (0.4%)	1 (0.4%)
NICERGOLINE	1 (0.4%)	1 (0.4%)
PENTOXIFYLLINE	1 (0.4%)	2 (0.7%)
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES		
Total number of patients with at least one treatment	0	1 (0.4%)
Total number of treatments	0	1
DESMOPRESSIN	0	1 (0.4%)
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS		
Total number of patients with at least one treatment	11 (4.0%)	12 (4.3%)
Total number of treatments	15	17
ABUSCULUS HIPPOCASTANUM	1 (0.4%)	0
ALPROSTADIL	1 (0.4%)	0
AMBER (FOSSILIZED TREE RESIN)/BORNEOL/CALAMINE/COW BEZOAR/MUSK/PEARL/SODIUM BORATE	0	1 (0.4%)
CHITTELLA ASIATICA HERB	0	1 (0.4%)
COD-LIVER OIL	1 (0.4%)	0
DIMETICONE	2 (0.7%)	0
FISH OIL	2 (0.7%)	3 (1.1%)
HYALURONATE SODIUM	1 (0.4%)	2 (0.7%)
HYLAN G-F 20	1 (0.4%)	0
LYSINE	0	1 (0.4%)
PASTINACA SATIVA	1 (0.4%)	1 (0.4%)
ROSAMUNES OFFICINALIS	1 (0.4%)	0
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)
STREPTODORNASE/STREPTOKINASE	0	1 (0.4%)
PSYCHONALEPTICS		
Total number of patients with at least one treatment	27 (9.8%)	42 (15.2%)
Total number of treatments	40	55
AMPETAMINE/DEKAMETAMINE	0	1 (0.4%)
AMITRIPTYLINE	2 (0.7%)	0
AMITRIPTYLINE HYDROCHLORIDE	1 (0.4%)	0
BUPROPION	3 (1.1%)	1 (0.4%)
BUPROPION HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
CITALOPRAM	3 (1.1%)	4 (1.4%)
CITALOPRAM HYDROBROMIDE	1 (0.4%)	2 (0.7%)
CITRUS AURANTIUM PEEL/CYPERUS ROTUNDUS RHIZOME/GLYCYRRHIZA SPP. ROOT/PERILLA FRUTESCENS VAR. CRISPA HERB/LEONURUS OFFICINALIS RHIZOME	0	1 (0.4%)
CLONIPRAMINE HYDROCHLORIDE	1 (0.4%)	0
CLONIDINE	1 (0.4%)	2 (0.7%)
DESERVILAFAXINE	0	1 (0.4%)
DOMPEFON	0	1 (0.4%)
DULOXETINE	4 (1.4%)	4 (1.4%)
DULOXETINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
ESCITALOPRAM	2 (0.7%)	4 (1.4%)
ESCITALOPRAM OXALATE	0	1 (0.4%)
FLIOPXETINE	0	1 (0.4%)
FLIOPXETINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
FLIPIENTINOL DIHYDROCHLORIDE/MLITRACEN HYDROCHLORIDE	1 (0.4%)	0
FLIPROXAMINE MALEATE	1 (0.4%)	0
GINKGO BILOBA	1 (0.4%)	0
GINKGO BILOBA EXTRACT	1 (0.4%)	1 (0.4%)
GINKGO BILOBA LEAF	1 (0.4%)	1 (0.4%)
HYPERICUM PERFORATUM EXTRACT	0	1 (0.4%)
LAMOTRIGINE	0	2 (0.7%)
MEMANTINE	1 (0.4%)	0
METHYLPHENIDATE	0	1 (0.4%)
MILANSERIN HYDROCHLORIDE	1 (0.4%)	0
MIFEPRISTONE	0	4 (1.4%)
MODAFINIL	0	1 (0.4%)
NIMODIPINE	0	1 (0.4%)
OPIPRAMOL HYDROCHLORIDE	1 (0.4%)	0
OXACETETAM	0	1 (0.4%)
PAROXETINE	1 (0.4%)	2 (0.7%)
PAROXETINE HYDROCHLORIDE	0	1 (0.4%)
PIRACETAM	2 (0.7%)	0
RIVASTIGMINE	0	1 (0.4%)
SEKTRALINE	0	3 (1.1%)
SEKTRALINE HYDROCHLORIDE	3 (1.1%)	1 (0.4%)
TRANLYCPROMINE SULFATE/TRIFLUOPERAZINE HYDROCHLORIDE	0	1 (0.4%)
TRAZOCONE	1 (0.4%)	1 (0.4%)
TRAZOCONE HYDROCHLORIDE	0	1 (0.4%)
VENLAFAXINE	0	2 (0.7%)
VENLAFAXINE HYDROCHLORIDE	0	2 (0.7%)
VINDOCETINE	1 (0.4%)	0
WITHANIA SOMNIFERA ROOT	1 (0.4%)	0
PSYCHOLEPTICS		
Total number of patients with at least one treatment	39 (14.1%)	49 (17.7%)
Total number of treatments	56	81
ALPRAZOLAM	2 (0.7%)	5 (1.8%)
AMITRIPTYLINE	2 (0.7%)	0

AMITRIPTYLINE HYDROCHLORIDE	1 (0.4%)	0
ARIPIPRAZOLE	0	3 (1.1%)
BENZOCLOAZEPINE DERIVATIVES	0	1 (0.4%)
BROMOSETAN	1 (0.4%)	2 (0.7%)
BROPTILOLAM	0	2 (0.7%)
BUPROPIONE	0	1 (0.4%)
CANNABIDIOL	0	1 (0.4%)
CANNABIS SATIVA	1 (0.4%)	0
CLAMIPRAMINE HYDROCHLORIDE	1 (0.4%)	0
CLONAZEPAM	1 (0.4%)	5 (1.8%)
CLORAZEPATE DIPOTASSIUM	1 (0.4%)	1 (0.4%)
DEER VELVET/EPHEDRUM SPP. LEAF/FALLOPIA MULTIFLORA ROOT TUBER/GLYCYRRHIZA SPP. ROOT WITH SHELCHU/VITAMIN B1 NOBI/ELCIBEN OFFICINALE RHIZOME/IZIZHINUS JUDINA FRUIT	1 (0.4%)	0
DIAZEPAM	2 (0.7%)	4 (1.4%)
DIPHENHYDRAMINE	2 (0.7%)	0
DIPHENHYDRAMINE HYDROCHLORIDE	4 (1.4%)	4 (1.4%)
DIPHENHYDRAMINE HYDROCHLORIDE/PARACETAMOL	1 (0.4%)	0
DIPHENHYDRAMINE/PARACETAMOL	1 (0.4%)	0
DOXEPIN	0	1 (0.4%)
DROPERIDOL	0	1 (0.4%)
DULOXETINE	4 (1.4%)	4 (1.4%)
DULOXETINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
ESITALOPRAM	2 (0.7%)	4 (1.4%)
ESITALOPRAM OXALATE	0	1 (0.4%)
ESZOPICLONE	1 (0.4%)	0
EUCOMMA ULMOIDES	1 (0.4%)	0
FLUNITRAZEPAM	0	1 (0.4%)
FLOROXETINE	0	1 (0.4%)
FLOROXETINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
HYDROXYZINE	3 (1.1%)	0
HYDROXYZINE HYDROCHLORIDE	0	2 (0.7%)
HYPERICUM PERFORATUM EXTRACT	0	1 (0.4%)
LITHIUM CARBONATE	1 (0.4%)	1 (0.4%)
LOXAZEPAM	2 (0.7%)	1 (0.4%)
LORMETAZEPAM	1 (0.4%)	1 (0.4%)
MEDAZEPAM	0	1 (0.4%)
MELATONIN	2 (0.7%)	2 (0.7%)
MILACIPAM	0	1 (0.4%)
OXAZEPAM	0	1 (0.4%)
PALIPERIDONE	0	1 (0.4%)
PAROXETINE	1 (0.4%)	2 (0.7%)
PAROXETINE HYDROCHLORIDE	0	1 (0.4%)
PENDAMOLIN	3 (1.1%)	3 (1.1%)
PRENCHLOPRIDAZINE	0	1 (0.4%)
PRIMETHAZINE	0	1 (0.4%)
QUETIAPINE	1 (0.4%)	0
QUETIAPINE FUMARATE	0	1 (0.4%)
RISPERIDONE	1 (0.4%)	1 (0.4%)
ROMANSINUS OFFICINALIS	1 (0.4%)	0
SERTRALINE	0	3 (1.1%)
SERTRALINE HYDROCHLORIDE	3 (1.1%)	1 (0.4%)
TENAZEPAM	2 (0.7%)	0
THANINE	1 (0.4%)	0
VALPROIC ACID	0	1 (0.4%)
VENLAFAXINE	0	2 (0.7%)
VENLAFAXINE HYDROCHLORIDE	0	2 (0.7%)
WITHANIA SOMNIFERA ROOT	1 (0.4%)	0
ZOLPIDEM	0	1 (0.4%)
ZOLPIDEM TARTRATE	0	1 (0.4%)
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM		
Total number of patients with at least one treatment	1 (0.4%)	8 (2.9%)
Total number of treatments	2	14
DESORTRINOL	1 (0.4%)	0
DYNOGEST/ETHINYLESTRADIOL	1 (0.4%)	0
DYNOGEST/ESTRONE/ESTRADIOL	0	1 (0.4%)
ESTRADIOL	0	4 (1.4%)
ESTRADIOL/ESTRINOL	0	1 (0.4%)
ESTRADIOL/NORETHISTERONE ACETATE	0	1 (0.4%)
ESTRINOL	0	1 (0.4%)
ESTROGENS COMBINED	0	1 (0.4%)
PROGESTERONE	0	1 (0.4%)
TESTOSTERONE	0	4 (1.4%)
STOMATOLOGICAL PREPARATIONS		
Total number of patients with at least one treatment	58 (21.0%)	63 (22.7%)
Total number of treatments	74	84
ACETYLSALICYLIC ACID	41 (14.9%)	39 (14.1%)
ASCORBIC ACID/CHLORHEXIDINE	1 (0.4%)	0
BETAMETHASONE	1 (0.4%)	1 (0.4%)
CARBOMER	1 (0.4%)	0
CHLORHEXIDINE GLUCONATE	0	1 (0.4%)
CLOBETASOL	0	1 (0.4%)
CLOBETASOL PROPIONATE	1 (0.4%)	0
CLOTRIMAZOLE	1 (0.4%)	0
DEKAMETHASONE	1 (0.4%)	1 (0.4%)
DEKAMETHASONE SODIUM PHOSPHATE	0	3 (1.1%)
DICLOFENAC	3 (1.1%)	4 (1.4%)
DICLOFENAC SODIUM	0	2 (0.7%)
DIMETICONE	2 (0.7%)	0
EPINEPHRINE	1 (0.4%)	1 (0.4%)
HYALURONATE SODIUM	1 (0.4%)	2 (0.7%)
METOPROLOL	1 (0.4%)	2 (0.7%)
LIDOCAINE	3 (1.1%)	3 (1.1%)
METRONIDAZOLE	0	3 (1.1%)
NAPROXEN	1 (0.4%)	3 (1.1%)
NIMESULIDE	1 (0.4%)	0
OXYGEN	0	1 (0.4%)
POTASSIUM	1 (0.4%)	3 (1.1%)
POYIDINE-LICLINE	1 (0.4%)	0
PRENILESCOLONE	1 (0.4%)	0
SODIUM CHLORIDE	2 (0.7%)	3 (1.1%)
SUCRALFATE	1 (0.4%)	0
TRANEKZAMIC ACID	1 (0.4%)	2 (0.7%)
TRAMACETOLONE ACETONIDE	2 (0.7%)	0
ZINC	1 (0.4%)	1 (0.4%)
THROAT PREPARATIONS		
Total number of patients with at least one treatment	20 (7.2%)	22 (7.9%)
Total number of treatments	23	20
AMBROXOL HYDROCHLORIDE	1 (0.4%)	0
ASCORBIC ACID/CHLORHEXIDINE	1 (0.4%)	0

CHLORHEXIDINE GLUCONATE	0	1 (0.4%)
DICLOFENAC	3 (1.1%)	4 (1.4%)
DICLOFENAC SODIUM	0	2 (0.7%)
IBUPROFEN	12 (4.3%)	10 (3.6%)
ISATIS TINCTORIA ROOT	0	1 (0.4%)
KETOPROFEN	1 (0.4%)	2 (0.7%)
LIDOCAINE	3 (1.1%)	3 (1.1%)
POVIDONE-IODINE	1 (0.4%)	0
UNCOMED	0	1 (0.4%)
THYROID THERAPY		
Total number of patients with at least one treatment	28 (10.1%)	23 (8.3%)
Total number of treatments	29	23
LEVOTHYROXINE	10 (3.6%)	11 (4.0%)
LEVOTHYROXINE SODIUM	16 (5.9%)	11 (4.0%)
LEVOTHYROXINE/LIOTHYRONINE	0	1 (0.4%)
THIAMAZOLE	1 (0.4%)	0
THYROID	1 (0.4%)	0
TONICS		
Total number of patients with at least one treatment	12 (4.3%)	5 (1.8%)
Total number of treatments	14	6
ALUM SATIVUM	2 (0.7%)	0
CINCUA LONGA	3 (1.1%)	2 (0.7%)
CINCUIN	1 (0.4%)	0
DIETARY SUPPLEMENT	3 (1.1%)	2 (0.7%)
EUCOMIA ULMOIDES	1 (0.4%)	0
HERBAL NOS/MINERALS NOS/VITAMINS NOS	1 (0.4%)	0
MINERALS NOS/VITAMINS NOS	2 (0.7%)	1 (0.4%)
SOPHORA FLAVESCENS	0	1 (0.4%)
SPIRULLINA SPP.	1 (0.4%)	0
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN		
Total number of patients with at least one treatment	64 (23.2%)	69 (24.9%)
Total number of treatments	80	92
ACETOPHENAC	2 (0.7%)	0
ACETYLSALICYLIC ACID	41 (14.9%)	39 (14.1%)
CHEMOSITIN	0	1 (0.4%)
CHEMOSITIN SULFATE SODIUM	1 (0.4%)	0
CHEMOSITIN SULFATE/GLUCOSAMINE HYDROCHLORIDE	1 (0.4%)	0
DICLOFENAC	3 (1.1%)	4 (1.4%)
DICLOFENAC SODIUM	0	2 (0.7%)
ETOFENAMATE	0	1 (0.4%)
FELBINAC	0	1 (0.4%)
FLUBIPROFEN AXETIL	1 (0.4%)	1 (0.4%)
FOLIC ACID	4 (1.4%)	7 (2.5%)
GLUCOSAMINE	4 (1.4%)	2 (0.7%)
IBUPROFEN	12 (4.3%)	10 (3.6%)
IBUPROFEN ARGININE	1 (0.4%)	0
KETOPROFEN	1 (0.4%)	2 (0.7%)
KETOROLAC	1 (0.4%)	1 (0.4%)
LOXOPROFEN SODIUM	1 (0.4%)	5 (1.8%)
MELOXICAM	2 (0.7%)	5 (1.8%)
MENTHOL	0	1 (0.4%)
METHYLSULFONYLMETHANE	0	1 (0.4%)
NAFROLEN	1 (0.4%)	3 (1.1%)
NAFROLEN SODIUM	1 (0.4%)	1 (0.4%)
NIMESULIDE	1 (0.4%)	0
ROGIMARINUS OFFICINALIS	1 (0.4%)	0
VACCINIUM MACROCARPON	0	1 (0.4%)
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE		
Total number of patients with at least one treatment	25 (9.1%)	27 (9.7%)
Total number of treatments	38	55
ACHILLEA MILEFOLIUM/AYURVEDIC PREPARATION NOS/CAPPARIS SPINOSA/CICORIUM INTYBUS/SINNA CUCURBITALIS/SOLANUM HIBERNICUM/TARAXACUM GALLICA/FERRELLA ALBA	1 (0.4%)	0
ACONITUM KUNZEZOFFII ROOT/HERBAL NOS	1 (0.4%)	0
ARBUSCULUS HIPPOCASTANUM	1 (0.4%)	0
ARBUSCULUS HIPPOCASTANUM EXTRACT	1 (0.4%)	0
ARBUSCULUS HIPPOCASTANUM SEED	0	1 (0.4%)
ALLIUM SATIVUM	2 (0.7%)	0
AMBER (FOSSILIZED TREE RESIN)/BORNEOL/CALAMINE/COW BEZOAR/MUSK/PEARL/SODIUM BORATE	0	1 (0.4%)
ANDROGAPHIS PANICULATA HERB/ANGELICA SINENSIS ROOT/COCONOPSIS PILLOSIA ROOT/PLEMINGIA PROSTRATA ROOT/PANACEA BHALI STEM/ROSA LARYGATA ROOT/SPATHULORIS SUBRECTUS STEM/ZANTHOXYLUM DISSEITUM ROOT	0	1 (0.4%)
ANGELICA DAMURICA ROOT/ASTRAGALUS MENGHOLICUS ROOT/ATRACTYLODES MACROCEPHALA, RHIZOMA/MAGNOLIA SPP. FLOWER BUD/MENTHA CANADENSIS/SAPONIN/KOVIA DIVARICATA ROOT/XANTHIUM SIBIRICUM FRUIT	0	1 (0.4%)
ANGELICA SINENSIS ROOT/BORNEOL/BOSEHELLIA SACRA BARK RESIN/EUPOLYPHAGA SINENSIS/PANAX NOTOGINSENG ROOT WITH RHIZOME/PYRITE	0	1 (0.4%)
ANGELICA SPP.	0	1 (0.4%)
ARISTOLOCHIA MANSHURIENSIS	0	1 (0.4%)
ASCORBIC ACID/BETA VULGARIS ROOT/LIPASE/PEPTIDASE/PHOSPHOLIPIDS SOYBEAN/SILYBUM MARIANUM SEED/PANACOM OFFICINALE ROOT/PRINUS/PRINUS OFFICINALE ROOT	1 (0.4%)	0
ASTRAGALUS MENGHOLICUS ROOT/CORYDALIS YANHSUO TUBER/DEER HORN/EUCOMIA ULMOIDES BARK/SALVIA MILTIORRHIZA ROOT WITH RHIZOME	0	1 (0.4%)
ASTRAGALUS MENGHOLICUS ROOT/PANAX NOTOGINSENG ROOT WITH RHIZOME/SALVIA MILTIORRHIZA ROOT WITH RHIZOME/SOPHORA FLAVESCENS ROOT	0	1 (0.4%)
ATRACTYLODES MACROCEPHALA, RHIZOMA/COCONOPSIS SPP. ROOT/CULLEN CORYLIFOLIUM FRUIT/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/OPHIPOGON JAPONICUS ROOT TUBER/PORIA COCOS SCLEROTIUM/SCI GANERA CHINENSIS FRUIT	1 (0.4%)	0
ATRACTYLODES SPP.	0	1 (0.4%)
AYURVEDIC PREPARATION NOS	0	1 (0.4%)
BETA VULGARIS	1 (0.4%)	0
BETA VULGARIS ROOT/CRATAEGUS LARYGATA/FOENICULUM VULGARE SEED/GLYCYRRHIZA GLABRA ROOT	0	1 (0.4%)
BORNEOL/PANAX NOTOGINSENG ROOT WITH RHIZOME/SALVIA MILTIORRHIZA ROOT WITH RHIZOME	1 (0.4%)	1 (0.4%)
CINERIS SATIVA	0	1 (0.4%)
CITRELLA ASIATICA HERB	0	1 (0.4%)
CICADA SLOXII	0	1 (0.4%)
CINNAMOMUM CASSIA TWIG/GLYCYRRHIZA URALENSIS ROOT WITH RHIZOME/PANONIA LACTIFLORA ROOT/ZINGIBER OFFICINALE RHIZOME/ZIZIPHUS JUTURA FRUIT	1 (0.4%)	0
CINNAMOMUM SPP.	1 (0.4%)	0
CITRUS AURANTIUM PHEL/CYPERUS ROTUNDIS RHIZOME/GLYCYRRHIZA SPP. ROOT/PERILLA FRUTESCENS VAR. CRISPA HERB/ZINGIBER OFFICINALE RHIZOME	0	1 (0.4%)
CUCURBITA PEPO SEED OIL	0	1 (0.4%)
CUCURMA LONGA	3 (1.1%)	2 (0.7%)
DEER VELVET/EPIMEDIUM SPP. LEAF/FALLOPIA MULTIFLORA ROOT TUBER/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/VITAMIN B1 NOS/ZINGIBER OFFICINALE RHIZOME/ZIZIPHUS JUTURA FRUIT	1 (0.4%)	0
ECHINACEA SPP.	1 (0.4%)	0
EUCOMIA ULMOIDES	1 (0.4%)	0
GINKGO BILOBA	1 (0.4%)	0

GINKGO BILOBA EXTRACT	1 (0.4%)	1 (0.4%)
GINKGO BILOBA LEAF	1 (0.4%)	1 (0.4%)
GLYCINE MAX/PERSEA AMERICANA EXTRACT	0	1 (0.4%)
GLYCYRRHIZA GLABRA	0	1 (0.4%)
GLYCYRRHIZA SPP. ROOT/PANONIA LACTIFLORA ROOT	1 (0.4%)	0
GYNEMA SYLVESTRE	1 (0.4%)	0
HERBAL NOS	2 (0.7%)	3 (1.1%)
HYPERICUM PERFORATUM EXTRACT	0	1 (0.4%)
ISATIS TINCTORIA ROOT	0	1 (0.4%)
JELLY OIL	1 (0.4%)	2 (0.7%)
LINUM USITATISSIMUM SEED	0	2 (0.7%)
MALUS SPP. VINDGAR EXTRACT	1 (0.4%)	1 (0.4%)
MORASUS PURPUREUS	0	1 (0.4%)
PASTINACA SATIVA	0	1 (0.4%)
PETIVERIA ALLIACA	0	1 (0.4%)
PLANTAGO SPP.	0	1 (0.4%)
ROSMARINUS OFFICINALIS	1 (0.4%)	0
SALICIA RETICULATA	1 (0.4%)	0
SCHIZONEPETA SPP.	0	1 (0.4%)
SEBENGA REPENS	1 (0.4%)	2 (0.7%)
SIBERKAYAN SPINOSUM OIL	0	1 (0.4%)
SOPHORA FLAVESCENS	0	1 (0.4%)
SPIRULINA SPP.	1 (0.4%)	0
TIGER BONE	0	1 (0.4%)
UNCAGED	1 (0.4%)	7 (2.5%)
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	2 (0.7%)	1 (0.4%)
VACCINIUM MACROCARPON	0	1 (0.4%)
VACCINIUM MYRTILLUS	1 (0.4%)	0
VITIS VINIFERA SEED	0	1 (0.4%)
WITHANIA SOMNIFERA ROOT	1 (0.4%)	0
UROLOGICALS		
Total number of patients with at least one treatment	37 (13.4%)	25 (9.0%)
Total number of treatments	51	43
ALFUZOSIN	1 (0.4%)	0
ALFUZOSIN HYDROCHLORIDE	1 (0.4%)	0
ALPROSTADIL	1 (0.4%)	0
AMTRIPTYLINE	2 (0.7%)	0
AMTRIPTYLINE HYDROCHLORIDE	1 (0.4%)	0
BUSPİRİNE	0	1 (0.4%)
CALCIUM CHLORIDE	0	1 (0.4%)
CHEMBROITIN	0	1 (0.4%)
CHEMBROITIN SULFATE SODIUM	1 (0.4%)	0
CLMIFRAMINE HYDROCHLORIDE	1 (0.4%)	0
COLLAGEN	2 (0.7%)	1 (0.4%)
CUCURBITA PEPO SEED OIL	0	1 (0.4%)
DOXAZOSIN	3 (1.1%)	3 (1.1%)
DOXAZOSIN MESILATE	2 (0.7%)	1 (0.4%)
DULOXETINE	4 (1.4%)	4 (1.4%)
DULOXETINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
DUTASTERİDE	3 (1.1%)	0
DUTASTERİDE/TAMUSOSIN HYDROCHLORIDE	1 (0.4%)	0
EUCONNIA ULMOIDES	1 (0.4%)	0
FINASTERİDE	5 (1.8%)	3 (1.1%)
HYALURONATE SODIUM	1 (0.4%)	2 (0.7%)
LIDOCAINE	3 (1.1%)	3 (1.1%)
MAGNESIUM HYDROXİDE	0	2 (0.7%)
MIRABRON	1 (0.4%)	3 (1.1%)
OXYBUTYNIN	0	1 (0.4%)
SEBENGA REPENS	1 (0.4%)	2 (0.7%)
SILDENAFİL	1 (0.4%)	0
SILDOSİN	2 (0.7%)	1 (0.4%)
SOLİFENACİN	0	2 (0.7%)
SOLİFENACİN SUCCİNATE	2 (0.7%)	1 (0.4%)
TAMALAFİL	2 (0.7%)	1 (0.4%)
TAMUSOSİN	1 (0.4%)	1 (0.4%)
TAMUSOSİN HYDROCHLORİDE	3 (1.1%)	4 (1.4%)
TOLTERODİNE	0	1 (0.4%)
WITHANIA SOMNIFERA ROOT	1 (0.4%)	0
VACCINES		
Total number of patients with at least one treatment	78 (28.3%)	72 (26.0%)
Total number of treatments	105	105
COVID-19 VACCINE	3 (1.1%)	2 (0.7%)
COVID-19 VACCINE INACT	1 (0.4%)	1 (0.4%)
COVID-19 VACCINE INACT (VERO) C202	0	1 (0.4%)
COVID-19 VACCINE INACT (VERO) H802	0	1 (0.4%)
COVID-19 VACCINE NIVV AD (CHADOXI NIVV-19)	13 (4.7%)	16 (5.8%)
COVID-19 VACCINE NRVV AD26 (GAM-COVID-VAC) / COVID-19 VACCINE NRVV AD5 (GAM-COVID-VAC)	1 (0.4%)	3 (1.1%)
ELASOMER	16 (5.8%)	9 (3.2%)
İNFLUENZA VACCINE	3 (1.1%)	9 (3.2%)
İNFLUENZA VACCINE INACT SAG 3V	0	1 (0.4%)
İNFLUENZA VACCINE INACT SPLIT 3V	1 (0.4%)	0
İNFLUENZA VACCINE INACT SPLIT 4V	0	1 (0.4%)
İNFLUENZA VACCINE INACT SPLIT 4V	1 (0.4%)	0
PNEUMOCOCCAL VACCINE	1 (0.4%)	0
PNEUMOCOCCAL VACCINE POLYSACCH 23V	0	1 (0.4%)
TETANIS VACCINE TOXOID	0	1 (0.4%)
TOZINAMERAN	42 (15.2%)	38 (13.7%)
VASOPROTECTİVES		
Total number of patients with at least one treatment	31 (11.2%)	33 (11.9%)
Total number of treatments	36	50
ARSCULUS HIPPOCASTANUM	1 (0.4%)	0
ARSCULUS HIPPOCASTANUM EXTRACT	1 (0.4%)	0
ARSCULUS HIPPOCASTANUM SEED	0	1 (0.4%)
AMBER (FOSSILIZED TREE RESIN) /BORNEOL /CALAMINE /COW BEZOAR /MUSK /PEARL /SODIUM BORATE	0	1 (0.4%)
ASCORBIC ACID/HESPERİDİN METHYL CHALCONE/RIBUCUS ACULAEATUS	1 (0.4%)	0
ASCORBIC ACID/KUTİDİNE	0	2 (0.7%)
BEKLOMETHASONE	1 (0.4%)	0
BETAMETHASONE	1 (0.4%)	1 (0.4%)
BETAMETHASONE DİPROPİONATE	1 (0.4%)	0
BETAMETHASONE VALERATE	1 (0.4%)	0
BİOFLAVONOİD NOS	0	1 (0.4%)
CALCIUM BORSİLİATE	1 (0.4%)	4 (1.4%)
CHITELLA ASIATICA HERB	0	1 (0.4%)
CINCHOCALINE HYDROCHLORİDE /ESCULOSİDE /HYDROCORTİSONE /HEMOMYCİN SULFATE	1 (0.4%)	0
DEKAMETHASONE	1 (0.4%)	1 (0.4%)
DEKAMETHASONE SODIUM PHOSPHATE	0	3 (1.1%)
DİFLUKORTİLONE VALERATE /LIDOCAİNE	1 (0.4%)	0
DİLTİAZEM	1 (0.4%)	5 (1.8%)
DİLTİAZEM HYDROCHLORİDE	0	1 (0.4%)

DIOSMIN	0	2 (0.7%)
DIOSMIN/HESPERIDIN	2 (0.7%)	1 (0.4%)
EGCIN	1 (0.4%)	0
GLYCERYL TRINITRATE	3 (1.1%)	5 (1.8%)
HEPARIN	1 (0.4%)	3 (1.1%)
HESPERIDIN	0	1 (0.4%)
HYALURONATE SODIUM	1 (0.4%)	2 (0.7%)
LIDOCAINE	3 (1.1%)	3 (1.1%)
NIPEPIRINE	7 (2.5%)	5 (1.8%)
PHENYLEPHRINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
PRIMIDOLONE	1 (0.4%)	0
TRAMCETOLONE ACETONIDE	2 (0.7%)	0
TROXERUTIN	1 (0.4%)	1 (0.4%)
VITIS VINIFERA SEED	0	1 (0.4%)
ZINC	1 (0.4%)	1 (0.4%)
VITAMINS		
Total number of patients with at least one treatment	45 (16.3%)	42 (15.2%)
Total number of treatments	76	60
AMINO ACIDS NOS/HERBAL NOS/MINERALS NOS/VITAMINS NOS	1 (0.4%)	0
AMINO BENZOIC ACID/BIOTIN/CALCIUM PANTOTHENATE/CALCIUM PHOSPHATE DIBASIC/CHOLINE BITARTRATE/CYANOCOBALAMIN/FOLIC ACID/INOSITOL/NICOTINAMIDE/PPRIDOXINE HYDROCHLORIDE/RIBOFLAVIN/THIAMINE HYDROCHLORIDE	1 (0.4%)	0
ASCORBIC ACID	9 (3.3%)	8 (2.9%)
ASCORBIC ACID/BETACAROTENE/CURCIC OXIDE/TOCOPHERYL ACETATE/ZINC OXIDE	1 (0.4%)	0
ASCORBIC ACID/BIOTIN	1 (0.4%)	0
ASCORBIC ACID/BIOTIN/CALCIUM PANTOTHENATE/CYANOCOBALAMIN/FOLIC ACID/NICOTINAMIDE/PPRIDOXINE HYDROCHLORIDE/RIBOFLAVIN/THIAMINE HYDROCHLORIDE	1 (0.4%)	0
ASCORBIC ACID/CALCIUM CARBONATE/COLECALCIFEROL	1 (0.4%)	0
ASCORBIC ACID/CALCIUM CHROMIUM/FOLIC ACID/MAGNESIUM/PANTOTHENIC ACID/PPRIDOXINE HYDROCHLORIDE/RETINOL/VITAMIN B12 NOS/VITAMIN D NOS/VITAMIN E NOS	0	1 (0.4%)
ASCORBIC ACID/COPPER GLUCONATE/FISH OIL/TOCOPHERYL ACETATE/XANTOPYL/ZEAXANTHIN/ZINC OXIDE	0	1 (0.4%)
BENZOYLAMINE	1 (0.4%)	0
BETACAROTENE	0	1 (0.4%)
BETAINE/LIVOMEPOLIC ACID/PPRIDOXINE HYDROCHLORIDE/RIBOFLAVIN/VITAMIN B12 NOS/ZINC	0	1 (0.4%)
BIOTIN	1 (0.4%)	1 (0.4%)
CALCIFEROL	0	1 (0.4%)
CALCITRIOL	1 (0.4%)	0
COD-LIVER OIL	1 (0.4%)	0
COLECALCIFEROL	16 (5.8%)	13 (4.7%)
COLECALCIFEROL/LINUM USITATISSIMUM	1 (0.4%)	0
CYANOCOBALAMIN/FURSULTAMINE HYDROCHLORIDE/PPRIDOXINE HYDROCHLORIDE/RIBOFLAVIN	0	1 (0.4%)
CYANOCOBALAMIN/PPRIDOXINE HYDROCHLORIDE/THIAMINE HYDROCHLORIDE	3 (1.1%)	0
ERGOCALCIFEROL	1 (0.4%)	1 (0.4%)
OTHERS BILBOA/MINERALS NOS/VITAMINS NOS	0	1 (0.4%)
HERBAL NOS/MINERALS NOS/VITAMINS NOS	1 (0.4%)	0
MAGNESIUM OXIDE/PPRIDOXINE HYDROCHLORIDE	1 (0.4%)	0
MAGNESIUM/PPRIDOXINE HYDROCHLORIDE	1 (0.4%)	1 (0.4%)
MINERALS NOS/VITAMINS NOS	2 (0.7%)	1 (0.4%)
MULTIVITAMINS, OTHER COMBINATIONS	0	1 (0.4%)
THIAMINE DISULFIDE	1 (0.4%)	0
THIAMINE HYDROCHLORIDE	0	1 (0.4%)
UNCODED	1 (0.4%)	1 (0.4%)
VITAMIN B COMPLEX	3 (1.1%)	1 (0.4%)
VITAMIN B NOS	1 (0.4%)	2 (0.7%)
VITAMIN B1 NOS	0	1 (0.4%)
VITAMIN D NOS	8 (2.9%)	6 (2.2%)
VITAMIN E NOS	2 (0.7%)	4 (1.4%)
VITAMINS NOS	12 (4.3%)	11 (4.0%)

Treatments are coded using the WHO Drug Global B3 Format dictionary Version September 1, 2020. Treatments can appear under multiple classes. Multiple uses of a specific medication for a patient were counted once in the frequency for the medication. Likewise, multiple uses within a specific medication class for a patient were counted once in the frequency for the medication class. For frequency counts in the "total number of treatments", multiple uses of the same treatment for a patient were counted separately. Clinical cut-off: 06JUL2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_cm.sas
Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Primary/prod/output/t_cm CONC_NOCUL_WP24_IT_06JUL2022_41984.xls
12JUL2023 16:07

POPULATION: Intent-To-Treat Population
 ENDPOINT: --
 MODEL: descriptive
 STUDY: GR41986
 Number of Centers/Countries/Geographical Regions with <10, >=10 Patients per Arm

	Center				Country				Geographical region			
	n	%	n of patients randomized	% randomized patients	n	%	n of patients randomized	% randomized patients	n	%	n of patients randomized	% randomized patients
Overall	192	100,0	729	100,0	22	100,0	729	100,0	3	100,0	729	100,0
with <10 patients per arm	192	100,0	729	100,0	12	54,5	118	16,2	0	NE	NE	NE
with >=10 patients per arm	0	NE	NE	NE	10	45,5	611	83,8	3	100,0	729	100,0

'<10 patients' category if at least one treatment arm has <10 patients; '>=10 patients' category if all treatment arms have >=10 patients.

Geographical regions: Europe, America, Asia Pacific

'n': Number of centers/countries/regions; "%": Percent of centers/countries/regions compared to overall number of centers/countries/regions

'n of patients randomized': Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)

'% randomized patients': Percent of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm compared to overall number of randomized patients)

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_center.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_center_IT_09AUG2022_41986.xls

18AUG2023 11:17

POPULATION: Intent-To-Treat Population

ENDPOINT: --

MODEL: descriptive

STUDY: GR41986

Times in which patient reported outcomes were collected through Week 24

	Faricimab (N=366)	Aflibercept (N=363)
PRO (NEI VFQ-25) (weeks)		
n	366	363
Median	24,14	24,14

Times were calculated as:

PRO (NEI VFQ-25): Last Date of answered questionnaire - Randomization Date + 1.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_fu.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_fu_IT_09AUG2022_41986.xls

17JUL2023 18:40

POPULATION: Safety-Evaluable Population

ENDPOINT: --

MODEL: descriptive

STUDY: GR41986

Duration of Exposure to Treatment through Week 24

	Faricimab (N=365)	Aflibercept (N=361)
Treatment duration (weeks)		
n	365	361
Mean (SD)	19.9 (2.06)	19.7 (2.25)
Median	20,1	20,1
Min-max	0 - 22	0 - 22
Number of study drug administrations		
n	365	361
Mean (SD)	5.7 (0.68)	5.7 (0.72)
Median	6	6
Min-max	1 - 6	1 - 6
Dose interruption		
Number of doses interrupted	21	14
At least one interrupted dose	15 (4.1%)	11 (3.0%)
Intraocular inflammation	2 (0.5%)	1 (0.3%)
BCVA decrease	3 (0.8%)	0
Elevated intraocular pressure	1 (0.3%)	1 (0.3%)
Rhegmatogenous retinal break	1 (0.3%)	0
Rhegmatogenous retinal detachment or macular hole	0	0
Active or suspected infection	1 (0.3%)	1 (0.3%)
Cataract surgery in the study eye	0	0
Vitrectomy	1 (0.3%)	0
Intraocular surgery in study eye	0	0
On-study prohibited medications	0	0
Other	11 (3.0%)	8 (2.2%)
Interruptions per patient		
n	15	11
1	10 (2.7%)	9 (2.5%)
2	4 (1.1%)	1 (0.3%)
3	1 (0.3%)	1 (0.3%)

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ex.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_ex_SE_09AUG2022_41986.xls

19JUL2023 17:14

POPULATION: Intent-To-Treat Population

ENDPOINT: Disposition of Patients per Arm through Week 24

MODEL: descriptive

STUDY: GR41986

Status / Primary Reason for Discontinuation	Faricimab (N=366)	Aflibercept (N=363)	All (N=729)
Number of Patients Randomized	366 (100%)	363 (100%)	729 (100%)
Number of Patients Treated	365 (99.7%)	361 (99.4%)	726 (99.6%)
Discontinued Study*			
Total	6 (1.6%)	10 (2.8%)	16 (2.2%)
Adverse Event	1 (0.3%)	1 (0.3%)	2 (0.3%)
Pregnancy	0	0	0
Death	1 (0.3%)	2 (0.6%)	3 (0.4%)
Lack of Efficacy	0	0	0
Lost To Follow-up	0	1 (0.3%)	1 (0.1%)
Protocol Deviation	0	1 (0.3%)	1 (0.1%)
Withdrawal by Subject	0	4 (1.1%)	4 (0.5%)
Study Terminated By Sponsor	0	0	0
Non-Compliance With Study Drug	2 (0.5%)	0	2 (0.3%)
Physician decision	0	1 (0.3%)	1 (0.1%)
Other	2 (0.5%)	0	2 (0.3%)
Discontinued Treatment**			
Total	11 (3.0%)	15 (4.2%)	26 (3.6%)
Adverse Event	2 (0.5%)	2 (0.6%)	4 (0.6%)
Pregnancy	0	0	0
Death	1 (0.3%)	2 (0.6%)	3 (0.4%)
Lack of Efficacy	0	0	0
Lost To Follow-up	0	4 (1.1%)	4 (0.6%)
Protocol Deviation	0	0	0
Withdrawal by Subject	3 (0.8%)	6 (1.7%)	9 (1.2%)
Study Terminated By Sponsor	0	0	0
Non-Compliance With Study Drug	2 (0.5%)	0	2 (0.3%)
Physician decision	2 (0.5%)	1 (0.3%)	3 (0.4%)
Other	1 (0.3%)	0	1 (0.1%)

Includes discontinuation occurring prior to day 154 (first day of week 24 analysis visit window).

* Percentages are based on number of patients randomized.

**Percentages are based on number of patients treated.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/program/t_ds.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_ds_IT_09AUG2022_41986.xls

17JUL2023 18:38

POPULATION: Intent-To-Treat Population

ENDPOINT: --

MODEL: descriptive

STUDY: GR41986

Baseline Demographics

	Faricimab 6 mg Q4W (N=366)	Aflibercept 2 mg Q4W (N=363)	All Patients (N=729)
Region			
n	366	363	729
Rest of the World	187 (51.1%)	187 (51.5%)	374 (51.3%)
US and Canada	95 (26.0%)	93 (25.6%)	188 (25.8%)
Asia	84 (23.0%)	83 (22.9%)	167 (22.9%)
Age (years)			
n	366	363	729
Mean (SD)	65.6 (13.1)	64.7 (13.3)	65.1 (13.2)
Median	67	66	66
Min - Max	22 - 100	27 - 95	22 - 100
Age group (years)			
n	366	363	729
<65	162 (44.3%)	158 (43.5%)	320 (43.9%)
>=65	204 (55.7%)	205 (56.5%)	409 (56.1%)
Sex			
n	366	363	729
Male	193 (52.7%)	200 (55.1%)	393 (53.9%)
Female	173 (47.3%)	163 (44.9%)	336 (46.1%)
Ethnicity			
n	366	363	729
Not Hispanic or Latino	286 (78.1%)	283 (78.0%)	569 (78.1%)
Hispanic or Latino	66 (18.0%)	73 (20.1%)	139 (19.1%)
Unknown	10 (2.7%)	3 (0.8%)	13 (1.8%)
Not Reported	4 (1.1%)	4 (1.1%)	8 (1.1%)
Race			
n	366	363	729
American Indian or Alaska Native	2 (0.5%)	3 (0.8%)	5 (0.7%)
Black or African American	10 (2.7%)	13 (3.6%)	23 (3.2%)
Native Hawaiian or other Pacific Islander	0	1 (0.3%)	1 (0.1%)
White	243 (66.4%)	253 (69.7%)	496 (68.0%)
Multiple	1 (0.3%)	0	1 (0.1%)
Unknown	21 (5.7%)	5 (1.4%)	26 (3.6%)
Asian	89 (24.3%)	88 (24.2%)	177 (24.3%)
Chinese	36 (40.4%)	33 (37.5%)	69 (39.0%)
Taiwanese	0	0	0
Asian Indian	1 (1.1%)	0	1 (0.6%)
Korean	21 (23.6%)	22 (25.0%)	43 (24.3%)
Malaysian	0	0	0
Vietnamese	1 (1.1%)	0	1 (0.6%)
Japanese	24 (27.0%)	27 (30.7%)	51 (28.8%)
Filipino	0	3 (3.4%)	3 (1.7%)
Other Asian	6 (6.7%)	3 (3.4%)	9 (5.1%)

Age at randomization.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_dm.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_dm_IT_09AUG2022_41986.xls
17JUL2023 18:39

POPULATION: Intent-To-Treat Population
 ENDPOINT: --
 MODEL: descriptive
 STUDY: GR41986
 Baseline Ocular Characteristics in the Study Eye

	Faricimab (N=366)	Aflibercept (N=363)
Study Eye		
n	366	363
Left	180 (49.2%)	181 (49.9%)
Right	186 (50.8%)	182 (50.1%)
Bilateral Eligibility		
n	0	0
Eye with worse BCVA selected	0	0
Eye with better BCVA selected	0	0
No difference in BCVA between eyes	0	0
Months since RVO diagnosis in the Study Eye		
n	360	352
Mean (SD)	1.57 (6.39)	1.10 (0.95)
Median	0,89	0,79
Min - Max	0.1 - 120.3	0.1 - 8.9
Unknown	6	11
BCVA (letters)		
n	366	363
Mean (SD)	50.25 (16.25)	50.71 (16.34)
Median	54	54
Min - Max	19.0 - 87.0	19.0 - 73.0
Missing/Invalid	0	0
BCVA (letters) categories		
n	366	363
<= 34 letters (20/200 or worse)	79 (21.6%)	80 (22.0%)
>34 (better than 20/200) - <55 (worse than 20/80)	106 (29.0%)	105 (28.9%)
>= 55 letters (20/80 or better)	181 (49.5%)	178 (49.0%)
CST (ILM-BM) (microns)		
n	359	359
Mean (SD)	702.21 (244.00)	721.07 (242.86)
Median	668	701
Min - Max	266.0 - 1500.0	281.0 - 1419.0
Missing/Ungradable	7	4
Macular Ischemic Non-Perfusion		
n	366	363
Yes	38 (10.4%)	37 (10.2%)
No	194 (53.0%)	177 (48.8%)
Missing/Ungradable	134 (36.6%)	149 (41.0%)
Intraocular pressure (mmHg)		
n	366	363
Mean (SD)	14.89 (3.06)	14.97 (3.17)
Median	15	15
Min - Max	7.0 - 25.0	7.0 - 26.0
Lens Status		
n	366	363
Phakic	308 (84.2%)	314 (86.5%)
Pseudophakic	57 (15.6%)	48 (13.2%)
Aphakic	1 (0.3%)	1 (0.3%)
Other	0	0

BCVA=Best Corrected Visual Acuity; CRC = Central Reading Center; CST=Central Subfield Thickness; ILM = Internal Limiting Membrane.
 Baseline is defined as the last available measurement obtained on or prior to randomization. CST(ILM-BM) is defined as the distance between ILM and Bruch's membrane (BM) as assessed by the CRC.
 Absence of macular ischemic non perfusion is defined as an area of ischemic non perfusion within the macula of 0 to 0.1 mm²
 Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_blc.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_blc_SOCULCH_IT_09AUG2022_41986.xls
 17JUL2023 18:34

POPULATION: Intent-To-Treat Population
 ENDPOINT: --
 MODEL: descriptive
 STUDY: GR41986
 Non-Ocular Baseline Characteristics

	Faricimab (N=366)	Aflibercept (N=363)
Weight (kg)		
n	364	359
Mean (SD)	76.75 (18.03)	79.76 (19.40)
Median	75	77
Min - Max	37.0 - 185.0	37.6 - 188.0
Missing/Not Done	2	4
Height (cm)		
n	364	359
Mean (SD)	166.93 (9.87)	166.57 (10.44)
Median	167	166.37
Min - Max	142.5 - 194.5	110.0 - 200.7
Missing/Not Done	2	4
BMI (kg/m2)		
n	364	359
Mean (SD)	27.38 (5.19)	28.64 (5.97)
Median	26.73	27.55
Min - Max	14.9 - 62.0	14.8 - 57.0
Missing/Not Done	2	4
BMI (kg/m2) categories		
n	366	363
< 30	276 (75.4%)	240 (66.1%)
>= 30	88 (24.0%)	119 (32.8%)
Missing/Not Done	2 (0.5%)	4 (1.1%)
Systolic blood pressure (mmHg)		
n	365	360
Mean (SD)	135.62 (15.55)	136.63 (15.78)
Median	134	135
Min - Max	74.0 - 199.0	86.0 - 190.0
Missing/Not Done	1	3
Systolic blood pressure (mmHg) categories		
n	366	363
< 140	235 (64.2%)	219 (60.3%)
>= 140 and < 160	100 (27.3%)	106 (29.2%)
>= 160	30 (8.2%)	35 (9.6%)
Missing/Not Done	1 (0.3%)	3 (0.8%)
Diastolic blood pressure (mmHg)		
n	365	360
Mean (SD)	80.44 (9.79)	81.24 (10.35)
Median	80	82
Min - Max	53.0 - 109.0	10.0 - 107.0
Missing/Not Done	1	3
Blood pressure (mmHg)		
n	365	360
> 160 systolic or > 90 diastolic	60 (16.4%)	61 (16.9%)
<= 140 systolic and <= 85 diastolic	202 (55.3%)	188 (52.2%)
<= 120 systolic and <= 80 diastolic	49 (13.4%)	51 (14.2%)
Missing/Invalid	1	3

BMI = Body Mass Index.

Baseline is the last available measurement prior to first exposure to study drug.

Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_blc.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_blc_NOCULCH_IT_09AUG2022_41986.xls

17JUL2023 18:32

POPULATION: Intent-To-Treat Population
 ENDPOINT: --
 MODEL: descriptive
 STUDY: GR41986
 Ocular Medical History in the Study Eye

Ocular Medical History Description	Faricimab (N=366)	Aflibercept (N=363)
Total Number of patients with at least one condition	175 (47.8%)	190 (52.3%)
Total number of conditions	254	270
CATARACT	132 (36.1%)	139 (38.3%)
GLAUCOMA	39 (10.7%)	34 (9.4%)
RETINOPATHY - HYPERTENSIVE	21 (5.7%)	24 (6.6%)
RETINAL VEIN OCCLUSION	16 (4.4%)	19 (5.2%)
DRY EYE DISEASE	16 (4.4%)	17 (4.7%)
OCULAR HYPERTENSION	6 (1.6%)	7 (1.9%)
BLEPHARITIS/MGD	4 (1.1%)	7 (1.9%)
EYELID DISORDERS	4 (1.1%)	4 (1.1%)
RETINAL TEAR/HOLE	3 (0.8%)	4 (1.1%)
CONJUNCTIVITIS	3 (0.8%)	1 (0.3%)
STRABISMUS	0	3 (0.8%)
CORNEAL DYSTROPHY	1 (0.3%)	1 (0.3%)
POSTERIOR CAPSULE OPACIFICATION	1 (0.3%)	1 (0.3%)
VITREOUS HAEMORRHAGE	1 (0.3%)	1 (0.3%)
ASTEROID HYALOSIS	1 (0.3%)	0
CENTRAL SEROUS CHORIORETINOPATHY	1 (0.3%)	0
OPTIC ATROPHY	0	1 (0.3%)
PAPILLEDEMA	0	1 (0.3%)
PIGMENT DISPERSION SYNDROME	0	1 (0.3%)
PSEUDOEXFOLIATION SYNDROME	0	1 (0.3%)
RETINAL DETACHMENT	0	1 (0.3%)
RETINOSCHISIS	1 (0.3%)	0
SCLERITIS	0	1 (0.3%)

Percentages are based on N in the column headings. Includes all diseases and conditions reported as part of ocular medical history at baseline.
 Clinical cut-off: 09AUG2022

Program: ../clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_mh.sas
 Output: ../GR41986/data_analysis/ACE_CSR_Primary/prod/output/t_mh_SOMH_IT_09AUG2022_41986.xls
 17JUL2023 18:28

POPULATION: Intent-To-Treat Population
 ENDPOINT: --
 MODEL: descriptive
 STUDY: GR41986
 Prior Targeted Non-Ocular Medical History

Medical Condition	Faricimab (N=366)	Aflibercept (N=363)
Total number of patients with at least one condition	236 (64.5%)	238 (65.6%)
SYSTEMIC HYPERTENSION	200 (54.6%)	204 (56.2%)
TYPE 2 DIABETES	74 (20.2%)	79 (21.8%)
DIABETES MELLITUS UNCOMPLICATED	34 (9.3%)	41 (11.3%)
CORONARY ARTERY DISEASE	26 (7.1%)	22 (6.1%)
ATRIAL FIBRILATION	26 (7.1%)	20 (5.5%)
SOLID TUMOR	19 (5.2%)	12 (3.3%)
CEREBROVASCULAR ACCIDENTS (STROKE)	14 (3.8%)	8 (2.2%)
COPD	10 (2.7%)	12 (3.3%)
ANGINA	7 (1.9%)	12 (3.3%)
MYOCARDIAL INFARCTION	10 (2.7%)	8 (2.2%)
PERIPHERAL VASCULAR DISEASE	11 (3.0%)	7 (1.9%)
RENAL FAILURE	10 (2.7%)	8 (2.2%)
CONGESTIVE HEART FAILURE	11 (3.0%)	6 (1.7%)
CEREBROVASCULAR DISEASE	10 (2.7%)	5 (1.4%)
PEPTIC ULCER DISEASE	8 (2.2%)	7 (1.9%)
MODERATE TO SEVERE CKD	7 (1.9%)	7 (1.9%)
DEEP VENOUS THROMBOSIS	5 (1.4%)	6 (1.7%)
EEP VENOUS THROMBOSIS	4 (1.1%)	4 (1.1%)
TRANSIENT ISCHEMIC ATTACK	6 (1.6%)	2 (0.6%)
DIABETES MELLITUS END ORGAN DAMAGE	2 (0.5%)	4 (1.1%)
LIVER DISEASE MILD	3 (0.8%)	3 (0.8%)
TYPE 1 DIABETES	3 (0.8%)	3 (0.8%)
CONNECTIVE TISSUE DISEASE	3 (0.8%)	2 (0.6%)
DEMENTIA	3 (0.8%)	1 (0.3%)
LEUKAEMIA	2 (0.5%)	2 (0.6%)
MALIGNANT LYMPHOMA	1 (0.3%)	2 (0.6%)
AIDS	1 (0.3%)	1 (0.3%)
HEMIPLEGIA	1 (0.3%)	1 (0.3%)

Clinical cut-off: 09AUG2022

Program: ..nical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_mh_cat.sas
 Output: ..ata_analysis/ACE_CSR_Primary/prod/output/t_mh_cat_TARG_NOCUL_IT_09AUG2022_41986.xls
 17JUL2023 18:29

POPULATION: Intent-To-Treat Population

ENDPOINT: --

MODEL: descriptive

STUDY: GR41986

Prior Targeted Ocular Therapies/Treatment in the Study Eye

Therapy/Treatment Category Therapy/Treatment	Faricimab (N=366)	Aflibercept (N=363)
Total number of patients with at least one applicable therapy or treatment	21 (5.7%)	18 (5.0%)
Total number of applicable therapies or treatments	23	22
Any other prior ocular therapy		
Total number of patients with at least one applicable therapy or treatment	19 (5.2%)	16 (4.4%)
Total number of applicable therapies or treatments	21	20
OTHER	18 (4.9%)	15 (4.1%)
DIETARY SUPPLEMENT	1 (0.3%)	1 (0.3%)
Other laser photocoagulation		
Total number of patients with at least one applicable therapy or treatment	2 (0.5%)	0
Total number of applicable therapies or treatments	2	0
OTHER LASER PHOTOCOAGULATION	2 (0.5%)	0
Panretinal photocoagulation (PRP) therapy		
Total number of patients with at least one applicable therapy or treatment	0	1 (0.3%)
Total number of applicable therapies or treatments	0	1
PANRETINAL PHOTOCOAGULATION LASER (PRP)	0	1 (0.3%)
Steroid therapy		
Total number of patients with at least one applicable therapy or treatment	0	1 (0.3%)
Total number of applicable therapies or treatments	0	1
TOPICAL STEROIDS	0	1 (0.3%)

PRP = Panretinal Photocoagulation.

Percentages are based on N in the column headings.

For frequency counts by therapy or treatment, multiple occurrences of the same therapy or treatment in an individual are counted only once.

For the total number of therapies or treatments, multiple occurrences of the same therapy or treatment in an individual are counted separately.

Clinical cut-off: 09AUG2022

Program: ../clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_cm.sas

Output: ../86/data_analysis/ACE_CSR_Primary/prod/output/t_cm_POTT_SOCUL_IT_09AUG2022_41986.xls

17JUL2023 18:30

POPULATION: Intent-To-Treat Population

ENDPOINT: --

NOTE: descriptive

STUDY: GW4194

Concomitant Non-Ocular Medications by Medication Class and Preferred Name through Week 24

ATC Class Level 2	Faricimab (N=366)	Aflibercept (N=363)
Other Treatment		
Total number of patients with at least one treatment	313 (85.5)	315 (86.6)
Total number of treatments	1890	1914
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM		
Total number of patients with at least one treatment	147 (40.2)	152 (41.9)
Total number of treatments	160	168
AMLODIPINE BESILATE/ BENAZEPRIL HYDROCHLORIDE	0	3 (0.8)
AMLODIPINE BESILATE/ CANDESARTAN CILEXTEL	0	2 (0.6)
AMLODIPINE BESILATE/ FIMASARTAN POTASSIUM TRIHYDRATE	0	1 (0.3)
AMLODIPINE BESILATE/ HYDROCHLOROTHIAZIDE/ VALSARTAN	0	1 (0.3)
AMLODIPINE BESILATE/ INDAPAMIDE/ PERINDOPRIL ARGININE	1 (0.3)	3 (0.8)
AMLODIPINE BESILATE/ PERINDOPRIL ARGININE	4 (1.1)	4 (1.1)
AMLODIPINE BESILATE/ PERINDOPRIL ERBUMINE	1 (0.3)	1 (0.3)
AMLODIPINE BESILATE/ RAMIPRIL	3 (0.8)	0
AMLODIPINE BESILATE/ TELMISARTAN	1 (0.3)	1 (0.3)
AMLODIPINE BESILATE/ VALSARTAN	2 (0.5)	2 (0.6)
AMLODIPINE/ BENAZEPRIL	0	1 (0.3)
AMLODIPINE/ HYDROCHLOROTHIAZIDE/ VALSARTAN	0	2 (0.6)
AMLODIPINE/ PERINDOPRIL	1 (0.3)	0
AZILSARTAN	0	1 (0.3)
AZILSARTAN KAMEDOMKIL	0	1 (0.3)
AZILSARTAN MEDOKOMIL	1 (0.3)	0
BENAZEPRIL	1 (0.3)	1 (0.3)
BIDOPROLOL FUMARATE/ PERINDOPRIL ARGININE	1 (0.3)	1 (0.3)
BIDOPROLOL/ PERINDOPRIL ARGININE	0	1 (0.3)
CANDESARTAN	3 (0.8)	1 (0.3)
CANDESARTAN CILEXTEL	2 (0.5)	4 (1.1)
CANDESARTAN CILEXTEL/ HYDROCHLOROTHIAZIDE	0	1 (0.3)
CAPTORIL	4 (1.1)	1 (0.3)
CILAZAPRIL	1 (0.3)	0
ENALAPRIL	7 (1.9)	8 (2.2)
ENALAPRIL MALEATE	2 (0.5)	1 (0.3)
ENALAPRIL MALEATE/ FOLIC ACID	1 (0.3)	0
ENALAPRIL MALEATE/ HYDROCHLOROTHIAZIDE	0	2 (0.6)
ENALAPRILAT	0	2 (0.6)
FIMASARTAN POTASSIUM TRIHYDRATE	1 (0.3)	0
FOGINOPRIL SODIUM	0	1 (0.3)
HYDROCHLOROTHIAZIDE/ IRBESARTAN	1 (0.3)	2 (0.6)
HYDROCHLOROTHIAZIDE/ LISINAPRIL	1 (0.3)	0
HYDROCHLOROTHIAZIDE/ LOSARTAN POTASSIUM	3 (0.8)	1 (0.3)
HYDROCHLOROTHIAZIDE/ OLMESARTAN	1 (0.3)	0
HYDROCHLOROTHIAZIDE/ OLMESARTAN MEDOKOMIL	0	1 (0.3)
HYDROCHLOROTHIAZIDE/ RAMIPRIL	1 (0.3)	0
HYDROCHLOROTHIAZIDE/ TELMISARTAN	5 (1.4)	2 (0.6)
HYDROCHLOROTHIAZIDE/ VALSARTAN	4 (1.1)	2 (0.6)
INDAPAMIDE/ PERINDOPRIL	1 (0.3)	1 (0.3)
INDAPAMIDE/ PERINDOPRIL ARGININE	1 (0.3)	0
INDAPAMIDE/ PERINDOPRIL ERBUMINE	0	1 (0.3)
IRBESARTAN	5 (1.4)	4 (1.1)
LISINAPRIL	22 (6.0)	24 (6.6)
LISINAPRIL DIHYDRATE	0	1 (0.3)
LOSARTAN	26 (7.1)	31 (8.5)
LOSARTAN POTASSIUM	7 (1.9)	9 (2.5)
OLMESARTAN MEDOKOMIL	1 (0.3)	4 (1.1)
PERINDOPRIL	4 (1.1)	3 (0.8)
PERINDOPRIL ARGININE	1 (0.3)	0
PERINDOPRIL ERBUMINE	1 (0.3)	2 (0.6)
RAMIPRIL	12 (3.3)	14 (3.9)
SACUBUTRIL/ VALSARTAN	1 (0.3)	2 (0.6)
TELMISARTAN	13 (3.6)	5 (1.4)
TRANDOLAPRIL	1 (0.3)	0
VALSARTAN	7 (1.9)	8 (2.2)
ALL OTHER NON-THERAPEUTIC PRODUCTS		
Total number of patients with at least one treatment	14 (3.8)	23 (6.3)
Total number of treatments	17	23
ALL OTHER NON-THERAPEUTIC PRODUCTS	2 (0.5)	2 (0.6)
ASCORBIC ACID	7 (1.9)	13 (3.6)
HYALURONIC ACID	0	1 (0.3)
SODIUM CHLORIDE	5 (1.4)	7 (1.9)
ALL OTHER THERAPEUTIC PRODUCTS		
Total number of patients with at least one treatment	28 (7.7)	30 (8.3)
Total number of treatments	1 (0.3)	38
ACTIVASTYRENE	1 (0.3)	1 (0.3)
ALL OTHER THERAPEUTIC PRODUCTS	1 (0.3)	2 (0.6)
ASCORBIC ACID	7 (1.9)	13 (3.6)
ASTRAGALUS PROPINQUUS	1 (0.3)	0
CALCIUM CARBONATE	2 (0.5)	4 (1.1)
CALCIUM CITRATE/ VITAMIN D NOS	1 (0.3)	1 (0.3)
CALCIUM/ MAGNESIUM	1 (0.3)	0
CALCIUM/ VITAMIN D NOS	1 (0.3)	0
CHEMBRODITIN	0	1 (0.3)
CHEMBRODITIN SULFATE	0	1 (0.3)
CHEMBRODITIN SULFATE SODIUM	0	1 (0.3)
HERBAL NOS/ MINERAL NOS/ VITAMINS NOS	1 (0.3)	0
HYDROXYCOBALAMIN	1 (0.3)	0
IMIDAZOLYL ETHANAMIDE PENTAMIDIC ACID	1 (0.3)	0
IRON	4 (1.1)	6 (1.7)
OXIBEN	1 (0.3)	0
STROIDS	1 (0.3)	1 (0.3)
VITAMIN B12 NOS	9 (2.5)	9 (2.5)
WATER	1 (0.3)	0
AMBOLIC AGENTS FOR SYSTEMIC USE		
Total number of patients with at least one treatment	1 (0.3)	0
Total number of treatments	1	0
STEROIDS	1 (0.3)	0

ANALGESICS		
Total number of patients with at least one treatment	133 (36.3%)	131 (36.1%)
Total number of treatments	216	212
ACETYLSALICYLIC ACID/LIDOCINE	0	1 (0.3%)
ACETYLSALICYLIC ACID	58 (15.8%)	70 (19.3%)
ACETYLSALICYLIC ACID/ALUMINIUM GLYCINATE/MAGNESIUM CARBONATE	1 (0.3%)	0
ACETYLSALICYLIC ACID/ASCORBIC ACID	0	1 (0.3%)
ACETYLSALICYLIC ACID/GLYCINE	0	1 (0.3%)
ACETYLSALICYLIC ACID/MAGNESIUM HYDROXIDE	1 (0.3%)	1 (0.3%)
ACTYMATHE HIBENTATA ROOT	1 (0.3%)	0
ALUMINIUM HYDROXIDE/ASPRONAL/CAFFEINE/IBUPROFEN/PARACETAMOL	1 (0.3%)	0
AMTRIPTYLINE	1 (0.3%)	4 (1.1%)
AMTRIPTYLINE HYDROCHLORIDE	1 (0.3%)	3 (0.8%)
ANALGESIC	0	1 (0.3%)
ARTHEMISIA ASYTI	1 (0.3%)	0
ASCORBIC ACID/RUTOSIDE/SALICYLAMIDE	1 (0.3%)	0
BOTULINUM TOXIN TYPE A	1 (0.3%)	0
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	0	1 (0.3%)
BUPROPION TARTRATE	1 (0.3%)	0
CAFFEINE/COCAINE PHOSPHATE/PARACETAMOL	0	1 (0.3%)
CAFFEINE/ETHENZAMIDE/PHENAZONE	1 (0.3%)	0
CAFFEINE/PARACETAMOL/PROPETHAZINE METHYLENE DISALICYLATE/SALICYLAMIDE	1 (0.3%)	0
CARBAMAZEPINE	1 (0.3%)	1 (0.3%)
CHLORPHENIRAMINE MALEATE/DEXTROMETHORPHAN HYDROBROMIDE/PARACETAMOL/PSEUDOEPHEDRINE HYDROCHLORIDE	0	1 (0.3%)
CHLORPHENIRAMINE MALEATE/PARACETAMOL/PHENYLEPHRINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
CLOMIPRAMINE	1 (0.3%)	0
CLONIDINE	3 (0.8%)	3 (0.8%)
COCAINE	2 (0.5%)	0
COCAINE PHOSPHATE/HEMISYBRATE/PARACETAMOL	1 (0.3%)	1 (0.3%)
COCAINE PHOSPHATE/IBUPROFEN	0	1 (0.3%)
COCAINE PHOSPHATE/PARACETAMOL	1 (0.3%)	3 (0.8%)
COCAINE/PARACETAMOL	1 (0.3%)	1 (0.3%)
DEXTROMETHORPHAN HYDROBROMIDE/DOXYLAMINE SUCCINATE/EPHEDRINE SULFATE/ETHANOL/PARACETAMOL	0	1 (0.3%)
DEXTROMETHORPHAN HYDROBROMIDE/GUAFENESIN/PARACETAMOL/PSEUDOEPHEDRINE HYDROCHLORIDE	0	1 (0.3%)
DEXTROMETHORPHAN HYDROBROMIDE/PARACETAMOL/PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.3%)	1 (0.3%)
DIPHENHYDRAZINE	1 (0.3%)	0
DULOXETINE	2 (0.5%)	5 (1.4%)
DULOXETINE HYDROCHLORIDE	1 (0.3%)	3 (0.8%)
PENTANYL CITRATE	1 (0.3%)	0
FLORAZEPINE	1 (0.3%)	0
FLORAZEPINE DIHYDROCHLORIDE	0	1 (0.3%)
GABAPENTIN	10 (2.7%)	7 (1.9%)
HIPPOPHAE RHAMNOIDES	0	1 (0.3%)
HYDROCODONE	2 (0.5%)	0
HYDROCODONE BITARTRATE/PARACETAMOL	1 (0.3%)	0
HYDROCODONE/IBUPROFEN	1 (0.3%)	0
HYDROCODONE/PARACETAMOL	0	1 (0.3%)
HYDROPHENE	1 (0.3%)	0
METAMIZOLE	1 (0.3%)	0
METAMIZOLE/MAGNESIUM	0	1 (0.3%)
METAMIZOLE SODIUM	2 (0.5%)	2 (0.6%)
METHADONE	0	1 (0.3%)
METOPROLOL	17 (4.6%)	15 (4.1%)
METOPROLOL SUCCINATE	5 (1.4%)	9 (2.5%)
METOPROLOL TARTRATE	3 (0.8%)	2 (0.6%)
MELAXONE HYDROCHLORIDE/OXYCODONE HYDROCHLORIDE	1 (0.3%)	0
MIBACTRIPTAN	0	1 (0.3%)
OTHER ANALGESICS AND ANTI-EPHETICS	1 (0.3%)	0
OXYCODONE	2 (0.5%)	1 (0.3%)
OXYCODONE HYDROCHLORIDE	1 (0.3%)	0
OXYCODONE HYDROCHLORIDE/PARACETAMOL	2 (0.5%)	1 (0.3%)
OXYCODONE/PARACETAMOL	1 (0.3%)	0
PARACETAMOL	36 (9.8%)	23 (6.3%)
PARACETAMOL/TRAMADOL HYDROCHLORIDE	4 (1.1%)	4 (1.1%)
PERFAROCICINE	1 (0.3%)	0
PRIMIDALIN	6 (1.6%)	3 (0.8%)
PROPRANOLOL	2 (0.5%)	3 (0.8%)
RIZATRIPTAN	0	1 (0.3%)
SALICYLIC ACID	2 (0.5%)	0
SIBNATRIPTAN	2 (0.5%)	2 (0.6%)
SIBNATRIPTAN SUCCINATE	1 (0.3%)	0
TARPENTADOL	0	2 (0.6%)
TOPIRAMATE	2 (0.5%)	1 (0.3%)
TRAMADOL	4 (1.1%)	5 (1.4%)
TRAMADOL HYDROCHLORIDE	1 (0.3%)	2 (0.6%)
VALPROIC ACID	0	1 (0.3%)
VENLAFAXINE	0	3 (0.8%)
VENLAFAXINE HYDROCHLORIDE	0	2 (0.6%)
VERAPAMIL	0	1 (0.3%)
ANESTHETICS		
Total number of patients with at least one treatment	11 (3.0%)	3 (0.8%)
Total number of treatments	15	4
EPINEPHRINE BITARTRATE/LIDOCAINE HYDROCHLORIDE	1 (0.3%)	0
EPINEPHRINE/LIDOCAINE	1 (0.3%)	0
EPINEPHRINE	1 (0.3%)	0
PENTANYL CITRATE	1 (0.3%)	0
LIDOCAINE	6 (1.6%)	2 (0.6%)
LIDOCAINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
PROPPOLOL	2 (0.5%)	0
ANTI-ACNE PREPARATIONS		
Total number of patients with at least one treatment	21 (5.7%)	25 (6.9%)
Total number of treatments	30	27
AZITHROMYCIN	7 (1.9%)	6 (1.7%)
CHLORHEXIDINE	1 (0.3%)	0
CHLORHEXIDINE GLUCONATE	1 (0.3%)	0
CLINDAMYCIN	1 (0.3%)	3 (0.8%)
DEKAMETHASONE	3 (0.8%)	1 (0.3%)
DIMETICONE	1 (0.3%)	0
DOKYCLINE	2 (0.5%)	3 (0.8%)
DOKYCLINE MENOXYBRATE	1 (0.3%)	0
ERYTHROMYCIN	1 (0.3%)	0
IBUPROFEN	7 (1.9%)	9 (2.5%)
METHYLPRENIZOLONE	1 (0.3%)	1 (0.3%)
METHYLPRENIZOLONE ACETATE	0	1 (0.3%)
NADIFLOXACIN	0	1 (0.3%)
NICOTINAMIDE	0	1 (0.3%)
SALICYLIC ACID	2 (0.5%)	0

ANTI-PARKINSON DRUGS		
Total number of patients with at least one treatment	11 (3.0%)	5 (1.4%)
Total number of treatments	14	5
AMANTADINE	1 (0.3%)	0
CARBENOXOLINE	0	1 (0.3%)
CARBIDOPA/MONOHYDRATE/LEVODOPA	1 (0.3%)	2 (0.6%)
CARBIDOPA/ENTACAPONE/LEVODOPA	1 (0.3%)	0
CARBIDOPA/LEVODOPA	2 (0.5%)	0
DIPHENHYDRAMINE HYDROCHLORIDE	3 (0.8%)	2 (0.6%)
PRAMIPEXOLE	3 (0.8%)	0
ROPINIROLE	2 (0.5%)	0
ANTIANEMIC PREPARATIONS		
Total number of patients with at least one treatment	34 (9.3%)	31 (8.5%)
Total number of treatments	41	43
CYANOCOBALAMIN	3 (0.8%)	6 (1.7%)
DABHEFOPTIN ALFA	0	1 (0.3%)
FERRIC HYDROXIDE POLYMALTOSE COMPLEX	1 (0.3%)	0
FERROUS FUMARATE	1 (0.3%)	0
FERROUS GLYCINE SULFATE	0	1 (0.3%)
FERROUS SULFATE	3 (0.8%)	5 (1.4%)
FERROUS SULFATE/FOLIC ACID	2 (0.5%)	0
FOLIC ACID	6 (1.6%)	6 (1.7%)
FOLIC ACID/IRON/SERINE	1 (0.3%)	0
HYDROCOBALAMIN	1 (0.3%)	0
IRON	4 (1.1%)	6 (1.7%)
IRON POLYSACCHARIDE COMPLEX	0	1 (0.3%)
IRON/VITAMINS NOS	0	1 (0.3%)
MECOBALAMIN	1 (0.3%)	1 (0.3%)
METHIONYL METHYLENE GLYCYL-EPHEDIN BETA	1 (0.3%)	0
MINERALS NOS/VITAMINS NOS	3 (0.8%)	4 (1.1%)
SACCHARATED IRON OXIDE	1 (0.3%)	0
VITAMIN B NOS	3 (0.8%)	0
VITAMIN B12 NOS	9 (2.5%)	9 (2.5%)
ANTIBACTERIALS FOR SYSTEMIC USE		
Total number of patients with at least one treatment	36 (9.8%)	45 (12.4%)
Total number of treatments	50	63
ALBISIA ORIENTALE TUBER/GELATIN/POLYPORUS UMBELLATUS SCLEROTIUM/PORIA COCCOS	0	1 (0.3%)
SCLEROTIUM	0	1 (0.3%)
ALBUM SATIVUM	1 (0.3%)	1 (0.3%)
AMOXICILLIN	3 (0.8%)	2 (0.6%)
AMOXICILLIN TRIHYDRATE	0	1 (0.3%)
AMOXICILLIN TRIHYDRATE/CLAVULANATE POTASSIUM	0	1 (0.3%)
AMOXICILLIN/CLAVULANATE POTASSIUM	6 (1.6%)	4 (1.1%)
AMOXICILLIN/CLAVULANIC ACID	0	1 (0.3%)
AMBILCA SIMENSIS	1 (0.3%)	0
ARTEMISIA ARGYI	1 (0.3%)	0
AZITHROMYCIN	7 (1.9%)	6 (1.7%)
BACTRACIN	0	1 (0.3%)
CEFADROXIL	1 (0.3%)	0
CEFALEXIN	3 (0.8%)	5 (1.4%)
CEFAZOLIN	0	1 (0.3%)
CEFAZOLIN SODIUM	1 (0.3%)	0
CEFODIN	0	2 (0.6%)
CEFTIOXAN PIVOXIL	0	1 (0.3%)
CEFTIPIME	1 (0.3%)	0
CEFTIPIME	0	1 (0.3%)
CEFTIPIME PIVOXIL	0	1 (0.3%)
CEFTIOXIME SODIUM	1 (0.3%)	0
CEFTRIAXONE	1 (0.3%)	1 (0.3%)
CEFTRIAXONE SODIUM	0	1 (0.3%)
CEFTRIAXONE SODIUM SESQUATESHYDRATE	0	1 (0.3%)
CEFUROXIME	0	2 (0.6%)
CEFUROXIME ARTIL	2 (0.5%)	0
CIPROFLOXACIN	1 (0.3%)	3 (0.8%)
CIPROFLOXACIN HYDROCHLORIDE	0	1 (0.3%)
CLARITHROMYCIN	2 (0.5%)	3 (0.8%)
CLINDAMYCIN	1 (0.3%)	3 (0.8%)
DAPTOMYCIN	1 (0.3%)	0
DOXYCYCLINE	2 (0.5%)	3 (0.8%)
DOXYCYCLINE MONOHYDRATE	1 (0.3%)	0
ERYTHROMYCIN	1 (0.3%)	0
POSEFOMYCIN TRIMETANOL	0	1 (0.3%)
FUSIDIC ACID	0	1 (0.3%)
LEVOPLOXACIN	3 (0.8%)	0
LEVOPLOXACIN HYDROCHLORIDE	0	1 (0.3%)
METHNAMINE	1 (0.3%)	0
METRONIDAZOLE	2 (0.5%)	1 (0.3%)
MOXIFLOXACIN HYDROCHLORIDE	0	1 (0.3%)
MYCELA SATIVA SEED OIL	0	1 (0.3%)
NITROURANTIN	0	2 (0.6%)
NOFLOXACIN	1 (0.3%)	0
PIPERACILLIN SODIUM/TAZOBACTAM SODIUM	1 (0.3%)	0
SULFAMETHOXAZOLE/TRIMETHOPRIM	1 (0.3%)	2 (0.6%)
SULFATHIAZOLE	0	1 (0.3%)
TEMETHOBRIN	1 (0.3%)	0
VACCINIUM SPP.	0	2 (0.6%)
VANCOMYCIN	1 (0.3%)	0
ANTIBIOTICS AND CHEMOTHERAPUTICS FOR DERMATOLOGICAL USE		
Total number of patients with at least one treatment	11 (3.0%)	17 (4.7%)
Total number of treatments	13	19
ACICLOVIR	3 (0.8%)	1 (0.3%)
BACTRACIN	0	1 (0.3%)
CIPROFLOXACIN	1 (0.3%)	3 (0.8%)
CIPROFLOXACIN HYDROCHLORIDE	0	1 (0.3%)
CLARITHROMYCIN	2 (0.5%)	3 (0.8%)
DOXYCYCLINE	2 (0.5%)	3 (0.8%)
ERYTHROMYCIN	1 (0.3%)	0
FUSIDIC ACID	0	1 (0.3%)
INTERFERON ALFA-2B	0	1 (0.3%)
METRONIDAZOLE	2 (0.5%)	1 (0.3%)
MUPIROCIN	1 (0.3%)	0
NADIFLOXACIN	0	1 (0.3%)
NOFLOXACIN	1 (0.3%)	0
RIFAXIMIN	0	1 (0.3%)
SULFATHIAZOLE	0	1 (0.3%)
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS		
Total number of patients with at least one treatment	20 (5.5%)	17 (4.7%)
Total number of treatments	26	26

BACITRACIN	0	1 (0.3%)
BEHEERINE	1 (0.3%)	0
BETAMETHASONE	1 (0.3%)	1 (0.3%)
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.3%)	1 (0.3%)
BETAMETHASONE VALERATE	0	1 (0.3%)
BIFIDOBACTERIUM INFANTIS	1 (0.3%)	0
BIFIDOBACTERIUM LACTIS/BIOLIFLORUM/LACTOBACILLUS ACIDOPHILUS	0	1 (0.3%)
BURESONIDE	2 (0.5%)	5 (1.4%)
CHAMCML, ACTIVATED	0	2 (0.6%)
CITRUS ADRANTIIUM PHEL/CHROSOTI/GLYCYRRHIZA SPP. ROOT/PRELLDENERON SPP. BARK/UNCARIA	0	1 (0.3%)
GAMBIR LEAF WITH TWIG	0	1 (0.3%)
COCHRINE	2 (0.5%)	0
DIGMOCTITE	0	1 (0.3%)
HYDROCORTISONE BUTYRATE	0	1 (0.3%)
HYDROCORTISONE SODIUM PHOSPHATE	0	1 (0.3%)
LACTOBACILLUS ACIDOPHILUS	1 (0.3%)	1 (0.3%)
LOPERAMIDE	1 (0.3%)	1 (0.3%)
LOPERAMIDE HYDROCHLORIDE	1 (0.3%)	0
MACRODOL 4000/POTASSIUM CHLORIDE/SODIUM BICARBONATE/SODIUM CHLORIDE/SODIUM SULFATE	1 (0.3%)	0
MICONAZOLE NITRATE	1 (0.3%)	0
NYSTATIN	2 (0.5%)	0
PLANTAGO OVATA	3 (0.8%)	1 (0.3%)
PREMISOLONE	2 (0.5%)	0
PREMISOLONE	3 (0.8%)	0
PROBIOTIC NOS	0	5 (1.4%)
RIFAXIMIN	0	1 (0.3%)
SACCHAROMYCES BOULARDII	1 (0.3%)	0
VANCOMYCIN	1 (0.3%)	0
ANTIEMETICS AND ANTINAUSEANTS		
Total number of patients with at least one treatment	9 (2.5%)	12 (3.3%)
Total number of treatments	10	13
CYANOCOBALAMIN/PIRIDOXINE HYDROCHLORIDE/THIAMINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
DIPENDOL	0	1 (0.3%)
DIPHENHYDRAMINE HYDROCHLORIDE	3 (0.8%)	2 (0.6%)
HYDROXYZINE	0	2 (0.6%)
MECLOZINE	0	1 (0.3%)
METOCLOPRAMIDE	1 (0.3%)	1 (0.3%)
ONDANSETRON	2 (0.5%)	0
ONDANSETRON HYDROCHLORIDE	0	1 (0.3%)
PROMETHAZINE	2 (0.5%)	2 (0.6%)
ZIMMIBER OFFICINALE	0	1 (0.3%)
ANTI-EPILEPTICS		
Total number of patients with at least one treatment	29 (7.9%)	24 (6.6%)
Total number of treatments	39	29
ACETAZOLAMIDE	3 (0.8%)	4 (1.1%)
CARBAMAZEPINE	2 (0.5%)	1 (0.3%)
CLONAZEPAM	4 (1.1%)	7 (1.9%)
DIASEPAM	3 (0.8%)	0
GABAPENTIN	10 (2.7%)	7 (1.9%)
LAMOTRIGINE	2 (0.5%)	1 (0.3%)
MAGNESIUM SULFATE	1 (0.3%)	0
PHENYTOIN	6 (1.6%)	3 (0.8%)
PREMIDONE	1 (0.3%)	0
TOPISAMATE	2 (0.5%)	1 (0.3%)
VALPROATE SODIUM/VALPROIC ACID	1 (0.3%)	1 (0.3%)
VALPROIC ACID	0	1 (0.3%)
ANTIFUNGALS FOR DERMATOLOGICAL USE		
Total number of patients with at least one treatment	9 (2.5%)	5 (1.4%)
Total number of treatments	13	6
AMOROLFINE HYDROCHLORIDE	0	1 (0.3%)
BETAMETHASONE/CLOTRIMAZOLE	1 (0.3%)	0
BIFONAZOLE	0	1 (0.3%)
CLOTRIMAZOLE	1 (0.3%)	0
FLUCONAZOLE	1 (0.3%)	1 (0.3%)
LULICONAZOLE	1 (0.3%)	0
MICONAZOLE NITRATE	1 (0.3%)	0
NYSTATIN	2 (0.5%)	0
SALICYLIC ACID	2 (0.5%)	0
TERBINAFINE	0	2 (0.6%)
TERBINAFINE HYDROCHLORIDE	2 (0.5%)	0
UREA	1 (0.3%)	0
ANTIGOUT PREPARATIONS		
Total number of patients with at least one treatment	15 (4.1%)	22 (6.1%)
Total number of treatments	15	22
ALLOPURINOL	11 (3.0%)	17 (4.7%)
BENZBROMARONE	1 (0.3%)	0
COLCHICINE	1 (0.3%)	0
DOCSAHEXAENOIC ACID/EICOSAPENTAENOIC ACID	1 (0.3%)	4 (1.1%)
FEBUXOSTAT	1 (0.3%)	1 (0.3%)
ANTHRACENES		
Total number of patients with at least one treatment	2 (0.5%)	10 (2.8%)
Total number of treatments	3	10
AMINO ACIDS NOS	0	1 (0.3%)
COLLAGEN	0	2 (0.6%)
DESMOPRESSIN	0	1 (0.3%)
ETANERCEPT	0	2 (0.6%)
TRANSGAMIC ACID	1 (0.3%)	2 (0.6%)
UNCODED	1 (0.3%)	2 (0.6%)
ANTIHISTAMINES FOR SYSTEMIC USE		
Total number of patients with at least one treatment	26 (7.1%)	27 (7.4%)
Total number of treatments	31	32
BEFOTASTINE BESILATE	0	1 (0.3%)
CALCIUM/COLECALCIFEROL/PERILLA FRUTESCENS/QUERCETIN	0	1 (0.3%)
CETIRIZINE	3 (0.8%)	2 (0.6%)
CETIRIZINE HYDROCHLORIDE	4 (1.1%)	0
CHLORPHENIRAMINE MALEATE	1 (0.3%)	1 (0.3%)
DESLOKATADINE	3 (0.8%)	1 (0.3%)
DESLOKATADINE CITRATE DIIODIUM	0	1 (0.3%)
DIPHENHYDRAMINE HYDROCHLORIDE	3 (0.8%)	2 (0.6%)
DOXYLAMINE	0	1 (0.3%)
EBASTINE	0	1 (0.3%)
EPINASTINE HYDROCHLORIDE	1 (0.3%)	2 (0.6%)
FEKOPARADINE HYDROCHLORIDE	4 (1.1%)	4 (1.1%)
HYBROMIZINE	0	2 (0.6%)
LEVOCETIRIZINE DIHYDROCHLORIDE	1 (0.3%)	1 (0.3%)
LORATADINE	7 (1.9%)	6 (1.7%)

MECLOZINE	0	1 (0.3%)
OLEPATADINE HYDROCHLORIDE	0	1 (0.3%)
PROMETHAZINE	2 (0.5%)	2 (0.6%)
ANTIHYPERTENSIVES		
Total number of patients with at least one treatment	20 (5.5%)	17 (4.7%)
Total number of treatments	24	18
CLONIDINE	3 (0.8%)	3 (0.8%)
CURCMA MANGALITIFERA/FINIS SPP. NEEDLE/PURBARIA LOBATA ROOT	1 (0.3%)	1 (0.3%)
DOKAZOSIN	3 (0.8%)	4 (1.1%)
DOKAZOSIN MESILATE	3 (0.8%)	3 (0.8%)
HYDRALAZINE	3 (0.8%)	1 (0.3%)
HYDRALAZINE HYDROCHLORIDE	1 (0.3%)	0
MAGNESIUM SULFATE	1 (0.3%)	0
METHYLOXA	1 (0.3%)	0
MINOXIDIL	0	2 (0.6%)
MOXONIDINE	0	1 (0.3%)
RILMENIDINE	0	1 (0.3%)
SILDENAFIL	1 (0.3%)	0
SILDENAFIL CITRATE	1 (0.3%)	1 (0.3%)
TADALAFIL	1 (0.3%)	0
TERAZOSIN	1 (0.3%)	0
TERAZOSIN HYDROCHLORIDE	1 (0.3%)	0
URAPIDIL	1 (0.3%)	1 (0.3%)
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS		
Total number of patients with at least one treatment	48 (13.1%)	38 (10.5%)
Total number of treatments	67	54
ACECLOFENAC	1 (0.3%)	2 (0.6%)
ACTIPRAETHES BIDENTATA ROOT	1 (0.3%)	0
ANGELICA SINENSIS	1 (0.3%)	0
BETULA PUBESCENS	1 (0.3%)	0
BOMELLA SERBATA/CURCUMA LONGA/PIPER NIGRUM/WITHANIA SOMNIFERA/ZINGIBER OFFICINALE	0	1 (0.3%)
BROMFENAC SODIUM	1 (0.3%)	0
CELECOXIB	1 (0.3%)	1 (0.3%)
CHENPODITIN	0	1 (0.3%)
CHENPODITIN SULFATE	0	1 (0.3%)
CHENPODITIN SULFATE SODIUM	0	1 (0.3%)
CHENPODITIN/GLUCOSAMINE	5 (1.4%)	1 (0.3%)
COLLAGEN	0	2 (0.6%)
CURCUMA LONGA	4 (1.1%)	2 (0.6%)
DEKIBUPROFEN	2 (0.5%)	0
DICLOFENAC	6 (1.6%)	1 (0.3%)
DICLOFENAC DIETHYLAMINE	0	1 (0.3%)
DICLOFENAC SODIUM	2 (0.5%)	1 (0.3%)
ETOFENAMATE	1 (0.3%)	1 (0.3%)
ETORICOXIB	2 (0.5%)	2 (0.6%)
FLURBIPROFEN	1 (0.3%)	0
GLUCOSAMINE	2 (0.5%)	2 (0.6%)
GLUCOSAMINE HYDROCHLORIDE	1 (0.3%)	0
GLUCOSAMINE SULFATE	0	2 (0.6%)
GLUCINE MAX SEED OIL/PERSEA AMERICANA OIL	3 (0.8%)	0
GLYCYRRHIZA SPP. ROOT/PARONIA LACTIFLORA ROOT	1 (0.3%)	1 (0.3%)
IBUPROFEN	1 (0.3%)	0
HYDROCODONE/IBUPROFEN	1 (0.3%)	0
IBUPROFEN	7 (1.9%)	9 (2.5%)
IBUPROFEN/PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.3%)	0
KETOPROFEN	0	1 (0.3%)
KETOROLAC	1 (0.3%)	0
KETOROLAC TROMETHAMINE	1 (0.3%)	0
LOXAPROFEN SODIUM	3 (0.8%)	2 (0.6%)
MELXICAM	3 (0.8%)	3 (0.8%)
METHYLSULFONYLMETHANE	0	1 (0.3%)
MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER	1 (0.3%)	0
NAFROLEN	1 (0.3%)	5 (1.4%)
NAFROLEN SODIUM	3 (0.8%)	2 (0.6%)
NIMESULIDE	0	2 (0.6%)
OTHER ANTIINFLAMMATORY AND ANTIRHEUMATIC AGENTS, NON-STEROIDS	1 (0.3%)	0
PHENYLBUZONONE/PRETRISOLONE	1 (0.3%)	0
PIROXICAM BETADEX	0	1 (0.3%)
RABBIT VACCINIA EXTRACT	0	1 (0.3%)
TENOXICAM	0	1 (0.3%)
ZINGIBER OFFICINALE	0	1 (0.3%)
ANTIMYCOTICS FOR SYSTEMIC USE		
Total number of patients with at least one treatment	3 (0.8%)	1 (0.3%)
Total number of treatments	5	2
FLUCONAZOLE	1 (0.3%)	1 (0.3%)
MICONAZOLE NITRATE	1 (0.3%)	0
MYSTATIN	2 (0.5%)	0
ANTINEOPLASTIC AGENTS		
Total number of patients with at least one treatment	6 (1.6%)	9 (2.5%)
Total number of treatments	8	9
CHEKOSIN	1 (0.3%)	1 (0.3%)
FLUDOURACIL	1 (0.3%)	3 (0.8%)
METHOTREXATE	2 (0.5%)	2 (0.6%)
PROPRANOLOL	2 (0.5%)	3 (0.8%)
ANTIONCEIT PREPARATIONS INCL. DIET PRODUCTS		
Total number of patients with at least one treatment	3 (0.8%)	6 (1.7%)
Total number of treatments	3	7
AMPEZAMINE ASPARTATE/AMPEZAMINE SULFATE/DEKAMPETAMINE SACCHARATE/DEKAMPETAMINE SULFATE	0	2 (0.6%)
COLLAGEN	0	2 (0.6%)
LIRAGLUTIDE	0	1 (0.3%)
PLANTAGO OVATA	3 (0.8%)	1 (0.3%)
ANTIPROTOZOALS		
Total number of patients with at least one treatment	3 (0.8%)	3 (0.8%)
Total number of treatments	5	3
CLOTIMAZOLE	1 (0.3%)	0
HYDROXYCHLOROQUINE	0	1 (0.3%)
METRONIDAZOLE	2 (0.5%)	1 (0.3%)
MICONAZOLE NITRATE	1 (0.3%)	0
QUININE SULFATE	0	1 (0.3%)
ANTIPIRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.		
Total number of patients with at least one treatment	30 (8.2%)	22 (6.1%)
Total number of treatments	37	28
ANGELICA SINENSIS ROOT/BASSIA SCOPARIA FRUIT/BORNOL/CLAMATIS SPP. ROOT WITH		
BHIZONE/CNIDIUM MONNIERI FRUIT/SOPHERA FLAVESCENS ROOT/STEMONA SPP. ROOT	0	1 (0.3%)

CETIRIZINE	3 (0.8%)	2 (0.6%)
CETIRIZINE HYDROCHLORIDE	4 (1.1%)	0
CHLORPHENIRAMINE MALEATE	1 (0.3%)	1 (0.3%)
CHUFAMINOL	1 (0.3%)	0
DESLOMATADINE	2 (0.5%)	1 (0.3%)
DESLOMATADINE CITRATE DIOSODIUM	0	1 (0.3%)
DIPHENHYDRAMINE HYDROCHLORIDE	3 (0.8%)	2 (0.6%)
ERASTINE	0	1 (0.3%)
HYBROKIZINE	0	2 (0.6%)
LEVOCETIRIZINE DIHYDROCHLORIDE	1 (0.3%)	1 (0.3%)
LIDOCAINE	6 (1.6%)	2 (0.6%)
LIDOCAINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
LORATADINE	7 (1.9%)	6 (1.7%)
METHA X PIPERITA OIL	1 (0.3%)	0
OLOPATADINE HYDROCHLORIDE	0	1 (0.3%)
PROMETHAZINE	2 (0.5%)	2 (0.6%)
UNCODED	0	2 (0.6%)
ANTIPEPTICACTICS		
Total number of patients with at least one treatment	2 (0.5%)	2 (0.6%)
Total number of treatments	2	2
ACITRETIN	0	1 (0.3%)
AMBIUCA SINENSIS	1 (0.3%)	0
BETAMETHASONE DIPROPIONATE/CALCIPOTRIOL	1 (0.3%)	1 (0.3%)
CALCITRIOL	1 (0.3%)	0
ANTISEPTICS AND DISINFECTANTS		
Total number of patients with at least one treatment	3 (0.8%)	2 (0.6%)
Total number of treatments	3	2
CHLORHEXIDINE	1 (0.3%)	0
CHLORHEXIDINE GLUCONATE	1 (0.3%)	0
DEQUALINIUM CHLORIDE	0	1 (0.3%)
POVIDONE-IODINE	1 (0.3%)	1 (0.3%)
ANTITHROMBOTIC AGENTS		
Total number of patients with at least one treatment	96 (26.2%)	114 (31.4%)
Total number of treatments	118	136
ACEROCUMABOL	1 (0.3%)	3 (0.8%)
ACETYSALICYLATE LYISINE	0	1 (0.3%)
ACETYSALICYLIC ACID	58 (15.8%)	70 (19.3%)
ACETYSALICYLIC ACID/ALUMINIUM GLYCINATE/MAGNESIUM CARBONATE	1 (0.3%)	0
ACETYSALICYLIC ACID/GLYCINE	0	1 (0.3%)
ACETYSALICYLIC ACID/MAGNESIUM HYDROXIDE	1 (0.3%)	1 (0.3%)
APEXABAN	15 (4.1%)	11 (3.0%)
CHLOSTAZOL	3 (0.8%)	1 (0.3%)
CLOPIDOGREL	1 (0.3%)	2 (0.6%)
CLOPIDOGREL BISULFATE	3 (0.8%)	2 (0.6%)
DAHIGATRAN ETEXILATE MESILATE	1 (0.3%)	2 (0.6%)
EDOXABAN	0	1 (0.3%)
ENOXAPARIN SODIUM	2 (0.5%)	4 (1.1%)
HEPARIN	2 (0.5%)	0
HEPARIN CALCIUM	1 (0.3%)	0
HEPARIN SODIUM	0	1 (0.3%)
HEPARINOID	1 (0.3%)	0
LIMAPROST ALPADEX	2 (0.5%)	0
LOW MOLECULAR WEIGHT HEPARIN	0	1 (0.3%)
MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER	1 (0.3%)	0
PHENPROCOUMON	0	1 (0.3%)
RIVAROXABAN	7 (1.9%)	6 (1.7%)
SABROXELATE HYDROCHLORIDE	0	1 (0.3%)
STREPTODORASE/STREPTOLIMASE	1 (0.3%)	1 (0.3%)
SULOXIDINE	8 (2.2%)	15 (4.1%)
TICAGRELOR	1 (0.3%)	2 (0.6%)
WARFARIN	3 (0.8%)	0
WARFARIN POTASSIUM	0	1 (0.3%)
WARFARIN SODIUM	2 (0.5%)	1 (0.3%)
ANTIVIRALS FOR SYSTEMIC USE		
Total number of patients with at least one treatment	12 (3.3%)	6 (1.7%)
Total number of treatments	13	7
ACICLOVIR	3 (0.8%)	1 (0.3%)
AMANTADINE	1 (0.3%)	0
BICTECRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFANAMIDE FUMARATE	1 (0.3%)	1 (0.3%)
FAMCICLOVIR	1 (0.3%)	0
FAVIPICRAVIR	0	1 (0.3%)
GLECAPREVIR/FIBRENTAVIR	0	1 (0.3%)
HIVORNAK RIBAVIRIDES	0	1 (0.3%)
IMIDAZOLYL ETANAMIDE PENTAMIDIC ACID	1 (0.3%)	0
NIRMATRELVIR/RITONAVIR	0	1 (0.3%)
REMSDESIVIR	2 (0.5%)	0
TELAPREVIR	1 (0.3%)	1 (0.3%)
UMIFENOVIR	1 (0.3%)	0
VALACICLOVIR	1 (0.3%)	0
VALACICLOVIR HYDROCHLORIDE	1 (0.3%)	0
BETA BLOCKING AGENTS		
Total number of patients with at least one treatment	76 (20.8%)	74 (20.4%)
Total number of treatments	84	78
ACEBUTOLOL HYDROCHLORIDE	0	1 (0.3%)
ATENOLOL	11 (3.0%)	8 (2.2%)
BETAHALOL	1 (0.3%)	1 (0.3%)
BISOPROLOL	7 (1.9%)	5 (1.4%)
BISOPROLOL FUMARATE	12 (3.3%)	14 (3.9%)
BISOPROLOL FUMARATE HYDROCHLOROTHIAZIDE	0	1 (0.3%)
CARVEDILOL	11 (3.0%)	8 (2.2%)
MEFOPROLOL	17 (4.6%)	15 (4.1%)
METOPROLOL SUCCINATE	5 (1.4%)	9 (2.5%)
METOPROLOL TARTRATE	3 (0.8%)	2 (0.6%)
NEBIVOLOL	2 (0.5%)	4 (1.1%)
NEBIVOLOL HYDROCHLORIDE	8 (2.2%)	5 (1.4%)
PROPRANOLOL	2 (0.5%)	3 (0.8%)
SOTALOL	1 (0.3%)	0
SOTALOL HYDROCHLORIDE	0	1 (0.3%)
BILE AND LIVER THERAPY		
Total number of patients with at least one treatment	12 (3.3%)	13 (3.6%)
Total number of treatments	13	14
ACETYLCYSTEINE	1 (0.3%)	1 (0.3%)
ARGININE	1 (0.3%)	0
CURCUMA LONGA	4 (1.1%)	2 (0.6%)
DL-METHIONINE/GLYCINE/GLUCYRRHIZIC ACID, AMMONIUM SALT	0	1 (0.3%)
DROTAVERINE HYDROCHLORIDE	0	1 (0.3%)

HIPPOPHAE RHAMNOIDES	0	1 (0.3%)
ORNITHINE ASPARTATE	0	1 (0.3%)
PHOSPHOLIPIDS	1 (0.3%)	0
PHOSPHOLIPIDS SOYBEAN	1 (0.3%)	0
RIFAXIMIN	0	1 (0.3%)
SILYBUM MARIANUM	2 (0.5%)	2 (0.6%)
UNCODED	1 (0.3%)	1 (0.3%)
URSOXYCHOLIC ACID	2 (0.5%)	3 (0.8%)
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS		
Total number of patients with at least one treatment	38 (10.4%)	39 (10.7%)
Total number of treatments	48	51
AMINO ACIDS NOS	0	1 (0.3%)
ARGININE	1 (0.3%)	0
CALCIUM CHLORIDE DIHYDRATE/POTASSIUM CHLORIDE/SODIUM CHLORIDE/SODIUM LACTATE	1 (0.3%)	0
CALCIUM CHLORIDE/MAGNESIUM CHLORIDE HEXAHYDRATE/POTASSIUM CHLORIDE/SODIUM BICARBONATE/SODIUM CHLORIDE	1 (0.3%)	0
CHLORHEXIDINE	1 (0.3%)	0
CHLORHEXIDINE GLUCONATE	1 (0.3%)	0
GLUCOSE	0	1 (0.3%)
GLYCEROL	0	2 (0.6%)
HETASTARCH/SODIUM CHLORIDE	1 (0.3%)	0
ISSOSORBIDE	0	1 (0.3%)
LYSINE	0	1 (0.3%)
LYSINE HYDROCHLORIDE	1 (0.3%)	0
MAGNESIUM SULFATE	1 (0.3%)	0
MANNITOL	0	1 (0.3%)
MINERALS NOS/VITAMINS NOS	3 (0.8%)	4 (1.1%)
OTHER BLOOD PRODUCTS	0	1 (0.3%)
PHOSPHOLIPIDS	1 (0.3%)	0
POTASSIUM	3 (0.8%)	3 (0.8%)
POTASSIUM CHLORIDE	4 (1.1%)	7 (1.9%)
POTASSIUM CHLORIDE/SODIUM BICARBONATE/SODIUM CHLORIDE	0	1 (0.3%)
SODIUM BICARBONATE	2 (0.5%)	1 (0.3%)
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
UREA	1 (0.3%)	0
VITAMINS NOS	17 (4.6%)	9 (2.5%)
ZINC	1 (0.3%)	6 (1.7%)
CALCIUM CHANNEL BLOCKERS		
Total number of patients with at least one treatment	65 (17.8%)	78 (21.5%)
Total number of treatments	67	81
AMLODIPINE	35 (9.6%)	35 (9.6%)
AMLODIPINE BESILATE	10 (2.7%)	20 (5.5%)
AMLODIPINE BESILATE/INDAPAMIDE	0	1 (0.3%)
AMLODIPINE OROTATE	0	1 (0.3%)
BEHIDIPINE HYDROCHLORIDE	1 (0.3%)	0
DILTIAZEM HYDROCHLORIDE	3 (0.8%)	6 (1.7%)
FELDIPINE	1 (0.3%)	2 (0.6%)
LACIDIPINE	1 (0.3%)	1 (0.3%)
LESCANIDIPINE	2 (0.5%)	3 (0.8%)
LESCANIDIPINE HYDROCHLORIDE	6 (1.6%)	1 (0.3%)
LEVAMLODIPINE BESILATE	1 (0.3%)	0
LEVAMLODIPINE MALATE	0	1 (0.3%)
NIREDIPINE	4 (1.1%)	4 (1.1%)
NINEDIPINE	0	1 (0.3%)
NITRENDIPINE	0	1 (0.3%)
S AMLODIPINE NICOTINATE	1 (0.3%)	0
VERAPAMIL	0	1 (0.3%)
CALCIUM HEMOSTASIS		
Total number of patients with at least one treatment	0	3 (0.8%)
Total number of treatments	0	3
CALCIFEDIOL	0	3 (0.8%)
CARDIAC THERAPY		
Total number of patients with at least one treatment	38 (10.4%)	40 (11.0%)
Total number of treatments	57	47
ACHYRANTHES BIDENTATA ROOT	1 (0.3%)	0
AMIODARONE	3 (0.8%)	2 (0.6%)
AMIODARONE HYDROCHLORIDE	1 (0.3%)	0
CANTHARIS TINCTORIS FETAL EXTRACT	1 (0.3%)	0
CRATAEGUS SPP. FRUIT	1 (0.3%)	0
CRATAEGUS SPP. FRUIT/MAGNESIUM CITRATE/POTASSIUM PYRIDOXINE HYDROCHLORIDE/THIAMINE	0	1 (0.3%)
CYANOCOBALAMIN/FOLIC ACID/MAGNESIUM ASPARTATE DIHYDRATE/MAGNESIUM OXIDE/NICOTINAMIDE/POTASSIUM CHLORIDE/URIDECARBONATE	0	1 (0.3%)
DIGOXIN	1 (0.3%)	1 (0.3%)
EMOGLIFLOZIN	5 (1.4%)	4 (1.1%)
FLICANTHIN	1 (0.3%)	2 (0.6%)
GLYCERYL TRINITRATE	4 (1.1%)	2 (0.6%)
HIPPOPHAE RHAMNOIDES	0	1 (0.3%)
IBUPROFEN	7 (1.9%)	9 (2.5%)
IPRAVOPROFUM	0	1 (0.3%)
IPRAVOPROFUM BROMIDE	0	2 (0.6%)
ISSOSORBIDE DINITRATE	1 (0.3%)	1 (0.3%)
ISSOSORBIDE MONONITRATE	2 (0.5%)	1 (0.3%)
IYABRADINE HYDROCHLORIDE	0	1 (0.3%)
LIDOCAINE	6 (1.6%)	2 (0.6%)
LIDOCAINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
LIMAPROST ALFADEX	2 (0.5%)	0
MAGNESIUM ASPARTATE/POTASSIUM ASPARTATE	1 (0.3%)	0
MEKILATINE	1 (0.3%)	0
MEKILATINE HYDROCHLORIDE	1 (0.3%)	0
MELTIOXONE	0	1 (0.3%)
NICERGOLINE	1 (0.3%)	1 (0.3%)
NICOTINAMIDE	0	1 (0.3%)
NITRIC OXIDE	0	1 (0.3%)
PHENYLEPHRINE HYDROCHLORIDE	1 (0.3%)	0
PROPARENE HYDROCHLORIDE	2 (0.5%)	0
SODIUM ALGINATE	1 (0.3%)	0
TRIMETAZIDINE	0	1 (0.3%)
TRIMETAZIDINE HYDROCHLORIDE	1 (0.3%)	1 (0.3%)
ULIBICARBENE	3 (0.8%)	3 (0.8%)
UNCODED	0	1 (0.3%)
ZINZIBER OFFICINALE	0	1 (0.3%)
CONTRAST MEDIA		
Total number of patients with at least one treatment	1 (0.3%)	0
Total number of treatments	1	0
PERFLUTREN	1 (0.3%)	0
CORTICOSTEROIDS FOR SYSTEMIC USE		

Total number of patients with at least one treatment	13 (3.6%)	9 (2.5%)
Total number of treatments	14	12
BETAMETHASONE	1 (0.3%)	1 (0.3%)
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.3%)	1 (0.3%)
BETAMETHASONE DIPROPIONATE/BETAMETHASONE SODIUM PHOSPHATE	0	1 (0.3%)
BETAMETHASONE VALERATE	0	1 (0.3%)
CORTISONE	1 (0.3%)	1 (0.3%)
DEKAMETHASONE	3 (0.8%)	1 (0.3%)
HYDROCORTISONE BUTYRATE	0	1 (0.3%)
HYDROCORTISONE SODIUM PHOSPHATE	0	1 (0.3%)
METHYLPREDNISOLONE	1 (0.3%)	1 (0.3%)
METHYLPREDNISOLONE ACETATE	0	1 (0.3%)
PREDNISOLONE	2 (0.5%)	0
PREDNISOLONE	3 (0.8%)	0
STEROIDS	1 (0.3%)	0
TRIAMCINOLONE ACETONIDE	0	1 (0.3%)
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS		
Total number of patients with at least one treatment	24 (6.6%)	24 (6.6%)
Total number of treatments	29	20
BETAMETHASONE	1 (0.3%)	1 (0.3%)
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.3%)	1 (0.3%)
BETAMETHASONE DIPROPIONATE/BETAMETHASONE SODIUM PHOSPHATE	0	1 (0.3%)
BETAMETHASONE DIPROPIONATE/CLOTRIMAZOLE/GENTAMICIN SULFATE	1 (0.3%)	0
BETAMETHASONE DIPROPIONATE/SALICYLIC ACID	1 (0.3%)	0
BETAMETHASONE VALERATE	0	1 (0.3%)
BETAMETHASONE VALERATE/GENTAMICIN SULFATE	0	1 (0.3%)
BUDERSONIDE	2 (0.5%)	5 (1.4%)
CLABETASOL	1 (0.3%)	0
CLABETASOL PROPIONATE	1 (0.3%)	0
CLABETASONE	1 (0.3%)	0
DEKAMETHASONE	3 (0.8%)	1 (0.3%)
FLUTICASONE	1 (0.3%)	2 (0.6%)
FLUTICASONE PROPIONATE	3 (0.8%)	6 (1.7%)
FUSIDIC ACID-HYDROCORTISONE ACETATE	0	1 (0.3%)
GENTAMICIN SULFATE/PREDNISOLONE	0	1 (0.3%)
HYDROCORTISONE BUTYRATE	0	1 (0.3%)
HYDROCORTISONE SODIUM PHOSPHATE	0	1 (0.3%)
METHYLPREDNISOLONE	1 (0.3%)	1 (0.3%)
METHYLPREDNISOLONE ACETATE	0	0
METHYLPREDNISOLONE ACETATE/BROMOCYCLIN SULFATE	1 (0.3%)	1 (0.3%)
MOMETASONE	0	1 (0.3%)
MOMETASONE FURATE	2 (0.5%)	1 (0.3%)
PREDNICARBATE	1 (0.3%)	0
PREDNISOLONE	2 (0.5%)	0
PREDNISOLONE	3 (0.8%)	0
STEROIDS	1 (0.3%)	0
TRIAMCINOLONE ACETONIDE	0	1 (0.3%)
COUGH AND COLD PREPARATIONS		
Total number of patients with at least one treatment	24 (6.6%)	33 (9.1%)
Total number of treatments	34	44
ACETYLCYSTEINE	1 (0.3%)	1 (0.3%)
AMBRISOL HYDROCHLORIDE	2 (0.5%)	2 (0.6%)
AMONIUM BICARBONATE/CEPHEPARIS SPP. TINCTURE	0	1 (0.3%)
AMONIUM CHLORIDE/CHLORPHENIRAMINE MALEATE/DIBENZOYLCAINE BITARTRATE/METHYLEPHEDRINE HYDROCHLORIDE-DL	1 (0.3%)	1 (0.3%)
CARBOCISTEINE	1 (0.3%)	2 (0.6%)
CHLORPHENIRAMINE MALEATE/PARACETAMOL/PHENYLEPHRINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
CODEINE	2 (0.5%)	0
CODEINE PHOSPHATE HEMIHYDRATE/SILFOPOLACOL	0	1 (0.3%)
CODEINE PHOSPHATE/DRIMLIA MARITIMA/RUPHORRIA HIRTA/GUAREA GUIDONIA/POLYGALA SENEGAL	0	1 (0.3%)
COUGH AND COLD PREPARATIONS	0	1 (0.3%)
DEXTROMETHORPHAN HYDROBROMIDE	0	2 (0.6%)
DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE	1 (0.3%)	1 (0.3%)
DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE/POTASSIUM CREZOLSULFONATE	0	1 (0.3%)
DEXTROMETHORPHAN HYDROBROMIDE/PROMETHAZINE HYDROCHLORIDE	1 (0.3%)	0
DIPHENOXIDE	1 (0.3%)	0
EDOSTEINE	1 (0.3%)	1 (0.3%)
GLYCEROL	0	2 (0.6%)
GLUCYRRHIZIA SPP. ROOT/OPHIOPOGON JAPONICUS TUBER/ORYZA SATIVA FRUIT/PANAX GINSENG	0	0
ROOPI/PIMELLIA TERNATA TUBER/ZIZIPHUS JUZUBA FRUIT	0	1 (0.3%)
QUALIFENSIN	1 (0.3%)	1 (0.3%)
QUALIFENSIN/PSEUDOEPHEDRINE HYDROCHLORIDE	0	1 (0.3%)
HIPPOPHAE RHAMNOIDES	0	1 (0.3%)
HYDROCODONE	2 (0.5%)	0
HYDROCODONE/IBUPROFEN	1 (0.3%)	0
MANNITOL	0	1 (0.3%)
PLANTAGO MAJOR	1 (0.3%)	0
PRENODIAZIN HYDROCHLORIDE	1 (0.3%)	0
QUININE SULFATE	0	1 (0.3%)
SAMBUCUS NIGRA	0	2 (0.6%)
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
STREPTOCOCINASE/STREPTOKINASE	1 (0.3%)	1 (0.3%)
TEPEIN	1 (0.3%)	0
THYMIS VULGARIS	1 (0.3%)	0
TIPREPIDINE BISBENATE	0	1 (0.3%)
TUSSILAGO PARFARA	1 (0.3%)	0
ZINC	1 (0.3%)	6 (1.7%)
DIAGNOSTIC AGENTS		
Total number of patients with at least one treatment	10 (2.7%)	8 (2.2%)
Total number of treatments	10	9
FLUOROCIN	3 (0.8%)	0
FOLIC ACID	6 (1.6%)	6 (1.7%)
GLUCOSE	0	1 (0.3%)
MAGNESIUM SULFATE	1 (0.3%)	0
MANNITOL	0	1 (0.3%)
DIGESTIVES, INCL. ENZYMES		
Total number of patients with at least one treatment	5 (1.4%)	7 (1.9%)
Total number of treatments	5	7
ACHYRANTHES BIDENTATA ROOT	1 (0.3%)	0
ADONIS SODIUM SULFONATE/LEVOLUTAMIDE	1 (0.3%)	0
ENZYMES NOE	1 (0.3%)	0
HIPPOPHAE RHAMNOIDES	0	1 (0.3%)
MONASCUS PURPUREUS	0	2 (0.6%)
PANCREATIN	0	1 (0.3%)
SILYBUM MARIANUM	2 (0.5%)	2 (0.6%)
ZIMMIBER OFFICINALE	0	1 (0.3%)
DIURETICS		

Total number of patients with at least one treatment	45 (12.3%)	52 (14.3%)
Total number of treatments	59	60
ACETAZOLAMIDE	3 (0.8%)	4 (1.1%)
ACHTHANTHUS BICHBATA ROOT	1 (0.3%)	0
AMLORILIN HYDROCHLORIDE/HYDROCHLOROTHIAZIDE	0	3 (0.8%)
ASTRAGALUS PROPINQUEUS	1 (0.3%)	0
AZOSERIMIDE	0	1 (0.3%)
BENEFOPAMETHIAZIDE	1 (0.3%)	0
BETULA PYRUSCENS	1 (0.3%)	0
BUNEXAMIDE	1 (0.3%)	1 (0.3%)
CHLORTALIDONE	1 (0.3%)	0
ESAXEPERONE	1 (0.3%)	0
FUROSEMIDE	9 (2.5%)	19 (5.2%)
HYDROCHLOROTHIAZIDE	16 (4.4%)	11 (3.0%)
HYDROCHLOROTHIAZIDE/EPINOLACTONE	0	1 (0.3%)
HYDROCHLOROTHIAZIDE/TRIAMTERENE	1 (0.3%)	1 (0.3%)
INDAPAMIDE	5 (1.4%)	8 (2.2%)
ISOSERIMIDE	0	1 (0.3%)
METOLAZONE	0	2 (0.6%)
SAMBUCUS NIGRA	0	2 (0.6%)
SPEROLACTONE	7 (1.9%)	2 (0.6%)
TORASEMIDE	4 (1.1%)	2 (0.6%)
DRUGS FOR ACID RELATED DISORDERS		
Total number of patients with at least one treatment	72 (19.7%)	64 (17.6%)
Total number of treatments	88	78
ALUMINIUM HYDROXIDE/MAGNESIUM HYDROXIDE/SIMETICONE	0	1 (0.3%)
ANTACIDS, OTHER COMBINATIONS	2 (0.5%)	0
ARTEMISIA ANGYI	1 (0.3%)	0
ARLENE SODIUM SULFINATE/LEVOLUTAMIDE	1 (0.3%)	0
BISMUTH CITRATE	0	1 (0.3%)
CALCIUM CARBONATE	2 (0.5%)	4 (1.1%)
CALCIUM/MAGNESIUM	1 (0.3%)	0
CIMETIDINE	1 (0.3%)	0
COMBINATIONS AND COMPLEXES OF ALUMINIUM, CALCIUM AND MAGNESIUM COMPOUNDS	1 (0.3%)	0
DEGLANSOPRAZOLE	2 (0.5%)	0
ESOMEPRAZOLE	9 (2.5%)	5 (1.4%)
ESOMEPRAZOLE MAGNESIUM	3 (0.8%)	2 (0.6%)
FAMOTIDINE	2 (0.5%)	3 (0.8%)
HELICTHUM BULBOCORNUS MYCELIUM	0	1 (0.3%)
HEPCORAN BISMOLIDES	0	1 (0.3%)
LANSOPRAZOLE	6 (1.6%)	2 (0.6%)
MAGNESIUM HYDROXIDE	1 (0.3%)	1 (0.3%)
MAGNESIUM OXIDE	2 (0.5%)	3 (0.8%)
MISOPROSTOL	2 (0.5%)	0
OMEPRAZOLE	20 (5.5%)	28 (7.7%)
OTHER DRUGS FOR PEPTIC ULCER AND GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)	1 (0.3%)	0
PANTOPRAZOLE	10 (2.7%)	8 (2.2%)
PANTOPRAZOLE SODIUM SESQUIHYDRATE	6 (1.6%)	7 (1.9%)
PELIPLANTIA AMERICANA	1 (0.3%)	0
PLANTAGO MAJOR	1 (0.3%)	0
RABEPRAZOLE	1 (0.3%)	0
RABEPRAZOLE SODIUM	1 (0.3%)	2 (0.6%)
REBAMIPIDE	2 (0.5%)	1 (0.3%)
SODIUM ALGINATE	1 (0.3%)	0
SODIUM BICARBONATE	2 (0.5%)	1 (0.3%)
SODIUM GYALANATE HYDRATE	0	1 (0.3%)
SULPIDIUM	0	1 (0.3%)
TEGAPRAZAN	1 (0.3%)	0
TEPRENONE	1 (0.3%)	0
TRIFLUORANIL DICHLOROBISMUTHATE	0	2 (0.6%)
VONOPRAZAN PIRASATE	1 (0.3%)	0
DRUGS FOR CONSTIPATION		
Total number of patients with at least one treatment	16 (4.4%)	20 (5.5%)
Total number of treatments	36	28
ANGELICA SINENSIS	1 (0.3%)	0
BISACODYL	1 (0.3%)	1 (0.3%)
CITRIC ACID/MAGNESIUM OXIDE/SODIUM PICOSULFATE	1 (0.3%)	0
CONTACT LAXATIVES	1 (0.3%)	0
DOCUSATE	1 (0.3%)	0
DOCUSATE SODIUM	0	2 (0.6%)
DOCUSATE SODIUM/SENNOGLIDE A+B	1 (0.3%)	1 (0.3%)
ELBIXIBAT	1 (0.3%)	0
FIBRE, DIETARY/SENNA ALEXANDRINA LEAF	1 (0.3%)	0
GLYCEROL	0	2 (0.6%)
LINACLOTIDE	2 (0.5%)	0
LUBIPROSTONE	1 (0.3%)	1 (0.3%)
MACRODOL	1 (0.3%)	1 (0.3%)
MACRODOL 400/POTASSIUM CHLORIDE/SODIUM BICARBONATE/SODIUM CHLORIDE/SODIUM SULFATE	1 (0.3%)	0
MAGNESIUM HYDROXIDE	1 (0.3%)	1 (0.3%)
MAGNESIUM OXIDE	2 (0.5%)	3 (0.8%)
MAGNESIUM SULFATE	1 (0.3%)	0
MANNITOL	0	1 (0.3%)
PLANTAGO MAJOR	1 (0.3%)	0
PLANTAGO OVATA	2 (0.5%)	1 (0.3%)
PRUNIS SPP./SENNA SPP. LEAF	1 (0.3%)	0
SAMBUCUS NIGRA	0	2 (0.6%)
SENNA ALEXANDRINA	1 (0.3%)	0
SENNA SPP.	1 (0.3%)	0
SENNA SPP. SEED	1 (0.3%)	0
SENNOGLIDE A+B	1 (0.3%)	1 (0.3%)
SENNOGLIDE A+B CALCIUM	0	1 (0.3%)
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS		
Total number of patients with at least one treatment	14 (3.8%)	12 (3.3%)
Total number of treatments	17	13
BONELLIA SERBATA/CURCUMA LONGA/PIPER NIGRUM/WITHANIA SOMNIFERA/SINGIBER OFFICINALE	0	1 (0.3%)
CHINAMOMUM VERUM	0	1 (0.3%)
CLIBOPRIDE	0	1 (0.3%)
CLIBOPRIDE MALATE/SIMETICONE	1 (0.3%)	0
COYDALIS YANSHUO TUBER/POKOKA NIL SEED	1 (0.3%)	0
CURCUMA LONGA	4 (1.1%)	2 (0.6%)
DICYCLOVERINE	1 (0.3%)	0
DIMETICONE	1 (0.3%)	0
DROTAVERINE HYDROCHLORIDE	0	1 (0.3%)
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	1 (0.3%)	0
HYOSCINE BUTYLBROMIDE	0	2 (0.6%)
LYSPERID	0	1 (0.3%)
MENTHA X PIPERITA OIL	1 (0.3%)	0

METOCLOPRAMIDE	1 (0.3%)	1 (0.3%)
MOGAPIRIDE CITRATE	0	1 (0.3%)
NIGELLA SATIVA SEED OIL	0	1 (0.3%)
PHENOLGOLICINOL	1 (0.3%)	0
SIMETICONE	1 (0.3%)	0
SIMETICONE/TRIMETHYLLINE MALEATE	1 (0.3%)	0
THYMUS VULGARIS	1 (0.3%)	0
VALERIANA OFFICINALIS	1 (0.3%)	0
ZINGIBER OFFICINALE	0	1 (0.3%)
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES		
Total number of patients with at least one treatment	27 (7.4%)	43 (11.8%)
Total number of treatments	48	76
ACILDINUM BROMIDE	0	1 (0.3%)
AMBROGOL ACETYLSALICATE	0	1 (0.3%)
ARTEMISIA ARGYI	1 (0.3%)	0
BECLOMETASONE DIPROPIONATE/FORMOTEROL FUMARATE	0	1 (0.3%)
BECLOMETASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRONIUM BROMIDE	0	1 (0.3%)
BETAMETHASONE	1 (0.3%)	1 (0.3%)
BETAMETHASONE VALERATE	0	1 (0.3%)
BUDESONIDE	2 (0.5%)	5 (1.4%)
BUDESONIDE/FORMOTEROL FUMARATE	1 (0.3%)	1 (0.3%)
BUDESONIDE/FORMOTEROL FUMARATE DIHYDRATE	0	2 (0.6%)
DEKAMETHASONE	3 (0.8%)	1 (0.3%)
DIPROPRIVLINE	0	1 (0.3%)
DOMOPILLINE	0	1 (0.3%)
FENOTEROL HYDROBROMIDE/IPRATROPIUM BROMIDE	0	2 (0.6%)
FLUTICASON	1 (0.3%)	2 (0.6%)
FLUTICASON PIRUATE	1 (0.3%)	3 (0.8%)
FLUTICASON PIRUATE/UMECILDINIUM BROMIDE/VILANTEROL TRIPHENATE	0	2 (0.6%)
FLUTICASON PIRUATE/VILANTEROL TRIPHENATE	2 (0.5%)	2 (0.6%)
FLUTICASON PROPIONATE	3 (0.8%)	6 (1.7%)
FLUTICASON PROPIONATE/FORMOTEROL FUMARATE	1 (0.3%)	0
FLUTICASON PROPIONATE/SALMETEROL XINAFOATE	4 (1.1%)	2 (0.6%)
FORMOTEROL	0	1 (0.3%)
GANJYONHISA SPP. ROOT/OPHIPODON JAPONICUS TUBER/ORYZA SATIVA FRUIT/PANAX GINSENG	0	1 (0.3%)
ROOT/FINELLIA TERNATA TUBER/ZIZIPHUS JUJUBA FRUIT	0	1 (0.3%)
INDACATEROL MALEATE	0	1 (0.3%)
IPRATROPIUM	0	1 (0.3%)
IPRATROPIUM BROMIDE	0	2 (0.6%)
IPRATROPIUM/SALBUTAMOL	0	1 (0.3%)
LEVOSALBUTAMOL TARTRATE	1 (0.3%)	1 (0.3%)
MOMETASONE	0	1 (0.3%)
MOMETASONE PIRUATE	2 (0.5%)	1 (0.3%)
MONTelukAST	1 (0.3%)	4 (1.1%)
MONTelukAST SODIUM	4 (1.1%)	2 (0.6%)
OLIGATEROL/TIOTROPIUM	1 (0.3%)	0
PROCATEROL HYDROCHLORIDE	1 (0.3%)	1 (0.3%)
SALBUTAMOL	11 (3.0%)	7 (1.9%)
SALBUTAMOL SULFATE	4 (1.1%)	7 (1.9%)
SALMETEROL	0	1 (0.3%)
SALMETEROL XINAFOATE	0	1 (0.3%)
THIOPHYLLINE	2 (0.5%)	0
TIOTROPIUM BROMIDE	0	1 (0.3%)
TRAMAZOLONE ACETIBROMIDE	0	1 (0.3%)
UMECILDINIUM BROMIDE	0	1 (0.3%)
UMECILDINIUM BROMIDE/VILANTEROL TRIPHENATE	0	2 (0.6%)
DRUGS FOR TREATMENT OF BONE DISEASES		
Total number of patients with at least one treatment	8 (2.2%)	11 (3.0%)
Total number of treatments	8	11
ALENDRONATE SODIUM	3 (0.8%)	4 (1.1%)
ALENDRONIC ACID	0	1 (0.3%)
DEXOSRMAN	2 (0.5%)	2 (0.6%)
IBANDRONATE MONOSODIUM MONOHYDRATE	2 (0.5%)	0
TERANONATE SODIUM	1 (0.3%)	1 (0.3%)
RISERONATE SODIUM	0	3 (0.8%)
DRUGS USED IN DIABETES		
Total number of patients with at least one treatment	75 (20.5%)	78 (21.5%)
Total number of treatments	131	132
ACARBOSE	1 (0.3%)	0
ALGLIPTIN BENZOATE	0	1 (0.3%)
CINNAMOMUM VERUM	0	1 (0.3%)
DAPAGLIFLOZIN PROPRANEDIL MONOHYDRATE	2 (0.5%)	1 (0.3%)
DULAGLITIC	6 (1.6%)	2 (0.6%)
EMPAGLIFLOZIN	5 (1.4%)	4 (1.1%)
EMPAGLIFLOZIN/METFORMIN HYDROCHLORIDE	0	1 (0.3%)
ERTUGLIFLOZIN PIRUATE	0	1 (0.3%)
ERUGLIFLOZIN	0	1 (0.3%)
ERUGLIFLOZIN TARTRATE/METFORMIN HYDROCHLORIDE	1 (0.3%)	0
GLICAZIDE	6 (1.6%)	4 (1.1%)
GLIMEPIRIDE	6 (1.6%)	4 (1.1%)
GLIPIZIDE	9 (2.5%)	3 (0.8%)
GLIPIZIDE/METFORMIN	1 (0.3%)	1 (0.3%)
INSULIN	1 (0.3%)	4 (1.1%)
INSULIN ASPART	1 (0.3%)	4 (1.1%)
INSULIN ASPART/INSULIN ASPART PROTAMINE (CRYSTALLINE)	1 (0.3%)	0
INSULIN ASPART/INSULIN DEXIUDOC	0	1 (0.3%)
INSULIN DEXIUDOC	1 (0.3%)	1 (0.3%)
INSULIN HEMIN	3 (0.8%)	0
INSULIN GLARGINE	7 (1.9%)	8 (2.2%)
INSULIN GLULISINE	1 (0.3%)	0
INSULIN HUMAN	2 (0.5%)	1 (0.3%)
INSULIN HUMAN INJECTION, ISOPHANE	1 (0.3%)	1 (0.3%)
INSULIN ISOPHANE PORCINE	0	1 (0.3%)
INSULIN LISPRO	2 (0.5%)	5 (1.4%)
LINAHLIPTIN	1 (0.3%)	3 (0.8%)
LIRAGLUTIDE	0	1 (0.3%)
METFORMIN	36 (9.8%)	33 (9.1%)
METFORMIN HYDROCHLORIDE	22 (6.0%)	21 (5.8%)
METFORMIN HYDROCHLORIDE/SITAGLIPTIN PHOSPHATE	1 (0.3%)	0
METFORMIN HYDROCHLORIDE/SITAGLIPTIN PHOSPHATE MONOHYDRATE	1 (0.3%)	2 (0.6%)
METFORMIN HYDROCHLORIDE/VILDAGLIPTIN	2 (0.5%)	5 (1.4%)
PIGLITAZONE HYDROCHLORIDE	1 (0.3%)	0
REPAGLINIDE	3 (0.8%)	3 (0.8%)
SEMAGLITIC	1 (0.3%)	5 (1.4%)
SITAGLIPTIN PHOSPHATE	3 (0.8%)	0
SITAGLIPTIN PHOSPHATE MONOHYDRATE	1 (0.3%)	0
TENSELIGLIPTIN HYDROBROMIDE	0	1 (0.3%)
VILDAGLIPTIN	0	1 (0.3%)
VOGLIBOSE	0	1 (0.3%)

ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS		
Total number of patients with at least one treatment	2 (0.5%)	0
Total number of treatments	3	0
BENETHI BROMAZATE	1 (0.3%)	0
CROFAMITON	1 (0.3%)	0
DIMETICONE	1 (0.3%)	0
EMOLLIENTS AND PROTECTIVES		
Total number of patients with at least one treatment	12 (3.3%)	18 (5.0%)
Total number of treatments	13	22
AVENA SATIVA FLUID EXTRACT	1 (0.3%)	0
DIMETICONE	1 (0.3%)	0
GLYCEROL	0	2 (0.6%)
HEPARINOID	1 (0.3%)	0
HIPPOPHAE RHAMNOIDES	0	1 (0.3%)
MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER	1 (0.3%)	0
PARAFFIN SOFT/PARAFFIN, LIQUID	0	1 (0.3%)
PRURUS AMENIACA	1 (0.3%)	0
RETINOYLIC ACID	1 (0.3%)	0
GALACTIC ACID	2 (0.5%)	0
SESAMUM INDICUM SEED OIL	1 (0.3%)	0
THIOCTIC ACID	1 (0.3%)	1 (0.3%)
UREA	1 (0.3%)	0
VITAMIN E NOS	1 (0.3%)	8 (2.2%)
ZINC	1 (0.3%)	6 (1.7%)
ENDOCRINE THERAPY		
Total number of patients with at least one treatment	3 (0.8%)	5 (1.4%)
Total number of treatments	3	5
ANASTROZOLE	2 (0.5%)	1 (0.3%)
ESTRADIOL	1 (0.3%)	2 (0.6%)
ESTROGENS CONJUGATED	0	1 (0.3%)
LETROZOLE	0	1 (0.3%)
GENERAL NUTRIENTS		
Total number of patients with at least one treatment	8 (2.2%)	16 (4.4%)
Total number of treatments	11	17
AMINO ACIDS NOS	0	1 (0.3%)
ARGININE	1 (0.3%)	0
ECOSAPENTAENOIC ACID/EICOSAPENTAENOIC ACID	1 (0.3%)	4 (1.1%)
FISH OIL	4 (1.1%)	4 (1.1%)
GLUCOSE	0	1 (0.3%)
HERBAL NOS/MINERALS NOS/VITAMINS NOS	1 (0.3%)	0
LYSINE	0	1 (0.3%)
LYSINE HYDROCHLORIDE	1 (0.3%)	0
MINERALS NOS/VITAMINS NOS	3 (0.8%)	4 (1.1%)
POTASSIUM ASPARTATE	0	1 (0.3%)
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS		
Total number of patients with at least one treatment	18 (4.9%)	24 (6.6%)
Total number of treatments	25	27
ASCORBIC ACID	7 (1.9%)	13 (3.6%)
BEHEBINE	1 (0.3%)	0
CHLORHEXIDINE	1 (0.3%)	0
CHLORHEXIDINE GLUCONATE	1 (0.3%)	0
CITROFLOXACIN	1 (0.3%)	3 (0.8%)
CLINDAMYCIN	1 (0.3%)	3 (0.8%)
CLOTRIMAZOLE	1 (0.3%)	0
DEQUALINUM CHLORIDE	0	1 (0.3%)
LACTOBACILLUS ACIDOPHILUS	1 (0.3%)	1 (0.3%)
METRONIDAZOLE	2 (0.5%)	1 (0.3%)
MICONAZOLE NITRATE	1 (0.3%)	0
NORFLOXACIN	1 (0.3%)	0
NYSTATIN	2 (0.5%)	0
POTASSIUM	3 (0.8%)	3 (0.8%)
POVIDONE-IODINE	1 (0.3%)	1 (0.3%)
HOMIOPATHIC PREPARATION		
Total number of patients with at least one treatment	30 (8.2%)	47 (12.9%)
Total number of treatments	42	64
ASCORBIC ACID	7 (1.9%)	13 (3.6%)
CALCIUM CARBONATE	2 (0.5%)	4 (1.1%)
CHARCOAL, ACTIVATED	0	2 (0.6%)
CORTISONE	1 (0.3%)	1 (0.3%)
CYANOCOBALAMIN	3 (0.8%)	6 (1.7%)
IRON	4 (1.1%)	6 (1.7%)
PLANTAGO MAJOR	1 (0.3%)	0
POTASSIUM	3 (0.8%)	3 (0.8%)
POTASSIUM CHLORIDE	4 (1.1%)	7 (1.9%)
RIBOPFLAVIN	0	1 (0.3%)
SAMBUCUS NIGRA	0	2 (0.6%)
SILVER MARIANUM	2 (0.5%)	2 (0.6%)
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
THYMUS VULGARIS	1 (0.3%)	0
UREBICARBONENE	3 (0.8%)	3 (0.8%)
UREA	1 (0.3%)	0
ZINC	1 (0.3%)	6 (1.7%)
IMMUNE SERA AND IMMUNOGLOBULINS		
Total number of patients with at least one treatment	1 (0.3%)	0
Total number of treatments	1	0
CASIRIVIMAB IMBEVIMAB	1 (0.3%)	0
IMMUNOSTIMULANTS		
Total number of patients with at least one treatment	3 (0.8%)	2 (0.6%)
Total number of treatments	4	3
ASTRAGALUS PROPINQUUS	1 (0.3%)	0
ECHINACEA SPP.	1 (0.3%)	0
IMMUNOTHERAPY	1 (0.3%)	0
INTERFERON ALFA-2B	0	1 (0.3%)
INOSINID	0	2 (0.6%)
IMMUNOSUPPRESSANTS		
Total number of patients with at least one treatment	5 (1.4%)	4 (1.1%)
Total number of treatments	6	5
CYCLOSPORIN	0	1 (0.3%)
HYDROXYCHLOROQUINE	0	1 (0.3%)
IMMUNOTHERAPY	1 (0.3%)	0
LEFLUNOMIDE	0	1 (0.3%)
METHOTREXATE	2 (0.5%)	2 (0.6%)
MYCOPHENOLATE MOFETIL	1 (0.3%)	0

SECUKINUMAB	1 (0.3%)	0
TOCILIZUMAB	1 (0.3%)	0
INVESTIGATIONAL DRUG		
Total number of patients with at least one treatment	1 (0.3%)	0
Total number of treatments	1	0
ESAXERENONE	1 (0.3%)	0
LIPID MODIFYING AGENTS		
Total number of patients with at least one treatment	123 (33.6%)	127 (35.0%)
Total number of treatments	163	148
ALIROCUMAB	0	1 (0.3%)
ALIMUM SATIVUM	1 (0.3%)	1 (0.3%)
ALLIUM SATIVUM/CITRUS BERGAMIA	1 (0.3%)	0
AMLODIPINE BESILATE/ATORVASTATIN CALCIUM TRIHYDRATE	0	1 (0.3%)
AMLODIPINE BESILATE/OLMESARTAN MEDOXOMIL/ROSUVASTATIN CALCIUM	1 (0.3%)	0
AMLODIPINE CAMSILATE/LOSARTAN POTASSIUM/ROSUVASTATIN CALCIUM	0	1 (0.3%)
AMLODIPINE/ATORVASTATIN	1 (0.3%)	0
ATORVASTATIN	38 (10.4%)	35 (9.6%)
ATORVASTATIN CALCIUM	20 (5.5%)	19 (5.2%)
ATORVASTATIN CALCIUM TRIHYDRATE	1 (0.3%)	1 (0.3%)
ATORVASTATIN CALCIUM TRIHYDRATE/EZETIMIBE	1 (0.3%)	0
ATORVASTATIN CALCIUM/EZETIMIBE	0	1 (0.3%)
BEGBESINE	1 (0.3%)	0
BEMAFIBRATE	1 (0.3%)	0
CHROMIUM/OLIC ACID/LOVASTATIN/PYRIDOXINE HYDROCHLORIDE/UBIDECARBONE/VITAMIN B12 NOS	1 (0.3%)	0
CIFPROFIBRATE	1 (0.3%)	0
COLESEVELAM	1 (0.3%)	0
COLESEVELAM HYDROCHLORIDE	1 (0.3%)	0
CURCUMA LONGA	4 (1.1%)	2 (0.6%)
DOOSANEKANOIC ACID/EICOSAPENTAENOIC ACID	1 (0.3%)	4 (1.1%)
EICOSAPENTAENOIC ACID	1 (0.3%)	0
EVLACUMAB	0	1 (0.3%)
EZETIMIBE	7 (1.9%)	4 (1.1%)
EZETIMIBE/ROSUVASTATIN CALCIUM	2 (0.5%)	3 (0.8%)
EZETIMIBE/SIMVASTATIN	1 (0.3%)	0
FENOFIBRATE	3 (0.8%)	8 (2.2%)
FISH OIL	4 (1.1%)	4 (1.1%)
GENEPROL	1 (0.3%)	0
KRILL OIL	0	2 (0.6%)
LOVASTATIN	1 (0.3%)	1 (0.3%)
MENASCUS PURPUREUS	0	2 (0.6%)
NICTOTINIC ACID	1 (0.3%)	0
OMEGA-3-ACID ETHYL ESTER	0	2 (0.6%)
PHOSPHOLIPIDS	1 (0.3%)	0
PITAVASTATIN CALCIUM	6 (1.6%)	1 (0.3%)
PRAVASTATIN	2 (0.5%)	3 (0.8%)
PRAVASTATIN SODIUM	1 (0.3%)	2 (0.6%)
ROSUVASTATIN	10 (2.7%)	14 (3.9%)
ROSUVASTATIN CALCIUM	12 (3.3%)	18 (5.0%)
SIMVASTATIN	17 (4.6%)	17 (4.7%)
TOCOPHERYL NICOTINATE	1 (0.3%)	0
MEDICATED DRUGS		
Total number of patients with at least one treatment	10 (2.7%)	15 (4.1%)
Total number of treatments	13	15
CHLORHEXIDINE	1 (0.3%)	0
CHLORHEXIDINE GLUCONATE	1 (0.3%)	0
FOSFIC ACID	0	1 (0.3%)
POVIDONE-IODINE	1 (0.3%)	1 (0.3%)
SODIUM ALGINATE	1 (0.3%)	0
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
ZINC	1 (0.3%)	6 (1.7%)
MINERAL SUPPLEMENTS		
Total number of patients with at least one treatment	38 (10.4%)	46 (12.7%)
Total number of treatments	60	61
ASCORBIC ACID/POTASSIUM BICARBONATE	1 (0.3%)	0
CALCIUM	6 (1.6%)	7 (1.9%)
CALCIUM CARBONATE	2 (0.5%)	4 (1.1%)
CALCIUM CARBONATE/COLECALCIFEROL	1 (0.3%)	4 (1.1%)
CALCIUM CITRATE	3 (0.8%)	0
CALCIUM CITRATE/COLECALCIFEROL	0	1 (0.3%)
CALCIUM CITRATE/VITAMIN D NOS	1 (0.3%)	0
CALCIUM/COLECALCIFEROL	1 (0.3%)	0
CALCIUM/COLECALCIFEROL/RETINOL	1 (0.3%)	0
CALCIUM/MAGNESIUM	1 (0.3%)	0
CALCIUM/MAGNESIUM/ZINC	1 (0.3%)	0
CALCIUM/VITAMIN D NOS	1 (0.3%)	0
MAGNESIUM	4 (1.1%)	9 (2.5%)
MAGNESIUM ASPARTATE/POTASSIUM ASPARTATE	1 (0.3%)	0
MAGNESIUM GLUCONATE	0	1 (0.3%)
MAGNESIUM HYDROGEN ASPARTATE	0	1 (0.3%)
MAGNESIUM HYDROXIDE	1 (0.3%)	1 (0.3%)
MAGNESIUM OXIDE	2 (0.5%)	3 (0.8%)
MAGNESIUM SULFATE	1 (0.3%)	0
MAGNESIUM/PYRIDOXINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
MINERALS NOS/VITAMINS NOS	3 (0.8%)	4 (1.1%)
POTASSIUM	3 (0.8%)	3 (0.8%)
POTASSIUM ASPARTATE	0	1 (0.3%)
POTASSIUM CHLORIDE	4 (1.1%)	7 (1.9%)
RETINOL/ZINC OXIDE	1 (0.3%)	0
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
ZINC	1 (0.3%)	6 (1.7%)
MUSCLE RELAXANTS		
Total number of patients with at least one treatment	14 (3.8%)	5 (1.4%)
Total number of treatments	14	6
AFLOQUALONE	1 (0.3%)	0
BACLOFEN	1 (0.3%)	1 (0.3%)
BUTILIUM TOXIN TYPE A	1 (0.3%)	0
CHLORZOXAZONE/IBUPROFEN	0	1 (0.3%)
CYCLOBENZAPRINE	2 (0.5%)	2 (0.6%)
CYCLOBENZAPRINE HYDROCHLORIDE	1 (0.3%)	0
DIAZEPAM	3 (0.8%)	0
LIDOCaine HYDROCHLORIDE/TOLPERISONE HYDROCHLORIDE	1 (0.3%)	0
METHOCARBAMOL	0	1 (0.3%)
MEKILATINE	1 (0.3%)	0
MEKILATINE HYDROCHLORIDE	1 (0.3%)	0
PARACETAMOL/THIOCYLCHOSIDE	1 (0.3%)	0
TIZANIDINE	1 (0.3%)	1 (0.3%)

N/A		
Total number of patients with at least one treatment	3 (0.8%)	2 (0.6%)
Total number of treatments	3	2
ALLIUM SATIVUM	1 (0.3%)	1 (0.3%)
ARGININE	1 (0.3%)	0
DIGIBICTITE	0	1 (0.3%)
RADIOTHERAPY	1 (0.3%)	0
NASAL PREPARATIONS		
Total number of patients with at least one treatment	25 (6.8%)	39 (10.7%)
Total number of treatments	37	48
ACETYLCYSTEINE	1 (0.3%)	1 (0.3%)
AZELASTINE HYDROCHLORIDE/FLUTICASON PROPRIONATE	0	1 (0.3%)
BETAMETHASONE	1 (0.3%)	1 (0.3%)
BETAMETHASONE VALERATE	0	1 (0.3%)
BURSESIDE	2 (0.5%)	5 (1.4%)
CALCIUM CHLORIDE/MAGNESIUM CHLORIDE HEXAHYDRATE/POTASSIUM CHLORIDE/SODIUM BICARBONATE/SODIUM CHLORIDE	1 (0.3%)	0
DEXAMETHASONE	3 (0.8%)	1 (0.3%)
FLUTICASON	1 (0.3%)	2 (0.6%)
FLUTICASON FURCATE	1 (0.3%)	3 (0.8%)
FLUTICASON PROPRIONATE	3 (0.8%)	6 (1.7%)
HYALURONATE SODIUM	1 (0.3%)	2 (0.6%)
HYALURONIC ACID	0	1 (0.3%)
LEUPROPEN/PSEUDOPHEDRINE HYDROCHLORIDE	1 (0.3%)	0
IPRATROPIUM	0	1 (0.3%)
IPRATROPIUM BROMIDE	0	2 (0.6%)
MOMETASONE	0	1 (0.3%)
MOMETASONE FURCATE	2 (0.5%)	1 (0.3%)
MUPIROCIN	1 (0.3%)	0
NAPHAZOLINE NITRATE/PRENISOLONE	1 (0.3%)	0
OLopatADINE HYDROCHLORIDE	0	1 (0.3%)
PERNYLPHEDRINE HYDROCHLORIDE	1 (0.3%)	0
PRENISIOLONE	2 (0.5%)	0
PSEUDOPHEDRINE HYDROCHLORIDE	1 (0.3%)	2 (0.6%)
SESAMUM INDICUM SEED OIL	1 (0.3%)	0
SODIUM BICARBONATE	2 (0.5%)	1 (0.3%)
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
TRIMANTINOLONE ACETONIDE	0	1 (0.3%)
ZINC	1 (0.3%)	6 (1.7%)
OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS		
Total number of patients with at least one treatment	16 (4.4%)	8 (2.2%)
Total number of treatments	27	9
BETAMETHASONE	1 (0.3%)	1 (0.3%)
BETAMETHASONE VALERATE/GENTAMICIN SULFATE	0	1 (0.3%)
CHLORHEXIDINE	1 (0.3%)	0
CHLORHEXIDINE GLUCONATE	1 (0.3%)	0
CIPROFLOXACIN	1 (0.3%)	3 (0.8%)
CIPROFLOXACIN HYDROCHLORIDE	0	1 (0.3%)
DEXAMETHASONE	3 (0.8%)	1 (0.3%)
DEXAMETHASONE/NEOMYCIN SULFATE/POLYMYXIN B SULFATE	1 (0.3%)	0
GENTAMICIN SULFATE/PRENISOLONE	0	1 (0.3%)
LEVOPROXACIN	3 (0.8%)	0
METHYLPRENISOLONE ACETATE/NEOMYCIN SULFATE	1 (0.3%)	0
NEFLOXACIN	1 (0.3%)	0
PRENISOLONE	2 (0.5%)	0
STEROIDS	1 (0.3%)	0
OPHTHALMOLOGICALS		
Total number of patients with at least one treatment	80 (21.9%)	92 (25.3%)
Total number of treatments	162	147
ACETAZOLAMIDE	3 (0.8%)	4 (1.1%)
ACETYLTYROSINE	1 (0.3%)	1 (0.3%)
ACTICLOVIR	3 (0.8%)	1 (0.3%)
AMINO ACIDS NOS	0	1 (0.3%)
ASCORBIC ACID	7 (1.9%)	13 (3.6%)
ASCORBIC ACID/COPPER/TOCOPHERYL ACETATE/XANTOPYL/ZEAXANTHIN/ZINC	0	1 (0.3%)
ALTRIMONTIN	7 (1.9%)	6 (1.7%)
BACTRACIN	0	1 (0.3%)
BEPOTASTINE BESILATE	0	1 (0.3%)
BETAMETHASONE	1 (0.3%)	1 (0.3%)
BETAMETHASONE VALERATE	0	1 (0.3%)
BETAMETHASONE VALERATE/GENTAMICIN SULFATE	0	1 (0.3%)
BETAXOL	1 (0.3%)	1 (0.3%)
BIMATOPROST	1 (0.3%)	0
BRIMONIDINE	0	1 (0.3%)
BRIMONIDINE TARTRATE	1 (0.3%)	0
BRIMONIDINE TARTRATE/TIMOLOL MALEATE	1 (0.3%)	0
BRINOLAMINE	1 (0.3%)	0
BRINZOLAMIDE/TIMOLOL	1 (0.3%)	0
BROMFENAC SODIUM	1 (0.3%)	0
CEFUROXIME	0	2 (0.6%)
CETIRIZINE	3 (0.8%)	2 (0.6%)
CETIRIZINE HYDROCHLORIDE	1 (0.3%)	4 (1.1%)
CHLORHEXIDINE	1 (0.3%)	0
CHLORHEXIDINE GLUCONATE	1 (0.3%)	0
CHENODIOLIN	0	1 (0.3%)
CHENODIOLIN SULFATE	0	1 (0.3%)
CHENODIOLIN SULFATE SODIUM	0	1 (0.3%)
CYCLOSPORIN	0	1 (0.3%)
CIPROFLOXACIN	1 (0.3%)	3 (0.8%)
CIPROFLOXACIN HYDROCHLORIDE	0	1 (0.3%)
CLOBETASONE	1 (0.3%)	0
CLARIDINE	3 (0.8%)	3 (0.8%)
CLOTTING AGLE	1 (0.3%)	0
CORTISONE	1 (0.3%)	1 (0.3%)
CYANOCOBALAMIN	3 (0.8%)	6 (1.7%)
DEXAMETHASONE	3 (0.8%)	1 (0.3%)
DEXAMETHASONE/NEOMYCIN SULFATE/POLYMYXIN B SULFATE	1 (0.3%)	0
DICLOFENAC	6 (1.6%)	1 (0.3%)
DICLOFENAC DIETHYLAMINE	0	1 (0.3%)
DICLOFENAC SODIUM	2 (0.5%)	1 (0.3%)
DIGITALIS PURPUREA LEAF/ESCULOSIDE	1 (0.3%)	0
DIMETICONE	1 (0.3%)	0
DORZOLAMIDE HYDROCHLORIDE	1 (0.3%)	0
DORZOLAMIDE HYDROCHLORIDE/TIMOLOL MALEATE	1 (0.3%)	1 (0.3%)
EPINASTINE HYDROCHLORIDE	1 (0.3%)	2 (0.6%)
KRYTHROMYCIN	1 (0.3%)	0
PANICLOLOVIR	1 (0.3%)	0
FLUCONAZOLE	1 (0.3%)	1 (0.3%)

FLUORESCIN	3 (0.8%)	0
FLURBIPROFEN	1 (0.3%)	0
FUSIDIC ACID	0	1 (0.3%)
GWITAMICIN SULFATE/PREINISOLONE	0	1 (0.3%)
GLUCAGON	0	2 (0.6%)
HEPARIN	2 (0.5%)	0
HEPARIN CALCIUM	1 (0.3%)	0
HEPARIN SODIUM	0	1 (0.3%)
HEPARINOID	1 (0.3%)	0
HEPROMAN RHAMNOLIDES	0	1 (0.3%)
HYALURONATE SODIUM	1 (0.3%)	2 (0.6%)
HYALURONIC ACID	0	1 (0.3%)
HYDROCORTISONE SODIUM PHOSPHATE	0	1 (0.3%)
INTERFERON ALFA-2B	0	1 (0.3%)
ISOSORBIDE	0	1 (0.3%)
KETOROLAC	1 (0.3%)	0
KETOROLAC TROMETHAMINE	1 (0.3%)	0
LATANOPROST	0	1 (0.3%)
LEVOPLOXACIN	3 (0.8%)	0
LEVOPLOXACIN HYDROCHLORIDE	0	1 (0.3%)
LIDOCAINE	6 (1.6%)	2 (0.6%)
LIDOCAINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
MACROGOL	1 (0.3%)	1 (0.3%)
MELoxicam	3 (0.8%)	3 (0.8%)
METHYLPREINISOLONE	1 (0.3%)	1 (0.3%)
METHYLPREINISOLONE ACETATE	0	1 (0.3%)
MINERALS NOS/VITAMINS NOS	3 (0.8%)	4 (1.1%)
MINERALS NOS/VITAMINS NOS/XANTOPYL/ZEAXANTHIN	1 (0.3%)	0
MOXIFLOXACIN HYDROCHLORIDE	0	1 (0.3%)
MUCOPOLYCARBONATE POLYSULFURIC ACID ESTER	1 (0.3%)	0
NAFROLEN	1 (0.3%)	5 (1.4%)
NAFROLEN SODIUM	3 (0.8%)	2 (0.6%)
NEPAFENAC	1 (0.3%)	0
NEPFLONACIN	1 (0.3%)	0
OLAPATANIB HYDROCHLORIDE	0	1 (0.3%)
OTHER ANTI-GLAUCOMA PREPARATIONS	0	1 (0.3%)
OTHER OPHTHALMOLOGICALS	0	1 (0.3%)
PANCREATIN	0	1 (0.3%)
PERFLUTREN	1 (0.3%)	0
PHENYLEPHRINE HYDROCHLORIDE	1 (0.3%)	0
PIRACICAM BETADEX	0	1 (0.3%)
POTASSIUM	3 (0.8%)	3 (0.8%)
POTASSIUM CHLORIDE	4 (1.1%)	7 (1.9%)
POVIDONE- IODINE	1 (0.3%)	1 (0.3%)
PRENIZOLONE	2 (0.5%)	0
PRENIZOLONE	2 (0.5%)	0
REBAMIPIDE	2 (0.5%)	1 (0.3%)
RIBOFLAVIN	0	1 (0.3%)
SALICYLIC ACID	2 (0.5%)	0
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
SODIUM CHALCANATE HYDRATE	0	1 (0.3%)
STEROIDS	1 (0.3%)	0
TRIAMCINOLONE ACETONIDE	0	1 (0.3%)
TROXERUTIN	3 (0.8%)	4 (1.1%)
UBIDECARENONE	3 (0.8%)	3 (0.8%)
VANCOMICIN	1 (0.3%)	0
VASENICLINE TARTRATE	1 (0.3%)	0
XANTOPYL	0	1 (0.3%)
ZINC	1 (0.3%)	6 (1.7%)
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS		
Total number of patients with at least one treatment	8 (2.2%)	20 (5.5%)
Total number of treatments	10	22
ACETYLCYSTEINE	1 (0.3%)	1 (0.3%)
AMINO ACIDS NOS	0	1 (0.3%)
AMINOINOS	1 (0.3%)	0
ESCHERICHIA COLI	0	1 (0.3%)
LYSINE	0	1 (0.3%)
LYSINE HYDROCHLORIDE	1 (0.3%)	0
PROBIOTICS NOS	0	5 (1.4%)
SODIUM BICARBONATE	2 (0.5%)	1 (0.3%)
THIOCTIC ACID	1 (0.3%)	1 (0.3%)
THIOCTIC ACID TROMETHAMINE	0	2 (0.6%)
UBIDECARENONE	3 (0.8%)	3 (0.8%)
ZINC	1 (0.3%)	6 (1.7%)
OTHER DERMATOLOGICAL PREPARATIONS		
Total number of patients with at least one treatment	40 (10.9%)	48 (13.2%)
Total number of treatments	55	59
AMORFICA SINENSIS	1 (0.3%)	0
ASCORBIC ACID	7 (1.9%)	13 (3.6%)
ASCORBIC ACID/TOCOPHEROL	0	1 (0.3%)
BETULA PUBESCENS	1 (0.3%)	0
BIMATOPOST	1 (0.3%)	0
BOTULINUM TOXIN TYPE A	1 (0.3%)	0
BREMIDINE	0	1 (0.3%)
BREMIDINE TARTRATE	1 (0.3%)	0
COLLAGEN	0	2 (0.6%)
DICLOFENAC	6 (1.6%)	1 (0.3%)
DICLOFENAC SODIUM	2 (0.5%)	1 (0.3%)
DL-METHIONINE/GLYCINE/GLYCYSRRHIC ACID, AMMONIUM SALT	0	1 (0.3%)
DUFATERIBINE	1 (0.3%)	5 (1.4%)
ESTRADIOL	1 (0.3%)	2 (0.6%)
FINASTERIDE	5 (1.4%)	4 (1.1%)
HYALURONATE SODIUM	1 (0.3%)	2 (0.6%)
HYALURONIC ACID	0	1 (0.3%)
IBUPROFEN	7 (1.9%)	9 (2.5%)
MAGNESIUM SULFATE	1 (0.3%)	0
MINERALS NOS/VITAMINS NOS	3 (0.8%)	4 (1.1%)
MINEPIDIL	0	2 (0.6%)
ONCOTHERA BIENNIS OIL	1 (0.3%)	0
OTHER DERMATOLOGICALS	1 (0.3%)	0
OXYGEN	1 (0.3%)	0
POVIDONE- IODINE	1 (0.3%)	1 (0.3%)
PRIDOXINE HYDROCHLORIDE	1 (0.3%)	2 (0.6%)
SALICYLIC ACID	2 (0.5%)	0
SODIUM BICARBONATE	2 (0.5%)	1 (0.3%)
TRANSAMIC ACID	1 (0.3%)	2 (0.6%)
UBIDECARENONE	3 (0.8%)	3 (0.8%)
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM		
Total number of patients with at least one treatment	4 (1.1%)	4 (1.1%)

Total number of treatments	5	4
CLORIMFRAMINE	1 (0.3%)	0
ENZYMES NOS	1 (0.3%)	0
HYALURONATE SODIUM	1 (0.3%)	2 (0.6%)
HYALURONIC ACID	0	1 (0.3%)
QUININE SULFATE	0	1 (0.3%)
SEMPROPTEASE	1 (0.3%)	0
OTHER GYNECOLOGICALS		
Total number of patients with at least one treatment	41 (11.2%)	45 (12.4%)
Total number of treatments	50	53
ACHYRANTHES BIDENTATA ROOT	1 (0.3%)	0
ANGELICA SINENSIS	1 (0.3%)	0
ARTEMISIA ANOVI	1 (0.3%)	0
CAMERDOLINE	0	1 (0.3%)
CLONIDINE	3 (0.8%)	3 (0.8%)
GLYCEROL	0	2 (0.6%)
HYALURONATE SODIUM	1 (0.3%)	2 (0.6%)
HYALURONIC ACID	0	1 (0.3%)
IBUPROFEN	7 (1.9%)	9 (2.5%)
INTERFERON ALFA-2B	0	1 (0.3%)
LEVONORGESTREL	0	1 (0.3%)
METHOTREXATE	2 (0.5%)	2 (0.6%)
MISOPROSTOL	2 (0.5%)	0
MAPROFEN	1 (0.3%)	5 (1.4%)
NAPROFEN SODIUM	3 (0.8%)	2 (0.6%)
NIFEDIPINE	4 (1.1%)	4 (1.1%)
ONCOTHERA BIENNIS OIL	1 (0.3%)	0
PANOXETINE	1 (0.3%)	0
PANOXETINE HYDROCHLORIDE	1 (0.3%)	0
PHLONDIS ROTATA HERB	1 (0.3%)	0
SALBUTAMOL	11 (3.0%)	7 (1.9%)
SALBUTAMOL SULFATE	4 (1.1%)	7 (1.9%)
SODIUM BICARBONATE	2 (0.5%)	1 (0.3%)
STREPTODORNASE/STREPTOKINASE	1 (0.3%)	1 (0.3%)
OTHER HEMATOLOGICAL AGENTS		
Total number of patients with at least one treatment	2 (0.5%)	1 (0.3%)
Total number of treatments	2	1
ENZYMES NOS	1 (0.3%)	0
STREPTODORNASE/STREPTOKINASE	1 (0.3%)	1 (0.3%)
OTHER NERVOUS SYSTEM DRUGS		
Total number of patients with at least one treatment	41 (11.2%)	38 (10.5%)
Total number of treatments	47	43
ACETYLCHOLINE	0	1 (0.3%)
BETAHISTINE	0	2 (0.6%)
BETAHISTINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
BETHANECHOL CHLORIDE	1 (0.3%)	0
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	0	1 (0.3%)
BUPROPION	0	1 (0.3%)
BUPROPION HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
CHLILINE ALFOSCERATE	1 (0.3%)	2 (0.6%)
CLONIDINE	3 (0.8%)	3 (0.8%)
FLORAZETINE	1 (0.3%)	0
FLORAZETINE DIHYDROCHLORIDE	0	1 (0.3%)
FLIOPXETINE	2 (0.5%)	3 (0.8%)
FLIOPXETINE HYDROCHLORIDE	4 (1.1%)	0
GABAPENTIN	10 (2.7%)	7 (1.9%)
GINKGO BILOBA EXTRACT	0	1 (0.3%)
HYDROCOBALAMIN	1 (0.3%)	0
MECLOZINE	0	1 (0.3%)
MECOBALAMIN	1 (0.3%)	1 (0.3%)
METHADONE	0	1 (0.3%)
NALOXONE HYDROCHLORIDE/OXYCODONE HYDROCHLORIDE	1 (0.3%)	0
PRESIPHELIPIDS	1 (0.3%)	0
PRESPANOLOL	2 (0.5%)	3 (0.8%)
RILUZOLE	1 (0.3%)	0
TRIOCTIC ACID	1 (0.3%)	1 (0.3%)
TRIMETAZIDINE	0	1 (0.3%)
TRIMETAZIDINE HYDROCHLORIDE	1 (0.3%)	1 (0.3%)
VAMENICLINE SALICYLATE	1 (0.3%)	0
VAMENICLINE TARTRATE	1 (0.3%)	0
VITAMIN B12 NOS	9 (2.5%)	9 (2.5%)
OTHER RESPIRATORY SYSTEM PRODUCTS		
Total number of patients with at least one treatment	3 (0.8%)	3 (0.8%)
Total number of treatments	4	4
AMBROCOL HYDROCHLORIDE	2 (0.5%)	2 (0.6%)
GLYCYRRHIZA SPP. ROOT/OPHIPOPON JAPONICUS TUBER/ORYZA SATIVA FRUIT/PANAX GINSENG ROOT/PINELLIA TERNATA TUBER/IZIPIBUS QUUBA FRUIT	0	1 (0.3%)
NITRIC OXIDE	0	1 (0.3%)
PRESIPHELIPIDS	1 (0.3%)	0
OTOLOGICALS		
Total number of patients with at least one treatment	25 (6.8%)	21 (5.8%)
Total number of treatments	40	29
BETAMETHASONE	1 (0.3%)	1 (0.3%)
BETAMETHASONE VALERATE	0	1 (0.3%)
CHLORHEXIDINE	1 (0.3%)	0
CHLORHEXIDINE GLUCONATE	2 (0.5%)	0
CIPROFLOXACIN	1 (0.3%)	3 (0.8%)
CIPROFLOXACIN HYDROCHLORIDE	0	1 (0.3%)
CLOTRIMAZOLE	1 (0.3%)	0
DEXAMETHASONE	3 (0.8%)	1 (0.3%)
DEXAMETHASONE/NEOMYCIN SULFATE/POLIMYXIN B SULFATE	1 (0.3%)	0
DOCUSATE	1 (0.3%)	0
DOCUSATE SODIUM	0	2 (0.6%)
GLYCEROL	0	2 (0.6%)
HYDROCORTISONE SODIUM PHOSPHATE	0	1 (0.3%)
LEVOPROXACIN	3 (0.8%)	0
LEVOPROXACIN HYDROCHLORIDE	0	1 (0.3%)
LIDOCAINE	6 (1.6%)	2 (0.6%)
LIDOCAINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
MICONAZOLE NITRATE	1 (0.3%)	0
PRENITOLONE	2 (0.5%)	0
SALICYLIC ACID	2 (0.5%)	0
SODIUM BICARBONATE	2 (0.5%)	1 (0.3%)
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
STEROIDS	1 (0.3%)	0
PANCREATIC HORMONES		

Total number of patients with at least one treatment	0	1 (0.3%)
Total number of treatments	0	1
GLUCAGON	0	1 (0.3%)
PERIPHERAL VASODILATORS		
Total number of patients with at least one treatment	6 (1.6%)	3 (0.8%)
Total number of treatments	7	3
ACHYRANTHES BIDENTATA ROOT	1 (0.3%)	0
ENZYMES NOS	1 (0.3%)	0
GINKGO BILOBA EXTRACT	0	1 (0.3%)
KALLIDINOHIDROLASE	1 (0.3%)	0
NICERGOLINE	1 (0.3%)	1 (0.3%)
NICOTINIC ACID	1 (0.3%)	0
PEROXYPYLLINE	1 (0.3%)	1 (0.3%)
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES		
Total number of patients with at least one treatment	0	1 (0.3%)
Total number of treatments	0	1
DESMOPRESSIN	0	1 (0.3%)
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS		
Total number of patients with at least one treatment	14 (3.8%)	16 (4.4%)
Total number of treatments	21	17
BETULA PUBESCENS	1 (0.3%)	0
ONE-LIVEN OIL	1 (0.3%)	0
DIMETHICONE	1 (0.3%)	0
FISH OIL	4 (1.1%)	4 (1.1%)
HIPPOCRAS RHAMNOLIDES	0	1 (0.3%)
HYALURONATE SODIUM	1 (0.3%)	2 (0.6%)
HYALURONIC ACID	0	1 (0.3%)
LYSINE	0	1 (0.3%)
LYSINE HYDROCHLORIDE	1 (0.3%)	0
PERIPLANETA AMERICANA	1 (0.3%)	0
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS	1 (0.3%)	0
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
STREPTODORNASE/STREPTOKINASE	1 (0.3%)	1 (0.3%)
PSYCHONALEPTICS		
Total number of patients with at least one treatment	38 (10.4%)	47 (12.9%)
Total number of treatments	52	63
AMPHETAMINE ASPARTATE/AMPHETAMINE SULFATE/DEXAMPETAMINE SACCHARATE/DEXAMPETAMINE SULFATE	0	2 (0.6%)
AMITRIPTYLINE	1 (0.3%)	4 (1.1%)
AMITRIPTYLINE HYDROCHLORIDE	1 (0.3%)	3 (0.8%)
ANHELICA ACUTILOBA ROOT/ATRACTYLODES LANCEA RHIZOME/BUPLERUM FALCATUM ROOT/CHIDIM OFFICINALE RHIZOME/GLYCYRRHIZA SPP. ROOT/PORIA COCOS SCLEROTIUM/INCANARIA SPP. HOOD	1 (0.3%)	0
APCARBOCICLIN/CALCALIFEROL	0	2 (0.6%)
BUPROPION	0	1 (0.3%)
BUPROPION HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
CITALOPRAM	1 (0.3%)	0
CITALOPRAM HYDROBROMIDE	0	3 (0.8%)
CLAMIPRAMINE	1 (0.3%)	0
CLAMIPRONE	3 (0.8%)	3 (0.8%)
DESVENLAFAXINE SUCCINATE MONOHYDRATE	1 (0.3%)	0
DEKAMPETAMINE SULFATE	1 (0.3%)	0
DOMPERIDON	1 (0.3%)	1 (0.3%)
DOMPERIDON HYDROCHLORIDE	1 (0.3%)	2 (0.6%)
DULOXETINE	2 (0.5%)	5 (1.4%)
DULOXETINE HYDROCHLORIDE	1 (0.3%)	3 (0.8%)
ENZYMES NOS	1 (0.3%)	0
ESCITALOPRAM	3 (0.8%)	2 (0.6%)
ESCITALOPRAM OXALATE	4 (1.1%)	3 (0.8%)
FLAOXETINE	2 (0.5%)	3 (0.8%)
FLAOXETINE HYDROCHLORIDE	4 (1.1%)	0
GALANTAMINE HYDROBROMIDE	1 (0.3%)	0
GINKGO BILOBA EXTRACT	0	1 (0.3%)
LAMOTRIGINE	2 (0.5%)	1 (0.3%)
MORANTINE	0	1 (0.3%)
METAPRIPINE	2 (0.5%)	2 (0.6%)
MODAFINIL	1 (0.3%)	0
NIMODIPINE	0	1 (0.3%)
NORTRIPTYLINE	0	1 (0.3%)
PAROXETINE	1 (0.3%)	0
PAROXETINE HYDROCHLORIDE	1 (0.3%)	0
PHENIBUT	0	1 (0.3%)
PIRACETAM	1 (0.3%)	0
RIVASTIGMINE	1 (0.3%)	0
SETRALINE	2 (0.5%)	2 (0.6%)
SETRALINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
TRAZODONE	2 (0.5%)	3 (0.8%)
TRAZODONE HYDROCHLORIDE	1 (0.3%)	1 (0.3%)
VENLAFAXINE	0	3 (0.8%)
VENLAFAXINE HYDROCHLORIDE	0	2 (0.6%)
VIMOCETINE	3 (0.8%)	0
PSYCHOLEPTICS		
Total number of patients with at least one treatment	54 (14.8%)	62 (17.1%)
Total number of treatments	74	85
ALPACICAM	6 (1.6%)	7 (1.9%)
AMITRIPTYLINE	1 (0.3%)	4 (1.1%)
AMITRIPTYLINE HYDROCHLORIDE	1 (0.3%)	3 (0.8%)
ANHELICA ACUTILOBA ROOT/ATRACTYLODES LANCEA RHIZOME/BUPLERUM FALCATUM ROOT/CHIDIM OFFICINALE RHIZOME/GLYCYRRHIZA SPP. ROOT/PORIA COCOS SCLEROTIUM/INCANARIA SPP. HOOD	1 (0.3%)	0
BROMAZEPAM	0	2 (0.6%)
BROTIZOLAM	1 (0.3%)	0
BUPROPION	1 (0.3%)	1 (0.3%)
CARBAMAZEPINE	1 (0.3%)	1 (0.3%)
CLONAZEPAM	1 (0.3%)	0
CLONAZEPAM	4 (1.1%)	7 (1.9%)
CRATAGEUS LAEVIGATA/GUAIFENESIN/HEMELIS LUPULIS/HYPERICUM PERFORATUM/MELISSA OFFICINALIS/PASSIFLORA INCARNATA/SAMBUCUS NIGRA/VALERIANA SPP.	1 (0.3%)	0
DIPIPRAM	3 (0.8%)	0
DIPHENHYDRAMINE HYDROCHLORIDE	3 (0.8%)	2 (0.6%)
DOXYLAMINE	0	1 (0.3%)
DULOXETINE	2 (0.5%)	5 (1.4%)
DULOXETINE HYDROCHLORIDE	1 (0.3%)	3 (0.8%)
ESCITALOPRAM	3 (0.8%)	2 (0.6%)
ESCITALOPRAM OXALATE	4 (1.1%)	3 (0.8%)
ETIZOLAM	0	1 (0.3%)
FLAOXETINE	2 (0.5%)	3 (0.8%)
FLAOXETINE HYDROCHLORIDE	4 (1.1%)	0

HYDROXYZINE	0	2 (0.6%)
LORMEZEPAM	0	1 (0.3%)
MELATONIN	4 (1.3%)	7 (1.9%)
MELISSA OFFICINALIS HERB	1 (0.3%)	0
PAROXETINE	1 (0.3%)	0
PAROXETINE HYDROCHLORIDE	1 (0.3%)	0
PERAZINE DIMALONATE	1 (0.3%)	0
PHENIBUT	0	1 (0.3%)
PRALIDEM	0	1 (0.3%)
PRIMAALIN	6 (1.6%)	3 (0.8%)
PROMETHAZINE	2 (0.5%)	2 (0.6%)
PROPRANOLOL	2 (0.5%)	3 (0.8%)
QUETIAPINE	1 (0.3%)	0
QUETIAPINE FUMARATE	2 (0.5%)	0
SETRALINE	2 (0.5%)	2 (0.6%)
SETRALINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
SULPIDIUM	0	1 (0.3%)
TRAZOLAM	0	1 (0.3%)
VALERIANA OFFICINALIS	1 (0.3%)	0
VALPROIC ACID	0	1 (0.3%)
VENLAFAXINE	0	3 (0.8%)
VENLAFAXINE HYDROCHLORIDE	0	2 (0.6%)
ZOLPIDEM	2 (0.5%)	1 (0.3%)
ZOLPIDEM TARTRATE	3 (0.8%)	2 (0.6%)
ZOPICLONE	0	1 (0.3%)
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM		
Total number of patients with at least one treatment	3 (0.8%)	6 (1.7%)
Total number of treatments	3	6
ESTRADIOL	1 (0.3%)	2 (0.6%)
ESTROGENS COMBINED	0	1 (0.3%)
ETHINYLESTRADIOL/FERROUS FUMARATE/NORETHISTERONE ACETATE	0	1 (0.3%)
ETHINYLESTRADIOL/LEVONORGESTREL	1 (0.3%)	0
LEVONORGESTREL	0	1 (0.3%)
TESTOSTERONE	0	1 (0.3%)
TIBOLONE	1 (0.3%)	0
STOMATOLOGICAL PREPARATIONS		
Total number of patients with at least one treatment	86 (23.5%)	101 (27.8%)
Total number of treatments	126	128
ACETYLSALICYLIC ACID	58 (15.8%)	70 (19.3%)
BETAMETHASONE	1 (0.3%)	1 (0.3%)
BOTULINUM TOXIN TYPE A	1 (0.3%)	0
CHLORHEXIDINE	1 (0.3%)	0
CHLORHEXIDINE GLUCONATE	1 (0.3%)	0
CLORETHANE	1 (0.3%)	0
CLOBETAOL PROPIONATE	1 (0.3%)	0
CLOTRIMAZOLE	1 (0.3%)	0
DEKAMETHASONE	3 (0.8%)	1 (0.3%)
DICLOFENAC	6 (1.6%)	1 (0.3%)
DICLOFENAC SODIUM	2 (0.5%)	1 (0.3%)
DIMETICONE	1 (0.3%)	0
DOXYCYCLINE	2 (0.5%)	3 (0.8%)
DOXYCYCLINE MONOHYDRATE	1 (0.3%)	0
FLURBIPROFEN	1 (0.3%)	0
GLYCEROL	0	2 (0.6%)
GLYCEROL/HYDROXYMETHYLCELLULOSE/METHYLPARABEN/POLOXAMER 407/PROPYLENE GLYCOL/PROPYLPARABEN/SODIUM BENZOATE/SODIUM PHOSPHATE/SODIUM PHOSPHATE DIRASIC/SORBITOL/XYLITOL	1 (0.3%)	1 (0.3%)
HYALURONIC SODIUM	1 (0.3%)	2 (0.6%)
HYALURONIC ACID	0	1 (0.3%)
KETOPROFEN	0	1 (0.3%)
LIDOCAINE	6 (1.6%)	2 (0.6%)
LIDOCAINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
MENTH X PIPERITA OIL	1 (0.3%)	0
METRONIDAZOLE	2 (0.5%)	1 (0.3%)
MICONAZOLE NITRATE	1 (0.3%)	0
NAPROXEN	1 (0.3%)	5 (1.4%)
NIMESULIDE	0	2 (0.6%)
HYSTAIN	2 (0.5%)	0
OXIDIN	1 (0.3%)	0
POTASSIUM	3 (0.8%)	3 (0.8%)
POVIDONE-IODINE	1 (0.3%)	1 (0.3%)
PRENIZOLONE	2 (0.5%)	0
SALICYLIC ACID	2 (0.5%)	0
SODIUM BICARBONATE	2 (0.5%)	1 (0.3%)
SODIUM CHLORIDE	5 (1.4%)	7 (1.9%)
SODIUM CHLORIDE HYDRATE	0	1 (0.3%)
THYMUS VULGARIS	1 (0.3%)	0
TRANSAMIC ACID	1 (0.3%)	2 (0.6%)
TRIAMCINOLONE ACETONIDE	0	1 (0.3%)
ZINC	1 (0.3%)	6 (1.7%)
THROAT PREPARATIONS		
Total number of patients with at least one treatment	24 (6.6%)	20 (5.5%)
Total number of treatments	24	24
AMBROXOL HYDROCHLORIDE	2 (0.5%)	2 (0.6%)
BACITRACIN	0	1 (0.3%)
CHLORHEXIDINE	1 (0.3%)	0
CHLORHEXIDINE GLUCONATE	1 (0.3%)	0
DIQUALINUM CHLORIDE	0	1 (0.3%)
DICLOFENAC	6 (1.6%)	1 (0.3%)
DICLOFENAC SODIUM	2 (0.5%)	1 (0.3%)
FLURBIPROFEN	1 (0.3%)	0
HYALURONIC ACID	0	1 (0.3%)
IBUPROFEN	7 (1.9%)	9 (2.5%)
KETOPROFEN	0	1 (0.3%)
LIDOCAINE	6 (1.6%)	2 (0.6%)
LIDOCAINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
POVIDONE-IODINE	1 (0.3%)	1 (0.3%)
SODIUM CHLORIDE HYDRATE	0	1 (0.3%)
THYROID THERAPY		
Total number of patients with at least one treatment	31 (8.5%)	29 (8.0%)
Total number of treatments	32	30
LEVOTHYRINE	9 (2.5%)	11 (3.0%)
LEVOTHYRINE SODIUM	20 (5.5%)	15 (4.1%)
PROPRANOLOL	2 (0.5%)	3 (0.8%)
THIAMAZOLE	1 (0.3%)	0
TONICS		
Total number of patients with at least one treatment	10 (2.7%)	9 (2.5%)
Total number of treatments	13	9

SIENNA SPP. SEED	1 (0.3%)	0
SIENNA REPENS EXTRACT	1 (0.3%)	0
SIENNA REPENS/URTICA DIOICA	0	1 (0.3%)
SIENNA REPENS SEED OIL	1 (0.3%)	0
SILYBIUM MARIANUM	2 (0.5%)	2 (0.6%)
THYMUS VULGARIS	1 (0.3%)	0
TURBILAGO FARFARA	1 (0.3%)	0
UNCODED	2 (0.5%)	7 (1.9%)
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	2 (0.5%)	2 (0.6%)
VACCINIUM SPP.	0	2 (0.6%)
VALERIANA OFFICINALIS	1 (0.3%)	0
VITIS VINIFERA SEED	1 (0.3%)	1 (0.3%)
ZINGIBER OFFICINALE	0	1 (0.3%)
UROLOGICALS		
Total number of patients with at least one treatment	45 (12.3%)	64 (17.6%)
Total number of treatments	63	82
AREBIA QUINATA FRUIT/CENTELLA ASIATICA HERB/YOQODIUM JAPONICUM SPORE/ROSA LAEVIGATA	0	0
ROST/AMLIAN CHINA	1 (0.3%)	0
ALISMA ORIENTALE TUBER/GELATIN/POLYPORUS UMBELLATUS SCLEROTIUM/PORIA COCOS	0	1 (0.3%)
SCLEROTIUM/TALC	0	1 (0.3%)
AMITRIPTYLIN	1 (0.3%)	4 (1.1%)
AMITRIPTYLIN HYDROCHLORIDE	1 (0.3%)	3 (0.8%)
SPYLLA PIRENEUS	1 (0.3%)	0
BOTULINUM TOXIN TYPE A	1 (0.3%)	0
BURSINIDE	2 (0.5%)	5 (1.4%)
CHEMOKITIN	0	1 (0.3%)
CHEMOKITIN SULFATE	0	1 (0.3%)
CHEMOKITIN SULFATE SODIUM	0	1 (0.3%)
CIRSIIUM ABLVENSE HERB/IMPERATA CYLINDRICA RHIZOME/ORTHOSIPHON ARISTATUS VAR.	0	1 (0.3%)
ARISTATUS/PHELODENDRON CHINENSIS BARK	0	1 (0.3%)
CLMIFRAMINE	1 (0.3%)	0
COLLAGEN	0	2 (0.6%)
DOKAZOSIN	3 (0.8%)	4 (1.1%)
DOKAZOSIN MESILATE	3 (0.8%)	3 (0.8%)
DROTAVERINE HYDROCHLORIDE	0	1 (0.3%)
DULOXETINE	2 (0.5%)	5 (1.4%)
DULOXETINE HYDROCHLORIDE	1 (0.3%)	3 (0.8%)
DUTASTERIDE	1 (0.3%)	5 (1.4%)
DUTASTERIDE/TAMUSOLIN	0	1 (0.3%)
DUTASTERIDE/TAMUSOLIN HYDROCHLORIDE	0	1 (0.3%)
ESCHERICHIA COLI	0	1 (0.3%)
FENOTROLOLINE FUMARATE	0	1 (0.3%)
FINASTERIDE	5 (1.4%)	4 (1.1%)
HYALURONATE SODIUM	1 (0.3%)	2 (0.6%)
HYALURONIC ACID	0	1 (0.3%)
LIDOCAINE	6 (1.6%)	2 (0.6%)
LIDOCAINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
MAGNESIUM HYDROXIDE	1 (0.3%)	1 (0.3%)
MIRABEGRON	2 (0.5%)	2 (0.6%)
OXBUPTYNIN	2 (0.5%)	1 (0.3%)
PHENAZOPYRIDINE HYDROCHLORIDE	0	1 (0.3%)
PHYTOSTEROLS NON/SIENNA REPENS FRUIT	0	1 (0.3%)
SIENNA REPENS EXTRACT	1 (0.3%)	0
SIENNA REPENS/URTICA DIOICA	0	1 (0.3%)
SILDENAFIL	1 (0.3%)	0
SILDENAFIL CITRATE	1 (0.3%)	1 (0.3%)
SODIUM BICARBONATE	2 (0.5%)	1 (0.3%)
SOLIFENACIN	0	1 (0.3%)
SOLIFENACIN SUCCINATE	0	1 (0.3%)
SOLIFENACIN SUCCINATE/TAMUSOLIN HYDROCHLORIDE	1 (0.3%)	0
TADALAFIL	1 (0.3%)	0
TAMUSOLIN	9 (2.5%)	7 (1.9%)
TAMUSOLIN HYDROCHLORIDE	6 (1.6%)	7 (1.9%)
TERAZOSIN	1 (0.3%)	0
TERAZOSIN HYDROCHLORIDE	1 (0.3%)	0
VACCINES		
Total number of patients with at least one treatment	89 (24.3%)	94 (25.9%)
Total number of treatments	116	123
COVID-19 VACCINE	5 (1.4%)	6 (1.7%)
COVID-19 VACCINE INACT (VERO)	0	1 (0.3%)
COVID-19 VACCINE INACT (VERO) HB02	1 (0.3%)	2 (0.6%)
COVID-19 VACCINE NRVV Ad (CHAD001 MCOV-19)	11 (3.0%)	8 (2.2%)
COVID-19 VACCINE NRVV AD26 (GAM-COVID-VAC)/COVID-19 VACCINE NRVV AD5 (GAM-COVID-VAC)	3 (0.8%)	2 (0.6%)
COVID-19 VACCINE PROT. SUBUNIT (MVC-COV1901)	1 (0.3%)	0
ELANVEDAN	24 (6.6%)	20 (5.5%)
INFLUENZA VACCINE	5 (1.4%)	12 (3.3%)
INFLUENZA VACCINE INACT	1 (0.3%)	0
INFLUENZA VACCINE INACT SAG 3V	0	2 (0.6%)
INFLUENZA VACCINE INACT SPLIT 3V	1 (0.3%)	1 (0.3%)
INFLUENZA VACCINE INACT SPLIT 4V	2 (0.5%)	1 (0.3%)
PNEUMOCOCCAL VACCINE POLYSACCH 23V	2 (0.5%)	0
TETANUS VACCINE	0	1 (0.3%)
TOZINAMERAN	41 (11.2%)	46 (12.7%)
VARICELLA ZOSTER VACCINE	2 (0.5%)	0
VARICELLA ZOSTER VACCINE RHE (CHO)	1 (0.3%)	0
VASOPROTECTIVES		
Total number of patients with at least one treatment	38 (10.4%)	46 (12.7%)
Total number of treatments	64	56
ARGOLUSIUM HIPPOCASTANUM SEED/RUTOSIDE	1 (0.3%)	0
AMYLICA STYRACIS	1 (0.3%)	0
ASCORBIC ACID/HESPERIDIN METHYL CHALCONE/RIBUSUS ACULEATUS	1 (0.3%)	1 (0.3%)
ASCORBIC ACID/RUTOSIDE	0	1 (0.3%)
BETAMETHASONE	1 (0.3%)	1 (0.3%)
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.3%)	1 (0.3%)
BETAMETHASONE VALERATE	0	1 (0.3%)
BIGFLAVONOIDS NON	0	1 (0.3%)
CALCIUM DOBESILATE	6 (1.6%)	9 (2.5%)
CALCIUM DOBESILATE/LIDOCAINE HYDROCHLORIDE	1 (0.3%)	0
DEKAMETHASONE	3 (0.8%)	1 (0.3%)
DELTAHEM HYDROCHLORIDE	3 (0.8%)	6 (1.7%)
DIOSEMID	2 (0.5%)	0
DIOSEMID/HESPERIDIN	1 (0.3%)	3 (0.8%)
ESCHERICHIA COLI	0	1 (0.3%)
GLYCERYL TRINITRATE	4 (1.1%)	2 (0.6%)
HEPARIN	2 (0.5%)	0
HEPARIN CALCIUM	1 (0.3%)	0
HEPARIN SODIUM	0	1 (0.3%)
HEPARINOID	1 (0.3%)	0
HIPPOPHOS RHANNOIDES	0	1 (0.3%)

HYALURONATE SODIUM	1 (0.3%)	2 (0.6%)
HYALURONIC ACID	0	1 (0.3%)
HYDROCORTISONE SODIUM PHOSPHATE	0	1 (0.3%)
IBUPROFEN DINITRATE	1 (0.3%)	1 (0.3%)
LIDOCAINE	6 (1.6%)	2 (0.6%)
LIDOCAINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER	1 (0.3%)	0
NIFEDIPINE	4 (1.1%)	4 (1.1%)
OTHER AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	1 (0.3%)	0
PHENYLEPHRINE HYDROCHLORIDE	1 (0.3%)	0
PLANTAGO MAJOR	1 (0.3%)	0
PRINISOLONE	2 (0.5%)	0
SODIUM ALGINATE	1 (0.3%)	0
TRAMANTOLONE ACETONIDE	0	1 (0.3%)
TROSPIDIUM	3 (0.8%)	4 (1.1%)
VITIS VINIFERA SEED	1 (0.3%)	1 (0.3%)
ZINC	1 (0.3%)	6 (1.7%)
VITAMINS		
Total number of patients with at least one treatment	60 (16.4%)	65 (17.9%)
Total number of treatments	88	89
ACETYL-CYSTEINE/ASCORBIC ACID/CHOLINE BITARTRATE/COPPER/CYANOCOBALAMIN/FOLIC ACID/INOSITOL/MAGNESIUM CHELATE/MANGANESE/METHYLOXINE/PYRIDOXINE HYDROCHLORIDE/SILYBIUM	1 (0.3%)	0
MAGNESIUM/CHOLINE/ZINC	2 (0.5%)	0
ALPACALCIPEROL	7 (1.9%)	13 (3.6%)
ASCORBIC ACID	0	0
ASCORBIC ACID/DL-ALPHA TOCOPHERYL ACETATE/FURSULTIAMIUM/HYDROXYCOBALAMIN	0	1 (0.3%)
ACETATE/PERIDOLAL PHOSPHATE/RIBOFLAVIN TETRAHYDRATE	0	1 (0.3%)
ASCORBIC ACID/TOCOPHEROL	0	1 (0.3%)
ASCORBIC ACID/VITAMIN B COMPLEX	0	1 (0.3%)
BIOPOTIAMINE	1 (0.3%)	0
BIOTIN	4 (1.1%)	5 (1.4%)
CALCITRIOL	0	3 (0.8%)
CALCITRIOL	1 (0.3%)	0
CALCIUM/COLECALCIFEROL/RETINOL	1 (0.3%)	0
COD-LIVER OIL	1 (0.3%)	0
COLECALCIFEROL	23 (6.3%)	21 (5.8%)
CYANOCOBALAMIN/PERIDOXINE HYDROCHLORIDE/THIAMINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
ERGOCALCIFOL	1 (0.3%)	1 (0.3%)
ERGOCALCIFEROL	1 (0.3%)	0
HERBAL NOS/MINERALS NOS/VITAMINS NOS	1 (0.3%)	0
IRON/VITAMINS NOS	0	1 (0.3%)
MAGNESIUM/PYRIDOXINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
MALPICHIA CHAMA EXTRACT	0	1 (0.3%)
MINERALS NOS/VITAMINS NOS	3 (0.8%)	4 (1.1%)
NICOTINAMIDE	0	1 (0.3%)
NICOTINIC ACID	1 (0.3%)	0
PYRIDOLAL PHOSPHATE	0	1 (0.3%)
PYRIDOXINE HYDROCHLORIDE	1 (0.3%)	2 (0.6%)
RIBOFLAVIN	0	1 (0.3%)
THIAMINE DISULFIDE	0	1 (0.3%)
THIAMINE HYDROCHLORIDE	2 (0.5%)	1 (0.3%)
UNCODED	1 (0.3%)	2 (0.6%)
VITAMIN B COMPLEX	1 (0.3%)	3 (0.8%)
VITAMIN B NOS	3 (0.8%)	0
VITAMIN D NOS	10 (2.7%)	15 (4.1%)
VITAMIN E NOS	1 (0.3%)	8 (2.2%)
VITAMINS NOS	17 (4.6%)	9 (2.5%)
VITAMINS NOS/XANTOPYL	0	1 (0.3%)

Treatments are coded using the WHO Drug Global B3 Format dictionary Version September 1, 2020. Treatments can appear under multiple classes. Multiple uses of a specific medication for a patient were counted once in the frequency for the medication. Likewise, multiple uses within a specific medication class for a patient were counted once in the frequency for the medication class. For frequency counts in the 'total number of treatments', multiple uses of the same treatment for a patient were counted separately. Clinical cut-off: 09AUG2022

Program: root/clinical_studies/RO6867461/CST30303/share/ACK_data_analysis/prod/program/t_cm.sas
Output: root/clinical_studies/RO6867461/CST30303/GR41986/data_analysis/ACK_CSR_Primary/prod/output/t_cm_CONC_NOCUL_WP24_IT_09AUG2022_41986.xls
17JUL2023 18:31

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Best Corrected Visual Acuity in Study Eye averaged over Weeks 64, 68 and 72
 MODEL: Adjusted Analysis for Baseline BCVA ETDRS letter score, Geographic region
 STUDY: GR41984
 Change from Baseline (Analysis of MMRM)

		Faricimab (N=544)					
		N			Statistics		
Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at Week 64, 68 or 72	LSMeans[2]	SE (LSMeans)	
All	n/a	544	544	496	18,46	0,45	
Gender	Male	267	267	247	18,95	0,67	
	Female	277	277	249	17,96	0,61	
Age	<65 years	274	274	252	20,87	0,51	
	>=65 years	270	270	244	16,06	0,68	
Baseline BCVA ETDRS letter score	<=54 letters	179	179	161	25,45	1,03	
	>=55 letters	365	365	335	15,08	0,45	
Geographic Region	Europe	150	150	135	19,21	0,80	
	America	199	199	181	18,16	0,84	
	Asia Pacific (inc. Australia)	195	195	180	18,14	0,68	
Race/ethnicity	White	338	338	305	NE	NE	
	Asian	181	181	167	18,76	0,57	
	Other	17	17	17	NE	NE	
	Unknown	8	8	7	NE	NE	

[1] Patients included in the analysis: with a value at baseline and at least one post-baseline value at the selected visits.

[2] LSMeans of change from baseline from MMRM (including all available records from all selected visits). Selected visits: every 4 weeks from Week 4 to 72. Early Termination (ET) visit was mapped to closest regular visit.

Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition adjusted for randomization stratification factors. The stratification factor is excluded if it is the subgroup.

Units: letters. Data as observed (no imputation of missing values). Covariance matrix: unstructured. Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mmrn_avg.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mmrn_avg_sg_adj_SBCVA_PREST_ITa24_30AUG2023_41984.xls

09JUL2024 12:23

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Best Corrected Visual Acuity in Study Eye averaged over Weeks 64, 68 and 72
 MODEL: Adjusted Analysis for Baseline BCVA ETDRS letter score, Geographic region
 STUDY: GR41984
 Change from Week 24 (Analysis of MMRM)

		Faricimab (N=544)				
		N			Statistics	
Name	Level	With Week 24 value	With Week 24 value and at least one post-Week 24 value	With Week 24 value and a value at Week 64, 68 or 72	LSMeans[2]	SE (LSMeans)
All	n/a	500	497	470	1,23	0,33
Gender	Male	251	248	236	0,45	0,43
	Female	249	249	234	2,03	0,49
Age	<65 years	249	247	236	1,62	0,46
	>=65 years	251	250	234	0,83	0,45
Baseline BCVA ETDRS letter score	<=54 letters	164	163	151	2,43	0,62
	>=55 letters	336	334	319	0,64	0,37
Geographic Region	Europe	140	139	131	1,76	0,47
	America	188	186	174	0,83	0,64
	Asia Pacific (inc. Australia)	172	172	165	1,21	0,52
Race/ethnicity	White	317	315	295	NE	NE
	Asian	159	159	152	1,65	0,38
	Other	16	16	16	NE	NE
	Unknown	8	7	7	NE	NE

[1] Patients included in the analysis: with a value at Week 24 and at least one post-Week 24 value at the selected visits.

[2] LSMeans of change from Week 24 from MMRM (including all available records from all selected visits). Selected visits: every 4 weeks from Week 28 to 72. Early Termination (ET) visit was mapped to closest regular visit.
 Factors/Covariates: treatment, visit, treatment-by-visit interaction, Week 24 value. In addition adjusted for randomization stratification factors. The stratification factor is excluded if it is the subgroup.
 Units: letters. Data as observed (no imputation of missing values). Covariance matrix: unstructured. Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mmrn_avg.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mmrn_avg_sg_adj_SBCVA_PREST_fw24_ITa24_30AUG2023_41984.xls

09JUL2024 12:19

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Best Corrected Visual Acuity in Study Eye over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients			Statistics		
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	500	91,9	74,81	12,20
Week 28	n/a	542	99,6	492	90,8	74,55	12,18
Week 32	n/a	541	99,4	491	90,8	74,99	12,33
Week 36	n/a	537	98,7	498	92,7	75,50	11,87
Week 40	n/a	532	97,8	495	93,0	75,31	11,96
Week 44	n/a	524	96,3	489	93,3	75,69	12,36
Week 48	n/a	522	96,0	486	93,1	75,94	12,55
Week 52	n/a	521	95,8	477	91,6	76,18	12,51
Week 56	n/a	514	94,5	473	92,0	75,71	12,18
Week 60	n/a	509	93,6	469	92,1	76,22	12,45
Week 64	n/a	503	92,5	469	93,2	76,35	12,20
Week 68	n/a	500	91,9	472	94,4	76,24	12,24
Week 72	n/a	493	90,6	471	95,5	76,46	12,11
Gender							
Week 24	Male	267	100,0	251	94,0	76,10	11,69
Week 28	Male	266	99,6	245	92,1	75,45	11,84
Week 32	Male	265	99,3	241	90,9	76,24	11,61
Week 36	Male	264	98,9	246	93,2	76,88	10,93
Week 40	Male	262	98,1	246	93,9	76,16	11,84
Week 44	Male	261	97,8	241	92,3	76,68	12,52
Week 48	Male	260	97,4	244	93,8	76,43	12,86
Week 52	Male	259	97,0	236	91,1	76,76	12,93
Week 56	Male	253	94,8	239	94,5	76,01	12,99
Week 60	Male	253	94,8	236	93,3	76,61	12,72
Week 64	Male	250	93,6	234	93,6	76,83	12,17
Week 68	Male	249	93,3	234	94,0	76,92	12,39
Week 72	Male	245	91,8	231	94,3	77,00	12,34
Week 24	Female	277	100,0	249	89,9	73,50	12,59
Week 28	Female	276	99,6	247	89,5	73,66	12,48
Week 32	Female	276	99,6	250	90,6	73,80	12,89
Week 36	Female	273	98,6	252	92,3	74,14	12,59
Week 40	Female	270	97,5	249	92,2	74,46	12,03
Week 44	Female	263	94,9	248	94,3	74,73	12,15
Week 48	Female	262	94,6	242	92,4	75,44	12,24
Week 52	Female	262	94,6	241	92,0	75,61	12,10
Week 56	Female	261	94,2	234	89,7	75,39	11,30
Week 60	Female	256	92,4	233	91,0	75,83	12,19
Week 64	Female	253	91,3	235	92,9	75,88	12,24
Week 68	Female	251	90,6	238	94,8	75,57	12,07
Week 72	Female	248	89,5	240	96,8	75,95	11,89

Age							
Week 24	<65 years	274	100,0	249	90,9	78,20	11,00
Week 28	<65 years	272	99,3	244	89,7	77,77	10,79
Week 32	<65 years	271	98,9	249	91,9	78,39	11,29
Week 36	<65 years	269	98,2	252	93,7	78,71	10,18
Week 40	<65 years	265	96,7	251	94,7	78,56	10,10
Week 44	<65 years	263	96,0	246	93,5	79,08	10,42
Week 48	<65 years	263	96,0	246	93,5	79,59	10,17
Week 52	<65 years	263	96,0	233	88,6	80,00	9,52
Week 56	<65 years	260	94,9	240	92,3	79,35	9,92
Week 60	<65 years	258	94,2	235	91,1	80,33	9,15
Week 64	<65 years	255	93,1	234	91,8	79,94	9,96
Week 68	<65 years	254	92,7	242	95,3	80,00	9,41
Week 72	<65 years	250	91,2	237	94,8	80,33	8,94
Week 24	>=65 years	270	100,0	251	93,0	71,44	12,42
Week 28	>=65 years	270	100,0	248	91,9	71,39	12,65
Week 32	>=65 years	270	100,0	242	89,6	71,50	12,39
Week 36	>=65 years	268	99,3	246	91,8	72,20	12,57
Week 40	>=65 years	267	98,9	244	91,4	71,96	12,78
Week 44	>=65 years	261	96,7	243	93,1	72,26	13,21
Week 48	>=65 years	259	95,9	240	92,7	72,20	13,64
Week 52	>=65 years	258	95,6	244	94,6	72,52	13,88
Week 56	>=65 years	254	94,1	233	91,7	71,95	13,12
Week 60	>=65 years	251	93,0	234	93,2	72,10	13,90
Week 64	>=65 years	248	91,9	235	94,8	72,79	13,16
Week 68	>=65 years	246	91,1	230	93,5	72,28	13,57
Week 72	>=65 years	243	90,0	234	96,3	72,55	13,58
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	164	91,6	66,01	13,38
Week 28	<=54 letters	178	99,4	164	92,1	65,34	13,50
Week 32	<=54 letters	178	99,4	161	90,4	66,02	13,43
Week 36	<=54 letters	177	98,9	158	89,3	66,75	13,71
Week 40	<=54 letters	175	97,8	159	90,9	65,99	13,90
Week 44	<=54 letters	172	96,1	161	93,6	66,81	14,70
Week 48	<=54 letters	170	95,0	159	93,5	66,55	14,93
Week 52	<=54 letters	170	95,0	151	88,8	67,35	15,17
Week 56	<=54 letters	167	93,3	151	90,4	67,50	14,44
Week 60	<=54 letters	164	91,6	150	91,5	67,68	14,97
Week 64	<=54 letters	162	90,5	149	92,0	68,40	14,67
Week 68	<=54 letters	161	89,9	152	94,4	68,66	14,78
Week 72	<=54 letters	159	88,8	153	96,2	68,54	14,43
Week 24	>=55 letters	365	100,0	336	92,1	79,10	8,85
Week 28	>=55 letters	364	99,7	328	90,1	79,16	8,25
Week 32	>=55 letters	363	99,5	330	90,9	79,37	8,94
Week 36	>=55 letters	360	98,6	340	94,4	79,56	8,20
Week 40	>=55 letters	357	97,8	336	94,1	79,71	7,68
Week 44	>=55 letters	352	96,4	328	93,2	80,05	8,02
Week 48	>=55 letters	352	96,4	327	92,9	80,50	7,91
Week 52	>=55 letters	351	96,2	326	92,9	80,27	8,38
Week 56	>=55 letters	347	95,1	322	92,8	79,56	8,60
Week 60	>=55 letters	345	94,5	319	92,5	80,24	8,52
Week 64	>=55 letters	341	93,4	320	93,8	80,06	8,68
Week 68	>=55 letters	339	92,9	320	94,4	79,84	8,79
Week 72	>=55 letters	334	91,5	318	95,2	80,28	8,53

Geographic Region							
Week 24	Europe	150	100,0	140	93,3	76,72	12,72
Week 28	Europe	150	100,0	139	92,7	76,19	13,31
Week 32	Europe	150	100,0	137	91,3	76,61	13,03
Week 36	Europe	149	99,3	139	93,3	77,50	12,75
Week 40	Europe	147	98,0	136	92,5	76,99	13,75
Week 44	Europe	144	96,0	135	93,8	77,76	13,87
Week 48	Europe	143	95,3	132	92,3	78,29	13,45
Week 52	Europe	143	95,3	133	93,0	78,36	13,19
Week 56	Europe	141	94,0	129	91,5	77,68	12,80
Week 60	Europe	139	92,7	134	96,4	78,14	13,68
Week 64	Europe	137	91,3	132	96,4	77,86	13,31
Week 68	Europe	136	90,7	130	95,6	77,97	13,14
Week 72	Europe	135	90,0	133	98,5	78,61	13,06
Week 24	America	199	100,0	188	94,5	74,03	13,00
Week 28	America	198	99,5	180	90,9	74,12	12,29
Week 32	America	198	99,5	182	91,9	74,53	13,29
Week 36	America	195	98,0	183	93,8	75,10	12,22
Week 40	America	193	97,0	183	94,8	74,66	11,52
Week 44	America	191	96,0	179	93,7	74,91	12,33
Week 48	America	191	96,0	180	94,2	75,32	13,05
Week 52	America	190	95,5	172	90,5	75,51	12,93
Week 56	America	186	93,5	180	96,8	75,10	12,62
Week 60	America	185	93,0	172	93,0	75,40	12,71
Week 64	America	183	92,0	171	93,4	75,91	11,49
Week 68	America	183	92,0	177	96,7	75,80	12,65
Week 72	America	178	89,4	168	94,4	75,39	12,90
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	74,09	10,68
Week 28	Asia Pacific (inc. Australia)	194	99,5	173	89,2	73,69	11,01
Week 32	Asia Pacific (inc. Australia)	193	99,0	172	89,1	74,20	10,50
Week 36	Asia Pacific (inc. Australia)	193	99,0	176	91,2	74,32	10,58
Week 40	Asia Pacific (inc. Australia)	192	98,5	176	91,7	74,68	10,80
Week 44	Asia Pacific (inc. Australia)	189	96,9	175	92,6	74,89	10,96
Week 48	Asia Pacific (inc. Australia)	188	96,4	174	92,6	74,79	11,07
Week 52	Asia Pacific (inc. Australia)	188	96,4	172	91,5	75,16	11,36
Week 56	Asia Pacific (inc. Australia)	187	95,9	164	87,7	74,82	11,03
Week 60	Asia Pacific (inc. Australia)	185	94,9	163	88,1	75,52	10,94
Week 64	Asia Pacific (inc. Australia)	183	93,8	166	90,7	75,62	11,96
Week 68	Asia Pacific (inc. Australia)	181	92,8	165	91,2	75,35	10,91
Week 72	Asia Pacific (inc. Australia)	180	92,3	170	94,4	75,85	10,26
Race/ethnicity							
Week 24	White	338	100,0	317	93,8	75,08	13,44
Week 28	White	337	99,7	309	91,7	74,81	13,27
Week 32	White	336	99,4	310	92,3	75,23	13,73
Week 36	White	332	98,2	310	93,4	76,10	12,84
Week 40	White	328	97,0	305	93,0	75,43	13,14
Week 44	White	323	95,6	304	94,1	75,65	13,77
Week 48	White	322	95,3	302	93,8	76,23	13,69
Week 52	White	321	95,0	297	92,5	76,58	13,36
Week 56	White	316	93,5	294	93,0	76,08	13,11
Week 60	White	313	92,6	294	93,9	76,46	13,56
Week 64	White	309	91,4	294	95,1	76,37	13,21
Week 68	White	308	91,1	296	96,1	76,56	13,36

Week 72	White	302	89,3	292	96,7	76,87	13,13
Week 24	Asian	181	100,0	159	87,8	74,32	9,99
Week 28	Asian	180	99,4	160	88,9	74,14	10,34
Week 32	Asian	180	99,4	159	88,3	74,53	9,73
Week 36	Asian	180	99,4	165	91,7	74,23	10,19
Week 40	Asian	179	98,9	166	92,7	75,01	10,00
Week 44	Asian	176	97,2	163	92,6	75,61	9,87
Week 48	Asian	175	96,7	162	92,6	75,67	9,85
Week 52	Asian	175	96,7	157	89,7	75,93	9,81
Week 56	Asian	174	96,1	156	89,7	75,37	9,79
Week 60	Asian	172	95,0	152	88,4	76,32	9,38
Week 64	Asian	170	93,9	154	90,6	76,56	9,88
Week 68	Asian	168	92,8	153	91,1	76,21	9,30
Week 72	Asian	168	92,8	158	94,0	76,37	9,18
Week 24	Other	17	100,0	16	94,1	72,81	7,97
Week 28	Other	17	100,0	16	94,1	71,06	8,38
Week 32	Other	17	100,0	17	100,0	74,53	7,24
Week 36	Other	17	100,0	16	94,1	74,69	8,54
Week 40	Other	17	100,0	17	100,0	75,53	7,91
Week 44	Other	17	100,0	16	94,1	76,94	7,56
Week 48	Other	17	100,0	16	94,1	72,81	16,19
Week 52	Other	17	100,0	16	94,1	69,13	19,07
Week 56	Other	17	100,0	17	100,0	71,29	16,08
Week 60	Other	17	100,0	16	94,1	70,63	16,86
Week 64	Other	17	100,0	15	88,2	73,20	14,76
Week 68	Other	17	100,0	16	94,1	69,50	15,44
Week 72	Other	16	94,1	14	87,5	67,93	17,88
Week 24	Unknown	8	100,0	8	100,0	77,50	7,03
Week 28	Unknown	8	100,0	7	87,5	80,71	4,39
Week 32	Unknown	8	100,0	5	62,5	76,80	8,93
Week 36	Unknown	8	100,0	7	87,5	80,57	7,61
Week 40	Unknown	8	100,0	7	87,5	76,29	9,89
Week 44	Unknown	8	100,0	6	75,0	76,67	9,24
Week 48	Unknown	8	100,0	6	75,0	76,83	7,57
Week 52	Unknown	8	100,0	7	87,5	81,00	6,00
Week 56	Unknown	7	87,5	6	85,7	78,50	6,19
Week 60	Unknown	7	87,5	7	100,0	76,86	9,89
Week 64	Unknown	7	87,5	6	85,7	78,33	9,09
Week 68	Unknown	7	87,5	7	100,0	78,86	7,88
Week 72	Unknown	7	87,5	7	100,0	78,86	7,20

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Units: letters.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_SBCVA_ITa24_30AUG2023_41984.xls

26APR2024 15:26

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Study Eye - Proportion of Patients Gaining ≥ 10 in BCVA from Baseline averaged over Weeks 64, 68 and 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	496	91,2	403	81,3

Only patients with at least one value at Week 64, 68 or 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_SBCVAIMP10_PREST_AVG_ITa24_30AUG2023_41984.xls
 26APR2024 15:02

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Study Eye - Proportion of Patients Gaining ≥ 15 in BCVA from Baseline averaged over Weeks 64, 68 and 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	496	91,2	324	65,3

Only patients with at least one value at Week 64, 68 or 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_SBCVAIMP15_PREST_AVG_ITa24_30AUG2023_41984.xls
 26APR2024 15:01

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Study Eye - Proportion of Patients Avoiding a Loss of ≥ 10 in BCVA from Baseline averaged over Weeks 64, 68 and 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	496	91,2	490	98,8

Only patients with at least one value at Week 64, 68 or 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_SBCVANOL10_PREST_AVG_ITa24_30AUG2023_41984.xls
 26APR2024 15:05

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Study Eye - Proportion of Patients Avoiding a Loss of ≥ 15 in BCVA from Baseline averaged over Weeks 64, 68 and 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	496	91,2	492	99,2

Only patients with at least one value at Week 64, 68 or 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_SBCVANOL15_PREST_AVG_ITa24_30AUG2023_41984.xls
 26APR2024 15:04

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Best Corrected Visual Acuity in Study Eye averaged over Weeks 64, 68 and 72
 MODEL: Adjusted Analysis for Baseline BCVA ETDRS letter score, Geographic region
 STUDY: GR41986
 Change from Baseline (Analysis of MMRM)

		Faricimab (N=711)				
		N			Statistics	
Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at Week 64, 68 or 72	LSMeans[2]	SE (LSMeans)
All	n/a	711	710	662	17,19	0,61
Gender	Male	382	381	356	18,60	0,77
	Female	329	329	306	15,60	0,96
Age	<65 years	312	311	296	23,07	0,72
	>=65 years	399	399	366	12,64	0,84
Baseline BCVA ETDRS letter score	<=34 letters	158	158	151	27,37	1,45
	35 - 54 letters	208	208	191	20,55	0,99
	>=55 letters	345	344	320	10,43	0,85
Baseline BCVA ETDRS letter score	<=23 letters	70	70	67	25,90	2,26
	>=24 letters	641	640	595	16,21	0,62
Geographic Region	Europe	217	217	204	18,24	1,01
	America	285	284	269	16,73	1,02
	Asia Pacific (inc. Australia)	209	209	189	16,63	1,10
Race/ethnicity	White	481	480	450	NE	NE
	Asian	179	179	163	17,41	1,06
	Other	27	27	26	NE	NE
	Unknown	24	24	23	NE	NE
Baseline RVO status	CRVO	583	583	540	16,32	0,70
	HRVO	122	121	117	20,54	1,10
	Missing	6	6	5	NE	NE

[1] Patients included in the analysis: with a value at baseline and at least one post-baseline value at the selected visits.

[2] LSMeans of change from baseline from MMRM (including all available records from all selected visits). Selected visits: every 4 weeks from Week 4 to 72. Early Termination (ET) visit was mapped to closest regular visit. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition adjusted for randomization stratification factors. The stratification factor is excluded if it is the subgroup. Units: letters. Data as observed (no imputation of missing values). Covariance matrix: unstructured. Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mmrn_avg.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mmrn_avg_sg_adj_SBCVA_PREST_ITa24_29AUG2023_41986.xls
 09JUL2024 12:24

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Best Corrected Visual Acuity in Study Eye averaged over Weeks 64, 68 and 72
 MODEL: Adjusted Analysis for Baseline BCVA ETDRS letter score, Geographic region
 STUDY: GR41986
 Change from Week 24 (Analysis of MMRM)

		Faricimab (N=711)				
		N			Statistics	
Name	Level	With Week 24 value	With Week 24 value and at least one post-Week 24 value	With Week 24 value and a value at Week 64, 68 or 72	LSMeans[2]	SE (LSMeans)
All	n/a	669	668	633	-0,25	0,38
Gender	Male	354	353	336	0,15	0,52
	Female	315	315	297	-0,68	0,55
Age	<65 years	291	291	280	0,93	0,51
	>=65 years	378	377	353	-1,15	0,53
Baseline BCVA ETDRS letter score	<=34 letters	148	148	145	0,57	0,73
	35 - 54 letters	196	196	181	0,18	0,68
	>=55 letters	325	324	307	-0,91	0,57
Baseline BCVA ETDRS letter score	<=23 letters	65	65	64	1,91	0,96
	>=24 letters	604	603	569	-0,48	0,41
Geographic Region	Europe	204	204	195	0,37	0,66
	America	270	270	259	-0,90	0,63
	Asia Pacific (inc. Australia)	195	194	179	-0,01	0,66
Race/ethnicity	White	455	454	432	NE	NE
	Asian	167	167	156	0,03	0,69
	Other	25	25	24	NE	NE
	Unknown	22	22	21	NE	NE
Baseline RVO status	CRVO	548	547	515	-0,28	0,42
	HRVO	116	116	113	-0,17	0,93
	Missing	5	5	5	NE	NE

[1] Patients included in the analysis: with a value at Week 24 and at least one post-Week 24 value at the selected visits.

[2] LSMeans of change from Week 24 from MMRM (including all available records from all selected visits). Selected visits: every 4 weeks from Week 28 to 72. Early Termination (ET) visit was mapped to closest regular visit.
 Factors/Covariates: treatment, visit, treatment-by-visit interaction, Week 24 value. In addition adjusted for randomization stratification factors. The stratification factor is excluded if it is the subgroup.

Units: letters. Data as observed (no imputation of missing values). Covariance matrix: unstructured. Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mmrn_avg.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mmrn_avg_sg_adj_SBCVA_PREST_fw24_ITa24_29AUG2023_41986.xls

09JUL2024 12:18

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Best Corrected Visual Acuity in Study Eye over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
Visit							
All							
Week 24	n/a	711	100,0	669	94,1	67,90	16,48
Week 28	n/a	710	99,9	675	95,1	66,58	17,43
Week 32	n/a	709	99,7	660	93,1	67,91	17,01
Week 36	n/a	703	98,9	654	93,0	67,86	17,26
Week 40	n/a	700	98,5	657	93,9	66,63	17,95
Week 44	n/a	696	97,9	647	93,0	67,45	17,94
Week 48	n/a	691	97,2	633	91,6	67,77	18,19
Week 52	n/a	686	96,5	641	93,4	68,00	18,00
Week 56	n/a	683	96,1	636	93,1	67,29	18,14
Week 60	n/a	679	95,5	631	92,9	67,77	18,22
Week 64	n/a	675	94,9	636	94,2	67,69	18,14
Week 68	n/a	670	94,2	628	93,7	67,74	18,37
Week 72	n/a	662	93,1	634	95,8	67,75	18,33
Gender							
Week 24	Male	382	100,0	354	92,7	69,55	15,38
Week 28	Male	381	99,7	357	93,7	68,11	16,71
Week 32	Male	381	99,7	351	92,1	69,75	15,54
Week 36	Male	376	98,4	349	92,8	69,61	16,44
Week 40	Male	374	97,9	347	92,8	68,43	16,70
Week 44	Male	372	97,4	341	91,7	69,21	17,46
Week 48	Male	369	96,6	337	91,3	69,85	17,36
Week 52	Male	367	96,1	345	94,0	69,62	17,35
Week 56	Male	365	95,5	338	92,6	68,97	17,55
Week 60	Male	362	94,8	340	93,9	70,10	17,12
Week 64	Male	361	94,5	341	94,5	69,96	17,03
Week 68	Male	359	94,0	336	93,6	69,94	16,89
Week 72	Male	356	93,2	344	96,6	69,67	16,82
Female							
Week 24	Female	329	100,0	315	95,7	66,05	17,47
Week 28	Female	329	100,0	318	96,7	64,87	18,07
Week 32	Female	328	99,7	309	94,2	65,82	18,35
Week 36	Female	327	99,4	305	93,3	65,85	17,97
Week 40	Female	326	99,1	310	95,1	64,61	19,08
Week 44	Female	324	98,5	306	94,4	65,49	18,29
Week 48	Female	322	97,9	296	91,9	65,41	18,84
Week 52	Female	319	97,0	296	92,8	66,11	18,57
Week 56	Female	318	96,7	298	93,7	65,38	18,64
Week 60	Female	317	96,4	291	91,8	65,05	19,10
Week 64	Female	314	95,4	295	93,9	65,07	19,03
Week 68	Female	311	94,5	292	93,9	65,22	19,67
Week 72	Female	306	93,0	290	94,8	65,48	19,77
Age							
Week 24	<65 years	312	100,0	291	93,3	73,34	13,50
Week 28	<65 years	312	100,0	294	94,2	72,02	14,64
Week 32	<65 years	312	100,0	292	93,6	73,30	13,86
Week 36	<65 years	311	99,7	286	92,0	74,22	13,63
Week 40	<65 years	309	99,0	288	93,2	72,86	14,55

Week 44	<65 years	307	98,4	284	92,5	74,25	13,86
Week 48	<65 years	304	97,4	274	90,1	73,54	15,20
Week 52	<65 years	302	96,8	288	95,4	73,95	14,55
Week 56	<65 years	301	96,5	276	91,7	73,99	14,18
Week 60	<65 years	299	95,8	277	92,6	74,55	14,22
Week 64	<65 years	298	95,5	282	94,6	74,20	14,37
Week 68	<65 years	296	94,9	284	95,9	73,71	14,91
Week 72	<65 years	293	93,9	284	96,9	74,52	14,02
Week 24	>=65 years	399	100,0	378	94,7	63,71	17,33
Week 28	>=65 years	398	99,7	381	95,7	62,39	18,24
Week 32	>=65 years	397	99,5	368	92,7	63,63	18,05
Week 36	>=65 years	392	98,2	368	93,9	62,91	18,16
Week 40	>=65 years	391	98,0	369	94,4	61,76	18,85
Week 44	>=65 years	389	97,5	363	93,3	62,13	18,96
Week 48	>=65 years	387	97,0	359	92,8	63,37	19,05
Week 52	>=65 years	384	96,2	353	91,9	63,14	19,07
Week 56	>=65 years	382	95,7	360	94,2	62,15	19,16
Week 60	>=65 years	380	95,2	354	93,2	62,47	19,24
Week 64	>=65 years	377	94,5	354	93,9	62,51	19,15
Week 68	>=65 years	374	93,7	344	92,0	62,81	19,49
Week 72	>=65 years	369	92,5	350	94,9	62,25	19,56
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	196	94,2	66,67	12,98
Week 28	35 - 54 letters	208	100,0	197	94,7	65,00	14,48
Week 32	35 - 54 letters	208	100,0	193	92,8	66,42	13,06
Week 36	35 - 54 letters	206	99,0	192	93,2	66,86	13,78
Week 40	35 - 54 letters	204	98,1	193	94,6	66,28	13,67
Week 44	35 - 54 letters	203	97,6	194	95,6	66,93	14,20
Week 48	35 - 54 letters	203	97,6	183	90,1	68,15	13,04
Week 52	35 - 54 letters	202	97,1	189	93,6	67,32	13,56
Week 56	35 - 54 letters	202	97,1	191	94,6	66,64	13,29
Week 60	35 - 54 letters	200	96,2	183	91,5	67,17	13,83
Week 64	35 - 54 letters	197	94,7	184	93,4	67,08	14,50
Week 68	35 - 54 letters	195	93,8	177	90,8	67,38	14,57
Week 72	35 - 54 letters	193	92,8	181	93,8	67,36	14,55
Week 24	<=34 letters	158	100,0	148	93,7	52,69	17,14
Week 28	<=34 letters	158	100,0	149	94,3	51,70	17,87
Week 32	<=34 letters	158	100,0	150	94,9	52,43	17,78
Week 36	<=34 letters	157	99,4	149	94,9	52,33	17,32
Week 40	<=34 letters	157	99,4	150	95,5	51,79	17,87
Week 44	<=34 letters	156	98,7	145	92,9	52,65	17,98
Week 48	<=34 letters	156	98,7	144	92,3	51,63	18,69
Week 52	<=34 letters	155	98,1	143	92,3	53,18	18,47
Week 56	<=34 letters	154	97,5	143	92,9	52,87	19,39
Week 60	<=34 letters	153	96,8	141	92,2	52,90	19,21
Week 64	<=34 letters	153	96,8	145	94,8	53,59	18,97
Week 68	<=34 letters	153	96,8	146	95,4	52,76	19,90
Week 72	<=34 letters	152	96,2	144	94,7	53,69	19,10
Week 24	>=55 letters	345	100,0	325	94,2	75,57	12,63
Week 28	>=55 letters	344	99,7	329	95,6	74,27	13,90
Week 32	>=55 letters	343	99,4	317	92,4	76,14	12,95
Week 36	>=55 letters	340	98,6	313	92,1	75,86	13,60
Week 40	>=55 letters	339	98,3	314	92,6	73,93	15,80
Week 44	>=55 letters	337	97,7	308	91,4	74,75	15,55
Week 48	>=55 letters	332	96,2	306	92,2	75,14	15,57
Week 52	>=55 letters	329	95,4	309	93,9	75,27	15,75
Week 56	>=55 letters	327	94,8	302	92,4	74,52	15,94
Week 60	>=55 letters	326	94,5	307	94,2	74,96	15,71
Week 64	>=55 letters	325	94,2	307	94,5	74,73	15,60

Week 68	>=55 letters	322	93,3	305	94,7	75,12	14,90
Week 72	>=55 letters	317	91,9	309	97,5	74,52	16,09
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	65	92,9	45,18	16,68
Week 28	<=23 letters	70	100,0	66	94,3	43,21	17,11
Week 32	<=23 letters	70	100,0	67	95,7	45,52	17,51
Week 36	<=23 letters	69	98,6	67	97,1	44,76	17,13
Week 40	<=23 letters	69	98,6	68	98,6	44,54	17,70
Week 44	<=23 letters	68	97,1	64	94,1	45,47	18,21
Week 48	<=23 letters	68	97,1	64	94,1	45,67	18,55
Week 52	<=23 letters	68	97,1	64	94,1	45,91	18,16
Week 56	<=23 letters	68	97,1	62	91,2	44,82	20,42
Week 60	<=23 letters	68	97,1	63	92,6	45,92	19,30
Week 64	<=23 letters	68	97,1	65	95,6	46,52	19,63
Week 68	<=23 letters	68	97,1	65	95,6	46,26	19,40
Week 72	<=23 letters	68	97,1	66	97,1	48,02	18,56
Week 24	>=24 letters	641	100,0	604	94,2	70,35	14,48
Week 28	>=24 letters	640	99,8	609	95,2	69,11	15,48
Week 32	>=24 letters	639	99,7	593	92,8	70,44	15,00
Week 36	>=24 letters	634	98,9	587	92,6	70,49	15,20
Week 40	>=24 letters	631	98,4	589	93,3	69,18	16,15
Week 44	>=24 letters	628	98,0	583	92,8	69,86	16,20
Week 48	>=24 letters	623	97,2	569	91,3	70,25	16,39
Week 52	>=24 letters	618	96,4	577	93,4	70,45	16,23
Week 56	>=24 letters	615	95,9	574	93,3	69,71	16,12
Week 60	>=24 letters	611	95,3	568	93,0	70,20	16,41
Week 64	>=24 letters	607	94,7	571	94,1	70,11	16,32
Week 68	>=24 letters	602	93,9	563	93,5	70,22	16,56
Week 72	>=24 letters	594	92,7	568	95,6	70,04	16,88
Geographic Region							
Week 24	Europe	217	100,0	204	94,0	68,26	17,12
Week 28	Europe	217	100,0	206	94,9	67,00	18,18
Week 32	Europe	217	100,0	201	92,6	67,89	17,90
Week 36	Europe	215	99,1	203	94,4	68,08	18,56
Week 40	Europe	214	98,6	200	93,5	66,91	18,80
Week 44	Europe	214	98,6	199	93,0	67,66	18,81
Week 48	Europe	212	97,7	196	92,5	68,18	18,39
Week 52	Europe	212	97,7	201	94,8	68,63	18,31
Week 56	Europe	211	97,2	197	93,4	67,60	18,77
Week 60	Europe	210	96,8	198	94,3	68,71	18,54
Week 64	Europe	209	96,3	197	94,3	68,33	18,65
Week 68	Europe	206	94,9	198	96,1	68,60	19,22
Week 72	Europe	206	94,9	198	96,1	68,65	18,61
Week 24	America	285	100,0	270	94,7	67,30	17,17
Week 28	America	285	100,0	274	96,1	66,46	18,25
Week 32	America	285	100,0	267	93,7	67,34	17,81
Week 36	America	285	100,0	265	93,0	67,30	17,28
Week 40	America	284	99,6	268	94,4	65,78	18,79
Week 44	America	283	99,3	265	93,6	66,60	18,82
Week 48	America	281	98,6	257	91,5	66,77	19,69
Week 52	America	278	97,5	260	93,5	67,31	19,11
Week 56	America	277	97,2	254	91,7	66,36	19,08
Week 60	America	275	96,5	260	94,5	66,48	19,49
Week 64	America	273	95,8	259	94,9	66,50	19,65
Week 68	America	271	95,1	252	93,0	66,13	19,99
Week 72	America	265	93,0	253	95,5	66,11	19,93
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	68,36	14,78
Week 28	Asia Pacific (inc. Australia)	208	99,5	195	93,8	66,31	15,38

Week 32	Asia Pacific (inc. Australia)	207	99,0	192	92,8	68,72	14,84
Week 36	Asia Pacific (inc. Australia)	203	97,1	186	91,6	68,41	15,76
Week 40	Asia Pacific (inc. Australia)	202	96,7	189	93,6	67,54	15,73
Week 44	Asia Pacific (inc. Australia)	199	95,2	183	92,0	68,45	15,55
Week 48	Asia Pacific (inc. Australia)	198	94,7	180	90,9	68,74	15,57
Week 52	Asia Pacific (inc. Australia)	196	93,8	180	91,8	68,29	15,93
Week 56	Asia Pacific (inc. Australia)	195	93,3	185	94,9	68,22	16,06
Week 60	Asia Pacific (inc. Australia)	194	92,8	173	89,2	68,64	15,67
Week 64	Asia Pacific (inc. Australia)	193	92,3	180	93,3	68,72	15,05
Week 68	Asia Pacific (inc. Australia)	193	92,3	178	92,2	69,07	14,55
Week 72	Asia Pacific (inc. Australia)	191	91,4	183	95,8	69,04	15,43
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	67,64	17,39
Week 28	White	480	99,8	460	95,8	66,15	18,34
Week 32	White	480	99,8	449	93,5	67,44	17,97
Week 36	White	476	99,0	445	93,5	67,51	18,15
Week 40	White	474	98,5	450	94,9	65,98	19,03
Week 44	White	473	98,3	442	93,4	66,65	19,07
Week 48	White	470	97,7	435	92,6	67,14	19,36
Week 52	White	467	97,1	439	94,0	67,50	19,14
Week 56	White	465	96,7	433	93,1	66,65	19,19
Week 60	White	463	96,3	434	93,7	67,15	19,66
Week 64	White	460	95,6	436	94,8	66,97	19,73
Week 68	White	456	94,8	428	93,9	66,94	20,00
Week 72	White	449	93,3	427	95,1	66,93	20,06
Week 24	Asian	179	100,0	167	93,3	68,16	14,39
Week 28	Asian	179	100,0	166	92,7	67,10	15,08
Week 32	Asian	178	99,4	164	92,1	69,13	14,14
Week 36	Asian	176	98,3	159	90,3	68,58	15,23
Week 40	Asian	175	97,8	162	92,6	67,90	15,24
Week 44	Asian	172	96,1	157	91,3	68,98	15,07
Week 48	Asian	170	95,0	154	90,6	69,16	15,27
Week 52	Asian	168	93,9	154	91,7	68,47	15,33
Week 56	Asian	167	93,3	159	95,2	68,76	15,34
Week 60	Asian	166	92,7	150	90,4	69,25	14,48
Week 64	Asian	165	92,2	154	93,3	69,23	13,96
Week 68	Asian	165	92,2	154	93,3	69,58	13,91
Week 72	Asian	164	91,6	159	97,0	69,16	13,94
Week 24	Other	27	100,0	25	92,6	71,40	11,30
Week 28	Other	27	100,0	26	96,3	72,12	11,31
Week 32	Other	27	100,0	24	88,9	70,67	11,96
Week 36	Other	27	100,0	26	96,3	70,38	13,16
Week 40	Other	27	100,0	23	85,2	71,26	12,16
Week 44	Other	27	100,0	26	96,3	71,58	12,19
Week 48	Other	27	100,0	22	81,5	70,73	10,68
Week 52	Other	27	100,0	25	92,6	72,36	11,39
Week 56	Other	27	100,0	24	88,9	68,17	16,51
Week 60	Other	27	100,0	24	88,9	70,50	10,04
Week 64	Other	27	100,0	24	88,9	71,21	10,21
Week 68	Other	26	96,3	23	88,5	71,09	11,88
Week 72	Other	26	96,3	25	96,2	72,00	9,54
Week 24	Unknown	24	100,0	22	91,7	67,41	17,19
Week 28	Unknown	24	100,0	23	95,8	65,26	19,72
Week 32	Unknown	24	100,0	23	95,8	65,52	20,80
Week 36	Unknown	24	100,0	24	100,0	66,71	17,32
Week 40	Unknown	24	100,0	22	91,7	65,64	18,48
Week 44	Unknown	24	100,0	22	91,7	67,77	18,69
Week 48	Unknown	24	100,0	22	91,7	67,50	19,07
Week 52	Unknown	24	100,0	23	95,8	69,65	17,78

Week 56	Unknown	24	100,0	20	83,3	68,20	17,64
Week 60	Unknown	23	95,8	23	100,0	67,22	18,38
Week 64	Unknown	23	95,8	22	95,7	67,50	17,64
Week 68	Unknown	23	95,8	23	100,0	67,13	17,98
Week 72	Unknown	23	95,8	23	100,0	68,48	18,24
Baseline RVO status							
Week 24	CRVO	583	100,0	548	94,0	66,85	17,19
Week 28	CRVO	582	99,8	554	95,2	65,19	18,19
Week 32	CRVO	581	99,7	540	92,9	66,90	17,71
Week 36	CRVO	576	98,8	537	93,2	66,81	17,81
Week 40	CRVO	574	98,5	537	93,6	65,30	18,59
Week 44	CRVO	570	97,8	528	92,6	66,13	18,56
Week 48	CRVO	565	96,9	518	91,7	66,72	18,91
Week 52	CRVO	560	96,1	520	92,9	66,80	18,68
Week 56	CRVO	557	95,5	520	93,4	66,02	18,93
Week 60	CRVO	553	94,9	513	92,8	66,55	18,87
Week 64	CRVO	550	94,3	519	94,4	66,66	18,64
Week 68	CRVO	547	93,8	513	93,8	66,63	19,09
Week 72	CRVO	540	92,6	517	95,7	66,71	19,17
Week 24	HRVO	122	100,0	116	95,1	72,52	11,82
Week 28	HRVO	122	100,0	116	95,1	72,92	11,61
Week 32	HRVO	122	100,0	114	93,4	72,60	12,30
Week 36	HRVO	121	99,2	111	91,7	72,74	13,33
Week 40	HRVO	120	98,4	115	95,8	72,61	13,33
Week 44	HRVO	120	98,4	113	94,2	73,20	13,52
Week 48	HRVO	120	98,4	109	90,8	72,58	13,73
Week 52	HRVO	120	98,4	115	95,8	73,10	13,68
Week 56	HRVO	120	98,4	111	92,5	72,70	12,82
Week 60	HRVO	120	98,4	113	94,2	72,93	14,13
Week 64	HRVO	119	97,5	112	94,1	71,93	15,14
Week 68	HRVO	117	95,9	110	94,0	72,45	13,95
Week 72	HRVO	116	95,1	112	96,6	72,04	13,31
Week 24	Missing	6	100,0	5	83,3	76,20	7,89
Week 28	Missing	6	100,0	5	83,3	74,00	5,24
Week 32	Missing	6	100,0	6	100,0	69,67	17,73
Week 36	Missing	6	100,0	6	100,0	71,00	18,18
Week 40	Missing	6	100,0	5	83,3	72,00	13,69
Week 44	Missing	6	100,0	6	100,0	75,67	12,88
Week 48	Missing	6	100,0	6	100,0	70,67	11,43
Week 52	Missing	6	100,0	6	100,0	74,50	12,77
Week 56	Missing	6	100,0	5	83,3	78,60	7,50
Week 60	Missing	6	100,0	5	83,3	77,20	6,50
Week 64	Missing	6	100,0	5	83,3	80,40	4,22
Week 68	Missing	6	100,0	5	83,3	78,00	8,72
Week 72	Missing	6	100,0	5	83,3	78,80	7,01

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Units: letters.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_SBCVA_ITa24_29AUG2023_41986.xls

26APR2024 15:41

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Study Eye - Proportion of Patients Gaining ≥ 10 in BCVA from Baseline averaged over Weeks 64, 68 and 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	662	93,1	480	72,5

Only patients with at least one value at Week 64, 68 or 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_SBCVAIMP10_PREST_AVG_ITa24_29AUG2023_41986.xls
 26APR2024 15:15

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Study Eye - Proportion of Patients Gaining ≥ 15 in BCVA from Baseline averaged over Weeks 64, 68 and 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	662	93,1	404	61,0

Only patients with at least one value at Week 64, 68 or 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_SBCVAIMP15_PREST_AVG_ITa24_29AUG2023_41986.xls
 26APR2024 15:14

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Study Eye - Proportion of Patients Avoiding a Loss of ≥ 10 in BCVA from Baseline averaged over Weeks 64, 68 and 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	662	93,1	629	95,0

Only patients with at least one value at Week 64, 68 or 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_SBCVANOL10_PREST_AVG_ITa24_29AUG2023_41986.xls
 26APR2024 15:18

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Study Eye - Proportion of Patients Avoiding a Loss of ≥ 15 in BCVA from Baseline averaged over Weeks 64, 68 and 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	662	93,1	635	95,9

Only patients with at least one value at Week 64, 68 or 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_SBCVANOL15_PREST_AVG_ITa24_29AUG2023_41986.xls
 26APR2024 15:17

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Center Subfield Thickness ILM-BM in Study Eye averaged over Weeks 64, 68 and 72
 MODEL: Adjusted Analysis for Baseline BCVA ETDRS letter score, Geographic region
 STUDY: GR41984
 Change from Baseline (Analysis of MMRM)

		Faricimab (N=544)					
		N			Statistics		
Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at Week 64, 68 or 72	LSMeans[2]	SE (LSMeans)	
All	n/a	544	544	496	-309,28	1,69	
Gender	Male	267	267	247	-329,71	2,37	
	Female	277	277	249	-289,35	2,29	
Age	<65 years	274	274	252	-314,99	1,94	
	>=65 years	270	270	244	-303,76	2,73	
Baseline BCVA ETDRS letter score	<=54 letters	179	179	161	-404,36	3,23	
	>=55 letters	365	365	335	-263,50	1,97	
Geographic Region	Europe	150	150	135	-306,51	3,53	
	America	199	199	181	-303,42	2,76	
	Asia Pacific (inc. Australia)	195	195	180	-317,89	2,70	
Race/ethnicity	White	338	338	305	NE	NE	
	Asian	181	181	167	-317,12	2,47	
	Other	17	17	17	NE	NE	
	Unknown	8	8	7	NE	NE	

[1] Patients included in the analysis: with a value at baseline and at least one post-baseline value at the selected visits.

[2] LSMeans of change from baseline from MMRM (including all available records from all selected visits). Selected visits: every 4 weeks from Week 4 to 72. Early Termination (ET) visit was mapped to closest regular visit.

Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition adjusted for randomization stratification factors. The stratification factor is excluded if it is the subgroup.

Units: microns. Data as observed (no imputation of missing values). Covariance matrix: unstructured. Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mmrn_avg.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mmrn_avg_sg_adj_SBCST_PREST_ITa24_30AUG2023_41984.xls

09JUL2024 12:27

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Center Subfield Thickness ILM-BM in Study Eye over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients			Statistics		
Name	Level	in	%	with	%	Mean ²	SD(Mean)
Visit		study ¹		value ¹			
All							
Week 24	n/a	544	100,0	498	91,5	249,84	43,74
Week 28	n/a	542	99,6	491	90,6	268,91	67,50
Week 32	n/a	541	99,4	488	90,2	253,54	51,32
Week 36	n/a	537	98,7	496	92,4	258,76	54,69
Week 40	n/a	532	97,8	494	92,9	267,53	63,17
Week 44	n/a	524	96,3	487	92,9	254,03	54,56
Week 48	n/a	522	96,0	484	92,7	253,55	49,48
Week 52	n/a	521	95,8	474	91,0	257,32	53,23
Week 56	n/a	514	94,5	473	92,0	269,66	67,86
Week 60	n/a	509	93,6	469	92,1	251,65	46,48
Week 64	n/a	503	92,5	467	92,8	251,76	42,10
Week 68	n/a	500	91,9	471	94,2	250,91	42,91
Week 72	n/a	493	90,6	470	95,3	250,60	42,34
Gender							
Week 24	Male	267	100,0	251	94,0	256,35	46,37
Week 28	Male	266	99,6	245	92,1	278,78	72,89
Week 32	Male	265	99,3	241	90,9	258,26	51,34
Week 36	Male	264	98,9	246	93,2	266,70	58,20
Week 40	Male	262	98,1	246	93,9	271,08	60,41
Week 44	Male	261	97,8	240	92,0	261,20	60,01
Week 48	Male	260	97,4	244	93,8	261,10	54,97
Week 52	Male	259	97,0	234	90,3	263,11	51,31
Week 56	Male	253	94,8	239	94,5	278,51	77,13
Week 60	Male	253	94,8	236	93,3	256,03	45,09
Week 64	Male	250	93,6	232	92,8	254,69	37,98
Week 68	Male	249	93,3	234	94,0	257,60	43,03
Week 72	Male	245	91,8	230	93,9	257,94	43,89
Female							
Week 24	Female	277	100,0	247	89,2	243,22	39,91
Week 28	Female	276	99,6	246	89,1	259,08	60,22
Week 32	Female	276	99,6	247	89,5	248,93	50,98
Week 36	Female	273	98,6	250	91,6	250,95	49,90
Week 40	Female	270	97,5	248	91,9	264,00	65,72
Week 44	Female	263	94,9	247	93,9	247,07	47,78
Week 48	Female	262	94,6	240	91,6	245,87	41,93
Week 52	Female	262	94,6	240	91,6	251,68	54,56
Week 56	Female	261	94,2	234	89,7	260,62	55,57
Week 60	Female	256	92,4	233	91,0	247,21	47,52
Week 64	Female	253	91,3	235	92,9	248,88	45,70
Week 68	Female	251	90,6	237	94,4	244,31	41,84
Week 72	Female	248	89,5	240	96,8	243,56	39,63

Age							
Week 24	<65 years	274	100,0	248	90,5	250,02	41,79
Week 28	<65 years	272	99,3	243	89,3	271,00	64,76
Week 32	<65 years	271	98,9	247	91,1	254,00	45,68
Week 36	<65 years	269	98,2	251	93,3	260,90	49,51
Week 40	<65 years	265	96,7	250	94,3	268,77	64,98
Week 44	<65 years	263	96,0	245	93,2	257,41	57,55
Week 48	<65 years	263	96,0	245	93,2	256,80	51,93
Week 52	<65 years	263	96,0	231	87,8	257,12	45,39
Week 56	<65 years	260	94,9	240	92,3	267,96	63,83
Week 60	<65 years	258	94,2	235	91,1	250,36	37,29
Week 64	<65 years	255	93,1	232	91,0	251,94	38,89
Week 68	<65 years	254	92,7	242	95,3	251,06	35,71
Week 72	<65 years	250	91,2	237	94,8	249,59	32,11
Week 24	>=65 years	270	100,0	250	92,6	249,65	45,67
Week 28	>=65 years	270	100,0	248	91,9	266,85	70,15
Week 32	>=65 years	270	100,0	241	89,3	253,07	56,60
Week 36	>=65 years	268	99,3	245	91,4	256,57	59,55
Week 40	>=65 years	267	98,9	244	91,4	266,25	61,36
Week 44	>=65 years	261	96,7	242	92,7	250,62	51,24
Week 48	>=65 years	259	95,9	239	92,3	250,21	46,71
Week 52	>=65 years	258	95,6	243	94,2	257,51	59,84
Week 56	>=65 years	254	94,1	233	91,7	271,40	71,87
Week 60	>=65 years	251	93,0	234	93,2	252,94	54,21
Week 64	>=65 years	248	91,9	235	94,8	251,59	45,13
Week 68	>=65 years	246	91,1	229	93,1	250,76	49,48
Week 72	>=65 years	243	90,0	233	95,9	251,63	50,72
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	164	91,6	235,25	42,17
Week 28	<=54 letters	178	99,4	164	92,1	254,58	70,67
Week 32	<=54 letters	178	99,4	161	90,4	236,70	45,39
Week 36	<=54 letters	177	98,9	157	88,7	240,96	50,83
Week 40	<=54 letters	175	97,8	159	90,9	255,81	73,30
Week 44	<=54 letters	172	96,1	161	93,6	242,15	67,78
Week 48	<=54 letters	170	95,0	158	92,9	240,68	58,96
Week 52	<=54 letters	170	95,0	150	88,2	241,77	54,38
Week 56	<=54 letters	167	93,3	151	90,4	262,41	84,67
Week 60	<=54 letters	164	91,6	150	91,5	236,67	42,53
Week 64	<=54 letters	162	90,5	149	92,0	238,61	44,14
Week 68	<=54 letters	161	89,9	151	93,8	236,60	45,79
Week 72	<=54 letters	159	88,8	153	96,2	235,07	41,41
Week 24	>=55 letters	365	100,0	334	91,5	257,00	42,76
Week 28	>=55 letters	364	99,7	327	89,8	276,09	64,77
Week 32	>=55 letters	363	99,5	327	90,1	261,83	52,09
Week 36	>=55 letters	360	98,6	339	94,2	267,01	54,52
Week 40	>=55 letters	357	97,8	335	93,8	273,09	57,02
Week 44	>=55 letters	352	96,4	326	92,6	259,90	45,65
Week 48	>=55 letters	352	96,4	326	92,6	259,78	42,89
Week 52	>=55 letters	351	96,2	324	92,3	264,52	51,20
Week 56	>=55 letters	347	95,1	322	92,8	273,05	58,17
Week 60	>=55 letters	345	94,5	319	92,5	258,69	46,64
Week 64	>=55 letters	341	93,4	318	93,3	257,93	39,71
Week 68	>=55 letters	339	92,9	320	94,4	257,67	39,81
Week 72	>=55 letters	334	91,5	317	94,9	258,09	40,77

Geographic Region							
Week 24	Europe	150	100,0	140	93,3	250,44	43,34
Week 28	Europe	150	100,0	139	92,7	275,06	73,16
Week 32	Europe	150	100,0	137	91,3	257,83	61,59
Week 36	Europe	149	99,3	138	92,6	258,52	49,81
Week 40	Europe	147	98,0	136	92,5	270,13	61,19
Week 44	Europe	144	96,0	134	93,1	254,93	49,13
Week 48	Europe	143	95,3	132	92,3	253,54	41,34
Week 52	Europe	143	95,3	131	91,6	259,41	53,48
Week 56	Europe	141	94,0	129	91,5	270,00	63,16
Week 60	Europe	139	92,7	134	96,4	255,04	54,33
Week 64	Europe	137	91,3	130	94,9	250,97	44,17
Week 68	Europe	136	90,7	130	95,6	248,91	40,99
Week 72	Europe	135	90,0	133	98,5	255,18	49,99
Week 24	America	199	100,0	186	93,5	258,89	47,89
Week 28	America	198	99,5	179	90,4	275,14	64,11
Week 32	America	198	99,5	179	90,4	260,70	48,92
Week 36	America	195	98,0	182	93,3	268,48	63,89
Week 40	America	193	97,0	182	94,3	275,16	60,58
Week 44	America	191	96,0	178	93,2	260,76	54,19
Week 48	America	191	96,0	179	93,7	261,07	51,46
Week 52	America	190	95,5	171	90,0	264,97	55,05
Week 56	America	186	93,5	180	96,8	276,34	69,80
Week 60	America	185	93,0	172	93,0	256,41	40,69
Week 64	America	183	92,0	171	93,4	256,19	38,87
Week 68	America	183	92,0	176	96,2	258,05	44,15
Week 72	America	178	89,4	167	93,8	254,41	40,87
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	239,56	36,85
Week 28	Asia Pacific (inc. Australia)	194	99,5	173	89,2	257,52	65,04
Week 32	Asia Pacific (inc. Australia)	193	99,0	172	89,1	242,67	42,47
Week 36	Asia Pacific (inc. Australia)	193	99,0	176	91,2	248,90	45,83
Week 40	Asia Pacific (inc. Australia)	192	98,5	176	91,7	257,61	66,27
Week 44	Asia Pacific (inc. Australia)	189	96,9	175	92,6	246,51	58,11
Week 48	Asia Pacific (inc. Australia)	188	96,4	173	92,0	245,76	52,08
Week 52	Asia Pacific (inc. Australia)	188	96,4	172	91,5	248,12	50,04
Week 56	Asia Pacific (inc. Australia)	187	95,9	164	87,7	262,04	68,87
Week 60	Asia Pacific (inc. Australia)	185	94,9	163	88,1	243,83	44,44
Week 64	Asia Pacific (inc. Australia)	183	93,8	166	90,7	247,83	43,45
Week 68	Asia Pacific (inc. Australia)	181	92,8	165	91,2	244,88	42,20
Week 72	Asia Pacific (inc. Australia)	180	92,3	170	94,4	243,27	36,02
Race/ethnicity							
Week 24	White	338	100,0	315	93,2	254,68	43,82
Week 28	White	337	99,7	308	91,4	277,27	71,05
Week 32	White	336	99,4	307	91,4	260,26	55,76
Week 36	White	332	98,2	308	92,8	265,35	59,79
Week 40	White	328	97,0	304	92,7	275,83	66,03
Week 44	White	323	95,6	302	93,5	260,43	60,52
Week 48	White	322	95,3	301	93,5	259,81	52,64
Week 52	White	321	95,0	295	91,9	263,59	56,50
Week 56	White	316	93,5	294	93,0	273,76	70,72
Week 60	White	313	92,6	294	93,9	256,98	49,88
Week 64	White	309	91,4	292	94,5	256,03	43,83
Week 68	White	308	91,1	296	96,1	254,49	44,71

Week 72	White	302	89,3	291	96,4	254,85	44,12
Week 24	Asian	181	100,0	159	87,8	239,88	42,05
Week 28	Asian	180	99,4	160	88,9	249,16	50,69
Week 32	Asian	180	99,4	159	88,3	241,21	39,93
Week 36	Asian	180	99,4	165	91,7	247,27	42,39
Week 40	Asian	179	98,9	166	92,7	255,34	58,35
Week 44	Asian	176	97,2	163	92,6	242,78	41,75
Week 48	Asian	175	96,7	161	92,0	242,30	42,08
Week 52	Asian	175	96,7	157	89,7	246,20	45,52
Week 56	Asian	174	96,1	156	89,7	262,47	64,65
Week 60	Asian	172	95,0	152	88,4	242,68	39,58
Week 64	Asian	170	93,9	154	90,6	245,83	39,17
Week 68	Asian	168	92,8	153	91,1	244,76	39,55
Week 72	Asian	168	92,8	158	94,0	243,32	36,03
Week 24	Other	17	100,0	16	94,1	253,94	38,29
Week 28	Other	17	100,0	16	94,1	312,06	96,98
Week 32	Other	17	100,0	17	100,0	254,82	44,15
Week 36	Other	17	100,0	16	94,1	251,75	39,93
Week 40	Other	17	100,0	17	100,0	249,94	34,65
Week 44	Other	17	100,0	16	94,1	247,25	36,03
Week 48	Other	17	100,0	16	94,1	248,50	29,87
Week 52	Other	17	100,0	15	88,2	252,00	41,17
Week 56	Other	17	100,0	17	100,0	259,12	47,79
Week 60	Other	17	100,0	16	94,1	245,94	30,63
Week 64	Other	17	100,0	15	88,2	237,13	25,82
Week 68	Other	17	100,0	16	94,1	241,25	32,13
Week 72	Other	16	94,1	14	87,5	248,14	60,71
Week 24	Unknown	8	100,0	8	100,0	248,88	57,65
Week 28	Unknown	8	100,0	7	87,5	253,71	54,24
Week 32	Unknown	8	100,0	5	62,5	228,80	41,51
Week 36	Unknown	8	100,0	7	87,5	255,86	68,81
Week 40	Unknown	8	100,0	7	87,5	238,43	36,43
Week 44	Unknown	8	100,0	6	75,0	256,17	41,32
Week 48	Unknown	8	100,0	6	75,0	254,17	65,98
Week 52	Unknown	8	100,0	7	87,5	254,00	62,13
Week 56	Unknown	7	87,5	6	85,7	285,17	38,70
Week 60	Unknown	7	87,5	7	100,0	235,43	37,20
Week 64	Unknown	7	87,5	6	85,7	233,00	37,42
Week 68	Unknown	7	87,5	6	85,7	257,33	47,24
Week 72	Unknown	7	87,5	7	100,0	243,14	41,21

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Units: microns.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_SBCST_ITa24_30AUG2023_41984.xls

26APR2024 15:29

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Study Eye - Proportion of Patients with Absence of Macular Edema averaged over Weeks 64, 68 and 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	496	91,2	474	95,6

Only patients with at least one value at Week 64, 68 or 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_SNOMACED_PREST_AVG_ITa24_30AUG2023_41984.xls
 26APR2024 15:07

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Center Subfield Thickness ILM-BM in Study Eye averaged over Weeks 64, 68 and 72
 MODEL: Adjusted Analysis for Baseline BCVA ETDRS letter score, Geographic region
 STUDY: GR41986
 Change from Baseline (Analysis of MMRM)

		Faricimab (N=711)					
		N			Statistics		
Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at Week 64, 68 or 72	LSMeans[2]	SE (LSMeans)	
All	n/a	702	701	653	-464,19	2,38	
Gender	Male	375	374	348	-462,12	3,58	
	Female	327	327	305	-466,23	3,21	
Age	<65 years	308	307	291	-485,75	2,89	
	>=65 years	394	394	362	-448,00	3,41	
Baseline BCVA ETDRS letter score	<=34 letters	154	154	147	NE	NE	
	35 - 54 letters	204	204	188	-514,72	3,40	
	>=55 letters	344	343	318	-335,93	3,82	
Baseline BCVA ETDRS letter score	<=23 letters	69	69	66	NE	NE	
	>=24 letters	633	632	587	-433,36	2,60	
Geographic Region	Europe	217	217	204	-456,70	5,64	
	America	276	275	260	-463,95	3,06	
	Asia Pacific (inc. Australia)	209	209	189	NE	NE	
Race/ethnicity	White	472	471	441	NE	NE	
	Asian	179	179	163	-460,68	4,38	
	Other	27	27	26	NE	NE	
	Unknown	24	24	23	NE	NE	
Baseline RVO status	CRVO	577	577	535	-480,05	2,63	
	HRVO	119	118	113	-380,00	5,38	
	Missing	6	6	5	NE	NE	

[1] Patients included in the analysis: with a value at baseline and at least one post-baseline value at the selected visits.

[2] LSMeans of change from baseline from MMRM (including all available records from all selected visits). Selected visits: every 4 weeks from Week 4 to 72. Early Termination (ET) visit was mapped to closest regular visit. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition adjusted for randomization stratification factors. The stratification factor is excluded if it is the subgroup.

Units: microns. Data as observed (no imputation of missing values). Covariance matrix: unstructured. Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mmrn_avg.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mmrn_avg_sg_adj_SBCST_PREST_ITa24_29AUG2023_41986.xls

09JUL2024 12:30

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Center Subfield Thickness ILM-BM in Study Eye over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name	Level	in	%	with	%	Mean ²	SD(Mean)
Visit		study ¹		value ¹			
All							
Week 24	n/a	711	100,0	665	93,5	259,75	92,94
Week 28	n/a	710	99,9	672	94,6	297,65	148,81
Week 32	n/a	709	99,7	657	92,7	261,00	86,43
Week 36	n/a	703	98,9	651	92,6	267,32	101,40
Week 40	n/a	700	98,5	652	93,1	301,99	146,76
Week 44	n/a	696	97,9	641	92,1	259,21	93,70
Week 48	n/a	691	97,2	625	90,4	258,92	89,50
Week 52	n/a	686	96,5	638	93,0	267,01	102,31
Week 56	n/a	683	96,1	633	92,7	281,91	122,04
Week 60	n/a	679	95,5	625	92,0	250,30	75,80
Week 64	n/a	675	94,9	628	93,0	247,72	64,05
Week 68	n/a	670	94,2	623	93,0	251,52	72,79
Week 72	n/a	662	93,1	627	94,7	253,00	82,03
Gender							
Week 24	Male	382	100,0	354	92,7	268,51	106,50
Week 28	Male	381	99,7	355	93,2	307,04	161,02
Week 32	Male	381	99,7	350	91,9	267,63	83,14
Week 36	Male	376	98,4	349	92,8	276,66	111,99
Week 40	Male	374	97,9	344	92,0	309,63	149,03
Week 44	Male	372	97,4	336	90,3	265,93	102,98
Week 48	Male	369	96,6	332	90,0	270,07	104,67
Week 52	Male	367	96,1	343	93,5	272,53	107,06
Week 56	Male	365	95,5	336	92,1	279,54	101,02
Week 60	Male	362	94,8	338	93,4	254,32	75,82
Week 64	Male	361	94,5	337	93,4	252,82	68,96
Week 68	Male	359	94,0	333	92,8	258,16	78,01
Week 72	Male	356	93,2	339	95,2	258,89	76,93
Week 24	Female	329	100,0	311	94,5	249,78	73,48
Week 28	Female	329	100,0	317	96,4	287,14	133,29
Week 32	Female	328	99,7	307	93,6	253,45	89,57
Week 36	Female	327	99,4	302	92,4	256,52	86,53
Week 40	Female	326	99,1	308	94,5	293,46	143,95
Week 44	Female	324	98,5	305	94,1	251,82	81,80
Week 48	Female	322	97,9	293	91,0	246,30	66,30
Week 52	Female	319	97,0	295	92,5	260,59	96,27
Week 56	Female	318	96,7	297	93,4	284,59	142,25

Week 60	Female	317	96,4	287	90,5	245,57	75,63
Week 64	Female	314	95,4	291	92,7	241,83	57,39
Week 68	Female	311	94,5	290	93,2	243,89	65,58
Week 72	Female	306	93,0	288	94,1	246,05	87,28
Age							
Week 24	<65 years	312	100,0	286	91,7	270,22	106,55
Week 28	<65 years	312	100,0	293	93,9	324,00	174,55
Week 32	<65 years	312	100,0	291	93,3	267,20	83,43
Week 36	<65 years	311	99,7	285	91,6	267,30	82,57
Week 40	<65 years	309	99,0	286	92,6	294,16	127,52
Week 44	<65 years	307	98,4	282	91,9	263,44	87,02
Week 48	<65 years	304	97,4	271	89,1	267,66	90,58
Week 52	<65 years	302	96,8	287	95,0	269,10	90,06
Week 56	<65 years	301	96,5	275	91,4	267,32	79,06
Week 60	<65 years	299	95,8	276	92,3	253,16	68,56
Week 64	<65 years	298	95,5	280	94,0	250,88	49,36
Week 68	<65 years	296	94,9	283	95,6	257,31	80,85
Week 72	<65 years	293	93,9	282	96,2	255,19	64,91
Week 24	>=65 years	399	100,0	379	95,0	251,85	80,43
Week 28	>=65 years	398	99,7	379	95,2	277,28	121,72
Week 32	>=65 years	397	99,5	366	92,2	256,07	88,55
Week 36	>=65 years	392	98,2	366	93,4	267,34	114,04
Week 40	>=65 years	391	98,0	366	93,6	308,11	160,10
Week 44	>=65 years	389	97,5	359	92,3	255,89	98,62
Week 48	>=65 years	387	97,0	354	91,5	252,24	88,20
Week 52	>=65 years	384	96,2	351	91,4	265,30	111,42
Week 56	>=65 years	382	95,7	358	93,7	293,12	145,87
Week 60	>=65 years	380	95,2	349	91,8	248,05	81,10
Week 64	>=65 years	377	94,5	348	92,3	245,19	73,75
Week 68	>=65 years	374	93,7	340	90,9	246,70	65,05
Week 72	>=65 years	369	92,5	345	93,5	251,20	93,79
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	197	94,7	257,15	95,03
Week 28	35 - 54 letters	208	100,0	197	94,7	290,35	142,44
Week 32	35 - 54 letters	208	100,0	191	91,8	251,48	61,69
Week 36	35 - 54 letters	206	99,0	193	93,7	261,82	77,27
Week 40	35 - 54 letters	204	98,1	191	93,6	301,68	126,42
Week 44	35 - 54 letters	203	97,6	193	95,1	259,67	95,82
Week 48	35 - 54 letters	203	97,6	184	90,6	254,94	78,70
Week 52	35 - 54 letters	202	97,1	188	93,1	266,96	101,39
Week 56	35 - 54 letters	202	97,1	191	94,6	282,17	111,02
Week 60	35 - 54 letters	200	96,2	182	91,0	241,19	42,15
Week 64	35 - 54 letters	197	94,7	182	92,4	245,69	50,89
Week 68	35 - 54 letters	195	93,8	176	90,3	245,14	52,93
Week 72	35 - 54 letters	193	92,8	180	93,3	251,16	69,91
Week 24	<=34 letters	158	100,0	147	93,0	235,12	72,33
Week 28	<=34 letters	158	100,0	148	93,7	288,74	157,94
Week 32	<=34 letters	158	100,0	149	94,3	253,72	115,66

Week 36	<=34 letters	157	99,4	149	94,9	251,13	118,17
Week 40	<=34 letters	157	99,4	150	95,5	280,13	145,93
Week 44	<=34 letters	156	98,7	145	92,9	233,08	93,70
Week 48	<=34 letters	156	98,7	141	90,4	249,55	138,28
Week 52	<=34 letters	155	98,1	142	91,6	239,10	86,94
Week 56	<=34 letters	154	97,5	141	91,6	274,17	162,82
Week 60	<=34 letters	153	96,8	138	90,2	226,94	85,44
Week 64	<=34 letters	153	96,8	144	94,1	221,03	46,69
Week 68	<=34 letters	153	96,8	144	94,1	232,92	95,91
Week 72	<=34 letters	152	96,2	144	94,7	222,18	91,15
Week 24	>=55 letters	345	100,0	321	93,0	272,62	97,76
Week 28	>=55 letters	344	99,7	327	95,1	306,09	148,30
Week 32	>=55 letters	343	99,4	317	92,4	270,16	82,41
Week 36	>=55 letters	340	98,6	309	90,9	278,56	104,86
Week 40	>=55 letters	339	98,3	311	91,7	312,72	157,65
Week 44	>=55 letters	337	97,7	303	89,9	271,43	90,02
Week 48	>=55 letters	332	96,2	300	90,4	265,77	62,24
Week 52	>=55 letters	329	95,4	308	93,6	279,90	107,04
Week 56	>=55 letters	327	94,8	301	92,0	285,38	105,63
Week 60	>=55 letters	326	94,5	305	93,6	266,31	83,01
Week 64	>=55 letters	325	94,2	302	92,9	261,68	73,57
Week 68	>=55 letters	322	93,3	303	94,1	264,06	67,72
Week 72	>=55 letters	317	91,9	303	95,6	268,73	80,09
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	65	92,9	227,80	73,29
Week 28	<=23 letters	70	100,0	66	94,3	298,79	194,27
Week 32	<=23 letters	70	100,0	67	95,7	235,15	91,65
Week 36	<=23 letters	69	98,6	67	97,1	241,24	114,65
Week 40	<=23 letters	69	98,6	68	98,6	264,94	127,16
Week 44	<=23 letters	68	97,1	64	94,1	227,20	115,80
Week 48	<=23 letters	68	97,1	63	92,6	236,84	121,89
Week 52	<=23 letters	68	97,1	63	92,6	240,63	101,41
Week 56	<=23 letters	68	97,1	60	88,2	286,10	214,77
Week 60	<=23 letters	68	97,1	60	88,2	222,07	85,22
Week 64	<=23 letters	68	97,1	64	94,1	211,58	32,69
Week 68	<=23 letters	68	97,1	63	92,6	210,13	31,08
Week 72	<=23 letters	68	97,1	66	97,1	210,42	47,81
Week 24	>=24 letters	641	100,0	600	93,6	263,21	94,23
Week 28	>=24 letters	640	99,8	606	94,7	297,53	143,19
Week 32	>=24 letters	639	99,7	590	92,3	263,94	85,41
Week 36	>=24 letters	634	98,9	584	92,1	270,31	99,44
Week 40	>=24 letters	631	98,4	584	92,6	306,30	148,37
Week 44	>=24 letters	628	98,0	577	91,9	262,76	90,34
Week 48	>=24 letters	623	97,2	562	90,2	261,40	84,89
Week 52	>=24 letters	618	96,4	575	93,0	269,90	102,08
Week 56	>=24 letters	615	95,9	573	93,2	281,47	108,15
Week 60	>=24 letters	611	95,3	565	92,5	253,30	74,19
Week 64	>=24 letters	607	94,7	564	92,9	251,83	65,45
Week 68	>=24 letters	602	93,9	560	93,0	256,18	74,65

Week 72	>=24 letters	594	92,7	561	94,4	258,00	83,77
Geographic Region							
Week 24	Europe	217	100,0	202	93,1	260,76	95,48
Week 28	Europe	217	100,0	205	94,5	298,14	143,49
Week 32	Europe	217	100,0	199	91,7	273,68	123,90
Week 36	Europe	215	99,1	201	93,5	271,90	122,60
Week 40	Europe	214	98,6	200	93,5	305,73	151,94
Week 44	Europe	214	98,6	199	93,0	261,31	103,10
Week 48	Europe	212	97,7	191	90,1	258,69	87,05
Week 52	Europe	212	97,7	200	94,3	279,92	135,56
Week 56	Europe	211	97,2	196	92,9	288,01	144,60
Week 60	Europe	210	96,8	194	92,4	245,27	60,61
Week 64	Europe	209	96,3	193	92,3	249,87	89,13
Week 68	Europe	206	94,9	194	94,2	249,85	69,62
Week 72	Europe	206	94,9	196	95,1	254,82	92,73
Week 24	America	285	100,0	268	94,0	256,15	71,65
Week 28	America	285	100,0	272	95,4	285,82	118,98
Week 32	America	285	100,0	267	93,7	257,67	65,38
Week 36	America	285	100,0	264	92,6	265,89	86,39
Week 40	America	284	99,6	263	92,6	305,78	140,06
Week 44	America	283	99,3	259	91,5	258,84	86,31
Week 48	America	281	98,6	254	90,4	256,73	87,76
Week 52	America	278	97,5	258	92,8	259,44	71,36
Week 56	America	277	97,2	252	91,0	276,50	100,52
Week 60	America	275	96,5	258	93,8	255,95	85,94
Week 64	America	273	95,8	255	93,4	247,82	47,09
Week 68	America	271	95,1	251	92,6	250,31	51,48
Week 72	America	265	93,0	249	94,0	251,77	74,77
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	263,66	114,10
Week 28	Asia Pacific (inc. Australia)	208	99,5	195	93,8	313,64	186,31
Week 32	Asia Pacific (inc. Australia)	207	99,0	191	92,3	252,45	59,60
Week 36	Asia Pacific (inc. Australia)	203	97,1	186	91,6	264,40	96,09
Week 40	Asia Pacific (inc. Australia)	202	96,7	189	93,6	292,76	150,62
Week 44	Asia Pacific (inc. Australia)	199	95,2	183	92,0	257,46	93,48
Week 48	Asia Pacific (inc. Australia)	198	94,7	180	90,9	262,28	94,74
Week 52	Asia Pacific (inc. Australia)	196	93,8	180	91,8	263,50	96,04
Week 56	Asia Pacific (inc. Australia)	195	93,3	185	94,9	282,82	123,00
Week 60	Asia Pacific (inc. Australia)	194	92,8	173	89,2	247,53	74,85
Week 64	Asia Pacific (inc. Australia)	193	92,3	180	93,3	245,29	51,86
Week 68	Asia Pacific (inc. Australia)	193	92,3	178	92,2	255,03	97,83
Week 72	Asia Pacific (inc. Australia)	191	91,4	182	95,3	252,71	79,64
Race/ethnicity							
Week 24	White	481	100,0	453	94,2	263,36	98,45
Week 28	White	480	99,8	458	95,4	298,48	144,21
Week 32	White	480	99,8	446	92,9	262,04	83,80
Week 36	White	476	99,0	442	92,9	271,76	106,87
Week 40	White	474	98,5	446	94,1	305,50	142,79
Week 44	White	473	98,3	437	92,4	259,23	86,90

Week 48	White	470	97,7	428	91,1	256,83	79,68
Week 52	White	467	97,1	436	93,4	269,44	106,33
Week 56	White	465	96,7	430	92,5	285,87	128,16
Week 60	White	463	96,3	428	92,4	253,64	81,49
Week 64	White	460	95,6	429	93,3	250,12	70,21
Week 68	White	456	94,8	423	92,8	255,67	79,08
Week 72	White	449	93,3	421	93,8	253,33	83,56
Week 24	Asian	179	100,0	165	92,2	256,09	88,14
Week 28	Asian	179	100,0	166	92,7	295,23	155,02
Week 32	Asian	178	99,4	164	92,1	248,58	54,73
Week 36	Asian	176	98,3	159	90,3	254,62	84,61
Week 40	Asian	175	97,8	162	92,6	288,15	153,35
Week 44	Asian	172	96,1	157	91,3	257,11	97,06
Week 48	Asian	170	95,0	154	90,6	264,55	104,80
Week 52	Asian	168	93,9	154	91,7	265,58	102,77
Week 56	Asian	167	93,3	158	94,6	274,30	112,35
Week 60	Asian	166	92,7	150	90,4	245,03	67,35
Week 64	Asian	165	92,2	154	93,3	244,29	50,93
Week 68	Asian	165	92,2	154	93,3	243,55	59,70
Week 72	Asian	164	91,6	158	96,3	254,84	84,81
Week 24	Other	27	100,0	25	92,6	239,40	35,16
Week 28	Other	27	100,0	25	92,6	252,20	49,61
Week 32	Other	27	100,0	24	88,9	272,29	94,03
Week 36	Other	27	100,0	26	96,3	271,96	98,70
Week 40	Other	27	100,0	23	85,2	300,22	124,90
Week 44	Other	27	100,0	25	92,6	254,08	74,89
Week 48	Other	27	100,0	22	81,5	239,86	32,83
Week 52	Other	27	100,0	25	92,6	241,40	31,66
Week 56	Other	27	100,0	24	88,9	273,38	112,45
Week 60	Other	27	100,0	24	88,9	235,63	33,90
Week 64	Other	27	100,0	24	88,9	238,00	34,38
Week 68	Other	26	96,3	23	88,5	247,30	50,77
Week 72	Other	26	96,3	25	96,2	244,24	60,64
Week 24	Unknown	24	100,0	22	91,7	235,95	30,74
Week 28	Unknown	24	100,0	23	95,8	348,00	235,42
Week 32	Unknown	24	100,0	23	95,8	317,70	211,23
Week 36	Unknown	24	100,0	24	100,0	264,63	101,57
Week 40	Unknown	24	100,0	21	87,5	336,14	194,74
Week 44	Unknown	24	100,0	22	91,7	279,64	184,03
Week 48	Unknown	24	100,0	21	87,5	280,24	167,32
Week 52	Unknown	24	100,0	23	95,8	258,22	63,23
Week 56	Unknown	24	100,0	21	87,5	267,90	59,99
Week 60	Unknown	23	95,8	23	100,0	237,91	36,96
Week 64	Unknown	23	95,8	21	91,3	235,19	37,41
Week 68	Unknown	23	95,8	23	100,0	232,78	35,88
Week 72	Unknown	23	95,8	23	100,0	243,61	51,32
Baseline RVO status							
Week 24	CRVO	583	100,0	545	93,5	259,46	93,92

Week 28	CRVO	582	99,8	552	94,8	302,27	157,45
Week 32	CRVO	581	99,7	538	92,6	258,51	84,51
Week 36	CRVO	576	98,8	535	92,9	264,25	97,34
Week 40	CRVO	574	98,5	533	92,9	303,99	153,63
Week 44	CRVO	570	97,8	524	91,9	259,45	96,99
Week 48	CRVO	565	96,9	512	90,6	261,11	96,53
Week 52	CRVO	560	96,1	518	92,5	268,91	107,88
Week 56	CRVO	557	95,5	518	93,0	283,53	127,48
Week 60	CRVO	553	94,9	508	91,9	249,94	77,47
Week 64	CRVO	550	94,3	513	93,3	246,24	62,08
Week 68	CRVO	547	93,8	510	93,2	252,10	78,25
Week 72	CRVO	540	92,6	512	94,8	253,01	87,53
Week 24	HRVO	122	100,0	115	94,3	262,03	90,33
Week 28	HRVO	122	100,0	115	94,3	276,64	98,89
Week 32	HRVO	122	100,0	113	92,6	267,11	81,82
Week 36	HRVO	121	99,2	110	90,9	279,39	112,81
Week 40	HRVO	120	98,4	114	95,0	294,39	112,78
Week 44	HRVO	120	98,4	111	92,5	259,13	79,35
Week 48	HRVO	120	98,4	107	89,2	250,11	45,19
Week 52	HRVO	120	98,4	114	95,0	260,39	74,75
Week 56	HRVO	120	98,4	110	91,7	272,02	88,19
Week 60	HRVO	120	98,4	112	93,3	252,93	69,60
Week 64	HRVO	119	97,5	110	92,4	255,60	73,42
Week 68	HRVO	117	95,9	108	92,3	249,73	40,31
Week 72	HRVO	116	95,1	110	94,8	254,25	51,68
Week 24	Missing	6	100,0	5	83,3	239,60	34,02
Week 28	Missing	6	100,0	5	83,3	271,40	67,48
Week 32	Missing	6	100,0	6	100,0	369,33	217,90
Week 36	Missing	6	100,0	6	100,0	319,50	199,45
Week 40	Missing	6	100,0	5	83,3	261,80	52,90
Week 44	Missing	6	100,0	6	100,0	240,33	29,10
Week 48	Missing	6	100,0	6	100,0	230,00	28,98
Week 52	Missing	6	100,0	6	100,0	228,00	22,51
Week 56	Missing	6	100,0	5	83,3	331,80	186,01
Week 60	Missing	6	100,0	5	83,3	228,80	20,38
Week 64	Missing	6	100,0	5	83,3	227,00	19,30
Week 68	Missing	6	100,0	5	83,3	230,60	21,94
Week 72	Missing	6	100,0	5	83,3	223,60	20,26

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Units: microns.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_SBCST_ITa24_29AUG2023_41986.xls

26APR2024 15:43

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Study Eye - Proportion of Patients with Absence of Macular Edema averaged over Weeks 64, 68 and 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	661	93,0	616	93,2

Only patients with at least one value at Week 64, 68 or 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_SNOMACED_PREST_AVG_ITa24_29AUG2023_41986.xls
 26APR2024 15:20

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Composite Score over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	498	91,5	86,02	12,13
Week 48	n/a	542	99,6	492	90,8	86,79	11,70
Week 72	n/a	506	93,0	471	93,1	87,35	11,86
Gender							
Week 24	Male	267	100,0	250	93,6	87,91	10,29
Week 48	Male	266	99,6	248	93,2	88,49	10,26
Week 72	Male	252	94,4	230	91,3	88,95	10,84
Female							
Week 24	Female	277	100,0	248	89,5	84,11	13,49
Week 48	Female	276	99,6	244	88,4	85,06	12,79
Week 72	Female	254	91,7	241	94,9	85,81	12,59
Age							
Week 24	<65 years	274	100,0	248	90,5	86,90	10,98
Week 48	<65 years	272	99,3	249	91,5	87,87	10,73
Week 72	<65 years	256	93,4	238	93,0	88,78	9,84
>=65 years							
Week 24	>=65 years	270	100,0	250	92,6	85,14	13,13
Week 48	>=65 years	270	100,0	243	90,0	85,68	12,55
Week 72	>=65 years	250	92,6	233	93,2	85,88	13,48
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	84,11	13,69
Week 48	<=54 letters	178	99,4	162	91,0	83,85	13,83
Week 72	<=54 letters	162	90,5	153	94,4	85,39	13,42
>=55 letters							
Week 24	>=55 letters	365	100,0	336	92,1	86,93	11,20

Week 48	>=55 letters	364	99,7	330	90,7	88,23	10,22
Week 72	>=55 letters	344	94,2	318	92,4	88,29	10,92
Geographic Region							
Week 24	Europe	150	100,0	140	93,3	84,51	13,96
Week 48	Europe	150	100,0	136	90,7	85,97	12,25
Week 72	Europe	138	92,0	133	96,4	86,53	12,91
Week 24							
Week 24	America	199	100,0	186	93,5	86,87	11,14
Week 48	America	198	99,5	179	90,4	87,44	11,73
Week 72	America	183	92,0	168	91,8	87,98	11,66
Week 24							
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	86,32	11,49
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	86,76	11,26
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	87,36	11,20
Race/ethnicity							
Week 24	White	338	100,0	316	93,5	86,18	12,58
Week 48	White	337	99,7	305	90,5	87,02	12,08
Week 72	White	311	92,0	293	94,2	87,78	11,84
Week 24							
Week 24	Asian	181	100,0	158	87,3	85,61	11,28
Week 48	Asian	180	99,4	165	91,7	86,33	11,37
Week 72	Asian	171	94,5	157	91,8	86,92	11,58
Week 24							
Week 24	Other	17	100,0	16	94,1	84,91	13,63
Week 48	Other	17	100,0	16	94,1	87,56	8,82
Week 72	Other	17	100,0	14	82,4	83,96	16,07
Week 24							
Week 24	Unknown	8	100,0	8	100,0	89,91	6,11
Week 48	Unknown	8	100,0	6	75,0	85,60	8,90
Week 72	Unknown	7	87,5	7	100,0	85,53	10,22

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QBCS
03JUN2024 17:02

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Composite Score at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	470	86,4	99	21,1

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QBCSCORE15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:02

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 General Health subscale over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	498	91,5	53,92	21,51
Week 48	n/a	542	99,6	492	90,8	54,17	21,42
Week 72	n/a	506	93,0	471	93,1	54,78	23,37
Gender							
Week 24	Male	267	100,0	250	93,6	55,50	21,43
Week 48	Male	266	99,6	248	93,2	55,04	20,12
Week 72	Male	252	94,4	230	91,3	57,07	23,17
Female							
Week 24	Female	277	100,0	248	89,5	52,32	21,51
Week 48	Female	276	99,6	244	88,4	53,28	22,67
Week 72	Female	254	91,7	241	94,9	52,59	23,41
Age							
Week 24	<65 years	274	100,0	248	90,5	55,44	20,63
Week 48	<65 years	272	99,3	249	91,5	54,82	20,62
Week 72	<65 years	256	93,4	238	93,0	55,67	22,13
>=65 years							
Week 24	>=65 years	270	100,0	250	92,6	52,40	22,28
Week 48	>=65 years	270	100,0	243	90,0	53,50	22,22
Week 72	>=65 years	250	92,6	233	93,2	53,86	24,59
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	52,78	21,58
Week 48	<=54 letters	178	99,4	162	91,0	53,24	20,88
Week 72	<=54 letters	162	90,5	153	94,4	54,08	23,38
>=55 letters							
Week 24	>=55 letters	365	100,0	336	92,1	54,46	21,48

Week 48	>=55 letters	364	99,7	330	90,7	54,62	21,69
Week 72	>=55 letters	344	94,2	318	92,4	55,11	23,40
Geographic Region							
Week 24	Europe	150	100,0	140	93,3	49,46	21,72
Week 48	Europe	150	100,0	136	90,7	47,06	22,16
Week 72	Europe	138	92,0	133	96,4	48,87	22,58
Week 24	America	199	100,0	186	93,5	59,68	21,13
Week 48	America	198	99,5	179	90,4	59,92	20,08
Week 72	America	183	92,0	168	91,8	62,95	22,39
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	51,31	20,46
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	53,81	20,55
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	51,32	22,80
Race/ethnicity							
Week 24	White	338	100,0	316	93,5	54,98	21,84
Week 48	White	337	99,7	305	90,5	54,26	21,80
Week 72	White	311	92,0	293	94,2	56,66	23,92
Week 24	Asian	181	100,0	158	87,3	50,32	20,73
Week 48	Asian	180	99,4	165	91,7	52,58	20,22
Week 72	Asian	171	94,5	157	91,8	50,80	22,36
Week 24	Other	17	100,0	16	94,1	64,06	20,35
Week 48	Other	17	100,0	16	94,1	68,75	23,27
Week 72	Other	17	100,0	14	82,4	64,29	18,90
Week 24	Unknown	8	100,0	8	100,0	62,50	13,36
Week 48	Unknown	8	100,0	6	75,0	54,17	18,82
Week 72	Unknown	7	87,5	7	100,0	46,43	17,25

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBG
03JUN2024 17:10

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 General Health subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	470	86,4	147	31,3

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBGH15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:09

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 General Vision subscale over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	498	91,5	70,72	14,12
Week 48	n/a	542	99,6	492	90,8	72,60	13,89
Week 72	n/a	506	93,0	471	93,1	73,25	13,41
Gender							
Week 24	Male	267	100,0	250	93,6	71,12	13,15
Week 48	Male	266	99,6	248	93,2	73,06	13,24
Week 72	Male	252	94,4	230	91,3	74,09	13,60
Female							
Week 24	Female	277	100,0	248	89,5	70,32	15,05
Week 48	Female	276	99,6	244	88,4	72,13	14,53
Week 72	Female	254	91,7	241	94,9	72,45	13,21
Age							
Week 24	<65 years	274	100,0	248	90,5	71,85	13,09
Week 48	<65 years	272	99,3	249	91,5	73,49	13,72
Week 72	<65 years	256	93,4	238	93,0	73,87	13,29
>=65 years							
Week 24	>=65 years	270	100,0	250	92,6	69,60	15,02
Week 48	>=65 years	270	100,0	243	90,0	71,69	14,03
Week 72	>=65 years	250	92,6	233	93,2	72,62	13,54
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	68,02	14,00
Week 48	<=54 letters	178	99,4	162	91,0	70,12	14,83
Week 72	<=54 letters	162	90,5	153	94,4	72,94	13,47
>=55 letters							
Week 24	>=55 letters	365	100,0	336	92,1	72,02	14,02

Week 48	>=55 letters	364	99,7	330	90,7	73,82	13,25
Week 72	>=55 letters	344	94,2	318	92,4	73,40	13,40
Geographic Region							
Week 24	Europe	150	100,0	140	93,3	70,71	14,07
Week 48	Europe	150	100,0	136	90,7	72,94	13,45
Week 72	Europe	138	92,0	133	96,4	73,53	12,68
Week 24	America	199	100,0	186	93,5	74,52	12,74
Week 48	America	198	99,5	179	90,4	77,21	13,20
Week 72	America	183	92,0	168	91,8	77,86	12,39
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	66,63	14,52
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	67,68	13,30
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	68,47	13,37
Race/ethnicity							
Week 24	White	338	100,0	316	93,5	72,97	13,24
Week 48	White	337	99,7	305	90,5	75,08	13,50
Week 72	White	311	92,0	293	94,2	76,04	12,74
Week 24	Asian	181	100,0	158	87,3	65,57	14,43
Week 48	Asian	180	99,4	165	91,7	67,39	13,11
Week 72	Asian	171	94,5	157	91,8	68,15	13,20
Week 24	Other	17	100,0	16	94,1	72,50	16,12
Week 48	Other	17	100,0	16	94,1	77,50	14,38
Week 72	Other	17	100,0	14	82,4	70,00	13,01
Week 24	Unknown	8	100,0	8	100,0	80,00	10,69
Week 48	Unknown	8	100,0	6	75,0	76,67	15,06
Week 72	Unknown	7	87,5	7	100,0	77,14	13,80

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBG
03JUN2024 17:12

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 General Vision subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	470	86,4	261	55,5

Only patients with a value at baseline and Week 72 are used for analysis.

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBGV15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:11

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Ocular Pain subscale over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in	%	with	%	Mean ²	SD(Mean)
Visit		study ¹		value ¹			
All							
Week 24	n/a	544	100,0	498	91,5	87,22	17,38
Week 48	n/a	542	99,6	492	90,8	87,07	16,51
Week 72	n/a	506	93,0	471	93,1	88,24	15,96
Gender							
Week 24	Male	267	100,0	250	93,6	89,70	15,16
Week 48	Male	266	99,6	248	93,2	89,47	15,40
Week 72	Male	252	94,4	230	91,3	90,11	15,19
Female							
Week 24	Female	277	100,0	248	89,5	84,73	19,07
Week 48	Female	276	99,6	244	88,4	84,63	17,26
Week 72	Female	254	91,7	241	94,9	86,46	16,50
Age							
Week 24	<65 years	274	100,0	248	90,5	87,70	17,02
Week 48	<65 years	272	99,3	249	91,5	87,50	16,11
Week 72	<65 years	256	93,4	238	93,0	89,65	14,20
>=65 years							
Week 24	>=65 years	270	100,0	250	92,6	86,75	17,75
Week 48	>=65 years	270	100,0	243	90,0	86,63	16,93
Week 72	>=65 years	250	92,6	233	93,2	86,80	17,49
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	87,27	17,70
Week 48	<=54 letters	178	99,4	162	91,0	85,11	17,54
Week 72	<=54 letters	162	90,5	153	94,4	87,58	17,24
>=55 letters							
Week 24	>=55 letters	365	100,0	336	92,1	87,20	17,25

Week 48	>=55 letters	364	99,7	330	90,7	88,03	15,92
Week 72	>=55 letters	344	94,2	318	92,4	88,56	15,33
Geographic Region							
Week 24	Europe	150	100,0	140	93,3	83,75	18,65
Week 48	Europe	150	100,0	136	90,7	85,02	17,20
Week 72	Europe	138	92,0	133	96,4	86,00	16,29
Week 24							
Week 24	America	199	100,0	186	93,5	89,11	15,89
Week 48	America	198	99,5	179	90,4	88,13	16,56
Week 72	America	183	92,0	168	91,8	90,10	15,29
Week 24							
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	88,01	17,54
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	87,57	15,85
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	88,16	16,22
Race/ethnicity							
Week 24	White	338	100,0	316	93,5	87,03	17,42
Week 48	White	337	99,7	305	90,5	87,21	17,04
Week 72	White	311	92,0	293	94,2	88,01	16,05
Week 24							
Week 24	Asian	181	100,0	158	87,3	87,97	17,10
Week 48	Asian	180	99,4	165	91,7	87,20	15,49
Week 72	Asian	171	94,5	157	91,8	88,61	15,78
Week 24							
Week 24	Other	17	100,0	16	94,1	80,47	20,40
Week 48	Other	17	100,0	16	94,1	81,25	17,08
Week 72	Other	17	100,0	14	82,4	83,93	18,62
Week 24							
Week 24	Unknown	8	100,0	8	100,0	93,75	13,36
Week 48	Unknown	8	100,0	6	75,0	91,67	15,14
Week 72	Unknown	7	87,5	7	100,0	98,21	4,72

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based o

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBO
03JUN2024 17:15

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Ocular Pain subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	470	86,4	81	17,2

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBOP15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:14

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Near Activities Subscale over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	498	91,5	82,74	17,99
Week 48	n/a	542	99,6	492	90,8	84,60	16,49
Week 72	n/a	506	93,0	470	92,9	84,95	17,07
Gender							
Week 24	Male	267	100,0	250	93,6	84,35	17,02
Week 48	Male	266	99,6	248	93,2	86,21	15,00
Week 72	Male	252	94,4	229	90,9	86,08	16,28
Female							
Week 24	Female	277	100,0	248	89,5	81,12	18,82
Week 48	Female	276	99,6	244	88,4	82,97	17,76
Week 72	Female	254	91,7	241	94,9	83,87	17,75
Age							
Week 24	<65 years	274	100,0	248	90,5	83,87	16,91
Week 48	<65 years	272	99,3	249	91,5	85,74	15,24
Week 72	<65 years	256	93,4	237	92,6	87,08	15,08
>=65 years							
Week 24	>=65 years	270	100,0	250	92,6	81,62	18,98
Week 48	>=65 years	270	100,0	243	90,0	83,44	17,64
Week 72	>=65 years	250	92,6	233	93,2	82,78	18,66
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	81,43	20,52
Week 48	<=54 letters	178	99,4	162	91,0	82,15	18,53
Week 72	<=54 letters	162	90,5	153	94,4	82,54	18,03
>=55 letters							
Week 24	>=55 letters	365	100,0	336	92,1	83,37	16,64

Week 48	>=55 letters	364	99,7	330	90,7	85,81	15,28
Week 72	>=55 letters	344	94,2	317	92,2	86,11	16,49
Geographic Region							
Week 24	Europe	150	100,0	140	93,3	80,18	20,52
Week 48	Europe	150	100,0	136	90,7	83,12	17,89
Week 72	Europe	138	92,0	132	95,7	84,41	17,69
Week 24	America	199	100,0	186	93,5	81,47	18,20
Week 48	America	198	99,5	179	90,4	83,61	17,43
Week 72	America	183	92,0	168	91,8	83,36	17,84
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	86,19	14,87
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	86,75	14,10
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	86,94	15,64
Race/ethnicity							
Week 24	White	338	100,0	316	93,5	81,58	19,13
Week 48	White	337	99,7	305	90,5	83,76	17,60
Week 72	White	311	92,0	292	93,9	84,47	17,82
Week 24	Asian	181	100,0	158	87,3	85,50	15,47
Week 48	Asian	180	99,4	165	91,7	86,04	14,40
Week 72	Asian	171	94,5	157	91,8	86,25	15,18
Week 24	Other	17	100,0	16	94,1	78,13	18,23
Week 48	Other	17	100,0	16	94,1	84,90	16,45
Week 72	Other	17	100,0	14	82,4	79,17	22,82
Week 24	Unknown	8	100,0	8	100,0	83,33	12,60
Week 48	Unknown	8	100,0	6	75,0	87,50	11,49
Week 72	Unknown	7	87,5	7	100,0	86,90	10,60

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBN
03JUN2024 17:04

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Near Activities Subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	469	86,2	186	39,7

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBNA15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:03

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Distance Activities Subscale over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	498	91,5	87,70	16,31
Week 48	n/a	542	99,6	492	90,8	87,88	15,99
Week 72	n/a	506	93,0	471	93,1	88,61	15,27
Gender							
Week 24	Male	267	100,0	250	93,6	91,07	12,95
Week 48	Male	266	99,6	248	93,2	90,94	12,93
Week 72	Male	252	94,4	230	91,3	90,20	13,74
Female							
Week 24	Female	277	100,0	248	89,5	84,31	18,52
Week 48	Female	276	99,6	244	88,4	84,77	18,08
Week 72	Female	254	91,7	241	94,9	87,09	16,48
Age							
Week 24	<65 years	274	100,0	248	90,5	89,89	14,21
Week 48	<65 years	272	99,3	249	91,5	90,08	13,98
Week 72	<65 years	256	93,4	238	93,0	90,86	12,76
>=65 years							
Week 24	>=65 years	270	100,0	250	92,6	85,53	17,91
Week 48	>=65 years	270	100,0	243	90,0	85,63	17,55
Week 72	>=65 years	250	92,6	233	93,2	86,30	17,18
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	87,06	17,87
Week 48	<=54 letters	178	99,4	162	91,0	85,57	18,39
Week 72	<=54 letters	162	90,5	153	94,4	85,70	18,10
>=55 letters							
Week 24	>=55 letters	365	100,0	336	92,1	88,01	15,51

Week 48	>=55 letters	364	99,7	330	90,7	89,02	14,56
Week 72	>=55 letters	344	94,2	318	92,4	90,00	13,51
Geographic Region							
Week 24	Europe	150	100,0	140	93,3	85,36	18,45
Week 48	Europe	150	100,0	136	90,7	86,92	17,06
Week 72	Europe	138	92,0	133	96,4	88,03	16,73
Week 24	America	199	100,0	186	93,5	87,28	16,82
Week 48	America	198	99,5	179	90,4	86,94	17,56
Week 72	America	183	92,0	168	91,8	88,94	14,88
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	90,07	13,40
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	89,57	13,15
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	88,73	14,50
Race/ethnicity							
Week 24	White	338	100,0	316	93,5	86,76	17,68
Week 48	White	337	99,7	305	90,5	87,35	17,22
Week 72	White	311	92,0	293	94,2	88,77	15,71
Week 24	Asian	181	100,0	158	87,3	89,58	13,27
Week 48	Asian	180	99,4	165	91,7	88,91	13,36
Week 72	Asian	171	94,5	157	91,8	88,59	14,46
Week 24	Other	17	100,0	16	94,1	86,72	16,89
Week 48	Other	17	100,0	16	94,1	86,98	18,75
Week 72	Other	17	100,0	14	82,4	85,12	17,35
Week 24	Unknown	8	100,0	8	100,0	89,58	10,68
Week 48	Unknown	8	100,0	6	75,0	88,89	10,09
Week 72	Unknown	7	87,5	7	100,0	89,29	11,50

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBD

03JUN2024 17:05

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2

ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Distance Activities Subscale at Week 72

MODEL: descriptive

STUDY: GR41984

Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	470	86,4	145	30,9

Only patients with a value at baseline and Week 72 are used for analysis.

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBDA15_ITa24_30AUG2023_41984.xls

09JUL2024 16:05

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2

ENDPOINT: NEI VFQ-25 Vision Specific Social Functioning subscale over Time after Week 24

MODEL: --

STUDY: GR41984

Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in	%	with	%	Mean ²	SD(Mean)
Visit		study ¹		value ¹			
All							
Week 24	n/a	544	100,0	496	91,2	94,86	11,41
Week 48	n/a	542	99,6	492	90,8	94,79	11,58
Week 72	n/a	506	93,0	471	93,1	94,88	11,33
Gender							
Week 24	Male	267	100,0	249	93,3	96,54	9,18
Week 48	Male	266	99,6	248	93,2	95,77	10,30
Week 72	Male	252	94,4	230	91,3	95,27	10,90
Week 24 Female							
Week 48	Female	277	100,0	247	89,2	93,17	13,08
Week 48	Female	276	99,6	244	88,4	93,80	12,70
Week 72	Female	254	91,7	241	94,9	94,50	11,73
Age							
Week 24	<65 years	274	100,0	247	90,1	95,80	9,93
Week 48	<65 years	272	99,3	249	91,5	95,48	10,75
Week 72	<65 years	256	93,4	238	93,0	96,11	9,00
Week 24 >=65 years							
Week 48	>=65 years	270	100,0	249	92,2	93,93	12,66
Week 48	>=65 years	270	100,0	243	90,0	94,08	12,36
Week 72	>=65 years	250	92,6	233	93,2	93,62	13,19
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	160	89,4	93,28	12,92
Week 48	<=54 letters	178	99,4	162	91,0	93,44	13,08
Week 72	<=54 letters	162	90,5	153	94,4	93,46	14,06
Week 24 >=55 letters							
Week 24	>=55 letters	365	100,0	336	92,1	95,61	10,55

Week 48	>=55 letters	364	99,7	330	90,7	95,45	10,73
Week 72	>=55 letters	344	94,2	318	92,4	95,56	9,70
Geographic Region							
Week 24	Europe	150	100,0	139	92,7	93,71	13,49
Week 48	Europe	150	100,0	136	90,7	94,67	12,79
Week 72	Europe	138	92,0	133	96,4	93,80	13,47
Week 24	America	199	100,0	185	93,0	94,80	11,32
Week 48	America	198	99,5	179	90,4	94,97	11,59
Week 72	America	183	92,0	168	91,8	95,31	11,34
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	95,86	9,47
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	94,70	10,63
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	95,29	9,32
Race/ethnicity							
Week 24	White	338	100,0	315	93,2	94,60	12,04
Week 48	White	337	99,7	305	90,5	94,88	12,20
Week 72	White	311	92,0	293	94,2	95,26	11,59
Week 24	Asian	181	100,0	157	86,7	95,14	10,17
Week 48	Asian	180	99,4	165	91,7	94,39	10,90
Week 72	Asian	171	94,5	157	91,8	94,43	10,63
Week 24	Other	17	100,0	16	94,1	95,31	12,81
Week 48	Other	17	100,0	16	94,1	96,88	7,22
Week 72	Other	17	100,0	14	82,4	91,96	14,38
Week 24	Unknown	8	100,0	8	100,0	98,44	4,42
Week 48	Unknown	8	100,0	6	75,0	95,83	6,45
Week 72	Unknown	7	87,5	7	100,0	94,64	9,83

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBS
03JUN2024 17:19

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Social Functioning subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	468	86,0	59	12,6

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBSF15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:19

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Vision Specific Mental Health subscale over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	498	91,5	79,39	18,84
Week 48	n/a	542	99,6	492	90,8	80,82	18,53
Week 72	n/a	506	93,0	471	93,1	82,28	17,82
Gender							
Week 24	Male	267	100,0	250	93,6	81,48	16,98
Week 48	Male	266	99,6	248	93,2	82,51	17,61
Week 72	Male	252	94,4	230	91,3	84,82	16,39
Gender							
Week 24	Female	277	100,0	248	89,5	77,29	20,37
Week 48	Female	276	99,6	244	88,4	79,10	19,30
Week 72	Female	254	91,7	241	94,9	79,85	18,81
Age							
Week 24	<65 years	274	100,0	248	90,5	78,91	18,45
Week 48	<65 years	272	99,3	249	91,5	80,87	18,23
Week 72	<65 years	256	93,4	238	93,0	83,10	16,14
Age							
Week 24	>=65 years	270	100,0	250	92,6	79,88	19,25
Week 48	>=65 years	270	100,0	243	90,0	80,76	18,86
Week 72	>=65 years	250	92,6	233	93,2	81,44	19,39
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	75,62	21,12
Week 48	<=54 letters	178	99,4	162	91,0	76,77	21,17
Week 72	<=54 letters	162	90,5	153	94,4	79,62	19,58
Baseline BCVA ETDRS letter score							
Week 24	>=55 letters	365	100,0	336	92,1	81,21	17,38

Week 48	>=55 letters	364	99,7	330	90,7	82,80	16,76
Week 72	>=55 letters	344	94,2	318	92,4	83,56	16,80
Geographic Region							
Week 24	Europe	150	100,0	140	93,3	77,32	20,40
Week 48	Europe	150	100,0	136	90,7	80,47	16,83
Week 72	Europe	138	92,0	133	96,4	80,89	18,28
Week 24	America	199	100,0	186	93,5	80,38	18,36
Week 48	America	198	99,5	179	90,4	81,91	19,32
Week 72	America	183	92,0	168	91,8	83,18	17,82
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	80,01	18,01
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	79,98	18,99
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	82,46	17,50
Race/ethnicity							
Week 24	White	338	100,0	316	93,5	79,77	19,15
Week 48	White	337	99,7	305	90,5	81,17	18,29
Week 72	White	311	92,0	293	94,2	82,66	17,27
Week 24	Asian	181	100,0	158	87,3	78,84	18,17
Week 48	Asian	180	99,4	165	91,7	80,00	19,43
Week 72	Asian	171	94,5	157	91,8	81,73	18,45
Week 24	Other	17	100,0	16	94,1	75,39	22,88
Week 48	Other	17	100,0	16	94,1	83,59	12,68
Week 72	Other	17	100,0	14	82,4	82,14	23,88
Week 24	Unknown	8	100,0	8	100,0	83,59	10,53
Week 48	Unknown	8	100,0	6	75,0	78,13	20,82
Week 72	Unknown	7	87,5	7	100,0	78,57	16,08

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based o

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBM
03JUN2024 17:13

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Mental Health subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	470	86,4	180	38,3

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBMH15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:12

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Vision Specific Role Difficulties subscale over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	498	91,5	82,45	22,62
Week 48	n/a	542	99,6	492	90,8	84,20	22,12
Week 72	n/a	506	93,0	471	93,1	85,48	22,00
Gender							
Week 24	Male	267	100,0	250	93,6	84,25	21,72
Week 48	Male	266	99,6	248	93,2	85,64	21,95
Week 72	Male	252	94,4	230	91,3	88,59	19,13
Female							
Week 24	Female	277	100,0	248	89,5	80,65	23,40
Week 48	Female	276	99,6	244	88,4	82,74	22,24
Week 72	Female	254	91,7	241	94,9	82,52	24,10
Age							
Week 24	<65 years	274	100,0	248	90,5	83,06	22,22
Week 48	<65 years	272	99,3	249	91,5	86,65	20,73
Week 72	<65 years	256	93,4	238	93,0	86,87	19,75
>=65 years							
Week 24	>=65 years	270	100,0	250	92,6	81,85	23,04
Week 48	>=65 years	270	100,0	243	90,0	81,69	23,24
Week 72	>=65 years	250	92,6	233	93,2	84,07	24,04
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	79,48	25,37
Week 48	<=54 letters	178	99,4	162	91,0	77,93	25,37
Week 72	<=54 letters	162	90,5	153	94,4	81,45	25,53
>=55 letters							
Week 24	>=55 letters	365	100,0	336	92,1	83,89	21,06

Week 48	>=55 letters	364	99,7	330	90,7	87,27	19,66
Week 72	>=55 letters	344	94,2	318	92,4	87,42	19,83
Geographic Region							
Week 24	Europe	150	100,0	140	93,3	81,88	23,63
Week 48	Europe	150	100,0	136	90,7	82,26	23,15
Week 72	Europe	138	92,0	133	96,4	84,02	24,15
Week 24							
Week 24	America	199	100,0	186	93,5	85,89	21,02
Week 48	America	198	99,5	179	90,4	85,89	22,60
Week 72	America	183	92,0	168	91,8	87,13	21,69
Week 24							
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	79,22	23,07
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	83,97	20,77
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	85,00	20,51
Race/ethnicity							
Week 24	White	338	100,0	316	93,5	84,41	22,26
Week 48	White	337	99,7	305	90,5	84,39	23,11
Week 72	White	311	92,0	293	94,2	86,65	22,15
Week 24							
Week 24	Asian	181	100,0	158	87,3	77,85	23,18
Week 48	Asian	180	99,4	165	91,7	83,26	21,00
Week 72	Asian	171	94,5	157	91,8	83,60	21,50
Week 24							
Week 24	Other	17	100,0	16	94,1	83,59	22,23
Week 48	Other	17	100,0	16	94,1	88,28	15,46
Week 72	Other	17	100,0	14	82,4	81,25	26,29
Week 24							
Week 24	Unknown	8	100,0	8	100,0	93,75	11,57
Week 48	Unknown	8	100,0	6	75,0	89,58	16,61
Week 72	Unknown	7	87,5	7	100,0	87,50	17,68

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based o

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBR
03JUN2024 17:18

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Role Difficulties subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	470	86,4	165	35,1

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBRD15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:17

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Vision Specific Dependency subscale over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	498	91,5	91,52	17,80
Week 48	n/a	542	99,6	492	90,8	92,16	17,38
Week 72	n/a	506	93,0	471	93,1	92,00	17,58
Gender							
Week 24	Male	267	100,0	250	93,6	93,57	15,12
Week 48	Male	266	99,6	248	93,2	94,29	14,24
Week 72	Male	252	94,4	230	91,3	94,09	15,20
Female							
Week 24	Female	277	100,0	248	89,5	89,45	19,96
Week 48	Female	276	99,6	244	88,4	89,99	19,87
Week 72	Female	254	91,7	241	94,9	90,01	19,41
Age							
Week 24	<65 years	274	100,0	248	90,5	92,74	16,20
Week 48	<65 years	272	99,3	249	91,5	93,04	16,45
Week 72	<65 years	256	93,4	238	93,0	93,70	14,82
>=65 years							
Week 24	>=65 years	270	100,0	250	92,6	90,30	19,20
Week 48	>=65 years	270	100,0	243	90,0	91,26	18,27
Week 72	>=65 years	250	92,6	233	93,2	90,27	19,90
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	88,17	20,30
Week 48	<=54 letters	178	99,4	162	91,0	88,22	21,74
Week 72	<=54 letters	162	90,5	153	94,4	89,60	18,96
>=55 letters							
Week 24	>=55 letters	365	100,0	336	92,1	93,13	16,24

Week 48	>=55 letters	364	99,7	330	90,7	94,09	14,43
Week 72	>=55 letters	344	94,2	318	92,4	93,16	16,79
Geographic Region							
Week 24	Europe	150	100,0	140	93,3	91,79	17,26
Week 48	Europe	150	100,0	136	90,7	94,55	14,07
Week 72	Europe	138	92,0	133	96,4	91,17	19,88
Week 24	America	199	100,0	186	93,5	92,52	16,36
Week 48	America	198	99,5	179	90,4	92,27	15,58
Week 72	America	183	92,0	168	91,8	92,01	16,63
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	90,21	19,65
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	90,21	20,90
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	92,65	16,64
Race/ethnicity							
Week 24	White	338	100,0	316	93,5	92,43	17,11
Week 48	White	337	99,7	305	90,5	93,01	15,92
Week 72	White	311	92,0	293	94,2	92,26	18,01
Week 24	Asian	181	100,0	158	87,3	89,45	19,29
Week 48	Asian	180	99,4	165	91,7	90,40	20,30
Week 72	Asian	171	94,5	157	91,8	92,14	16,46
Week 24	Other	17	100,0	16	94,1	91,15	18,38
Week 48	Other	17	100,0	16	94,1	94,79	10,49
Week 72	Other	17	100,0	14	82,4	89,29	20,52
Week 24	Unknown	8	100,0	8	100,0	96,88	8,84
Week 48	Unknown	8	100,0	6	75,0	90,28	15,29
Week 72	Unknown	7	87,5	7	100,0	83,33	19,25

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based o

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBD
03JUN2024 17:21

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Dependency subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	470	86,4	103	21,9

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBDP15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:20

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Driving subscale over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	326	59,9	82,04	21,79
Week 48	n/a	542	99,6	331	61,1	80,36	23,72
Week 72	n/a	506	93,0	310	61,3	81,83	23,55
Gender							
Week 24	Male	267	100,0	209	78,3	84,97	20,05
Week 48	Male	266	99,6	204	76,7	83,66	20,81
Week 72	Male	252	94,4	191	75,8	85,03	21,11
Gender							
Week 24	Female	277	100,0	117	42,2	76,82	23,81
Week 48	Female	276	99,6	127	46,0	75,07	27,02
Week 72	Female	254	91,7	119	46,9	76,68	26,29
Age							
Week 24	<65 years	274	100,0	186	67,9	83,18	21,82
Week 48	<65 years	272	99,3	188	69,1	82,60	21,57
Week 72	<65 years	256	93,4	174	68,0	83,86	21,68
Age							
Week 24	>=65 years	270	100,0	140	51,9	80,54	21,75
Week 48	>=65 years	270	100,0	143	53,0	77,42	26,07
Week 72	>=65 years	250	92,6	136	54,4	79,23	25,59
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	105	58,7	78,02	24,63
Week 48	<=54 letters	178	99,4	108	60,7	73,84	27,60
Week 72	<=54 letters	162	90,5	98	60,5	77,81	25,12
Baseline BCVA ETDRS letter score							
Week 24	>=55 letters	365	100,0	221	60,5	83,96	20,09

Week 48	>=55 letters	364	99,7	223	61,3	83,52	20,94
Week 72	>=55 letters	344	94,2	212	61,6	83,69	22,61
Geographic Region							
Week 24	Europe	150	100,0	88	58,7	80,35	25,19
Week 48	Europe	150	100,0	93	62,0	76,30	29,42
Week 72	Europe	138	92,0	86	62,3	82,80	25,61
America							
Week 24	America	199	100,0	152	76,4	80,76	20,46
Week 48	America	198	99,5	148	74,7	81,93	19,89
Week 72	America	183	92,0	138	75,4	81,79	20,67
Asia Pacific (inc. Australia)							
Week 24	Asia Pacific (inc. Australia)	195	100,0	86	44,1	86,05	20,03
Week 48	Asia Pacific (inc. Australia)	194	99,5	90	46,4	81,99	22,67
Week 72	Asia Pacific (inc. Australia)	185	94,9	86	46,5	80,91	25,88
Race/ethnicity							
Week 24	White	338	100,0	228	67,5	81,12	22,65
Week 48	White	337	99,7	226	67,1	80,66	24,19
Week 72	White	311	92,0	212	68,2	82,82	22,98
Asian							
Week 24	Asian	181	100,0	79	43,6	84,07	20,38
Week 48	Asian	180	99,4	85	47,2	81,52	21,39
Week 72	Asian	171	94,5	80	46,8	81,15	23,75
Other							
Week 24	Other	17	100,0	13	76,5	88,46	14,65
Week 48	Other	17	100,0	14	82,4	79,17	21,37
Week 72	Other	17	100,0	11	64,7	81,82	17,00
Unknown							
Week 24	Unknown	8	100,0	6	75,0	76,39	18,57
Week 48	Unknown	8	100,0	6	75,0	55,56	34,02
Week 72	Unknown	7	87,5	7	100,0	59,52	38,32

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBD
03JUN2024 17:07

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Driving subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	297	54,6	91	30,6

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBDR15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:06

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Peripheral Vision subscale over Time after Week 24
 MODEL: --
 STUDY: GR41984
 Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	497	91,4	90,09	16,98
Week 48	n/a	542	99,6	492	90,8	90,96	16,80
Week 72	n/a	506	93,0	470	92,9	90,48	17,31
Gender							
Week 24	Male	267	100,0	249	93,3	92,17	14,16
Week 48	Male	266	99,6	248	93,2	92,84	14,46
Week 72	Male	252	94,4	229	90,9	91,59	16,32
Week 24 Female							
Week 48	Female	276	99,6	244	88,4	89,04	18,71
Week 72	Female	254	91,7	241	94,9	89,42	18,17
Age							
Week 24	<65 years	274	100,0	248	90,5	90,73	16,06
Week 48	<65 years	272	99,3	249	91,5	91,87	15,11
Week 72	<65 years	256	93,4	238	93,0	92,23	15,32
Week 24 >=65 years							
Week 48	>=65 years	270	100,0	243	90,0	90,02	18,34
Week 72	>=65 years	250	92,6	232	92,8	88,69	19,00
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	89,51	19,25
Week 48	<=54 letters	178	99,4	162	91,0	89,66	19,63
Week 72	<=54 letters	162	90,5	153	94,4	89,22	18,53
Week 24 >=55 letters							
Week 24	>=55 letters	365	100,0	335	91,8	90,37	15,80

Week 48	>=55 letters	364	99,7	330	90,7	91,59	15,20
Week 72	>=55 letters	344	94,2	317	92,2	91,09	16,68
Geographic Region							
Week 24	Europe	150	100,0	139	92,7	87,59	19,59
Week 48	Europe	150	100,0	136	90,7	89,89	17,84
Week 72	Europe	138	92,0	132	95,7	90,72	16,75
Week 24	America	199	100,0	186	93,5	91,13	15,44
Week 48	America	198	99,5	179	90,4	90,78	18,14
Week 72	America	183	92,0	168	91,8	89,14	18,88
Week 24	Asia Pacific (inc. Australia)	195	100,0	172	88,2	90,99	16,18
Week 48	Asia Pacific (inc. Australia)	194	99,5	177	91,2	91,95	14,43
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	91,62	16,08
Race/ethnicity							
Week 24	White	338	100,0	315	93,2	90,00	17,71
Week 48	White	337	99,7	305	90,5	90,98	17,58
Week 72	White	311	92,0	292	93,9	90,15	18,05
Week 24	Asian	181	100,0	158	87,3	90,35	15,64
Week 48	Asian	180	99,4	165	91,7	90,76	15,43
Week 72	Asian	171	94,5	157	91,8	91,56	15,39
Week 24	Other	17	100,0	16	94,1	89,06	18,19
Week 48	Other	17	100,0	16	94,1	93,75	14,43
Week 72	Other	17	100,0	14	82,4	87,50	21,37
Week 24	Unknown	8	100,0	8	100,0	90,63	12,94
Week 48	Unknown	8	100,0	6	75,0	87,50	20,92
Week 72	Unknown	7	87,5	7	100,0	85,71	19,67

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based o

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBF
03JUN2024 17:17

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Peripheral Vision subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	466	85,7	118	25,3

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBPV15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:16

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2

ENDPOINT: NEI VFQ-25 Color Vision subscale over Time after Week 24

MODEL: --

STUDY: GR41984

Compliance/Mean

		Faricimab (N=544)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	544	100,0	497	91,4	97,18	9,77
Week 48	n/a	542	99,6	489	90,2	97,65	8,29
Week 72	n/a	506	93,0	470	92,9	97,50	8,96
Gender							
Week 24	Male	267	100,0	250	93,6	97,70	8,51
Week 48	Male	266	99,6	246	92,5	98,17	7,61
Week 72	Male	252	94,4	230	91,3	97,93	7,65
Week 24	Female	277	100,0	247	89,2	96,66	10,88
Week 48	Female	276	99,6	243	88,0	97,12	8,92
Week 72	Female	254	91,7	240	94,5	97,08	10,06
Age							
Week 24	<65 years	274	100,0	247	90,1	97,98	8,49
Week 48	<65 years	272	99,3	246	90,4	98,37	6,58
Week 72	<65 years	256	93,4	237	92,6	98,10	7,74
Week 24	>=65 years	270	100,0	250	92,6	96,40	10,84
Week 48	>=65 years	270	100,0	243	90,0	96,91	9,68
Week 72	>=65 years	250	92,6	233	93,2	96,89	10,04
Baseline BCVA ETDRS letter score							
Week 24	<=54 letters	179	100,0	162	90,5	95,99	11,12
Week 48	<=54 letters	178	99,4	162	91,0	96,45	10,38
Week 72	<=54 letters	162	90,5	153	94,4	96,73	10,61
Week 24	>=55 letters	365	100,0	335	91,8	97,76	9,00

Week 48	>=55 letters	364	99,7	327	89,8	98,24	6,98
Week 72	>=55 letters	344	94,2	317	92,2	97,87	8,04
Geographic Region							
Week 24	Europe	150	100,0	140	93,3	96,79	10,32
Week 48	Europe	150	100,0	135	90,0	97,04	9,19
Week 72	Europe	138	92,0	132	95,7	96,59	10,60
Week 24	America	199	100,0	186	93,5	97,45	9,20
Week 48	America	198	99,5	178	89,9	97,89	8,35
Week 72	America	183	92,0	168	91,8	98,36	7,31
Week 24	Asia Pacific (inc. Australia)	195	100,0	171	87,7	97,22	9,94
Week 48	Asia Pacific (inc. Australia)	194	99,5	176	90,7	97,87	7,49
Week 72	Asia Pacific (inc. Australia)	185	94,9	170	91,9	97,35	9,04
Race/ethnicity							
Week 24	White	338	100,0	316	93,5	96,99	10,30
Week 48	White	337	99,7	303	89,9	97,77	8,21
Week 72	White	311	92,0	292	93,9	98,03	7,92
Week 24	Asian	181	100,0	157	86,7	97,61	8,39
Week 48	Asian	180	99,4	164	91,1	97,56	7,94
Week 72	Asian	171	94,5	157	91,8	96,82	10,10
Week 24	Other	17	100,0	16	94,1	95,31	13,60
Week 48	Other	17	100,0	16	94,1	95,31	13,60
Week 72	Other	17	100,0	14	82,4	92,86	15,28
Week 24	Unknown	8	100,0	8	100,0	100,00	0,00
Week 48	Unknown	8	100,0	6	75,0	100,00	0,00
Week 72	Unknown	7	87,5	7	100,0	100,00	0,00

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patient

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBCV_ITa24_

03JUN2024 17:08

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Color Vision subscale at Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

		Faricimab (N=544)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	468	86,0	44	9,4

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBCV15_ITa24_30AUG2023_41984.xls
 09JUL2024 16:08

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Composite Score over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	668	94,0	84,18	13,25
Week 48	n/a	710	99,9	640	90,1	84,13	13,61
Week 72	n/a	677	95,2	634	93,6	84,90	13,63
Gender							
Week 24	Male	382	100,0	356	93,2	86,20	11,53
Week 48	Male	381	99,7	342	89,8	86,26	12,14
Week 72	Male	362	94,8	343	94,8	86,86	12,49
Week 24	Female	329	100,0	312	94,8	81,87	14,66
Week 48	Female	329	100,0	298	90,6	81,70	14,78
Week 72	Female	315	95,7	291	92,4	82,59	14,55
Age							
Week 24	<65 years	312	100,0	289	92,6	85,01	12,38
Week 48	<65 years	312	100,0	277	88,8	85,63	12,29
Week 72	<65 years	299	95,8	284	95,0	86,62	11,75
Week 24	>=65 years	399	100,0	379	95,0	83,54	13,86
Week 48	>=65 years	398	99,7	363	91,2	82,99	14,45
Week 72	>=65 years	378	94,7	350	92,6	83,50	14,86
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	198	95,2	83,73	13,13
Week 48	35 - 54 letters	208	100,0	186	89,4	84,17	13,57
Week 72	35 - 54 letters	198	95,2	181	91,4	84,57	12,86
Week 24	<=34 letters	158	100,0	145	91,8	79,47	15,35
Week 48	<=34 letters	158	100,0	144	91,1	79,22	15,86
Week 72	<=34 letters	153	96,8	144	94,1	80,47	16,45
Week 24	>=55 letters	345	100,0	325	94,2	86,55	11,67
Week 48	>=55 letters	344	99,7	310	90,1	86,40	11,84
Week 72	>=55 letters	326	94,5	309	94,8	87,15	12,06
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	77,74	15,91
Week 48	<=23 letters	70	100,0	64	91,4	77,43	15,40
Week 72	<=23 letters	68	97,1	66	97,1	77,39	17,45
Week 24	>=24 letters	641	100,0	604	94,2	84,86	12,76

Week 48	>=24 letters	640	99,8	576	90,0	84,88	13,21
Week 72	>=24 letters	609	95,0	568	93,3	85,77	12,86
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	81,70	15,60
Week 48	Europe	217	100,0	197	90,8	81,17	15,22
Week 72	Europe	210	96,8	199	94,8	83,67	14,24
Week 24	America	285	100,0	270	94,7	85,12	12,56
Week 48	America	285	100,0	258	90,5	85,54	13,11
Week 72	America	274	96,1	252	92,0	85,22	14,36
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	85,45	11,04
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	85,33	11,96
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	85,79	11,79
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	84,02	14,03
Week 48	White	480	99,8	439	91,5	84,31	13,97
Week 72	White	462	96,0	427	92,4	84,89	14,53
Week 24	Asian	179	100,0	167	93,3	85,05	11,24
Week 48	Asian	179	100,0	157	87,7	83,98	12,98
Week 72	Asian	165	92,2	159	96,4	85,05	11,86
Week 24	Other	27	100,0	25	92,6	82,83	10,41
Week 48	Other	27	100,0	22	81,5	83,82	9,26
Week 72	Other	27	100,0	25	92,6	85,72	10,24
Week 24	Unknown	24	100,0	21	87,5	82,36	14,09
Week 48	Unknown	24	100,0	22	91,7	81,99	14,93
Week 72	Unknown	23	95,8	23	100,0	83,01	11,30
Baseline RVO status							
Week 24	CRVO	583	100,0	547	93,8	84,37	13,37
Week 48	CRVO	582	99,8	525	90,2	84,30	13,80
Week 72	CRVO	552	94,7	517	93,7	85,17	13,78
Week 24	HRVO	122	100,0	116	95,1	83,35	12,87
Week 48	HRVO	122	100,0	109	89,3	83,61	12,92
Week 72	HRVO	119	97,5	112	94,1	83,73	13,06
Week 24	Missing	6	100,0	5	83,3	82,49	10,02
Week 48	Missing	6	100,0	6	100,0	78,78	8,62
Week 72	Missing	6	100,0	5	83,3	83,28	11,10

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QBCSCORE_ITa24_29AUG2023_41986.xls

03JUN2024 17:06

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2

ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Composite Score at Week 72

MODEL: descriptive

STUDY: GR41986

Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	631	88,7	174	27,6

Only patients with a value at baseline and Week 72 are used for analysis.

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QBCSCORE15_ITa24_29AUG2023_41986.xls
09JUL2024 16:09

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 General Health subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	668	94,0	54,45	21,98
Week 48	n/a	710	99,9	640	90,1	54,30	23,51
Week 72	n/a	677	95,2	634	93,6	54,46	23,95
Gender							
Week 24	Male	382	100,0	356	93,2	57,58	21,61
Week 48	Male	381	99,7	342	89,8	57,89	22,49
Week 72	Male	362	94,8	343	94,8	57,00	23,92
Week 24	Female	329	100,0	312	94,8	50,88	21,90
Week 48	Female	329	100,0	298	90,6	50,17	24,01
Week 72	Female	315	95,7	291	92,4	51,46	23,67
Age							
Week 24	<65 years	312	100,0	289	92,6	54,41	21,45
Week 48	<65 years	312	100,0	277	88,8	56,86	22,98
Week 72	<65 years	299	95,8	284	95,0	55,63	24,58
Week 24	>=65 years	399	100,0	379	95,0	54,49	22,41
Week 48	>=65 years	398	99,7	363	91,2	52,34	23,75
Week 72	>=65 years	378	94,7	350	92,6	53,50	23,41
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	198	95,2	53,91	22,11
Week 48	35 - 54 letters	208	100,0	186	89,4	54,17	24,09
Week 72	35 - 54 letters	198	95,2	181	91,4	54,42	22,85
Week 24	<=34 letters	158	100,0	145	91,8	50,52	21,54
Week 48	<=34 letters	158	100,0	144	91,1	50,69	21,31
Week 72	<=34 letters	153	96,8	144	94,1	50,52	24,82
Week 24	>=55 letters	345	100,0	325	94,2	56,54	21,91
Week 48	>=55 letters	344	99,7	310	90,1	56,05	24,00
Week 72	>=55 letters	326	94,5	309	94,8	56,31	24,02
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	49,61	22,04
Week 48	<=23 letters	70	100,0	64	91,4	49,61	21,59
Week 72	<=23 letters	68	97,1	66	97,1	48,48	25,90
Week 24	>=24 letters	641	100,0	604	94,2	54,97	21,93

Week 48	>=24 letters	640	99,8	576	90,0	54,82	23,67
Week 72	>=24 letters	609	95,0	568	93,3	55,15	23,64
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	52,09	22,63
Week 48	Europe	217	100,0	197	90,8	52,41	24,56
Week 72	Europe	210	96,8	199	94,8	52,89	23,99
Week 24	America	285	100,0	270	94,7	58,89	20,10
Week 48	America	285	100,0	258	90,5	59,30	22,51
Week 72	America	274	96,1	252	92,0	59,62	22,52
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	50,77	22,83
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	49,32	22,49
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	49,04	24,50
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	56,87	21,97
Week 48	White	480	99,8	439	91,5	57,29	23,79
Week 72	White	462	96,0	427	92,4	57,44	23,46
Week 24	Asian	179	100,0	167	93,3	48,50	21,73
Week 48	Asian	179	100,0	157	87,7	46,34	20,96
Week 72	Asian	165	92,2	159	96,4	47,01	23,93
Week 24	Other	27	100,0	25	92,6	52,00	21,55
Week 48	Other	27	100,0	22	81,5	53,41	23,52
Week 72	Other	27	100,0	25	92,6	54,00	25,70
Week 24	Unknown	24	100,0	21	87,5	52,38	15,62
Week 48	Unknown	24	100,0	22	91,7	52,27	23,03
Week 72	Unknown	23	95,8	23	100,0	51,09	20,61
Baseline RVO status							
Week 24	CRVO	583	100,0	547	93,8	54,43	22,54
Week 48	CRVO	582	99,8	525	90,2	54,24	23,78
Week 72	CRVO	552	94,7	517	93,7	54,79	24,46
Week 24	HRVO	122	100,0	116	95,1	54,31	19,30
Week 48	HRVO	122	100,0	109	89,3	54,59	22,61
Week 72	HRVO	119	97,5	112	94,1	52,90	21,68
Week 24	Missing	6	100,0	5	83,3	60,00	22,36
Week 48	Missing	6	100,0	6	100,0	54,17	18,82
Week 72	Missing	6	100,0	5	83,3	55,00	20,92

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBGH_ITa24_29AUG2023_41986.xls

03JUN2024 17:15

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2

ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 General Health subscale at Week 72

MODEL: descriptive

STUDY: GR41986

Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	631	88,7	164	26,0

Only patients with a value at baseline and Week 72 are used for analysis.

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBGH15_ITa24_29AUG2023_41986.xls

09JUL2024 16:15

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 General Vision subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	668	94,0	69,43	15,07
Week 48	n/a	710	99,9	640	90,1	70,88	15,36
Week 72	n/a	677	95,2	634	93,6	71,20	15,50
Gender							
Week 24	Male	382	100,0	356	93,2	71,12	14,63
Week 48	Male	381	99,7	342	89,8	73,33	14,53
Week 72	Male	362	94,8	343	94,8	72,89	14,61
Week 24	Female	329	100,0	312	94,8	67,50	15,35
Week 48	Female	329	100,0	298	90,6	68,05	15,81
Week 72	Female	315	95,7	291	92,4	69,21	16,29
Age							
Week 24	<65 years	312	100,0	289	92,6	70,45	14,72
Week 48	<65 years	312	100,0	277	88,8	72,35	14,62
Week 72	<65 years	299	95,8	284	95,0	72,18	15,48
Week 24	>=65 years	399	100,0	379	95,0	68,65	15,29
Week 48	>=65 years	398	99,7	363	91,2	69,75	15,83
Week 72	>=65 years	378	94,7	350	92,6	70,40	15,49
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	198	95,2	69,19	15,16
Week 48	35 - 54 letters	208	100,0	186	89,4	70,22	15,03
Week 72	35 - 54 letters	198	95,2	181	91,4	70,94	15,26
Week 24	<=34 letters	158	100,0	145	91,8	65,52	14,62
Week 48	<=34 letters	158	100,0	144	91,1	66,81	15,90
Week 72	<=34 letters	153	96,8	144	94,1	68,19	14,27
Week 24	>=55 letters	345	100,0	325	94,2	71,32	14,90
Week 48	>=55 letters	344	99,7	310	90,1	73,16	14,91
Week 72	>=55 letters	326	94,5	309	94,8	72,75	16,01
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	64,06	16,40
Week 48	<=23 letters	70	100,0	64	91,4	65,31	17,18
Week 72	<=23 letters	68	97,1	66	97,1	66,06	15,68
Week 24	>=24 letters	641	100,0	604	94,2	70,00	14,82

Week 48	>=24 letters	640	99,8	576	90,0	71,49	15,03
Week 72	>=24 letters	609	95,0	568	93,3	71,80	15,38
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	69,26	15,45
Week 48	Europe	217	100,0	197	90,8	70,76	15,05
Week 72	Europe	210	96,8	199	94,8	70,95	15,13
Week 24	America	285	100,0	270	94,7	73,04	13,21
Week 48	America	285	100,0	258	90,5	74,88	14,07
Week 72	America	274	96,1	252	92,0	74,84	15,27
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	64,62	15,77
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	65,41	15,78
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	66,45	14,97
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	71,60	14,81
Week 48	White	480	99,8	439	91,5	73,39	14,15
Week 72	White	462	96,0	427	92,4	73,44	15,32
Week 24	Asian	179	100,0	167	93,3	62,51	14,26
Week 48	Asian	179	100,0	157	87,7	62,93	15,33
Week 72	Asian	165	92,2	159	96,4	64,65	14,62
Week 24	Other	27	100,0	25	92,6	74,40	13,56
Week 48	Other	27	100,0	22	81,5	72,73	19,07
Week 72	Other	27	100,0	25	92,6	73,60	14,97
Week 24	Unknown	24	100,0	21	87,5	71,43	11,95
Week 48	Unknown	24	100,0	22	91,7	75,45	16,25
Week 72	Unknown	23	95,8	23	100,0	72,17	13,13
Baseline RVO status							
Week 24	CRVO	583	100,0	547	93,8	69,32	15,22
Week 48	CRVO	582	99,8	525	90,2	70,67	15,45
Week 72	CRVO	552	94,7	517	93,7	71,10	15,64
Week 24	HRVO	122	100,0	116	95,1	69,66	14,56
Week 48	HRVO	122	100,0	109	89,3	71,74	14,96
Week 72	HRVO	119	97,5	112	94,1	71,25	15,13
Week 24	Missing	6	100,0	5	83,3	76,00	8,94
Week 48	Missing	6	100,0	6	100,0	73,33	16,33
Week 72	Missing	6	100,0	5	83,3	80,00	0,00

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBGV_ITa24_29AUG2023_41986.xls

03JUN2024 17:17

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 General Vision subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	631	88,7	307	48,7

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBGV15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:16

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Ocular Pain subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	668	94,0	87,95	16,63
Week 48	n/a	710	99,9	640	90,1	87,56	16,64
Week 72	n/a	677	95,2	634	93,6	88,41	15,61
Gender							
Week 24	Male	382	100,0	356	93,2	90,31	14,20
Week 48	Male	381	99,7	342	89,8	89,14	15,51
Week 72	Male	362	94,8	343	94,8	90,38	14,45
Week 24	Female	329	100,0	312	94,8	85,26	18,70
Week 48	Female	329	100,0	298	90,6	85,74	17,71
Week 72	Female	315	95,7	291	92,4	86,08	16,60
Age							
Week 24	<65 years	312	100,0	289	92,6	88,02	16,33
Week 48	<65 years	312	100,0	277	88,8	88,18	16,38
Week 72	<65 years	299	95,8	284	95,0	88,95	14,96
Week 24	>=65 years	399	100,0	379	95,0	87,90	16,88
Week 48	>=65 years	398	99,7	363	91,2	87,09	16,85
Week 72	>=65 years	378	94,7	350	92,6	87,96	16,12
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	198	95,2	87,56	17,83
Week 48	35 - 54 letters	208	100,0	186	89,4	88,51	16,02
Week 72	35 - 54 letters	198	95,2	181	91,4	88,88	14,84
Week 24	<=34 letters	158	100,0	145	91,8	87,59	15,76
Week 48	<=34 letters	158	100,0	144	91,1	84,11	17,38
Week 72	<=34 letters	153	96,8	144	94,1	86,11	17,12
Week 24	>=55 letters	345	100,0	325	94,2	88,35	16,29
Week 48	>=55 letters	344	99,7	310	90,1	88,59	16,50
Week 72	>=55 letters	326	94,5	309	94,8	89,20	15,25
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	89,65	14,70
Week 48	<=23 letters	70	100,0	64	91,4	83,59	18,75
Week 72	<=23 letters	68	97,1	66	97,1	87,12	16,98
Week 24	>=24 letters	641	100,0	604	94,2	87,77	16,83
Week 48	>=24 letters	640	99,8	576	90,0	88,00	16,35

Week 72	>=24 letters	609	95,0	568	93,3	88,56	15,45
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	84,24	20,46
Week 48	Europe	217	100,0	197	90,8	82,87	19,36
Week 72	Europe	210	96,8	199	94,8	85,74	17,59
America							
Week 24	America	285	100,0	270	94,7	89,49	14,98
Week 48	America	285	100,0	258	90,5	89,20	15,40
Week 72	America	274	96,1	252	92,0	90,18	14,39
Asia Pacific (inc. Australia)							
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	89,68	13,55
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	90,27	14,03
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	88,87	14,59
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	87,34	17,54
Week 48	White	480	99,8	439	91,5	87,16	17,06
Week 72	White	462	96,0	427	92,4	88,41	16,10
Asian							
Week 24	Asian	179	100,0	167	93,3	91,02	12,64
Week 48	Asian	179	100,0	157	87,7	90,05	14,28
Week 72	Asian	165	92,2	159	96,4	89,15	13,93
Other							
Week 24	Other	27	100,0	25	92,6	87,00	15,51
Week 48	Other	27	100,0	22	81,5	90,34	13,87
Week 72	Other	27	100,0	25	92,6	90,00	13,01
Unknown							
Week 24	Unknown	24	100,0	21	87,5	77,98	20,88
Week 48	Unknown	24	100,0	22	91,7	75,00	20,77
Week 72	Unknown	23	95,8	23	100,0	81,52	18,80
Baseline RVO status							
Week 24	CRVO	583	100,0	547	93,8	87,80	16,85
Week 48	CRVO	582	99,8	525	90,2	87,60	16,80
Week 72	CRVO	552	94,7	517	93,7	88,97	15,21
HRVO							
Week 24	HRVO	122	100,0	116	95,1	88,58	15,86
Week 48	HRVO	122	100,0	109	89,3	87,96	16,04
Week 72	HRVO	119	97,5	112	94,1	86,38	16,99
Missing							
Week 24	Missing	6	100,0	5	83,3	90,00	10,46
Week 48	Missing	6	100,0	6	100,0	77,08	12,29
Week 72	Missing	6	100,0	5	83,3	75,00	17,68

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBOP_ITa24_29AUG2023_41986.xls

03JUN2024 17:20

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Ocular Pain subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	631	88,7	118	18,7

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBOP15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:19

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Near Activities Subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	668	94,0	79,71	19,33
Week 48	n/a	710	99,9	640	90,1	79,77	19,38
Week 72	n/a	677	95,2	634	93,6	81,07	19,42
Gender							
Week 24	Male	382	100,0	356	93,2	80,91	18,23
Week 48	Male	381	99,7	342	89,8	82,08	17,84
Week 72	Male	362	94,8	343	94,8	82,82	18,47
Week 24	Female	329	100,0	312	94,8	78,34	20,45
Week 48	Female	329	100,0	298	90,6	77,11	20,73
Week 72	Female	315	95,7	291	92,4	79,01	20,34
Age							
Week 24	<65 years	312	100,0	289	92,6	81,03	18,60
Week 48	<65 years	312	100,0	277	88,8	81,69	18,98
Week 72	<65 years	299	95,8	284	95,0	82,97	17,88
Week 24	>=65 years	399	100,0	379	95,0	78,70	19,83
Week 48	>=65 years	398	99,7	363	91,2	78,29	19,59
Week 72	>=65 years	378	94,7	350	92,6	79,54	20,49
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	198	95,2	78,68	18,54
Week 48	35 - 54 letters	208	100,0	186	89,4	79,35	19,59
Week 72	35 - 54 letters	198	95,2	181	91,4	80,46	18,22
Week 24	<=34 letters	158	100,0	145	91,8	74,02	21,51
Week 48	<=34 letters	158	100,0	144	91,1	74,54	21,45
Week 72	<=34 letters	153	96,8	144	94,1	76,04	22,91
Week 24	>=55 letters	345	100,0	325	94,2	82,87	18,15
Week 48	>=55 letters	344	99,7	310	90,1	82,45	17,73
Week 72	>=55 letters	326	94,5	309	94,8	83,78	17,84
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	68,88	22,23
Week 48	<=23 letters	70	100,0	64	91,4	73,05	20,61
Week 72	<=23 letters	68	97,1	66	97,1	71,59	24,24
Week 24	>=24 letters	641	100,0	604	94,2	80,86	18,65

Week 48	>=24 letters	640	99,8	576	90,0	80,51	19,12
Week 72	>=24 letters	609	95,0	568	93,3	82,17	18,50
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	76,60	21,19
Week 48	Europe	217	100,0	197	90,8	77,88	19,93
Week 72	Europe	210	96,8	199	94,8	79,10	19,33
Week 24	America	285	100,0	270	94,7	80,20	18,58
Week 48	America	285	100,0	258	90,5	79,89	19,22
Week 72	America	274	96,1	252	92,0	81,53	20,06
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	82,26	17,93
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	81,60	18,93
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	82,58	18,55
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	78,86	19,93
Week 48	White	480	99,8	439	91,5	79,52	19,76
Week 72	White	462	96,0	427	92,4	80,61	20,18
Week 24	Asian	179	100,0	167	93,3	82,24	18,35
Week 48	Asian	179	100,0	157	87,7	80,44	19,71
Week 72	Asian	165	92,2	159	96,4	82,15	18,13
Week 24	Other	27	100,0	25	92,6	77,67	16,44
Week 48	Other	27	100,0	22	81,5	77,27	15,47
Week 72	Other	27	100,0	25	92,6	82,67	18,15
Week 24	Unknown	24	100,0	21	87,5	80,36	15,76
Week 48	Unknown	24	100,0	22	91,7	82,39	12,19
Week 72	Unknown	23	95,8	23	100,0	80,43	15,20
Baseline RVO status							
Week 24	CRVO	583	100,0	547	93,8	80,29	19,08
Week 48	CRVO	582	99,8	525	90,2	80,12	19,11
Week 72	CRVO	552	94,7	517	93,7	81,62	19,39
Week 24	HRVO	122	100,0	116	95,1	76,80	20,35
Week 48	HRVO	122	100,0	109	89,3	78,02	21,09
Week 72	HRVO	119	97,5	112	94,1	78,57	19,55
Week 24	Missing	6	100,0	5	83,3	83,33	19,54
Week 48	Missing	6	100,0	6	100,0	80,56	6,80
Week 72	Missing	6	100,0	5	83,3	80,00	19,18

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBNA_ITa24_29AUG2023_41986.xls

03JUN2024 17:08

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Near Activities Subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	631	88,7	250	39,6

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBNA15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:10

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Distance Activities Subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	668	94,0	84,81	17,53
Week 48	n/a	710	99,9	639	90,0	84,27	18,36
Week 72	n/a	677	95,2	634	93,6	84,85	18,35
Gender							
Week 24	Male	382	100,0	356	93,2	87,66	14,57
Week 48	Male	381	99,7	342	89,8	87,21	16,18
Week 72	Male	362	94,8	343	94,8	87,59	16,65
Week 24	Female	329	100,0	312	94,8	81,54	19,92
Week 48	Female	329	100,0	297	90,3	80,88	20,09
Week 72	Female	315	95,7	291	92,4	81,63	19,72
Age							
Week 24	<65 years	312	100,0	289	92,6	86,69	16,21
Week 48	<65 years	312	100,0	276	88,5	87,15	16,35
Week 72	<65 years	299	95,8	284	95,0	87,66	15,39
Week 24	>=65 years	399	100,0	379	95,0	83,37	18,37
Week 48	>=65 years	398	99,7	363	91,2	82,07	19,49
Week 72	>=65 years	378	94,7	350	92,6	82,57	20,18
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	198	95,2	85,75	16,80
Week 48	35 - 54 letters	208	100,0	186	89,4	85,28	17,65
Week 72	35 - 54 letters	198	95,2	181	91,4	84,88	17,95
Week 24	<=34 letters	158	100,0	145	91,8	78,13	21,17
Week 48	<=34 letters	158	100,0	143	90,5	77,33	21,11
Week 72	<=34 letters	153	96,8	144	94,1	78,50	21,98
Week 24	>=55 letters	345	100,0	325	94,2	87,21	15,35
Week 48	>=55 letters	344	99,7	310	90,1	86,85	16,59
Week 72	>=55 letters	326	94,5	309	94,8	87,80	15,88
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	76,50	20,17
Week 48	<=23 letters	70	100,0	64	91,4	74,74	21,57
Week 72	<=23 letters	68	97,1	66	97,1	72,60	23,29
Week 24	>=24 letters	641	100,0	604	94,2	85,69	17,01

Week 48	>=24 letters	640	99,8	575	89,8	85,33	17,68
Week 72	>=24 letters	609	95,0	568	93,3	86,27	17,16
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	83,27	20,41
Week 48	Europe	217	100,0	197	90,8	81,66	20,42
Week 72	Europe	210	96,8	199	94,8	84,63	19,47
Week 24	America	285	100,0	270	94,7	84,81	17,34
Week 48	America	285	100,0	257	90,2	84,55	17,56
Week 72	America	274	96,1	252	92,0	83,76	19,42
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	86,39	14,17
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	86,64	16,81
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	86,59	15,32
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	84,55	18,17
Week 48	White	480	99,8	438	91,3	83,93	18,68
Week 72	White	462	96,0	427	92,4	84,67	19,21
Week 24	Asian	179	100,0	167	93,3	86,23	14,84
Week 48	Asian	179	100,0	157	87,7	85,24	17,93
Week 72	Asian	165	92,2	159	96,4	85,61	15,97
Week 24	Other	27	100,0	25	92,6	80,83	22,02
Week 48	Other	27	100,0	22	81,5	85,23	14,70
Week 72	Other	27	100,0	25	92,6	85,17	14,59
Week 24	Unknown	24	100,0	21	87,5	83,73	17,62
Week 48	Unknown	24	100,0	22	91,7	82,95	18,98
Week 72	Unknown	23	95,8	23	100,0	82,61	21,75
Baseline RVO status							
Week 24	CRVO	583	100,0	547	93,8	85,12	17,25
Week 48	CRVO	582	99,8	524	90,0	84,53	18,66
Week 72	CRVO	552	94,7	517	93,7	84,90	18,84
Week 24	HRVO	122	100,0	116	95,1	83,33	18,76
Week 48	HRVO	122	100,0	109	89,3	83,33	17,16
Week 72	HRVO	119	97,5	112	94,1	84,38	16,31
Week 24	Missing	6	100,0	5	83,3	84,17	20,50
Week 48	Missing	6	100,0	6	100,0	78,47	13,54
Week 72	Missing	6	100,0	5	83,3	90,83	10,37

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBDA_ITa24_29AUG2023_41986.xls

03JUN2024 17:10

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Distance Activities Subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	629	88,5	218	34,7

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBDA15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:11

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Vision Specific Social Functioning subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	668	94,0	93,81	12,92
Week 48	n/a	710	99,9	639	90,0	93,09	14,14
Week 72	n/a	677	95,2	634	93,6	93,08	14,64
Gender							
Week 24	Male	382	100,0	356	93,2	94,73	10,59
Week 48	Male	381	99,7	342	89,8	94,23	12,57
Week 72	Male	362	94,8	343	94,8	93,48	14,46
Week 24	Female	329	100,0	312	94,8	92,75	15,10
Week 48	Female	329	100,0	297	90,3	91,79	15,67
Week 72	Female	315	95,7	291	92,4	92,61	14,87
Age							
Week 24	<65 years	312	100,0	289	92,6	94,46	11,95
Week 48	<65 years	312	100,0	276	88,5	94,34	12,98
Week 72	<65 years	299	95,8	284	95,0	95,11	11,06
Week 24	>=65 years	399	100,0	379	95,0	93,30	13,61
Week 48	>=65 years	398	99,7	363	91,2	92,15	14,91
Week 72	>=65 years	378	94,7	350	92,6	91,43	16,84
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	198	95,2	93,24	13,54
Week 48	35 - 54 letters	208	100,0	186	89,4	93,55	13,01
Week 72	35 - 54 letters	198	95,2	181	91,4	92,20	14,57
Week 24	<=34 letters	158	100,0	145	91,8	89,40	17,45
Week 48	<=34 letters	158	100,0	143	90,5	88,55	19,26
Week 72	<=34 letters	153	96,8	144	94,1	89,41	19,06
Week 24	>=55 letters	345	100,0	325	94,2	96,12	9,10
Week 48	>=55 letters	344	99,7	310	90,1	94,92	11,31
Week 72	>=55 letters	326	94,5	309	94,8	95,31	11,67
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	87,11	18,36
Week 48	<=23 letters	70	100,0	64	91,4	85,55	17,99
Week 72	<=23 letters	68	97,1	66	97,1	87,12	18,73
Week 24	>=24 letters	641	100,0	604	94,2	94,52	12,01
Week 48	>=24 letters	640	99,8	575	89,8	93,93	13,40

Week 72	>=24 letters	609	95,0	568	93,3	93,77	13,95
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	91,69	16,58
Week 48	Europe	217	100,0	197	90,8	90,99	16,31
Week 72	Europe	210	96,8	199	94,8	92,15	15,75
America							
Week 24	America	285	100,0	270	94,7	94,07	11,74
Week 48	America	285	100,0	257	90,2	93,24	14,27
Week 72	America	274	96,1	252	92,0	93,20	15,06
Asia Pacific (inc. Australia)							
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	95,64	9,42
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	95,14	10,82
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	93,92	12,69
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	93,46	13,65
Week 48	White	480	99,8	438	91,3	92,92	14,79
Week 72	White	462	96,0	427	92,4	92,92	15,43
Asian							
Week 24	Asian	179	100,0	167	93,3	94,91	10,55
Week 48	Asian	179	100,0	157	87,7	94,19	11,97
Week 72	Asian	165	92,2	159	96,4	93,55	13,18
Other							
Week 24	Other	27	100,0	25	92,6	94,00	10,90
Week 48	Other	27	100,0	22	81,5	89,77	16,65
Week 72	Other	27	100,0	25	92,6	93,50	12,56
Unknown							
Week 24	Unknown	24	100,0	21	87,5	92,26	16,04
Week 48	Unknown	24	100,0	22	91,7	92,05	12,53
Week 72	Unknown	23	95,8	23	100,0	92,39	11,76
Baseline RVO status							
Week 24	CRVO	583	100,0	547	93,8	93,94	12,58
Week 48	CRVO	582	99,8	524	90,0	93,18	14,15
Week 72	CRVO	552	94,7	517	93,7	93,13	14,95
HRVO							
Week 24	HRVO	122	100,0	116	95,1	93,21	14,60
Week 48	HRVO	122	100,0	109	89,3	93,35	13,77
Week 72	HRVO	119	97,5	112	94,1	92,75	13,49
Missing							
Week 24	Missing	6	100,0	5	83,3	92,50	11,18
Week 48	Missing	6	100,0	6	100,0	81,25	17,23
Week 72	Missing	6	100,0	5	83,3	95,00	6,85

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBSF_ITa24_29AUG2023_41986.xls

03JUN2024 17:25

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Social Functioning subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	631	88,7	118	18,7

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBSF15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:22

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Vision Specific Mental Health subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	668	94,0	76,73	20,89
Week 48	n/a	710	99,9	640	90,1	78,12	20,20
Week 72	n/a	677	95,2	634	93,6	79,43	20,20
Gender							
Week 24	Male	382	100,0	356	93,2	78,76	18,89
Week 48	Male	381	99,7	342	89,8	81,16	17,83
Week 72	Male	362	94,8	343	94,8	81,83	18,77
Week 24	Female	329	100,0	312	94,8	74,42	22,78
Week 48	Female	329	100,0	298	90,6	74,62	22,13
Week 72	Female	315	95,7	291	92,4	76,59	21,46
Age							
Week 24	<65 years	312	100,0	289	92,6	76,32	20,72
Week 48	<65 years	312	100,0	277	88,8	78,63	19,34
Week 72	<65 years	299	95,8	284	95,0	80,39	19,01
Week 24	>=65 years	399	100,0	379	95,0	77,04	21,05
Week 48	>=65 years	398	99,7	363	91,2	77,72	20,85
Week 72	>=65 years	378	94,7	350	92,6	78,64	21,11
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	198	95,2	74,49	21,56
Week 48	35 - 54 letters	208	100,0	186	89,4	76,31	21,72
Week 72	35 - 54 letters	198	95,2	181	91,4	78,31	21,44
Week 24	<=34 letters	158	100,0	145	91,8	72,16	22,74
Week 48	<=34 letters	158	100,0	144	91,1	74,57	20,35
Week 72	<=34 letters	153	96,8	144	94,1	74,48	22,30
Week 24	>=55 letters	345	100,0	325	94,2	80,13	19,03
Week 48	>=55 letters	344	99,7	310	90,1	80,85	18,82
Week 72	>=55 letters	326	94,5	309	94,8	82,38	17,83
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	71,48	23,41
Week 48	<=23 letters	70	100,0	64	91,4	75,78	19,18
Week 72	<=23 letters	68	97,1	66	97,1	72,16	23,57
Week 24	>=24 letters	641	100,0	604	94,2	77,29	20,55

Week 48	>=24 letters	640	99,8	576	90,0	78,37	20,31
Week 72	>=24 letters	609	95,0	568	93,3	80,27	19,62
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	74,08	22,37
Week 48	Europe	217	100,0	197	90,8	74,71	21,00
Week 72	Europe	210	96,8	199	94,8	77,70	20,14
Week 24	America	285	100,0	270	94,7	77,48	20,85
Week 48	America	285	100,0	258	90,5	80,33	19,70
Week 72	America	274	96,1	252	92,0	79,69	21,08
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	78,46	19,12
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	78,65	19,63
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	80,94	18,96
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	76,70	21,45
Week 48	White	480	99,8	439	91,5	78,77	20,01
Week 72	White	462	96,0	427	92,4	79,49	20,76
Week 24	Asian	179	100,0	167	93,3	77,51	19,76
Week 48	Asian	179	100,0	157	87,7	76,87	20,97
Week 72	Asian	165	92,2	159	96,4	79,83	19,13
Week 24	Other	27	100,0	25	92,6	76,00	17,18
Week 48	Other	27	100,0	22	81,5	75,85	14,60
Week 72	Other	27	100,0	25	92,6	80,75	18,30
Week 24	Unknown	24	100,0	21	87,5	72,02	22,06
Week 48	Unknown	24	100,0	22	91,7	76,14	23,36
Week 72	Unknown	23	95,8	23	100,0	73,91	19,28
Baseline RVO status							
Week 24	CRVO	583	100,0	547	93,8	77,24	20,54
Week 48	CRVO	582	99,8	525	90,2	78,57	19,96
Week 72	CRVO	552	94,7	517	93,7	79,92	20,08
Week 24	HRVO	122	100,0	116	95,1	74,68	22,42
Week 48	HRVO	122	100,0	109	89,3	76,43	20,88
Week 72	HRVO	119	97,5	112	94,1	77,23	20,77
Week 24	Missing	6	100,0	5	83,3	68,75	22,10
Week 48	Missing	6	100,0	6	100,0	68,75	27,67
Week 72	Missing	6	100,0	5	83,3	77,50	20,06

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBMH_ITa24_29AUG2023_41986.xls

03JUN2024 17:19

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Mental Health subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	631	88,7	261	41,4

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBMH15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:17

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Vision Specific Role Difficulties subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	667	93,8	80,12	24,33
Week 48	n/a	710	99,9	640	90,1	79,82	24,54
Week 72	n/a	677	95,2	634	93,6	81,51	23,83
Gender							
Week 24	Male	382	100,0	355	92,9	83,66	21,46
Week 48	Male	381	99,7	342	89,8	82,60	22,43
Week 72	Male	362	94,8	343	94,8	84,55	21,33
Week 24	Female	329	100,0	312	94,8	76,08	26,70
Week 48	Female	329	100,0	298	90,6	76,64	26,45
Week 72	Female	315	95,7	291	92,4	77,92	26,06
Age							
Week 24	<65 years	312	100,0	289	92,6	80,93	22,54
Week 48	<65 years	312	100,0	277	88,8	80,73	23,49
Week 72	<65 years	299	95,8	284	95,0	83,23	22,12
Week 24	>=65 years	399	100,0	378	94,7	79,50	25,63
Week 48	>=65 years	398	99,7	363	91,2	79,13	25,33
Week 72	>=65 years	378	94,7	350	92,6	80,11	25,08
Baseline BCVA ETRS letter score							
Week 24	35 - 54 letters	208	100,0	197	94,7	78,62	25,89
Week 48	35 - 54 letters	208	100,0	186	89,4	80,85	23,76
Week 72	35 - 54 letters	198	95,2	181	91,4	81,42	22,69
Week 24	<=34 letters	158	100,0	145	91,8	74,14	25,24
Week 48	<=34 letters	158	100,0	144	91,1	74,31	26,06
Week 72	<=34 letters	153	96,8	144	94,1	75,52	26,81
Week 24	>=55 letters	345	100,0	325	94,2	83,69	22,32
Week 48	>=55 letters	344	99,7	310	90,1	81,77	23,98
Week 72	>=55 letters	326	94,5	309	94,8	84,34	22,53
Baseline BCVA ETRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	74,02	25,03
Week 48	<=23 letters	70	100,0	64	91,4	71,68	26,47
Week 72	<=23 letters	68	97,1	66	97,1	72,54	27,05
Week 24	>=24 letters	641	100,0	603	94,1	80,76	24,19
Week 48	>=24 letters	640	99,8	576	90,0	80,73	24,18

Week 72	>=24 letters	609	95,0	568	93,3	82,55	23,23
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	75,43	26,83
Week 48	Europe	217	100,0	197	90,8	72,14	28,02
Week 72	Europe	210	96,8	199	94,8	77,32	24,94
Week 24	America	285	100,0	269	94,4	82,53	23,56
Week 48	America	285	100,0	258	90,5	84,35	22,25
Week 72	America	274	96,1	252	92,0	83,48	23,94
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	81,67	21,96
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	81,69	21,65
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	83,33	21,90
Race/ethnicity							
Week 24	White	481	100,0	454	94,4	79,27	25,44
Week 48	White	480	99,8	439	91,5	79,47	25,53
Week 72	White	462	96,0	427	92,4	81,06	24,77
Week 24	Asian	179	100,0	167	93,3	81,81	22,03
Week 48	Asian	179	100,0	157	87,7	80,97	22,09
Week 72	Asian	165	92,2	159	96,4	82,47	22,20
Week 24	Other	27	100,0	25	92,6	81,50	18,09
Week 48	Other	27	100,0	22	81,5	80,68	20,31
Week 72	Other	27	100,0	25	92,6	84,50	21,73
Week 24	Unknown	24	100,0	21	87,5	83,33	24,15
Week 48	Unknown	24	100,0	22	91,7	77,84	26,14
Week 72	Unknown	23	95,8	23	100,0	79,89	19,49
Baseline RVO status							
Week 24	CRVO	583	100,0	546	93,7	80,38	24,28
Week 48	CRVO	582	99,8	525	90,2	80,00	24,77
Week 72	CRVO	552	94,7	517	93,7	82,21	23,13
Week 24	HRVO	122	100,0	116	95,1	79,85	23,76
Week 48	HRVO	122	100,0	109	89,3	80,50	21,81
Week 72	HRVO	119	97,5	112	94,1	79,13	26,12
Week 24	Missing	6	100,0	5	83,3	57,50	37,08
Week 48	Missing	6	100,0	6	100,0	52,08	38,26
Week 72	Missing	6	100,0	5	83,3	62,50	35,36

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBRD_ITa24_29AUG2023_41986.xls

03JUN2024 17:23

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a >= 15-point Improvement from Baseline in NEI VFQ-25 Role Difficulties subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	631	88,7	232	36,8

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBRD15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:21

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Vision Specific Dependency subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	668	94,0	89,65	18,97
Week 48	n/a	710	99,9	640	90,1	89,17	19,95
Week 72	n/a	677	95,2	634	93,6	90,23	19,79
Gender							
Week 24	Male	382	100,0	356	93,2	92,51	15,64
Week 48	Male	381	99,7	342	89,8	91,50	18,40
Week 72	Male	362	94,8	343	94,8	92,86	18,04
Week 24	Female	329	100,0	312	94,8	86,38	21,73
Week 48	Female	329	100,0	298	90,6	86,49	21,31
Week 72	Female	315	95,7	291	92,4	87,14	21,30
Age							
Week 24	<65 years	312	100,0	289	92,6	90,77	18,46
Week 48	<65 years	312	100,0	277	88,8	90,94	17,90
Week 72	<65 years	299	95,8	284	95,0	93,05	16,59
Week 24	>=65 years	399	100,0	379	95,0	88,79	19,32
Week 48	>=65 years	398	99,7	363	91,2	87,81	21,31
Week 72	>=65 years	378	94,7	350	92,6	87,95	21,81
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	198	95,2	89,10	19,50
Week 48	35 - 54 letters	208	100,0	186	89,4	88,13	21,24
Week 72	35 - 54 letters	198	95,2	181	91,4	88,81	21,54
Week 24	<=34 letters	158	100,0	145	91,8	84,02	21,77
Week 48	<=34 letters	158	100,0	144	91,1	84,55	22,90
Week 72	<=34 letters	153	96,8	144	94,1	85,88	22,33
Week 24	>=55 letters	345	100,0	325	94,2	92,49	16,62
Week 48	>=55 letters	344	99,7	310	90,1	91,94	17,09
Week 72	>=55 letters	326	94,5	309	94,8	93,10	16,85
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	83,46	21,13
Week 48	<=23 letters	70	100,0	64	91,4	84,38	23,96
Week 72	<=23 letters	68	97,1	66	97,1	82,45	24,51
Week 24	>=24 letters	641	100,0	604	94,2	90,30	18,62

Week 48	>=24 letters	640	99,8	576	90,0	89,70	19,41
Week 72	>=24 letters	609	95,0	568	93,3	91,14	18,99
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	88,55	20,19
Week 48	Europe	217	100,0	197	90,8	87,77	21,34
Week 72	Europe	210	96,8	199	94,8	90,83	18,20
Week 24	America	285	100,0	270	94,7	90,15	18,63
Week 48	America	285	100,0	258	90,5	90,25	18,85
Week 72	America	274	96,1	252	92,0	89,32	21,59
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	90,09	18,15
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	89,14	19,94
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	90,85	18,90
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	90,09	18,62
Week 48	White	480	99,8	439	91,5	90,00	19,37
Week 72	White	462	96,0	427	92,4	90,22	20,05
Week 24	Asian	179	100,0	167	93,3	89,07	18,83
Week 48	Asian	179	100,0	157	87,7	87,47	21,11
Week 72	Asian	165	92,2	159	96,4	90,51	18,67
Week 24	Other	27	100,0	25	92,6	86,67	20,27
Week 48	Other	27	100,0	22	81,5	86,36	20,50
Week 72	Other	27	100,0	25	92,6	89,00	22,53
Week 24	Unknown	24	100,0	21	87,5	88,10	25,76
Week 48	Unknown	24	100,0	22	91,7	87,50	22,53
Week 72	Unknown	23	95,8	23	100,0	89,86	20,56
Baseline RVO status							
Week 24	CRVO	583	100,0	547	93,8	89,56	19,28
Week 48	CRVO	582	99,8	525	90,2	89,52	19,37
Week 72	CRVO	552	94,7	517	93,7	90,47	19,51
Week 24	HRVO	122	100,0	116	95,1	90,30	17,44
Week 48	HRVO	122	100,0	109	89,3	87,61	22,67
Week 72	HRVO	119	97,5	112	94,1	89,21	21,27
Week 24	Missing	6	100,0	5	83,3	83,33	20,41
Week 48	Missing	6	100,0	6	100,0	86,11	18,76
Week 72	Missing	6	100,0	5	83,3	88,33	16,24

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBDP_ITa24_29AUG2023_41986.xls

03JUN2024 17:26

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Dependency subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	631	88,7	183	29,0

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBDP15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:23

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Driving subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	443	62,3	77,72	26,13
Week 48	n/a	710	99,9	422	59,4	78,56	25,46
Week 72	n/a	677	95,2	420	62,0	79,05	25,39
Gender							
Week 24	Male	382	100,0	288	75,4	83,02	21,22
Week 48	Male	381	99,7	281	73,8	81,97	22,20
Week 72	Male	362	94,8	279	77,1	83,35	21,40
Week 24	Female	329	100,0	155	47,1	67,88	31,14
Week 48	Female	329	100,0	141	42,9	71,78	29,91
Week 72	Female	315	95,7	141	44,8	70,54	30,16
Age							
Week 24	<65 years	312	100,0	209	67,0	79,92	22,39
Week 48	<65 years	312	100,0	202	64,7	81,19	21,86
Week 72	<65 years	299	95,8	206	68,9	81,82	21,55
Week 24	>=65 years	399	100,0	234	58,6	75,75	28,97
Week 48	>=65 years	398	99,7	220	55,3	76,16	28,21
Week 72	>=65 years	378	94,7	214	56,6	76,38	28,40
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	130	62,5	77,31	25,82
Week 48	35 - 54 letters	208	100,0	124	59,6	78,73	25,03
Week 72	35 - 54 letters	198	95,2	121	61,1	78,37	23,27
Week 24	<=34 letters	158	100,0	86	54,4	68,46	30,93
Week 48	<=34 letters	158	100,0	82	51,9	71,29	31,02
Week 72	<=34 letters	153	96,8	85	55,6	72,79	30,34
Week 24	>=55 letters	345	100,0	227	65,8	81,46	23,41
Week 48	>=55 letters	344	99,7	216	62,8	81,23	22,84
Week 72	>=55 letters	326	94,5	214	65,6	81,91	23,99
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	39	55,7	64,96	31,66
Week 48	<=23 letters	70	100,0	38	54,3	65,68	31,62
Week 72	<=23 letters	68	97,1	41	60,3	65,24	32,75
Week 24	>=24 letters	641	100,0	404	63,0	78,95	25,24

Week 48	>=24 letters	640	99,8	384	60,0	79,84	24,46
Week 72	>=24 letters	609	95,0	379	62,2	80,54	24,04
Geographic Region							
Week 24	Europe	217	100,0	129	59,4	74,16	30,90
Week 48	Europe	217	100,0	121	55,8	75,86	28,71
Week 72	Europe	210	96,8	128	61,0	77,44	27,57
Week 24	America	285	100,0	208	73,0	77,62	24,95
Week 48	America	285	100,0	197	69,1	78,34	24,98
Week 72	America	274	96,1	194	70,8	77,71	26,30
Week 24	Asia Pacific (inc. Australia)	209	100,0	106	50,7	82,23	21,12
Week 48	Asia Pacific (inc. Australia)	208	99,5	104	50,0	82,13	21,92
Week 72	Asia Pacific (inc. Australia)	193	92,3	98	50,8	83,80	19,55
Race/ethnicity							
Week 24	White	481	100,0	326	67,8	77,28	27,07
Week 48	White	480	99,8	310	64,6	78,63	25,74
Week 72	White	462	96,0	306	66,2	78,53	26,29
Week 24	Asian	179	100,0	83	46,4	82,58	20,22
Week 48	Asian	179	100,0	81	45,3	79,58	22,88
Week 72	Asian	165	92,2	80	48,5	82,24	18,82
Week 24	Other	27	100,0	20	74,1	68,75	24,61
Week 48	Other	27	100,0	17	63,0	76,23	25,59
Week 72	Other	27	100,0	20	74,1	78,33	26,82
Week 24	Unknown	24	100,0	14	58,3	72,02	33,43
Week 48	Unknown	24	100,0	14	58,3	74,11	34,44
Week 72	Unknown	23	95,8	14	60,9	73,21	35,38
Baseline RVO status							
Week 24	CRVO	583	100,0	364	62,4	78,24	26,12
Week 48	CRVO	582	99,8	352	60,5	78,69	25,84
Week 72	CRVO	552	94,7	345	62,5	79,09	25,83
Week 24	HRVO	122	100,0	76	62,3	74,89	26,60
Week 48	HRVO	122	100,0	67	54,9	77,30	23,97
Week 72	HRVO	119	97,5	72	60,5	78,41	23,56
Week 24	Missing	6	100,0	3	50,0	86,11	4,81
Week 48	Missing	6	100,0	3	50,0	91,67	8,33
Week 72	Missing	6	100,0	3	50,0	88,89	19,25

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBDR_ITa24_29AUG2023_41986.xls

03JUN2024 17:12

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Driving subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	404	56,8	160	39,6

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBDR15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:12

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Peripheral Vision subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	668	94,0	88,06	18,64
Week 48	n/a	710	99,9	637	89,7	87,13	20,05
Week 72	n/a	677	95,2	634	93,6	87,15	19,43
Gender							
Week 24	Male	382	100,0	356	93,2	88,62	17,52
Week 48	Male	381	99,7	341	89,5	89,00	18,09
Week 72	Male	362	94,8	343	94,8	88,56	18,88
Week 24	Female	329	100,0	312	94,8	87,42	19,85
Week 48	Female	329	100,0	296	90,0	84,97	21,93
Week 72	Female	315	95,7	291	92,4	85,48	19,96
Age							
Week 24	<65 years	312	100,0	289	92,6	88,06	18,17
Week 48	<65 years	312	100,0	275	88,1	88,18	18,78
Week 72	<65 years	299	95,8	284	95,0	88,56	18,11
Week 24	>=65 years	399	100,0	379	95,0	88,06	19,01
Week 48	>=65 years	398	99,7	362	91,0	86,33	20,96
Week 72	>=65 years	378	94,7	350	92,6	86,00	20,39
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	198	95,2	87,75	19,47
Week 48	35 - 54 letters	208	100,0	186	89,4	87,77	19,67
Week 72	35 - 54 letters	198	95,2	181	91,4	87,85	17,99
Week 24	<=34 letters	158	100,0	145	91,8	83,62	21,73
Week 48	<=34 letters	158	100,0	143	90,5	79,72	24,64
Week 72	<=34 letters	153	96,8	144	94,1	81,25	23,00
Week 24	>=55 letters	345	100,0	325	94,2	90,23	16,16
Week 48	>=55 letters	344	99,7	308	89,5	90,18	16,85
Week 72	>=55 letters	326	94,5	309	94,8	89,48	17,87
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	80,08	23,22
Week 48	<=23 letters	70	100,0	64	91,4	76,17	25,75
Week 72	<=23 letters	68	97,1	66	97,1	78,79	22,89
Week 24	>=24 letters	641	100,0	604	94,2	88,91	17,90
Week 48	>=24 letters	640	99,8	573	89,5	88,35	18,95

Week 72	>=24 letters	609	95,0	568	93,3	88,12	18,77
Geographic Region							
Week 24	Europe	217	100,0	203	93,5	86,21	19,45
Week 48	Europe	217	100,0	197	90,8	83,88	21,66
Week 72	Europe	210	96,8	199	94,8	87,31	19,28
America							
Week 24	America	285	100,0	270	94,7	87,96	19,84
Week 48	America	285	100,0	255	89,5	87,06	20,79
Week 72	America	274	96,1	252	92,0	85,12	21,91
Asia Pacific (inc. Australia)							
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	90,13	15,71
Week 48	Asia Pacific (inc. Australia)	208	99,5	185	88,9	90,68	16,41
Week 72	Asia Pacific (inc. Australia)	193	92,3	183	94,8	89,75	15,31
Race/ethnicity							
Week 24	White	481	100,0	455	94,6	87,80	19,48
Week 48	White	480	99,8	436	90,8	86,53	20,70
Week 72	White	462	96,0	427	92,4	86,42	20,84
Asian							
Week 24	Asian	179	100,0	167	93,3	89,37	15,38
Week 48	Asian	179	100,0	157	87,7	89,01	17,98
Week 72	Asian	165	92,2	159	96,4	88,52	16,34
Other							
Week 24	Other	27	100,0	25	92,6	85,00	20,41
Week 48	Other	27	100,0	22	81,5	90,91	16,45
Week 72	Other	27	100,0	25	92,6	88,00	16,33
Unknown							
Week 24	Unknown	24	100,0	21	87,5	86,90	21,82
Week 48	Unknown	24	100,0	22	91,7	81,82	23,38
Week 72	Unknown	23	95,8	23	100,0	90,22	14,58
Baseline RVO status							
Week 24	CRVO	583	100,0	547	93,8	88,48	18,65
Week 48	CRVO	582	99,8	522	89,7	87,40	19,97
Week 72	CRVO	552	94,7	517	93,7	87,52	19,48
HRVO							
Week 24	HRVO	122	100,0	116	95,1	85,99	18,73
Week 48	HRVO	122	100,0	109	89,3	85,78	20,80
Week 72	HRVO	119	97,5	112	94,1	85,71	19,19
Missing							
Week 24	Missing	6	100,0	5	83,3	90,00	13,69
Week 48	Missing	6	100,0	6	100,0	87,50	13,69
Week 72	Missing	6	100,0	5	83,3	80,00	20,92

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBPV_ITa24_29AUG2023_41986.xls

03JUN2024 17:21

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Peripheral Vision subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	631	88,7	205	32,5

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBPV15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:20

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: NEI VFQ-25 Color Vision subscale over Time after Week 24
 MODEL: --
 STUDY: GR41986
 Compliance/Mean

		Faricimab (N=711)					
Name Visit	Level	Patients				Statistics	
		in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All							
Week 24	n/a	711	100,0	663	93,2	96,49	10,90
Week 48	n/a	710	99,9	636	89,6	96,15	12,19
Week 72	n/a	677	95,2	631	93,2	96,75	9,83
Gender							
Week 24	Male	382	100,0	352	92,1	96,59	10,96
Week 48	Male	381	99,7	339	89,0	96,24	12,56
Week 72	Male	362	94,8	342	94,5	97,00	9,19
Week 24	Female	329	100,0	311	94,5	96,38	10,86
Week 48	Female	329	100,0	297	90,3	96,04	11,77
Week 72	Female	315	95,7	289	91,7	96,45	10,54
Age							
Week 24	<65 years	312	100,0	289	92,6	97,06	9,99
Week 48	<65 years	312	100,0	276	88,5	97,55	9,58
Week 72	<65 years	299	95,8	283	94,6	97,70	8,37
Week 24	>=65 years	399	100,0	374	93,7	96,06	11,56
Week 48	>=65 years	398	99,7	360	90,5	95,07	13,78
Week 72	>=65 years	378	94,7	348	92,1	95,98	10,82
Baseline BCVA ETDRS letter score							
Week 24	35 - 54 letters	208	100,0	196	94,2	97,83	7,91
Week 48	35 - 54 letters	208	100,0	186	89,4	96,24	11,59
Week 72	35 - 54 letters	198	95,2	181	91,4	96,82	8,76
Week 24	<=34 letters	158	100,0	145	91,8	92,93	15,78
Week 48	<=34 letters	158	100,0	143	90,5	93,36	17,03
Week 72	<=34 letters	153	96,8	143	93,5	94,93	13,45
Week 24	>=55 letters	345	100,0	322	93,3	97,28	9,38
Week 48	>=55 letters	344	99,7	307	89,2	97,39	9,33
Week 72	>=55 letters	326	94,5	307	94,2	97,56	8,22
Baseline BCVA ETDRS letter score							
Week 24	<=23 letters	70	100,0	64	91,4	89,84	18,75
Week 48	<=23 letters	70	100,0	64	91,4	92,19	17,18
Week 72	<=23 letters	68	97,1	65	95,6	91,92	16,60
Week 24	>=24 letters	641	100,0	599	93,4	97,20	9,45

Week 48	>=24 letters	640	99,8	572	89,4	96,59	11,43
Week 72	>=24 letters	609	95,0	566	92,9	97,31	8,57
Geographic Region							
Week 24	Europe	217	100,0	201	92,6	94,15	14,14
Week 48	Europe	217	100,0	195	89,9	94,36	14,37
Week 72	Europe	210	96,8	198	94,3	96,21	11,19
Week 24	America	285	100,0	267	93,7	97,66	9,02
Week 48	America	285	100,0	257	90,2	97,47	10,05
Week 72	America	274	96,1	251	91,6	97,41	8,56
Week 24	Asia Pacific (inc. Australia)	209	100,0	195	93,3	97,31	8,93
Week 48	Asia Pacific (inc. Australia)	208	99,5	184	88,5	96,20	12,22
Week 72	Asia Pacific (inc. Australia)	193	92,3	182	94,3	96,43	9,88
Race/ethnicity							
Week 24	White	481	100,0	450	93,6	96,28	11,74
Week 48	White	480	99,8	436	90,8	96,62	11,31
Week 72	White	462	96,0	425	92,0	97,06	9,57
Week 24	Asian	179	100,0	167	93,3	97,01	8,59
Week 48	Asian	179	100,0	156	87,2	95,03	13,74
Week 72	Asian	165	92,2	158	95,8	96,04	10,38
Week 24	Other	27	100,0	25	92,6	97,00	8,29
Week 48	Other	27	100,0	22	81,5	95,45	12,53
Week 72	Other	27	100,0	25	92,6	97,00	8,29
Week 24	Unknown	24	100,0	21	87,5	96,43	11,95
Week 48	Unknown	24	100,0	22	91,7	95,45	16,61
Week 72	Unknown	23	95,8	23	100,0	95,65	12,28
Baseline RVO status							
Week 24	CRVO	583	100,0	544	93,3	96,32	11,37
Week 48	CRVO	582	99,8	522	89,7	96,22	11,75
Week 72	CRVO	552	94,7	514	93,1	96,69	9,93
Week 24	HRVO	122	100,0	114	93,4	97,15	8,65
Week 48	HRVO	122	100,0	108	88,5	95,60	14,43
Week 72	HRVO	119	97,5	112	94,1	96,88	9,57
Week 24	Missing	6	100,0	5	83,3	100,00	0,00
Week 48	Missing	6	100,0	6	100,0	100,00	0,00
Week 72	Missing	6	100,0	5	83,3	100,00	0,00

¹ in study: number of subjects in study at respective visit; % based on Week 24

with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit

² mean: descriptive statistics - absolute values

Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_mean_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_mean_a24_sg_PREST_W2472_QSBCV_ITa24_29AUG2023_41986.xls

03JUN2024 17:14

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients with a \geq 15-point Improvement from Baseline in NEI VFQ-25 Color Vision subscale at Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

		Faricimab (N=711)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	625	87,9	94	15,0

Only patients with a value at baseline and Week 72 are used for analysis.
 Observed assessments were used regardless of the occurrence of intercurrent events (Primary Estimand).

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_a24_PREST_W72_QSBCV15_ITa24_29AUG2023_41986.xls
 09JUL2024 16:14

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	343	63,9
Gender	Male	264	49,2	156	59,1
	Female	273	50,8	187	68,5
Age	<65 years	270	50,3	161	59,6
	>=65 years	267	49,7	182	68,2
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	109	61,9
	>=55 letters	361	67,2	234	64,8
Geographic Region	Europe	147	27,4	108	73,5
	America	197	36,7	114	57,9
	Asia Pacific (inc. Australia)	193	35,9	121	62,7
Race/ethnicity	White	332	61,8	213	64,2
	Asian	180	33,5	112	62,2
	Other	17	3,2	12	70,6
	Unknown	8	1,5	6	75,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:01

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Ocular AEs (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	158	29,4
Gender	Male	264	49,2	69	26,1
	Female	273	50,8	89	32,6
Age	<65 years	270	50,3	76	28,1
	>=65 years	267	49,7	82	30,7
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	52	29,5
	>=55 letters	361	67,2	106	29,4
Geographic Region	Europe	147	27,4	49	33,3
	America	197	36,7	55	27,9
	Asia Pacific (inc. Australia)	193	35,9	54	28,0
Race/ethnicity	White	332	61,8	101	30,4
	Asian	180	33,5	49	27,2
	Other	17	3,2	6	35,3
	Unknown	8	1,5	2	25,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_SOCAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:13

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Ocular AEs (Fellow Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	68	12,7
Gender	Male	264	49,2	22	8,3
	Female	273	50,8	46	16,8
Age	<65 years	270	50,3	26	9,6
	>=65 years	267	49,7	42	15,7
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	25	14,2
	>=55 letters	361	67,2	43	11,9
Geographic Region	Europe	147	27,4	21	14,3
	America	197	36,7	22	11,2
	Asia Pacific (inc. Australia)	193	35,9	25	13,0
Race/ethnicity	White	332	61,8	39	11,7
	Asian	180	33,5	23	12,8
	Other	17	3,2	5	29,4
	Unknown	8	1,5	1	12,5

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_FOCAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:11

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	121	22,5
Gender	Male	264	49,2	57	21,6
	Female	273	50,8	64	23,4
Age	<65 years	270	50,3	49	18,1
	>=65 years	267	49,7	72	27,0
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	38	21,6
	>=55 letters	361	67,2	83	23,0
Geographic Region	Europe	147	27,4	54	36,7
	America	197	36,7	47	23,9
	Asia Pacific (inc. Australia)	193	35,9	20	10,4
Race/ethnicity	White	332	61,8	93	28,0
	Asian	180	33,5	18	10,0
	Other	17	3,2	6	35,3
	Unknown	8	1,5	4	50,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_WMODAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:04

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	38	7,1
Gender	Male	264	49,2	13	4,9
	Female	273	50,8	25	9,2
Age	<65 years	270	50,3	14	5,2
	>=65 years	267	49,7	24	9,0
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	15	8,5
	>=55 letters	361	67,2	23	6,4
Geographic Region	Europe	147	27,4	12	8,2
	America	197	36,7	15	7,6
	Asia Pacific (inc. Australia)	193	35,9	11	5,7
Race/ethnicity	White	332	61,8	27	8,1
	Asian	180	33,5	8	4,4
	Other	17	3,2	3	17,6
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_WSEVAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:05

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	59	11,0
Gender	Male	264	49,2	27	10,2
	Female	273	50,8	32	11,7
Age	<65 years	270	50,3	24	8,9
	>=65 years	267	49,7	35	13,1
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	17	9,7
	>=55 letters	361	67,2	42	11,6
Geographic Region	Europe	147	27,4	20	13,6
	America	197	36,7	24	12,2
	Asia Pacific (inc. Australia)	193	35,9	15	7,8
Race/ethnicity	White	332	61,8	40	12,0
	Asian	180	33,5	13	7,2
	Other	17	3,2	5	29,4
	Unknown	8	1,5	1	12,5

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_SAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:08

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Ocular SAEs (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	7	1,3
Gender	Male	264	49,2	4	1,5
	Female	273	50,8	3	1,1
Age	<65 years	270	50,3	2	0,7
	>=65 years	267	49,7	5	1,9
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	2	1,1
	>=55 letters	361	67,2	5	1,4
Geographic Region	Europe	147	27,4	0	0,0
	America	197	36,7	5	2,5
	Asia Pacific (inc. Australia)	193	35,9	2	1,0
Race/ethnicity	White	332	61,8	5	1,5
	Asian	180	33,5	0	0,0
	Other	17	3,2	2	11,8
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_SOCSAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:16

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Ocular SAEs (Fellow Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	1	0,2
Gender	Male	264	49,2	0	0,0
	Female	273	50,8	1	0,4
Age	<65 years	270	50,3	0	0,0
	>=65 years	267	49,7	1	0,4
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	0	0,0
	>=55 letters	361	67,2	1	0,3
Geographic Region	Europe	147	27,4	1	0,7
	America	197	36,7	0	0,0
	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Race/ethnicity	White	332	61,8	1	0,3
	Asian	180	33,5	0	0,0
	Other	17	3,2	0	0,0
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_FOCSAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:14

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	5	0,9
Gender	Male	264	49,2	2	0,8
	Female	273	50,8	3	1,1
Age	<65 years	270	50,3	2	0,7
	>=65 years	267	49,7	3	1,1
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	2	1,1
	>=55 letters	361	67,2	3	0,8
Geographic Region	Europe	147	27,4	1	0,7
	America	197	36,7	2	1,0
	Asia Pacific (inc. Australia)	193	35,9	2	1,0
Race/ethnicity	White	332	61,8	2	0,6
	Asian	180	33,5	3	1,7
	Other	17	3,2	0	0,0
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_WDSTAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:10

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	3	0,6
Gender	Male	264	49,2	2	0,8
	Female	273	50,8	1	0,4
Age	<65 years	270	50,3	0	0,0
	>=65 years	267	49,7	3	1,1
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	1	0,6
	>=55 letters	361	67,2	2	0,6
Geographic Region	Europe	147	27,4	0	0,0
	America	197	36,7	3	1,5
	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Race/ethnicity	White	332	61,8	3	0,9
	Asian	180	33,5	0	0,0
	Other	17	3,2	0	0,0
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_DTHAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:07

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

All

			Paricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		n/a	537	100,0	5	0,9
Blood and lymphatic system disorders	Anaemia	n/a	537	100,0	2	0,4
Blood and lymphatic system disorders	Antiphospholipid syndrome	n/a	537	100,0	1	0,2
Blood and lymphatic system disorders	Coagulopathy	n/a	537	100,0	1	0,2
Blood and lymphatic system disorders	Macrocytosis	n/a	537	100,0	1	0,2
Cardiac disorders		n/a	537	100,0	21	3,9
Cardiac disorders	Acute myocardial infarction	n/a	537	100,0	1	0,2
Cardiac disorders	Angina pectoris	n/a	537	100,0	1	0,2
Cardiac disorders	Angina unstable	n/a	537	100,0	2	0,4
Cardiac disorders	Aortic valve incompetence	n/a	537	100,0	1	0,2
Cardiac disorders	Arrhythmia	n/a	537	100,0	2	0,4
Cardiac disorders	Arteriosclerosis coronary artery	n/a	537	100,0	2	0,4
Cardiac disorders	Atrial fibrillation	n/a	537	100,0	2	0,4
Cardiac disorders	Bundle branch block right	n/a	537	100,0	1	0,2
Cardiac disorders	Cardiac failure	n/a	537	100,0	2	0,4
Cardiac disorders	Cardiac failure congestive	n/a	537	100,0	1	0,2
Cardiac disorders	Cardiomegaly	n/a	537	100,0	1	0,2
Cardiac disorders	Coronary artery disease	n/a	537	100,0	2	0,4
Cardiac disorders	Dilatation ventricular	n/a	537	100,0	1	0,2
Cardiac disorders	Left atrial enlargement	n/a	537	100,0	1	0,2
Cardiac disorders	Left ventricular failure	n/a	537	100,0	1	0,2
Cardiac disorders	Mitral valve incompetence	n/a	537	100,0	1	0,2
Cardiac disorders	Myocardial fibrosis	n/a	537	100,0	1	0,2
Cardiac disorders	Myocardial infarction	n/a	537	100,0	4	0,7
Cardiac disorders	Myocardial ischaemia	n/a	537	100,0	1	0,2
Cardiac disorders	Pericarditis	n/a	537	100,0	1	0,2
Cardiac disorders	Sinus bradycardia	n/a	537	100,0	1	0,2
Cardiac disorders	Supraventricular extrasystoles	n/a	537	100,0	2	0,4
Cardiac disorders	Tricuspid valve incompetence	n/a	537	100,0	1	0,2
Congenital, familial and genetic disorders		n/a	537	100,0	3	0,6
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	n/a	537	100,0	1	0,2
Congenital, familial and genetic disorders	Corneal dystrophy	n/a	537	100,0	1	0,2
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	n/a	537	100,0	1	0,2
Ear and labyrinth disorders		n/a	537	100,0	10	1,9
Ear and labyrinth disorders	Cerumen impaction	n/a	537	100,0	2	0,4
Ear and labyrinth disorders	Ear disorder	n/a	537	100,0	1	0,2
Ear and labyrinth disorders	Hypoacusis	n/a	537	100,0	1	0,2
Ear and labyrinth disorders	Tinnitus	n/a	537	100,0	1	0,2
Ear and labyrinth disorders	Vertigo	n/a	537	100,0	3	0,6
Ear and labyrinth disorders	Vertigo positional	n/a	537	100,0	2	0,4
Endocrine disorders		n/a	537	100,0	3	0,6

Endocrine disorders	Hypothyroidism	n/a	537	100,0	3	0,6
Eye disorders		n/a	537	100,0	159	29,6
Eye disorders	Abnormal sensation in eye	n/a	537	100,0	1	0,2
Eye disorders	Asthenopia	n/a	537	100,0	1	0,2
Eye disorders	Blepharitis allergic	n/a	537	100,0	1	0,2
Eye disorders	Borderline glaucoma	n/a	537	100,0	1	0,2
Eye disorders	Cataract	n/a	537	100,0	22	4,1
Eye disorders	Cataract nuclear	n/a	537	100,0	1	0,2
Eye disorders	Cataract subcapsular	n/a	537	100,0	2	0,4
Eye disorders	Chalazion	n/a	537	100,0	2	0,4
Eye disorders	Conjunctival erosion	n/a	537	100,0	1	0,2
Eye disorders	Conjunctival haemorrhage	n/a	537	100,0	23	4,3
Eye disorders	Conjunctivitis allergic	n/a	537	100,0	3	0,6
Eye disorders	Conjunctivochalasis	n/a	537	100,0	1	0,2
Eye disorders	Corneal erosion	n/a	537	100,0	2	0,4
Eye disorders	Corneal infiltrates	n/a	537	100,0	1	0,2
Eye disorders	Corneal opacity	n/a	537	100,0	1	0,2
Eye disorders	Cystoid macular oedema	n/a	537	100,0	6	1,1
Eye disorders	Dacryostenosis acquired	n/a	537	100,0	1	0,2
Eye disorders	Dermatochalasis	n/a	537	100,0	1	0,2
Eye disorders	Diplopia	n/a	537	100,0	1	0,2
Eye disorders	Dry age-related macular degeneration	n/a	537	100,0	1	0,2
Eye disorders	Dry eye	n/a	537	100,0	10	1,9
Eye disorders	Entropion	n/a	537	100,0	1	0,2
Eye disorders	Epi-retinal membrane	n/a	537	100,0	10	1,9
Eye disorders	Episcleritis	n/a	537	100,0	1	0,2
Eye disorders	Erythema of eyelid	n/a	537	100,0	1	0,2
Eye disorders	Eye allergy	n/a	537	100,0	1	0,2
Eye disorders	Eye discharge	n/a	537	100,0	2	0,4
Eye disorders	Eye irritation	n/a	537	100,0	1	0,2
Eye disorders	Eye pain	n/a	537	100,0	3	0,6
Eye disorders	Eye pruritus	n/a	537	100,0	2	0,4
Eye disorders	Eyelid oedema	n/a	537	100,0	1	0,2
Eye disorders	Eyelid pain	n/a	537	100,0	1	0,2
Eye disorders	Eyelid ptosis	n/a	537	100,0	1	0,2
Eye disorders	Glaucoma	n/a	537	100,0	4	0,7
Eye disorders	Iridocyclitis	n/a	537	100,0	2	0,4
Eye disorders	Iritis	n/a	537	100,0	2	0,4
Eye disorders	Keratitis	n/a	537	100,0	2	0,4
Eye disorders	Lacrimation increased	n/a	537	100,0	3	0,6
Eye disorders	Macular ischaemia	n/a	537	100,0	1	0,2
Eye disorders	Macular oedema	n/a	537	100,0	17	3,2
Eye disorders	Maculopathy	n/a	537	100,0	1	0,2
Eye disorders	Narrow anterior chamber angle	n/a	537	100,0	1	0,2
Eye disorders	Normal tension glaucoma	n/a	537	100,0	1	0,2
Eye disorders	Ocular discomfort	n/a	537	100,0	2	0,4
Eye disorders	Ocular hypertension	n/a	537	100,0	2	0,4
Eye disorders	Ocular vascular disorder	n/a	537	100,0	1	0,2
Eye disorders	Optic disc haemorrhage	n/a	537	100,0	1	0,2
Eye disorders	Optic disc vascular disorder	n/a	537	100,0	1	0,2
Eye disorders	Periorbital pain	n/a	537	100,0	1	0,2
Eye disorders	Photopsia	n/a	537	100,0	1	0,2
Eye disorders	Posterior capsule opacification	n/a	537	100,0	2	0,4
Eye disorders	Pterygium	n/a	537	100,0	1	0,2
Eye disorders	Punctate keratitis	n/a	537	100,0	1	0,2
Eye disorders	Retinal aneurysm	n/a	537	100,0	2	0,4

Eye disorders	Retinal artery embolism	n/a	537	100,0	1	0,2
Eye disorders	Retinal collateral vessels	n/a	537	100,0	1	0,2
Eye disorders	Retinal cyst	n/a	537	100,0	4	0,7
Eye disorders	Retinal exudates	n/a	537	100,0	3	0,6
Eye disorders	Retinal haemorrhage	n/a	537	100,0	10	1,9
Eye disorders	Retinal ischaemia	n/a	537	100,0	5	0,9
Eye disorders	Retinal neovascularisation	n/a	537	100,0	2	0,4
Eye disorders	Retinal oedema	n/a	537	100,0	1	0,2
Eye disorders	Retinal tear	n/a	537	100,0	3	0,6
Eye disorders	Retinal thickening	n/a	537	100,0	1	0,2
Eye disorders	Retinal vascular disorder	n/a	537	100,0	1	0,2
Eye disorders	Retinal vein occlusion	n/a	537	100,0	21	3,9
Eye disorders	Retinopathy hypertensive	n/a	537	100,0	1	0,2
Eye disorders	Rhegmatogenous retinal detachment	n/a	537	100,0	1	0,2
Eye disorders	Swelling of eyelid	n/a	537	100,0	1	0,2
Eye disorders	Tractional retinal detachment	n/a	537	100,0	1	0,2
Eye disorders	Trichiasis	n/a	537	100,0	1	0,2
Eye disorders	Vision blurred	n/a	537	100,0	4	0,7
Eye disorders	Visual acuity reduced	n/a	537	100,0	6	1,1
Eye disorders	Visual field defect	n/a	537	100,0	1	0,2
Eye disorders	Vitreoretinal traction syndrome	n/a	537	100,0	2	0,4
Eye disorders	Vitreous degeneration	n/a	537	100,0	1	0,2
Eye disorders	Vitreous detachment	n/a	537	100,0	21	3,9
Eye disorders	Vitreous floaters	n/a	537	100,0	10	1,9
Eye disorders	Vitreous haemorrhage	n/a	537	100,0	2	0,4
Eye disorders	Vitritis	n/a	537	100,0	1	0,2
Gastrointestinal disorders		n/a	537	100,0	34	6,3
Gastrointestinal disorders	Abdominal pain	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Abdominal pain upper	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Chronic gastritis	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Colitis	n/a	537	100,0	3	0,6
Gastrointestinal disorders	Constipation	n/a	537	100,0	2	0,4
Gastrointestinal disorders	Diarrhoea	n/a	537	100,0	4	0,7
Gastrointestinal disorders	Erosive duodenitis	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Functional gastrointestinal disorder	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Gastric haemorrhage	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Gastric polyps	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Gastritis	n/a	537	100,0	4	0,7
Gastrointestinal disorders	Gastrooesophageal reflux disease	n/a	537	100,0	6	1,1
Gastrointestinal disorders	Gingival pain	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Haemorrhoids	n/a	537	100,0	2	0,4
Gastrointestinal disorders	Hyperchlorhydria	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Large intestine polyp	n/a	537	100,0	4	0,7
Gastrointestinal disorders	Mesenteric vein thrombosis	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Nausea	n/a	537	100,0	3	0,6
Gastrointestinal disorders	Oesophagitis	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Pancreatitis acute	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Toothache	n/a	537	100,0	4	0,7
Gastrointestinal disorders	Vomiting	n/a	537	100,0	3	0,6
General disorders and administration site conditions		n/a	537	100,0	14	2,6
General disorders and administration site conditions	Asthenia	n/a	537	100,0	2	0,4
General disorders and administration site conditions	Chest discomfort	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Death	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Fatigue	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Gait disturbance	n/a	537	100,0	1	0,2

General disorders and administration site conditions	Illness	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Influenza like illness	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Oedema	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Pain	n/a	537	100,0	3	0,6
General disorders and administration site conditions	Peripheral swelling	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Physical deconditioning	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Pyrexia	n/a	537	100,0	3	0,6
General disorders and administration site conditions	Vascular stent stenosis	n/a	537	100,0	1	0,2
Hepatobiliary disorders		n/a	537	100,0	9	1,7
Hepatobiliary disorders	Bile duct stone	n/a	537	100,0	1	0,2
Hepatobiliary disorders	Cholecystitis chronic	n/a	537	100,0	1	0,2
Hepatobiliary disorders	Cholelithiasis	n/a	537	100,0	4	0,7
Hepatobiliary disorders	Hepatic cyst	n/a	537	100,0	1	0,2
Hepatobiliary disorders	Hepatic failure	n/a	537	100,0	1	0,2
Hepatobiliary disorders	Hepatic function abnormal	n/a	537	100,0	1	0,2
Hepatobiliary disorders	Hepatic steatosis	n/a	537	100,0	1	0,2
Immune system disorders		n/a	537	100,0	5	0,9
Immune system disorders	Allergic oedema	n/a	537	100,0	1	0,2
Immune system disorders	Allergy to plants	n/a	537	100,0	1	0,2
Immune system disorders	Hypersensitivity	n/a	537	100,0	2	0,4
Immune system disorders	Seasonal allergy	n/a	537	100,0	1	0,2
Infections and infestations		n/a	537	100,0	146	27,2
Infections and infestations	Borrelia infection	n/a	537	100,0	1	0,2
Infections and infestations	Bronchitis	n/a	537	100,0	6	1,1
Infections and infestations	COVID-19	n/a	537	100,0	58	10,8
Infections and infestations	Cellulitis	n/a	537	100,0	3	0,6
Infections and infestations	Conjunctivitis	n/a	537	100,0	5	0,9
Infections and infestations	Coronavirus infection	n/a	537	100,0	1	0,2
Infections and infestations	Cystitis	n/a	537	100,0	2	0,4
Infections and infestations	Dermatophytosis of nail	n/a	537	100,0	1	0,2
Infections and infestations	Ear infection	n/a	537	100,0	2	0,4
Infections and infestations	Furuncle	n/a	537	100,0	1	0,2
Infections and infestations	Gastroenteritis	n/a	537	100,0	5	0,9
Infections and infestations	Gastroenteritis viral	n/a	537	100,0	2	0,4
Infections and infestations	Gastrointestinal infection	n/a	537	100,0	2	0,4
Infections and infestations	Gingival abscess	n/a	537	100,0	1	0,2
Infections and infestations	Groin abscess	n/a	537	100,0	1	0,2
Infections and infestations	Herpes zoster	n/a	537	100,0	3	0,6
Infections and infestations	Hordeolum	n/a	537	100,0	3	0,6
Infections and infestations	Influenza	n/a	537	100,0	9	1,7
Infections and infestations	Intestinal sepsis	n/a	537	100,0	1	0,2
Infections and infestations	Lower respiratory tract infection	n/a	537	100,0	1	0,2
Infections and infestations	Nail infection	n/a	537	100,0	1	0,2
Infections and infestations	Nasopharyngitis	n/a	537	100,0	17	3,2
Infections and infestations	Oral herpes	n/a	537	100,0	1	0,2
Infections and infestations	Otitis media	n/a	537	100,0	2	0,4
Infections and infestations	Otitis media acute	n/a	537	100,0	1	0,2
Infections and infestations	Pelvic inflammatory disease	n/a	537	100,0	1	0,2
Infections and infestations	Periodontitis	n/a	537	100,0	1	0,2
Infections and infestations	Pharyngitis	n/a	537	100,0	2	0,4
Infections and infestations	Pneumonia	n/a	537	100,0	5	0,9
Infections and infestations	Post-acute COVID-19 syndrome	n/a	537	100,0	1	0,2
Infections and infestations	Postoperative wound infection	n/a	537	100,0	2	0,4
Infections and infestations	Pulpitis dental	n/a	537	100,0	1	0,2

Infections and infestations	Pyelonephritis	n/a	537	100,0	1	0,2
Infections and infestations	Respiratory tract infection	n/a	537	100,0	4	0,7
Infections and infestations	Rhinitis	n/a	537	100,0	1	0,2
Infections and infestations	Rotavirus infection	n/a	537	100,0	1	0,2
Infections and infestations	Sepsis	n/a	537	100,0	1	0,2
Infections and infestations	Sinusitis	n/a	537	100,0	2	0,4
Infections and infestations	Suspected COVID-19	n/a	537	100,0	9	1,7
Infections and infestations	Tinea cruris	n/a	537	100,0	1	0,2
Infections and infestations	Tinea pedis	n/a	537	100,0	1	0,2
Infections and infestations	Tonsillitis	n/a	537	100,0	2	0,4
Infections and infestations	Tooth infection	n/a	537	100,0	3	0,6
Infections and infestations	Tracheitis	n/a	537	100,0	1	0,2
Infections and infestations	Upper respiratory tract infection	n/a	537	100,0	16	3,0
Infections and infestations	Urinary tract infection	n/a	537	100,0	4	0,7
Infections and infestations	Viral infection	n/a	537	100,0	2	0,4
Infections and infestations	Vulvovaginal candidiasis	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications		n/a	537	100,0	42	7,8
Injury, poisoning and procedural complications	Arthropod bite	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Back injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Burns third degree	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Chillblains	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Clavicle fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Comminuted fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Contusion	n/a	537	100,0	6	1,1
Injury, poisoning and procedural complications	Corneal abrasion	n/a	537	100,0	2	0,4
Injury, poisoning and procedural complications	Eye injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Facial bones fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Fall	n/a	537	100,0	14	2,6
Injury, poisoning and procedural complications	Femur fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Foot fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Foreign body in eye	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Head injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Hip fracture	n/a	537	100,0	2	0,4
Injury, poisoning and procedural complications	Immunisation reaction	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Joint injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Ligament sprain	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Limb injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Medication error	n/a	537	100,0	2	0,4
Injury, poisoning and procedural complications	Meniscus injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Muscle strain	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Radius fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Skin abrasion	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Skin injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Skin laceration	n/a	537	100,0	2	0,4
Injury, poisoning and procedural complications	Spinal column injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Sternal fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Subdural haematoma	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Thermal burn	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Tooth fracture	n/a	537	100,0	2	0,4
Injury, poisoning and procedural complications	Ulna fracture	n/a	537	100,0	2	0,4
Investigations		n/a	537	100,0	34	6,3
Investigations	Blood glucose increased	n/a	537	100,0	1	0,2
Investigations	Blood potassium decreased	n/a	537	100,0	1	0,2
Investigations	Blood pressure increased	n/a	537	100,0	3	0,6
Investigations	Blood sodium decreased	n/a	537	100,0	1	0,2

Investigations	Glomerular filtration rate decreased	n/a	537	100,0	1	0,2
Investigations	Intraocular pressure increased	n/a	537	100,0	21	3,9
Investigations	Platelet count increased	n/a	537	100,0	1	0,2
Investigations	SARS-CoV-2 test positive	n/a	537	100,0	2	0,4
Investigations	Troponin increased	n/a	537	100,0	1	0,2
Investigations	Weight decreased	n/a	537	100,0	1	0,2
Investigations	White blood cell count decreased	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders		n/a	537	100,0	27	5,0
Metabolism and nutrition disorders	Dehydration	n/a	537	100,0	2	0,4
Metabolism and nutrition disorders	Diabetes mellitus	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Folate deficiency	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Gout	n/a	537	100,0	2	0,4
Metabolism and nutrition disorders	Hypercholesterolaemia	n/a	537	100,0	9	1,7
Metabolism and nutrition disorders	Hyperglycaemia	n/a	537	100,0	2	0,4
Metabolism and nutrition disorders	Hyperhomocysteinaemia	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Hyperkalaemia	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Hyperlipidaemia	n/a	537	100,0	4	0,7
Metabolism and nutrition disorders	Hyperuricaemia	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Hypoproteinaemia	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Obesity	n/a	537	100,0	2	0,4
Metabolism and nutrition disorders	Type 2 diabetes mellitus	n/a	537	100,0	3	0,6
Metabolism and nutrition disorders	Vitamin B12 deficiency	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Vitamin D deficiency	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders		n/a	537	100,0	59	11,0
Musculoskeletal and connective tissue disorders	Arthralgia	n/a	537	100,0	7	1,3
Musculoskeletal and connective tissue disorders	Arthritis	n/a	537	100,0	3	0,6
Musculoskeletal and connective tissue disorders	Back pain	n/a	537	100,0	10	1,9
Musculoskeletal and connective tissue disorders	Bone disorder	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Bursitis	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Exostosis	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Fibromyalgia	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	n/a	537	100,0	3	0,6
Musculoskeletal and connective tissue disorders	Joint swelling	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Muscle contracture	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Muscle spasms	n/a	537	100,0	3	0,6
Musculoskeletal and connective tissue disorders	Muscular weakness	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Myalgia	n/a	537	100,0	5	0,9
Musculoskeletal and connective tissue disorders	Neck pain	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Osteoarthritis	n/a	537	100,0	8	1,5
Musculoskeletal and connective tissue disorders	Osteopenia	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Osteoporosis	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Pain in extremity	n/a	537	100,0	5	0,9
Musculoskeletal and connective tissue disorders	Plantar fasciitis	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Rheumatoid arthritis	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	n/a	537	100,0	4	0,7
Musculoskeletal and connective tissue disorders	Spinal pain	n/a	537	100,0	5	0,9
Musculoskeletal and connective tissue disorders	Tendon disorder	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Tenosynovitis	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Vertebral foraminal stenosis	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	537	100,0	7	1,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bowen's disease	n/a	537	100,0	1	0,2

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lung neoplasm	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	n/a	537	100,0	1	0,2
Nervous system disorders		n/a	537	100,0	47	8,8
Nervous system disorders	Carotid arteriosclerosis	n/a	537	100,0	1	0,2
Nervous system disorders	Carotid artery stenosis	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebral atrophy	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebral haematoma	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebral infarction	n/a	537	100,0	2	0,4
Nervous system disorders	Cerebral thrombosis	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebrovascular accident	n/a	537	100,0	2	0,4
Nervous system disorders	Cervical radiculopathy	n/a	537	100,0	1	0,2
Nervous system disorders	Cognitive disorder	n/a	537	100,0	1	0,2
Nervous system disorders	Dementia Alzheimer's type	n/a	537	100,0	1	0,2
Nervous system disorders	Diabetic neuropathy	n/a	537	100,0	1	0,2
Nervous system disorders	Disturbance in attention	n/a	537	100,0	1	0,2
Nervous system disorders	Dizziness	n/a	537	100,0	4	0,7
Nervous system disorders	Epilepsy	n/a	537	100,0	1	0,2
Nervous system disorders	Headache	n/a	537	100,0	10	1,9
Nervous system disorders	Hypertensive encephalopathy	n/a	537	100,0	1	0,2
Nervous system disorders	Hypoaesthesia	n/a	537	100,0	1	0,2
Nervous system disorders	Intracranial aneurysm	n/a	537	100,0	1	0,2
Nervous system disorders	Ischaemic stroke	n/a	537	100,0	2	0,4
Nervous system disorders	Loss of consciousness	n/a	537	100,0	1	0,2
Nervous system disorders	Memory impairment	n/a	537	100,0	1	0,2
Nervous system disorders	Migraine	n/a	537	100,0	1	0,2
Nervous system disorders	Multiple sclerosis	n/a	537	100,0	1	0,2
Nervous system disorders	Myelopathy	n/a	537	100,0	1	0,2
Nervous system disorders	Narcolepsy	n/a	537	100,0	1	0,2
Nervous system disorders	Neuropathy peripheral	n/a	537	100,0	2	0,4
Nervous system disorders	Ophthalmic migraine	n/a	537	100,0	1	0,2
Nervous system disorders	Presyncope	n/a	537	100,0	1	0,2
Nervous system disorders	Sciatica	n/a	537	100,0	5	0,9
Nervous system disorders	Sinus headache	n/a	537	100,0	1	0,2
Nervous system disorders	Syncope	n/a	537	100,0	2	0,4
Nervous system disorders	Tension headache	n/a	537	100,0	2	0,4
Nervous system disorders	White matter lesion	n/a	537	100,0	1	0,2
Product issues		n/a	537	100,0	1	0,2
Product issues	Device malfunction	n/a	537	100,0	1	0,2
Psychiatric disorders		n/a	537	100,0	9	1,7
Psychiatric disorders	Anxiety	n/a	537	100,0	2	0,4
Psychiatric disorders	Confusional state	n/a	537	100,0	2	0,4
Psychiatric disorders	Delirium	n/a	537	100,0	1	0,2
Psychiatric disorders	Depression	n/a	537	100,0	2	0,4
Psychiatric disorders	Insomnia	n/a	537	100,0	2	0,4
Psychiatric disorders	Somatic symptom disorder	n/a	537	100,0	1	0,2
Renal and urinary disorders		n/a	537	100,0	14	2,6
Renal and urinary disorders	Acute kidney injury	n/a	537	100,0	2	0,4
Renal and urinary disorders	Chronic kidney disease	n/a	537	100,0	2	0,4

Renal and urinary disorders	Diabetic nephropathy	n/a	537	100,0	1	0,2
Renal and urinary disorders	Haematuria	n/a	537	100,0	1	0,2
Renal and urinary disorders	Nephrolithiasis	n/a	537	100,0	2	0,4
Renal and urinary disorders	Renal colic	n/a	537	100,0	1	0,2
Renal and urinary disorders	Renal cyst	n/a	537	100,0	4	0,7
Renal and urinary disorders	Renal mass	n/a	537	100,0	1	0,2
Renal and urinary disorders	Urinary incontinence	n/a	537	100,0	1	0,2
Reproductive system and breast disorders		n/a	537	100,0	5	0,9
Reproductive system and breast disorders	Benign prostatic hyperplasia	n/a	537	100,0	3	0,6
Reproductive system and breast disorders	Erectile dysfunction	n/a	537	100,0	2	0,4
Reproductive system and breast disorders	Prostatitis	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders		n/a	537	100,0	20	3,7
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	537	100,0	2	0,4
Respiratory, thoracic and mediastinal disorders	Cough	n/a	537	100,0	3	0,6
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	537	100,0	2	0,4
Respiratory, thoracic and mediastinal disorders	Emphysema	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Epistaxis	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Hypoventilation	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Lung disorder	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Lung hyperinflation	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary fibrosis	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary mass	n/a	537	100,0	2	0,4
Respiratory, thoracic and mediastinal disorders	Respiratory failure	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	n/a	537	100,0	2	0,4
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	n/a	537	100,0	2	0,4
Skin and subcutaneous tissue disorders		n/a	537	100,0	12	2,2
Skin and subcutaneous tissue disorders	Actinic keratosis	n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders	Dermatitis	n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders	Dermatitis contact	n/a	537	100,0	2	0,4
Skin and subcutaneous tissue disorders	Eczema	n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders	Miliaria	n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders	Pemphigoid	n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders	Pruritus	n/a	537	100,0	2	0,4
Skin and subcutaneous tissue disorders	Rash	n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders	Seborrhoeic dermatitis	n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders	Skin ulcer	n/a	537	100,0	1	0,2
Social circumstances		n/a	537	100,0	1	0,2
Social circumstances	Joint prosthesis user	n/a	537	100,0	1	0,2
Surgical and medical procedures		n/a	537	100,0	5	0,9
Surgical and medical procedures	Knee arthroplasty	n/a	537	100,0	1	0,2
Surgical and medical procedures	Large intestinal polypectomy	n/a	537	100,0	1	0,2
Surgical and medical procedures	Mole excision	n/a	537	100,0	1	0,2
Surgical and medical procedures	Shoulder arthroplasty	n/a	537	100,0	1	0,2
Surgical and medical procedures	Transurethral prostatectomy	n/a	537	100,0	1	0,2

Vascular disorders		n/a	537	100,0	38	7,1
Vascular disorders	Aortic stenosis	n/a	537	100,0	1	0,2
Vascular disorders	Arteriosclerosis	n/a	537	100,0	4	0,7
Vascular disorders	Brachiocephalic arteriosclerosis	n/a	537	100,0	1	0,2
Vascular disorders	Diabetic vascular disorder	n/a	537	100,0	1	0,2
Vascular disorders	Hypertension	n/a	537	100,0	23	4,3
Vascular disorders	Hypertensive crisis	n/a	537	100,0	2	0,4
Vascular disorders	Hypotension	n/a	537	100,0	3	0,6
Vascular disorders	Ischaemic limb pain	n/a	537	100,0	1	0,2
Vascular disorders	Orthostatic hypotension	n/a	537	100,0	1	0,2
Vascular disorders	Varicose vein	n/a	537	100,0	1	0,2
Vascular disorders	Vascular occlusion	n/a	537	100,0	1	0,2
Vascular disorders	Venous occlusion	n/a	537	100,0	1	0,2
Vascular disorders	Venous thrombosis limb	n/a	537	100,0	1	0,2

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_AE_WK72_SEa24_30AUG2023_41984.xls
26APR2024 17:45

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Any AEs

MODEL: Unstratified Analysis

STUDY: GR41984

Descriptive Analysis (Safety) after Week 24

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=537)			
			Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		Male	264	49.2	4	1.5
Blood and lymphatic system disorders		Female	273	50.8	1	0.4
Blood and lymphatic system disorders	Anaemia	Male	264	49.2	2	0.8
Blood and lymphatic system disorders	Anaemia	Female	273	50.8	0	0.0
Blood and lymphatic system disorders	Antiphospholipid syndrome	Male	264	49.2	0	0.0
Blood and lymphatic system disorders	Antiphospholipid syndrome	Female	273	50.8	1	0.4
Blood and lymphatic system disorders	Coagulopathy	Male	264	49.2	1	0.4
Blood and lymphatic system disorders	Coagulopathy	Female	273	50.8	0	0.0
Blood and lymphatic system disorders	Macrocytosis	Male	264	49.2	1	0.4
Blood and lymphatic system disorders	Macrocytosis	Female	273	50.8	0	0.0
Cardiac disorders		Male	264	49.2	10	3.8
Cardiac disorders		Female	273	50.8	11	4.0
Cardiac disorders	Acute myocardial infarction	Male	264	49.2	1	0.4
Cardiac disorders	Acute myocardial infarction	Female	273	50.8	0	0.0
Cardiac disorders	Angina pectoris	Male	264	49.2	1	0.4
Cardiac disorders	Angina pectoris	Female	273	50.8	0	0.0
Cardiac disorders	Angina unstable	Male	264	49.2	2	0.8
Cardiac disorders	Angina unstable	Female	273	50.8	0	0.0
Cardiac disorders	Aortic valve incompetence	Male	264	49.2	1	0.4
Cardiac disorders	Aortic valve incompetence	Female	273	50.8	0	0.0
Cardiac disorders	Arrhythmia	Male	264	49.2	0	0.0
Cardiac disorders	Arrhythmia	Female	273	50.8	2	0.7
Cardiac disorders	Arteriosclerosis coronary artery	Male	264	49.2	1	0.4
Cardiac disorders	Arteriosclerosis coronary artery	Female	273	50.8	1	0.4
Cardiac disorders	Atrial fibrillation	Male	264	49.2	1	0.4
Cardiac disorders	Atrial fibrillation	Female	273	50.8	1	0.4
Cardiac disorders	Bundle branch block right	Male	264	49.2	1	0.4
Cardiac disorders	Bundle branch block right	Female	273	50.8	0	0.0
Cardiac disorders	Cardiac failure	Male	264	49.2	1	0.4
Cardiac disorders	Cardiac failure	Female	273	50.8	1	0.4
Cardiac disorders	Cardiac failure congestive	Male	264	49.2	0	0.0
Cardiac disorders	Cardiac failure congestive	Female	273	50.8	1	0.4
Cardiac disorders	Cardiomegaly	Male	264	49.2	1	0.4
Cardiac disorders	Cardiomegaly	Female	273	50.8	0	0.0
Cardiac disorders	Coronary artery disease	Male	264	49.2	2	0.8
Cardiac disorders	Coronary artery disease	Female	273	50.8	0	0.0
Cardiac disorders	Dilatation ventricular	Male	264	49.2	1	0.4
Cardiac disorders	Dilatation ventricular	Female	273	50.8	0	0.0
Cardiac disorders	Left atrial enlargement	Male	264	49.2	1	0.4
Cardiac disorders	Left atrial enlargement	Female	273	50.8	0	0.0
Cardiac disorders	Left ventricular failure	Male	264	49.2	1	0.4
Cardiac disorders	Left ventricular failure	Female	273	50.8	0	0.0
Cardiac disorders	Mitral valve incompetence	Male	264	49.2	1	0.4
Cardiac disorders	Mitral valve incompetence	Female	273	50.8	0	0.0
Cardiac disorders	Myocardial fibrosis	Male	264	49.2	1	0.4
Cardiac disorders	Myocardial fibrosis	Female	273	50.8	0	0.0
Cardiac disorders	Myocardial infarction	Male	264	49.2	1	0.4
Cardiac disorders	Myocardial infarction	Female	273	50.8	3	1.1
Cardiac disorders	Myocardial ischaemia	Male	264	49.2	0	0.0
Cardiac disorders	Myocardial ischaemia	Female	273	50.8	1	0.4
Cardiac disorders	Pericarditis	Male	264	49.2	0	0.0
Cardiac disorders	Pericarditis	Female	273	50.8	1	0.4
Cardiac disorders	Sinus bradycardia	Male	264	49.2	1	0.4
Cardiac disorders	Sinus bradycardia	Female	273	50.8	0	0.0
Cardiac disorders	Supraventricular extrasystoles	Male	264	49.2	2	0.8
Cardiac disorders	Supraventricular extrasystoles	Female	273	50.8	0	0.0
Cardiac disorders	Tricuspid valve incompetence	Male	264	49.2	1	0.4
Cardiac disorders	Tricuspid valve incompetence	Female	273	50.8	0	0.0
Congenital, familial and genetic disorders		Male	264	49.2	1	0.4
Congenital, familial and genetic disorders		Female	273	50.8	2	0.7
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Male	264	49.2	1	0.4
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Female	273	50.8	0	0.0
Congenital, familial and genetic disorders	Corneal dystrophy	Male	264	49.2	0	0.0
Congenital, familial and genetic disorders	Corneal dystrophy	Female	273	50.8	1	0.4
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Male	264	49.2	0	0.0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Female	273	50.8	1	0.4
Ear and labyrinth disorders		Male	264	49.2	1	0.4
Ear and labyrinth disorders		Female	273	50.8	9	3.3
Ear and labyrinth disorders	Cerumen impaction	Male	264	49.2	1	0.4
Ear and labyrinth disorders	Cerumen impaction	Female	273	50.8	1	0.4
Ear and labyrinth disorders	Ear disorder	Male	264	49.2	0	0.0
Ear and labyrinth disorders	Ear disorder	Female	273	50.8	1	0.4
Ear and labyrinth disorders	Hypoaacusis	Male	264	49.2	0	0.0
Ear and labyrinth disorders	Hypoaacusis	Female	273	50.8	1	0.4
Ear and labyrinth disorders	Tinnitus	Male	264	49.2	0	0.0
Ear and labyrinth disorders	Tinnitus	Female	273	50.8	1	0.4
Ear and labyrinth disorders	Vertigo	Male	264	49.2	0	0.0
Ear and labyrinth disorders	Vertigo	Female	273	50.8	3	1.1

Ear and labyrinth disorders	Vertigo positional	Male	264	49,2	0	0,0
Ear and labyrinth disorders	Vertigo positional	Female	273	50,8	2	0,7
Endocrine disorders		Male	264	49,2	0	0,0
Endocrine disorders		Female	273	50,8	3	1,1
Endocrine disorders	Hypothyroidism	Male	264	49,2	0	0,0
Endocrine disorders	Hypothyroidism	Female	273	50,8	3	1,1
Eye disorders		Male	264	49,2	69	26,1
Eye disorders		Female	273	50,8	90	33,0
Eye disorders	Abnormal sensation in eye	Male	264	49,2	0	0,0
Eye disorders	Abnormal sensation in eye	Female	273	50,8	1	0,4
Eye disorders	Asthenopia	Male	264	49,2	0	0,0
Eye disorders	Asthenopia	Female	273	50,8	1	0,4
Eye disorders	Blepharitis allergic	Male	264	49,2	0	0,0
Eye disorders	Blepharitis allergic	Female	273	50,8	1	0,4
Eye disorders	Borderline glaucoma	Male	264	49,2	0	0,0
Eye disorders	Borderline glaucoma	Female	273	50,8	1	0,4
Eye disorders	Cataract	Male	264	49,2	7	2,7
Eye disorders	Cataract	Female	273	50,8	15	5,5
Eye disorders	Cataract nuclear	Male	264	49,2	0	0,0
Eye disorders	Cataract nuclear	Female	273	50,8	1	0,4
Eye disorders	Cataract subcapsular	Male	264	49,2	1	0,4
Eye disorders	Cataract subcapsular	Female	273	50,8	1	0,4
Eye disorders	Chalazion	Male	264	49,2	1	0,4
Eye disorders	Chalazion	Female	273	50,8	1	0,4
Eye disorders	Conjunctival erosion	Male	264	49,2	1	0,4
Eye disorders	Conjunctival erosion	Female	273	50,8	0	0,0
Eye disorders	Conjunctival haemorrhage	Male	264	49,2	7	2,7
Eye disorders	Conjunctival haemorrhage	Female	273	50,8	16	5,9
Eye disorders	Conjunctivitis allergic	Male	264	49,2	1	0,4
Eye disorders	Conjunctivitis allergic	Female	273	50,8	2	0,7
Eye disorders	Conjunctivochalasis	Male	264	49,2	0	0,0
Eye disorders	Conjunctivochalasis	Female	273	50,8	1	0,4
Eye disorders	Corneal erosion	Male	264	49,2	2	0,8
Eye disorders	Corneal erosion	Female	273	50,8	0	0,0
Eye disorders	Corneal infiltrates	Male	264	49,2	1	0,4
Eye disorders	Corneal infiltrates	Female	273	50,8	0	0,0
Eye disorders	Corneal opacity	Male	264	49,2	1	0,4
Eye disorders	Corneal opacity	Female	273	50,8	0	0,0
Eye disorders	Cystoid macular oedema	Male	264	49,2	3	1,1
Eye disorders	Cystoid macular oedema	Female	273	50,8	3	1,1
Eye disorders	Dacryostenosis acquired	Male	264	49,2	1	0,4
Eye disorders	Dacryostenosis acquired	Female	273	50,8	0	0,0
Eye disorders	Dermatochalasis	Male	264	49,2	1	0,4
Eye disorders	Dermatochalasis	Female	273	50,8	0	0,0
Eye disorders	Diplopia	Male	264	49,2	0	0,0
Eye disorders	Diplopia	Female	273	50,8	1	0,4
Eye disorders	Dry age-related macular degeneration	Male	264	49,2	1	0,4
Eye disorders	Dry age-related macular degeneration	Female	273	50,8	0	0,0
Eye disorders	Dry eye	Male	264	49,2	2	0,8
Eye disorders	Dry eye	Female	273	50,8	8	2,9
Eye disorders	Entropion	Male	264	49,2	0	0,0
Eye disorders	Entropion	Female	273	50,8	1	0,4
Eye disorders	Epi-retinal membrane	Male	264	49,2	4	1,5
Eye disorders	Epi-retinal membrane	Female	273	50,8	6	2,2
Eye disorders	Episcleritis	Male	264	49,2	1	0,4
Eye disorders	Episcleritis	Female	273	50,8	0	0,0
Eye disorders	Erythema of eyelid	Male	264	49,2	0	0,0
Eye disorders	Erythema of eyelid	Female	273	50,8	1	0,4
Eye disorders	Eye allergy	Male	264	49,2	0	0,0
Eye disorders	Eye allergy	Female	273	50,8	1	0,4
Eye disorders	Eye discharge	Male	264	49,2	1	0,4
Eye disorders	Eye discharge	Female	273	50,8	1	0,4
Eye disorders	Eye irritation	Male	264	49,2	0	0,0
Eye disorders	Eye irritation	Female	273	50,8	1	0,4
Eye disorders	Eye pain	Male	264	49,2	2	0,8
Eye disorders	Eye pain	Female	273	50,8	1	0,4
Eye disorders	Eye pruritus	Male	264	49,2	0	0,0
Eye disorders	Eye pruritus	Female	273	50,8	2	0,7
Eye disorders	Eyelid oedema	Male	264	49,2	0	0,0
Eye disorders	Eyelid oedema	Female	273	50,8	1	0,4
Eye disorders	Eyelid pain	Male	264	49,2	0	0,0
Eye disorders	Eyelid pain	Female	273	50,8	1	0,4
Eye disorders	Eyelid ptosis	Male	264	49,2	1	0,4
Eye disorders	Eyelid ptosis	Female	273	50,8	0	0,0
Eye disorders	Glaucoma	Male	264	49,2	2	0,8
Eye disorders	Glaucoma	Female	273	50,8	2	0,7
Eye disorders	Iridocyclitis	Male	264	49,2	0	0,0
Eye disorders	Iridocyclitis	Female	273	50,8	2	0,7
Eye disorders	Iritis	Male	264	49,2	0	0,0
Eye disorders	Iritis	Female	273	50,8	2	0,7
Eye disorders	Keratitis	Male	264	49,2	0	0,0
Eye disorders	Keratitis	Female	273	50,8	2	0,7
Eye disorders	Lacrimation increased	Male	264	49,2	3	1,1
Eye disorders	Lacrimation increased	Female	273	50,8	0	0,0
Eye disorders	Macular ischaemia	Male	264	49,2	0	0,0
Eye disorders	Macular ischaemia	Female	273	50,8	1	0,4
Eye disorders	Macular oedema	Male	264	49,2	7	2,7
Eye disorders	Macular oedema	Female	273	50,8	10	3,7
Eye disorders	Maculopathy	Male	264	49,2	1	0,4
Eye disorders	Maculopathy	Female	273	50,8	0	0,0
Eye disorders	Narrow anterior chamber angle	Male	264	49,2	1	0,4
Eye disorders	Narrow anterior chamber angle	Female	273	50,8	0	0,0

Eye disorders	Normal tension glaucoma	Male	264	49,2	0	0,0
Eye disorders	Normal tension glaucoma	Female	273	50,8	1	0,4
Eye disorders	Ocular discomfort	Male	264	49,2	2	0,8
Eye disorders	Ocular discomfort	Female	273	50,8	0	0,0
Eye disorders	Ocular hypertension	Male	264	49,2	2	0,8
Eye disorders	Ocular hypertension	Female	273	50,8	0	0,0
Eye disorders	Ocular vascular disorder	Male	264	49,2	0	0,0
Eye disorders	Ocular vascular disorder	Female	273	50,8	1	0,4
Eye disorders	Optic disc haemorrhage	Male	264	49,2	0	0,0
Eye disorders	Optic disc haemorrhage	Female	273	50,8	1	0,4
Eye disorders	Optic disc vascular disorder	Male	264	49,2	0	0,0
Eye disorders	Optic disc vascular disorder	Female	273	50,8	1	0,4
Eye disorders	Periorbital pain	Male	264	49,2	0	0,0
Eye disorders	Periorbital pain	Female	273	50,8	1	0,4
Eye disorders	Photopsia	Male	264	49,2	0	0,0
Eye disorders	Photopsia	Female	273	50,8	1	0,4
Eye disorders	Posterior capsule opacification	Male	264	49,2	1	0,4
Eye disorders	Posterior capsule opacification	Female	273	50,8	1	0,4
Eye disorders	Pterygium	Male	264	49,2	1	0,4
Eye disorders	Pterygium	Female	273	50,8	0	0,0
Eye disorders	Punctate keratitis	Male	264	49,2	1	0,4
Eye disorders	Punctate keratitis	Female	273	50,8	0	0,0
Eye disorders	Retinal aneurysm	Male	264	49,2	0	0,0
Eye disorders	Retinal aneurysm	Female	273	50,8	2	0,7
Eye disorders	Retinal artery embolism	Male	264	49,2	0	0,0
Eye disorders	Retinal artery embolism	Female	273	50,8	1	0,4
Eye disorders	Retinal collateral vessels	Male	264	49,2	0	0,0
Eye disorders	Retinal collateral vessels	Female	273	50,8	1	0,4
Eye disorders	Retinal cyst	Male	264	49,2	2	0,8
Eye disorders	Retinal cyst	Female	273	50,8	2	0,7
Eye disorders	Retinal exudates	Male	264	49,2	1	0,4
Eye disorders	Retinal exudates	Female	273	50,8	2	0,7
Eye disorders	Retinal haemorrhage	Male	264	49,2	5	1,9
Eye disorders	Retinal haemorrhage	Female	273	50,8	5	1,8
Eye disorders	Retinal ischaemia	Male	264	49,2	3	1,1
Eye disorders	Retinal ischaemia	Female	273	50,8	2	0,7
Eye disorders	Retinal neovascularisation	Male	264	49,2	1	0,4
Eye disorders	Retinal neovascularisation	Female	273	50,8	1	0,4
Eye disorders	Retinal oedema	Male	264	49,2	0	0,0
Eye disorders	Retinal oedema	Female	273	50,8	1	0,4
Eye disorders	Retinal tear	Male	264	49,2	3	1,1
Eye disorders	Retinal tear	Female	273	50,8	0	0,0
Eye disorders	Retinal thickening	Male	264	49,2	0	0,0
Eye disorders	Retinal thickening	Female	273	50,8	1	0,4
Eye disorders	Retinal vascular disorder	Male	264	49,2	0	0,0
Eye disorders	Retinal vascular disorder	Female	273	50,8	1	0,4
Eye disorders	Retinal vein occlusion	Male	264	49,2	11	4,2
Eye disorders	Retinal vein occlusion	Female	273	50,8	10	3,7
Eye disorders	Retinopathy hypertensive	Male	264	49,2	1	0,4
Eye disorders	Retinopathy hypertensive	Female	273	50,8	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Male	264	49,2	1	0,4
Eye disorders	Rhegmatogenous retinal detachment	Female	273	50,8	0	0,0
Eye disorders	Swelling of eyelid	Male	264	49,2	0	0,0
Eye disorders	Swelling of eyelid	Female	273	50,8	1	0,4
Eye disorders	Tractional retinal detachment	Male	264	49,2	1	0,4
Eye disorders	Tractional retinal detachment	Female	273	50,8	0	0,0
Eye disorders	Trichiasis	Male	264	49,2	0	0,0
Eye disorders	Trichiasis	Female	273	50,8	1	0,4
Eye disorders	Vision blurred	Male	264	49,2	1	0,4
Eye disorders	Vision blurred	Female	273	50,8	3	1,1
Eye disorders	Visual acuity reduced	Male	264	49,2	4	1,5
Eye disorders	Visual acuity reduced	Female	273	50,8	2	0,7
Eye disorders	Visual field defect	Male	264	49,2	1	0,4
Eye disorders	Visual field defect	Female	273	50,8	0	0,0
Eye disorders	Vitreoretinal traction syndrome	Male	264	49,2	0	0,0
Eye disorders	Vitreoretinal traction syndrome	Female	273	50,8	2	0,7
Eye disorders	Vitreous degeneration	Male	264	49,2	0	0,0
Eye disorders	Vitreous degeneration	Female	273	50,8	1	0,4
Eye disorders	Vitreous detachment	Male	264	49,2	10	3,8
Eye disorders	Vitreous detachment	Female	273	50,8	11	4,0
Eye disorders	Vitreous floaters	Male	264	49,2	3	1,1
Eye disorders	Vitreous floaters	Female	273	50,8	7	2,6
Eye disorders	Vitreous haemorrhage	Male	264	49,2	1	0,4
Eye disorders	Vitreous haemorrhage	Female	273	50,8	1	0,4
Eye disorders	Vitritis	Male	264	49,2	0	0,0
Eye disorders	Vitritis	Female	273	50,8	1	0,4
Gastrointestinal disorders		Male	264	49,2	14	5,3
Gastrointestinal disorders		Female	273	50,8	20	7,3
Gastrointestinal disorders	Abdominal pain	Male	264	49,2	0	0,0
Gastrointestinal disorders	Abdominal pain	Female	273	50,8	1	0,4
Gastrointestinal disorders	Abdominal pain upper	Male	264	49,2	0	0,0
Gastrointestinal disorders	Abdominal pain upper	Female	273	50,8	1	0,4
Gastrointestinal disorders	Chronic gastritis	Male	264	49,2	0	0,0
Gastrointestinal disorders	Chronic gastritis	Female	273	50,8	1	0,4
Gastrointestinal disorders	Colitis	Male	264	49,2	0	0,0
Gastrointestinal disorders	Colitis	Female	273	50,8	3	1,1
Gastrointestinal disorders	Constipation	Male	264	49,2	2	0,8
Gastrointestinal disorders	Constipation	Female	273	50,8	0	0,0
Gastrointestinal disorders	Diarrhoea	Male	264	49,2	0	0,0
Gastrointestinal disorders	Diarrhoea	Female	273	50,8	4	1,5
Gastrointestinal disorders	Erosive duodenitis	Male	264	49,2	0	0,0
Gastrointestinal disorders	Erosive duodenitis	Female	273	50,8	1	0,4
Gastrointestinal disorders	Functional gastrointestinal disorder	Male	264	49,2	1	0,4

Gastrointestinal disorders	Functional gastrointestinal disorder	Female	273	50,8	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Male	264	49,2	1	0,4
Gastrointestinal disorders	Gastric haemorrhage	Female	273	50,8	0	0,0
Gastrointestinal disorders	Gastric polyps	Male	264	49,2	0	0,0
Gastrointestinal disorders	Gastric polyps	Female	273	50,8	1	0,4
Gastrointestinal disorders	Gastritis	Male	264	49,2	2	0,8
Gastrointestinal disorders	Gastritis	Female	273	50,8	2	0,7
Gastrointestinal disorders	Gastroesophageal reflux disease	Male	264	49,2	4	1,5
Gastrointestinal disorders	Gastroesophageal reflux disease	Female	273	50,8	2	0,7
Gastrointestinal disorders	Gingival pain	Male	264	49,2	0	0,0
Gastrointestinal disorders	Gingival pain	Female	273	50,8	1	0,4
Gastrointestinal disorders	Haemorrhoids	Male	264	49,2	1	0,4
Gastrointestinal disorders	Haemorrhoids	Female	273	50,8	1	0,4
Gastrointestinal disorders	Hyperchlorhydria	Male	264	49,2	1	0,4
Gastrointestinal disorders	Hyperchlorhydria	Female	273	50,8	0	0,0
Gastrointestinal disorders	Large intestine polyp	Male	264	49,2	3	1,1
Gastrointestinal disorders	Large intestine polyp	Female	273	50,8	1	0,4
Gastrointestinal disorders	Mesenteric vein thrombosis	Male	264	49,2	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	Female	273	50,8	1	0,4
Gastrointestinal disorders	Nausea	Male	264	49,2	0	0,0
Gastrointestinal disorders	Nausea	Female	273	50,8	3	1,1
Gastrointestinal disorders	Oesophagitis	Male	264	49,2	0	0,0
Gastrointestinal disorders	Oesophagitis	Female	273	50,8	1	0,4
Gastrointestinal disorders	Pancreatitis acute	Male	264	49,2	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Female	273	50,8	1	0,4
Gastrointestinal disorders	Toothache	Male	264	49,2	2	0,8
Gastrointestinal disorders	Toothache	Female	273	50,8	2	0,7
Gastrointestinal disorders	Vomiting	Male	264	49,2	1	0,4
Gastrointestinal disorders	Vomiting	Female	273	50,8	2	0,7
General disorders and administration site conditions		Male	264	49,2	5	1,9
General disorders and administration site conditions		Female	273	50,8	9	3,3
General disorders and administration site conditions	Asthenia	Male	264	49,2	1	0,4
General disorders and administration site conditions	Asthenia	Female	273	50,8	1	0,4
General disorders and administration site conditions	Chest discomfort	Male	264	49,2	0	0,0
General disorders and administration site conditions	Chest discomfort	Female	273	50,8	1	0,4
General disorders and administration site conditions	Death	Male	264	49,2	1	0,4
General disorders and administration site conditions	Death	Female	273	50,8	0	0,0
General disorders and administration site conditions	Fatigue	Male	264	49,2	1	0,4
General disorders and administration site conditions	Fatigue	Female	273	50,8	0	0,0
General disorders and administration site conditions	Gait disturbance	Male	264	49,2	1	0,4
General disorders and administration site conditions	Gait disturbance	Female	273	50,8	0	0,0
General disorders and administration site conditions	Illness	Male	264	49,2	0	0,0
General disorders and administration site conditions	Illness	Female	273	50,8	1	0,4
General disorders and administration site conditions	Influenza like illness	Male	264	49,2	0	0,0
General disorders and administration site conditions	Influenza like illness	Female	273	50,8	1	0,4
General disorders and administration site conditions	Oedema	Male	264	49,2	0	0,0
General disorders and administration site conditions	Oedema	Female	273	50,8	1	0,4
General disorders and administration site conditions	Pain	Male	264	49,2	0	0,0
General disorders and administration site conditions	Pain	Female	273	50,8	3	1,1
General disorders and administration site conditions	Peripheral swelling	Male	264	49,2	0	0,0
General disorders and administration site conditions	Peripheral swelling	Female	273	50,8	1	0,4
General disorders and administration site conditions	Physical deconditioning	Male	264	49,2	1	0,4
General disorders and administration site conditions	Physical deconditioning	Female	273	50,8	0	0,0
General disorders and administration site conditions	Pyrexia	Male	264	49,2	2	0,8
General disorders and administration site conditions	Pyrexia	Female	273	50,8	1	0,4
General disorders and administration site conditions	Vascular stent stenosis	Male	264	49,2	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Female	273	50,8	1	0,4
Hepatobiliary disorders		Male	264	49,2	5	1,9
Hepatobiliary disorders		Female	273	50,8	4	1,5
Hepatobiliary disorders	Bile duct stone	Male	264	49,2	1	0,4
Hepatobiliary disorders	Bile duct stone	Female	273	50,8	0	0,0
Hepatobiliary disorders	Cholecystitis chronic	Male	264	49,2	1	0,4
Hepatobiliary disorders	Cholecystitis chronic	Female	273	50,8	0	0,0
Hepatobiliary disorders	Cholelithiasis	Male	264	49,2	0	0,0
Hepatobiliary disorders	Cholelithiasis	Female	273	50,8	4	1,5
Hepatobiliary disorders	Hepatic cyst	Male	264	49,2	0	0,0
Hepatobiliary disorders	Hepatic cyst	Female	273	50,8	1	0,4
Hepatobiliary disorders	Hepatic failure	Male	264	49,2	1	0,4
Hepatobiliary disorders	Hepatic failure	Female	273	50,8	0	0,0
Hepatobiliary disorders	Hepatic function abnormal	Male	264	49,2	1	0,4
Hepatobiliary disorders	Hepatic function abnormal	Female	273	50,8	0	0,0
Hepatobiliary disorders	Hepatic steatosis	Male	264	49,2	1	0,4
Hepatobiliary disorders	Hepatic steatosis	Female	273	50,8	0	0,0
Immune system disorders		Male	264	49,2	2	0,8
Immune system disorders		Female	273	50,8	3	1,1
Immune system disorders	Allergic oedema	Male	264	49,2	0	0,0
Immune system disorders	Allergic oedema	Female	273	50,8	1	0,4
Immune system disorders	Allergy to plants	Male	264	49,2	0	0,0
Immune system disorders	Allergy to plants	Female	273	50,8	1	0,4
Immune system disorders	Hypersensitivity	Male	264	49,2	2	0,8
Immune system disorders	Hypersensitivity	Female	273	50,8	0	0,0
Immune system disorders	Seasonal allergy	Male	264	49,2	0	0,0
Immune system disorders	Seasonal allergy	Female	273	50,8	1	0,4
Infections and infestations		Male	264	49,2	63	23,9
Infections and infestations		Female	273	50,8	83	30,4
Infections and infestations	Borrelia infection	Male	264	49,2	1	0,4
Infections and infestations	Borrelia infection	Female	273	50,8	0	0,0
Infections and infestations	Bronchitis	Male	264	49,2	1	0,4
Infections and infestations	Bronchitis	Female	273	50,8	5	1,8
Infections and infestations	COVID-19	Male	264	49,2	22	8,3

Infections and infestations	COVID-19	Female	273	50,8	36	13,2
Infections and infestations	Cellulitis	Male	264	49,2	2	0,8
Infections and infestations	Cellulitis	Female	273	50,8	1	0,4
Infections and infestations	Conjunctivitis	Male	264	49,2	1	0,4
Infections and infestations	Conjunctivitis	Female	273	50,8	4	1,5
Infections and infestations	Coronavirus infection	Male	264	49,2	1	0,4
Infections and infestations	Coronavirus infection	Female	273	50,8	0	0,0
Infections and infestations	Cystitis	Male	264	49,2	1	0,4
Infections and infestations	Cystitis	Female	273	50,8	1	0,4
Infections and infestations	Dermatophytosis of nail	Male	264	49,2	0	0,0
Infections and infestations	Dermatophytosis of nail	Female	273	50,8	1	0,4
Infections and infestations	Ear infection	Male	264	49,2	1	0,4
Infections and infestations	Ear infection	Female	273	50,8	1	0,4
Infections and infestations	Furuncle	Male	264	49,2	1	0,4
Infections and infestations	Furuncle	Female	273	50,8	0	0,0
Infections and infestations	Gastroenteritis	Male	264	49,2	3	1,1
Infections and infestations	Gastroenteritis	Female	273	50,8	2	0,7
Infections and infestations	Gastroenteritis viral	Male	264	49,2	1	0,4
Infections and infestations	Gastroenteritis viral	Female	273	50,8	1	0,4
Infections and infestations	Gastrointestinal infection	Male	264	49,2	1	0,4
Infections and infestations	Gastrointestinal infection	Female	273	50,8	1	0,4
Infections and infestations	Gingival abscess	Male	264	49,2	1	0,4
Infections and infestations	Gingival abscess	Female	273	50,8	0	0,0
Infections and infestations	Groin abscess	Male	264	49,2	1	0,4
Infections and infestations	Groin abscess	Female	273	50,8	0	0,0
Infections and infestations	Herpes zoster	Male	264	49,2	1	0,4
Infections and infestations	Herpes zoster	Female	273	50,8	2	0,7
Infections and infestations	Hordeolum	Male	264	49,2	0	0,0
Infections and infestations	Hordeolum	Female	273	50,8	3	1,1
Infections and infestations	Influenza	Male	264	49,2	6	2,3
Infections and infestations	Influenza	Female	273	50,8	3	1,1
Infections and infestations	Intestinal sepsis	Male	264	49,2	0	0,0
Infections and infestations	Intestinal sepsis	Female	273	50,8	1	0,4
Infections and infestations	Lower respiratory tract infection	Male	264	49,2	0	0,0
Infections and infestations	Lower respiratory tract infection	Female	273	50,8	1	0,4
Infections and infestations	Nail infection	Male	264	49,2	1	0,4
Infections and infestations	Nail infection	Female	273	50,8	0	0,0
Infections and infestations	Nasopharyngitis	Male	264	49,2	7	2,7
Infections and infestations	Nasopharyngitis	Female	273	50,8	10	3,7
Infections and infestations	Oral herpes	Male	264	49,2	0	0,0
Infections and infestations	Oral herpes	Female	273	50,8	1	0,4
Infections and infestations	Otitis media	Male	264	49,2	2	0,8
Infections and infestations	Otitis media	Female	273	50,8	0	0,0
Infections and infestations	Otitis media acute	Male	264	49,2	1	0,4
Infections and infestations	Otitis media acute	Female	273	50,8	0	0,0
Infections and infestations	Pelvic inflammatory disease	Male	264	49,2	0	0,0
Infections and infestations	Pelvic inflammatory disease	Female	273	50,8	1	0,4
Infections and infestations	Periodontitis	Male	264	49,2	0	0,0
Infections and infestations	Periodontitis	Female	273	50,8	1	0,4
Infections and infestations	Pharyngitis	Male	264	49,2	1	0,4
Infections and infestations	Pharyngitis	Female	273	50,8	1	0,4
Infections and infestations	Pneumonia	Male	264	49,2	2	0,8
Infections and infestations	Pneumonia	Female	273	50,8	3	1,1
Infections and infestations	Post-acute COVID-19 syndrome	Male	264	49,2	1	0,4
Infections and infestations	Post-acute COVID-19 syndrome	Female	273	50,8	0	0,0
Infections and infestations	Postoperative wound infection	Male	264	49,2	1	0,4
Infections and infestations	Postoperative wound infection	Female	273	50,8	1	0,4
Infections and infestations	Pulpitis dental	Male	264	49,2	1	0,4
Infections and infestations	Pulpitis dental	Female	273	50,8	0	0,0
Infections and infestations	Pyelonephritis	Male	264	49,2	1	0,4
Infections and infestations	Pyelonephritis	Female	273	50,8	0	0,0
Infections and infestations	Respiratory tract infection	Male	264	49,2	1	0,4
Infections and infestations	Respiratory tract infection	Female	273	50,8	3	1,1
Infections and infestations	Rhinitis	Male	264	49,2	0	0,0
Infections and infestations	Rhinitis	Female	273	50,8	1	0,4
Infections and infestations	Rotavirus infection	Male	264	49,2	0	0,0
Infections and infestations	Rotavirus infection	Female	273	50,8	1	0,4
Infections and infestations	Sepsis	Male	264	49,2	1	0,4
Infections and infestations	Sepsis	Female	273	50,8	0	0,0
Infections and infestations	Sinusitis	Male	264	49,2	1	0,4
Infections and infestations	Sinusitis	Female	273	50,8	1	0,4
Infections and infestations	Suspected COVID-19	Male	264	49,2	4	1,5
Infections and infestations	Suspected COVID-19	Female	273	50,8	5	1,8
Infections and infestations	Tinea cruris	Male	264	49,2	0	0,0
Infections and infestations	Tinea cruris	Female	273	50,8	1	0,4
Infections and infestations	Tinea pedis	Male	264	49,2	1	0,4
Infections and infestations	Tinea pedis	Female	273	50,8	0	0,0
Infections and infestations	Tonsillitis	Male	264	49,2	0	0,0
Infections and infestations	Tonsillitis	Female	273	50,8	2	0,7
Infections and infestations	Tooth infection	Male	264	49,2	0	0,0
Infections and infestations	Tooth infection	Female	273	50,8	3	1,1
Infections and infestations	Tracheitis	Male	264	49,2	1	0,4
Infections and infestations	Tracheitis	Female	273	50,8	0	0,0
Infections and infestations	Upper respiratory tract infection	Male	264	49,2	8	3,0
Infections and infestations	Upper respiratory tract infection	Female	273	50,8	8	2,9
Infections and infestations	Urinary tract infection	Male	264	49,2	3	1,1
Infections and infestations	Urinary tract infection	Female	273	50,8	1	0,4
Infections and infestations	Viral infection	Male	264	49,2	0	0,0
Infections and infestations	Viral infection	Female	273	50,8	2	0,7
Infections and infestations	Vulvovaginal candidiasis	Male	264	49,2	0	0,0
Infections and infestations	Vulvovaginal candidiasis	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications		Male	264	49,2	17	6,4
Injury, poisoning and procedural complications		Female	273	50,8	25	9,2

Injury, poisoning and procedural complications	Arthropod bite	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Arthropod bite	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Back injury	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Back injury	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Burns third degree	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Burns third degree	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Chilblains	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Chilblains	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Clavicle fracture	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Clavicle fracture	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Comminuted fracture	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Comminuted fracture	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Contusion	Male	264	49.2	3	1.1
Injury, poisoning and procedural complications	Contusion	Female	273	50.8	3	1.1
Injury, poisoning and procedural complications	Corneal abrasion	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Corneal abrasion	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Eye injury	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Eye injury	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Facial bones fracture	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Facial bones fracture	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Fall	Male	264	49.2	4	1.5
Injury, poisoning and procedural complications	Fall	Female	273	50.8	10	3.7
Injury, poisoning and procedural complications	Femur fracture	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Femur fracture	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Foot fracture	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Foot fracture	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Foreign body in eye	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Foreign body in eye	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Head injury	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Head injury	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Hip fracture	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Hip fracture	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Immunisation reaction	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Immunisation reaction	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Joint injury	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Joint injury	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Ligament sprain	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Ligament sprain	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Limb injury	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Limb injury	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Medication error	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Medication error	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Meniscus injury	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Meniscus injury	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Muscle strain	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Muscle strain	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Radius fracture	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Radius fracture	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Skin abrasion	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Skin abrasion	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Skin injury	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Skin injury	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Skin laceration	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Skin laceration	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Spinal column injury	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Spinal column injury	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Sternal fracture	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Sternal fracture	Female	273	50.8	1	0.4
Injury, poisoning and procedural complications	Subdural haematoma	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Subdural haematoma	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Thermal burn	Male	264	49.2	1	0.4
Injury, poisoning and procedural complications	Thermal burn	Female	273	50.8	0	0.0
Injury, poisoning and procedural complications	Tooth fracture	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Tooth fracture	Female	273	50.8	2	0.7
Injury, poisoning and procedural complications	Ulna fracture	Male	264	49.2	0	0.0
Injury, poisoning and procedural complications	Ulna fracture	Female	273	50.8	2	0.7
Investigations		Male	264	49.2	18	6.8
Investigations		Female	273	50.8	16	5.9
Investigations	Blood glucose increased	Male	264	49.2	1	0.4
Investigations	Blood glucose increased	Female	273	50.8	0	0.0
Investigations	Blood potassium decreased	Male	264	49.2	0	0.0
Investigations	Blood potassium decreased	Female	273	50.8	1	0.4
Investigations	Blood pressure increased	Male	264	49.2	3	1.1
Investigations	Blood pressure increased	Female	273	50.8	0	0.0
Investigations	Blood sodium decreased	Male	264	49.2	0	0.0
Investigations	Blood sodium decreased	Female	273	50.8	1	0.4
Investigations	Glomerular filtration rate decreased	Male	264	49.2	0	0.0
Investigations	Glomerular filtration rate decreased	Female	273	50.8	1	0.4
Investigations	Intraocular pressure increased	Male	264	49.2	11	4.2
Investigations	Intraocular pressure increased	Female	273	50.8	10	3.7
Investigations	Platelet count increased	Male	264	49.2	1	0.4
Investigations	Platelet count increased	Female	273	50.8	0	0.0
Investigations	SARS-CoV-2 test positive	Male	264	49.2	0	0.0
Investigations	SARS-CoV-2 test positive	Female	273	50.8	2	0.7
Investigations	Troponin increased	Male	264	49.2	1	0.4
Investigations	Troponin increased	Female	273	50.8	0	0.0
Investigations	Weight decreased	Male	264	49.2	0	0.0
Investigations	Weight decreased	Female	273	50.8	1	0.4
Investigations	White blood cell count decreased	Male	264	49.2	1	0.4
Investigations	White blood cell count decreased	Female	273	50.8	0	0.0
Metabolism and nutrition disorders		Male	264	49.2	13	4.9
Metabolism and nutrition disorders		Female	273	50.8	14	5.1

Metabolism and nutrition disorders	Dehydration	Male	264	49.2	0	0.0
Metabolism and nutrition disorders	Dehydration	Female	273	50.8	2	0.7
Metabolism and nutrition disorders	Diabetes mellitus	Male	264	49.2	1	0.4
Metabolism and nutrition disorders	Diabetes mellitus	Female	273	50.8	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Male	264	49.2	1	0.4
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Female	273	50.8	0	0.0
Metabolism and nutrition disorders	Folate deficiency	Male	264	49.2	0	0.0
Metabolism and nutrition disorders	Folate deficiency	Female	273	50.8	1	0.4
Metabolism and nutrition disorders	Gout	Male	264	49.2	2	0.8
Metabolism and nutrition disorders	Gout	Female	273	50.8	0	0.0
Metabolism and nutrition disorders	Hypercholesterolaemia	Male	264	49.2	4	1.5
Metabolism and nutrition disorders	Hypercholesterolaemia	Female	273	50.8	5	1.8
Metabolism and nutrition disorders	Hyperglycaemia	Male	264	49.2	0	0.0
Metabolism and nutrition disorders	Hyperglycaemia	Female	273	50.8	2	0.7
Metabolism and nutrition disorders	Hyperhomocysteinaemia	Male	264	49.2	1	0.4
Metabolism and nutrition disorders	Hyperhomocysteinaemia	Female	273	50.8	0	0.0
Metabolism and nutrition disorders	Hyperkalaemia	Male	264	49.2	0	0.0
Metabolism and nutrition disorders	Hyperkalaemia	Female	273	50.8	1	0.4
Metabolism and nutrition disorders	Hyperlipidaemia	Male	264	49.2	3	1.1
Metabolism and nutrition disorders	Hyperlipidaemia	Female	273	50.8	1	0.4
Metabolism and nutrition disorders	Hyperuricaemia	Male	264	49.2	0	0.0
Metabolism and nutrition disorders	Hyperuricaemia	Female	273	50.8	1	0.4
Metabolism and nutrition disorders	Hypoproteinaemia	Male	264	49.2	1	0.4
Metabolism and nutrition disorders	Hypoproteinaemia	Female	273	50.8	0	0.0
Metabolism and nutrition disorders	Obesity	Male	264	49.2	0	0.0
Metabolism and nutrition disorders	Obesity	Female	273	50.8	2	0.7
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Male	264	49.2	2	0.8
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Female	273	50.8	1	0.4
Metabolism and nutrition disorders	Vitamin B12 deficiency	Male	264	49.2	0	0.0
Metabolism and nutrition disorders	Vitamin B12 deficiency	Female	273	50.8	1	0.4
Metabolism and nutrition disorders	Vitamin D deficiency	Male	264	49.2	1	0.4
Metabolism and nutrition disorders	Vitamin D deficiency	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders		Male	264	49.2	25	9.5
Musculoskeletal and connective tissue disorders		Female	273	50.8	34	12.5
Musculoskeletal and connective tissue disorders	Arthralgia	Male	264	49.2	2	0.8
Musculoskeletal and connective tissue disorders	Arthralgia	Female	273	50.8	5	1.8
Musculoskeletal and connective tissue disorders	Arthritis	Male	264	49.2	2	0.8
Musculoskeletal and connective tissue disorders	Arthritis	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Back pain	Male	264	49.2	5	1.9
Musculoskeletal and connective tissue disorders	Back pain	Female	273	50.8	5	1.8
Musculoskeletal and connective tissue disorders	Bone disorder	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Bone disorder	Female	273	50.8	0	0.0
Musculoskeletal and connective tissue disorders	Bursitis	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Bursitis	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Exostosis	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Exostosis	Female	273	50.8	0	0.0
Musculoskeletal and connective tissue disorders	Fibromyalgia	Male	264	49.2	0	0.0
Musculoskeletal and connective tissue disorders	Fibromyalgia	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Female	273	50.8	2	0.7
Musculoskeletal and connective tissue disorders	Joint swelling	Male	264	49.2	0	0.0
Musculoskeletal and connective tissue disorders	Joint swelling	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Male	264	49.2	0	0.0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Muscle contracture	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Muscle contracture	Female	273	50.8	0	0.0
Musculoskeletal and connective tissue disorders	Muscle spasms	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Muscle spasms	Female	273	50.8	2	0.7
Musculoskeletal and connective tissue disorders	Muscular weakness	Male	264	49.2	0	0.0
Musculoskeletal and connective tissue disorders	Muscular weakness	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Myalgia	Male	264	49.2	2	0.8
Musculoskeletal and connective tissue disorders	Myalgia	Female	273	50.8	3	1.1
Musculoskeletal and connective tissue disorders	Neck pain	Male	264	49.2	0	0.0
Musculoskeletal and connective tissue disorders	Neck pain	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Osteoarthritis	Male	264	49.2	3	1.1
Musculoskeletal and connective tissue disorders	Osteoarthritis	Female	273	50.8	5	1.8
Musculoskeletal and connective tissue disorders	Osteopenia	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Osteopenia	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Osteoporosis	Male	264	49.2	0	0.0
Musculoskeletal and connective tissue disorders	Osteoporosis	Female	273	50.8	2	0.7
Musculoskeletal and connective tissue disorders	Pain in extremity	Male	264	49.2	3	1.1
Musculoskeletal and connective tissue disorders	Pain in extremity	Female	273	50.8	2	0.7
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Female	273	50.8	0	0.0
Musculoskeletal and connective tissue disorders	Rheumatoid arthritis	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Rheumatoid arthritis	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	Male	264	49.2	0	0.0
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Male	264	49.2	3	1.1
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Spinal pain	Male	264	49.2	2	0.8
Musculoskeletal and connective tissue disorders	Spinal pain	Female	273	50.8	3	1.1
Musculoskeletal and connective tissue disorders	Tendon disorder	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Tendon disorder	Female	273	50.8	0	0.0
Musculoskeletal and connective tissue disorders	Tenosynovitis	Male	264	49.2	0	0.0
Musculoskeletal and connective tissue disorders	Tenosynovitis	Female	273	50.8	1	0.4
Musculoskeletal and connective tissue disorders	Vertebral foraminal stenosis	Male	264	49.2	1	0.4
Musculoskeletal and connective tissue disorders	Vertebral foraminal stenosis	Female	273	50.8	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Male	264	49.2	3	1.1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Female	273	50.8	4	1.5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bowen's disease	Male	264	49.2	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bowen's disease	Female	273	50.8	1	0.4

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lung neoplasm	Male	264	49,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lung neoplasm	Female	273	50,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Male	264	49,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Female	273	50,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Male	264	49,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Female	273	50,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Female	273	50,8	1	0,4
Nervous system disorders		Male	264	49,2	18	6,8
Nervous system disorders		Female	273	50,8	29	10,6
Nervous system disorders	Carotid arteriosclerosis	Male	264	49,2	0	0,0
Nervous system disorders	Carotid arteriosclerosis	Female	273	50,8	1	0,4
Nervous system disorders	Carotid artery stenosis	Male	264	49,2	0	0,0
Nervous system disorders	Carotid artery stenosis	Female	273	50,8	1	0,4
Nervous system disorders	Cerebral atrophy	Male	264	49,2	0	0,0
Nervous system disorders	Cerebral atrophy	Female	273	50,8	1	0,4
Nervous system disorders	Cerebral haematoma	Male	264	49,2	0	0,0
Nervous system disorders	Cerebral haematoma	Female	273	50,8	1	0,4
Nervous system disorders	Cerebral infarction	Male	264	49,2	1	0,4
Nervous system disorders	Cerebral infarction	Female	273	50,8	1	0,4
Nervous system disorders	Cerebral thrombosis	Male	264	49,2	1	0,4
Nervous system disorders	Cerebral thrombosis	Female	273	50,8	0	0,0
Nervous system disorders	Cerebrovascular accident	Male	264	49,2	0	0,0
Nervous system disorders	Cerebrovascular accident	Female	273	50,8	2	0,7
Nervous system disorders	Cervical radiculopathy	Male	264	49,2	1	0,4
Nervous system disorders	Cervical radiculopathy	Female	273	50,8	0	0,0
Nervous system disorders	Cognitive disorder	Male	264	49,2	0	0,0
Nervous system disorders	Cognitive disorder	Female	273	50,8	1	0,4
Nervous system disorders	Dementia Alzheimer's type	Male	264	49,2	0	0,0
Nervous system disorders	Dementia Alzheimer's type	Female	273	50,8	1	0,4
Nervous system disorders	Diabetic neuropathy	Male	264	49,2	1	0,4
Nervous system disorders	Diabetic neuropathy	Female	273	50,8	0	0,0
Nervous system disorders	Disturbance in attention	Male	264	49,2	0	0,0
Nervous system disorders	Disturbance in attention	Female	273	50,8	1	0,4
Nervous system disorders	Dizziness	Male	264	49,2	3	1,1
Nervous system disorders	Dizziness	Female	273	50,8	1	0,4
Nervous system disorders	Epilepsy	Male	264	49,2	1	0,4
Nervous system disorders	Epilepsy	Female	273	50,8	0	0,0
Nervous system disorders	Headache	Male	264	49,2	3	1,1
Nervous system disorders	Headache	Female	273	50,8	7	2,6
Nervous system disorders	Hypertensive encephalopathy	Male	264	49,2	0	0,0
Nervous system disorders	Hypertensive encephalopathy	Female	273	50,8	1	0,4
Nervous system disorders	Hypoesthesia	Male	264	49,2	1	0,4
Nervous system disorders	Hypoesthesia	Female	273	50,8	0	0,0
Nervous system disorders	Intracranial aneurysm	Male	264	49,2	0	0,0
Nervous system disorders	Intracranial aneurysm	Female	273	50,8	1	0,4
Nervous system disorders	Ischaemic stroke	Male	264	49,2	1	0,4
Nervous system disorders	Ischaemic stroke	Female	273	50,8	1	0,4
Nervous system disorders	Loss of consciousness	Male	264	49,2	1	0,4
Nervous system disorders	Loss of consciousness	Female	273	50,8	0	0,0
Nervous system disorders	Memory impairment	Male	264	49,2	1	0,4
Nervous system disorders	Memory impairment	Female	273	50,8	0	0,0
Nervous system disorders	Migraine	Male	264	49,2	0	0,0
Nervous system disorders	Migraine	Female	273	50,8	1	0,4
Nervous system disorders	Multiple sclerosis	Male	264	49,2	0	0,0
Nervous system disorders	Multiple sclerosis	Female	273	50,8	1	0,4
Nervous system disorders	Myelopathy	Male	264	49,2	0	0,0
Nervous system disorders	Myelopathy	Female	273	50,8	1	0,4
Nervous system disorders	Narcolepsy	Male	264	49,2	0	0,0
Nervous system disorders	Narcolepsy	Female	273	50,8	1	0,4
Nervous system disorders	Neuropathy peripheral	Male	264	49,2	2	0,8
Nervous system disorders	Neuropathy peripheral	Female	273	50,8	0	0,0
Nervous system disorders	Ophthalmic migraine	Male	264	49,2	0	0,0
Nervous system disorders	Ophthalmic migraine	Female	273	50,8	1	0,4
Nervous system disorders	Presyncope	Male	264	49,2	0	0,0
Nervous system disorders	Presyncope	Female	273	50,8	1	0,4
Nervous system disorders	Sciatica	Male	264	49,2	3	1,1
Nervous system disorders	Sciatica	Female	273	50,8	2	0,7
Nervous system disorders	Sinus headache	Male	264	49,2	0	0,0
Nervous system disorders	Sinus headache	Female	273	50,8	1	0,4
Nervous system disorders	Syncope	Male	264	49,2	0	0,0
Nervous system disorders	Syncope	Female	273	50,8	2	0,7
Nervous system disorders	Tension headache	Male	264	49,2	1	0,4
Nervous system disorders	Tension headache	Female	273	50,8	1	0,4
Nervous system disorders	White matter lesion	Male	264	49,2	1	0,4
Nervous system disorders	White matter lesion	Female	273	50,8	0	0,0
Product issues		Male	264	49,2	1	0,4
Product issues		Female	273	50,8	0	0,0
Product issues	Device malfunction	Male	264	49,2	1	0,4
Product issues	Device malfunction	Female	273	50,8	0	0,0
Psychiatric disorders		Male	264	49,2	3	1,1
Psychiatric disorders		Female	273	50,8	6	2,2
Psychiatric disorders	Anxiety	Male	264	49,2	0	0,0
Psychiatric disorders	Anxiety	Female	273	50,8	2	0,7
Psychiatric disorders	Confusional state	Male	264	49,2	2	0,8

Psychiatric disorders	Confusional state	Female	273	50,8	0	0,0
Psychiatric disorders	Delirium	Male	264	49,2	0	0,0
Psychiatric disorders	Delirium	Female	273	50,8	1	0,4
Psychiatric disorders	Depression	Male	264	49,2	1	0,4
Psychiatric disorders	Depression	Female	273	50,8	1	0,4
Psychiatric disorders	Insomnia	Male	264	49,2	0	0,0
Psychiatric disorders	Insomnia	Female	273	50,8	2	0,7
Psychiatric disorders	Somatic symptom disorder	Male	264	49,2	0	0,0
Psychiatric disorders	Somatic symptom disorder	Female	273	50,8	1	0,4
Renal and urinary disorders		Male	264	49,2	7	2,7
Renal and urinary disorders		Female	273	50,8	7	2,6
Renal and urinary disorders	Acute kidney injury	Male	264	49,2	2	0,8
Renal and urinary disorders	Acute kidney injury	Female	273	50,8	0	0,0
Renal and urinary disorders	Chronic kidney disease	Male	264	49,2	2	0,8
Renal and urinary disorders	Chronic kidney disease	Female	273	50,8	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Male	264	49,2	1	0,4
Renal and urinary disorders	Diabetic nephropathy	Female	273	50,8	0	0,0
Renal and urinary disorders	Haematuria	Male	264	49,2	1	0,4
Renal and urinary disorders	Haematuria	Female	273	50,8	0	0,0
Renal and urinary disorders	Nephrolithiasis	Male	264	49,2	0	0,0
Renal and urinary disorders	Nephrolithiasis	Female	273	50,8	2	0,7
Renal and urinary disorders	Renal colic	Male	264	49,2	0	0,0
Renal and urinary disorders	Renal colic	Female	273	50,8	1	0,4
Renal and urinary disorders	Renal cyst	Male	264	49,2	1	0,4
Renal and urinary disorders	Renal cyst	Female	273	50,8	3	1,1
Renal and urinary disorders	Renal mass	Male	264	49,2	0	0,0
Renal and urinary disorders	Renal mass	Female	273	50,8	1	0,4
Renal and urinary disorders	Urinary incontinence	Male	264	49,2	0	0,0
Renal and urinary disorders	Urinary incontinence	Female	273	50,8	1	0,4
Reproductive system and breast disorders		Male	264	49,2	5	1,9
Reproductive system and breast disorders		Female	273	50,8	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Male	264	49,2	3	1,1
Reproductive system and breast disorders	Benign prostatic hyperplasia	Female	273	50,8	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	Male	264	49,2	2	0,8
Reproductive system and breast disorders	Erectile dysfunction	Female	273	50,8	0	0,0
Reproductive system and breast disorders	Prostatitis	Male	264	49,2	1	0,4
Reproductive system and breast disorders	Prostatitis	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders		Male	264	49,2	9	3,4
Respiratory, thoracic and mediastinal disorders		Female	273	50,8	11	4,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Female	273	50,8	2	0,7
Respiratory, thoracic and mediastinal disorders	Cough	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	Female	273	50,8	3	1,1
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Emphysema	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Emphysema	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Epistaxis	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Hypoventilation	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Hypoventilation	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Lung disorder	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Lung disorder	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung hyperinflation	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Lung hyperinflation	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Pneumonitis	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Pneumonitis	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary fibrosis	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary fibrosis	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary mass	Male	264	49,2	2	0,8
Respiratory, thoracic and mediastinal disorders	Pulmonary mass	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Respiratory failure	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Respiratory failure	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	Female	273	50,8	2	0,7
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Female	273	50,8	1	0,4
Skin and subcutaneous tissue disorders		Male	264	49,2	5	1,9
Skin and subcutaneous tissue disorders		Female	273	50,8	7	2,6
Skin and subcutaneous tissue disorders	Actinic keratosis	Male	264	49,2	0	0,0
Skin and subcutaneous tissue disorders	Actinic keratosis	Female	273	50,8	1	0,4
Skin and subcutaneous tissue disorders	Dermatitis	Male	264	49,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	Female	273	50,8	1	0,4
Skin and subcutaneous tissue disorders	Dermatitis contact	Male	264	49,2	1	0,4
Skin and subcutaneous tissue disorders	Dermatitis contact	Female	273	50,8	1	0,4
Skin and subcutaneous tissue disorders	Eczema	Male	264	49,2	1	0,4
Skin and subcutaneous tissue disorders	Eczema	Female	273	50,8	0	0,0
Skin and subcutaneous tissue disorders	Miliaria	Male	264	49,2	1	0,4

Skin and subcutaneous tissue disorders	Miliaria	Female	273	50,8	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	Male	264	49,2	1	0,4
Skin and subcutaneous tissue disorders	Pemphigoid	Female	273	50,8	0	0,0
Skin and subcutaneous tissue disorders	Pruritus	Male	264	49,2	0	0,0
Skin and subcutaneous tissue disorders	Pruritus	Female	273	50,8	2	0,7
Skin and subcutaneous tissue disorders	Rash	Male	264	49,2	0	0,0
Skin and subcutaneous tissue disorders	Rash	Female	273	50,8	1	0,4
Skin and subcutaneous tissue disorders	Seborrhoeic dermatitis	Male	264	49,2	1	0,4
Skin and subcutaneous tissue disorders	Seborrhoeic dermatitis	Female	273	50,8	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	Male	264	49,2	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	Female	273	50,8	1	0,4
Social circumstances		Male	264	49,2	0	0,0
Social circumstances		Female	273	50,8	1	0,4
Social circumstances	Joint prosthesis user	Male	264	49,2	0	0,0
Social circumstances	Joint prosthesis user	Female	273	50,8	1	0,4
Surgical and medical procedures		Male	264	49,2	3	1,1
Surgical and medical procedures		Female	273	50,8	2	0,7
Surgical and medical procedures	Knee arthroplasty	Male	264	49,2	0	0,0
Surgical and medical procedures	Knee arthroplasty	Female	273	50,8	1	0,4
Surgical and medical procedures	Large intestinal polypectomy	Male	264	49,2	1	0,4
Surgical and medical procedures	Large intestinal polypectomy	Female	273	50,8	0	0,0
Surgical and medical procedures	Mole excision	Male	264	49,2	0	0,0
Surgical and medical procedures	Mole excision	Female	273	50,8	1	0,4
Surgical and medical procedures	Shoulder arthroplasty	Male	264	49,2	1	0,4
Surgical and medical procedures	Shoulder arthroplasty	Female	273	50,8	0	0,0
Surgical and medical procedures	Transurethral prostatectomy	Male	264	49,2	1	0,4
Surgical and medical procedures	Transurethral prostatectomy	Female	273	50,8	0	0,0
Vascular disorders		Male	264	49,2	19	7,2
Vascular disorders		Female	273	50,8	19	7,0
Vascular disorders	Aortic stenosis	Male	264	49,2	1	0,4
Vascular disorders	Aortic stenosis	Female	273	50,8	0	0,0
Vascular disorders	Arteriosclerosis	Male	264	49,2	1	0,4
Vascular disorders	Arteriosclerosis	Female	273	50,8	3	1,1
Vascular disorders	Brachiocephalic arteriosclerosis	Male	264	49,2	1	0,4
Vascular disorders	Brachiocephalic arteriosclerosis	Female	273	50,8	0	0,0
Vascular disorders	Diabetic vascular disorder	Male	264	49,2	1	0,4
Vascular disorders	Diabetic vascular disorder	Female	273	50,8	0	0,0
Vascular disorders	Hypertension	Male	264	49,2	11	4,2
Vascular disorders	Hypertension	Female	273	50,8	12	4,4
Vascular disorders	Hypertensive crisis	Male	264	49,2	1	0,4
Vascular disorders	Hypertensive crisis	Female	273	50,8	1	0,4
Vascular disorders	Hypotension	Male	264	49,2	2	0,8
Vascular disorders	Hypotension	Female	273	50,8	1	0,4
Vascular disorders	Ischaemic limb pain	Male	264	49,2	1	0,4
Vascular disorders	Ischaemic limb pain	Female	273	50,8	0	0,0
Vascular disorders	Orthostatic hypotension	Male	264	49,2	1	0,4
Vascular disorders	Orthostatic hypotension	Female	273	50,8	0	0,0
Vascular disorders	Varicose vein	Male	264	49,2	0	0,0
Vascular disorders	Varicose vein	Female	273	50,8	1	0,4
Vascular disorders	Vascular occlusion	Male	264	49,2	1	0,4
Vascular disorders	Vascular occlusion	Female	273	50,8	0	0,0
Vascular disorders	Venous occlusion	Male	264	49,2	1	0,4
Vascular disorders	Venous occlusion	Female	273	50,8	0	0,0
Vascular disorders	Venous thrombosis limb	Male	264	49,2	0	0,0
Vascular disorders	Venous thrombosis limb	Female	273	50,8	1	0,4

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_AE_MK72_Sea24_30AUG2023_41984.xls
26APR2024 17:45

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Age	MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=537)			
				Patients		Patients with Event	
				n	%	n	%
	Blood and lymphatic system disorders		<65 years	270	50.3	3	1.1
	Blood and lymphatic system disorders		>=65 years	267	49.7	2	0.7
	Blood and lymphatic system disorders	Anaemia	<65 years	270	50.3	1	0.4
	Blood and lymphatic system disorders	Anaemia	>=65 years	267	49.7	1	0.4
	Blood and lymphatic system disorders	Antiphospholipid syndrome	<65 years	270	50.3	1	0.4
	Blood and lymphatic system disorders	Antiphospholipid syndrome	>=65 years	267	49.7	0	0.0
	Blood and lymphatic system disorders	Coagulopathy	<65 years	270	50.3	1	0.4
	Blood and lymphatic system disorders	Coagulopathy	>=65 years	267	49.7	0	0.0
	Blood and lymphatic system disorders	Macrocytosis	<65 years	270	50.3	0	0.0
	Blood and lymphatic system disorders	Macrocytosis	>=65 years	267	49.7	1	0.4
	Cardiac disorders		<65 years	270	50.3	11	4.1
	Cardiac disorders		>=65 years	267	49.7	10	3.7
	Cardiac disorders	Acute myocardial infarction	<65 years	270	50.3	1	0.4
	Cardiac disorders	Acute myocardial infarction	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Angina pectoris	<65 years	270	50.3	1	0.4
	Cardiac disorders	Angina pectoris	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Angina unstable	<65 years	270	50.3	2	0.7
	Cardiac disorders	Angina unstable	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Aortic valve incompetence	<65 years	270	50.3	1	0.4
	Cardiac disorders	Aortic valve incompetence	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Arrhythmia	<65 years	270	50.3	1	0.4
	Cardiac disorders	Arrhythmia	>=65 years	267	49.7	1	0.4
	Cardiac disorders	Arteriosclerosis coronary artery	<65 years	270	50.3	1	0.4
	Cardiac disorders	Arteriosclerosis coronary artery	>=65 years	267	49.7	1	0.4
	Cardiac disorders	Atrial fibrillation	<65 years	270	50.3	2	0.7
	Cardiac disorders	Atrial fibrillation	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Bundle branch block right	<65 years	270	50.3	1	0.4
	Cardiac disorders	Bundle branch block right	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Cardiac failure	<65 years	270	50.3	1	0.4
	Cardiac disorders	Cardiac failure	>=65 years	267	49.7	1	0.4
	Cardiac disorders	Cardiac failure congestive	<65 years	270	50.3	1	0.4
	Cardiac disorders	Cardiac failure congestive	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Cardiomegaly	<65 years	270	50.3	0	0.0
	Cardiac disorders	Cardiomegaly	>=65 years	267	49.7	1	0.4
	Cardiac disorders	Coronary artery disease	<65 years	270	50.3	1	0.4
	Cardiac disorders	Coronary artery disease	>=65 years	267	49.7	1	0.4
	Cardiac disorders	Dilatation ventricular	<65 years	270	50.3	0	0.0
	Cardiac disorders	Dilatation ventricular	>=65 years	267	49.7	1	0.4
	Cardiac disorders	Left atrial enlargement	<65 years	270	50.3	1	0.4
	Cardiac disorders	Left atrial enlargement	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Left ventricular failure	<65 years	270	50.3	0	0.0
	Cardiac disorders	Left ventricular failure	>=65 years	267	49.7	1	0.4
	Cardiac disorders	Mitral valve incompetence	<65 years	270	50.3	1	0.4
	Cardiac disorders	Mitral valve incompetence	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Myocardial fibrosis	<65 years	270	50.3	1	0.4
	Cardiac disorders	Myocardial fibrosis	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Myocardial infarction	<65 years	270	50.3	0	0.0
	Cardiac disorders	Myocardial infarction	>=65 years	267	49.7	4	1.5
	Cardiac disorders	Myocardial ischaemia	<65 years	270	50.3	1	0.4
	Cardiac disorders	Myocardial ischaemia	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Pericarditis	<65 years	270	50.3	0	0.0
	Cardiac disorders	Pericarditis	>=65 years	267	49.7	1	0.4
	Cardiac disorders	Sinus bradycardia	<65 years	270	50.3	1	0.4
	Cardiac disorders	Sinus bradycardia	>=65 years	267	49.7	0	0.0
	Cardiac disorders	Supraventricular extrasystoles	<65 years	270	50.3	1	0.4
	Cardiac disorders	Supraventricular extrasystoles	>=65 years	267	49.7	1	0.4
	Cardiac disorders	Tricuspid valve incompetence	<65 years	270	50.3	1	0.4
	Cardiac disorders	Tricuspid valve incompetence	>=65 years	267	49.7	0	0.0
	Congenital, familial and genetic disorders		<65 years	270	50.3	3	1.1
	Congenital, familial and genetic disorders		>=65 years	267	49.7	0	0.0
	Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	<65 years	270	50.3	1	0.4
	Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	>=65 years	267	49.7	0	0.0
	Congenital, familial and genetic disorders	Corneal dystrophy	<65 years	270	50.3	1	0.4
	Congenital, familial and genetic disorders	Corneal dystrophy	>=65 years	267	49.7	0	0.0
	Congenital, familial and genetic disorders	Vertebral artery hypoplasia	<65 years	270	50.3	1	0.4
	Congenital, familial and genetic disorders	Vertebral artery hypoplasia	>=65 years	267	49.7	0	0.0
	Ear and labyrinth disorders		<65 years	270	50.3	3	1.1
	Ear and labyrinth disorders		>=65 years	267	49.7	7	2.6
	Ear and labyrinth disorders	Cerumen impaction	<65 years	270	50.3	0	0.0
	Ear and labyrinth disorders	Cerumen impaction	>=65 years	267	49.7	2	0.7
	Ear and labyrinth disorders	Ear disorder	<65 years	270	50.3	0	0.0
	Ear and labyrinth disorders	Ear disorder	>=65 years	267	49.7	1	0.4
	Ear and labyrinth disorders	Hypoaacusia	<65 years	270	50.3	1	0.4
	Ear and labyrinth disorders	Hypoaacusia	>=65 years	267	49.7	0	0.0
	Ear and labyrinth disorders	Tinnitus	<65 years	270	50.3	1	0.4
	Ear and labyrinth disorders	Tinnitus	>=65 years	267	49.7	0	0.0
	Ear and labyrinth disorders	Vertigo	<65 years	270	50.3	0	0.0
	Ear and labyrinth disorders	Vertigo	>=65 years	267	49.7	3	1.1
	Ear and labyrinth disorders	Vertigo positional	<65 years	270	50.3	1	0.4
	Ear and labyrinth disorders	Vertigo positional	>=65 years	267	49.7	1	0.4
	Endocrine disorders		<65 years	270	50.3	2	0.7

Endocrine disorders		>=65 years	267	49,7	1	0,4
Endocrine disorders	Hypothyroidism	<65 years	270	50,3	2	0,7
Endocrine disorders	Hypothyroidism	>=65 years	267	49,7	1	0,4
Eye disorders		<65 years	270	50,3	74	27,4
Eye disorders		>=65 years	267	49,7	85	31,8
Eye disorders	Abnormal sensation in eye	<65 years	270	50,3	1	0,4
Eye disorders	Abnormal sensation in eye	>=65 years	267	49,7	0	0,0
Eye disorders	Asthenopia	<65 years	270	50,3	0	0,0
Eye disorders	Asthenopia	>=65 years	267	49,7	1	0,4
Eye disorders	Blepharitis allergic	<65 years	270	50,3	0	0,0
Eye disorders	Blepharitis allergic	>=65 years	267	49,7	1	0,4
Eye disorders	Borderline glaucoma	<65 years	270	50,3	0	0,0
Eye disorders	Borderline glaucoma	>=65 years	267	49,7	1	0,4
Eye disorders	Cataract	<65 years	270	50,3	7	2,6
Eye disorders	Cataract	>=65 years	267	49,7	15	5,6
Eye disorders	Cataract nuclear	<65 years	270	50,3	0	0,0
Eye disorders	Cataract nuclear	>=65 years	267	49,7	1	0,4
Eye disorders	Cataract subcapsular	<65 years	270	50,3	0	0,0
Eye disorders	Cataract subcapsular	>=65 years	267	49,7	2	0,7
Eye disorders	Chalazion	<65 years	270	50,3	1	0,4
Eye disorders	Chalazion	>=65 years	267	49,7	1	0,4
Eye disorders	Conjunctival erosion	<65 years	270	50,3	0	0,0
Eye disorders	Conjunctival erosion	>=65 years	267	49,7	1	0,4
Eye disorders	Conjunctival haemorrhage	<65 years	270	50,3	9	3,3
Eye disorders	Conjunctival haemorrhage	>=65 years	267	49,7	14	5,2
Eye disorders	Conjunctivitis allergic	<65 years	270	50,3	1	0,4
Eye disorders	Conjunctivitis allergic	>=65 years	267	49,7	2	0,7
Eye disorders	Conjunctivochalasis	<65 years	270	50,3	0	0,0
Eye disorders	Conjunctivochalasis	>=65 years	267	49,7	1	0,4
Eye disorders	Corneal erosion	<65 years	270	50,3	1	0,4
Eye disorders	Corneal erosion	>=65 years	267	49,7	1	0,4
Eye disorders	Corneal infiltrates	<65 years	270	50,3	0	0,0
Eye disorders	Corneal infiltrates	>=65 years	267	49,7	1	0,4
Eye disorders	Corneal opacity	<65 years	270	50,3	1	0,4
Eye disorders	Corneal opacity	>=65 years	267	49,7	0	0,0
Eye disorders	Cystoid macular oedema	<65 years	270	50,3	5	1,9
Eye disorders	Cystoid macular oedema	>=65 years	267	49,7	1	0,4
Eye disorders	Dacryostenosis acquired	<65 years	270	50,3	0	0,0
Eye disorders	Dacryostenosis acquired	>=65 years	267	49,7	1	0,4
Eye disorders	Dermatochalasia	<65 years	270	50,3	0	0,0
Eye disorders	Dermatochalasia	>=65 years	267	49,7	1	0,4
Eye disorders	Diplopia	<65 years	270	50,3	0	0,0
Eye disorders	Diplopia	>=65 years	267	49,7	1	0,4
Eye disorders	Dry age-related macular degeneration	<65 years	270	50,3	0	0,0
Eye disorders	Dry age-related macular degeneration	>=65 years	267	49,7	1	0,4
Eye disorders	Dry eye	<65 years	270	50,3	5	1,9
Eye disorders	Dry eye	>=65 years	267	49,7	5	1,9
Eye disorders	Entropion	<65 years	270	50,3	0	0,0
Eye disorders	Entropion	>=65 years	267	49,7	1	0,4
Eye disorders	Epiretinal membrane	<65 years	270	50,3	3	1,1
Eye disorders	Epiretinal membrane	>=65 years	267	49,7	7	2,6
Eye disorders	Epi scleritis	<65 years	270	50,3	0	0,0
Eye disorders	Epi scleritis	>=65 years	267	49,7	1	0,4
Eye disorders	Erythema of eyelid	<65 years	270	50,3	1	0,4
Eye disorders	Erythema of eyelid	>=65 years	267	49,7	0	0,0
Eye disorders	Eye allergy	<65 years	270	50,3	1	0,4
Eye disorders	Eye allergy	>=65 years	267	49,7	0	0,0
Eye disorders	Eye discharge	<65 years	270	50,3	0	0,0
Eye disorders	Eye discharge	>=65 years	267	49,7	2	0,7
Eye disorders	Eye irritation	<65 years	270	50,3	0	0,0
Eye disorders	Eye irritation	>=65 years	267	49,7	1	0,4
Eye disorders	Eye pain	<65 years	270	50,3	2	0,7
Eye disorders	Eye pain	>=65 years	267	49,7	1	0,4
Eye disorders	Eye pruritus	<65 years	270	50,3	0	0,0
Eye disorders	Eye pruritus	>=65 years	267	49,7	2	0,7
Eye disorders	Eyelid oedema	<65 years	270	50,3	1	0,4
Eye disorders	Eyelid oedema	>=65 years	267	49,7	0	0,0
Eye disorders	Eyelid pain	<65 years	270	50,3	0	0,0
Eye disorders	Eyelid pain	>=65 years	267	49,7	1	0,4
Eye disorders	Eyelid ptosis	<65 years	270	50,3	1	0,4
Eye disorders	Eyelid ptosis	>=65 years	267	49,7	0	0,0
Eye disorders	Glaucoma	<65 years	270	50,3	2	0,7
Eye disorders	Glaucoma	>=65 years	267	49,7	2	0,7
Eye disorders	Iridocyclitis	<65 years	270	50,3	0	0,0
Eye disorders	Iridocyclitis	>=65 years	267	49,7	2	0,7
Eye disorders	Iritis	<65 years	270	50,3	1	0,4
Eye disorders	Iritis	>=65 years	267	49,7	1	0,4
Eye disorders	Keratitis	<65 years	270	50,3	0	0,0
Eye disorders	Keratitis	>=65 years	267	49,7	2	0,7
Eye disorders	Lacrimation increased	<65 years	270	50,3	3	1,1
Eye disorders	Lacrimation increased	>=65 years	267	49,7	0	0,0
Eye disorders	Macular ischaemia	<65 years	270	50,3	0	0,0
Eye disorders	Macular ischaemia	>=65 years	267	49,7	1	0,4
Eye disorders	Macular oedema	<65 years	270	50,3	10	3,7
Eye disorders	Macular oedema	>=65 years	267	49,7	7	2,6
Eye disorders	Maculopathy	<65 years	270	50,3	1	0,4
Eye disorders	Maculopathy	>=65 years	267	49,7	0	0,0
Eye disorders	Narrow anterior chamber angle	<65 years	270	50,3	1	0,4
Eye disorders	Narrow anterior chamber angle	>=65 years	267	49,7	0	0,0
Eye disorders	Normal tension glaucoma	<65 years	270	50,3	1	0,4
Eye disorders	Normal tension glaucoma	>=65 years	267	49,7	0	0,0
Eye disorders	Ocular discomfort	<65 years	270	50,3	2	0,7
Eye disorders	Ocular discomfort	>=65 years	267	49,7	0	0,0
Eye disorders	Ocular hypertension	<65 years	270	50,3	1	0,4
Eye disorders	Ocular hypertension	>=65 years	267	49,7	1	0,4
Eye disorders	Ocular vascular disorder	<65 years	270	50,3	0	0,0
Eye disorders	Ocular vascular disorder	>=65 years	267	49,7	1	0,4

Eye disorders	Optic disc haemorrhage	<65 years	270	50,3	0	0,0
Eye disorders	Optic disc haemorrhage	>=65 years	267	49,7	1	0,4
Eye disorders	Optic disc vascular disorder	<65 years	270	50,3	1	0,4
Eye disorders	Optic disc vascular disorder	>=65 years	267	49,7	0	0,0
Eye disorders	Periorbital pain	<65 years	270	50,3	1	0,4
Eye disorders	Periorbital pain	>=65 years	267	49,7	0	0,0
Eye disorders	Photopsia	<65 years	270	50,3	1	0,4
Eye disorders	Photopsia	>=65 years	267	49,7	0	0,0
Eye disorders	Posterior capsule opacification	<65 years	270	50,3	1	0,4
Eye disorders	Posterior capsule opacification	>=65 years	267	49,7	1	0,4
Eye disorders	Pterygium	<65 years	270	50,3	0	0,0
Eye disorders	Pterygium	>=65 years	267	49,7	1	0,4
Eye disorders	Punctate keratitis	<65 years	270	50,3	0	0,0
Eye disorders	Punctate keratitis	>=65 years	267	49,7	1	0,4
Eye disorders	Retinal aneurysm	<65 years	270	50,3	0	0,0
Eye disorders	Retinal aneurysm	>=65 years	267	49,7	2	0,7
Eye disorders	Retinal artery embolism	<65 years	270	50,3	0	0,0
Eye disorders	Retinal artery embolism	>=65 years	267	49,7	1	0,4
Eye disorders	Retinal collateral vessels	<65 years	270	50,3	1	0,4
Eye disorders	Retinal collateral vessels	>=65 years	267	49,7	0	0,0
Eye disorders	Retinal cyst	<65 years	270	50,3	4	1,5
Eye disorders	Retinal cyst	>=65 years	267	49,7	0	0,0
Eye disorders	Retinal exudates	<65 years	270	50,3	1	0,4
Eye disorders	Retinal exudates	>=65 years	267	49,7	2	0,7
Eye disorders	Retinal haemorrhage	<65 years	270	50,3	7	2,6
Eye disorders	Retinal haemorrhage	>=65 years	267	49,7	3	1,1
Eye disorders	Retinal ischaemia	<65 years	270	50,3	3	1,1
Eye disorders	Retinal ischaemia	>=65 years	267	49,7	2	0,7
Eye disorders	Retinal neovascularisation	<65 years	270	50,3	2	0,7
Eye disorders	Retinal neovascularisation	>=65 years	267	49,7	0	0,0
Eye disorders	Retinal oedema	<65 years	270	50,3	0	0,0
Eye disorders	Retinal oedema	>=65 years	267	49,7	1	0,4
Eye disorders	Retinal tear	<65 years	270	50,3	1	0,4
Eye disorders	Retinal tear	>=65 years	267	49,7	2	0,7
Eye disorders	Retinal thickening	<65 years	270	50,3	1	0,4
Eye disorders	Retinal thickening	>=65 years	267	49,7	0	0,0
Eye disorders	Retinal vascular disorder	<65 years	270	50,3	0	0,0
Eye disorders	Retinal vascular disorder	>=65 years	267	49,7	1	0,4
Eye disorders	Retinal vein occlusion	<65 years	270	50,3	11	4,1
Eye disorders	Retinal vein occlusion	>=65 years	267	49,7	10	3,7
Eye disorders	Retinopathy hypertensive	<65 years	270	50,3	0	0,0
Eye disorders	Retinopathy hypertensive	>=65 years	267	49,7	1	0,4
Eye disorders	Rhegmatogenous retinal detachment	<65 years	270	50,3	1	0,4
Eye disorders	Rhegmatogenous retinal detachment	>=65 years	267	49,7	0	0,0
Eye disorders	Swelling of eyelid	<65 years	270	50,3	0	0,0
Eye disorders	Swelling of eyelid	>=65 years	267	49,7	1	0,4
Eye disorders	Tractional retinal detachment	<65 years	270	50,3	1	0,4
Eye disorders	Tractional retinal detachment	>=65 years	267	49,7	0	0,0
Eye disorders	Trichiasis	<65 years	270	50,3	0	0,0
Eye disorders	Trichiasis	>=65 years	267	49,7	1	0,4
Eye disorders	Vision blurred	<65 years	270	50,3	0	0,0
Eye disorders	Vision blurred	>=65 years	267	49,7	4	1,5
Eye disorders	Visual acuity reduced	<65 years	270	50,3	5	1,9
Eye disorders	Visual acuity reduced	>=65 years	267	49,7	1	0,4
Eye disorders	Visual field defect	<65 years	270	50,3	0	0,0
Eye disorders	Visual field defect	>=65 years	267	49,7	1	0,4
Eye disorders	Vitreoretinal traction syndrome	<65 years	270	50,3	0	0,0
Eye disorders	Vitreoretinal traction syndrome	>=65 years	267	49,7	2	0,7
Eye disorders	Vitreous degeneration	<65 years	270	50,3	1	0,4
Eye disorders	Vitreous degeneration	>=65 years	267	49,7	0	0,0
Eye disorders	Vitreous detachment	<65 years	270	50,3	10	3,7
Eye disorders	Vitreous detachment	>=65 years	267	49,7	11	4,1
Eye disorders	Vitreous floaters	<65 years	270	50,3	6	2,2
Eye disorders	Vitreous floaters	>=65 years	267	49,7	4	1,5
Eye disorders	Vitreous haemorrhage	<65 years	270	50,3	1	0,4
Eye disorders	Vitreous haemorrhage	>=65 years	267	49,7	1	0,4
Eye disorders	Vitritis	<65 years	270	50,3	1	0,4
Eye disorders	Vitritis	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders		<65 years	270	50,3	20	7,4
Gastrointestinal disorders		>=65 years	267	49,7	14	5,2
Gastrointestinal disorders	Abdominal pain	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Abdominal pain	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders	Abdominal pain upper	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Abdominal pain upper	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Chronic gastritis	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Chronic gastritis	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders	Colitis	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Colitis	>=65 years	267	49,7	2	0,7
Gastrointestinal disorders	Constipation	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Constipation	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Diarrhoea	<65 years	270	50,3	3	1,1
Gastrointestinal disorders	Diarrhoea	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Erosive duodenitis	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Erosive duodenitis	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Functional gastrointestinal disorder	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Gastric haemorrhage	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Gastric polyps	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Gastric polyps	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Gastritis	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Gastritis	>=65 years	267	49,7	3	1,1
Gastrointestinal disorders	Gastroesophageal reflux disease	<65 years	270	50,3	4	1,5
Gastrointestinal disorders	Gastroesophageal reflux disease	>=65 years	267	49,7	2	0,7
Gastrointestinal disorders	Gingival pain	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Gingival pain	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Haemorrhoids	<65 years	270	50,3	2	0,7

Gastrointestinal disorders	Haemorrhoids	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders	Hyperchlorhydria	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Hyperchlorhydria	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders	Large intestine polyp	<65 years	270	50,3	3	1,1
Gastrointestinal disorders	Large intestine polyp	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Mesenteric vein thrombosis	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Nausea	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Nausea	>=65 years	267	49,7	2	0,7
Gastrointestinal disorders	Oesophagitis	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Oesophagitis	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders	Pancreatitis acute	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Pancreatitis acute	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders	Toothache	<65 years	270	50,3	4	1,5
Gastrointestinal disorders	Toothache	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders	Vomiting	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Vomiting	>=65 years	267	49,7	2	0,7
General disorders and administration site conditions		<65 years	270	50,3	8	3,0
General disorders and administration site conditions		>=65 years	267	49,7	6	2,2
General disorders and administration site conditions	Asthenia	<65 years	270	50,3	0	0,0
General disorders and administration site conditions	Asthenia	>=65 years	267	49,7	2	0,7
General disorders and administration site conditions	Chest discomfort	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Chest discomfort	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions	Death	<65 years	270	50,3	0	0,0
General disorders and administration site conditions	Death	>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Fatigue	<65 years	270	50,3	0	0,0
General disorders and administration site conditions	Fatigue	>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Gait disturbance	<65 years	270	50,3	0	0,0
General disorders and administration site conditions	Gait disturbance	>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Illness	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Illness	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions	Influenza like illness	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Influenza like illness	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions	Oedema	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Oedema	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions	Pain	<65 years	270	50,3	3	1,1
General disorders and administration site conditions	Pain	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions	Peripheral swelling	<65 years	270	50,3	0	0,0
General disorders and administration site conditions	Peripheral swelling	>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Physical deconditioning	<65 years	270	50,3	0	0,0
General disorders and administration site conditions	Physical deconditioning	>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Pyrexia	<65 years	270	50,3	2	0,7
General disorders and administration site conditions	Pyrexia	>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Vascular stent stenosis	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Vascular stent stenosis	>=65 years	267	49,7	0	0,0
Hepatobiliary disorders		<65 years	270	50,3	5	1,9
Hepatobiliary disorders		>=65 years	267	49,7	4	1,5
Hepatobiliary disorders	Bile duct stone	<65 years	270	50,3	1	0,4
Hepatobiliary disorders	Bile duct stone	>=65 years	267	49,7	0	0,0
Hepatobiliary disorders	Cholecystitis chronic	<65 years	270	50,3	0	0,0
Hepatobiliary disorders	Cholecystitis chronic	>=65 years	267	49,7	1	0,4
Hepatobiliary disorders	Cholelithiasis	<65 years	270	50,3	1	0,4
Hepatobiliary disorders	Cholelithiasis	>=65 years	267	49,7	3	1,1
Hepatobiliary disorders	Hepatic cyst	<65 years	270	50,3	0	0,0
Hepatobiliary disorders	Hepatic cyst	>=65 years	267	49,7	1	0,4
Hepatobiliary disorders	Hepatic failure	<65 years	270	50,3	1	0,4
Hepatobiliary disorders	Hepatic failure	>=65 years	267	49,7	0	0,0
Hepatobiliary disorders	Hepatic function abnormal	<65 years	270	50,3	1	0,4
Hepatobiliary disorders	Hepatic function abnormal	>=65 years	267	49,7	0	0,0
Hepatobiliary disorders	Hepatic steatosis	<65 years	270	50,3	1	0,4
Hepatobiliary disorders	Hepatic steatosis	>=65 years	267	49,7	0	0,0
Immune system disorders		<65 years	270	50,3	2	0,7
Immune system disorders		>=65 years	267	49,7	3	1,1
Immune system disorders	Allergic oedema	<65 years	270	50,3	0	0,0
Immune system disorders	Allergic oedema	>=65 years	267	49,7	1	0,4
Immune system disorders	Allergy to plants	<65 years	270	50,3	1	0,4
Immune system disorders	Allergy to plants	>=65 years	267	49,7	0	0,0
Immune system disorders	Hypersensitivity	<65 years	270	50,3	1	0,4
Immune system disorders	Hypersensitivity	>=65 years	267	49,7	1	0,4
Immune system disorders	Seasonal allergy	<65 years	270	50,3	0	0,0
Immune system disorders	Seasonal allergy	>=65 years	267	49,7	1	0,4
Infections and infestations		<65 years	270	50,3	73	27,0
Infections and infestations		>=65 years	267	49,7	73	27,3
Infections and infestations	Borrelia infection	<65 years	270	50,3	0	0,0
Infections and infestations	Borrelia infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Bronchitis	<65 years	270	50,3	3	1,1
Infections and infestations	Bronchitis	>=65 years	267	49,7	3	1,1
Infections and infestations	COVID-19	<65 years	270	50,3	30	11,1
Infections and infestations	COVID-19	>=65 years	267	49,7	28	10,5
Infections and infestations	Cellulitis	<65 years	270	50,3	0	0,0
Infections and infestations	Cellulitis	>=65 years	267	49,7	3	1,1
Infections and infestations	Conjunctivitis	<65 years	270	50,3	0	0,0
Infections and infestations	Conjunctivitis	>=65 years	267	49,7	5	1,9
Infections and infestations	Coronavirus infection	<65 years	270	50,3	1	0,4
Infections and infestations	Coronavirus infection	>=65 years	267	49,7	0	0,0
Infections and infestations	Cytitis	<65 years	270	50,3	2	0,7
Infections and infestations	Cytitis	>=65 years	267	49,7	0	0,0
Infections and infestations	Dermatophytosis of nail	<65 years	270	50,3	0	0,0
Infections and infestations	Dermatophytosis of nail	>=65 years	267	49,7	1	0,4
Infections and infestations	Ear infection	<65 years	270	50,3	1	0,4
Infections and infestations	Ear infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Furuncle	<65 years	270	50,3	0	0,0
Infections and infestations	Furuncle	>=65 years	267	49,7	1	0,4
Infections and infestations	Gastroenteritis	<65 years	270	50,3	3	1,1

Infections and infestations	Gastroenteritis	>=65 years	267	49,7	2	0,7
Infections and infestations	Gastroenteritis viral	<65 years	270	50,3	1	0,4
Infections and infestations	Gastroenteritis viral	>=65 years	267	49,7	1	0,4
Infections and infestations	Gastrointestinal infection	<65 years	270	50,3	1	0,4
Infections and infestations	Gastrointestinal infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Gingival abscess	<65 years	270	50,3	0	0,0
Infections and infestations	Gingival abscess	>=65 years	267	49,7	1	0,4
Infections and infestations	Groin abscess	<65 years	270	50,3	1	0,4
Infections and infestations	Groin abscess	>=65 years	267	49,7	0	0,0
Infections and infestations	Herpes zoster	<65 years	270	50,3	1	0,4
Infections and infestations	Herpes zoster	>=65 years	267	49,7	2	0,7
Infections and infestations	Hordeolum	<65 years	270	50,3	0	0,0
Infections and infestations	Hordeolum	>=65 years	267	49,7	3	1,1
Infections and infestations	Influenza	<65 years	270	50,3	7	2,6
Infections and infestations	Influenza	>=65 years	267	49,7	2	0,7
Infections and infestations	Intestinal sepsis	<65 years	270	50,3	0	0,0
Infections and infestations	Intestinal sepsis	>=65 years	267	49,7	1	0,4
Infections and infestations	Lower respiratory tract infection	<65 years	270	50,3	0	0,0
Infections and infestations	Lower respiratory tract infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Nail infection	<65 years	270	50,3	0	0,0
Infections and infestations	Nail infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Nasopharyngitis	<65 years	270	50,3	11	4,1
Infections and infestations	Nasopharyngitis	>=65 years	267	49,7	6	2,2
Infections and infestations	Oral herpes	<65 years	267	49,7	1	0,4
Infections and infestations	Oral herpes	>=65 years	267	49,7	0	0,0
Infections and infestations	Otitis media	<65 years	270	50,3	1	0,4
Infections and infestations	Otitis media	>=65 years	267	49,7	1	0,4
Infections and infestations	Otitis media acute	<65 years	270	50,3	1	0,4
Infections and infestations	Otitis media acute	>=65 years	267	49,7	0	0,0
Infections and infestations	Pelvic inflammatory disease	<65 years	270	50,3	1	0,4
Infections and infestations	Pelvic inflammatory disease	>=65 years	267	49,7	0	0,0
Infections and infestations	Periodontitis	<65 years	270	50,3	0	0,0
Infections and infestations	Periodontitis	>=65 years	267	49,7	1	0,4
Infections and infestations	Pharyngitis	<65 years	270	50,3	1	0,4
Infections and infestations	Pharyngitis	>=65 years	267	49,7	1	0,4
Infections and infestations	Pneumonia	<65 years	270	50,3	2	0,7
Infections and infestations	Pneumonia	>=65 years	267	49,7	3	1,1
Infections and infestations	Post-acute COVID-19 syndrome	<65 years	270	50,3	1	0,4
Infections and infestations	Post-acute COVID-19 syndrome	>=65 years	267	49,7	0	0,0
Infections and infestations	Postoperative wound infection	<65 years	270	50,3	1	0,4
Infections and infestations	Postoperative wound infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Pulpitis dental	<65 years	270	50,3	0	0,0
Infections and infestations	Pulpitis dental	>=65 years	267	49,7	1	0,4
Infections and infestations	Pyelonephritis	<65 years	270	50,3	0	0,0
Infections and infestations	Pyelonephritis	>=65 years	267	49,7	1	0,4
Infections and infestations	Respiratory tract infection	<65 years	270	50,3	4	1,5
Infections and infestations	Respiratory tract infection	>=65 years	267	49,7	0	0,0
Infections and infestations	Rhinitis	<65 years	270	50,3	1	0,4
Infections and infestations	Rhinitis	>=65 years	267	49,7	0	0,0
Infections and infestations	Rotavirus infection	<65 years	270	50,3	1	0,4
Infections and infestations	Rotavirus infection	>=65 years	267	49,7	0	0,0
Infections and infestations	Sepsis	<65 years	270	50,3	0	0,0
Infections and infestations	Sepsis	>=65 years	267	49,7	1	0,4
Infections and infestations	Sinusitis	<65 years	270	50,3	0	0,0
Infections and infestations	Sinusitis	>=65 years	267	49,7	2	0,7
Infections and infestations	Suspected COVID-19	<65 years	270	50,3	6	2,2
Infections and infestations	Suspected COVID-19	>=65 years	267	49,7	3	1,1
Infections and infestations	Tinea cruris	<65 years	270	50,3	0	0,0
Infections and infestations	Tinea cruris	>=65 years	267	49,7	1	0,4
Infections and infestations	Tinea pedis	<65 years	270	50,3	1	0,4
Infections and infestations	Tinea pedis	>=65 years	267	49,7	0	0,0
Infections and infestations	Tonsillitis	<65 years	270	50,3	1	0,4
Infections and infestations	Tonsillitis	>=65 years	267	49,7	1	0,4
Infections and infestations	Tooth infection	<65 years	270	50,3	0	0,0
Infections and infestations	Tooth infection	>=65 years	267	49,7	3	1,1
Infections and infestations	Tracheitis	<65 years	270	50,3	1	0,4
Infections and infestations	Tracheitis	>=65 years	267	49,7	0	0,0
Infections and infestations	Upper respiratory tract infection	<65 years	270	50,3	10	3,7
Infections and infestations	Upper respiratory tract infection	>=65 years	267	49,7	6	2,2
Infections and infestations	Urinary tract infection	<65 years	270	50,3	2	0,7
Infections and infestations	Urinary tract infection	>=65 years	267	49,7	2	0,7
Infections and infestations	Viral infection	<65 years	270	50,3	1	0,4
Infections and infestations	Viral infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Vulvovaginal candidiasis	<65 years	270	50,3	1	0,4
Infections and infestations	Vulvovaginal candidiasis	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications		<65 years	270	50,3	18	6,7
Injury, poisoning and procedural complications		>=65 years	267	49,7	24	9,0
Injury, poisoning and procedural complications	Arthropod bite	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Arthropod bite	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Back injury	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Back injury	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Burns third degree	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Burns third degree	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Chillblains	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Chillblains	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Clavicle fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Clavicle fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Comminuted fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Contusion	<65 years	270	50,3	4	1,5
Injury, poisoning and procedural complications	Contusion	>=65 years	267	49,7	2	0,7
Injury, poisoning and procedural complications	Corneal abrasion	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Corneal abrasion	>=65 years	267	49,7	2	0,7
Injury, poisoning and procedural complications	Eye injury	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Eye injury	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Facial bones fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Facial bones fracture	>=65 years	267	49,7	0	0,0

Injury, poisoning and procedural complications	Fall	<65 years	270	50,3	5	1,9
Injury, poisoning and procedural complications	Fall	>=65 years	267	49,7	9	3,4
Injury, poisoning and procedural complications	Femur fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Foot fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Foot fracture	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Head injury	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Head injury	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Hip fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Hip fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Immunisation reaction	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Immunisation reaction	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Joint injury	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Joint injury	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Ligament sprain	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Ligament sprain	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Limb injury	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Limb injury	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Medication error	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Medication error	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Meningeal injury	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Meningeal injury	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Muscle strain	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Muscle strain	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Radius fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Radius fracture	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Skin abrasion	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Skin abrasion	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Skin injury	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Skin injury	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Skin laceration	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Skin laceration	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Spinal column injury	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Spinal column injury	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Sternal fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Subdural haematoma	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Thermal burn	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Thermal burn	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Tooth fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Ulna fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Ulna fracture	>=65 years	267	49,7	1	0,4
Investigations		<65 years	270	50,3	19	7,0
Investigations		>=65 years	267	49,7	15	5,6
Investigations	Blood glucose increased	<65 years	270	50,3	1	0,4
Investigations	Blood glucose increased	>=65 years	267	49,7	0	0,0
Investigations	Blood potassium decreased	<65 years	270	50,3	1	0,4
Investigations	Blood potassium decreased	>=65 years	267	49,7	0	0,0
Investigations	Blood pressure increased	<65 years	270	50,3	2	0,7
Investigations	Blood pressure increased	>=65 years	267	49,7	1	0,4
Investigations	Blood sodium decreased	<65 years	270	50,3	0	0,0
Investigations	Blood sodium decreased	>=65 years	267	49,7	1	0,4
Investigations	Glomerular filtration rate decreased	<65 years	270	50,3	0	0,0
Investigations	Glomerular filtration rate decreased	>=65 years	267	49,7	1	0,4
Investigations	Intraocular pressure increased	<65 years	270	50,3	13	4,8
Investigations	Intraocular pressure increased	>=65 years	267	49,7	8	3,0
Investigations	Platelet count increased	<65 years	270	50,3	1	0,4
Investigations	Platelet count increased	>=65 years	267	49,7	0	0,0
Investigations	SARS-Cov-2 test positive	<65 years	270	50,3	0	0,0
Investigations	SARS-Cov-2 test positive	>=65 years	267	49,7	2	0,7
Investigations	Troponin increased	<65 years	270	50,3	0	0,0
Investigations	Troponin increased	>=65 years	267	49,7	1	0,4
Investigations	Weight decreased	<65 years	270	50,3	0	0,0
Investigations	Weight decreased	>=65 years	267	49,7	1	0,4
Investigations	White blood cell count decreased	<65 years	270	50,3	1	0,4
Investigations	White blood cell count decreased	>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders		<65 years	270	50,3	16	5,9
Metabolism and nutrition disorders		>=65 years	267	49,7	11	4,1
Metabolism and nutrition disorders	Dehydration	<65 years	270	50,3	0	0,0
Metabolism and nutrition disorders	Dehydration	>=65 years	267	49,7	2	0,7
Metabolism and nutrition disorders	Diabetes mellitus	<65 years	270	50,3	1	0,4
Metabolism and nutrition disorders	Diabetes mellitus	>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	<65 years	270	50,3	1	0,4
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders	Folate deficiency	<65 years	270	50,3	1	0,4
Metabolism and nutrition disorders	Folate deficiency	>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders	Gout	<65 years	270	50,3	2	0,7
Metabolism and nutrition disorders	Gout	>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	<65 years	270	50,3	5	1,9
Metabolism and nutrition disorders	Hypercholesterolaemia	>=65 years	267	49,7	4	1,5
Metabolism and nutrition disorders	Hyperglycaemia	<65 years	270	50,3	1	0,4
Metabolism and nutrition disorders	Hyperglycaemia	>=65 years	267	49,7	1	0,4
Metabolism and nutrition disorders	Hyperhomocysteinaemia	<65 years	270	50,3	1	0,4
Metabolism and nutrition disorders	Hyperhomocysteinaemia	>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders	Hyperkalaemia	<65 years	270	50,3	0	0,0
Metabolism and nutrition disorders	Hyperkalaemia	>=65 years	267	49,7	1	0,4
Metabolism and nutrition disorders	Hyperlipidaemia	<65 years	270	50,3	2	0,7
Metabolism and nutrition disorders	Hyperlipidaemia	>=65 years	267	49,7	2	0,7
Metabolism and nutrition disorders	Hyperuricaemia	<65 years	270	50,3	0	0,0
Metabolism and nutrition disorders	Hyperuricaemia	>=65 years	267	49,7	1	0,4
Metabolism and nutrition disorders	Hypoproteinaemia	<65 years	270	50,3	1	0,4
Metabolism and nutrition disorders	Hypoproteinaemia	>=65 years	267	49,7	0	0,0

Metabolism and nutrition disorders	Obesity	<65 years	270	50.3	0	0.0
Metabolism and nutrition disorders	Obesity	>=65 years	267	49.7	2	0.7
Metabolism and nutrition disorders	Type 2 diabetes mellitus	<65 years	270	50.3	3	1.1
Metabolism and nutrition disorders	Type 2 diabetes mellitus	>=65 years	267	49.7	0	0.0
Metabolism and nutrition disorders	Vitamin B12 deficiency	<65 years	270	50.3	0	0.0
Metabolism and nutrition disorders	Vitamin B12 deficiency	>=65 years	267	49.7	1	0.4
Metabolism and nutrition disorders	Vitamin D deficiency	<65 years	270	50.3	2	0.7
Metabolism and nutrition disorders	Vitamin D deficiency	>=65 years	267	49.7	0	0.0
Musculoskeletal and connective tissue disorders		<65 years	270	50.3	20	7.4
Musculoskeletal and connective tissue disorders		>=65 years	267	49.7	39	14.6
Musculoskeletal and connective tissue disorders	Arthralgia	<65 years	270	50.3	2	0.7
Musculoskeletal and connective tissue disorders	Arthralgia	>=65 years	267	49.7	5	1.9
Musculoskeletal and connective tissue disorders	Arthritis	<65 years	270	50.3	1	0.4
Musculoskeletal and connective tissue disorders	Arthritis	>=65 years	267	49.7	2	0.7
Musculoskeletal and connective tissue disorders	Back pain	<65 years	270	50.3	3	1.1
Musculoskeletal and connective tissue disorders	Back pain	>=65 years	267	49.7	7	2.6
Musculoskeletal and connective tissue disorders	Bone disorder	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Bone disorder	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Bursitis	<65 years	270	50.3	1	0.4
Musculoskeletal and connective tissue disorders	Bursitis	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Exostosis	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Exostosis	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Fibromyalgia	<65 years	270	50.3	1	0.4
Musculoskeletal and connective tissue disorders	Fibromyalgia	>=65 years	267	49.7	0	0.0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	<65 years	270	50.3	2	0.7
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Joint swelling	<65 years	270	50.3	1	0.4
Musculoskeletal and connective tissue disorders	Joint swelling	>=65 years	267	49.7	0	0.0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Muscle contracture	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Muscle contracture	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Muscle spasms	<65 years	270	50.3	1	0.4
Musculoskeletal and connective tissue disorders	Muscle spasms	>=65 years	267	49.7	2	0.7
Musculoskeletal and connective tissue disorders	Muscular weakness	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Muscular weakness	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Myalgia	<65 years	270	50.3	1	0.4
Musculoskeletal and connective tissue disorders	Myalgia	>=65 years	267	49.7	4	1.5
Musculoskeletal and connective tissue disorders	Neck pain	<65 years	270	50.3	1	0.4
Musculoskeletal and connective tissue disorders	Neck pain	>=65 years	267	49.7	0	0.0
Musculoskeletal and connective tissue disorders	Osteoarthritis	<65 years	270	50.3	3	1.1
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=65 years	267	49.7	5	1.9
Musculoskeletal and connective tissue disorders	Osteopenia	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Osteopenia	>=65 years	267	49.7	2	0.7
Musculoskeletal and connective tissue disorders	Osteoporosis	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Osteoporosis	>=65 years	267	49.7	2	0.7
Musculoskeletal and connective tissue disorders	Pain in extremity	<65 years	270	50.3	2	0.7
Musculoskeletal and connective tissue disorders	Pain in extremity	>=65 years	267	49.7	3	1.1
Musculoskeletal and connective tissue disorders	Plantar fasciitis	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Rheumatoid arthritis	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Rheumatoid arthritis	>=65 years	267	49.7	2	0.7
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	<65 years	270	50.3	2	0.7
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	>=65 years	267	49.7	2	0.7
Musculoskeletal and connective tissue disorders	Spinal pain	<65 years	270	50.3	1	0.4
Musculoskeletal and connective tissue disorders	Spinal pain	>=65 years	267	49.7	4	1.5
Musculoskeletal and connective tissue disorders	Tendon disorder	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Tendon disorder	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Tenosynovitis	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Tenosynovitis	>=65 years	267	49.7	1	0.4
Musculoskeletal and connective tissue disorders	Vertebral foraminal stenosis	<65 years	270	50.3	0	0.0
Musculoskeletal and connective tissue disorders	Vertebral foraminal stenosis	>=65 years	267	49.7	1	0.4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<65 years	270	50.3	2	0.7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=65 years	267	49.7	5	1.9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bowen's disease	<65 years	270	50.3	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bowen's disease	>=65 years	267	49.7	1	0.4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<65 years	270	50.3	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=65 years	267	49.7	1	0.4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	<65 years	270	50.3	1	0.4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	>=65 years	267	49.7	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lung neoplasm	<65 years	270	50.3	1	0.4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lung neoplasm	>=65 years	267	49.7	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	<65 years	270	50.3	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	>=65 years	267	49.7	1	0.4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	<65 years	270	50.3	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	>=65 years	267	49.7	1	0.4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	<65 years	270	50.3	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	>=65 years	267	49.7	1	0.4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	<65 years	270	50.3	0	0.0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	>=65 years	267	49.7	1	0.4
Nervous system disorders		<65 years	270	50.3	22	8.1
Nervous system disorders		>=65 years	267	49.7	25	9.4
Nervous system disorders	Carotid arteriosclerosis	<65 years	270	50.3	0	0.0
Nervous system disorders	Carotid arteriosclerosis	>=65 years	267	49.7	1	0.4
Nervous system disorders	Carotid artery stenosis	<65 years	270	50.3	0	0.0
Nervous system disorders	Carotid artery stenosis	>=65 years	267	49.7	1	0.4
Nervous system disorders	Cerebral atrophy	<65 years	270	50.3	0	0.0
Nervous system disorders	Cerebral atrophy	>=65 years	267	49.7	1	0.4
Nervous system disorders	Cerebral haematoma	<65 years	270	50.3	0	0.0
Nervous system disorders	Cerebral haematoma	>=65 years	267	49.7	1	0.4
Nervous system disorders	Cerebral infarction	<65 years	270	50.3	2	0.7
Nervous system disorders	Cerebral infarction	>=65 years	267	49.7	0	0.0
Nervous system disorders	Cerebral thrombosis	<65 years	270	50.3	1	0.4
Nervous system disorders	Cerebral thrombosis	>=65 years	267	49.7	0	0.0
Nervous system disorders	Cerebrovascular accident	<65 years	270	50.3	0	0.0
Nervous system disorders	Cerebrovascular accident	>=65 years	267	49.7	2	0.7
Nervous system disorders	Cervical radiculopathy	<65 years	270	50.3	1	0.4
Nervous system disorders	Cervical radiculopathy	>=65 years	267	49.7	0	0.0
Nervous system disorders	Cognitive disorder	<65 years	270	50.3	0	0.0
Nervous system disorders	Cognitive disorder	>=65 years	267	49.7	1	0.4
Nervous system disorders	Dementia Alzheimer's type	<65 years	270	50.3	0	0.0
Nervous system disorders	Dementia Alzheimer's type	>=65 years	267	49.7	1	0.4
Nervous system disorders	Diabetic neuropathy	<65 years	270	50.3	1	0.4
Nervous system disorders	Diabetic neuropathy	>=65 years	267	49.7	0	0.0
Nervous system disorders	Disturbance in attention	<65 years	270	50.3	0	0.0
Nervous system disorders	Disturbance in attention	>=65 years	267	49.7	1	0.4
Nervous system disorders	Dizziness	<65 years	270	50.3	3	1.1
Nervous system disorders	Dizziness	>=65 years	267	49.7	1	0.4
Nervous system disorders	Epilepsy	<65 years	270	50.3	0	0.0
Nervous system disorders	Epilepsy	>=65 years	267	49.7	1	0.4
Nervous system disorders	Headache	<65 years	270	50.3	7	2.6
Nervous system disorders	Headache	>=65 years	267	49.7	3	1.1
Nervous system disorders	Hypertensive encephalopathy	<65 years	270	50.3	1	0.4
Nervous system disorders	Hypertensive encephalopathy	>=65 years	267	49.7	0	0.0
Nervous system disorders	Hypoaesthesia	<65 years	270	50.3	1	0.4
Nervous system disorders	Hypoaesthesia	>=65 years	267	49.7	0	0.0
Nervous system disorders	Intracranial aneurysm	<65 years	270	50.3	0	0.0
Nervous system disorders	Intracranial aneurysm	>=65 years	267	49.7	1	0.4
Nervous system disorders	Ischaemic stroke	<65 years	270	50.3	0	0.0
Nervous system disorders	Ischaemic stroke	>=65 years	267	49.7	2	0.7
Nervous system disorders	Loss of consciousness	<65 years	270	50.3	0	0.0
Nervous system disorders	Loss of consciousness	>=65 years	267	49.7	1	0.4
Nervous system disorders	Memory impairment	<65 years	270	50.3	0	0.0
Nervous system disorders	Memory impairment	>=65 years	267	49.7	1	0.4
Nervous system disorders	Migraine	<65 years	270	50.3	1	0.4
Nervous system disorders	Migraine	>=65 years	267	49.7	0	0.0
Nervous system disorders	Multiple sclerosis	<65 years	270	50.3	0	0.0
Nervous system disorders	Multiple sclerosis	>=65 years	267	49.7	1	0.4
Nervous system disorders	Myelopathy	<65 years	270	50.3	0	0.0
Nervous system disorders	Myelopathy	>=65 years	267	49.7	1	0.4
Nervous system disorders	Narcolepsy	<65 years	270	50.3	1	0.4
Nervous system disorders	Narcolepsy	>=65 years	267	49.7	0	0.0
Nervous system disorders	Neuropathy peripheral	<65 years	270	50.3	1	0.4
Nervous system disorders	Neuropathy peripheral	>=65 years	267	49.7	1	0.4
Nervous system disorders	Ophthalmic migraine	<65 years	270	50.3	1	0.4
Nervous system disorders	Ophthalmic migraine	>=65 years	267	49.7	0	0.0
Nervous system disorders	Presyncope	<65 years	270	50.3	1	0.4
Nervous system disorders	Presyncope	>=65 years	267	49.7	0	0.0
Nervous system disorders	Sciatica	<65 years	270	50.3	3	1.1
Nervous system disorders	Sciatica	>=65 years	267	49.7	2	0.7
Nervous system disorders	Sinus headache	<65 years	270	50.3	0	0.0
Nervous system disorders	Sinus headache	>=65 years	267	49.7	1	0.4
Nervous system disorders	Syncope	<65 years	270	50.3	2	0.7
Nervous system disorders	Syncope	>=65 years	267	49.7	0	0.0
Nervous system disorders	Tension headache	<65 years	270	50.3	1	0.4
Nervous system disorders	Tension headache	>=65 years	267	49.7	1	0.4
Nervous system disorders	White matter lesion	<65 years	270	50.3	0	0.0
Nervous system disorders	White matter lesion	>=65 years	267	49.7	1	0.4
Product issues		<65 years	270	50.3	0	0.0
Product issues		>=65 years	267	49.7	1	0.4
Product issues	Device malfunction	<65 years	270	50.3	0	0.0
Product issues	Device malfunction	>=65 years	267	49.7	1	0.4
Psychiatric disorders		<65 years	270	50.3	3	1.1
Psychiatric disorders		>=65 years	267	49.7	6	2.2
Psychiatric disorders	Anxiety	<65 years	270	50.3	1	0.4
Psychiatric disorders	Anxiety	>=65 years	267	49.7	1	0.4
Psychiatric disorders	Confusional state	<65 years	270	50.3	0	0.0
Psychiatric disorders	Confusional state	>=65 years	267	49.7	2	0.7
Psychiatric disorders	Delirium	<65 years	270	50.3	0	0.0
Psychiatric disorders	Delirium	>=65 years	267	49.7	1	0.4
Psychiatric disorders	Depression	<65 years	270	50.3	1	0.4
Psychiatric disorders	Depression	>=65 years	267	49.7	1	0.4
Psychiatric disorders	Insomnia	<65 years	270	50.3	1	0.4
Psychiatric disorders	Insomnia	>=65 years	267	49.7	1	0.4
Psychiatric disorders	Somatic symptom disorder	<65 years	270	50.3	1	0.4
Psychiatric disorders	Somatic symptom disorder	>=65 years	267	49.7	0	0.0
Renal and urinary disorders		<65 years	270	50.3	4	1.5
Renal and urinary disorders		>=65 years	267	49.7	10	3.7
Renal and urinary disorders	Acute kidney injury	<65 years	270	50.3	0	0.0
Renal and urinary disorders	Acute kidney injury	>=65 years	267	49.7	2	0.7
Renal and urinary disorders	Chronic kidney disease	<65 years	270	50.3	1	0.4
Renal and urinary disorders	Chronic kidney disease	>=65 years	267	49.7	1	0.4

Renal and urinary disorders	Diabetic nephropathy	<65 years	270	50,3	1	0,4
Renal and urinary disorders	Diabetic nephropathy	>=65 years	267	49,7	0	0,0
Renal and urinary disorders	Haematuria	<65 years	270	50,3	0	0,0
Renal and urinary disorders	Haematuria	>=65 years	267	49,7	1	0,4
Renal and urinary disorders	Nephrolithiasis	<65 years	270	50,3	1	0,4
Renal and urinary disorders	Nephrolithiasis	>=65 years	267	49,7	1	0,4
Renal and urinary disorders	Renal colic	<65 years	270	50,3	0	0,0
Renal and urinary disorders	Renal colic	>=65 years	267	49,7	1	0,4
Renal and urinary disorders	Renal cyst	<65 years	270	50,3	2	0,7
Renal and urinary disorders	Renal cyst	>=65 years	267	49,7	2	0,7
Renal and urinary disorders	Renal mass	<65 years	270	50,3	0	0,0
Renal and urinary disorders	Renal mass	>=65 years	267	49,7	1	0,4
Renal and urinary disorders	Urinary incontinence	<65 years	270	50,3	0	0,0
Renal and urinary disorders	Urinary incontinence	>=65 years	267	49,7	1	0,4
Reproductive system and breast disorders		<65 years	270	50,3	2	0,7
Reproductive system and breast disorders		>=65 years	267	49,7	3	1,1
Reproductive system and breast disorders	Benign prostatic hyperplasia	<65 years	270	50,3	2	0,7
Reproductive system and breast disorders	Benign prostatic hyperplasia	>=65 years	267	49,7	1	0,4
Reproductive system and breast disorders	Erectile dysfunction	<65 years	270	50,3	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	>=65 years	267	49,7	2	0,7
Reproductive system and breast disorders	Prostatitis	<65 years	270	50,3	0	0,0
Reproductive system and breast disorders	Prostatitis	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders		<65 years	270	50,3	7	2,6
Respiratory, thoracic and mediastinal disorders		>=65 years	267	49,7	13	4,9
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=65 years	267	49,7	2	0,7
Respiratory, thoracic and mediastinal disorders	Cough	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	>=65 years	267	49,7	3	1,1
Respiratory, thoracic and mediastinal disorders	Dyspnoea	<65 years	270	50,3	1	0,4
Respiratory, thoracic and mediastinal disorders	Dyspnoea	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Emphysema	<65 years	270	50,3	1	0,4
Respiratory, thoracic and mediastinal disorders	Emphysema	>=65 years	267	49,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Eplaxaxis	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Eplaxaxis	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Hypoventilation	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Hypoventilation	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Lung disorder	<65 years	270	50,3	1	0,4
Respiratory, thoracic and mediastinal disorders	Lung disorder	>=65 years	267	49,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung hyperinflation	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung hyperinflation	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<65 years	270	50,3	1	0,4
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=65 years	267	49,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Pneumonitis	<65 years	270	50,3	1	0,4
Respiratory, thoracic and mediastinal disorders	Pneumonitis	>=65 years	267	49,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary fibrosis	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary fibrosis	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary mass	<65 years	270	50,3	2	0,7
Respiratory, thoracic and mediastinal disorders	Pulmonary mass	>=65 years	267	49,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Respiratory failure	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Respiratory failure	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	<65 years	270	50,3	2	0,7
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	>=65 years	267	49,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	<65 years	270	50,3	1	0,4
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	>=65 years	267	49,7	1	0,4
Skin and subcutaneous tissue disorders		<65 years	270	50,3	8	3,0
Skin and subcutaneous tissue disorders		>=65 years	267	49,7	4	1,5
Skin and subcutaneous tissue disorders	Actinic keratosis	<65 years	270	50,3	0	0,0
Skin and subcutaneous tissue disorders	Actinic keratosis	>=65 years	267	49,7	1	0,4
Skin and subcutaneous tissue disorders	Dermatitis	<65 years	270	50,3	1	0,4
Skin and subcutaneous tissue disorders	Dermatitis	>=65 years	267	49,7	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	<65 years	270	50,3	2	0,7
Skin and subcutaneous tissue disorders	Dermatitis contact	>=65 years	267	49,7	0	0,0
Skin and subcutaneous tissue disorders	Eczema	<65 years	270	50,3	1	0,4
Skin and subcutaneous tissue disorders	Eczema	>=65 years	267	49,7	0	0,0
Skin and subcutaneous tissue disorders	Miliaria	<65 years	270	50,3	1	0,4
Skin and subcutaneous tissue disorders	Miliaria	>=65 years	267	49,7	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	<65 years	270	50,3	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	>=65 years	267	49,7	1	0,4
Skin and subcutaneous tissue disorders	Pruritus	<65 years	270	50,3	0	0,0
Skin and subcutaneous tissue disorders	Pruritus	>=65 years	267	49,7	2	0,7
Skin and subcutaneous tissue disorders	Rash	<65 years	270	50,3	1	0,4
Skin and subcutaneous tissue disorders	Rash	>=65 years	267	49,7	0	0,0
Skin and subcutaneous tissue disorders	Seborrhoeic dermatitis	<65 years	270	50,3	1	0,4
Skin and subcutaneous tissue disorders	Seborrhoeic dermatitis	>=65 years	267	49,7	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	<65 years	270	50,3	1	0,4
Skin and subcutaneous tissue disorders	Skin ulcer	>=65 years	267	49,7	0	0,0
Social circumstances		<65 years	270	50,3	0	0,0
Social circumstances		>=65 years	267	49,7	1	0,4
Social circumstances	Joint prosthesis user	<65 years	270	50,3	0	0,0
Social circumstances	Joint prosthesis user	>=65 years	267	49,7	1	0,4
Surgical and medical procedures		<65 years	270	50,3	1	0,4
Surgical and medical procedures		>=65 years	267	49,7	4	1,5
Surgical and medical procedures	Knee arthroplasty	<65 years	270	50,3	1	0,4

Surgical and medical procedures	Knee arthroplasty	>=65 years	267	49.7	0	0.0
Surgical and medical procedures	Large intestinal polypectomy	<65 years	270	50.3	0	0.0
Surgical and medical procedures	Large intestinal polypectomy	>=65 years	267	49.7	1	0.4
Surgical and medical procedures	Mole excision	<65 years	270	50.3	0	0.0
Surgical and medical procedures	Mole excision	>=65 years	267	49.7	1	0.4
Surgical and medical procedures	Shoulder arthroplasty	<65 years	270	50.3	0	0.0
Surgical and medical procedures	Shoulder arthroplasty	>=65 years	267	49.7	1	0.4
Surgical and medical procedures	Transurethral prostatectomy	<65 years	270	50.3	0	0.0
Surgical and medical procedures	Transurethral prostatectomy	>=65 years	267	49.7	1	0.4
Vascular disorders		<65 years	270	50.3	26	9.6
Vascular disorders		>=65 years	267	49.7	12	4.5
Vascular disorders	Aortic stenosis	<65 years	270	50.3	0	0.0
Vascular disorders	Aortic stenosis	>=65 years	267	49.7	1	0.4
Vascular disorders	Arteriosclerosis	<65 years	270	50.3	3	1.1
Vascular disorders	Arteriosclerosis	>=65 years	267	49.7	1	0.4
Vascular disorders	Brachiocephalic arteriosclerosis	<65 years	270	50.3	1	0.4
Vascular disorders	Brachiocephalic arteriosclerosis	>=65 years	267	49.7	0	0.0
Vascular disorders	Diabetic vascular disorder	<65 years	270	50.3	1	0.4
Vascular disorders	Diabetic vascular disorder	>=65 years	267	49.7	0	0.0
Vascular disorders	Hypertension	<65 years	270	50.3	17	6.3
Vascular disorders	Hypertension	>=65 years	267	49.7	6	2.2
Vascular disorders	Hypertensive crisis	<65 years	270	50.3	2	0.7
Vascular disorders	Hypertensive crisis	>=65 years	267	49.7	0	0.0
Vascular disorders	Hypotension	<65 years	270	50.3	1	0.4
Vascular disorders	Hypotension	>=65 years	267	49.7	2	0.7
Vascular disorders	Ischaemic limb pain	<65 years	270	50.3	0	0.0
Vascular disorders	Ischaemic limb pain	>=65 years	267	49.7	1	0.4
Vascular disorders	Orthostatic hypotension	<65 years	270	50.3	0	0.0
Vascular disorders	Orthostatic hypotension	>=65 years	267	49.7	1	0.4
Vascular disorders	Varicose vein	<65 years	270	50.3	0	0.0
Vascular disorders	Varicose vein	>=65 years	267	49.7	1	0.4
Vascular disorders	Vascular occlusion	<65 years	270	50.3	1	0.4
Vascular disorders	Vascular occlusion	>=65 years	267	49.7	0	0.0
Vascular disorders	Venous occlusion	<65 years	270	50.3	1	0.4
Vascular disorders	Venous occlusion	>=65 years	267	49.7	0	0.0
Vascular disorders	Venous thrombosis limb	<65 years	270	50.3	1	0.4
Vascular disorders	Venous thrombosis limb	>=65 years	267	49.7	0	0.0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_AE_WK72_Sea24_30AUG2023_41984.xls
26APR2024 17:45

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETRS letter score			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<=54 letters	176	32,8	2	1,1
Blood and lymphatic system disorders		>=55 letters	361	67,2	3	0,8
Blood and lymphatic system disorders	Anaemia	<=54 letters	176	32,8	2	1,1
Blood and lymphatic system disorders	Anaemia	>=55 letters	361	67,2	0	0,0
Blood and lymphatic system disorders	Antiphospholipid syndrome	<=54 letters	176	32,8	0	0,0
Blood and lymphatic system disorders	Antiphospholipid syndrome	>=55 letters	361	67,2	1	0,3
Blood and lymphatic system disorders	Coagulopathy	<=54 letters	176	32,8	0	0,0
Blood and lymphatic system disorders	Coagulopathy	>=55 letters	361	67,2	1	0,3
Blood and lymphatic system disorders	Macrocytosis	<=54 letters	176	32,8	0	0,0
Blood and lymphatic system disorders	Macrocytosis	>=55 letters	361	67,2	1	0,3
Cardiac disorders		<=54 letters	176	32,8	11	6,3
Cardiac disorders		>=55 letters	361	67,2	10	2,8
Cardiac disorders	Acute myocardial infarction	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Acute myocardial infarction	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Angina pectoris	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Angina pectoris	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Angina unstable	<=54 letters	176	32,8	2	1,1
Cardiac disorders	Angina unstable	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Aortic valve incompetence	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Aortic valve incompetence	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Arrhythmia	<=54 letters	176	32,8	2	1,1
Cardiac disorders	Arrhythmia	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Arteriosclerosis coronary artery	<=54 letters	176	32,8	2	1,1
Cardiac disorders	Arteriosclerosis coronary artery	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Atrial fibrillation	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Atrial fibrillation	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Bundle branch block right	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Bundle branch block right	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Cardiac failure	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Cardiac failure	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Cardiac failure congestive	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Cardiac failure congestive	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Cardiomegaly	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Cardiomegaly	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Coronary artery disease	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Coronary artery disease	>=55 letters	361	67,2	2	0,6
Cardiac disorders	Dilatation ventricular	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Dilatation ventricular	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Left atrial enlargement	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Left atrial enlargement	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Left ventricular failure	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Left ventricular failure	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Mitral valve incompetence	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Mitral valve incompetence	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Myocardial fibrosis	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Myocardial fibrosis	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Myocardial infarction	<=54 letters	176	32,8	3	1,7
Cardiac disorders	Myocardial infarction	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Myocardial ischaemia	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Myocardial ischaemia	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Pericarditis	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Pericarditis	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Sinus bradycardia	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Sinus bradycardia	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Supraventricular extrasystoles	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Supraventricular extrasystoles	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Tricuspid valve incompetence	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Tricuspid valve incompetence	>=55 letters	361	67,2	1	0,3
Congenital, familial and genetic disorders		<=54 letters	176	32,8	1	0,6
Congenital, familial and genetic disorders		>=55 letters	361	67,2	2	0,6
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	<=54 letters	176	32,8	1	0,6
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	>=55 letters	361	67,2	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	<=54 letters	176	32,8	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	>=55 letters	361	67,2	1	0,3
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	<=54 letters	176	32,8	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	>=55 letters	361	67,2	1	0,3
Ear and labyrinth disorders		<=54 letters	176	32,8	2	1,1
Ear and labyrinth disorders		>=55 letters	361	67,2	8	2,2
Ear and labyrinth disorders	Cerumen impaction	<=54 letters	176	32,8	1	0,6
Ear and labyrinth disorders	Cerumen impaction	>=55 letters	361	67,2	1	0,3
Ear and labyrinth disorders	Ear disorder	<=54 letters	176	32,8	0	0,0
Ear and labyrinth disorders	Ear disorder	>=55 letters	361	67,2	1	0,3
Ear and labyrinth disorders	Hypacusis	<=54 letters	176	32,8	1	0,6
Ear and labyrinth disorders	Hypacusis	>=55 letters	361	67,2	0	0,0

Ear and labyrinth disorders	Tinnitus	<=54 letters	176	32,8	0	0,0
Ear and labyrinth disorders	Tinnitus	>=55 letters	361	67,2	1	0,3
Ear and labyrinth disorders	Vertigo	<=54 letters	176	32,8	0	0,0
Ear and labyrinth disorders	Vertigo	>=55 letters	361	67,2	3	0,8
Ear and labyrinth disorders	Vertigo positional	<=54 letters	176	32,8	0	0,0
Ear and labyrinth disorders	Vertigo positional	>=55 letters	361	67,2	2	0,6
Endocrine disorders		<=54 letters	176	32,8	1	0,6
Endocrine disorders		>=55 letters	361	67,2	2	0,6
Endocrine disorders	Hypothyroidism	<=54 letters	176	32,8	1	0,6
Endocrine disorders	Hypothyroidism	>=55 letters	361	67,2	2	0,6
Eye disorders		<=54 letters	176	32,8	54	30,7
Eye disorders		>=55 letters	361	67,2	105	29,1
Eye disorders	Abnormal sensation in eye	<=54 letters	176	32,8	0	0,0
Eye disorders	Abnormal sensation in eye	>=55 letters	361	67,2	1	0,3
Eye disorders	Asthenopia	<=54 letters	176	32,8	0	0,0
Eye disorders	Asthenopia	>=55 letters	361	67,2	1	0,3
Eye disorders	Blepharitis allergic	<=54 letters	176	32,8	0	0,0
Eye disorders	Blepharitis allergic	>=55 letters	361	67,2	1	0,3
Eye disorders	Borderline glaucoma	<=54 letters	176	32,8	0	0,0
Eye disorders	Borderline glaucoma	>=55 letters	361	67,2	1	0,3
Eye disorders	Cataract	<=54 letters	176	32,8	9	5,1
Eye disorders	Cataract	>=55 letters	361	67,2	13	3,6
Eye disorders	Cataract nuclear	<=54 letters	176	32,8	0	0,0
Eye disorders	Cataract nuclear	>=55 letters	361	67,2	1	0,3
Eye disorders	Cataract subcapsular	<=54 letters	176	32,8	1	0,6
Eye disorders	Cataract subcapsular	>=55 letters	361	67,2	1	0,3
Eye disorders	Chalazion	<=54 letters	176	32,8	0	0,0
Eye disorders	Chalazion	>=55 letters	361	67,2	2	0,6
Eye disorders	Conjunctival erosion	<=54 letters	176	32,8	0	0,0
Eye disorders	Conjunctival erosion	>=55 letters	361	67,2	1	0,3
Eye disorders	Conjunctival haemorrhage	<=54 letters	176	32,8	6	3,4
Eye disorders	Conjunctival haemorrhage	>=55 letters	361	67,2	17	4,7
Eye disorders	Conjunctivitis allergic	<=54 letters	176	32,8	0	0,0
Eye disorders	Conjunctivitis allergic	>=55 letters	361	67,2	3	0,8
Eye disorders	Conjunctivochalasis	<=54 letters	176	32,8	0	0,0
Eye disorders	Conjunctivochalasis	>=55 letters	361	67,2	1	0,3
Eye disorders	Corneal erosion	<=54 letters	176	32,8	0	0,0
Eye disorders	Corneal erosion	>=55 letters	361	67,2	2	0,6
Eye disorders	Corneal infiltrates	<=54 letters	176	32,8	0	0,0
Eye disorders	Corneal infiltrates	>=55 letters	361	67,2	1	0,3
Eye disorders	Corneal opacity	<=54 letters	176	32,8	1	0,6
Eye disorders	Corneal opacity	>=55 letters	361	67,2	0	0,0
Eye disorders	Cystoid macular oedema	<=54 letters	176	32,8	2	1,1
Eye disorders	Cystoid macular oedema	>=55 letters	361	67,2	4	1,1
Eye disorders	Dacryostenosis acquired	<=54 letters	176	32,8	1	0,6
Eye disorders	Dacryostenosis acquired	>=55 letters	361	67,2	0	0,0
Eye disorders	Dermatochalasis	<=54 letters	176	32,8	0	0,0
Eye disorders	Dermatochalasis	>=55 letters	361	67,2	1	0,3
Eye disorders	Diplopia	<=54 letters	176	32,8	1	0,6
Eye disorders	Diplopia	>=55 letters	361	67,2	0	0,0
Eye disorders	Dry age-related macular degeneration	<=54 letters	176	32,8	1	0,6
Eye disorders	Dry age-related macular degeneration	>=55 letters	361	67,2	0	0,0
Eye disorders	Dry eye	<=54 letters	176	32,8	4	2,3
Eye disorders	Dry eye	>=55 letters	361	67,2	6	1,7
Eye disorders	Entropion	<=54 letters	176	32,8	0	0,0
Eye disorders	Entropion	>=55 letters	361	67,2	1	0,3
Eye disorders	Epi-retinal membrane	<=54 letters	176	32,8	4	2,3
Eye disorders	Epi-retinal membrane	>=55 letters	361	67,2	6	1,7
Eye disorders	Episcleritis	<=54 letters	176	32,8	0	0,0
Eye disorders	Episcleritis	>=55 letters	361	67,2	1	0,3
Eye disorders	Erythema of eyelid	<=54 letters	176	32,8	0	0,0
Eye disorders	Erythema of eyelid	>=55 letters	361	67,2	1	0,3
Eye disorders	Eye allergy	<=54 letters	176	32,8	1	0,6
Eye disorders	Eye allergy	>=55 letters	361	67,2	0	0,0
Eye disorders	Eye discharge	<=54 letters	176	32,8	1	0,6
Eye disorders	Eye discharge	>=55 letters	361	67,2	1	0,3
Eye disorders	Eye irritation	<=54 letters	176	32,8	0	0,0
Eye disorders	Eye irritation	>=55 letters	361	67,2	1	0,3
Eye disorders	Eye pain	<=54 letters	176	32,8	0	0,0
Eye disorders	Eye pain	>=55 letters	361	67,2	3	0,8
Eye disorders	Eye pruritus	<=54 letters	176	32,8	2	1,1
Eye disorders	Eye pruritus	>=55 letters	361	67,2	0	0,0
Eye disorders	Eyelid oedema	<=54 letters	176	32,8	0	0,0
Eye disorders	Eyelid oedema	>=55 letters	361	67,2	1	0,3
Eye disorders	Eyelid pain	<=54 letters	176	32,8	0	0,0
Eye disorders	Eyelid pain	>=55 letters	361	67,2	1	0,3
Eye disorders	Eyelid ptosis	<=54 letters	176	32,8	0	0,0
Eye disorders	Eyelid ptosis	>=55 letters	361	67,2	1	0,3
Eye disorders	Glaucoma	<=54 letters	176	32,8	3	1,7
Eye disorders	Glaucoma	>=55 letters	361	67,2	1	0,3
Eye disorders	Iridocyclitis	<=54 letters	176	32,8	0	0,0
Eye disorders	Iridocyclitis	>=55 letters	361	67,2	2	0,6
Eye disorders	Iritis	<=54 letters	176	32,8	1	0,6
Eye disorders	Iritis	>=55 letters	361	67,2	1	0,3
Eye disorders	Keratitis	<=54 letters	176	32,8	0	0,0
Eye disorders	Keratitis	>=55 letters	361	67,2	2	0,6
Eye disorders	Lacrimation increased	<=54 letters	176	32,8	2	1,1
Eye disorders	Lacrimation increased	>=55 letters	361	67,2	1	0,3

Eye disorders	Macular ischaemia	<=54 letters	176	32,8	0	0,0
Eye disorders	Macular ischaemia	>=55 letters	361	67,2	1	0,3
Eye disorders	Macular oedema	<=54 letters	176	32,8	6	3,4
Eye disorders	Macular oedema	>=55 letters	361	67,2	11	3,0
Eye disorders	Maculopathy	<=54 letters	176	32,8	0	0,0
Eye disorders	Maculopathy	>=55 letters	361	67,2	1	0,3
Eye disorders	Narrow anterior chamber angle	<=54 letters	176	32,8	0	0,0
Eye disorders	Narrow anterior chamber angle	>=55 letters	361	67,2	1	0,3
Eye disorders	Normal tension glaucoma	<=54 letters	176	32,8	0	0,0
Eye disorders	Normal tension glaucoma	>=55 letters	361	67,2	1	0,3
Eye disorders	Ocular discomfort	<=54 letters	176	32,8	0	0,0
Eye disorders	Ocular discomfort	>=55 letters	361	67,2	2	0,6
Eye disorders	Ocular hypertension	<=54 letters	176	32,8	1	0,6
Eye disorders	Ocular hypertension	>=55 letters	361	67,2	1	0,3
Eye disorders	Ocular vascular disorder	<=54 letters	176	32,8	0	0,0
Eye disorders	Ocular vascular disorder	>=55 letters	361	67,2	1	0,3
Eye disorders	Optic disc haemorrhage	<=54 letters	176	32,8	1	0,6
Eye disorders	Optic disc haemorrhage	>=55 letters	361	67,2	0	0,0
Eye disorders	Optic disc vascular disorder	<=54 letters	176	32,8	1	0,6
Eye disorders	Optic disc vascular disorder	>=55 letters	361	67,2	0	0,0
Eye disorders	Periorbital pain	<=54 letters	176	32,8	0	0,0
Eye disorders	Periorbital pain	>=55 letters	361	67,2	1	0,3
Eye disorders	Photopsia	<=54 letters	176	32,8	0	0,0
Eye disorders	Photopsia	>=55 letters	361	67,2	1	0,3
Eye disorders	Posterior capsule opacification	<=54 letters	176	32,8	1	0,6
Eye disorders	Posterior capsule opacification	>=55 letters	361	67,2	1	0,3
Eye disorders	Pterygium	<=54 letters	176	32,8	1	0,6
Eye disorders	Pterygium	>=55 letters	361	67,2	0	0,0
Eye disorders	Punctate keratitis	<=54 letters	176	32,8	1	0,6
Eye disorders	Punctate keratitis	>=55 letters	361	67,2	0	0,0
Eye disorders	Retinal aneurysm	<=54 letters	176	32,8	2	1,1
Eye disorders	Retinal aneurysm	>=55 letters	361	67,2	0	0,0
Eye disorders	Retinal artery embolism	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinal artery embolism	>=55 letters	361	67,2	0	0,0
Eye disorders	Retinal collateral vessels	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinal collateral vessels	>=55 letters	361	67,2	0	0,0
Eye disorders	Retinal cyst	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinal cyst	>=55 letters	361	67,2	3	0,8
Eye disorders	Retinal exudates	<=54 letters	176	32,8	0	0,0
Eye disorders	Retinal exudates	>=55 letters	361	67,2	3	0,8
Eye disorders	Retinal haemorrhage	<=54 letters	176	32,8	4	2,3
Eye disorders	Retinal haemorrhage	>=55 letters	361	67,2	6	1,7
Eye disorders	Retinal ischaemia	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinal ischaemia	>=55 letters	361	67,2	4	1,1
Eye disorders	Retinal neovascularisation	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinal neovascularisation	>=55 letters	361	67,2	1	0,3
Eye disorders	Retinal oedema	<=54 letters	176	32,8	0	0,0
Eye disorders	Retinal oedema	>=55 letters	361	67,2	1	0,3
Eye disorders	Retinal tear	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinal tear	>=55 letters	361	67,2	2	0,6
Eye disorders	Retinal thickening	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinal thickening	>=55 letters	361	67,2	0	0,0
Eye disorders	Retinal vascular disorder	<=54 letters	176	32,8	0	0,0
Eye disorders	Retinal vascular disorder	>=55 letters	361	67,2	1	0,3
Eye disorders	Retinal vein occlusion	<=54 letters	176	32,8	8	4,5
Eye disorders	Retinal vein occlusion	>=55 letters	361	67,2	13	3,6
Eye disorders	Retinopathy hypertensive	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinopathy hypertensive	>=55 letters	361	67,2	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	<=54 letters	176	32,8	1	0,6
Eye disorders	Rhegmatogenous retinal detachment	>=55 letters	361	67,2	0	0,0
Eye disorders	Swelling of eyelid	<=54 letters	176	32,8	0	0,0
Eye disorders	Swelling of eyelid	>=55 letters	361	67,2	1	0,3
Eye disorders	Tractional retinal detachment	<=54 letters	176	32,8	1	0,6
Eye disorders	Tractional retinal detachment	>=55 letters	361	67,2	0	0,0
Eye disorders	Trichiasis	<=54 letters	176	32,8	1	0,6
Eye disorders	Trichiasis	>=55 letters	361	67,2	0	0,0
Eye disorders	Vision blurred	<=54 letters	176	32,8	1	0,6
Eye disorders	Vision blurred	>=55 letters	361	67,2	3	0,8
Eye disorders	Visual acuity reduced	<=54 letters	176	32,8	2	1,1
Eye disorders	Visual acuity reduced	>=55 letters	361	67,2	4	1,1
Eye disorders	Visual field defect	<=54 letters	176	32,8	0	0,0
Eye disorders	Visual field defect	>=55 letters	361	67,2	1	0,3
Eye disorders	Vitreoretinal traction syndrome	<=54 letters	176	32,8	0	0,0
Eye disorders	Vitreoretinal traction syndrome	>=55 letters	361	67,2	2	0,6
Eye disorders	Vitreous degeneration	<=54 letters	176	32,8	1	0,6
Eye disorders	Vitreous degeneration	>=55 letters	361	67,2	0	0,0
Eye disorders	Vitreous detachment	<=54 letters	176	32,8	4	2,3
Eye disorders	Vitreous detachment	>=55 letters	361	67,2	17	4,7
Eye disorders	Vitreous floaters	<=54 letters	176	32,8	2	1,1
Eye disorders	Vitreous floaters	>=55 letters	361	67,2	8	2,2
Eye disorders	Vitreous haemorrhage	<=54 letters	176	32,8	2	1,1
Eye disorders	Vitreous haemorrhage	>=55 letters	361	67,2	0	0,0
Eye disorders	Vitritis	<=54 letters	176	32,8	1	0,6
Eye disorders	Vitritis	>=55 letters	361	67,2	0	0,0
Gastrointestinal disorders		<=54 letters	176	32,8	12	6,8
Gastrointestinal disorders		>=55 letters	361	67,2	22	6,1
Gastrointestinal disorders	Abdominal pain	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Abdominal pain	>=55 letters	361	67,2	0	0,0
Gastrointestinal disorders	Abdominal pain upper	<=54 letters	176	32,8	0	0,0

Gastrointestinal disorders	Abdominal pain upper	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Chronic gastritis	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Chronic gastritis	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Colitis	<=54 letters	176	32,8	2	1,1
Gastrointestinal disorders	Colitis	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Constipation	<=54 letters	176	32,8	2	1,1
Gastrointestinal disorders	Constipation	>=55 letters	361	67,2	0	0,0
Gastrointestinal disorders	Diarrhoea	<=54 letters	176	32,8	3	1,7
Gastrointestinal disorders	Diarrhoea	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Erosive duodenitis	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Erosive duodenitis	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Functional gastrointestinal disorder	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Gastric haemorrhage	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Gastric haemorrhage	>=55 letters	361	67,2	0	0,0
Gastrointestinal disorders	Gastric polyps	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Gastric polyps	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Gastritis	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Gastritis	>=55 letters	361	67,2	3	0,8
Gastrointestinal disorders	Gastroesophageal reflux disease	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Gastroesophageal reflux disease	>=55 letters	361	67,2	5	1,4
Gastrointestinal disorders	Gingival pain	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Gingival pain	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Haemorrhoids	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Haemorrhoids	>=55 letters	361	67,2	2	0,6
Gastrointestinal disorders	Hyperchlorhydria	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Hyperchlorhydria	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Large intestine polyp	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Large intestine polyp	>=55 letters	361	67,2	3	0,8
Gastrointestinal disorders	Mesenteric vein thrombosis	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Nausea	<=54 letters	176	32,8	2	1,1
Gastrointestinal disorders	Nausea	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Oesophagitis	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Oesophagitis	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Pancreatitis acute	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Pancreatitis acute	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Toothache	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Toothache	>=55 letters	361	67,2	3	0,8
Gastrointestinal disorders	Vomiting	<=54 letters	176	32,8	2	1,1
Gastrointestinal disorders	Vomiting	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions		<=54 letters	176	32,8	3	1,7
General disorders and administration site conditions		>=55 letters	361	67,2	11	3,0
General disorders and administration site conditions	Asthenia	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Asthenia	>=55 letters	361	67,2	2	0,6
General disorders and administration site conditions	Chest discomfort	<=54 letters	176	32,8	1	0,6
General disorders and administration site conditions	Chest discomfort	>=55 letters	361	67,2	0	0,0
General disorders and administration site conditions	Death	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Death	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Fatigue	<=54 letters	176	32,8	1	0,6
General disorders and administration site conditions	Fatigue	>=55 letters	361	67,2	0	0,0
General disorders and administration site conditions	Gait disturbance	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Gait disturbance	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Illness	<=54 letters	176	32,8	1	0,6
General disorders and administration site conditions	Illness	>=55 letters	361	67,2	0	0,0
General disorders and administration site conditions	Influenza like illness	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Influenza like illness	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Oedema	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Oedema	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Pain	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Pain	>=55 letters	361	67,2	3	0,8
General disorders and administration site conditions	Peripheral swelling	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Peripheral swelling	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Physical deconditioning	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Physical deconditioning	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Pyrexia	<=54 letters	176	32,8	1	0,6
General disorders and administration site conditions	Pyrexia	>=55 letters	361	67,2	2	0,6
General disorders and administration site conditions	Vascular stent stenosis	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	>=55 letters	361	67,2	1	0,3
Hepatobiliary disorders		<=54 letters	176	32,8	4	2,3
Hepatobiliary disorders		>=55 letters	361	67,2	5	1,4
Hepatobiliary disorders	Bile duct stone	<=54 letters	176	32,8	1	0,6
Hepatobiliary disorders	Bile duct stone	>=55 letters	361	67,2	0	0,0
Hepatobiliary disorders	Cholecystitis chronic	<=54 letters	176	32,8	0	0,0
Hepatobiliary disorders	Cholecystitis chronic	>=55 letters	361	67,2	1	0,3
Hepatobiliary disorders	Cholelithiasis	<=54 letters	176	32,8	1	0,6
Hepatobiliary disorders	Cholelithiasis	>=55 letters	361	67,2	3	0,8
Hepatobiliary disorders	Hepatic cyst	<=54 letters	176	32,8	0	0,0
Hepatobiliary disorders	Hepatic cyst	>=55 letters	361	67,2	1	0,3
Hepatobiliary disorders	Hepatic failure	<=54 letters	176	32,8	1	0,6
Hepatobiliary disorders	Hepatic failure	>=55 letters	361	67,2	0	0,0
Hepatobiliary disorders	Hepatic function abnormal	<=54 letters	176	32,8	0	0,0
Hepatobiliary disorders	Hepatic function abnormal	>=55 letters	361	67,2	1	0,3
Hepatobiliary disorders	Hepatic steatosis	<=54 letters	176	32,8	1	0,6
Hepatobiliary disorders	Hepatic steatosis	>=55 letters	361	67,2	0	0,0
Immune system disorders		<=54 letters	176	32,8	3	1,7
Immune system disorders		>=55 letters	361	67,2	2	0,6

Immune system disorders	Allergic oedema	<=54 letters	176	32,8	0	0,0
Immune system disorders	Allergic oedema	>=55 letters	361	67,2	1	0,3
Immune system disorders	Allergy to plants	<=54 letters	176	32,8	0	0,0
Immune system disorders	Allergy to plants	>=55 letters	361	67,2	1	0,3
Immune system disorders	Hypersensitivity	<=54 letters	176	32,8	2	1,1
Immune system disorders	Hypersensitivity	>=55 letters	361	67,2	0	0,0
Immune system disorders	Seasonal allergy	<=54 letters	176	32,8	1	0,6
Immune system disorders	Seasonal allergy	>=55 letters	361	67,2	0	0,0
Infections and infestations		<=54 letters	176	32,8	48	27,3
Infections and infestations		>=55 letters	361	67,2	98	27,1
Infections and infestations	Borrelia infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Borrelia infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Bronchitis	<=54 letters	176	32,8	1	0,6
Infections and infestations	Bronchitis	>=55 letters	361	67,2	5	1,4
Infections and infestations	COVID-19	<=54 letters	176	32,8	19	10,8
Infections and infestations	COVID-19	>=55 letters	361	67,2	39	10,8
Infections and infestations	Cellulitis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Cellulitis	>=55 letters	361	67,2	3	0,8
Infections and infestations	Conjunctivitis	<=54 letters	176	32,8	2	1,1
Infections and infestations	Conjunctivitis	>=55 letters	361	67,2	3	0,8
Infections and infestations	Coronavirus infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Coronavirus infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Cystitis	<=54 letters	176	32,8	1	0,6
Infections and infestations	Cystitis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Dermatophytosis of nail	<=54 letters	176	32,8	0	0,0
Infections and infestations	Dermatophytosis of nail	>=55 letters	361	67,2	1	0,3
Infections and infestations	Ear infection	<=54 letters	176	32,8	1	0,6
Infections and infestations	Ear infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Furuncle	<=54 letters	176	32,8	1	0,6
Infections and infestations	Furuncle	>=55 letters	361	67,2	0	0,0
Infections and infestations	Gastroenteritis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Gastroenteritis	>=55 letters	361	67,2	5	1,4
Infections and infestations	Gastroenteritis viral	<=54 letters	176	32,8	0	0,0
Infections and infestations	Gastroenteritis viral	>=55 letters	361	67,2	2	0,6
Infections and infestations	Gastrointestinal infection	<=54 letters	176	32,8	1	0,6
Infections and infestations	Gastrointestinal infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Gingival abscess	<=54 letters	176	32,8	1	0,6
Infections and infestations	Gingival abscess	>=55 letters	361	67,2	0	0,0
Infections and infestations	Groin abscess	<=54 letters	176	32,8	0	0,0
Infections and infestations	Groin abscess	>=55 letters	361	67,2	1	0,3
Infections and infestations	Herpes zoster	<=54 letters	176	32,8	1	0,6
Infections and infestations	Herpes zoster	>=55 letters	361	67,2	2	0,6
Infections and infestations	Hordeolum	<=54 letters	176	32,8	2	1,1
Infections and infestations	Hordeolum	>=55 letters	361	67,2	1	0,3
Infections and infestations	Influenza	<=54 letters	176	32,8	5	2,8
Infections and infestations	Influenza	>=55 letters	361	67,2	4	1,1
Infections and infestations	Intestinal sepsis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Intestinal sepsis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Lower respiratory tract infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Lower respiratory tract infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Nail infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Nail infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Nasopharyngitis	<=54 letters	176	32,8	6	3,4
Infections and infestations	Nasopharyngitis	>=55 letters	361	67,2	11	3,0
Infections and infestations	Oral herpes	<=54 letters	176	32,8	0	0,0
Infections and infestations	Oral herpes	>=55 letters	361	67,2	1	0,3
Infections and infestations	Otitis media	<=54 letters	176	32,8	2	1,1
Infections and infestations	Otitis media	>=55 letters	361	67,2	0	0,0
Infections and infestations	Otitis media acute	<=54 letters	176	32,8	0	0,0
Infections and infestations	Otitis media acute	>=55 letters	361	67,2	1	0,3
Infections and infestations	Pelvic inflammatory disease	<=54 letters	176	32,8	1	0,6
Infections and infestations	Pelvic inflammatory disease	>=55 letters	361	67,2	0	0,0
Infections and infestations	Periodontitis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Periodontitis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Pharyngitis	<=54 letters	176	32,8	1	0,6
Infections and infestations	Pharyngitis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Pneumonia	<=54 letters	176	32,8	2	1,1
Infections and infestations	Pneumonia	>=55 letters	361	67,2	3	0,8
Infections and infestations	Post-acute COVID-19 syndrome	<=54 letters	176	32,8	0	0,0
Infections and infestations	Post-acute COVID-19 syndrome	>=55 letters	361	67,2	1	0,3
Infections and infestations	Postoperative wound infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Postoperative wound infection	>=55 letters	361	67,2	2	0,6
Infections and infestations	Pulpitis dental	<=54 letters	176	32,8	1	0,6
Infections and infestations	Pulpitis dental	>=55 letters	361	67,2	0	0,0
Infections and infestations	Pyelonephritis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Pyelonephritis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Respiratory tract infection	<=54 letters	176	32,8	1	0,6
Infections and infestations	Respiratory tract infection	>=55 letters	361	67,2	3	0,8
Infections and infestations	Rhinitis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Rhinitis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Rotavirus infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Rotavirus infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Sepsis	<=54 letters	176	32,8	1	0,6
Infections and infestations	Sepsis	>=55 letters	361	67,2	0	0,0
Infections and infestations	Sinusitis	<=54 letters	176	32,8	1	0,6
Infections and infestations	Sinusitis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Suspected COVID-19	<=54 letters	176	32,8	2	1,1
Infections and infestations	Suspected COVID-19	>=55 letters	361	67,2	7	1,9
Infections and infestations	Tinea cruris	<=54 letters	176	32,8	0	0,0

Infections and infestations	Tinea cruris	>=55 letters	361	67,2	1	0,3
Infections and infestations	Tinea pedis	<=54 letters	176	32,8	1	0,6
Infections and infestations	Tinea pedis	>=55 letters	361	67,2	0	0,0
Infections and infestations	Tonsillitis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Tonsillitis	>=55 letters	361	67,2	2	0,6
Infections and infestations	Tooth infection	<=54 letters	176	32,8	2	1,1
Infections and infestations	Tooth infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Tracheitis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Tracheitis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Upper respiratory tract infection	<=54 letters	176	32,8	6	3,4
Infections and infestations	Upper respiratory tract infection	>=55 letters	361	67,2	10	2,8
Infections and infestations	Urinary tract infection	<=54 letters	176	32,8	1	0,6
Infections and infestations	Urinary tract infection	>=55 letters	361	67,2	3	0,8
Infections and infestations	Viral infection	<=54 letters	176	32,8	1	0,6
Infections and infestations	Viral infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Vulvovaginal candidiasis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Vulvovaginal candidiasis	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications		<=54 letters	176	32,8	11	6,3
Injury, poisoning and procedural complications		>=55 letters	361	67,2	31	8,6
Injury, poisoning and procedural complications	Arthropod bite	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Arthropod bite	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Back injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Back injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Burns third degree	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Burns third degree	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Chillblains	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Chillblains	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Clavicle fracture	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Clavicle fracture	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Contusion	<=54 letters	176	32,8	2	1,1
Injury, poisoning and procedural complications	Contusion	>=55 letters	361	67,2	4	1,1
Injury, poisoning and procedural complications	Corneal abrasion	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Corneal abrasion	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Eye injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Eye injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Facial bones fracture	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Facial bones fracture	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Fall	<=54 letters	176	32,8	3	1,7
Injury, poisoning and procedural complications	Fall	>=55 letters	361	67,2	11	3,0
Injury, poisoning and procedural complications	Femur fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Foot fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Foot fracture	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Foreign body in eye	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Foreign body in eye	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Head injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Head injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Hip fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Hip fracture	>=55 letters	361	67,2	2	0,6
Injury, poisoning and procedural complications	Immunisation reaction	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Immunisation reaction	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Joint injury	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Joint injury	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Ligament sprain	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Ligament sprain	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Limb injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Limb injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Medication error	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Medication error	>=55 letters	361	67,2	2	0,6
Injury, poisoning and procedural complications	Meniscus injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Meniscus injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Muscle strain	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Muscle strain	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Radius fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Radius fracture	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Skin abrasion	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Skin abrasion	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Skin injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Skin injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Skin laceration	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Skin laceration	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Spinal column injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Spinal column injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Sternal fracture	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Sternal fracture	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Thermal burn	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Thermal burn	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	>=55 letters	361	67,2	2	0,6
Injury, poisoning and procedural complications	Ulna fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	>=55 letters	361	67,2	2	0,6
Investigations		<=54 letters	176	32,8	13	7,4
Investigations		>=55 letters	361	67,2	21	5,8
Investigations	Blood glucose increased	<=54 letters	176	32,8	1	0,6

Investigations	Blood glucose increased	>=55 letters	361	67,2	0	0,0
Investigations	Blood potassium decreased	<=54 letters	176	32,8	1	0,6
Investigations	Blood potassium decreased	>=55 letters	361	67,2	0	0,0
Investigations	Blood pressure increased	<=54 letters	176	32,8	1	0,6
Investigations	Blood pressure increased	>=55 letters	361	67,2	2	0,6
Investigations	Blood sodium decreased	<=54 letters	176	32,8	1	0,6
Investigations	Blood sodium decreased	>=55 letters	361	67,2	0	0,0
Investigations	Glomerular filtration rate decreased	<=54 letters	176	32,8	0	0,0
Investigations	Glomerular filtration rate decreased	>=55 letters	361	67,2	1	0,3
Investigations	Intraocular pressure increased	<=54 letters	176	32,8	8	4,5
Investigations	Intraocular pressure increased	>=55 letters	361	67,2	13	3,6
Investigations	Platelet count increased	<=54 letters	176	32,8	0	0,0
Investigations	Platelet count increased	>=55 letters	361	67,2	1	0,3
Investigations	SARS-CoV-2 test positive	<=54 letters	176	32,8	1	0,6
Investigations	SARS-CoV-2 test positive	>=55 letters	361	67,2	1	0,3
Investigations	Troponin increased	<=54 letters	176	32,8	0	0,0
Investigations	Troponin increased	>=55 letters	361	67,2	1	0,3
Investigations	Weight decreased	<=54 letters	176	32,8	0	0,0
Investigations	Weight decreased	>=55 letters	361	67,2	1	0,3
Investigations	White blood cell count decreased	<=54 letters	176	32,8	0	0,0
Investigations	White blood cell count decreased	>=55 letters	361	67,2	1	0,3
Metabolism and nutrition disorders		<=54 letters	176	32,8	9	5,1
Metabolism and nutrition disorders		>=55 letters	361	67,2	18	5,0
Metabolism and nutrition disorders	Dehydration	<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders	Dehydration	>=55 letters	361	67,2	1	0,3
Metabolism and nutrition disorders	Diabetes mellitus	<=54 letters	176	32,8	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	>=55 letters	361	67,2	1	0,3
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	>=55 letters	361	67,2	0	0,0
Metabolism and nutrition disorders	Folate deficiency	<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders	Folate deficiency	>=55 letters	361	67,2	0	0,0
Metabolism and nutrition disorders	Gout	<=54 letters	176	32,8	0	0,0
Metabolism and nutrition disorders	Gout	>=55 letters	361	67,2	2	0,6
Metabolism and nutrition disorders	Hypercholesterolaemia	<=54 letters	176	32,8	3	1,7
Metabolism and nutrition disorders	Hypercholesterolaemia	>=55 letters	361	67,2	6	1,7
Metabolism and nutrition disorders	Hyperglycaemia	<=54 letters	176	32,8	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	>=55 letters	361	67,2	2	0,6
Metabolism and nutrition disorders	Hyperhomocysteinaemia	<=54 letters	176	32,8	0	0,0
Metabolism and nutrition disorders	Hyperhomocysteinaemia	>=55 letters	361	67,2	1	0,3
Metabolism and nutrition disorders	Hyperkalaemia	<=54 letters	176	32,8	0	0,0
Metabolism and nutrition disorders	Hyperkalaemia	>=55 letters	361	67,2	1	0,3
Metabolism and nutrition disorders	Hyperlipidaemia	<=54 letters	176	32,8	2	1,1
Metabolism and nutrition disorders	Hyperlipidaemia	>=55 letters	361	67,2	2	0,6
Metabolism and nutrition disorders	Hyperuricaemia	<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders	Hyperuricaemia	>=55 letters	361	67,2	0	0,0
Metabolism and nutrition disorders	Hypoproteinaemia	<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders	Hypoproteinaemia	>=55 letters	361	67,2	0	0,0
Metabolism and nutrition disorders	Obesity	<=54 letters	176	32,8	0	0,0
Metabolism and nutrition disorders	Obesity	>=55 letters	361	67,2	2	0,6
Metabolism and nutrition disorders	Type 2 diabetes mellitus	<=54 letters	176	32,8	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	>=55 letters	361	67,2	3	0,8
Metabolism and nutrition disorders	Vitamin B12 deficiency	<=54 letters	176	32,8	0	0,0
Metabolism and nutrition disorders	Vitamin B12 deficiency	>=55 letters	361	67,2	1	0,3
Metabolism and nutrition disorders	Vitamin D deficiency	<=54 letters	176	32,8	2	1,1
Metabolism and nutrition disorders	Vitamin D deficiency	>=55 letters	361	67,2	0	0,0
Musculoskeletal and connective tissue disorders		<=54 letters	176	32,8	18	10,2
Musculoskeletal and connective tissue disorders		>=55 letters	361	67,2	41	11,4
Musculoskeletal and connective tissue disorders	Arthralgia	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Arthralgia	>=55 letters	361	67,2	6	1,7
Musculoskeletal and connective tissue disorders	Arthritis	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Arthritis	>=55 letters	361	67,2	2	0,6
Musculoskeletal and connective tissue disorders	Back pain	<=54 letters	176	32,8	4	2,3
Musculoskeletal and connective tissue disorders	Back pain	>=55 letters	361	67,2	6	1,7
Musculoskeletal and connective tissue disorders	Bone disorder	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Bone disorder	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Bursitis	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Bursitis	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Exostosis	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Exostosis	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Fibromyalgia	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Fibromyalgia	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	<=54 letters	176	32,8	2	1,1
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Joint swelling	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	>=55 letters	361	67,2	0	0,0
Musculoskeletal and connective tissue disorders	Muscle contracture	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Muscle contracture	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Muscle spasms	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Muscle spasms	>=55 letters	361	67,2	3	0,8
Musculoskeletal and connective tissue disorders	Muscular weakness	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Muscular weakness	>=55 letters	361	67,2	0	0,0
Musculoskeletal and connective tissue disorders	Myalgia	<=54 letters	176	32,8	2	1,1
Musculoskeletal and connective tissue disorders	Myalgia	>=55 letters	361	67,2	3	0,8
Musculoskeletal and connective tissue disorders	Neck pain	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Neck pain	>=55 letters	361	67,2	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	<=54 letters	176	32,8	2	1,1

Musculoskeletal and connective tissue disorders	Osteoarthritis	>=55 letters	361	67,2	6	1,7
Musculoskeletal and connective tissue disorders	Osteopenia	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Osteopenia	>=55 letters	361	67,2	2	0,6
Musculoskeletal and connective tissue disorders	Osteoporosis	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Osteoporosis	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Pain in extremity	<=54 letters	176	32,8	2	1,1
Musculoskeletal and connective tissue disorders	Pain in extremity	>=55 letters	361	67,2	3	0,8
Musculoskeletal and connective tissue disorders	Plantar fasciitis	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Rheumatoid arthritis	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Rheumatoid arthritis	>=55 letters	361	67,2	2	0,6
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	>=55 letters	361	67,2	4	1,1
Musculoskeletal and connective tissue disorders	Spinal pain	<=54 letters	176	32,8	2	1,1
Musculoskeletal and connective tissue disorders	Spinal pain	>=55 letters	361	67,2	3	0,8
Musculoskeletal and connective tissue disorders	Tendon disorder	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Tendon disorder	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Tenosynovitis	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Tenosynovitis	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Vertebral foraminal stenosis	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Vertebral foraminal stenosis	>=55 letters	361	67,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=54 letters	176	32,8	4	2,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=55 letters	361	67,2	3	0,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bowen's disease	<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bowen's disease	>=55 letters	361	67,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=55 letters	361	67,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	<=54 letters	176	32,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lung neoplasm	<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lung neoplasm	>=55 letters	361	67,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	<=54 letters	176	32,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	<=54 letters	176	32,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	>=55 letters	361	67,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	>=55 letters	361	67,2	0	0,0
Nervous system disorders		<=54 letters	176	32,8	15	8,5
Nervous system disorders		>=55 letters	361	67,2	32	8,9
Nervous system disorders	Carotid arteriosclerosis	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Carotid arteriosclerosis	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Carotid artery stenosis	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Carotid artery stenosis	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Cerebral atrophy	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cerebral atrophy	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cerebral haematoma	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cerebral haematoma	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cerebral infarction	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Cerebral infarction	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cerebral thrombosis	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cerebral thrombosis	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cerebrovascular accident	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Cerebrovascular accident	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cervical radiculopathy	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cervical radiculopathy	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cognitive disorder	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cognitive disorder	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Dementia Alzheimer's type	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Dementia Alzheimer's type	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Diabetic neuropathy	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Diabetic neuropathy	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Disturbance in attention	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Disturbance in attention	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Dizziness	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Dizziness	>=55 letters	361	67,2	3	0,8
Nervous system disorders	Epilepsy	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Epilepsy	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Headache	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Headache	>=55 letters	361	67,2	9	2,5

Nervous system disorders	Hypertensive encephalopathy	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Hypertensive encephalopathy	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Hypoesthesia	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Hypoesthesia	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Intracranial aneurysm	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Intracranial aneurysm	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Ischaemic stroke	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Ischaemic stroke	>=55 letters	361	67,2	2	0,6
Nervous system disorders	Loss of consciousness	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Loss of consciousness	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Memory impairment	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Memory impairment	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Migraine	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Migraine	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Multiple sclerosis	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Multiple sclerosis	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Myelopathy	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Myelopathy	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Narcolepsy	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Narcolepsy	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Neuropathy peripheral	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Neuropathy peripheral	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Ophthalmic migraine	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Ophthalmic migraine	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Presyncope	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Presyncope	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Sciatica	<=54 letters	176	32,8	4	2,3
Nervous system disorders	Sciatica	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Sinus headache	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Sinus headache	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Syncope	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Syncope	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Tension headache	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Tension headache	>=55 letters	361	67,2	2	0,6
Nervous system disorders	White matter lesion	<=54 letters	176	32,8	0	0,0
Nervous system disorders	White matter lesion	>=55 letters	361	67,2	1	0,3
Product issues		<=54 letters	176	32,8	0	0,0
Product issues		>=55 letters	361	67,2	1	0,3
Product issues	Device malfunction	<=54 letters	176	32,8	0	0,0
Product issues	Device malfunction	>=55 letters	361	67,2	1	0,3
Psychiatric disorders		<=54 letters	176	32,8	3	1,7
Psychiatric disorders		>=55 letters	361	67,2	6	1,7
Psychiatric disorders	Anxiety	<=54 letters	176	32,8	0	0,0
Psychiatric disorders	Anxiety	>=55 letters	361	67,2	2	0,6
Psychiatric disorders	Confusional state	<=54 letters	176	32,8	0	0,0
Psychiatric disorders	Confusional state	>=55 letters	361	67,2	2	0,6
Psychiatric disorders	Delirium	<=54 letters	176	32,8	1	0,6
Psychiatric disorders	Delirium	>=55 letters	361	67,2	0	0,0
Psychiatric disorders	Depression	<=54 letters	176	32,8	1	0,6
Psychiatric disorders	Depression	>=55 letters	361	67,2	1	0,3
Psychiatric disorders	Insomnia	<=54 letters	176	32,8	1	0,6
Psychiatric disorders	Insomnia	>=55 letters	361	67,2	1	0,3
Psychiatric disorders	Somatic symptom disorder	<=54 letters	176	32,8	0	0,0
Psychiatric disorders	Somatic symptom disorder	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders		<=54 letters	176	32,8	5	2,8
Renal and urinary disorders		>=55 letters	361	67,2	9	2,5
Renal and urinary disorders	Acute kidney injury	<=54 letters	176	32,8	1	0,6
Renal and urinary disorders	Acute kidney injury	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders	Chronic kidney disease	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Chronic kidney disease	>=55 letters	361	67,2	2	0,6
Renal and urinary disorders	Diabetic nephropathy	<=54 letters	176	32,8	1	0,6
Renal and urinary disorders	Diabetic nephropathy	>=55 letters	361	67,2	0	0,0
Renal and urinary disorders	Haematuria	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Haematuria	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders	Nephrolithiasis	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Nephrolithiasis	>=55 letters	361	67,2	2	0,6
Renal and urinary disorders	Renal colic	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Renal colic	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders	Renal cyst	<=54 letters	176	32,8	1	0,6
Renal and urinary disorders	Renal cyst	>=55 letters	361	67,2	3	0,8
Renal and urinary disorders	Renal mass	<=54 letters	176	32,8	1	0,6
Renal and urinary disorders	Renal mass	>=55 letters	361	67,2	0	0,0
Renal and urinary disorders	Urinary incontinence	<=54 letters	176	32,8	1	0,6
Renal and urinary disorders	Urinary incontinence	>=55 letters	361	67,2	0	0,0
Reproductive system and breast disorders		<=54 letters	176	32,8	2	1,1
Reproductive system and breast disorders		>=55 letters	361	67,2	3	0,8
Reproductive system and breast disorders	Benign prostatic hyperplasia	<=54 letters	176	32,8	2	1,1
Reproductive system and breast disorders	Benign prostatic hyperplasia	>=55 letters	361	67,2	1	0,3
Reproductive system and breast disorders	Erectile dysfunction	<=54 letters	176	32,8	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	>=55 letters	361	67,2	2	0,6
Reproductive system and breast disorders	Prostatitis	<=54 letters	176	32,8	0	0,0
Reproductive system and breast disorders	Prostatitis	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders		<=54 letters	176	32,8	6	3,4
Respiratory, thoracic and mediastinal disorders		>=55 letters	361	67,2	14	3,9
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	<=54 letters	176	32,8	0	0,0

Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=55 letters	361	67,2	2	0,6
Respiratory, thoracic and mediastinal disorders	Cough	<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders	Cough	>=55 letters	361	67,2	2	0,6
Respiratory, thoracic and mediastinal disorders	Dyspnoea	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	>=55 letters	361	67,2	2	0,6
Respiratory, thoracic and mediastinal disorders	Emphysema	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Emphysema	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Epistaxis	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Hypoventilation	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Hypoventilation	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Lung disorder	<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders	Lung disorder	>=55 letters	361	67,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung hyperinflation	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung hyperinflation	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Pleural effusion	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Pneumonitis	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pneumonitis	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=55 letters	361	67,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary fibrosis	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary fibrosis	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary mass	<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders	Pulmonary mass	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Respiratory failure	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Respiratory failure	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	>=55 letters	361	67,2	2	0,6
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	>=55 letters	361	67,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	>=55 letters	361	67,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders		<=54 letters	176	32,8	4	2,3
Skin and subcutaneous tissue disorders		>=55 letters	361	67,2	8	2,2
Skin and subcutaneous tissue disorders	Actinic keratosis	<=54 letters	176	32,8	1	0,6
Skin and subcutaneous tissue disorders	Actinic keratosis	>=55 letters	361	67,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	<=54 letters	176	32,8	1	0,6
Skin and subcutaneous tissue disorders	Dermatitis	>=55 letters	361	67,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	<=54 letters	176	32,8	1	0,6
Skin and subcutaneous tissue disorders	Dermatitis contact	>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders	Eczema	<=54 letters	176	32,8	0	0,0
Skin and subcutaneous tissue disorders	Eczema	>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders	Millaria	<=54 letters	176	32,8	0	0,0
Skin and subcutaneous tissue disorders	Millaria	>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders	Pemphigoid	<=54 letters	176	32,8	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders	Pruritus	<=54 letters	176	32,8	1	0,6
Skin and subcutaneous tissue disorders	Pruritus	>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders	Rash	<=54 letters	176	32,8	0	0,0
Skin and subcutaneous tissue disorders	Rash	>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders	Seborrheic dermatitis	<=54 letters	176	32,8	0	0,0
Skin and subcutaneous tissue disorders	Seborrheic dermatitis	>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders	Skin ulcer	<=54 letters	176	32,8	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	>=55 letters	361	67,2	1	0,3
Social circumstances		<=54 letters	176	32,8	1	0,6
Social circumstances		>=55 letters	361	67,2	0	0,0
Social circumstances	Joint prosthesis user	<=54 letters	176	32,8	1	0,6
Social circumstances	Joint prosthesis user	>=55 letters	361	67,2	0	0,0
Surgical and medical procedures		<=54 letters	176	32,8	1	0,6
Surgical and medical procedures		>=55 letters	361	67,2	4	1,1
Surgical and medical procedures	Knee arthroplasty	<=54 letters	176	32,8	0	0,0
Surgical and medical procedures	Knee arthroplasty	>=55 letters	361	67,2	1	0,3
Surgical and medical procedures	Large intestinal polypectomy	<=54 letters	176	32,8	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	>=55 letters	361	67,2	1	0,3
Surgical and medical procedures	Mole excision	<=54 letters	176	32,8	0	0,0
Surgical and medical procedures	Mole excision	>=55 letters	361	67,2	1	0,3
Surgical and medical procedures	Shoulder arthroplasty	<=54 letters	176	32,8	0	0,0
Surgical and medical procedures	Shoulder arthroplasty	>=55 letters	361	67,2	1	0,3
Surgical and medical procedures	Transurethral prostatectomy	<=54 letters	176	32,8	1	0,6
Surgical and medical procedures	Transurethral prostatectomy	>=55 letters	361	67,2	0	0,0
Vascular disorders		<=54 letters	176	32,8	16	9,1
Vascular disorders		>=55 letters	361	67,2	22	6,1
Vascular disorders	Aortic stenosis	<=54 letters	176	32,8	0	0,0
Vascular disorders	Aortic stenosis	>=55 letters	361	67,2	1	0,3
Vascular disorders	Arteriosclerosis	<=54 letters	176	32,8	1	0,6
Vascular disorders	Arteriosclerosis	>=55 letters	361	67,2	3	0,8
Vascular disorders	Brachiocephalic arteriosclerosis	<=54 letters	176	32,8	1	0,6
Vascular disorders	Brachiocephalic arteriosclerosis	>=55 letters	361	67,2	0	0,0
Vascular disorders	Diabetic vascular disorder	<=54 letters	176	32,8	1	0,6

Vascular disorders	Diabetic vascular disorder	>=55 letters	361	67,2	0	0,0
Vascular disorders	Hypertension	<=54 letters	176	32,8	10	5,7
Vascular disorders	Hypertension	>=55 letters	361	67,2	13	3,6
Vascular disorders	Hypertensive crisis	<=54 letters	176	32,8	1	0,6
Vascular disorders	Hypertensive crisis	>=55 letters	361	67,2	1	0,3
Vascular disorders	Hypotension	<=54 letters	176	32,8	1	0,6
Vascular disorders	Hypotension	>=55 letters	361	67,2	2	0,6
Vascular disorders	Ischaemic limb pain	<=54 letters	176	32,8	1	0,6
Vascular disorders	Ischaemic limb pain	>=55 letters	361	67,2	0	0,0
Vascular disorders	Orthostatic hypotension	<=54 letters	176	32,8	0	0,0
Vascular disorders	Orthostatic hypotension	>=55 letters	361	67,2	1	0,3
Vascular disorders	Varicose vein	<=54 letters	176	32,8	1	0,6
Vascular disorders	Varicose vein	>=55 letters	361	67,2	0	0,0
Vascular disorders	Vascular occlusion	<=54 letters	176	32,8	0	0,0
Vascular disorders	Vascular occlusion	>=55 letters	361	67,2	1	0,3
Vascular disorders	Venous occlusion	<=54 letters	176	32,8	0	0,0
Vascular disorders	Venous occlusion	>=55 letters	361	67,2	1	0,3
Vascular disorders	Venous thrombosis limb	<=54 letters	176	32,8	0	0,0
Vascular disorders	Venous thrombosis limb	>=55 letters	361	67,2	1	0,3

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sq_AE_WK72_SEa24_30AUG2023_41984.xls
26APR2024 17:45

POPULATION: Safety-Evaluable Population after Week 24
 INCLUSION: Any AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Geographic Region			Paricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients n	%	Patients with Event n	%
Blood and lymphatic system disorders		Europe	147	27.4	2	1.4
Blood and lymphatic system disorders		America	197	36.7	0	0.0
Blood and lymphatic system disorders		Asia Pacific (inc. Australia)	193	35.9	3	1.6
Blood and lymphatic system disorders		Europe	147	27.4	0	0.0
Blood and lymphatic system disorders	Anemia	America	197	36.7	0	0.0
Blood and lymphatic system disorders	Anemia	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Blood and lymphatic system disorders	Antiphospholipid syndrome	Europe	147	27.4	1	0.7
Blood and lymphatic system disorders	Antiphospholipid syndrome	America	197	36.7	0	0.0
Blood and lymphatic system disorders	Antiphospholipid syndrome	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Blood and lymphatic system disorders	Coagulopathy	Europe	147	27.4	0	0.0
Blood and lymphatic system disorders	Coagulopathy	America	197	36.7	0	0.0
Blood and lymphatic system disorders	Coagulopathy	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Blood and lymphatic system disorders	Macrocytosis	Europe	147	27.4	1	0.7
Blood and lymphatic system disorders	Macrocytosis	America	197	36.7	0	0.0
Blood and lymphatic system disorders	Macrocytosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders		Europe	147	27.4	7	4.8
Cardiac disorders		America	197	36.7	7	3.6
Cardiac disorders		Asia Pacific (inc. Australia)	193	35.9	7	3.6
Cardiac disorders	Acute myocardial infarction	Europe	147	27.4	0	0.0
Cardiac disorders	Acute myocardial infarction	America	197	36.7	0	0.0
Cardiac disorders	Acute myocardial infarction	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Cardiac disorders	Angina pectoris	Europe	147	27.4	1	0.7
Cardiac disorders	Angina pectoris	America	197	36.7	0	0.0
Cardiac disorders	Angina pectoris	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Angina unstable	Europe	147	27.4	1	0.7
Cardiac disorders	Angina unstable	America	197	36.7	0	0.0
Cardiac disorders	Angina unstable	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Cardiac disorders	Aortic valve incompetence	Europe	147	27.4	0	0.0
Cardiac disorders	Aortic valve incompetence	America	197	36.7	0	0.0
Cardiac disorders	Aortic valve incompetence	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Cardiac disorders	Arrhythmia	Europe	147	27.4	2	1.4
Cardiac disorders	Arrhythmia	America	197	36.7	0	0.0
Cardiac disorders	Arrhythmia	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Arteriosclerosis coronary artery	Europe	147	27.4	0	0.0
Cardiac disorders	Arteriosclerosis coronary artery	America	197	36.7	0	0.0
Cardiac disorders	Arteriosclerosis coronary artery	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Cardiac disorders	Atrial fibrillation	Europe	147	27.4	1	0.7
Cardiac disorders	Atrial fibrillation	America	197	36.7	1	0.5
Cardiac disorders	Atrial fibrillation	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Bundle branch block right	Europe	147	27.4	0	0.0
Cardiac disorders	Bundle branch block right	America	197	36.7	0	0.0
Cardiac disorders	Bundle branch block right	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Cardiac disorders	Cardiac failure	Europe	147	27.4	2	1.4
Cardiac disorders	Cardiac failure	America	197	36.7	0	0.0
Cardiac disorders	Cardiac failure	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Cardiac failure congestive	Europe	147	27.4	0	0.0
Cardiac disorders	Cardiac failure congestive	America	197	36.7	1	0.5
Cardiac disorders	Cardiac failure congestive	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Cardiomegaly	Europe	147	27.4	0	0.0
Cardiac disorders	Cardiomegaly	America	197	36.7	1	0.5
Cardiac disorders	Cardiomegaly	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Coronary artery disease	Europe	147	27.4	1	0.7
Cardiac disorders	Coronary artery disease	America	197	36.7	1	0.5
Cardiac disorders	Coronary artery disease	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Dilatation ventricular	Europe	147	27.4	0	0.0
Cardiac disorders	Dilatation ventricular	America	197	36.7	1	0.5
Cardiac disorders	Dilatation ventricular	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Left atrial enlargement	Europe	147	27.4	0	0.0
Cardiac disorders	Left atrial enlargement	America	197	36.7	0	0.0
Cardiac disorders	Left atrial enlargement	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Cardiac disorders	Left ventricular failure	Europe	147	27.4	0	0.0
Cardiac disorders	Left ventricular failure	America	197	36.7	1	0.5
Cardiac disorders	Left ventricular failure	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Mitral valve incompetence	Europe	147	27.4	0	0.0
Cardiac disorders	Mitral valve incompetence	America	197	36.7	0	0.0
Cardiac disorders	Mitral valve incompetence	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Cardiac disorders	Myocardial fibrosis	Europe	147	27.4	1	0.7
Cardiac disorders	Myocardial fibrosis	America	197	36.7	0	0.0
Cardiac disorders	Myocardial fibrosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Myocardial infarction	Europe	147	27.4	1	0.7
Cardiac disorders	Myocardial infarction	America	197	36.7	3	1.5
Cardiac disorders	Myocardial infarction	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Myocardial ischemia	Europe	147	27.4	0	0.0
Cardiac disorders	Myocardial ischemia	America	197	36.7	0	0.0
Cardiac disorders	Myocardial ischemia	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Cardiac disorders	Pericarditis	Europe	147	27.4	0	0.0
Cardiac disorders	Pericarditis	America	197	36.7	0	0.0
Cardiac disorders	Pericarditis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Cardiac disorders	Sinus bradycardia	Europe	147	27.4	0	0.0
Cardiac disorders	Sinus bradycardia	America	197	36.7	0	0.0
Cardiac disorders	Sinus bradycardia	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Cardiac disorders	Supraventricular extrasystoles	Europe	147	27.4	1	0.7
Cardiac disorders	Supraventricular extrasystoles	America	197	36.7	1	0.5
Cardiac disorders	Supraventricular extrasystoles	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Cardiac disorders	Tricuspid valve incompetence	Europe	147	27.4	0	0.0
Cardiac disorders	Tricuspid valve incompetence	America	197	36.7	0	0.0
Cardiac disorders	Tricuspid valve incompetence	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Congenital, familial and genetic disorders		Europe	147	27.4	3	2.0
Congenital, familial and genetic disorders		America	197	36.7	0	0.0
Congenital, familial and genetic disorders		Asia Pacific (inc. Australia)	193	35.9	0	0.0
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Europe	147	27.4	1	0.7
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	America	197	36.7	0	0.0
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Congenital, familial and genetic disorders	Corneal dystrophy	Europe	147	27.4	1	0.7
Congenital, familial and genetic disorders	Corneal dystrophy	America	197	36.7	0	0.0
Congenital, familial and genetic disorders	Corneal dystrophy	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Europe	147	27.4	1	0.7
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	America	197	36.7	0	0.0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Ear and labyrinth disorders		Europe	147	27.4	4	2.7
Ear and labyrinth disorders		America	197	36.7	0	0.0
Ear and labyrinth disorders		Asia Pacific (inc. Australia)	193	35.9	2	1.0
Ear and labyrinth disorders	Cerumen impaction	Europe	147	27.4	1	0.7

Eye disorders	Eyelid oedema	Europe	147	27.4	0	0.0
Eye disorders	Eyelid oedema	America	197	36.7	1	0.5
Eye disorders	Eyelid oedema	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Eyelid pain	Europe	147	27.4	0	0.0
Eye disorders	Eyelid pain	America	197	36.7	1	0.5
Eye disorders	Eyelid pain	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Eyelid ptosis	Europe	147	27.4	0	0.0
Eye disorders	Eyelid ptosis	America	197	36.7	0	0.0
Eye disorders	Eyelid ptosis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Glaucoma	Europe	147	27.4	2	1.4
Eye disorders	Glaucoma	America	197	36.7	1	0.5
Eye disorders	Glaucoma	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Iridocyclitis	Europe	147	27.4	2	1.4
Eye disorders	Iridocyclitis	America	197	36.7	0	0.0
Eye disorders	Iridocyclitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Iritis	Europe	147	27.4	0	0.0
Eye disorders	Iritis	America	197	36.7	1	0.5
Eye disorders	Iritis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Keratitis	Europe	147	27.4	1	0.7
Eye disorders	Keratitis	America	197	36.7	1	0.5
Eye disorders	Keratitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Lacrimation increased	Europe	147	27.4	2	1.4
Eye disorders	Lacrimation increased	America	197	36.7	0	0.0
Eye disorders	Lacrimation increased	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Macular ischaemia	Europe	147	27.4	0	0.0
Eye disorders	Macular ischaemia	America	197	36.7	0	0.0
Eye disorders	Macular ischaemia	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Macular oedema	Europe	147	27.4	7	4.8
Eye disorders	Macular oedema	America	197	36.7	7	3.6
Eye disorders	Macular oedema	Asia Pacific (inc. Australia)	193	35.9	3	1.6
Eye disorders	Maculopathy	Europe	147	27.4	1	0.7
Eye disorders	Maculopathy	America	197	36.7	0	0.0
Eye disorders	Maculopathy	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Narrow anterior chamber angle	Europe	147	27.4	0	0.0
Eye disorders	Narrow anterior chamber angle	America	197	36.7	0	0.0
Eye disorders	Narrow anterior chamber angle	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Normal tension glaucoma	Europe	147	27.4	1	0.7
Eye disorders	Normal tension glaucoma	America	197	36.7	0	0.0
Eye disorders	Normal tension glaucoma	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Ocular discomfort	Europe	147	27.4	2	1.4
Eye disorders	Ocular discomfort	America	197	36.7	0	0.0
Eye disorders	Ocular discomfort	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Ocular hypertension	Europe	147	27.4	1	0.7
Eye disorders	Ocular hypertension	America	197	36.7	1	0.5
Eye disorders	Ocular hypertension	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Ocular vascular disorder	Europe	147	27.4	1	0.7
Eye disorders	Ocular vascular disorder	America	197	36.7	0	0.0
Eye disorders	Ocular vascular disorder	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Optic disc haemorrhage	Europe	147	27.4	0	0.0
Eye disorders	Optic disc haemorrhage	America	197	36.7	1	0.5
Eye disorders	Optic disc haemorrhage	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Optic disc vascular disorder	Europe	147	27.4	1	0.7
Eye disorders	Optic disc vascular disorder	America	197	36.7	0	0.0
Eye disorders	Optic disc vascular disorder	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Periorbital pain	Europe	147	27.4	1	0.7
Eye disorders	Periorbital pain	America	197	36.7	0	0.0
Eye disorders	Periorbital pain	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Photopsia	Europe	147	27.4	1	0.7
Eye disorders	Photopsia	America	197	36.7	0	0.0
Eye disorders	Photopsia	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Posterior capsule opacification	Europe	147	27.4	1	0.7
Eye disorders	Posterior capsule opacification	America	197	36.7	0	0.0
Eye disorders	Posterior capsule opacification	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Pterygium	Europe	147	27.4	0	0.0
Eye disorders	Pterygium	America	197	36.7	0	0.0
Eye disorders	Pterygium	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Punctate keratitis	Europe	147	27.4	0	0.0
Eye disorders	Punctate keratitis	America	197	36.7	1	0.5
Eye disorders	Punctate keratitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Retinal aneurysm	Europe	147	27.4	0	0.0
Eye disorders	Retinal aneurysm	America	197	36.7	1	0.5
Eye disorders	Retinal aneurysm	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Retinal artery embolism	Europe	147	27.4	0	0.0
Eye disorders	Retinal artery embolism	America	197	36.7	1	0.5
Eye disorders	Retinal artery embolism	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Retinal collateral vessels	Europe	147	27.4	0	0.0
Eye disorders	Retinal collateral vessels	America	197	36.7	1	0.5
Eye disorders	Retinal collateral vessels	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Retinal cyst	Europe	147	27.4	4	2.7
Eye disorders	Retinal cyst	America	197	36.7	0	0.0
Eye disorders	Retinal cyst	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Retinal exudates	Europe	147	27.4	0	0.0
Eye disorders	Retinal exudates	America	197	36.7	3	1.5
Eye disorders	Retinal exudates	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Retinal haemorrhage	Europe	147	27.4	7	4.8
Eye disorders	Retinal haemorrhage	America	197	36.7	2	1.0
Eye disorders	Retinal haemorrhage	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Retinal ischaemia	Europe	147	27.4	2	1.4
Eye disorders	Retinal ischaemia	America	197	36.7	2	1.0
Eye disorders	Retinal ischaemia	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Retinal neovascularisation	Europe	147	27.4	0	0.0
Eye disorders	Retinal neovascularisation	America	197	36.7	1	0.5
Eye disorders	Retinal neovascularisation	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Retinal oedema	Europe	147	27.4	0	0.0
Eye disorders	Retinal oedema	America	197	36.7	1	0.5
Eye disorders	Retinal oedema	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Retinal tear	Europe	147	27.4	2	1.4
Eye disorders	Retinal tear	America	197	36.7	1	0.5
Eye disorders	Retinal tear	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Retinal thickening	Europe	147	27.4	0	0.0
Eye disorders	Retinal thickening	America	197	36.7	1	0.5
Eye disorders	Retinal thickening	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Retinal vascular disorder	Europe	147	27.4	1	0.7
Eye disorders	Retinal vascular disorder	America	197	36.7	0	0.0
Eye disorders	Retinal vascular disorder	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Retinal vein occlusion	Europe	147	27.4	4	2.7
Eye disorders	Retinal vein occlusion	America	197	36.7	10	5.1
Eye disorders	Retinal vein occlusion	Asia Pacific (inc. Australia)	193	35.9	5	2.6
Eye disorders	Retinopathy hypertensive	Europe	147	27.4	0	0.0
Eye disorders	Retinopathy hypertensive	America	197	36.7	0	0.0
Eye disorders	Retinopathy hypertensive	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Rhegmatogenous retinal detachment	Europe	147	27.4	0	0.0
Eye disorders	Rhegmatogenous retinal detachment	America	197	36.7	0	0.0
Eye disorders	Rhegmatogenous retinal detachment	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Swelling of eyelid	Europe	147	27.4	1	0.7
Eye disorders	Swelling of eyelid	America	197	36.7	0	0.0
Eye disorders	Swelling of eyelid	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Tractional retinal detachment	Europe	147	27.4	0	0.0

Eye disorders	Tractional retinal detachment	America	197	36.7	0	0.0
Eye disorders	Tractional retinal detachment	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Trichiasis	Europe	147	27.4	0	0.0
Eye disorders	Trichiasis	America	197	36.7	0	0.0
Eye disorders	Trichiasis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Vision blurred	Europe	147	27.4	0	0.0
Eye disorders	Vision blurred	America	197	36.7	4	2.0
Eye disorders	Vision blurred	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Visual acuity reduced	Europe	147	27.4	4	2.7
Eye disorders	Visual acuity reduced	America	197	36.7	2	1.0
Eye disorders	Visual acuity reduced	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Visual field defect	Europe	147	27.4	0	0.0
Eye disorders	Visual field defect	America	197	36.7	1	0.5
Eye disorders	Visual field defect	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Vitreoretinal traction syndrome	Europe	147	27.4	2	1.4
Eye disorders	Vitreoretinal traction syndrome	America	197	36.7	0	0.0
Eye disorders	Vitreoretinal traction syndrome	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Vitreous degeneration	Europe	147	27.4	0	0.0
Eye disorders	Vitreous degeneration	America	197	36.7	1	0.5
Eye disorders	Vitreous degeneration	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Eye disorders	Vitreous detachment	Europe	147	27.4	2	1.4
Eye disorders	Vitreous detachment	America	197	36.7	12	6.1
Eye disorders	Vitreous detachment	Asia Pacific (inc. Australia)	193	35.9	7	3.6
Eye disorders	Vitreous floaters	Europe	147	27.4	6	4.1
Eye disorders	Vitreous floaters	America	197	36.7	2	1.0
Eye disorders	Vitreous floaters	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Eye disorders	Vitreous hemorrhage	Europe	147	27.4	0	0.0
Eye disorders	Vitreous hemorrhage	America	197	36.7	1	0.5
Eye disorders	Vitreous hemorrhage	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Eye disorders	Vitritis	Europe	147	27.4	1	0.7
Eye disorders	Vitritis	America	197	36.7	0	0.0
Eye disorders	Vitritis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Gastrointestinal disorders		Europe	147	27.4	13	8.8
Gastrointestinal disorders		America	197	36.7	7	3.6
Gastrointestinal disorders		Asia Pacific (inc. Australia)	193	35.9	14	7.3
Gastrointestinal disorders	Abdominal pain	Europe	147	27.4	0	0.0
Gastrointestinal disorders	Abdominal pain	America	197	36.7	0	0.0
Gastrointestinal disorders	Abdominal pain	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Gastrointestinal disorders	Abdominal pain upper	Europe	147	27.4	1	0.7
Gastrointestinal disorders	Abdominal pain upper	America	197	36.7	0	0.0
Gastrointestinal disorders	Abdominal pain upper	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Gastrointestinal disorders	Chronic gastritis	Europe	147	27.4	0	0.0
Gastrointestinal disorders	Chronic gastritis	America	197	36.7	0	0.0
Gastrointestinal disorders	Chronic gastritis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Gastrointestinal disorders	Colitis	Europe	147	27.4	0	0.0
Gastrointestinal disorders	Colitis	America	197	36.7	2	1.0
Gastrointestinal disorders	Colitis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Gastrointestinal disorders	Constipation	Europe	147	27.4	0	0.0
Gastrointestinal disorders	Constipation	America	197	36.7	1	0.5
Gastrointestinal disorders	Constipation	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Gastrointestinal disorders	Diarrhoea	Europe	147	27.4	1	0.7
Gastrointestinal disorders	Diarrhoea	America	197	36.7	1	0.5
Gastrointestinal disorders	Diarrhoea	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Gastrointestinal disorders	Erosive duodenitis	Europe	147	27.4	1	0.7
Gastrointestinal disorders	Erosive duodenitis	America	197	36.7	0	0.0
Gastrointestinal disorders	Erosive duodenitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Gastrointestinal disorders	Functional gastrointestinal disorder	Europe	147	27.4	1	0.7
Gastrointestinal disorders	Functional gastrointestinal disorder	America	197	36.7	0	0.0
Gastrointestinal disorders	Functional gastrointestinal disorder	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Gastrointestinal disorders	Gastric haemorrhage	Europe	147	27.4	1	0.7
Gastrointestinal disorders	Gastric haemorrhage	America	197	36.7	0	0.0
Gastrointestinal disorders	Gastric haemorrhage	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Gastrointestinal disorders	Gastric polyps	Europe	147	27.4	0	0.0
Gastrointestinal disorders	Gastric polyps	America	197	36.7	0	0.0
Gastrointestinal disorders	Gastric polyps	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Gastrointestinal disorders	Gastritis	Europe	147	27.4	2	1.4
Gastrointestinal disorders	Gastritis	America	197	36.7	0	0.0
Gastrointestinal disorders	Gastritis	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Gastrointestinal disorders	Gastroesophageal reflux disease	Europe	147	27.4	4	2.7
Gastrointestinal disorders	Gastroesophageal reflux disease	America	197	36.7	0	0.0
Gastrointestinal disorders	Gastroesophageal reflux disease	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Gastrointestinal disorders	Gingival pain	Europe	147	27.4	0	0.0
Gastrointestinal disorders	Gingival pain	America	197	36.7	1	0.5
Gastrointestinal disorders	Gingival pain	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Gastrointestinal disorders	Haemorrhoids	Europe	147	27.4	0	0.0
Gastrointestinal disorders	Haemorrhoids	America	197	36.7	0	0.0
Gastrointestinal disorders	Haemorrhoids	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Gastrointestinal disorders	Hyperchlorhydria	Europe	147	27.4	1	0.7
Gastrointestinal disorders	Hyperchlorhydria	America	197	36.7	0	0.0
Gastrointestinal disorders	Hyperchlorhydria	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Gastrointestinal disorders	Large intestine polyp	Europe	147	27.4	0	0.0
Gastrointestinal disorders	Large intestine polyp	America	197	36.7	0	0.0
Gastrointestinal disorders	Large intestine polyp	Asia Pacific (inc. Australia)	193	35.9	4	2.1
Gastrointestinal disorders	Mesenteric vein thrombosis	Europe	147	27.4	1	0.7
Gastrointestinal disorders	Mesenteric vein thrombosis	America	197	36.7	0	0.0
Gastrointestinal disorders	Mesenteric vein thrombosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Gastrointestinal disorders	Nausea	Europe	147	27.4	1	0.7
Gastrointestinal disorders	Nausea	America	197	36.7	0	0.0
Gastrointestinal disorders	Nausea	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Gastrointestinal disorders	Oesophagitis	Europe	147	27.4	0	0.0
Gastrointestinal disorders	Oesophagitis	America	197	36.7	0	0.0
Gastrointestinal disorders	Oesophagitis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Gastrointestinal disorders	Pancreatitis acute	Europe	147	27.4	0	0.0
Gastrointestinal disorders	Pancreatitis acute	America	197	36.7	1	0.5
Gastrointestinal disorders	Pancreatitis acute	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Gastrointestinal disorders	Toothache	Europe	147	27.4	2	1.4
Gastrointestinal disorders	Toothache	America	197	36.7	1	0.5
Gastrointestinal disorders	Toothache	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Gastrointestinal disorders	Vomiting	Europe	147	27.4	1	0.7
Gastrointestinal disorders	Vomiting	America	197	36.7	0	0.0
Gastrointestinal disorders	Vomiting	Asia Pacific (inc. Australia)	193	35.9	2	1.0
General disorders and administration site conditions		Europe	147	27.4	6	4.1
General disorders and administration site conditions		America	197	36.7	9	4.5
General disorders and administration site conditions		Asia Pacific (inc. Australia)	193	35.9	5	2.6
General disorders and administration site conditions	Asthenia	Europe	147	27.4	1	0.7
General disorders and administration site conditions	Asthenia	America	197	36.7	1	0.5
General disorders and administration site conditions	Asthenia	Asia Pacific (inc. Australia)	193	35.9	0	0.0
General disorders and administration site conditions	Chest discomfort	Europe	147	27.4	1	0.7
General disorders and administration site conditions	Chest discomfort	America	197	36.7	0	0.0
General disorders and administration site conditions	Chest discomfort	Asia Pacific (inc. Australia)	193	35.9	0	0.0
General disorders and administration site conditions	Death	Europe	147	27.4	0	0.0
General disorders and administration site conditions	Death	America	197	36.7	1	0.5
General disorders and administration site conditions	Death	Asia Pacific (inc. Australia)	193	35.9	0	0.0
General disorders and administration site conditions	Fatigue	Europe	147	27.4	0	0.0
General disorders and administration site conditions	Fatigue	America	197	36.7	1	0.5
General disorders and administration site conditions	Fatigue	Asia Pacific (inc. Australia)	193	35.9	0	0.0

General disorders and administration site conditions	Gait disturbance	Europe	147	27.4	0	0.0
General disorders and administration site conditions	Gait disturbance	America	197	36.7	1	0.5
General disorders and administration site conditions	Gait disturbance	Asia Pacific (inc. Australia)	193	35.9	0	0.0
General disorders and administration site conditions	Illness	Europe	147	27.4	1	0.7
General disorders and administration site conditions	Illness	America	197	36.7	0	0.0
General disorders and administration site conditions	Illness	Asia Pacific (inc. Australia)	193	35.9	0	0.0
General disorders and administration site conditions	Influenza like illness	Europe	147	27.4	1	0.7
General disorders and administration site conditions	Influenza like illness	America	197	36.7	0	0.0
General disorders and administration site conditions	Influenza like illness	Asia Pacific (inc. Australia)	193	35.9	0	0.0
General disorders and administration site conditions	Oedema	Europe	147	27.4	0	0.0
General disorders and administration site conditions	Oedema	America	197	36.7	0	0.0
General disorders and administration site conditions	Oedema	Asia Pacific (inc. Australia)	193	35.9	1	0.5
General disorders and administration site conditions	Pain	Europe	147	27.4	2	1.4
General disorders and administration site conditions	Pain	America	197	36.7	0	0.0
General disorders and administration site conditions	Pain	Asia Pacific (inc. Australia)	193	35.9	1	0.5
General disorders and administration site conditions	Peripheral swelling	Europe	147	27.4	0	0.0
General disorders and administration site conditions	Peripheral swelling	America	197	36.7	0	0.0
General disorders and administration site conditions	Peripheral swelling	Asia Pacific (inc. Australia)	193	35.9	1	0.5
General disorders and administration site conditions	Physical deconditioning	Europe	147	27.4	0	0.0
General disorders and administration site conditions	Physical deconditioning	America	197	36.7	1	0.5
General disorders and administration site conditions	Physical deconditioning	Asia Pacific (inc. Australia)	193	35.9	0	0.0
General disorders and administration site conditions	Pyrexia	Europe	147	27.4	1	0.7
General disorders and administration site conditions	Pyrexia	America	197	36.7	0	0.0
General disorders and administration site conditions	Pyrexia	Asia Pacific (inc. Australia)	193	35.9	2	1.0
General disorders and administration site conditions	Vascular stent stenosis	Europe	147	27.4	1	0.7
General disorders and administration site conditions	Vascular stent stenosis	America	197	36.7	0	0.0
General disorders and administration site conditions	Vascular stent stenosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Hepatobiliary disorders		Europe	147	27.4	4	2.7
Hepatobiliary disorders		America	197	36.7	3	1.5
Hepatobiliary disorders		Asia Pacific (inc. Australia)	193	35.9	2	1.0
Hepatobiliary disorders	Bile duct stone	Europe	147	27.4	0	0.0
Hepatobiliary disorders	Bile duct stone	America	197	36.7	1	0.5
Hepatobiliary disorders	Bile duct stone	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Hepatobiliary disorders	Cholecystitis chronic	Europe	147	27.4	0	0.0
Hepatobiliary disorders	Cholecystitis chronic	America	197	36.7	1	0.5
Hepatobiliary disorders	Cholecystitis chronic	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Hepatobiliary disorders	Cholelithiasis	Europe	147	27.4	3	2.0
Hepatobiliary disorders	Cholelithiasis	America	197	36.7	1	0.5
Hepatobiliary disorders	Cholelithiasis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Hepatobiliary disorders	Hepatic cyst	Europe	147	27.4	1	0.7
Hepatobiliary disorders	Hepatic cyst	America	197	36.7	0	0.0
Hepatobiliary disorders	Hepatic cyst	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Hepatobiliary disorders	Hepatic failure	Europe	147	27.4	1	0.7
Hepatobiliary disorders	Hepatic failure	America	197	36.7	0	0.0
Hepatobiliary disorders	Hepatic failure	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Hepatobiliary disorders	Hepatic function abnormal	Europe	147	27.4	0	0.0
Hepatobiliary disorders	Hepatic function abnormal	America	197	36.7	0	0.0
Hepatobiliary disorders	Hepatic function abnormal	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Hepatobiliary disorders	Hepatic steatosis	Europe	147	27.4	0	0.0
Hepatobiliary disorders	Hepatic steatosis	America	197	36.7	0	0.0
Hepatobiliary disorders	Hepatic steatosis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Immune system disorders		Europe	147	27.4	1	0.7
Immune system disorders		America	197	36.7	3	1.5
Immune system disorders		Asia Pacific (inc. Australia)	193	35.9	1	0.5
Immune system disorders	Allergic oedema	Europe	147	27.4	1	0.7
Immune system disorders	Allergic oedema	America	197	36.7	0	0.0
Immune system disorders	Allergic oedema	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Immune system disorders	Allergy to plants	Europe	147	27.4	0	0.0
Immune system disorders	Allergy to plants	America	197	36.7	1	0.5
Immune system disorders	Allergy to plants	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Immune system disorders	Hypersensitivity	Europe	147	27.4	0	0.0
Immune system disorders	Hypersensitivity	America	197	36.7	1	0.5
Immune system disorders	Hypersensitivity	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Immune system disorders	Seasonal allergy	Europe	147	27.4	0	0.0
Immune system disorders	Seasonal allergy	America	197	36.7	1	0.5
Immune system disorders	Seasonal allergy	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations		Europe	147	27.4	49	32.7
Infections and infestations		America	197	36.7	39	19.8
Infections and infestations		Asia Pacific (inc. Australia)	193	35.9	59	30.4
Infections and infestations	Borrelia infection	Europe	147	27.4	1	0.7
Infections and infestations	Borrelia infection	America	197	36.7	0	0.0
Infections and infestations	Borrelia infection	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Bronchitis	Europe	147	27.4	4	2.7
Infections and infestations	Bronchitis	America	197	36.7	1	0.5
Infections and infestations	Bronchitis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	COVID-19	Europe	147	27.4	11	7.5
Infections and infestations	COVID-19	America	197	36.7	17	8.6
Infections and infestations	COVID-19	Asia Pacific (inc. Australia)	193	35.9	30	15.5
Infections and infestations	Cellulitis	Europe	147	27.4	0	0.0
Infections and infestations	Cellulitis	America	197	36.7	3	1.5
Infections and infestations	Cellulitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Conjunctivitis	Europe	147	27.4	2	1.4
Infections and infestations	Conjunctivitis	America	197	36.7	1	0.5
Infections and infestations	Conjunctivitis	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Infections and infestations	Coronavirus infection	Europe	147	27.4	0	0.0
Infections and infestations	Coronavirus infection	America	197	36.7	0	0.0
Infections and infestations	Coronavirus infection	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Cystitis	Europe	147	27.4	1	0.7
Infections and infestations	Cystitis	America	197	36.7	1	0.5
Infections and infestations	Cystitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Dermatophytosis of nail	Europe	147	27.4	0	0.0
Infections and infestations	Dermatophytosis of nail	America	197	36.7	0	0.0
Infections and infestations	Dermatophytosis of nail	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Ear infection	Europe	147	27.4	0	0.0
Infections and infestations	Ear infection	America	197	36.7	0	0.0
Infections and infestations	Ear infection	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Furuncle	Europe	147	27.4	1	0.7
Infections and infestations	Furuncle	America	197	36.7	0	0.0
Infections and infestations	Furuncle	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Gastroenteritis	Europe	147	27.4	1	0.7
Infections and infestations	Gastroenteritis	America	197	36.7	1	0.5
Infections and infestations	Gastroenteritis	Asia Pacific (inc. Australia)	193	35.9	3	1.6
Infections and infestations	Gastroenteritis viral	Europe	147	27.4	1	0.7
Infections and infestations	Gastroenteritis viral	America	197	36.7	1	0.5
Infections and infestations	Gastroenteritis viral	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Gastrointestinal infection	Europe	147	27.4	1	0.7
Infections and infestations	Gastrointestinal infection	America	197	36.7	1	0.5
Infections and infestations	Gastrointestinal infection	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Gingival abscess	Europe	147	27.4	1	0.7
Infections and infestations	Gingival abscess	America	197	36.7	0	0.0
Infections and infestations	Gingival abscess	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Groin abscess	Europe	147	27.4	1	0.7
Infections and infestations	Groin abscess	America	197	36.7	0	0.0
Infections and infestations	Groin abscess	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Herpes zoster	Europe	147	27.4	1	0.7

Infections and infestations	Herpes zoster	America	197	36.7	0	0.0
Infections and infestations	Herpes zoster	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Infections and infestations	Herpes zoster	America	147	27.4	1	0.7
Infections and infestations	Herpes zoster	America	197	36.7	2	1.0
Infections and infestations	Herpes zoster	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Influenza	Europe	147	27.4	3	2.0
Infections and infestations	Influenza	America	147	27.4	5	2.5
Infections and infestations	Influenza	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Intestinal sepsis	Europe	147	27.4	1	0.7
Infections and infestations	Intestinal sepsis	America	197	36.7	0	0.0
Infections and infestations	Intestinal sepsis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Lower respiratory tract infection	Europe	147	27.4	1	0.7
Infections and infestations	Lower respiratory tract infection	America	197	36.7	0	0.0
Infections and infestations	Lower respiratory tract infection	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Nail infection	Europe	147	27.4	1	0.7
Infections and infestations	Nail infection	America	197	36.7	0	0.0
Infections and infestations	Nail infection	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Nasopharyngitis	Europe	147	27.4	9	6.1
Infections and infestations	Nasopharyngitis	America	197	36.7	4	2.0
Infections and infestations	Nasopharyngitis	Asia Pacific (inc. Australia)	193	35.9	4	2.1
Infections and infestations	Oral herpes	Europe	147	27.4	0	0.0
Infections and infestations	Oral herpes	America	197	36.7	1	0.5
Infections and infestations	Oral herpes	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Cytitis media	Europe	147	27.4	1	0.7
Infections and infestations	Cytitis media	America	197	36.7	0	0.0
Infections and infestations	Cytitis media	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Cytitis media acute	Europe	147	27.4	1	0.7
Infections and infestations	Cytitis media acute	America	197	36.7	0	0.0
Infections and infestations	Cytitis media acute	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Pelvic inflammatory disease	Europe	147	27.4	0	0.0
Infections and infestations	Pelvic inflammatory disease	America	197	36.7	0	0.0
Infections and infestations	Pelvic inflammatory disease	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Periodontitis	Europe	147	27.4	0	0.0
Infections and infestations	Periodontitis	America	197	36.7	0	0.0
Infections and infestations	Periodontitis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Pharyngitis	Europe	147	27.4	0	0.0
Infections and infestations	Pharyngitis	America	197	36.7	1	0.5
Infections and infestations	Pharyngitis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Pneumonia	Europe	147	27.4	1	0.7
Infections and infestations	Pneumonia	America	197	36.7	2	1.0
Infections and infestations	Pneumonia	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Infections and infestations	Post-acute COVID-19 syndrome	Europe	147	27.4	0	0.0
Infections and infestations	Post-acute COVID-19 syndrome	America	197	36.7	1	0.5
Infections and infestations	Post-acute COVID-19 syndrome	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Postoperative wound infection	Europe	147	27.4	1	0.7
Infections and infestations	Postoperative wound infection	America	197	36.7	1	0.5
Infections and infestations	Postoperative wound infection	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Pulpitis dental	Europe	147	27.4	0	0.0
Infections and infestations	Pulpitis dental	America	197	36.7	0	0.0
Infections and infestations	Pulpitis dental	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Pyelonephritis	Europe	147	27.4	0	0.0
Infections and infestations	Pyelonephritis	America	197	36.7	0	0.0
Infections and infestations	Pyelonephritis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Respiratory tract infection	Europe	147	27.4	3	2.0
Infections and infestations	Respiratory tract infection	America	197	36.7	0	0.0
Infections and infestations	Respiratory tract infection	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Rhinitis	Europe	147	27.4	0	0.0
Infections and infestations	Rhinitis	America	197	36.7	0	0.0
Infections and infestations	Rhinitis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Rotavirus infection	Europe	147	27.4	1	0.7
Infections and infestations	Rotavirus infection	America	197	36.7	0	0.0
Infections and infestations	Rotavirus infection	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Sepsis	Europe	147	27.4	0	0.0
Infections and infestations	Sepsis	America	197	36.7	1	0.5
Infections and infestations	Sepsis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Sinusitis	Europe	147	27.4	0	0.0
Infections and infestations	Sinusitis	America	197	36.7	2	1.0
Infections and infestations	Sinusitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Suspected COVID-19	Europe	147	27.4	0	0.0
Infections and infestations	Suspected COVID-19	America	197	36.7	0	0.0
Infections and infestations	Suspected COVID-19	Asia Pacific (inc. Australia)	193	35.9	9	4.7
Infections and infestations	Tinea cruris	Europe	147	27.4	0	0.0
Infections and infestations	Tinea cruris	America	197	36.7	0	0.0
Infections and infestations	Tinea cruris	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Tinea pedis	Europe	147	27.4	0	0.0
Infections and infestations	Tinea pedis	America	197	36.7	0	0.0
Infections and infestations	Tinea pedis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Infections and infestations	Tonsillitis	Europe	147	27.4	0	0.0
Infections and infestations	Tonsillitis	America	197	36.7	0	0.0
Infections and infestations	Tonsillitis	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Infections and infestations	Tooth infection	Europe	147	27.4	0	0.0
Infections and infestations	Tooth infection	America	197	36.7	3	1.5
Infections and infestations	Tooth infection	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Tracheitis	Europe	147	27.4	1	0.7
Infections and infestations	Tracheitis	America	197	36.7	0	0.0
Infections and infestations	Tracheitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Upper respiratory tract infection	Europe	147	27.4	7	4.8
Infections and infestations	Upper respiratory tract infection	America	197	36.7	2	1.0
Infections and infestations	Upper respiratory tract infection	Asia Pacific (inc. Australia)	193	35.9	7	3.6
Infections and infestations	Urinary tract infection	Europe	147	27.4	2	1.4
Infections and infestations	Urinary tract infection	America	197	36.7	2	1.0
Infections and infestations	Urinary tract infection	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Viral infection	Europe	147	27.4	2	1.4
Infections and infestations	Viral infection	America	197	36.7	0	0.0
Infections and infestations	Viral infection	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Infections and infestations	Vulvovaginal candidiasis	Europe	147	27.4	0	0.0
Infections and infestations	Vulvovaginal candidiasis	America	197	36.7	1	0.5
Infections and infestations	Vulvovaginal candidiasis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Injury, poisoning and procedural complications		Europe	147	27.4	20	13.6
Injury, poisoning and procedural complications		America	197	36.7	13	6.6
Injury, poisoning and procedural complications		Asia Pacific (inc. Australia)	193	35.9	9	4.7
Injury, poisoning and procedural complications	Arthropod bite	Europe	147	27.4	1	0.7
Injury, poisoning and procedural complications	Arthropod bite	America	197	36.7	0	0.0
Injury, poisoning and procedural complications	Arthropod bite	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Injury, poisoning and procedural complications	Back injury	Europe	147	27.4	0	0.0
Injury, poisoning and procedural complications	Back injury	America	197	36.7	0	0.0
Injury, poisoning and procedural complications	Back injury	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Injury, poisoning and procedural complications	Burns third degree	Europe	147	27.4	0	0.0
Injury, poisoning and procedural complications	Burns third degree	America	197	36.7	1	0.5
Injury, poisoning and procedural complications	Burns third degree	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Injury, poisoning and procedural complications	Chilblains	Europe	147	27.4	1	0.7
Injury, poisoning and procedural complications	Chilblains	America	197	36.7	0	0.0
Injury, poisoning and procedural complications	Chilblains	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Injury, poisoning and procedural complications	Clavicle fracture	Europe	147	27.4	0	0.0
Injury, poisoning and procedural complications	Clavicle fracture	America	197	36.7	1	0.5
Injury, poisoning and procedural complications	Clavicle fracture	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Injury, poisoning and procedural complications	Comminuted fracture	Europe	147	27.4	0	0.0

Investigations	White blood cell count decreased	America	197	36.7	0	0.0
Investigations	White blood cell count decreased	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Metabolism and nutrition disorders		Europe	147	27.4	11	7.5
Metabolism and nutrition disorders		America	197	36.7	8	4.6
Metabolism and nutrition disorders		Asia Pacific (inc. Australia)	193	35.9	7	3.6
Metabolism and nutrition disorders	Dehydration	Europe	147	27.4	0	0.0
Metabolism and nutrition disorders	Dehydration	America	197	36.7	2	1.0
Metabolism and nutrition disorders	Dehydration	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus	Europe	147	27.4	1	0.7
Metabolism and nutrition disorders	Diabetes mellitus	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Europe	147	27.4	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Metabolism and nutrition disorders	Folate deficiency	Europe	147	27.4	1	0.7
Metabolism and nutrition disorders	Folate deficiency	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Folate deficiency	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Metabolism and nutrition disorders	Gout	Europe	147	27.4	1	0.7
Metabolism and nutrition disorders	Gout	America	197	36.7	1	0.5
Metabolism and nutrition disorders	Gout	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Metabolism and nutrition disorders	Hypercholesterolaemia	Europe	147	27.4	6	4.1
Metabolism and nutrition disorders	Hypercholesterolaemia	America	197	36.7	3	1.5
Metabolism and nutrition disorders	Hypercholesterolaemia	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Metabolism and nutrition disorders	Hyperglycaemia	Europe	147	27.4	1	0.7
Metabolism and nutrition disorders	Hyperglycaemia	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Hyperglycaemia	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Metabolism and nutrition disorders	Hyperhomocysteinaemia	Europe	147	27.4	0	0.0
Metabolism and nutrition disorders	Hyperhomocysteinaemia	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Hyperhomocysteinaemia	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Metabolism and nutrition disorders	Hyperkalaemia	Europe	147	27.4	1	0.7
Metabolism and nutrition disorders	Hyperkalaemia	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Hyperkalaemia	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Metabolism and nutrition disorders	Hyperlipidaemia	Europe	147	27.4	0	0.0
Metabolism and nutrition disorders	Hyperlipidaemia	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Hyperlipidaemia	Asia Pacific (inc. Australia)	193	35.9	4	2.1
Metabolism and nutrition disorders	Hyperuricaemia	Europe	147	27.4	0	0.0
Metabolism and nutrition disorders	Hyperuricaemia	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Hyperuricaemia	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Metabolism and nutrition disorders	Hypoproteinaemia	Europe	147	27.4	0	0.0
Metabolism and nutrition disorders	Hypoproteinaemia	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Hypoproteinaemia	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Metabolism and nutrition disorders	Obesity	Europe	147	27.4	2	1.4
Metabolism and nutrition disorders	Obesity	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Obesity	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Europe	147	27.4	1	0.7
Metabolism and nutrition disorders	Type 2 diabetes mellitus	America	197	36.7	2	1.0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Metabolism and nutrition disorders	Vitamin B12 deficiency	Europe	147	27.4	0	0.0
Metabolism and nutrition disorders	Vitamin B12 deficiency	America	197	36.7	1	0.5
Metabolism and nutrition disorders	Vitamin B12 deficiency	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Metabolism and nutrition disorders	Vitamin D deficiency	Europe	147	27.4	1	0.7
Metabolism and nutrition disorders	Vitamin D deficiency	America	197	36.7	0	0.0
Metabolism and nutrition disorders	Vitamin D deficiency	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Musculoskeletal and connective tissue disorders		Europe	147	27.4	25	17.0
Musculoskeletal and connective tissue disorders		America	197	36.7	17	8.6
Musculoskeletal and connective tissue disorders		Asia Pacific (inc. Australia)	193	35.9	17	8.8
Musculoskeletal and connective tissue disorders	Arthralgia	Europe	147	27.4	3	1.4
Musculoskeletal and connective tissue disorders	Arthralgia	America	197	36.7	1	0.5
Musculoskeletal and connective tissue disorders	Arthralgia	Asia Pacific (inc. Australia)	193	35.9	4	2.1
Musculoskeletal and connective tissue disorders	Arthritis	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Arthritis	America	197	36.7	2	1.0
Musculoskeletal and connective tissue disorders	Arthritis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Musculoskeletal and connective tissue disorders	Back pain	Europe	147	27.4	5	3.4
Musculoskeletal and connective tissue disorders	Back pain	America	197	36.7	3	1.5
Musculoskeletal and connective tissue disorders	Back pain	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Musculoskeletal and connective tissue disorders	Bone disorder	Europe	147	27.4	1	0.7
Musculoskeletal and connective tissue disorders	Bone disorder	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Bone disorder	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Bursitis	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Bursitis	America	197	36.7	2	1.0
Musculoskeletal and connective tissue disorders	Bursitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Enostosis	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Enostosis	America	197	36.7	1	0.5
Musculoskeletal and connective tissue disorders	Enostosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Fibromyalgia	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Fibromyalgia	America	197	36.7	1	0.5
Musculoskeletal and connective tissue disorders	Fibromyalgia	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Europe	147	27.4	1	0.7
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Musculoskeletal and connective tissue disorders	Joint swelling	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Joint swelling	America	197	36.7	1	0.5
Musculoskeletal and connective tissue disorders	Joint swelling	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Musculoskeletal and connective tissue disorders	Muscle contracture	Europe	147	27.4	1	0.7
Musculoskeletal and connective tissue disorders	Muscle contracture	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Muscle contracture	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Muscle spasms	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Muscle spasms	America	197	36.7	1	0.5
Musculoskeletal and connective tissue disorders	Muscle spasms	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Musculoskeletal and connective tissue disorders	Muscular weakness	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Muscular weakness	America	197	36.7	1	0.5
Musculoskeletal and connective tissue disorders	Muscular weakness	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Myalgia	Europe	147	27.4	1	0.7
Musculoskeletal and connective tissue disorders	Myalgia	America	197	36.7	2	1.0
Musculoskeletal and connective tissue disorders	Myalgia	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Musculoskeletal and connective tissue disorders	Neck pain	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Neck pain	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Neck pain	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Musculoskeletal and connective tissue disorders	Osteoarthritis	Europe	147	27.4	6	4.1
Musculoskeletal and connective tissue disorders	Osteoarthritis	America	197	36.7	2	1.0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Osteopenia	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Osteopenia	America	197	36.7	2	1.0
Musculoskeletal and connective tissue disorders	Osteopenia	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Osteoporosis	Europe	147	27.4	2	1.4
Musculoskeletal and connective tissue disorders	Osteoporosis	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Osteoporosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Pain in extremity	Europe	147	27.4	1	0.7
Musculoskeletal and connective tissue disorders	Pain in extremity	America	197	36.7	1	0.5
Musculoskeletal and connective tissue disorders	Pain in extremity	Asia Pacific (inc. Australia)	193	35.9	3	1.6
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Europe	147	27.4	1	0.7
Musculoskeletal and connective tissue disorders	Plantar fasciitis	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0

Musculoskeletal and connective tissue disorders	Rheumatoid arthritis	Europe	147	27.4	1	0.7
Musculoskeletal and connective tissue disorders	Rheumatoid arthritis	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Rheumatoid arthritis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	Europe	147	27.4	1	0.7
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Europe	147	27.4	2	1.4
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	America	197	36.7	2	1.3
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Spinal pain	Europe	147	27.4	5	3.4
Musculoskeletal and connective tissue disorders	Spinal pain	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Spinal pain	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Tendon disorder	Europe	147	27.4	1	0.7
Musculoskeletal and connective tissue disorders	Tendon disorder	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Tendon disorder	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Musculoskeletal and connective tissue disorders	Tenosynovitis	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Tenosynovitis	America	197	36.7	0	0.0
Musculoskeletal and connective tissue disorders	Tenosynovitis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Musculoskeletal and connective tissue disorders	Vertebral foraminal stenosis	Europe	147	27.4	0	0.0
Musculoskeletal and connective tissue disorders	Vertebral foraminal stenosis	America	197	36.7	1	0.5
Musculoskeletal and connective tissue disorders	Vertebral foraminal stenosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Europe	147	27.4	3	2.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		America	197	36.7	1	0.5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asia Pacific (inc. Australia)	193	35.9	3	1.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bowen's disease	Europe	147	27.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bowen's disease	America	197	36.7	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bowen's disease	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Europe	147	27.4	1	0.7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	America	197	36.7	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Europe	147	27.4	1	0.7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	America	197	36.7	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	lung neoplasm	Europe	147	27.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	lung neoplasm	America	197	36.7	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	lung neoplasm	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Europe	147	27.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	America	197	36.7	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Europe	147	27.4	1	0.7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	America	197	36.7	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Europe	147	27.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	America	197	36.7	1	0.5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Europe	147	27.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	America	197	36.7	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Nervous system disorders		Europe	147	27.4	17	11.6
Nervous system disorders		America	197	36.7	17	8.6
Nervous system disorders		Asia Pacific (inc. Australia)	193	35.9	13	6.7
Nervous system disorders	Carotid arteriosclerosis	Europe	147	27.4	0	0.0
Nervous system disorders	Carotid arteriosclerosis	America	197	36.7	1	0.5
Nervous system disorders	Carotid arteriosclerosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Carotid artery stenosis	Europe	147	27.4	0	0.0
Nervous system disorders	Carotid artery stenosis	America	197	36.7	1	0.5
Nervous system disorders	Carotid artery stenosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Cerebral atrophy	Europe	147	27.4	0	0.0
Nervous system disorders	Cerebral atrophy	America	197	36.7	0	0.0
Nervous system disorders	Cerebral atrophy	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Cerebral haematoma	Europe	147	27.4	1	0.7
Nervous system disorders	Cerebral haematoma	America	197	36.7	0	0.0
Nervous system disorders	Cerebral haematoma	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Cerebral infarction	Europe	147	27.4	0	0.0
Nervous system disorders	Cerebral infarction	America	197	36.7	0	0.0
Nervous system disorders	Cerebral infarction	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Nervous system disorders	Cerebral thrombosis	Europe	147	27.4	0	0.0
Nervous system disorders	Cerebral thrombosis	America	197	36.7	0	0.0
Nervous system disorders	Cerebral thrombosis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Nervous system disorders	Cerebrovascular accident	Europe	147	27.4	1	0.7
Nervous system disorders	Cerebrovascular accident	America	197	36.7	1	0.5
Nervous system disorders	Cerebrovascular accident	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Cervical radiculopathy	Europe	147	27.4	0	0.0
Nervous system disorders	Cervical radiculopathy	America	197	36.7	0	0.0
Nervous system disorders	Cervical radiculopathy	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Nervous system disorders	Cognitive disorder	Europe	147	27.4	0	0.0
Nervous system disorders	Cognitive disorder	America	197	36.7	1	0.5
Nervous system disorders	Cognitive disorder	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Dementia Alzheimer's type	Europe	147	27.4	0	0.0
Nervous system disorders	Dementia Alzheimer's type	America	197	36.7	1	0.5
Nervous system disorders	Dementia Alzheimer's type	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Diabetic neuropathy	Europe	147	27.4	0	0.0
Nervous system disorders	Diabetic neuropathy	America	197	36.7	0	0.0
Nervous system disorders	Diabetic neuropathy	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Nervous system disorders	Disturbance in attention	Europe	147	27.4	1	0.7
Nervous system disorders	Disturbance in attention	America	197	36.7	0	0.0
Nervous system disorders	Disturbance in attention	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Dizziness	Europe	147	27.4	1	0.7
Nervous system disorders	Dizziness	America	197	36.7	1	0.5
Nervous system disorders	Dizziness	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Nervous system disorders	Epilepsy	Europe	147	27.4	0	0.0
Nervous system disorders	Epilepsy	America	197	36.7	1	0.5
Nervous system disorders	Epilepsy	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Headache	Europe	147	27.4	5	3.4
Nervous system disorders	Headache	America	197	36.7	1	0.5

Nervous system disorders	Headache	Asia Pacific (inc. Australia)	193	35.9	4	2.1
Nervous system disorders	Hypertensive encephalopathy	Europe	147	27.4	1	0.7
Nervous system disorders	Hypertensive encephalopathy	America	197	36.7	0	0.0
Nervous system disorders	Hypertensive encephalopathy	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Hypoaesthesia	Europe	147	27.4	1	0.7
Nervous system disorders	Hypoaesthesia	America	197	36.7	0	0.0
Nervous system disorders	Hypoaesthesia	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Intracranial aneurysm	Europe	147	27.4	0	0.0
Nervous system disorders	Intracranial aneurysm	America	197	36.7	0	0.0
Nervous system disorders	Intracranial aneurysm	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Nervous system disorders	Ischaemic stroke	Europe	147	27.4	0	0.0
Nervous system disorders	Ischaemic stroke	America	197	36.7	2	1.0
Nervous system disorders	Ischaemic stroke	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Loss of consciousness	Europe	147	27.4	0	0.0
Nervous system disorders	Loss of consciousness	America	197	36.7	0	0.0
Nervous system disorders	Loss of consciousness	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Nervous system disorders	Memory impairment	Europe	147	27.4	0	0.0
Nervous system disorders	Memory impairment	America	197	36.7	1	0.5
Nervous system disorders	Memory impairment	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Migraine	Europe	147	27.4	1	0.7
Nervous system disorders	Migraine	America	197	36.7	0	0.0
Nervous system disorders	Migraine	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Multiple sclerosis	Europe	147	27.4	0	0.0
Nervous system disorders	Multiple sclerosis	America	197	36.7	1	0.5
Nervous system disorders	Multiple sclerosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Myelopathy	Europe	147	27.4	1	0.7
Nervous system disorders	Myelopathy	America	197	36.7	0	0.0
Nervous system disorders	Myelopathy	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Narcolepsy	Europe	147	27.4	0	0.0
Nervous system disorders	Narcolepsy	America	197	36.7	1	0.5
Nervous system disorders	Narcolepsy	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Neuropathy peripheral	Europe	147	27.4	0	0.0
Nervous system disorders	Neuropathy peripheral	America	197	36.7	0	0.0
Nervous system disorders	Neuropathy peripheral	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Nervous system disorders	Ophthalmic migraine	Europe	147	27.4	0	0.0
Nervous system disorders	Ophthalmic migraine	America	197	36.7	1	0.5
Nervous system disorders	Ophthalmic migraine	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Presyncope	Europe	147	27.4	1	0.7
Nervous system disorders	Presyncope	America	197	36.7	0	0.0
Nervous system disorders	Presyncope	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Sciatica	Europe	147	27.4	3	2.0
Nervous system disorders	Sciatica	America	197	36.7	1	0.5
Nervous system disorders	Sciatica	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Nervous system disorders	Sinus headache	Europe	147	27.4	0	0.0
Nervous system disorders	Sinus headache	America	197	36.7	1	0.5
Nervous system disorders	Sinus headache	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Syncope	Europe	147	27.4	2	1.4
Nervous system disorders	Syncope	America	197	36.7	0	0.0
Nervous system disorders	Syncope	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	Tension headache	Europe	147	27.4	2	1.4
Nervous system disorders	Tension headache	America	197	36.7	0	0.0
Nervous system disorders	Tension headache	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Nervous system disorders	White matter lesion	Europe	147	27.4	0	0.0
Nervous system disorders	White matter lesion	America	197	36.7	1	0.5
Nervous system disorders	White matter lesion	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Product issues		Europe	147	27.4	0	0.0
Product issues		America	197	36.7	1	0.5
Product issues		Asia Pacific (inc. Australia)	193	35.9	0	0.0
Product issues	Device malfunction	Europe	147	27.4	0	0.0
Product issues	Device malfunction	America	197	36.7	1	0.5
Product issues	Device malfunction	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Psychiatric disorders		Europe	147	27.4	1	0.7
Psychiatric disorders		America	197	36.7	5	2.5
Psychiatric disorders		Asia Pacific (inc. Australia)	193	35.9	3	1.6
Psychiatric disorders	Anxiety	Europe	147	27.4	0	0.0
Psychiatric disorders	Anxiety	America	197	36.7	1	0.5
Psychiatric disorders	Anxiety	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Psychiatric disorders	Confusional state	Europe	147	27.4	0	0.0
Psychiatric disorders	Confusional state	America	197	36.7	2	1.0
Psychiatric disorders	Confusional state	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Psychiatric disorders	Delirium	Europe	147	27.4	0	0.0
Psychiatric disorders	Delirium	America	197	36.7	1	0.5
Psychiatric disorders	Delirium	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Psychiatric disorders	Depression	Europe	147	27.4	0	0.0
Psychiatric disorders	Depression	America	197	36.7	1	0.5
Psychiatric disorders	Depression	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Psychiatric disorders	Insomnia	Europe	147	27.4	1	0.7
Psychiatric disorders	Insomnia	America	197	36.7	0	0.0
Psychiatric disorders	Insomnia	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Psychiatric disorders	Somatic symptom disorder	Europe	147	27.4	0	0.0
Psychiatric disorders	Somatic symptom disorder	America	197	36.7	0	0.0
Psychiatric disorders	Somatic symptom disorder	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Renal and urinary disorders		Europe	147	27.4	3	2.0
Renal and urinary disorders		America	197	36.7	9	4.1
Renal and urinary disorders		Asia Pacific (inc. Australia)	193	35.9	3	1.6
Renal and urinary disorders	Acute kidney injury	Europe	147	27.4	0	0.0
Renal and urinary disorders	Acute kidney injury	America	197	36.7	2	1.0
Renal and urinary disorders	Acute kidney injury	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Renal and urinary disorders	Chronic kidney disease	Europe	147	27.4	0	0.0
Renal and urinary disorders	Chronic kidney disease	America	197	36.7	2	1.0
Renal and urinary disorders	Chronic kidney disease	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Renal and urinary disorders	Diabetic nephropathy	Europe	147	27.4	0	0.0
Renal and urinary disorders	Diabetic nephropathy	America	197	36.7	0	0.0
Renal and urinary disorders	Diabetic nephropathy	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Renal and urinary disorders	Haematuria	Europe	147	27.4	0	0.0
Renal and urinary disorders	Haematuria	America	197	36.7	1	0.5
Renal and urinary disorders	Haematuria	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Renal and urinary disorders	Nephrolithiasis	Europe	147	27.4	0	0.0
Renal and urinary disorders	Nephrolithiasis	America	197	36.7	1	0.5
Renal and urinary disorders	Nephrolithiasis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Renal and urinary disorders	Renal colic	Europe	147	27.4	1	0.7
Renal and urinary disorders	Renal colic	America	197	36.7	0	0.0
Renal and urinary disorders	Renal colic	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Renal and urinary disorders	Renal cyst	Europe	147	27.4	2	1.4
Renal and urinary disorders	Renal cyst	America	197	36.7	0	0.0
Renal and urinary disorders	Renal cyst	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Renal and urinary disorders	Renal mass	Europe	147	27.4	0	0.0
Renal and urinary disorders	Renal mass	America	197	36.7	1	0.5
Renal and urinary disorders	Renal mass	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Renal and urinary disorders	Urinary incontinence	Europe	147	27.4	0	0.0
Renal and urinary disorders	Urinary incontinence	America	197	36.7	1	0.5
Renal and urinary disorders	Urinary incontinence	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Reproductive system and breast disorders		Europe	147	27.4	3	2.0
Reproductive system and breast disorders		America	197	36.7	0	0.0

Reproductive system and breast disorders		Asia Pacific (inc. Australia)	193	35.9	2	1.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Europe	147	27.4	1	0.7
Reproductive system and breast disorders	Benign prostatic hyperplasia	America	197	36.7	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Reproductive system and breast disorders	Erectile dysfunction	Europe	147	27.4	2	1.4
Reproductive system and breast disorders	Erectile dysfunction	America	197	36.7	0	0.0
Reproductive system and breast disorders	Erectile dysfunction	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Reproductive system and breast disorders	Prostatitis	Europe	147	27.4	1	0.7
Reproductive system and breast disorders	Prostatitis	America	197	36.7	0	0.0
Reproductive system and breast disorders	Prostatitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders		Europe	147	27.4	10	6.8
Respiratory, thoracic and mediastinal disorders		America	197	36.7	5	2.5
Respiratory, thoracic and mediastinal disorders		Asia Pacific (inc. Australia)	193	35.9	5	2.6
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Europe	147	27.4	1	0.7
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Europe	147	27.4	2	1.4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Cough	Europe	147	27.4	1	0.7
Respiratory, thoracic and mediastinal disorders	Cough	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Cough	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Europe	147	27.4	1	0.7
Respiratory, thoracic and mediastinal disorders	Dyspnoea	America	197	36.7	1	0.6
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Emphysema	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Emphysema	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Emphysema	Asia Pacific (inc. Australia)	193	35.9	1	0.6
Respiratory, thoracic and mediastinal disorders	Hemoptysis	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Hemoptysis	America	197	36.7	1	0.5
Respiratory, thoracic and mediastinal disorders	Hemoptysis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Hypopentilation	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Hypopentilation	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Hypopentilation	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Lung disorder	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Lung disorder	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Lung disorder	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Lung hyperinflation	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Lung hyperinflation	America	197	36.7	1	0.5
Respiratory, thoracic and mediastinal disorders	Lung hyperinflation	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	America	197	36.7	1	0.5
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Europe	147	27.4	1	0.7
Respiratory, thoracic and mediastinal disorders	Pleural effusion	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Pneumonitis	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Pneumonitis	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Pneumonitis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary fibrosis	Europe	147	27.4	1	0.7
Respiratory, thoracic and mediastinal disorders	Pulmonary fibrosis	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary fibrosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary mass	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary mass	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary mass	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Respiratory, thoracic and mediastinal disorders	Respiratory failure	Europe	147	27.4	1	0.7
Respiratory, thoracic and mediastinal disorders	Respiratory failure	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Respiratory failure	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	Europe	147	27.4	1	0.7
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	America	197	36.7	1	0.5
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Europe	147	27.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	America	197	36.7	1	0.5
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Europe	147	27.4	2	1.4
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	America	197	36.7	0	0.0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Skin and subcutaneous tissue disorders		Europe	147	27.4	2	1.4
Skin and subcutaneous tissue disorders		America	197	36.7	3	1.5
Skin and subcutaneous tissue disorders		Asia Pacific (inc. Australia)	193	35.9	7	3.6
Skin and subcutaneous tissue disorders	Actinic keratosis	Europe	147	27.4	0	0.0
Skin and subcutaneous tissue disorders	Actinic keratosis	America	197	36.7	0	0.0
Skin and subcutaneous tissue disorders	Actinic keratosis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Skin and subcutaneous tissue disorders	Dermatitis	Europe	147	27.4	0	0.0
Skin and subcutaneous tissue disorders	Dermatitis	America	197	36.7	0	0.0
Skin and subcutaneous tissue disorders	Dermatitis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Skin and subcutaneous tissue disorders	Dermatitis contact	Europe	147	27.4	0	0.0
Skin and subcutaneous tissue disorders	Dermatitis contact	America	197	36.7	1	0.5
Skin and subcutaneous tissue disorders	Dermatitis contact	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Skin and subcutaneous tissue disorders	Eczema	Europe	147	27.4	0	0.0
Skin and subcutaneous tissue disorders	Eczema	America	197	36.7	0	0.0
Skin and subcutaneous tissue disorders	Eczema	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Skin and subcutaneous tissue disorders	Miliaria	Europe	147	27.4	0	0.0
Skin and subcutaneous tissue disorders	Miliaria	America	197	36.7	0	0.0
Skin and subcutaneous tissue disorders	Miliaria	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Skin and subcutaneous tissue disorders	Pemphigoid	Europe	147	27.4	0	0.0
Skin and subcutaneous tissue disorders	Pemphigoid	America	197	36.7	1	0.5
Skin and subcutaneous tissue disorders	Pemphigoid	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Skin and subcutaneous tissue disorders	Pruritus	Europe	147	27.4	0	0.0
Skin and subcutaneous tissue disorders	Pruritus	America	197	36.7	0	0.0
Skin and subcutaneous tissue disorders	Pruritus	Asia Pacific (inc. Australia)	193	35.9	2	1.0
Skin and subcutaneous tissue disorders	Rash	Europe	147	27.4	1	0.7
Skin and subcutaneous tissue disorders	Rash	America	197	36.7	0	0.0
Skin and subcutaneous tissue disorders	Rash	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Skin and subcutaneous tissue disorders	Seborrheic dermatitis	Europe	147	27.4	0	0.0
Skin and subcutaneous tissue disorders	Seborrheic dermatitis	America	197	36.7	1	0.5
Skin and subcutaneous tissue disorders	Seborrheic dermatitis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Skin and subcutaneous tissue disorders	Skin ulcer	Europe	147	27.4	0	0.0
Skin and subcutaneous tissue disorders	Skin ulcer	America	197	36.7	0	0.0
Skin and subcutaneous tissue disorders	Skin ulcer	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Social circumstances		Europe	147	27.4	0	0.0
Social circumstances		America	197	36.7	1	0.5
Social circumstances		Asia Pacific (inc. Australia)	193	35.9	0	0.0
Social circumstances	Joint prosthesis user	Europe	147	27.4	0	0.0
Social circumstances	Joint prosthesis user	America	197	36.7	1	0.5
Social circumstances	Joint prosthesis user	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Surgical and medical procedures		Europe	147	27.4	1	0.7
Surgical and medical procedures		America	197	36.7	3	1.5

Surgical and medical procedures		Asia Pacific (inc. Australia)	193	35.9	1	0.5
Surgical and medical procedures	Knee arthroplasty	Europe	147	27.4	0	0.0
Surgical and medical procedures	Knee arthroplasty	America	197	36.7	1	0.5
Surgical and medical procedures	Knee arthroplasty	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Surgical and medical procedures	Large intestinal polypectomy	Europe	147	27.4	1	0.7
Surgical and medical procedures	Large intestinal polypectomy	America	197	36.7	0	0.0
Surgical and medical procedures	Large intestinal polypectomy	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Surgical and medical procedures	Mole excision	Europe	147	27.4	0	0.0
Surgical and medical procedures	Mole excision	America	197	36.7	1	0.5
Surgical and medical procedures	Mole excision	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Surgical and medical procedures	Shoulder arthroplasty	Europe	147	27.4	0	0.0
Surgical and medical procedures	Shoulder arthroplasty	America	197	36.7	0	0.0
Surgical and medical procedures	Shoulder arthroplasty	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Surgical and medical procedures	Transurethral prostatectomy	Europe	147	27.4	0	0.0
Surgical and medical procedures	Transurethral prostatectomy	America	197	36.7	1	0.5
Surgical and medical procedures	Transurethral prostatectomy	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Vascular disorders		Europe	147	27.4	19	12.9
Vascular disorders		America	197	36.7	10	5.1
Vascular disorders		Asia Pacific (inc. Australia)	193	35.9	9	4.7
Vascular disorders	Aortic stenosis	Europe	147	27.4	0	0.0
Vascular disorders	Aortic stenosis	America	197	36.7	0	0.0
Vascular disorders	Aortic stenosis	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Vascular disorders	Arteriosclerosis	Europe	147	27.4	1	0.7
Vascular disorders	Arteriosclerosis	America	197	36.7	0	0.0
Vascular disorders	Arteriosclerosis	Asia Pacific (inc. Australia)	193	35.9	3	1.6
Vascular disorders	Brachiocephalic arteriosclerosis	Europe	147	27.4	1	0.7
Vascular disorders	Brachiocephalic arteriosclerosis	America	197	36.7	0	0.0
Vascular disorders	Brachiocephalic arteriosclerosis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Vascular disorders	Diabetic vascular disorder	Europe	147	27.4	0	0.0
Vascular disorders	Diabetic vascular disorder	America	197	36.7	0	0.0
Vascular disorders	Diabetic vascular disorder	Asia Pacific (inc. Australia)	193	35.9	1	0.5
Vascular disorders	Hypertension	Europe	147	27.4	11	7.5
Vascular disorders	Hypertension	America	197	36.7	7	3.6
Vascular disorders	Hypertension	Asia Pacific (inc. Australia)	193	35.9	5	2.6
Vascular disorders	Hypertensive crisis	Europe	147	27.4	2	1.4
Vascular disorders	Hypertensive crisis	America	197	36.7	0	0.0
Vascular disorders	Hypertensive crisis	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Vascular disorders	Hypotension	Europe	147	27.4	0	0.0
Vascular disorders	Hypotension	America	197	36.7	3	1.5
Vascular disorders	Hypotension	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Vascular disorders	Ischaemic limb pain	Europe	147	27.4	1	0.7
Vascular disorders	Ischaemic limb pain	America	197	36.7	0	0.0
Vascular disorders	Ischaemic limb pain	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Vascular disorders	Orthostatic hypotension	Europe	147	27.4	0	0.0
Vascular disorders	Orthostatic hypotension	America	197	36.7	1	0.5
Vascular disorders	Orthostatic hypotension	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Vascular disorders	Varicose vein	Europe	147	27.4	1	0.7
Vascular disorders	Varicose vein	America	197	36.7	0	0.0
Vascular disorders	Varicose vein	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Vascular disorders	Vascular occlusion	Europe	147	27.4	1	0.7
Vascular disorders	Vascular occlusion	America	197	36.7	0	0.0
Vascular disorders	Vascular occlusion	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Vascular disorders	Venous occlusion	Europe	147	27.4	1	0.7
Vascular disorders	Venous occlusion	America	197	36.7	0	0.0
Vascular disorders	Venous occlusion	Asia Pacific (inc. Australia)	193	35.9	0	0.0
Vascular disorders	Venous thrombosis limb	Europe	147	27.4	1	0.7
Vascular disorders	Venous thrombosis limb	America	197	36.7	0	0.0
Vascular disorders	Venous thrombosis limb	Asia Pacific (inc. Australia)	193	35.9	0	0.0

Program: root:/clinical_studies/R06867461/CDT30303/share/ACK_data_analysis/prod/program/t_ae_soc_descriptive_v72.sas
Output: root:/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACK_CSR_Final/prod/output/t_ae_soc_descriptive_v72_sq_AR_MW2_Sea24_30AND2023_41984.xls
26APR2024 17:45

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any AE
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

MedDRA System Organ Class	MedDRA Preferred Term	Level	Patient with Event			
			n	%	n	%
Blood and lymphatic system disorders		White	332	61.8	2	0.6
Blood and lymphatic system disorders		Asian	180	33.5	3	1.7
Blood and lymphatic system disorders		Other	17	3.2	0	0.0
Blood and lymphatic system disorders		Unknown	8	1.5	0	0.0
Blood and lymphatic system disorders	Anaemia	White	332	61.8	0	0.0
Blood and lymphatic system disorders	Anaemia	Asian	180	33.5	1	0.6
Blood and lymphatic system disorders	Anaemia	Other	17	3.2	0	0.0
Blood and lymphatic system disorders	Anaemia	Unknown	8	1.5	0	0.0
Blood and lymphatic system disorders	Antiphospholipid syndrome	White	332	61.8	0	0.0
Blood and lymphatic system disorders	Antiphospholipid syndrome	Asian	180	33.5	0	0.0
Blood and lymphatic system disorders	Antiphospholipid syndrome	Other	17	3.2	0	0.0
Blood and lymphatic system disorders	Antiphospholipid syndrome	Unknown	8	1.5	0	0.0
Blood and lymphatic system disorders	Cosmopolitan	White	332	61.8	0	0.0
Blood and lymphatic system disorders	Cosmopolitan	Asian	180	33.5	1	0.6
Blood and lymphatic system disorders	Cosmopolitan	Other	17	3.2	0	0.0
Blood and lymphatic system disorders	Cosmopolitan	Unknown	8	1.5	0	0.0
Blood and lymphatic system disorders	Macropoiesis	White	332	61.8	1	0.3
Blood and lymphatic system disorders	Macropoiesis	Asian	180	33.5	0	0.0
Blood and lymphatic system disorders	Macropoiesis	Other	17	3.2	0	0.0
Blood and lymphatic system disorders	Macropoiesis	Unknown	8	1.5	0	0.0
Cardiac disorders		White	332	61.8	15	4.5
Cardiac disorders		Asian	180	33.5	5	2.8
Cardiac disorders		Other	17	3.2	0	0.0
Cardiac disorders		Unknown	8	1.5	0	0.0
Cardiac disorders	Acute myocardial infarction	White	332	61.8	0	0.0
Cardiac disorders	Acute myocardial infarction	Asian	180	33.5	1	0.6
Cardiac disorders	Acute myocardial infarction	Other	17	3.2	0	0.0
Cardiac disorders	Acute myocardial infarction	Unknown	8	1.5	0	0.0
Cardiac disorders	Angina pectoris	White	332	61.8	1	0.3
Cardiac disorders	Angina pectoris	Asian	180	33.5	0	0.0
Cardiac disorders	Angina pectoris	Other	17	3.2	0	0.0
Cardiac disorders	Angina pectoris	Unknown	8	1.5	0	0.0
Cardiac disorders	Angina unstable	White	332	61.8	1	0.3
Cardiac disorders	Angina unstable	Asian	180	33.5	1	0.6
Cardiac disorders	Angina unstable	Other	17	3.2	0	0.0
Cardiac disorders	Angina unstable	Unknown	8	1.5	0	0.0
Cardiac disorders	Aortic valve incompetence	White	332	61.8	0	0.0
Cardiac disorders	Aortic valve incompetence	Asian	180	33.5	0	0.0
Cardiac disorders	Aortic valve incompetence	Other	17	3.2	0	0.0
Cardiac disorders	Aortic valve incompetence	Unknown	8	1.5	0	0.0
Cardiac disorders	Arrhythmias	White	332	61.8	2	0.6
Cardiac disorders	Arrhythmias	Asian	180	33.5	0	0.0
Cardiac disorders	Arrhythmias	Other	17	3.2	0	0.0
Cardiac disorders	Arrhythmias	Unknown	8	1.5	0	0.0
Cardiac disorders	Arteriosclerosis coronary artery	White	332	61.8	0	0.0
Cardiac disorders	Arteriosclerosis coronary artery	Asian	180	33.5	2	1.1
Cardiac disorders	Arteriosclerosis coronary artery	Other	17	3.2	0	0.0
Cardiac disorders	Arteriosclerosis coronary artery	Unknown	8	1.5	0	0.0
Cardiac disorders	Atrial fibrillation	White	332	61.8	2	0.6
Cardiac disorders	Atrial fibrillation	Asian	180	33.5	0	0.0
Cardiac disorders	Atrial fibrillation	Other	17	3.2	0	0.0
Cardiac disorders	Atrial fibrillation	Unknown	8	1.5	0	0.0
Cardiac disorders	Bicuspid aortic valve	White	332	61.8	0	0.0
Cardiac disorders	Bicuspid aortic valve	Asian	180	33.5	1	0.6
Cardiac disorders	Bicuspid aortic valve	Other	17	3.2	0	0.0
Cardiac disorders	Bicuspid aortic valve	Unknown	8	1.5	0	0.0
Cardiac disorders	Cardiac failure	White	332	61.8	2	0.6
Cardiac disorders	Cardiac failure	Asian	180	33.5	0	0.0
Cardiac disorders	Cardiac failure	Other	17	3.2	0	0.0
Cardiac disorders	Cardiac failure	Unknown	8	1.5	0	0.0
Cardiac disorders	Cardiac failure congestive	White	332	61.8	1	0.3
Cardiac disorders	Cardiac failure congestive	Asian	180	33.5	0	0.0
Cardiac disorders	Cardiac failure congestive	Other	17	3.2	0	0.0
Cardiac disorders	Cardiac failure congestive	Unknown	8	1.5	0	0.0
Cardiac disorders	Cardiomegaly	White	332	61.8	1	0.3
Cardiac disorders	Cardiomegaly	Asian	180	33.5	0	0.0
Cardiac disorders	Cardiomegaly	Other	17	3.2	0	0.0
Cardiac disorders	Cardiomegaly	Unknown	8	1.5	0	0.0
Cardiac disorders	Coronary artery disease	White	332	61.8	0	0.0
Cardiac disorders	Coronary artery disease	Asian	180	33.5	0	0.0
Cardiac disorders	Coronary artery disease	Other	17	3.2	0	0.0
Cardiac disorders	Coronary artery disease	Unknown	8	1.5	0	0.0
Cardiac disorders	Dilatation ventricular	White	332	61.8	1	0.3
Cardiac disorders	Dilatation ventricular	Asian	180	33.5	0	0.0
Cardiac disorders	Dilatation ventricular	Other	17	3.2	0	0.0
Cardiac disorders	Dilatation ventricular	Unknown	8	1.5	0	0.0
Cardiac disorders	Left atrial enlargement	White	332	61.8	0	0.0
Cardiac disorders	Left atrial enlargement	Asian	180	33.5	1	0.6
Cardiac disorders	Left atrial enlargement	Other	17	3.2	0	0.0
Cardiac disorders	Left atrial enlargement	Unknown	8	1.5	0	0.0
Cardiac disorders	Left ventricular failure	White	332	61.8	1	0.3
Cardiac disorders	Left ventricular failure	Asian	180	33.5	0	0.0
Cardiac disorders	Left ventricular failure	Other	17	3.2	0	0.0
Cardiac disorders	Left ventricular failure	Unknown	8	1.5	0	0.0
Cardiac disorders	Mitral valve incompetence	White	332	61.8	0	0.0
Cardiac disorders	Mitral valve incompetence	Asian	180	33.5	1	0.6
Cardiac disorders	Mitral valve incompetence	Other	17	3.2	0	0.0
Cardiac disorders	Mitral valve incompetence	Unknown	8	1.5	0	0.0
Cardiac disorders	Myocardial fibrosis	White	332	61.8	1	0.3
Cardiac disorders	Myocardial fibrosis	Asian	180	33.5	0	0.0
Cardiac disorders	Myocardial fibrosis	Other	17	3.2	0	0.0
Cardiac disorders	Myocardial fibrosis	Unknown	8	1.5	0	0.0
Cardiac disorders	Myocardial infarction	White	332	61.8	4	1.2
Cardiac disorders	Myocardial infarction	Asian	180	33.5	0	0.0
Cardiac disorders	Myocardial infarction	Other	17	3.2	0	0.0
Cardiac disorders	Myocardial infarction	Unknown	8	1.5	0	0.0
Cardiac disorders	Myocardial ischaemia	White	332	61.8	0	0.0
Cardiac disorders	Myocardial ischaemia	Asian	180	33.5	0	0.0
Cardiac disorders	Myocardial ischaemia	Other	17	3.2	0	0.0
Cardiac disorders	Myocardial ischaemia	Unknown	8	1.5	0	0.0
Cardiac disorders	Pericarditis	White	332	61.8	1	0.3
Cardiac disorders	Pericarditis	Asian	180	33.5	0	0.0
Cardiac disorders	Pericarditis	Other	17	3.2	0	0.0
Cardiac disorders	Pericarditis	Unknown	8	1.5	0	0.0
Cardiac disorders	Sinus bradycardia	White	332	61.8	0	0.0
Cardiac disorders	Sinus bradycardia	Asian	180	33.5	1	0.6
Cardiac disorders	Sinus bradycardia	Other	17	3.2	0	0.0
Cardiac disorders	Sinus bradycardia	Unknown	8	1.5	0	0.0
Cardiac disorders	Supraventricular extrasystoles	White	332	61.8	2	0.6
Cardiac disorders	Supraventricular extrasystoles	Asian	180	33.5	0	0.0
Cardiac disorders	Supraventricular extrasystoles	Other	17	3.2	0	0.0
Cardiac disorders	Supraventricular extrasystoles	Unknown	8	1.5	0	0.0
Cardiac disorders	Tricuspid valve incompetence	White	332	61.8	0	0.0
Cardiac disorders	Tricuspid valve incompetence	Asian	180	33.5	1	0.6
Cardiac disorders	Tricuspid valve incompetence	Other	17	3.2	0	0.0
Cardiac disorders	Tricuspid valve incompetence	Unknown	8	1.5	0	0.0
Congenital, familial and genetic disorders		White	332	61.8	3	0.9
Congenital, familial and genetic disorders		Asian	180	33.5	0	0.0
Congenital, familial and genetic disorders		Other	17	3.2	0	0.0
Congenital, familial and genetic disorders		Unknown	8	1.5	0	0.0
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	White	332	61.8	1	0.3
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Asian	180	33.5	0	0.0
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Other	17	3.2	0	0.0
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Unknown	8	1.5	0	0.0
Congenital, familial and genetic disorders	Corneal dystrophy	White	332	61.8	1	0.3
Congenital, familial and genetic disorders	Corneal dystrophy	Asian	180	33.5	0	0.0

Congenital, familial and genetic disorders	Cornual dystrophy	Other	17	3.2	0	0.0
Congenital, familial and genetic disorders	Cornual dystrophy	Unknown	8	1.5	0	0.0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	White	332	61.8	1	0.3
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Asian	180	33.5	0	0.0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Other	17	3.2	0	0.0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Unknown	8	1.5	0	0.0
Ear and labyrinth disorders		White	332	61.8	7	2.1
Ear and labyrinth disorders		Asian	180	33.5	1	0.3
Ear and labyrinth disorders		Other	17	3.2	0	0.0
Ear and labyrinth disorders		Unknown	8	1.5	0	0.0
Ear and labyrinth disorders	Cerumen impaction	White	332	61.8	2	0.6
Ear and labyrinth disorders	Cerumen impaction	Asian	180	33.5	0	0.0
Ear and labyrinth disorders	Cerumen impaction	Other	17	3.2	0	0.0
Ear and labyrinth disorders	Cerumen impaction	Unknown	8	1.5	0	0.0
Ear and labyrinth disorders	Ear disorder	White	332	61.8	0	0.0
Ear and labyrinth disorders	Ear disorder	Asian	180	33.5	1	0.3
Ear and labyrinth disorders	Ear disorder	Other	17	3.2	0	0.0
Ear and labyrinth disorders	Ear disorder	Unknown	8	1.5	0	0.0
Ear and labyrinth disorders	Hypacusis	White	332	61.8	1	0.3
Ear and labyrinth disorders	Hypacusis	Asian	180	33.5	0	0.0
Ear and labyrinth disorders	Hypacusis	Other	17	3.2	0	0.0
Ear and labyrinth disorders	Hypacusis	Unknown	8	1.5	0	0.0
Ear and labyrinth disorders	Flaccid	White	332	61.8	1	0.3
Ear and labyrinth disorders	Flaccid	Asian	180	33.5	0	0.0
Ear and labyrinth disorders	Flaccid	Other	17	3.2	0	0.0
Ear and labyrinth disorders	Flaccid	Unknown	8	1.5	0	0.0
Ear and labyrinth disorders	Vertigo	White	332	61.8	3	0.9
Ear and labyrinth disorders	Vertigo	Asian	180	33.5	0	0.0
Ear and labyrinth disorders	Vertigo	Other	17	3.2	0	0.0
Ear and labyrinth disorders	Vertigo	Unknown	8	1.5	0	0.0
Ear and labyrinth disorders	Vertigo positional	White	332	61.8	0	0.0
Ear and labyrinth disorders	Vertigo positional	Asian	180	33.5	2	0.6
Ear and labyrinth disorders	Vertigo positional	Other	17	3.2	0	0.0
Ear and labyrinth disorders	Vertigo positional	Unknown	8	1.5	0	0.0
Endocrine disorders		White	332	61.8	2	0.6
Endocrine disorders		Asian	180	33.5	1	0.3
Endocrine disorders		Other	17	3.2	0	0.0
Endocrine disorders		Unknown	8	1.5	0	0.0
Endocrine disorders	Hypothyroidism	White	332	61.8	2	0.6
Endocrine disorders	Hypothyroidism	Asian	180	33.5	1	0.3
Endocrine disorders	Hypothyroidism	Other	17	3.2	0	0.0
Endocrine disorders	Hypothyroidism	Unknown	8	1.5	0	0.0
Eye disorders		White	332	61.8	100	30.1
Eye disorders		Asian	180	33.5	61	18.1
Eye disorders		Other	17	3.2	6	18.1
Eye disorders		Unknown	8	1.5	2	25.0
Eye disorders	Abnormal sensation in eye	White	332	61.8	0	0.0
Eye disorders	Abnormal sensation in eye	Asian	180	33.5	1	0.3
Eye disorders	Abnormal sensation in eye	Other	17	3.2	0	0.0
Eye disorders	Abnormal sensation in eye	Unknown	8	1.5	0	0.0
Eye disorders	Abnormal sensation in eye	White	332	61.8	0	0.0
Eye disorders	Arthropgia	Asian	180	33.5	1	0.3
Eye disorders	Arthropgia	Other	17	3.2	0	0.0
Eye disorders	Arthropgia	Unknown	8	1.5	0	0.0
Eye disorders	Blepharitis allergic	White	332	61.8	1	0.3
Eye disorders	Blepharitis allergic	Asian	180	33.5	0	0.0
Eye disorders	Blepharitis allergic	Other	17	3.2	0	0.0
Eye disorders	Blepharitis allergic	Unknown	8	1.5	0	0.0
Eye disorders	Bordetline glaucoma	White	332	61.8	0	0.0
Eye disorders	Bordetline glaucoma	Asian	180	33.5	1	0.3
Eye disorders	Bordetline glaucoma	Other	17	3.2	0	0.0
Eye disorders	Bordetline glaucoma	Unknown	8	1.5	0	0.0
Eye disorders	Cataract	White	332	61.8	14	4.2
Eye disorders	Cataract	Asian	180	33.5	4	11.4
Eye disorders	Cataract	Other	17	3.2	6	25.0
Eye disorders	Cataract	Unknown	8	1.5	0	0.0
Eye disorders	Cataract nucleus	White	332	61.8	0	0.0
Eye disorders	Cataract nucleus	Asian	180	33.5	0	0.0
Eye disorders	Cataract nucleus	Other	17	3.2	0	0.0
Eye disorders	Cataract nucleus	Unknown	8	1.5	0	0.0
Eye disorders	Cataract subcapsular	White	332	61.8	2	0.6
Eye disorders	Cataract subcapsular	Asian	180	33.5	0	0.0
Eye disorders	Cataract subcapsular	Other	17	3.2	0	0.0
Eye disorders	Cataract subcapsular	Unknown	8	1.5	0	0.0
Eye disorders	Chalazion	White	332	61.8	2	0.6
Eye disorders	Chalazion	Asian	180	33.5	1	0.3
Eye disorders	Chalazion	Other	17	3.2	0	0.0
Eye disorders	Chalazion	Unknown	8	1.5	0	0.0
Eye disorders	Conjunctival erosion	White	332	61.8	1	0.3
Eye disorders	Conjunctival erosion	Asian	180	33.5	1	0.3
Eye disorders	Conjunctival erosion	Other	17	3.2	0	0.0
Eye disorders	Conjunctival erosion	Unknown	8	1.5	0	0.0
Eye disorders	Conjunctival hemorrhage	White	332	61.8	17	5.1
Eye disorders	Conjunctival hemorrhage	Asian	180	33.5	1	0.3
Eye disorders	Conjunctival hemorrhage	Other	17	3.2	1	6.8
Eye disorders	Conjunctival hemorrhage	Unknown	8	1.5	0	0.0
Eye disorders	Conjunctivitis allergic	White	332	61.8	1	0.3
Eye disorders	Conjunctivitis allergic	Asian	180	33.5	2	1.1
Eye disorders	Conjunctivitis allergic	Other	17	3.2	0	0.0
Eye disorders	Conjunctivitis allergic	Unknown	8	1.5	0	0.0
Eye disorders	Conjunctivochalasis	White	332	61.8	0	0.0
Eye disorders	Conjunctivochalasis	Asian	180	33.5	1	0.3
Eye disorders	Conjunctivochalasis	Other	17	3.2	0	0.0
Eye disorders	Conjunctivochalasis	Unknown	8	1.5	0	0.0
Eye disorders	Cornual erosion	White	332	61.8	2	0.6
Eye disorders	Cornual erosion	Asian	180	33.5	0	0.0
Eye disorders	Cornual erosion	Other	17	3.2	0	0.0
Eye disorders	Cornual erosion	Unknown	8	1.5	0	0.0
Eye disorders	Cornual infiltrates	White	332	61.8	1	0.3
Eye disorders	Cornual infiltrates	Asian	180	33.5	0	0.0
Eye disorders	Cornual infiltrates	Other	17	3.2	0	0.0
Eye disorders	Cornual infiltrates	Unknown	8	1.5	0	0.0
Eye disorders	Cornual opacity	White	332	61.8	0	0.0
Eye disorders	Cornual opacity	Asian	180	33.5	1	0.3
Eye disorders	Cornual opacity	Other	17	3.2	0	0.0
Eye disorders	Cornual opacity	Unknown	8	1.5	0	0.0
Eye disorders	Cystoid macular edema	White	332	61.8	2	0.6
Eye disorders	Cystoid macular edema	Asian	180	33.5	2	1.1
Eye disorders	Cystoid macular edema	Other	17	3.2	0	0.0
Eye disorders	Cystoid macular edema	Unknown	8	1.5	0	0.0
Eye disorders	Dacryostenosis acquired	White	332	61.8	1	0.3
Eye disorders	Dacryostenosis acquired	Asian	180	33.5	0	0.0
Eye disorders	Dacryostenosis acquired	Other	17	3.2	0	0.0
Eye disorders	Dacryostenosis acquired	Unknown	8	1.5	0	0.0
Eye disorders	Dermatochalasis	White	332	61.8	1	0.3
Eye disorders	Dermatochalasis	Asian	180	33.5	0	0.0
Eye disorders	Dermatochalasis	Other	17	3.2	0	0.0
Eye disorders	Dermatochalasis	Unknown	8	1.5	0	0.0
Eye disorders	Diplopia	White	332	61.8	1	0.3
Eye disorders	Diplopia	Asian	180	33.5	0	0.0
Eye disorders	Diplopia	Other	17	3.2	0	0.0
Eye disorders	Diplopia	Unknown	8	1.5	0	0.0
Eye disorders	Dry age-related macular degeneration	White	332	61.8	1	0.3
Eye disorders	Dry age-related macular degeneration	Asian	180	33.5	0	0.0
Eye disorders	Dry age-related macular degeneration	Other	17	3.2	0	0.0
Eye disorders	Dry age-related macular degeneration	Unknown	8	1.5	0	0.0
Eye disorders	Dry eye	White	332	61.8	0	0.0
Eye disorders	Dry eye	Asian	180	33.5	4	1.2
Eye disorders	Dry eye	Other	17	3.2	0	0.0
Eye disorders	Dry eye	Unknown	8	1.5	0	0.0
Eye disorders	Entropion	White	332	61.8	0	0.0
Eye disorders	Entropion	Asian	180	33.5	1	0.3
Eye disorders	Entropion	Other	17	3.2	0	0.0
Eye disorders	Entropion	Unknown	8	1.5	0	0.0
Eye disorders	Epiretinal membrane	White	332	61.8	5	1.5
Eye disorders	Epiretinal membrane	Asian	180	33.5	4	1.2
Eye disorders	Epiretinal membrane	Other	17	3.2	1	6.8
Eye disorders	Epiretinal membrane	Unknown	8	1.5	0	0.0

Eye disorders	Blepharitis	White	332	61.8	1	0.0
Eye disorders	Blepharitis	Asian	180	33.5	0	0.0
Eye disorders	Blepharitis	Other	17	3.2	0	0.0
Eye disorders	Blepharitis	Unknown	8	1.5	0	0.0
Eye disorders	Bryhema of eyelid	White	332	61.8	0	0.0
Eye disorders	Bryhema of eyelid	Asian	180	33.5	0	0.0
Eye disorders	Bryhema of eyelid	Other	17	3.2	0	0.0
Eye disorders	Bryhema of eyelid	Unknown	8	1.5	0	0.0
Eye disorders	Eye allergy	White	332	61.8	1	0.0
Eye disorders	Eye allergy	Asian	180	33.5	0	0.0
Eye disorders	Eye allergy	Other	17	3.2	0	0.0
Eye disorders	Eye allergy	Unknown	8	1.5	0	0.0
Eye disorders	Eye discharge	White	332	61.8	0	0.0
Eye disorders	Eye discharge	Asian	180	33.5	2	0.3
Eye disorders	Eye discharge	Other	17	3.2	0	0.0
Eye disorders	Eye discharge	Unknown	8	1.5	0	0.0
Eye disorders	Eye discharge	White	332	61.8	1	0.0
Eye disorders	Eye discharge	Asian	180	33.5	0	0.0
Eye disorders	Eye discharge	Other	17	3.2	0	0.0
Eye disorders	Eye discharge	Unknown	8	1.5	0	0.0
Eye disorders	Eye irritation	White	332	61.8	1	0.0
Eye disorders	Eye irritation	Asian	180	33.5	0	0.0
Eye disorders	Eye irritation	Other	17	3.2	0	0.0
Eye disorders	Eye irritation	Unknown	8	1.5	0	0.0
Eye disorders	Eye pain	White	332	61.8	1	0.0
Eye disorders	Eye pain	Asian	180	33.5	1	0.6
Eye disorders	Eye pain	Other	17	3.2	1	0.3
Eye disorders	Eye pain	Unknown	8	1.5	0	0.0
Eye disorders	Eye pruritus	White	332	61.8	1	0.0
Eye disorders	Eye pruritus	Asian	180	33.5	1	0.6
Eye disorders	Eye pruritus	Other	17	3.2	0	0.0
Eye disorders	Eye pruritus	Unknown	8	1.5	0	0.0
Eye disorders	Eye lid edema	White	332	61.8	0	0.0
Eye disorders	Eye lid edema	Asian	180	33.5	1	0.6
Eye disorders	Eye lid edema	Other	17	3.2	0	0.0
Eye disorders	Eye lid edema	Unknown	8	1.5	0	0.0
Eye disorders	Eye lid pain	White	332	61.8	1	0.0
Eye disorders	Eye lid pain	Asian	180	33.5	1	0.3
Eye disorders	Eye lid pain	Other	17	3.2	0	0.0
Eye disorders	Eye lid pain	Unknown	8	1.5	0	0.0
Eye disorders	Eye lid ptosis	White	332	61.8	0	0.0
Eye disorders	Eye lid ptosis	Asian	180	33.5	1	0.6
Eye disorders	Eye lid ptosis	Other	17	3.2	0	0.0
Eye disorders	Eye lid ptosis	Unknown	8	1.5	0	0.0
Eye disorders	Glaucoma	White	332	61.8	4	1.2
Eye disorders	Glaucoma	Asian	180	33.5	1	0.6
Eye disorders	Glaucoma	Other	17	3.2	0	0.0
Eye disorders	Glaucoma	Unknown	8	1.5	0	0.0
Eye disorders	Iridocyclitis	White	332	61.8	1	0.3
Eye disorders	Iridocyclitis	Asian	180	33.5	1	0.6
Eye disorders	Iridocyclitis	Other	17	3.2	0	0.0
Eye disorders	Iridocyclitis	Unknown	8	1.5	0	0.0
Eye disorders	Iritis	White	332	61.8	1	0.3
Eye disorders	Iritis	Asian	180	33.5	1	0.6
Eye disorders	Iritis	Other	17	3.2	0	0.0
Eye disorders	Iritis	Unknown	8	1.5	0	0.0
Eye disorders	Iritis	White	332	61.8	2	0.6
Eye disorders	Iritis	Asian	180	33.5	0	0.0
Eye disorders	Iritis	Other	17	3.2	0	0.0
Eye disorders	Iritis	Unknown	8	1.5	0	0.0
Eye disorders	Keratitis	White	332	61.8	0	0.0
Eye disorders	Keratitis	Asian	180	33.5	0	0.0
Eye disorders	Keratitis	Other	17	3.2	0	0.0
Eye disorders	Keratitis	Unknown	8	1.5	0	0.0
Eye disorders	Lacrimation increased	White	332	61.8	3	0.9
Eye disorders	Lacrimation increased	Asian	180	33.5	0	0.0
Eye disorders	Lacrimation increased	Other	17	3.2	0	0.0
Eye disorders	Lacrimation increased	Unknown	8	1.5	0	0.0
Eye disorders	Macular lachemia	White	332	61.8	0	0.0
Eye disorders	Macular lachemia	Asian	180	33.5	0	0.0
Eye disorders	Macular lachemia	Other	17	3.2	1	0.3
Eye disorders	Macular lachemia	Unknown	8	1.5	0	0.0
Eye disorders	Macular oedema	White	332	61.8	12	3.6
Eye disorders	Macular oedema	Asian	180	33.5	4	1.2
Eye disorders	Macular oedema	Other	17	3.2	0	0.0
Eye disorders	Macular oedema	Unknown	8	1.5	0	0.0
Eye disorders	Multipathy	White	332	61.8	1	0.3
Eye disorders	Multipathy	Asian	180	33.5	0	0.0
Eye disorders	Multipathy	Other	17	3.2	0	0.0
Eye disorders	Multipathy	Unknown	8	1.5	0	0.0
Eye disorders	Narrow anterior chamber angle	White	332	61.8	1	0.3
Eye disorders	Narrow anterior chamber angle	Asian	180	33.5	0	0.0
Eye disorders	Narrow anterior chamber angle	Other	17	3.2	0	0.0
Eye disorders	Narrow anterior chamber angle	Unknown	8	1.5	0	0.0
Eye disorders	Normal tension glaucoma	White	332	61.8	1	0.3
Eye disorders	Normal tension glaucoma	Asian	180	33.5	0	0.0
Eye disorders	Normal tension glaucoma	Other	17	3.2	0	0.0
Eye disorders	Normal tension glaucoma	Unknown	8	1.5	0	0.0
Eye disorders	Ocular discomfort	White	332	61.8	2	0.6
Eye disorders	Ocular discomfort	Asian	180	33.5	0	0.0
Eye disorders	Ocular discomfort	Other	17	3.2	0	0.0
Eye disorders	Ocular discomfort	Unknown	8	1.5	0	0.0
Eye disorders	Ocular hypertension	White	332	61.8	0	0.0
Eye disorders	Ocular hypertension	Asian	180	33.5	0	0.0
Eye disorders	Ocular hypertension	Other	17	3.2	0	0.0
Eye disorders	Ocular hypertension	Unknown	8	1.5	0	0.0
Eye disorders	Ocular vascular disorder	White	332	61.8	1	0.3
Eye disorders	Ocular vascular disorder	Asian	180	33.5	0	0.0
Eye disorders	Ocular vascular disorder	Other	17	3.2	0	0.0
Eye disorders	Ocular vascular disorder	Unknown	8	1.5	0	0.0
Eye disorders	Optic disc haemorrhage	White	332	61.8	0	0.0
Eye disorders	Optic disc haemorrhage	Asian	180	33.5	0	0.0
Eye disorders	Optic disc haemorrhage	Other	17	3.2	0	0.0
Eye disorders	Optic disc haemorrhage	Unknown	8	1.5	0	0.0
Eye disorders	Optic disc vascular disorder	White	332	61.8	1	0.3
Eye disorders	Optic disc vascular disorder	Asian	180	33.5	0	0.0
Eye disorders	Optic disc vascular disorder	Other	17	3.2	0	0.0
Eye disorders	Optic disc vascular disorder	Unknown	8	1.5	0	0.0
Eye disorders	Periorbital pain	White	332	61.8	0	0.0
Eye disorders	Periorbital pain	Asian	180	33.5	0	0.0
Eye disorders	Periorbital pain	Other	17	3.2	0	0.0
Eye disorders	Periorbital pain	Unknown	8	1.5	0	0.0
Eye disorders	Photopsia	White	332	61.8	1	0.3
Eye disorders	Photopsia	Asian	180	33.5	0	0.0
Eye disorders	Photopsia	Other	17	3.2	0	0.0
Eye disorders	Photopsia	Unknown	8	1.5	0	0.0
Eye disorders	Posterior capsule opacification	White	332	61.8	1	0.3
Eye disorders	Posterior capsule opacification	Asian	180	33.5	0	0.0
Eye disorders	Posterior capsule opacification	Other	17	3.2	0	0.0
Eye disorders	Posterior capsule opacification	Unknown	8	1.5	0	0.0
Eye disorders	Pterygium	White	332	61.8	0	0.0
Eye disorders	Pterygium	Asian	180	33.5	0	0.0
Eye disorders	Pterygium	Other	17	3.2	0	0.0
Eye disorders	Pterygium	Unknown	8	1.5	0	0.0
Eye disorders	Punctate keratitis	White	332	61.8	1	0.3
Eye disorders	Punctate keratitis	Asian	180	33.5	0	0.0
Eye disorders	Punctate keratitis	Other	17	3.2	0	0.0
Eye disorders	Punctate keratitis	Unknown	8	1.5	0	0.0
Eye disorders	Retinal aneurysm	White	332	61.8	0	0.0
Eye disorders	Retinal aneurysm	Asian	180	33.5	1	0.6
Eye disorders	Retinal aneurysm	Other	17	3.2	0	0.0
Eye disorders	Retinal aneurysm	Unknown	8	1.5	0	0.0
Eye disorders	Retinal artery embolism	White	332	61.8	1	0.3
Eye disorders	Retinal artery embolism	Asian	180	33.5	0	0.0
Eye disorders	Retinal artery embolism	Other	17	3.2	0	0.0
Eye disorders	Retinal artery embolism	Unknown	8	1.5	0	0.0
Eye disorders	Retinal collateral vessels	White	332	61.8	0	0.0
Eye disorders	Retinal collateral vessels	Asian	180	33.5	0	0.0
Eye disorders	Retinal collateral vessels	Other	17	3.2	0	0.0
Eye disorders	Retinal collateral vessels	Unknown	8	1.5	0	0.0
Eye disorders	Retinal cyst	White	332	61.8	4	1.2
Eye disorders	Retinal cyst	Asian	180	33.5	0	0.0
Eye disorders	Retinal cyst	Other	17	3.2	0	0.0
Eye disorders	Retinal cyst	Unknown	8	1.5	0	0.0
Eye disorders	Retinal neovascularization	White	332	61.8	1	0.3
Eye disorders	Retinal neovascularization	Asian	180	33.5	2	0.6
Eye disorders	Retinal neovascularization	Other	17	3.2	0	0.0
Eye disorders	Retinal neovascularization	Unknown	8	1.5	0	0.0
Eye disorders	Retinal hemorrhage	White	332	61.8	9	2.7

Eye disorders	Retinal hemorrhage	Asian	180	33.1	1	0.0
Eye disorders	Retinal hemorrhage	Other	17	3.2	0	0.0
Eye disorders	Retinal hemorrhage	Unknown	8	1.5	0	0.0
Eye disorders	Retinal ischemia	White	332	61.8	4	0.2
Eye disorders	Retinal ischemia	Asian	180	33.1	1	0.0
Eye disorders	Retinal ischemia	Other	17	3.2	0	0.0
Eye disorders	Retinal ischemia	Unknown	8	1.5	0	0.0
Eye disorders	Retinal neovascularization	White	332	61.8	1	0.0
Eye disorders	Retinal neovascularization	Asian	180	33.1	1	0.0
Eye disorders	Retinal neovascularization	Other	17	3.2	0	0.0
Eye disorders	Retinal neovascularization	Unknown	8	1.5	0	0.0
Eye disorders	Retinal oedema	White	332	61.8	1	0.0
Eye disorders	Retinal oedema	Asian	180	33.1	0	0.0
Eye disorders	Retinal oedema	Other	17	3.2	0	0.0
Eye disorders	Retinal oedema	Unknown	8	1.5	0	0.0
Eye disorders	Retinal tear	White	332	61.8	2	0.0
Eye disorders	Retinal tear	Asian	180	33.1	0	0.0
Eye disorders	Retinal tear	Other	17	3.2	1	0.0
Eye disorders	Retinal tear	Unknown	8	1.5	0	0.0
Eye disorders	Retinal thickening	White	332	61.8	0	0.0
Eye disorders	Retinal thickening	Asian	180	33.1	0	0.0
Eye disorders	Retinal thickening	Other	17	3.2	0	0.0
Eye disorders	Retinal thickening	Unknown	8	1.5	0	0.0
Eye disorders	Retinal vascular disorder	White	332	61.8	1	0.0
Eye disorders	Retinal vascular disorder	Asian	180	33.1	0	0.0
Eye disorders	Retinal vascular disorder	Other	17	3.2	0	0.0
Eye disorders	Retinal vascular disorder	Unknown	8	1.5	0	0.0
Eye disorders	Retinal vein occlusion	White	332	61.8	14	4.2
Eye disorders	Retinal vein occlusion	Asian	180	33.1	6	1.8
Eye disorders	Retinal vein occlusion	Other	17	3.2	1	0.0
Eye disorders	Retinal vein occlusion	Unknown	8	1.5	0	0.0
Eye disorders	Retinopathy hypertensive	White	332	61.8	1	0.0
Eye disorders	Retinopathy hypertensive	Asian	180	33.1	0	0.0
Eye disorders	Retinopathy hypertensive	Other	17	3.2	0	0.0
Eye disorders	Retinopathy hypertensive	Unknown	8	1.5	0	0.0
Eye disorders	Spontaneous retinal detachment	White	332	61.8	0	0.0
Eye disorders	Spontaneous retinal detachment	Asian	180	33.1	0	0.0
Eye disorders	Spontaneous retinal detachment	Other	17	3.2	0	0.0
Eye disorders	Spontaneous retinal detachment	Unknown	8	1.5	0	0.0
Eye disorders	Swelling of eyelid	White	332	61.8	1	0.0
Eye disorders	Swelling of eyelid	Asian	180	33.1	0	0.0
Eye disorders	Swelling of eyelid	Other	17	3.2	0	0.0
Eye disorders	Swelling of eyelid	Unknown	8	1.5	0	0.0
Eye disorders	Tractional retinal detachment	White	332	61.8	1	0.0
Eye disorders	Tractional retinal detachment	Asian	180	33.1	0	0.0
Eye disorders	Tractional retinal detachment	Other	17	3.2	0	0.0
Eye disorders	Tractional retinal detachment	Unknown	8	1.5	0	0.0
Eye disorders	Trichiasis	White	332	61.8	0	0.0
Eye disorders	Trichiasis	Asian	180	33.1	1	0.0
Eye disorders	Trichiasis	Other	17	3.2	0	0.0
Eye disorders	Trichiasis	Unknown	8	1.5	0	0.0
Eye disorders	Vision blurred	White	332	61.8	3	0.0
Eye disorders	Vision blurred	Asian	180	33.1	0	0.0
Eye disorders	Vision blurred	Other	17	3.2	0	0.0
Eye disorders	Vision blurred	Unknown	8	1.5	0	0.0
Eye disorders	Visual acuity reduced	White	332	61.8	4	0.0
Eye disorders	Visual acuity reduced	Asian	180	33.1	0	0.0
Eye disorders	Visual acuity reduced	Other	17	3.2	0	0.0
Eye disorders	Visual acuity reduced	Unknown	8	1.5	0	0.0
Eye disorders	Visual field defect	White	332	61.8	1	0.0
Eye disorders	Visual field defect	Asian	180	33.1	0	0.0
Eye disorders	Visual field defect	Other	17	3.2	0	0.0
Eye disorders	Visual field defect	Unknown	8	1.5	0	0.0
Eye disorders	Vitreoretinal traction syndrome	White	332	61.8	2	0.0
Eye disorders	Vitreoretinal traction syndrome	Asian	180	33.1	0	0.0
Eye disorders	Vitreoretinal traction syndrome	Other	17	3.2	0	0.0
Eye disorders	Vitreoretinal traction syndrome	Unknown	8	1.5	0	0.0
Eye disorders	Vitreous degeneration	White	332	61.8	0	0.0
Eye disorders	Vitreous degeneration	Asian	180	33.1	1	0.0
Eye disorders	Vitreous degeneration	Other	17	3.2	0	0.0
Eye disorders	Vitreous degeneration	Unknown	8	1.5	0	0.0
Eye disorders	Vitreous detachment	White	332	61.8	14	4.2
Eye disorders	Vitreous detachment	Asian	180	33.1	7	0.0
Eye disorders	Vitreous detachment	Other	17	3.2	0	0.0
Eye disorders	Vitreous detachment	Unknown	8	1.5	0	0.0
Eye disorders	Vitreous floaters	White	332	61.8	0	0.0
Eye disorders	Vitreous floaters	Asian	180	33.1	1	0.0
Eye disorders	Vitreous floaters	Other	17	3.2	0	0.0
Eye disorders	Vitreous floaters	Unknown	8	1.5	0	0.0
Eye disorders	Vitreous hemorrhage	White	332	61.8	1	0.0
Eye disorders	Vitreous hemorrhage	Asian	180	33.1	1	0.0
Eye disorders	Vitreous hemorrhage	Other	17	3.2	0	0.0
Eye disorders	Vitreous hemorrhage	Unknown	8	1.5	0	0.0
Eye disorders	Vitritis	White	332	61.8	0	0.0
Eye disorders	Vitritis	Asian	180	33.1	0	0.0
Eye disorders	Vitritis	Other	17	3.2	0	0.0
Eye disorders	Vitritis	Unknown	8	1.5	0	0.0
Gastrointestinal disorders		White	332	61.8	19	5.7
Gastrointestinal disorders		Asian	180	33.1	14	3.8
Gastrointestinal disorders		Other	17	3.2	1	0.0
Gastrointestinal disorders		Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Abdominal pain	White	332	61.8	0	0.0
Gastrointestinal disorders	Abdominal pain	Asian	180	33.1	1	0.0
Gastrointestinal disorders	Abdominal pain	Other	17	3.2	0	0.0
Gastrointestinal disorders	Abdominal pain	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Abdominal pain upper	White	332	61.8	1	0.0
Gastrointestinal disorders	Abdominal pain upper	Asian	180	33.1	0	0.0
Gastrointestinal disorders	Abdominal pain upper	Other	17	3.2	0	0.0
Gastrointestinal disorders	Abdominal pain upper	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Chronic gastritis	White	332	61.8	1	0.0
Gastrointestinal disorders	Chronic gastritis	Asian	180	33.1	1	0.0
Gastrointestinal disorders	Chronic gastritis	Other	17	3.2	0	0.0
Gastrointestinal disorders	Chronic gastritis	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Colitis	White	332	61.8	2	0.0
Gastrointestinal disorders	Colitis	Asian	180	33.1	1	0.0
Gastrointestinal disorders	Colitis	Other	17	3.2	0	0.0
Gastrointestinal disorders	Colitis	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Constipation	White	332	61.8	1	0.0
Gastrointestinal disorders	Constipation	Asian	180	33.1	0	0.0
Gastrointestinal disorders	Constipation	Other	17	3.2	0	0.0
Gastrointestinal disorders	Constipation	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Diarrhoea	White	332	61.8	0	0.0
Gastrointestinal disorders	Diarrhoea	Asian	180	33.1	2	0.0
Gastrointestinal disorders	Diarrhoea	Other	17	3.2	0	0.0
Gastrointestinal disorders	Diarrhoea	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Erosive duodenitis	White	332	61.8	1	0.0
Gastrointestinal disorders	Erosive duodenitis	Asian	180	33.1	0	0.0
Gastrointestinal disorders	Erosive duodenitis	Other	17	3.2	0	0.0
Gastrointestinal disorders	Erosive duodenitis	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Functional gastrointestinal disorder	White	332	61.8	1	0.0
Gastrointestinal disorders	Functional gastrointestinal disorder	Asian	180	33.1	0	0.0
Gastrointestinal disorders	Functional gastrointestinal disorder	Other	17	3.2	0	0.0
Gastrointestinal disorders	Functional gastrointestinal disorder	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Gastric hemorrhage	White	332	61.8	1	0.0
Gastrointestinal disorders	Gastric hemorrhage	Asian	180	33.1	0	0.0
Gastrointestinal disorders	Gastric hemorrhage	Other	17	3.2	0	0.0
Gastrointestinal disorders	Gastric hemorrhage	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Gastric polyps	White	332	61.8	0	0.0
Gastrointestinal disorders	Gastric polyps	Asian	180	33.1	0	0.0
Gastrointestinal disorders	Gastric polyps	Other	17	3.2	0	0.0
Gastrointestinal disorders	Gastric polyps	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Gastroparesis	White	332	61.8	2	0.0
Gastrointestinal disorders	Gastroparesis	Asian	180	33.1	2	0.0
Gastrointestinal disorders	Gastroparesis	Other	17	3.2	0	0.0
Gastrointestinal disorders	Gastroparesis	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Gastroesophageal reflux disease	White	332	61.8	4	1.2
Gastrointestinal disorders	Gastroesophageal reflux disease	Asian	180	33.1	1	0.0
Gastrointestinal disorders	Gastroesophageal reflux disease	Other	17	3.2	0	0.0
Gastrointestinal disorders	Gastroesophageal reflux disease	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Gingivitis	White	332	61.8	1	0.0

Gastrointestinal disorders	Diarrhoeal enter	Asian	180	33.4	0	0.0
Gastrointestinal disorders	Diarrhoeal pain	Other	17	3.2	0	0.0
Gastrointestinal disorders	Diarrhoeal pain	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Haemorrhoids	White	332	61.8	0	0.0
Gastrointestinal disorders	Haemorrhoids	Asian	180	33.4	2	0.4
Gastrointestinal disorders	Haemorrhoids	Other	17	3.2	0	0.0
Gastrointestinal disorders	Haemorrhoids	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Hypertichthyria	White	332	61.8	0	0.0
Gastrointestinal disorders	Hypertichthyria	Asian	180	33.4	0	0.0
Gastrointestinal disorders	Hypertichthyria	Other	17	3.2	0	0.0
Gastrointestinal disorders	Hypertichthyria	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Large intestine polyp	White	332	61.8	0	0.0
Gastrointestinal disorders	Large intestine polyp	Asian	180	33.4	4	0.8
Gastrointestinal disorders	Large intestine polyp	Other	17	3.2	0	0.0
Gastrointestinal disorders	Large intestine polyp	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Measenteric vein thrombosis	White	332	61.8	1	0.3
Gastrointestinal disorders	Measenteric vein thrombosis	Asian	180	33.4	0	0.0
Gastrointestinal disorders	Measenteric vein thrombosis	Other	17	3.2	0	0.0
Gastrointestinal disorders	Measenteric vein thrombosis	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Mucosa	White	332	61.8	0.3	0.1
Gastrointestinal disorders	Mucosa	Asian	180	33.4	2	0.4
Gastrointestinal disorders	Mucosa	Other	17	3.2	0	0.0
Gastrointestinal disorders	Mucosa	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Oesophagitis	White	332	61.8	0	0.0
Gastrointestinal disorders	Oesophagitis	Asian	180	33.4	0	0.0
Gastrointestinal disorders	Oesophagitis	Other	17	3.2	0	0.0
Gastrointestinal disorders	Oesophagitis	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Pancreatitis acute	White	332	61.8	1	0.3
Gastrointestinal disorders	Pancreatitis acute	Asian	180	33.4	0	0.0
Gastrointestinal disorders	Pancreatitis acute	Other	17	3.2	0	0.0
Gastrointestinal disorders	Pancreatitis acute	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Pancreatitis acute	White	332	61.8	2	0.4
Gastrointestinal disorders	Toothache	Asian	180	33.4	1	0.2
Gastrointestinal disorders	Toothache	Other	17	3.2	0	0.0
Gastrointestinal disorders	Toothache	Unknown	8	1.5	0	0.0
Gastrointestinal disorders	Uvulitis	White	332	61.8	1	0.3
Gastrointestinal disorders	Uvulitis	Asian	180	33.4	0	0.0
Gastrointestinal disorders	Uvulitis	Other	17	3.2	0	0.0
Gastrointestinal disorders	Uvulitis	Unknown	8	1.5	0	0.0
General disorders and administration site conditions		White	332	61.8	10	3.0
General disorders and administration site conditions		Asian	180	33.4	4	0.8
General disorders and administration site conditions		Other	17	3.2	0	0.0
General disorders and administration site conditions		Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Arthralgia	White	332	61.8	2	0.4
General disorders and administration site conditions	Arthralgia	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Arthralgia	Other	17	3.2	0	0.0
General disorders and administration site conditions	Arthralgia	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Chest discomfort	White	332	61.8	1	0.3
General disorders and administration site conditions	Chest discomfort	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Chest discomfort	Other	17	3.2	0	0.0
General disorders and administration site conditions	Chest discomfort	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Death	White	332	61.8	0	0.0
General disorders and administration site conditions	Death	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Death	Other	17	3.2	0	0.0
General disorders and administration site conditions	Death	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Fatigue	White	332	61.8	1	0.3
General disorders and administration site conditions	Fatigue	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Fatigue	Other	17	3.2	0	0.0
General disorders and administration site conditions	Fatigue	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Gait disturbance	White	332	61.8	1	0.3
General disorders and administration site conditions	Gait disturbance	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Gait disturbance	Other	17	3.2	0	0.0
General disorders and administration site conditions	Gait disturbance	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Illness	White	332	61.8	0.3	0.1
General disorders and administration site conditions	Illness	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Illness	Other	17	3.2	0	0.0
General disorders and administration site conditions	Illness	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Influenza like illness	White	332	61.8	1	0.3
General disorders and administration site conditions	Influenza like illness	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Influenza like illness	Other	17	3.2	0	0.0
General disorders and administration site conditions	Influenza like illness	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Oedema	White	332	61.8	0	0.0
General disorders and administration site conditions	Oedema	Asian	180	33.4	1	0.2
General disorders and administration site conditions	Oedema	Other	17	3.2	0	0.0
General disorders and administration site conditions	Oedema	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Pain	White	332	61.8	2	0.4
General disorders and administration site conditions	Pain	Asian	180	33.4	1	0.2
General disorders and administration site conditions	Pain	Other	17	3.2	0	0.0
General disorders and administration site conditions	Pain	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Periaphral swelling	White	332	61.8	1	0.3
General disorders and administration site conditions	Periaphral swelling	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Periaphral swelling	Other	17	3.2	0	0.0
General disorders and administration site conditions	Periaphral swelling	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Physical deconditioning	White	332	61.8	0	0.0
General disorders and administration site conditions	Physical deconditioning	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Physical deconditioning	Other	17	3.2	0	0.0
General disorders and administration site conditions	Physical deconditioning	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Pyrexia	White	332	61.8	1	0.3
General disorders and administration site conditions	Pyrexia	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Pyrexia	Other	17	3.2	0	0.0
General disorders and administration site conditions	Pyrexia	Unknown	8	1.5	0	0.0
General disorders and administration site conditions	Vascular event stenosis	White	332	61.8	0	0.0
General disorders and administration site conditions	Vascular event stenosis	Asian	180	33.4	0	0.0
General disorders and administration site conditions	Vascular event stenosis	Other	17	3.2	0	0.0
General disorders and administration site conditions	Vascular event stenosis	Unknown	8	1.5	0	0.0
Hepatobiliary disorders		White	332	61.8	3	0.9
Hepatobiliary disorders		Asian	180	33.4	0	0.0
Hepatobiliary disorders		Other	17	3.2	0	0.0
Hepatobiliary disorders		Unknown	8	1.5	0	0.0
Hepatobiliary disorders	Bile duct stone	White	332	61.8	1	0.3
Hepatobiliary disorders	Bile duct stone	Asian	180	33.4	0	0.0
Hepatobiliary disorders	Bile duct stone	Other	17	3.2	0	0.0
Hepatobiliary disorders	Bile duct stone	Unknown	8	1.5	0	0.0
Hepatobiliary disorders	Cholecystitis chronic	White	332	61.8	1	0.3
Hepatobiliary disorders	Cholecystitis chronic	Asian	180	33.4	0	0.0
Hepatobiliary disorders	Cholecystitis chronic	Other	17	3.2	0	0.0
Hepatobiliary disorders	Cholecystitis chronic	Unknown	8	1.5	0	0.0
Hepatobiliary disorders	Cholelithiasis	White	332	61.8	0	0.0
Hepatobiliary disorders	Cholelithiasis	Asian	180	33.4	0	0.0
Hepatobiliary disorders	Cholelithiasis	Other	17	3.2	0	0.0
Hepatobiliary disorders	Cholelithiasis	Unknown	8	1.5	0	0.0
Hepatobiliary disorders	Hepatic cyst	White	332	61.8	1	0.3
Hepatobiliary disorders	Hepatic cyst	Asian	180	33.4	0	0.0
Hepatobiliary disorders	Hepatic cyst	Other	17	3.2	0	0.0
Hepatobiliary disorders	Hepatic cyst	Unknown	8	1.5	0	0.0
Hepatobiliary disorders	Hepatic failure	White	332	61.8	0	0.0
Hepatobiliary disorders	Hepatic failure	Asian	180	33.4	0	0.0
Hepatobiliary disorders	Hepatic failure	Other	17	3.2	0	0.0
Hepatobiliary disorders	Hepatic failure	Unknown	8	1.5	0	0.0
Hepatobiliary disorders	Hepatic function abnormal	White	332	61.8	0	0.0
Hepatobiliary disorders	Hepatic function abnormal	Asian	180	33.4	1	0.2
Hepatobiliary disorders	Hepatic function abnormal	Other	17	3.2	0	0.0
Hepatobiliary disorders	Hepatic function abnormal	Unknown	8	1.5	0	0.0
Hepatobiliary disorders	Hepatic steatosis	White	332	61.8	0	0.0
Hepatobiliary disorders	Hepatic steatosis	Asian	180	33.4	0	0.0
Hepatobiliary disorders	Hepatic steatosis	Other	17	3.2	0	0.0
Hepatobiliary disorders	Hepatic steatosis	Unknown	8	1.5	0	0.0
Immune system disorders		White	332	61.8	4	1.2
Immune system disorders		Asian	180	33.4	0	0.0
Immune system disorders		Other	17	3.2	0	0.0
Immune system disorders		Unknown	8	1.5	0	0.0
Immune system disorders	Allergic oedema	White	332	61.8	1	0.3
Immune system disorders	Allergic oedema	Asian	180	33.4	0	0.0
Immune system disorders	Allergic oedema	Other	17	3.2	0	0.0
Immune system disorders	Allergic oedema	Unknown	8	1.5	0	0.0
Immune system disorders	Allergy to plants	White	332	61.8	1	0.3
Immune system disorders	Allergy to plants	Asian	180	33.4	0	0.0
Immune system disorders	Allergy to plants	Other	17	3.2	0	0.0

Injury poisoning and procedural complications	Joint injury	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Ligament sprain	White	332	61.8	0	0.0
Injury poisoning and procedural complications	Ligament sprain	Asian	180	33.5	1	0.3
Injury poisoning and procedural complications	Ligament sprain	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Ligament sprain	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Limb injury	White	332	61.8	0	0.0
Injury poisoning and procedural complications	Limb injury	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Limb injury	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Limb injury	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Medication error	White	332	61.8	1	0.3
Injury poisoning and procedural complications	Medication error	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Medication error	Other	17	3.2	1	0.3
Injury poisoning and procedural complications	Medication error	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Meniscus injury	White	332	61.8	1	0.3
Injury poisoning and procedural complications	Meniscus injury	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Meniscus injury	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Meniscus injury	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Muscle strain	White	332	61.8	1	0.3
Injury poisoning and procedural complications	Muscle strain	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Muscle strain	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Muscle strain	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Radius fracture	White	332	61.8	1	0.3
Injury poisoning and procedural complications	Radius fracture	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Radius fracture	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Radius fracture	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Skin abrasion	White	332	61.8	1	0.3
Injury poisoning and procedural complications	Skin abrasion	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Skin abrasion	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Skin abrasion	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Skin injury	White	332	61.8	0	0.0
Injury poisoning and procedural complications	Skin injury	Asian	180	33.5	1	0.3
Injury poisoning and procedural complications	Skin injury	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Skin injury	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Skin laceration	White	332	61.8	0	0.0
Injury poisoning and procedural complications	Skin laceration	Asian	180	33.5	1	0.3
Injury poisoning and procedural complications	Skin laceration	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Skin laceration	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Spinal column injury	White	332	61.8	1	0.3
Injury poisoning and procedural complications	Spinal column injury	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Spinal column injury	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Spinal column injury	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Sternal fracture	White	332	61.8	1	0.3
Injury poisoning and procedural complications	Sternal fracture	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Sternal fracture	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Sternal fracture	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Subdural hematoma	White	332	61.8	1	0.3
Injury poisoning and procedural complications	Subdural hematoma	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Subdural hematoma	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Subdural hematoma	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Thermal burn	White	332	61.8	1	0.3
Injury poisoning and procedural complications	Thermal burn	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Thermal burn	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Thermal burn	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Tooth fracture	White	332	61.8	0	0.0
Injury poisoning and procedural complications	Tooth fracture	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Tooth fracture	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Tooth fracture	Unknown	8	1.5	0	0.0
Injury poisoning and procedural complications	Ulna fracture	White	332	61.8	1	0.3
Injury poisoning and procedural complications	Ulna fracture	Asian	180	33.5	0	0.0
Injury poisoning and procedural complications	Ulna fracture	Other	17	3.2	0	0.0
Injury poisoning and procedural complications	Ulna fracture	Unknown	8	1.5	0	0.0
Investigations		White	332	61.8	22	6.4
Investigations		Asian	180	33.5	10	5.6
Investigations		Other	17	3.2	0	0.0
Investigations		Unknown	8	1.5	1	12.8
Investigations	Blood glucose increased	White	332	61.8	0	0.0
Investigations	Blood glucose increased	Asian	180	33.5	1	0.3
Investigations	Blood glucose increased	Other	17	3.2	0	0.0
Investigations	Blood glucose increased	Unknown	8	1.5	0	0.0
Investigations	Blood potassium decreased	White	332	61.8	0	0.0
Investigations	Blood potassium decreased	Asian	180	33.5	0	0.0
Investigations	Blood potassium decreased	Other	17	3.2	0	0.0
Investigations	Blood potassium decreased	Unknown	8	1.5	1	12.8
Investigations	Blood pressure increased	White	332	61.8	3	0.9
Investigations	Blood pressure increased	Asian	180	33.5	0	0.0
Investigations	Blood pressure increased	Other	17	3.2	0	0.0
Investigations	Blood pressure increased	Unknown	8	1.5	0	0.0
Investigations	Blood sodium decreased	White	332	61.8	0	0.0
Investigations	Blood sodium decreased	Asian	180	33.5	0	0.0
Investigations	Blood sodium decreased	Other	17	3.2	0	0.0
Investigations	Blood sodium decreased	Unknown	8	1.5	0	0.0
Investigations	Glomerular filtration rate decreased	White	332	61.8	1	0.3
Investigations	Glomerular filtration rate decreased	Asian	180	33.5	0	0.0
Investigations	Glomerular filtration rate decreased	Other	17	3.2	0	0.0
Investigations	Glomerular filtration rate decreased	Unknown	8	1.5	0	0.0
Investigations	Intracranial pressure increased	White	332	61.8	3	0.9
Investigations	Intracranial pressure increased	Asian	180	33.5	7	3.9
Investigations	Intracranial pressure increased	Other	17	3.2	1	0.3
Investigations	Intracranial pressure increased	Unknown	8	1.5	0	0.0
Investigations	Platelet count increased	White	332	61.8	1	0.3
Investigations	Platelet count increased	Asian	180	33.5	0	0.0
Investigations	Platelet count increased	Other	17	3.2	0	0.0
Investigations	Platelet count increased	Unknown	8	1.5	0	0.0
Investigations	SARS-CoV-2 test positive	White	332	61.8	1	0.3
Investigations	SARS-CoV-2 test positive	Asian	180	33.5	1	0.3
Investigations	SARS-CoV-2 test positive	Other	17	3.2	0	0.0
Investigations	SARS-CoV-2 test positive	Unknown	8	1.5	0	0.0
Investigations	Topoisin increased	White	332	61.8	0	0.0
Investigations	Topoisin increased	Asian	180	33.5	0	0.0
Investigations	Topoisin increased	Other	17	3.2	0	0.0
Investigations	Topoisin increased	Unknown	8	1.5	0	0.0
Investigations	Weight decreased	White	332	61.8	1	0.3
Investigations	Weight decreased	Asian	180	33.5	0	0.0
Investigations	Weight decreased	Other	17	3.2	0	0.0
Investigations	Weight decreased	Unknown	8	1.5	0	0.0
Investigations	White blood cell count decreased	White	332	61.8	0	0.0
Investigations	White blood cell count decreased	Asian	180	33.5	1	0.3
Investigations	White blood cell count decreased	Other	17	3.2	0	0.0
Investigations	White blood cell count decreased	Unknown	8	1.5	0	0.0
Metabolism and nutrition disorders		White	332	61.8	17	5.1
Metabolism and nutrition disorders		Asian	180	33.5	8	4.4
Metabolism and nutrition disorders		Other	17	3.2	2	11.8
Metabolism and nutrition disorders		Unknown	8	1.5	0	0.0
Metabolism and nutrition disorders	Dehydration	White	332	61.8	2	0.6
Metabolism and nutrition disorders	Dehydration	Asian	180	33.5	0	0.0
Metabolism and nutrition disorders	Dehydration	Other	17	3.2	0	0.0
Metabolism and nutrition disorders	Dehydration	Unknown	8	1.5	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus	White	332	61.8	1	0.3
Metabolism and nutrition disorders	Diabetes mellitus	Asian	180	33.5	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus	Other	17	3.2	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus	Unknown	8	1.5	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	White	332	61.8	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Asian	180	33.5	1	0.3
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Other	17	3.2	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Unknown	8	1.5	0	0.0
Metabolism and nutrition disorders	Folate deficiency	White	332	61.8	1	0.3
Metabolism and nutrition disorders	Folate deficiency	Asian	180	33.5	0	0.0
Metabolism and nutrition disorders	Folate deficiency	Other	17	3.2	0	0.0
Metabolism and nutrition disorders	Folate deficiency	Unknown	8	1.5	0	0.0
Metabolism and nutrition disorders	Gout	White	332	61.8	0	0.0
Metabolism and nutrition disorders	Gout	Asian	180	33.5	0	0.0
Metabolism and nutrition disorders	Gout	Other	17	3.2	0	0.0
Metabolism and nutrition disorders	Gout	Unknown	8	1.5	0	0.0
Metabolism and nutrition disorders	Hypercholesterolemia	White	332	61.8	8	2.4
Metabolism and nutrition disorders	Hypercholesterolemia	Asian	180	33.5	0	0.0
Metabolism and nutrition disorders	Hypercholesterolemia	Other	17	3.2	1	0.3
Metabolism and nutrition disorders	Hypercholesterolemia	Unknown	8	1.5	0	0.0
Metabolism and nutrition disorders	Hyperlycemia	White	332	61.8	1	0.3
Metabolism and nutrition disorders	Hyperlycemia	Asian	180	33.5	0	0.0

Neovous system disorders	Multiple sclerosis	Asian	180	33.1	0	0.0
Neovous system disorders	Multiple sclerosis	Other	17	3.2	0	0.0
Neovous system disorders	Multiple sclerosis	Unknown	8	1.5	0	0.0
Neovous system disorders	Myelopathy	White	332	61.8	1	0.3
Neovous system disorders	Myelopathy	Asian	180	33.1	0	0.0
Neovous system disorders	Myelopathy	Other	17	3.2	0	0.0
Neovous system disorders	Myelopathy	Unknown	8	1.5	0	0.0
Neovous system disorders	Neurology	White	332	61.8	1	0.3
Neovous system disorders	Neurology	Asian	180	33.1	0	0.0
Neovous system disorders	Neurology	Other	17	3.2	0	0.0
Neovous system disorders	Neurology	Unknown	8	1.5	0	0.0
Neovous system disorders	Neuropathy peripheral	White	332	61.8	0	0.0
Neovous system disorders	Neuropathy peripheral	Asian	180	33.1	2	1.1
Neovous system disorders	Neuropathy peripheral	Other	17	3.2	0	0.0
Neovous system disorders	Neuropathy peripheral	Unknown	8	1.5	0	0.0
Neovous system disorders	Optic chiasm disease	White	332	61.8	1	0.3
Neovous system disorders	Optic chiasm disease	Asian	180	33.1	0	0.0
Neovous system disorders	Optic chiasm disease	Other	17	3.2	0	0.0
Neovous system disorders	Optic chiasm disease	Unknown	8	1.5	0	0.0
Neovous system disorders	Ophthalmic migraine	White	332	61.8	0	0.0
Neovous system disorders	Ophthalmic migraine	Asian	180	33.1	0	0.0
Neovous system disorders	Ophthalmic migraine	Other	17	3.2	0	0.0
Neovous system disorders	Ophthalmic migraine	Unknown	8	1.5	0	0.0
Neovous system disorders	Otitis media	White	332	61.8	0	0.0
Neovous system disorders	Otitis media	Asian	180	33.1	0	0.0
Neovous system disorders	Otitis media	Other	17	3.2	0	0.0
Neovous system disorders	Otitis media	Unknown	8	1.5	0	0.0
Neovous system disorders	Otitis media	Asian	180	33.1	3	0.9
Neovous system disorders	Otitis media	Other	17	3.2	0	0.0
Neovous system disorders	Otitis media	Unknown	8	1.5	0	0.0
Neovous system disorders	Otitis media	Asian	180	33.1	1	0.6
Neovous system disorders	Otitis media	Other	17	3.2	0	0.0
Neovous system disorders	Otitis media	Unknown	8	1.5	1	12.5
Neovous system disorders	Stimulant abuse	White	332	61.8	1	0.3
Neovous system disorders	Stimulant abuse	Asian	180	33.1	0	0.0
Neovous system disorders	Stimulant abuse	Other	17	3.2	0	0.0
Neovous system disorders	Stimulant abuse	Unknown	8	1.5	0	0.0
Neovous system disorders	Syncope	White	332	61.8	2	0.8
Neovous system disorders	Syncope	Asian	180	33.1	0	0.0
Neovous system disorders	Syncope	Other	17	3.2	0	0.0
Neovous system disorders	Syncope	Unknown	8	1.5	0	0.0
Neovous system disorders	Tension headache	White	332	61.8	2	0.8
Neovous system disorders	Tension headache	Asian	180	33.1	0	0.0
Neovous system disorders	Tension headache	Other	17	3.2	0	0.0
Neovous system disorders	Tension headache	Unknown	8	1.5	0	0.0
Neovous system disorders	Tension headache	Asian	180	33.1	0	0.0
Neovous system disorders	White matter lesion	White	332	61.8	1	0.3
Neovous system disorders	White matter lesion	Asian	180	33.1	0	0.0
Neovous system disorders	White matter lesion	Other	17	3.2	0	0.0
Neovous system disorders	White matter lesion	Unknown	8	1.5	0	0.0
Product issues		White	332	61.8	1	0.3
Product issues		Asian	180	33.1	0	0.0
Product issues		Other	17	3.2	0	0.0
Product issues		Unknown	8	1.5	0	0.0
Product issues	Device malfunction	White	332	61.8	1	0.3
Product issues	Device malfunction	Asian	180	33.1	0	0.0
Product issues	Device malfunction	Other	17	3.2	0	0.0
Product issues	Device malfunction	Unknown	8	1.5	0	0.0
Psychiatric disorders		White	332	61.8	4	1.8
Psychiatric disorders		Asian	180	33.1	3	1.7
Psychiatric disorders		Other	17	3.2	0	0.0
Psychiatric disorders		Unknown	8	1.5	0	0.0
Psychiatric disorders	Anxiety	White	332	61.8	1	0.3
Psychiatric disorders	Anxiety	Asian	180	33.1	1	0.6
Psychiatric disorders	Anxiety	Other	17	3.2	0	0.0
Psychiatric disorders	Anxiety	Unknown	8	1.5	0	0.0
Psychiatric disorders	Confusional state	White	332	61.8	2	0.8
Psychiatric disorders	Confusional state	Asian	180	33.1	0	0.0
Psychiatric disorders	Confusional state	Other	17	3.2	0	0.0
Psychiatric disorders	Confusional state	Unknown	8	1.5	0	0.0
Psychiatric disorders	Delirium	White	332	61.8	1	0.3
Psychiatric disorders	Delirium	Asian	180	33.1	0	0.0
Psychiatric disorders	Delirium	Other	17	3.2	0	0.0
Psychiatric disorders	Delirium	Unknown	8	1.5	0	0.0
Psychiatric disorders	Depression	White	332	61.8	1	0.3
Psychiatric disorders	Depression	Asian	180	33.1	1	0.6
Psychiatric disorders	Depression	Other	17	3.2	0	0.0
Psychiatric disorders	Depression	Unknown	8	1.5	0	0.0
Psychiatric disorders	Insomnia	White	332	61.8	1	0.3
Psychiatric disorders	Insomnia	Asian	180	33.1	1	0.6
Psychiatric disorders	Insomnia	Other	17	3.2	0	0.0
Psychiatric disorders	Insomnia	Unknown	8	1.5	0	0.0
Psychiatric disorders	Somatic symptom disorder	White	332	61.8	0	0.0
Psychiatric disorders	Somatic symptom disorder	Asian	180	33.1	0	0.0
Psychiatric disorders	Somatic symptom disorder	Other	17	3.2	0	0.0
Psychiatric disorders	Somatic symptom disorder	Unknown	8	1.5	0	0.0
Renal and urinary disorders		White	332	61.8	11	3.3
Renal and urinary disorders		Asian	180	33.1	0	0.0
Renal and urinary disorders		Other	17	3.2	0	0.0
Renal and urinary disorders		Unknown	8	1.5	0	0.0
Renal and urinary disorders	Acute kidney injury	White	332	61.8	0	0.0
Renal and urinary disorders	Acute kidney injury	Asian	180	33.1	0	0.0
Renal and urinary disorders	Acute kidney injury	Other	17	3.2	0	0.0
Renal and urinary disorders	Acute kidney injury	Unknown	8	1.5	0	0.0
Renal and urinary disorders	Chronic kidney disease	White	332	61.8	2	0.8
Renal and urinary disorders	Chronic kidney disease	Asian	180	33.1	0	0.0
Renal and urinary disorders	Chronic kidney disease	Other	17	3.2	0	0.0
Renal and urinary disorders	Chronic kidney disease	Unknown	8	1.5	0	0.0
Renal and urinary disorders	Diabetic nephropathy	White	332	61.8	0	0.0
Renal and urinary disorders	Diabetic nephropathy	Asian	180	33.1	1	0.6
Renal and urinary disorders	Diabetic nephropathy	Other	17	3.2	0	0.0
Renal and urinary disorders	Diabetic nephropathy	Unknown	8	1.5	0	0.0
Renal and urinary disorders	Hematuria	White	332	61.8	0	0.0
Renal and urinary disorders	Hematuria	Asian	180	33.1	0	0.0
Renal and urinary disorders	Hematuria	Other	17	3.2	0	0.0
Renal and urinary disorders	Hematuria	Unknown	8	1.5	0	0.0
Renal and urinary disorders	Nephrolithiasis	White	332	61.8	1	0.3
Renal and urinary disorders	Nephrolithiasis	Asian	180	33.1	1	0.6
Renal and urinary disorders	Nephrolithiasis	Other	17	3.2	0	0.0
Renal and urinary disorders	Nephrolithiasis	Unknown	8	1.5	0	0.0
Renal and urinary disorders	Renal colic	White	332	61.8	0	0.0
Renal and urinary disorders	Renal colic	Asian	180	33.1	0	0.0
Renal and urinary disorders	Renal colic	Other	17	3.2	0	0.0
Renal and urinary disorders	Renal colic	Unknown	8	1.5	0	0.0
Renal and urinary disorders	Renal cyst	White	332	61.8	2	0.8
Renal and urinary disorders	Renal cyst	Asian	180	33.1	2	1.1
Renal and urinary disorders	Renal cyst	Other	17	3.2	0	0.0
Renal and urinary disorders	Renal cyst	Unknown	8	1.5	0	0.0
Renal and urinary disorders	Renal mass	White	332	61.8	0	0.0
Renal and urinary disorders	Renal mass	Asian	180	33.1	0	0.0
Renal and urinary disorders	Renal mass	Other	17	3.2	0	0.0
Renal and urinary disorders	Renal mass	Unknown	8	1.5	0	0.0
Renal and urinary disorders	Urinary incontinence	White	332	61.8	1	0.3
Renal and urinary disorders	Urinary incontinence	Asian	180	33.1	0	0.0
Renal and urinary disorders	Urinary incontinence	Other	17	3.2	0	0.0
Renal and urinary disorders	Urinary incontinence	Unknown	8	1.5	0	0.0
Reproductive system and breast disorders		White	332	61.8	3	0.9
Reproductive system and breast disorders		Asian	180	33.1	2	1.1
Reproductive system and breast disorders		Other	17	3.2	0	0.0
Reproductive system and breast disorders		Unknown	8	1.5	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	White	332	61.8	1	0.3
Reproductive system and breast disorders	Benign prostatic hyperplasia	Asian	180	33.1	2	1.1
Reproductive system and breast disorders	Benign prostatic hyperplasia	Other	17	3.2	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Unknown	8	1.5	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Asian	180	33.1	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Other	17	3.2	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Unknown	8	1.5	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Asian	180	33.1	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Other	17	3.2	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Unknown	8	1.5	0	0.0
Reproductive system and breast disorders	Prostatitis	White	332	61.8	1	0.3
Reproductive system and breast disorders	Prostatitis	Asian	180	33.1	0	0.0
Reproductive system and breast disorders	Prostatitis	Other	17	3.2	0	0.0
Reproductive system and breast disorders	Prostatitis	Unknown	8	1.5	0	0.0
Respiratory, thoracic and mediastinal disorders		White	332	61.8	14	4.2

Surgical and medical procedures			Unknown	8	1.4	0	0.0
Surgical and medical procedures	Knee arthroplasty	White	332	61.8	1	0.3	
Surgical and medical procedures	Knee arthroplasty	Asian	180	33.5	0	0.0	
Surgical and medical procedures	Knee arthroplasty	Other	17	3.2	0	0.0	
Surgical and medical procedures	Knee arthroplasty	Unknown	8	1.4	0	0.0	
Surgical and medical procedures	Large intestinal polypectomy	White	332	61.8	1	0.3	
Surgical and medical procedures	Large intestinal polypectomy	Asian	180	33.5	0	0.0	
Surgical and medical procedures	Large intestinal polypectomy	Other	17	3.2	0	0.0	
Surgical and medical procedures	Large intestinal polypectomy	Unknown	8	1.4	0	0.0	
Surgical and medical procedures	Mole excision	White	332	61.8	1	0.3	
Surgical and medical procedures	Mole excision	Asian	180	33.5	0	0.0	
Surgical and medical procedures	Mole excision	Other	17	3.2	0	0.0	
Surgical and medical procedures	Mole excision	Unknown	8	1.4	0	0.0	
Surgical and medical procedures	Shoulder arthroplasty	White	332	61.8	0	0.0	
Surgical and medical procedures	Shoulder arthroplasty	Asian	180	33.5	0	0.0	
Surgical and medical procedures	Shoulder arthroplasty	Other	17	3.2	1	5.9	
Surgical and medical procedures	Shoulder arthroplasty	Unknown	8	1.4	0	0.0	
Surgical and medical procedures	Transurethral prostatectomy	White	332	61.8	1	0.3	
Surgical and medical procedures	Transurethral prostatectomy	Asian	180	33.5	0	0.0	
Surgical and medical procedures	Transurethral prostatectomy	Other	17	3.2	0	0.0	
Surgical and medical procedures	Transurethral prostatectomy	Unknown	8	1.4	0	0.0	
Vascular disorders		White	332	61.8	26	7.8	
Vascular disorders		Asian	180	33.5	11	6.1	
Vascular disorders		Other	17	3.2	0	0.0	
Vascular disorders		Unknown	8	1.4	1	12.5	
Vascular disorders	Aortic stenosis	White	332	61.8	0	0.0	
Vascular disorders	Aortic stenosis	Asian	180	33.5	1	0.6	
Vascular disorders	Aortic stenosis	Other	17	3.2	0	0.0	
Vascular disorders	Aortic stenosis	Unknown	8	1.4	0	0.0	
Vascular disorders	Atherosclerosis	White	332	61.8	1	0.3	
Vascular disorders	Atherosclerosis	Asian	180	33.5	3	1.7	
Vascular disorders	Atherosclerosis	Other	17	3.2	0	0.0	
Vascular disorders	Atherosclerosis	Unknown	8	1.4	0	0.0	
Vascular disorders	Branchocephalic arteriooclerosis	White	332	61.8	1	0.3	
Vascular disorders	Branchocephalic arteriooclerosis	Asian	180	33.5	0	0.0	
Vascular disorders	Branchocephalic arteriooclerosis	Other	17	3.2	0	0.0	
Vascular disorders	Branchocephalic arteriooclerosis	Unknown	8	1.4	0	0.0	
Vascular disorders	Diabetic vascular disorder	White	332	61.8	0	0.0	
Vascular disorders	Diabetic vascular disorder	Asian	180	33.5	1	0.6	
Vascular disorders	Diabetic vascular disorder	Other	17	3.2	0	0.0	
Vascular disorders	Diabetic vascular disorder	Unknown	8	1.4	0	0.0	
Vascular disorders	Hypertension	White	332	61.8	15	4.5	
Vascular disorders	Hypertension	Asian	180	33.5	7	3.9	
Vascular disorders	Hypertension	Other	17	3.2	0	0.0	
Vascular disorders	Hypertension	Unknown	8	1.4	1	12.5	
Vascular disorders	Hypertensive crisis	White	332	61.8	2	0.6	
Vascular disorders	Hypertensive crisis	Asian	180	33.5	0	0.0	
Vascular disorders	Hypertensive crisis	Other	17	3.2	0	0.0	
Vascular disorders	Hypertensive crisis	Unknown	8	1.4	0	0.0	
Vascular disorders	Hypotension	White	332	61.8	3	0.9	
Vascular disorders	Hypotension	Asian	180	33.5	0	0.0	
Vascular disorders	Hypotension	Other	17	3.2	0	0.0	
Vascular disorders	Hypotension	Unknown	8	1.4	0	0.0	
Vascular disorders	Ischaemic limb pain	White	332	61.8	1	0.3	
Vascular disorders	Ischaemic limb pain	Asian	180	33.5	0	0.0	
Vascular disorders	Ischaemic limb pain	Other	17	3.2	0	0.0	
Vascular disorders	Ischaemic limb pain	Unknown	8	1.4	0	0.0	
Vascular disorders	Orthostatic hypotension	White	332	61.8	1	0.3	
Vascular disorders	Orthostatic hypotension	Asian	180	33.5	0	0.0	
Vascular disorders	Orthostatic hypotension	Other	17	3.2	0	0.0	
Vascular disorders	Orthostatic hypotension	Unknown	8	1.4	0	0.0	
Vascular disorders	Varicose vein	White	332	61.8	1	0.3	
Vascular disorders	Varicose vein	Asian	180	33.5	0	0.0	
Vascular disorders	Varicose vein	Other	17	3.2	0	0.0	
Vascular disorders	Varicose vein	Unknown	8	1.4	0	0.0	
Vascular disorders	Vascular occlusion	White	332	61.8	1	0.3	
Vascular disorders	Vascular occlusion	Asian	180	33.5	0	0.0	
Vascular disorders	Vascular occlusion	Other	17	3.2	0	0.0	
Vascular disorders	Vascular occlusion	Unknown	8	1.4	0	0.0	
Vascular disorders	Venous occlusion	White	332	61.8	1	0.3	
Vascular disorders	Venous occlusion	Asian	180	33.5	0	0.0	
Vascular disorders	Venous occlusion	Other	17	3.2	0	0.0	
Vascular disorders	Venous occlusion	Unknown	8	1.4	0	0.0	
Vascular disorders	Venous thrombosis limb	White	332	61.8	1	0.3	
Vascular disorders	Venous thrombosis limb	Asian	180	33.5	0	0.0	
Vascular disorders	Venous thrombosis limb	Other	17	3.2	0	0.0	
Vascular disorders	Venous thrombosis limb	Unknown	8	1.4	0	0.0	

Program: root/c/clinical_studies/R06867461/CVT30303/share/ACR_data_analysis/prod/program/t_ae_soc_descriptive_w72.asx
Output: root/c/clinical_studies/R06867461/CVT30303/R41984/data_analysis/ACR_CSR_Final/prod/output/t_ae_soc_descriptive_w72_ag_MR72_SRA24_30AN0203_41984.xis
#6869204 17:45

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		n/a	537	100,0	5	0,9
Cardiac disorders	Angina pectoris	n/a	537	100,0	1	0,2
Cardiac disorders	Angina unstable	n/a	537	100,0	1	0,2
Cardiac disorders	Arteriosclerosis coronary artery	n/a	537	100,0	1	0,2
Cardiac disorders	Atrial fibrillation	n/a	537	100,0	1	0,2
Cardiac disorders	Cardiac failure	n/a	537	100,0	1	0,2
Cardiac disorders	Myocardial fibrosis	n/a	537	100,0	1	0,2
Cardiac disorders	Myocardial infarction	n/a	537	100,0	1	0,2
Cardiac disorders	Pericarditis	n/a	537	100,0	1	0,2
Cardiac disorders	Supraventricular extrasystoles	n/a	537	100,0	1	0,2
Congenital, familial and genetic disorders		n/a	537	100,0	2	0,4
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	n/a	537	100,0	1	0,2
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	n/a	537	100,0	1	0,2
Ear and labyrinth disorders		n/a	537	100,0	2	0,4
Ear and labyrinth disorders	Vertigo	n/a	537	100,0	1	0,2
Ear and labyrinth disorders	Vertigo positional	n/a	537	100,0	1	0,2
Eye disorders		n/a	537	100,0	39	7,3
Eye disorders	Cataract	n/a	537	100,0	6	1,1
Eye disorders	Cataract subcapsular	n/a	537	100,0	2	0,4
Eye disorders	Conjunctivitis allergic	n/a	537	100,0	1	0,2
Eye disorders	Corneal infiltrates	n/a	537	100,0	1	0,2
Eye disorders	Cystoid macular oedema	n/a	537	100,0	3	0,6
Eye disorders	Dry age-related macular degeneration	n/a	537	100,0	1	0,2
Eye disorders	Dry eye	n/a	537	100,0	2	0,4
Eye disorders	Epiretinal membrane	n/a	537	100,0	1	0,2
Eye disorders	Eye allergy	n/a	537	100,0	1	0,2
Eye disorders	Glaucoma	n/a	537	100,0	1	0,2
Eye disorders	Macular ischaemia	n/a	537	100,0	1	0,2
Eye disorders	Macular oedema	n/a	537	100,0	3	0,6
Eye disorders	Ocular hypertension	n/a	537	100,0	1	0,2
Eye disorders	Periorbital pain	n/a	537	100,0	1	0,2
Eye disorders	Posterior capsule opacification	n/a	537	100,0	1	0,2
Eye disorders	Retinal aneurysm	n/a	537	100,0	1	0,2
Eye disorders	Retinal cyst	n/a	537	100,0	1	0,2
Eye disorders	Retinal haemorrhage	n/a	537	100,0	1	0,2
Eye disorders	Retinal ischaemia	n/a	537	100,0	2	0,4
Eye disorders	Retinal neovascularisation	n/a	537	100,0	1	0,2
Eye disorders	Retinal vein occlusion	n/a	537	100,0	5	0,9
Eye disorders	Retinopathy hypertensive	n/a	537	100,0	1	0,2
Eye disorders	Swelling of eyelid	n/a	537	100,0	1	0,2
Eye disorders	Tractional retinal detachment	n/a	537	100,0	1	0,2
Eye disorders	Vitreous detachment	n/a	537	100,0	2	0,4

Gastrointestinal disorders		n/a	537	100,0	10	1,9
Gastrointestinal disorders	Colitis	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Constipation	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Erosive duodenitis	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Functional gastrointestinal disorder	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Gastric haemorrhage	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Gastritis	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Gastrooesophageal reflux disease	n/a	537	100,0	2	0,4
Gastrointestinal disorders	Gingival pain	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Hyperchlorhydria	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Toothache	n/a	537	100,0	1	0,2
General disorders and administration site conditions		n/a	537	100,0	3	0,6
General disorders and administration site conditions	Chest discomfort	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Pain	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Pyrexia	n/a	537	100,0	1	0,2
Hepatobiliary disorders		n/a	537	100,0	2	0,4
Hepatobiliary disorders	Cholelithiasis	n/a	537	100,0	1	0,2
Hepatobiliary disorders	Hepatic failure	n/a	537	100,0	1	0,2
Immune system disorders		n/a	537	100,0	3	0,6
Immune system disorders	Allergic oedema	n/a	537	100,0	1	0,2
Immune system disorders	Hypersensitivity	n/a	537	100,0	1	0,2
Immune system disorders	Seasonal allergy	n/a	537	100,0	1	0,2
Infections and infestations		n/a	537	100,0	41	7,6
Infections and infestations	Bronchitis	n/a	537	100,0	3	0,6
Infections and infestations	COVID-19	n/a	537	100,0	8	1,5
Infections and infestations	Cellulitis	n/a	537	100,0	3	0,6
Infections and infestations	Cystitis	n/a	537	100,0	1	0,2
Infections and infestations	Ear infection	n/a	537	100,0	1	0,2
Infections and infestations	Furuncle	n/a	537	100,0	1	0,2
Infections and infestations	Gastroenteritis	n/a	537	100,0	2	0,4
Infections and infestations	Gastrointestinal infection	n/a	537	100,0	2	0,4
Infections and infestations	Gingival abscess	n/a	537	100,0	1	0,2
Infections and infestations	Herpes zoster	n/a	537	100,0	1	0,2
Infections and infestations	Hordeolum	n/a	537	100,0	1	0,2
Infections and infestations	Influenza	n/a	537	100,0	5	0,9
Infections and infestations	Nasopharyngitis	n/a	537	100,0	1	0,2
Infections and infestations	Otitis media	n/a	537	100,0	1	0,2
Infections and infestations	Pneumonia	n/a	537	100,0	3	0,6
Infections and infestations	Post-acute COVID-19 syndrome	n/a	537	100,0	1	0,2
Infections and infestations	Postoperative wound infection	n/a	537	100,0	1	0,2
Infections and infestations	Pyelonephritis	n/a	537	100,0	1	0,2
Infections and infestations	Respiratory tract infection	n/a	537	100,0	2	0,4
Infections and infestations	Rotavirus infection	n/a	537	100,0	1	0,2
Infections and infestations	Sinusitis	n/a	537	100,0	1	0,2
Infections and infestations	Suspected COVID-19	n/a	537	100,0	1	0,2
Infections and infestations	Tooth infection	n/a	537	100,0	1	0,2
Infections and infestations	Tracheitis	n/a	537	100,0	1	0,2
Infections and infestations	Upper respiratory tract infection	n/a	537	100,0	5	0,9
Infections and infestations	Urinary tract infection	n/a	537	100,0	1	0,2
Infections and infestations	Viral infection	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications		n/a	537	100,0	14	2,6

Injury, poisoning and procedural complications	Back injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Burns third degree	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Facial bones fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Fall	n/a	537	100,0	7	1,3
Injury, poisoning and procedural complications	Femur fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Head injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Meniscus injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Skin laceration	n/a	537	100,0	2	0,4
Injury, poisoning and procedural complications	Spinal column injury	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Subdural haematoma	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Tooth fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Ulna fracture	n/a	537	100,0	1	0,2
Investigations		n/a	537	100,0	8	1,5
Investigations	Intraocular pressure increased	n/a	537	100,0	5	0,9
Investigations	Platelet count increased	n/a	537	100,0	1	0,2
Investigations	SARS-CoV-2 test positive	n/a	537	100,0	1	0,2
Investigations	Troponin increased	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders		n/a	537	100,0	4	0,7
Metabolism and nutrition disorders	Dehydration	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Gout	n/a	537	100,0	2	0,4
Metabolism and nutrition disorders	Hyperglycaemia	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders		n/a	537	100,0	17	3,2
Musculoskeletal and connective tissue disorders	Arthralgia	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Arthritis	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Back pain	n/a	537	100,0	3	0,6
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Joint swelling	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Muscle spasms	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Osteoarthritis	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Osteoporosis	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Plantar fasciitis	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Spinal pain	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	537	100,0	2	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	n/a	537	100,0	1	0,2
Nervous system disorders		n/a	537	100,0	16	3,0
Nervous system disorders	Carotid artery stenosis	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebral infarction	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebrovascular accident	n/a	537	100,0	2	0,4
Nervous system disorders	Cognitive disorder	n/a	537	100,0	1	0,2
Nervous system disorders	Epilepsy	n/a	537	100,0	1	0,2
Nervous system disorders	Headache	n/a	537	100,0	3	0,6
Nervous system disorders	Hypertensive encephalopathy	n/a	537	100,0	1	0,2
Nervous system disorders	Memory impairment	n/a	537	100,0	1	0,2
Nervous system disorders	Migraine	n/a	537	100,0	1	0,2
Nervous system disorders	Myelopathy	n/a	537	100,0	1	0,2
Nervous system disorders	Narcolepsy	n/a	537	100,0	1	0,2
Nervous system disorders	Presyncope	n/a	537	100,0	1	0,2
Nervous system disorders	Sciatica	n/a	537	100,0	1	0,2
Nervous system disorders	Sinus headache	n/a	537	100,0	1	0,2

Product issues		n/a	537	100,0	1	0,2
Product issues	Device malfunction	n/a	537	100,0	1	0,2
Psychiatric disorders		n/a	537	100,0	1	0,2
Psychiatric disorders	Anxiety	n/a	537	100,0	1	0,2
Renal and urinary disorders		n/a	537	100,0	3	0,6
Renal and urinary disorders	Chronic kidney disease	n/a	537	100,0	1	0,2
Renal and urinary disorders	Haematuria	n/a	537	100,0	1	0,2
Renal and urinary disorders	Nephrolithiasis	n/a	537	100,0	1	0,2
Reproductive system and breast disorders		n/a	537	100,0	2	0,4
Reproductive system and breast disorders	Erectile dysfunction	n/a	537	100,0	1	0,2
Reproductive system and breast disorders	Prostatitis	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders		n/a	537	100,0	5	0,9
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders		n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders	Pemphigoid	n/a	537	100,0	1	0,2
Surgical and medical procedures		n/a	537	100,0	2	0,4
Surgical and medical procedures	Shoulder arthroplasty	n/a	537	100,0	1	0,2
Surgical and medical procedures	Transurethral prostatectomy	n/a	537	100,0	1	0,2
Vascular disorders		n/a	537	100,0	14	2,6
Vascular disorders	Brachiocephalic arteriosclerosis	n/a	537	100,0	1	0,2
Vascular disorders	Hypertension	n/a	537	100,0	8	1,5
Vascular disorders	Hypertensive crisis	n/a	537	100,0	1	0,2
Vascular disorders	Hypotension	n/a	537	100,0	1	0,2
Vascular disorders	Orthostatic hypotension	n/a	537	100,0	1	0,2
Vascular disorders	Varicose vein	n/a	537	100,0	1	0,2
Vascular disorders	Vascular occlusion	n/a	537	100,0	1	0,2
Vascular disorders	Venous occlusion	n/a	537	100,0	1	0,2

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WMODAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 17:51

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Moderate AEs

MODEL: Unstratified Analysis

STUDY: GR41984

Descriptive Analysis (Safety) after Week 24

Gender

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		Male	264	49,2	2	0,8
Cardiac disorders		Female	273	50,8	3	1,1
Cardiac disorders	Angina pectoris	Male	264	49,2	1	0,4
Cardiac disorders	Angina pectoris	Female	273	50,8	0	0,0
Cardiac disorders	Angina unstable	Male	264	49,2	1	0,4
Cardiac disorders	Angina unstable	Female	273	50,8	0	0,0
Cardiac disorders	Arteriosclerosis coronary artery	Male	264	49,2	1	0,4
Cardiac disorders	Arteriosclerosis coronary artery	Female	273	50,8	0	0,0
Cardiac disorders	Atrial fibrillation	Male	264	49,2	1	0,4
Cardiac disorders	Atrial fibrillation	Female	273	50,8	0	0,0
Cardiac disorders	Cardiac failure	Male	264	49,2	0	0,0
Cardiac disorders	Cardiac failure	Female	273	50,8	1	0,4
Cardiac disorders	Myocardial fibrosis	Male	264	49,2	1	0,4
Cardiac disorders	Myocardial fibrosis	Female	273	50,8	0	0,0
Cardiac disorders	Myocardial infarction	Male	264	49,2	0	0,0
Cardiac disorders	Myocardial infarction	Female	273	50,8	1	0,4
Cardiac disorders	Pericarditis	Male	264	49,2	0	0,0
Cardiac disorders	Pericarditis	Female	273	50,8	1	0,4
Cardiac disorders	Supraventricular extrasystoles	Male	264	49,2	1	0,4
Cardiac disorders	Supraventricular extrasystoles	Female	273	50,8	0	0,0
Congenital, familial and genetic disorders		Male	264	49,2	1	0,4
Congenital, familial and genetic disorders		Female	273	50,8	1	0,4
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Male	264	49,2	1	0,4
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Female	273	50,8	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Male	264	49,2	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Female	273	50,8	1	0,4
Ear and labyrinth disorders		Male	264	49,2	0	0,0
Ear and labyrinth disorders		Female	273	50,8	2	0,7
Ear and labyrinth disorders	Vertigo	Male	264	49,2	0	0,0
Ear and labyrinth disorders	Vertigo	Female	273	50,8	1	0,4
Ear and labyrinth disorders	Vertigo positional	Male	264	49,2	0	0,0
Ear and labyrinth disorders	Vertigo positional	Female	273	50,8	1	0,4
Eye disorders		Male	264	49,2	16	6,1
Eye disorders		Female	273	50,8	23	8,4
Eye disorders	Cataract	Male	264	49,2	0	0,0
Eye disorders	Cataract	Female	273	50,8	6	2,2
Eye disorders	Cataract subcapsular	Male	264	49,2	1	0,4
Eye disorders	Cataract subcapsular	Female	273	50,8	1	0,4
Eye disorders	Conjunctivitis allergic	Male	264	49,2	0	0,0
Eye disorders	Conjunctivitis allergic	Female	273	50,8	1	0,4
Eye disorders	Corneal infiltrates	Male	264	49,2	1	0,4
Eye disorders	Corneal infiltrates	Female	273	50,8	0	0,0
Eye disorders	Cystoid macular oedema	Male	264	49,2	2	0,8
Eye disorders	Cystoid macular oedema	Female	273	50,8	1	0,4
Eye disorders	Dry age-related macular degeneration	Male	264	49,2	1	0,4
Eye disorders	Dry age-related macular degeneration	Female	273	50,8	0	0,0
Eye disorders	Dry eye	Male	264	49,2	1	0,4
Eye disorders	Dry eye	Female	273	50,8	1	0,4
Eye disorders	Epi-retinal membrane	Male	264	49,2	1	0,4
Eye disorders	Epi-retinal membrane	Female	273	50,8	0	0,0
Eye disorders	Eye allergy	Male	264	49,2	0	0,0
Eye disorders	Eye allergy	Female	273	50,8	1	0,4

Eye disorders	Glaucoma	Male	264	49,2	0	0,0
Eye disorders	Glaucoma	Female	273	50,8	1	0,4
Eye disorders	Macular ischaemia	Male	264	49,2	0	0,0
Eye disorders	Macular ischaemia	Female	273	50,8	1	0,4
Eye disorders	Macular oedema	Male	264	49,2	1	0,4
Eye disorders	Macular oedema	Female	273	50,8	2	0,7
Eye disorders	Ocular hypertension	Male	264	49,2	1	0,4
Eye disorders	Ocular hypertension	Female	273	50,8	0	0,0
Eye disorders	Periorbital pain	Male	264	49,2	0	0,0
Eye disorders	Periorbital pain	Female	273	50,8	1	0,4
Eye disorders	Posterior capsule opacification	Male	264	49,2	1	0,4
Eye disorders	Posterior capsule opacification	Female	273	50,8	0	0,0
Eye disorders	Retinal aneurysm	Male	264	49,2	0	0,0
Eye disorders	Retinal aneurysm	Female	273	50,8	1	0,4
Eye disorders	Retinal cyst	Male	264	49,2	1	0,4
Eye disorders	Retinal cyst	Female	273	50,8	0	0,0
Eye disorders	Retinal haemorrhage	Male	264	49,2	0	0,0
Eye disorders	Retinal haemorrhage	Female	273	50,8	1	0,4
Eye disorders	Retinal ischaemia	Male	264	49,2	1	0,4
Eye disorders	Retinal ischaemia	Female	273	50,8	1	0,4
Eye disorders	Retinal neovascularisation	Male	264	49,2	0	0,0
Eye disorders	Retinal neovascularisation	Female	273	50,8	1	0,4
Eye disorders	Retinal vein occlusion	Male	264	49,2	2	0,8
Eye disorders	Retinal vein occlusion	Female	273	50,8	3	1,1
Eye disorders	Retinopathy hypertensive	Male	264	49,2	1	0,4
Eye disorders	Retinopathy hypertensive	Female	273	50,8	0	0,0
Eye disorders	Swelling of eyelid	Male	264	49,2	0	0,0
Eye disorders	Swelling of eyelid	Female	273	50,8	1	0,4
Eye disorders	Tractional retinal detachment	Male	264	49,2	1	0,4
Eye disorders	Tractional retinal detachment	Female	273	50,8	0	0,0
Eye disorders	Vitreous detachment	Male	264	49,2	2	0,8
Eye disorders	Vitreous detachment	Female	273	50,8	0	0,0
Gastrointestinal disorders		Male	264	49,2	6	2,3
Gastrointestinal disorders		Female	273	50,8	4	1,5
Gastrointestinal disorders	Colitis	Male	264	49,2	0	0,0
Gastrointestinal disorders	Colitis	Female	273	50,8	1	0,4
Gastrointestinal disorders	Constipation	Male	264	49,2	1	0,4
Gastrointestinal disorders	Constipation	Female	273	50,8	0	0,0
Gastrointestinal disorders	Erosive duodenitis	Male	264	49,2	0	0,0
Gastrointestinal disorders	Erosive duodenitis	Female	273	50,8	1	0,4
Gastrointestinal disorders	Functional gastrointestinal disorder	Male	264	49,2	1	0,4
Gastrointestinal disorders	Functional gastrointestinal disorder	Female	273	50,8	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Male	264	49,2	1	0,4
Gastrointestinal disorders	Gastric haemorrhage	Female	273	50,8	0	0,0
Gastrointestinal disorders	Gastritis	Male	264	49,2	0	0,0
Gastrointestinal disorders	Gastritis	Female	273	50,8	1	0,4
Gastrointestinal disorders	Gastroesophageal reflux disease	Male	264	49,2	1	0,4
Gastrointestinal disorders	Gastroesophageal reflux disease	Female	273	50,8	1	0,4
Gastrointestinal disorders	Gingival pain	Male	264	49,2	0	0,0
Gastrointestinal disorders	Gingival pain	Female	273	50,8	1	0,4
Gastrointestinal disorders	Hyperchlorhydria	Male	264	49,2	1	0,4
Gastrointestinal disorders	Hyperchlorhydria	Female	273	50,8	0	0,0
Gastrointestinal disorders	Toothache	Male	264	49,2	1	0,4
Gastrointestinal disorders	Toothache	Female	273	50,8	0	0,0
General disorders and administration site conditions		Male	264	49,2	1	0,4
General disorders and administration site conditions		Female	273	50,8	2	0,7
General disorders and administration site conditions	Chest discomfort	Male	264	49,2	0	0,0
General disorders and administration site conditions	Chest discomfort	Female	273	50,8	1	0,4
General disorders and administration site conditions	Pain	Male	264	49,2	0	0,0
General disorders and administration site conditions	Pain	Female	273	50,8	1	0,4
General disorders and administration site conditions	Pyrexia	Male	264	49,2	1	0,4
General disorders and administration site conditions	Pyrexia	Female	273	50,8	0	0,0
Hepatobiliary disorders		Male	264	49,2	1	0,4
Hepatobiliary disorders		Female	273	50,8	1	0,4
Hepatobiliary disorders	Cholelithiasis	Male	264	49,2	0	0,0

Hepatobiliary disorders	Cholelithiasis	Female	273	50,8	1	0,4
Hepatobiliary disorders	Hepatic failure	Male	264	49,2	1	0,4
Hepatobiliary disorders	Hepatic failure	Female	273	50,8	0	0,0
Immune system disorders		Male	264	49,2	1	0,4
Immune system disorders		Female	273	50,8	2	0,7
Immune system disorders	Allergic oedema	Male	264	49,2	0	0,0
Immune system disorders	Allergic oedema	Female	273	50,8	1	0,4
Immune system disorders	Hypersensitivity	Male	264	49,2	1	0,4
Immune system disorders	Hypersensitivity	Female	273	50,8	0	0,0
Immune system disorders	Seasonal allergy	Male	264	49,2	0	0,0
Immune system disorders	Seasonal allergy	Female	273	50,8	1	0,4
Infections and infestations		Male	264	49,2	19	7,2
Infections and infestations		Female	273	50,8	22	8,1
Infections and infestations	Bronchitis	Male	264	49,2	1	0,4
Infections and infestations	Bronchitis	Female	273	50,8	2	0,7
Infections and infestations	COVID-19	Male	264	49,2	3	1,1
Infections and infestations	COVID-19	Female	273	50,8	5	1,8
Infections and infestations	Cellulitis	Male	264	49,2	2	0,8
Infections and infestations	Cellulitis	Female	273	50,8	1	0,4
Infections and infestations	Cystitis	Male	264	49,2	0	0,0
Infections and infestations	Cystitis	Female	273	50,8	1	0,4
Infections and infestations	Ear infection	Male	264	49,2	1	0,4
Infections and infestations	Ear infection	Female	273	50,8	0	0,0
Infections and infestations	Furuncle	Male	264	49,2	1	0,4
Infections and infestations	Furuncle	Female	273	50,8	0	0,0
Infections and infestations	Gastroenteritis	Male	264	49,2	1	0,4
Infections and infestations	Gastroenteritis	Female	273	50,8	1	0,4
Infections and infestations	Gastrointestinal infection	Male	264	49,2	1	0,4
Infections and infestations	Gastrointestinal infection	Female	273	50,8	1	0,4
Infections and infestations	Gingival abscess	Male	264	49,2	1	0,4
Infections and infestations	Gingival abscess	Female	273	50,8	0	0,0
Infections and infestations	Herpes zoster	Male	264	49,2	0	0,0
Infections and infestations	Herpes zoster	Female	273	50,8	1	0,4
Infections and infestations	Hordeolum	Male	264	49,2	0	0,0
Infections and infestations	Hordeolum	Female	273	50,8	1	0,4
Infections and infestations	Influenza	Male	264	49,2	2	0,8
Infections and infestations	Influenza	Female	273	50,8	3	1,1
Infections and infestations	Nasopharyngitis	Male	264	49,2	0	0,0
Infections and infestations	Nasopharyngitis	Female	273	50,8	1	0,4
Infections and infestations	Otitis media	Male	264	49,2	1	0,4
Infections and infestations	Otitis media	Female	273	50,8	0	0,0
Infections and infestations	Pneumonia	Male	264	49,2	2	0,8
Infections and infestations	Pneumonia	Female	273	50,8	1	0,4
Infections and infestations	Post-acute COVID-19 syndrome	Male	264	49,2	1	0,4
Infections and infestations	Post-acute COVID-19 syndrome	Female	273	50,8	0	0,0
Infections and infestations	Postoperative wound infection	Male	264	49,2	0	0,0
Infections and infestations	Postoperative wound infection	Female	273	50,8	1	0,4
Infections and infestations	Pyelonephritis	Male	264	49,2	1	0,4
Infections and infestations	Pyelonephritis	Female	273	50,8	0	0,0
Infections and infestations	Respiratory tract infection	Male	264	49,2	1	0,4
Infections and infestations	Respiratory tract infection	Female	273	50,8	1	0,4
Infections and infestations	Rotavirus infection	Male	264	49,2	0	0,0
Infections and infestations	Rotavirus infection	Female	273	50,8	1	0,4
Infections and infestations	Sinusitis	Male	264	49,2	1	0,4
Infections and infestations	Sinusitis	Female	273	50,8	0	0,0
Infections and infestations	Suspected COVID-19	Male	264	49,2	1	0,4
Infections and infestations	Suspected COVID-19	Female	273	50,8	0	0,0
Infections and infestations	Tooth infection	Male	264	49,2	0	0,0
Infections and infestations	Tooth infection	Female	273	50,8	1	0,4
Infections and infestations	Tracheitis	Male	264	49,2	1	0,4
Infections and infestations	Tracheitis	Female	273	50,8	0	0,0
Infections and infestations	Upper respiratory tract infection	Male	264	49,2	3	1,1
Infections and infestations	Upper respiratory tract infection	Female	273	50,8	2	0,7
Infections and infestations	Urinary tract infection	Male	264	49,2	1	0,4
Infections and infestations	Urinary tract infection	Female	273	50,8	0	0,0
Infections and infestations	Viral infection	Male	264	49,2	0	0,0

Infections and infestations	Viral infection	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications		Male	264	49,2	5	1,9
Injury, poisoning and procedural complications		Female	273	50,8	9	3,3
Injury, poisoning and procedural complications	Back injury	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Back injury	Female	273	50,8	0	0,0
Injury, poisoning and procedural complications	Burns third degree	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Burns third degree	Female	273	50,8	0	0,0
Injury, poisoning and procedural complications	Facial bones fracture	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Facial bones fracture	Female	273	50,8	0	0,0
Injury, poisoning and procedural complications	Fall	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Fall	Female	273	50,8	6	2,2
Injury, poisoning and procedural complications	Femur fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Head injury	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Head injury	Female	273	50,8	0	0,0
Injury, poisoning and procedural complications	Meniscus injury	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Meniscus injury	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Skin laceration	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Skin laceration	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Spinal column injury	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Spinal column injury	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Subdural haematoma	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Subdural haematoma	Female	273	50,8	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Ulna fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Female	273	50,8	1	0,4
Investigations		Male	264	49,2	5	1,9
Investigations		Female	273	50,8	3	1,1
Investigations	Intraocular pressure increased	Male	264	49,2	3	1,1
Investigations	Intraocular pressure increased	Female	273	50,8	2	0,7
Investigations	Platelet count increased	Male	264	49,2	1	0,4
Investigations	Platelet count increased	Female	273	50,8	0	0,0
Investigations	SARS-CoV-2 test positive	Male	264	49,2	0	0,0
Investigations	SARS-CoV-2 test positive	Female	273	50,8	1	0,4
Investigations	Troponin increased	Male	264	49,2	1	0,4
Investigations	Troponin increased	Female	273	50,8	0	0,0
Metabolism and nutrition disorders		Male	264	49,2	2	0,8
Metabolism and nutrition disorders		Female	273	50,8	2	0,7
Metabolism and nutrition disorders	Dehydration	Male	264	49,2	0	0,0
Metabolism and nutrition disorders	Dehydration	Female	273	50,8	1	0,4
Metabolism and nutrition disorders	Gout	Male	264	49,2	2	0,8
Metabolism and nutrition disorders	Gout	Female	273	50,8	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Male	264	49,2	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Female	273	50,8	1	0,4
Musculoskeletal and connective tissue disorders		Male	264	49,2	7	2,7
Musculoskeletal and connective tissue disorders		Female	273	50,8	10	3,7
Musculoskeletal and connective tissue disorders	Arthralgia	Male	264	49,2	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	Female	273	50,8	2	0,7
Musculoskeletal and connective tissue disorders	Arthritis	Male	264	49,2	2	0,8
Musculoskeletal and connective tissue disorders	Arthritis	Female	273	50,8	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	Male	264	49,2	1	0,4
Musculoskeletal and connective tissue disorders	Back pain	Female	273	50,8	2	0,7
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Male	264	49,2	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Female	273	50,8	2	0,7
Musculoskeletal and connective tissue disorders	Joint swelling	Male	264	49,2	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	Female	273	50,8	1	0,4
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Male	264	49,2	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Female	273	50,8	1	0,4
Musculoskeletal and connective tissue disorders	Muscle spasms	Male	264	49,2	0	0,0
Musculoskeletal and connective tissue disorders	Muscle spasms	Female	273	50,8	1	0,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	Male	264	49,2	2	0,8
Musculoskeletal and connective tissue disorders	Osteoarthritis	Female	273	50,8	0	0,0
Musculoskeletal and connective tissue disorders	Osteoporosis	Male	264	49,2	0	0,0

Musculoskeletal and connective tissue disorders	Osteoporosis	Female	273	50,8	1	0,4
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Male	264	49,2	1	0,4
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Female	273	50,8	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Male	264	49,2	1	0,4
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Female	273	50,8	1	0,4
Musculoskeletal and connective tissue disorders	Spinal pain	Male	264	49,2	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Male	264	49,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Male	264	49,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Female	273	50,8	0	0,0
Nervous system disorders		Male	264	49,2	4	1,5
Nervous system disorders		Female	273	50,8	12	4,4
Nervous system disorders	Carotid artery stenosis	Male	264	49,2	0	0,0
Nervous system disorders	Carotid artery stenosis	Female	273	50,8	1	0,4
Nervous system disorders	Cerebral infarction	Male	264	49,2	1	0,4
Nervous system disorders	Cerebral infarction	Female	273	50,8	0	0,0
Nervous system disorders	Cerebrovascular accident	Male	264	49,2	0	0,0
Nervous system disorders	Cerebrovascular accident	Female	273	50,8	2	0,7
Nervous system disorders	Cognitive disorder	Male	264	49,2	0	0,0
Nervous system disorders	Cognitive disorder	Female	273	50,8	1	0,4
Nervous system disorders	Epilepsy	Male	264	49,2	1	0,4
Nervous system disorders	Epilepsy	Female	273	50,8	0	0,0
Nervous system disorders	Headache	Male	264	49,2	1	0,4
Nervous system disorders	Headache	Female	273	50,8	2	0,7
Nervous system disorders	Hypertensive encephalopathy	Male	264	49,2	0	0,0
Nervous system disorders	Hypertensive encephalopathy	Female	273	50,8	1	0,4
Nervous system disorders	Memory impairment	Male	264	49,2	1	0,4
Nervous system disorders	Memory impairment	Female	273	50,8	0	0,0
Nervous system disorders	Migraine	Male	264	49,2	0	0,0
Nervous system disorders	Migraine	Female	273	50,8	1	0,4
Nervous system disorders	Myelopathy	Male	264	49,2	0	0,0
Nervous system disorders	Myelopathy	Female	273	50,8	1	0,4
Nervous system disorders	Narcolepsy	Male	264	49,2	0	0,0
Nervous system disorders	Narcolepsy	Female	273	50,8	1	0,4
Nervous system disorders	Presyncope	Male	264	49,2	0	0,0
Nervous system disorders	Presyncope	Female	273	50,8	1	0,4
Nervous system disorders	Sciatica	Male	264	49,2	1	0,4
Nervous system disorders	Sciatica	Female	273	50,8	0	0,0
Nervous system disorders	Sinus headache	Male	264	49,2	0	0,0
Nervous system disorders	Sinus headache	Female	273	50,8	1	0,4
Product issues		Male	264	49,2	1	0,4
Product issues		Female	273	50,8	0	0,0
Product issues	Device malfunction	Male	264	49,2	1	0,4
Product issues	Device malfunction	Female	273	50,8	0	0,0
Psychiatric disorders		Male	264	49,2	0	0,0
Psychiatric disorders		Female	273	50,8	1	0,4
Psychiatric disorders	Anxiety	Male	264	49,2	0	0,0
Psychiatric disorders	Anxiety	Female	273	50,8	1	0,4
Renal and urinary disorders		Male	264	49,2	2	0,8
Renal and urinary disorders		Female	273	50,8	1	0,4
Renal and urinary disorders	Chronic kidney disease	Male	264	49,2	1	0,4
Renal and urinary disorders	Chronic kidney disease	Female	273	50,8	0	0,0
Renal and urinary disorders	Haematuria	Male	264	49,2	1	0,4
Renal and urinary disorders	Haematuria	Female	273	50,8	0	0,0
Renal and urinary disorders	Nephrolithiasis	Male	264	49,2	0	0,0

Renal and urinary disorders	Nephrolithiasis	Female	273	50,8	1	0,4
Reproductive system and breast disorders		Male	264	49,2	2	0,8
Reproductive system and breast disorders		Female	273	50,8	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	Male	264	49,2	1	0,4
Reproductive system and breast disorders	Erectile dysfunction	Female	273	50,8	0	0,0
Reproductive system and breast disorders	Prostatitis	Male	264	49,2	1	0,4
Reproductive system and breast disorders	Prostatitis	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders		Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders		Female	273	50,8	4	1,5
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Male	264	49,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Female	273	50,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Female	273	50,8	1	0,4
Skin and subcutaneous tissue disorders		Male	264	49,2	1	0,4
Skin and subcutaneous tissue disorders		Female	273	50,8	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	Male	264	49,2	1	0,4
Skin and subcutaneous tissue disorders	Pemphigoid	Female	273	50,8	0	0,0
Surgical and medical procedures		Male	264	49,2	2	0,8
Surgical and medical procedures		Female	273	50,8	0	0,0
Surgical and medical procedures	Shoulder arthroplasty	Male	264	49,2	1	0,4
Surgical and medical procedures	Shoulder arthroplasty	Female	273	50,8	0	0,0
Surgical and medical procedures	Transurethral prostatectomy	Male	264	49,2	1	0,4
Surgical and medical procedures	Transurethral prostatectomy	Female	273	50,8	0	0,0
Vascular disorders		Male	264	49,2	6	2,3
Vascular disorders		Female	273	50,8	8	2,9
Vascular disorders	Brachiocephalic arteriosclerosis	Male	264	49,2	1	0,4
Vascular disorders	Brachiocephalic arteriosclerosis	Female	273	50,8	0	0,0
Vascular disorders	Hypertension	Male	264	49,2	3	1,1
Vascular disorders	Hypertension	Female	273	50,8	5	1,8
Vascular disorders	Hypertensive crisis	Male	264	49,2	0	0,0
Vascular disorders	Hypertensive crisis	Female	273	50,8	1	0,4
Vascular disorders	Hypotension	Male	264	49,2	0	0,0
Vascular disorders	Hypotension	Female	273	50,8	1	0,4
Vascular disorders	Orthostatic hypotension	Male	264	49,2	1	0,4
Vascular disorders	Orthostatic hypotension	Female	273	50,8	0	0,0
Vascular disorders	Varicose vein	Male	264	49,2	0	0,0
Vascular disorders	Varicose vein	Female	273	50,8	1	0,4
Vascular disorders	Vascular occlusion	Male	264	49,2	1	0,4
Vascular disorders	Vascular occlusion	Female	273	50,8	0	0,0
Vascular disorders	Venous occlusion	Male	264	49,2	1	0,4
Vascular disorders	Venous occlusion	Female	273	50,8	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WM0DAE_WK72_SBa24_30AUG2023_41984.xls

26APR2024 17:51

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Moderate AEs

MODEL: Unstratified Analysis

STUDY: GR41984

Descriptive Analysis (Safety) after Week 24

Age

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		<65 years	270	50,3	2	0,7
Cardiac disorders		>=65 years	267	49,7	3	1,1
Cardiac disorders	Angina pectoris	<65 years	270	50,3	1	0,4
Cardiac disorders	Angina pectoris	>=65 years	267	49,7	0	0,0
Cardiac disorders	Angina unstable	<65 years	270	50,3	1	0,4
Cardiac disorders	Angina unstable	>=65 years	267	49,7	0	0,0
Cardiac disorders	Arteriosclerosis coronary artery	<65 years	270	50,3	1	0,4
Cardiac disorders	Arteriosclerosis coronary artery	>=65 years	267	49,7	0	0,0
Cardiac disorders	Atrial fibrillation	<65 years	270	50,3	1	0,4
Cardiac disorders	Atrial fibrillation	>=65 years	267	49,7	0	0,0
Cardiac disorders	Cardiac failure	<65 years	270	50,3	0	0,0
Cardiac disorders	Cardiac failure	>=65 years	267	49,7	1	0,4
Cardiac disorders	Myocardial fibrosis	<65 years	270	50,3	1	0,4
Cardiac disorders	Myocardial fibrosis	>=65 years	267	49,7	0	0,0
Cardiac disorders	Myocardial infarction	<65 years	270	50,3	0	0,0
Cardiac disorders	Myocardial infarction	>=65 years	267	49,7	1	0,4
Cardiac disorders	Pericarditis	<65 years	270	50,3	0	0,0
Cardiac disorders	Pericarditis	>=65 years	267	49,7	1	0,4
Cardiac disorders	Supraventricular extrasystoles	<65 years	270	50,3	1	0,4
Cardiac disorders	Supraventricular extrasystoles	>=65 years	267	49,7	0	0,0
Congenital, familial and genetic disorders		<65 years	270	50,3	2	0,7
Congenital, familial and genetic disorders		>=65 years	267	49,7	0	0,0
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	<65 years	270	50,3	1	0,4
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	>=65 years	267	49,7	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	<65 years	270	50,3	1	0,4
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	>=65 years	267	49,7	0	0,0
Ear and labyrinth disorders		<65 years	270	50,3	0	0,0
Ear and labyrinth disorders		>=65 years	267	49,7	2	0,7
Ear and labyrinth disorders	Vertigo	<65 years	270	50,3	0	0,0
Ear and labyrinth disorders	Vertigo	>=65 years	267	49,7	1	0,4
Ear and labyrinth disorders	Vertigo positional	<65 years	270	50,3	0	0,0
Ear and labyrinth disorders	Vertigo positional	>=65 years	267	49,7	1	0,4
Eye disorders		<65 years	270	50,3	20	7,4
Eye disorders		>=65 years	267	49,7	19	7,1
Eye disorders	Cataract	<65 years	270	50,3	1	0,4
Eye disorders	Cataract	>=65 years	267	49,7	5	1,9
Eye disorders	Cataract subcapsular	<65 years	270	50,3	0	0,0
Eye disorders	Cataract subcapsular	>=65 years	267	49,7	2	0,7
Eye disorders	Conjunctivitis allergic	<65 years	270	50,3	1	0,4
Eye disorders	Conjunctivitis allergic	>=65 years	267	49,7	0	0,0
Eye disorders	Corneal infiltrates	<65 years	270	50,3	0	0,0
Eye disorders	Corneal infiltrates	>=65 years	267	49,7	1	0,4
Eye disorders	Cystoid macular oedema	<65 years	270	50,3	2	0,7
Eye disorders	Cystoid macular oedema	>=65 years	267	49,7	1	0,4
Eye disorders	Dry age-related macular degeneration	<65 years	270	50,3	0	0,0
Eye disorders	Dry age-related macular degeneration	>=65 years	267	49,7	1	0,4
Eye disorders	Dry eye	<65 years	270	50,3	1	0,4
Eye disorders	Dry eye	>=65 years	267	49,7	1	0,4
Eye disorders	Epi-retinal membrane	<65 years	270	50,3	1	0,4
Eye disorders	Epi-retinal membrane	>=65 years	267	49,7	0	0,0
Eye disorders	Eye allergy	<65 years	270	50,3	1	0,4
Eye disorders	Eye allergy	>=65 years	267	49,7	0	0,0

Eye disorders	Glaucoma	<65 years	270	50,3	1	0,4
Eye disorders	Glaucoma	>=65 years	267	49,7	0	0,0
Eye disorders	Macular ischaemia	<65 years	270	50,3	0	0,0
Eye disorders	Macular ischaemia	>=65 years	267	49,7	1	0,4
Eye disorders	Macular oedema	<65 years	270	50,3	1	0,4
Eye disorders	Macular oedema	>=65 years	267	49,7	2	0,7
Eye disorders	Ocular hypertension	<65 years	270	50,3	1	0,4
Eye disorders	Ocular hypertension	>=65 years	267	49,7	0	0,0
Eye disorders	Periorbital pain	<65 years	270	50,3	1	0,4
Eye disorders	Periorbital pain	>=65 years	267	49,7	0	0,0
Eye disorders	Posterior capsule opacification	<65 years	270	50,3	1	0,4
Eye disorders	Posterior capsule opacification	>=65 years	267	49,7	0	0,0
Eye disorders	Retinal aneurysm	<65 years	270	50,3	0	0,0
Eye disorders	Retinal aneurysm	>=65 years	267	49,7	1	0,4
Eye disorders	Retinal cyst	<65 years	270	50,3	1	0,4
Eye disorders	Retinal cyst	>=65 years	267	49,7	0	0,0
Eye disorders	Retinal haemorrhage	<65 years	270	50,3	0	0,0
Eye disorders	Retinal haemorrhage	>=65 years	267	49,7	1	0,4
Eye disorders	Retinal ischaemia	<65 years	270	50,3	2	0,7
Eye disorders	Retinal ischaemia	>=65 years	267	49,7	0	0,0
Eye disorders	Retinal neovascularisation	<65 years	270	50,3	1	0,4
Eye disorders	Retinal neovascularisation	>=65 years	267	49,7	0	0,0
Eye disorders	Retinal vein occlusion	<65 years	270	50,3	4	1,5
Eye disorders	Retinal vein occlusion	>=65 years	267	49,7	1	0,4
Eye disorders	Retinopathy hypertensive	<65 years	270	50,3	0	0,0
Eye disorders	Retinopathy hypertensive	>=65 years	267	49,7	1	0,4
Eye disorders	Swelling of eyelid	<65 years	270	50,3	0	0,0
Eye disorders	Swelling of eyelid	>=65 years	267	49,7	1	0,4
Eye disorders	Tractional retinal detachment	<65 years	270	50,3	1	0,4
Eye disorders	Tractional retinal detachment	>=65 years	267	49,7	0	0,0
Eye disorders	Vitreous detachment	<65 years	270	50,3	1	0,4
Eye disorders	Vitreous detachment	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders		<65 years	270	50,3	4	1,5
Gastrointestinal disorders		>=65 years	267	49,7	6	2,2
Gastrointestinal disorders	Colitis	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Colitis	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Constipation	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Constipation	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Erosive duodenitis	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Erosive duodenitis	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Functional gastrointestinal disorder	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Gastric haemorrhage	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Gastritis	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Gastritis	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Gastrooesophageal reflux disease	<65 years	270	50,3	2	0,7
Gastrointestinal disorders	Gastrooesophageal reflux disease	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders	Gingival pain	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Gingival pain	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Hyperchlorhydria	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Hyperchlorhydria	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders	Toothache	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Toothache	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions		<65 years	270	50,3	3	1,1
General disorders and administration site conditions		>=65 years	267	49,7	0	0,0
General disorders and administration site conditions	Chest discomfort	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Chest discomfort	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions	Pain	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Pain	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions	Pyrexia	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Pyrexia	>=65 years	267	49,7	0	0,0
Hepatobiliary disorders		<65 years	270	50,3	1	0,4
Hepatobiliary disorders		>=65 years	267	49,7	1	0,4
Hepatobiliary disorders	Cholelithiasis	<65 years	270	50,3	0	0,0

Hepatobiliary disorders	Cholelithiasis	>=65 years	267	49,7	1	0,4
Hepatobiliary disorders	Hepatic failure	<65 years	270	50,3	1	0,4
Hepatobiliary disorders	Hepatic failure	>=65 years	267	49,7	0	0,0
Immune system disorders		<65 years	270	50,3	0	0,0
Immune system disorders		>=65 years	267	49,7	3	1,1
Immune system disorders	Allergic oedema	<65 years	270	50,3	0	0,0
Immune system disorders	Allergic oedema	>=65 years	267	49,7	1	0,4
Immune system disorders	Hypersensitivity	<65 years	270	50,3	0	0,0
Immune system disorders	Hypersensitivity	>=65 years	267	49,7	1	0,4
Immune system disorders	Seasonal allergy	<65 years	270	50,3	0	0,0
Immune system disorders	Seasonal allergy	>=65 years	267	49,7	1	0,4
Infections and infestations		<65 years	270	50,3	19	7,0
Infections and infestations		>=65 years	267	49,7	22	8,2
Infections and infestations	Bronchitis	<65 years	270	50,3	2	0,7
Infections and infestations	Bronchitis	>=65 years	267	49,7	1	0,4
Infections and infestations	COVID-19	<65 years	270	50,3	2	0,7
Infections and infestations	COVID-19	>=65 years	267	49,7	6	2,2
Infections and infestations	Cellulitis	<65 years	270	50,3	0	0,0
Infections and infestations	Cellulitis	>=65 years	267	49,7	3	1,1
Infections and infestations	Cystitis	<65 years	270	50,3	1	0,4
Infections and infestations	Cystitis	>=65 years	267	49,7	0	0,0
Infections and infestations	Ear infection	<65 years	270	50,3	0	0,0
Infections and infestations	Ear infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Furuncle	<65 years	270	50,3	0	0,0
Infections and infestations	Furuncle	>=65 years	267	49,7	1	0,4
Infections and infestations	Gastroenteritis	<65 years	270	50,3	1	0,4
Infections and infestations	Gastroenteritis	>=65 years	267	49,7	1	0,4
Infections and infestations	Gastrointestinal infection	<65 years	270	50,3	1	0,4
Infections and infestations	Gastrointestinal infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Gingival abscess	<65 years	270	50,3	0	0,0
Infections and infestations	Gingival abscess	>=65 years	267	49,7	1	0,4
Infections and infestations	Herpes zoster	<65 years	270	50,3	1	0,4
Infections and infestations	Herpes zoster	>=65 years	267	49,7	0	0,0
Infections and infestations	Hordeolum	<65 years	270	50,3	0	0,0
Infections and infestations	Hordeolum	>=65 years	267	49,7	1	0,4
Infections and infestations	Influenza	<65 years	270	50,3	4	1,5
Infections and infestations	Influenza	>=65 years	267	49,7	1	0,4
Infections and infestations	Nasopharyngitis	<65 years	270	50,3	0	0,0
Infections and infestations	Nasopharyngitis	>=65 years	267	49,7	1	0,4
Infections and infestations	Otitis media	<65 years	270	50,3	0	0,0
Infections and infestations	Otitis media	>=65 years	267	49,7	1	0,4
Infections and infestations	Pneumonia	<65 years	270	50,3	1	0,4
Infections and infestations	Pneumonia	>=65 years	267	49,7	2	0,7
Infections and infestations	Post-acute COVID-19 syndrome	<65 years	270	50,3	1	0,4
Infections and infestations	Post-acute COVID-19 syndrome	>=65 years	267	49,7	0	0,0
Infections and infestations	Postoperative wound infection	<65 years	270	50,3	1	0,4
Infections and infestations	Postoperative wound infection	>=65 years	267	49,7	0	0,0
Infections and infestations	Pyelonephritis	<65 years	270	50,3	0	0,0
Infections and infestations	Pyelonephritis	>=65 years	267	49,7	1	0,4
Infections and infestations	Respiratory tract infection	<65 years	270	50,3	2	0,7
Infections and infestations	Respiratory tract infection	>=65 years	267	49,7	0	0,0
Infections and infestations	Rotavirus infection	<65 years	270	50,3	1	0,4
Infections and infestations	Rotavirus infection	>=65 years	267	49,7	0	0,0
Infections and infestations	Sinusitis	<65 years	270	50,3	0	0,0
Infections and infestations	Sinusitis	>=65 years	267	49,7	1	0,4
Infections and infestations	Suspected COVID-19	<65 years	270	50,3	1	0,4
Infections and infestations	Suspected COVID-19	>=65 years	267	49,7	0	0,0
Infections and infestations	Tooth infection	<65 years	270	50,3	0	0,0
Infections and infestations	Tooth infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Tracheitis	<65 years	270	50,3	1	0,4
Infections and infestations	Tracheitis	>=65 years	267	49,7	0	0,0
Infections and infestations	Upper respiratory tract infection	<65 years	270	50,3	3	1,1
Infections and infestations	Upper respiratory tract infection	>=65 years	267	49,7	2	0,7
Infections and infestations	Urinary tract infection	<65 years	270	50,3	0	0,0
Infections and infestations	Urinary tract infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Viral infection	<65 years	270	50,3	0	0,0

Infections and infestations	Viral infection	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications		<65 years	270	50,3	6	2,2
Injury, poisoning and procedural complications		>=65 years	267	49,7	8	3,0
Injury, poisoning and procedural complications	Back injury	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Back injury	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Burns third degree	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Burns third degree	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Facial bones fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Facial bones fracture	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Fall	<65 years	270	50,3	4	1,5
Injury, poisoning and procedural complications	Fall	>=65 years	267	49,7	3	1,1
Injury, poisoning and procedural complications	Femur fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Head injury	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Head injury	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Meniscus injury	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Meniscus injury	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Skin laceration	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Skin laceration	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Spinal column injury	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Spinal column injury	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Subdural haematoma	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Subdural haematoma	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Ulna fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Ulna fracture	>=65 years	267	49,7	0	0,0
Investigations		<65 years	270	50,3	3	1,1
Investigations		>=65 years	267	49,7	5	1,9
Investigations	Intraocular pressure increased	<65 years	270	50,3	2	0,7
Investigations	Intraocular pressure increased	>=65 years	267	49,7	3	1,1
Investigations	Platelet count increased	<65 years	270	50,3	1	0,4
Investigations	Platelet count increased	>=65 years	267	49,7	0	0,0
Investigations	SARS-CoV-2 test positive	<65 years	270	50,3	0	0,0
Investigations	SARS-CoV-2 test positive	>=65 years	267	49,7	1	0,4
Investigations	Troponin increased	<65 years	270	50,3	0	0,0
Investigations	Troponin increased	>=65 years	267	49,7	1	0,4
Metabolism and nutrition disorders		<65 years	270	50,3	2	0,7
Metabolism and nutrition disorders		>=65 years	267	49,7	2	0,7
Metabolism and nutrition disorders	Dehydration	<65 years	270	50,3	0	0,0
Metabolism and nutrition disorders	Dehydration	>=65 years	267	49,7	1	0,4
Metabolism and nutrition disorders	Gout	<65 years	270	50,3	2	0,7
Metabolism and nutrition disorders	Gout	>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	<65 years	270	50,3	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders		<65 years	270	50,3	6	2,2
Musculoskeletal and connective tissue disorders		>=65 years	267	49,7	11	4,1
Musculoskeletal and connective tissue disorders	Arthralgia	<65 years	270	50,3	1	0,4
Musculoskeletal and connective tissue disorders	Arthralgia	>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders	Arthritis	<65 years	270	50,3	1	0,4
Musculoskeletal and connective tissue disorders	Arthritis	>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders	Back pain	<65 years	270	50,3	1	0,4
Musculoskeletal and connective tissue disorders	Back pain	>=65 years	267	49,7	2	0,7
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	<65 years	270	50,3	1	0,4
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders	Joint swelling	<65 years	270	50,3	1	0,4
Musculoskeletal and connective tissue disorders	Joint swelling	>=65 years	267	49,7	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	<65 years	270	50,3	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders	Muscle spasms	<65 years	270	50,3	0	0,0
Musculoskeletal and connective tissue disorders	Muscle spasms	>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	<65 years	270	50,3	1	0,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders	Osteoporosis	<65 years	270	50,3	0	0,0

Musculoskeletal and connective tissue disorders	Osteoporosis	>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders	Plantar fasciitis	<65 years	270	50,3	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	<65 years	270	50,3	1	0,4
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders	Spinal pain	<65 years	270	50,3	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	>=65 years	267	49,7	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<65 years	270	50,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=65 years	267	49,7	2	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	<65 years	270	50,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	>=65 years	267	49,7	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	<65 years	270	50,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	>=65 years	267	49,7	1	0,4
Nervous system disorders		<65 years	270	50,3	6	2,2
Nervous system disorders		>=65 years	267	49,7	10	3,7
Nervous system disorders	Carotid artery stenosis	<65 years	270	50,3	0	0,0
Nervous system disorders	Carotid artery stenosis	>=65 years	267	49,7	1	0,4
Nervous system disorders	Cerebral infarction	<65 years	270	50,3	1	0,4
Nervous system disorders	Cerebral infarction	>=65 years	267	49,7	0	0,0
Nervous system disorders	Cerebrovascular accident	<65 years	270	50,3	0	0,0
Nervous system disorders	Cerebrovascular accident	>=65 years	267	49,7	2	0,7
Nervous system disorders	Cognitive disorder	<65 years	270	50,3	0	0,0
Nervous system disorders	Cognitive disorder	>=65 years	267	49,7	1	0,4
Nervous system disorders	Epilepsy	<65 years	270	50,3	0	0,0
Nervous system disorders	Epilepsy	>=65 years	267	49,7	1	0,4
Nervous system disorders	Headache	<65 years	270	50,3	2	0,7
Nervous system disorders	Headache	>=65 years	267	49,7	1	0,4
Nervous system disorders	Hypertensive encephalopathy	<65 years	270	50,3	1	0,4
Nervous system disorders	Hypertensive encephalopathy	>=65 years	267	49,7	0	0,0
Nervous system disorders	Memory impairment	<65 years	270	50,3	0	0,0
Nervous system disorders	Memory impairment	>=65 years	267	49,7	1	0,4
Nervous system disorders	Migraine	<65 years	270	50,3	1	0,4
Nervous system disorders	Migraine	>=65 years	267	49,7	0	0,0
Nervous system disorders	Myelopathy	<65 years	270	50,3	0	0,0
Nervous system disorders	Myelopathy	>=65 years	267	49,7	1	0,4
Nervous system disorders	Narcolepsy	<65 years	270	50,3	1	0,4
Nervous system disorders	Narcolepsy	>=65 years	267	49,7	0	0,0
Nervous system disorders	Presyncope	<65 years	270	50,3	1	0,4
Nervous system disorders	Presyncope	>=65 years	267	49,7	0	0,0
Nervous system disorders	Sciatica	<65 years	270	50,3	0	0,0
Nervous system disorders	Sciatica	>=65 years	267	49,7	1	0,4
Nervous system disorders	Sinus headache	<65 years	270	50,3	0	0,0
Nervous system disorders	Sinus headache	>=65 years	267	49,7	1	0,4
Product issues		<65 years	270	50,3	0	0,0
Product issues		>=65 years	267	49,7	1	0,4
Product issues	Device malfunction	<65 years	270	50,3	0	0,0
Product issues	Device malfunction	>=65 years	267	49,7	1	0,4
Psychiatric disorders		<65 years	270	50,3	1	0,4
Psychiatric disorders		>=65 years	267	49,7	0	0,0
Psychiatric disorders	Anxiety	<65 years	270	50,3	1	0,4
Psychiatric disorders	Anxiety	>=65 years	267	49,7	0	0,0
Renal and urinary disorders		<65 years	270	50,3	1	0,4
Renal and urinary disorders		>=65 years	267	49,7	2	0,7
Renal and urinary disorders	Chronic kidney disease	<65 years	270	50,3	1	0,4
Renal and urinary disorders	Chronic kidney disease	>=65 years	267	49,7	0	0,0
Renal and urinary disorders	Haematuria	<65 years	270	50,3	0	0,0
Renal and urinary disorders	Haematuria	>=65 years	267	49,7	1	0,4
Renal and urinary disorders	Nephrolithiasis	<65 years	270	50,3	0	0,0

Renal and urinary disorders	Nephrolithiasis	>=65 years	267	49,7	1	0,4
Reproductive system and breast disorders		<65 years	270	50,3	0	0,0
Reproductive system and breast disorders		>=65 years	267	49,7	2	0,7
Reproductive system and breast disorders	Erectile dysfunction	<65 years	270	50,3	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	>=65 years	267	49,7	1	0,4
Reproductive system and breast disorders	Prostatitis	<65 years	270	50,3	0	0,0
Reproductive system and breast disorders	Prostatitis	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders		<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders		>=65 years	267	49,7	5	1,9
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Pleural effusion	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	>=65 years	267	49,7	1	0,4
Skin and subcutaneous tissue disorders		<65 years	270	50,3	0	0,0
Skin and subcutaneous tissue disorders		>=65 years	267	49,7	1	0,4
Skin and subcutaneous tissue disorders	Pemphigoid	<65 years	270	50,3	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	>=65 years	267	49,7	1	0,4
Surgical and medical procedures		<65 years	270	50,3	0	0,0
Surgical and medical procedures		>=65 years	267	49,7	2	0,7
Surgical and medical procedures	Shoulder arthroplasty	<65 years	270	50,3	0	0,0
Surgical and medical procedures	Shoulder arthroplasty	>=65 years	267	49,7	1	0,4
Surgical and medical procedures	Transurethral prostatectomy	<65 years	270	50,3	0	0,0
Surgical and medical procedures	Transurethral prostatectomy	>=65 years	267	49,7	1	0,4
Vascular disorders		<65 years	270	50,3	9	3,3
Vascular disorders		>=65 years	267	49,7	5	1,9
Vascular disorders	Brachiocephalic arteriosclerosis	<65 years	270	50,3	1	0,4
Vascular disorders	Brachiocephalic arteriosclerosis	>=65 years	267	49,7	0	0,0
Vascular disorders	Hypertension	<65 years	270	50,3	6	2,2
Vascular disorders	Hypertension	>=65 years	267	49,7	2	0,7
Vascular disorders	Hypertensive crisis	<65 years	270	50,3	1	0,4
Vascular disorders	Hypertensive crisis	>=65 years	267	49,7	0	0,0
Vascular disorders	Hypotension	<65 years	270	50,3	0	0,0
Vascular disorders	Hypotension	>=65 years	267	49,7	1	0,4
Vascular disorders	Orthostatic hypotension	<65 years	270	50,3	0	0,0
Vascular disorders	Orthostatic hypotension	>=65 years	267	49,7	1	0,4
Vascular disorders	Varicose vein	<65 years	270	50,3	0	0,0
Vascular disorders	Varicose vein	>=65 years	267	49,7	1	0,4
Vascular disorders	Vascular occlusion	<65 years	270	50,3	1	0,4
Vascular disorders	Vascular occlusion	>=65 years	267	49,7	0	0,0
Vascular disorders	Venous occlusion	<65 years	270	50,3	1	0,4
Vascular disorders	Venous occlusion	>=65 years	267	49,7	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WM0DAE_WK72_SBa24_30AUG2023_41984.xls

26APR2024 17:51

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETDRS letter score

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		<=54 letters	176	32,8	4	2,3
Cardiac disorders		>=55 letters	361	67,2	1	0,3
Cardiac disorders	Angina pectoris	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Angina pectoris	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Angina unstable	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Angina unstable	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Arteriosclerosis coronary artery	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Arteriosclerosis coronary artery	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Atrial fibrillation	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Atrial fibrillation	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Cardiac failure	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Cardiac failure	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Myocardial fibrosis	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Myocardial fibrosis	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Myocardial infarction	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Myocardial infarction	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Pericarditis	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Pericarditis	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Supraventricular extrasystoles	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Supraventricular extrasystoles	>=55 letters	361	67,2	0	0,0
Congenital, familial and genetic disorders		<=54 letters	176	32,8	1	0,6
Congenital, familial and genetic disorders		>=55 letters	361	67,2	1	0,3
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	<=54 letters	176	32,8	1	0,6
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	>=55 letters	361	67,2	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	<=54 letters	176	32,8	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	>=55 letters	361	67,2	1	0,3
Ear and labyrinth disorders		<=54 letters	176	32,8	0	0,0
Ear and labyrinth disorders		>=55 letters	361	67,2	2	0,6
Ear and labyrinth disorders	Vertigo	<=54 letters	176	32,8	0	0,0
Ear and labyrinth disorders	Vertigo	>=55 letters	361	67,2	1	0,3
Ear and labyrinth disorders	Vertigo positional	<=54 letters	176	32,8	0	0,0
Ear and labyrinth disorders	Vertigo positional	>=55 letters	361	67,2	1	0,3
Eye disorders		<=54 letters	176	32,8	15	8,5
Eye disorders		>=55 letters	361	67,2	24	6,6
Eye disorders	Cataract	<=54 letters	176	32,8	3	1,7
Eye disorders	Cataract	>=55 letters	361	67,2	3	0,8
Eye disorders	Cataract subcapsular	<=54 letters	176	32,8	1	0,6
Eye disorders	Cataract subcapsular	>=55 letters	361	67,2	1	0,3
Eye disorders	Conjunctivitis allergic	<=54 letters	176	32,8	0	0,0
Eye disorders	Conjunctivitis allergic	>=55 letters	361	67,2	1	0,3
Eye disorders	Corneal infiltrates	<=54 letters	176	32,8	0	0,0
Eye disorders	Corneal infiltrates	>=55 letters	361	67,2	1	0,3

Eye disorders	Cystoid macular oedema	<=54 letters	176	32,8	0	0,0
Eye disorders	Cystoid macular oedema	>=55 letters	361	67,2	3	0,8
Eye disorders	Dry age-related macular degeneration	<=54 letters	176	32,8	1	0,6
Eye disorders	Dry age-related macular degeneration	>=55 letters	361	67,2	0	0,0
Eye disorders	Dry eye	<=54 letters	176	32,8	1	0,6
Eye disorders	Dry eye	>=55 letters	361	67,2	1	0,3
Eye disorders	Epiretinal membrane	<=54 letters	176	32,8	0	0,0
Eye disorders	Epiretinal membrane	>=55 letters	361	67,2	1	0,3
Eye disorders	Eye allergy	<=54 letters	176	32,8	1	0,6
Eye disorders	Eye allergy	>=55 letters	361	67,2	0	0,0
Eye disorders	Glaucoma	<=54 letters	176	32,8	1	0,6
Eye disorders	Glaucoma	>=55 letters	361	67,2	0	0,0
Eye disorders	Macular ischaemia	<=54 letters	176	32,8	0	0,0
Eye disorders	Macular ischaemia	>=55 letters	361	67,2	1	0,3
Eye disorders	Macular oedema	<=54 letters	176	32,8	1	0,6
Eye disorders	Macular oedema	>=55 letters	361	67,2	2	0,6
Eye disorders	Ocular hypertension	<=54 letters	176	32,8	1	0,6
Eye disorders	Ocular hypertension	>=55 letters	361	67,2	0	0,0
Eye disorders	Periorbital pain	<=54 letters	176	32,8	0	0,0
Eye disorders	Periorbital pain	>=55 letters	361	67,2	1	0,3
Eye disorders	Posterior capsule opacification	<=54 letters	176	32,8	0	0,0
Eye disorders	Posterior capsule opacification	>=55 letters	361	67,2	1	0,3
Eye disorders	Retinal aneurysm	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinal aneurysm	>=55 letters	361	67,2	0	0,0
Eye disorders	Retinal cyst	<=54 letters	176	32,8	0	0,0
Eye disorders	Retinal cyst	>=55 letters	361	67,2	1	0,3
Eye disorders	Retinal haemorrhage	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinal haemorrhage	>=55 letters	361	67,2	0	0,0
Eye disorders	Retinal ischaemia	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinal ischaemia	>=55 letters	361	67,2	1	0,3
Eye disorders	Retinal neovascularisation	<=54 letters	176	32,8	0	0,0
Eye disorders	Retinal neovascularisation	>=55 letters	361	67,2	1	0,3
Eye disorders	Retinal vein occlusion	<=54 letters	176	32,8	2	1,1
Eye disorders	Retinal vein occlusion	>=55 letters	361	67,2	3	0,8
Eye disorders	Retinopathy hypertensive	<=54 letters	176	32,8	1	0,6
Eye disorders	Retinopathy hypertensive	>=55 letters	361	67,2	0	0,0
Eye disorders	Swelling of eyelid	<=54 letters	176	32,8	0	0,0
Eye disorders	Swelling of eyelid	>=55 letters	361	67,2	1	0,3
Eye disorders	Tractional retinal detachment	<=54 letters	176	32,8	1	0,6
Eye disorders	Tractional retinal detachment	>=55 letters	361	67,2	0	0,0
Eye disorders	Vitreous detachment	<=54 letters	176	32,8	0	0,0
Eye disorders	Vitreous detachment	>=55 letters	361	67,2	2	0,6
Gastrointestinal disorders		<=54 letters	176	32,8	5	2,8
Gastrointestinal disorders		>=55 letters	361	67,2	5	1,4
Gastrointestinal disorders	Colitis	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Colitis	>=55 letters	361	67,2	0	0,0
Gastrointestinal disorders	Constipation	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Constipation	>=55 letters	361	67,2	0	0,0
Gastrointestinal disorders	Erosive duodenitis	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Erosive duodenitis	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Functional gastrointestinal disorder	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Gastric haemorrhage	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Gastric haemorrhage	>=55 letters	361	67,2	0	0,0
Gastrointestinal disorders	Gastritis	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Gastritis	>=55 letters	361	67,2	0	0,0

Gastrointestinal disorders	Gastroesophageal reflux disease	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Gastroesophageal reflux disease	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Gingival pain	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Gingival pain	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Hyperchlorhydria	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Hyperchlorhydria	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Toothache	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Toothache	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions		<=54 letters	176	32,8	1	0,6
General disorders and administration site conditions		>=55 letters	361	67,2	2	0,6
General disorders and administration site conditions	Chest discomfort	<=54 letters	176	32,8	1	0,6
General disorders and administration site conditions	Chest discomfort	>=55 letters	361	67,2	0	0,0
General disorders and administration site conditions	Pain	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Pain	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Pyrexia	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Pyrexia	>=55 letters	361	67,2	1	0,3
Hepatobiliary disorders		<=54 letters	176	32,8	2	1,1
Hepatobiliary disorders		>=55 letters	361	67,2	0	0,0
Hepatobiliary disorders	Cholelithiasis	<=54 letters	176	32,8	1	0,6
Hepatobiliary disorders	Cholelithiasis	>=55 letters	361	67,2	0	0,0
Hepatobiliary disorders	Hepatic failure	<=54 letters	176	32,8	1	0,6
Hepatobiliary disorders	Hepatic failure	>=55 letters	361	67,2	0	0,0
Immune system disorders		<=54 letters	176	32,8	2	1,1
Immune system disorders		>=55 letters	361	67,2	1	0,3
Immune system disorders	Allergic oedema	<=54 letters	176	32,8	0	0,0
Immune system disorders	Allergic oedema	>=55 letters	361	67,2	1	0,3
Immune system disorders	Hypersensitivity	<=54 letters	176	32,8	1	0,6
Immune system disorders	Hypersensitivity	>=55 letters	361	67,2	0	0,0
Immune system disorders	Seasonal allergy	<=54 letters	176	32,8	1	0,6
Immune system disorders	Seasonal allergy	>=55 letters	361	67,2	0	0,0
Infections and infestations		<=54 letters	176	32,8	10	5,7
Infections and infestations		>=55 letters	361	67,2	31	8,6
Infections and infestations	Bronchitis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Bronchitis	>=55 letters	361	67,2	3	0,8
Infections and infestations	COVID-19	<=54 letters	176	32,8	3	1,7
Infections and infestations	COVID-19	>=55 letters	361	67,2	5	1,4
Infections and infestations	Cellulitis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Cellulitis	>=55 letters	361	67,2	3	0,8
Infections and infestations	Cystitis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Cystitis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Ear infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Ear infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Furuncle	<=54 letters	176	32,8	1	0,6
Infections and infestations	Furuncle	>=55 letters	361	67,2	0	0,0
Infections and infestations	Gastroenteritis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Gastroenteritis	>=55 letters	361	67,2	2	0,6
Infections and infestations	Gastrointestinal infection	<=54 letters	176	32,8	1	0,6
Infections and infestations	Gastrointestinal infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Gingival abscess	<=54 letters	176	32,8	1	0,6
Infections and infestations	Gingival abscess	>=55 letters	361	67,2	0	0,0
Infections and infestations	Herpes zoster	<=54 letters	176	32,8	0	0,0
Infections and infestations	Herpes zoster	>=55 letters	361	67,2	1	0,3
Infections and infestations	Hordeolum	<=54 letters	176	32,8	0	0,0

Infections and infestations	Hordeolum	>=55 letters	361	67,2	1	0,3
Infections and infestations	Influenza	<=54 letters	176	32,8	2	1,1
Infections and infestations	Influenza	>=55 letters	361	67,2	3	0,8
Infections and infestations	Nasopharyngitis	<=54 letters	176	32,8	1	0,6
Infections and infestations	Nasopharyngitis	>=55 letters	361	67,2	0	0,0
Infections and infestations	Otitis media	<=54 letters	176	32,8	1	0,6
Infections and infestations	Otitis media	>=55 letters	361	67,2	0	0,0
Infections and infestations	Pneumonia	<=54 letters	176	32,8	1	0,6
Infections and infestations	Pneumonia	>=55 letters	361	67,2	2	0,6
Infections and infestations	Post-acute COVID-19 syndrome	<=54 letters	176	32,8	0	0,0
Infections and infestations	Post-acute COVID-19 syndrome	>=55 letters	361	67,2	1	0,3
Infections and infestations	Postoperative wound infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Postoperative wound infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Pyelonephritis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Pyelonephritis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Respiratory tract infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Respiratory tract infection	>=55 letters	361	67,2	2	0,6
Infections and infestations	Rotavirus infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Rotavirus infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Sinusitis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Sinusitis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Suspected COVID-19	<=54 letters	176	32,8	0	0,0
Infections and infestations	Suspected COVID-19	>=55 letters	361	67,2	1	0,3
Infections and infestations	Tooth infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Tooth infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Tracheitis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Tracheitis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Upper respiratory tract infection	<=54 letters	176	32,8	1	0,6
Infections and infestations	Upper respiratory tract infection	>=55 letters	361	67,2	4	1,1
Infections and infestations	Urinary tract infection	<=54 letters	176	32,8	0	0,0
Infections and infestations	Urinary tract infection	>=55 letters	361	67,2	1	0,3
Infections and infestations	Viral infection	<=54 letters	176	32,8	1	0,6
Infections and infestations	Viral infection	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications		<=54 letters	176	32,8	2	1,1
Injury, poisoning and procedural complications		>=55 letters	361	67,2	12	3,3
Injury, poisoning and procedural complications	Back injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Back injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Burns third degree	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Burns third degree	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Facial bones fracture	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Facial bones fracture	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Fall	<=54 letters	176	32,8	2	1,1
Injury, poisoning and procedural complications	Fall	>=55 letters	361	67,2	5	1,4
Injury, poisoning and procedural complications	Femur fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Head injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Head injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Meniscus injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Meniscus injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Skin laceration	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Skin laceration	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Spinal column injury	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Spinal column injury	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Subdural haematoma	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Tooth fracture	<=54 letters	176	32,8	0	0,0

Injury, poisoning and procedural complications	Tooth fracture	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Ulna fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	>=55 letters	361	67,2	1	0,3
Investigations		<=54 letters	176	32,8	1	0,6
Investigations		>=55 letters	361	67,2	7	1,9
Investigations	Intraocular pressure increased	<=54 letters	176	32,8	0	0,0
Investigations	Intraocular pressure increased	>=55 letters	361	67,2	5	1,4
Investigations	Platelet count increased	<=54 letters	176	32,8	0	0,0
Investigations	Platelet count increased	>=55 letters	361	67,2	1	0,3
Investigations	SARS-CoV-2 test positive	<=54 letters	176	32,8	1	0,6
Investigations	SARS-CoV-2 test positive	>=55 letters	361	67,2	0	0,0
Investigations	Troponin increased	<=54 letters	176	32,8	0	0,0
Investigations	Troponin increased	>=55 letters	361	67,2	1	0,3
Metabolism and nutrition disorders		<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders		>=55 letters	361	67,2	3	0,8
Metabolism and nutrition disorders	Dehydration	<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders	Dehydration	>=55 letters	361	67,2	0	0,0
Metabolism and nutrition disorders	Gout	<=54 letters	176	32,8	0	0,0
Metabolism and nutrition disorders	Gout	>=55 letters	361	67,2	2	0,6
Metabolism and nutrition disorders	Hyperglycaemia	<=54 letters	176	32,8	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders		<=54 letters	176	32,8	3	1,7
Musculoskeletal and connective tissue disorders		>=55 letters	361	67,2	14	3,9
Musculoskeletal and connective tissue disorders	Arthralgia	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	>=55 letters	361	67,2	2	0,6
Musculoskeletal and connective tissue disorders	Arthritis	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Arthritis	>=55 letters	361	67,2	2	0,6
Musculoskeletal and connective tissue disorders	Back pain	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Back pain	>=55 letters	361	67,2	2	0,6
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Joint swelling	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	>=55 letters	361	67,2	0	0,0
Musculoskeletal and connective tissue disorders	Muscle spasms	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Muscle spasms	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Osteoarthritis	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=55 letters	361	67,2	2	0,6
Musculoskeletal and connective tissue disorders	Osteoporosis	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Osteoporosis	>=55 letters	361	67,2	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	>=55 letters	361	67,2	2	0,6
Musculoskeletal and connective tissue disorders	Spinal pain	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	<=54 letters	176	32,8	0	0,0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	>=55 letters	361	67,2	0	0,0
Nervous system disorders		<=54 letters	176	32,8	9	5,1
Nervous system disorders		>=55 letters	361	67,2	7	1,9
Nervous system disorders	Carotid artery stenosis	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Carotid artery stenosis	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Cerebral infarction	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Cerebral infarction	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Cerebrovascular accident	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Cerebrovascular accident	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cognitive disorder	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cognitive disorder	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Epilepsy	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Epilepsy	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Headache	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Headache	>=55 letters	361	67,2	2	0,6
Nervous system disorders	Hypertensive encephalopathy	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Hypertensive encephalopathy	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Memory impairment	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Memory impairment	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Migraine	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Migraine	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Myelopathy	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Myelopathy	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Narcolepsy	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Narcolepsy	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Presyncope	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Presyncope	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Sciatica	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Sciatica	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Sinus headache	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Sinus headache	>=55 letters	361	67,2	0	0,0
Product issues		<=54 letters	176	32,8	0	0,0
Product issues		>=55 letters	361	67,2	1	0,3
Product issues	Device malfunction	<=54 letters	176	32,8	0	0,0
Product issues	Device malfunction	>=55 letters	361	67,2	1	0,3
Psychiatric disorders		<=54 letters	176	32,8	0	0,0
Psychiatric disorders		>=55 letters	361	67,2	1	0,3
Psychiatric disorders	Anxiety	<=54 letters	176	32,8	0	0,0
Psychiatric disorders	Anxiety	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders		<=54 letters	176	32,8	0	0,0
Renal and urinary disorders		>=55 letters	361	67,2	3	0,8
Renal and urinary disorders	Chronic kidney disease	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Chronic kidney disease	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders	Haematuria	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Haematuria	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders	Nephrolithiasis	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Nephrolithiasis	>=55 letters	361	67,2	1	0,3
Reproductive system and breast disorders		<=54 letters	176	32,8	0	0,0

Reproductive system and breast disorders		>=55 letters	361	67,2	2	0,6
Reproductive system and breast disorders	Erectile dysfunction	<=54 letters	176	32,8	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	>=55 letters	361	67,2	1	0,3
Reproductive system and breast disorders	Prostatitis	<=54 letters	176	32,8	0	0,0
Reproductive system and breast disorders	Prostatitis	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders		<=54 letters	176	32,8	2	1,1
Respiratory, thoracic and mediastinal disorders		>=55 letters	361	67,2	3	0,8
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Pleural effusion	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=55 letters	361	67,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	>=55 letters	361	67,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders		<=54 letters	176	32,8	0	0,0
Skin and subcutaneous tissue disorders		>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders	Pemphigoid	<=54 letters	176	32,8	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	>=55 letters	361	67,2	1	0,3
Surgical and medical procedures		<=54 letters	176	32,8	1	0,6
Surgical and medical procedures		>=55 letters	361	67,2	1	0,3
Surgical and medical procedures	Shoulder arthroplasty	<=54 letters	176	32,8	0	0,0
Surgical and medical procedures	Shoulder arthroplasty	>=55 letters	361	67,2	1	0,3
Surgical and medical procedures	Transurethral prostatectomy	<=54 letters	176	32,8	1	0,6
Surgical and medical procedures	Transurethral prostatectomy	>=55 letters	361	67,2	0	0,0
Vascular disorders		<=54 letters	176	32,8	6	3,4
Vascular disorders		>=55 letters	361	67,2	8	2,2
Vascular disorders	Brachiocephalic arteriosclerosis	<=54 letters	176	32,8	1	0,6
Vascular disorders	Brachiocephalic arteriosclerosis	>=55 letters	361	67,2	0	0,0
Vascular disorders	Hypertension	<=54 letters	176	32,8	2	1,1
Vascular disorders	Hypertension	>=55 letters	361	67,2	6	1,7
Vascular disorders	Hypertensive crisis	<=54 letters	176	32,8	1	0,6
Vascular disorders	Hypertensive crisis	>=55 letters	361	67,2	0	0,0
Vascular disorders	Hypotension	<=54 letters	176	32,8	1	0,6
Vascular disorders	Hypotension	>=55 letters	361	67,2	0	0,0
Vascular disorders	Orthostatic hypotension	<=54 letters	176	32,8	0	0,0
Vascular disorders	Orthostatic hypotension	>=55 letters	361	67,2	1	0,3
Vascular disorders	Varicose vein	<=54 letters	176	32,8	1	0,6
Vascular disorders	Varicose vein	>=55 letters	361	67,2	0	0,0
Vascular disorders	Vascular occlusion	<=54 letters	176	32,8	0	0,0
Vascular disorders	Vascular occlusion	>=55 letters	361	67,2	1	0,3
Vascular disorders	Venous occlusion	<=54 letters	176	32,8	0	0,0
Vascular disorders	Venous occlusion	>=55 letters	361	67,2	1	0,3

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WM0DAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 17:51

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Geographic Region

			Faricimab (N=537)				
			Patients		Patients with Event		
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	
Cardiac disorders		Europe	147	27,4	4	2,7	
Cardiac disorders		America	197	36,7	0	0,0	
Cardiac disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5	
Cardiac disorders	Angina pectoris	Europe	147	27,4	1	0,7	
Cardiac disorders	Angina pectoris	America	197	36,7	0	0,0	
Cardiac disorders	Angina pectoris	Asia Pacific (inc. Australia)	193	35,9	0	0,0	
Cardiac disorders	Angina unstable	Europe	147	27,4	1	0,7	
Cardiac disorders	Angina unstable	America	197	36,7	0	0,0	
Cardiac disorders	Angina unstable	Asia Pacific (inc. Australia)	193	35,9	0	0,0	
Cardiac disorders	Arteriosclerosis coronary artery	Europe	147	27,4	0	0,0	
Cardiac disorders	Arteriosclerosis coronary artery	America	197	36,7	0	0,0	
Cardiac disorders	Arteriosclerosis coronary artery	Asia Pacific (inc. Australia)	193	35,9	1	0,5	
Cardiac disorders	Atrial fibrillation	Europe	147	27,4	1	0,7	
Cardiac disorders	Atrial fibrillation	America	197	36,7	0	0,0	
Cardiac disorders	Atrial fibrillation	Asia Pacific (inc. Australia)	193	35,9	0	0,0	
Cardiac disorders	Cardiac failure	Europe	147	27,4	1	0,7	
Cardiac disorders	Cardiac failure	America	197	36,7	0	0,0	
Cardiac disorders	Cardiac failure	Asia Pacific (inc. Australia)	193	35,9	0	0,0	
Cardiac disorders	Myocardial fibrosis	Europe	147	27,4	1	0,7	
Cardiac disorders	Myocardial fibrosis	America	197	36,7	0	0,0	
Cardiac disorders	Myocardial fibrosis	Asia Pacific (inc. Australia)	193	35,9	0	0,0	
Cardiac disorders	Myocardial infarction	Europe	147	27,4	1	0,7	
Cardiac disorders	Myocardial infarction	America	197	36,7	0	0,0	
Cardiac disorders	Myocardial infarction	Asia Pacific (inc. Australia)	193	35,9	0	0,0	
Cardiac disorders	Pericarditis	Europe	147	27,4	0	0,0	
Cardiac disorders	Pericarditis	America	197	36,7	0	0,0	
Cardiac disorders	Pericarditis	Asia Pacific (inc. Australia)	193	35,9	1	0,5	
Cardiac disorders	Supraventricular extrasystoles	Europe	147	27,4	1	0,7	
Cardiac disorders	Supraventricular extrasystoles	America	197	36,7	0	0,0	
Cardiac disorders	Supraventricular extrasystoles	Asia Pacific (inc. Australia)	193	35,9	0	0,0	
Congenital, familial and genetic disorders		Europe	147	27,4	2	1,4	
Congenital, familial and genetic disorders		America	197	36,7	0	0,0	
Congenital, familial and genetic disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0	
Congenital, familial and genetic disorders		Congenital cardiovascular anomaly	Europe	147	27,4	1	0,7
Congenital, familial and genetic disorders		Congenital cardiovascular anomaly	America	197	36,7	0	0,0
Congenital, familial and genetic disorders		Congenital cardiovascular anomaly	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Congenital, familial and genetic disorders		Vertebral artery hypoplasia	Europe	147	27,4	1	0,7
Congenital, familial and genetic disorders		Vertebral artery hypoplasia	America	197	36,7	0	0,0
Congenital, familial and genetic disorders		Vertebral artery hypoplasia	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Ear and labyrinth disorders		Europe	147	27,4	1	0,7	
Ear and labyrinth disorders		America	197	36,7	1	0,5	
Ear and labyrinth disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0	
Ear and labyrinth disorders		Vertigo	Europe	147	27,4	1	0,7
Ear and labyrinth disorders		Vertigo	America	197	36,7	0	0,0
Ear and labyrinth disorders		Vertigo	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Ear and labyrinth disorders		Vertigo positional	Europe	147	27,4	0	0,0
Ear and labyrinth disorders		Vertigo positional	America	197	36,7	1	0,5
Ear and labyrinth disorders		Vertigo positional	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders		Europe	147	27,4	19	12,9	
Eye disorders		America	197	36,7	13	6,6	

Eye disorders		Asia Pacific (inc. Australia)	193	35,9	7	3,6
Eye disorders	Cataract	Europe	147	27,4	3	2,0
Eye disorders	Cataract	America	197	36,7	2	1,0
Eye disorders	Cataract	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Cataract subcapsular	Europe	147	27,4	1	0,7
Eye disorders	Cataract subcapsular	America	197	36,7	1	0,5
Eye disorders	Cataract subcapsular	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Conjunctivitis allergic	Europe	147	27,4	0	0,0
Eye disorders	Conjunctivitis allergic	America	197	36,7	0	0,0
Eye disorders	Conjunctivitis allergic	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Corneal infiltrates	Europe	147	27,4	1	0,7
Eye disorders	Corneal infiltrates	America	197	36,7	0	0,0
Eye disorders	Corneal infiltrates	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Cystoid macular oedema	Europe	147	27,4	3	2,0
Eye disorders	Cystoid macular oedema	America	197	36,7	0	0,0
Eye disorders	Cystoid macular oedema	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Dry age-related macular degeneration	Europe	147	27,4	0	0,0
Eye disorders	Dry age-related macular degeneration	America	197	36,7	1	0,5
Eye disorders	Dry age-related macular degeneration	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Dry eye	Europe	147	27,4	1	0,7
Eye disorders	Dry eye	America	197	36,7	1	0,5
Eye disorders	Dry eye	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Epi-retinal membrane	Europe	147	27,4	0	0,0
Eye disorders	Epi-retinal membrane	America	197	36,7	0	0,0
Eye disorders	Epi-retinal membrane	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Eye allergy	Europe	147	27,4	0	0,0
Eye disorders	Eye allergy	America	197	36,7	1	0,5
Eye disorders	Eye allergy	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Glaucoma	Europe	147	27,4	1	0,7
Eye disorders	Glaucoma	America	197	36,7	0	0,0
Eye disorders	Glaucoma	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Macular ischaemia	Europe	147	27,4	0	0,0
Eye disorders	Macular ischaemia	America	197	36,7	0	0,0
Eye disorders	Macular ischaemia	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Macular oedema	Europe	147	27,4	0	0,0
Eye disorders	Macular oedema	America	197	36,7	2	1,0
Eye disorders	Macular oedema	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Ocular hypertension	Europe	147	27,4	1	0,7
Eye disorders	Ocular hypertension	America	197	36,7	0	0,0
Eye disorders	Ocular hypertension	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Periorbital pain	Europe	147	27,4	1	0,7
Eye disorders	Periorbital pain	America	197	36,7	0	0,0
Eye disorders	Periorbital pain	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Posterior capsule opacification	Europe	147	27,4	0	0,0
Eye disorders	Posterior capsule opacification	America	197	36,7	0	0,0
Eye disorders	Posterior capsule opacification	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Retinal aneurysm	Europe	147	27,4	0	0,0
Eye disorders	Retinal aneurysm	America	197	36,7	1	0,5
Eye disorders	Retinal aneurysm	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Retinal cyst	Europe	147	27,4	1	0,7
Eye disorders	Retinal cyst	America	197	36,7	0	0,0
Eye disorders	Retinal cyst	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Retinal haemorrhage	Europe	147	27,4	1	0,7
Eye disorders	Retinal haemorrhage	America	197	36,7	0	0,0
Eye disorders	Retinal haemorrhage	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Retinal ischaemia	Europe	147	27,4	2	1,4
Eye disorders	Retinal ischaemia	America	197	36,7	0	0,0
Eye disorders	Retinal ischaemia	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Retinal neovascularisation	Europe	147	27,4	0	0,0
Eye disorders	Retinal neovascularisation	America	197	36,7	1	0,5
Eye disorders	Retinal neovascularisation	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Retinal vein occlusion	Europe	147	27,4	4	2,7
Eye disorders	Retinal vein occlusion	America	197	36,7	1	0,5
Eye disorders	Retinal vein occlusion	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Retinopathy hypertensive	Europe	147	27,4	0	0,0
Eye disorders	Retinopathy hypertensive	America	197	36,7	0	0,0

Eye disorders	Retinopathy hypertensive	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Swelling of eyelid	Europe	147	27,4	1	0,7
Eye disorders	Swelling of eyelid	America	197	36,7	0	0,0
Eye disorders	Swelling of eyelid	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Tractional retinal detachment	Europe	147	27,4	0	0,0
Eye disorders	Tractional retinal detachment	America	197	36,7	0	0,0
Eye disorders	Tractional retinal detachment	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Vitreous detachment	Europe	147	27,4	0	0,0
Eye disorders	Vitreous detachment	America	197	36,7	2	1,0
Eye disorders	Vitreous detachment	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders		Europe	147	27,4	7	4,8
Gastrointestinal disorders		America	197	36,7	3	1,5
Gastrointestinal disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Colitis	Europe	147	27,4	0	0,0
Gastrointestinal disorders	Colitis	America	197	36,7	1	0,5
Gastrointestinal disorders	Colitis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Constipation	Europe	147	27,4	0	0,0
Gastrointestinal disorders	Constipation	America	197	36,7	1	0,5
Gastrointestinal disorders	Constipation	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Erosive duodenitis	Europe	147	27,4	1	0,7
Gastrointestinal disorders	Erosive duodenitis	America	197	36,7	0	0,0
Gastrointestinal disorders	Erosive duodenitis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	Europe	147	27,4	1	0,7
Gastrointestinal disorders	Functional gastrointestinal disorder	America	197	36,7	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Europe	147	27,4	1	0,7
Gastrointestinal disorders	Gastric haemorrhage	America	197	36,7	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Gastritis	Europe	147	27,4	1	0,7
Gastrointestinal disorders	Gastritis	America	197	36,7	0	0,0
Gastrointestinal disorders	Gastritis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Gastroesophageal reflux disease	Europe	147	27,4	2	1,4
Gastrointestinal disorders	Gastroesophageal reflux disease	America	197	36,7	0	0,0
Gastrointestinal disorders	Gastroesophageal reflux disease	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Gingival pain	Europe	147	27,4	0	0,0
Gastrointestinal disorders	Gingival pain	America	197	36,7	1	0,5
Gastrointestinal disorders	Gingival pain	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Hyperchlorhydria	Europe	147	27,4	1	0,7
Gastrointestinal disorders	Hyperchlorhydria	America	197	36,7	0	0,0
Gastrointestinal disorders	Hyperchlorhydria	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Toothache	Europe	147	27,4	1	0,7
Gastrointestinal disorders	Toothache	America	197	36,7	0	0,0
Gastrointestinal disorders	Toothache	Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions		Europe	147	27,4	2	1,4
General disorders and administration site conditions		America	197	36,7	0	0,0
General disorders and administration site conditions		Asia Pacific (inc. Australia)	193	35,9	1	0,5
General disorders and administration site conditions	Chest discomfort	Europe	147	27,4	1	0,7
General disorders and administration site conditions	Chest discomfort	America	197	36,7	0	0,0
General disorders and administration site conditions	Chest discomfort	Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions	Pain	Europe	147	27,4	1	0,7
General disorders and administration site conditions	Pain	America	197	36,7	0	0,0
General disorders and administration site conditions	Pain	Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions	Pyrexia	Europe	147	27,4	0	0,0
General disorders and administration site conditions	Pyrexia	America	197	36,7	0	0,0
General disorders and administration site conditions	Pyrexia	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Hepatobiliary disorders		Europe	147	27,4	1	0,7
Hepatobiliary disorders		America	197	36,7	1	0,5
Hepatobiliary disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Hepatobiliary disorders	Cholelithiasis	Europe	147	27,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	America	197	36,7	1	0,5
Hepatobiliary disorders	Cholelithiasis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Hepatobiliary disorders	Hepatic failure	Europe	147	27,4	1	0,7
Hepatobiliary disorders	Hepatic failure	America	197	36,7	0	0,0

Hepatobiliary disorders	Hepatic failure	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Immune system disorders		Europe	147	27,4	1	0,7
Immune system disorders		America	197	36,7	2	1,0
Immune system disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Immune system disorders	Allergic oedema	Europe	147	27,4	1	0,7
Immune system disorders	Allergic oedema	America	197	36,7	0	0,0
Immune system disorders	Allergic oedema	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Immune system disorders	Hypersensitivity	Europe	147	27,4	0	0,0
Immune system disorders	Hypersensitivity	America	197	36,7	1	0,5
Immune system disorders	Hypersensitivity	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Immune system disorders	Seasonal allergy	Europe	147	27,4	0	0,0
Immune system disorders	Seasonal allergy	America	197	36,7	1	0,5
Immune system disorders	Seasonal allergy	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations		Europe	147	27,4	16	10,9
Infections and infestations		America	197	36,7	16	8,1
Infections and infestations		Asia Pacific (inc. Australia)	193	35,9	9	4,7
Infections and infestations	Bronchitis	Europe	147	27,4	2	1,4
Infections and infestations	Bronchitis	America	197	36,7	0	0,0
Infections and infestations	Bronchitis	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	COVID-19	Europe	147	27,4	2	1,4
Infections and infestations	COVID-19	America	197	36,7	3	1,5
Infections and infestations	COVID-19	Asia Pacific (inc. Australia)	193	35,9	3	1,6
Infections and infestations	Cellulitis	Europe	147	27,4	0	0,0
Infections and infestations	Cellulitis	America	197	36,7	3	1,5
Infections and infestations	Cellulitis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Cystitis	Europe	147	27,4	0	0,0
Infections and infestations	Cystitis	America	197	36,7	1	0,5
Infections and infestations	Cystitis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Ear infection	Europe	147	27,4	0	0,0
Infections and infestations	Ear infection	America	197	36,7	1	0,5
Infections and infestations	Ear infection	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Furuncle	Europe	147	27,4	1	0,7
Infections and infestations	Furuncle	America	197	36,7	0	0,0
Infections and infestations	Furuncle	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Gastroenteritis	Europe	147	27,4	0	0,0
Infections and infestations	Gastroenteritis	America	197	36,7	1	0,5
Infections and infestations	Gastroenteritis	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Gastrointestinal infection	Europe	147	27,4	1	0,7
Infections and infestations	Gastrointestinal infection	America	197	36,7	1	0,5
Infections and infestations	Gastrointestinal infection	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Gingival abscess	Europe	147	27,4	1	0,7
Infections and infestations	Gingival abscess	America	197	36,7	0	0,0
Infections and infestations	Gingival abscess	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Herpes zoster	Europe	147	27,4	0	0,0
Infections and infestations	Herpes zoster	America	197	36,7	0	0,0
Infections and infestations	Herpes zoster	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Hordeolum	Europe	147	27,4	1	0,7
Infections and infestations	Hordeolum	America	197	36,7	0	0,0
Infections and infestations	Hordeolum	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Influenza	Europe	147	27,4	1	0,7
Infections and infestations	Influenza	America	197	36,7	3	1,5
Infections and infestations	Influenza	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Nasopharyngitis	Europe	147	27,4	0	0,0
Infections and infestations	Nasopharyngitis	America	197	36,7	1	0,5
Infections and infestations	Nasopharyngitis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Otitis media	Europe	147	27,4	1	0,7
Infections and infestations	Otitis media	America	197	36,7	0	0,0
Infections and infestations	Otitis media	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Pneumonia	Europe	147	27,4	1	0,7
Infections and infestations	Pneumonia	America	197	36,7	2	1,0
Infections and infestations	Pneumonia	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Post-acute COVID-19 syndrome	Europe	147	27,4	0	0,0
Infections and infestations	Post-acute COVID-19 syndrome	America	197	36,7	1	0,5
Infections and infestations	Post-acute COVID-19 syndrome	Asia Pacific (inc. Australia)	193	35,9	0	0,0

Infections and infestations	Postoperative wound infection	Europe	147	27,4	1	0,7
Infections and infestations	Postoperative wound infection	America	197	36,7	0	0,0
Infections and infestations	Postoperative wound infection	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Pyelonephritis	Europe	147	27,4	0	0,0
Infections and infestations	Pyelonephritis	America	197	36,7	0	0,0
Infections and infestations	Pyelonephritis	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Respiratory tract infection	Europe	147	27,4	2	1,4
Infections and infestations	Respiratory tract infection	America	197	36,7	0	0,0
Infections and infestations	Respiratory tract infection	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Rotavirus infection	Europe	147	27,4	1	0,7
Infections and infestations	Rotavirus infection	America	197	36,7	0	0,0
Infections and infestations	Rotavirus infection	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Sinusitis	Europe	147	27,4	0	0,0
Infections and infestations	Sinusitis	America	197	36,7	1	0,5
Infections and infestations	Sinusitis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Suspected COVID-19	Europe	147	27,4	0	0,0
Infections and infestations	Suspected COVID-19	America	197	36,7	0	0,0
Infections and infestations	Suspected COVID-19	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Tooth infection	Europe	147	27,4	0	0,0
Infections and infestations	Tooth infection	America	197	36,7	1	0,5
Infections and infestations	Tooth infection	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Tracheitis	Europe	147	27,4	1	0,7
Infections and infestations	Tracheitis	America	197	36,7	0	0,0
Infections and infestations	Tracheitis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Upper respiratory tract infection	Europe	147	27,4	3	2,0
Infections and infestations	Upper respiratory tract infection	America	197	36,7	2	1,0
Infections and infestations	Upper respiratory tract infection	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Urinary tract infection	Europe	147	27,4	0	0,0
Infections and infestations	Urinary tract infection	America	197	36,7	1	0,5
Infections and infestations	Urinary tract infection	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Viral infection	Europe	147	27,4	1	0,7
Infections and infestations	Viral infection	America	197	36,7	0	0,0
Infections and infestations	Viral infection	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications		Europe	147	27,4	7	4,8
Injury, poisoning and procedural complications		America	197	36,7	6	3,0
Injury, poisoning and procedural complications		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Injury, poisoning and procedural complications	Back injury	Europe	147	27,4	0	0,0
Injury, poisoning and procedural complications	Back injury	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Back injury	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Injury, poisoning and procedural complications	Burns third degree	Europe	147	27,4	0	0,0
Injury, poisoning and procedural complications	Burns third degree	America	197	36,7	1	0,5
Injury, poisoning and procedural complications	Burns third degree	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Facial bones fracture	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Facial bones fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Facial bones fracture	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Fall	Europe	147	27,4	4	2,7
Injury, poisoning and procedural complications	Fall	America	197	36,7	3	1,5
Injury, poisoning and procedural complications	Fall	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Femur fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Head injury	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Head injury	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Head injury	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Meniscus injury	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Meniscus injury	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Meniscus injury	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Skin laceration	America	197	36,7	1	0,5
Injury, poisoning and procedural complications	Skin laceration	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Spinal column injury	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Spinal column injury	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Spinal column injury	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Subdural haematoma	America	197	36,7	0	0,0

Injury, poisoning and procedural complications	Subdural haematoma	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Europe	147	27,4	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	America	197	36,7	1	0,5
Injury, poisoning and procedural complications	Tooth fracture	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Ulna fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Investigations		Europe	147	27,4	5	3,4
Investigations		America	197	36,7	2	1,0
Investigations		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Investigations	Intraocular pressure increased	Europe	147	27,4	4	2,7
Investigations	Intraocular pressure increased	America	197	36,7	1	0,5
Investigations	Intraocular pressure increased	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Investigations	Platelet count increased	Europe	147	27,4	1	0,7
Investigations	Platelet count increased	America	197	36,7	0	0,0
Investigations	Platelet count increased	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Investigations	SARS-CoV-2 test positive	Europe	147	27,4	0	0,0
Investigations	SARS-CoV-2 test positive	America	197	36,7	0	0,0
Investigations	SARS-CoV-2 test positive	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Investigations	Troponin increased	Europe	147	27,4	0	0,0
Investigations	Troponin increased	America	197	36,7	1	0,5
Investigations	Troponin increased	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Metabolism and nutrition disorders		Europe	147	27,4	2	1,4
Metabolism and nutrition disorders		America	197	36,7	2	1,0
Metabolism and nutrition disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Metabolism and nutrition disorders	Dehydration	Europe	147	27,4	0	0,0
Metabolism and nutrition disorders	Dehydration	America	197	36,7	1	0,5
Metabolism and nutrition disorders	Dehydration	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Metabolism and nutrition disorders	Gout	Europe	147	27,4	1	0,7
Metabolism and nutrition disorders	Gout	America	197	36,7	1	0,5
Metabolism and nutrition disorders	Gout	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Europe	147	27,4	1	0,7
Metabolism and nutrition disorders	Hyperglycaemia	America	197	36,7	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Musculoskeletal and connective tissue disorders		Europe	147	27,4	7	4,8
Musculoskeletal and connective tissue disorders		America	197	36,7	7	3,6
Musculoskeletal and connective tissue disorders		Asia Pacific (inc. Australia)	193	35,9	3	1,6
Musculoskeletal and connective tissue disorders	Arthralgia	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Arthralgia	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Musculoskeletal and connective tissue disorders	Arthritis	Europe	147	27,4	0	0,0
Musculoskeletal and connective tissue disorders	Arthritis	America	197	36,7	2	1,0
Musculoskeletal and connective tissue disorders	Arthritis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Back pain	America	197	36,7	1	0,5
Musculoskeletal and connective tissue disorders	Back pain	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Musculoskeletal and connective tissue disorders	Joint swelling	Europe	147	27,4	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	America	197	36,7	1	0,5
Musculoskeletal and connective tissue disorders	Joint swelling	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Europe	147	27,4	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Musculoskeletal and connective tissue disorders	Muscle spasms	Europe	147	27,4	0	0,0
Musculoskeletal and connective tissue disorders	Muscle spasms	America	197	36,7	1	0,5
Musculoskeletal and connective tissue disorders	Muscle spasms	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Osteoarthritis	America	197	36,7	1	0,5
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Musculoskeletal and connective tissue disorders	Osteoporosis	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Osteoporosis	America	197	36,7	0	0,0

Musculoskeletal and connective tissue disorders	Osteoporosis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Plantar fasciitis	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	America	197	36,7	1	0,5
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Spinal pain	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Europe	147	27,4	1	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		America	197	36,7	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Europe	147	27,4	1	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	America	197	36,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Europe	147	27,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	America	197	36,7	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders		Europe	147	27,4	8	5,4
Nervous system disorders		America	197	36,7	7	3,6
Nervous system disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Carotid artery stenosis	Europe	147	27,4	0	0,0
Nervous system disorders	Carotid artery stenosis	America	197	36,7	1	0,5
Nervous system disorders	Carotid artery stenosis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Cerebral infarction	Europe	147	27,4	0	0,0
Nervous system disorders	Cerebral infarction	America	197	36,7	0	0,0
Nervous system disorders	Cerebral infarction	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Cerebrovascular accident	Europe	147	27,4	1	0,7
Nervous system disorders	Cerebrovascular accident	America	197	36,7	1	0,5
Nervous system disorders	Cerebrovascular accident	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Cognitive disorder	Europe	147	27,4	0	0,0
Nervous system disorders	Cognitive disorder	America	197	36,7	1	0,5
Nervous system disorders	Cognitive disorder	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Epilepsy	Europe	147	27,4	0	0,0
Nervous system disorders	Epilepsy	America	197	36,7	1	0,5
Nervous system disorders	Epilepsy	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Headache	Europe	147	27,4	2	1,4
Nervous system disorders	Headache	America	197	36,7	0	0,0
Nervous system disorders	Headache	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Hypertensive encephalopathy	Europe	147	27,4	1	0,7
Nervous system disorders	Hypertensive encephalopathy	America	197	36,7	0	0,0
Nervous system disorders	Hypertensive encephalopathy	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Memory impairment	Europe	147	27,4	0	0,0
Nervous system disorders	Memory impairment	America	197	36,7	1	0,5
Nervous system disorders	Memory impairment	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Migraine	Europe	147	27,4	1	0,7
Nervous system disorders	Migraine	America	197	36,7	0	0,0
Nervous system disorders	Migraine	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Myelopathy	Europe	147	27,4	1	0,7
Nervous system disorders	Myelopathy	America	197	36,7	0	0,0
Nervous system disorders	Myelopathy	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Narcolepsy	Europe	147	27,4	0	0,0
Nervous system disorders	Narcolepsy	America	197	36,7	1	0,5
Nervous system disorders	Narcolepsy	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Presyncope	Europe	147	27,4	1	0,7

Nervous system disorders	Presyncope	America	197	36,7	0	0,0
Nervous system disorders	Presyncope	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Sciatica	Europe	147	27,4	1	0,7
Nervous system disorders	Sciatica	America	197	36,7	0	0,0
Nervous system disorders	Sciatica	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Sinus headache	Europe	147	27,4	0	0,0
Nervous system disorders	Sinus headache	America	197	36,7	1	0,5
Nervous system disorders	Sinus headache	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Product issues		Europe	147	27,4	0	0,0
Product issues		America	197	36,7	1	0,5
Product issues		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Product issues	Device malfunction	Europe	147	27,4	0	0,0
Product issues	Device malfunction	America	197	36,7	1	0,5
Product issues	Device malfunction	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Psychiatric disorders		Europe	147	27,4	0	0,0
Psychiatric disorders		America	197	36,7	0	0,0
Psychiatric disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Psychiatric disorders	Anxiety	Europe	147	27,4	0	0,0
Psychiatric disorders	Anxiety	America	197	36,7	0	0,0
Psychiatric disorders	Anxiety	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Renal and urinary disorders		Europe	147	27,4	0	0,0
Renal and urinary disorders		America	197	36,7	3	1,5
Renal and urinary disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Renal and urinary disorders	Chronic kidney disease	Europe	147	27,4	0	0,0
Renal and urinary disorders	Chronic kidney disease	America	197	36,7	1	0,5
Renal and urinary disorders	Chronic kidney disease	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Renal and urinary disorders	Haematuria	Europe	147	27,4	0	0,0
Renal and urinary disorders	Haematuria	America	197	36,7	1	0,5
Renal and urinary disorders	Haematuria	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Renal and urinary disorders	Nephrolithiasis	Europe	147	27,4	0	0,0
Renal and urinary disorders	Nephrolithiasis	America	197	36,7	1	0,5
Renal and urinary disorders	Nephrolithiasis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Reproductive system and breast disorders		Europe	147	27,4	2	1,4
Reproductive system and breast disorders		America	197	36,7	0	0,0
Reproductive system and breast disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	Europe	147	27,4	1	0,7
Reproductive system and breast disorders	Erectile dysfunction	America	197	36,7	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Reproductive system and breast disorders	Prostatitis	Europe	147	27,4	1	0,7
Reproductive system and breast disorders	Prostatitis	America	197	36,7	0	0,0
Reproductive system and breast disorders	Prostatitis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Respiratory, thoracic and mediastinal disorders		Europe	147	27,4	4	2,7
Respiratory, thoracic and mediastinal disorders		America	197	36,7	1	0,5
Respiratory, thoracic and mediastinal disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Europe	147	27,4	1	0,7
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	America	197	36,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Europe	147	27,4	1	0,7
Respiratory, thoracic and mediastinal disorders	Pleural effusion	America	197	36,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Europe	147	27,4	1	0,7
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	America	197	36,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Europe	147	27,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	America	197	36,7	1	0,5
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Europe	147	27,4	1	0,7
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	America	197	36,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Skin and subcutaneous tissue disorders		Europe	147	27,4	0	0,0

Skin and subcutaneous tissue disorders		America	197	36,7	1	0,5
Skin and subcutaneous tissue disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	Europe	147	27,4	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	America	197	36,7	1	0,5
Skin and subcutaneous tissue disorders	Pemphigoid	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Surgical and medical procedures		Europe	147	27,4	0	0,0
Surgical and medical procedures		America	197	36,7	1	0,5
Surgical and medical procedures		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Surgical and medical procedures	Shoulder arthroplasty	Europe	147	27,4	0	0,0
Surgical and medical procedures	Shoulder arthroplasty	America	197	36,7	0	0,0
Surgical and medical procedures	Shoulder arthroplasty	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Surgical and medical procedures	Transurethral prostatectomy	Europe	147	27,4	0	0,0
Surgical and medical procedures	Transurethral prostatectomy	America	197	36,7	1	0,5
Surgical and medical procedures	Transurethral prostatectomy	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Vascular disorders		Europe	147	27,4	10	6,8
Vascular disorders		America	197	36,7	4	2,0
Vascular disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Vascular disorders	Brachiocephalic arteriosclerosis	Europe	147	27,4	1	0,7
Vascular disorders	Brachiocephalic arteriosclerosis	America	197	36,7	0	0,0
Vascular disorders	Brachiocephalic arteriosclerosis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Vascular disorders	Hypertension	Europe	147	27,4	6	4,1
Vascular disorders	Hypertension	America	197	36,7	2	1,0
Vascular disorders	Hypertension	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Vascular disorders	Hypertensive crisis	Europe	147	27,4	1	0,7
Vascular disorders	Hypertensive crisis	America	197	36,7	0	0,0
Vascular disorders	Hypertensive crisis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Vascular disorders	Hypotension	Europe	147	27,4	0	0,0
Vascular disorders	Hypotension	America	197	36,7	1	0,5
Vascular disorders	Hypotension	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Vascular disorders	Orthostatic hypotension	Europe	147	27,4	0	0,0
Vascular disorders	Orthostatic hypotension	America	197	36,7	1	0,5
Vascular disorders	Orthostatic hypotension	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Vascular disorders	Varicose vein	Europe	147	27,4	1	0,7
Vascular disorders	Varicose vein	America	197	36,7	0	0,0
Vascular disorders	Varicose vein	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Vascular disorders	Vascular occlusion	Europe	147	27,4	1	0,7
Vascular disorders	Vascular occlusion	America	197	36,7	0	0,0
Vascular disorders	Vascular occlusion	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Vascular disorders	Venous occlusion	Europe	147	27,4	1	0,7
Vascular disorders	Venous occlusion	America	197	36,7	0	0,0
Vascular disorders	Venous occlusion	Asia Pacific (inc. Australia)	193	35,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WMODAE_WK72_SBa24_30AUG2023_41984.xls

26APR2024 17:51

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AES
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=537)			
			Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		White	332	61,8	5	1,5
Cardiac disorders		Asian	180	33,5	0	0,0
Cardiac disorders		Other	17	3,2	0	0,0
Cardiac disorders		Unknown	8	1,5	0	0,0
Cardiac disorders	Angina pectoris	White	332	61,8	1	0,3
Cardiac disorders	Angina pectoris	Asian	180	33,5	0	0,0
Cardiac disorders	Angina pectoris	Other	17	3,2	0	0,0
Cardiac disorders	Angina pectoris	Unknown	8	1,5	0	0,0
Cardiac disorders	Angina unstable	White	332	61,8	1	0,3
Cardiac disorders	Angina unstable	Asian	180	33,5	0	0,0
Cardiac disorders	Angina unstable	Other	17	3,2	0	0,0
Cardiac disorders	Angina unstable	Unknown	8	1,5	0	0,0
Cardiac disorders	Arteriosclerosis coronary artery	White	332	61,8	0	0,0
Cardiac disorders	Arteriosclerosis coronary artery	Asian	180	33,5	1	0,6
Cardiac disorders	Arteriosclerosis coronary artery	Other	17	3,2	0	0,0
Cardiac disorders	Arteriosclerosis coronary artery	Unknown	8	1,5	0	0,0
Cardiac disorders	Atrial fibrillation	White	332	61,8	1	0,3
Cardiac disorders	Atrial fibrillation	Asian	180	33,5	0	0,0
Cardiac disorders	Atrial fibrillation	Other	17	3,2	0	0,0
Cardiac disorders	Atrial fibrillation	Unknown	8	1,5	0	0,0
Cardiac disorders	Cardiac failure	White	332	61,8	1	0,3
Cardiac disorders	Cardiac failure	Asian	180	33,5	0	0,0
Cardiac disorders	Cardiac failure	Other	17	3,2	0	0,0
Cardiac disorders	Cardiac failure	Unknown	8	1,5	0	0,0
Cardiac disorders	Myocardial fibrosis	White	332	61,8	1	0,3
Cardiac disorders	Myocardial fibrosis	Asian	180	33,5	0	0,0
Cardiac disorders	Myocardial fibrosis	Other	17	3,2	0	0,0
Cardiac disorders	Myocardial fibrosis	Unknown	8	1,5	0	0,0
Cardiac disorders	Myocardial infarction	White	332	61,8	1	0,3
Cardiac disorders	Myocardial infarction	Asian	180	33,5	0	0,0
Cardiac disorders	Myocardial infarction	Other	17	3,2	0	0,0
Cardiac disorders	Myocardial infarction	Unknown	8	1,5	0	0,0
Cardiac disorders	Pericarditis	White	332	61,8	1	0,3
Cardiac disorders	Pericarditis	Asian	180	33,5	0	0,0
Cardiac disorders	Pericarditis	Other	17	3,2	0	0,0
Cardiac disorders	Pericarditis	Unknown	8	1,5	0	0,0
Cardiac disorders	Supraventricular extrasystoles	White	332	61,8	1	0,3
Cardiac disorders	Supraventricular extrasystoles	Asian	180	33,5	0	0,0
Cardiac disorders	Supraventricular extrasystoles	Other	17	3,2	0	0,0
Cardiac disorders	Supraventricular extrasystoles	Unknown	8	1,5	0	0,0
Congenital, familial and genetic disorders		White	332	61,8	2	0,6
Congenital, familial and genetic disorders		Asian	180	33,5	0	0,0
Congenital, familial and genetic disorders		Other	17	3,2	0	0,0
Congenital, familial and genetic disorders		Unknown	8	1,5	0	0,0
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	White	332	61,8	1	0,3
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Asian	180	33,5	0	0,0
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Other	17	3,2	0	0,0
Congenital, familial and genetic disorders	Congenital cardiovascular anomaly	Unknown	8	1,5	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	White	332	61,8	1	0,3
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Asian	180	33,5	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Other	17	3,2	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Unknown	8	1,5	0	0,0
Ear and labyrinth disorders		White	332	61,8	1	0,3
Ear and labyrinth disorders		Asian	180	33,5	1	0,6
Ear and labyrinth disorders		Other	17	3,2	0	0,0
Ear and labyrinth disorders		Unknown	8	1,5	0	0,0
Ear and labyrinth disorders	Vertigo	White	332	61,8	1	0,3
Ear and labyrinth disorders	Vertigo	Asian	180	33,5	0	0,0
Ear and labyrinth disorders	Vertigo	Other	17	3,2	0	0,0
Ear and labyrinth disorders	Vertigo	Unknown	8	1,5	0	0,0
Ear and labyrinth disorders	Vertigo positional	White	332	61,8	0	0,0
Ear and labyrinth disorders	Vertigo positional	Asian	180	33,5	1	0,6
Ear and labyrinth disorders	Vertigo positional	Other	17	3,2	0	0,0

Ear and labyrinth disorders	Vertigo positional	Unknown	8	1,5	0	0,0
Eye disorders		White	332	61,8	32	9,6
Eye disorders		Asian	180	33,5	6	3,3
Eye disorders		Other	17	3,2	1	5,9
Eye disorders		Unknown	8	1,5	0	0,0
Eye disorders	Cataract	White	332	61,8	5	1,5
Eye disorders	Cataract	Asian	180	33,5	1	0,6
Eye disorders	Cataract	Other	17	3,2	0	0,0
Eye disorders	Cataract	Unknown	8	1,5	0	0,0
Eye disorders	Cataract subcapsular	White	332	61,8	2	0,6
Eye disorders	Cataract subcapsular	Asian	180	33,5	0	0,0
Eye disorders	Cataract subcapsular	Other	17	3,2	0	0,0
Eye disorders	Cataract subcapsular	Unknown	8	1,5	0	0,0
Eye disorders	Conjunctivitis allergic	White	332	61,8	0	0,0
Eye disorders	Conjunctivitis allergic	Asian	180	33,5	1	0,6
Eye disorders	Conjunctivitis allergic	Other	17	3,2	0	0,0
Eye disorders	Conjunctivitis allergic	Unknown	8	1,5	0	0,0
Eye disorders	Corneal infiltrates	White	332	61,8	1	0,3
Eye disorders	Corneal infiltrates	Asian	180	33,5	0	0,0
Eye disorders	Corneal infiltrates	Other	17	3,2	0	0,0
Eye disorders	Corneal infiltrates	Unknown	8	1,5	0	0,0
Eye disorders	Cystoid macular oedema	White	332	61,8	3	0,9
Eye disorders	Cystoid macular oedema	Asian	180	33,5	0	0,0
Eye disorders	Cystoid macular oedema	Other	17	3,2	0	0,0
Eye disorders	Cystoid macular oedema	Unknown	8	1,5	0	0,0
Eye disorders	Dry age-related macular degeneration	White	332	61,8	1	0,3
Eye disorders	Dry age-related macular degeneration	Asian	180	33,5	0	0,0
Eye disorders	Dry age-related macular degeneration	Other	17	3,2	0	0,0
Eye disorders	Dry age-related macular degeneration	Unknown	8	1,5	0	0,0
Eye disorders	Dry eye	White	332	61,8	2	0,6
Eye disorders	Dry eye	Asian	180	33,5	0	0,0
Eye disorders	Dry eye	Other	17	3,2	0	0,0
Eye disorders	Dry eye	Unknown	8	1,5	0	0,0
Eye disorders	Epiretinal membrane	White	332	61,8	0	0,0
Eye disorders	Epiretinal membrane	Asian	180	33,5	1	0,6
Eye disorders	Epiretinal membrane	Other	17	3,2	0	0,0
Eye disorders	Epiretinal membrane	Unknown	8	1,5	0	0,0
Eye disorders	Eye allergy	White	332	61,8	1	0,3
Eye disorders	Eye allergy	Asian	180	33,5	0	0,0
Eye disorders	Eye allergy	Other	17	3,2	0	0,0
Eye disorders	Eye allergy	Unknown	8	1,5	0	0,0
Eye disorders	Glaucoma	White	332	61,8	1	0,3
Eye disorders	Glaucoma	Asian	180	33,5	0	0,0
Eye disorders	Glaucoma	Other	17	3,2	0	0,0
Eye disorders	Glaucoma	Unknown	8	1,5	0	0,0
Eye disorders	Macular ischaemia	White	332	61,8	0	0,0
Eye disorders	Macular ischaemia	Asian	180	33,5	0	0,0
Eye disorders	Macular ischaemia	Other	17	3,2	1	5,9
Eye disorders	Macular ischaemia	Unknown	8	1,5	0	0,0
Eye disorders	Macular oedema	White	332	61,8	1	0,3
Eye disorders	Macular oedema	Asian	180	33,5	2	1,1
Eye disorders	Macular oedema	Other	17	3,2	0	0,0
Eye disorders	Macular oedema	Unknown	8	1,5	0	0,0
Eye disorders	Ocular hypertension	White	332	61,8	1	0,3
Eye disorders	Ocular hypertension	Asian	180	33,5	0	0,0
Eye disorders	Ocular hypertension	Other	17	3,2	0	0,0
Eye disorders	Ocular hypertension	Unknown	8	1,5	0	0,0
Eye disorders	Periorbital pain	White	332	61,8	1	0,3
Eye disorders	Periorbital pain	Asian	180	33,5	0	0,0
Eye disorders	Periorbital pain	Other	17	3,2	0	0,0
Eye disorders	Periorbital pain	Unknown	8	1,5	0	0,0
Eye disorders	Posterior capsule opacification	White	332	61,8	0	0,0
Eye disorders	Posterior capsule opacification	Asian	180	33,5	1	0,6
Eye disorders	Posterior capsule opacification	Other	17	3,2	0	0,0
Eye disorders	Posterior capsule opacification	Unknown	8	1,5	0	0,0
Eye disorders	Retinal aneurysm	White	332	61,8	1	0,3
Eye disorders	Retinal aneurysm	Asian	180	33,5	0	0,0
Eye disorders	Retinal aneurysm	Other	17	3,2	0	0,0
Eye disorders	Retinal aneurysm	Unknown	8	1,5	0	0,0
Eye disorders	Retinal cyst	White	332	61,8	1	0,3
Eye disorders	Retinal cyst	Asian	180	33,5	0	0,0
Eye disorders	Retinal cyst	Other	17	3,2	0	0,0
Eye disorders	Retinal cyst	Unknown	8	1,5	0	0,0
Eye disorders	Retinal haemorrhage	White	332	61,8	1	0,3
Eye disorders	Retinal haemorrhage	Asian	180	33,5	0	0,0
Eye disorders	Retinal haemorrhage	Other	17	3,2	0	0,0

Eye disorders	Retinal haemorrhage	Unknown	8	1,5	0	0,0
Eye disorders	Retinal ischaemia	White	332	61,8	2	0,6
Eye disorders	Retinal ischaemia	Asian	180	33,5	0	0,0
Eye disorders	Retinal ischaemia	Other	17	3,2	0	0,0
Eye disorders	Retinal ischaemia	Unknown	8	1,5	0	0,0
Eye disorders	Retinal neovascularisation	White	332	61,8	1	0,3
Eye disorders	Retinal neovascularisation	Asian	180	33,5	0	0,0
Eye disorders	Retinal neovascularisation	Other	17	3,2	0	0,0
Eye disorders	Retinal neovascularisation	Unknown	8	1,5	0	0,0
Eye disorders	Retinal vein occlusion	White	332	61,8	5	1,5
Eye disorders	Retinal vein occlusion	Asian	180	33,5	0	0,0
Eye disorders	Retinal vein occlusion	Other	17	3,2	0	0,0
Eye disorders	Retinal vein occlusion	Unknown	8	1,5	0	0,0
Eye disorders	Retinopathy hypertensive	White	332	61,8	1	0,3
Eye disorders	Retinopathy hypertensive	Asian	180	33,5	0	0,0
Eye disorders	Retinopathy hypertensive	Other	17	3,2	0	0,0
Eye disorders	Retinopathy hypertensive	Unknown	8	1,5	0	0,0
Eye disorders	Swelling of eyelid	White	332	61,8	1	0,3
Eye disorders	Swelling of eyelid	Asian	180	33,5	0	0,0
Eye disorders	Swelling of eyelid	Other	17	3,2	0	0,0
Eye disorders	Swelling of eyelid	Unknown	8	1,5	0	0,0
Eye disorders	Tractional retinal detachment	White	332	61,8	1	0,3
Eye disorders	Tractional retinal detachment	Asian	180	33,5	0	0,0
Eye disorders	Tractional retinal detachment	Other	17	3,2	0	0,0
Eye disorders	Tractional retinal detachment	Unknown	8	1,5	0	0,0
Eye disorders	Vitreous detachment	White	332	61,8	2	0,6
Eye disorders	Vitreous detachment	Asian	180	33,5	0	0,0
Eye disorders	Vitreous detachment	Other	17	3,2	0	0,0
Eye disorders	Vitreous detachment	Unknown	8	1,5	0	0,0
Gastrointestinal disorders		White	332	61,8	10	3,0
Gastrointestinal disorders		Asian	180	33,5	0	0,0
Gastrointestinal disorders		Other	17	3,2	0	0,0
Gastrointestinal disorders		Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Colitis	White	332	61,8	1	0,3
Gastrointestinal disorders	Colitis	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Colitis	Other	17	3,2	0	0,0
Gastrointestinal disorders	Colitis	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Constipation	White	332	61,8	1	0,3
Gastrointestinal disorders	Constipation	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Constipation	Other	17	3,2	0	0,0
Gastrointestinal disorders	Constipation	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Erosive duodenitis	White	332	61,8	1	0,3
Gastrointestinal disorders	Erosive duodenitis	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Erosive duodenitis	Other	17	3,2	0	0,0
Gastrointestinal disorders	Erosive duodenitis	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	White	332	61,8	1	0,3
Gastrointestinal disorders	Functional gastrointestinal disorder	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	Other	17	3,2	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	White	332	61,8	1	0,3
Gastrointestinal disorders	Gastric haemorrhage	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Other	17	3,2	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Gastritis	White	332	61,8	1	0,3
Gastrointestinal disorders	Gastritis	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Gastritis	Other	17	3,2	0	0,0
Gastrointestinal disorders	Gastritis	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Gastroesophageal reflux disease	White	332	61,8	2	0,6
Gastrointestinal disorders	Gastroesophageal reflux disease	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Gastroesophageal reflux disease	Other	17	3,2	0	0,0
Gastrointestinal disorders	Gastroesophageal reflux disease	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Gingival pain	White	332	61,8	1	0,3
Gastrointestinal disorders	Gingival pain	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Gingival pain	Other	17	3,2	0	0,0
Gastrointestinal disorders	Gingival pain	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Hyperchlorhydria	White	332	61,8	1	0,3
Gastrointestinal disorders	Hyperchlorhydria	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Hyperchlorhydria	Other	17	3,2	0	0,0
Gastrointestinal disorders	Hyperchlorhydria	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Toothache	White	332	61,8	1	0,3
Gastrointestinal disorders	Toothache	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Toothache	Other	17	3,2	0	0,0
Gastrointestinal disorders	Toothache	Unknown	8	1,5	0	0,0
General disorders and administration site conditions		White	332	61,8	2	0,6
General disorders and administration site conditions		Asian	180	33,5	1	0,6

General disorders and administration site conditions		Other	17	3,2	0	0,0
General disorders and administration site conditions		Unknown	8	1,5	0	0,0
General disorders and administration site conditions	Chest discomfort	White	332	61,8	1	0,3
General disorders and administration site conditions	Chest discomfort	Asian	180	33,5	0	0,0
General disorders and administration site conditions	Chest discomfort	Other	17	3,2	0	0,0
General disorders and administration site conditions	Chest discomfort	Unknown	8	1,5	0	0,0
General disorders and administration site conditions	Pain	White	332	61,8	1	0,3
General disorders and administration site conditions	Pain	Asian	180	33,5	0	0,0
General disorders and administration site conditions	Pain	Other	17	3,2	0	0,0
General disorders and administration site conditions	Pain	Unknown	8	1,5	0	0,0
General disorders and administration site conditions	Pyrexia	White	332	61,8	0	0,0
General disorders and administration site conditions	Pyrexia	Asian	180	33,5	1	0,6
General disorders and administration site conditions	Pyrexia	Other	17	3,2	0	0,0
General disorders and administration site conditions	Pyrexia	Unknown	8	1,5	0	0,0
Hepatobiliary disorders		White	332	61,8	2	0,6
Hepatobiliary disorders		Asian	180	33,5	0	0,0
Hepatobiliary disorders		Other	17	3,2	0	0,0
Hepatobiliary disorders		Unknown	8	1,5	0	0,0
Hepatobiliary disorders	Cholelithiasis	White	332	61,8	1	0,3
Hepatobiliary disorders	Cholelithiasis	Asian	180	33,5	0	0,0
Hepatobiliary disorders	Cholelithiasis	Other	17	3,2	0	0,0
Hepatobiliary disorders	Cholelithiasis	Unknown	8	1,5	0	0,0
Hepatobiliary disorders	Hepatic failure	White	332	61,8	1	0,3
Hepatobiliary disorders	Hepatic failure	Asian	180	33,5	0	0,0
Hepatobiliary disorders	Hepatic failure	Other	17	3,2	0	0,0
Hepatobiliary disorders	Hepatic failure	Unknown	8	1,5	0	0,0
Immune system disorders		White	332	61,8	3	0,9
Immune system disorders		Asian	180	33,5	0	0,0
Immune system disorders		Other	17	3,2	0	0,0
Immune system disorders		Unknown	8	1,5	0	0,0
Immune system disorders	Allergic oedema	White	332	61,8	1	0,3
Immune system disorders	Allergic oedema	Asian	180	33,5	0	0,0
Immune system disorders	Allergic oedema	Other	17	3,2	0	0,0
Immune system disorders	Allergic oedema	Unknown	8	1,5	0	0,0
Immune system disorders	Hypersensitivity	White	332	61,8	1	0,3
Immune system disorders	Hypersensitivity	Asian	180	33,5	0	0,0
Immune system disorders	Hypersensitivity	Other	17	3,2	0	0,0
Immune system disorders	Hypersensitivity	Unknown	8	1,5	0	0,0
Immune system disorders	Seasonal allergy	White	332	61,8	1	0,3
Immune system disorders	Seasonal allergy	Asian	180	33,5	0	0,0
Immune system disorders	Seasonal allergy	Other	17	3,2	0	0,0
Immune system disorders	Seasonal allergy	Unknown	8	1,5	0	0,0
Infections and infestations		White	332	61,8	31	9,3
Infections and infestations		Asian	180	33,5	7	3,9
Infections and infestations		Other	17	3,2	1	5,9
Infections and infestations		Unknown	8	1,5	2	25,0
Infections and infestations	Bronchitis	White	332	61,8	3	0,9
Infections and infestations	Bronchitis	Asian	180	33,5	0	0,0
Infections and infestations	Bronchitis	Other	17	3,2	0	0,0
Infections and infestations	Bronchitis	Unknown	8	1,5	0	0,0
Infections and infestations	COVID-19	White	332	61,8	5	1,5
Infections and infestations	COVID-19	Asian	180	33,5	2	1,1
Infections and infestations	COVID-19	Other	17	3,2	1	5,9
Infections and infestations	COVID-19	Unknown	8	1,5	0	0,0
Infections and infestations	Cellulitis	White	332	61,8	3	0,9
Infections and infestations	Cellulitis	Asian	180	33,5	0	0,0
Infections and infestations	Cellulitis	Other	17	3,2	0	0,0
Infections and infestations	Cellulitis	Unknown	8	1,5	0	0,0
Infections and infestations	Cystitis	White	332	61,8	1	0,3
Infections and infestations	Cystitis	Asian	180	33,5	0	0,0
Infections and infestations	Cystitis	Other	17	3,2	0	0,0
Infections and infestations	Cystitis	Unknown	8	1,5	0	0,0
Infections and infestations	Ear infection	White	332	61,8	1	0,3
Infections and infestations	Ear infection	Asian	180	33,5	0	0,0
Infections and infestations	Ear infection	Other	17	3,2	0	0,0
Infections and infestations	Ear infection	Unknown	8	1,5	0	0,0
Infections and infestations	Furuncle	White	332	61,8	0	0,0
Infections and infestations	Furuncle	Asian	180	33,5	0	0,0
Infections and infestations	Furuncle	Other	17	3,2	0	0,0
Infections and infestations	Furuncle	Unknown	8	1,5	1	12,5
Infections and infestations	Gastroenteritis	White	332	61,8	1	0,3
Infections and infestations	Gastroenteritis	Asian	180	33,5	1	0,6
Infections and infestations	Gastroenteritis	Other	17	3,2	0	0,0
Infections and infestations	Gastroenteritis	Unknown	8	1,5	0	0,0

Infections and infestations	Gastrointestinal infection	White	332	61,8	2	0,6
Infections and infestations	Gastrointestinal infection	Asian	180	33,5	0	0,0
Infections and infestations	Gastrointestinal infection	Other	17	3,2	0	0,0
Infections and infestations	Gastrointestinal infection	Unknown	8	1,5	0	0,0
Infections and infestations	Gingival abscess	White	332	61,8	0	0,0
Infections and infestations	Gingival abscess	Asian	180	33,5	0	0,0
Infections and infestations	Gingival abscess	Other	17	3,2	0	0,0
Infections and infestations	Gingival abscess	Unknown	8	1,5	1	12,5
Infections and infestations	Herpes zoster	White	332	61,8	0	0,0
Infections and infestations	Herpes zoster	Asian	180	33,5	1	0,6
Infections and infestations	Herpes zoster	Other	17	3,2	0	0,0
Infections and infestations	Herpes zoster	Unknown	8	1,5	0	0,0
Infections and infestations	Hordeolum	White	332	61,8	1	0,3
Infections and infestations	Hordeolum	Asian	180	33,5	0	0,0
Infections and infestations	Hordeolum	Other	17	3,2	0	0,0
Infections and infestations	Hordeolum	Unknown	8	1,5	0	0,0
Infections and infestations	Influenza	White	332	61,8	4	1,2
Infections and infestations	Influenza	Asian	180	33,5	1	0,6
Infections and infestations	Influenza	Other	17	3,2	0	0,0
Infections and infestations	Influenza	Unknown	8	1,5	0	0,0
Infections and infestations	Nasopharyngitis	White	332	61,8	0	0,0
Infections and infestations	Nasopharyngitis	Asian	180	33,5	0	0,0
Infections and infestations	Nasopharyngitis	Other	17	3,2	0	0,0
Infections and infestations	Nasopharyngitis	Unknown	8	1,5	1	12,5
Infections and infestations	Otitis media	White	332	61,8	0	0,0
Infections and infestations	Otitis media	Asian	180	33,5	0	0,0
Infections and infestations	Otitis media	Other	17	3,2	0	0,0
Infections and infestations	Otitis media	Unknown	8	1,5	1	12,5
Infections and infestations	Pneumonia	White	332	61,8	3	0,9
Infections and infestations	Pneumonia	Asian	180	33,5	0	0,0
Infections and infestations	Pneumonia	Other	17	3,2	0	0,0
Infections and infestations	Pneumonia	Unknown	8	1,5	0	0,0
Infections and infestations	Post-acute COVID-19 syndrome	White	332	61,8	1	0,3
Infections and infestations	Post-acute COVID-19 syndrome	Asian	180	33,5	0	0,0
Infections and infestations	Post-acute COVID-19 syndrome	Other	17	3,2	0	0,0
Infections and infestations	Post-acute COVID-19 syndrome	Unknown	8	1,5	0	0,0
Infections and infestations	Postoperative wound infection	White	332	61,8	1	0,3
Infections and infestations	Postoperative wound infection	Asian	180	33,5	0	0,0
Infections and infestations	Postoperative wound infection	Other	17	3,2	0	0,0
Infections and infestations	Postoperative wound infection	Unknown	8	1,5	0	0,0
Infections and infestations	Pyelonephritis	White	332	61,8	0	0,0
Infections and infestations	Pyelonephritis	Asian	180	33,5	1	0,6
Infections and infestations	Pyelonephritis	Other	17	3,2	0	0,0
Infections and infestations	Pyelonephritis	Unknown	8	1,5	0	0,0
Infections and infestations	Respiratory tract infection	White	332	61,8	2	0,6
Infections and infestations	Respiratory tract infection	Asian	180	33,5	0	0,0
Infections and infestations	Respiratory tract infection	Other	17	3,2	0	0,0
Infections and infestations	Respiratory tract infection	Unknown	8	1,5	0	0,0
Infections and infestations	Rotavirus infection	White	332	61,8	1	0,3
Infections and infestations	Rotavirus infection	Asian	180	33,5	0	0,0
Infections and infestations	Rotavirus infection	Other	17	3,2	0	0,0
Infections and infestations	Rotavirus infection	Unknown	8	1,5	0	0,0
Infections and infestations	Sinusitis	White	332	61,8	1	0,3
Infections and infestations	Sinusitis	Asian	180	33,5	0	0,0
Infections and infestations	Sinusitis	Other	17	3,2	0	0,0
Infections and infestations	Sinusitis	Unknown	8	1,5	0	0,0
Infections and infestations	Suspected COVID-19	White	332	61,8	0	0,0
Infections and infestations	Suspected COVID-19	Asian	180	33,5	1	0,6
Infections and infestations	Suspected COVID-19	Other	17	3,2	0	0,0
Infections and infestations	Suspected COVID-19	Unknown	8	1,5	0	0,0
Infections and infestations	Tooth infection	White	332	61,8	1	0,3
Infections and infestations	Tooth infection	Asian	180	33,5	0	0,0
Infections and infestations	Tooth infection	Other	17	3,2	0	0,0
Infections and infestations	Tooth infection	Unknown	8	1,5	0	0,0
Infections and infestations	Tracheitis	White	332	61,8	1	0,3
Infections and infestations	Tracheitis	Asian	180	33,5	0	0,0
Infections and infestations	Tracheitis	Other	17	3,2	0	0,0
Infections and infestations	Tracheitis	Unknown	8	1,5	0	0,0
Infections and infestations	Upper respiratory tract infection	White	332	61,8	5	1,5
Infections and infestations	Upper respiratory tract infection	Asian	180	33,5	0	0,0
Infections and infestations	Upper respiratory tract infection	Other	17	3,2	0	0,0
Infections and infestations	Upper respiratory tract infection	Unknown	8	1,5	0	0,0
Infections and infestations	Urinary tract infection	White	332	61,8	1	0,3
Infections and infestations	Urinary tract infection	Asian	180	33,5	0	0,0
Infections and infestations	Urinary tract infection	Other	17	3,2	0	0,0
Infections and infestations	Urinary tract infection	Unknown	8	1,5	0	0,0
Infections and infestations	Viral infection	White	332	61,8	1	0,3

Infections and infestations	Viral infection	Asian	180	33,5	0	0,0
Infections and infestations	Viral infection	Other	17	3,2	0	0,0
Infections and infestations	Viral infection	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications		White	332	61,8	13	3,9
Injury, poisoning and procedural complications		Asian	180	33,5	1	0,6
Injury, poisoning and procedural complications		Other	17	3,2	0	0,0
Injury, poisoning and procedural complications		Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Back injury	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Back injury	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Back injury	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Back injury	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Burns third degree	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Burns third degree	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Burns third degree	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Burns third degree	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Facial bones fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Facial bones fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Facial bones fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Facial bones fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Fall	White	332	61,8	7	2,1
Injury, poisoning and procedural complications	Fall	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Fall	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Fall	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Femur fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Femur fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Head injury	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Head injury	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Head injury	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Head injury	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Meniscus injury	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Meniscus injury	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Meniscus injury	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Meniscus injury	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Skin laceration	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Skin laceration	Asian	180	33,5	1	0,6
Injury, poisoning and procedural complications	Skin laceration	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Spinal column injury	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Spinal column injury	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Spinal column injury	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Spinal column injury	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Subdural haematoma	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Tooth fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Ulna fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Unknown	8	1,5	0	0,0
Investigations		White	332	61,8	7	2,1
Investigations		Asian	180	33,5	0	0,0
Investigations		Other	17	3,2	1	5,9
Investigations		Unknown	8	1,5	0	0,0
Investigations	Intraocular pressure increased	White	332	61,8	4	1,2
Investigations	Intraocular pressure increased	Asian	180	33,5	0	0,0
Investigations	Intraocular pressure increased	Other	17	3,2	1	5,9
Investigations	Intraocular pressure increased	Unknown	8	1,5	0	0,0
Investigations	Platelet count increased	White	332	61,8	1	0,3
Investigations	Platelet count increased	Asian	180	33,5	0	0,0
Investigations	Platelet count increased	Other	17	3,2	0	0,0
Investigations	Platelet count increased	Unknown	8	1,5	0	0,0
Investigations	SARS-CoV-2 test positive	White	332	61,8	1	0,3
Investigations	SARS-CoV-2 test positive	Asian	180	33,5	0	0,0
Investigations	SARS-CoV-2 test positive	Other	17	3,2	0	0,0
Investigations	SARS-CoV-2 test positive	Unknown	8	1,5	0	0,0
Investigations	Troponin increased	White	332	61,8	1	0,3
Investigations	Troponin increased	Asian	180	33,5	0	0,0
Investigations	Troponin increased	Other	17	3,2	0	0,0
Investigations	Troponin increased	Unknown	8	1,5	0	0,0

Metabolism and nutrition disorders		White	332	61,8	4	1,2
Metabolism and nutrition disorders		Asian	180	33,5	0	0,0
Metabolism and nutrition disorders		Other	17	3,2	0	0,0
Metabolism and nutrition disorders		Unknown	8	1,5	0	0,0
Metabolism and nutrition disorders	Dehydration	White	332	61,8	1	0,3
Metabolism and nutrition disorders	Dehydration	Asian	180	33,5	0	0,0
Metabolism and nutrition disorders	Dehydration	Other	17	3,2	0	0,0
Metabolism and nutrition disorders	Dehydration	Unknown	8	1,5	0	0,0
Metabolism and nutrition disorders	Gout	White	332	61,8	2	0,6
Metabolism and nutrition disorders	Gout	Asian	180	33,5	0	0,0
Metabolism and nutrition disorders	Gout	Other	17	3,2	0	0,0
Metabolism and nutrition disorders	Gout	Unknown	8	1,5	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	White	332	61,8	1	0,3
Metabolism and nutrition disorders	Hyperglycaemia	Asian	180	33,5	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Other	17	3,2	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders		White	332	61,8	14	4,2
Musculoskeletal and connective tissue disorders		Asian	180	33,5	2	1,1
Musculoskeletal and connective tissue disorders		Other	17	3,2	1	5,9
Musculoskeletal and connective tissue disorders		Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	White	332	61,8	1	0,3
Musculoskeletal and connective tissue disorders	Arthralgia	Asian	180	33,5	1	0,6
Musculoskeletal and connective tissue disorders	Arthralgia	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Arthritis	White	332	61,8	2	0,6
Musculoskeletal and connective tissue disorders	Arthritis	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Arthritis	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Arthritis	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	White	332	61,8	3	0,9
Musculoskeletal and connective tissue disorders	Back pain	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	White	332	61,8	1	0,3
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Asian	180	33,5	1	0,6
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	White	332	61,8	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	Other	17	3,2	1	5,9
Musculoskeletal and connective tissue disorders	Joint swelling	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	White	332	61,8	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Asian	180	33,5	1	0,6
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Muscle spasms	White	332	61,8	1	0,3
Musculoskeletal and connective tissue disorders	Muscle spasms	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Muscle spasms	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Muscle spasms	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	White	332	61,8	2	0,6
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Osteoporosis	White	332	61,8	1	0,3
Musculoskeletal and connective tissue disorders	Osteoporosis	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Osteoporosis	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Osteoporosis	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	White	332	61,8	1	0,3
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	White	332	61,8	2	0,6
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	White	332	61,8	1	0,3
Musculoskeletal and connective tissue disorders	Spinal pain	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		White	332	61,8	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Other	17	3,2	1	5,9

Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	White	332	61,8	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Other	17	3,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	White	332	61,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Other	17	3,2	1	5,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Unknown	8	1,5	0	0,0
Nervous system disorders		White	332	61,8	12	3,6
Nervous system disorders		Asian	180	33,5	0	0,0
Nervous system disorders		Other	17	3,2	2	11,8
Nervous system disorders		Unknown	8	1,5	2	25,0
Nervous system disorders	Carotid artery stenosis	White	332	61,8	1	0,3
Nervous system disorders	Carotid artery stenosis	Asian	180	33,5	0	0,0
Nervous system disorders	Carotid artery stenosis	Other	17	3,2	0	0,0
Nervous system disorders	Carotid artery stenosis	Unknown	8	1,5	0	0,0
Nervous system disorders	Cerebral infarction	White	332	61,8	0	0,0
Nervous system disorders	Cerebral infarction	Asian	180	33,5	1	0,6
Nervous system disorders	Cerebral infarction	Other	17	3,2	0	0,0
Nervous system disorders	Cerebral infarction	Unknown	8	1,5	0	0,0
Nervous system disorders	Cerebrovascular accident	White	332	61,8	1	0,3
Nervous system disorders	Cerebrovascular accident	Asian	180	33,5	0	0,0
Nervous system disorders	Cerebrovascular accident	Other	17	3,2	0	0,0
Nervous system disorders	Cerebrovascular accident	Unknown	8	1,5	1	12,5
Nervous system disorders	Cognitive disorder	White	332	61,8	0	0,0
Nervous system disorders	Cognitive disorder	Asian	180	33,5	0	0,0
Nervous system disorders	Cognitive disorder	Other	17	3,2	1	5,9
Nervous system disorders	Cognitive disorder	Unknown	8	1,5	0	0,0
Nervous system disorders	Epilepsy	White	332	61,8	1	0,3
Nervous system disorders	Epilepsy	Asian	180	33,5	0	0,0
Nervous system disorders	Epilepsy	Other	17	3,2	0	0,0
Nervous system disorders	Epilepsy	Unknown	8	1,5	0	0,0
Nervous system disorders	Headache	White	332	61,8	3	0,9
Nervous system disorders	Headache	Asian	180	33,5	0	0,0
Nervous system disorders	Headache	Other	17	3,2	0	0,0
Nervous system disorders	Headache	Unknown	8	1,5	0	0,0
Nervous system disorders	Hypertensive encephalopathy	White	332	61,8	1	0,3
Nervous system disorders	Hypertensive encephalopathy	Asian	180	33,5	0	0,0
Nervous system disorders	Hypertensive encephalopathy	Other	17	3,2	0	0,0
Nervous system disorders	Hypertensive encephalopathy	Unknown	8	1,5	0	0,0
Nervous system disorders	Memory impairment	White	332	61,8	1	0,3
Nervous system disorders	Memory impairment	Asian	180	33,5	0	0,0
Nervous system disorders	Memory impairment	Other	17	3,2	0	0,0
Nervous system disorders	Memory impairment	Unknown	8	1,5	0	0,0
Nervous system disorders	Migraine	White	332	61,8	1	0,3
Nervous system disorders	Migraine	Asian	180	33,5	0	0,0
Nervous system disorders	Migraine	Other	17	3,2	0	0,0
Nervous system disorders	Migraine	Unknown	8	1,5	0	0,0
Nervous system disorders	Myelopathy	White	332	61,8	1	0,3
Nervous system disorders	Myelopathy	Asian	180	33,5	0	0,0
Nervous system disorders	Myelopathy	Other	17	3,2	0	0,0
Nervous system disorders	Myelopathy	Unknown	8	1,5	0	0,0
Nervous system disorders	Narcolepsy	White	332	61,8	1	0,3
Nervous system disorders	Narcolepsy	Asian	180	33,5	0	0,0
Nervous system disorders	Narcolepsy	Other	17	3,2	0	0,0
Nervous system disorders	Narcolepsy	Unknown	8	1,5	0	0,0
Nervous system disorders	Presyncope	White	332	61,8	0	0,0
Nervous system disorders	Presyncope	Asian	180	33,5	0	0,0
Nervous system disorders	Presyncope	Other	17	3,2	1	5,9
Nervous system disorders	Presyncope	Unknown	8	1,5	0	0,0
Nervous system disorders	Sciatica	White	332	61,8	0	0,0
Nervous system disorders	Sciatica	Asian	180	33,5	0	0,0
Nervous system disorders	Sciatica	Other	17	3,2	0	0,0
Nervous system disorders	Sciatica	Unknown	8	1,5	1	12,5
Nervous system disorders	Sinus headache	White	332	61,8	1	0,3
Nervous system disorders	Sinus headache	Asian	180	33,5	0	0,0
Nervous system disorders	Sinus headache	Other	17	3,2	0	0,0
Nervous system disorders	Sinus headache	Unknown	8	1,5	0	0,0

Product issues		White	332	61,8	1	0,3
Product issues		Asian	180	33,5	0	0,0
Product issues		Other	17	3,2	0	0,0
Product issues		Unknown	8	1,5	0	0,0
Product issues	Device malfunction	White	332	61,8	1	0,3
Product issues	Device malfunction	Asian	180	33,5	0	0,0
Product issues	Device malfunction	Other	17	3,2	0	0,0
Product issues	Device malfunction	Unknown	8	1,5	0	0,0
Psychiatric disorders		White	332	61,8	0	0,0
Psychiatric disorders		Asian	180	33,5	1	0,6
Psychiatric disorders		Other	17	3,2	0	0,0
Psychiatric disorders		Unknown	8	1,5	0	0,0
Psychiatric disorders	Anxiety	White	332	61,8	0	0,0
Psychiatric disorders	Anxiety	Asian	180	33,5	1	0,6
Psychiatric disorders	Anxiety	Other	17	3,2	0	0,0
Psychiatric disorders	Anxiety	Unknown	8	1,5	0	0,0
Renal and urinary disorders		White	332	61,8	3	0,9
Renal and urinary disorders		Asian	180	33,5	0	0,0
Renal and urinary disorders		Other	17	3,2	0	0,0
Renal and urinary disorders		Unknown	8	1,5	0	0,0
Renal and urinary disorders	Chronic kidney disease	White	332	61,8	1	0,3
Renal and urinary disorders	Chronic kidney disease	Asian	180	33,5	0	0,0
Renal and urinary disorders	Chronic kidney disease	Other	17	3,2	0	0,0
Renal and urinary disorders	Chronic kidney disease	Unknown	8	1,5	0	0,0
Renal and urinary disorders	Haematuria	White	332	61,8	1	0,3
Renal and urinary disorders	Haematuria	Asian	180	33,5	0	0,0
Renal and urinary disorders	Haematuria	Other	17	3,2	0	0,0
Renal and urinary disorders	Haematuria	Unknown	8	1,5	0	0,0
Renal and urinary disorders	Nephrolithiasis	White	332	61,8	1	0,3
Renal and urinary disorders	Nephrolithiasis	Asian	180	33,5	0	0,0
Renal and urinary disorders	Nephrolithiasis	Other	17	3,2	0	0,0
Renal and urinary disorders	Nephrolithiasis	Unknown	8	1,5	0	0,0
Reproductive system and breast disorders		White	332	61,8	2	0,6
Reproductive system and breast disorders		Asian	180	33,5	0	0,0
Reproductive system and breast disorders		Other	17	3,2	0	0,0
Reproductive system and breast disorders		Unknown	8	1,5	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	White	332	61,8	1	0,3
Reproductive system and breast disorders	Erectile dysfunction	Asian	180	33,5	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	Other	17	3,2	0	0,0
Reproductive system and breast disorders	Erectile dysfunction	Unknown	8	1,5	0	0,0
Reproductive system and breast disorders	Prostatitis	White	332	61,8	1	0,3
Reproductive system and breast disorders	Prostatitis	Asian	180	33,5	0	0,0
Reproductive system and breast disorders	Prostatitis	Other	17	3,2	0	0,0
Reproductive system and breast disorders	Prostatitis	Unknown	8	1,5	0	0,0
Respiratory, thoracic and mediastinal disorders		White	332	61,8	5	1,5
Respiratory, thoracic and mediastinal disorders		Asian	180	33,5	0	0,0
Respiratory, thoracic and mediastinal disorders		Other	17	3,2	0	0,0
Respiratory, thoracic and mediastinal disorders		Unknown	8	1,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	White	332	61,8	1	0,3
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Asian	180	33,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Other	17	3,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Unknown	8	1,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	White	332	61,8	1	0,3
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Asian	180	33,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Other	17	3,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural effusion	Unknown	8	1,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	White	332	61,8	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Asian	180	33,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Other	17	3,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Unknown	8	1,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	White	332	61,8	1	0,3
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Asian	180	33,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Other	17	3,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	Unknown	8	1,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	White	332	61,8	1	0,3
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Asian	180	33,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Other	17	3,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Unknown	8	1,5	0	0,0
Skin and subcutaneous tissue disorders		White	332	61,8	1	0,3
Skin and subcutaneous tissue disorders		Asian	180	33,5	0	0,0
Skin and subcutaneous tissue disorders		Other	17	3,2	0	0,0

Skin and subcutaneous tissue disorders		Unknown	8	1,5	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	White	332	61,8	1	0,3
Skin and subcutaneous tissue disorders	Pemphigoid	Asian	180	33,5	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	Other	17	3,2	0	0,0
Skin and subcutaneous tissue disorders	Pemphigoid	Unknown	8	1,5	0	0,0
Surgical and medical procedures		White	332	61,8	1	0,3
Surgical and medical procedures		Asian	180	33,5	0	0,0
Surgical and medical procedures		Other	17	3,2	1	5,9
Surgical and medical procedures		Unknown	8	1,5	0	0,0
Surgical and medical procedures	Shoulder arthroplasty	White	332	61,8	0	0,0
Surgical and medical procedures	Shoulder arthroplasty	Asian	180	33,5	0	0,0
Surgical and medical procedures	Shoulder arthroplasty	Other	17	3,2	1	5,9
Surgical and medical procedures	Shoulder arthroplasty	Unknown	8	1,5	0	0,0
Surgical and medical procedures	Transurethral prostatectomy	White	332	61,8	1	0,3
Surgical and medical procedures	Transurethral prostatectomy	Asian	180	33,5	0	0,0
Surgical and medical procedures	Transurethral prostatectomy	Other	17	3,2	0	0,0
Surgical and medical procedures	Transurethral prostatectomy	Unknown	8	1,5	0	0,0
Vascular disorders		White	332	61,8	12	3,6
Vascular disorders		Asian	180	33,5	2	1,1
Vascular disorders		Other	17	3,2	0	0,0
Vascular disorders		Unknown	8	1,5	0	0,0
Vascular disorders	Brachiocephalic arteriosclerosis	White	332	61,8	1	0,3
Vascular disorders	Brachiocephalic arteriosclerosis	Asian	180	33,5	0	0,0
Vascular disorders	Brachiocephalic arteriosclerosis	Other	17	3,2	0	0,0
Vascular disorders	Brachiocephalic arteriosclerosis	Unknown	8	1,5	0	0,0
Vascular disorders	Hypertension	White	332	61,8	6	1,8
Vascular disorders	Hypertension	Asian	180	33,5	2	1,1
Vascular disorders	Hypertension	Other	17	3,2	0	0,0
Vascular disorders	Hypertension	Unknown	8	1,5	0	0,0
Vascular disorders	Hypertensive crisis	White	332	61,8	1	0,3
Vascular disorders	Hypertensive crisis	Asian	180	33,5	0	0,0
Vascular disorders	Hypertensive crisis	Other	17	3,2	0	0,0
Vascular disorders	Hypertensive crisis	Unknown	8	1,5	0	0,0
Vascular disorders	Hypotension	White	332	61,8	1	0,3
Vascular disorders	Hypotension	Asian	180	33,5	0	0,0
Vascular disorders	Hypotension	Other	17	3,2	0	0,0
Vascular disorders	Hypotension	Unknown	8	1,5	0	0,0
Vascular disorders	Orthostatic hypotension	White	332	61,8	1	0,3
Vascular disorders	Orthostatic hypotension	Asian	180	33,5	0	0,0
Vascular disorders	Orthostatic hypotension	Other	17	3,2	0	0,0
Vascular disorders	Orthostatic hypotension	Unknown	8	1,5	0	0,0
Vascular disorders	Varicose vein	White	332	61,8	1	0,3
Vascular disorders	Varicose vein	Asian	180	33,5	0	0,0
Vascular disorders	Varicose vein	Other	17	3,2	0	0,0
Vascular disorders	Varicose vein	Unknown	8	1,5	0	0,0
Vascular disorders	Vascular occlusion	White	332	61,8	1	0,3
Vascular disorders	Vascular occlusion	Asian	180	33,5	0	0,0
Vascular disorders	Vascular occlusion	Other	17	3,2	0	0,0
Vascular disorders	Vascular occlusion	Unknown	8	1,5	0	0,0
Vascular disorders	Venous occlusion	White	332	61,8	1	0,3
Vascular disorders	Venous occlusion	Asian	180	33,5	0	0,0
Vascular disorders	Venous occlusion	Other	17	3,2	0	0,0
Vascular disorders	Venous occlusion	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sq_WMODAE_WK72_SEa24_30AUG2023_41984.xls
26APR2024 17:51

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		n/a	537	100,0	7	1,3
Cardiac disorders	Acute myocardial infarction	n/a	537	100,0	1	0,2
Cardiac disorders	Angina unstable	n/a	537	100,0	1	0,2
Cardiac disorders	Atrial fibrillation	n/a	537	100,0	1	0,2
Cardiac disorders	Cardiac failure congestive	n/a	537	100,0	1	0,2
Cardiac disorders	Coronary artery disease	n/a	537	100,0	1	0,2
Cardiac disorders	Myocardial infarction	n/a	537	100,0	2	0,4
Eye disorders		n/a	537	100,0	3	0,6
Eye disorders	Cataract	n/a	537	100,0	1	0,2
Eye disorders	Ocular vascular disorder	n/a	537	100,0	1	0,2
Eye disorders	Rhegmatogenous retinal detachment	n/a	537	100,0	1	0,2
Gastrointestinal disorders		n/a	537	100,0	2	0,4
Gastrointestinal disorders	Mesenteric vein thrombosis	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Pancreatitis acute	n/a	537	100,0	1	0,2
General disorders and administration site conditions		n/a	537	100,0	3	0,6
General disorders and administration site conditions	Asthenia	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Death	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Vascular stent stenosis	n/a	537	100,0	1	0,2
Infections and infestations		n/a	537	100,0	3	0,6
Infections and infestations	Intestinal sepsis	n/a	537	100,0	1	0,2
Infections and infestations	Pneumonia	n/a	537	100,0	1	0,2
Infections and infestations	Sepsis	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications		n/a	537	100,0	6	1,1
Injury, poisoning and procedural complications	Clavicle fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Comminuted fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Hip fracture	n/a	537	100,0	2	0,4
Injury, poisoning and procedural complications	Sternal fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Tooth fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Ulna fracture	n/a	537	100,0	1	0,2
Investigations		n/a	537	100,0	1	0,2
Investigations	Blood pressure increased	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders		n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders		n/a	537	100,0	3	0,6
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Osteoarthritis	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders	Spinal pain	n/a	537	100,0	1	0,2

Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	537	100,0	2	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	n/a	537	100,0	1	0,2
Nervous system disorders		n/a	537	100,0	9	1,7
Nervous system disorders	Cerebral haematoma	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebral infarction	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebral thrombosis	n/a	537	100,0	1	0,2
Nervous system disorders	Intracranial aneurysm	n/a	537	100,0	1	0,2
Nervous system disorders	Ischaemic stroke	n/a	537	100,0	2	0,4
Nervous system disorders	Loss of consciousness	n/a	537	100,0	1	0,2
Nervous system disorders	Multiple sclerosis	n/a	537	100,0	1	0,2
Nervous system disorders	Sciatica	n/a	537	100,0	1	0,2
Renal and urinary disorders		n/a	537	100,0	2	0,4
Renal and urinary disorders	Acute kidney injury	n/a	537	100,0	1	0,2
Renal and urinary disorders	Renal mass	n/a	537	100,0	1	0,2
Social circumstances		n/a	537	100,0	1	0,2
Social circumstances	Joint prosthesis user	n/a	537	100,0	1	0,2
Vascular disorders		n/a	537	100,0	3	0,6
Vascular disorders	Aortic stenosis	n/a	537	100,0	1	0,2
Vascular disorders	Hypertension	n/a	537	100,0	1	0,2
Vascular disorders	Hypertensive crisis	n/a	537	100,0	1	0,2

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 17:54

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Gender

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		Male	264	49,2	3	1,1
Cardiac disorders		Female	273	50,8	4	1,5
Cardiac disorders	Acute myocardial infarction	Male	264	49,2	1	0,4
Cardiac disorders	Acute myocardial infarction	Female	273	50,8	0	0,0
Cardiac disorders	Angina unstable	Male	264	49,2	1	0,4
Cardiac disorders	Angina unstable	Female	273	50,8	0	0,0
Cardiac disorders	Atrial fibrillation	Male	264	49,2	0	0,0
Cardiac disorders	Atrial fibrillation	Female	273	50,8	1	0,4
Cardiac disorders	Cardiac failure congestive	Male	264	49,2	0	0,0
Cardiac disorders	Cardiac failure congestive	Female	273	50,8	1	0,4
Cardiac disorders	Coronary artery disease	Male	264	49,2	1	0,4
Cardiac disorders	Coronary artery disease	Female	273	50,8	0	0,0
Cardiac disorders	Myocardial infarction	Male	264	49,2	0	0,0
Cardiac disorders	Myocardial infarction	Female	273	50,8	2	0,7
Eye disorders		Male	264	49,2	2	0,8
Eye disorders		Female	273	50,8	1	0,4
Eye disorders	Cataract	Male	264	49,2	1	0,4
Eye disorders	Cataract	Female	273	50,8	0	0,0
Eye disorders	Ocular vascular disorder	Male	264	49,2	0	0,0
Eye disorders	Ocular vascular disorder	Female	273	50,8	1	0,4
Eye disorders	Rhegmatogenous retinal detachment	Male	264	49,2	1	0,4
Eye disorders	Rhegmatogenous retinal detachment	Female	273	50,8	0	0,0
Gastrointestinal disorders		Male	264	49,2	0	0,0
Gastrointestinal disorders		Female	273	50,8	2	0,7
Gastrointestinal disorders	Mesenteric vein thrombosis	Male	264	49,2	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	Female	273	50,8	1	0,4
Gastrointestinal disorders	Pancreatitis acute	Male	264	49,2	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Female	273	50,8	1	0,4
General disorders and administration site conditions		Male	264	49,2	1	0,4
General disorders and administration site conditions		Female	273	50,8	2	0,7
General disorders and administration site conditions	Asthenia	Male	264	49,2	0	0,0
General disorders and administration site conditions	Asthenia	Female	273	50,8	1	0,4
General disorders and administration site conditions	Death	Male	264	49,2	1	0,4
General disorders and administration site conditions	Death	Female	273	50,8	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Male	264	49,2	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Female	273	50,8	1	0,4
Infections and infestations		Male	264	49,2	1	0,4
Infections and infestations		Female	273	50,8	2	0,7
Infections and infestations	Intestinal sepsis	Male	264	49,2	0	0,0
Infections and infestations	Intestinal sepsis	Female	273	50,8	1	0,4
Infections and infestations	Pneumonia	Male	264	49,2	0	0,0

Infections and infestations	Pneumonia	Female	273	50,8	1	0,4
Infections and infestations	Sepsis	Male	264	49,2	1	0,4
Infections and infestations	Sepsis	Female	273	50,8	0	0,0
Injury, poisoning and procedural complications		Male	264	49,2	1	0,4
Injury, poisoning and procedural complications		Female	273	50,8	5	1,8
Injury, poisoning and procedural complications	Clavicle fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Clavicle fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Comminuted fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Hip fracture	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Hip fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Sternal fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Tooth fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Ulna fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Female	273	50,8	1	0,4
Investigations		Male	264	49,2	1	0,4
Investigations		Female	273	50,8	0	0,0
Investigations	Blood pressure increased	Male	264	49,2	1	0,4
Investigations	Blood pressure increased	Female	273	50,8	0	0,0
Metabolism and nutrition disorders		Male	264	49,2	1	0,4
Metabolism and nutrition disorders		Female	273	50,8	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Male	264	49,2	1	0,4
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Female	273	50,8	0	0,0
Musculoskeletal and connective tissue disorders		Male	264	49,2	2	0,8
Musculoskeletal and connective tissue disorders		Female	273	50,8	1	0,4
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Male	264	49,2	1	0,4
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Female	273	50,8	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Male	264	49,2	1	0,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	Female	273	50,8	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Male	264	49,2	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Female	273	50,8	2	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Female	273	50,8	1	0,4
Nervous system disorders		Male	264	49,2	4	1,5
Nervous system disorders		Female	273	50,8	5	1,8
Nervous system disorders	Cerebral haematoma	Male	264	49,2	0	0,0
Nervous system disorders	Cerebral haematoma	Female	273	50,8	1	0,4
Nervous system disorders	Cerebral infarction	Male	264	49,2	0	0,0
Nervous system disorders	Cerebral infarction	Female	273	50,8	1	0,4
Nervous system disorders	Cerebral thrombosis	Male	264	49,2	1	0,4
Nervous system disorders	Cerebral thrombosis	Female	273	50,8	0	0,0
Nervous system disorders	Intracranial aneurysm	Male	264	49,2	0	0,0
Nervous system disorders	Intracranial aneurysm	Female	273	50,8	1	0,4
Nervous system disorders	Ischaemic stroke	Male	264	49,2	1	0,4
Nervous system disorders	Ischaemic stroke	Female	273	50,8	1	0,4

Nervous system disorders	Loss of consciousness	Male	264	49,2	1	0,4
Nervous system disorders	Loss of consciousness	Female	273	50,8	0	0,0
Nervous system disorders	Multiple sclerosis	Male	264	49,2	0	0,0
Nervous system disorders	Multiple sclerosis	Female	273	50,8	1	0,4
Nervous system disorders	Sciatica	Male	264	49,2	1	0,4
Nervous system disorders	Sciatica	Female	273	50,8	0	0,0
Renal and urinary disorders		Male	264	49,2	1	0,4
Renal and urinary disorders		Female	273	50,8	1	0,4
Renal and urinary disorders	Acute kidney injury	Male	264	49,2	1	0,4
Renal and urinary disorders	Acute kidney injury	Female	273	50,8	0	0,0
Renal and urinary disorders	Renal mass	Male	264	49,2	0	0,0
Renal and urinary disorders	Renal mass	Female	273	50,8	1	0,4
Social circumstances		Male	264	49,2	0	0,0
Social circumstances		Female	273	50,8	1	0,4
Social circumstances	Joint prosthesis user	Male	264	49,2	0	0,0
Social circumstances	Joint prosthesis user	Female	273	50,8	1	0,4
Vascular disorders		Male	264	49,2	2	0,8
Vascular disorders		Female	273	50,8	1	0,4
Vascular disorders	Aortic stenosis	Male	264	49,2	1	0,4
Vascular disorders	Aortic stenosis	Female	273	50,8	0	0,0
Vascular disorders	Hypertension	Male	264	49,2	0	0,0
Vascular disorders	Hypertension	Female	273	50,8	1	0,4
Vascular disorders	Hypertensive crisis	Male	264	49,2	1	0,4
Vascular disorders	Hypertensive crisis	Female	273	50,8	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 17:54

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Age

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		<65 years	270	50,3	4	1,5
Cardiac disorders		>=65 years	267	49,7	3	1,1
Cardiac disorders	Acute myocardial infarction	<65 years	270	50,3	1	0,4
Cardiac disorders	Acute myocardial infarction	>=65 years	267	49,7	0	0,0
Cardiac disorders	Angina unstable	<65 years	270	50,3	1	0,4
Cardiac disorders	Angina unstable	>=65 years	267	49,7	0	0,0
Cardiac disorders	Atrial fibrillation	<65 years	270	50,3	1	0,4
Cardiac disorders	Atrial fibrillation	>=65 years	267	49,7	0	0,0
Cardiac disorders	Cardiac failure congestive	<65 years	270	50,3	1	0,4
Cardiac disorders	Cardiac failure congestive	>=65 years	267	49,7	0	0,0
Cardiac disorders	Coronary artery disease	<65 years	270	50,3	0	0,0
Cardiac disorders	Coronary artery disease	>=65 years	267	49,7	1	0,4
Cardiac disorders	Myocardial infarction	<65 years	270	50,3	0	0,0
Cardiac disorders	Myocardial infarction	>=65 years	267	49,7	2	0,7
Eye disorders		<65 years	270	50,3	1	0,4
Eye disorders		>=65 years	267	49,7	2	0,7
Eye disorders	Cataract	<65 years	270	50,3	0	0,0
Eye disorders	Cataract	>=65 years	267	49,7	1	0,4
Eye disorders	Ocular vascular disorder	<65 years	270	50,3	0	0,0
Eye disorders	Ocular vascular disorder	>=65 years	267	49,7	1	0,4
Eye disorders	Rhegmatogenous retinal detachment	<65 years	270	50,3	1	0,4
Eye disorders	Rhegmatogenous retinal detachment	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders		<65 years	270	50,3	1	0,4
Gastrointestinal disorders		>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Mesenteric vein thrombosis	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Pancreatitis acute	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Pancreatitis acute	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions		<65 years	270	50,3	1	0,4
General disorders and administration site conditions		>=65 years	267	49,7	2	0,7
General disorders and administration site conditions	Asthenia	<65 years	270	50,3	0	0,0
General disorders and administration site conditions	Asthenia	>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Death	<65 years	270	50,3	0	0,0
General disorders and administration site conditions	Death	>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Vascular stent stenosis	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Vascular stent stenosis	>=65 years	267	49,7	0	0,0
Infections and infestations		<65 years	270	50,3	0	0,0
Infections and infestations		>=65 years	267	49,7	3	1,1
Infections and infestations	Intestinal sepsis	<65 years	270	50,3	0	0,0
Infections and infestations	Intestinal sepsis	>=65 years	267	49,7	1	0,4
Infections and infestations	Pneumonia	<65 years	270	50,3	0	0,0

Infections and infestations	Pneumonia	>=65 years	267	49,7	1	0,4
Infections and infestations	Sepsis	<65 years	270	50,3	0	0,0
Infections and infestations	Sepsis	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications		<65 years	270	50,3	2	0,7
Injury, poisoning and procedural complications		>=65 years	267	49,7	4	1,5
Injury, poisoning and procedural complications	Clavicle fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Clavicle fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Comminuted fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Hip fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Hip fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Sternal fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Tooth fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Tooth fracture	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	>=65 years	267	49,7	1	0,4
Investigations		<65 years	270	50,3	1	0,4
Investigations		>=65 years	267	49,7	0	0,0
Investigations	Blood pressure increased	<65 years	270	50,3	1	0,4
Investigations	Blood pressure increased	>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders		<65 years	270	50,3	1	0,4
Metabolism and nutrition disorders		>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	<65 years	270	50,3	1	0,4
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	>=65 years	267	49,7	0	0,0
Musculoskeletal and connective tissue disorders		<65 years	270	50,3	2	0,7
Musculoskeletal and connective tissue disorders		>=65 years	267	49,7	1	0,4
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	<65 years	270	50,3	1	0,4
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	>=65 years	267	49,7	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	<65 years	270	50,3	1	0,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=65 years	267	49,7	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	<65 years	270	50,3	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	>=65 years	267	49,7	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<65 years	270	50,3	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=65 years	267	49,7	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<65 years	270	50,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=65 years	267	49,7	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	<65 years	270	50,3	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	>=65 years	267	49,7	0	0,0
Nervous system disorders		<65 years	270	50,3	3	1,1
Nervous system disorders		>=65 years	267	49,7	6	2,2
Nervous system disorders	Cerebral haematoma	<65 years	270	50,3	0	0,0
Nervous system disorders	Cerebral haematoma	>=65 years	267	49,7	1	0,4
Nervous system disorders	Cerebral infarction	<65 years	270	50,3	1	0,4
Nervous system disorders	Cerebral infarction	>=65 years	267	49,7	0	0,0
Nervous system disorders	Cerebral thrombosis	<65 years	270	50,3	1	0,4
Nervous system disorders	Cerebral thrombosis	>=65 years	267	49,7	0	0,0
Nervous system disorders	Intracranial aneurysm	<65 years	270	50,3	0	0,0
Nervous system disorders	Intracranial aneurysm	>=65 years	267	49,7	1	0,4
Nervous system disorders	Ischaemic stroke	<65 years	270	50,3	0	0,0
Nervous system disorders	Ischaemic stroke	>=65 years	267	49,7	2	0,7

Nervous system disorders	Loss of consciousness	<65 years	270	50,3	0	0,0
Nervous system disorders	Loss of consciousness	>=65 years	267	49,7	1	0,4
Nervous system disorders	Multiple sclerosis	<65 years	270	50,3	0	0,0
Nervous system disorders	Multiple sclerosis	>=65 years	267	49,7	1	0,4
Nervous system disorders	Sciatica	<65 years	270	50,3	1	0,4
Nervous system disorders	Sciatica	>=65 years	267	49,7	0	0,0
Renal and urinary disorders		<65 years	270	50,3	0	0,0
Renal and urinary disorders		>=65 years	267	49,7	2	0,7
Renal and urinary disorders	Acute kidney injury	<65 years	270	50,3	0	0,0
Renal and urinary disorders	Acute kidney injury	>=65 years	267	49,7	1	0,4
Renal and urinary disorders	Renal mass	<65 years	270	50,3	0	0,0
Renal and urinary disorders	Renal mass	>=65 years	267	49,7	1	0,4
Social circumstances		<65 years	270	50,3	0	0,0
Social circumstances		>=65 years	267	49,7	1	0,4
Social circumstances	Joint prosthesis user	<65 years	270	50,3	0	0,0
Social circumstances	Joint prosthesis user	>=65 years	267	49,7	1	0,4
Vascular disorders		<65 years	270	50,3	2	0,7
Vascular disorders		>=65 years	267	49,7	1	0,4
Vascular disorders	Aortic stenosis	<65 years	270	50,3	0	0,0
Vascular disorders	Aortic stenosis	>=65 years	267	49,7	1	0,4
Vascular disorders	Hypertension	<65 years	270	50,3	1	0,4
Vascular disorders	Hypertension	>=65 years	267	49,7	0	0,0
Vascular disorders	Hypertensive crisis	<65 years	270	50,3	1	0,4
Vascular disorders	Hypertensive crisis	>=65 years	267	49,7	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 17:54

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETRS letter score

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		<=54 letters	176	32,8	4	2,3
Cardiac disorders		>=55 letters	361	67,2	3	0,8
Cardiac disorders	Acute myocardial infarction	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Acute myocardial infarction	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Angina unstable	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Angina unstable	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Atrial fibrillation	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Atrial fibrillation	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Cardiac failure congestive	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Cardiac failure congestive	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Coronary artery disease	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Coronary artery disease	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Myocardial infarction	<=54 letters	176	32,8	2	1,1
Cardiac disorders	Myocardial infarction	>=55 letters	361	67,2	0	0,0
Eye disorders		<=54 letters	176	32,8	2	1,1
Eye disorders		>=55 letters	361	67,2	1	0,3
Eye disorders	Cataract	<=54 letters	176	32,8	1	0,6
Eye disorders	Cataract	>=55 letters	361	67,2	0	0,0
Eye disorders	Ocular vascular disorder	<=54 letters	176	32,8	0	0,0
Eye disorders	Ocular vascular disorder	>=55 letters	361	67,2	1	0,3
Eye disorders	Rhegmatogenous retinal detachment	<=54 letters	176	32,8	1	0,6
Eye disorders	Rhegmatogenous retinal detachment	>=55 letters	361	67,2	0	0,0
Gastrointestinal disorders		<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders		>=55 letters	361	67,2	2	0,6
Gastrointestinal disorders	Mesenteric vein thrombosis	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Pancreatitis acute	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Pancreatitis acute	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions		<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions		>=55 letters	361	67,2	3	0,8
General disorders and administration site conditions	Asthenia	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Asthenia	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Death	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Death	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Vascular stent stenosis	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	>=55 letters	361	67,2	1	0,3
Infections and infestations		<=54 letters	176	32,8	2	1,1
Infections and infestations		>=55 letters	361	67,2	1	0,3
Infections and infestations	Intestinal sepsis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Intestinal sepsis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Pneumonia	<=54 letters	176	32,8	1	0,6

Infections and infestations	Pneumonia	>=55 letters	361	67,2	0	0,0
Infections and infestations	Sepsis	<=54 letters	176	32,8	1	0,6
Infections and infestations	Sepsis	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications		<=54 letters	176	32,8	2	1,1
Injury, poisoning and procedural complications		>=55 letters	361	67,2	4	1,1
Injury, poisoning and procedural complications	Clavicle fracture	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Clavicle fracture	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Hip fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Hip fracture	>=55 letters	361	67,2	2	0,6
Injury, poisoning and procedural complications	Sternal fracture	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Sternal fracture	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Ulna fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	>=55 letters	361	67,2	1	0,3
Investigations		<=54 letters	176	32,8	0	0,0
Investigations		>=55 letters	361	67,2	1	0,3
Investigations	Blood pressure increased	<=54 letters	176	32,8	0	0,0
Investigations	Blood pressure increased	>=55 letters	361	67,2	1	0,3
Metabolism and nutrition disorders		<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders		>=55 letters	361	67,2	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	>=55 letters	361	67,2	0	0,0
Musculoskeletal and connective tissue disorders		<=54 letters	176	32,8	2	1,1
Musculoskeletal and connective tissue disorders		>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	>=55 letters	361	67,2	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=55 letters	361	67,2	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=55 letters	361	67,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	<=54 letters	176	32,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	>=55 letters	361	67,2	1	0,3
Nervous system disorders		<=54 letters	176	32,8	2	1,1
Nervous system disorders		>=55 letters	361	67,2	7	1,9
Nervous system disorders	Cerebral haematoma	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cerebral haematoma	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cerebral infarction	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cerebral infarction	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cerebral thrombosis	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cerebral thrombosis	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Intracranial aneurysm	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Intracranial aneurysm	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Ischaemic stroke	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Ischaemic stroke	>=55 letters	361	67,2	2	0,6

Nervous system disorders	Loss of consciousness	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Loss of consciousness	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Multiple sclerosis	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Multiple sclerosis	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Sciatica	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Sciatica	>=55 letters	361	67,2	0	0,0
Renal and urinary disorders		<=54 letters	176	32,8	1	0,6
Renal and urinary disorders		>=55 letters	361	67,2	1	0,3
Renal and urinary disorders	Acute kidney injury	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Acute kidney injury	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders	Renal mass	<=54 letters	176	32,8	1	0,6
Renal and urinary disorders	Renal mass	>=55 letters	361	67,2	0	0,0
Social circumstances		<=54 letters	176	32,8	1	0,6
Social circumstances		>=55 letters	361	67,2	0	0,0
Social circumstances	Joint prosthesis user	<=54 letters	176	32,8	1	0,6
Social circumstances	Joint prosthesis user	>=55 letters	361	67,2	0	0,0
Vascular disorders		<=54 letters	176	32,8	0	0,0
Vascular disorders		>=55 letters	361	67,2	3	0,8
Vascular disorders	Aortic stenosis	<=54 letters	176	32,8	0	0,0
Vascular disorders	Aortic stenosis	>=55 letters	361	67,2	1	0,3
Vascular disorders	Hypertension	<=54 letters	176	32,8	0	0,0
Vascular disorders	Hypertension	>=55 letters	361	67,2	1	0,3
Vascular disorders	Hypertensive crisis	<=54 letters	176	32,8	0	0,0
Vascular disorders	Hypertensive crisis	>=55 letters	361	67,2	1	0,3

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 17:54

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Geographic Region

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		Europe	147	27,4	0	0,0
Cardiac disorders		America	197	36,7	5	2,5
Cardiac disorders		Asia Pacific (inc. Australia)	193	35,9	2	1,0
Cardiac disorders	Acute myocardial infarction	Europe	147	27,4	0	0,0
Cardiac disorders	Acute myocardial infarction	America	197	36,7	0	0,0
Cardiac disorders	Acute myocardial infarction	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Cardiac disorders	Angina unstable	Europe	147	27,4	0	0,0
Cardiac disorders	Angina unstable	America	197	36,7	0	0,0
Cardiac disorders	Angina unstable	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Cardiac disorders	Atrial fibrillation	Europe	147	27,4	0	0,0
Cardiac disorders	Atrial fibrillation	America	197	36,7	1	0,5
Cardiac disorders	Atrial fibrillation	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Cardiac disorders	Cardiac failure congestive	Europe	147	27,4	0	0,0
Cardiac disorders	Cardiac failure congestive	America	197	36,7	1	0,5
Cardiac disorders	Cardiac failure congestive	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Cardiac disorders	Coronary artery disease	Europe	147	27,4	0	0,0
Cardiac disorders	Coronary artery disease	America	197	36,7	1	0,5
Cardiac disorders	Coronary artery disease	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Cardiac disorders	Myocardial infarction	Europe	147	27,4	0	0,0
Cardiac disorders	Myocardial infarction	America	197	36,7	2	1,0
Cardiac disorders	Myocardial infarction	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders		Europe	147	27,4	1	0,7
Eye disorders		America	197	36,7	1	0,5
Eye disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Cataract	Europe	147	27,4	0	0,0
Eye disorders	Cataract	America	197	36,7	1	0,5
Eye disorders	Cataract	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Ocular vascular disorder	Europe	147	27,4	1	0,7
Eye disorders	Ocular vascular disorder	America	197	36,7	0	0,0
Eye disorders	Ocular vascular disorder	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Europe	147	27,4	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	America	197	36,7	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Gastrointestinal disorders		Europe	147	27,4	1	0,7
Gastrointestinal disorders		America	197	36,7	1	0,5
Gastrointestinal disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	Europe	147	27,4	1	0,7
Gastrointestinal disorders	Mesenteric vein thrombosis	America	197	36,7	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Europe	147	27,4	0	0,0
Gastrointestinal disorders	Pancreatitis acute	America	197	36,7	1	0,5
Gastrointestinal disorders	Pancreatitis acute	Asia Pacific (inc. Australia)	193	35,9	0	0,0

General disorders and administration site conditions		Europe	147	27,4	2	1,4
General disorders and administration site conditions		America	197	36,7	1	0,5
General disorders and administration site conditions		Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions	Asthenia	Europe	147	27,4	1	0,7
General disorders and administration site conditions	Asthenia	America	197	36,7	0	0,0
General disorders and administration site conditions	Asthenia	Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions	Death	Europe	147	27,4	0	0,0
General disorders and administration site conditions	Death	America	197	36,7	1	0,5
General disorders and administration site conditions	Death	Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Europe	147	27,4	1	0,7
General disorders and administration site conditions	Vascular stent stenosis	America	197	36,7	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations		Europe	147	27,4	1	0,7
Infections and infestations		America	197	36,7	1	0,5
Infections and infestations		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Intestinal sepsis	Europe	147	27,4	1	0,7
Infections and infestations	Intestinal sepsis	America	197	36,7	0	0,0
Infections and infestations	Intestinal sepsis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Pneumonia	Europe	147	27,4	0	0,0
Infections and infestations	Pneumonia	America	197	36,7	0	0,0
Infections and infestations	Pneumonia	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Sepsis	Europe	147	27,4	0	0,0
Infections and infestations	Sepsis	America	197	36,7	1	0,5
Infections and infestations	Sepsis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications		Europe	147	27,4	2	1,4
Injury, poisoning and procedural complications		America	197	36,7	2	1,0
Injury, poisoning and procedural complications		Asia Pacific (inc. Australia)	193	35,9	2	1,0
Injury, poisoning and procedural complications	Clavicle fracture	Europe	147	27,4	0	0,0
Injury, poisoning and procedural complications	Clavicle fracture	America	197	36,7	1	0,5
Injury, poisoning and procedural complications	Clavicle fracture	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	Europe	147	27,4	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Injury, poisoning and procedural complications	Hip fracture	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Hip fracture	America	197	36,7	1	0,5
Injury, poisoning and procedural complications	Hip fracture	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	Europe	147	27,4	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Injury, poisoning and procedural complications	Tooth fracture	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Tooth fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Europe	147	27,4	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Investigations		Europe	147	27,4	1	0,7
Investigations		America	197	36,7	0	0,0
Investigations		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Investigations	Blood pressure increased	Europe	147	27,4	1	0,7
Investigations	Blood pressure increased	America	197	36,7	0	0,0
Investigations	Blood pressure increased	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Metabolism and nutrition disorders		Europe	147	27,4	0	0,0
Metabolism and nutrition disorders		America	197	36,7	0	0,0

Metabolism and nutrition disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Europe	147	27,4	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	America	197	36,7	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Musculoskeletal and connective tissue disorders		Europe	147	27,4	2	1,4
Musculoskeletal and connective tissue disorders		America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Europe	147	27,4	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Musculoskeletal and connective tissue disorders	Osteoarthritis	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Osteoarthritis	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Spinal pain	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Europe	147	27,4	2	1,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		America	197	36,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Europe	147	27,4	1	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	America	197	36,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Europe	147	27,4	1	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	America	197	36,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders		Europe	147	27,4	1	0,7
Nervous system disorders		America	197	36,7	3	1,5
Nervous system disorders		Asia Pacific (inc. Australia)	193	35,9	5	2,6
Nervous system disorders	Cerebral haematoma	Europe	147	27,4	1	0,7
Nervous system disorders	Cerebral haematoma	America	197	36,7	0	0,0
Nervous system disorders	Cerebral haematoma	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Cerebral infarction	Europe	147	27,4	0	0,0
Nervous system disorders	Cerebral infarction	America	197	36,7	0	0,0
Nervous system disorders	Cerebral infarction	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Cerebral thrombosis	Europe	147	27,4	0	0,0
Nervous system disorders	Cerebral thrombosis	America	197	36,7	0	0,0
Nervous system disorders	Cerebral thrombosis	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Intracranial aneurysm	Europe	147	27,4	0	0,0
Nervous system disorders	Intracranial aneurysm	America	197	36,7	0	0,0
Nervous system disorders	Intracranial aneurysm	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Ischaemic stroke	Europe	147	27,4	0	0,0
Nervous system disorders	Ischaemic stroke	America	197	36,7	2	1,0
Nervous system disorders	Ischaemic stroke	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Loss of consciousness	Europe	147	27,4	0	0,0
Nervous system disorders	Loss of consciousness	America	197	36,7	0	0,0
Nervous system disorders	Loss of consciousness	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Multiple sclerosis	Europe	147	27,4	0	0,0
Nervous system disorders	Multiple sclerosis	America	197	36,7	1	0,5
Nervous system disorders	Multiple sclerosis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Sciatica	Europe	147	27,4	0	0,0
Nervous system disorders	Sciatica	America	197	36,7	0	0,0
Nervous system disorders	Sciatica	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Renal and urinary disorders		Europe	147	27,4	0	0,0

Renal and urinary disorders		America	197	36,7	2	1,0
Renal and urinary disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Renal and urinary disorders	Acute kidney injury	Europe	147	27,4	0	0,0
Renal and urinary disorders	Acute kidney injury	America	197	36,7	1	0,5
Renal and urinary disorders	Acute kidney injury	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Renal and urinary disorders	Renal mass	Europe	147	27,4	0	0,0
Renal and urinary disorders	Renal mass	America	197	36,7	1	0,5
Renal and urinary disorders	Renal mass	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Social circumstances		Europe	147	27,4	0	0,0
Social circumstances		America	197	36,7	1	0,5
Social circumstances		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Social circumstances	Joint prosthesis user	Europe	147	27,4	0	0,0
Social circumstances	Joint prosthesis user	America	197	36,7	1	0,5
Social circumstances	Joint prosthesis user	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Vascular disorders		Europe	147	27,4	1	0,7
Vascular disorders		America	197	36,7	0	0,0
Vascular disorders		Asia Pacific (inc. Australia)	193	35,9	2	1,0
Vascular disorders	Aortic stenosis	Europe	147	27,4	0	0,0
Vascular disorders	Aortic stenosis	America	197	36,7	0	0,0
Vascular disorders	Aortic stenosis	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Vascular disorders	Hypertension	Europe	147	27,4	0	0,0
Vascular disorders	Hypertension	America	197	36,7	0	0,0
Vascular disorders	Hypertension	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Vascular disorders	Hypertensive crisis	Europe	147	27,4	1	0,7
Vascular disorders	Hypertensive crisis	America	197	36,7	0	0,0
Vascular disorders	Hypertensive crisis	Asia Pacific (inc. Australia)	193	35,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 17:54

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		White	332	61,8	5	1,5
Cardiac disorders		Asian	180	33,5	2	1,1
Cardiac disorders		Other	17	3,2	0	0,0
Cardiac disorders		Unknown	8	1,5	0	0,0
Cardiac disorders	Acute myocardial infarction	White	332	61,8	0	0,0
Cardiac disorders	Acute myocardial infarction	Asian	180	33,5	1	0,6
Cardiac disorders	Acute myocardial infarction	Other	17	3,2	0	0,0
Cardiac disorders	Acute myocardial infarction	Unknown	8	1,5	0	0,0
Cardiac disorders	Angina unstable	White	332	61,8	0	0,0
Cardiac disorders	Angina unstable	Asian	180	33,5	1	0,6
Cardiac disorders	Angina unstable	Other	17	3,2	0	0,0
Cardiac disorders	Angina unstable	Unknown	8	1,5	0	0,0
Cardiac disorders	Atrial fibrillation	White	332	61,8	1	0,3
Cardiac disorders	Atrial fibrillation	Asian	180	33,5	0	0,0
Cardiac disorders	Atrial fibrillation	Other	17	3,2	0	0,0
Cardiac disorders	Atrial fibrillation	Unknown	8	1,5	0	0,0
Cardiac disorders	Cardiac failure congestive	White	332	61,8	1	0,3
Cardiac disorders	Cardiac failure congestive	Asian	180	33,5	0	0,0
Cardiac disorders	Cardiac failure congestive	Other	17	3,2	0	0,0
Cardiac disorders	Cardiac failure congestive	Unknown	8	1,5	0	0,0
Cardiac disorders	Coronary artery disease	White	332	61,8	1	0,3
Cardiac disorders	Coronary artery disease	Asian	180	33,5	0	0,0
Cardiac disorders	Coronary artery disease	Other	17	3,2	0	0,0
Cardiac disorders	Coronary artery disease	Unknown	8	1,5	0	0,0
Cardiac disorders	Myocardial infarction	White	332	61,8	2	0,6
Cardiac disorders	Myocardial infarction	Asian	180	33,5	0	0,0
Cardiac disorders	Myocardial infarction	Other	17	3,2	0	0,0
Cardiac disorders	Myocardial infarction	Unknown	8	1,5	0	0,0
Eye disorders		White	332	61,8	2	0,6
Eye disorders		Asian	180	33,5	0	0,0
Eye disorders		Other	17	3,2	1	5,9
Eye disorders		Unknown	8	1,5	0	0,0
Eye disorders	Cataract	White	332	61,8	0	0,0
Eye disorders	Cataract	Asian	180	33,5	0	0,0
Eye disorders	Cataract	Other	17	3,2	1	5,9
Eye disorders	Cataract	Unknown	8	1,5	0	0,0
Eye disorders	Ocular vascular disorder	White	332	61,8	1	0,3
Eye disorders	Ocular vascular disorder	Asian	180	33,5	0	0,0
Eye disorders	Ocular vascular disorder	Other	17	3,2	0	0,0
Eye disorders	Ocular vascular disorder	Unknown	8	1,5	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	White	332	61,8	1	0,3
Eye disorders	Rhegmatogenous retinal detachment	Asian	180	33,5	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Other	17	3,2	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Unknown	8	1,5	0	0,0

Gastrointestinal disorders		White	332	61,8	2	0,6
Gastrointestinal disorders		Asian	180	33,5	0	0,0
Gastrointestinal disorders		Other	17	3,2	0	0,0
Gastrointestinal disorders		Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	White	332	61,8	1	0,3
Gastrointestinal disorders	Mesenteric vein thrombosis	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	Other	17	3,2	0	0,0
Gastrointestinal disorders	Mesenteric vein thrombosis	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Pancreatitis acute	White	332	61,8	1	0,3
Gastrointestinal disorders	Pancreatitis acute	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Other	17	3,2	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Unknown	8	1,5	0	0,0
General disorders and administration site conditions		White	332	61,8	3	0,9
General disorders and administration site conditions		Asian	180	33,5	0	0,0
General disorders and administration site conditions		Other	17	3,2	0	0,0
General disorders and administration site conditions		Unknown	8	1,5	0	0,0
General disorders and administration site conditions	Asthenia	White	332	61,8	1	0,3
General disorders and administration site conditions	Asthenia	Asian	180	33,5	0	0,0
General disorders and administration site conditions	Asthenia	Other	17	3,2	0	0,0
General disorders and administration site conditions	Asthenia	Unknown	8	1,5	0	0,0
General disorders and administration site conditions	Death	White	332	61,8	1	0,3
General disorders and administration site conditions	Death	Asian	180	33,5	0	0,0
General disorders and administration site conditions	Death	Other	17	3,2	0	0,0
General disorders and administration site conditions	Death	Unknown	8	1,5	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	White	332	61,8	1	0,3
General disorders and administration site conditions	Vascular stent stenosis	Asian	180	33,5	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Other	17	3,2	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Unknown	8	1,5	0	0,0
Infections and infestations		White	332	61,8	3	0,9
Infections and infestations		Asian	180	33,5	0	0,0
Infections and infestations		Other	17	3,2	0	0,0
Infections and infestations		Unknown	8	1,5	0	0,0
Infections and infestations	Intestinal sepsis	White	332	61,8	1	0,3
Infections and infestations	Intestinal sepsis	Asian	180	33,5	0	0,0
Infections and infestations	Intestinal sepsis	Other	17	3,2	0	0,0
Infections and infestations	Intestinal sepsis	Unknown	8	1,5	0	0,0
Infections and infestations	Pneumonia	White	332	61,8	1	0,3
Infections and infestations	Pneumonia	Asian	180	33,5	0	0,0
Infections and infestations	Pneumonia	Other	17	3,2	0	0,0
Infections and infestations	Pneumonia	Unknown	8	1,5	0	0,0
Infections and infestations	Sepsis	White	332	61,8	1	0,3
Infections and infestations	Sepsis	Asian	180	33,5	0	0,0
Infections and infestations	Sepsis	Other	17	3,2	0	0,0
Infections and infestations	Sepsis	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications		White	332	61,8	4	1,2
Injury, poisoning and procedural complications		Asian	180	33,5	1	0,6
Injury, poisoning and procedural complications		Other	17	3,2	1	5,9
Injury, poisoning and procedural complications		Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Clavicle fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Clavicle fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Clavicle fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Clavicle fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	White	332	61,8	0	0,0

Injury, poisoning and procedural complications	Comminuted fracture	Asian	180	33,5	1	0,6
Injury, poisoning and procedural complications	Comminuted fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Hip fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Hip fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Other	17	3,2	1	5,9
Injury, poisoning and procedural complications	Hip fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Sternal fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Tooth fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	White	332	61,8	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Asian	180	33,5	1	0,6
Injury, poisoning and procedural complications	Ulna fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Unknown	8	1,5	0	0,0
Investigations		White	332	61,8	1	0,3
Investigations		Asian	180	33,5	0	0,0
Investigations		Other	17	3,2	0	0,0
Investigations		Unknown	8	1,5	0	0,0
Investigations	Blood pressure increased	White	332	61,8	1	0,3
Investigations	Blood pressure increased	Asian	180	33,5	0	0,0
Investigations	Blood pressure increased	Other	17	3,2	0	0,0
Investigations	Blood pressure increased	Unknown	8	1,5	0	0,0
Metabolism and nutrition disorders		White	332	61,8	0	0,0
Metabolism and nutrition disorders		Asian	180	33,5	1	0,6
Metabolism and nutrition disorders		Other	17	3,2	0	0,0
Metabolism and nutrition disorders		Unknown	8	1,5	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	White	332	61,8	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Asian	180	33,5	1	0,6
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Other	17	3,2	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders		White	332	61,8	2	0,6
Musculoskeletal and connective tissue disorders		Asian	180	33,5	1	0,6
Musculoskeletal and connective tissue disorders		Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders		Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	White	332	61,8	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Asian	180	33,5	1	0,6
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	White	332	61,8	1	0,3
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	White	332	61,8	1	0,3
Musculoskeletal and connective tissue disorders	Spinal pain	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		White	332	61,8	2	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asian	180	33,5	0	0,0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Other	17	3,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	White	332	61,8	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Other	17	3,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	White	332	61,8	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Other	17	3,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Unknown	8	1,5	0	0,0
Nervous system disorders		White	332	61,8	3	0,9
Nervous system disorders		Asian	180	33,5	5	2,8
Nervous system disorders		Other	17	3,2	1	5,9
Nervous system disorders		Unknown	8	1,5	0	0,0
Nervous system disorders	Cerebral haematoma	White	332	61,8	1	0,3
Nervous system disorders	Cerebral haematoma	Asian	180	33,5	0	0,0
Nervous system disorders	Cerebral haematoma	Other	17	3,2	0	0,0
Nervous system disorders	Cerebral haematoma	Unknown	8	1,5	0	0,0
Nervous system disorders	Cerebral infarction	White	332	61,8	0	0,0
Nervous system disorders	Cerebral infarction	Asian	180	33,5	1	0,6
Nervous system disorders	Cerebral infarction	Other	17	3,2	0	0,0
Nervous system disorders	Cerebral infarction	Unknown	8	1,5	0	0,0
Nervous system disorders	Cerebral thrombosis	White	332	61,8	0	0,0
Nervous system disorders	Cerebral thrombosis	Asian	180	33,5	1	0,6
Nervous system disorders	Cerebral thrombosis	Other	17	3,2	0	0,0
Nervous system disorders	Cerebral thrombosis	Unknown	8	1,5	0	0,0
Nervous system disorders	Intracranial aneurysm	White	332	61,8	0	0,0
Nervous system disorders	Intracranial aneurysm	Asian	180	33,5	1	0,6
Nervous system disorders	Intracranial aneurysm	Other	17	3,2	0	0,0
Nervous system disorders	Intracranial aneurysm	Unknown	8	1,5	0	0,0
Nervous system disorders	Ischaemic stroke	White	332	61,8	1	0,3
Nervous system disorders	Ischaemic stroke	Asian	180	33,5	1	0,6
Nervous system disorders	Ischaemic stroke	Other	17	3,2	0	0,0
Nervous system disorders	Ischaemic stroke	Unknown	8	1,5	0	0,0
Nervous system disorders	Loss of consciousness	White	332	61,8	0	0,0
Nervous system disorders	Loss of consciousness	Asian	180	33,5	0	0,0
Nervous system disorders	Loss of consciousness	Other	17	3,2	1	5,9
Nervous system disorders	Loss of consciousness	Unknown	8	1,5	0	0,0
Nervous system disorders	Multiple sclerosis	White	332	61,8	1	0,3
Nervous system disorders	Multiple sclerosis	Asian	180	33,5	0	0,0
Nervous system disorders	Multiple sclerosis	Other	17	3,2	0	0,0
Nervous system disorders	Multiple sclerosis	Unknown	8	1,5	0	0,0
Nervous system disorders	Sciatica	White	332	61,8	0	0,0
Nervous system disorders	Sciatica	Asian	180	33,5	1	0,6
Nervous system disorders	Sciatica	Other	17	3,2	0	0,0
Nervous system disorders	Sciatica	Unknown	8	1,5	0	0,0
Renal and urinary disorders		White	332	61,8	2	0,6
Renal and urinary disorders		Asian	180	33,5	0	0,0
Renal and urinary disorders		Other	17	3,2	0	0,0
Renal and urinary disorders		Unknown	8	1,5	0	0,0
Renal and urinary disorders	Acute kidney injury	White	332	61,8	1	0,3
Renal and urinary disorders	Acute kidney injury	Asian	180	33,5	0	0,0
Renal and urinary disorders	Acute kidney injury	Other	17	3,2	0	0,0
Renal and urinary disorders	Acute kidney injury	Unknown	8	1,5	0	0,0
Renal and urinary disorders	Renal mass	White	332	61,8	1	0,3

Renal and urinary disorders	Renal mass	Asian	180	33,5	0	0,0
Renal and urinary disorders	Renal mass	Other	17	3,2	0	0,0
Renal and urinary disorders	Renal mass	Unknown	8	1,5	0	0,0
Social circumstances		White	332	61,8	1	0,3
Social circumstances		Asian	180	33,5	0	0,0
Social circumstances		Other	17	3,2	0	0,0
Social circumstances		Unknown	8	1,5	0	0,0
Social circumstances	Joint prosthesis user	White	332	61,8	1	0,3
Social circumstances	Joint prosthesis user	Asian	180	33,5	0	0,0
Social circumstances	Joint prosthesis user	Other	17	3,2	0	0,0
Social circumstances	Joint prosthesis user	Unknown	8	1,5	0	0,0
Vascular disorders		White	332	61,8	1	0,3
Vascular disorders		Asian	180	33,5	2	1,1
Vascular disorders		Other	17	3,2	0	0,0
Vascular disorders		Unknown	8	1,5	0	0,0
Vascular disorders	Aortic stenosis	White	332	61,8	0	0,0
Vascular disorders	Aortic stenosis	Asian	180	33,5	1	0,6
Vascular disorders	Aortic stenosis	Other	17	3,2	0	0,0
Vascular disorders	Aortic stenosis	Unknown	8	1,5	0	0,0
Vascular disorders	Hypertension	White	332	61,8	0	0,0
Vascular disorders	Hypertension	Asian	180	33,5	1	0,6
Vascular disorders	Hypertension	Other	17	3,2	0	0,0
Vascular disorders	Hypertension	Unknown	8	1,5	0	0,0
Vascular disorders	Hypertensive crisis	White	332	61,8	1	0,3
Vascular disorders	Hypertensive crisis	Asian	180	33,5	0	0,0
Vascular disorders	Hypertensive crisis	Other	17	3,2	0	0,0
Vascular disorders	Hypertensive crisis	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_30AUG2023_41984.xls
26APR2024 17:54

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		n/a	537	100,0	11	2,0
Cardiac disorders	Acute myocardial infarction	n/a	537	100,0	1	0,2
Cardiac disorders	Angina unstable	n/a	537	100,0	2	0,4
Cardiac disorders	Atrial fibrillation	n/a	537	100,0	2	0,4
Cardiac disorders	Cardiac failure	n/a	537	100,0	1	0,2
Cardiac disorders	Cardiac failure congestive	n/a	537	100,0	1	0,2
Cardiac disorders	Coronary artery disease	n/a	537	100,0	1	0,2
Cardiac disorders	Myocardial infarction	n/a	537	100,0	3	0,6
Congenital, familial and genetic disorders		n/a	537	100,0	1	0,2
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	n/a	537	100,0	1	0,2
Ear and labyrinth disorders		n/a	537	100,0	1	0,2
Ear and labyrinth disorders	Vertigo positional	n/a	537	100,0	1	0,2
Eye disorders		n/a	537	100,0	8	1,5
Eye disorders	Cataract	n/a	537	100,0	1	0,2
Eye disorders	Macular ischaemia	n/a	537	100,0	1	0,2
Eye disorders	Macular oedema	n/a	537	100,0	1	0,2
Eye disorders	Ocular vascular disorder	n/a	537	100,0	1	0,2
Eye disorders	Retinal ischaemia	n/a	537	100,0	2	0,4
Eye disorders	Retinal neovascularisation	n/a	537	100,0	1	0,2
Eye disorders	Rhegmatogenous retinal detachment	n/a	537	100,0	1	0,2
Eye disorders	Tractional retinal detachment	n/a	537	100,0	1	0,2
Gastrointestinal disorders		n/a	537	100,0	4	0,7
Gastrointestinal disorders	Colitis	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Functional gastrointestinal disorder	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Gastric haemorrhage	n/a	537	100,0	1	0,2
Gastrointestinal disorders	Pancreatitis acute	n/a	537	100,0	1	0,2
General disorders and administration site conditions		n/a	537	100,0	3	0,6
General disorders and administration site conditions	Death	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Pain	n/a	537	100,0	1	0,2
General disorders and administration site conditions	Vascular stent stenosis	n/a	537	100,0	1	0,2
Infections and infestations		n/a	537	100,0	7	1,3
Infections and infestations	COVID-19	n/a	537	100,0	1	0,2
Infections and infestations	Gastroenteritis	n/a	537	100,0	1	0,2
Infections and infestations	Gastrointestinal infection	n/a	537	100,0	1	0,2
Infections and infestations	Herpes zoster	n/a	537	100,0	1	0,2
Infections and infestations	Intestinal sepsis	n/a	537	100,0	1	0,2
Infections and infestations	Pyelonephritis	n/a	537	100,0	1	0,2
Infections and infestations	Sepsis	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications		n/a	537	100,0	7	1,3
Injury, poisoning and procedural complications	Burns third degree	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Comminuted fracture	n/a	537	100,0	1	0,2

Injury, poisoning and procedural complications	Femur fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Hip fracture	n/a	537	100,0	2	0,4
Injury, poisoning and procedural complications	Sternal fracture	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Subdural haematoma	n/a	537	100,0	1	0,2
Injury, poisoning and procedural complications	Ulna fracture	n/a	537	100,0	1	0,2
Investigations		n/a	537	100,0	1	0,2
Investigations	Blood pressure increased	n/a	537	100,0	1	0,2
Metabolism and nutrition disorders		n/a	537	100,0	1	0,2
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	n/a	537	100,0	1	0,2
Musculoskeletal and connective tissue disorders		n/a	537	100,0	4	0,7
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	n/a	537	100,0	2	0,4
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	537	100,0	5	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	n/a	537	100,0	1	0,2
Nervous system disorders		n/a	537	100,0	11	2,0
Nervous system disorders	Cerebral haematoma	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebral infarction	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebral thrombosis	n/a	537	100,0	1	0,2
Nervous system disorders	Cerebrovascular accident	n/a	537	100,0	2	0,4
Nervous system disorders	Hypertensive encephalopathy	n/a	537	100,0	1	0,2
Nervous system disorders	Intracranial aneurysm	n/a	537	100,0	1	0,2
Nervous system disorders	Ischaemic stroke	n/a	537	100,0	2	0,4
Nervous system disorders	Multiple sclerosis	n/a	537	100,0	1	0,2
Nervous system disorders	Sciatica	n/a	537	100,0	1	0,2
Product issues		n/a	537	100,0	1	0,2
Product issues	Device malfunction	n/a	537	100,0	1	0,2
Renal and urinary disorders		n/a	537	100,0	4	0,7
Renal and urinary disorders	Acute kidney injury	n/a	537	100,0	1	0,2
Renal and urinary disorders	Chronic kidney disease	n/a	537	100,0	1	0,2
Renal and urinary disorders	Haematuria	n/a	537	100,0	1	0,2
Renal and urinary disorders	Renal mass	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders		n/a	537	100,0	2	0,4
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	537	100,0	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders		n/a	537	100,0	1	0,2
Skin and subcutaneous tissue disorders	Skin ulcer	n/a	537	100,0	1	0,2

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_SEa24_30AUG2023_41984.xls
26APR2024 17:59

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Gender

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=537)			
			Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		Male	264	49,2	5	1,9
Cardiac disorders		Female	273	50,8	6	2,2
Cardiac disorders	Acute myocardial infarction	Male	264	49,2	1	0,4
Cardiac disorders	Acute myocardial infarction	Female	273	50,8	0	0,0
Cardiac disorders	Angina unstable	Male	264	49,2	2	0,8
Cardiac disorders	Angina unstable	Female	273	50,8	0	0,0
Cardiac disorders	Atrial fibrillation	Male	264	49,2	1	0,4
Cardiac disorders	Atrial fibrillation	Female	273	50,8	1	0,4
Cardiac disorders	Cardiac failure	Male	264	49,2	0	0,0
Cardiac disorders	Cardiac failure	Female	273	50,8	1	0,4
Cardiac disorders	Cardiac failure congestive	Male	264	49,2	0	0,0
Cardiac disorders	Cardiac failure congestive	Female	273	50,8	1	0,4
Cardiac disorders	Coronary artery disease	Male	264	49,2	1	0,4
Cardiac disorders	Coronary artery disease	Female	273	50,8	0	0,0
Cardiac disorders	Myocardial infarction	Male	264	49,2	0	0,0
Cardiac disorders	Myocardial infarction	Female	273	50,8	3	1,1
Congenital, familial and genetic disorders		Male	264	49,2	0	0,0
Congenital, familial and genetic disorders		Female	273	50,8	1	0,4
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Male	264	49,2	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Female	273	50,8	1	0,4
Ear and labyrinth disorders		Male	264	49,2	0	0,0
Ear and labyrinth disorders		Female	273	50,8	1	0,4
Ear and labyrinth disorders	Vertigo positional	Male	264	49,2	0	0,0
Ear and labyrinth disorders	Vertigo positional	Female	273	50,8	1	0,4
Eye disorders		Male	264	49,2	4	1,5
Eye disorders		Female	273	50,8	4	1,5
Eye disorders	Cataract	Male	264	49,2	1	0,4
Eye disorders	Cataract	Female	273	50,8	0	0,0
Eye disorders	Macular ischaemia	Male	264	49,2	0	0,0
Eye disorders	Macular ischaemia	Female	273	50,8	1	0,4
Eye disorders	Macular oedema	Male	264	49,2	0	0,0
Eye disorders	Macular oedema	Female	273	50,8	1	0,4
Eye disorders	Ocular vascular disorder	Male	264	49,2	0	0,0
Eye disorders	Ocular vascular disorder	Female	273	50,8	1	0,4
Eye disorders	Retinal ischaemia	Male	264	49,2	2	0,8
Eye disorders	Retinal ischaemia	Female	273	50,8	0	0,0
Eye disorders	Retinal neovascularisation	Male	264	49,2	0	0,0
Eye disorders	Retinal neovascularisation	Female	273	50,8	1	0,4
Eye disorders	Rhegmatogenous retinal detachment	Male	264	49,2	1	0,4
Eye disorders	Rhegmatogenous retinal detachment	Female	273	50,8	0	0,0
Eye disorders	Tractional retinal detachment	Male	264	49,2	1	0,4
Eye disorders	Tractional retinal detachment	Female	273	50,8	0	0,0
Gastrointestinal disorders		Male	264	49,2	2	0,8
Gastrointestinal disorders		Female	273	50,8	2	0,7
Gastrointestinal disorders	Colitis	Male	264	49,2	0	0,0
Gastrointestinal disorders	Colitis	Female	273	50,8	1	0,4
Gastrointestinal disorders	Functional gastrointestinal disorder	Male	264	49,2	1	0,4
Gastrointestinal disorders	Functional gastrointestinal disorder	Female	273	50,8	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Male	264	49,2	1	0,4
Gastrointestinal disorders	Gastric haemorrhage	Female	273	50,8	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Male	264	49,2	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Female	273	50,8	1	0,4
General disorders and administration site conditions		Male	264	49,2	1	0,4
General disorders and administration site conditions		Female	273	50,8	2	0,7
General disorders and administration site conditions	Death	Male	264	49,2	1	0,4

General disorders and administration site conditions	Death	Female	273	50,8	0	0,0
General disorders and administration site conditions	Pain	Male	264	49,2	0	0,0
General disorders and administration site conditions	Pain	Female	273	50,8	1	0,4
General disorders and administration site conditions	Vascular stent stenosis	Male	264	49,2	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Female	273	50,8	1	0,4
Infections and infestations		Male	264	49,2	4	1,5
Infections and infestations		Female	273	50,8	3	1,1
Infections and infestations	COVID-19	Male	264	49,2	1	0,4
Infections and infestations	COVID-19	Female	273	50,8	0	0,0
Infections and infestations	Gastroenteritis	Male	264	49,2	1	0,4
Infections and infestations	Gastroenteritis	Female	273	50,8	0	0,0
Infections and infestations	Gastrointestinal infection	Male	264	49,2	0	0,0
Infections and infestations	Gastrointestinal infection	Female	273	50,8	1	0,4
Infections and infestations	Herpes zoster	Male	264	49,2	0	0,0
Infections and infestations	Herpes zoster	Female	273	50,8	1	0,4
Infections and infestations	Intestinal sepsis	Male	264	49,2	0	0,0
Infections and infestations	Intestinal sepsis	Female	273	50,8	1	0,4
Infections and infestations	Pyelonephritis	Male	264	49,2	1	0,4
Infections and infestations	Pyelonephritis	Female	273	50,8	0	0,0
Infections and infestations	Sepsis	Male	264	49,2	1	0,4
Infections and infestations	Sepsis	Female	273	50,8	0	0,0
Injury, poisoning and procedural complications		Male	264	49,2	3	1,1
Injury, poisoning and procedural complications		Female	273	50,8	4	1,5
Injury, poisoning and procedural complications	Burns third degree	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Burns third degree	Female	273	50,8	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Femur fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Hip fracture	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Hip fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Sternal fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	Female	273	50,8	1	0,4
Injury, poisoning and procedural complications	Subdural haematoma	Male	264	49,2	1	0,4
Injury, poisoning and procedural complications	Subdural haematoma	Female	273	50,8	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Male	264	49,2	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Female	273	50,8	1	0,4
Investigations		Male	264	49,2	1	0,4
Investigations		Female	273	50,8	0	0,0
Investigations	Blood pressure increased	Male	264	49,2	1	0,4
Investigations	Blood pressure increased	Female	273	50,8	0	0,0
Metabolism and nutrition disorders		Male	264	49,2	1	0,4
Metabolism and nutrition disorders		Female	273	50,8	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Male	264	49,2	1	0,4
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Female	273	50,8	0	0,0
Musculoskeletal and connective tissue disorders		Male	264	49,2	2	0,8
Musculoskeletal and connective tissue disorders		Female	273	50,8	2	0,7
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Male	264	49,2	1	0,4
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Female	273	50,8	1	0,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	Male	264	49,2	1	0,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	Female	273	50,8	1	0,4
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Male	264	49,2	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Male	264	49,2	2	0,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Female	273	50,8	3	1,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Male	264	49,2	1	0,4

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Female	273	50,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Male	264	49,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Female	273	50,8	0	0,0
Nervous system disorders		Male	264	49,2	3	1,1
Nervous system disorders		Female	273	50,8	8	2,9
Nervous system disorders	Cerebral haematoma	Male	264	49,2	0	0,0
Nervous system disorders	Cerebral haematoma	Female	273	50,8	1	0,4
Nervous system disorders	Cerebral infarction	Male	264	49,2	0	0,0
Nervous system disorders	Cerebral infarction	Female	273	50,8	1	0,4
Nervous system disorders	Cerebral thrombosis	Male	264	49,2	1	0,4
Nervous system disorders	Cerebral thrombosis	Female	273	50,8	0	0,0
Nervous system disorders	Cerebrovascular accident	Male	264	49,2	0	0,0
Nervous system disorders	Cerebrovascular accident	Female	273	50,8	2	0,7
Nervous system disorders	Hypertensive encephalopathy	Male	264	49,2	0	0,0
Nervous system disorders	Hypertensive encephalopathy	Female	273	50,8	1	0,4
Nervous system disorders	Intracranial aneurysm	Male	264	49,2	0	0,0
Nervous system disorders	Intracranial aneurysm	Female	273	50,8	1	0,4
Nervous system disorders	Ischaemic stroke	Male	264	49,2	1	0,4
Nervous system disorders	Ischaemic stroke	Female	273	50,8	1	0,4
Nervous system disorders	Multiple sclerosis	Male	264	49,2	0	0,0
Nervous system disorders	Multiple sclerosis	Female	273	50,8	1	0,4
Nervous system disorders	Sciatica	Male	264	49,2	1	0,4
Nervous system disorders	Sciatica	Female	273	50,8	0	0,0
Product issues		Male	264	49,2	1	0,4
Product issues		Female	273	50,8	0	0,0
Product issues	Device malfunction	Male	264	49,2	1	0,4
Product issues	Device malfunction	Female	273	50,8	0	0,0
Renal and urinary disorders		Male	264	49,2	3	1,1
Renal and urinary disorders		Female	273	50,8	1	0,4
Renal and urinary disorders	Acute kidney injury	Male	264	49,2	1	0,4
Renal and urinary disorders	Acute kidney injury	Female	273	50,8	0	0,0
Renal and urinary disorders	Chronic kidney disease	Male	264	49,2	1	0,4
Renal and urinary disorders	Chronic kidney disease	Female	273	50,8	0	0,0
Renal and urinary disorders	Haematuria	Male	264	49,2	1	0,4
Renal and urinary disorders	Haematuria	Female	273	50,8	0	0,0
Renal and urinary disorders	Renal mass	Male	264	49,2	0	0,0
Renal and urinary disorders	Renal mass	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders		Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders		Female	273	50,8	2	0,7
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Female	273	50,8	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Male	264	49,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Female	273	50,8	1	0,4
Skin and subcutaneous tissue disorders		Male	264	49,2	0	0,0
Skin and subcutaneous tissue disorders		Female	273	50,8	1	0,4
Skin and subcutaneous tissue disorders	Skin ulcer	Male	264	49,2	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	Female	273	50,8	1	0,4

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 17:59

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Age			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		<65 years	270	50,3	6	2,2
Cardiac disorders		>=65 years	267	49,7	5	1,9
Cardiac disorders	Acute myocardial infarction	<65 years	270	50,3	1	0,4
Cardiac disorders	Acute myocardial infarction	>=65 years	267	49,7	0	0,0
Cardiac disorders	Angina unstable	<65 years	270	50,3	2	0,7
Cardiac disorders	Angina unstable	>=65 years	267	49,7	0	0,0
Cardiac disorders	Atrial fibrillation	<65 years	270	50,3	2	0,7
Cardiac disorders	Atrial fibrillation	>=65 years	267	49,7	0	0,0
Cardiac disorders	Cardiac failure	<65 years	270	50,3	0	0,0
Cardiac disorders	Cardiac failure	>=65 years	267	49,7	1	0,4
Cardiac disorders	Cardiac failure congestive	<65 years	270	50,3	1	0,4
Cardiac disorders	Cardiac failure congestive	>=65 years	267	49,7	0	0,0
Cardiac disorders	Coronary artery disease	<65 years	270	50,3	0	0,0
Cardiac disorders	Coronary artery disease	>=65 years	267	49,7	1	0,4
Cardiac disorders	Myocardial infarction	<65 years	270	50,3	0	0,0
Cardiac disorders	Myocardial infarction	>=65 years	267	49,7	3	1,1
Congenital, familial and genetic disorders		<65 years	270	50,3	1	0,4
Congenital, familial and genetic disorders		>=65 years	267	49,7	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	<65 years	270	50,3	1	0,4
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	>=65 years	267	49,7	0	0,0
Ear and labyrinth disorders		<65 years	270	50,3	0	0,0
Ear and labyrinth disorders		>=65 years	267	49,7	1	0,4
Ear and labyrinth disorders	Vertigo positional	<65 years	270	50,3	0	0,0
Ear and labyrinth disorders	Vertigo positional	>=65 years	267	49,7	1	0,4
Eye disorders		<65 years	270	50,3	2	0,7
Eye disorders		>=65 years	267	49,7	6	2,2
Eye disorders	Cataract	<65 years	270	50,3	0	0,0
Eye disorders	Cataract	>=65 years	267	49,7	1	0,4
Eye disorders	Macular ischaemia	<65 years	270	50,3	0	0,0
Eye disorders	Macular ischaemia	>=65 years	267	49,7	1	0,4
Eye disorders	Macular oedema	<65 years	270	50,3	0	0,0
Eye disorders	Macular oedema	>=65 years	267	49,7	1	0,4
Eye disorders	Ocular vascular disorder	<65 years	270	50,3	0	0,0
Eye disorders	Ocular vascular disorder	>=65 years	267	49,7	1	0,4
Eye disorders	Retinal ischaemia	<65 years	270	50,3	0	0,0
Eye disorders	Retinal ischaemia	>=65 years	267	49,7	2	0,7
Eye disorders	Retinal neovascularisation	<65 years	270	50,3	1	0,4
Eye disorders	Retinal neovascularisation	>=65 years	267	49,7	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	<65 years	270	50,3	1	0,4
Eye disorders	Rhegmatogenous retinal detachment	>=65 years	267	49,7	0	0,0
Eye disorders	Tractional retinal detachment	<65 years	270	50,3	1	0,4
Eye disorders	Tractional retinal detachment	>=65 years	267	49,7	0	0,0
Gastrointestinal disorders		<65 years	270	50,3	1	0,4
Gastrointestinal disorders		>=65 years	267	49,7	3	1,1
Gastrointestinal disorders	Colitis	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Colitis	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Functional gastrointestinal disorder	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Gastric haemorrhage	<65 years	270	50,3	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	>=65 years	267	49,7	1	0,4
Gastrointestinal disorders	Pancreatitis acute	<65 years	270	50,3	1	0,4
Gastrointestinal disorders	Pancreatitis acute	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions		<65 years	270	50,3	2	0,7
General disorders and administration site conditions		>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Death	<65 years	270	50,3	0	0,0

General disorders and administration site conditions	Death	>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Pain	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Pain	>=65 years	267	49,7	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	<65 years	270	50,3	1	0,4
General disorders and administration site conditions	Vascular stent stenosis	>=65 years	267	49,7	0	0,0
Infections and infestations		<65 years	270	50,3	2	0,7
Infections and infestations		>=65 years	267	49,7	5	1,9
Infections and infestations	COVID-19	<65 years	270	50,3	0	0,0
Infections and infestations	COVID-19	>=65 years	267	49,7	1	0,4
Infections and infestations	Gastroenteritis	<65 years	270	50,3	1	0,4
Infections and infestations	Gastroenteritis	>=65 years	267	49,7	0	0,0
Infections and infestations	Gastrointestinal infection	<65 years	270	50,3	0	0,0
Infections and infestations	Gastrointestinal infection	>=65 years	267	49,7	1	0,4
Infections and infestations	Herpes zoster	<65 years	270	50,3	1	0,4
Infections and infestations	Herpes zoster	>=65 years	267	49,7	0	0,0
Infections and infestations	Intestinal sepsis	<65 years	270	50,3	0	0,0
Infections and infestations	Intestinal sepsis	>=65 years	267	49,7	1	0,4
Infections and infestations	Pyelonephritis	<65 years	270	50,3	0	0,0
Infections and infestations	Pyelonephritis	>=65 years	267	49,7	1	0,4
Infections and infestations	Sepsis	<65 years	270	50,3	0	0,0
Infections and infestations	Sepsis	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications		<65 years	270	50,3	3	1,1
Injury, poisoning and procedural complications		>=65 years	267	49,7	4	1,5
Injury, poisoning and procedural complications	Burns third degree	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Burns third degree	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Femur fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Hip fracture	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Hip fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Sternal fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	>=65 years	267	49,7	1	0,4
Injury, poisoning and procedural complications	Subdural haematoma	<65 years	270	50,3	1	0,4
Injury, poisoning and procedural complications	Subdural haematoma	>=65 years	267	49,7	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	<65 years	270	50,3	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	>=65 years	267	49,7	1	0,4
Investigations		<65 years	270	50,3	1	0,4
Investigations		>=65 years	267	49,7	0	0,0
Investigations	Blood pressure increased	<65 years	270	50,3	1	0,4
Investigations	Blood pressure increased	>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders		<65 years	270	50,3	1	0,4
Metabolism and nutrition disorders		>=65 years	267	49,7	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	<65 years	270	50,3	1	0,4
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	>=65 years	267	49,7	0	0,0
Musculoskeletal and connective tissue disorders		<65 years	270	50,3	4	1,5
Musculoskeletal and connective tissue disorders		>=65 years	267	49,7	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	<65 years	270	50,3	2	0,7
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	>=65 years	267	49,7	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	<65 years	270	50,3	2	0,7
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=65 years	267	49,7	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	<65 years	270	50,3	1	0,4
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	>=65 years	267	49,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<65 years	270	50,3	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=65 years	267	49,7	4	1,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<65 years	270	50,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=65 years	267	49,7	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	<65 years	270	50,3	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	>=65 years	267	49,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	<65 years	270	50,3	0	0,0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	>=65 years	267	49,7	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	<65 years	270	50,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	>=65 years	267	49,7	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	<65 years	270	50,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	>=65 years	267	49,7	1	0,4
Nervous system disorders		<65 years	270	50,3	4	1,5
Nervous system disorders		>=65 years	267	49,7	7	2,6
Nervous system disorders	Cerebral haematoma	<65 years	270	50,3	0	0,0
Nervous system disorders	Cerebral haematoma	>=65 years	267	49,7	1	0,4
Nervous system disorders	Cerebral infarction	<65 years	270	50,3	1	0,4
Nervous system disorders	Cerebral infarction	>=65 years	267	49,7	0	0,0
Nervous system disorders	Cerebral thrombosis	<65 years	270	50,3	1	0,4
Nervous system disorders	Cerebral thrombosis	>=65 years	267	49,7	0	0,0
Nervous system disorders	Cerebrovascular accident	<65 years	270	50,3	0	0,0
Nervous system disorders	Cerebrovascular accident	>=65 years	267	49,7	2	0,7
Nervous system disorders	Hypertensive encephalopathy	<65 years	270	50,3	1	0,4
Nervous system disorders	Hypertensive encephalopathy	>=65 years	267	49,7	0	0,0
Nervous system disorders	Intracranial aneurysm	<65 years	270	50,3	0	0,0
Nervous system disorders	Intracranial aneurysm	>=65 years	267	49,7	1	0,4
Nervous system disorders	Ischaemic stroke	<65 years	270	50,3	0	0,0
Nervous system disorders	Ischaemic stroke	>=65 years	267	49,7	2	0,7
Nervous system disorders	Multiple sclerosis	<65 years	270	50,3	0	0,0
Nervous system disorders	Multiple sclerosis	>=65 years	267	49,7	1	0,4
Nervous system disorders	Sciatica	<65 years	270	50,3	1	0,4
Nervous system disorders	Sciatica	>=65 years	267	49,7	0	0,0
Product issues		<65 years	270	50,3	0	0,0
Product issues		>=65 years	267	49,7	1	0,4
Product issues	Device malfunction	<65 years	270	50,3	0	0,0
Product issues	Device malfunction	>=65 years	267	49,7	1	0,4
Renal and urinary disorders		<65 years	270	50,3	1	0,4
Renal and urinary disorders		>=65 years	267	49,7	3	1,1
Renal and urinary disorders	Acute kidney injury	<65 years	270	50,3	0	0,0
Renal and urinary disorders	Acute kidney injury	>=65 years	267	49,7	1	0,4
Renal and urinary disorders	Chronic kidney disease	<65 years	270	50,3	1	0,4
Renal and urinary disorders	Chronic kidney disease	>=65 years	267	49,7	0	0,0
Renal and urinary disorders	Haematuria	<65 years	270	50,3	0	0,0
Renal and urinary disorders	Haematuria	>=65 years	267	49,7	1	0,4
Renal and urinary disorders	Renal mass	<65 years	270	50,3	0	0,0
Renal and urinary disorders	Renal mass	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders		<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders		>=65 years	267	49,7	2	0,7
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=65 years	267	49,7	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<65 years	270	50,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=65 years	267	49,7	1	0,4
Skin and subcutaneous tissue disorders		<65 years	270	50,3	1	0,4
Skin and subcutaneous tissue disorders		>=65 years	267	49,7	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	<65 years	270	50,3	1	0,4
Skin and subcutaneous tissue disorders	Skin ulcer	>=65 years	267	49,7	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 17:59

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETRS letter score

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		<=54 letters	176	32,8	7	4,0
Cardiac disorders		>=55 letters	361	67,2	4	1,1
Cardiac disorders	Acute myocardial infarction	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Acute myocardial infarction	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Angina unstable	<=54 letters	176	32,8	2	1,1
Cardiac disorders	Angina unstable	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Atrial fibrillation	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Atrial fibrillation	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Cardiac failure	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Cardiac failure	>=55 letters	361	67,2	0	0,0
Cardiac disorders	Cardiac failure congestive	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Cardiac failure congestive	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Coronary artery disease	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Coronary artery disease	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Myocardial infarction	<=54 letters	176	32,8	3	1,7
Cardiac disorders	Myocardial infarction	>=55 letters	361	67,2	0	0,0
Congenital, familial and genetic disorders		<=54 letters	176	32,8	0	0,0
Congenital, familial and genetic disorders		>=55 letters	361	67,2	1	0,3
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	<=54 letters	176	32,8	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	>=55 letters	361	67,2	1	0,3
Ear and labyrinth disorders		<=54 letters	176	32,8	0	0,0
Ear and labyrinth disorders		>=55 letters	361	67,2	1	0,3
Ear and labyrinth disorders	Vertigo positional	<=54 letters	176	32,8	0	0,0
Ear and labyrinth disorders	Vertigo positional	>=55 letters	361	67,2	1	0,3
Eye disorders		<=54 letters	176	32,8	2	1,1
Eye disorders		>=55 letters	361	67,2	6	1,7
Eye disorders	Cataract	<=54 letters	176	32,8	1	0,6
Eye disorders	Cataract	>=55 letters	361	67,2	0	0,0
Eye disorders	Macular ischaemia	<=54 letters	176	32,8	0	0,0
Eye disorders	Macular ischaemia	>=55 letters	361	67,2	1	0,3
Eye disorders	Macular oedema	<=54 letters	176	32,8	0	0,0
Eye disorders	Macular oedema	>=55 letters	361	67,2	1	0,3
Eye disorders	Ocular vascular disorder	<=54 letters	176	32,8	0	0,0
Eye disorders	Ocular vascular disorder	>=55 letters	361	67,2	1	0,3
Eye disorders	Retinal ischaemia	<=54 letters	176	32,8	0	0,0
Eye disorders	Retinal ischaemia	>=55 letters	361	67,2	2	0,6
Eye disorders	Retinal neovascularisation	<=54 letters	176	32,8	0	0,0
Eye disorders	Retinal neovascularisation	>=55 letters	361	67,2	1	0,3
Eye disorders	Rhegmatogenous retinal detachment	<=54 letters	176	32,8	1	0,6
Eye disorders	Rhegmatogenous retinal detachment	>=55 letters	361	67,2	0	0,0
Eye disorders	Tractional retinal detachment	<=54 letters	176	32,8	1	0,6
Eye disorders	Tractional retinal detachment	>=55 letters	361	67,2	0	0,0

Gastrointestinal disorders		<=54 letters	176	32,8	2	1,1
Gastrointestinal disorders		>=55 letters	361	67,2	2	0,6
Gastrointestinal disorders	Colitis	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Colitis	>=55 letters	361	67,2	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	>=55 letters	361	67,2	1	0,3
Gastrointestinal disorders	Gastric haemorrhage	<=54 letters	176	32,8	1	0,6
Gastrointestinal disorders	Gastric haemorrhage	>=55 letters	361	67,2	0	0,0
Gastrointestinal disorders	Pancreatitis acute	<=54 letters	176	32,8	0	0,0
Gastrointestinal disorders	Pancreatitis acute	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions		<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions		>=55 letters	361	67,2	3	0,8
General disorders and administration site conditions	Death	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Death	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Pain	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Pain	>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Vascular stent stenosis	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	>=55 letters	361	67,2	1	0,3
Infections and infestations		<=54 letters	176	32,8	2	1,1
Infections and infestations		>=55 letters	361	67,2	5	1,4
Infections and infestations	COVID-19	<=54 letters	176	32,8	0	0,0
Infections and infestations	COVID-19	>=55 letters	361	67,2	1	0,3
Infections and infestations	Gastroenteritis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Gastroenteritis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Gastrointestinal infection	<=54 letters	176	32,8	1	0,6
Infections and infestations	Gastrointestinal infection	>=55 letters	361	67,2	0	0,0
Infections and infestations	Herpes zoster	<=54 letters	176	32,8	0	0,0
Infections and infestations	Herpes zoster	>=55 letters	361	67,2	1	0,3
Infections and infestations	Intestinal sepsis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Intestinal sepsis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Pyelonephritis	<=54 letters	176	32,8	0	0,0
Infections and infestations	Pyelonephritis	>=55 letters	361	67,2	1	0,3
Infections and infestations	Sepsis	<=54 letters	176	32,8	1	0,6
Infections and infestations	Sepsis	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications		<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications		>=55 letters	361	67,2	6	1,7
Injury, poisoning and procedural complications	Burns third degree	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Burns third degree	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Comminuted fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Femur fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Hip fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Hip fracture	>=55 letters	361	67,2	2	0,6
Injury, poisoning and procedural complications	Sternal fracture	<=54 letters	176	32,8	1	0,6
Injury, poisoning and procedural complications	Sternal fracture	>=55 letters	361	67,2	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	>=55 letters	361	67,2	1	0,3
Injury, poisoning and procedural complications	Ulna fracture	<=54 letters	176	32,8	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	>=55 letters	361	67,2	1	0,3
Investigations		<=54 letters	176	32,8	0	0,0
Investigations		>=55 letters	361	67,2	1	0,3

Investigations	Blood pressure increased	<=54 letters	176	32,8	0	0,0
Investigations	Blood pressure increased	>=55 letters	361	67,2	1	0,3
Metabolism and nutrition disorders		<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders		>=55 letters	361	67,2	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	<=54 letters	176	32,8	1	0,6
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	>=55 letters	361	67,2	0	0,0
Musculoskeletal and connective tissue disorders		<=54 letters	176	32,8	2	1,1
Musculoskeletal and connective tissue disorders		>=55 letters	361	67,2	2	0,6
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Osteoarthritis	<=54 letters	176	32,8	1	0,6
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=55 letters	361	67,2	1	0,3
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	<=54 letters	176	32,8	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=54 letters	176	32,8	2	1,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=55 letters	361	67,2	3	0,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=55 letters	361	67,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	<=54 letters	176	32,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	<=54 letters	176	32,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	<=54 letters	176	32,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	>=55 letters	361	67,2	0	0,0
Nervous system disorders		<=54 letters	176	32,8	3	1,7
Nervous system disorders		>=55 letters	361	67,2	8	2,2
Nervous system disorders	Cerebral haematoma	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cerebral haematoma	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cerebral infarction	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cerebral infarction	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cerebral thrombosis	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Cerebral thrombosis	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Cerebrovascular accident	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Cerebrovascular accident	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Hypertensive encephalopathy	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Hypertensive encephalopathy	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Intracranial aneurysm	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Intracranial aneurysm	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Ischaemic stroke	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Ischaemic stroke	>=55 letters	361	67,2	2	0,6
Nervous system disorders	Multiple sclerosis	<=54 letters	176	32,8	1	0,6

Nervous system disorders	Multiple sclerosis	>=55 letters	361	67,2	0	0,0
Nervous system disorders	Sciatica	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Sciatica	>=55 letters	361	67,2	0	0,0
Product issues		<=54 letters	176	32,8	0	0,0
Product issues		>=55 letters	361	67,2	1	0,3
Product issues	Device malfunction	<=54 letters	176	32,8	0	0,0
Product issues	Device malfunction	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders		<=54 letters	176	32,8	1	0,6
Renal and urinary disorders		>=55 letters	361	67,2	3	0,8
Renal and urinary disorders	Acute kidney injury	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Acute kidney injury	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders	Chronic kidney disease	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Chronic kidney disease	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders	Haematuria	<=54 letters	176	32,8	0	0,0
Renal and urinary disorders	Haematuria	>=55 letters	361	67,2	1	0,3
Renal and urinary disorders	Renal mass	<=54 letters	176	32,8	1	0,6
Renal and urinary disorders	Renal mass	>=55 letters	361	67,2	0	0,0
Respiratory, thoracic and mediastinal disorders		<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders		>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<=54 letters	176	32,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=55 letters	361	67,2	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<=54 letters	176	32,8	1	0,6
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=55 letters	361	67,2	0	0,0
Skin and subcutaneous tissue disorders		<=54 letters	176	32,8	0	0,0
Skin and subcutaneous tissue disorders		>=55 letters	361	67,2	1	0,3
Skin and subcutaneous tissue disorders	Skin ulcer	<=54 letters	176	32,8	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	>=55 letters	361	67,2	1	0,3

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 17:59

POPULATION: Safety-Evaluable Population after Week 24
 ENDPPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Geographic Region			Paricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		Europe	147	27,4	4	2,7
Cardiac disorders		America	197	36,7	5	2,5
Cardiac disorders		Asia Pacific (inc. Australia)	193	35,9	2	1,0
Cardiac disorders	Acute myocardial infarction	Europe	147	27,4	0	0,0
Cardiac disorders	Acute myocardial infarction	America	197	36,7	0	0,0
Cardiac disorders	Acute myocardial infarction	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Cardiac disorders	Angina unstable	Europe	147	27,4	1	0,7
Cardiac disorders	Angina unstable	America	197	36,7	0	0,0
Cardiac disorders	Angina unstable	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Cardiac disorders	Atrial fibrillation	Europe	147	27,4	1	0,7
Cardiac disorders	Atrial fibrillation	America	197	36,7	1	0,5
Cardiac disorders	Atrial fibrillation	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Cardiac disorders	Cardiac failure	Europe	147	27,4	1	0,7
Cardiac disorders	Cardiac failure	America	197	36,7	0	0,0
Cardiac disorders	Cardiac failure	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Cardiac disorders	Cardiac failure congestive	Europe	147	27,4	0	0,0
Cardiac disorders	Cardiac failure congestive	America	197	36,7	1	0,5
Cardiac disorders	Cardiac failure congestive	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Cardiac disorders	Coronary artery disease	Europe	147	27,4	0	0,0
Cardiac disorders	Coronary artery disease	America	197	36,7	1	0,5
Cardiac disorders	Coronary artery disease	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Cardiac disorders	Myocardial infarction	Europe	147	27,4	1	0,7
Cardiac disorders	Myocardial infarction	America	197	36,7	2	1,0
Cardiac disorders	Myocardial infarction	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Congenital, familial and genetic disorders		Europe	147	27,4	1	0,7
Congenital, familial and genetic disorders		America	197	36,7	0	0,0
Congenital, familial and genetic disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Europe	147	27,4	1	0,7
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	America	197	36,7	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Ear and labyrinth disorders		Europe	147	27,4	0	0,0
Ear and labyrinth disorders		America	197	36,7	1	0,5
Ear and labyrinth disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Ear and labyrinth disorders	Vertigo positional	Europe	147	27,4	0	0,0
Ear and labyrinth disorders	Vertigo positional	America	197	36,7	1	0,5
Ear and labyrinth disorders	Vertigo positional	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders		Europe	147	27,4	1	0,7
Eye disorders		America	197	36,7	5	2,5
Eye disorders		Asia Pacific (inc. Australia)	193	35,9	2	1,0
Eye disorders	Cataract	Europe	147	27,4	0	0,0
Eye disorders	Cataract	America	197	36,7	1	0,5
Eye disorders	Cataract	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Macular ischaemia	Europe	147	27,4	0	0,0
Eye disorders	Macular ischaemia	America	197	36,7	0	0,0
Eye disorders	Macular ischaemia	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Macular oedema	Europe	147	27,4	0	0,0
Eye disorders	Macular oedema	America	197	36,7	1	0,5
Eye disorders	Macular oedema	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Ocular vascular disorder	Europe	147	27,4	1	0,7
Eye disorders	Ocular vascular disorder	America	197	36,7	0	0,0
Eye disorders	Ocular vascular disorder	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Retinal ischaemia	Europe	147	27,4	0	0,0
Eye disorders	Retinal ischaemia	America	197	36,7	2	1,0
Eye disorders	Retinal ischaemia	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Retinal neovascularisation	Europe	147	27,4	0	0,0
Eye disorders	Retinal neovascularisation	America	197	36,7	1	0,5
Eye disorders	Retinal neovascularisation	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Europe	147	27,4	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	America	197	36,7	0	0,0

Eye disorders	Rhegmatogenous retinal detachment	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Tractional retinal detachment	Europe	147	27,4	0	0,0
Eye disorders	Tractional retinal detachment	America	197	36,7	0	0,0
Eye disorders	Tractional retinal detachment	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Gastrointestinal disorders		Europe	147	27,4	2	1,4
Gastrointestinal disorders		America	197	36,7	2	1,0
Gastrointestinal disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Colitis	Europe	147	27,4	0	0,0
Gastrointestinal disorders	Colitis	America	197	36,7	1	0,5
Gastrointestinal disorders	Colitis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	Europe	147	27,4	1	0,7
Gastrointestinal disorders	Functional gastrointestinal disorder	America	197	36,7	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Europe	147	27,4	1	0,7
Gastrointestinal disorders	Gastric haemorrhage	America	197	36,7	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Europe	147	27,4	0	0,0
Gastrointestinal disorders	Pancreatitis acute	America	197	36,7	1	0,5
Gastrointestinal disorders	Pancreatitis acute	Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions		Europe	147	27,4	2	1,4
General disorders and administration site conditions		America	197	36,7	1	0,5
General disorders and administration site conditions		Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions	Death	Europe	147	27,4	0	0,0
General disorders and administration site conditions	Death	America	197	36,7	1	0,5
General disorders and administration site conditions	Death	Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions	Pain	Europe	147	27,4	1	0,7
General disorders and administration site conditions	Pain	America	197	36,7	0	0,0
General disorders and administration site conditions	Pain	Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Europe	147	27,4	1	0,7
General disorders and administration site conditions	Vascular stent stenosis	America	197	36,7	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations		Europe	147	27,4	1	0,7
Infections and infestations		America	197	36,7	2	1,0
Infections and infestations		Asia Pacific (inc. Australia)	193	35,9	4	2,1
Infections and infestations	COVID-19	Europe	147	27,4	0	0,0
Infections and infestations	COVID-19	America	197	36,7	0	0,0
Infections and infestations	COVID-19	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Gastroenteritis	Europe	147	27,4	0	0,0
Infections and infestations	Gastroenteritis	America	197	36,7	0	0,0
Infections and infestations	Gastroenteritis	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Gastrointestinal infection	Europe	147	27,4	0	0,0
Infections and infestations	Gastrointestinal infection	America	197	36,7	1	0,5
Infections and infestations	Gastrointestinal infection	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Herpes zoster	Europe	147	27,4	0	0,0
Infections and infestations	Herpes zoster	America	197	36,7	0	0,0
Infections and infestations	Herpes zoster	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Intestinal sepsis	Europe	147	27,4	1	0,7
Infections and infestations	Intestinal sepsis	America	197	36,7	0	0,0
Infections and infestations	Intestinal sepsis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Infections and infestations	Pyelonephritis	Europe	147	27,4	0	0,0
Infections and infestations	Pyelonephritis	America	197	36,7	0	0,0
Infections and infestations	Pyelonephritis	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Infections and infestations	Sepsis	Europe	147	27,4	0	0,0
Infections and infestations	Sepsis	America	197	36,7	1	0,5
Infections and infestations	Sepsis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications		Europe	147	27,4	3	2,0
Injury, poisoning and procedural complications		America	197	36,7	2	1,0
Injury, poisoning and procedural complications		Asia Pacific (inc. Australia)	193	35,9	2	1,0
Injury, poisoning and procedural complications	Burns third degree	Europe	147	27,4	0	0,0
Injury, poisoning and procedural complications	Burns third degree	America	197	36,7	1	0,5
Injury, poisoning and procedural complications	Burns third degree	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	Europe	147	27,4	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Injury, poisoning and procedural complications	Femur fracture	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Femur fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Hip fracture	America	197	36,7	1	0,5
Injury, poisoning and procedural complications	Hip fracture	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	Europe	147	27,4	0	0,0

Injury, poisoning and procedural complications	Sternal fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Injury, poisoning and procedural complications	Subdural haematoma	Europe	147	27,4	1	0,7
Injury, poisoning and procedural complications	Subdural haematoma	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Europe	147	27,4	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	America	197	36,7	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Investigations		Europe	147	27,4	1	0,7
Investigations		America	197	36,7	0	0,0
Investigations		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Investigations	Blood pressure increased	Europe	147	27,4	1	0,7
Investigations	Blood pressure increased	America	197	36,7	0	0,0
Investigations	Blood pressure increased	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Metabolism and nutrition disorders		Europe	147	27,4	0	0,0
Metabolism and nutrition disorders		America	197	36,7	0	0,0
Metabolism and nutrition disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Europe	147	27,4	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	America	197	36,7	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Musculoskeletal and connective tissue disorders		Europe	147	27,4	3	2,0
Musculoskeletal and connective tissue disorders		America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Musculoskeletal and connective tissue disorders	Osteoarthritis	Europe	147	27,4	2	1,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Europe	147	27,4	1	0,7
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	America	197	36,7	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Europe	147	27,4	3	2,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		America	197	36,7	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Europe	147	27,4	1	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	America	197	36,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Europe	147	27,4	1	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	America	197	36,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Europe	147	27,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	America	197	36,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Europe	147	27,4	1	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	America	197	36,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Europe	147	27,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	America	197	36,7	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders		Europe	147	27,4	3	2,0
Nervous system disorders		America	197	36,7	4	2,0
Nervous system disorders		Asia Pacific (inc. Australia)	193	35,9	4	2,1
Nervous system disorders	Cerebral haematoma	Europe	147	27,4	1	0,7
Nervous system disorders	Cerebral haematoma	America	197	36,7	0	0,0

Nervous system disorders	Cerebral haematoma	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Cerebral infarction	Europe	147	27,4	0	0,0
Nervous system disorders	Cerebral infarction	America	197	36,7	0	0,0
Nervous system disorders	Cerebral infarction	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Cerebral thrombosis	Europe	147	27,4	0	0,0
Nervous system disorders	Cerebral thrombosis	America	197	36,7	0	0,0
Nervous system disorders	Cerebral thrombosis	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Cerebrovascular accident	Europe	147	27,4	1	0,7
Nervous system disorders	Cerebrovascular accident	America	197	36,7	1	0,5
Nervous system disorders	Cerebrovascular accident	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Hypertensive encephalopathy	Europe	147	27,4	1	0,7
Nervous system disorders	Hypertensive encephalopathy	America	197	36,7	0	0,0
Nervous system disorders	Hypertensive encephalopathy	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Intracranial aneurysm	Europe	147	27,4	0	0,0
Nervous system disorders	Intracranial aneurysm	America	197	36,7	0	0,0
Nervous system disorders	Intracranial aneurysm	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Ischaemic stroke	Europe	147	27,4	0	0,0
Nervous system disorders	Ischaemic stroke	America	197	36,7	2	1,0
Nervous system disorders	Ischaemic stroke	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Multiple sclerosis	Europe	147	27,4	0	0,0
Nervous system disorders	Multiple sclerosis	America	197	36,7	1	0,5
Nervous system disorders	Multiple sclerosis	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Sciatica	Europe	147	27,4	0	0,0
Nervous system disorders	Sciatica	America	197	36,7	0	0,0
Nervous system disorders	Sciatica	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Product issues		Europe	147	27,4	0	0,0
Product issues		America	197	36,7	1	0,5
Product issues		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Product issues	Device malfunction	Europe	147	27,4	0	0,0
Product issues	Device malfunction	America	197	36,7	1	0,5
Product issues	Device malfunction	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Renal and urinary disorders		Europe	147	27,4	0	0,0
Renal and urinary disorders		America	197	36,7	4	2,0
Renal and urinary disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Renal and urinary disorders	Acute kidney injury	Europe	147	27,4	0	0,0
Renal and urinary disorders	Acute kidney injury	America	197	36,7	1	0,5
Renal and urinary disorders	Acute kidney injury	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Renal and urinary disorders	Chronic kidney disease	Europe	147	27,4	0	0,0
Renal and urinary disorders	Chronic kidney disease	America	197	36,7	1	0,5
Renal and urinary disorders	Chronic kidney disease	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Renal and urinary disorders	Haematuria	Europe	147	27,4	0	0,0
Renal and urinary disorders	Haematuria	America	197	36,7	1	0,5
Renal and urinary disorders	Haematuria	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Renal and urinary disorders	Renal mass	Europe	147	27,4	0	0,0
Renal and urinary disorders	Renal mass	America	197	36,7	1	0,5
Renal and urinary disorders	Renal mass	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Respiratory, thoracic and mediastinal disorders		Europe	147	27,4	2	1,4
Respiratory, thoracic and mediastinal disorders		America	197	36,7	0	0,0
Respiratory, thoracic and mediastinal disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Europe	147	27,4	1	0,7
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	America	197	36,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Europe	147	27,4	1	0,7
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	America	197	36,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Europe	147	27,4	1	0,7
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	America	197	36,7	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Skin and subcutaneous tissue disorders		Europe	147	27,4	0	0,0
Skin and subcutaneous tissue disorders		America	197	36,7	0	0,0
Skin and subcutaneous tissue disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Skin and subcutaneous tissue disorders	Skin ulcer	Europe	147	27,4	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	America	197	36,7	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	Asia Pacific (inc. Australia)	193	35,9	1	0,5

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		White	332	61,8	9	2,7
Cardiac disorders		Asian	180	33,5	2	1,1
Cardiac disorders		Other	17	3,2	0	0,0
Cardiac disorders		Unknown	8	1,5	0	0,0
Cardiac disorders	Acute myocardial infarction	White	332	61,8	0	0,0
Cardiac disorders	Acute myocardial infarction	Asian	180	33,5	1	0,6
Cardiac disorders	Acute myocardial infarction	Other	17	3,2	0	0,0
Cardiac disorders	Acute myocardial infarction	Unknown	8	1,5	0	0,0
Cardiac disorders	Angina unstable	White	332	61,8	1	0,3
Cardiac disorders	Angina unstable	Asian	180	33,5	1	0,6
Cardiac disorders	Angina unstable	Other	17	3,2	0	0,0
Cardiac disorders	Angina unstable	Unknown	8	1,5	0	0,0
Cardiac disorders	Atrial fibrillation	White	332	61,8	2	0,6
Cardiac disorders	Atrial fibrillation	Asian	180	33,5	0	0,0
Cardiac disorders	Atrial fibrillation	Other	17	3,2	0	0,0
Cardiac disorders	Atrial fibrillation	Unknown	8	1,5	0	0,0
Cardiac disorders	Cardiac failure	White	332	61,8	1	0,3
Cardiac disorders	Cardiac failure	Asian	180	33,5	0	0,0
Cardiac disorders	Cardiac failure	Other	17	3,2	0	0,0
Cardiac disorders	Cardiac failure	Unknown	8	1,5	0	0,0
Cardiac disorders	Cardiac failure congestive	White	332	61,8	1	0,3
Cardiac disorders	Cardiac failure congestive	Asian	180	33,5	0	0,0
Cardiac disorders	Cardiac failure congestive	Other	17	3,2	0	0,0
Cardiac disorders	Cardiac failure congestive	Unknown	8	1,5	0	0,0
Cardiac disorders	Coronary artery disease	White	332	61,8	1	0,3
Cardiac disorders	Coronary artery disease	Asian	180	33,5	0	0,0
Cardiac disorders	Coronary artery disease	Other	17	3,2	0	0,0
Cardiac disorders	Coronary artery disease	Unknown	8	1,5	0	0,0
Cardiac disorders	Myocardial infarction	White	332	61,8	3	0,9
Cardiac disorders	Myocardial infarction	Asian	180	33,5	0	0,0
Cardiac disorders	Myocardial infarction	Other	17	3,2	0	0,0
Cardiac disorders	Myocardial infarction	Unknown	8	1,5	0	0,0
Congenital, familial and genetic disorders		White	332	61,8	1	0,3
Congenital, familial and genetic disorders		Asian	180	33,5	0	0,0
Congenital, familial and genetic disorders		Other	17	3,2	0	0,0
Congenital, familial and genetic disorders		Unknown	8	1,5	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	White	332	61,8	1	0,3
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Asian	180	33,5	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Other	17	3,2	0	0,0
Congenital, familial and genetic disorders	Vertebral artery hypoplasia	Unknown	8	1,5	0	0,0
Ear and labyrinth disorders		White	332	61,8	0	0,0
Ear and labyrinth disorders		Asian	180	33,5	1	0,6
Ear and labyrinth disorders		Other	17	3,2	0	0,0
Ear and labyrinth disorders		Unknown	8	1,5	0	0,0
Ear and labyrinth disorders	Vertigo positional	White	332	61,8	0	0,0
Ear and labyrinth disorders	Vertigo positional	Asian	180	33,5	1	0,6
Ear and labyrinth disorders	Vertigo positional	Other	17	3,2	0	0,0
Ear and labyrinth disorders	Vertigo positional	Unknown	8	1,5	0	0,0
Eye disorders		White	332	61,8	6	1,8
Eye disorders		Asian	180	33,5	0	0,0
Eye disorders		Other	17	3,2	2	11,8
Eye disorders		Unknown	8	1,5	0	0,0
Eye disorders	Cataract	White	332	61,8	0	0,0
Eye disorders	Cataract	Asian	180	33,5	0	0,0
Eye disorders	Cataract	Other	17	3,2	1	5,9
Eye disorders	Cataract	Unknown	8	1,5	0	0,0
Eye disorders	Macular ischaemia	White	332	61,8	0	0,0
Eye disorders	Macular ischaemia	Asian	180	33,5	0	0,0
Eye disorders	Macular ischaemia	Other	17	3,2	1	5,9
Eye disorders	Macular ischaemia	Unknown	8	1,5	0	0,0
Eye disorders	Macular oedema	White	332	61,8	1	0,3
Eye disorders	Macular oedema	Asian	180	33,5	0	0,0
Eye disorders	Macular oedema	Other	17	3,2	0	0,0
Eye disorders	Macular oedema	Unknown	8	1,5	0	0,0

Eye disorders	Ocular vascular disorder	White	332	61,8	1	0,3
Eye disorders	Ocular vascular disorder	Asian	180	33,5	0	0,0
Eye disorders	Ocular vascular disorder	Other	17	3,2	0	0,0
Eye disorders	Ocular vascular disorder	Unknown	8	1,5	0	0,0
Eye disorders	Retinal ischaemia	White	332	61,8	2	0,6
Eye disorders	Retinal ischaemia	Asian	180	33,5	0	0,0
Eye disorders	Retinal ischaemia	Other	17	3,2	0	0,0
Eye disorders	Retinal ischaemia	Unknown	8	1,5	0	0,0
Eye disorders	Retinal neovascularisation	White	332	61,8	1	0,3
Eye disorders	Retinal neovascularisation	Asian	180	33,5	0	0,0
Eye disorders	Retinal neovascularisation	Other	17	3,2	0	0,0
Eye disorders	Retinal neovascularisation	Unknown	8	1,5	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	White	332	61,8	1	0,3
Eye disorders	Rhegmatogenous retinal detachment	Asian	180	33,5	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Other	17	3,2	0	0,0
Eye disorders	Rhegmatogenous retinal detachment	Unknown	8	1,5	0	0,0
Eye disorders	Tractional retinal detachment	White	332	61,8	1	0,3
Eye disorders	Tractional retinal detachment	Asian	180	33,5	0	0,0
Eye disorders	Tractional retinal detachment	Other	17	3,2	0	0,0
Eye disorders	Tractional retinal detachment	Unknown	8	1,5	0	0,0
Gastrointestinal disorders		White	332	61,8	4	1,2
Gastrointestinal disorders		Asian	180	33,5	0	0,0
Gastrointestinal disorders		Other	17	3,2	0	0,0
Gastrointestinal disorders		Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Colitis	White	332	61,8	1	0,3
Gastrointestinal disorders	Colitis	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Colitis	Other	17	3,2	0	0,0
Gastrointestinal disorders	Colitis	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	White	332	61,8	1	0,3
Gastrointestinal disorders	Functional gastrointestinal disorder	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	Other	17	3,2	0	0,0
Gastrointestinal disorders	Functional gastrointestinal disorder	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	White	332	61,8	1	0,3
Gastrointestinal disorders	Gastric haemorrhage	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Other	17	3,2	0	0,0
Gastrointestinal disorders	Gastric haemorrhage	Unknown	8	1,5	0	0,0
Gastrointestinal disorders	Pancreatitis acute	White	332	61,8	1	0,3
Gastrointestinal disorders	Pancreatitis acute	Asian	180	33,5	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Other	17	3,2	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Unknown	8	1,5	0	0,0
General disorders and administration site conditions		White	332	61,8	3	0,9
General disorders and administration site conditions		Asian	180	33,5	0	0,0
General disorders and administration site conditions		Other	17	3,2	0	0,0
General disorders and administration site conditions		Unknown	8	1,5	0	0,0
General disorders and administration site conditions	Death	White	332	61,8	1	0,3
General disorders and administration site conditions	Death	Asian	180	33,5	0	0,0
General disorders and administration site conditions	Death	Other	17	3,2	0	0,0
General disorders and administration site conditions	Death	Unknown	8	1,5	0	0,0
General disorders and administration site conditions	Pain	White	332	61,8	1	0,3
General disorders and administration site conditions	Pain	Asian	180	33,5	0	0,0
General disorders and administration site conditions	Pain	Other	17	3,2	0	0,0
General disorders and administration site conditions	Pain	Unknown	8	1,5	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	White	332	61,8	1	0,3
General disorders and administration site conditions	Vascular stent stenosis	Asian	180	33,5	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Other	17	3,2	0	0,0
General disorders and administration site conditions	Vascular stent stenosis	Unknown	8	1,5	0	0,0
Infections and infestations		White	332	61,8	3	0,9
Infections and infestations		Asian	180	33,5	3	1,7
Infections and infestations		Other	17	3,2	1	5,9
Infections and infestations		Unknown	8	1,5	0	0,0
Infections and infestations	COVID-19	White	332	61,8	0	0,0
Infections and infestations	COVID-19	Asian	180	33,5	0	0,0
Infections and infestations	COVID-19	Other	17	3,2	1	5,9
Infections and infestations	COVID-19	Unknown	8	1,5	0	0,0
Infections and infestations	Gastroenteritis	White	332	61,8	0	0,0
Infections and infestations	Gastroenteritis	Asian	180	33,5	1	0,6
Infections and infestations	Gastroenteritis	Other	17	3,2	0	0,0
Infections and infestations	Gastroenteritis	Unknown	8	1,5	0	0,0
Infections and infestations	Gastrointestinal infection	White	332	61,8	1	0,3
Infections and infestations	Gastrointestinal infection	Asian	180	33,5	0	0,0
Infections and infestations	Gastrointestinal infection	Other	17	3,2	0	0,0
Infections and infestations	Gastrointestinal infection	Unknown	8	1,5	0	0,0
Infections and infestations	Herpes zoster	White	332	61,8	0	0,0
Infections and infestations	Herpes zoster	Asian	180	33,5	1	0,6
Infections and infestations	Herpes zoster	Other	17	3,2	0	0,0
Infections and infestations	Herpes zoster	Unknown	8	1,5	0	0,0
Infections and infestations	Intestinal sepsis	White	332	61,8	1	0,3

Infections and infestations	Intestinal sepsis	Asian	180	33,5	0	0,0
Infections and infestations	Intestinal sepsis	Other	17	3,2	0	0,0
Infections and infestations	Intestinal sepsis	Unknown	8	1,5	0	0,0
Infections and infestations	Pyelonephritis	White	332	61,8	0	0,0
Infections and infestations	Pyelonephritis	Asian	180	33,5	1	0,6
Infections and infestations	Pyelonephritis	Other	17	3,2	0	0,0
Infections and infestations	Pyelonephritis	Unknown	8	1,5	0	0,0
Infections and infestations	Sepsis	White	332	61,8	1	0,3
Infections and infestations	Sepsis	Asian	180	33,5	0	0,0
Infections and infestations	Sepsis	Other	17	3,2	0	0,0
Infections and infestations	Sepsis	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications		White	332	61,8	5	1,5
Injury, poisoning and procedural complications		Asian	180	33,5	1	0,6
Injury, poisoning and procedural complications		Other	17	3,2	1	5,9
Injury, poisoning and procedural complications		Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Burns third degree	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Burns third degree	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Burns third degree	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Burns third degree	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	White	332	61,8	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	Asian	180	33,5	1	0,6
Injury, poisoning and procedural complications	Comminuted fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Comminuted fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Femur fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Femur fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Hip fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Hip fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Other	17	3,2	1	5,9
Injury, poisoning and procedural complications	Hip fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Sternal fracture	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Sternal fracture	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	White	332	61,8	1	0,3
Injury, poisoning and procedural complications	Subdural haematoma	Asian	180	33,5	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Subdural haematoma	Unknown	8	1,5	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	White	332	61,8	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Asian	180	33,5	1	0,6
Injury, poisoning and procedural complications	Ulna fracture	Other	17	3,2	0	0,0
Injury, poisoning and procedural complications	Ulna fracture	Unknown	8	1,5	0	0,0
Investigations		White	332	61,8	1	0,3
Investigations		Asian	180	33,5	0	0,0
Investigations		Other	17	3,2	0	0,0
Investigations		Unknown	8	1,5	0	0,0
Investigations	Blood pressure increased	White	332	61,8	1	0,3
Investigations	Blood pressure increased	Asian	180	33,5	0	0,0
Investigations	Blood pressure increased	Other	17	3,2	0	0,0
Investigations	Blood pressure increased	Unknown	8	1,5	0	0,0
Metabolism and nutrition disorders		White	332	61,8	0	0,0
Metabolism and nutrition disorders		Asian	180	33,5	1	0,6
Metabolism and nutrition disorders		Other	17	3,2	0	0,0
Metabolism and nutrition disorders		Unknown	8	1,5	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	White	332	61,8	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Asian	180	33,5	1	0,6
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Other	17	3,2	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders		White	332	61,8	3	0,9
Musculoskeletal and connective tissue disorders		Asian	180	33,5	1	0,6
Musculoskeletal and connective tissue disorders		Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders		Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	White	332	61,8	1	0,3
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Asian	180	33,5	1	0,6
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	White	332	61,8	2	0,6
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Unknown	8	1,5	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	White	332	61,8	1	0,3
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Asian	180	33,5	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Other	17	3,2	0	0,0
Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	Unknown	8	1,5	0	0,0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)		White	332	61,8	3	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asian	180	33,5	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Other	17	3,2	1	5,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	White	332	61,8	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Other	17	3,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	White	332	61,8	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Other	17	3,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer recurrent	Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	White	332	61,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Asian	180	33,5	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Other	17	3,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Non-small cell lung cancer metastatic	Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	White	332	61,8	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Other	17	3,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pancreatic neoplasm	Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	White	332	61,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Other	17	3,2	1	5,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer metastatic	Unknown	8	1,5	0	0,0
Nervous system disorders		White	332	61,8	5	1,5
Nervous system disorders		Asian	180	33,5	5	2,8
Nervous system disorders		Other	17	3,2	0	0,0
Nervous system disorders		Unknown	8	1,5	1	12,5
Nervous system disorders	Cerebral haematoma	White	332	61,8	1	0,3
Nervous system disorders	Cerebral haematoma	Asian	180	33,5	0	0,0
Nervous system disorders	Cerebral haematoma	Other	17	3,2	0	0,0
Nervous system disorders	Cerebral haematoma	Unknown	8	1,5	0	0,0
Nervous system disorders	Cerebral infarction	White	332	61,8	0	0,0
Nervous system disorders	Cerebral infarction	Asian	180	33,5	1	0,6
Nervous system disorders	Cerebral infarction	Other	17	3,2	0	0,0
Nervous system disorders	Cerebral infarction	Unknown	8	1,5	0	0,0
Nervous system disorders	Cerebral thrombosis	White	332	61,8	0	0,0
Nervous system disorders	Cerebral thrombosis	Asian	180	33,5	1	0,6
Nervous system disorders	Cerebral thrombosis	Other	17	3,2	0	0,0
Nervous system disorders	Cerebral thrombosis	Unknown	8	1,5	0	0,0
Nervous system disorders	Cerebrovascular accident	White	332	61,8	1	0,3
Nervous system disorders	Cerebrovascular accident	Asian	180	33,5	0	0,0
Nervous system disorders	Cerebrovascular accident	Other	17	3,2	0	0,0
Nervous system disorders	Cerebrovascular accident	Unknown	8	1,5	1	12,5
Nervous system disorders	Hypertensive encephalopathy	White	332	61,8	1	0,3
Nervous system disorders	Hypertensive encephalopathy	Asian	180	33,5	0	0,0
Nervous system disorders	Hypertensive encephalopathy	Other	17	3,2	0	0,0
Nervous system disorders	Hypertensive encephalopathy	Unknown	8	1,5	0	0,0
Nervous system disorders	Intracranial aneurysm	White	332	61,8	0	0,0
Nervous system disorders	Intracranial aneurysm	Asian	180	33,5	1	0,6
Nervous system disorders	Intracranial aneurysm	Other	17	3,2	0	0,0
Nervous system disorders	Intracranial aneurysm	Unknown	8	1,5	0	0,0
Nervous system disorders	Ischaemic stroke	White	332	61,8	1	0,3
Nervous system disorders	Ischaemic stroke	Asian	180	33,5	1	0,6
Nervous system disorders	Ischaemic stroke	Other	17	3,2	0	0,0
Nervous system disorders	Ischaemic stroke	Unknown	8	1,5	0	0,0
Nervous system disorders	Multiple sclerosis	White	332	61,8	1	0,3
Nervous system disorders	Multiple sclerosis	Asian	180	33,5	0	0,0
Nervous system disorders	Multiple sclerosis	Other	17	3,2	0	0,0

Nervous system disorders	Multiple sclerosis	Unknown	8	1,5	0	0,0
Nervous system disorders	Sciatica	White	332	61,8	0	0,0
Nervous system disorders	Sciatica	Asian	180	33,5	1	0,6
Nervous system disorders	Sciatica	Other	17	3,2	0	0,0
Nervous system disorders	Sciatica	Unknown	8	1,5	0	0,0
Product issues		White	332	61,8	1	0,3
Product issues		Asian	180	33,5	0	0,0
Product issues		Other	17	3,2	0	0,0
Product issues		Unknown	8	1,5	0	0,0
Product issues	Device malfunction	White	332	61,8	1	0,3
Product issues	Device malfunction	Asian	180	33,5	0	0,0
Product issues	Device malfunction	Other	17	3,2	0	0,0
Product issues	Device malfunction	Unknown	8	1,5	0	0,0
Renal and urinary disorders		White	332	61,8	4	1,2
Renal and urinary disorders		Asian	180	33,5	0	0,0
Renal and urinary disorders		Other	17	3,2	0	0,0
Renal and urinary disorders		Unknown	8	1,5	0	0,0
Renal and urinary disorders	Acute kidney injury	White	332	61,8	1	0,3
Renal and urinary disorders	Acute kidney injury	Asian	180	33,5	0	0,0
Renal and urinary disorders	Acute kidney injury	Other	17	3,2	0	0,0
Renal and urinary disorders	Acute kidney injury	Unknown	8	1,5	0	0,0
Renal and urinary disorders	Chronic kidney disease	White	332	61,8	1	0,3
Renal and urinary disorders	Chronic kidney disease	Asian	180	33,5	0	0,0
Renal and urinary disorders	Chronic kidney disease	Other	17	3,2	0	0,0
Renal and urinary disorders	Chronic kidney disease	Unknown	8	1,5	0	0,0
Renal and urinary disorders	Haematuria	White	332	61,8	1	0,3
Renal and urinary disorders	Haematuria	Asian	180	33,5	0	0,0
Renal and urinary disorders	Haematuria	Other	17	3,2	0	0,0
Renal and urinary disorders	Haematuria	Unknown	8	1,5	0	0,0
Renal and urinary disorders	Renal mass	White	332	61,8	1	0,3
Renal and urinary disorders	Renal mass	Asian	180	33,5	0	0,0
Renal and urinary disorders	Renal mass	Other	17	3,2	0	0,0
Renal and urinary disorders	Renal mass	Unknown	8	1,5	0	0,0
Respiratory, thoracic and mediastinal disorders		White	332	61,8	2	0,6
Respiratory, thoracic and mediastinal disorders		Asian	180	33,5	0	0,0
Respiratory, thoracic and mediastinal disorders		Other	17	3,2	0	0,0
Respiratory, thoracic and mediastinal disorders		Unknown	8	1,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	White	332	61,8	1	0,3
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Asian	180	33,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Other	17	3,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute pulmonary oedema	Unknown	8	1,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	White	332	61,8	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Asian	180	33,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Other	17	3,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Unknown	8	1,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	White	332	61,8	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Asian	180	33,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Other	17	3,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Unknown	8	1,5	0	0,0
Skin and subcutaneous tissue disorders		White	332	61,8	0	0,0
Skin and subcutaneous tissue disorders		Asian	180	33,5	1	0,6
Skin and subcutaneous tissue disorders		Other	17	3,2	0	0,0
Skin and subcutaneous tissue disorders		Unknown	8	1,5	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	White	332	61,8	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	Asian	180	33,5	1	0,6
Skin and subcutaneous tissue disorders	Skin ulcer	Other	17	3,2	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_MK72_SEa24_30AUG2023_41984.xls

26APR2024 17:59

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Eye disorders		n/a	537	100,0	1	0,2
Eye disorders	Epiretinal membrane	n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	537	100,0	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	n/a	537	100,0	1	0,2
Nervous system disorders		n/a	537	100,0	3	0,6
Nervous system disorders	Dizziness	n/a	537	100,0	1	0,2
Nervous system disorders	Ischaemic stroke	n/a	537	100,0	1	0,2
Nervous system disorders	Multiple sclerosis	n/a	537	100,0	1	0,2

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 18:02

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Gender

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Eye disorders		Male	264	49,2	1	0,4
Eye disorders		Female	273	50,8	0	0,0
Eye disorders	Epiretinal membrane	Male	264	49,2	1	0,4
Eye disorders	Epiretinal membrane	Female	273	50,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Female	273	50,8	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Male	264	49,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Female	273	50,8	1	0,4
Nervous system disorders		Male	264	49,2	1	0,4
Nervous system disorders		Female	273	50,8	2	0,7
Nervous system disorders	Dizziness	Male	264	49,2	1	0,4
Nervous system disorders	Dizziness	Female	273	50,8	0	0,0
Nervous system disorders	Ischaemic stroke	Male	264	49,2	0	0,0
Nervous system disorders	Ischaemic stroke	Female	273	50,8	1	0,4
Nervous system disorders	Multiple sclerosis	Male	264	49,2	0	0,0
Nervous system disorders	Multiple sclerosis	Female	273	50,8	1	0,4

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 18:02

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Age

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Eye disorders		<65 years	270	50,3	1	0,4
Eye disorders		>=65 years	267	49,7	0	0,0
Eye disorders	Epiretinal membrane	<65 years	270	50,3	1	0,4
Eye disorders	Epiretinal membrane	>=65 years	267	49,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<65 years	270	50,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=65 years	267	49,7	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<65 years	270	50,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=65 years	267	49,7	1	0,4
Nervous system disorders		<65 years	270	50,3	1	0,4
Nervous system disorders		>=65 years	267	49,7	2	0,7
Nervous system disorders	Dizziness	<65 years	270	50,3	1	0,4
Nervous system disorders	Dizziness	>=65 years	267	49,7	0	0,0
Nervous system disorders	Ischaemic stroke	<65 years	270	50,3	0	0,0
Nervous system disorders	Ischaemic stroke	>=65 years	267	49,7	1	0,4
Nervous system disorders	Multiple sclerosis	<65 years	270	50,3	0	0,0
Nervous system disorders	Multiple sclerosis	>=65 years	267	49,7	1	0,4

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 18:02

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETDRS letter score

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Eye disorders		<=54 letters	176	32,8	0	0,0
Eye disorders		>=55 letters	361	67,2	1	0,3
Eye disorders	Epiretinal membrane	<=54 letters	176	32,8	0	0,0
Eye disorders	Epiretinal membrane	>=55 letters	361	67,2	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=55 letters	361	67,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<=54 letters	176	32,8	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=55 letters	361	67,2	0	0,0
Nervous system disorders		<=54 letters	176	32,8	1	0,6
Nervous system disorders		>=55 letters	361	67,2	2	0,6
Nervous system disorders	Dizziness	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Dizziness	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Ischaemic stroke	<=54 letters	176	32,8	0	0,0
Nervous system disorders	Ischaemic stroke	>=55 letters	361	67,2	1	0,3
Nervous system disorders	Multiple sclerosis	<=54 letters	176	32,8	1	0,6
Nervous system disorders	Multiple sclerosis	>=55 letters	361	67,2	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 18:02

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Geographic Region

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Eye disorders		Europe	147	27,4	0	0,0
Eye disorders		America	197	36,7	0	0,0
Eye disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Eye disorders	Epiretinal membrane	Europe	147	27,4	0	0,0
Eye disorders	Epiretinal membrane	America	197	36,7	0	0,0
Eye disorders	Epiretinal membrane	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Europe	147	27,4	1	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		America	197	36,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Europe	147	27,4	1	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	America	197	36,7	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders		Europe	147	27,4	0	0,0
Nervous system disorders		America	197	36,7	2	1,0
Nervous system disorders		Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Dizziness	Europe	147	27,4	0	0,0
Nervous system disorders	Dizziness	America	197	36,7	0	0,0
Nervous system disorders	Dizziness	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Nervous system disorders	Ischaemic stroke	Europe	147	27,4	0	0,0
Nervous system disorders	Ischaemic stroke	America	197	36,7	1	0,5
Nervous system disorders	Ischaemic stroke	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Nervous system disorders	Multiple sclerosis	Europe	147	27,4	0	0,0
Nervous system disorders	Multiple sclerosis	America	197	36,7	1	0,5
Nervous system disorders	Multiple sclerosis	Asia Pacific (inc. Australia)	193	35,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 18:02

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Eye disorders		White	332	61,8	0	0,0
Eye disorders		Asian	180	33,5	1	0,6
Eye disorders		Other	17	3,2	0	0,0
Eye disorders		Unknown	8	1,5	0	0,0
Eye disorders	Epiretinal membrane	White	332	61,8	0	0,0
Eye disorders	Epiretinal membrane	Asian	180	33,5	1	0,6
Eye disorders	Epiretinal membrane	Other	17	3,2	0	0,0
Eye disorders	Epiretinal membrane	Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		White	332	61,8	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Other	17	3,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Unknown	8	1,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	White	332	61,8	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asian	180	33,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Other	17	3,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Unknown	8	1,5	0	0,0
Nervous system disorders		White	332	61,8	1	0,3
Nervous system disorders		Asian	180	33,5	2	1,1
Nervous system disorders		Other	17	3,2	0	0,0
Nervous system disorders		Unknown	8	1,5	0	0,0
Nervous system disorders	Dizziness	White	332	61,8	0	0,0
Nervous system disorders	Dizziness	Asian	180	33,5	1	0,6
Nervous system disorders	Dizziness	Other	17	3,2	0	0,0
Nervous system disorders	Dizziness	Unknown	8	1,5	0	0,0
Nervous system disorders	Ischaemic stroke	White	332	61,8	0	0,0
Nervous system disorders	Ischaemic stroke	Asian	180	33,5	1	0,6
Nervous system disorders	Ischaemic stroke	Other	17	3,2	0	0,0
Nervous system disorders	Ischaemic stroke	Unknown	8	1,5	0	0,0
Nervous system disorders	Multiple sclerosis	White	332	61,8	1	0,3
Nervous system disorders	Multiple sclerosis	Asian	180	33,5	0	0,0
Nervous system disorders	Multiple sclerosis	Other	17	3,2	0	0,0
Nervous system disorders	Multiple sclerosis	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_30AUG2023_41984.xls

26APR2024 18:02

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		n/a	537	100,0	2	0,4
Cardiac disorders	Coronary artery disease	n/a	537	100,0	1	0,2
Cardiac disorders	Myocardial infarction	n/a	537	100,0	1	0,2
General disorders and administration site conditions		n/a	537	100,0	1	0,2
General disorders and administration site conditions	Death	n/a	537	100,0	1	0,2

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 17:57

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Gender

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		Male	264	49,2	1	0,4
Cardiac disorders		Female	273	50,8	1	0,4
Cardiac disorders	Coronary artery disease	Male	264	49,2	1	0,4
Cardiac disorders	Coronary artery disease	Female	273	50,8	0	0,0
Cardiac disorders	Myocardial infarction	Male	264	49,2	0	0,0
Cardiac disorders	Myocardial infarction	Female	273	50,8	1	0,4
General disorders and administration site conditions		Male	264	49,2	1	0,4
General disorders and administration site conditions		Female	273	50,8	0	0,0
General disorders and administration site conditions	Death	Male	264	49,2	1	0,4
General disorders and administration site conditions	Death	Female	273	50,8	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 17:57

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Age

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		<65 years	270	50,3	0	0,0
Cardiac disorders		>=65 years	267	49,7	2	0,7
Cardiac disorders	Coronary artery disease	<65 years	270	50,3	0	0,0
Cardiac disorders	Coronary artery disease	>=65 years	267	49,7	1	0,4
Cardiac disorders	Myocardial infarction	<65 years	270	50,3	0	0,0
Cardiac disorders	Myocardial infarction	>=65 years	267	49,7	1	0,4
General disorders and administration site conditions		<65 years	270	50,3	0	0,0
General disorders and administration site conditions		>=65 years	267	49,7	1	0,4
General disorders and administration site conditions	Death	<65 years	270	50,3	0	0,0
General disorders and administration site conditions	Death	>=65 years	267	49,7	1	0,4

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 17:57

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETRS letter score

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		<=54 letters	176	32,8	1	0,6
Cardiac disorders		>=55 letters	361	67,2	1	0,3
Cardiac disorders	Coronary artery disease	<=54 letters	176	32,8	0	0,0
Cardiac disorders	Coronary artery disease	>=55 letters	361	67,2	1	0,3
Cardiac disorders	Myocardial infarction	<=54 letters	176	32,8	1	0,6
Cardiac disorders	Myocardial infarction	>=55 letters	361	67,2	0	0,0
General disorders and administration site conditions		<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions		>=55 letters	361	67,2	1	0,3
General disorders and administration site conditions	Death	<=54 letters	176	32,8	0	0,0
General disorders and administration site conditions	Death	>=55 letters	361	67,2	1	0,3

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 17:57

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Geographic Region

			Faricimab (N=537)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Cardiac disorders		Europe	147	27,4	0	0,0
Cardiac disorders		America	197	36,7	2	1,0
Cardiac disorders		Asia Pacific (inc. Australia)	193	35,9	0	0,0
Cardiac disorders	Coronary artery disease	Europe	147	27,4	0	0,0
Cardiac disorders	Coronary artery disease	America	197	36,7	1	0,5
Cardiac disorders	Coronary artery disease	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Cardiac disorders	Myocardial infarction	Europe	147	27,4	0	0,0
Cardiac disorders	Myocardial infarction	America	197	36,7	1	0,5
Cardiac disorders	Myocardial infarction	Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions		Europe	147	27,4	0	0,0
General disorders and administration site conditions		America	197	36,7	1	0,5
General disorders and administration site conditions		Asia Pacific (inc. Australia)	193	35,9	0	0,0
General disorders and administration site conditions	Death	Europe	147	27,4	0	0,0
General disorders and administration site conditions	Death	America	197	36,7	1	0,5
General disorders and administration site conditions	Death	Asia Pacific (inc. Australia)	193	35,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 17:57

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity

			Faricimab (N=537)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		White	332	61,8	2	0,6
Cardiac disorders		Asian	180	33,5	0	0,0
Cardiac disorders		Other	17	3,2	0	0,0
Cardiac disorders		Unknown	8	1,5	0	0,0
Cardiac disorders	Coronary artery disease	White	332	61,8	1	0,3
Cardiac disorders	Coronary artery disease	Asian	180	33,5	0	0,0
Cardiac disorders	Coronary artery disease	Other	17	3,2	0	0,0
Cardiac disorders	Coronary artery disease	Unknown	8	1,5	0	0,0
Cardiac disorders	Myocardial infarction	White	332	61,8	1	0,3
Cardiac disorders	Myocardial infarction	Asian	180	33,5	0	0,0
Cardiac disorders	Myocardial infarction	Other	17	3,2	0	0,0
Cardiac disorders	Myocardial infarction	Unknown	8	1,5	0	0,0
General disorders and administration site conditions		White	332	61,8	1	0,3
General disorders and administration site conditions		Asian	180	33,5	0	0,0
General disorders and administration site conditions		Other	17	3,2	0	0,0
General disorders and administration site conditions		Unknown	8	1,5	0	0,0
General disorders and administration site conditions	Death	White	332	61,8	1	0,3
General disorders and administration site conditions	Death	Asian	180	33,5	0	0,0
General disorders and administration site conditions	Death	Other	17	3,2	0	0,0
General disorders and administration site conditions	Death	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 17:57

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Any AEs

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	486	69,3
Gender	Male	374	53,4	247	66,0
	Female	327	46,6	239	73,1
Age	<65 years	308	43,9	212	68,8
	>=65 years	393	56,1	274	69,7
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	107	68,6
	35 - 54 letters	206	29,4	144	69,9
	>=55 letters	339	48,4	235	69,3
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	46	66,7
	>=24 letters	632	90,2	440	69,6
Geographic Region	Europe	214	30,5	161	75,2
	America	282	40,2	182	64,5
	Asia Pacific (inc. Australia)	205	29,2	143	69,8
Race/ethnicity	White	474	67,6	332	70,0
	Asian	176	25,1	117	66,5
	Other	27	3,9	19	70,4
	Unknown	24	3,4	18	75,0
Baseline RVO status	CRVO	574	81,9	403	70,2
	HRVO	121	17,3	79	65,3
	Missing	6	0,9	4	66,7

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 15:15

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Ocular AEs (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	258	36,8
Gender	Male	374	53,4	131	35,0
	Female	327	46,6	127	38,8
Age	<65 years	308	43,9	114	37,0
	>=65 years	393	56,1	144	36,6
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	63	40,4
	35 - 54 letters	206	29,4	73	35,4
	>=55 letters	339	48,4	122	36,0
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	25	36,2
	>=24 letters	632	90,2	233	36,9
Geographic Region	Europe	214	30,5	93	43,5
	America	282	40,2	94	33,3
	Asia Pacific (inc. Australia)	205	29,2	71	34,6
Race/ethnicity	White	474	67,6	184	38,8
	Asian	176	25,1	53	30,1
	Other	27	3,9	11	40,7
	Unknown	24	3,4	10	41,7
Baseline RVO status	CRVO	574	81,9	216	37,6
	HRVO	121	17,3	39	32,2
	Missing	6	0,9	3	50,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_SOCAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:28

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Ocular AEs (Fellow Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	126	18,0
Gender	Male	374	53,4	66	17,6
	Female	327	46,6	60	18,3
Age	<65 years	308	43,9	51	16,6
	>=65 years	393	56,1	75	19,1
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	29	18,6
	35 - 54 letters	206	29,4	40	19,4
	>=55 letters	339	48,4	57	16,8
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	10	14,5
	>=24 letters	632	90,2	116	18,4
Geographic Region	Europe	214	30,5	44	20,6
	America	282	40,2	49	17,4
	Asia Pacific (inc. Australia)	205	29,2	33	16,1
Race/ethnicity	White	474	67,6	84	17,7
	Asian	176	25,1	25	14,2
	Other	27	3,9	10	37,0
	Unknown	24	3,4	7	29,2
Baseline RVO status	CRVO	574	81,9	98	17,1
	HRVO	121	17,3	25	20,7
	Missing	6	0,9	3	50,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_FOCAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:26

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	199	28,4
Gender	Male	374	53,4	98	26,2
	Female	327	46,6	101	30,9
Age	<65 years	308	43,9	91	29,5
	>=65 years	393	56,1	108	27,5
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	50	32,1
	35 - 54 letters	206	29,4	57	27,7
	>=55 letters	339	48,4	92	27,1
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	26	37,7
	>=24 letters	632	90,2	173	27,4
Geographic Region	Europe	214	30,5	78	36,4
	America	282	40,2	73	25,9
	Asia Pacific (inc. Australia)	205	29,2	48	23,4
Race/ethnicity	White	474	67,6	146	30,8
	Asian	176	25,1	39	22,2
	Other	27	3,9	9	33,3
	Unknown	24	3,4	5	20,8
Baseline RVO status	CRVO	574	81,9	162	28,2
	HRVO	121	17,3	36	29,8
	Missing	6	0,9	1	16,7

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_WMODAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:18

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Severe AEs

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	66	9,4
Gender	Male	374	53,4	36	9,6
	Female	327	46,6	30	9,2
Age	<65 years	308	43,9	15	4,9
	>=65 years	393	56,1	51	13,0
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	10	6,4
	35 - 54 letters	206	29,4	22	10,7
	>=55 letters	339	48,4	34	10,0
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	1	1,4
	>=24 letters	632	90,2	65	10,3
Geographic Region	Europe	214	30,5	16	7,5
	America	282	40,2	30	10,6
	Asia Pacific (inc. Australia)	205	29,2	20	9,8
Race/ethnicity	White	474	67,6	49	10,3
	Asian	176	25,1	11	6,3
	Other	27	3,9	4	14,8
	Unknown	24	3,4	2	8,3
Baseline RVO status	CRVO	574	81,9	57	9,9
	HRVO	121	17,3	9	7,4
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_WSEVAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 15:20

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Any SAEs

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	107	15,3
Gender	Male	374	53,4	57	15,2
	Female	327	46,6	50	15,3
Age	<65 years	308	43,9	34	11,0
	>=65 years	393	56,1	73	18,6
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	23	14,7
	35 - 54 letters	206	29,4	38	18,4
	>=55 letters	339	48,4	46	13,6
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	9	13,0
	>=24 letters	632	90,2	98	15,5
Geographic Region	Europe	214	30,5	30	14,0
	America	282	40,2	43	15,2
	Asia Pacific (inc. Australia)	205	29,2	34	16,6
Race/ethnicity	White	474	67,6	77	16,2
	Asian	176	25,1	22	12,5
	Other	27	3,9	5	18,5
	Unknown	24	3,4	3	12,5
Baseline RVO status	CRVO	574	81,9	91	15,9
	HRVO	121	17,3	16	13,2
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_SAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 15:23

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Ocular SAEs (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	39	5,6
Gender	Male	374	53,4	23	6,1
	Female	327	46,6	16	4,9
Age	<65 years	308	43,9	18	5,8
	>=65 years	393	56,1	21	5,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	9	5,8
	35 - 54 letters	206	29,4	10	4,9
	>=55 letters	339	48,4	20	5,9
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	3	4,3
	>=24 letters	632	90,2	36	5,7
Geographic Region	Europe	214	30,5	10	4,7
	America	282	40,2	15	5,3
	Asia Pacific (inc. Australia)	205	29,2	14	6,8
Race/ethnicity	White	474	67,6	30	6,3
	Asian	176	25,1	6	3,4
	Other	27	3,9	1	3,7
	Unknown	24	3,4	2	8,3
Baseline RVO status	CRVO	574	81,9	33	5,7
	HRVO	121	17,3	6	5,0
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_SOCSAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:31

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Ocular SAEs (Fellow Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	1	0,1
Gender	Male	374	53,4	0	0,0
	Female	327	46,6	1	0,3
Age	<65 years	308	43,9	0	0,0
	>=65 years	393	56,1	1	0,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	1	0,5
	>=55 letters	339	48,4	0	0,0
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	1	0,2
Geographic Region	Europe	214	30,5	0	0,0
	America	282	40,2	0	0,0
	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Race/ethnicity	White	474	67,6	0	0,0
	Asian	176	25,1	1	0,6
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	1	0,2
	HRVO	121	17,3	0	0,0
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_FOCSAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:30

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	14	2,0
Gender	Male	374	53,4	6	1,6
	Female	327	46,6	8	2,4
Age	<65 years	308	43,9	2	0,6
	>=65 years	393	56,1	12	3,1
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	2	1,3
	35 - 54 letters	206	29,4	5	2,4
	>=55 letters	339	48,4	7	2,1
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	14	2,2
Geographic Region	Europe	214	30,5	5	2,3
	America	282	40,2	3	1,1
	Asia Pacific (inc. Australia)	205	29,2	6	2,9
Race/ethnicity	White	474	67,6	11	2,3
	Asian	176	25,1	3	1,7
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	10	1,7
	HRVO	121	17,3	4	3,3
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_WDSTAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:25

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	5	0,7
Gender	Male	374	53,4	2	0,5
	Female	327	46,6	3	0,9
Age	<65 years	308	43,9	0	0,0
	>=65 years	393	56,1	5	1,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	3	1,5
	>=55 letters	339	48,4	2	0,6
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	5	0,8
Geographic Region	Europe	214	30,5	2	0,9
	America	282	40,2	3	1,1
	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Race/ethnicity	White	474	67,6	5	1,1
	Asian	176	25,1	0	0,0
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	4	0,7
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_DTHAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:22

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		n/a	701	100,0	10	1,4
Blood and lymphatic system disorders	Anaemia	n/a	701	100,0	8	1,1
Blood and lymphatic system disorders	Deficiency anaemia	n/a	701	100,0	1	0,1
Blood and lymphatic system disorders	Iron deficiency anaemia	n/a	701	100,0	1	0,1
Blood and lymphatic system disorders	Mesenteric lymphadenitis	n/a	701	100,0	1	0,1
Cardiac disorders		n/a	701	100,0	30	4,3
Cardiac disorders	Acute left ventricular failure	n/a	701	100,0	1	0,1
Cardiac disorders	Acute myocardial infarction	n/a	701	100,0	2	0,3
Cardiac disorders	Aortic valve incompetence	n/a	701	100,0	1	0,1
Cardiac disorders	Arrhythmia	n/a	701	100,0	1	0,1
Cardiac disorders	Atrial fibrillation	n/a	701	100,0	9	1,3
Cardiac disorders	Bradycardia	n/a	701	100,0	1	0,1
Cardiac disorders	Cardiac failure	n/a	701	100,0	1	0,1
Cardiac disorders	Cardiac failure congestive	n/a	701	100,0	2	0,3
Cardiac disorders	Cardiomegaly	n/a	701	100,0	1	0,1
Cardiac disorders	Coronary artery disease	n/a	701	100,0	1	0,1
Cardiac disorders	Coronary artery stenosis	n/a	701	100,0	1	0,1
Cardiac disorders	Left ventricular dysfunction	n/a	701	100,0	2	0,3
Cardiac disorders	Myocardial infarction	n/a	701	100,0	3	0,4
Cardiac disorders	Myocardial ischaemia	n/a	701	100,0	1	0,1
Cardiac disorders	Palpitations	n/a	701	100,0	1	0,1
Cardiac disorders	Pericardial effusion	n/a	701	100,0	1	0,1
Cardiac disorders	Sinus tachycardia	n/a	701	100,0	1	0,1
Cardiac disorders	Stress cardiomyopathy	n/a	701	100,0	1	0,1
Cardiac disorders	Supraventricular tachycardia	n/a	701	100,0	1	0,1
Cardiac disorders	Tachycardia	n/a	701	100,0	2	0,3
Congenital, familial and genetic disorders		n/a	701	100,0	2	0,3
Congenital, familial and genetic disorders	Corneal dystrophy	n/a	701	100,0	2	0,3
Ear and labyrinth disorders		n/a	701	100,0	4	0,6
Ear and labyrinth disorders	Vertigo	n/a	701	100,0	4	0,6
Endocrine disorders		n/a	701	100,0	10	1,4
Endocrine disorders	Adrenal insufficiency	n/a	701	100,0	1	0,1
Endocrine disorders	Adrenal mass	n/a	701	100,0	2	0,3
Endocrine disorders	Adrenomegaly	n/a	701	100,0	1	0,1
Endocrine disorders	Androgen deficiency	n/a	701	100,0	1	0,1
Endocrine disorders	Goitre	n/a	701	100,0	1	0,1
Endocrine disorders	Hypothyroidism	n/a	701	100,0	4	0,6
Endocrine disorders	Thyroid cyst	n/a	701	100,0	1	0,1
Endocrine disorders	Thyroid mass	n/a	701	100,0	1	0,1
Eye disorders		n/a	701	100,0	262	37,4
Eye disorders	Age-related macular degeneration	n/a	701	100,0	1	0,1
Eye disorders	Anisocoria	n/a	701	100,0	1	0,1
Eye disorders	Asthenopia	n/a	701	100,0	2	0,3
Eye disorders	Blepharitis	n/a	701	100,0	5	0,7
Eye disorders	Borderline glaucoma	n/a	701	100,0	2	0,3
Eye disorders	Cataract	n/a	701	100,0	34	4,9

Eye disorders	Cataract nuclear	n/a	701	100,0	1	0,1
Eye disorders	Cataract subcapsular	n/a	701	100,0	1	0,1
Eye disorders	Central serous chorioretinopathy	n/a	701	100,0	4	0,6
Eye disorders	Chalazion	n/a	701	100,0	4	0,6
Eye disorders	Choroidal effusion	n/a	701	100,0	1	0,1
Eye disorders	Conjunctival haemorrhage	n/a	701	100,0	21	3,0
Eye disorders	Conjunctival hyperaemia	n/a	701	100,0	2	0,3
Eye disorders	Conjunctival telangiectasia	n/a	701	100,0	1	0,1
Eye disorders	Conjunctivitis allergic	n/a	701	100,0	1	0,1
Eye disorders	Corneal deposits	n/a	701	100,0	1	0,1
Eye disorders	Corneal erosion	n/a	701	100,0	1	0,1
Eye disorders	Corneal infiltrates	n/a	701	100,0	1	0,1
Eye disorders	Corneal opacity	n/a	701	100,0	1	0,1
Eye disorders	Corneal pigmentation	n/a	701	100,0	1	0,1
Eye disorders	Cystoid macular oedema	n/a	701	100,0	28	4,0
Eye disorders	Detachment of retinal pigment epithelium	n/a	701	100,0	2	0,3
Eye disorders	Diabetic retinal oedema	n/a	701	100,0	1	0,1
Eye disorders	Diabetic retinopathy	n/a	701	100,0	2	0,3
Eye disorders	Diplopia	n/a	701	100,0	1	0,1
Eye disorders	Dry age-related macular degeneration	n/a	701	100,0	1	0,1
Eye disorders	Dry eye	n/a	701	100,0	15	2,1
Eye disorders	Eczema eyelids	n/a	701	100,0	1	0,1
Eye disorders	Epiretinal membrane	n/a	701	100,0	17	2,4
Eye disorders	Episcleritis	n/a	701	100,0	1	0,1
Eye disorders	Eye irritation	n/a	701	100,0	1	0,1
Eye disorders	Eye pain	n/a	701	100,0	10	1,4
Eye disorders	Eye pruritus	n/a	701	100,0	4	0,6
Eye disorders	Eyelid cyst	n/a	701	100,0	1	0,1
Eye disorders	Eyelid oedema	n/a	701	100,0	1	0,1
Eye disorders	Foreign body sensation in eyes	n/a	701	100,0	3	0,4
Eye disorders	Glaucoma	n/a	701	100,0	15	2,1
Eye disorders	Hypotony of eye	n/a	701	100,0	1	0,1
Eye disorders	Iridocyclitis	n/a	701	100,0	7	1,0
Eye disorders	Iris neovascularisation	n/a	701	100,0	2	0,3
Eye disorders	Iritis	n/a	701	100,0	4	0,6
Eye disorders	Keratic precipitates	n/a	701	100,0	1	0,1
Eye disorders	Keratitis	n/a	701	100,0	2	0,3
Eye disorders	Keratopathy	n/a	701	100,0	1	0,1
Eye disorders	Lacrimal disorder	n/a	701	100,0	1	0,1
Eye disorders	Lacrimation increased	n/a	701	100,0	5	0,7
Eye disorders	Lenticular opacities	n/a	701	100,0	1	0,1
Eye disorders	Macular degeneration	n/a	701	100,0	2	0,3
Eye disorders	Macular detachment	n/a	701	100,0	2	0,3
Eye disorders	Macular hole	n/a	701	100,0	2	0,3
Eye disorders	Macular ischaemia	n/a	701	100,0	2	0,3
Eye disorders	Macular oedema	n/a	701	100,0	26	3,7
Eye disorders	Macular scar	n/a	701	100,0	1	0,1
Eye disorders	Meibomianitis	n/a	701	100,0	1	0,1
Eye disorders	Neovascular age-related macular degeneration	n/a	701	100,0	1	0,1
Eye disorders	Non-infectious endophthalmitis	n/a	701	100,0	1	0,1
Eye disorders	Noninfective conjunctivitis	n/a	701	100,0	1	0,1
Eye disorders	Normal tension glaucoma	n/a	701	100,0	1	0,1
Eye disorders	Ocular hyperaemia	n/a	701	100,0	2	0,3
Eye disorders	Ocular hypertension	n/a	701	100,0	12	1,7
Eye disorders	Open angle glaucoma	n/a	701	100,0	2	0,3
Eye disorders	Optic atrophy	n/a	701	100,0	1	0,1
Eye disorders	Optic disc disorder	n/a	701	100,0	1	0,1
Eye disorders	Optic disc haemorrhage	n/a	701	100,0	3	0,4
Eye disorders	Optic disc vascular disorder	n/a	701	100,0	1	0,1
Eye disorders	Papilloedema	n/a	701	100,0	2	0,3
Eye disorders	Periorbital pain	n/a	701	100,0	1	0,1
Eye disorders	Photopsia	n/a	701	100,0	2	0,3
Eye disorders	Pinguecula	n/a	701	100,0	1	0,1
Eye disorders	Posterior capsule opacification	n/a	701	100,0	7	1,0

Eye disorders	Punctate keratitis	n/a	701	100,0	6	0,9
Eye disorders	Retinal aneurysm	n/a	701	100,0	2	0,3
Eye disorders	Retinal artery embolism	n/a	701	100,0	1	0,1
Eye disorders	Retinal artery occlusion	n/a	701	100,0	4	0,6
Eye disorders	Retinal collateral vessels	n/a	701	100,0	3	0,4
Eye disorders	Retinal depigmentation	n/a	701	100,0	1	0,1
Eye disorders	Retinal detachment	n/a	701	100,0	2	0,3
Eye disorders	Retinal disorder	n/a	701	100,0	1	0,1
Eye disorders	Retinal drusen	n/a	701	100,0	1	0,1
Eye disorders	Retinal exudates	n/a	701	100,0	2	0,3
Eye disorders	Retinal haemorrhage	n/a	701	100,0	7	1,0
Eye disorders	Retinal ischaemia	n/a	701	100,0	2	0,3
Eye disorders	Retinal neovascularisation	n/a	701	100,0	3	0,4
Eye disorders	Retinal tear	n/a	701	100,0	3	0,4
Eye disorders	Retinal vein occlusion	n/a	701	100,0	23	3,3
Eye disorders	Retinopathy hypertensive	n/a	701	100,0	1	0,1
Eye disorders	Subretinal fluid	n/a	701	100,0	1	0,1
Eye disorders	Uveitis	n/a	701	100,0	1	0,1
Eye disorders	Vision blurred	n/a	701	100,0	3	0,4
Eye disorders	Visual acuity reduced	n/a	701	100,0	8	1,1
Eye disorders	Visual acuity reduced transiently	n/a	701	100,0	1	0,1
Eye disorders	Visual field defect	n/a	701	100,0	1	0,1
Eye disorders	Visual impairment	n/a	701	100,0	4	0,6
Eye disorders	Vitreoretinal traction syndrome	n/a	701	100,0	3	0,4
Eye disorders	Vitreous detachment	n/a	701	100,0	29	4,1
Eye disorders	Vitreous floaters	n/a	701	100,0	10	1,4
Eye disorders	Vitreous haemorrhage	n/a	701	100,0	4	0,6
Eye disorders	Vitreous opacities	n/a	701	100,0	1	0,1
Eye disorders	Vitritis	n/a	701	100,0	4	0,6
Gastrointestinal disorders		n/a	701	100,0	42	6,0
Gastrointestinal disorders	Abdominal discomfort	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Abdominal pain	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Abdominal pain upper	n/a	701	100,0	2	0,3
Gastrointestinal disorders	Barrett's oesophagus	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Chronic gastritis	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Coeliac disease	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Colitis	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Constipation	n/a	701	100,0	5	0,7
Gastrointestinal disorders	Dental discomfort	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Diarrhoea	n/a	701	100,0	11	1,6
Gastrointestinal disorders	Diverticulum intestinal	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Duodenal ulcer haemorrhage	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Duodenitis	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Dyspepsia	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Gastric ulcer	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Gastritis	n/a	701	100,0	3	0,4
Gastrointestinal disorders	Gastrointestinal inflammation	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Gastrooesophageal reflux disease	n/a	701	100,0	2	0,3
Gastrointestinal disorders	Haemorrhagic erosive gastritis	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Haemorrhoids	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Hiatus hernia	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Ileus	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Inguinal hernia	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Large intestine polyp	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Nausea	n/a	701	100,0	3	0,4
Gastrointestinal disorders	Pancreatitis	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Pancreatitis acute	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Pulpless tooth	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Salivary gland disorder	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Toothache	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Umbilical hernia	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Vomiting	n/a	701	100,0	2	0,3

General disorders and administration site conditions		n/a	701	100,0	32	4,6
General disorders and administration site conditions	Asthenia	n/a	701	100,0	7	1,0
General disorders and administration site conditions	Chest pain	n/a	701	100,0	4	0,6
General disorders and administration site conditions	Chills	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Death	n/a	701	100,0	2	0,3
General disorders and administration site conditions	Drug intolerance	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Drug withdrawal syndrome	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Fatigue	n/a	701	100,0	2	0,3
General disorders and administration site conditions	Injection site pain	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Injection site reaction	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Oedema peripheral	n/a	701	100,0	4	0,6
General disorders and administration site conditions	Pain	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Peripheral swelling	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Polyp	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Pyrexia	n/a	701	100,0	5	0,7
General disorders and administration site conditions	Stent-graft endoleak	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Systemic inflammatory response syndrome	n/a	701	100,0	1	0,1
Hepatobiliary disorders		n/a	701	100,0	8	1,1
Hepatobiliary disorders	Cholecystitis	n/a	701	100,0	1	0,1
Hepatobiliary disorders	Cholelithiasis	n/a	701	100,0	4	0,6
Hepatobiliary disorders	Hepatic cyst	n/a	701	100,0	1	0,1
Hepatobiliary disorders	Hepatic steatosis	n/a	701	100,0	3	0,4
Hepatobiliary disorders	Portal hypertension	n/a	701	100,0	1	0,1
Immune system disorders		n/a	701	100,0	11	1,6
Immune system disorders	Contrast media allergy	n/a	701	100,0	3	0,4
Immune system disorders	Contrast media reaction	n/a	701	100,0	1	0,1
Immune system disorders	Drug hypersensitivity	n/a	701	100,0	1	0,1
Immune system disorders	Food allergy	n/a	701	100,0	1	0,1
Immune system disorders	Iodine allergy	n/a	701	100,0	1	0,1
Immune system disorders	Seasonal allergy	n/a	701	100,0	4	0,6
Infections and infestations		n/a	701	100,0	225	32,1
Infections and infestations	Adenoviral conjunctivitis	n/a	701	100,0	1	0,1
Infections and infestations	Arthritis infective	n/a	701	100,0	1	0,1
Infections and infestations	Bronchitis	n/a	701	100,0	9	1,3
Infections and infestations	COVID-19	n/a	701	100,0	91	13,0
Infections and infestations	COVID-19 pneumonia	n/a	701	100,0	1	0,1
Infections and infestations	Cellulitis	n/a	701	100,0	7	1,0
Infections and infestations	Chronic sinusitis	n/a	701	100,0	2	0,3
Infections and infestations	Clostridium difficile infection	n/a	701	100,0	1	0,1
Infections and infestations	Conjunctivitis	n/a	701	100,0	14	2,0
Infections and infestations	Conjunctivitis bacterial	n/a	701	100,0	1	0,1
Infections and infestations	Conjunctivitis viral	n/a	701	100,0	1	0,1
Infections and infestations	Cystitis	n/a	701	100,0	3	0,4
Infections and infestations	Device related infection	n/a	701	100,0	1	0,1
Infections and infestations	Diabetic foot infection	n/a	701	100,0	1	0,1
Infections and infestations	Ear infection	n/a	701	100,0	3	0,4
Infections and infestations	Endophthalmitis	n/a	701	100,0	1	0,1
Infections and infestations	Enteritis infectious	n/a	701	100,0	1	0,1
Infections and infestations	Escherichia urinary tract infection	n/a	701	100,0	1	0,1
Infections and infestations	Eye infection	n/a	701	100,0	1	0,1
Infections and infestations	Eye infection bacterial	n/a	701	100,0	1	0,1
Infections and infestations	Folliculitis	n/a	701	100,0	1	0,1
Infections and infestations	Fungal skin infection	n/a	701	100,0	1	0,1
Infections and infestations	Gastroenteritis	n/a	701	100,0	1	0,1
Infections and infestations	Gastroenteritis viral	n/a	701	100,0	4	0,6
Infections and infestations	Gastrointestinal infection	n/a	701	100,0	1	0,1
Infections and infestations	Helicobacter infection	n/a	701	100,0	1	0,1
Infections and infestations	Herpes virus infection	n/a	701	100,0	1	0,1
Infections and infestations	Herpes zoster	n/a	701	100,0	6	0,9
Infections and infestations	Hordeolum	n/a	701	100,0	5	0,7

Infections and infestations	Infected bite	n/a	701	100,0	1	0,1
Infections and infestations	Influenza	n/a	701	100,0	19	2,7
Infections and infestations	Kidney infection	n/a	701	100,0	1	0,1
Infections and infestations	Laryngitis	n/a	701	100,0	1	0,1
Infections and infestations	Localised infection	n/a	701	100,0	1	0,1
Infections and infestations	Lower respiratory tract infection	n/a	701	100,0	1	0,1
Infections and infestations	Nasopharyngitis	n/a	701	100,0	27	3,9
Infections and infestations	Necrotising fasciitis	n/a	701	100,0	1	0,1
Infections and infestations	Oral herpes	n/a	701	100,0	2	0,3
Infections and infestations	Otitis externa	n/a	701	100,0	1	0,1
Infections and infestations	Otosalpingitis	n/a	701	100,0	1	0,1
Infections and infestations	Perichondritis	n/a	701	100,0	1	0,1
Infections and infestations	Periodontitis	n/a	701	100,0	2	0,3
Infections and infestations	Pharyngitis	n/a	701	100,0	2	0,3
Infections and infestations	Pneumonia	n/a	701	100,0	10	1,4
Infections and infestations	Pneumonia viral	n/a	701	100,0	3	0,4
Infections and infestations	Pulpitis dental	n/a	701	100,0	3	0,4
Infections and infestations	Respiratory syncytial virus infection	n/a	701	100,0	1	0,1
Infections and infestations	Respiratory tract infection	n/a	701	100,0	2	0,3
Infections and infestations	Respiratory tract infection viral	n/a	701	100,0	1	0,1
Infections and infestations	Rhinitis	n/a	701	100,0	1	0,1
Infections and infestations	Sepsis	n/a	701	100,0	2	0,3
Infections and infestations	Septic arthritis staphylococcal	n/a	701	100,0	1	0,1
Infections and infestations	Sinusitis	n/a	701	100,0	9	1,3
Infections and infestations	Staphylococcal infection	n/a	701	100,0	1	0,1
Infections and infestations	Suspected COVID-19	n/a	701	100,0	10	1,4
Infections and infestations	Tinea pedis	n/a	701	100,0	1	0,1
Infections and infestations	Tooth abscess	n/a	701	100,0	2	0,3
Infections and infestations	Tooth infection	n/a	701	100,0	3	0,4
Infections and infestations	Upper respiratory tract infection	n/a	701	100,0	17	2,4
Infections and infestations	Urinary tract candidiasis	n/a	701	100,0	1	0,1
Infections and infestations	Urinary tract infection	n/a	701	100,0	14	2,0
Infections and infestations	Urosepsis	n/a	701	100,0	1	0,1
Infections and infestations	Viral rash	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications		n/a	701	100,0	55	7,8
Injury, poisoning and procedural complications	Accident	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Arthropod bite	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Arthropod sting	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Contusion	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Eye contusion	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Fall	n/a	701	100,0	10	1,4
Injury, poisoning and procedural complications	Femur fracture	n/a	701	100,0	3	0,4
Injury, poisoning and procedural complications	Fibula fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Foreign body in eye	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Hand fracture	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Hip fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Hypobarism	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Ligament rupture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Ligament sprain	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Limb injury	n/a	701	100,0	5	0,7
Injury, poisoning and procedural complications	Lower limb fracture	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Lumbar vertebral fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Medication error	n/a	701	100,0	4	0,6
Injury, poisoning and procedural complications	Muscle strain	n/a	701	100,0	3	0,4
Injury, poisoning and procedural complications	Posterior capsule rupture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Postoperative thoracic procedure complication	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Procedural nausea	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Procedural pain	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Rib fracture	n/a	701	100,0	3	0,4
Injury, poisoning and procedural complications	Road traffic accident	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Shunt stenosis	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Skin laceration	n/a	701	100,0	3	0,4

Injury, poisoning and procedural complications	Soft tissue injury	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Spinal compression fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Sunburn	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Thermal burn	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Tibia fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Tooth fracture	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Wrist fracture	n/a	701	100,0	3	0,4
Investigations		n/a	701	100,0	62	8,8
Investigations	Alanine aminotransferase increased	n/a	701	100,0	1	0,1
Investigations	Aspartate aminotransferase increased	n/a	701	100,0	1	0,1
Investigations	Blood albumin increased	n/a	701	100,0	1	0,1
Investigations	Blood bilirubin increased	n/a	701	100,0	1	0,1
Investigations	Blood cholesterol increased	n/a	701	100,0	2	0,3
Investigations	Blood creatinine increased	n/a	701	100,0	2	0,3
Investigations	Blood glucose abnormal	n/a	701	100,0	1	0,1
Investigations	Blood glucose increased	n/a	701	100,0	4	0,6
Investigations	Blood potassium increased	n/a	701	100,0	1	0,1
Investigations	Blood pressure decreased	n/a	701	100,0	1	0,1
Investigations	Blood pressure increased	n/a	701	100,0	3	0,4
Investigations	Blood testosterone decreased	n/a	701	100,0	1	0,1
Investigations	Blood thyroid stimulating hormone increased	n/a	701	100,0	1	0,1
Investigations	Blood triglycerides increased	n/a	701	100,0	1	0,1
Investigations	Blood uric acid increased	n/a	701	100,0	1	0,1
Investigations	Grip strength decreased	n/a	701	100,0	1	0,1
Investigations	Haematocrit decreased	n/a	701	100,0	1	0,1
Investigations	Haemoglobin decreased	n/a	701	100,0	1	0,1
Investigations	Heart rate irregular	n/a	701	100,0	1	0,1
Investigations	Intraocular pressure increased	n/a	701	100,0	34	4,9
Investigations	Liver function test increased	n/a	701	100,0	1	0,1
Investigations	Occult blood positive	n/a	701	100,0	1	0,1
Investigations	Optic nerve cup/disc ratio increased	n/a	701	100,0	1	0,1
Investigations	Red blood cell count decreased	n/a	701	100,0	1	0,1
Investigations	SARS-CoV-2 test positive	n/a	701	100,0	4	0,6
Investigations	Urinary occult blood	n/a	701	100,0	1	0,1
Investigations	Weight decreased	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders		n/a	701	100,0	34	4,9
Metabolism and nutrition disorders	Decreased appetite	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Dehydration	n/a	701	100,0	2	0,3
Metabolism and nutrition disorders	Diabetes mellitus	n/a	701	100,0	2	0,3
Metabolism and nutrition disorders	Dyslipidaemia	n/a	701	100,0	2	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Gout	n/a	701	100,0	2	0,3
Metabolism and nutrition disorders	Hypercholesterolaemia	n/a	701	100,0	7	1,0
Metabolism and nutrition disorders	Hyperglycaemia	n/a	701	100,0	2	0,3
Metabolism and nutrition disorders	Hyperlipidaemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hyperuricaemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hypervolaemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hypoglycaemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hypokalaemia	n/a	701	100,0	7	1,0
Metabolism and nutrition disorders	Hyponatraemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Type 2 diabetes mellitus	n/a	701	100,0	8	1,1
Metabolism and nutrition disorders	Vitamin B12 deficiency	n/a	701	100,0	2	0,3
Metabolism and nutrition disorders	Vitamin D deficiency	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders		n/a	701	100,0	61	8,7
Musculoskeletal and connective tissue disorders	Arthralgia	n/a	701	100,0	13	1,9
Musculoskeletal and connective tissue disorders	Arthritis	n/a	701	100,0	3	0,4
Musculoskeletal and connective tissue disorders	Back pain	n/a	701	100,0	14	2,0
Musculoskeletal and connective tissue disorders	Bone disorder	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Bone loss	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Bursitis	n/a	701	100,0	2	0,3
Musculoskeletal and connective tissue disorders	Coccydynia	n/a	701	100,0	1	0,1

Musculoskeletal and connective tissue disorders	Fibromyalgia	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Flank pain	n/a	701	100,0	2	0,3
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Joint effusion	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Joint swelling	n/a	701	100,0	3	0,4
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Mobility decreased	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Muscle contracture	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Muscular weakness	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Myalgia	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Neck pain	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Osteoarthritis	n/a	701	100,0	5	0,7
Musculoskeletal and connective tissue disorders	Pain in extremity	n/a	701	100,0	4	0,6
Musculoskeletal and connective tissue disorders	Periarthritis	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Plantar fasciitis	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Polymyositis	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	n/a	701	100,0	3	0,4
Musculoskeletal and connective tissue disorders	Scoliosis	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Spinal pain	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Synovial cyst	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Tendonitis	n/a	701	100,0	2	0,3
Musculoskeletal and connective tissue disorders	Trigger finger	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	701	100,0	16	2,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	n/a	701	100,0	2	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	n/a	701	100,0	2	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	n/a	701	100,0	4	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	n/a	701	100,0	1	0,1
Nervous system disorders		n/a	701	100,0	51	7,3
Nervous system disorders	Autonomic neuropathy	n/a	701	100,0	1	0,1
Nervous system disorders	Balance disorder	n/a	701	100,0	1	0,1
Nervous system disorders	Carotid arteriosclerosis	n/a	701	100,0	1	0,1
Nervous system disorders	Carpal tunnel syndrome	n/a	701	100,0	1	0,1
Nervous system disorders	Cerebral atrophy	n/a	701	100,0	1	0,1
Nervous system disorders	Cerebral disorder	n/a	701	100,0	1	0,1
Nervous system disorders	Cerebral infarction	n/a	701	100,0	1	0,1
Nervous system disorders	Cerebrovascular accident	n/a	701	100,0	1	0,1
Nervous system disorders	Cervicobrachial syndrome	n/a	701	100,0	1	0,1
Nervous system disorders	Cognitive disorder	n/a	701	100,0	1	0,1
Nervous system disorders	Dementia Alzheimer's type	n/a	701	100,0	2	0,3
Nervous system disorders	Diabetic neuropathy	n/a	701	100,0	2	0,3
Nervous system disorders	Dizziness	n/a	701	100,0	7	1,0
Nervous system disorders	Dysarthria	n/a	701	100,0	1	0,1
Nervous system disorders	Encephalopathy	n/a	701	100,0	1	0,1
Nervous system disorders	Headache	n/a	701	100,0	11	1,6
Nervous system disorders	Hypoaesthesia	n/a	701	100,0	1	0,1
Nervous system disorders	Intercostal neuralgia	n/a	701	100,0	1	0,1
Nervous system disorders	Ischaemic stroke	n/a	701	100,0	2	0,3
Nervous system disorders	Lacunar infarction	n/a	701	100,0	2	0,3
Nervous system disorders	Loss of consciousness	n/a	701	100,0	1	0,1
Nervous system disorders	Lumbar radiculopathy	n/a	701	100,0	1	0,1
Nervous system disorders	Migraine	n/a	701	100,0	1	0,1
Nervous system disorders	Neuralgia	n/a	701	100,0	2	0,3

Nervous system disorders	Neuropathy peripheral	n/a	701	100,0	2	0,3
Nervous system disorders	Ophthalmic migraine	n/a	701	100,0	1	0,1
Nervous system disorders	Paralysis	n/a	701	100,0	1	0,1
Nervous system disorders	Parkinsonism	n/a	701	100,0	1	0,1
Nervous system disorders	Presyncope	n/a	701	100,0	1	0,1
Nervous system disorders	Sciatica	n/a	701	100,0	2	0,3
Nervous system disorders	Syncope	n/a	701	100,0	4	0,6
Product issues		n/a	701	100,0	1	0,1
Product issues	Device physical property issue	n/a	701	100,0	1	0,1
Psychiatric disorders		n/a	701	100,0	9	1,3
Psychiatric disorders	Anxiety	n/a	701	100,0	1	0,1
Psychiatric disorders	Attention deficit hyperactivity disorder	n/a	701	100,0	1	0,1
Psychiatric disorders	Depression	n/a	701	100,0	2	0,3
Psychiatric disorders	Generalised anxiety disorder	n/a	701	100,0	1	0,1
Psychiatric disorders	Insomnia	n/a	701	100,0	3	0,4
Psychiatric disorders	Sleep disorder	n/a	701	100,0	1	0,1
Renal and urinary disorders		n/a	701	100,0	16	2,3
Renal and urinary disorders	Acute kidney injury	n/a	701	100,0	3	0,4
Renal and urinary disorders	Cystitis interstitial	n/a	701	100,0	1	0,1
Renal and urinary disorders	Diabetic nephropathy	n/a	701	100,0	1	0,1
Renal and urinary disorders	Dysuria	n/a	701	100,0	1	0,1
Renal and urinary disorders	End stage renal disease	n/a	701	100,0	1	0,1
Renal and urinary disorders	Haematuria	n/a	701	100,0	1	0,1
Renal and urinary disorders	Hypertonic bladder	n/a	701	100,0	1	0,1
Renal and urinary disorders	Nephrolithiasis	n/a	701	100,0	3	0,4
Renal and urinary disorders	Nephropathy	n/a	701	100,0	1	0,1
Renal and urinary disorders	Renal failure	n/a	701	100,0	2	0,3
Renal and urinary disorders	Urinary retention	n/a	701	100,0	1	0,1
Renal and urinary disorders	Urinary tract inflammation	n/a	701	100,0	1	0,1
Reproductive system and breast disorders		n/a	701	100,0	6	0,9
Reproductive system and breast disorders	Benign prostatic hyperplasia	n/a	701	100,0	3	0,4
Reproductive system and breast disorders	Cystocele	n/a	701	100,0	1	0,1
Reproductive system and breast disorders	Gynaecomastia	n/a	701	100,0	1	0,1
Reproductive system and breast disorders	Prostatitis	n/a	701	100,0	1	0,1
Reproductive system and breast disorders	Vaginal ulceration	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders		n/a	701	100,0	31	4,4
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Asthma	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	701	100,0	6	0,9
Respiratory, thoracic and mediastinal disorders	Cough	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Dry throat	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Epistaxis	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Lung opacity	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Nasal congestion	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Nasal polyps	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	n/a	701	100,0	4	0,6
Respiratory, thoracic and mediastinal disorders	Pleural thickening	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Sinus disorder	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	n/a	701	100,0	1	0,1

Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders		n/a	701	100,0	22	3,1
Skin and subcutaneous tissue disorders	Androgenetic alopecia	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Dermal cyst	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Dermatitis	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Dermatitis allergic	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Dermatitis contact	n/a	701	100,0	3	0,4
Skin and subcutaneous tissue disorders	Diabetic foot	n/a	701	100,0	2	0,3
Skin and subcutaneous tissue disorders	Eczema	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Erythema	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Hyperkeratosis	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Ingrowing nail	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Nail bed bleeding	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Nail dystrophy	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Purpura	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Rash	n/a	701	100,0	4	0,6
Skin and subcutaneous tissue disorders	Skin lesion	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Skin ulcer	n/a	701	100,0	2	0,3
Skin and subcutaneous tissue disorders	Toxic skin eruption	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Urticaria	n/a	701	100,0	1	0,1
Surgical and medical procedures		n/a	701	100,0	10	1,4
Surgical and medical procedures	Dental implantation	n/a	701	100,0	3	0,4
Surgical and medical procedures	Large intestinal polypectomy	n/a	701	100,0	1	0,1
Surgical and medical procedures	Ligament operation	n/a	701	100,0	1	0,1
Surgical and medical procedures	Neurectomy	n/a	701	100,0	1	0,1
Surgical and medical procedures	Renal transplant	n/a	701	100,0	1	0,1
Surgical and medical procedures	Toe operation	n/a	701	100,0	1	0,1
Surgical and medical procedures	Tooth extraction	n/a	701	100,0	4	0,6
Vascular disorders		n/a	701	100,0	39	5,6
Vascular disorders	Aortic aneurysm	n/a	701	100,0	1	0,1
Vascular disorders	Aortic dissection	n/a	701	100,0	1	0,1
Vascular disorders	Aortic stenosis	n/a	701	100,0	1	0,1
Vascular disorders	Deep vein thrombosis	n/a	701	100,0	1	0,1
Vascular disorders	Haematoma	n/a	701	100,0	1	0,1
Vascular disorders	Haemorrhage	n/a	701	100,0	1	0,1
Vascular disorders	Hypertension	n/a	701	100,0	23	3,3
Vascular disorders	Hypertensive crisis	n/a	701	100,0	3	0,4
Vascular disorders	Hypotension	n/a	701	100,0	4	0,6
Vascular disorders	Internal haemorrhage	n/a	701	100,0	1	0,1
Vascular disorders	Lymphoedema	n/a	701	100,0	1	0,1
Vascular disorders	Peripheral artery aneurysm	n/a	701	100,0	1	0,1
Vascular disorders	Secondary hypertension	n/a	701	100,0	1	0,1
Vascular disorders	Thrombosis	n/a	701	100,0	1	0,1

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_AE_WK72_SEa24_29AUG2023_41986.xls
26APR2024 18:00

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Gender

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		Male	374	53,4	6	1,6
Blood and lymphatic system disorders		Female	327	46,6	4	1,2
Blood and lymphatic system disorders	Anaemia	Male	374	53,4	4	1,1
Blood and lymphatic system disorders	Anaemia	Female	327	46,6	4	1,2
Blood and lymphatic system disorders	Deficiency anaemia	Male	374	53,4	1	0,3
Blood and lymphatic system disorders	Deficiency anaemia	Female	327	46,6	0	0,0
Blood and lymphatic system disorders	Iron deficiency anaemia	Male	374	53,4	1	0,3
Blood and lymphatic system disorders	Iron deficiency anaemia	Female	327	46,6	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Male	374	53,4	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Female	327	46,6	1	0,3
Cardiac disorders		Male	374	53,4	15	4,0
Cardiac disorders		Female	327	46,6	15	4,6
Cardiac disorders	Acute left ventricular failure	Male	374	53,4	0	0,0
Cardiac disorders	Acute left ventricular failure	Female	327	46,6	1	0,3
Cardiac disorders	Acute myocardial infarction	Male	374	53,4	1	0,3
Cardiac disorders	Acute myocardial infarction	Female	327	46,6	1	0,3
Cardiac disorders	Aortic valve incompetence	Male	374	53,4	0	0,0
Cardiac disorders	Aortic valve incompetence	Female	327	46,6	1	0,3
Cardiac disorders	Arrhythmia	Male	374	53,4	0	0,0
Cardiac disorders	Arrhythmia	Female	327	46,6	1	0,3
Cardiac disorders	Atrial fibrillation	Male	374	53,4	5	1,3
Cardiac disorders	Atrial fibrillation	Female	327	46,6	4	1,2
Cardiac disorders	Bradycardia	Male	374	53,4	1	0,3
Cardiac disorders	Bradycardia	Female	327	46,6	0	0,0
Cardiac disorders	Cardiac failure	Male	374	53,4	0	0,0
Cardiac disorders	Cardiac failure	Female	327	46,6	1	0,3
Cardiac disorders	Cardiac failure congestive	Male	374	53,4	1	0,3
Cardiac disorders	Cardiac failure congestive	Female	327	46,6	1	0,3
Cardiac disorders	Cardiomegaly	Male	374	53,4	0	0,0
Cardiac disorders	Cardiomegaly	Female	327	46,6	1	0,3
Cardiac disorders	Coronary artery disease	Male	374	53,4	1	0,3
Cardiac disorders	Coronary artery disease	Female	327	46,6	0	0,0
Cardiac disorders	Coronary artery stenosis	Male	374	53,4	0	0,0
Cardiac disorders	Coronary artery stenosis	Female	327	46,6	1	0,3
Cardiac disorders	Left ventricular dysfunction	Male	374	53,4	2	0,5
Cardiac disorders	Left ventricular dysfunction	Female	327	46,6	0	0,0
Cardiac disorders	Myocardial infarction	Male	374	53,4	2	0,5
Cardiac disorders	Myocardial infarction	Female	327	46,6	1	0,3
Cardiac disorders	Myocardial ischaemia	Male	374	53,4	1	0,3
Cardiac disorders	Myocardial ischaemia	Female	327	46,6	0	0,0
Cardiac disorders	Palpitations	Male	374	53,4	0	0,0
Cardiac disorders	Palpitations	Female	327	46,6	1	0,3
Cardiac disorders	Pericardial effusion	Male	374	53,4	1	0,3
Cardiac disorders	Pericardial effusion	Female	327	46,6	0	0,0
Cardiac disorders	Sinus tachycardia	Male	374	53,4	0	0,0
Cardiac disorders	Sinus tachycardia	Female	327	46,6	1	0,3
Cardiac disorders	Stress cardiomyopathy	Male	374	53,4	0	0,0
Cardiac disorders	Stress cardiomyopathy	Female	327	46,6	1	0,3
Cardiac disorders	Supraventricular tachycardia	Male	374	53,4	1	0,3
Cardiac disorders	Supraventricular tachycardia	Female	327	46,6	0	0,0
Cardiac disorders	Tachycardia	Male	374	53,4	1	0,3
Cardiac disorders	Tachycardia	Female	327	46,6	1	0,3
Congenital, familial and genetic disorders		Male	374	53,4	1	0,3
Congenital, familial and genetic disorders		Female	327	46,6	1	0,3
Congenital, familial and genetic disorders	Corneal dystrophy	Male	374	53,4	1	0,3
Congenital, familial and genetic disorders	Corneal dystrophy	Female	327	46,6	1	0,3
Ear and labyrinth disorders		Male	374	53,4	2	0,5

Ear and labyrinth disorders		Female	327	46,6	2	0,6
Ear and labyrinth disorders	Vertigo	Male	374	53,4	2	0,5
Ear and labyrinth disorders	Vertigo	Female	327	46,6	2	0,6
Endocrine disorders		Male	374	53,4	5	1,3
Endocrine disorders		Female	327	46,6	5	1,5
Endocrine disorders	Adrenal insufficiency	Male	374	53,4	1	0,3
Endocrine disorders	Adrenal insufficiency	Female	327	46,6	0	0,0
Endocrine disorders	Adrenal mass	Male	374	53,4	1	0,3
Endocrine disorders	Adrenal mass	Female	327	46,6	1	0,3
Endocrine disorders	Adrenomegaly	Male	374	53,4	0	0,0
Endocrine disorders	Adrenomegaly	Female	327	46,6	1	0,3
Endocrine disorders	Androgen deficiency	Male	374	53,4	1	0,3
Endocrine disorders	Androgen deficiency	Female	327	46,6	0	0,0
Endocrine disorders	Goitre	Male	374	53,4	1	0,3
Endocrine disorders	Goitre	Female	327	46,6	0	0,0
Endocrine disorders	Hypothyroidism	Male	374	53,4	1	0,3
Endocrine disorders	Hypothyroidism	Female	327	46,6	3	0,9
Endocrine disorders	Thyroid cyst	Male	374	53,4	0	0,0
Endocrine disorders	Thyroid cyst	Female	327	46,6	1	0,3
Endocrine disorders	Thyroid mass	Male	374	53,4	0	0,0
Endocrine disorders	Thyroid mass	Female	327	46,6	1	0,3
Eye disorders		Male	374	53,4	132	35,3
Eye disorders		Female	327	46,6	130	39,8
Eye disorders	Age-related macular degeneration	Male	374	53,4	1	0,3
Eye disorders	Age-related macular degeneration	Female	327	46,6	0	0,0
Eye disorders	Anisocoria	Male	374	53,4	1	0,3
Eye disorders	Anisocoria	Female	327	46,6	0	0,0
Eye disorders	Asthenopia	Male	374	53,4	2	0,5
Eye disorders	Asthenopia	Female	327	46,6	0	0,0
Eye disorders	Blepharitis	Male	374	53,4	4	1,1
Eye disorders	Blepharitis	Female	327	46,6	1	0,3
Eye disorders	Borderline glaucoma	Male	374	53,4	1	0,3
Eye disorders	Borderline glaucoma	Female	327	46,6	1	0,3
Eye disorders	Cataract	Male	374	53,4	16	4,3
Eye disorders	Cataract	Female	327	46,6	18	5,5
Eye disorders	Cataract nuclear	Male	374	53,4	0	0,0
Eye disorders	Cataract nuclear	Female	327	46,6	1	0,3
Eye disorders	Cataract subcapsular	Male	374	53,4	1	0,3
Eye disorders	Cataract subcapsular	Female	327	46,6	0	0,0
Eye disorders	Central serous chorioretinopathy	Male	374	53,4	3	0,8
Eye disorders	Central serous chorioretinopathy	Female	327	46,6	1	0,3
Eye disorders	Chalazion	Male	374	53,4	2	0,5
Eye disorders	Chalazion	Female	327	46,6	2	0,6
Eye disorders	Choroidal effusion	Male	374	53,4	1	0,3
Eye disorders	Choroidal effusion	Female	327	46,6	0	0,0
Eye disorders	Conjunctival haemorrhage	Male	374	53,4	8	2,1
Eye disorders	Conjunctival haemorrhage	Female	327	46,6	13	4,0
Eye disorders	Conjunctival hyperaemia	Male	374	53,4	1	0,3
Eye disorders	Conjunctival hyperaemia	Female	327	46,6	1	0,3
Eye disorders	Conjunctival telangiectasia	Male	374	53,4	0	0,0
Eye disorders	Conjunctival telangiectasia	Female	327	46,6	1	0,3
Eye disorders	Conjunctivitis allergic	Male	374	53,4	0	0,0
Eye disorders	Conjunctivitis allergic	Female	327	46,6	1	0,3
Eye disorders	Corneal deposits	Male	374	53,4	1	0,3
Eye disorders	Corneal deposits	Female	327	46,6	0	0,0
Eye disorders	Corneal erosion	Male	374	53,4	0	0,0
Eye disorders	Corneal erosion	Female	327	46,6	1	0,3
Eye disorders	Corneal infiltrates	Male	374	53,4	1	0,3
Eye disorders	Corneal infiltrates	Female	327	46,6	0	0,0
Eye disorders	Corneal opacity	Male	374	53,4	0	0,0
Eye disorders	Corneal opacity	Female	327	46,6	1	0,3
Eye disorders	Corneal pigmentation	Male	374	53,4	0	0,0
Eye disorders	Corneal pigmentation	Female	327	46,6	1	0,3
Eye disorders	Cystoid macular oedema	Male	374	53,4	16	4,3
Eye disorders	Cystoid macular oedema	Female	327	46,6	12	3,7
Eye disorders	Detachment of retinal pigment epithelium	Male	374	53,4	1	0,3
Eye disorders	Detachment of retinal pigment epithelium	Female	327	46,6	1	0,3
Eye disorders	Diabetic retinal oedema	Male	374	53,4	1	0,3
Eye disorders	Diabetic retinal oedema	Female	327	46,6	0	0,0
Eye disorders	Diabetic retinopathy	Male	374	53,4	1	0,3

Eye disorders	Diabetic retinopathy	Female	327	46,6	1	0,3
Eye disorders	Diplopia	Male	374	53,4	0	0,0
Eye disorders	Diplopia	Female	327	46,6	1	0,3
Eye disorders	Dry age-related macular degeneration	Male	374	53,4	1	0,3
Eye disorders	Dry age-related macular degeneration	Female	327	46,6	0	0,0
Eye disorders	Dry eye	Male	374	53,4	9	2,4
Eye disorders	Dry eye	Female	327	46,6	6	1,8
Eye disorders	Eczema eyelids	Male	374	53,4	0	0,0
Eye disorders	Eczema eyelids	Female	327	46,6	1	0,3
Eye disorders	Epiretinal membrane	Male	374	53,4	7	1,9
Eye disorders	Epiretinal membrane	Female	327	46,6	10	3,1
Eye disorders	Episcleritis	Male	374	53,4	1	0,3
Eye disorders	Episcleritis	Female	327	46,6	0	0,0
Eye disorders	Eye irritation	Male	374	53,4	1	0,3
Eye disorders	Eye irritation	Female	327	46,6	0	0,0
Eye disorders	Eye pain	Male	374	53,4	2	0,5
Eye disorders	Eye pain	Female	327	46,6	8	2,4
Eye disorders	Eye pruritus	Male	374	53,4	3	0,8
Eye disorders	Eye pruritus	Female	327	46,6	1	0,3
Eye disorders	Eyelid cyst	Male	374	53,4	0	0,0
Eye disorders	Eyelid cyst	Female	327	46,6	1	0,3
Eye disorders	Eyelid oedema	Male	374	53,4	0	0,0
Eye disorders	Eyelid oedema	Female	327	46,6	1	0,3
Eye disorders	Foreign body sensation in eyes	Male	374	53,4	0	0,0
Eye disorders	Foreign body sensation in eyes	Female	327	46,6	3	0,9
Eye disorders	Glaucoma	Male	374	53,4	12	3,2
Eye disorders	Glaucoma	Female	327	46,6	3	0,9
Eye disorders	Hypotony of eye	Male	374	53,4	0	0,0
Eye disorders	Hypotony of eye	Female	327	46,6	1	0,3
Eye disorders	Iridocyclitis	Male	374	53,4	4	1,1
Eye disorders	Iridocyclitis	Female	327	46,6	3	0,9
Eye disorders	Iris neovascularisation	Male	374	53,4	2	0,5
Eye disorders	Iris neovascularisation	Female	327	46,6	0	0,0
Eye disorders	Iritis	Male	374	53,4	4	1,1
Eye disorders	Iritis	Female	327	46,6	0	0,0
Eye disorders	Keratic precipitates	Male	374	53,4	0	0,0
Eye disorders	Keratic precipitates	Female	327	46,6	1	0,3
Eye disorders	Keratitis	Male	374	53,4	1	0,3
Eye disorders	Keratitis	Female	327	46,6	1	0,3
Eye disorders	Keratopathy	Male	374	53,4	0	0,0
Eye disorders	Keratopathy	Female	327	46,6	1	0,3
Eye disorders	Lacrimal disorder	Male	374	53,4	0	0,0
Eye disorders	Lacrimal disorder	Female	327	46,6	1	0,3
Eye disorders	Lacrimation increased	Male	374	53,4	4	1,1
Eye disorders	Lacrimation increased	Female	327	46,6	1	0,3
Eye disorders	Lenticular opacities	Male	374	53,4	1	0,3
Eye disorders	Lenticular opacities	Female	327	46,6	0	0,0
Eye disorders	Macular degeneration	Male	374	53,4	1	0,3
Eye disorders	Macular degeneration	Female	327	46,6	1	0,3
Eye disorders	Macular detachment	Male	374	53,4	0	0,0
Eye disorders	Macular detachment	Female	327	46,6	2	0,6
Eye disorders	Macular hole	Male	374	53,4	1	0,3
Eye disorders	Macular hole	Female	327	46,6	1	0,3
Eye disorders	Macular ischaemia	Male	374	53,4	2	0,5
Eye disorders	Macular ischaemia	Female	327	46,6	0	0,0
Eye disorders	Macular oedema	Male	374	53,4	6	1,6
Eye disorders	Macular oedema	Female	327	46,6	20	6,1
Eye disorders	Macular scar	Male	374	53,4	1	0,3
Eye disorders	Macular scar	Female	327	46,6	0	0,0
Eye disorders	Meibomianitis	Male	374	53,4	1	0,3
Eye disorders	Meibomianitis	Female	327	46,6	0	0,0
Eye disorders	Neovascular age-related macular degeneration	Male	374	53,4	1	0,3
Eye disorders	Neovascular age-related macular degeneration	Female	327	46,6	0	0,0
Eye disorders	Non-infectious endophthalmitis	Male	374	53,4	0	0,0
Eye disorders	Non-infectious endophthalmitis	Female	327	46,6	1	0,3
Eye disorders	Noninfective conjunctivitis	Male	374	53,4	1	0,3
Eye disorders	Noninfective conjunctivitis	Female	327	46,6	0	0,0
Eye disorders	Normal tension glaucoma	Male	374	53,4	0	0,0
Eye disorders	Normal tension glaucoma	Female	327	46,6	1	0,3
Eye disorders	Ocular hyperaemia	Male	374	53,4	2	0,5
Eye disorders	Ocular hyperaemia	Female	327	46,6	0	0,0
Eye disorders	Ocular hypertension	Male	374	53,4	8	2,1

Eye disorders	Ocular hypertension	Female	327	46,6	4	1,2
Eye disorders	Open angle glaucoma	Male	374	53,4	2	0,5
Eye disorders	Open angle glaucoma	Female	327	46,6	0	0,0
Eye disorders	Optic atrophy	Male	374	53,4	1	0,3
Eye disorders	Optic atrophy	Female	327	46,6	0	0,0
Eye disorders	Optic disc disorder	Male	374	53,4	1	0,3
Eye disorders	Optic disc disorder	Female	327	46,6	0	0,0
Eye disorders	Optic disc haemorrhage	Male	374	53,4	2	0,5
Eye disorders	Optic disc haemorrhage	Female	327	46,6	1	0,3
Eye disorders	Optic disc vascular disorder	Male	374	53,4	0	0,0
Eye disorders	Optic disc vascular disorder	Female	327	46,6	1	0,3
Eye disorders	Papilloedema	Male	374	53,4	0	0,0
Eye disorders	Papilloedema	Female	327	46,6	2	0,6
Eye disorders	Periorbital pain	Male	374	53,4	0	0,0
Eye disorders	Periorbital pain	Female	327	46,6	1	0,3
Eye disorders	Photopsia	Male	374	53,4	0	0,0
Eye disorders	Photopsia	Female	327	46,6	2	0,6
Eye disorders	Pinguecula	Male	374	53,4	1	0,3
Eye disorders	Pinguecula	Female	327	46,6	0	0,0
Eye disorders	Posterior capsule opacification	Male	374	53,4	1	0,3
Eye disorders	Posterior capsule opacification	Female	327	46,6	6	1,8
Eye disorders	Punctate keratitis	Male	374	53,4	4	1,1
Eye disorders	Punctate keratitis	Female	327	46,6	2	0,6
Eye disorders	Retinal aneurysm	Male	374	53,4	1	0,3
Eye disorders	Retinal aneurysm	Female	327	46,6	1	0,3
Eye disorders	Retinal artery embolism	Male	374	53,4	1	0,3
Eye disorders	Retinal artery embolism	Female	327	46,6	0	0,0
Eye disorders	Retinal artery occlusion	Male	374	53,4	4	1,1
Eye disorders	Retinal artery occlusion	Female	327	46,6	0	0,0
Eye disorders	Retinal collateral vessels	Male	374	53,4	2	0,5
Eye disorders	Retinal collateral vessels	Female	327	46,6	1	0,3
Eye disorders	Retinal depigmentation	Male	374	53,4	0	0,0
Eye disorders	Retinal depigmentation	Female	327	46,6	1	0,3
Eye disorders	Retinal detachment	Male	374	53,4	2	0,5
Eye disorders	Retinal detachment	Female	327	46,6	0	0,0
Eye disorders	Retinal disorder	Male	374	53,4	1	0,3
Eye disorders	Retinal disorder	Female	327	46,6	0	0,0
Eye disorders	Retinal drusen	Male	374	53,4	0	0,0
Eye disorders	Retinal drusen	Female	327	46,6	1	0,3
Eye disorders	Retinal exudates	Male	374	53,4	1	0,3
Eye disorders	Retinal exudates	Female	327	46,6	1	0,3
Eye disorders	Retinal haemorrhage	Male	374	53,4	6	1,6
Eye disorders	Retinal haemorrhage	Female	327	46,6	1	0,3
Eye disorders	Retinal ischaemia	Male	374	53,4	1	0,3
Eye disorders	Retinal ischaemia	Female	327	46,6	1	0,3
Eye disorders	Retinal neovascularisation	Male	374	53,4	2	0,5
Eye disorders	Retinal neovascularisation	Female	327	46,6	1	0,3
Eye disorders	Retinal tear	Male	374	53,4	1	0,3
Eye disorders	Retinal tear	Female	327	46,6	2	0,6
Eye disorders	Retinal vein occlusion	Male	374	53,4	11	2,9
Eye disorders	Retinal vein occlusion	Female	327	46,6	12	3,7
Eye disorders	Retinopathy hypertensive	Male	374	53,4	0	0,0
Eye disorders	Retinopathy hypertensive	Female	327	46,6	1	0,3
Eye disorders	Subretinal fluid	Male	374	53,4	1	0,3
Eye disorders	Subretinal fluid	Female	327	46,6	0	0,0
Eye disorders	Uveitis	Male	374	53,4	0	0,0
Eye disorders	Uveitis	Female	327	46,6	1	0,3
Eye disorders	Vision blurred	Male	374	53,4	2	0,5
Eye disorders	Vision blurred	Female	327	46,6	1	0,3
Eye disorders	Visual acuity reduced	Male	374	53,4	5	1,3
Eye disorders	Visual acuity reduced	Female	327	46,6	3	0,9
Eye disorders	Visual acuity reduced transiently	Male	374	53,4	1	0,3
Eye disorders	Visual acuity reduced transiently	Female	327	46,6	0	0,0
Eye disorders	Visual field defect	Male	374	53,4	1	0,3
Eye disorders	Visual field defect	Female	327	46,6	0	0,0
Eye disorders	Visual impairment	Male	374	53,4	3	0,8
Eye disorders	Visual impairment	Female	327	46,6	1	0,3
Eye disorders	Vitreoretinal traction syndrome	Male	374	53,4	1	0,3
Eye disorders	Vitreoretinal traction syndrome	Female	327	46,6	2	0,6
Eye disorders	Vitreous detachment	Male	374	53,4	16	4,3
Eye disorders	Vitreous detachment	Female	327	46,6	13	4,0
Eye disorders	Vitreous floaters	Male	374	53,4	4	1,1

Eye disorders	Vitreous floaters	Female	327	46,6	6	1,8
Eye disorders	Vitreous haemorrhage	Male	374	53,4	3	0,8
Eye disorders	Vitreous haemorrhage	Female	327	46,6	1	0,3
Eye disorders	Vitreous opacities	Male	374	53,4	1	0,3
Eye disorders	Vitreous opacities	Female	327	46,6	0	0,0
Eye disorders	Vitritis	Male	374	53,4	3	0,8
Eye disorders	Vitritis	Female	327	46,6	1	0,3
Gastrointestinal disorders		Male	374	53,4	18	4,8
Gastrointestinal disorders		Female	327	46,6	24	7,3
Gastrointestinal disorders	Abdominal discomfort	Male	374	53,4	0	0,0
Gastrointestinal disorders	Abdominal discomfort	Female	327	46,6	1	0,3
Gastrointestinal disorders	Abdominal pain	Male	374	53,4	1	0,3
Gastrointestinal disorders	Abdominal pain	Female	327	46,6	0	0,0
Gastrointestinal disorders	Abdominal pain upper	Male	374	53,4	1	0,3
Gastrointestinal disorders	Abdominal pain upper	Female	327	46,6	1	0,3
Gastrointestinal disorders	Barrett's oesophagus	Male	374	53,4	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	Female	327	46,6	1	0,3
Gastrointestinal disorders	Chronic gastritis	Male	374	53,4	0	0,0
Gastrointestinal disorders	Chronic gastritis	Female	327	46,6	1	0,3
Gastrointestinal disorders	Coeliac disease	Male	374	53,4	0	0,0
Gastrointestinal disorders	Coeliac disease	Female	327	46,6	1	0,3
Gastrointestinal disorders	Colitis	Male	374	53,4	0	0,0
Gastrointestinal disorders	Colitis	Female	327	46,6	1	0,3
Gastrointestinal disorders	Constipation	Male	374	53,4	2	0,5
Gastrointestinal disorders	Constipation	Female	327	46,6	3	0,9
Gastrointestinal disorders	Dental discomfort	Male	374	53,4	0	0,0
Gastrointestinal disorders	Dental discomfort	Female	327	46,6	1	0,3
Gastrointestinal disorders	Diarrhoea	Male	374	53,4	5	1,3
Gastrointestinal disorders	Diarrhoea	Female	327	46,6	6	1,8
Gastrointestinal disorders	Diverticulum intestinal	Male	374	53,4	0	0,0
Gastrointestinal disorders	Diverticulum intestinal	Female	327	46,6	1	0,3
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Male	374	53,4	1	0,3
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Female	327	46,6	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Male	374	53,4	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Female	327	46,6	0	0,0
Gastrointestinal disorders	Duodenitis	Male	374	53,4	1	0,3
Gastrointestinal disorders	Duodenitis	Female	327	46,6	0	0,0
Gastrointestinal disorders	Dyspepsia	Male	374	53,4	0	0,0
Gastrointestinal disorders	Dyspepsia	Female	327	46,6	1	0,3
Gastrointestinal disorders	Gastric ulcer	Male	374	53,4	1	0,3
Gastrointestinal disorders	Gastric ulcer	Female	327	46,6	0	0,0
Gastrointestinal disorders	Gastritis	Male	374	53,4	2	0,5
Gastrointestinal disorders	Gastritis	Female	327	46,6	1	0,3
Gastrointestinal disorders	Gastrointestinal inflammation	Male	374	53,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Female	327	46,6	1	0,3
Gastrointestinal disorders	Gastrooesophageal reflux disease	Male	374	53,4	1	0,3
Gastrointestinal disorders	Gastrooesophageal reflux disease	Female	327	46,6	1	0,3
Gastrointestinal disorders	Haemorrhagic erosive gastritis	Male	374	53,4	1	0,3
Gastrointestinal disorders	Haemorrhagic erosive gastritis	Female	327	46,6	0	0,0
Gastrointestinal disorders	Haemorrhoids	Male	374	53,4	0	0,0
Gastrointestinal disorders	Haemorrhoids	Female	327	46,6	1	0,3
Gastrointestinal disorders	Hiatus hernia	Male	374	53,4	0	0,0
Gastrointestinal disorders	Hiatus hernia	Female	327	46,6	1	0,3
Gastrointestinal disorders	Ileus	Male	374	53,4	1	0,3
Gastrointestinal disorders	Ileus	Female	327	46,6	0	0,0
Gastrointestinal disorders	Inguinal hernia	Male	374	53,4	1	0,3
Gastrointestinal disorders	Inguinal hernia	Female	327	46,6	0	0,0
Gastrointestinal disorders	Large intestine polyp	Male	374	53,4	0	0,0
Gastrointestinal disorders	Large intestine polyp	Female	327	46,6	1	0,3
Gastrointestinal disorders	Nausea	Male	374	53,4	1	0,3
Gastrointestinal disorders	Nausea	Female	327	46,6	2	0,6
Gastrointestinal disorders	Pancreatitis	Male	374	53,4	1	0,3
Gastrointestinal disorders	Pancreatitis	Female	327	46,6	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Male	374	53,4	1	0,3
Gastrointestinal disorders	Pancreatitis acute	Female	327	46,6	0	0,0
Gastrointestinal disorders	Pulpless tooth	Male	374	53,4	0	0,0
Gastrointestinal disorders	Pulpless tooth	Female	327	46,6	1	0,3
Gastrointestinal disorders	Salivary gland disorder	Male	374	53,4	0	0,0
Gastrointestinal disorders	Salivary gland disorder	Female	327	46,6	1	0,3
Gastrointestinal disorders	Toothache	Male	374	53,4	0	0,0
Gastrointestinal disorders	Toothache	Female	327	46,6	1	0,3

Gastrointestinal disorders	Umbilical hernia	Male	374	53,4	1	0,3
Gastrointestinal disorders	Umbilical hernia	Female	327	46,6	0	0,0
Gastrointestinal disorders	Vomiting	Male	374	53,4	1	0,3
Gastrointestinal disorders	Vomiting	Female	327	46,6	1	0,3
General disorders and administration site conditions		Male	374	53,4	11	2,9
General disorders and administration site conditions		Female	327	46,6	21	6,4
General disorders and administration site conditions	Asthenia	Male	374	53,4	2	0,5
General disorders and administration site conditions	Asthenia	Female	327	46,6	5	1,5
General disorders and administration site conditions	Chest pain	Male	374	53,4	2	0,5
General disorders and administration site conditions	Chest pain	Female	327	46,6	2	0,6
General disorders and administration site conditions	Chills	Male	374	53,4	0	0,0
General disorders and administration site conditions	Chills	Female	327	46,6	1	0,3
General disorders and administration site conditions	Death	Male	374	53,4	1	0,3
General disorders and administration site conditions	Death	Female	327	46,6	1	0,3
General disorders and administration site conditions	Drug intolerance	Male	374	53,4	1	0,3
General disorders and administration site conditions	Drug intolerance	Female	327	46,6	0	0,0
General disorders and administration site conditions	Drug withdrawal syndrome	Male	374	53,4	0	0,0
General disorders and administration site conditions	Drug withdrawal syndrome	Female	327	46,6	1	0,3
General disorders and administration site conditions	Fatigue	Male	374	53,4	0	0,0
General disorders and administration site conditions	Fatigue	Female	327	46,6	2	0,6
General disorders and administration site conditions	Injection site pain	Male	374	53,4	0	0,0
General disorders and administration site conditions	Injection site pain	Female	327	46,6	1	0,3
General disorders and administration site conditions	Injection site reaction	Male	374	53,4	0	0,0
General disorders and administration site conditions	Injection site reaction	Female	327	46,6	1	0,3
General disorders and administration site conditions	Oedema peripheral	Male	374	53,4	1	0,3
General disorders and administration site conditions	Oedema peripheral	Female	327	46,6	3	0,9
General disorders and administration site conditions	Pain	Male	374	53,4	1	0,3
General disorders and administration site conditions	Pain	Female	327	46,6	0	0,0
General disorders and administration site conditions	Peripheral swelling	Male	374	53,4	0	0,0
General disorders and administration site conditions	Peripheral swelling	Female	327	46,6	1	0,3
General disorders and administration site conditions	Polyp	Male	374	53,4	0	0,0
General disorders and administration site conditions	Polyp	Female	327	46,6	1	0,3
General disorders and administration site conditions	Pyrexia	Male	374	53,4	3	0,8
General disorders and administration site conditions	Pyrexia	Female	327	46,6	2	0,6
General disorders and administration site conditions	Stent-graft endoleak	Male	374	53,4	1	0,3
General disorders and administration site conditions	Stent-graft endoleak	Female	327	46,6	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	Male	374	53,4	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	Female	327	46,6	1	0,3
Hepatobiliary disorders		Male	374	53,4	2	0,5
Hepatobiliary disorders		Female	327	46,6	6	1,8
Hepatobiliary disorders	Cholecystitis	Male	374	53,4	0	0,0
Hepatobiliary disorders	Cholecystitis	Female	327	46,6	1	0,3
Hepatobiliary disorders	Cholelithiasis	Male	374	53,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	Female	327	46,6	4	1,2
Hepatobiliary disorders	Hepatic cyst	Male	374	53,4	0	0,0
Hepatobiliary disorders	Hepatic cyst	Female	327	46,6	1	0,3
Hepatobiliary disorders	Hepatic steatosis	Male	374	53,4	1	0,3
Hepatobiliary disorders	Hepatic steatosis	Female	327	46,6	2	0,6
Hepatobiliary disorders	Portal hypertension	Male	374	53,4	1	0,3
Hepatobiliary disorders	Portal hypertension	Female	327	46,6	0	0,0
Immune system disorders		Male	374	53,4	4	1,1
Immune system disorders		Female	327	46,6	7	2,1
Immune system disorders	Contrast media allergy	Male	374	53,4	1	0,3
Immune system disorders	Contrast media allergy	Female	327	46,6	2	0,6
Immune system disorders	Contrast media reaction	Male	374	53,4	0	0,0
Immune system disorders	Contrast media reaction	Female	327	46,6	1	0,3
Immune system disorders	Drug hypersensitivity	Male	374	53,4	0	0,0
Immune system disorders	Drug hypersensitivity	Female	327	46,6	1	0,3
Immune system disorders	Food allergy	Male	374	53,4	0	0,0
Immune system disorders	Food allergy	Female	327	46,6	1	0,3
Immune system disorders	Iodine allergy	Male	374	53,4	1	0,3
Immune system disorders	Iodine allergy	Female	327	46,6	0	0,0
Immune system disorders	Seasonal allergy	Male	374	53,4	2	0,5
Immune system disorders	Seasonal allergy	Female	327	46,6	2	0,6
Infections and infestations		Male	374	53,4	103	27,5
Infections and infestations		Female	327	46,6	122	37,3
Infections and infestations	Adenoviral conjunctivitis	Male	374	53,4	1	0,3
Infections and infestations	Adenoviral conjunctivitis	Female	327	46,6	0	0,0

Infections and infestations	Arthritis infective	Male	374	53,4	0	0,0
Infections and infestations	Arthritis infective	Female	327	46,6	1	0,3
Infections and infestations	Bronchitis	Male	374	53,4	4	1,1
Infections and infestations	Bronchitis	Female	327	46,6	5	1,5
Infections and infestations	COVID-19	Male	374	53,4	47	12,6
Infections and infestations	COVID-19	Female	327	46,6	44	13,5
Infections and infestations	COVID-19 pneumonia	Male	374	53,4	0	0,0
Infections and infestations	COVID-19 pneumonia	Female	327	46,6	1	0,3
Infections and infestations	Cellulitis	Male	374	53,4	2	0,5
Infections and infestations	Cellulitis	Female	327	46,6	5	1,5
Infections and infestations	Chronic sinusitis	Male	374	53,4	1	0,3
Infections and infestations	Chronic sinusitis	Female	327	46,6	1	0,3
Infections and infestations	Clostridium difficile infection	Male	374	53,4	1	0,3
Infections and infestations	Clostridium difficile infection	Female	327	46,6	0	0,0
Infections and infestations	Conjunctivitis	Male	374	53,4	7	1,9
Infections and infestations	Conjunctivitis	Female	327	46,6	7	2,1
Infections and infestations	Conjunctivitis bacterial	Male	374	53,4	0	0,0
Infections and infestations	Conjunctivitis bacterial	Female	327	46,6	1	0,3
Infections and infestations	Conjunctivitis viral	Male	374	53,4	0	0,0
Infections and infestations	Conjunctivitis viral	Female	327	46,6	1	0,3
Infections and infestations	Cystitis	Male	374	53,4	1	0,3
Infections and infestations	Cystitis	Female	327	46,6	2	0,6
Infections and infestations	Device related infection	Male	374	53,4	1	0,3
Infections and infestations	Device related infection	Female	327	46,6	0	0,0
Infections and infestations	Diabetic foot infection	Male	374	53,4	1	0,3
Infections and infestations	Diabetic foot infection	Female	327	46,6	0	0,0
Infections and infestations	Ear infection	Male	374	53,4	1	0,3
Infections and infestations	Ear infection	Female	327	46,6	2	0,6
Infections and infestations	Endophthalmitis	Male	374	53,4	1	0,3
Infections and infestations	Endophthalmitis	Female	327	46,6	0	0,0
Infections and infestations	Enteritis infectious	Male	374	53,4	0	0,0
Infections and infestations	Enteritis infectious	Female	327	46,6	1	0,3
Infections and infestations	Escherichia urinary tract infection	Male	374	53,4	0	0,0
Infections and infestations	Escherichia urinary tract infection	Female	327	46,6	1	0,3
Infections and infestations	Eye infection	Male	374	53,4	0	0,0
Infections and infestations	Eye infection	Female	327	46,6	1	0,3
Infections and infestations	Eye infection bacterial	Male	374	53,4	0	0,0
Infections and infestations	Eye infection bacterial	Female	327	46,6	1	0,3
Infections and infestations	Folliculitis	Male	374	53,4	1	0,3
Infections and infestations	Folliculitis	Female	327	46,6	0	0,0
Infections and infestations	Fungal skin infection	Male	374	53,4	0	0,0
Infections and infestations	Fungal skin infection	Female	327	46,6	1	0,3
Infections and infestations	Gastroenteritis	Male	374	53,4	0	0,0
Infections and infestations	Gastroenteritis	Female	327	46,6	1	0,3
Infections and infestations	Gastroenteritis viral	Male	374	53,4	3	0,8
Infections and infestations	Gastroenteritis viral	Female	327	46,6	1	0,3
Infections and infestations	Gastrointestinal infection	Male	374	53,4	0	0,0
Infections and infestations	Gastrointestinal infection	Female	327	46,6	1	0,3
Infections and infestations	Helicobacter infection	Male	374	53,4	0	0,0
Infections and infestations	Helicobacter infection	Female	327	46,6	1	0,3
Infections and infestations	Herpes virus infection	Male	374	53,4	1	0,3
Infections and infestations	Herpes virus infection	Female	327	46,6	0	0,0
Infections and infestations	Herpes zoster	Male	374	53,4	1	0,3
Infections and infestations	Herpes zoster	Female	327	46,6	5	1,5
Infections and infestations	Hordeolum	Male	374	53,4	3	0,8
Infections and infestations	Hordeolum	Female	327	46,6	2	0,6
Infections and infestations	Infected bite	Male	374	53,4	0	0,0
Infections and infestations	Infected bite	Female	327	46,6	1	0,3
Infections and infestations	Influenza	Male	374	53,4	10	2,7
Infections and infestations	Influenza	Female	327	46,6	9	2,8
Infections and infestations	Kidney infection	Male	374	53,4	0	0,0
Infections and infestations	Kidney infection	Female	327	46,6	1	0,3
Infections and infestations	Laryngitis	Male	374	53,4	0	0,0
Infections and infestations	Laryngitis	Female	327	46,6	1	0,3
Infections and infestations	Localised infection	Male	374	53,4	1	0,3
Infections and infestations	Localised infection	Female	327	46,6	0	0,0
Infections and infestations	Lower respiratory tract infection	Male	374	53,4	1	0,3
Infections and infestations	Lower respiratory tract infection	Female	327	46,6	0	0,0
Infections and infestations	Nasopharyngitis	Male	374	53,4	10	2,7
Infections and infestations	Nasopharyngitis	Female	327	46,6	17	5,2
Infections and infestations	Necrotising fasciitis	Male	374	53,4	1	0,3
Infections and infestations	Necrotising fasciitis	Female	327	46,6	0	0,0

Infections and infestations	Oral herpes	Male	374	53,4	2	0,5
Infections and infestations	Oral herpes	Female	327	46,6	0	0,0
Infections and infestations	Otitis externa	Male	374	53,4	0	0,0
Infections and infestations	Otitis externa	Female	327	46,6	1	0,3
Infections and infestations	Otosalpingitis	Male	374	53,4	1	0,3
Infections and infestations	Otosalpingitis	Female	327	46,6	0	0,0
Infections and infestations	Perichondritis	Male	374	53,4	0	0,0
Infections and infestations	Perichondritis	Female	327	46,6	1	0,3
Infections and infestations	Periodontitis	Male	374	53,4	2	0,5
Infections and infestations	Periodontitis	Female	327	46,6	0	0,0
Infections and infestations	Pharyngitis	Male	374	53,4	1	0,3
Infections and infestations	Pharyngitis	Female	327	46,6	1	0,3
Infections and infestations	Pneumonia	Male	374	53,4	3	0,8
Infections and infestations	Pneumonia	Female	327	46,6	7	2,1
Infections and infestations	Pneumonia viral	Male	374	53,4	1	0,3
Infections and infestations	Pneumonia viral	Female	327	46,6	2	0,6
Infections and infestations	Pulpitis dental	Male	374	53,4	0	0,0
Infections and infestations	Pulpitis dental	Female	327	46,6	3	0,9
Infections and infestations	Respiratory syncytial virus infection	Male	374	53,4	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Female	327	46,6	1	0,3
Infections and infestations	Respiratory tract infection	Male	374	53,4	0	0,0
Infections and infestations	Respiratory tract infection	Female	327	46,6	2	0,6
Infections and infestations	Respiratory tract infection viral	Male	374	53,4	0	0,0
Infections and infestations	Respiratory tract infection viral	Female	327	46,6	1	0,3
Infections and infestations	Rhinitis	Male	374	53,4	0	0,0
Infections and infestations	Rhinitis	Female	327	46,6	1	0,3
Infections and infestations	Sepsis	Male	374	53,4	1	0,3
Infections and infestations	Sepsis	Female	327	46,6	1	0,3
Infections and infestations	Septic arthritis staphylococcal	Male	374	53,4	0	0,0
Infections and infestations	Septic arthritis staphylococcal	Female	327	46,6	1	0,3
Infections and infestations	Sinusitis	Male	374	53,4	0	0,0
Infections and infestations	Sinusitis	Female	327	46,6	9	2,8
Infections and infestations	Staphylococcal infection	Male	374	53,4	0	0,0
Infections and infestations	Staphylococcal infection	Female	327	46,6	1	0,3
Infections and infestations	Suspected COVID-19	Male	374	53,4	6	1,6
Infections and infestations	Suspected COVID-19	Female	327	46,6	4	1,2
Infections and infestations	Tinea pedis	Male	374	53,4	0	0,0
Infections and infestations	Tinea pedis	Female	327	46,6	1	0,3
Infections and infestations	Tooth abscess	Male	374	53,4	2	0,5
Infections and infestations	Tooth abscess	Female	327	46,6	0	0,0
Infections and infestations	Tooth infection	Male	374	53,4	0	0,0
Infections and infestations	Tooth infection	Female	327	46,6	3	0,9
Infections and infestations	Upper respiratory tract infection	Male	374	53,4	5	1,3
Infections and infestations	Upper respiratory tract infection	Female	327	46,6	12	3,7
Infections and infestations	Urinary tract candidiasis	Male	374	53,4	0	0,0
Infections and infestations	Urinary tract candidiasis	Female	327	46,6	1	0,3
Infections and infestations	Urinary tract infection	Male	374	53,4	4	1,1
Infections and infestations	Urinary tract infection	Female	327	46,6	10	3,1
Infections and infestations	Urosepsis	Male	374	53,4	1	0,3
Infections and infestations	Urosepsis	Female	327	46,6	0	0,0
Infections and infestations	Viral rash	Male	374	53,4	1	0,3
Infections and infestations	Viral rash	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications		Male	374	53,4	27	7,2
Injury, poisoning and procedural complications		Female	327	46,6	28	8,6
Injury, poisoning and procedural complications	Accident	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Accident	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Arthropod bite	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Arthropod bite	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Arthropod sting	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Arthropod sting	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Contusion	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Contusion	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Eye contusion	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Eye contusion	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Fall	Male	374	53,4	5	1,3
Injury, poisoning and procedural complications	Fall	Female	327	46,6	5	1,5
Injury, poisoning and procedural complications	Femur fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Femur fracture	Female	327	46,6	2	0,6
Injury, poisoning and procedural complications	Fibula fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Fibula fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	Male	374	53,4	2	0,5

Injury, poisoning and procedural complications	Foreign body in eye	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Hand fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Hand fracture	Female	327	46,6	2	0,6
Injury, poisoning and procedural complications	Hip fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Hypobarism	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Hypobarism	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Ligament rupture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Ligament sprain	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Ligament sprain	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Limb injury	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Limb injury	Female	327	46,6	4	1,2
Injury, poisoning and procedural complications	Lower limb fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Lower limb fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Lumbar vertebral fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Lumbar vertebral fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Medication error	Male	374	53,4	2	0,5
Injury, poisoning and procedural complications	Medication error	Female	327	46,6	2	0,6
Injury, poisoning and procedural complications	Muscle strain	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Muscle strain	Female	327	46,6	2	0,6
Injury, poisoning and procedural complications	Posterior capsule rupture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Posterior capsule rupture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Postoperative thoracic procedure complication	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Postoperative thoracic procedure complication	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Procedural nausea	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Procedural nausea	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Procedural pain	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Procedural pain	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Rib fracture	Male	374	53,4	2	0,5
Injury, poisoning and procedural complications	Rib fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Road traffic accident	Male	374	53,4	2	0,5
Injury, poisoning and procedural complications	Road traffic accident	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Shunt stenosis	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Male	374	53,4	3	0,8
Injury, poisoning and procedural complications	Skin laceration	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Soft tissue injury	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Soft tissue injury	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Spinal compression fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Spinal compression fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Sunburn	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Sunburn	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Thermal burn	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Thermal burn	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Tibia fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Tibia fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Tooth fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Wrist fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Wrist fracture	Female	327	46,6	2	0,6
Investigations		Male	374	53,4	35	9,4
Investigations		Female	327	46,6	27	8,3
Investigations	Alanine aminotransferase increased	Male	374	53,4	1	0,3
Investigations	Alanine aminotransferase increased	Female	327	46,6	0	0,0
Investigations	Aspartate aminotransferase increased	Male	374	53,4	1	0,3
Investigations	Aspartate aminotransferase increased	Female	327	46,6	0	0,0
Investigations	Blood albumin increased	Male	374	53,4	0	0,0
Investigations	Blood albumin increased	Female	327	46,6	1	0,3
Investigations	Blood bilirubin increased	Male	374	53,4	1	0,3
Investigations	Blood bilirubin increased	Female	327	46,6	0	0,0
Investigations	Blood cholesterol increased	Male	374	53,4	2	0,5
Investigations	Blood cholesterol increased	Female	327	46,6	0	0,0
Investigations	Blood creatinine increased	Male	374	53,4	1	0,3
Investigations	Blood creatinine increased	Female	327	46,6	1	0,3
Investigations	Blood glucose abnormal	Male	374	53,4	1	0,3
Investigations	Blood glucose abnormal	Female	327	46,6	0	0,0
Investigations	Blood glucose increased	Male	374	53,4	3	0,8
Investigations	Blood glucose increased	Female	327	46,6	1	0,3

Investigations	Blood potassium increased	Male	374	53,4	0	0,0
Investigations	Blood potassium increased	Female	327	46,6	1	0,3
Investigations	Blood pressure decreased	Male	374	53,4	1	0,3
Investigations	Blood pressure decreased	Female	327	46,6	0	0,0
Investigations	Blood pressure increased	Male	374	53,4	1	0,3
Investigations	Blood pressure increased	Female	327	46,6	2	0,6
Investigations	Blood testosterone decreased	Male	374	53,4	1	0,3
Investigations	Blood testosterone decreased	Female	327	46,6	0	0,0
Investigations	Blood thyroid stimulating hormone increased	Male	374	53,4	0	0,0
Investigations	Blood thyroid stimulating hormone increased	Female	327	46,6	1	0,3
Investigations	Blood triglycerides increased	Male	374	53,4	0	0,0
Investigations	Blood triglycerides increased	Female	327	46,6	1	0,3
Investigations	Blood uric acid increased	Male	374	53,4	0	0,0
Investigations	Blood uric acid increased	Female	327	46,6	1	0,3
Investigations	Grip strength decreased	Male	374	53,4	1	0,3
Investigations	Grip strength decreased	Female	327	46,6	0	0,0
Investigations	Haematocrit decreased	Male	374	53,4	0	0,0
Investigations	Haematocrit decreased	Female	327	46,6	1	0,3
Investigations	Haemoglobin decreased	Male	374	53,4	0	0,0
Investigations	Haemoglobin decreased	Female	327	46,6	1	0,3
Investigations	Heart rate irregular	Male	374	53,4	1	0,3
Investigations	Heart rate irregular	Female	327	46,6	0	0,0
Investigations	Intraocular pressure increased	Male	374	53,4	17	4,5
Investigations	Intraocular pressure increased	Female	327	46,6	17	5,2
Investigations	Liver function test increased	Male	374	53,4	1	0,3
Investigations	Liver function test increased	Female	327	46,6	0	0,0
Investigations	Occult blood positive	Male	374	53,4	0	0,0
Investigations	Occult blood positive	Female	327	46,6	1	0,3
Investigations	Optic nerve cup/disc ratio increased	Male	374	53,4	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Female	327	46,6	1	0,3
Investigations	Red blood cell count decreased	Male	374	53,4	0	0,0
Investigations	Red blood cell count decreased	Female	327	46,6	1	0,3
Investigations	SARS-CoV-2 test positive	Male	374	53,4	3	0,8
Investigations	SARS-CoV-2 test positive	Female	327	46,6	1	0,3
Investigations	Urinary occult blood	Male	374	53,4	1	0,3
Investigations	Urinary occult blood	Female	327	46,6	0	0,0
Investigations	Weight decreased	Male	374	53,4	0	0,0
Investigations	Weight decreased	Female	327	46,6	1	0,3
Metabolism and nutrition disorders		Male	374	53,4	18	4,8
Metabolism and nutrition disorders		Female	327	46,6	16	4,9
Metabolism and nutrition disorders	Decreased appetite	Male	374	53,4	0	0,0
Metabolism and nutrition disorders	Decreased appetite	Female	327	46,6	1	0,3
Metabolism and nutrition disorders	Dehydration	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Dehydration	Female	327	46,6	1	0,3
Metabolism and nutrition disorders	Diabetes mellitus	Male	374	53,4	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	Female	327	46,6	2	0,6
Metabolism and nutrition disorders	Dyslipidaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Dyslipidaemia	Female	327	46,6	1	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Gout	Male	374	53,4	2	0,5
Metabolism and nutrition disorders	Gout	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	Male	374	53,4	4	1,1
Metabolism and nutrition disorders	Hypercholesterolaemia	Female	327	46,6	3	0,9
Metabolism and nutrition disorders	Hyperglycaemia	Male	374	53,4	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Female	327	46,6	2	0,6
Metabolism and nutrition disorders	Hyperlipidaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Hyperlipidaemia	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hyperuricaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Hyperuricaemia	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Hypervolaemia	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Hypoglycaemia	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Male	374	53,4	3	0,8
Metabolism and nutrition disorders	Hypokalaemia	Female	327	46,6	4	1,2
Metabolism and nutrition disorders	Hyponatraemia	Male	374	53,4	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	Female	327	46,6	1	0,3
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Male	374	53,4	6	1,6
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Female	327	46,6	2	0,6
Metabolism and nutrition disorders	Vitamin B12 deficiency	Male	374	53,4	0	0,0

Metabolism and nutrition disorders	Vitamin B12 deficiency	Female	327	46,6	2	0,6
Metabolism and nutrition disorders	Vitamin D deficiency	Male	374	53,4	0	0,0
Metabolism and nutrition disorders	Vitamin D deficiency	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders		Male	374	53,4	31	8,3
Musculoskeletal and connective tissue disorders		Female	327	46,6	30	9,2
Musculoskeletal and connective tissue disorders	Arthralgia	Male	374	53,4	8	2,1
Musculoskeletal and connective tissue disorders	Arthralgia	Female	327	46,6	5	1,5
Musculoskeletal and connective tissue disorders	Arthritis	Male	374	53,4	2	0,5
Musculoskeletal and connective tissue disorders	Arthritis	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Back pain	Male	374	53,4	6	1,6
Musculoskeletal and connective tissue disorders	Back pain	Female	327	46,6	8	2,4
Musculoskeletal and connective tissue disorders	Bone disorder	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Bone disorder	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Bone loss	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Bursitis	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Bursitis	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Coccydynia	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Coccydynia	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Fibromyalgia	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Fibromyalgia	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Flank pain	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Flank pain	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	Female	327	46,6	3	0,9
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Muscle contracture	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Muscle contracture	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Muscular weakness	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Muscular weakness	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Myalgia	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Myalgia	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Neck pain	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Neck pain	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Male	374	53,4	2	0,5
Musculoskeletal and connective tissue disorders	Osteoarthritis	Female	327	46,6	3	0,9
Musculoskeletal and connective tissue disorders	Pain in extremity	Male	374	53,4	4	1,1
Musculoskeletal and connective tissue disorders	Pain in extremity	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Periarthritis	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Polymyositis	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Female	327	46,6	2	0,6
Musculoskeletal and connective tissue disorders	Scoliosis	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Spinal pain	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Spinal pain	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Synovial cyst	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Synovial cyst	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Tendonitis	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Tendonitis	Female	327	46,6	2	0,6
Musculoskeletal and connective tissue disorders	Trigger finger	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Trigger finger	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Male	374	53,4	8	2,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Female	327	46,6	8	2,4

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	Male	374	53,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Male	374	53,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	Male	374	53,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Male	374	53,4	2	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Female	327	46,6	2	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Male	374	53,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Female	327	46,6	1	0,3
Nervous system disorders		Male	374	53,4	19	5,1
Nervous system disorders		Female	327	46,6	32	9,8
Nervous system disorders	Autonomic neuropathy	Male	374	53,4	1	0,3
Nervous system disorders	Autonomic neuropathy	Female	327	46,6	0	0,0
Nervous system disorders	Balance disorder	Male	374	53,4	1	0,3
Nervous system disorders	Balance disorder	Female	327	46,6	0	0,0
Nervous system disorders	Carotid arteriosclerosis	Male	374	53,4	0	0,0
Nervous system disorders	Carotid arteriosclerosis	Female	327	46,6	1	0,3
Nervous system disorders	Carpal tunnel syndrome	Male	374	53,4	0	0,0
Nervous system disorders	Carpal tunnel syndrome	Female	327	46,6	1	0,3
Nervous system disorders	Cerebral atrophy	Male	374	53,4	0	0,0
Nervous system disorders	Cerebral atrophy	Female	327	46,6	1	0,3
Nervous system disorders	Cerebral disorder	Male	374	53,4	0	0,0
Nervous system disorders	Cerebral disorder	Female	327	46,6	1	0,3
Nervous system disorders	Cerebral infarction	Male	374	53,4	1	0,3
Nervous system disorders	Cerebral infarction	Female	327	46,6	0	0,0
Nervous system disorders	Cerebrovascular accident	Male	374	53,4	0	0,0
Nervous system disorders	Cerebrovascular accident	Female	327	46,6	1	0,3
Nervous system disorders	Cervicobrachial syndrome	Male	374	53,4	1	0,3
Nervous system disorders	Cervicobrachial syndrome	Female	327	46,6	0	0,0
Nervous system disorders	Cognitive disorder	Male	374	53,4	0	0,0
Nervous system disorders	Cognitive disorder	Female	327	46,6	1	0,3
Nervous system disorders	Dementia Alzheimer's type	Male	374	53,4	0	0,0
Nervous system disorders	Dementia Alzheimer's type	Female	327	46,6	2	0,6
Nervous system disorders	Diabetic neuropathy	Male	374	53,4	1	0,3
Nervous system disorders	Diabetic neuropathy	Female	327	46,6	1	0,3
Nervous system disorders	Dizziness	Male	374	53,4	2	0,5
Nervous system disorders	Dizziness	Female	327	46,6	5	1,5

Nervous system disorders	Dysarthria	Male	374	53,4	0	0,0
Nervous system disorders	Dysarthria	Female	327	46,6	1	0,3
Nervous system disorders	Encephalopathy	Male	374	53,4	0	0,0
Nervous system disorders	Encephalopathy	Female	327	46,6	1	0,3
Nervous system disorders	Headache	Male	374	53,4	4	1,1
Nervous system disorders	Headache	Female	327	46,6	7	2,1
Nervous system disorders	Hypoaesthesia	Male	374	53,4	0	0,0
Nervous system disorders	Hypoaesthesia	Female	327	46,6	1	0,3
Nervous system disorders	Intercostal neuralgia	Male	374	53,4	1	0,3
Nervous system disorders	Intercostal neuralgia	Female	327	46,6	0	0,0
Nervous system disorders	Ischaemic stroke	Male	374	53,4	2	0,5
Nervous system disorders	Ischaemic stroke	Female	327	46,6	0	0,0
Nervous system disorders	Lacunar infarction	Male	374	53,4	1	0,3
Nervous system disorders	Lacunar infarction	Female	327	46,6	1	0,3
Nervous system disorders	Loss of consciousness	Male	374	53,4	0	0,0
Nervous system disorders	Loss of consciousness	Female	327	46,6	1	0,3
Nervous system disorders	Lumbar radiculopathy	Male	374	53,4	0	0,0
Nervous system disorders	Lumbar radiculopathy	Female	327	46,6	1	0,3
Nervous system disorders	Migraine	Male	374	53,4	0	0,0
Nervous system disorders	Migraine	Female	327	46,6	1	0,3
Nervous system disorders	Neuralgia	Male	374	53,4	0	0,0
Nervous system disorders	Neuralgia	Female	327	46,6	2	0,6
Nervous system disorders	Neuropathy peripheral	Male	374	53,4	1	0,3
Nervous system disorders	Neuropathy peripheral	Female	327	46,6	1	0,3
Nervous system disorders	Ophthalmic migraine	Male	374	53,4	0	0,0
Nervous system disorders	Ophthalmic migraine	Female	327	46,6	1	0,3
Nervous system disorders	Paralysis	Male	374	53,4	0	0,0
Nervous system disorders	Paralysis	Female	327	46,6	1	0,3
Nervous system disorders	Parkinsonism	Male	374	53,4	1	0,3
Nervous system disorders	Parkinsonism	Female	327	46,6	0	0,0
Nervous system disorders	Presyncope	Male	374	53,4	0	0,0
Nervous system disorders	Presyncope	Female	327	46,6	1	0,3
Nervous system disorders	Sciatica	Male	374	53,4	2	0,5
Nervous system disorders	Sciatica	Female	327	46,6	0	0,0
Nervous system disorders	Syncope	Male	374	53,4	1	0,3
Nervous system disorders	Syncope	Female	327	46,6	3	0,9
Product issues		Male	374	53,4	0	0,0
Product issues		Female	327	46,6	1	0,3
Product issues	Device physical property issue	Male	374	53,4	0	0,0
Product issues	Device physical property issue	Female	327	46,6	1	0,3
Psychiatric disorders		Male	374	53,4	4	1,1
Psychiatric disorders		Female	327	46,6	5	1,5
Psychiatric disorders	Anxiety	Male	374	53,4	1	0,3
Psychiatric disorders	Anxiety	Female	327	46,6	0	0,0
Psychiatric disorders	Attention deficit hyperactivity disorder	Male	374	53,4	1	0,3
Psychiatric disorders	Attention deficit hyperactivity disorder	Female	327	46,6	0	0,0
Psychiatric disorders	Depression	Male	374	53,4	0	0,0
Psychiatric disorders	Depression	Female	327	46,6	2	0,6
Psychiatric disorders	Generalised anxiety disorder	Male	374	53,4	0	0,0
Psychiatric disorders	Generalised anxiety disorder	Female	327	46,6	1	0,3
Psychiatric disorders	Insomnia	Male	374	53,4	2	0,5
Psychiatric disorders	Insomnia	Female	327	46,6	1	0,3
Psychiatric disorders	Sleep disorder	Male	374	53,4	0	0,0
Psychiatric disorders	Sleep disorder	Female	327	46,6	1	0,3
Renal and urinary disorders		Male	374	53,4	11	2,9
Renal and urinary disorders		Female	327	46,6	5	1,5
Renal and urinary disorders	Acute kidney injury	Male	374	53,4	2	0,5
Renal and urinary disorders	Acute kidney injury	Female	327	46,6	1	0,3
Renal and urinary disorders	Cystitis interstitial	Male	374	53,4	0	0,0
Renal and urinary disorders	Cystitis interstitial	Female	327	46,6	1	0,3
Renal and urinary disorders	Diabetic nephropathy	Male	374	53,4	1	0,3
Renal and urinary disorders	Diabetic nephropathy	Female	327	46,6	0	0,0
Renal and urinary disorders	Dysuria	Male	374	53,4	1	0,3
Renal and urinary disorders	Dysuria	Female	327	46,6	0	0,0
Renal and urinary disorders	End stage renal disease	Male	374	53,4	1	0,3
Renal and urinary disorders	End stage renal disease	Female	327	46,6	0	0,0
Renal and urinary disorders	Haematuria	Male	374	53,4	1	0,3
Renal and urinary disorders	Haematuria	Female	327	46,6	0	0,0
Renal and urinary disorders	Hypertonic bladder	Male	374	53,4	1	0,3

Renal and urinary disorders	Hypertonic bladder	Female	327	46,6	0	0,0
Renal and urinary disorders	Nephrolithiasis	Male	374	53,4	1	0,3
Renal and urinary disorders	Nephrolithiasis	Female	327	46,6	2	0,6
Renal and urinary disorders	Nephropathy	Male	374	53,4	1	0,3
Renal and urinary disorders	Nephropathy	Female	327	46,6	0	0,0
Renal and urinary disorders	Renal failure	Male	374	53,4	1	0,3
Renal and urinary disorders	Renal failure	Female	327	46,6	1	0,3
Renal and urinary disorders	Urinary retention	Male	374	53,4	0	0,0
Renal and urinary disorders	Urinary retention	Female	327	46,6	1	0,3
Renal and urinary disorders	Urinary tract inflammation	Male	374	53,4	1	0,3
Renal and urinary disorders	Urinary tract inflammation	Female	327	46,6	0	0,0
Reproductive system and breast disorders		Male	374	53,4	4	1,1
Reproductive system and breast disorders		Female	327	46,6	2	0,6
Reproductive system and breast disorders	Benign prostatic hyperplasia	Male	374	53,4	3	0,8
Reproductive system and breast disorders	Benign prostatic hyperplasia	Female	327	46,6	0	0,0
Reproductive system and breast disorders	Cystocele	Male	374	53,4	0	0,0
Reproductive system and breast disorders	Cystocele	Female	327	46,6	1	0,3
Reproductive system and breast disorders	Gynaecomastia	Male	374	53,4	1	0,3
Reproductive system and breast disorders	Gynaecomastia	Female	327	46,6	0	0,0
Reproductive system and breast disorders	Prostatitis	Male	374	53,4	1	0,3
Reproductive system and breast disorders	Prostatitis	Female	327	46,6	0	0,0
Reproductive system and breast disorders	Vaginal ulceration	Male	374	53,4	0	0,0
Reproductive system and breast disorders	Vaginal ulceration	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders		Male	374	53,4	17	4,5
Respiratory, thoracic and mediastinal disorders		Female	327	46,6	14	4,3
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Female	327	46,6	2	0,6
Respiratory, thoracic and mediastinal disorders	Asthma	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Asthma	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Male	374	53,4	5	1,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Cough	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	Female	327	46,6	2	0,6
Respiratory, thoracic and mediastinal disorders	Dry throat	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Dry throat	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Epistaxis	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Epistaxis	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung opacity	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Lung opacity	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	Male	374	53,4	3	0,8
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Pleural thickening	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural thickening	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Male	374	53,4	2	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	Male	374	53,4	2	0,5
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	Male	374	53,4	1	0,3

Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders		Male	374	53,4	9	2,4
Skin and subcutaneous tissue disorders		Female	327	46,6	13	4,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Dermal cyst	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Dermal cyst	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis allergic	Male	374	53,4	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis allergic	Female	327	46,6	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	Male	374	53,4	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis contact	Female	327	46,6	2	0,6
Skin and subcutaneous tissue disorders	Diabetic foot	Male	374	53,4	2	0,5
Skin and subcutaneous tissue disorders	Diabetic foot	Female	327	46,6	0	0,0
Skin and subcutaneous tissue disorders	Eczema	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Eczema	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Erythema	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Erythema	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Hyperkeratosis	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Hyperkeratosis	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Ingrowing nail	Male	374	53,4	1	0,3
Skin and subcutaneous tissue disorders	Ingrowing nail	Female	327	46,6	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Nail dystrophy	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Purpura	Male	374	53,4	1	0,3
Skin and subcutaneous tissue disorders	Purpura	Female	327	46,6	0	0,0
Skin and subcutaneous tissue disorders	Rash	Male	374	53,4	3	0,8
Skin and subcutaneous tissue disorders	Rash	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Skin lesion	Male	374	53,4	1	0,3
Skin and subcutaneous tissue disorders	Skin lesion	Female	327	46,6	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	Male	374	53,4	1	0,3
Skin and subcutaneous tissue disorders	Skin ulcer	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Toxic skin eruption	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Toxic skin eruption	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Urticaria	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	Female	327	46,6	1	0,3
Surgical and medical procedures		Male	374	53,4	4	1,1
Surgical and medical procedures		Female	327	46,6	6	1,8
Surgical and medical procedures	Dental implantation	Male	374	53,4	1	0,3
Surgical and medical procedures	Dental implantation	Female	327	46,6	2	0,6
Surgical and medical procedures	Large intestinal polypectomy	Male	374	53,4	1	0,3
Surgical and medical procedures	Large intestinal polypectomy	Female	327	46,6	0	0,0
Surgical and medical procedures	Ligament operation	Male	374	53,4	1	0,3
Surgical and medical procedures	Ligament operation	Female	327	46,6	0	0,0
Surgical and medical procedures	Neurectomy	Male	374	53,4	0	0,0
Surgical and medical procedures	Neurectomy	Female	327	46,6	1	0,3
Surgical and medical procedures	Renal transplant	Male	374	53,4	1	0,3
Surgical and medical procedures	Renal transplant	Female	327	46,6	0	0,0
Surgical and medical procedures	Toe operation	Male	374	53,4	0	0,0
Surgical and medical procedures	Toe operation	Female	327	46,6	1	0,3
Surgical and medical procedures	Tooth extraction	Male	374	53,4	1	0,3
Surgical and medical procedures	Tooth extraction	Female	327	46,6	3	0,9
Vascular disorders		Male	374	53,4	22	5,9
Vascular disorders		Female	327	46,6	17	5,2
Vascular disorders	Aortic aneurysm	Male	374	53,4	1	0,3
Vascular disorders	Aortic aneurysm	Female	327	46,6	0	0,0
Vascular disorders	Aortic dissection	Male	374	53,4	0	0,0
Vascular disorders	Aortic dissection	Female	327	46,6	1	0,3
Vascular disorders	Aortic stenosis	Male	374	53,4	1	0,3
Vascular disorders	Aortic stenosis	Female	327	46,6	0	0,0
Vascular disorders	Deep vein thrombosis	Male	374	53,4	1	0,3
Vascular disorders	Deep vein thrombosis	Female	327	46,6	0	0,0
Vascular disorders	Haematoma	Male	374	53,4	0	0,0
Vascular disorders	Haematoma	Female	327	46,6	1	0,3

Vascular disorders	Haemorrhage	Male	374	53,4	1	0,3
Vascular disorders	Haemorrhage	Female	327	46,6	0	0,0
Vascular disorders	Hypertension	Male	374	53,4	15	4,0
Vascular disorders	Hypertension	Female	327	46,6	8	2,4
Vascular disorders	Hypertensive crisis	Male	374	53,4	2	0,5
Vascular disorders	Hypertensive crisis	Female	327	46,6	1	0,3
Vascular disorders	Hypotension	Male	374	53,4	2	0,5
Vascular disorders	Hypotension	Female	327	46,6	2	0,6
Vascular disorders	Internal haemorrhage	Male	374	53,4	0	0,0
Vascular disorders	Internal haemorrhage	Female	327	46,6	1	0,3
Vascular disorders	Lymphoedema	Male	374	53,4	0	0,0
Vascular disorders	Lymphoedema	Female	327	46,6	1	0,3
Vascular disorders	Peripheral artery aneurysm	Male	374	53,4	1	0,3
Vascular disorders	Peripheral artery aneurysm	Female	327	46,6	0	0,0
Vascular disorders	Secondary hypertension	Male	374	53,4	0	0,0
Vascular disorders	Secondary hypertension	Female	327	46,6	1	0,3
Vascular disorders	Thrombosis	Male	374	53,4	0	0,0
Vascular disorders	Thrombosis	Female	327	46,6	1	0,3

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_AE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:00

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Age			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Blood and lymphatic system disorders		<65 years	308	43,9	3	1,0
Blood and lymphatic system disorders		>=65 years	393	56,1	7	1,8
Blood and lymphatic system disorders	Anaemia	<65 years	308	43,9	3	1,0
Blood and lymphatic system disorders	Anaemia	>=65 years	393	56,1	5	1,3
Blood and lymphatic system disorders	Deficiency anaemia	<65 years	308	43,9	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	>=65 years	393	56,1	1	0,3
Blood and lymphatic system disorders	Iron deficiency anaemia	<65 years	308	43,9	0	0,0
Blood and lymphatic system disorders	Iron deficiency anaemia	>=65 years	393	56,1	1	0,3
Blood and lymphatic system disorders	Mesenteric lymphadenitis	<65 years	308	43,9	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	>=65 years	393	56,1	1	0,3
Cardiac disorders		<65 years	308	43,9	8	2,6
Cardiac disorders		>=65 years	393	56,1	22	5,6
Cardiac disorders	Acute left ventricular failure	<65 years	308	43,9	0	0,0
Cardiac disorders	Acute left ventricular failure	>=65 years	393	56,1	1	0,3
Cardiac disorders	Acute myocardial infarction	<65 years	308	43,9	0	0,0
Cardiac disorders	Acute myocardial infarction	>=65 years	393	56,1	2	0,5
Cardiac disorders	Aortic valve incompetence	<65 years	308	43,9	0	0,0
Cardiac disorders	Aortic valve incompetence	>=65 years	393	56,1	1	0,3
Cardiac disorders	Arrhythmia	<65 years	308	43,9	0	0,0
Cardiac disorders	Arrhythmia	>=65 years	393	56,1	1	0,3
Cardiac disorders	Atrial fibrillation	<65 years	308	43,9	1	0,3
Cardiac disorders	Atrial fibrillation	>=65 years	393	56,1	8	2,0
Cardiac disorders	Bradycardia	<65 years	308	43,9	0	0,0
Cardiac disorders	Bradycardia	>=65 years	393	56,1	1	0,3
Cardiac disorders	Cardiac failure	<65 years	308	43,9	0	0,0
Cardiac disorders	Cardiac failure	>=65 years	393	56,1	1	0,3
Cardiac disorders	Cardiac failure congestive	<65 years	308	43,9	0	0,0
Cardiac disorders	Cardiac failure congestive	>=65 years	393	56,1	2	0,5
Cardiac disorders	Cardiomegaly	<65 years	308	43,9	0	0,0
Cardiac disorders	Cardiomegaly	>=65 years	393	56,1	1	0,3
Cardiac disorders	Coronary artery disease	<65 years	308	43,9	0	0,0
Cardiac disorders	Coronary artery disease	>=65 years	393	56,1	1	0,3
Cardiac disorders	Coronary artery stenosis	<65 years	308	43,9	0	0,0
Cardiac disorders	Coronary artery stenosis	>=65 years	393	56,1	1	0,3
Cardiac disorders	Left ventricular dysfunction	<65 years	308	43,9	0	0,0
Cardiac disorders	Left ventricular dysfunction	>=65 years	393	56,1	2	0,5
Cardiac disorders	Myocardial infarction	<65 years	308	43,9	2	0,6
Cardiac disorders	Myocardial infarction	>=65 years	393	56,1	1	0,3
Cardiac disorders	Myocardial ischaemia	<65 years	308	43,9	1	0,3
Cardiac disorders	Myocardial ischaemia	>=65 years	393	56,1	0	0,0
Cardiac disorders	Palpitations	<65 years	308	43,9	1	0,3
Cardiac disorders	Palpitations	>=65 years	393	56,1	0	0,0
Cardiac disorders	Pericardial effusion	<65 years	308	43,9	1	0,3
Cardiac disorders	Pericardial effusion	>=65 years	393	56,1	0	0,0
Cardiac disorders	Sinus tachycardia	<65 years	308	43,9	0	0,0
Cardiac disorders	Sinus tachycardia	>=65 years	393	56,1	1	0,3
Cardiac disorders	Stress cardiomyopathy	<65 years	308	43,9	1	0,3
Cardiac disorders	Stress cardiomyopathy	>=65 years	393	56,1	0	0,0
Cardiac disorders	Supraventricular tachycardia	<65 years	308	43,9	0	0,0
Cardiac disorders	Supraventricular tachycardia	>=65 years	393	56,1	1	0,3
Cardiac disorders	Tachycardia	<65 years	308	43,9	1	0,3
Cardiac disorders	Tachycardia	>=65 years	393	56,1	1	0,3
Congenital, familial and genetic disorders		<65 years	308	43,9	0	0,0
Congenital, familial and genetic disorders		>=65 years	393	56,1	2	0,5
Congenital, familial and genetic disorders	Corneal dystrophy	<65 years	308	43,9	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	>=65 years	393	56,1	2	0,5
Ear and labyrinth disorders		<65 years	308	43,9	2	0,6
Ear and labyrinth disorders		>=65 years	393	56,1	2	0,5
Ear and labyrinth disorders	Vertigo	<65 years	308	43,9	2	0,6

Ear and labyrinth disorders	Vertigo	>=65 years	393	56,1	2	0,5
Endocrine disorders		<65 years	308	43,9	3	1,0
Endocrine disorders		>=65 years	393	56,1	7	1,8
Endocrine disorders	Adrenal insufficiency	<65 years	308	43,9	0	0,0
Endocrine disorders	Adrenal insufficiency	>=65 years	393	56,1	1	0,3
Endocrine disorders	Adrenal mass	<65 years	308	43,9	2	0,6
Endocrine disorders	Adrenal mass	>=65 years	393	56,1	0	0,0
Endocrine disorders	Adrenomegaly	<65 years	308	43,9	1	0,3
Endocrine disorders	Adrenomegaly	>=65 years	393	56,1	0	0,0
Endocrine disorders	Androgen deficiency	<65 years	308	43,9	1	0,3
Endocrine disorders	Androgen deficiency	>=65 years	393	56,1	0	0,0
Endocrine disorders	Goitre	<65 years	308	43,9	0	0,0
Endocrine disorders	Goitre	>=65 years	393	56,1	1	0,3
Endocrine disorders	Hypothyroidism	<65 years	308	43,9	0	0,0
Endocrine disorders	Hypothyroidism	>=65 years	393	56,1	4	1,0
Endocrine disorders	Thyroid cyst	<65 years	308	43,9	0	0,0
Endocrine disorders	Thyroid cyst	>=65 years	393	56,1	1	0,3
Endocrine disorders	Thyroid mass	<65 years	308	43,9	0	0,0
Endocrine disorders	Thyroid mass	>=65 years	393	56,1	1	0,3
Eye disorders		<65 years	308	43,9	113	36,7
Eye disorders		>=65 years	393	56,1	149	37,9
Eye disorders	Age-related macular degeneration	<65 years	308	43,9	0	0,0
Eye disorders	Age-related macular degeneration	>=65 years	393	56,1	1	0,3
Eye disorders	Anisocoria	<65 years	308	43,9	0	0,0
Eye disorders	Anisocoria	>=65 years	393	56,1	1	0,3
Eye disorders	Asthenopia	<65 years	308	43,9	1	0,3
Eye disorders	Asthenopia	>=65 years	393	56,1	1	0,3
Eye disorders	Blepharitis	<65 years	308	43,9	1	0,3
Eye disorders	Blepharitis	>=65 years	393	56,1	4	1,0
Eye disorders	Borderline glaucoma	<65 years	308	43,9	2	0,6
Eye disorders	Borderline glaucoma	>=65 years	393	56,1	0	0,0
Eye disorders	Cataract	<65 years	308	43,9	9	2,9
Eye disorders	Cataract	>=65 years	393	56,1	25	6,4
Eye disorders	Cataract nuclear	<65 years	308	43,9	0	0,0
Eye disorders	Cataract nuclear	>=65 years	393	56,1	1	0,3
Eye disorders	Cataract subcapsular	<65 years	308	43,9	0	0,0
Eye disorders	Cataract subcapsular	>=65 years	393	56,1	1	0,3
Eye disorders	Central serous chorioretinopathy	<65 years	308	43,9	4	1,3
Eye disorders	Central serous chorioretinopathy	>=65 years	393	56,1	0	0,0
Eye disorders	Chalazion	<65 years	308	43,9	2	0,6
Eye disorders	Chalazion	>=65 years	393	56,1	2	0,5
Eye disorders	Choroidal effusion	<65 years	308	43,9	0	0,0
Eye disorders	Choroidal effusion	>=65 years	393	56,1	1	0,3
Eye disorders	Conjunctival haemorrhage	<65 years	308	43,9	11	3,6
Eye disorders	Conjunctival haemorrhage	>=65 years	393	56,1	10	2,5
Eye disorders	Conjunctival hyperaemia	<65 years	308	43,9	1	0,3
Eye disorders	Conjunctival hyperaemia	>=65 years	393	56,1	1	0,3
Eye disorders	Conjunctival telangiectasia	<65 years	308	43,9	1	0,3
Eye disorders	Conjunctival telangiectasia	>=65 years	393	56,1	0	0,0
Eye disorders	Conjunctivitis allergic	<65 years	308	43,9	0	0,0
Eye disorders	Conjunctivitis allergic	>=65 years	393	56,1	1	0,3
Eye disorders	Corneal deposits	<65 years	308	43,9	0	0,0
Eye disorders	Corneal deposits	>=65 years	393	56,1	1	0,3
Eye disorders	Corneal erosion	<65 years	308	43,9	1	0,3
Eye disorders	Corneal erosion	>=65 years	393	56,1	0	0,0
Eye disorders	Corneal infiltrates	<65 years	308	43,9	1	0,3
Eye disorders	Corneal infiltrates	>=65 years	393	56,1	0	0,0
Eye disorders	Corneal opacity	<65 years	308	43,9	0	0,0
Eye disorders	Corneal opacity	>=65 years	393	56,1	1	0,3
Eye disorders	Corneal pigmentation	<65 years	308	43,9	1	0,3
Eye disorders	Corneal pigmentation	>=65 years	393	56,1	0	0,0
Eye disorders	Cystoid macular oedema	<65 years	308	43,9	14	4,5
Eye disorders	Cystoid macular oedema	>=65 years	393	56,1	14	3,6
Eye disorders	Detachment of retinal pigment epithelium	<65 years	308	43,9	1	0,3
Eye disorders	Detachment of retinal pigment epithelium	>=65 years	393	56,1	1	0,3
Eye disorders	Diabetic retinal oedema	<65 years	308	43,9	1	0,3
Eye disorders	Diabetic retinal oedema	>=65 years	393	56,1	0	0,0
Eye disorders	Diabetic retinopathy	<65 years	308	43,9	2	0,6
Eye disorders	Diabetic retinopathy	>=65 years	393	56,1	0	0,0
Eye disorders	Diplopia	<65 years	308	43,9	1	0,3
Eye disorders	Diplopia	>=65 years	393	56,1	0	0,0
Eye disorders	Dry age-related macular degeneration	<65 years	308	43,9	0	0,0
Eye disorders	Dry age-related macular degeneration	>=65 years	393	56,1	1	0,3

Eye disorders	Dry eye	<65 years	308	43,9	7	2,3
Eye disorders	Dry eye	>=65 years	393	56,1	8	2,0
Eye disorders	Eczema eyelids	<65 years	308	43,9	0	0,0
Eye disorders	Eczema eyelids	>=65 years	393	56,1	1	0,3
Eye disorders	Epiretinal membrane	<65 years	308	43,9	8	2,6
Eye disorders	Epiretinal membrane	>=65 years	393	56,1	9	2,3
Eye disorders	Episcleritis	<65 years	308	43,9	0	0,0
Eye disorders	Episcleritis	>=65 years	393	56,1	1	0,3
Eye disorders	Eye irritation	<65 years	308	43,9	0	0,0
Eye disorders	Eye irritation	>=65 years	393	56,1	1	0,3
Eye disorders	Eye pain	<65 years	308	43,9	6	1,9
Eye disorders	Eye pain	>=65 years	393	56,1	4	1,0
Eye disorders	Eye pruritus	<65 years	308	43,9	2	0,6
Eye disorders	Eye pruritus	>=65 years	393	56,1	2	0,5
Eye disorders	Eyelid cyst	<65 years	308	43,9	1	0,3
Eye disorders	Eyelid cyst	>=65 years	393	56,1	0	0,0
Eye disorders	Eyelid oedema	<65 years	308	43,9	0	0,0
Eye disorders	Eyelid oedema	>=65 years	393	56,1	1	0,3
Eye disorders	Foreign body sensation in eyes	<65 years	308	43,9	1	0,3
Eye disorders	Foreign body sensation in eyes	>=65 years	393	56,1	2	0,5
Eye disorders	Glaucoma	<65 years	308	43,9	3	1,0
Eye disorders	Glaucoma	>=65 years	393	56,1	12	3,1
Eye disorders	Hypotony of eye	<65 years	308	43,9	1	0,3
Eye disorders	Hypotony of eye	>=65 years	393	56,1	0	0,0
Eye disorders	Iridocyclitis	<65 years	308	43,9	4	1,3
Eye disorders	Iridocyclitis	>=65 years	393	56,1	3	0,8
Eye disorders	Iris neovascularisation	<65 years	308	43,9	1	0,3
Eye disorders	Iris neovascularisation	>=65 years	393	56,1	1	0,3
Eye disorders	Iritis	<65 years	308	43,9	2	0,6
Eye disorders	Iritis	>=65 years	393	56,1	2	0,5
Eye disorders	Keratic precipitates	<65 years	308	43,9	1	0,3
Eye disorders	Keratic precipitates	>=65 years	393	56,1	0	0,0
Eye disorders	Keratitis	<65 years	308	43,9	2	0,6
Eye disorders	Keratitis	>=65 years	393	56,1	0	0,0
Eye disorders	Keratopathy	<65 years	308	43,9	0	0,0
Eye disorders	Keratopathy	>=65 years	393	56,1	1	0,3
Eye disorders	Lacrimal disorder	<65 years	308	43,9	0	0,0
Eye disorders	Lacrimal disorder	>=65 years	393	56,1	1	0,3
Eye disorders	Lacrimation increased	<65 years	308	43,9	1	0,3
Eye disorders	Lacrimation increased	>=65 years	393	56,1	4	1,0
Eye disorders	Lenticular opacities	<65 years	308	43,9	1	0,3
Eye disorders	Lenticular opacities	>=65 years	393	56,1	0	0,0
Eye disorders	Macular degeneration	<65 years	308	43,9	2	0,6
Eye disorders	Macular degeneration	>=65 years	393	56,1	0	0,0
Eye disorders	Macular detachment	<65 years	308	43,9	2	0,6
Eye disorders	Macular detachment	>=65 years	393	56,1	0	0,0
Eye disorders	Macular hole	<65 years	308	43,9	1	0,3
Eye disorders	Macular hole	>=65 years	393	56,1	1	0,3
Eye disorders	Macular ischaemia	<65 years	308	43,9	1	0,3
Eye disorders	Macular ischaemia	>=65 years	393	56,1	1	0,3
Eye disorders	Macular oedema	<65 years	308	43,9	9	2,9
Eye disorders	Macular oedema	>=65 years	393	56,1	17	4,3
Eye disorders	Macular scar	<65 years	308	43,9	0	0,0
Eye disorders	Macular scar	>=65 years	393	56,1	1	0,3
Eye disorders	Meibomianitis	<65 years	308	43,9	1	0,3
Eye disorders	Meibomianitis	>=65 years	393	56,1	0	0,0
Eye disorders	Neovascular age-related macular degeneration	<65 years	308	43,9	0	0,0
Eye disorders	Neovascular age-related macular degeneration	>=65 years	393	56,1	1	0,3
Eye disorders	Non-infectious endophthalmitis	<65 years	308	43,9	0	0,0
Eye disorders	Non-infectious endophthalmitis	>=65 years	393	56,1	1	0,3
Eye disorders	Noninfective conjunctivitis	<65 years	308	43,9	0	0,0
Eye disorders	Noninfective conjunctivitis	>=65 years	393	56,1	1	0,3
Eye disorders	Normal tension glaucoma	<65 years	308	43,9	1	0,3
Eye disorders	Normal tension glaucoma	>=65 years	393	56,1	0	0,0
Eye disorders	Ocular hyperaemia	<65 years	308	43,9	2	0,6
Eye disorders	Ocular hyperaemia	>=65 years	393	56,1	0	0,0
Eye disorders	Ocular hypertension	<65 years	308	43,9	4	1,3
Eye disorders	Ocular hypertension	>=65 years	393	56,1	8	2,0
Eye disorders	Open angle glaucoma	<65 years	308	43,9	1	0,3
Eye disorders	Open angle glaucoma	>=65 years	393	56,1	1	0,3
Eye disorders	Optic atrophy	<65 years	308	43,9	1	0,3
Eye disorders	Optic atrophy	>=65 years	393	56,1	0	0,0
Eye disorders	Optic disc disorder	<65 years	308	43,9	1	0,3
Eye disorders	Optic disc disorder	>=65 years	393	56,1	0	0,0
Eye disorders	Optic disc haemorrhage	<65 years	308	43,9	0	0,0

Eye disorders	Optic disc haemorrhage	>=65 years	393	56,1	3	0,8
Eye disorders	Optic disc vascular disorder	<65 years	308	43,9	1	0,3
Eye disorders	Optic disc vascular disorder	>=65 years	393	56,1	0	0,0
Eye disorders	Papilloedema	<65 years	308	43,9	1	0,3
Eye disorders	Papilloedema	>=65 years	393	56,1	1	0,3
Eye disorders	Periorbital pain	<65 years	308	43,9	0	0,0
Eye disorders	Periorbital pain	>=65 years	393	56,1	1	0,3
Eye disorders	Photopsia	<65 years	308	43,9	1	0,3
Eye disorders	Photopsia	>=65 years	393	56,1	1	0,3
Eye disorders	Pinguecula	<65 years	308	43,9	0	0,0
Eye disorders	Pinguecula	>=65 years	393	56,1	1	0,3
Eye disorders	Posterior capsule opacification	<65 years	308	43,9	1	0,3
Eye disorders	Posterior capsule opacification	>=65 years	393	56,1	6	1,5
Eye disorders	Punctate keratitis	<65 years	308	43,9	4	1,3
Eye disorders	Punctate keratitis	>=65 years	393	56,1	2	0,5
Eye disorders	Retinal aneurysm	<65 years	308	43,9	2	0,6
Eye disorders	Retinal aneurysm	>=65 years	393	56,1	0	0,0
Eye disorders	Retinal artery embolism	<65 years	308	43,9	0	0,0
Eye disorders	Retinal artery embolism	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal artery occlusion	<65 years	308	43,9	0	0,0
Eye disorders	Retinal artery occlusion	>=65 years	393	56,1	4	1,0
Eye disorders	Retinal collateral vessels	<65 years	308	43,9	2	0,6
Eye disorders	Retinal collateral vessels	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal depigmentation	<65 years	308	43,9	1	0,3
Eye disorders	Retinal depigmentation	>=65 years	393	56,1	0	0,0
Eye disorders	Retinal detachment	<65 years	308	43,9	0	0,0
Eye disorders	Retinal detachment	>=65 years	393	56,1	2	0,5
Eye disorders	Retinal disorder	<65 years	308	43,9	0	0,0
Eye disorders	Retinal disorder	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal drusen	<65 years	308	43,9	0	0,0
Eye disorders	Retinal drusen	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal exudates	<65 years	308	43,9	2	0,6
Eye disorders	Retinal exudates	>=65 years	393	56,1	0	0,0
Eye disorders	Retinal haemorrhage	<65 years	308	43,9	3	1,0
Eye disorders	Retinal haemorrhage	>=65 years	393	56,1	4	1,0
Eye disorders	Retinal ischaemia	<65 years	308	43,9	0	0,0
Eye disorders	Retinal ischaemia	>=65 years	393	56,1	2	0,5
Eye disorders	Retinal neovascularisation	<65 years	308	43,9	2	0,6
Eye disorders	Retinal neovascularisation	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal tear	<65 years	308	43,9	1	0,3
Eye disorders	Retinal tear	>=65 years	393	56,1	2	0,5
Eye disorders	Retinal vein occlusion	<65 years	308	43,9	8	2,6
Eye disorders	Retinal vein occlusion	>=65 years	393	56,1	15	3,8
Eye disorders	Retinopathy hypertensive	<65 years	308	43,9	0	0,0
Eye disorders	Retinopathy hypertensive	>=65 years	393	56,1	1	0,3
Eye disorders	Subretinal fluid	<65 years	308	43,9	1	0,3
Eye disorders	Subretinal fluid	>=65 years	393	56,1	0	0,0
Eye disorders	Uveitis	<65 years	308	43,9	1	0,3
Eye disorders	Uveitis	>=65 years	393	56,1	0	0,0
Eye disorders	Vision blurred	<65 years	308	43,9	2	0,6
Eye disorders	Vision blurred	>=65 years	393	56,1	1	0,3
Eye disorders	Visual acuity reduced	<65 years	308	43,9	4	1,3
Eye disorders	Visual acuity reduced	>=65 years	393	56,1	4	1,0
Eye disorders	Visual acuity reduced transiently	<65 years	308	43,9	0	0,0
Eye disorders	Visual acuity reduced transiently	>=65 years	393	56,1	1	0,3
Eye disorders	Visual field defect	<65 years	308	43,9	0	0,0
Eye disorders	Visual field defect	>=65 years	393	56,1	1	0,3
Eye disorders	Visual impairment	<65 years	308	43,9	1	0,3
Eye disorders	Visual impairment	>=65 years	393	56,1	3	0,8
Eye disorders	Vitreoretinal traction syndrome	<65 years	308	43,9	1	0,3
Eye disorders	Vitreoretinal traction syndrome	>=65 years	393	56,1	2	0,5
Eye disorders	Vitreous detachment	<65 years	308	43,9	14	4,5
Eye disorders	Vitreous detachment	>=65 years	393	56,1	15	3,8
Eye disorders	Vitreous floaters	<65 years	308	43,9	7	2,3
Eye disorders	Vitreous floaters	>=65 years	393	56,1	3	0,8
Eye disorders	Vitreous haemorrhage	<65 years	308	43,9	2	0,6
Eye disorders	Vitreous haemorrhage	>=65 years	393	56,1	2	0,5
Eye disorders	Vitreous opacities	<65 years	308	43,9	1	0,3
Eye disorders	Vitreous opacities	>=65 years	393	56,1	0	0,0
Eye disorders	Vitritis	<65 years	308	43,9	1	0,3
Eye disorders	Vitritis	>=65 years	393	56,1	3	0,8
Gastrointestinal disorders		<65 years	308	43,9	10	3,2
Gastrointestinal disorders		>=65 years	393	56,1	32	8,1
Gastrointestinal disorders	Abdominal discomfort	<65 years	308	43,9	0	0,0

Gastrointestinal disorders	Abdominal discomfort	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Abdominal pain	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Abdominal pain	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Abdominal pain upper	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Abdominal pain upper	>=65 years	393	56,1	2	0,5
Gastrointestinal disorders	Barrett's oesophagus	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Barrett's oesophagus	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Chronic gastritis	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Chronic gastritis	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Coeliac disease	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Coeliac disease	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Colitis	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Colitis	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Constipation	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Constipation	>=65 years	393	56,1	4	1,0
Gastrointestinal disorders	Dental discomfort	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Dental discomfort	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Diarrhoea	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Diarrhoea	>=65 years	393	56,1	11	2,8
Gastrointestinal disorders	Diverticulum intestinal	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Diverticulum intestinal	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Duodenitis	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Duodenitis	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Dyspepsia	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Dyspepsia	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Gastric ulcer	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Gastric ulcer	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Gastritis	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Gastritis	>=65 years	393	56,1	2	0,5
Gastrointestinal disorders	Gastrointestinal inflammation	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Gastrooesophageal reflux disease	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Gastrooesophageal reflux disease	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Haemorrhagic erosive gastritis	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Haemorrhagic erosive gastritis	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Haemorrhoids	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Haemorrhoids	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Hiatus hernia	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Hiatus hernia	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Ileus	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Ileus	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Inguinal hernia	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Inguinal hernia	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Large intestine polyp	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Large intestine polyp	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Nausea	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Nausea	>=65 years	393	56,1	3	0,8
Gastrointestinal disorders	Pancreatitis	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Pancreatitis	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Pancreatitis acute	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Pancreatitis acute	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Pulpless tooth	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Pulpless tooth	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Salivary gland disorder	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Salivary gland disorder	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Toothache	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Toothache	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Umbilical hernia	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Umbilical hernia	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Vomiting	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Vomiting	>=65 years	393	56,1	2	0,5
General disorders and administration site conditions		<65 years	308	43,9	11	3,6
General disorders and administration site conditions		>=65 years	393	56,1	21	5,3
General disorders and administration site conditions	Asthenia	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Asthenia	>=65 years	393	56,1	6	1,5
General disorders and administration site conditions	Chest pain	<65 years	308	43,9	2	0,6
General disorders and administration site conditions	Chest pain	>=65 years	393	56,1	2	0,5
General disorders and administration site conditions	Chills	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Chills	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Death	<65 years	308	43,9	0	0,0

General disorders and administration site conditions	Death	>=65 years	393	56,1	2	0,5
General disorders and administration site conditions	Drug intolerance	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Drug intolerance	>=65 years	393	56,1	0	0,0
General disorders and administration site conditions	Drug withdrawal syndrome	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Drug withdrawal syndrome	>=65 years	393	56,1	0	0,0
General disorders and administration site conditions	Fatigue	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Fatigue	>=65 years	393	56,1	2	0,5
General disorders and administration site conditions	Injection site pain	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Injection site pain	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Injection site reaction	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Injection site reaction	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Oedema peripheral	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Oedema peripheral	>=65 years	393	56,1	3	0,8
General disorders and administration site conditions	Pain	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Pain	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Peripheral swelling	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Peripheral swelling	>=65 years	393	56,1	0	0,0
General disorders and administration site conditions	Polyp	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Polyp	>=65 years	393	56,1	0	0,0
General disorders and administration site conditions	Pyrexia	<65 years	308	43,9	3	1,0
General disorders and administration site conditions	Pyrexia	>=65 years	393	56,1	2	0,5
General disorders and administration site conditions	Stent-graft endoleak	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Stent-graft endoleak	>=65 years	393	56,1	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	>=65 years	393	56,1	1	0,3
Hepatobiliary disorders		<65 years	308	43,9	3	1,0
Hepatobiliary disorders		>=65 years	393	56,1	5	1,3
Hepatobiliary disorders	Cholecystitis	<65 years	308	43,9	1	0,3
Hepatobiliary disorders	Cholecystitis	>=65 years	393	56,1	0	0,0
Hepatobiliary disorders	Cholelithiasis	<65 years	308	43,9	1	0,3
Hepatobiliary disorders	Cholelithiasis	>=65 years	393	56,1	3	0,8
Hepatobiliary disorders	Hepatic cyst	<65 years	308	43,9	0	0,0
Hepatobiliary disorders	Hepatic cyst	>=65 years	393	56,1	1	0,3
Hepatobiliary disorders	Hepatic steatosis	<65 years	308	43,9	0	0,0
Hepatobiliary disorders	Hepatic steatosis	>=65 years	393	56,1	3	0,8
Hepatobiliary disorders	Portal hypertension	<65 years	308	43,9	1	0,3
Hepatobiliary disorders	Portal hypertension	>=65 years	393	56,1	0	0,0
Immune system disorders		<65 years	308	43,9	2	0,6
Immune system disorders		>=65 years	393	56,1	9	2,3
Immune system disorders	Contrast media allergy	<65 years	308	43,9	0	0,0
Immune system disorders	Contrast media allergy	>=65 years	393	56,1	3	0,8
Immune system disorders	Contrast media reaction	<65 years	308	43,9	0	0,0
Immune system disorders	Contrast media reaction	>=65 years	393	56,1	1	0,3
Immune system disorders	Drug hypersensitivity	<65 years	308	43,9	0	0,0
Immune system disorders	Drug hypersensitivity	>=65 years	393	56,1	1	0,3
Immune system disorders	Food allergy	<65 years	308	43,9	0	0,0
Immune system disorders	Food allergy	>=65 years	393	56,1	1	0,3
Immune system disorders	Iodine allergy	<65 years	308	43,9	0	0,0
Immune system disorders	Iodine allergy	>=65 years	393	56,1	1	0,3
Immune system disorders	Seasonal allergy	<65 years	308	43,9	2	0,6
Immune system disorders	Seasonal allergy	>=65 years	393	56,1	2	0,5
Infections and infestations		<65 years	308	43,9	101	32,8
Infections and infestations		>=65 years	393	56,1	124	31,6
Infections and infestations	Adenoviral conjunctivitis	<65 years	308	43,9	1	0,3
Infections and infestations	Adenoviral conjunctivitis	>=65 years	393	56,1	0	0,0
Infections and infestations	Arthritis infective	<65 years	308	43,9	0	0,0
Infections and infestations	Arthritis infective	>=65 years	393	56,1	1	0,3
Infections and infestations	Bronchitis	<65 years	308	43,9	3	1,0
Infections and infestations	Bronchitis	>=65 years	393	56,1	6	1,5
Infections and infestations	COVID-19	<65 years	308	43,9	42	13,6
Infections and infestations	COVID-19	>=65 years	393	56,1	49	12,5
Infections and infestations	COVID-19 pneumonia	<65 years	308	43,9	0	0,0
Infections and infestations	COVID-19 pneumonia	>=65 years	393	56,1	1	0,3
Infections and infestations	Cellulitis	<65 years	308	43,9	0	0,0
Infections and infestations	Cellulitis	>=65 years	393	56,1	7	1,8
Infections and infestations	Chronic sinusitis	<65 years	308	43,9	1	0,3
Infections and infestations	Chronic sinusitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Clostridium difficile infection	<65 years	308	43,9	0	0,0
Infections and infestations	Clostridium difficile infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Conjunctivitis	<65 years	308	43,9	5	1,6
Infections and infestations	Conjunctivitis	>=65 years	393	56,1	9	2,3
Infections and infestations	Conjunctivitis bacterial	<65 years	308	43,9	0	0,0

Infections and infestations	Conjunctivitis bacterial	>=65 years	393	56,1	1	0,3
Infections and infestations	Conjunctivitis viral	<65 years	308	43,9	0	0,0
Infections and infestations	Conjunctivitis viral	>=65 years	393	56,1	1	0,3
Infections and infestations	Cystitis	<65 years	308	43,9	0	0,0
Infections and infestations	Cystitis	>=65 years	393	56,1	3	0,8
Infections and infestations	Device related infection	<65 years	308	43,9	0	0,0
Infections and infestations	Device related infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Diabetic foot infection	<65 years	308	43,9	1	0,3
Infections and infestations	Diabetic foot infection	>=65 years	393	56,1	0	0,0
Infections and infestations	Ear infection	<65 years	308	43,9	1	0,3
Infections and infestations	Ear infection	>=65 years	393	56,1	2	0,5
Infections and infestations	Endophthalmitis	<65 years	308	43,9	0	0,0
Infections and infestations	Endophthalmitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Enteritis infectious	<65 years	308	43,9	0	0,0
Infections and infestations	Enteritis infectious	>=65 years	393	56,1	1	0,3
Infections and infestations	Escherichia urinary tract infection	<65 years	308	43,9	0	0,0
Infections and infestations	Escherichia urinary tract infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Eye infection	<65 years	308	43,9	1	0,3
Infections and infestations	Eye infection	>=65 years	393	56,1	0	0,0
Infections and infestations	Eye infection bacterial	<65 years	308	43,9	0	0,0
Infections and infestations	Eye infection bacterial	>=65 years	393	56,1	1	0,3
Infections and infestations	Folliculitis	<65 years	308	43,9	1	0,3
Infections and infestations	Folliculitis	>=65 years	393	56,1	0	0,0
Infections and infestations	Fungal skin infection	<65 years	308	43,9	0	0,0
Infections and infestations	Fungal skin infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Gastroenteritis	<65 years	308	43,9	1	0,3
Infections and infestations	Gastroenteritis	>=65 years	393	56,1	0	0,0
Infections and infestations	Gastroenteritis viral	<65 years	308	43,9	2	0,6
Infections and infestations	Gastroenteritis viral	>=65 years	393	56,1	2	0,5
Infections and infestations	Gastrointestinal infection	<65 years	308	43,9	0	0,0
Infections and infestations	Gastrointestinal infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Helicobacter infection	<65 years	308	43,9	1	0,3
Infections and infestations	Helicobacter infection	>=65 years	393	56,1	0	0,0
Infections and infestations	Herpes virus infection	<65 years	308	43,9	0	0,0
Infections and infestations	Herpes virus infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Herpes zoster	<65 years	308	43,9	0	0,0
Infections and infestations	Herpes zoster	>=65 years	393	56,1	6	1,5
Infections and infestations	Hordeolum	<65 years	308	43,9	2	0,6
Infections and infestations	Hordeolum	>=65 years	393	56,1	3	0,8
Infections and infestations	Infected bite	<65 years	308	43,9	1	0,3
Infections and infestations	Infected bite	>=65 years	393	56,1	0	0,0
Infections and infestations	Influenza	<65 years	308	43,9	12	3,9
Infections and infestations	Influenza	>=65 years	393	56,1	7	1,8
Infections and infestations	Kidney infection	<65 years	308	43,9	1	0,3
Infections and infestations	Kidney infection	>=65 years	393	56,1	0	0,0
Infections and infestations	Laryngitis	<65 years	308	43,9	0	0,0
Infections and infestations	Laryngitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Localised infection	<65 years	308	43,9	0	0,0
Infections and infestations	Localised infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Lower respiratory tract infection	<65 years	308	43,9	0	0,0
Infections and infestations	Lower respiratory tract infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Nasopharyngitis	<65 years	308	43,9	16	5,2
Infections and infestations	Nasopharyngitis	>=65 years	393	56,1	11	2,8
Infections and infestations	Necrotising fasciitis	<65 years	308	43,9	0	0,0
Infections and infestations	Necrotising fasciitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Oral herpes	<65 years	308	43,9	1	0,3
Infections and infestations	Oral herpes	>=65 years	393	56,1	1	0,3
Infections and infestations	Otitis externa	<65 years	308	43,9	1	0,3
Infections and infestations	Otitis externa	>=65 years	393	56,1	0	0,0
Infections and infestations	Otosalpingitis	<65 years	308	43,9	1	0,3
Infections and infestations	Otosalpingitis	>=65 years	393	56,1	0	0,0
Infections and infestations	Perichondritis	<65 years	308	43,9	1	0,3
Infections and infestations	Perichondritis	>=65 years	393	56,1	0	0,0
Infections and infestations	Periodontitis	<65 years	308	43,9	2	0,6
Infections and infestations	Periodontitis	>=65 years	393	56,1	0	0,0
Infections and infestations	Pharyngitis	<65 years	308	43,9	0	0,0
Infections and infestations	Pharyngitis	>=65 years	393	56,1	2	0,5
Infections and infestations	Pneumonia	<65 years	308	43,9	2	0,6
Infections and infestations	Pneumonia	>=65 years	393	56,1	8	2,0
Infections and infestations	Pneumonia viral	<65 years	308	43,9	2	0,6
Infections and infestations	Pneumonia viral	>=65 years	393	56,1	1	0,3
Infections and infestations	Pulpitis dental	<65 years	308	43,9	2	0,6
Infections and infestations	Pulpitis dental	>=65 years	393	56,1	1	0,3
Infections and infestations	Respiratory syncytial virus infection	<65 years	308	43,9	0	0,0
Infections and infestations	Respiratory syncytial virus infection	>=65 years	393	56,1	1	0,3

Infections and infestations	Respiratory tract infection	<65 years	308	43,9	0	0,0
Infections and infestations	Respiratory tract infection	>=65 years	393	56,1	2	0,5
Infections and infestations	Respiratory tract infection viral	<65 years	308	43,9	0	0,0
Infections and infestations	Respiratory tract infection viral	>=65 years	393	56,1	1	0,3
Infections and infestations	Rhinitis	<65 years	308	43,9	0	0,0
Infections and infestations	Rhinitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Sepsis	<65 years	308	43,9	0	0,0
Infections and infestations	Sepsis	>=65 years	393	56,1	2	0,5
Infections and infestations	Septic arthritis staphylococcal	<65 years	308	43,9	0	0,0
Infections and infestations	Septic arthritis staphylococcal	>=65 years	393	56,1	1	0,3
Infections and infestations	Sinusitis	<65 years	308	43,9	6	1,9
Infections and infestations	Sinusitis	>=65 years	393	56,1	3	0,8
Infections and infestations	Staphylococcal infection	<65 years	308	43,9	0	0,0
Infections and infestations	Staphylococcal infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Suspected COVID-19	<65 years	308	43,9	8	2,6
Infections and infestations	Suspected COVID-19	>=65 years	393	56,1	2	0,5
Infections and infestations	Tinea pedis	<65 years	308	43,9	0	0,0
Infections and infestations	Tinea pedis	>=65 years	393	56,1	1	0,3
Infections and infestations	Tooth abscess	<65 years	308	43,9	2	0,6
Infections and infestations	Tooth abscess	>=65 years	393	56,1	0	0,0
Infections and infestations	Tooth infection	<65 years	308	43,9	1	0,3
Infections and infestations	Tooth infection	>=65 years	393	56,1	2	0,5
Infections and infestations	Upper respiratory tract infection	<65 years	308	43,9	12	3,9
Infections and infestations	Upper respiratory tract infection	>=65 years	393	56,1	5	1,3
Infections and infestations	Urinary tract candidiasis	<65 years	308	43,9	0	0,0
Infections and infestations	Urinary tract candidiasis	>=65 years	393	56,1	1	0,3
Infections and infestations	Urinary tract infection	<65 years	308	43,9	2	0,6
Infections and infestations	Urinary tract infection	>=65 years	393	56,1	12	3,1
Infections and infestations	Urosepsis	<65 years	308	43,9	0	0,0
Infections and infestations	Urosepsis	>=65 years	393	56,1	1	0,3
Infections and infestations	Viral rash	<65 years	308	43,9	1	0,3
Infections and infestations	Viral rash	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications		<65 years	308	43,9	19	6,2
Injury, poisoning and procedural complications		>=65 years	393	56,1	36	9,2
Injury, poisoning and procedural complications	Accident	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Accident	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Arthropod bite	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Arthropod bite	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Arthropod sting	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Arthropod sting	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Contusion	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Contusion	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Eye contusion	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Eye contusion	>=65 years	393	56,1	2	0,5
Injury, poisoning and procedural complications	Fall	<65 years	308	43,9	2	0,6
Injury, poisoning and procedural complications	Fall	>=65 years	393	56,1	8	2,0
Injury, poisoning and procedural complications	Femur fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=65 years	393	56,1	3	0,8
Injury, poisoning and procedural complications	Fibula fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Fibula fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	<65 years	308	43,9	2	0,6
Injury, poisoning and procedural complications	Foreign body in eye	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Hand fracture	<65 years	308	43,9	2	0,6
Injury, poisoning and procedural complications	Hand fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Hip fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Hip fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Hypobarism	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Hypobarism	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Ligament rupture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Ligament rupture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Ligament sprain	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Ligament sprain	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Limb injury	<65 years	308	43,9	2	0,6
Injury, poisoning and procedural complications	Limb injury	>=65 years	393	56,1	3	0,8
Injury, poisoning and procedural complications	Lower limb fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Lower limb fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Lumbar vertebral fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Lumbar vertebral fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Medication error	<65 years	308	43,9	2	0,6
Injury, poisoning and procedural complications	Medication error	>=65 years	393	56,1	2	0,5
Injury, poisoning and procedural complications	Muscle strain	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Muscle strain	>=65 years	393	56,1	3	0,8

Injury, poisoning and procedural complications	Posterior capsule rupture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Postoperative thoracic procedure complication	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Postoperative thoracic procedure complication	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Procedural nausea	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Procedural nausea	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Procedural pain	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Procedural pain	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Rib fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Rib fracture	>=65 years	393	56,1	3	0,8
Injury, poisoning and procedural complications	Road traffic accident	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Road traffic accident	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Shunt stenosis	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Skin laceration	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Skin laceration	>=65 years	393	56,1	2	0,5
Injury, poisoning and procedural complications	Soft tissue injury	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Soft tissue injury	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Sunburn	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Sunburn	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Thermal burn	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Thermal burn	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Tibia fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Tibia fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	>=65 years	393	56,1	2	0,5
Injury, poisoning and procedural complications	Wrist fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Wrist fracture	>=65 years	393	56,1	2	0,5
Investigations		<65 years	308	43,9	35	11,4
Investigations		>=65 years	393	56,1	27	6,9
Investigations	Alanine aminotransferase increased	<65 years	308	43,9	1	0,3
Investigations	Alanine aminotransferase increased	>=65 years	393	56,1	0	0,0
Investigations	Aspartate aminotransferase increased	<65 years	308	43,9	1	0,3
Investigations	Aspartate aminotransferase increased	>=65 years	393	56,1	0	0,0
Investigations	Blood albumin increased	<65 years	308	43,9	0	0,0
Investigations	Blood albumin increased	>=65 years	393	56,1	1	0,3
Investigations	Blood bilirubin increased	<65 years	308	43,9	1	0,3
Investigations	Blood bilirubin increased	>=65 years	393	56,1	0	0,0
Investigations	Blood cholesterol increased	<65 years	308	43,9	1	0,3
Investigations	Blood cholesterol increased	>=65 years	393	56,1	1	0,3
Investigations	Blood creatinine increased	<65 years	308	43,9	1	0,3
Investigations	Blood creatinine increased	>=65 years	393	56,1	1	0,3
Investigations	Blood glucose abnormal	<65 years	308	43,9	1	0,3
Investigations	Blood glucose abnormal	>=65 years	393	56,1	0	0,0
Investigations	Blood glucose increased	<65 years	308	43,9	2	0,6
Investigations	Blood glucose increased	>=65 years	393	56,1	2	0,5
Investigations	Blood potassium increased	<65 years	308	43,9	0	0,0
Investigations	Blood potassium increased	>=65 years	393	56,1	1	0,3
Investigations	Blood pressure decreased	<65 years	308	43,9	0	0,0
Investigations	Blood pressure decreased	>=65 years	393	56,1	1	0,3
Investigations	Blood pressure increased	<65 years	308	43,9	1	0,3
Investigations	Blood pressure increased	>=65 years	393	56,1	2	0,5
Investigations	Blood testosterone decreased	<65 years	308	43,9	1	0,3
Investigations	Blood testosterone decreased	>=65 years	393	56,1	0	0,0
Investigations	Blood thyroid stimulating hormone increased	<65 years	308	43,9	0	0,0
Investigations	Blood thyroid stimulating hormone increased	>=65 years	393	56,1	1	0,3
Investigations	Blood triglycerides increased	<65 years	308	43,9	0	0,0
Investigations	Blood triglycerides increased	>=65 years	393	56,1	1	0,3
Investigations	Blood uric acid increased	<65 years	308	43,9	0	0,0
Investigations	Blood uric acid increased	>=65 years	393	56,1	1	0,3
Investigations	Grip strength decreased	<65 years	308	43,9	1	0,3
Investigations	Grip strength decreased	>=65 years	393	56,1	0	0,0
Investigations	Haematocrit decreased	<65 years	308	43,9	0	0,0
Investigations	Haematocrit decreased	>=65 years	393	56,1	1	0,3
Investigations	Haemoglobin decreased	<65 years	308	43,9	0	0,0
Investigations	Haemoglobin decreased	>=65 years	393	56,1	1	0,3
Investigations	Heart rate irregular	<65 years	308	43,9	0	0,0
Investigations	Heart rate irregular	>=65 years	393	56,1	1	0,3
Investigations	Intraocular pressure increased	<65 years	308	43,9	24	7,8
Investigations	Intraocular pressure increased	>=65 years	393	56,1	10	2,5
Investigations	Liver function test increased	<65 years	308	43,9	1	0,3
Investigations	Liver function test increased	>=65 years	393	56,1	0	0,0

Investigations	Occult blood positive	<65 years	308	43,9	0	0,0
Investigations	Occult blood positive	>=65 years	393	56,1	1	0,3
Investigations	Optic nerve cup/disc ratio increased	<65 years	308	43,9	1	0,3
Investigations	Optic nerve cup/disc ratio increased	>=65 years	393	56,1	0	0,0
Investigations	Red blood cell count decreased	<65 years	308	43,9	0	0,0
Investigations	Red blood cell count decreased	>=65 years	393	56,1	1	0,3
Investigations	SARS-CoV-2 test positive	<65 years	308	43,9	1	0,3
Investigations	SARS-CoV-2 test positive	>=65 years	393	56,1	3	0,8
Investigations	Urinary occult blood	<65 years	308	43,9	0	0,0
Investigations	Urinary occult blood	>=65 years	393	56,1	1	0,3
Investigations	Weight decreased	<65 years	308	43,9	0	0,0
Investigations	Weight decreased	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders		<65 years	308	43,9	14	4,5
Metabolism and nutrition disorders		>=65 years	393	56,1	20	5,1
Metabolism and nutrition disorders	Decreased appetite	<65 years	308	43,9	0	0,0
Metabolism and nutrition disorders	Decreased appetite	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Dehydration	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Dehydration	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Diabetes mellitus	<65 years	308	43,9	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	>=65 years	393	56,1	2	0,5
Metabolism and nutrition disorders	Dyslipidaemia	<65 years	308	43,9	2	0,6
Metabolism and nutrition disorders	Dyslipidaemia	>=65 years	393	56,1	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	>=65 years	393	56,1	0	0,0
Metabolism and nutrition disorders	Gout	<65 years	308	43,9	0	0,0
Metabolism and nutrition disorders	Gout	>=65 years	393	56,1	2	0,5
Metabolism and nutrition disorders	Hypercholesterolaemia	<65 years	308	43,9	3	1,0
Metabolism and nutrition disorders	Hypercholesterolaemia	>=65 years	393	56,1	4	1,0
Metabolism and nutrition disorders	Hyperglycaemia	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Hyperglycaemia	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Hyperlipidaemia	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Hyperlipidaemia	>=65 years	393	56,1	0	0,0
Metabolism and nutrition disorders	Hyperuricaemia	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Hyperuricaemia	>=65 years	393	56,1	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Hypervolaemia	>=65 years	393	56,1	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	<65 years	308	43,9	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Hypokalaemia	<65 years	308	43,9	2	0,6
Metabolism and nutrition disorders	Hypokalaemia	>=65 years	393	56,1	5	1,3
Metabolism and nutrition disorders	Hyponatraemia	<65 years	308	43,9	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Type 2 diabetes mellitus	<65 years	308	43,9	3	1,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	>=65 years	393	56,1	5	1,3
Metabolism and nutrition disorders	Vitamin B12 deficiency	<65 years	308	43,9	0	0,0
Metabolism and nutrition disorders	Vitamin B12 deficiency	>=65 years	393	56,1	2	0,5
Metabolism and nutrition disorders	Vitamin D deficiency	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Vitamin D deficiency	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders		<65 years	308	43,9	30	9,7
Musculoskeletal and connective tissue disorders		>=65 years	393	56,1	31	7,9
Musculoskeletal and connective tissue disorders	Arthralgia	<65 years	308	43,9	4	1,3
Musculoskeletal and connective tissue disorders	Arthralgia	>=65 years	393	56,1	9	2,3
Musculoskeletal and connective tissue disorders	Arthritis	<65 years	308	43,9	2	0,6
Musculoskeletal and connective tissue disorders	Arthritis	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Back pain	<65 years	308	43,9	6	1,9
Musculoskeletal and connective tissue disorders	Back pain	>=65 years	393	56,1	8	2,0
Musculoskeletal and connective tissue disorders	Bone disorder	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Bone disorder	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Bone loss	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Bursitis	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Coccydynia	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Coccydynia	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Fibromyalgia	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Fibromyalgia	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Flank pain	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Flank pain	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	<65 years	308	43,9	1	0,3

Musculoskeletal and connective tissue disorders	Joint swelling	>=65 years	393	56,1	2	0,5
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Mobility decreased	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Muscle contracture	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Muscle contracture	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Muscular weakness	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Muscular weakness	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Myalgia	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Myalgia	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Neck pain	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Neck pain	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	<65 years	308	43,9	2	0,6
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=65 years	393	56,1	3	0,8
Musculoskeletal and connective tissue disorders	Pain in extremity	<65 years	308	43,9	2	0,6
Musculoskeletal and connective tissue disorders	Pain in extremity	>=65 years	393	56,1	2	0,5
Musculoskeletal and connective tissue disorders	Periarthritis	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Periarthritis	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Plantar fasciitis	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	>=65 years	393	56,1	2	0,5
Musculoskeletal and connective tissue disorders	Scoliosis	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Spinal pain	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Spinal pain	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Synovial cyst	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Synovial cyst	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Tendonitis	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Tendonitis	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Trigger finger	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Trigger finger	>=65 years	393	56,1	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<65 years	308	43,9	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=65 years	393	56,1	15	3,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	>=65 years	393	56,1	2	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	>=65 years	393	56,1	2	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	<65 years	308	43,9	0	0,0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	>=65 years	393	56,1	4	1,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	<65 years	308	43,9	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	>=65 years	393	56,1	0	0,0
Nervous system disorders		<65 years	308	43,9	23	7,5
Nervous system disorders		>=65 years	393	56,1	28	7,1
Nervous system disorders	Autonomic neuropathy	<65 years	308	43,9	1	0,3
Nervous system disorders	Autonomic neuropathy	>=65 years	393	56,1	0	0,0
Nervous system disorders	Balance disorder	<65 years	308	43,9	1	0,3
Nervous system disorders	Balance disorder	>=65 years	393	56,1	0	0,0
Nervous system disorders	Carotid arteriosclerosis	<65 years	308	43,9	0	0,0
Nervous system disorders	Carotid arteriosclerosis	>=65 years	393	56,1	1	0,3
Nervous system disorders	Carpal tunnel syndrome	<65 years	308	43,9	0	0,0
Nervous system disorders	Carpal tunnel syndrome	>=65 years	393	56,1	1	0,3
Nervous system disorders	Cerebral atrophy	<65 years	308	43,9	0	0,0
Nervous system disorders	Cerebral atrophy	>=65 years	393	56,1	1	0,3
Nervous system disorders	Cerebral disorder	<65 years	308	43,9	1	0,3
Nervous system disorders	Cerebral disorder	>=65 years	393	56,1	0	0,0
Nervous system disorders	Cerebral infarction	<65 years	308	43,9	1	0,3
Nervous system disorders	Cerebral infarction	>=65 years	393	56,1	0	0,0
Nervous system disorders	Cerebrovascular accident	<65 years	308	43,9	0	0,0
Nervous system disorders	Cerebrovascular accident	>=65 years	393	56,1	1	0,3
Nervous system disorders	Cervicobrachial syndrome	<65 years	308	43,9	0	0,0
Nervous system disorders	Cervicobrachial syndrome	>=65 years	393	56,1	1	0,3
Nervous system disorders	Cognitive disorder	<65 years	308	43,9	0	0,0
Nervous system disorders	Cognitive disorder	>=65 years	393	56,1	1	0,3
Nervous system disorders	Dementia Alzheimer's type	<65 years	308	43,9	0	0,0
Nervous system disorders	Dementia Alzheimer's type	>=65 years	393	56,1	2	0,5
Nervous system disorders	Diabetic neuropathy	<65 years	308	43,9	0	0,0
Nervous system disorders	Diabetic neuropathy	>=65 years	393	56,1	2	0,5
Nervous system disorders	Dizziness	<65 years	308	43,9	3	1,0
Nervous system disorders	Dizziness	>=65 years	393	56,1	4	1,0
Nervous system disorders	Dysarthria	<65 years	308	43,9	1	0,3
Nervous system disorders	Dysarthria	>=65 years	393	56,1	0	0,0
Nervous system disorders	Encephalopathy	<65 years	308	43,9	0	0,0
Nervous system disorders	Encephalopathy	>=65 years	393	56,1	1	0,3
Nervous system disorders	Headache	<65 years	308	43,9	7	2,3
Nervous system disorders	Headache	>=65 years	393	56,1	4	1,0
Nervous system disorders	Hypoaesthesia	<65 years	308	43,9	1	0,3
Nervous system disorders	Hypoaesthesia	>=65 years	393	56,1	0	0,0
Nervous system disorders	Intercostal neuralgia	<65 years	308	43,9	1	0,3
Nervous system disorders	Intercostal neuralgia	>=65 years	393	56,1	0	0,0
Nervous system disorders	Ischaemic stroke	<65 years	308	43,9	0	0,0
Nervous system disorders	Ischaemic stroke	>=65 years	393	56,1	2	0,5
Nervous system disorders	Lacunar infarction	<65 years	308	43,9	0	0,0
Nervous system disorders	Lacunar infarction	>=65 years	393	56,1	2	0,5
Nervous system disorders	Loss of consciousness	<65 years	308	43,9	0	0,0
Nervous system disorders	Loss of consciousness	>=65 years	393	56,1	1	0,3
Nervous system disorders	Lumbar radiculopathy	<65 years	308	43,9	1	0,3
Nervous system disorders	Lumbar radiculopathy	>=65 years	393	56,1	0	0,0
Nervous system disorders	Migraine	<65 years	308	43,9	1	0,3
Nervous system disorders	Migraine	>=65 years	393	56,1	0	0,0
Nervous system disorders	Neuralgia	<65 years	308	43,9	1	0,3
Nervous system disorders	Neuralgia	>=65 years	393	56,1	1	0,3
Nervous system disorders	Neuropathy peripheral	<65 years	308	43,9	0	0,0
Nervous system disorders	Neuropathy peripheral	>=65 years	393	56,1	2	0,5
Nervous system disorders	Ophthalmic migraine	<65 years	308	43,9	1	0,3
Nervous system disorders	Ophthalmic migraine	>=65 years	393	56,1	0	0,0
Nervous system disorders	Paralysis	<65 years	308	43,9	1	0,3
Nervous system disorders	Paralysis	>=65 years	393	56,1	0	0,0
Nervous system disorders	Parkinsonism	<65 years	308	43,9	0	0,0
Nervous system disorders	Parkinsonism	>=65 years	393	56,1	1	0,3
Nervous system disorders	Presyncope	<65 years	308	43,9	0	0,0
Nervous system disorders	Presyncope	>=65 years	393	56,1	1	0,3
Nervous system disorders	Sciatica	<65 years	308	43,9	1	0,3

Nervous system disorders	Sciatica	>=65 years	393	56,1	1	0,3
Nervous system disorders	Syncope	<65 years	308	43,9	1	0,3
Nervous system disorders	Syncope	>=65 years	393	56,1	3	0,8
Product issues		<65 years	308	43,9	1	0,3
Product issues		>=65 years	393	56,1	0	0,0
Product issues	Device physical property issue	<65 years	308	43,9	1	0,3
Product issues	Device physical property issue	>=65 years	393	56,1	0	0,0
Psychiatric disorders		<65 years	308	43,9	4	1,3
Psychiatric disorders		>=65 years	393	56,1	5	1,3
Psychiatric disorders	Anxiety	<65 years	308	43,9	0	0,0
Psychiatric disorders	Anxiety	>=65 years	393	56,1	1	0,3
Psychiatric disorders	Attention deficit hyperactivity disorder	<65 years	308	43,9	1	0,3
Psychiatric disorders	Attention deficit hyperactivity disorder	>=65 years	393	56,1	0	0,0
Psychiatric disorders	Depression	<65 years	308	43,9	2	0,6
Psychiatric disorders	Depression	>=65 years	393	56,1	0	0,0
Psychiatric disorders	Generalised anxiety disorder	<65 years	308	43,9	0	0,0
Psychiatric disorders	Generalised anxiety disorder	>=65 years	393	56,1	1	0,3
Psychiatric disorders	Insomnia	<65 years	308	43,9	0	0,0
Psychiatric disorders	Insomnia	>=65 years	393	56,1	3	0,8
Psychiatric disorders	Sleep disorder	<65 years	308	43,9	1	0,3
Psychiatric disorders	Sleep disorder	>=65 years	393	56,1	0	0,0
Renal and urinary disorders		<65 years	308	43,9	4	1,3
Renal and urinary disorders		>=65 years	393	56,1	12	3,1
Renal and urinary disorders	Acute kidney injury	<65 years	308	43,9	1	0,3
Renal and urinary disorders	Acute kidney injury	>=65 years	393	56,1	2	0,5
Renal and urinary disorders	Cystitis interstitial	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Cystitis interstitial	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Diabetic nephropathy	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Diabetic nephropathy	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Dysuria	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Dysuria	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	End stage renal disease	<65 years	308	43,9	0	0,0
Renal and urinary disorders	End stage renal disease	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Haematuria	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Haematuria	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Hypertonic bladder	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Hypertonic bladder	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Nephrolithiasis	<65 years	308	43,9	1	0,3
Renal and urinary disorders	Nephrolithiasis	>=65 years	393	56,1	2	0,5
Renal and urinary disorders	Nephropathy	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Nephropathy	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Renal failure	<65 years	308	43,9	1	0,3
Renal and urinary disorders	Renal failure	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Urinary retention	<65 years	308	43,9	1	0,3
Renal and urinary disorders	Urinary retention	>=65 years	393	56,1	0	0,0
Renal and urinary disorders	Urinary tract inflammation	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Urinary tract inflammation	>=65 years	393	56,1	1	0,3
Reproductive system and breast disorders		<65 years	308	43,9	3	1,0
Reproductive system and breast disorders		>=65 years	393	56,1	3	0,8
Reproductive system and breast disorders	Benign prostatic hyperplasia	<65 years	308	43,9	1	0,3
Reproductive system and breast disorders	Benign prostatic hyperplasia	>=65 years	393	56,1	2	0,5
Reproductive system and breast disorders	Cystocele	<65 years	308	43,9	1	0,3
Reproductive system and breast disorders	Cystocele	>=65 years	393	56,1	0	0,0
Reproductive system and breast disorders	Gynaecomastia	<65 years	308	43,9	0	0,0
Reproductive system and breast disorders	Gynaecomastia	>=65 years	393	56,1	1	0,3
Reproductive system and breast disorders	Prostatitis	<65 years	308	43,9	0	0,0
Reproductive system and breast disorders	Prostatitis	>=65 years	393	56,1	1	0,3
Reproductive system and breast disorders	Vaginal ulceration	<65 years	308	43,9	1	0,3
Reproductive system and breast disorders	Vaginal ulceration	>=65 years	393	56,1	0	0,0
Respiratory, thoracic and mediastinal disorders		<65 years	308	43,9	10	3,2
Respiratory, thoracic and mediastinal disorders		>=65 years	393	56,1	21	5,3
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	>=65 years	393	56,1	2	0,5
Respiratory, thoracic and mediastinal disorders	Asthma	<65 years	308	43,9	1	0,3
Respiratory, thoracic and mediastinal disorders	Asthma	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=65 years	393	56,1	6	1,5
Respiratory, thoracic and mediastinal disorders	Cough	<65 years	308	43,9	1	0,3

Respiratory, thoracic and mediastinal disorders	Cough	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Dry throat	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Dry throat	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Dyspnoea	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Epistaxis	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Lung opacity	<65 years	308	43,9	1	0,3
Respiratory, thoracic and mediastinal disorders	Lung opacity	>=65 years	393	56,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Nasal polyps	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<65 years	308	43,9	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=65 years	393	56,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	<65 years	308	43,9	4	1,3
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	>=65 years	393	56,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural thickening	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural thickening	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=65 years	393	56,1	2	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=65 years	393	56,1	2	0,5
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	<65 years	308	43,9	2	0,6
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	>=65 years	393	56,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	<65 years	308	43,9	1	0,3
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	>=65 years	393	56,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders		<65 years	308	43,9	9	2,9
Skin and subcutaneous tissue disorders		>=65 years	393	56,1	13	3,3
Skin and subcutaneous tissue disorders	Androgenetic alopecia	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Dermal cyst	<65 years	308	43,9	1	0,3
Skin and subcutaneous tissue disorders	Dermal cyst	>=65 years	393	56,1	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis allergic	<65 years	308	43,9	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis allergic	>=65 years	393	56,1	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	<65 years	308	43,9	2	0,6
Skin and subcutaneous tissue disorders	Dermatitis contact	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	<65 years	308	43,9	1	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Eczema	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Eczema	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Erythema	<65 years	308	43,9	1	0,3
Skin and subcutaneous tissue disorders	Erythema	>=65 years	393	56,1	0	0,0
Skin and subcutaneous tissue disorders	Hyperkeratosis	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Hyperkeratosis	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Ingrowing nail	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Ingrowing nail	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Nail bed bleeding	<65 years	308	43,9	1	0,3
Skin and subcutaneous tissue disorders	Nail bed bleeding	>=65 years	393	56,1	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Purpura	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Purpura	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Rash	<65 years	308	43,9	2	0,6
Skin and subcutaneous tissue disorders	Rash	>=65 years	393	56,1	2	0,5
Skin and subcutaneous tissue disorders	Skin lesion	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Skin lesion	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Skin ulcer	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	>=65 years	393	56,1	2	0,5
Skin and subcutaneous tissue disorders	Toxic skin eruption	<65 years	308	43,9	0	0,0

Skin and subcutaneous tissue disorders	Toxic skin eruption	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Urticaria	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	>=65 years	393	56,1	1	0,3
Surgical and medical procedures		<65 years	308	43,9	4	1,3
Surgical and medical procedures		>=65 years	393	56,1	6	1,5
Surgical and medical procedures	Dental implantation	<65 years	308	43,9	2	0,6
Surgical and medical procedures	Dental implantation	>=65 years	393	56,1	1	0,3
Surgical and medical procedures	Large intestinal polypectomy	<65 years	308	43,9	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	>=65 years	393	56,1	1	0,3
Surgical and medical procedures	Ligament operation	<65 years	308	43,9	1	0,3
Surgical and medical procedures	Ligament operation	>=65 years	393	56,1	0	0,0
Surgical and medical procedures	Neurectomy	<65 years	308	43,9	1	0,3
Surgical and medical procedures	Neurectomy	>=65 years	393	56,1	0	0,0
Surgical and medical procedures	Renal transplant	<65 years	308	43,9	0	0,0
Surgical and medical procedures	Renal transplant	>=65 years	393	56,1	1	0,3
Surgical and medical procedures	Toe operation	<65 years	308	43,9	0	0,0
Surgical and medical procedures	Toe operation	>=65 years	393	56,1	1	0,3
Surgical and medical procedures	Tooth extraction	<65 years	308	43,9	1	0,3
Surgical and medical procedures	Tooth extraction	>=65 years	393	56,1	3	0,8
Vascular disorders		<65 years	308	43,9	12	3,9
Vascular disorders		>=65 years	393	56,1	27	6,9
Vascular disorders	Aortic aneurysm	<65 years	308	43,9	0	0,0
Vascular disorders	Aortic aneurysm	>=65 years	393	56,1	1	0,3
Vascular disorders	Aortic dissection	<65 years	308	43,9	0	0,0
Vascular disorders	Aortic dissection	>=65 years	393	56,1	1	0,3
Vascular disorders	Aortic stenosis	<65 years	308	43,9	0	0,0
Vascular disorders	Aortic stenosis	>=65 years	393	56,1	1	0,3
Vascular disorders	Deep vein thrombosis	<65 years	308	43,9	1	0,3
Vascular disorders	Deep vein thrombosis	>=65 years	393	56,1	0	0,0
Vascular disorders	Haematoma	<65 years	308	43,9	0	0,0
Vascular disorders	Haematoma	>=65 years	393	56,1	1	0,3
Vascular disorders	Haemorrhage	<65 years	308	43,9	0	0,0
Vascular disorders	Haemorrhage	>=65 years	393	56,1	1	0,3
Vascular disorders	Hypertension	<65 years	308	43,9	7	2,3
Vascular disorders	Hypertension	>=65 years	393	56,1	16	4,1
Vascular disorders	Hypertensive crisis	<65 years	308	43,9	0	0,0
Vascular disorders	Hypertensive crisis	>=65 years	393	56,1	3	0,8
Vascular disorders	Hypotension	<65 years	308	43,9	1	0,3
Vascular disorders	Hypotension	>=65 years	393	56,1	3	0,8
Vascular disorders	Internal haemorrhage	<65 years	308	43,9	1	0,3
Vascular disorders	Internal haemorrhage	>=65 years	393	56,1	0	0,0
Vascular disorders	Lymphoedema	<65 years	308	43,9	0	0,0
Vascular disorders	Lymphoedema	>=65 years	393	56,1	1	0,3
Vascular disorders	Peripheral artery aneurysm	<65 years	308	43,9	1	0,3
Vascular disorders	Peripheral artery aneurysm	>=65 years	393	56,1	0	0,0
Vascular disorders	Secondary hypertension	<65 years	308	43,9	1	0,3
Vascular disorders	Secondary hypertension	>=65 years	393	56,1	0	0,0
Vascular disorders	Thrombosis	<65 years	308	43,9	0	0,0
Vascular disorders	Thrombosis	>=65 years	393	56,1	1	0,3

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_AR_WK72_SEa24_29AUG2023_41986.xls
26APR2024 18:00

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETRS letter score

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=701)			
			Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<=34 letters	156	22,3	1	0,6
Blood and lymphatic system disorders		35 - 54 letters	206	29,4	3	1,5
Blood and lymphatic system disorders		>=55 letters	339	48,4	6	1,8
Blood and lymphatic system disorders	Anaemia	<=34 letters	156	22,3	1	0,6
Blood and lymphatic system disorders	Anaemia	35 - 54 letters	206	29,4	2	1,0
Blood and lymphatic system disorders	Anaemia	>=55 letters	339	48,4	5	1,5
Blood and lymphatic system disorders	Deficiency anaemia	<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	35 - 54 letters	206	29,4	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	>=55 letters	339	48,4	1	0,3
Blood and lymphatic system disorders	Iron deficiency anaemia	<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders	Iron deficiency anaemia	35 - 54 letters	206	29,4	1	0,5
Blood and lymphatic system disorders	Iron deficiency anaemia	>=55 letters	339	48,4	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	35 - 54 letters	206	29,4	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	>=55 letters	339	48,4	1	0,3
Cardiac disorders		<=34 letters	156	22,3	4	2,6
Cardiac disorders		35 - 54 letters	206	29,4	13	6,3
Cardiac disorders		>=55 letters	339	48,4	13	3,8
Cardiac disorders	Acute left ventricular failure	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Acute left ventricular failure	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Acute left ventricular failure	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Acute myocardial infarction	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Acute myocardial infarction	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Acute myocardial infarction	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Aortic valve incompetence	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Aortic valve incompetence	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Aortic valve incompetence	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Arrhythmia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Arrhythmia	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Arrhythmia	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Atrial fibrillation	<=34 letters	156	22,3	2	1,3
Cardiac disorders	Atrial fibrillation	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Atrial fibrillation	>=55 letters	339	48,4	6	1,8
Cardiac disorders	Bradycardia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Bradycardia	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Bradycardia	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Cardiac failure	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Cardiac failure	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Cardiac failure	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Cardiac failure congestive	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Cardiac failure congestive	35 - 54 letters	206	29,4	2	1,0
Cardiac disorders	Cardiac failure congestive	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Cardiomegaly	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Cardiomegaly	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Cardiomegaly	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Coronary artery disease	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Coronary artery disease	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Coronary artery disease	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Coronary artery stenosis	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Coronary artery stenosis	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Coronary artery stenosis	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Left ventricular dysfunction	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Left ventricular dysfunction	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Left ventricular dysfunction	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Myocardial infarction	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Myocardial infarction	35 - 54 letters	206	29,4	2	1,0
Cardiac disorders	Myocardial infarction	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Myocardial ischaemia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Myocardial ischaemia	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Myocardial ischaemia	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Palpitations	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Palpitations	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Palpitations	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Pericardial effusion	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Pericardial effusion	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Pericardial effusion	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Sinus tachycardia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Sinus tachycardia	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Sinus tachycardia	>=55 letters	339	48,4	1	0,3

Cardiac disorders	Stress cardiomyopathy	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Stress cardiomyopathy	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Stress cardiomyopathy	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Supraventricular tachycardia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Supraventricular tachycardia	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Supraventricular tachycardia	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Tachycardia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Tachycardia	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Tachycardia	>=55 letters	339	48,4	1	0,3
Congenital, familial and genetic disorders		<=34 letters	156	22,3	1	0,6
Congenital, familial and genetic disorders		35 - 54 letters	206	29,4	0	0,0
Congenital, familial and genetic disorders		>=55 letters	339	48,4	1	0,3
Congenital, familial and genetic disorders	Corneal dystrophy	<=34 letters	156	22,3	1	0,6
Congenital, familial and genetic disorders	Corneal dystrophy	35 - 54 letters	206	29,4	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	>=55 letters	339	48,4	1	0,3
Ear and labyrinth disorders		<=34 letters	156	22,3	0	0,0
Ear and labyrinth disorders		35 - 54 letters	206	29,4	1	0,5
Ear and labyrinth disorders		>=55 letters	339	48,4	3	0,9
Ear and labyrinth disorders	Vertigo	<=34 letters	156	22,3	0	0,0
Ear and labyrinth disorders	Vertigo	35 - 54 letters	206	29,4	1	0,5
Ear and labyrinth disorders	Vertigo	>=55 letters	339	48,4	3	0,9
Endocrine disorders		<=34 letters	156	22,3	2	1,3
Endocrine disorders		35 - 54 letters	206	29,4	4	1,9
Endocrine disorders		>=55 letters	339	48,4	4	1,2
Endocrine disorders	Adrenal insufficiency	<=34 letters	156	22,3	0	0,0
Endocrine disorders	Adrenal insufficiency	35 - 54 letters	206	29,4	0	0,0
Endocrine disorders	Adrenal insufficiency	>=55 letters	339	48,4	1	0,3
Endocrine disorders	Adrenal mass	<=34 letters	156	22,3	0	0,0
Endocrine disorders	Adrenal mass	35 - 54 letters	206	29,4	1	0,5
Endocrine disorders	Adrenal mass	>=55 letters	339	48,4	1	0,3
Endocrine disorders	Adrenomegaly	<=34 letters	156	22,3	0	0,0
Endocrine disorders	Adrenomegaly	35 - 54 letters	206	29,4	1	0,5
Endocrine disorders	Adrenomegaly	>=55 letters	339	48,4	0	0,0
Endocrine disorders	Androgen deficiency	<=34 letters	156	22,3	0	0,0
Endocrine disorders	Androgen deficiency	35 - 54 letters	206	29,4	1	0,5
Endocrine disorders	Androgen deficiency	>=55 letters	339	48,4	0	0,0
Endocrine disorders	Goitre	<=34 letters	156	22,3	0	0,0
Endocrine disorders	Goitre	35 - 54 letters	206	29,4	0	0,0
Endocrine disorders	Goitre	>=55 letters	339	48,4	1	0,3
Endocrine disorders	Hypothyroidism	<=34 letters	156	22,3	2	1,3
Endocrine disorders	Hypothyroidism	35 - 54 letters	206	29,4	1	0,5
Endocrine disorders	Hypothyroidism	>=55 letters	339	48,4	1	0,3
Endocrine disorders	Thyroid cyst	<=34 letters	156	22,3	0	0,0
Endocrine disorders	Thyroid cyst	35 - 54 letters	206	29,4	1	0,5
Endocrine disorders	Thyroid cyst	>=55 letters	339	48,4	0	0,0
Endocrine disorders	Thyroid mass	<=34 letters	156	22,3	0	0,0
Endocrine disorders	Thyroid mass	35 - 54 letters	206	29,4	1	0,5
Endocrine disorders	Thyroid mass	>=55 letters	339	48,4	0	0,0
Eye disorders		<=34 letters	156	22,3	68	43,6
Eye disorders		35 - 54 letters	206	29,4	76	36,9
Eye disorders		>=55 letters	339	48,4	118	34,8
Eye disorders	Age-related macular degeneration	<=34 letters	156	22,3	0	0,0
Eye disorders	Age-related macular degeneration	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Age-related macular degeneration	>=55 letters	339	48,4	1	0,3
Eye disorders	Anisocoria	<=34 letters	156	22,3	1	0,6
Eye disorders	Anisocoria	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Anisocoria	>=55 letters	339	48,4	0	0,0
Eye disorders	Asthenopia	<=34 letters	156	22,3	0	0,0
Eye disorders	Asthenopia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Asthenopia	>=55 letters	339	48,4	1	0,3
Eye disorders	Blepharitis	<=34 letters	156	22,3	2	1,3
Eye disorders	Blepharitis	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Blepharitis	>=55 letters	339	48,4	1	0,6
Eye disorders	Borderline glaucoma	<=34 letters	156	22,3	1	0,3
Eye disorders	Borderline glaucoma	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Borderline glaucoma	>=55 letters	339	48,4	0	0,0
Eye disorders	Cataract	<=34 letters	156	22,3	11	7,1
Eye disorders	Cataract	35 - 54 letters	206	29,4	9	4,4
Eye disorders	Cataract	>=55 letters	339	48,4	14	4,1
Eye disorders	Cataract nuclear	<=34 letters	156	22,3	0	0,0
Eye disorders	Cataract nuclear	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Cataract nuclear	>=55 letters	339	48,4	1	0,3
Eye disorders	Cataract subcapsular	<=34 letters	156	22,3	0	0,0
Eye disorders	Cataract subcapsular	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Cataract subcapsular	>=55 letters	339	48,4	1	0,3
Eye disorders	Central serous chorioretinopathy	<=34 letters	156	22,3	0	0,0
Eye disorders	Central serous chorioretinopathy	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Central serous chorioretinopathy	>=55 letters	339	48,4	3	0,9
Eye disorders	Chalazion	<=34 letters	156	22,3	1	0,6

Eye disorders	Chalazion	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Chalazion	>=55 letters	339	48,4	1	0,3
Eye disorders	Choroidal effusion	<=34 letters	156	22,3	0	0,0
Eye disorders	Choroidal effusion	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Choroidal effusion	>=55 letters	339	48,4	0	0,0
Eye disorders	Conjunctival haemorrhage	<=34 letters	156	22,3	6	3,8
Eye disorders	Conjunctival haemorrhage	35 - 54 letters	206	29,4	4	1,9
Eye disorders	Conjunctival haemorrhage	>=55 letters	339	48,4	11	3,2
Eye disorders	Conjunctival hyperaemia	<=34 letters	156	22,3	0	0,0
Eye disorders	Conjunctival hyperaemia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Conjunctival hyperaemia	>=55 letters	339	48,4	1	0,3
Eye disorders	Conjunctival telangiectasia	<=34 letters	156	22,3	0	0,0
Eye disorders	Conjunctival telangiectasia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Conjunctival telangiectasia	>=55 letters	339	48,4	0	0,0
Eye disorders	Conjunctivitis allergic	<=34 letters	156	22,3	0	0,0
Eye disorders	Conjunctivitis allergic	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Conjunctivitis allergic	>=55 letters	339	48,4	0	0,0
Eye disorders	Corneal deposits	<=34 letters	156	22,3	0	0,0
Eye disorders	Corneal deposits	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Corneal deposits	>=55 letters	339	48,4	1	0,3
Eye disorders	Corneal erosion	<=34 letters	156	22,3	0	0,0
Eye disorders	Corneal erosion	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Corneal erosion	>=55 letters	339	48,4	1	0,3
Eye disorders	Corneal infiltrates	<=34 letters	156	22,3	0	0,0
Eye disorders	Corneal infiltrates	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Corneal infiltrates	>=55 letters	339	48,4	1	0,3
Eye disorders	Corneal opacity	<=34 letters	156	22,3	0	0,0
Eye disorders	Corneal opacity	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Corneal opacity	>=55 letters	339	48,4	0	0,0
Eye disorders	Corneal pigmentation	<=34 letters	156	22,3	0	0,0
Eye disorders	Corneal pigmentation	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Corneal pigmentation	>=55 letters	339	48,4	0	0,0
Eye disorders	Cystoid macular oedema	<=34 letters	156	22,3	6	3,8
Eye disorders	Cystoid macular oedema	35 - 54 letters	206	29,4	6	2,9
Eye disorders	Cystoid macular oedema	>=55 letters	339	48,4	16	4,7
Eye disorders	Detachment of retinal pigment epithelium	<=34 letters	156	22,3	0	0,0
Eye disorders	Detachment of retinal pigment epithelium	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Detachment of retinal pigment epithelium	>=55 letters	339	48,4	2	0,6
Eye disorders	Diabetic retinal oedema	<=34 letters	156	22,3	0	0,0
Eye disorders	Diabetic retinal oedema	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Diabetic retinal oedema	>=55 letters	339	48,4	0	0,0
Eye disorders	Diabetic retinopathy	<=34 letters	156	22,3	1	0,6
Eye disorders	Diabetic retinopathy	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Diabetic retinopathy	>=55 letters	339	48,4	0	0,0
Eye disorders	Diplopia	<=34 letters	156	22,3	0	0,0
Eye disorders	Diplopia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Diplopia	>=55 letters	339	48,4	0	0,0
Eye disorders	Dry age-related macular degeneration	<=34 letters	156	22,3	0	0,0
Eye disorders	Dry age-related macular degeneration	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Dry age-related macular degeneration	>=55 letters	339	48,4	1	0,3
Eye disorders	Dry eye	<=34 letters	156	22,3	7	4,5
Eye disorders	Dry eye	35 - 54 letters	206	29,4	5	2,4
Eye disorders	Dry eye	>=55 letters	339	48,4	3	0,9
Eye disorders	Eczema eyelids	<=34 letters	156	22,3	0	0,0
Eye disorders	Eczema eyelids	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Eczema eyelids	>=55 letters	339	48,4	1	0,3
Eye disorders	Epi-retinal membrane	<=34 letters	156	22,3	3	1,9
Eye disorders	Epi-retinal membrane	35 - 54 letters	206	29,4	6	2,9
Eye disorders	Epi-retinal membrane	>=55 letters	339	48,4	8	2,4
Eye disorders	Episcleritis	<=34 letters	156	22,3	0	0,0
Eye disorders	Episcleritis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Episcleritis	>=55 letters	339	48,4	1	0,3
Eye disorders	Eye irritation	<=34 letters	156	22,3	0	0,0
Eye disorders	Eye irritation	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Eye irritation	>=55 letters	339	48,4	0	0,0
Eye disorders	Eye pain	<=34 letters	156	22,3	2	1,3
Eye disorders	Eye pain	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Eye pain	>=55 letters	339	48,4	6	1,8
Eye disorders	Eye pruritus	<=34 letters	156	22,3	0	0,0
Eye disorders	Eye pruritus	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Eye pruritus	>=55 letters	339	48,4	3	0,9
Eye disorders	Eyelid cyst	<=34 letters	156	22,3	1	0,6
Eye disorders	Eyelid cyst	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Eyelid cyst	>=55 letters	339	48,4	0	0,0
Eye disorders	Eyelid oedema	<=34 letters	156	22,3	1	0,6
Eye disorders	Eyelid oedema	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Eyelid oedema	>=55 letters	339	48,4	0	0,0
Eye disorders	Foreign body sensation in eyes	<=34 letters	156	22,3	0	0,0
Eye disorders	Foreign body sensation in eyes	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Foreign body sensation in eyes	>=55 letters	339	48,4	2	0,6
Eye disorders	Glaucoma	<=34 letters	156	22,3	3	1,9
Eye disorders	Glaucoma	35 - 54 letters	206	29,4	3	1,5
Eye disorders	Glaucoma	>=55 letters	339	48,4	9	2,7

Eye disorders	Hypotony of eye	<=34 letters	156	22,3	1	0,6
Eye disorders	Hypotony of eye	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Hypotony of eye	>=55 letters	339	48,4	0	0,0
Eye disorders	Iridocyclitis	<=34 letters	156	22,3	1	0,6
Eye disorders	Iridocyclitis	35 - 54 letters	206	29,4	3	1,5
Eye disorders	Iridocyclitis	>=55 letters	339	48,4	3	0,9
Eye disorders	Iris neovascularisation	<=34 letters	156	22,3	0	0,0
Eye disorders	Iris neovascularisation	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Iris neovascularisation	>=55 letters	339	48,4	1	0,3
Eye disorders	Iritis	<=34 letters	156	22,3	1	0,6
Eye disorders	Iritis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Iritis	>=55 letters	339	48,4	3	0,9
Eye disorders	Keratic precipitates	<=34 letters	156	22,3	0	0,0
Eye disorders	Keratic precipitates	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Keratic precipitates	>=55 letters	339	48,4	1	0,3
Eye disorders	Keratitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Keratitis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Keratitis	>=55 letters	339	48,4	2	0,6
Eye disorders	Keratopathy	<=34 letters	156	22,3	0	0,0
Eye disorders	Keratopathy	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Keratopathy	>=55 letters	339	48,4	1	0,3
Eye disorders	Lacrimal disorder	<=34 letters	156	22,3	0	0,0
Eye disorders	Lacrimal disorder	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Lacrimal disorder	>=55 letters	339	48,4	1	0,3
Eye disorders	Lacrimation increased	<=34 letters	156	22,3	0	0,0
Eye disorders	Lacrimation increased	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Lacrimation increased	>=55 letters	339	48,4	3	0,9
Eye disorders	Lenticular opacities	<=34 letters	156	22,3	0	0,0
Eye disorders	Lenticular opacities	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Lenticular opacities	>=55 letters	339	48,4	0	0,0
Eye disorders	Macular degeneration	<=34 letters	156	22,3	2	1,3
Eye disorders	Macular degeneration	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Macular degeneration	>=55 letters	339	48,4	0	0,0
Eye disorders	Macular detachment	<=34 letters	156	22,3	1	0,6
Eye disorders	Macular detachment	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Macular detachment	>=55 letters	339	48,4	1	0,3
Eye disorders	Macular hole	<=34 letters	156	22,3	0	0,0
Eye disorders	Macular hole	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Macular hole	>=55 letters	339	48,4	1	0,3
Eye disorders	Macular ischaemia	<=34 letters	156	22,3	0	0,0
Eye disorders	Macular ischaemia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Macular ischaemia	>=55 letters	339	48,4	1	0,3
Eye disorders	Macular oedema	<=34 letters	156	22,3	6	3,8
Eye disorders	Macular oedema	35 - 54 letters	206	29,4	12	5,8
Eye disorders	Macular oedema	>=55 letters	339	48,4	8	2,4
Eye disorders	Macular scar	<=34 letters	156	22,3	1	0,6
Eye disorders	Macular scar	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Macular scar	>=55 letters	339	48,4	0	0,0
Eye disorders	Meibomianitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Meibomianitis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Meibomianitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Neovascular age-related macular degeneration	<=34 letters	156	22,3	0	0,0
Eye disorders	Neovascular age-related macular degeneration	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Neovascular age-related macular degeneration	>=55 letters	339	48,4	1	0,3
Eye disorders	Non-infectious endophthalmitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Non-infectious endophthalmitis	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Non-infectious endophthalmitis	>=55 letters	339	48,4	0	0,0
Eye disorders	Noninfective conjunctivitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Noninfective conjunctivitis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Noninfective conjunctivitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Normal tension glaucoma	<=34 letters	156	22,3	0	0,0
Eye disorders	Normal tension glaucoma	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Normal tension glaucoma	>=55 letters	339	48,4	0	0,0
Eye disorders	Ocular hyperaemia	<=34 letters	156	22,3	0	0,0
Eye disorders	Ocular hyperaemia	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Ocular hyperaemia	>=55 letters	339	48,4	2	0,6
Eye disorders	Ocular hypertension	<=34 letters	156	22,3	2	1,3
Eye disorders	Ocular hypertension	35 - 54 letters	206	29,4	6	2,9
Eye disorders	Ocular hypertension	>=55 letters	339	48,4	4	1,2
Eye disorders	Open angle glaucoma	<=34 letters	156	22,3	1	0,6
Eye disorders	Open angle glaucoma	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Open angle glaucoma	>=55 letters	339	48,4	1	0,3
Eye disorders	Optic atrophy	<=34 letters	156	22,3	1	0,6
Eye disorders	Optic atrophy	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Optic atrophy	>=55 letters	339	48,4	0	0,0
Eye disorders	Optic disc disorder	<=34 letters	156	22,3	0	0,0
Eye disorders	Optic disc disorder	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Optic disc disorder	>=55 letters	339	48,4	0	0,0
Eye disorders	Optic disc haemorrhage	<=34 letters	156	22,3	0	0,0
Eye disorders	Optic disc haemorrhage	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Optic disc haemorrhage	>=55 letters	339	48,4	1	0,3
Eye disorders	Optic disc vascular disorder	<=34 letters	156	22,3	1	0,6
Eye disorders	Optic disc vascular disorder	35 - 54 letters	206	29,4	0	0,0

Eye disorders	Optic disc vascular disorder	>=55 letters	339	48,4	0	0,0
Eye disorders	Papilloedema	<=34 letters	156	22,3	0	0,0
Eye disorders	Papilloedema	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Papilloedema	>=55 letters	339	48,4	2	0,6
Eye disorders	Periorbital pain	<=34 letters	156	22,3	0	0,0
Eye disorders	Periorbital pain	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Periorbital pain	>=55 letters	339	48,4	0	0,0
Eye disorders	Photopsia	<=34 letters	156	22,3	0	0,0
Eye disorders	Photopsia	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Photopsia	>=55 letters	339	48,4	0	0,0
Eye disorders	Pinguecula	<=34 letters	156	22,3	0	0,0
Eye disorders	Pinguecula	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Pinguecula	>=55 letters	339	48,4	1	0,3
Eye disorders	Posterior capsule opacification	<=34 letters	156	22,3	2	1,3
Eye disorders	Posterior capsule opacification	35 - 54 letters	206	29,4	3	1,5
Eye disorders	Posterior capsule opacification	>=55 letters	339	48,4	2	0,6
Eye disorders	Punctate keratitis	<=34 letters	156	22,3	2	1,3
Eye disorders	Punctate keratitis	35 - 54 letters	206	29,4	3	1,5
Eye disorders	Punctate keratitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal aneurysm	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal aneurysm	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal aneurysm	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal artery embolism	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal artery embolism	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal artery embolism	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal artery occlusion	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal artery occlusion	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal artery occlusion	>=55 letters	339	48,4	4	1,2
Eye disorders	Retinal collateral vessels	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal collateral vessels	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Retinal collateral vessels	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal depigmentation	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal depigmentation	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal depigmentation	>=55 letters	339	48,4	0	0,0
Eye disorders	Retinal detachment	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal detachment	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal detachment	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal disorder	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal disorder	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal disorder	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal drusen	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal drusen	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal drusen	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal exudates	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal exudates	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal exudates	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal haemorrhage	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal haemorrhage	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Retinal haemorrhage	>=55 letters	339	48,4	4	1,2
Eye disorders	Retinal ischaemia	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal ischaemia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Retinal ischaemia	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal neovascularisation	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal neovascularisation	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Retinal neovascularisation	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal tear	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal tear	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Retinal tear	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal vein occlusion	<=34 letters	156	22,3	9	5,8
Eye disorders	Retinal vein occlusion	35 - 54 letters	206	29,4	4	1,9
Eye disorders	Retinal vein occlusion	>=55 letters	339	48,4	10	2,9
Eye disorders	Retinopathy hypertensive	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinopathy hypertensive	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinopathy hypertensive	>=55 letters	339	48,4	1	0,3
Eye disorders	Subretinal fluid	<=34 letters	156	22,3	0	0,0
Eye disorders	Subretinal fluid	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Subretinal fluid	>=55 letters	339	48,4	1	0,3
Eye disorders	Uveitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Uveitis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Uveitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Vision blurred	<=34 letters	156	22,3	0	0,0
Eye disorders	Vision blurred	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Vision blurred	>=55 letters	339	48,4	1	0,3
Eye disorders	Visual acuity reduced	<=34 letters	156	22,3	3	1,9
Eye disorders	Visual acuity reduced	35 - 54 letters	206	29,4	3	1,5
Eye disorders	Visual acuity reduced	>=55 letters	339	48,4	2	0,6
Eye disorders	Visual acuity reduced transiently	<=34 letters	156	22,3	0	0,0
Eye disorders	Visual acuity reduced transiently	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Visual acuity reduced transiently	>=55 letters	339	48,4	0	0,0
Eye disorders	Visual field defect	<=34 letters	156	22,3	0	0,0
Eye disorders	Visual field defect	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Visual field defect	>=55 letters	339	48,4	0	0,0
Eye disorders	Visual impairment	<=34 letters	156	22,3	1	0,6

Eye disorders	Visual impairment	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Visual impairment	>=55 letters	339	48,4	2	0,6
Eye disorders	Vitreoretinal traction syndrome	<=34 letters	156	22,3	0	0,0
Eye disorders	Vitreoretinal traction syndrome	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Vitreoretinal traction syndrome	>=55 letters	339	48,4	3	0,9
Eye disorders	Vitreous detachment	<=34 letters	156	22,3	6	3,8
Eye disorders	Vitreous detachment	35 - 54 letters	206	29,4	9	4,4
Eye disorders	Vitreous detachment	>=55 letters	339	48,4	14	4,1
Eye disorders	Vitreous floaters	<=34 letters	156	22,3	3	1,9
Eye disorders	Vitreous floaters	35 - 54 letters	206	29,4	4	1,9
Eye disorders	Vitreous floaters	>=55 letters	339	48,4	3	0,9
Eye disorders	Vitreous haemorrhage	<=34 letters	156	22,3	3	1,9
Eye disorders	Vitreous haemorrhage	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Vitreous haemorrhage	>=55 letters	339	48,4	0	0,0
Eye disorders	Vitreous opacities	<=34 letters	156	22,3	1	0,6
Eye disorders	Vitreous opacities	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Vitreous opacities	>=55 letters	339	48,4	0	0,0
Eye disorders	Vitritis	<=34 letters	156	22,3	1	0,6
Eye disorders	Vitritis	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Vitritis	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders		<=34 letters	156	22,3	6	3,8
Gastrointestinal disorders		35 - 54 letters	206	29,4	15	7,3
Gastrointestinal disorders		>=55 letters	339	48,4	21	6,2
Gastrointestinal disorders	Abdominal discomfort	<=34 letters	156	22,3	1	0,6
Gastrointestinal disorders	Abdominal discomfort	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Abdominal discomfort	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Abdominal pain	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Abdominal pain	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Abdominal pain	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Abdominal pain upper	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Abdominal pain upper	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Abdominal pain upper	>=55 letters	339	48,4	2	0,6
Gastrointestinal disorders	Barrett's oesophagus	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Chronic gastritis	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Chronic gastritis	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Chronic gastritis	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Coeliac disease	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Coeliac disease	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Coeliac disease	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Colitis	<=34 letters	156	22,3	1	0,6
Gastrointestinal disorders	Colitis	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Colitis	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Constipation	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Constipation	35 - 54 letters	206	29,4	3	1,5
Gastrointestinal disorders	Constipation	>=55 letters	339	48,4	2	0,6
Gastrointestinal disorders	Dental discomfort	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Dental discomfort	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Dental discomfort	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Diarrhoea	<=34 letters	156	22,3	4	2,6
Gastrointestinal disorders	Diarrhoea	35 - 54 letters	206	29,4	3	1,5
Gastrointestinal disorders	Diarrhoea	>=55 letters	339	48,4	4	1,2
Gastrointestinal disorders	Diverticulum intestinal	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Diverticulum intestinal	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Diverticulum intestinal	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Duodenitis	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Duodenitis	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Duodenitis	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Dyspepsia	<=34 letters	156	22,3	1	0,6
Gastrointestinal disorders	Dyspepsia	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Dyspepsia	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Gastric ulcer	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Gastric ulcer	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Gastric ulcer	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Gastritis	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Gastritis	35 - 54 letters	206	29,4	2	1,0
Gastrointestinal disorders	Gastritis	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Gastrointestinal inflammation	<=34 letters	156	22,3	1	0,6
Gastrointestinal disorders	Gastrointestinal inflammation	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	>=55 letters	339	48,4	2	0,6
Gastrointestinal disorders	Haemorrhagic erosive gastritis	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Haemorrhagic erosive gastritis	35 - 54 letters	206	29,4	0	0,0

Gastrointestinal disorders	Haemorrhagic erosive gastritis	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Haemorrhoids	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Haemorrhoids	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Haemorrhoids	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Hiatus hernia	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Hiatus hernia	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Hiatus hernia	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Ileus	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Ileus	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Ileus	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Inguinal hernia	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Inguinal hernia	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Inguinal hernia	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Large intestine polyp	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Large intestine polyp	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Large intestine polyp	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Nausea	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Nausea	35 - 54 letters	206	29,4	3	1,5
Gastrointestinal disorders	Nausea	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Pancreatitis	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Pancreatitis	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Pancreatitis	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Pancreatitis acute	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Pancreatitis acute	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Pancreatitis acute	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Pulpless tooth	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Pulpless tooth	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Pulpless tooth	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Salivary gland disorder	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Salivary gland disorder	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Salivary gland disorder	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Toothache	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Toothache	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Toothache	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Umbilical hernia	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Umbilical hernia	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Umbilical hernia	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Vomiting	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Vomiting	35 - 54 letters	206	29,4	2	1,0
Gastrointestinal disorders	Vomiting	>=55 letters	339	48,4	0	0,0
General disorders and administration site conditions		<=34 letters	156	22,3	6	3,8
General disorders and administration site conditions		35 - 54 letters	206	29,4	9	4,4
General disorders and administration site conditions		>=55 letters	339	48,4	17	5,0
General disorders and administration site conditions	Asthenia	<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions	Asthenia	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Asthenia	>=55 letters	339	48,4	5	1,5
General disorders and administration site conditions	Chest pain	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Chest pain	35 - 54 letters	206	29,4	2	1,0
General disorders and administration site conditions	Chest pain	>=55 letters	339	48,4	2	0,6
General disorders and administration site conditions	Chills	<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions	Chills	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Chills	>=55 letters	339	48,4	0	0,0
General disorders and administration site conditions	Death	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Death	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Death	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Drug intolerance	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Drug intolerance	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Drug intolerance	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Drug withdrawal syndrome	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Drug withdrawal syndrome	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Drug withdrawal syndrome	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Fatigue	<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions	Fatigue	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Fatigue	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Injection site pain	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Injection site pain	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Injection site pain	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Injection site reaction	<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions	Injection site reaction	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Injection site reaction	>=55 letters	339	48,4	0	0,0
General disorders and administration site conditions	Oedema peripheral	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Oedema peripheral	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Oedema peripheral	>=55 letters	339	48,4	3	0,9
General disorders and administration site conditions	Pain	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Pain	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Pain	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Peripheral swelling	<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions	Peripheral swelling	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Peripheral swelling	>=55 letters	339	48,4	0	0,0
General disorders and administration site conditions	Polyp	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Polyp	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Polyp	>=55 letters	339	48,4	0	0,0

General disorders and administration site conditions	Pyrexia	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Pyrexia	35 - 54 letters	206	29,4	3	1,5
General disorders and administration site conditions	Pyrexia	>=55 letters	339	48,4	2	0,6
General disorders and administration site conditions	Stent-graft endoleak	<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions	Stent-graft endoleak	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	>=55 letters	339	48,4	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	>=55 letters	339	48,4	1	0,3
Hepatobiliary disorders		<=34 letters	156	22,3	2	1,3
Hepatobiliary disorders		35 - 54 letters	206	29,4	2	1,0
Hepatobiliary disorders		>=55 letters	339	48,4	4	1,2
Hepatobiliary disorders	Cholecystitis	<=34 letters	156	22,3	1	0,6
Hepatobiliary disorders	Cholecystitis	35 - 54 letters	206	29,4	0	0,0
Hepatobiliary disorders	Cholecystitis	>=55 letters	339	48,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	<=34 letters	156	22,3	0	0,0
Hepatobiliary disorders	Cholelithiasis	35 - 54 letters	206	29,4	2	1,0
Hepatobiliary disorders	Cholelithiasis	>=55 letters	339	48,4	2	0,6
Hepatobiliary disorders	Hepatic cyst	<=34 letters	156	22,3	0	0,0
Hepatobiliary disorders	Hepatic cyst	35 - 54 letters	206	29,4	1	0,5
Hepatobiliary disorders	Hepatic cyst	>=55 letters	339	48,4	0	0,0
Hepatobiliary disorders	Hepatic steatosis	<=34 letters	156	22,3	1	0,6
Hepatobiliary disorders	Hepatic steatosis	35 - 54 letters	206	29,4	1	0,5
Hepatobiliary disorders	Hepatic steatosis	>=55 letters	339	48,4	1	0,3
Hepatobiliary disorders	Portal hypertension	<=34 letters	156	22,3	0	0,0
Hepatobiliary disorders	Portal hypertension	35 - 54 letters	206	29,4	0	0,0
Hepatobiliary disorders	Portal hypertension	>=55 letters	339	48,4	1	0,3
Immune system disorders		<=34 letters	156	22,3	2	1,3
Immune system disorders		35 - 54 letters	206	29,4	5	2,4
Immune system disorders		>=55 letters	339	48,4	4	1,2
Immune system disorders	Contrast media allergy	<=34 letters	156	22,3	0	0,0
Immune system disorders	Contrast media allergy	35 - 54 letters	206	29,4	2	1,0
Immune system disorders	Contrast media allergy	>=55 letters	339	48,4	1	0,3
Immune system disorders	Contrast media reaction	<=34 letters	156	22,3	1	0,6
Immune system disorders	Contrast media reaction	35 - 54 letters	206	29,4	0	0,0
Immune system disorders	Contrast media reaction	>=55 letters	339	48,4	0	0,0
Immune system disorders	Drug hypersensitivity	<=34 letters	156	22,3	0	0,0
Immune system disorders	Drug hypersensitivity	35 - 54 letters	206	29,4	0	0,0
Immune system disorders	Drug hypersensitivity	>=55 letters	339	48,4	1	0,3
Immune system disorders	Food allergy	<=34 letters	156	22,3	0	0,0
Immune system disorders	Food allergy	35 - 54 letters	206	29,4	1	0,5
Immune system disorders	Food allergy	>=55 letters	339	48,4	0	0,0
Immune system disorders	Iodine allergy	<=34 letters	156	22,3	0	0,0
Immune system disorders	Iodine allergy	35 - 54 letters	206	29,4	0	0,0
Immune system disorders	Iodine allergy	>=55 letters	339	48,4	1	0,3
Immune system disorders	Seasonal allergy	<=34 letters	156	22,3	1	0,6
Immune system disorders	Seasonal allergy	35 - 54 letters	206	29,4	2	1,0
Immune system disorders	Seasonal allergy	>=55 letters	339	48,4	1	0,3
Infections and infestations		<=34 letters	156	22,3	46	29,5
Infections and infestations		35 - 54 letters	206	29,4	68	33,0
Infections and infestations		>=55 letters	339	48,4	111	32,7
Infections and infestations	Adenoviral conjunctivitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Adenoviral conjunctivitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Adenoviral conjunctivitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Arthritis infective	<=34 letters	156	22,3	0	0,0
Infections and infestations	Arthritis infective	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Arthritis infective	>=55 letters	339	48,4	1	0,3
Infections and infestations	Bronchitis	<=34 letters	156	22,3	3	1,9
Infections and infestations	Bronchitis	35 - 54 letters	206	29,4	4	1,9
Infections and infestations	Bronchitis	>=55 letters	339	48,4	2	0,6
Infections and infestations	COVID-19	<=34 letters	156	22,3	13	8,3
Infections and infestations	COVID-19	35 - 54 letters	206	29,4	29	14,1
Infections and infestations	COVID-19	>=55 letters	339	48,4	49	14,5
Infections and infestations	COVID-19 pneumonia	<=34 letters	156	22,3	0	0,0
Infections and infestations	COVID-19 pneumonia	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	COVID-19 pneumonia	>=55 letters	339	48,4	0	0,0
Infections and infestations	Cellulitis	<=34 letters	156	22,3	2	1,3
Infections and infestations	Cellulitis	35 - 54 letters	206	29,4	3	1,5
Infections and infestations	Cellulitis	>=55 letters	339	48,4	2	0,6
Infections and infestations	Chronic sinusitis	<=34 letters	156	22,3	1	0,6
Infections and infestations	Chronic sinusitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Chronic sinusitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Clostridium difficile infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Clostridium difficile infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Clostridium difficile infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Conjunctivitis	<=34 letters	156	22,3	3	1,9
Infections and infestations	Conjunctivitis	35 - 54 letters	206	29,4	5	2,4
Infections and infestations	Conjunctivitis	>=55 letters	339	48,4	6	1,8
Infections and infestations	Conjunctivitis bacterial	<=34 letters	156	22,3	0	0,0
Infections and infestations	Conjunctivitis bacterial	35 - 54 letters	206	29,4	0	0,0

Infections and infestations	Conjunctivitis bacterial	>=55 letters	339	48,4	1	0,3
Infections and infestations	Conjunctivitis viral	<=34 letters	156	22,3	0	0,0
Infections and infestations	Conjunctivitis viral	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Conjunctivitis viral	>=55 letters	339	48,4	0	0,0
Infections and infestations	Cystitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Cystitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Cystitis	>=55 letters	339	48,4	3	0,9
Infections and infestations	Device related infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Device related infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Device related infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Diabetic foot infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Diabetic foot infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Diabetic foot infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Ear infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Ear infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Ear infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Endophthalmitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Endophthalmitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Endophthalmitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Enteritis infectious	<=34 letters	156	22,3	0	0,0
Infections and infestations	Enteritis infectious	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Enteritis infectious	>=55 letters	339	48,4	1	0,3
Infections and infestations	Escherichia urinary tract infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Escherichia urinary tract infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Escherichia urinary tract infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Eye infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Eye infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Eye infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Eye infection bacterial	<=34 letters	156	22,3	0	0,0
Infections and infestations	Eye infection bacterial	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Eye infection bacterial	>=55 letters	339	48,4	1	0,3
Infections and infestations	Folliculitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Folliculitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Folliculitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Fungal skin infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Fungal skin infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Fungal skin infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Gastroenteritis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Gastroenteritis	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Gastroenteritis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Gastroenteritis viral	<=34 letters	156	22,3	1	0,6
Infections and infestations	Gastroenteritis viral	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Gastroenteritis viral	>=55 letters	339	48,4	2	0,6
Infections and infestations	Gastrointestinal infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Gastrointestinal infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Gastrointestinal infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Helicobacter infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Helicobacter infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Helicobacter infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Herpes virus infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Herpes virus infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Herpes virus infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Herpes zoster	<=34 letters	156	22,3	2	1,3
Infections and infestations	Herpes zoster	35 - 54 letters	206	29,4	2	1,0
Infections and infestations	Herpes zoster	>=55 letters	339	48,4	2	0,6
Infections and infestations	Hordeolum	<=34 letters	156	22,3	1	0,6
Infections and infestations	Hordeolum	35 - 54 letters	206	29,4	2	1,0
Infections and infestations	Hordeolum	>=55 letters	339	48,4	2	0,6
Infections and infestations	Infected bite	<=34 letters	156	22,3	1	0,6
Infections and infestations	Infected bite	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Infected bite	>=55 letters	339	48,4	0	0,0
Infections and infestations	Influenza	<=34 letters	156	22,3	4	2,6
Infections and infestations	Influenza	35 - 54 letters	206	29,4	6	2,9
Infections and infestations	Influenza	>=55 letters	339	48,4	9	2,7
Infections and infestations	Kidney infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Kidney infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Kidney infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Laryngitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Laryngitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Laryngitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Localised infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Localised infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Localised infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Lower respiratory tract infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Lower respiratory tract infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Lower respiratory tract infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Nasopharyngitis	<=34 letters	156	22,3	3	1,9
Infections and infestations	Nasopharyngitis	35 - 54 letters	206	29,4	11	5,3
Infections and infestations	Nasopharyngitis	>=55 letters	339	48,4	13	3,8
Infections and infestations	Necrotising fasciitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Necrotising fasciitis	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Necrotising fasciitis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Oral herpes	<=34 letters	156	22,3	0	0,0

Infections and infestations	Oral herpes	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Oral herpes	>=55 letters	339	48,4	1	0,3
Infections and infestations	Otitis externa	<=34 letters	156	22,3	1	0,6
Infections and infestations	Otitis externa	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Otitis externa	>=55 letters	339	48,4	0	0,0
Infections and infestations	Otosalpingitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Otosalpingitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Otosalpingitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Perichondritis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Perichondritis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Perichondritis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Periodontitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Periodontitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Periodontitis	>=55 letters	339	48,4	2	0,6
Infections and infestations	Pharyngitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Pharyngitis	35 - 54 letters	206	29,4	2	1,0
Infections and infestations	Pharyngitis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Pneumonia	<=34 letters	156	22,3	4	2,6
Infections and infestations	Pneumonia	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Pneumonia	>=55 letters	339	48,4	5	1,5
Infections and infestations	Pneumonia viral	<=34 letters	156	22,3	1	0,6
Infections and infestations	Pneumonia viral	35 - 54 letters	206	29,4	2	1,0
Infections and infestations	Pneumonia viral	>=55 letters	339	48,4	0	0,0
Infections and infestations	Pulpitis dental	<=34 letters	156	22,3	0	0,0
Infections and infestations	Pulpitis dental	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Pulpitis dental	>=55 letters	339	48,4	3	0,9
Infections and infestations	Respiratory syncytial virus infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Respiratory syncytial virus infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Respiratory syncytial virus infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Respiratory tract infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Respiratory tract infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Respiratory tract infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Respiratory tract infection viral	<=34 letters	156	22,3	0	0,0
Infections and infestations	Respiratory tract infection viral	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Respiratory tract infection viral	>=55 letters	339	48,4	0	0,0
Infections and infestations	Rhinitis	<=34 letters	156	22,3	1	0,6
Infections and infestations	Rhinitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Rhinitis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Sepsis	<=34 letters	156	22,3	2	1,3
Infections and infestations	Sepsis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Sepsis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Septic arthritis staphylococcal	<=34 letters	156	22,3	0	0,0
Infections and infestations	Septic arthritis staphylococcal	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Septic arthritis staphylococcal	>=55 letters	339	48,4	1	0,3
Infections and infestations	Sinusitis	<=34 letters	156	22,3	4	2,6
Infections and infestations	Sinusitis	35 - 54 letters	206	29,4	2	1,0
Infections and infestations	Sinusitis	>=55 letters	339	48,4	3	0,9
Infections and infestations	Staphylococcal infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Staphylococcal infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Staphylococcal infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Suspected COVID-19	<=34 letters	156	22,3	1	0,6
Infections and infestations	Suspected COVID-19	35 - 54 letters	206	29,4	3	1,5
Infections and infestations	Suspected COVID-19	>=55 letters	339	48,4	6	1,8
Infections and infestations	Tinea pedis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Tinea pedis	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Tinea pedis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Tooth abscess	<=34 letters	156	22,3	1	0,6
Infections and infestations	Tooth abscess	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Tooth abscess	>=55 letters	339	48,4	1	0,3
Infections and infestations	Tooth infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Tooth infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Tooth infection	>=55 letters	339	48,4	2	0,6
Infections and infestations	Upper respiratory tract infection	<=34 letters	156	22,3	3	1,9
Infections and infestations	Upper respiratory tract infection	35 - 54 letters	206	29,4	3	1,5
Infections and infestations	Upper respiratory tract infection	>=55 letters	339	48,4	11	3,2
Infections and infestations	Urinary tract candidiasis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Urinary tract candidiasis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Urinary tract candidiasis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Urinary tract infection	<=34 letters	156	22,3	3	1,9
Infections and infestations	Urinary tract infection	35 - 54 letters	206	29,4	6	2,9
Infections and infestations	Urinary tract infection	>=55 letters	339	48,4	5	1,5
Infections and infestations	Urosepsis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Urosepsis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Urosepsis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Viral rash	<=34 letters	156	22,3	0	0,0
Infections and infestations	Viral rash	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Viral rash	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications		<=34 letters	156	22,3	9	5,8
Injury, poisoning and procedural complications		35 - 54 letters	206	29,4	16	7,8
Injury, poisoning and procedural complications		>=55 letters	339	48,4	30	8,8
Injury, poisoning and procedural complications	Accident	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Accident	35 - 54 letters	206	29,4	0	0,0

Injury, poisoning and procedural complications	Soft tissue injury	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Soft tissue injury	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Sunburn	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Sunburn	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Sunburn	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Thermal burn	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Thermal burn	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Thermal burn	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	<=34 letters	156	22,3	1	0,6
Injury, poisoning and procedural complications	Tibia fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	>=55 letters	339	48,4	2	0,6
Injury, poisoning and procedural complications	Wrist fracture	<=34 letters	156	22,3	1	0,6
Injury, poisoning and procedural complications	Wrist fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	>=55 letters	339	48,4	2	0,6
Investigations		<=34 letters	156	22,3	10	6,4
Investigations		35 - 54 letters	206	29,4	19	9,2
Investigations		>=55 letters	339	48,4	33	9,7
Investigations	Alanine aminotransferase increased	<=34 letters	156	22,3	1	0,6
Investigations	Alanine aminotransferase increased	35 - 54 letters	206	29,4	0	0,0
Investigations	Alanine aminotransferase increased	>=55 letters	339	48,4	0	0,0
Investigations	Aspartate aminotransferase increased	<=34 letters	156	22,3	1	0,6
Investigations	Aspartate aminotransferase increased	35 - 54 letters	206	29,4	0	0,0
Investigations	Aspartate aminotransferase increased	>=55 letters	339	48,4	0	0,0
Investigations	Blood albumin increased	<=34 letters	156	22,3	1	0,6
Investigations	Blood albumin increased	35 - 54 letters	206	29,4	0	0,0
Investigations	Blood albumin increased	>=55 letters	339	48,4	0	0,0
Investigations	Blood bilirubin increased	<=34 letters	156	22,3	1	0,6
Investigations	Blood bilirubin increased	35 - 54 letters	206	29,4	0	0,0
Investigations	Blood bilirubin increased	>=55 letters	339	48,4	0	0,0
Investigations	Blood cholesterol increased	<=34 letters	156	22,3	0	0,0
Investigations	Blood cholesterol increased	35 - 54 letters	206	29,4	1	0,5
Investigations	Blood cholesterol increased	>=55 letters	339	48,4	1	0,3
Investigations	Blood creatinine increased	<=34 letters	156	22,3	1	0,6
Investigations	Blood creatinine increased	35 - 54 letters	206	29,4	0	0,0
Investigations	Blood creatinine increased	>=55 letters	339	48,4	1	0,3
Investigations	Blood glucose abnormal	<=34 letters	156	22,3	0	0,0
Investigations	Blood glucose abnormal	35 - 54 letters	206	29,4	0	0,0
Investigations	Blood glucose abnormal	>=55 letters	339	48,4	1	0,3
Investigations	Blood glucose increased	<=34 letters	156	22,3	2	1,3
Investigations	Blood glucose increased	35 - 54 letters	206	29,4	1	0,5
Investigations	Blood glucose increased	>=55 letters	339	48,4	1	0,3
Investigations	Blood potassium increased	<=34 letters	156	22,3	0	0,0
Investigations	Blood potassium increased	35 - 54 letters	206	29,4	1	0,5
Investigations	Blood potassium increased	>=55 letters	339	48,4	0	0,0
Investigations	Blood pressure decreased	<=34 letters	156	22,3	0	0,0
Investigations	Blood pressure decreased	35 - 54 letters	206	29,4	1	0,5
Investigations	Blood pressure decreased	>=55 letters	339	48,4	0	0,0
Investigations	Blood pressure increased	<=34 letters	156	22,3	1	0,6
Investigations	Blood pressure increased	35 - 54 letters	206	29,4	1	0,5
Investigations	Blood pressure increased	>=55 letters	339	48,4	1	0,3
Investigations	Blood testosterone decreased	<=34 letters	156	22,3	0	0,0
Investigations	Blood testosterone decreased	35 - 54 letters	206	29,4	0	0,0
Investigations	Blood testosterone decreased	>=55 letters	339	48,4	1	0,3
Investigations	Blood thyroid stimulating hormone increased	<=34 letters	156	22,3	0	0,0
Investigations	Blood thyroid stimulating hormone increased	35 - 54 letters	206	29,4	1	0,5
Investigations	Blood thyroid stimulating hormone increased	>=55 letters	339	48,4	0	0,0
Investigations	Blood triglycerides increased	<=34 letters	156	22,3	0	0,0
Investigations	Blood triglycerides increased	35 - 54 letters	206	29,4	0	0,0
Investigations	Blood triglycerides increased	>=55 letters	339	48,4	1	0,3
Investigations	Blood uric acid increased	<=34 letters	156	22,3	0	0,0
Investigations	Blood uric acid increased	35 - 54 letters	206	29,4	0	0,0
Investigations	Blood uric acid increased	>=55 letters	339	48,4	1	0,3
Investigations	Grip strength decreased	<=34 letters	156	22,3	0	0,0
Investigations	Grip strength decreased	35 - 54 letters	206	29,4	1	0,5
Investigations	Grip strength decreased	>=55 letters	339	48,4	0	0,0
Investigations	Haematocrit decreased	<=34 letters	156	22,3	1	0,6
Investigations	Haematocrit decreased	35 - 54 letters	206	29,4	0	0,0
Investigations	Haematocrit decreased	>=55 letters	339	48,4	0	0,0
Investigations	Haemoglobin decreased	<=34 letters	156	22,3	1	0,6
Investigations	Haemoglobin decreased	35 - 54 letters	206	29,4	0	0,0
Investigations	Haemoglobin decreased	>=55 letters	339	48,4	0	0,0
Investigations	Heart rate irregular	<=34 letters	156	22,3	0	0,0
Investigations	Heart rate irregular	35 - 54 letters	206	29,4	1	0,5
Investigations	Heart rate irregular	>=55 letters	339	48,4	0	0,0
Investigations	Intraocular pressure increased	<=34 letters	156	22,3	4	2,6
Investigations	Intraocular pressure increased	35 - 54 letters	206	29,4	9	4,4

Investigations	Intraocular pressure increased	>=55 letters	339	48,4	21	6,2
Investigations	Liver function test increased	<=34 letters	156	22,3	0	0,0
Investigations	Liver function test increased	35 - 54 letters	206	29,4	0	0,0
Investigations	Liver function test increased	>=55 letters	339	48,4	1	0,3
Investigations	Occult blood positive	<=34 letters	156	22,3	0	0,0
Investigations	Occult blood positive	35 - 54 letters	206	29,4	0	0,0
Investigations	Occult blood positive	>=55 letters	339	48,4	1	0,3
Investigations	Optic nerve cup/disc ratio increased	<=34 letters	156	22,3	0	0,0
Investigations	Optic nerve cup/disc ratio increased	35 - 54 letters	206	29,4	1	0,5
Investigations	Optic nerve cup/disc ratio increased	>=55 letters	339	48,4	0	0,0
Investigations	Red blood cell count decreased	<=34 letters	156	22,3	1	0,6
Investigations	Red blood cell count decreased	35 - 54 letters	206	29,4	0	0,0
Investigations	Red blood cell count decreased	>=55 letters	339	48,4	0	0,0
Investigations	SARS-CoV-2 test positive	<=34 letters	156	22,3	1	0,6
Investigations	SARS-CoV-2 test positive	35 - 54 letters	206	29,4	1	0,5
Investigations	SARS-CoV-2 test positive	>=55 letters	339	48,4	2	0,6
Investigations	Urinary occult blood	<=34 letters	156	22,3	0	0,0
Investigations	Urinary occult blood	35 - 54 letters	206	29,4	1	0,5
Investigations	Urinary occult blood	>=55 letters	339	48,4	0	0,0
Investigations	Weight decreased	<=34 letters	156	22,3	0	0,0
Investigations	Weight decreased	35 - 54 letters	206	29,4	0	0,0
Investigations	Weight decreased	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders		<=34 letters	156	22,3	8	5,1
Metabolism and nutrition disorders		35 - 54 letters	206	29,4	11	5,3
Metabolism and nutrition disorders		>=55 letters	339	48,4	15	4,4
Metabolism and nutrition disorders	Decreased appetite	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Decreased appetite	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Decreased appetite	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Dehydration	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Dehydration	35 - 54 letters	206	29,4	1	0,5
Metabolism and nutrition disorders	Dehydration	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Diabetes mellitus	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	>=55 letters	339	48,4	2	0,6
Metabolism and nutrition disorders	Dyslipidaemia	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Dyslipidaemia	35 - 54 letters	206	29,4	1	0,5
Metabolism and nutrition disorders	Dyslipidaemia	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Gout	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Gout	35 - 54 letters	206	29,4	2	1,0
Metabolism and nutrition disorders	Gout	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Hypercholesterolaemia	35 - 54 letters	206	29,4	4	1,9
Metabolism and nutrition disorders	Hypercholesterolaemia	>=55 letters	339	48,4	2	0,6
Metabolism and nutrition disorders	Hyperglycaemia	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Hyperglycaemia	35 - 54 letters	206	29,4	1	0,5
Metabolism and nutrition disorders	Hyperglycaemia	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hyperlipidaemia	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Hyperlipidaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hyperlipidaemia	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Hyperuricaemia	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Hyperuricaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hyperuricaemia	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Hypervolaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Hypokalaemia	<=34 letters	156	22,3	2	1,3
Metabolism and nutrition disorders	Hypokalaemia	35 - 54 letters	206	29,4	1	0,5
Metabolism and nutrition disorders	Hypokalaemia	>=55 letters	339	48,4	4	1,2
Metabolism and nutrition disorders	Hyponatraemia	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Type 2 diabetes mellitus	<=34 letters	156	22,3	2	1,3
Metabolism and nutrition disorders	Type 2 diabetes mellitus	35 - 54 letters	206	29,4	3	1,5
Metabolism and nutrition disorders	Type 2 diabetes mellitus	>=55 letters	339	48,4	3	0,9
Metabolism and nutrition disorders	Vitamin B12 deficiency	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Vitamin B12 deficiency	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Vitamin B12 deficiency	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Vitamin D deficiency	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Vitamin D deficiency	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Vitamin D deficiency	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders		<=34 letters	156	22,3	18	11,5
Musculoskeletal and connective tissue disorders		35 - 54 letters	206	29,4	14	6,8
Musculoskeletal and connective tissue disorders		>=55 letters	339	48,4	29	8,6
Musculoskeletal and connective tissue disorders	Arthralgia	<=34 letters	156	22,3	5	3,2
Musculoskeletal and connective tissue disorders	Arthralgia	35 - 54 letters	206	29,4	5	2,4

Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	>=55 letters	339	48,4	1	0,3
Musculoskeletal and connective tissue disorders	Tendonitis	<=34 letters	156	22,3	1	0,6
Musculoskeletal and connective tissue disorders	Tendonitis	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Tendonitis	>=55 letters	339	48,4	1	0,3
Musculoskeletal and connective tissue disorders	Trigger finger	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Trigger finger	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Trigger finger	>=55 letters	339	48,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=34 letters	156	22,3	4	2,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		35 - 54 letters	206	29,4	6	2,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=55 letters	339	48,4	6	1,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	<=34 letters	156	22,3	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	>=55 letters	339	48,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	<=34 letters	156	22,3	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	<=34 letters	156	22,3	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	>=55 letters	339	48,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	>=55 letters	339	48,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	>=55 letters	339	48,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	<=34 letters	156	22,3	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	>=55 letters	339	48,4	2	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	>=55 letters	339	48,4	0	0,0
Nervous system disorders		<=34 letters	156	22,3	11	7,1
Nervous system disorders		35 - 54 letters	206	29,4	15	7,3

Nervous system disorders		>=55 letters	339	48,4	25	7,4
Nervous system disorders	Autonomic neuropathy	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Autonomic neuropathy	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Autonomic neuropathy	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Balance disorder	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Balance disorder	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Balance disorder	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Carotid arteriosclerosis	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Carotid arteriosclerosis	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Carotid arteriosclerosis	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Carpal tunnel syndrome	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Carpal tunnel syndrome	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Carpal tunnel syndrome	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Cerebral atrophy	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Cerebral atrophy	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Cerebral atrophy	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Cerebral disorder	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Cerebral disorder	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Cerebral disorder	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Cerebral infarction	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Cerebral infarction	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Cerebral infarction	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Cerebrovascular accident	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Cerebrovascular accident	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Cerebrovascular accident	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Cervicobrachial syndrome	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Cervicobrachial syndrome	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Cervicobrachial syndrome	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Cognitive disorder	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Cognitive disorder	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Cognitive disorder	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Dementia Alzheimer's type	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Dementia Alzheimer's type	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Dementia Alzheimer's type	>=55 letters	339	48,4	2	0,6
Nervous system disorders	Diabetic neuropathy	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Diabetic neuropathy	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Diabetic neuropathy	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Dizziness	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Dizziness	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Dizziness	>=55 letters	339	48,4	6	1,8
Nervous system disorders	Dysarthria	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Dysarthria	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Dysarthria	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Encephalopathy	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Encephalopathy	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Encephalopathy	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Headache	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Headache	35 - 54 letters	206	29,4	6	2,9
Nervous system disorders	Headache	>=55 letters	339	48,4	4	1,2
Nervous system disorders	Hypoaesthesia	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Hypoaesthesia	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Hypoaesthesia	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Intercostal neuralgia	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Intercostal neuralgia	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Intercostal neuralgia	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Ischaemic stroke	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Ischaemic stroke	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Ischaemic stroke	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Lacunar infarction	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Lacunar infarction	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Lacunar infarction	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Loss of consciousness	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Loss of consciousness	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Loss of consciousness	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Lumbar radiculopathy	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Lumbar radiculopathy	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Lumbar radiculopathy	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Migraine	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Migraine	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Migraine	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Neuralgia	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Neuralgia	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Neuralgia	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Neuropathy peripheral	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Neuropathy peripheral	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Neuropathy peripheral	>=55 letters	339	48,4	2	0,6
Nervous system disorders	Ophthalmic migraine	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Ophthalmic migraine	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Ophthalmic migraine	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Paralysis	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Paralysis	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Paralysis	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Parkinsonism	<=34 letters	156	22,3	0	0,0

Nervous system disorders	Parkinsonism	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Parkinsonism	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Presyncope	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Presyncope	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Presyncope	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Sciatica	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Sciatica	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Sciatica	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Syncope	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Syncope	35 - 54 letters	206	29,4	2	1,0
Nervous system disorders	Syncope	>=55 letters	339	48,4	1	0,3
Product issues		<=34 letters	156	22,3	0	0,0
Product issues		35 - 54 letters	206	29,4	0	0,0
Product issues		>=55 letters	339	48,4	1	0,3
Product issues	Device physical property issue	<=34 letters	156	22,3	0	0,0
Product issues	Device physical property issue	35 - 54 letters	206	29,4	0	0,0
Product issues	Device physical property issue	>=55 letters	339	48,4	1	0,3
Psychiatric disorders		<=34 letters	156	22,3	2	1,3
Psychiatric disorders		35 - 54 letters	206	29,4	2	1,0
Psychiatric disorders		>=55 letters	339	48,4	5	1,5
Psychiatric disorders	Anxiety	<=34 letters	156	22,3	0	0,0
Psychiatric disorders	Anxiety	35 - 54 letters	206	29,4	0	0,0
Psychiatric disorders	Anxiety	>=55 letters	339	48,4	1	0,3
Psychiatric disorders	Attention deficit hyperactivity disorder	<=34 letters	156	22,3	0	0,0
Psychiatric disorders	Attention deficit hyperactivity disorder	35 - 54 letters	206	29,4	1	0,5
Psychiatric disorders	Attention deficit hyperactivity disorder	>=55 letters	339	48,4	0	0,0
Psychiatric disorders	Depression	<=34 letters	156	22,3	1	0,6
Psychiatric disorders	Depression	35 - 54 letters	206	29,4	0	0,0
Psychiatric disorders	Depression	>=55 letters	339	48,4	1	0,3
Psychiatric disorders	Generalised anxiety disorder	<=34 letters	156	22,3	0	0,0
Psychiatric disorders	Generalised anxiety disorder	35 - 54 letters	206	29,4	0	0,0
Psychiatric disorders	Generalised anxiety disorder	>=55 letters	339	48,4	1	0,3
Psychiatric disorders	Insomnia	<=34 letters	156	22,3	1	0,6
Psychiatric disorders	Insomnia	35 - 54 letters	206	29,4	1	0,5
Psychiatric disorders	Insomnia	>=55 letters	339	48,4	1	0,3
Psychiatric disorders	Sleep disorder	<=34 letters	156	22,3	0	0,0
Psychiatric disorders	Sleep disorder	35 - 54 letters	206	29,4	0	0,0
Psychiatric disorders	Sleep disorder	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders		<=34 letters	156	22,3	2	1,3
Renal and urinary disorders		35 - 54 letters	206	29,4	5	2,4
Renal and urinary disorders		>=55 letters	339	48,4	9	2,7
Renal and urinary disorders	Acute kidney injury	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Acute kidney injury	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Acute kidney injury	>=55 letters	339	48,4	3	0,9
Renal and urinary disorders	Cystitis interstitial	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Cystitis interstitial	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Cystitis interstitial	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Diabetic nephropathy	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Diabetic nephropathy	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Diabetic nephropathy	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Dysuria	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Dysuria	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Dysuria	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	End stage renal disease	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	End stage renal disease	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	End stage renal disease	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Haematuria	<=34 letters	156	22,3	1	0,6
Renal and urinary disorders	Haematuria	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Haematuria	>=55 letters	339	48,4	0	0,0
Renal and urinary disorders	Hypertonic bladder	<=34 letters	156	22,3	1	0,6
Renal and urinary disorders	Hypertonic bladder	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Hypertonic bladder	>=55 letters	339	48,4	0	0,0
Renal and urinary disorders	Nephrolithiasis	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Nephrolithiasis	35 - 54 letters	206	29,4	2	1,0
Renal and urinary disorders	Nephrolithiasis	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Nephropathy	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Nephropathy	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Nephropathy	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Renal failure	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Renal failure	35 - 54 letters	206	29,4	1	0,5
Renal and urinary disorders	Renal failure	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Urinary retention	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Urinary retention	35 - 54 letters	206	29,4	1	0,5
Renal and urinary disorders	Urinary retention	>=55 letters	339	48,4	0	0,0
Renal and urinary disorders	Urinary tract inflammation	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Urinary tract inflammation	35 - 54 letters	206	29,4	1	0,5
Renal and urinary disorders	Urinary tract inflammation	>=55 letters	339	48,4	0	0,0
Reproductive system and breast disorders		<=34 letters	156	22,3	2	1,3
Reproductive system and breast disorders		35 - 54 letters	206	29,4	0	0,0

Reproductive system and breast disorders		>=55 letters	339	48,4	4	1,2
Reproductive system and breast disorders	Benign prostatic hyperplasia	<=34 letters	156	22,3	2	0,3
Reproductive system and breast disorders	Benign prostatic hyperplasia	35 - 54 letters	206	29,4	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	>=55 letters	339	48,4	1	0,3
Reproductive system and breast disorders	Cystocele	<=34 letters	156	22,3	0	0,0
Reproductive system and breast disorders	Cystocele	35 - 54 letters	206	29,4	0	0,0
Reproductive system and breast disorders	Cystocele	>=55 letters	339	48,4	1	0,3
Reproductive system and breast disorders	Gynaecomastia	<=34 letters	156	22,3	0	0,0
Reproductive system and breast disorders	Gynaecomastia	35 - 54 letters	206	29,4	0	0,0
Reproductive system and breast disorders	Gynaecomastia	>=55 letters	339	48,4	1	0,3
Reproductive system and breast disorders	Prostatitis	<=34 letters	156	22,3	0	0,0
Reproductive system and breast disorders	Prostatitis	35 - 54 letters	206	29,4	0	0,0
Reproductive system and breast disorders	Prostatitis	>=55 letters	339	48,4	1	0,3
Reproductive system and breast disorders	Vaginal ulceration	<=34 letters	156	22,3	0	0,0
Reproductive system and breast disorders	Vaginal ulceration	35 - 54 letters	206	29,4	0	0,0
Reproductive system and breast disorders	Vaginal ulceration	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders		<=34 letters	156	22,3	9	5,8
Respiratory, thoracic and mediastinal disorders		35 - 54 letters	206	29,4	8	3,9
Respiratory, thoracic and mediastinal disorders		>=55 letters	339	48,4	14	4,1
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Asthma	<=34 letters	156	22,3	2	1,3
Respiratory, thoracic and mediastinal disorders	Asthma	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Asthma	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=55 letters	339	48,4	4	1,2
Respiratory, thoracic and mediastinal disorders	Cough	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Cough	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Cough	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Dry throat	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Dry throat	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Dry throat	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Dyspnoea	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Lung opacity	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung opacity	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung opacity	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Nasal congestion	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Nasal polyps	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	>=55 letters	339	48,4	3	0,9
Respiratory, thoracic and mediastinal disorders	Pleural thickening	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural thickening	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Pleural thickening	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Sinus disorder	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	>=55 letters	339	48,4	1	0,3

Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders		<=34 letters	156	22,3	7	4,5
Skin and subcutaneous tissue disorders		35 - 54 letters	206	29,4	7	3,4
Skin and subcutaneous tissue disorders		>=55 letters	339	48,4	8	2,4
Skin and subcutaneous tissue disorders	Androgenetic alopecia	<=34 letters	156	22,3	1	0,6
Skin and subcutaneous tissue disorders	Androgenetic alopecia	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Dermal cyst	<=34 letters	156	22,3	1	0,6
Skin and subcutaneous tissue disorders	Dermal cyst	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Dermal cyst	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	35 - 54 letters	206	29,4	1	0,5
Skin and subcutaneous tissue disorders	Dermatitis	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis allergic	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis allergic	35 - 54 letters	206	29,4	1	0,5
Skin and subcutaneous tissue disorders	Dermatitis allergic	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	<=34 letters	156	22,3	3	1,9
Skin and subcutaneous tissue disorders	Dermatitis contact	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	>=55 letters	339	48,4	2	0,6
Skin and subcutaneous tissue disorders	Eczema	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Eczema	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Eczema	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Erythema	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Erythema	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Erythema	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Hyperkeratosis	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Hyperkeratosis	35 - 54 letters	206	29,4	1	0,5
Skin and subcutaneous tissue disorders	Hyperkeratosis	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Ingrowing nail	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Ingrowing nail	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Ingrowing nail	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Nail bed bleeding	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Nail dystrophy	<=34 letters	156	22,3	1	0,6
Skin and subcutaneous tissue disorders	Nail dystrophy	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Purpura	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Purpura	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Purpura	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Rash	<=34 letters	156	22,3	1	0,6
Skin and subcutaneous tissue disorders	Rash	35 - 54 letters	206	29,4	3	1,5
Skin and subcutaneous tissue disorders	Rash	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Skin lesion	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Skin lesion	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Skin lesion	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Skin ulcer	<=34 letters	156	22,3	1	0,6
Skin and subcutaneous tissue disorders	Skin ulcer	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Toxic skin eruption	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Toxic skin eruption	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Toxic skin eruption	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Urticaria	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	35 - 54 letters	206	29,4	1	0,5
Skin and subcutaneous tissue disorders	Urticaria	>=55 letters	339	48,4	0	0,0
Surgical and medical procedures		<=34 letters	156	22,3	1	0,6
Surgical and medical procedures		35 - 54 letters	206	29,4	3	1,5
Surgical and medical procedures		>=55 letters	339	48,4	6	1,8
Surgical and medical procedures	Dental implantation	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Dental implantation	35 - 54 letters	206	29,4	1	0,5
Surgical and medical procedures	Dental implantation	>=55 letters	339	48,4	2	0,6
Surgical and medical procedures	Large intestinal polypectomy	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	>=55 letters	339	48,4	1	0,3
Surgical and medical procedures	Ligament operation	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Ligament operation	35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures	Ligament operation	>=55 letters	339	48,4	1	0,3
Surgical and medical procedures	Neurectomy	<=34 letters	156	22,3	1	0,6
Surgical and medical procedures	Neurectomy	35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures	Neurectomy	>=55 letters	339	48,4	0	0,0

Surgical and medical procedures	Renal transplant	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Renal transplant	35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures	Renal transplant	>=55 letters	339	48,4	1	0,3
Surgical and medical procedures	Toe operation	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Toe operation	35 - 54 letters	206	29,4	1	0,5
Surgical and medical procedures	Toe operation	>=55 letters	339	48,4	0	0,0
Surgical and medical procedures	Tooth extraction	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Tooth extraction	35 - 54 letters	206	29,4	2	1,0
Surgical and medical procedures	Tooth extraction	>=55 letters	339	48,4	2	0,6
Vascular disorders		<=34 letters	156	22,3	9	5,8
Vascular disorders		35 - 54 letters	206	29,4	11	5,3
Vascular disorders		>=55 letters	339	48,4	19	5,6
Vascular disorders	Aortic aneurysm	<=34 letters	156	22,3	0	0,0
Vascular disorders	Aortic aneurysm	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Aortic aneurysm	>=55 letters	339	48,4	1	0,3
Vascular disorders	Aortic dissection	<=34 letters	156	22,3	0	0,0
Vascular disorders	Aortic dissection	35 - 54 letters	206	29,4	1	0,5
Vascular disorders	Aortic dissection	>=55 letters	339	48,4	0	0,0
Vascular disorders	Aortic stenosis	<=34 letters	156	22,3	0	0,0
Vascular disorders	Aortic stenosis	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Aortic stenosis	>=55 letters	339	48,4	1	0,3
Vascular disorders	Deep vein thrombosis	<=34 letters	156	22,3	0	0,0
Vascular disorders	Deep vein thrombosis	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Deep vein thrombosis	>=55 letters	339	48,4	1	0,3
Vascular disorders	Haematoma	<=34 letters	156	22,3	0	0,0
Vascular disorders	Haematoma	35 - 54 letters	206	29,4	1	0,5
Vascular disorders	Haematoma	>=55 letters	339	48,4	0	0,0
Vascular disorders	Haemorrhage	<=34 letters	156	22,3	0	0,0
Vascular disorders	Haemorrhage	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Haemorrhage	>=55 letters	339	48,4	1	0,3
Vascular disorders	Hypertension	<=34 letters	156	22,3	5	3,2
Vascular disorders	Hypertension	35 - 54 letters	206	29,4	7	3,4
Vascular disorders	Hypertension	>=55 letters	339	48,4	11	3,2
Vascular disorders	Hypertensive crisis	<=34 letters	156	22,3	0	0,0
Vascular disorders	Hypertensive crisis	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Hypertensive crisis	>=55 letters	339	48,4	3	0,9
Vascular disorders	Hypotension	<=34 letters	156	22,3	1	0,6
Vascular disorders	Hypotension	35 - 54 letters	206	29,4	1	0,5
Vascular disorders	Hypotension	>=55 letters	339	48,4	2	0,6
Vascular disorders	Internal haemorrhage	<=34 letters	156	22,3	0	0,0
Vascular disorders	Internal haemorrhage	35 - 54 letters	206	29,4	1	0,5
Vascular disorders	Internal haemorrhage	>=55 letters	339	48,4	0	0,0
Vascular disorders	Lymphoedema	<=34 letters	156	22,3	1	0,6
Vascular disorders	Lymphoedema	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Lymphoedema	>=55 letters	339	48,4	0	0,0
Vascular disorders	Peripheral artery aneurysm	<=34 letters	156	22,3	1	0,6
Vascular disorders	Peripheral artery aneurysm	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Peripheral artery aneurysm	>=55 letters	339	48,4	0	0,0
Vascular disorders	Secondary hypertension	<=34 letters	156	22,3	0	0,0
Vascular disorders	Secondary hypertension	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Secondary hypertension	>=55 letters	339	48,4	1	0,3
Vascular disorders	Thrombosis	<=34 letters	156	22,3	1	0,6
Vascular disorders	Thrombosis	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Thrombosis	>=55 letters	339	48,4	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_eg_AE_WK72_SEa24_29AUG2023_41986.xls
26APR2024 18:00

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Any AEs

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETDRS letter score

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Blood and lymphatic system disorders		<=23 letters	69	9,8	1	1,4
Blood and lymphatic system disorders		>=24 letters	632	90,2	9	1,4
Blood and lymphatic system disorders	Anaemia	<=23 letters	69	9,8	1	1,4
Blood and lymphatic system disorders	Anaemia	>=24 letters	632	90,2	7	1,1
Blood and lymphatic system disorders	Deficiency anaemia	<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	>=24 letters	632	90,2	1	0,2
Blood and lymphatic system disorders	Iron deficiency anaemia	<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders	Iron deficiency anaemia	>=24 letters	632	90,2	1	0,2
Blood and lymphatic system disorders	Mesenteric lymphadenitis	<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	>=24 letters	632	90,2	1	0,2
Cardiac disorders		<=23 letters	69	9,8	3	4,3
Cardiac disorders		>=24 letters	632	90,2	27	4,3
Cardiac disorders	Acute left ventricular failure	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Acute left ventricular failure	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Acute myocardial infarction	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Acute myocardial infarction	>=24 letters	632	90,2	2	0,3
Cardiac disorders	Aortic valve incompetence	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Aortic valve incompetence	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Arrhythmia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Arrhythmia	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Atrial fibrillation	<=23 letters	69	9,8	1	1,4
Cardiac disorders	Atrial fibrillation	>=24 letters	632	90,2	8	1,3
Cardiac disorders	Bradycardia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Bradycardia	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Cardiac failure	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Cardiac failure	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Cardiac failure congestive	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Cardiac failure congestive	>=24 letters	632	90,2	2	0,3
Cardiac disorders	Cardiomegaly	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Cardiomegaly	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Coronary artery disease	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Coronary artery disease	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Coronary artery stenosis	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Coronary artery stenosis	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Left ventricular dysfunction	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Left ventricular dysfunction	>=24 letters	632	90,2	2	0,3
Cardiac disorders	Myocardial infarction	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Myocardial infarction	>=24 letters	632	90,2	3	0,5
Cardiac disorders	Myocardial ischaemia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Myocardial ischaemia	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Palpitations	<=23 letters	69	9,8	1	1,4
Cardiac disorders	Palpitations	>=24 letters	632	90,2	0	0,0
Cardiac disorders	Pericardial effusion	<=23 letters	69	9,8	1	1,4
Cardiac disorders	Pericardial effusion	>=24 letters	632	90,2	0	0,0
Cardiac disorders	Sinus tachycardia	<=23 letters	69	9,8	0	0,0

Cardiac disorders	Sinus tachycardia	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Stress cardiomyopathy	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Stress cardiomyopathy	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Supraventricular tachycardia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Supraventricular tachycardia	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Tachycardia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Tachycardia	>=24 letters	632	90,2	2	0,3
Congenital, familial and genetic disorders		<=23 letters	69	9,8	0	0,0
Congenital, familial and genetic disorders		>=24 letters	632	90,2	2	0,3
Congenital, familial and genetic disorders	Corneal dystrophy	<=23 letters	69	9,8	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	>=24 letters	632	90,2	2	0,3
Ear and labyrinth disorders		<=23 letters	69	9,8	0	0,0
Ear and labyrinth disorders		>=24 letters	632	90,2	4	0,6
Ear and labyrinth disorders	Vertigo	<=23 letters	69	9,8	0	0,0
Ear and labyrinth disorders	Vertigo	>=24 letters	632	90,2	4	0,6
Endocrine disorders		<=23 letters	69	9,8	0	0,0
Endocrine disorders		>=24 letters	632	90,2	10	1,6
Endocrine disorders	Adrenal insufficiency	<=23 letters	69	9,8	0	0,0
Endocrine disorders	Adrenal insufficiency	>=24 letters	632	90,2	1	0,2
Endocrine disorders	Adrenal mass	<=23 letters	69	9,8	0	0,0
Endocrine disorders	Adrenal mass	>=24 letters	632	90,2	2	0,3
Endocrine disorders	Adrenomegaly	<=23 letters	69	9,8	0	0,0
Endocrine disorders	Adrenomegaly	>=24 letters	632	90,2	1	0,2
Endocrine disorders	Androgen deficiency	<=23 letters	69	9,8	0	0,0
Endocrine disorders	Androgen deficiency	>=24 letters	632	90,2	1	0,2
Endocrine disorders	Goitre	<=23 letters	69	9,8	0	0,0
Endocrine disorders	Goitre	>=24 letters	632	90,2	1	0,2
Endocrine disorders	Hypothyroidism	<=23 letters	69	9,8	0	0,0
Endocrine disorders	Hypothyroidism	>=24 letters	632	90,2	4	0,6
Endocrine disorders	Thyroid cyst	<=23 letters	69	9,8	0	0,0
Endocrine disorders	Thyroid cyst	>=24 letters	632	90,2	1	0,2
Endocrine disorders	Thyroid mass	<=23 letters	69	9,8	0	0,0
Endocrine disorders	Thyroid mass	>=24 letters	632	90,2	1	0,2
Eye disorders		<=23 letters	69	9,8	28	40,6
Eye disorders		>=24 letters	632	90,2	234	37,0
Eye disorders	Age-related macular degeneration	<=23 letters	69	9,8	0	0,0
Eye disorders	Age-related macular degeneration	>=24 letters	632	90,2	1	0,2
Eye disorders	Anisocoria	<=23 letters	69	9,8	1	1,4
Eye disorders	Anisocoria	>=24 letters	632	90,2	0	0,0
Eye disorders	Asthenopia	<=23 letters	69	9,8	0	0,0
Eye disorders	Asthenopia	>=24 letters	632	90,2	2	0,3
Eye disorders	Blepharitis	<=23 letters	69	9,8	1	1,4
Eye disorders	Blepharitis	>=24 letters	632	90,2	4	0,6
Eye disorders	Borderline glaucoma	<=23 letters	69	9,8	0	0,0
Eye disorders	Borderline glaucoma	>=24 letters	632	90,2	2	0,3
Eye disorders	Cataract	<=23 letters	69	9,8	6	8,7
Eye disorders	Cataract	>=24 letters	632	90,2	28	4,4
Eye disorders	Cataract nuclear	<=23 letters	69	9,8	0	0,0
Eye disorders	Cataract nuclear	>=24 letters	632	90,2	1	0,2
Eye disorders	Cataract subcapsular	<=23 letters	69	9,8	0	0,0
Eye disorders	Cataract subcapsular	>=24 letters	632	90,2	1	0,2
Eye disorders	Central serous chorioretinopathy	<=23 letters	69	9,8	0	0,0
Eye disorders	Central serous chorioretinopathy	>=24 letters	632	90,2	4	0,6
Eye disorders	Chalazion	<=23 letters	69	9,8	1	1,4
Eye disorders	Chalazion	>=24 letters	632	90,2	3	0,5

Eye disorders	Choroidal effusion	<=23 letters	69	9,8	0	0,0
Eye disorders	Choroidal effusion	>=24 letters	632	90,2	1	0,2
Eye disorders	Conjunctival haemorrhage	<=23 letters	69	9,8	2	2,9
Eye disorders	Conjunctival haemorrhage	>=24 letters	632	90,2	19	3,0
Eye disorders	Conjunctival hyperaemia	<=23 letters	69	9,8	0	0,0
Eye disorders	Conjunctival hyperaemia	>=24 letters	632	90,2	2	0,3
Eye disorders	Conjunctival telangiectasia	<=23 letters	69	9,8	0	0,0
Eye disorders	Conjunctival telangiectasia	>=24 letters	632	90,2	1	0,2
Eye disorders	Conjunctivitis allergic	<=23 letters	69	9,8	0	0,0
Eye disorders	Conjunctivitis allergic	>=24 letters	632	90,2	1	0,2
Eye disorders	Corneal deposits	<=23 letters	69	9,8	0	0,0
Eye disorders	Corneal deposits	>=24 letters	632	90,2	1	0,2
Eye disorders	Corneal erosion	<=23 letters	69	9,8	0	0,0
Eye disorders	Corneal erosion	>=24 letters	632	90,2	1	0,2
Eye disorders	Corneal infiltrates	<=23 letters	69	9,8	0	0,0
Eye disorders	Corneal infiltrates	>=24 letters	632	90,2	1	0,2
Eye disorders	Corneal opacity	<=23 letters	69	9,8	0	0,0
Eye disorders	Corneal opacity	>=24 letters	632	90,2	1	0,2
Eye disorders	Corneal pigmentation	<=23 letters	69	9,8	0	0,0
Eye disorders	Corneal pigmentation	>=24 letters	632	90,2	1	0,2
Eye disorders	Cystoid macular oedema	<=23 letters	69	9,8	3	4,3
Eye disorders	Cystoid macular oedema	>=24 letters	632	90,2	25	4,0
Eye disorders	Detachment of retinal pigment epithelium	<=23 letters	69	9,8	0	0,0
Eye disorders	Detachment of retinal pigment epithelium	>=24 letters	632	90,2	2	0,3
Eye disorders	Diabetic retinal oedema	<=23 letters	69	9,8	0	0,0
Eye disorders	Diabetic retinal oedema	>=24 letters	632	90,2	1	0,2
Eye disorders	Diabetic retinopathy	<=23 letters	69	9,8	0	0,0
Eye disorders	Diabetic retinopathy	>=24 letters	632	90,2	2	0,3
Eye disorders	Diplopia	<=23 letters	69	9,8	0	0,0
Eye disorders	Diplopia	>=24 letters	632	90,2	1	0,2
Eye disorders	Dry age-related macular degeneration	<=23 letters	69	9,8	0	0,0
Eye disorders	Dry age-related macular degeneration	>=24 letters	632	90,2	1	0,2
Eye disorders	Dry eye	<=23 letters	69	9,8	1	1,4
Eye disorders	Dry eye	>=24 letters	632	90,2	14	2,2
Eye disorders	Eczema eyelids	<=23 letters	69	9,8	0	0,0
Eye disorders	Eczema eyelids	>=24 letters	632	90,2	1	0,2
Eye disorders	Epiretinal membrane	<=23 letters	69	9,8	1	1,4
Eye disorders	Epiretinal membrane	>=24 letters	632	90,2	16	2,5
Eye disorders	Episcleritis	<=23 letters	69	9,8	0	0,0
Eye disorders	Episcleritis	>=24 letters	632	90,2	1	0,2
Eye disorders	Eye irritation	<=23 letters	69	9,8	0	0,0
Eye disorders	Eye irritation	>=24 letters	632	90,2	1	0,2
Eye disorders	Eye pain	<=23 letters	69	9,8	0	0,0
Eye disorders	Eye pain	>=24 letters	632	90,2	10	1,6
Eye disorders	Eye pruritus	<=23 letters	69	9,8	0	0,0
Eye disorders	Eye pruritus	>=24 letters	632	90,2	4	0,6
Eye disorders	Eyelid cyst	<=23 letters	69	9,8	0	0,0
Eye disorders	Eyelid cyst	>=24 letters	632	90,2	1	0,2
Eye disorders	Eyelid oedema	<=23 letters	69	9,8	1	1,4
Eye disorders	Eyelid oedema	>=24 letters	632	90,2	0	0,0
Eye disorders	Foreign body sensation in eyes	<=23 letters	69	9,8	0	0,0
Eye disorders	Foreign body sensation in eyes	>=24 letters	632	90,2	3	0,5
Eye disorders	Glaucoma	<=23 letters	69	9,8	1	1,4
Eye disorders	Glaucoma	>=24 letters	632	90,2	14	2,2
Eye disorders	Hypotony of eye	<=23 letters	69	9,8	0	0,0
Eye disorders	Hypotony of eye	>=24 letters	632	90,2	1	0,2
Eye disorders	Iridocyclitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Iridocyclitis	>=24 letters	632	90,2	7	1,1
Eye disorders	Irises neovascularisation	<=23 letters	69	9,8	0	0,0

Eye disorders	Iris neovascularisation	>=24 letters	632	90,2	2	0,3
Eye disorders	Iritis	<=23 letters	69	9,8	0	0,0
Eye disorders	Iritis	>=24 letters	632	90,2	4	0,6
Eye disorders	Keratic precipitates	<=23 letters	69	9,8	0	0,0
Eye disorders	Keratic precipitates	>=24 letters	632	90,2	1	0,2
Eye disorders	Keratitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Keratitis	>=24 letters	632	90,2	2	0,3
Eye disorders	Keratopathy	<=23 letters	69	9,8	0	0,0
Eye disorders	Keratopathy	>=24 letters	632	90,2	1	0,2
Eye disorders	Lacrimonal disorder	<=23 letters	69	9,8	0	0,0
Eye disorders	Lacrimonal disorder	>=24 letters	632	90,2	1	0,2
Eye disorders	Lacrimation increased	<=23 letters	69	9,8	0	0,0
Eye disorders	Lacrimation increased	>=24 letters	632	90,2	5	0,8
Eye disorders	Lenticular opacities	<=23 letters	69	9,8	0	0,0
Eye disorders	Lenticular opacities	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular degeneration	<=23 letters	69	9,8	1	1,4
Eye disorders	Macular degeneration	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular detachment	<=23 letters	69	9,8	1	1,4
Eye disorders	Macular detachment	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular hole	<=23 letters	69	9,8	0	0,0
Eye disorders	Macular hole	>=24 letters	632	90,2	2	0,3
Eye disorders	Macular ischaemia	<=23 letters	69	9,8	0	0,0
Eye disorders	Macular ischaemia	>=24 letters	632	90,2	2	0,3
Eye disorders	Macular oedema	<=23 letters	69	9,8	4	5,8
Eye disorders	Macular oedema	>=24 letters	632	90,2	22	3,5
Eye disorders	Macular scar	<=23 letters	69	9,8	1	1,4
Eye disorders	Macular scar	>=24 letters	632	90,2	0	0,0
Eye disorders	Meibomianitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Meibomianitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Neovascular age-related macular degeneration	<=23 letters	69	9,8	0	0,0
Eye disorders	Neovascular age-related macular degeneration	>=24 letters	632	90,2	1	0,2
Eye disorders	Non-infectious endophthalmitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Non-infectious endophthalmitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Noninfective conjunctivitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Noninfective conjunctivitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Normal tension glaucoma	<=23 letters	69	9,8	0	0,0
Eye disorders	Normal tension glaucoma	>=24 letters	632	90,2	1	0,2
Eye disorders	Ocular hyperaemia	<=23 letters	69	9,8	0	0,0
Eye disorders	Ocular hyperaemia	>=24 letters	632	90,2	2	0,3
Eye disorders	Ocular hypertension	<=23 letters	69	9,8	1	1,4
Eye disorders	Ocular hypertension	>=24 letters	632	90,2	11	1,7
Eye disorders	Open angle glaucoma	<=23 letters	69	9,8	1	1,4
Eye disorders	Open angle glaucoma	>=24 letters	632	90,2	1	0,2
Eye disorders	Optic atrophy	<=23 letters	69	9,8	0	0,0
Eye disorders	Optic atrophy	>=24 letters	632	90,2	1	0,2
Eye disorders	Optic disc disorder	<=23 letters	69	9,8	0	0,0
Eye disorders	Optic disc disorder	>=24 letters	632	90,2	1	0,2
Eye disorders	Optic disc haemorrhage	<=23 letters	69	9,8	0	0,0
Eye disorders	Optic disc haemorrhage	>=24 letters	632	90,2	3	0,5
Eye disorders	Optic disc vascular disorder	<=23 letters	69	9,8	1	1,4
Eye disorders	Optic disc vascular disorder	>=24 letters	632	90,2	0	0,0
Eye disorders	Papilloedema	<=23 letters	69	9,8	0	0,0
Eye disorders	Papilloedema	>=24 letters	632	90,2	2	0,3
Eye disorders	Periorbital pain	<=23 letters	69	9,8	0	0,0
Eye disorders	Periorbital pain	>=24 letters	632	90,2	1	0,2
Eye disorders	Photopsia	<=23 letters	69	9,8	0	0,0
Eye disorders	Photopsia	>=24 letters	632	90,2	2	0,3
Eye disorders	Pinguecula	<=23 letters	69	9,8	0	0,0
Eye disorders	Pinguecula	>=24 letters	632	90,2	1	0,2

Eye disorders	Posterior capsule opacification	<=23 letters	69	9,8	1	1,4
Eye disorders	Posterior capsule opacification	>=24 letters	632	90,2	6	0,9
Eye disorders	Punctate keratitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Punctate keratitis	>=24 letters	632	90,2	6	0,9
Eye disorders	Retinal aneurysm	<=23 letters	69	9,8	1	1,4
Eye disorders	Retinal aneurysm	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal artery embolism	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal artery embolism	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal artery occlusion	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal artery occlusion	>=24 letters	632	90,2	4	0,6
Eye disorders	Retinal collateral vessels	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal collateral vessels	>=24 letters	632	90,2	3	0,5
Eye disorders	Retinal depigmentation	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal depigmentation	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal detachment	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal detachment	>=24 letters	632	90,2	2	0,3
Eye disorders	Retinal disorder	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal disorder	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal drusen	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal drusen	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal exudates	<=23 letters	69	9,8	1	1,4
Eye disorders	Retinal exudates	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal haemorrhage	<=23 letters	69	9,8	1	1,4
Eye disorders	Retinal haemorrhage	>=24 letters	632	90,2	6	0,9
Eye disorders	Retinal ischaemia	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal ischaemia	>=24 letters	632	90,2	2	0,3
Eye disorders	Retinal neovascularisation	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal neovascularisation	>=24 letters	632	90,2	3	0,5
Eye disorders	Retinal tear	<=23 letters	69	9,8	1	1,4
Eye disorders	Retinal tear	>=24 letters	632	90,2	2	0,3
Eye disorders	Retinal vein occlusion	<=23 letters	69	9,8	3	4,3
Eye disorders	Retinal vein occlusion	>=24 letters	632	90,2	20	3,2
Eye disorders	Retinopathy hypertensive	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinopathy hypertensive	>=24 letters	632	90,2	1	0,2
Eye disorders	Subretinal fluid	<=23 letters	69	9,8	0	0,0
Eye disorders	Subretinal fluid	>=24 letters	632	90,2	1	0,2
Eye disorders	Uveitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Uveitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Vision blurred	<=23 letters	69	9,8	0	0,0
Eye disorders	Vision blurred	>=24 letters	632	90,2	3	0,5
Eye disorders	Visual acuity reduced	<=23 letters	69	9,8	0	0,0
Eye disorders	Visual acuity reduced	>=24 letters	632	90,2	8	1,3
Eye disorders	Visual acuity reduced transiently	<=23 letters	69	9,8	0	0,0
Eye disorders	Visual acuity reduced transiently	>=24 letters	632	90,2	1	0,2
Eye disorders	Visual field defect	<=23 letters	69	9,8	0	0,0
Eye disorders	Visual field defect	>=24 letters	632	90,2	1	0,2
Eye disorders	Visual impairment	<=23 letters	69	9,8	1	1,4
Eye disorders	Visual impairment	>=24 letters	632	90,2	3	0,5
Eye disorders	Vitreoretinal traction syndrome	<=23 letters	69	9,8	0	0,0
Eye disorders	Vitreoretinal traction syndrome	>=24 letters	632	90,2	3	0,5
Eye disorders	Vitreous detachment	<=23 letters	69	9,8	1	1,4
Eye disorders	Vitreous detachment	>=24 letters	632	90,2	28	4,4
Eye disorders	Vitreous floaters	<=23 letters	69	9,8	2	2,9
Eye disorders	Vitreous floaters	>=24 letters	632	90,2	8	1,3
Eye disorders	Vitreous haemorrhage	<=23 letters	69	9,8	2	2,9
Eye disorders	Vitreous haemorrhage	>=24 letters	632	90,2	2	0,3
Eye disorders	Vitreous opacities	<=23 letters	69	9,8	1	1,4
Eye disorders	Vitreous opacities	>=24 letters	632	90,2	0	0,0
Eye disorders	Vitritis	<=23 letters	69	9,8	0	0,0

Eye disorders	Vitritis	>=24 letters	632	90,2	4	0,6
Gastrointestinal disorders		<=23 letters	69	9,8	3	4,3
Gastrointestinal disorders		>=24 letters	632	90,2	39	6,2
Gastrointestinal disorders	Abdominal discomfort	<=23 letters	69	9,8	1	1,4
Gastrointestinal disorders	Abdominal discomfort	>=24 letters	632	90,2	0	0,0
Gastrointestinal disorders	Abdominal pain	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Abdominal pain	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Abdominal pain upper	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Abdominal pain upper	>=24 letters	632	90,2	2	0,3
Gastrointestinal disorders	Barrett's oesophagus	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Chronic gastritis	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Chronic gastritis	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Coeliac disease	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Coeliac disease	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Colitis	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Colitis	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Constipation	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Constipation	>=24 letters	632	90,2	5	0,8
Gastrointestinal disorders	Dental discomfort	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Dental discomfort	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Diarrhoea	<=23 letters	69	9,8	2	2,9
Gastrointestinal disorders	Diarrhoea	>=24 letters	632	90,2	9	1,4
Gastrointestinal disorders	Diverticulum intestinal	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Diverticulum intestinal	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Duodenal ulcer haemorrhage	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Duodenitis	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Duodenitis	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Dyspepsia	<=23 letters	69	9,8	1	1,4
Gastrointestinal disorders	Dyspepsia	>=24 letters	632	90,2	0	0,0
Gastrointestinal disorders	Gastric ulcer	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastric ulcer	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Gastritis	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastritis	>=24 letters	632	90,2	3	0,5
Gastrointestinal disorders	Gastrointestinal inflammation	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Gastrooesophageal reflux disease	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	>=24 letters	632	90,2	2	0,3
Gastrointestinal disorders	Haemorrhagic erosive gastritis	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Haemorrhagic erosive gastritis	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Haemorrhoids	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Haemorrhoids	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Hiatus hernia	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Hiatus hernia	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Ileus	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Ileus	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Inguinal hernia	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Inguinal hernia	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Large intestine polyp	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Large intestine polyp	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Nausea	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Nausea	>=24 letters	632	90,2	3	0,5
Gastrointestinal disorders	Pancreatitis	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Pancreatitis	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Pancreatitis acute	<=23 letters	69	9,8	0	0,0

Gastrointestinal disorders	Pancreatitis acute	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Pulpless tooth	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Pulpless tooth	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Salivary gland disorder	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Salivary gland disorder	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Toothache	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Toothache	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Umbilical hernia	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Umbilical hernia	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Vomiting	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Vomiting	>=24 letters	632	90,2	2	0,3
General disorders and administration site conditions		<=23 letters	69	9,8	3	4,3
General disorders and administration site conditions		>=24 letters	632	90,2	29	4,6
General disorders and administration site conditions	Asthenia	<=23 letters	69	9,8	1	1,4
General disorders and administration site conditions	Asthenia	>=24 letters	632	90,2	6	0,9
General disorders and administration site conditions	Chest pain	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Chest pain	>=24 letters	632	90,2	4	0,6
General disorders and administration site conditions	Chills	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Chills	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Death	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Death	>=24 letters	632	90,2	2	0,3
General disorders and administration site conditions	Drug intolerance	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Drug intolerance	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Drug withdrawal syndrome	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Drug withdrawal syndrome	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Fatigue	<=23 letters	69	9,8	1	1,4
General disorders and administration site conditions	Fatigue	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Injection site pain	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Injection site pain	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Injection site reaction	<=23 letters	69	9,8	1	1,4
General disorders and administration site conditions	Injection site reaction	>=24 letters	632	90,2	0	0,0
General disorders and administration site conditions	Oedema peripheral	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Oedema peripheral	>=24 letters	632	90,2	4	0,6
General disorders and administration site conditions	Pain	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Pain	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Peripheral swelling	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Peripheral swelling	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Polyp	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Polyp	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Pyrexia	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Pyrexia	>=24 letters	632	90,2	5	0,8
General disorders and administration site conditions	Stent-graft endoleak	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Systemic inflammatory response syndrome	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	>=24 letters	632	90,2	1	0,2
Hepatobiliary disorders		<=23 letters	69	9,8	1	1,4
Hepatobiliary disorders		>=24 letters	632	90,2	7	1,1
Hepatobiliary disorders	Cholecystitis	<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders	Cholecystitis	>=24 letters	632	90,2	1	0,2
Hepatobiliary disorders	Cholelithiasis	<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders	Cholelithiasis	>=24 letters	632	90,2	4	0,6
Hepatobiliary disorders	Hepatic cyst	<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders	Hepatic cyst	>=24 letters	632	90,2	1	0,2
Hepatobiliary disorders	Hepatic steatosis	<=23 letters	69	9,8	1	1,4
Hepatobiliary disorders	Hepatic steatosis	>=24 letters	632	90,2	2	0,3
Hepatobiliary disorders	Portal hypertension	<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders	Portal hypertension	>=24 letters	632	90,2	1	0,2

Immune system disorders		<=23 letters	69	9,8	1	1,4
Immune system disorders		>=24 letters	632	90,2	10	1,6
Immune system disorders	Contrast media allergy	<=23 letters	69	9,8	0	0,0
Immune system disorders	Contrast media allergy	>=24 letters	632	90,2	3	0,5
Immune system disorders	Contrast media reaction	<=23 letters	69	9,8	1	1,4
Immune system disorders	Contrast media reaction	>=24 letters	632	90,2	0	0,0
Immune system disorders	Drug hypersensitivity	<=23 letters	69	9,8	0	0,0
Immune system disorders	Drug hypersensitivity	>=24 letters	632	90,2	1	0,2
Immune system disorders	Food allergy	<=23 letters	69	9,8	0	0,0
Immune system disorders	Food allergy	>=24 letters	632	90,2	1	0,2
Immune system disorders	Iodine allergy	<=23 letters	69	9,8	0	0,0
Immune system disorders	Iodine allergy	>=24 letters	632	90,2	1	0,2
Immune system disorders	Seasonal allergy	<=23 letters	69	9,8	0	0,0
Immune system disorders	Seasonal allergy	>=24 letters	632	90,2	4	0,6
Infections and infestations		<=23 letters	69	9,8	17	24,6
Infections and infestations		>=24 letters	632	90,2	208	32,9
Infections and infestations	Adenoviral conjunctivitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Adenoviral conjunctivitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Arthritis infective	<=23 letters	69	9,8	0	0,0
Infections and infestations	Arthritis infective	>=24 letters	632	90,2	1	0,2
Infections and infestations	Bronchitis	<=23 letters	69	9,8	1	1,4
Infections and infestations	Bronchitis	>=24 letters	632	90,2	8	1,3
Infections and infestations	COVID-19	<=23 letters	69	9,8	7	10,1
Infections and infestations	COVID-19	>=24 letters	632	90,2	84	13,3
Infections and infestations	COVID-19 pneumonia	<=23 letters	69	9,8	0	0,0
Infections and infestations	COVID-19 pneumonia	>=24 letters	632	90,2	1	0,2
Infections and infestations	Cellulitis	<=23 letters	69	9,8	1	1,4
Infections and infestations	Cellulitis	>=24 letters	632	90,2	6	0,9
Infections and infestations	Chronic sinusitis	<=23 letters	69	9,8	1	1,4
Infections and infestations	Chronic sinusitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Clostridium difficile infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Clostridium difficile infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Conjunctivitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Conjunctivitis	>=24 letters	632	90,2	14	2,2
Infections and infestations	Conjunctivitis bacterial	<=23 letters	69	9,8	0	0,0
Infections and infestations	Conjunctivitis bacterial	>=24 letters	632	90,2	1	0,2
Infections and infestations	Conjunctivitis viral	<=23 letters	69	9,8	0	0,0
Infections and infestations	Conjunctivitis viral	>=24 letters	632	90,2	1	0,2
Infections and infestations	Cystitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Cystitis	>=24 letters	632	90,2	3	0,5
Infections and infestations	Device related infection	<=23 letters	69	9,8	1	1,4
Infections and infestations	Device related infection	>=24 letters	632	90,2	0	0,0
Infections and infestations	Diabetic foot infection	<=23 letters	69	9,8	1	1,4
Infections and infestations	Diabetic foot infection	>=24 letters	632	90,2	0	0,0
Infections and infestations	Ear infection	<=23 letters	69	9,8	1	1,4
Infections and infestations	Ear infection	>=24 letters	632	90,2	2	0,3
Infections and infestations	Endophthalmitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Endophthalmitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Enteritis infectious	<=23 letters	69	9,8	0	0,0
Infections and infestations	Enteritis infectious	>=24 letters	632	90,2	1	0,2
Infections and infestations	Escherichia urinary tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Escherichia urinary tract infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Eye infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Eye infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Eye infection bacterial	<=23 letters	69	9,8	0	0,0
Infections and infestations	Eye infection bacterial	>=24 letters	632	90,2	1	0,2
Infections and infestations	Folliculitis	<=23 letters	69	9,8	0	0,0

Infections and infestations	Folliculitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Fungal skin infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Fungal skin infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Gastroenteritis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Gastroenteritis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Gastroenteritis viral	<=23 letters	69	9,8	0	0,0
Infections and infestations	Gastroenteritis viral	>=24 letters	632	90,2	4	0,6
Infections and infestations	Gastrointestinal infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Gastrointestinal infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Helicobacter infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Helicobacter infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Herpes virus infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Herpes virus infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Herpes zoster	<=23 letters	69	9,8	2	2,9
Infections and infestations	Herpes zoster	>=24 letters	632	90,2	4	0,6
Infections and infestations	Hordeolum	<=23 letters	69	9,8	0	0,0
Infections and infestations	Hordeolum	>=24 letters	632	90,2	5	0,8
Infections and infestations	Infected bite	<=23 letters	69	9,8	0	0,0
Infections and infestations	Infected bite	>=24 letters	632	90,2	1	0,2
Infections and infestations	Influenza	<=23 letters	69	9,8	2	2,9
Infections and infestations	Influenza	>=24 letters	632	90,2	17	2,7
Infections and infestations	Kidney infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Kidney infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Laryngitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Laryngitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Localised infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Localised infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Lower respiratory tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Lower respiratory tract infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Nasopharyngitis	<=23 letters	69	9,8	1	1,4
Infections and infestations	Nasopharyngitis	>=24 letters	632	90,2	26	4,1
Infections and infestations	Necrotising fasciitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Necrotising fasciitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Oral herpes	<=23 letters	69	9,8	0	0,0
Infections and infestations	Oral herpes	>=24 letters	632	90,2	2	0,3
Infections and infestations	Otitis externa	<=23 letters	69	9,8	0	0,0
Infections and infestations	Otitis externa	>=24 letters	632	90,2	1	0,2
Infections and infestations	Otosalpingitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Otosalpingitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Perichondritis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Perichondritis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Periodontitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Periodontitis	>=24 letters	632	90,2	2	0,3
Infections and infestations	Pharyngitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Pharyngitis	>=24 letters	632	90,2	2	0,3
Infections and infestations	Pneumonia	<=23 letters	69	9,8	2	2,9
Infections and infestations	Pneumonia	>=24 letters	632	90,2	8	1,3
Infections and infestations	Pneumonia viral	<=23 letters	69	9,8	1	1,4
Infections and infestations	Pneumonia viral	>=24 letters	632	90,2	2	0,3
Infections and infestations	Pulpitis dental	<=23 letters	69	9,8	0	0,0
Infections and infestations	Pulpitis dental	>=24 letters	632	90,2	3	0,5
Infections and infestations	Respiratory syncytial virus infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Respiratory syncytial virus infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Respiratory tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Respiratory tract infection	>=24 letters	632	90,2	2	0,3
Infections and infestations	Respiratory tract infection viral	<=23 letters	69	9,8	0	0,0
Infections and infestations	Respiratory tract infection viral	>=24 letters	632	90,2	1	0,2
Infections and infestations	Rhinitis	<=23 letters	69	9,8	1	1,4
Infections and infestations	Rhinitis	>=24 letters	632	90,2	0	0,0

Infections and infestations	Sepsis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Sepsis	>=24 letters	632	90,2	2	0,3
Infections and infestations	Septic arthritis staphylococcal	<=23 letters	69	9,8	0	0,0
Infections and infestations	Septic arthritis staphylococcal	>=24 letters	632	90,2	1	0,2
Infections and infestations	Sinusitis	<=23 letters	69	9,8	2	2,9
Infections and infestations	Sinusitis	>=24 letters	632	90,2	7	1,1
Infections and infestations	Staphylococcal infection	<=23 letters	69	9,8	1	1,4
Infections and infestations	Staphylococcal infection	>=24 letters	632	90,2	0	0,0
Infections and infestations	Suspected COVID-19	<=23 letters	69	9,8	0	0,0
Infections and infestations	Suspected COVID-19	>=24 letters	632	90,2	10	1,6
Infections and infestations	Tinea pedis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Tinea pedis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Tooth abscess	<=23 letters	69	9,8	1	1,4
Infections and infestations	Tooth abscess	>=24 letters	632	90,2	1	0,2
Infections and infestations	Tooth infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Tooth infection	>=24 letters	632	90,2	3	0,5
Infections and infestations	Upper respiratory tract infection	<=23 letters	69	9,8	1	1,4
Infections and infestations	Upper respiratory tract infection	>=24 letters	632	90,2	16	2,5
Infections and infestations	Urinary tract candidiasis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Urinary tract candidiasis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Urinary tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Urinary tract infection	>=24 letters	632	90,2	14	2,2
Infections and infestations	Urosepsis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Urosepsis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Viral rash	<=23 letters	69	9,8	0	0,0
Infections and infestations	Viral rash	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications		<=23 letters	69	9,8	4	5,8
Injury, poisoning and procedural complications		>=24 letters	632	90,2	51	8,1
Injury, poisoning and procedural complications	Accident	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Accident	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Arthropod bite	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Arthropod bite	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Arthropod sting	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Arthropod sting	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Contusion	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Contusion	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Eye contusion	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Eye contusion	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Fall	<=23 letters	69	9,8	2	2,9
Injury, poisoning and procedural complications	Fall	>=24 letters	632	90,2	8	1,3
Injury, poisoning and procedural complications	Femur fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=24 letters	632	90,2	3	0,5
Injury, poisoning and procedural complications	Fibula fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Fibula fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Foreign body in eye	<=23 letters	69	9,8	1	1,4
Injury, poisoning and procedural complications	Foreign body in eye	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Hand fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Hand fracture	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Hip fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Hip fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Hypobarism	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Hypobarism	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Ligament rupture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Ligament sprain	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Ligament sprain	>=24 letters	632	90,2	1	0,2

Injury, poisoning and procedural complications	Limb injury	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Limb injury	>=24 letters	632	90,2	5	0,8
Injury, poisoning and procedural complications	Lower limb fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Lumbar vertebral fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Medication error	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Medication error	>=24 letters	632	90,2	4	0,6
Injury, poisoning and procedural complications	Muscle strain	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Muscle strain	>=24 letters	632	90,2	3	0,5
Injury, poisoning and procedural complications	Posterior capsule rupture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Postoperative thoracic procedure complication	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Postoperative thoracic procedure complication	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Procedural nausea	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Procedural nausea	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Procedural pain	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Procedural pain	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Rib fracture	<=23 letters	69	9,8	1	1,4
Injury, poisoning and procedural complications	Rib fracture	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Road traffic accident	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Shunt stenosis	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Skin laceration	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Skin laceration	>=24 letters	632	90,2	3	0,5
Injury, poisoning and procedural complications	Soft tissue injury	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Soft tissue injury	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Spinal compression fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Sunburn	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Sunburn	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Thermal burn	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Thermal burn	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Tibia fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Tooth fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Wrist fracture	<=23 letters	69	9,8	1	1,4
Injury, poisoning and procedural complications	Wrist fracture	>=24 letters	632	90,2	2	0,3
Investigations		<=23 letters	69	9,8	4	5,8
Investigations		>=24 letters	632	90,2	58	9,2
Investigations	Alanine aminotransferase increased	<=23 letters	69	9,8	0	0,0
Investigations	Alanine aminotransferase increased	>=24 letters	632	90,2	1	0,2
Investigations	Aspartate aminotransferase increased	<=23 letters	69	9,8	0	0,0
Investigations	Aspartate aminotransferase increased	>=24 letters	632	90,2	1	0,2
Investigations	Blood albumin increased	<=23 letters	69	9,8	0	0,0
Investigations	Blood albumin increased	>=24 letters	632	90,2	1	0,2
Investigations	Blood bilirubin increased	<=23 letters	69	9,8	0	0,0
Investigations	Blood bilirubin increased	>=24 letters	632	90,2	1	0,2
Investigations	Blood cholesterol increased	<=23 letters	69	9,8	0	0,0
Investigations	Blood cholesterol increased	>=24 letters	632	90,2	2	0,3
Investigations	Blood creatinine increased	<=23 letters	69	9,8	0	0,0
Investigations	Blood creatinine increased	>=24 letters	632	90,2	2	0,3
Investigations	Blood glucose abnormal	<=23 letters	69	9,8	0	0,0
Investigations	Blood glucose abnormal	>=24 letters	632	90,2	1	0,2
Investigations	Blood glucose increased	<=23 letters	69	9,8	0	0,0
Investigations	Blood glucose increased	>=24 letters	632	90,2	4	0,6

Investigations	Blood potassium increased	<=23 letters	69	9,8	0	0,0
Investigations	Blood potassium increased	>=24 letters	632	90,2	1	0,2
Investigations	Blood pressure decreased	<=23 letters	69	9,8	0	0,0
Investigations	Blood pressure decreased	>=24 letters	632	90,2	1	0,2
Investigations	Blood pressure increased	<=23 letters	69	9,8	1	1,4
Investigations	Blood pressure increased	>=24 letters	632	90,2	2	0,3
Investigations	Blood testosterone decreased	<=23 letters	69	9,8	0	0,0
Investigations	Blood testosterone decreased	>=24 letters	632	90,2	1	0,2
Investigations	Blood thyroid stimulating hormone increased	<=23 letters	69	9,8	0	0,0
Investigations	Blood thyroid stimulating hormone increased	>=24 letters	632	90,2	1	0,2
Investigations	Blood triglycerides increased	<=23 letters	69	9,8	0	0,0
Investigations	Blood triglycerides increased	>=24 letters	632	90,2	1	0,2
Investigations	Blood uric acid increased	<=23 letters	69	9,8	0	0,0
Investigations	Blood uric acid increased	>=24 letters	632	90,2	1	0,2
Investigations	Grip strength decreased	<=23 letters	69	9,8	0	0,0
Investigations	Grip strength decreased	>=24 letters	632	90,2	1	0,2
Investigations	Haematocrit decreased	<=23 letters	69	9,8	0	0,0
Investigations	Haematocrit decreased	>=24 letters	632	90,2	1	0,2
Investigations	Haemoglobin decreased	<=23 letters	69	9,8	0	0,0
Investigations	Haemoglobin decreased	>=24 letters	632	90,2	1	0,2
Investigations	Heart rate irregular	<=23 letters	69	9,8	0	0,0
Investigations	Heart rate irregular	>=24 letters	632	90,2	1	0,2
Investigations	Intraocular pressure increased	<=23 letters	69	9,8	3	4,3
Investigations	Intraocular pressure increased	>=24 letters	632	90,2	31	4,9
Investigations	Liver function test increased	<=23 letters	69	9,8	0	0,0
Investigations	Liver function test increased	>=24 letters	632	90,2	1	0,2
Investigations	Occult blood positive	<=23 letters	69	9,8	0	0,0
Investigations	Occult blood positive	>=24 letters	632	90,2	1	0,2
Investigations	Optic nerve cup/disc ratio increased	<=23 letters	69	9,8	0	0,0
Investigations	Optic nerve cup/disc ratio increased	>=24 letters	632	90,2	1	0,2
Investigations	Red blood cell count decreased	<=23 letters	69	9,8	0	0,0
Investigations	Red blood cell count decreased	>=24 letters	632	90,2	1	0,2
Investigations	SARS-CoV-2 test positive	<=23 letters	69	9,8	0	0,0
Investigations	SARS-CoV-2 test positive	>=24 letters	632	90,2	4	0,6
Investigations	Urinary occult blood	<=23 letters	69	9,8	0	0,0
Investigations	Urinary occult blood	>=24 letters	632	90,2	1	0,2
Investigations	Weight decreased	<=23 letters	69	9,8	0	0,0
Investigations	Weight decreased	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders		<=23 letters	69	9,8	4	5,8
Metabolism and nutrition disorders		>=24 letters	632	90,2	30	4,7
Metabolism and nutrition disorders	Decreased appetite	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Decreased appetite	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Dehydration	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Dehydration	>=24 letters	632	90,2	2	0,3
Metabolism and nutrition disorders	Diabetes mellitus	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	>=24 letters	632	90,2	2	0,3
Metabolism and nutrition disorders	Dyslipidaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Dyslipidaemia	>=24 letters	632	90,2	2	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Gout	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Gout	>=24 letters	632	90,2	2	0,3
Metabolism and nutrition disorders	Hypercholesterolaemia	<=23 letters	69	9,8	1	1,4
Metabolism and nutrition disorders	Hypercholesterolaemia	>=24 letters	632	90,2	6	0,9
Metabolism and nutrition disorders	Hyperglycaemia	<=23 letters	69	9,8	1	1,4
Metabolism and nutrition disorders	Hyperglycaemia	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hyperlipidaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hyperlipidaemia	>=24 letters	632	90,2	1	0,2

Metabolism and nutrition disorders	Hyperuricaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hyperuricaemia	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hypervolaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hypoglycaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hypokalaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	>=24 letters	632	90,2	7	1,1
Metabolism and nutrition disorders	Hyponatraemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Type 2 diabetes mellitus	<=23 letters	69	9,8	2	2,9
Metabolism and nutrition disorders	Type 2 diabetes mellitus	>=24 letters	632	90,2	6	0,9
Metabolism and nutrition disorders	Vitamin B12 deficiency	<=23 letters	69	9,8	1	1,4
Metabolism and nutrition disorders	Vitamin B12 deficiency	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Vitamin D deficiency	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Vitamin D deficiency	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders		<=23 letters	69	9,8	7	10,1
Musculoskeletal and connective tissue disorders		>=24 letters	632	90,2	54	8,5
Musculoskeletal and connective tissue disorders	Arthralgia	<=23 letters	69	9,8	1	1,4
Musculoskeletal and connective tissue disorders	Arthralgia	>=24 letters	632	90,2	12	1,9
Musculoskeletal and connective tissue disorders	Arthritis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Arthritis	>=24 letters	632	90,2	3	0,5
Musculoskeletal and connective tissue disorders	Back pain	<=23 letters	69	9,8	2	2,9
Musculoskeletal and connective tissue disorders	Back pain	>=24 letters	632	90,2	12	1,9
Musculoskeletal and connective tissue disorders	Bone disorder	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Bone disorder	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Bone loss	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Bursitis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	>=24 letters	632	90,2	2	0,3
Musculoskeletal and connective tissue disorders	Coccydynia	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Coccydynia	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Fibromyalgia	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Fibromyalgia	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Flank pain	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Flank pain	>=24 letters	632	90,2	2	0,3
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Joint effusion	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Joint swelling	<=23 letters	69	9,8	1	1,4
Musculoskeletal and connective tissue disorders	Joint swelling	>=24 letters	632	90,2	2	0,3
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Mobility decreased	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Muscle contracture	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Muscle contracture	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Muscular weakness	<=23 letters	69	9,8	1	1,4
Musculoskeletal and connective tissue disorders	Muscular weakness	>=24 letters	632	90,2	0	0,0
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Myalgia	<=23 letters	69	9,8	1	1,4
Musculoskeletal and connective tissue disorders	Myalgia	>=24 letters	632	90,2	0	0,0
Musculoskeletal and connective tissue disorders	Neck pain	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Neck pain	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Osteoarthritis	<=23 letters	69	9,8	1	1,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=24 letters	632	90,2	4	0,6

Musculoskeletal and connective tissue disorders	Pain in extremity	<=23 letters	69	9,8	1	1,4
Musculoskeletal and connective tissue disorders	Pain in extremity	>=24 letters	632	90,2	3	0,5
Musculoskeletal and connective tissue disorders	Periarthritis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Plantar fasciitis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Polymyositis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	>=24 letters	632	90,2	3	0,5
Musculoskeletal and connective tissue disorders	Scoliosis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Spinal pain	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Synovial cyst	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Synovial cyst	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Tendonitis	<=23 letters	69	9,8	1	1,4
Musculoskeletal and connective tissue disorders	Tendonitis	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Trigger finger	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Trigger finger	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=24 letters	632	90,2	16	2,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	>=24 letters	632	90,2	2	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	>=24 letters	632	90,2	2	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	>=24 letters	632	90,2	1	0,2

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	>=24 letters	632	90,2	4	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	>=24 letters	632	90,2	1	0,2
Nervous system disorders		<=23 letters	69	9,8	5	7,2
Nervous system disorders		>=24 letters	632	90,2	46	7,3
Nervous system disorders	Autonomic neuropathy	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Autonomic neuropathy	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Balance disorder	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Balance disorder	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Carotid arteriosclerosis	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Carotid arteriosclerosis	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Carpal tunnel syndrome	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Carpal tunnel syndrome	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Cerebral atrophy	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cerebral atrophy	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Cerebral disorder	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cerebral disorder	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Cerebral infarction	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cerebral infarction	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Cerebrovascular accident	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cerebrovascular accident	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Cervicobrachial syndrome	<=23 letters	69	9,8	1	1,4
Nervous system disorders	Cervicobrachial syndrome	>=24 letters	632	90,2	0	0,0
Nervous system disorders	Cognitive disorder	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cognitive disorder	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Dementia Alzheimer's type	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Dementia Alzheimer's type	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Diabetic neuropathy	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Diabetic neuropathy	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Dizziness	<=23 letters	69	9,8	1	1,4
Nervous system disorders	Dizziness	>=24 letters	632	90,2	6	0,9
Nervous system disorders	Dysarthria	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Dysarthria	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Encephalopathy	<=23 letters	69	9,8	1	1,4
Nervous system disorders	Encephalopathy	>=24 letters	632	90,2	0	0,0
Nervous system disorders	Headache	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Headache	>=24 letters	632	90,2	11	1,7
Nervous system disorders	Hypoaesthesia	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Hypoaesthesia	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Intercostal neuralgia	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Intercostal neuralgia	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Ischaemic stroke	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Ischaemic stroke	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Lacunar infarction	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Lacunar infarction	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Loss of consciousness	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Loss of consciousness	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Lumbar radiculopathy	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Lumbar radiculopathy	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Migraine	<=23 letters	69	9,8	1	1,4

Nervous system disorders	Migraine	>=24 letters	632	90,2	0	0,0
Nervous system disorders	Neuralgia	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Neuralgia	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Neuropathy peripheral	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Neuropathy peripheral	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Ophthalmic migraine	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Ophthalmic migraine	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Paralysis	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Paralysis	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Parkinsonism	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Parkinsonism	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Presyncope	<=23 letters	69	9,8	1	1,4
Nervous system disorders	Presyncope	>=24 letters	632	90,2	0	0,0
Nervous system disorders	Sciatica	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Sciatica	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Syncope	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Syncope	>=24 letters	632	90,2	4	0,6
Product issues		<=23 letters	69	9,8	0	0,0
Product issues		>=24 letters	632	90,2	1	0,2
Product issues	Device physical property issue	<=23 letters	69	9,8	0	0,0
Product issues	Device physical property issue	>=24 letters	632	90,2	1	0,2
Psychiatric disorders		<=23 letters	69	9,8	1	1,4
Psychiatric disorders		>=24 letters	632	90,2	8	1,3
Psychiatric disorders	Anxiety	<=23 letters	69	9,8	0	0,0
Psychiatric disorders	Anxiety	>=24 letters	632	90,2	1	0,2
Psychiatric disorders	Attention deficit hyperactivity disorder	<=23 letters	69	9,8	0	0,0
Psychiatric disorders	Attention deficit hyperactivity disorder	>=24 letters	632	90,2	1	0,2
Psychiatric disorders	Depression	<=23 letters	69	9,8	0	0,0
Psychiatric disorders	Depression	>=24 letters	632	90,2	2	0,3
Psychiatric disorders	Generalised anxiety disorder	<=23 letters	69	9,8	0	0,0
Psychiatric disorders	Generalised anxiety disorder	>=24 letters	632	90,2	1	0,2
Psychiatric disorders	Insomnia	<=23 letters	69	9,8	1	1,4
Psychiatric disorders	Insomnia	>=24 letters	632	90,2	2	0,3
Psychiatric disorders	Sleep disorder	<=23 letters	69	9,8	0	0,0
Psychiatric disorders	Sleep disorder	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders		<=23 letters	69	9,8	1	1,4
Renal and urinary disorders		>=24 letters	632	90,2	15	2,4
Renal and urinary disorders	Acute kidney injury	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Acute kidney injury	>=24 letters	632	90,2	3	0,5
Renal and urinary disorders	Cystitis interstitial	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Cystitis interstitial	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Diabetic nephropathy	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Diabetic nephropathy	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Dysuria	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Dysuria	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	End stage renal disease	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	End stage renal disease	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Haematuria	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Haematuria	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Hypertonic bladder	<=23 letters	69	9,8	1	1,4
Renal and urinary disorders	Hypertonic bladder	>=24 letters	632	90,2	0	0,0
Renal and urinary disorders	Nephrolithiasis	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Nephrolithiasis	>=24 letters	632	90,2	3	0,5
Renal and urinary disorders	Nephropathy	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Nephropathy	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Renal failure	<=23 letters	69	9,8	0	0,0

Renal and urinary disorders	Renal failure	>=24 letters	632	90,2	2	0,3
Renal and urinary disorders	Urinary retention	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Urinary retention	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Urinary tract inflammation	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Urinary tract inflammation	>=24 letters	632	90,2	1	0,2
Reproductive system and breast disorders		<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders		>=24 letters	632	90,2	6	0,9
Reproductive system and breast disorders	Benign prostatic hyperplasia	<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	>=24 letters	632	90,2	3	0,5
Reproductive system and breast disorders	Cystocele	<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders	Cystocele	>=24 letters	632	90,2	1	0,2
Reproductive system and breast disorders	Gynaecomastia	<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders	Gynaecomastia	>=24 letters	632	90,2	1	0,2
Reproductive system and breast disorders	Prostatitis	<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders	Prostatitis	>=24 letters	632	90,2	1	0,2
Reproductive system and breast disorders	Vaginal ulceration	<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders	Vaginal ulceration	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders		<=23 letters	69	9,8	5	7,2
Respiratory, thoracic and mediastinal disorders		>=24 letters	632	90,2	26	4,1
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	<=23 letters	69	9,8	1	1,4
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Asthma	<=23 letters	69	9,8	2	2,9
Respiratory, thoracic and mediastinal disorders	Asthma	>=24 letters	632	90,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<=23 letters	69	9,8	1	1,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=24 letters	632	90,2	5	0,8
Respiratory, thoracic and mediastinal disorders	Cough	<=23 letters	69	9,8	1	1,4
Respiratory, thoracic and mediastinal disorders	Cough	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Dry throat	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Dry throat	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Dyspnoea	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Epistaxis	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Lung opacity	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung opacity	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Nasal congestion	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Nasal polyps	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	>=24 letters	632	90,2	4	0,6
Respiratory, thoracic and mediastinal disorders	Pleural thickening	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural thickening	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=24 letters	632	90,2	2	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=24 letters	632	90,2	2	0,3
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	>=24 letters	632	90,2	1	0,2

Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	<=23 letters	69	9,8	1	1,4
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Sinus disorder	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders		<=23 letters	69	9,8	3	4,3
Skin and subcutaneous tissue disorders		>=24 letters	632	90,2	19	3,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	<=23 letters	69	9,8	1	1,4
Skin and subcutaneous tissue disorders	Androgenetic alopecia	>=24 letters	632	90,2	0	0,0
Skin and subcutaneous tissue disorders	Dermal cyst	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Dermal cyst	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Dermatitis	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Dermatitis allergic	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis allergic	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Dermatitis contact	<=23 letters	69	9,8	1	1,4
Skin and subcutaneous tissue disorders	Dermatitis contact	>=24 letters	632	90,2	2	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	>=24 letters	632	90,2	2	0,3
Skin and subcutaneous tissue disorders	Eczema	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Eczema	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Erythema	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Erythema	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Hyperkeratosis	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Hyperkeratosis	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Ingrowing nail	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Ingrowing nail	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Nail bed bleeding	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Nail dystrophy	<=23 letters	69	9,8	1	1,4
Skin and subcutaneous tissue disorders	Nail dystrophy	>=24 letters	632	90,2	0	0,0
Skin and subcutaneous tissue disorders	Purpura	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Purpura	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Rash	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Rash	>=24 letters	632	90,2	4	0,6
Skin and subcutaneous tissue disorders	Skin lesion	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Skin lesion	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Skin ulcer	<=23 letters	69	9,8	1	1,4
Skin and subcutaneous tissue disorders	Skin ulcer	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Toxic skin eruption	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Toxic skin eruption	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Urticaria	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures		<=23 letters	69	9,8	0	0,0
Surgical and medical procedures		>=24 letters	632	90,2	10	1,6
Surgical and medical procedures	Dental implantation	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Dental implantation	>=24 letters	632	90,2	3	0,5
Surgical and medical procedures	Large intestinal polypectomy	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures	Ligament operation	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Ligament operation	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures	Neurectomy	<=23 letters	69	9,8	0	0,0

Surgical and medical procedures	Neurectomy	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures	Renal transplant	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Renal transplant	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures	Toe operation	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Toe operation	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures	Tooth extraction	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Tooth extraction	>=24 letters	632	90,2	4	0,6
Vascular disorders		<=23 letters	69	9,8	4	5,8
Vascular disorders		>=24 letters	632	90,2	35	5,5
Vascular disorders	Aortic aneurysm	<=23 letters	69	9,8	0	0,0
Vascular disorders	Aortic aneurysm	>=24 letters	632	90,2	1	0,2
Vascular disorders	Aortic dissection	<=23 letters	69	9,8	0	0,0
Vascular disorders	Aortic dissection	>=24 letters	632	90,2	1	0,2
Vascular disorders	Aortic stenosis	<=23 letters	69	9,8	0	0,0
Vascular disorders	Aortic stenosis	>=24 letters	632	90,2	1	0,2
Vascular disorders	Deep vein thrombosis	<=23 letters	69	9,8	0	0,0
Vascular disorders	Deep vein thrombosis	>=24 letters	632	90,2	1	0,2
Vascular disorders	Haematoma	<=23 letters	69	9,8	0	0,0
Vascular disorders	Haematoma	>=24 letters	632	90,2	1	0,2
Vascular disorders	Haemorrhage	<=23 letters	69	9,8	0	0,0
Vascular disorders	Haemorrhage	>=24 letters	632	90,2	1	0,2
Vascular disorders	Hypertension	<=23 letters	69	9,8	2	2,9
Vascular disorders	Hypertension	>=24 letters	632	90,2	21	3,3
Vascular disorders	Hypertensive crisis	<=23 letters	69	9,8	0	0,0
Vascular disorders	Hypertensive crisis	>=24 letters	632	90,2	3	0,5
Vascular disorders	Hypotension	<=23 letters	69	9,8	1	1,4
Vascular disorders	Hypotension	>=24 letters	632	90,2	3	0,5
Vascular disorders	Internal haemorrhage	<=23 letters	69	9,8	0	0,0
Vascular disorders	Internal haemorrhage	>=24 letters	632	90,2	1	0,2
Vascular disorders	Lymphoedema	<=23 letters	69	9,8	1	1,4
Vascular disorders	Lymphoedema	>=24 letters	632	90,2	0	0,0
Vascular disorders	Peripheral artery aneurysm	<=23 letters	69	9,8	0	0,0
Vascular disorders	Peripheral artery aneurysm	>=24 letters	632	90,2	1	0,2
Vascular disorders	Secondary hypertension	<=23 letters	69	9,8	0	0,0
Vascular disorders	Secondary hypertension	>=24 letters	632	90,2	1	0,2
Vascular disorders	Thrombosis	<=23 letters	69	9,8	0	0,0
Vascular disorders	Thrombosis	>=24 letters	632	90,2	1	0,2

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_AE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:00

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Any AEs

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

Geographic Region			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		Europe	214	30,5	3	1,4
Blood and lymphatic system disorders		America	282	40,2	4	1,4
Blood and lymphatic system disorders		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Blood and lymphatic system disorders	Anaemia	Europe	214	30,5	3	1,4
Blood and lymphatic system disorders	Anaemia	America	282	40,2	4	1,4
Blood and lymphatic system disorders	Anaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Blood and lymphatic system disorders	Deficiency anaemia	Europe	214	30,5	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	America	282	40,2	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Blood and lymphatic system disorders	Iron deficiency anaemia	Europe	214	30,5	0	0,0
Blood and lymphatic system disorders	Iron deficiency anaemia	America	282	40,2	0	0,0
Blood and lymphatic system disorders	Iron deficiency anaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Europe	214	30,5	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	America	282	40,2	1	0,4
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders		Europe	214	30,5	12	5,6
Cardiac disorders		America	282	40,2	10	3,5
Cardiac disorders		Asia Pacific (inc. Australia)	205	29,2	8	3,9
Cardiac disorders	Acute left ventricular failure	Europe	214	30,5	0	0,0
Cardiac disorders	Acute left ventricular failure	America	282	40,2	1	0,4
Cardiac disorders	Acute left ventricular failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Acute myocardial infarction	Europe	214	30,5	1	0,5
Cardiac disorders	Acute myocardial infarction	America	282	40,2	0	0,0
Cardiac disorders	Acute myocardial infarction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Aortic valve incompetence	Europe	214	30,5	0	0,0
Cardiac disorders	Aortic valve incompetence	America	282	40,2	1	0,4
Cardiac disorders	Aortic valve incompetence	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Arrhythmia	Europe	214	30,5	1	0,5
Cardiac disorders	Arrhythmia	America	282	40,2	0	0,0
Cardiac disorders	Arrhythmia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Atrial fibrillation	Europe	214	30,5	3	1,4
Cardiac disorders	Atrial fibrillation	America	282	40,2	4	1,4
Cardiac disorders	Atrial fibrillation	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Cardiac disorders	Bradycardia	Europe	214	30,5	1	0,5
Cardiac disorders	Bradycardia	America	282	40,2	0	0,0
Cardiac disorders	Bradycardia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Cardiac failure	Europe	214	30,5	1	0,5
Cardiac disorders	Cardiac failure	America	282	40,2	0	0,0
Cardiac disorders	Cardiac failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Cardiac failure congestive	Europe	214	30,5	0	0,0
Cardiac disorders	Cardiac failure congestive	America	282	40,2	2	0,7
Cardiac disorders	Cardiac failure congestive	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Cardiomegaly	Europe	214	30,5	0	0,0
Cardiac disorders	Cardiomegaly	America	282	40,2	1	0,4
Cardiac disorders	Cardiomegaly	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Coronary artery disease	Europe	214	30,5	1	0,5
Cardiac disorders	Coronary artery disease	America	282	40,2	0	0,0
Cardiac disorders	Coronary artery disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Coronary artery stenosis	Europe	214	30,5	1	0,5
Cardiac disorders	Coronary artery stenosis	America	282	40,2	0	0,0
Cardiac disorders	Coronary artery stenosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Left ventricular dysfunction	Europe	214	30,5	1	0,5
Cardiac disorders	Left ventricular dysfunction	America	282	40,2	0	0,0
Cardiac disorders	Left ventricular dysfunction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Myocardial infarction	Europe	214	30,5	1	0,5
Cardiac disorders	Myocardial infarction	America	282	40,2	1	0,4
Cardiac disorders	Myocardial infarction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Myocardial ischaemia	Europe	214	30,5	1	0,5
Cardiac disorders	Myocardial ischaemia	America	282	40,2	0	0,0
Cardiac disorders	Myocardial ischaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Palpitations	Europe	214	30,5	1	0,5
Cardiac disorders	Palpitations	America	282	40,2	0	0,0
Cardiac disorders	Palpitations	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Pericardial effusion	Europe	214	30,5	0	0,0
Cardiac disorders	Pericardial effusion	America	282	40,2	0	0,0
Cardiac disorders	Pericardial effusion	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Sinus tachycardia	Europe	214	30,5	0	0,0
Cardiac disorders	Sinus tachycardia	America	282	40,2	1	0,4
Cardiac disorders	Sinus tachycardia	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Cardiac disorders	Stress cardiomyopathy	Europe	214	30,5	0	0,0
Cardiac disorders	Stress cardiomyopathy	America	282	40,2	0	0,0
Cardiac disorders	Stress cardiomyopathy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Supraventricular tachycardia	Europe	214	30,5	0	0,0
Cardiac disorders	Supraventricular tachycardia	America	282	40,2	1	0,4
Cardiac disorders	Supraventricular tachycardia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Tachycardia	Europe	214	30,5	1	0,5
Cardiac disorders	Tachycardia	America	282	40,2	0	0,0
Cardiac disorders	Tachycardia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Congenital, familial and genetic disorders		Europe	214	30,5	1	0,5
Congenital, familial and genetic disorders		America	282	40,2	1	0,4
Congenital, familial and genetic disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	Europe	214	30,5	1	0,5
Congenital, familial and genetic disorders	Corneal dystrophy	America	282	40,2	1	0,4
Congenital, familial and genetic disorders	Corneal dystrophy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Ear and labyrinth disorders		Europe	214	30,5	2	0,9
Ear and labyrinth disorders		America	282	40,2	0	0,0
Ear and labyrinth disorders		Asia Pacific (inc. Australia)	205	29,2	2	1,0
Ear and labyrinth disorders	Vertigo	Europe	214	30,5	2	0,9
Ear and labyrinth disorders	Vertigo	America	282	40,2	0	0,0
Ear and labyrinth disorders	Vertigo	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Endocrine disorders		Europe	214	30,5	1	0,5
Endocrine disorders		America	282	40,2	6	2,1
Endocrine disorders		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Endocrine disorders	Adrenal insufficiency	Europe	214	30,5	0	0,0
Endocrine disorders	Adrenal insufficiency	America	282	40,2	0	0,0
Endocrine disorders	Adrenal insufficiency	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Endocrine disorders	Adrenal mass	Europe	214	30,5	0	0,0
Endocrine disorders	Adrenal mass	America	282	40,2	1	0,4
Endocrine disorders	Adrenal mass	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Endocrine disorders	Adrenomegaly	Europe	214	30,5	0	0,0
Endocrine disorders	Adrenomegaly	America	282	40,2	0	0,0
Endocrine disorders	Adrenomegaly	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Endocrine disorders	Androgen deficiency	Europe	214	30,5	0	0,0
Endocrine disorders	Androgen deficiency	America	282	40,2	1	0,4
Endocrine disorders	Androgen deficiency	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Endocrine disorders	Goitre	Europe	214	30,5	1	0,5
Endocrine disorders	Goitre	America	282	40,2	0	0,0
Endocrine disorders	Goitre	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Endocrine disorders	Hypothyroidism	Europe	214	30,5	0	0,0
Endocrine disorders	Hypothyroidism	America	282	40,2	4	1,4
Endocrine disorders	Hypothyroidism	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Endocrine disorders	Thyroid cyst	Europe	214	30,5	0	0,0
Endocrine disorders	Thyroid cyst	America	282	40,2	0	0,0
Endocrine disorders	Thyroid cyst	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Endocrine disorders	Thyroid mass	Europe	214	30,5	0	0,0
Endocrine disorders	Thyroid mass	America	282	40,2	0	0,0
Endocrine disorders	Thyroid mass	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders		Europe	214	30,5	89	41,6
Eye disorders		America	282	40,2	96	34,0
Eye disorders		Asia Pacific (inc. Australia)	205	29,2	77	37,6
Eye disorders	Age-related macular degeneration	Europe	214	30,5	0	0,0
Eye disorders	Age-related macular degeneration	America	282	40,2	0	0,0
Eye disorders	Age-related macular degeneration	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Anisocoria	Europe	214	30,5	1	0,5
Eye disorders	Anisocoria	America	282	40,2	0	0,0
Eye disorders	Anisocoria	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Asthenopia	Europe	214	30,5	0	0,0
Eye disorders	Asthenopia	America	282	40,2	0	0,0
Eye disorders	Asthenopia	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Blepharitis	Europe	214	30,5	3	1,4
Eye disorders	Blepharitis	America	282	40,2	2	0,7
Eye disorders	Blepharitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Borderline glaucoma	Europe	214	30,5	1	0,5
Eye disorders	Borderline glaucoma	America	282	40,2	0	0,0
Eye disorders	Borderline glaucoma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Cataract	Europe	214	30,5	16	7,5
Eye disorders	Cataract	America	282	40,2	15	5,3
Eye disorders	Cataract	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Eye disorders	Cataract nuclear	Europe	214	30,5	1	0,5
Eye disorders	Cataract nuclear	America	282	40,2	0	0,0
Eye disorders	Cataract nuclear	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Cataract subcapsular	Europe	214	30,5	1	0,5
Eye disorders	Cataract subcapsular	America	282	40,2	0	0,0
Eye disorders	Cataract subcapsular	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Central serous chorioretinopathy	Europe	214	30,5	1	0,5
Eye disorders	Central serous chorioretinopathy	America	282	40,2	2	0,7
Eye disorders	Central serous chorioretinopathy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Chalazion	Europe	214	30,5	0	0,0

Eye disorders	Chalazion	America	282	40,2	1	0,4
Eye disorders	Chalazion	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Eye disorders	Choroidal effusion	Europe	214	30,5	0	0,0
Eye disorders	Choroidal effusion	America	282	40,2	1	0,4
Eye disorders	Choroidal effusion	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Conjunctival haemorrhage	Europe	214	30,5	7	3,3
Eye disorders	Conjunctival haemorrhage	America	282	40,2	10	3,5
Eye disorders	Conjunctival haemorrhage	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Eye disorders	Conjunctival hyperaemia	Europe	214	30,5	1	0,5
Eye disorders	Conjunctival hyperaemia	America	282	40,2	1	0,4
Eye disorders	Conjunctival hyperaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Conjunctival telangiectasia	Europe	214	30,5	0	0,0
Eye disorders	Conjunctival telangiectasia	America	282	40,2	0	0,0
Eye disorders	Conjunctival telangiectasia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Conjunctivitis allergic	Europe	214	30,5	0	0,0
Eye disorders	Conjunctivitis allergic	America	282	40,2	0	0,0
Eye disorders	Conjunctivitis allergic	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Corneal deposits	Europe	214	30,5	1	0,5
Eye disorders	Corneal deposits	America	282	40,2	0	0,0
Eye disorders	Corneal deposits	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Corneal erosion	Europe	214	30,5	0	0,0
Eye disorders	Corneal erosion	America	282	40,2	1	0,4
Eye disorders	Corneal erosion	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Corneal infiltrates	Europe	214	30,5	0	0,0
Eye disorders	Corneal infiltrates	America	282	40,2	1	0,4
Eye disorders	Corneal infiltrates	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Corneal opacity	Europe	214	30,5	1	0,5
Eye disorders	Corneal opacity	America	282	40,2	0	0,0
Eye disorders	Corneal opacity	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Corneal pigmentation	Europe	214	30,5	1	0,5
Eye disorders	Corneal pigmentation	America	282	40,2	0	0,0
Eye disorders	Corneal pigmentation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Cystoid macular oedema	Europe	214	30,5	6	2,8
Eye disorders	Cystoid macular oedema	America	282	40,2	7	2,5
Eye disorders	Cystoid macular oedema	Asia Pacific (inc. Australia)	205	29,2	15	7,3
Eye disorders	Detachment of retinal pigment epithelium	Europe	214	30,5	2	0,9
Eye disorders	Detachment of retinal pigment epithelium	America	282	40,2	0	0,0
Eye disorders	Detachment of retinal pigment epithelium	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Diabetic retinal oedema	Europe	214	30,5	0	0,0
Eye disorders	Diabetic retinal oedema	America	282	40,2	1	0,4
Eye disorders	Diabetic retinal oedema	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Diabetic retinopathy	Europe	214	30,5	0	0,0
Eye disorders	Diabetic retinopathy	America	282	40,2	1	0,4
Eye disorders	Diabetic retinopathy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Diplopia	Europe	214	30,5	1	0,5
Eye disorders	Diplopia	America	282	40,2	0	0,0
Eye disorders	Diplopia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Dry age-related macular degeneration	Europe	214	30,5	0	0,0
Eye disorders	Dry age-related macular degeneration	America	282	40,2	1	0,4
Eye disorders	Dry age-related macular degeneration	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Dry eye	Europe	214	30,5	4	1,9
Eye disorders	Dry eye	America	282	40,2	6	2,1
Eye disorders	Dry eye	Asia Pacific (inc. Australia)	205	29,2	5	2,4
Eye disorders	Eczema eyelids	Europe	214	30,5	1	0,5
Eye disorders	Eczema eyelids	America	282	40,2	0	0,0
Eye disorders	Eczema eyelids	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Epi-retinal membrane	Europe	214	30,5	7	3,3
Eye disorders	Epi-retinal membrane	America	282	40,2	6	2,1
Eye disorders	Epi-retinal membrane	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Eye disorders	Episcleritis	Europe	214	30,5	0	0,0
Eye disorders	Episcleritis	America	282	40,2	0	0,0
Eye disorders	Episcleritis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Eye irritation	Europe	214	30,5	1	0,5
Eye disorders	Eye irritation	America	282	40,2	0	0,0
Eye disorders	Eye irritation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Eye pain	Europe	214	30,5	6	2,8
Eye disorders	Eye pain	America	282	40,2	3	1,1
Eye disorders	Eye pain	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Eye pruritus	Europe	214	30,5	1	0,5
Eye disorders	Eye pruritus	America	282	40,2	1	0,4
Eye disorders	Eye pruritus	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Eyelid cyst	Europe	214	30,5	1	0,5
Eye disorders	Eyelid cyst	America	282	40,2	0	0,0
Eye disorders	Eyelid cyst	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Eyelid oedema	Europe	214	30,5	0	0,0
Eye disorders	Eyelid oedema	America	282	40,2	1	0,4
Eye disorders	Eyelid oedema	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Foreign body sensation in eyes	Europe	214	30,5	2	0,9
Eye disorders	Foreign body sensation in eyes	America	282	40,2	0	0,0
Eye disorders	Foreign body sensation in eyes	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Glaucoma	Europe	214	30,5	9	4,2
Eye disorders	Glaucoma	America	282	40,2	3	1,1
Eye disorders	Glaucoma	Asia Pacific (inc. Australia)	205	29,2	3	1,5

Eye disorders	Hypotony of eye	Europe	214	30,5	0	0,0
Eye disorders	Hypotony of eye	America	282	40,2	0	0,0
Eye disorders	Hypotony of eye	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Iridocyclitis	Europe	214	30,5	4	1,9
Eye disorders	Iridocyclitis	America	282	40,2	1	0,4
Eye disorders	Iridocyclitis	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Iris neovascularisation	Europe	214	30,5	2	0,9
Eye disorders	Iris neovascularisation	America	282	40,2	0	0,0
Eye disorders	Iris neovascularisation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Iritis	Europe	214	30,5	2	0,9
Eye disorders	Iritis	America	282	40,2	2	0,7
Eye disorders	Iritis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Keratic precipitates	Europe	214	30,5	0	0,0
Eye disorders	Keratic precipitates	America	282	40,2	0	0,0
Eye disorders	Keratic precipitates	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Keratitis	Europe	214	30,5	0	0,0
Eye disorders	Keratitis	America	282	40,2	2	0,7
Eye disorders	Keratitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Keratopathy	Europe	214	30,5	1	0,5
Eye disorders	Keratopathy	America	282	40,2	0	0,0
Eye disorders	Keratopathy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Lacrimal disorder	Europe	214	30,5	0	0,0
Eye disorders	Lacrimal disorder	America	282	40,2	0	0,0
Eye disorders	Lacrimal disorder	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Lacrimation increased	Europe	214	30,5	4	1,9
Eye disorders	Lacrimation increased	America	282	40,2	0	0,0
Eye disorders	Lacrimation increased	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Lenticular opacities	Europe	214	30,5	1	0,5
Eye disorders	Lenticular opacities	America	282	40,2	0	0,0
Eye disorders	Lenticular opacities	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular degeneration	Europe	214	30,5	2	0,9
Eye disorders	Macular degeneration	America	282	40,2	0	0,0
Eye disorders	Macular degeneration	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular detachment	Europe	214	30,5	0	0,0
Eye disorders	Macular detachment	America	282	40,2	2	0,7
Eye disorders	Macular detachment	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular hole	Europe	214	30,5	1	0,5
Eye disorders	Macular hole	America	282	40,2	1	0,4
Eye disorders	Macular hole	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular ischaemia	Europe	214	30,5	1	0,5
Eye disorders	Macular ischaemia	America	282	40,2	1	0,4
Eye disorders	Macular ischaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular oedema	Europe	214	30,5	7	3,3
Eye disorders	Macular oedema	America	282	40,2	11	3,9
Eye disorders	Macular oedema	Asia Pacific (inc. Australia)	205	29,2	8	3,9
Eye disorders	Macular scar	Europe	214	30,5	0	0,0
Eye disorders	Macular scar	America	282	40,2	0	0,0
Eye disorders	Macular scar	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Meibomianitis	Europe	214	30,5	1	0,5
Eye disorders	Meibomianitis	America	282	40,2	0	0,0
Eye disorders	Meibomianitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Neovascular age-related macular degeneration	Europe	214	30,5	0	0,0
Eye disorders	Neovascular age-related macular degeneration	America	282	40,2	0	0,0
Eye disorders	Neovascular age-related macular degeneration	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Non-infectious endophthalmitis	Europe	214	30,5	0	0,0
Eye disorders	Non-infectious endophthalmitis	America	282	40,2	0	0,0
Eye disorders	Non-infectious endophthalmitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Noninfective conjunctivitis	Europe	214	30,5	0	0,0
Eye disorders	Noninfective conjunctivitis	America	282	40,2	1	0,4
Eye disorders	Noninfective conjunctivitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Normal tension glaucoma	Europe	214	30,5	0	0,0
Eye disorders	Normal tension glaucoma	America	282	40,2	0	0,0
Eye disorders	Normal tension glaucoma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Ocular hyperaemia	Europe	214	30,5	1	0,5
Eye disorders	Ocular hyperaemia	America	282	40,2	1	0,4
Eye disorders	Ocular hyperaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Ocular hypertension	Europe	214	30,5	5	2,3
Eye disorders	Ocular hypertension	America	282	40,2	5	1,8
Eye disorders	Ocular hypertension	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Open angle glaucoma	Europe	214	30,5	0	0,0
Eye disorders	Open angle glaucoma	America	282	40,2	1	0,4
Eye disorders	Open angle glaucoma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Optic atrophy	Europe	214	30,5	0	0,0
Eye disorders	Optic atrophy	America	282	40,2	0	0,0
Eye disorders	Optic atrophy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Optic disc disorder	Europe	214	30,5	0	0,0
Eye disorders	Optic disc disorder	America	282	40,2	0	0,0
Eye disorders	Optic disc disorder	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Optic disc haemorrhage	Europe	214	30,5	1	0,5
Eye disorders	Optic disc haemorrhage	America	282	40,2	2	0,7
Eye disorders	Optic disc haemorrhage	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Optic disc vascular disorder	Europe	214	30,5	0	0,0
Eye disorders	Optic disc vascular disorder	America	282	40,2	1	0,4

Eye disorders	Optic disc vascular disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Papilloedema	Europe	214	30,5	0	0,0
Eye disorders	Papilloedema	America	282	40,2	1	0,4
Eye disorders	Papilloedema	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Periorbital pain	Europe	214	30,5	1	0,5
Eye disorders	Periorbital pain	America	282	40,2	0	0,0
Eye disorders	Periorbital pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Photopsia	Europe	214	30,5	1	0,5
Eye disorders	Photopsia	America	282	40,2	1	0,4
Eye disorders	Photopsia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Pinguecula	Europe	214	30,5	0	0,0
Eye disorders	Pinguecula	America	282	40,2	1	0,4
Eye disorders	Pinguecula	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Posterior capsule opacification	Europe	214	30,5	2	0,9
Eye disorders	Posterior capsule opacification	America	282	40,2	5	1,8
Eye disorders	Posterior capsule opacification	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Punctate keratitis	Europe	214	30,5	1	0,5
Eye disorders	Punctate keratitis	America	282	40,2	3	1,1
Eye disorders	Punctate keratitis	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Retinal aneurysm	Europe	214	30,5	1	0,5
Eye disorders	Retinal aneurysm	America	282	40,2	1	0,4
Eye disorders	Retinal aneurysm	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal artery embolism	Europe	214	30,5	0	0,0
Eye disorders	Retinal artery embolism	America	282	40,2	1	0,4
Eye disorders	Retinal artery embolism	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal artery occlusion	Europe	214	30,5	0	0,0
Eye disorders	Retinal artery occlusion	America	282	40,2	2	0,7
Eye disorders	Retinal artery occlusion	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Retinal collateral vessels	Europe	214	30,5	1	0,5
Eye disorders	Retinal collateral vessels	America	282	40,2	2	0,7
Eye disorders	Retinal collateral vessels	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal depigmentation	Europe	214	30,5	0	0,0
Eye disorders	Retinal depigmentation	America	282	40,2	1	0,4
Eye disorders	Retinal depigmentation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal detachment	Europe	214	30,5	0	0,0
Eye disorders	Retinal detachment	America	282	40,2	1	0,4
Eye disorders	Retinal detachment	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Retinal disorder	Europe	214	30,5	1	0,5
Eye disorders	Retinal disorder	America	282	40,2	0	0,0
Eye disorders	Retinal disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal drusen	Europe	214	30,5	0	0,0
Eye disorders	Retinal drusen	America	282	40,2	1	0,4
Eye disorders	Retinal drusen	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal exudates	Europe	214	30,5	0	0,0
Eye disorders	Retinal exudates	America	282	40,2	1	0,4
Eye disorders	Retinal exudates	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Retinal haemorrhage	Europe	214	30,5	1	0,5
Eye disorders	Retinal haemorrhage	America	282	40,2	5	1,8
Eye disorders	Retinal haemorrhage	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Retinal ischaemia	Europe	214	30,5	2	0,9
Eye disorders	Retinal ischaemia	America	282	40,2	0	0,0
Eye disorders	Retinal ischaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal neovascularisation	Europe	214	30,5	1	0,5
Eye disorders	Retinal neovascularisation	America	282	40,2	0	0,0
Eye disorders	Retinal neovascularisation	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Retinal tear	Europe	214	30,5	1	0,5
Eye disorders	Retinal tear	America	282	40,2	1	0,4
Eye disorders	Retinal tear	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Retinal vein occlusion	Europe	214	30,5	7	3,3
Eye disorders	Retinal vein occlusion	America	282	40,2	11	3,9
Eye disorders	Retinal vein occlusion	Asia Pacific (inc. Australia)	205	29,2	5	2,4
Eye disorders	Retinopathy hypertensive	Europe	214	30,5	1	0,5
Eye disorders	Retinopathy hypertensive	America	282	40,2	0	0,0
Eye disorders	Retinopathy hypertensive	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Subretinal fluid	Europe	214	30,5	0	0,0
Eye disorders	Subretinal fluid	America	282	40,2	1	0,4
Eye disorders	Subretinal fluid	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Uveitis	Europe	214	30,5	1	0,5
Eye disorders	Uveitis	America	282	40,2	0	0,0
Eye disorders	Uveitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Vision blurred	Europe	214	30,5	2	0,9
Eye disorders	Vision blurred	America	282	40,2	1	0,4
Eye disorders	Vision blurred	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Visual acuity reduced	Europe	214	30,5	4	1,9
Eye disorders	Visual acuity reduced	America	282	40,2	4	1,4
Eye disorders	Visual acuity reduced	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Visual acuity reduced transiently	Europe	214	30,5	0	0,0
Eye disorders	Visual acuity reduced transiently	America	282	40,2	0	0,0
Eye disorders	Visual acuity reduced transiently	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Visual field defect	Europe	214	30,5	1	0,5
Eye disorders	Visual field defect	America	282	40,2	0	0,0
Eye disorders	Visual field defect	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Visual impairment	Europe	214	30,5	3	1,4

Eye disorders	Visual impairment	America	282	40,2	0	0,0
Eye disorders	Visual impairment	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Vitreoretinal traction syndrome	Europe	214	30,5	1	0,5
Eye disorders	Vitreoretinal traction syndrome	America	282	40,2	1	0,4
Eye disorders	Vitreoretinal traction syndrome	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Vitreous detachment	Europe	214	30,5	9	4,2
Eye disorders	Vitreous detachment	America	282	40,2	11	3,9
Eye disorders	Vitreous detachment	Asia Pacific (inc. Australia)	205	29,2	9	4,4
Eye disorders	Vitreous floaters	Europe	214	30,5	5	2,3
Eye disorders	Vitreous floaters	America	282	40,2	3	1,1
Eye disorders	Vitreous floaters	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Vitreous haemorrhage	Europe	214	30,5	1	0,5
Eye disorders	Vitreous haemorrhage	America	282	40,2	2	0,7
Eye disorders	Vitreous haemorrhage	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Vitreous opacities	Europe	214	30,5	0	0,0
Eye disorders	Vitreous opacities	America	282	40,2	0	0,0
Eye disorders	Vitreous opacities	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Vitritis	Europe	214	30,5	2	0,9
Eye disorders	Vitritis	America	282	40,2	1	0,4
Eye disorders	Vitritis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders		Europe	214	30,5	16	7,5
Gastrointestinal disorders		America	282	40,2	14	5,0
Gastrointestinal disorders		Asia Pacific (inc. Australia)	205	29,2	12	5,9
Gastrointestinal disorders	Abdominal discomfort	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Abdominal discomfort	America	282	40,2	0	0,0
Gastrointestinal disorders	Abdominal discomfort	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Abdominal pain	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Abdominal pain	America	282	40,2	0	0,0
Gastrointestinal disorders	Abdominal pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Abdominal pain upper	Europe	214	30,5	2	0,9
Gastrointestinal disorders	Abdominal pain upper	America	282	40,2	0	0,0
Gastrointestinal disorders	Abdominal pain upper	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Barrett's oesophagus	America	282	40,2	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Chronic gastritis	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Chronic gastritis	America	282	40,2	0	0,0
Gastrointestinal disorders	Chronic gastritis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Coeliac disease	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Coeliac disease	America	282	40,2	0	0,0
Gastrointestinal disorders	Coeliac disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Colitis	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Colitis	America	282	40,2	1	0,4
Gastrointestinal disorders	Colitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Constipation	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Constipation	America	282	40,2	2	0,7
Gastrointestinal disorders	Constipation	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Gastrointestinal disorders	Dental discomfort	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Dental discomfort	America	282	40,2	0	0,0
Gastrointestinal disorders	Dental discomfort	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Diarrhoea	Europe	214	30,5	4	1,9
Gastrointestinal disorders	Diarrhoea	America	282	40,2	4	1,4
Gastrointestinal disorders	Diarrhoea	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Gastrointestinal disorders	Diverticulum intestinal	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Diverticulum intestinal	America	282	40,2	0	0,0
Gastrointestinal disorders	Diverticulum intestinal	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	America	282	40,2	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	America	282	40,2	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Duodenitis	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Duodenitis	America	282	40,2	0	0,0
Gastrointestinal disorders	Duodenitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Dyspepsia	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Dyspepsia	America	282	40,2	0	0,0
Gastrointestinal disorders	Dyspepsia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Gastric ulcer	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Gastric ulcer	America	282	40,2	0	0,0
Gastrointestinal disorders	Gastric ulcer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Gastritis	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Gastritis	America	282	40,2	1	0,4
Gastrointestinal disorders	Gastritis	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Gastrointestinal disorders	Gastrointestinal inflammation	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Gastrointestinal inflammation	America	282	40,2	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Gastrooesophageal reflux disease	America	282	40,2	1	0,4
Gastrointestinal disorders	Gastrooesophageal reflux disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Haemorrhagic erosive gastritis	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Haemorrhagic erosive gastritis	America	282	40,2	0	0,0

Gastrointestinal disorders	Haemorrhagic erosive gastritis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Haemorrhoids	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Haemorrhoids	America	282	40,2	0	0,0
Gastrointestinal disorders	Haemorrhoids	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Hiatus hernia	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Hiatus hernia	America	282	40,2	1	0,4
Gastrointestinal disorders	Hiatus hernia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Ileus	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Ileus	America	282	40,2	0	0,0
Gastrointestinal disorders	Ileus	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Inguinal hernia	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Inguinal hernia	America	282	40,2	0	0,0
Gastrointestinal disorders	Inguinal hernia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Large intestine polyp	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Large intestine polyp	America	282	40,2	0	0,0
Gastrointestinal disorders	Large intestine polyp	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Nausea	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Nausea	America	282	40,2	1	0,4
Gastrointestinal disorders	Nausea	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Pancreatitis	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Pancreatitis	America	282	40,2	1	0,4
Gastrointestinal disorders	Pancreatitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Pancreatitis acute	America	282	40,2	1	0,4
Gastrointestinal disorders	Pancreatitis acute	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Pulpless tooth	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Pulpless tooth	America	282	40,2	0	0,0
Gastrointestinal disorders	Pulpless tooth	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Salivary gland disorder	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Salivary gland disorder	America	282	40,2	1	0,4
Gastrointestinal disorders	Salivary gland disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Toothache	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Toothache	America	282	40,2	0	0,0
Gastrointestinal disorders	Toothache	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Umbilical hernia	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Umbilical hernia	America	282	40,2	1	0,4
Gastrointestinal disorders	Umbilical hernia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Vomiting	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Vomiting	America	282	40,2	2	0,7
Gastrointestinal disorders	Vomiting	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions		Europe	214	30,5	15	7,0
General disorders and administration site conditions		America	282	40,2	8	2,8
General disorders and administration site conditions		Asia Pacific (inc. Australia)	205	29,2	9	4,4
General disorders and administration site conditions	Asthenia	Europe	214	30,5	6	2,8
General disorders and administration site conditions	Asthenia	America	282	40,2	1	0,4
General disorders and administration site conditions	Asthenia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Chest pain	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Chest pain	America	282	40,2	1	0,4
General disorders and administration site conditions	Chest pain	Asia Pacific (inc. Australia)	205	29,2	2	1,0
General disorders and administration site conditions	Chills	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Chills	America	282	40,2	0	0,0
General disorders and administration site conditions	Chills	Asia Pacific (inc. Australia)	205	29,2	1	0,5
General disorders and administration site conditions	Death	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Death	America	282	40,2	1	0,4
General disorders and administration site conditions	Death	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Drug intolerance	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Drug intolerance	America	282	40,2	0	0,0
General disorders and administration site conditions	Drug intolerance	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Drug withdrawal syndrome	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Drug withdrawal syndrome	America	282	40,2	0	0,0
General disorders and administration site conditions	Drug withdrawal syndrome	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Fatigue	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Fatigue	America	282	40,2	1	0,4
General disorders and administration site conditions	Fatigue	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Injection site pain	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Injection site pain	America	282	40,2	0	0,0
General disorders and administration site conditions	Injection site pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Injection site reaction	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Injection site reaction	America	282	40,2	0	0,0
General disorders and administration site conditions	Injection site reaction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
General disorders and administration site conditions	Oedema peripheral	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Oedema peripheral	America	282	40,2	1	0,4
General disorders and administration site conditions	Oedema peripheral	Asia Pacific (inc. Australia)	205	29,2	2	1,0
General disorders and administration site conditions	Pain	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Pain	America	282	40,2	1	0,4
General disorders and administration site conditions	Pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Peripheral swelling	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Peripheral swelling	America	282	40,2	1	0,4
General disorders and administration site conditions	Peripheral swelling	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Polyp	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Polyp	America	282	40,2	0	0,0
General disorders and administration site conditions	Polyp	Asia Pacific (inc. Australia)	205	29,2	0	0,0

General disorders and administration site conditions	Pyrexia	Europe	214	30,5	2	0,9
General disorders and administration site conditions	Pyrexia	America	282	40,2	1	0,4
General disorders and administration site conditions	Pyrexia	Asia Pacific (inc. Australia)	205	29,2	2	1,0
General disorders and administration site conditions	Stent-graft endoleak	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	America	282	40,2	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Asia Pacific (inc. Australia)	205	29,2	1	0,5
General disorders and administration site conditions	Systemic inflammatory response syndrome	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	America	282	40,2	1	0,4
General disorders and administration site conditions	Systemic inflammatory response syndrome	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Hepatobiliary disorders		Europe	214	30,5	2	0,9
Hepatobiliary disorders		America	282	40,2	3	1,1
Hepatobiliary disorders		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Hepatobiliary disorders	Cholecystitis	Europe	214	30,5	0	0,0
Hepatobiliary disorders	Cholecystitis	America	282	40,2	0	0,0
Hepatobiliary disorders	Cholecystitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Hepatobiliary disorders	Cholelithiasis	Europe	214	30,5	1	0,5
Hepatobiliary disorders	Cholelithiasis	America	282	40,2	2	0,7
Hepatobiliary disorders	Cholelithiasis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Hepatobiliary disorders	Hepatic cyst	Europe	214	30,5	0	0,0
Hepatobiliary disorders	Hepatic cyst	America	282	40,2	0	0,0
Hepatobiliary disorders	Hepatic cyst	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Hepatobiliary disorders	Hepatic steatosis	Europe	214	30,5	1	0,5
Hepatobiliary disorders	Hepatic steatosis	America	282	40,2	0	0,0
Hepatobiliary disorders	Hepatic steatosis	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Hepatobiliary disorders	Portal hypertension	Europe	214	30,5	0	0,0
Hepatobiliary disorders	Portal hypertension	America	282	40,2	1	0,4
Hepatobiliary disorders	Portal hypertension	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Immune system disorders		Europe	214	30,5	4	1,9
Immune system disorders		America	282	40,2	2	0,7
Immune system disorders		Asia Pacific (inc. Australia)	205	29,2	5	2,4
Immune system disorders	Contrast media allergy	Europe	214	30,5	2	0,9
Immune system disorders	Contrast media allergy	America	282	40,2	0	0,0
Immune system disorders	Contrast media allergy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Immune system disorders	Contrast media reaction	Europe	214	30,5	0	0,0
Immune system disorders	Contrast media reaction	America	282	40,2	0	0,0
Immune system disorders	Contrast media reaction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Immune system disorders	Drug hypersensitivity	Europe	214	30,5	0	0,0
Immune system disorders	Drug hypersensitivity	America	282	40,2	0	0,0
Immune system disorders	Drug hypersensitivity	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Immune system disorders	Food allergy	Europe	214	30,5	1	0,5
Immune system disorders	Food allergy	America	282	40,2	0	0,0
Immune system disorders	Food allergy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Immune system disorders	Iodine allergy	Europe	214	30,5	1	0,5
Immune system disorders	Iodine allergy	America	282	40,2	0	0,0
Immune system disorders	Iodine allergy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Immune system disorders	Seasonal allergy	Europe	214	30,5	0	0,0
Immune system disorders	Seasonal allergy	America	282	40,2	2	0,7
Immune system disorders	Seasonal allergy	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Infections and infestations		Europe	214	30,5	86	40,2
Infections and infestations		America	282	40,2	69	24,5
Infections and infestations		Asia Pacific (inc. Australia)	205	29,2	70	34,1
Infections and infestations	Adenoviral conjunctivitis	Europe	214	30,5	1	0,5
Infections and infestations	Adenoviral conjunctivitis	America	282	40,2	0	0,0
Infections and infestations	Adenoviral conjunctivitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Arthritis infective	Europe	214	30,5	1	0,5
Infections and infestations	Arthritis infective	America	282	40,2	0	0,0
Infections and infestations	Arthritis infective	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Bronchitis	Europe	214	30,5	2	0,9
Infections and infestations	Bronchitis	America	282	40,2	4	1,4
Infections and infestations	Bronchitis	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Infections and infestations	COVID-19	Europe	214	30,5	33	15,4
Infections and infestations	COVID-19	America	282	40,2	24	8,5
Infections and infestations	COVID-19	Asia Pacific (inc. Australia)	205	29,2	34	16,6
Infections and infestations	COVID-19 pneumonia	Europe	214	30,5	1	0,5
Infections and infestations	COVID-19 pneumonia	America	282	40,2	0	0,0
Infections and infestations	COVID-19 pneumonia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Cellulitis	Europe	214	30,5	3	1,4
Infections and infestations	Cellulitis	America	282	40,2	3	1,1
Infections and infestations	Cellulitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Chronic sinusitis	Europe	214	30,5	2	0,9
Infections and infestations	Chronic sinusitis	America	282	40,2	0	0,0
Infections and infestations	Chronic sinusitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Clostridium difficile infection	Europe	214	30,5	0	0,0
Infections and infestations	Clostridium difficile infection	America	282	40,2	1	0,4
Infections and infestations	Clostridium difficile infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Conjunctivitis	Europe	214	30,5	5	2,3
Infections and infestations	Conjunctivitis	America	282	40,2	5	1,8
Infections and infestations	Conjunctivitis	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Infections and infestations	Conjunctivitis bacterial	Europe	214	30,5	0	0,0
Infections and infestations	Conjunctivitis bacterial	America	282	40,2	1	0,4

Infections and infestations	Conjunctivitis bacterial	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Conjunctivitis viral	Europe	214	30,5	0	0,0
Infections and infestations	Conjunctivitis viral	America	282	40,2	1	0,4
Infections and infestations	Conjunctivitis viral	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Cystitis	Europe	214	30,5	0	0,0
Infections and infestations	Cystitis	America	282	40,2	2	0,7
Infections and infestations	Cystitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Device related infection	Europe	214	30,5	1	0,5
Infections and infestations	Device related infection	America	282	40,2	0	0,0
Infections and infestations	Device related infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Diabetic foot infection	Europe	214	30,5	0	0,0
Infections and infestations	Diabetic foot infection	America	282	40,2	1	0,4
Infections and infestations	Diabetic foot infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Ear infection	Europe	214	30,5	1	0,5
Infections and infestations	Ear infection	America	282	40,2	2	0,7
Infections and infestations	Ear infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Endophthalmitis	Europe	214	30,5	1	0,5
Infections and infestations	Endophthalmitis	America	282	40,2	0	0,0
Infections and infestations	Endophthalmitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Enteritis infectious	Europe	214	30,5	0	0,0
Infections and infestations	Enteritis infectious	America	282	40,2	1	0,4
Infections and infestations	Enteritis infectious	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Escherichia urinary tract infection	Europe	214	30,5	0	0,0
Infections and infestations	Escherichia urinary tract infection	America	282	40,2	0	0,0
Infections and infestations	Escherichia urinary tract infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Eye infection	Europe	214	30,5	0	0,0
Infections and infestations	Eye infection	America	282	40,2	1	0,4
Infections and infestations	Eye infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Eye infection bacterial	Europe	214	30,5	0	0,0
Infections and infestations	Eye infection bacterial	America	282	40,2	1	0,4
Infections and infestations	Eye infection bacterial	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Folliculitis	Europe	214	30,5	1	0,5
Infections and infestations	Folliculitis	America	282	40,2	0	0,0
Infections and infestations	Folliculitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Fungal skin infection	Europe	214	30,5	0	0,0
Infections and infestations	Fungal skin infection	America	282	40,2	1	0,4
Infections and infestations	Fungal skin infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Gastroenteritis	Europe	214	30,5	0	0,0
Infections and infestations	Gastroenteritis	America	282	40,2	1	0,4
Infections and infestations	Gastroenteritis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Gastroenteritis viral	Europe	214	30,5	0	0,0
Infections and infestations	Gastroenteritis viral	America	282	40,2	4	1,4
Infections and infestations	Gastroenteritis viral	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Gastrointestinal infection	Europe	214	30,5	1	0,5
Infections and infestations	Gastrointestinal infection	America	282	40,2	0	0,0
Infections and infestations	Gastrointestinal infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Helicobacter infection	Europe	214	30,5	0	0,0
Infections and infestations	Helicobacter infection	America	282	40,2	0	0,0
Infections and infestations	Helicobacter infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Herpes virus infection	Europe	214	30,5	0	0,0
Infections and infestations	Herpes virus infection	America	282	40,2	0	0,0
Infections and infestations	Herpes virus infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Herpes zoster	Europe	214	30,5	2	0,9
Infections and infestations	Herpes zoster	America	282	40,2	2	0,7
Infections and infestations	Herpes zoster	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Infections and infestations	Hordeolum	Europe	214	30,5	3	1,4
Infections and infestations	Hordeolum	America	282	40,2	1	0,4
Infections and infestations	Hordeolum	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Infected bite	Europe	214	30,5	1	0,5
Infections and infestations	Infected bite	America	282	40,2	0	0,0
Infections and infestations	Infected bite	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Influenza	Europe	214	30,5	6	2,8
Infections and infestations	Influenza	America	282	40,2	9	3,2
Infections and infestations	Influenza	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Infections and infestations	Kidney infection	Europe	214	30,5	0	0,0
Infections and infestations	Kidney infection	America	282	40,2	1	0,4
Infections and infestations	Kidney infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Laryngitis	Europe	214	30,5	1	0,5
Infections and infestations	Laryngitis	America	282	40,2	0	0,0
Infections and infestations	Laryngitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Localised infection	Europe	214	30,5	1	0,5
Infections and infestations	Localised infection	America	282	40,2	0	0,0
Infections and infestations	Localised infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Lower respiratory tract infection	Europe	214	30,5	1	0,5
Infections and infestations	Lower respiratory tract infection	America	282	40,2	0	0,0
Infections and infestations	Lower respiratory tract infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Nasopharyngitis	Europe	214	30,5	16	7,5
Infections and infestations	Nasopharyngitis	America	282	40,2	4	1,4
Infections and infestations	Nasopharyngitis	Asia Pacific (inc. Australia)	205	29,2	7	3,4
Infections and infestations	Necrotising fasciitis	Europe	214	30,5	0	0,0
Infections and infestations	Necrotising fasciitis	America	282	40,2	1	0,4
Infections and infestations	Necrotising fasciitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Oral herpes	Europe	214	30,5	1	0,5

Infections and infestations	Oral herpes	America	282	40,2	0	0,0
Infections and infestations	Oral herpes	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Otitis externa	Europe	214	30,5	1	0,5
Infections and infestations	Otitis externa	America	282	40,2	0	0,0
Infections and infestations	Otitis externa	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Otosalpingitis	Europe	214	30,5	1	0,5
Infections and infestations	Otosalpingitis	America	282	40,2	0	0,0
Infections and infestations	Otosalpingitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Perichondritis	Europe	214	30,5	0	0,0
Infections and infestations	Perichondritis	America	282	40,2	0	0,0
Infections and infestations	Perichondritis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Periodontitis	Europe	214	30,5	0	0,0
Infections and infestations	Periodontitis	America	282	40,2	0	0,0
Infections and infestations	Periodontitis	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Infections and infestations	Pharyngitis	Europe	214	30,5	1	0,5
Infections and infestations	Pharyngitis	America	282	40,2	0	0,0
Infections and infestations	Pharyngitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Pneumonia	Europe	214	30,5	3	1,4
Infections and infestations	Pneumonia	America	282	40,2	5	1,8
Infections and infestations	Pneumonia	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Infections and infestations	Pneumonia viral	Europe	214	30,5	0	0,0
Infections and infestations	Pneumonia viral	America	282	40,2	0	0,0
Infections and infestations	Pneumonia viral	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Infections and infestations	Pulpitis dental	Europe	214	30,5	3	1,4
Infections and infestations	Pulpitis dental	America	282	40,2	0	0,0
Infections and infestations	Pulpitis dental	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Europe	214	30,5	0	0,0
Infections and infestations	Respiratory syncytial virus infection	America	282	40,2	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Respiratory tract infection	Europe	214	30,5	1	0,5
Infections and infestations	Respiratory tract infection	America	282	40,2	0	0,0
Infections and infestations	Respiratory tract infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Respiratory tract infection viral	Europe	214	30,5	1	0,5
Infections and infestations	Respiratory tract infection viral	America	282	40,2	0	0,0
Infections and infestations	Respiratory tract infection viral	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Rhinitis	Europe	214	30,5	0	0,0
Infections and infestations	Rhinitis	America	282	40,2	0	0,0
Infections and infestations	Rhinitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Sepsis	Europe	214	30,5	1	0,5
Infections and infestations	Sepsis	America	282	40,2	1	0,4
Infections and infestations	Sepsis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Septic arthritis staphylococcal	Europe	214	30,5	0	0,0
Infections and infestations	Septic arthritis staphylococcal	America	282	40,2	1	0,4
Infections and infestations	Septic arthritis staphylococcal	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Sinusitis	Europe	214	30,5	4	1,9
Infections and infestations	Sinusitis	America	282	40,2	4	1,4
Infections and infestations	Sinusitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Staphylococcal infection	Europe	214	30,5	0	0,0
Infections and infestations	Staphylococcal infection	America	282	40,2	1	0,4
Infections and infestations	Staphylococcal infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Suspected COVID-19	Europe	214	30,5	0	0,0
Infections and infestations	Suspected COVID-19	America	282	40,2	0	0,0
Infections and infestations	Suspected COVID-19	Asia Pacific (inc. Australia)	205	29,2	10	4,9
Infections and infestations	Tinea pedis	Europe	214	30,5	1	0,5
Infections and infestations	Tinea pedis	America	282	40,2	0	0,0
Infections and infestations	Tinea pedis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Tooth abscess	Europe	214	30,5	1	0,5
Infections and infestations	Tooth abscess	America	282	40,2	1	0,4
Infections and infestations	Tooth abscess	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Tooth infection	Europe	214	30,5	1	0,5
Infections and infestations	Tooth infection	America	282	40,2	1	0,4
Infections and infestations	Tooth infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Upper respiratory tract infection	Europe	214	30,5	14	6,5
Infections and infestations	Upper respiratory tract infection	America	282	40,2	0	0,0
Infections and infestations	Upper respiratory tract infection	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Infections and infestations	Urinary tract candidiasis	Europe	214	30,5	0	0,0
Infections and infestations	Urinary tract candidiasis	America	282	40,2	0	0,0
Infections and infestations	Urinary tract candidiasis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Urinary tract infection	Europe	214	30,5	4	1,9
Infections and infestations	Urinary tract infection	America	282	40,2	8	2,8
Infections and infestations	Urinary tract infection	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Infections and infestations	Urosepsis	Europe	214	30,5	0	0,0
Infections and infestations	Urosepsis	America	282	40,2	1	0,4
Infections and infestations	Urosepsis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Viral rash	Europe	214	30,5	1	0,5
Infections and infestations	Viral rash	America	282	40,2	0	0,0
Infections and infestations	Viral rash	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications		Europe	214	30,5	11	5,1
Injury, poisoning and procedural complications		America	282	40,2	26	9,2
Injury, poisoning and procedural complications		Asia Pacific (inc. Australia)	205	29,2	18	8,8
Injury, poisoning and procedural complications	Accident	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Accident	America	282	40,2	0	0,0

Injury, poisoning and procedural complications	Soft tissue injury	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Soft tissue injury	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Sunburn	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Sunburn	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Sunburn	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Thermal burn	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Thermal burn	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Thermal burn	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Tibia fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Tibia fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Tooth fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Tooth fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Wrist fracture	America	282	40,2	2	0,7
Injury, poisoning and procedural complications	Wrist fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations		Europe	214	30,5	24	11,2
Investigations		America	282	40,2	14	5,0
Investigations		Asia Pacific (inc. Australia)	205	29,2	24	11,7
Investigations	Alanine aminotransferase increased	Europe	214	30,5	0	0,0
Investigations	Alanine aminotransferase increased	America	282	40,2	0	0,0
Investigations	Alanine aminotransferase increased	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Investigations	Aspartate aminotransferase increased	Europe	214	30,5	0	0,0
Investigations	Aspartate aminotransferase increased	America	282	40,2	0	0,0
Investigations	Aspartate aminotransferase increased	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Investigations	Blood albumin increased	Europe	214	30,5	0	0,0
Investigations	Blood albumin increased	America	282	40,2	1	0,4
Investigations	Blood albumin increased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Blood bilirubin increased	Europe	214	30,5	0	0,0
Investigations	Blood bilirubin increased	America	282	40,2	0	0,0
Investigations	Blood bilirubin increased	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Investigations	Blood cholesterol increased	Europe	214	30,5	0	0,0
Investigations	Blood cholesterol increased	America	282	40,2	1	0,4
Investigations	Blood cholesterol increased	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Investigations	Blood creatinine increased	Europe	214	30,5	0	0,0
Investigations	Blood creatinine increased	America	282	40,2	1	0,4
Investigations	Blood creatinine increased	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Investigations	Blood glucose abnormal	Europe	214	30,5	0	0,0
Investigations	Blood glucose abnormal	America	282	40,2	0	0,0
Investigations	Blood glucose abnormal	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Investigations	Blood glucose increased	Europe	214	30,5	0	0,0
Investigations	Blood glucose increased	America	282	40,2	4	1,4
Investigations	Blood glucose increased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Blood potassium increased	Europe	214	30,5	1	0,5
Investigations	Blood potassium increased	America	282	40,2	0	0,0
Investigations	Blood potassium increased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Blood pressure decreased	Europe	214	30,5	1	0,5
Investigations	Blood pressure decreased	America	282	40,2	0	0,0
Investigations	Blood pressure decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Blood pressure increased	Europe	214	30,5	1	0,5
Investigations	Blood pressure increased	America	282	40,2	0	0,0
Investigations	Blood pressure increased	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Investigations	Blood testosterone decreased	Europe	214	30,5	0	0,0
Investigations	Blood testosterone decreased	America	282	40,2	1	0,4
Investigations	Blood testosterone decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Blood thyroid stimulating hormone increased	Europe	214	30,5	1	0,5
Investigations	Blood thyroid stimulating hormone increased	America	282	40,2	0	0,0
Investigations	Blood thyroid stimulating hormone increased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Blood triglycerides increased	Europe	214	30,5	0	0,0
Investigations	Blood triglycerides increased	America	282	40,2	0	0,0
Investigations	Blood triglycerides increased	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Investigations	Blood uric acid increased	Europe	214	30,5	0	0,0
Investigations	Blood uric acid increased	America	282	40,2	0	0,0
Investigations	Blood uric acid increased	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Investigations	Grip strength decreased	Europe	214	30,5	0	0,0
Investigations	Grip strength decreased	America	282	40,2	1	0,4
Investigations	Grip strength decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Haematocrit decreased	Europe	214	30,5	0	0,0
Investigations	Haematocrit decreased	America	282	40,2	1	0,4
Investigations	Haematocrit decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Haemoglobin decreased	Europe	214	30,5	0	0,0
Investigations	Haemoglobin decreased	America	282	40,2	1	0,4
Investigations	Haemoglobin decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Heart rate irregular	Europe	214	30,5	1	0,5
Investigations	Heart rate irregular	America	282	40,2	0	0,0
Investigations	Heart rate irregular	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Intraocular pressure increased	Europe	214	30,5	17	7,9
Investigations	Intraocular pressure increased	America	282	40,2	4	1,4

Investigations	Intraocular pressure increased	Asia Pacific (inc. Australia)	205	29,2	13	6,3
Investigations	Liver function test increased	Europe	214	30,5	0	0,0
Investigations	Liver function test increased	America	282	40,2	1	0,4
Investigations	Liver function test increased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Occult blood positive	Europe	214	30,5	0	0,0
Investigations	Occult blood positive	America	282	40,2	1	0,4
Investigations	Occult blood positive	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Europe	214	30,5	1	0,5
Investigations	Optic nerve cup/disc ratio increased	America	282	40,2	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Red blood cell count decreased	Europe	214	30,5	0	0,0
Investigations	Red blood cell count decreased	America	282	40,2	1	0,4
Investigations	Red blood cell count decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	SARS-CoV-2 test positive	Europe	214	30,5	1	0,5
Investigations	SARS-CoV-2 test positive	America	282	40,2	0	0,0
Investigations	SARS-CoV-2 test positive	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Investigations	Urinary occult blood	Europe	214	30,5	0	0,0
Investigations	Urinary occult blood	America	282	40,2	0	0,0
Investigations	Urinary occult blood	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Investigations	Weight decreased	Europe	214	30,5	1	0,5
Investigations	Weight decreased	America	282	40,2	0	0,0
Investigations	Weight decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders		Europe	214	30,5	8	3,7
Metabolism and nutrition disorders		America	282	40,2	13	4,6
Metabolism and nutrition disorders		Asia Pacific (inc. Australia)	205	29,2	13	6,3
Metabolism and nutrition disorders	Decreased appetite	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Decreased appetite	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Decreased appetite	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Dehydration	Europe	214	30,5	1	0,5
Metabolism and nutrition disorders	Dehydration	America	282	40,2	1	0,4
Metabolism and nutrition disorders	Dehydration	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Metabolism and nutrition disorders	Dyslipidaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Dyslipidaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Dyslipidaemia	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Metabolism and nutrition disorders	Glucose tolerance impaired	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	America	282	40,2	1	0,4
Metabolism and nutrition disorders	Glucose tolerance impaired	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Gout	Europe	214	30,5	1	0,5
Metabolism and nutrition disorders	Gout	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Gout	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Hypercholesterolaemia	Europe	214	30,5	3	1,4
Metabolism and nutrition disorders	Hypercholesterolaemia	America	282	40,2	4	1,4
Metabolism and nutrition disorders	Hypercholesterolaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Europe	214	30,5	2	0,9
Metabolism and nutrition disorders	Hyperglycaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Hyperlipidaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hyperlipidaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hyperlipidaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Hyperuricaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hyperuricaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hyperuricaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Hypervolaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Hypoglycaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Hypokalaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	America	282	40,2	5	1,8
Metabolism and nutrition disorders	Hypokalaemia	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Metabolism and nutrition disorders	Hyponatraemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	America	282	40,2	1	0,4
Metabolism and nutrition disorders	Hyponatraemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Europe	214	30,5	1	0,5
Metabolism and nutrition disorders	Type 2 diabetes mellitus	America	282	40,2	5	1,8
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Metabolism and nutrition disorders	Vitamin B12 deficiency	Europe	214	30,5	1	0,5
Metabolism and nutrition disorders	Vitamin B12 deficiency	America	282	40,2	1	0,4
Metabolism and nutrition disorders	Vitamin B12 deficiency	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Vitamin D deficiency	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Vitamin D deficiency	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Vitamin D deficiency	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders		Europe	214	30,5	23	10,7
Musculoskeletal and connective tissue disorders		America	282	40,2	19	6,7
Musculoskeletal and connective tissue disorders		Asia Pacific (inc. Australia)	205	29,2	19	9,3
Musculoskeletal and connective tissue disorders	Arthralgia	Europe	214	30,5	6	2,8
Musculoskeletal and connective tissue disorders	Arthralgia	America	282	40,2	1	0,4

Musculoskeletal and connective tissue disorders	Arthralgia	Asia Pacific (inc. Australia)	205	29,2	6	2,9
Musculoskeletal and connective tissue disorders	Arthritis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Arthritis	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Arthritis	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Musculoskeletal and connective tissue disorders	Back pain	Europe	214	30,5	4	1,9
Musculoskeletal and connective tissue disorders	Back pain	America	282	40,2	5	1,8
Musculoskeletal and connective tissue disorders	Back pain	Asia Pacific (inc. Australia)	205	29,2	5	2,4
Musculoskeletal and connective tissue disorders	Bone disorder	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Bone disorder	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Bone disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Bone loss	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Bursitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Coccydynia	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Coccydynia	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Coccydynia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Fibromyalgia	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Fibromyalgia	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Fibromyalgia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Flank pain	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Flank pain	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Flank pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Joint swelling	Europe	214	30,5	2	0,9
Musculoskeletal and connective tissue disorders	Joint swelling	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Mobility decreased	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Mobility decreased	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Muscle contracture	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Muscle contracture	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Muscle contracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Muscular weakness	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Muscular weakness	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Muscular weakness	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Myalgia	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Myalgia	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Myalgia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Neck pain	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Neck pain	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Neck pain	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Osteoarthritis	Europe	214	30,5	3	1,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	America	282	40,2	2	0,7
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	Europe	214	30,5	2	0,9
Musculoskeletal and connective tissue disorders	Pain in extremity	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Pain in extremity	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Periarthritis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Polymyositis	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Polymyositis	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Europe	214	30,5	2	0,9
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Scoliosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Spinal pain	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Synovial cyst	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Synovial cyst	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Synovial cyst	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Europe	214	30,5	0	0,0

Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Tendonitis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Tendonitis	America	282	40,2	2	0,7
Musculoskeletal and connective tissue disorders	Tendonitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Trigger finger	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Trigger finger	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Trigger finger	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Europe	214	30,5	3	1,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		America	282	40,2	6	2,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asia Pacific (inc. Australia)	205	29,2	7	3,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	America	282	40,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	America	282	40,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	America	282	40,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Europe	214	30,5	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	Europe	214	30,5	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Europe	214	30,5	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	America	282	40,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	America	282	40,2	2	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders		Europe	214	30,5	17	7,9
Nervous system disorders		America	282	40,2	16	5,7

Nervous system disorders		Asia Pacific (inc. Australia)	205	29,2	18	8,8
Nervous system disorders	Autonomic neuropathy	Europe	214	30,5	1	0,5
Nervous system disorders	Autonomic neuropathy	America	282	40,2	0	0,0
Nervous system disorders	Autonomic neuropathy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Balance disorder	Europe	214	30,5	1	0,5
Nervous system disorders	Balance disorder	America	282	40,2	0	0,0
Nervous system disorders	Balance disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Carotid arteriosclerosis	Europe	214	30,5	0	0,0
Nervous system disorders	Carotid arteriosclerosis	America	282	40,2	0	0,0
Nervous system disorders	Carotid arteriosclerosis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Carpal tunnel syndrome	Europe	214	30,5	0	0,0
Nervous system disorders	Carpal tunnel syndrome	America	282	40,2	0	0,0
Nervous system disorders	Carpal tunnel syndrome	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Cerebral atrophy	Europe	214	30,5	0	0,0
Nervous system disorders	Cerebral atrophy	America	282	40,2	0	0,0
Nervous system disorders	Cerebral atrophy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Cerebral disorder	Europe	214	30,5	0	0,0
Nervous system disorders	Cerebral disorder	America	282	40,2	0	0,0
Nervous system disorders	Cerebral disorder	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Cerebral infarction	Europe	214	30,5	0	0,0
Nervous system disorders	Cerebral infarction	America	282	40,2	0	0,0
Nervous system disorders	Cerebral infarction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Cerebrovascular accident	Europe	214	30,5	0	0,0
Nervous system disorders	Cerebrovascular accident	America	282	40,2	1	0,4
Nervous system disorders	Cerebrovascular accident	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Cervicobrachial syndrome	Europe	214	30,5	1	0,5
Nervous system disorders	Cervicobrachial syndrome	America	282	40,2	0	0,0
Nervous system disorders	Cervicobrachial syndrome	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Cognitive disorder	Europe	214	30,5	0	0,0
Nervous system disorders	Cognitive disorder	America	282	40,2	1	0,4
Nervous system disorders	Cognitive disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Dementia Alzheimer's type	Europe	214	30,5	0	0,0
Nervous system disorders	Dementia Alzheimer's type	America	282	40,2	2	0,7
Nervous system disorders	Dementia Alzheimer's type	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Diabetic neuropathy	Europe	214	30,5	0	0,0
Nervous system disorders	Diabetic neuropathy	America	282	40,2	1	0,4
Nervous system disorders	Diabetic neuropathy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Dizziness	Europe	214	30,5	3	1,4
Nervous system disorders	Dizziness	America	282	40,2	0	0,0
Nervous system disorders	Dizziness	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Nervous system disorders	Dysarthria	Europe	214	30,5	0	0,0
Nervous system disorders	Dysarthria	America	282	40,2	0	0,0
Nervous system disorders	Dysarthria	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Encephalopathy	Europe	214	30,5	0	0,0
Nervous system disorders	Encephalopathy	America	282	40,2	1	0,4
Nervous system disorders	Encephalopathy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Headache	Europe	214	30,5	6	2,8
Nervous system disorders	Headache	America	282	40,2	3	1,1
Nervous system disorders	Headache	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Nervous system disorders	Hypoaesthesia	Europe	214	30,5	0	0,0
Nervous system disorders	Hypoaesthesia	America	282	40,2	0	0,0
Nervous system disorders	Hypoaesthesia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Intercostal neuralgia	Europe	214	30,5	0	0,0
Nervous system disorders	Intercostal neuralgia	America	282	40,2	0	0,0
Nervous system disorders	Intercostal neuralgia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Ischaemic stroke	Europe	214	30,5	1	0,5
Nervous system disorders	Ischaemic stroke	America	282	40,2	0	0,0
Nervous system disorders	Ischaemic stroke	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Lacunar infarction	Europe	214	30,5	0	0,0
Nervous system disorders	Lacunar infarction	America	282	40,2	0	0,0
Nervous system disorders	Lacunar infarction	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Nervous system disorders	Loss of consciousness	Europe	214	30,5	1	0,5
Nervous system disorders	Loss of consciousness	America	282	40,2	0	0,0
Nervous system disorders	Loss of consciousness	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Lumbar radiculopathy	Europe	214	30,5	0	0,0
Nervous system disorders	Lumbar radiculopathy	America	282	40,2	1	0,4
Nervous system disorders	Lumbar radiculopathy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Migraine	Europe	214	30,5	1	0,5
Nervous system disorders	Migraine	America	282	40,2	0	0,0
Nervous system disorders	Migraine	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Neuralgia	Europe	214	30,5	0	0,0
Nervous system disorders	Neuralgia	America	282	40,2	1	0,4
Nervous system disorders	Neuralgia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Neuropathy peripheral	Europe	214	30,5	0	0,0
Nervous system disorders	Neuropathy peripheral	America	282	40,2	2	0,7
Nervous system disorders	Neuropathy peripheral	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Ophthalmic migraine	Europe	214	30,5	0	0,0
Nervous system disorders	Ophthalmic migraine	America	282	40,2	1	0,4
Nervous system disorders	Ophthalmic migraine	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Paralysis	Europe	214	30,5	0	0,0
Nervous system disorders	Paralysis	America	282	40,2	0	0,0
Nervous system disorders	Paralysis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Parkinsonism	Europe	214	30,5	0	0,0

Nervous system disorders	Parkinsonism	America	282	40,2	0	0,0
Nervous system disorders	Parkinsonism	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Presyncope	Europe	214	30,5	1	0,5
Nervous system disorders	Presyncope	America	282	40,2	0	0,0
Nervous system disorders	Presyncope	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Sciatica	Europe	214	30,5	2	0,9
Nervous system disorders	Sciatica	America	282	40,2	0	0,0
Nervous system disorders	Sciatica	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Syncope	Europe	214	30,5	0	0,0
Nervous system disorders	Syncope	America	282	40,2	3	1,1
Nervous system disorders	Syncope	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Product issues		Europe	214	30,5	0	0,0
Product issues		America	282	40,2	1	0,4
Product issues		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Product issues	Device physical property issue	Europe	214	30,5	0	0,0
Product issues	Device physical property issue	America	282	40,2	1	0,4
Product issues	Device physical property issue	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Psychiatric disorders		Europe	214	30,5	1	0,5
Psychiatric disorders		America	282	40,2	4	1,4
Psychiatric disorders		Asia Pacific (inc. Australia)	205	29,2	4	2,0
Psychiatric disorders	Anxiety	Europe	214	30,5	0	0,0
Psychiatric disorders	Anxiety	America	282	40,2	1	0,4
Psychiatric disorders	Anxiety	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Psychiatric disorders	Attention deficit hyperactivity disorder	Europe	214	30,5	0	0,0
Psychiatric disorders	Attention deficit hyperactivity disorder	America	282	40,2	1	0,4
Psychiatric disorders	Attention deficit hyperactivity disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Psychiatric disorders	Depression	Europe	214	30,5	1	0,5
Psychiatric disorders	Depression	America	282	40,2	0	0,0
Psychiatric disorders	Depression	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Psychiatric disorders	Generalised anxiety disorder	Europe	214	30,5	0	0,0
Psychiatric disorders	Generalised anxiety disorder	America	282	40,2	1	0,4
Psychiatric disorders	Generalised anxiety disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Psychiatric disorders	Insomnia	Europe	214	30,5	0	0,0
Psychiatric disorders	Insomnia	America	282	40,2	1	0,4
Psychiatric disorders	Insomnia	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Psychiatric disorders	Sleep disorder	Europe	214	30,5	0	0,0
Psychiatric disorders	Sleep disorder	America	282	40,2	0	0,0
Psychiatric disorders	Sleep disorder	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders		Europe	214	30,5	5	2,3
Renal and urinary disorders		America	282	40,2	8	2,8
Renal and urinary disorders		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Renal and urinary disorders	Acute kidney injury	Europe	214	30,5	1	0,5
Renal and urinary disorders	Acute kidney injury	America	282	40,2	1	0,4
Renal and urinary disorders	Acute kidney injury	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	Cystitis interstitial	Europe	214	30,5	0	0,0
Renal and urinary disorders	Cystitis interstitial	America	282	40,2	0	0,0
Renal and urinary disorders	Cystitis interstitial	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	Diabetic nephropathy	Europe	214	30,5	0	0,0
Renal and urinary disorders	Diabetic nephropathy	America	282	40,2	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	Dysuria	Europe	214	30,5	1	0,5
Renal and urinary disorders	Dysuria	America	282	40,2	0	0,0
Renal and urinary disorders	Dysuria	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	End stage renal disease	Europe	214	30,5	0	0,0
Renal and urinary disorders	End stage renal disease	America	282	40,2	1	0,4
Renal and urinary disorders	End stage renal disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Haematuria	Europe	214	30,5	1	0,5
Renal and urinary disorders	Haematuria	America	282	40,2	0	0,0
Renal and urinary disorders	Haematuria	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Hypertonic bladder	Europe	214	30,5	0	0,0
Renal and urinary disorders	Hypertonic bladder	America	282	40,2	1	0,4
Renal and urinary disorders	Hypertonic bladder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Nephrolithiasis	Europe	214	30,5	0	0,0
Renal and urinary disorders	Nephrolithiasis	America	282	40,2	2	0,7
Renal and urinary disorders	Nephrolithiasis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	Nephropathy	Europe	214	30,5	0	0,0
Renal and urinary disorders	Nephropathy	America	282	40,2	1	0,4
Renal and urinary disorders	Nephropathy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Renal failure	Europe	214	30,5	1	0,5
Renal and urinary disorders	Renal failure	America	282	40,2	1	0,4
Renal and urinary disorders	Renal failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Urinary retention	Europe	214	30,5	0	0,0
Renal and urinary disorders	Urinary retention	America	282	40,2	1	0,4
Renal and urinary disorders	Urinary retention	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Urinary tract inflammation	Europe	214	30,5	1	0,5
Renal and urinary disorders	Urinary tract inflammation	America	282	40,2	0	0,0
Renal and urinary disorders	Urinary tract inflammation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Reproductive system and breast disorders		Europe	214	30,5	1	0,5
Reproductive system and breast disorders		America	282	40,2	3	1,1

Reproductive system and breast disorders		Asia Pacific (inc. Australia)	205	29,2	2	1,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Europe	214	30,5	1	0,5
Reproductive system and breast disorders	Benign prostatic hyperplasia	America	282	40,2	1	0,4
Reproductive system and breast disorders	Benign prostatic hyperplasia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Reproductive system and breast disorders	Cystocele	Europe	214	30,5	0	0,0
Reproductive system and breast disorders	Cystocele	America	282	40,2	1	0,4
Reproductive system and breast disorders	Cystocele	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Reproductive system and breast disorders	Gynaecomastia	Europe	214	30,5	0	0,0
Reproductive system and breast disorders	Gynaecomastia	America	282	40,2	0	0,0
Reproductive system and breast disorders	Gynaecomastia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Reproductive system and breast disorders	Prostatitis	Europe	214	30,5	0	0,0
Reproductive system and breast disorders	Prostatitis	America	282	40,2	0	0,0
Reproductive system and breast disorders	Prostatitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Reproductive system and breast disorders	Vaginal ulceration	Europe	214	30,5	0	0,0
Reproductive system and breast disorders	Vaginal ulceration	America	282	40,2	1	0,4
Reproductive system and breast disorders	Vaginal ulceration	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders		Europe	214	30,5	10	4,7
Respiratory, thoracic and mediastinal disorders		America	282	40,2	9	3,2
Respiratory, thoracic and mediastinal disorders		Asia Pacific (inc. Australia)	205	29,2	12	5,9
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	America	282	40,2	2	0,7
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Asthma	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Asthma	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Asthma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Europe	214	30,5	3	1,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	America	282	40,2	3	1,1
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Cough	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Cough	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Dry throat	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Dry throat	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Dry throat	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Dyspnoea	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Epistaxis	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung opacity	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung opacity	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung opacity	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Nasal congestion	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Respiratory, thoracic and mediastinal disorders	Pleural thickening	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural thickening	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural thickening	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	America	282	40,2	2	0,7
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders		Europe	214	30,5	10	4,7
Skin and subcutaneous tissue disorders		America	282	40,2	6	2,1
Skin and subcutaneous tissue disorders		Asia Pacific (inc. Australia)	205	29,2	6	2,9
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Androgenetic alopecia	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Dermal cyst	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Dermal cyst	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Dermal cyst	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Skin and subcutaneous tissue disorders	Dermatitis allergic	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Dermatitis allergic	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis allergic	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	Europe	214	30,5	2	0,9
Skin and subcutaneous tissue disorders	Dermatitis contact	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Skin and subcutaneous tissue disorders	Diabetic foot	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	America	282	40,2	2	0,7
Skin and subcutaneous tissue disorders	Diabetic foot	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Eczema	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Eczema	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Eczema	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Skin and subcutaneous tissue disorders	Erythema	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Erythema	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Erythema	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Hyperkeratosis	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Hyperkeratosis	America	282	40,2	1	0,4
Skin and subcutaneous tissue disorders	Hyperkeratosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Ingrowing nail	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Ingrowing nail	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Ingrowing nail	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Skin and subcutaneous tissue disorders	Nail bed bleeding	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Skin and subcutaneous tissue disorders	Nail dystrophy	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Nail dystrophy	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Purpura	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Purpura	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Purpura	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Skin and subcutaneous tissue disorders	Rash	Europe	214	30,5	2	0,9
Skin and subcutaneous tissue disorders	Rash	America	282	40,2	1	0,4
Skin and subcutaneous tissue disorders	Rash	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Skin and subcutaneous tissue disorders	Skin lesion	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Skin lesion	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Skin lesion	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Skin ulcer	America	282	40,2	1	0,4
Skin and subcutaneous tissue disorders	Skin ulcer	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Toxic skin eruption	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Toxic skin eruption	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Toxic skin eruption	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	America	282	40,2	1	0,4
Skin and subcutaneous tissue disorders	Urticaria	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures		Europe	214	30,5	6	2,8
Surgical and medical procedures		America	282	40,2	4	1,4
Surgical and medical procedures		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Dental implantation	Europe	214	30,5	1	0,5
Surgical and medical procedures	Dental implantation	America	282	40,2	2	0,7
Surgical and medical procedures	Dental implantation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	Europe	214	30,5	1	0,5
Surgical and medical procedures	Large intestinal polypectomy	America	282	40,2	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Ligament operation	Europe	214	30,5	0	0,0
Surgical and medical procedures	Ligament operation	America	282	40,2	1	0,4
Surgical and medical procedures	Ligament operation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Neurectomy	Europe	214	30,5	1	0,5
Surgical and medical procedures	Neurectomy	America	282	40,2	0	0,0
Surgical and medical procedures	Neurectomy	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Surgical and medical procedures	Renal transplant	Europe	214	30,5	0	0,0
Surgical and medical procedures	Renal transplant	America	282	40,2	1	0,4
Surgical and medical procedures	Renal transplant	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Toe operation	Europe	214	30,5	1	0,5
Surgical and medical procedures	Toe operation	America	282	40,2	0	0,0
Surgical and medical procedures	Toe operation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Tooth extraction	Europe	214	30,5	3	1,4
Surgical and medical procedures	Tooth extraction	America	282	40,2	1	0,4
Surgical and medical procedures	Tooth extraction	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders		Europe	214	30,5	15	7,0
Vascular disorders		America	282	40,2	14	5,0
Vascular disorders		Asia Pacific (inc. Australia)	205	29,2	10	4,9
Vascular disorders	Aortic aneurysm	Europe	214	30,5	0	0,0
Vascular disorders	Aortic aneurysm	America	282	40,2	1	0,4
Vascular disorders	Aortic aneurysm	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Aortic dissection	Europe	214	30,5	0	0,0
Vascular disorders	Aortic dissection	America	282	40,2	1	0,4
Vascular disorders	Aortic dissection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Aortic stenosis	Europe	214	30,5	1	0,5
Vascular disorders	Aortic stenosis	America	282	40,2	0	0,0
Vascular disorders	Aortic stenosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Deep vein thrombosis	Europe	214	30,5	0	0,0
Vascular disorders	Deep vein thrombosis	America	282	40,2	1	0,4
Vascular disorders	Deep vein thrombosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Haematoma	Europe	214	30,5	0	0,0
Vascular disorders	Haematoma	America	282	40,2	0	0,0
Vascular disorders	Haematoma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Vascular disorders	Haemorrhage	Europe	214	30,5	0	0,0
Vascular disorders	Haemorrhage	America	282	40,2	0	0,0
Vascular disorders	Haemorrhage	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Vascular disorders	Hypertension	Europe	214	30,5	10	4,7
Vascular disorders	Hypertension	America	282	40,2	7	2,5
Vascular disorders	Hypertension	Asia Pacific (inc. Australia)	205	29,2	6	2,9
Vascular disorders	Hypertensive crisis	Europe	214	30,5	2	0,9
Vascular disorders	Hypertensive crisis	America	282	40,2	1	0,4
Vascular disorders	Hypertensive crisis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Hypotension	Europe	214	30,5	2	0,9
Vascular disorders	Hypotension	America	282	40,2	1	0,4
Vascular disorders	Hypotension	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Vascular disorders	Internal haemorrhage	Europe	214	30,5	0	0,0
Vascular disorders	Internal haemorrhage	America	282	40,2	0	0,0
Vascular disorders	Internal haemorrhage	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Vascular disorders	Lymphoedema	Europe	214	30,5	0	0,0
Vascular disorders	Lymphoedema	America	282	40,2	1	0,4
Vascular disorders	Lymphoedema	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Peripheral artery aneurysm	Europe	214	30,5	0	0,0
Vascular disorders	Peripheral artery aneurysm	America	282	40,2	0	0,0
Vascular disorders	Peripheral artery aneurysm	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Vascular disorders	Secondary hypertension	Europe	214	30,5	1	0,5
Vascular disorders	Secondary hypertension	America	282	40,2	0	0,0
Vascular disorders	Secondary hypertension	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Thrombosis	Europe	214	30,5	0	0,0
Vascular disorders	Thrombosis	America	282	40,2	1	0,4
Vascular disorders	Thrombosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_eg_AE_WK72_SEa24_29AUG2023_41986.xls
26APR2024 18:00

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any AEs
 MODEL: Unstratified Analysis
 STUDY: GW196
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity			Paricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Blood and lymphatic system disorders		White	474	67.6	7	1.5
Blood and lymphatic system disorders		Asian	176	25.1	3	1.7
Blood and lymphatic system disorders		Other	27	3.9	0	0.0
Blood and lymphatic system disorders		Unknown	24	3.4	0	0.0
Blood and lymphatic system disorders	Anaemia	White	474	67.6	7	1.5
Blood and lymphatic system disorders	Anaemia	Asian	176	25.1	1	0.6
Blood and lymphatic system disorders	Anaemia	Other	27	3.9	0	0.0
Blood and lymphatic system disorders	Anaemia	Unknown	24	3.4	0	0.0
Blood and lymphatic system disorders	Deficiency anaemia	White	474	67.6	0	0.0
Blood and lymphatic system disorders	Deficiency anaemia	Asian	176	25.1	1	0.6
Blood and lymphatic system disorders	Deficiency anaemia	Other	27	3.9	0	0.0
Blood and lymphatic system disorders	Deficiency anaemia	Unknown	24	3.4	0	0.0
Blood and lymphatic system disorders	Iron deficiency anaemia	White	474	67.6	0	0.0
Blood and lymphatic system disorders	Iron deficiency anaemia	Asian	176	25.1	1	0.6
Blood and lymphatic system disorders	Iron deficiency anaemia	Other	27	3.9	0	0.0
Blood and lymphatic system disorders	Iron deficiency anaemia	Unknown	24	3.4	0	0.0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	White	474	67.6	1	0.2
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Asian	176	25.1	0	0.0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Other	27	3.9	0	0.0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Unknown	24	3.4	0	0.0
Cardiac disorders		White	474	67.6	23	4.9
Cardiac disorders		Asian	176	25.1	6	3.4
Cardiac disorders		Other	27	3.9	1	3.7
Cardiac disorders		Unknown	24	3.4	0	0.0
Cardiac disorders	Acute left ventricular failure	White	474	67.6	1	0.2
Cardiac disorders	Acute left ventricular failure	Asian	176	25.1	0	0.0
Cardiac disorders	Acute left ventricular failure	Other	27	3.9	0	0.0
Cardiac disorders	Acute left ventricular failure	Unknown	24	3.4	0	0.0
Cardiac disorders	Acute myocardial infarction	White	474	67.6	2	0.4
Cardiac disorders	Acute myocardial infarction	Asian	176	25.1	0	0.0
Cardiac disorders	Acute myocardial infarction	Other	27	3.9	0	0.0
Cardiac disorders	Acute myocardial infarction	Unknown	24	3.4	0	0.0
Cardiac disorders	Aortic valve incompetence	White	474	67.6	1	0.2
Cardiac disorders	Aortic valve incompetence	Asian	176	25.1	0	0.0
Cardiac disorders	Aortic valve incompetence	Other	27	3.9	0	0.0
Cardiac disorders	Aortic valve incompetence	Unknown	24	3.4	0	0.0
Cardiac disorders	Arrhythmia	White	474	67.6	1	0.2
Cardiac disorders	Arrhythmia	Asian	176	25.1	0	0.0
Cardiac disorders	Arrhythmia	Other	27	3.9	0	0.0
Cardiac disorders	Arrhythmia	Unknown	24	3.4	0	0.0
Cardiac disorders	Atrial fibrillation	White	474	67.6	6	1.3
Cardiac disorders	Atrial fibrillation	Asian	176	25.1	2	1.1
Cardiac disorders	Atrial fibrillation	Other	27	3.9	1	3.7
Cardiac disorders	Atrial fibrillation	Unknown	24	3.4	0	0.0
Cardiac disorders	Bradycardia	White	474	67.6	1	0.2
Cardiac disorders	Bradycardia	Asian	176	25.1	0	0.0
Cardiac disorders	Bradycardia	Other	27	3.9	0	0.0
Cardiac disorders	Bradycardia	Unknown	24	3.4	0	0.0
Cardiac disorders	Cardiac failure	White	474	67.6	1	0.2
Cardiac disorders	Cardiac failure	Asian	176	25.1	0	0.0
Cardiac disorders	Cardiac failure	Other	27	3.9	0	0.0
Cardiac disorders	Cardiac failure	Unknown	24	3.4	0	0.0
Cardiac disorders	Cardiac failure congestive	White	474	67.6	2	0.4
Cardiac disorders	Cardiac failure congestive	Asian	176	25.1	0	0.0
Cardiac disorders	Cardiac failure congestive	Other	27	3.9	0	0.0
Cardiac disorders	Cardiac failure congestive	Unknown	24	3.4	0	0.0
Cardiac disorders	Cardiomegaly	White	474	67.6	1	0.2
Cardiac disorders	Cardiomegaly	Asian	176	25.1	0	0.0
Cardiac disorders	Cardiomegaly	Other	27	3.9	0	0.0
Cardiac disorders	Cardiomegaly	Unknown	24	3.4	0	0.0
Cardiac disorders	Coronary artery disease	White	474	67.6	1	0.2
Cardiac disorders	Coronary artery disease	Asian	176	25.1	0	0.0
Cardiac disorders	Coronary artery disease	Other	27	3.9	0	0.0
Cardiac disorders	Coronary artery disease	Unknown	24	3.4	0	0.0
Cardiac disorders	Coronary artery stenosis	White	474	67.6	1	0.2
Cardiac disorders	Coronary artery stenosis	Asian	176	25.1	0	0.0
Cardiac disorders	Coronary artery stenosis	Other	27	3.9	0	0.0
Cardiac disorders	Coronary artery stenosis	Unknown	24	3.4	0	0.0
Cardiac disorders	Left ventricular dysfunction	White	474	67.6	1	0.2
Cardiac disorders	Left ventricular dysfunction	Asian	176	25.1	1	0.6
Cardiac disorders	Left ventricular dysfunction	Other	27	3.9	0	0.0
Cardiac disorders	Left ventricular dysfunction	Unknown	24	3.4	0	0.0
Cardiac disorders	Myocardial infarction	White	474	67.6	2	0.4
Cardiac disorders	Myocardial infarction	Asian	176	25.1	1	0.6
Cardiac disorders	Myocardial infarction	Other	27	3.9	0	0.0
Cardiac disorders	Myocardial infarction	Unknown	24	3.4	0	0.0
Cardiac disorders	Myocardial ischaemia	White	474	67.6	3	0.6
Cardiac disorders	Myocardial ischaemia	Asian	176	25.1	0	0.0
Cardiac disorders	Myocardial ischaemia	Other	27	3.9	0	0.0
Cardiac disorders	Myocardial ischaemia	Unknown	24	3.4	0	0.0
Cardiac disorders	Palpitations	White	474	67.6	1	0.2
Cardiac disorders	Palpitations	Asian	176	25.1	0	0.0
Cardiac disorders	Palpitations	Other	27	3.9	0	0.0
Cardiac disorders	Palpitations	Unknown	24	3.4	0	0.0
Cardiac disorders	Pericardial effusion	White	474	67.6	0	0.0
Cardiac disorders	Pericardial effusion	Asian	176	25.1	1	0.6
Cardiac disorders	Pericardial effusion	Other	27	3.9	0	0.0
Cardiac disorders	Pericardial effusion	Unknown	24	3.4	0	0.0
Cardiac disorders	Sinus tachycardia	White	474	67.6	1	0.2
Cardiac disorders	Sinus tachycardia	Asian	176	25.1	0	0.0
Cardiac disorders	Sinus tachycardia	Other	27	3.9	0	0.0
Cardiac disorders	Sinus tachycardia	Unknown	24	3.4	0	0.0
Cardiac disorders	Stress cardiomyopathy	White	474	67.6	1	0.2
Cardiac disorders	Stress cardiomyopathy	Asian	176	25.1	0	0.0
Cardiac disorders	Stress cardiomyopathy	Other	27	3.9	0	0.0
Cardiac disorders	Stress cardiomyopathy	Unknown	24	3.4	0	0.0
Cardiac disorders	Supraventricular tachycardia	White	474	67.6	0	0.0
Cardiac disorders	Supraventricular tachycardia	Asian	176	25.1	0	0.0
Cardiac disorders	Supraventricular tachycardia	Other	27	3.9	0	0.0

Cardiac disorders	Supraventricular tachycardia	Unknown	24	3.4	0	0.0
Cardiac disorders	Tachycardia	White	474	67.6	1	0.2
Cardiac disorders	Tachycardia	Asian	176	25.1	1	0.6
Cardiac disorders	Tachycardia	Other	27	3.9	0	0.0
Cardiac disorders	Tachycardia	Unknown	24	3.4	0	0.0
Congenital, familial and genetic disorders		White	474	67.6	1	0.2
Congenital, familial and genetic disorders		Asian	176	25.1	0	0.0
Congenital, familial and genetic disorders		Other	27	3.9	1	3.7
Congenital, familial and genetic disorders		Unknown	24	3.4	0	0.0
Congenital, familial and genetic disorders	Corneal dystrophy	White	474	67.6	1	0.2
Congenital, familial and genetic disorders	Corneal dystrophy	Asian	176	25.1	0	0.0
Congenital, familial and genetic disorders	Corneal dystrophy	Other	27	3.9	1	3.7
Congenital, familial and genetic disorders	Corneal dystrophy	Unknown	24	3.4	0	0.0
Ear and labyrinth disorders		White	474	67.6	1	0.2
Ear and labyrinth disorders		Asian	176	25.1	2	1.1
Ear and labyrinth disorders		Other	27	3.9	0	0.0
Ear and labyrinth disorders		Unknown	24	3.4	1	4.2
Ear and labyrinth disorders	Vertigo	White	474	67.6	1	0.2
Ear and labyrinth disorders	Vertigo	Asian	176	25.1	2	1.1
Ear and labyrinth disorders	Vertigo	Other	27	3.9	0	0.0
Ear and labyrinth disorders	Vertigo	Unknown	24	3.4	1	4.2
Endocrine disorders		White	474	67.6	1	0.2
Endocrine disorders		Asian	176	25.1	2	1.1
Endocrine disorders		Other	27	3.9	1	3.7
Endocrine disorders		Unknown	24	3.4	0	0.0
Endocrine disorders	Adrenal insufficiency	White	474	67.6	0	0.0
Endocrine disorders	Adrenal insufficiency	Asian	176	25.1	1	0.6
Endocrine disorders	Adrenal insufficiency	Other	27	3.9	0	0.0
Endocrine disorders	Adrenal insufficiency	Unknown	24	3.4	0	0.0
Endocrine disorders	Adrenal mass	White	474	67.6	2	0.4
Endocrine disorders	Adrenal mass	Asian	176	25.1	0	0.0
Endocrine disorders	Adrenal mass	Other	27	3.9	0	0.0
Endocrine disorders	Adrenal mass	Unknown	24	3.4	1	0.0
Endocrine disorders	Adrenomegaly	White	474	67.6	1	0.2
Endocrine disorders	Adrenomegaly	Asian	176	25.1	0	0.0
Endocrine disorders	Adrenomegaly	Other	27	3.9	0	0.0
Endocrine disorders	Adrenomegaly	Unknown	24	3.4	0	0.0
Endocrine disorders	Androgen deficiency	White	474	67.6	0	0.2
Endocrine disorders	Androgen deficiency	Asian	176	25.1	0	0.0
Endocrine disorders	Androgen deficiency	Other	27	3.9	0	0.0
Endocrine disorders	Androgen deficiency	Unknown	24	3.4	0	0.0
Endocrine disorders	Goitre	White	474	67.6	1	0.2
Endocrine disorders	Goitre	Asian	176	25.1	0	0.0
Endocrine disorders	Goitre	Other	27	3.9	0	0.0
Endocrine disorders	Goitre	Unknown	24	3.4	0	0.0
Endocrine disorders	Hypothyroidism	White	474	67.6	3	0.6
Endocrine disorders	Hypothyroidism	Asian	176	25.1	0	0.0
Endocrine disorders	Hypothyroidism	Other	27	3.9	1	3.7
Endocrine disorders	Hypothyroidism	Unknown	24	3.4	0	0.0
Endocrine disorders	Thyroid cyst	White	474	67.6	0	0.0
Endocrine disorders	Thyroid cyst	Asian	176	25.1	1	0.6
Endocrine disorders	Thyroid cyst	Other	27	3.9	0	0.0
Endocrine disorders	Thyroid cyst	Unknown	24	3.4	0	0.0
Endocrine disorders	Thyroid mass	White	474	67.6	0	0.0
Endocrine disorders	Thyroid mass	Asian	176	25.1	1	0.6
Endocrine disorders	Thyroid mass	Other	27	3.9	0	0.0
Endocrine disorders	Thyroid mass	Unknown	24	3.4	0	0.0
Eye disorders		White	474	67.6	184	38.8
Eye disorders		Asian	176	25.1	57	32.4
Eye disorders		Other	27	3.9	12	44.4
Eye disorders		Unknown	24	3.4	9	37.5
Eye disorders	Age-related macular degeneration	White	474	67.6	0	0.0
Eye disorders	Age-related macular degeneration	Asian	176	25.1	1	0.6
Eye disorders	Age-related macular degeneration	Other	27	3.9	0	0.0
Eye disorders	Age-related macular degeneration	Unknown	24	3.4	0	0.0
Eye disorders	Anisocoria	White	474	67.6	1	0.2
Eye disorders	Anisocoria	Asian	176	25.1	0	0.0
Eye disorders	Anisocoria	Other	27	3.9	0	0.0
Eye disorders	Anisocoria	Unknown	24	3.4	0	0.0
Eye disorders	Asthenopia	White	474	67.6	0	0.0
Eye disorders	Asthenopia	Asian	176	25.1	2	1.1
Eye disorders	Asthenopia	Other	27	3.9	0	0.0
Eye disorders	Asthenopia	Unknown	24	3.4	0	0.0
Eye disorders	Blepharitis	White	474	67.6	5	1.1
Eye disorders	Blepharitis	Asian	176	25.1	0	0.0
Eye disorders	Blepharitis	Other	27	3.9	0	0.0
Eye disorders	Blepharitis	Unknown	24	3.4	0	0.0
Eye disorders	Borderline glaucoma	White	474	67.6	3	0.4
Eye disorders	Borderline glaucoma	Asian	176	25.1	0	0.0
Eye disorders	Borderline glaucoma	Other	27	3.9	0	0.0
Eye disorders	Borderline glaucoma	Unknown	24	3.4	0	0.0
Eye disorders	Cataract	White	474	67.6	28	5.9
Eye disorders	Cataract	Asian	176	25.1	1	1.7
Eye disorders	Cataract	Other	27	3.9	2	7.4
Eye disorders	Cataract	Unknown	24	3.4	1	4.2
Eye disorders	Cataract nuclear	White	474	67.6	1	0.2
Eye disorders	Cataract nuclear	Asian	176	25.1	0	0.0
Eye disorders	Cataract nuclear	Other	27	3.9	0	0.0
Eye disorders	Cataract nuclear	Unknown	24	3.4	0	0.0
Eye disorders	Cataract subcapsular	White	474	67.6	1	0.2
Eye disorders	Cataract subcapsular	Asian	176	25.1	0	0.0
Eye disorders	Cataract subcapsular	Other	27	3.9	0	0.0
Eye disorders	Cataract subcapsular	Unknown	24	3.4	0	0.0
Eye disorders	Central serous chorioretinopathy	White	474	67.6	0	0.4
Eye disorders	Central serous chorioretinopathy	Asian	176	25.1	2	1.1
Eye disorders	Central serous chorioretinopathy	Other	27	3.9	0	0.0
Eye disorders	Central serous chorioretinopathy	Unknown	24	3.4	0	0.0
Eye disorders	Chalazion	White	474	67.6	2	0.4
Eye disorders	Chalazion	Asian	176	25.1	2	1.1
Eye disorders	Chalazion	Other	27	3.9	0	0.0
Eye disorders	Chalazion	Unknown	24	3.4	0	0.0
Eye disorders	Choroidal effusion	White	474	67.6	1	0.2
Eye disorders	Choroidal effusion	Asian	176	25.1	0	0.0
Eye disorders	Choroidal effusion	Other	27	3.9	0	0.0
Eye disorders	Choroidal effusion	Unknown	24	3.4	0	0.0
Eye disorders	Conjunctival hemorrhage	White	474	67.6	15	3.2
Eye disorders	Conjunctival hemorrhage	Asian	176	25.1	2	1.1
Eye disorders	Conjunctival hemorrhage	Other	27	3.9	4	14.8

eye disorders	Conjunctival hemorrhage	Unknown	24	3.4	0	0.0
eye disorders	Conjunctival hyperaemia	White	474	67.6	2	0.4
eye disorders	Conjunctival hyperaemia	Asian	176	25.1	0	0.0
eye disorders	Conjunctival hyperaemia	Other	27	3.9	0	0.0
eye disorders	Conjunctival hyperaemia	Unknown	24	3.4	0	0.0
eye disorders	Conjunctival telangiectasia	White	474	67.6	0	0.0
eye disorders	Conjunctival telangiectasia	Asian	176	25.1	1	0.6
eye disorders	Conjunctival telangiectasia	Other	27	3.9	0	0.0
eye disorders	Conjunctival telangiectasia	Unknown	24	3.4	0	0.0
eye disorders	Conjunctivitis allergic	White	474	67.6	0	0.0
eye disorders	Conjunctivitis allergic	Asian	176	25.1	1	0.6
eye disorders	Conjunctivitis allergic	Other	27	3.9	0	0.0
eye disorders	Conjunctivitis allergic	Unknown	24	3.4	0	0.0
eye disorders	Corneal deposits	White	474	67.6	1	0.2
eye disorders	Corneal deposits	Asian	176	25.1	0	0.0
eye disorders	Corneal deposits	Other	27	3.9	0	0.0
eye disorders	Corneal deposits	Unknown	24	3.4	0	0.0
eye disorders	Corneal erosion	White	474	67.6	1	0.2
eye disorders	Corneal erosion	Asian	176	25.1	0	0.0
eye disorders	Corneal erosion	Other	27	3.9	0	0.0
eye disorders	Corneal erosion	Unknown	24	3.4	0	0.0
eye disorders	Corneal infiltrates	White	474	67.6	1	0.2
eye disorders	Corneal infiltrates	Asian	176	25.1	0	0.0
eye disorders	Corneal infiltrates	Other	27	3.9	0	0.0
eye disorders	Corneal infiltrates	Unknown	24	3.4	0	0.0
eye disorders	Corneal opacity	White	474	67.6	1	0.2
eye disorders	Corneal opacity	Asian	176	25.1	0	0.0
eye disorders	Corneal opacity	Other	27	3.9	0	0.0
eye disorders	Corneal opacity	Unknown	24	3.4	0	0.0
eye disorders	Corneal pigmentation	White	474	67.6	1	0.2
eye disorders	Corneal pigmentation	Asian	176	25.1	0	0.0
eye disorders	Corneal pigmentation	Other	27	3.9	0	0.0
eye disorders	Corneal pigmentation	Unknown	24	3.4	0	0.0
eye disorders	Cystoid macular oedema	White	474	67.6	19	4.0
eye disorders	Cystoid macular oedema	Asian	176	25.1	8	4.5
eye disorders	Cystoid macular oedema	Other	27	3.9	0	3.7
eye disorders	Cystoid macular oedema	Unknown	24	3.4	0	0.0
eye disorders	Detachment of retinal pigment epithelium	White	474	67.6	2	0.4
eye disorders	Detachment of retinal pigment epithelium	Asian	176	25.1	0	0.0
eye disorders	Detachment of retinal pigment epithelium	Other	27	3.9	0	0.0
eye disorders	Detachment of retinal pigment epithelium	Unknown	24	3.4	0	0.0
eye disorders	Diabetic retinal oedema	White	474	67.6	0	0.0
eye disorders	Diabetic retinal oedema	Asian	176	25.1	1	0.6
eye disorders	Diabetic retinal oedema	Other	27	3.9	0	0.0
eye disorders	Diabetic retinal oedema	Unknown	24	3.4	0	0.0
eye disorders	Diabetic retinopathy	White	474	67.6	0	0.0
eye disorders	Diabetic retinopathy	Asian	176	25.1	1	0.6
eye disorders	Diabetic retinopathy	Other	27	3.9	1	3.7
eye disorders	Diabetic retinopathy	Unknown	24	3.4	0	0.0
eye disorders	Diplopia	White	474	67.6	0	0.0
eye disorders	Diplopia	Asian	176	25.1	0	0.0
eye disorders	Diplopia	Other	27	3.9	0	0.0
eye disorders	Diplopia	Unknown	24	3.4	1	4.2
eye disorders	Dry age-related macular degeneration	White	474	67.6	1	0.2
eye disorders	Dry age-related macular degeneration	Asian	176	25.1	0	0.0
eye disorders	Dry age-related macular degeneration	Other	27	3.9	0	0.0
eye disorders	Dry age-related macular degeneration	Unknown	24	3.4	0	0.0
eye disorders	Dry eye	White	474	67.6	9	1.9
eye disorders	Dry eye	Asian	176	25.1	5	2.8
eye disorders	Dry eye	Other	27	3.9	1	3.7
eye disorders	Dry eye	Unknown	24	3.4	0	0.0
eye disorders	Eczema eyelids	White	474	67.6	0	0.0
eye disorders	Eczema eyelids	Asian	176	25.1	0	0.0
eye disorders	Eczema eyelids	Other	27	3.9	0	0.0
eye disorders	Eczema eyelids	Unknown	24	3.4	1	4.2
eye disorders	Epi-retinal membrane	White	474	67.6	19	2.5
eye disorders	Epi-retinal membrane	Asian	176	25.1	2	1.7
eye disorders	Epi-retinal membrane	Other	27	3.9	2	7.4
eye disorders	Epi-retinal membrane	Unknown	24	3.4	0	0.0
eye disorders	Episcleritis	White	474	67.6	1	0.2
eye disorders	Episcleritis	Asian	176	25.1	0	0.0
eye disorders	Episcleritis	Other	27	3.9	0	0.0
eye disorders	Episcleritis	Unknown	24	3.4	0	0.0
eye disorders	Eye irritation	White	474	67.6	1	0.2
eye disorders	Eye irritation	Asian	176	25.1	0	0.0
eye disorders	Eye irritation	Other	27	3.9	0	0.0
eye disorders	Eye irritation	Unknown	24	3.4	0	0.0
eye disorders	Eye pain	White	474	67.6	7	1.5
eye disorders	Eye pain	Asian	176	25.1	1	0.6
eye disorders	Eye pain	Other	27	3.9	2	7.4
eye disorders	Eye pain	Unknown	24	3.4	0	0.0
eye disorders	Eye pruritus	White	474	67.6	1	0.6
eye disorders	Eye pruritus	Asian	176	25.1	1	0.6
eye disorders	Eye pruritus	Other	27	3.9	0	0.0
eye disorders	Eye pruritus	Unknown	24	3.4	0	0.0
eye disorders	Eyelid cyst	White	474	67.6	1	0.2
eye disorders	Eyelid cyst	Asian	176	25.1	0	0.0
eye disorders	Eyelid cyst	Other	27	3.9	0	0.0
eye disorders	Eyelid cyst	Unknown	24	3.4	0	0.0
eye disorders	Eyelid oedema	White	474	67.6	1	0.2
eye disorders	Eyelid oedema	Asian	176	25.1	0	0.0
eye disorders	Eyelid oedema	Other	27	3.9	0	0.0
eye disorders	Eyelid oedema	Unknown	24	3.4	0	0.0
eye disorders	Foreign body sensation in eyes	White	474	67.6	2	0.4
eye disorders	Foreign body sensation in eyes	Asian	176	25.1	1	0.6
eye disorders	Foreign body sensation in eyes	Other	27	3.9	0	0.0
eye disorders	Foreign body sensation in eyes	Unknown	24	3.4	0	0.0
eye disorders	Glaucoma	White	474	67.6	11	2.3
eye disorders	Glaucoma	Asian	176	25.1	4	2.3
eye disorders	Glaucoma	Other	27	3.9	0	0.0
eye disorders	Glaucoma	Unknown	24	3.4	0	0.0
eye disorders	Hypotony of eye	White	474	67.6	1	0.2
eye disorders	Hypotony of eye	Asian	176	25.1	0	0.0
eye disorders	Hypotony of eye	Other	27	3.9	0	0.0
eye disorders	Hypotony of eye	Unknown	24	3.4	0	0.0
eye disorders	Iridocyclitis	White	474	67.6	6	1.3
eye disorders	Iridocyclitis	Asian	176	25.1	1	0.6
eye disorders	Iridocyclitis	Other	27	3.9	0	0.0
eye disorders	Iridocyclitis	Unknown	24	3.4	0	0.0
eye disorders	Iris neovascularisation	White	474	67.6	2	0.4
eye disorders	Iris neovascularisation	Asian	176	25.1	0	0.0
eye disorders	Iris neovascularisation	Other	27	3.9	0	0.0

eye disorders	Iris neovascularisation	Unknown	24	3.4	0	0.0
eye disorders	Iritis	White	474	67.6	4	0.8
eye disorders	Iritis	Asian	176	25.1	0	0.0
eye disorders	Iritis	Other	27	3.9	0	0.0
eye disorders	Iritis	Unknown	24	3.4	0	0.0
eye disorders	Keratic precipitates	White	474	67.6	0	0.0
eye disorders	Keratic precipitates	Asian	176	25.1	1	0.6
eye disorders	Keratic precipitates	Other	27	3.9	0	0.0
eye disorders	Keratic precipitates	Unknown	24	3.4	0	0.0
eye disorders	Keratitis	White	474	67.6	2	0.4
eye disorders	Keratitis	Asian	176	25.1	0	0.0
eye disorders	Keratitis	Other	27	3.9	0	0.0
eye disorders	Keratitis	Unknown	24	3.4	0	0.0
eye disorders	Keratopathy	White	474	67.6	1	0.2
eye disorders	Keratopathy	Asian	176	25.1	0	0.0
eye disorders	Keratopathy	Other	27	3.9	0	0.0
eye disorders	Keratopathy	Unknown	24	3.4	0	0.0
eye disorders	Lacrimal disorder	White	474	67.6	1	0.2
eye disorders	Lacrimal disorder	Asian	176	25.1	0	0.0
eye disorders	Lacrimal disorder	Other	27	3.9	0	0.0
eye disorders	Lacrimal disorder	Unknown	24	3.4	0	0.0
eye disorders	Lacrimation increased	White	474	67.6	1	1.1
eye disorders	Lacrimation increased	Asian	176	25.1	0	0.0
eye disorders	Lacrimation increased	Other	27	3.9	0	0.0
eye disorders	Lacrimation increased	Unknown	24	3.4	0	0.0
eye disorders	Lenticular opacities	White	474	67.6	1	0.2
eye disorders	Lenticular opacities	Asian	176	25.1	0	0.0
eye disorders	Lenticular opacities	Other	27	3.9	0	0.0
eye disorders	Lenticular opacities	Unknown	24	3.4	0	0.0
eye disorders	Macular degeneration	White	474	67.6	2	0.4
eye disorders	Macular degeneration	Asian	176	25.1	0	0.0
eye disorders	Macular degeneration	Other	27	3.9	0	0.0
eye disorders	Macular degeneration	Unknown	24	3.4	0	0.0
eye disorders	Macular degeneration	Other	27	3.9	0	0.0
eye disorders	Macular degeneration	Unknown	24	3.4	0	0.0
eye disorders	Macular detachment	White	474	67.6	2	0.4
eye disorders	Macular detachment	Asian	176	25.1	0	0.0
eye disorders	Macular detachment	Other	27	3.9	0	0.0
eye disorders	Macular detachment	Unknown	24	3.4	0	0.0
eye disorders	Macular hole	White	474	67.6	2	0.4
eye disorders	Macular hole	Asian	176	25.1	0	0.0
eye disorders	Macular hole	Other	27	3.9	0	0.0
eye disorders	Macular hole	Unknown	24	3.4	0	0.0
eye disorders	Macular ischaemia	White	474	67.6	2	0.4
eye disorders	Macular ischaemia	Asian	176	25.1	0	0.0
eye disorders	Macular ischaemia	Other	27	3.9	0	0.0
eye disorders	Macular ischaemia	Unknown	24	3.4	0	0.0
eye disorders	Macular oedema	White	474	67.6	18	3.8
eye disorders	Macular oedema	Asian	176	25.1	7	4.0
eye disorders	Macular oedema	Other	27	3.9	1	3.7
eye disorders	Macular oedema	Unknown	24	3.4	0	0.0
eye disorders	Macular scar	White	474	67.6	0	0.0
eye disorders	Macular scar	Asian	176	25.1	1	0.6
eye disorders	Macular scar	Other	27	3.9	0	0.0
eye disorders	Macular scar	Unknown	24	3.4	0	0.0
eye disorders	Melchiorianitis	White	474	67.6	1	0.2
eye disorders	Melchiorianitis	Asian	176	25.1	0	0.0
eye disorders	Melchiorianitis	Other	27	3.9	0	0.0
eye disorders	Melchiorianitis	Unknown	24	3.4	0	0.0
eye disorders	Neovascular age-related macular degeneration	White	474	67.6	1	0.2
eye disorders	Neovascular age-related macular degeneration	Asian	176	25.1	0	0.0
eye disorders	Neovascular age-related macular degeneration	Other	27	3.9	0	0.0
eye disorders	Neovascular age-related macular degeneration	Unknown	24	3.4	0	0.0
eye disorders	Non-infectious endophthalmitis	White	474	67.6	0	0.0
eye disorders	Non-infectious endophthalmitis	Asian	176	25.1	1	0.6
eye disorders	Non-infectious endophthalmitis	Other	27	3.9	0	0.0
eye disorders	Non-infectious endophthalmitis	Unknown	24	3.4	0	0.0
eye disorders	Noninfective conjunctivitis	White	474	67.6	1	0.2
eye disorders	Noninfective conjunctivitis	Asian	176	25.1	0	0.0
eye disorders	Noninfective conjunctivitis	Other	27	3.9	0	0.0
eye disorders	Noninfective conjunctivitis	Unknown	24	3.4	0	0.0
eye disorders	Normal tension glaucoma	White	474	67.6	0	0.0
eye disorders	Normal tension glaucoma	Asian	176	25.1	0	0.0
eye disorders	Normal tension glaucoma	Other	27	3.9	1	3.7
eye disorders	Normal tension glaucoma	Unknown	24	3.4	0	0.0
eye disorders	Ocular hyperaemia	White	474	67.6	2	0.4
eye disorders	Ocular hyperaemia	Asian	176	25.1	0	0.0
eye disorders	Ocular hyperaemia	Other	27	3.9	0	0.0
eye disorders	Ocular hyperaemia	Unknown	24	3.4	0	0.0
eye disorders	Ocular hypertension	White	474	67.6	7	1.5
eye disorders	Ocular hypertension	Asian	176	25.1	2	1.1
eye disorders	Ocular hypertension	Other	27	3.9	2	7.4
eye disorders	Ocular hypertension	Unknown	24	3.4	1	4.2
eye disorders	Open angle glaucoma	White	474	67.6	1	0.2
eye disorders	Open angle glaucoma	Asian	176	25.1	1	0.6
eye disorders	Open angle glaucoma	Other	27	3.9	0	0.0
eye disorders	Open angle glaucoma	Unknown	24	3.4	0	0.0
eye disorders	Optic atrophy	White	474	67.6	0	0.0
eye disorders	Optic atrophy	Asian	176	25.1	1	0.6
eye disorders	Optic atrophy	Other	27	3.9	0	0.0
eye disorders	Optic atrophy	Unknown	24	3.4	0	0.0
eye disorders	Optic disc disorder	White	474	67.6	0	0.0
eye disorders	Optic disc disorder	Asian	176	25.1	1	0.6
eye disorders	Optic disc disorder	Other	27	3.9	0	0.0
eye disorders	Optic disc disorder	Unknown	24	3.4	0	0.0
eye disorders	Optic disc haemorrhage	White	474	67.6	1	0.6
eye disorders	Optic disc haemorrhage	Asian	176	25.1	0	0.0
eye disorders	Optic disc haemorrhage	Other	27	3.9	0	0.0
eye disorders	Optic disc haemorrhage	Unknown	24	3.4	0	0.0
eye disorders	Optic disc vascular disorder	White	474	67.6	0	0.0
eye disorders	Optic disc vascular disorder	Asian	176	25.1	0	0.0
eye disorders	Optic disc vascular disorder	Other	27	3.9	0	0.0
eye disorders	Optic disc vascular disorder	Unknown	24	3.4	0	0.0
eye disorders	Papilloedema	White	474	67.6	1	0.2
eye disorders	Papilloedema	Asian	176	25.1	1	0.4
eye disorders	Papilloedema	Other	27	3.9	0	0.0
eye disorders	Papilloedema	Unknown	24	3.4	0	0.0
eye disorders	Periorbital pain	White	474	67.6	1	0.2
eye disorders	Periorbital pain	Asian	176	25.1	0	0.0
eye disorders	Periorbital pain	Other	27	3.9	0	0.0
eye disorders	Periorbital pain	Unknown	24	3.4	0	0.0
eye disorders	Photopsia	White	474	67.6	2	0.4
eye disorders	Photopsia	Asian	176	25.1	0	0.0
eye disorders	Photopsia	Other	27	3.9	0	0.0

eye disorders	Photopsia	Unknown	24	3.4	0	0.0
eye disorders	Pinguecula	White	474	67.6	1	0.2
eye disorders	Pinguecula	Asian	176	25.1	0	0.0
eye disorders	Pinguecula	Other	27	3.9	0	0.0
eye disorders	Pinguecula	Unknown	24	3.4	0	0.0
eye disorders	Posterior capsule opacification	White	474	67.6	7	1.5
eye disorders	Posterior capsule opacification	Asian	176	25.1	0	0.0
eye disorders	Posterior capsule opacification	Other	27	3.9	0	0.0
eye disorders	Posterior capsule opacification	Unknown	24	3.4	0	0.0
eye disorders	Punctate keratitis	White	474	67.6	3	0.6
eye disorders	Punctate keratitis	Asian	176	25.1	1	0.6
eye disorders	Punctate keratitis	Other	27	3.9	1	3.7
eye disorders	Punctate keratitis	Unknown	24	3.4	1	4.2
eye disorders	Retinal aneurysm	White	474	67.6	2	0.4
eye disorders	Retinal aneurysm	Asian	176	25.1	0	0.0
eye disorders	Retinal aneurysm	Other	27	3.9	0	0.0
eye disorders	Retinal aneurysm	Unknown	24	3.4	0	0.0
eye disorders	Retinal artery embolism	White	474	67.6	1	0.2
eye disorders	Retinal artery embolism	Asian	176	25.1	0	0.0
eye disorders	Retinal artery embolism	Other	27	3.9	0	0.0
eye disorders	Retinal artery embolism	Unknown	24	3.4	0	0.0
eye disorders	Retinal artery occlusion	White	474	67.6	2	0.4
eye disorders	Retinal artery occlusion	Asian	176	25.1	1	0.6
eye disorders	Retinal artery occlusion	Other	27	3.9	1	3.7
eye disorders	Retinal artery occlusion	Unknown	24	3.4	0	0.0
eye disorders	Retinal collateral vessels	White	474	67.6	3	0.6
eye disorders	Retinal collateral vessels	Asian	176	25.1	0	0.0
eye disorders	Retinal collateral vessels	Other	27	3.9	0	0.0
eye disorders	Retinal collateral vessels	Unknown	24	3.4	0	0.0
eye disorders	Retinal depigmentation	White	474	67.6	1	0.2
eye disorders	Retinal depigmentation	Asian	176	25.1	0	0.0
eye disorders	Retinal depigmentation	Other	27	3.9	0	0.0
eye disorders	Retinal depigmentation	Unknown	24	3.4	0	0.0
eye disorders	Retinal detachment	White	474	67.6	2	0.4
eye disorders	Retinal detachment	Asian	176	25.1	0	0.0
eye disorders	Retinal detachment	Other	27	3.9	0	0.0
eye disorders	Retinal detachment	Unknown	24	3.4	0	0.0
eye disorders	Retinal disorder	White	474	67.6	1	0.2
eye disorders	Retinal disorder	Asian	176	25.1	0	0.0
eye disorders	Retinal disorder	Other	27	3.9	0	0.0
eye disorders	Retinal disorder	Unknown	24	3.4	0	0.0
eye disorders	Retinal drusen	White	474	67.6	1	0.2
eye disorders	Retinal drusen	Asian	176	25.1	0	0.0
eye disorders	Retinal drusen	Other	27	3.9	0	0.0
eye disorders	Retinal drusen	Unknown	24	3.4	0	0.0
eye disorders	Retinal exudates	White	474	67.6	1	0.2
eye disorders	Retinal exudates	Asian	176	25.1	1	0.6
eye disorders	Retinal exudates	Other	27	3.9	0	0.0
eye disorders	Retinal exudates	Unknown	24	3.4	0	0.0
eye disorders	Retinal haemorrhage	White	474	67.6	8	1.1
eye disorders	Retinal haemorrhage	Asian	176	25.1	3	1.1
eye disorders	Retinal haemorrhage	Other	27	3.9	0	0.0
eye disorders	Retinal haemorrhage	Unknown	24	3.4	0	0.0
eye disorders	Retinal ischaemia	White	474	67.6	0	0.0
eye disorders	Retinal ischaemia	Asian	176	25.1	0	0.0
eye disorders	Retinal ischaemia	Other	27	3.9	0	0.0
eye disorders	Retinal ischaemia	Unknown	24	3.4	2	8.3
eye disorders	Retinal neovascularisation	White	474	67.6	1	0.2
eye disorders	Retinal neovascularisation	Asian	176	25.1	2	1.1
eye disorders	Retinal neovascularisation	Other	27	3.9	0	0.0
eye disorders	Retinal neovascularisation	Unknown	24	3.4	0	0.0
eye disorders	Retinal tear	White	474	67.6	2	0.4
eye disorders	Retinal tear	Asian	176	25.1	1	0.6
eye disorders	Retinal tear	Other	27	3.9	0	0.0
eye disorders	Retinal tear	Unknown	24	3.4	0	0.0
eye disorders	Retinal vein occlusion	White	474	67.6	20	4.2
eye disorders	Retinal vein occlusion	Asian	176	25.1	3	1.1
eye disorders	Retinal vein occlusion	Other	27	3.9	1	3.7
eye disorders	Retinal vein occlusion	Unknown	24	3.4	0	0.0
eye disorders	Retinopathy hypertensive	White	474	67.6	0	0.0
eye disorders	Retinopathy hypertensive	Asian	176	25.1	0	0.0
eye disorders	Retinopathy hypertensive	Other	27	3.9	0	0.0
eye disorders	Retinopathy hypertensive	Unknown	24	3.4	1	4.2
eye disorders	Subretinal fluid	White	474	67.6	0	0.0
eye disorders	Subretinal fluid	Asian	176	25.1	1	0.6
eye disorders	Subretinal fluid	Other	27	3.9	0	0.0
eye disorders	Subretinal fluid	Unknown	24	3.4	0	0.0
eye disorders	Uveitis	White	474	67.6	1	0.2
eye disorders	Uveitis	Asian	176	25.1	0	0.0
eye disorders	Uveitis	Other	27	3.9	0	0.0
eye disorders	Uveitis	Unknown	24	3.4	0	0.0
eye disorders	Vision blurred	White	474	67.6	3	0.6
eye disorders	Vision blurred	Asian	176	25.1	0	0.0
eye disorders	Vision blurred	Other	27	3.9	0	0.0
eye disorders	Vision blurred	Unknown	24	3.4	0	0.0
eye disorders	Visual acuity reduced	White	474	67.6	7	1.5
eye disorders	Visual acuity reduced	Asian	176	25.1	0	0.0
eye disorders	Visual acuity reduced	Other	27	3.9	1	3.7
eye disorders	Visual acuity reduced	Unknown	24	3.4	0	0.0
eye disorders	Visual acuity reduced transiently	White	474	67.6	0	0.0
eye disorders	Visual acuity reduced transiently	Asian	176	25.1	1	0.6
eye disorders	Visual acuity reduced transiently	Other	27	3.9	0	0.0
eye disorders	Visual acuity reduced transiently	Unknown	24	3.4	0	0.0
eye disorders	Visual field defect	White	474	67.6	1	0.2
eye disorders	Visual field defect	Asian	176	25.1	0	0.0
eye disorders	Visual field defect	Other	27	3.9	0	0.0
eye disorders	Visual field defect	Unknown	24	3.4	0	0.0
eye disorders	Visual impairment	White	474	67.6	1	0.2
eye disorders	Visual impairment	Asian	176	25.1	1	0.6
eye disorders	Visual impairment	Other	27	3.9	0	0.0
eye disorders	Visual impairment	Unknown	24	3.4	0	0.0
eye disorders	Vitreoretinal traction syndrome	White	474	67.6	2	0.4
eye disorders	Vitreoretinal traction syndrome	Asian	176	25.1	1	0.6
eye disorders	Vitreoretinal traction syndrome	Other	27	3.9	0	0.0
eye disorders	Vitreoretinal traction syndrome	Unknown	24	3.4	0	0.0
eye disorders	Vitreous detachment	White	474	67.6	22	4.6
eye disorders	Vitreous detachment	Asian	176	25.1	3	1.7
eye disorders	Vitreous detachment	Other	27	3.9	2	7.4
eye disorders	Vitreous detachment	Unknown	24	3.4	2	8.3
eye disorders	Vitreous floaters	White	474	67.6	7	1.5
eye disorders	Vitreous floaters	Asian	176	25.1	1	0.6
eye disorders	Vitreous floaters	Other	27	3.9	1	3.7

Eye disorders	Vitreous floaters	Unknown	24	3.4	1	4.2
Eye disorders	Vitreous haemorrhage	White	474	67.6	3	0.6
Eye disorders	Vitreous haemorrhage	Asian	176	25.1	1	0.6
Eye disorders	Vitreous haemorrhage	Other	27	3.9	0	0.0
Eye disorders	Vitreous haemorrhage	Unknown	24	3.4	0	0.0
Eye disorders	Vitreous opacities	White	474	67.6	0	0.0
Eye disorders	Vitreous opacities	Asian	176	25.1	1	0.6
Eye disorders	Vitreous opacities	Other	27	3.9	0	0.0
Eye disorders	Vitreous opacities	Unknown	24	3.4	0	0.0
Eye disorders	Vitritis	White	474	67.6	4	0.8
Eye disorders	Vitritis	Asian	176	25.1	0	0.0
Eye disorders	Vitritis	Other	27	3.9	0	0.0
Eye disorders	Vitritis	Unknown	24	3.4	0	0.0
Gastrointestinal disorders		White	474	67.6	28	6.1
Gastrointestinal disorders		Asian	176	25.1	12	6.8
Gastrointestinal disorders		Other	27	3.9	0	0.0
Gastrointestinal disorders		Unknown	24	3.4	1	4.2
Gastrointestinal disorders	Abdominal discomfort	White	474	67.6	0	0.0
Gastrointestinal disorders	Abdominal discomfort	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Abdominal discomfort	Other	27	3.9	0	0.0
Gastrointestinal disorders	Abdominal discomfort	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Abdominal pain	White	474	67.6	1	0.2
Gastrointestinal disorders	Abdominal pain	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Abdominal pain	Other	27	3.9	0	0.0
Gastrointestinal disorders	Abdominal pain	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Abdominal pain upper	White	474	67.6	1	0.2
Gastrointestinal disorders	Abdominal pain upper	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Abdominal pain upper	Other	27	3.9	0	0.0
Gastrointestinal disorders	Abdominal pain upper	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Barrett's oesophagus	White	474	67.6	1	4.2
Gastrointestinal disorders	Barrett's oesophagus	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Barrett's oesophagus	Other	27	3.9	0	0.0
Gastrointestinal disorders	Barrett's oesophagus	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Chronic gastritis	White	474	67.6	0	0.0
Gastrointestinal disorders	Chronic gastritis	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Chronic gastritis	Other	27	3.9	0	0.0
Gastrointestinal disorders	Chronic gastritis	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Coeliac disease	White	474	67.6	1	0.2
Gastrointestinal disorders	Coeliac disease	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Coeliac disease	Other	27	3.9	0	0.0
Gastrointestinal disorders	Coeliac disease	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Colitis	White	474	67.6	1	0.2
Gastrointestinal disorders	Colitis	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Colitis	Other	27	3.9	0	0.0
Gastrointestinal disorders	Colitis	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Constipation	White	474	67.6	3	0.6
Gastrointestinal disorders	Constipation	Asian	176	25.1	2	1.1
Gastrointestinal disorders	Constipation	Other	27	3.9	0	0.0
Gastrointestinal disorders	Constipation	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Dental discomfort	White	474	67.6	1	0.2
Gastrointestinal disorders	Dental discomfort	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Dental discomfort	Other	27	3.9	0	0.0
Gastrointestinal disorders	Dental discomfort	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Diarrhoea	White	474	67.6	8	1.7
Gastrointestinal disorders	Diarrhoea	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Diarrhoea	Other	27	3.9	0	0.0
Gastrointestinal disorders	Diarrhoea	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Diverticulum intestinal	White	474	67.6	0	0.0
Gastrointestinal disorders	Diverticulum intestinal	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Diverticulum intestinal	Other	27	3.9	0	0.0
Gastrointestinal disorders	Diverticulum intestinal	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	White	474	67.6	0	0.0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Other	27	3.9	0	0.0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	White	474	67.6	0	0.0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Other	27	3.9	0	0.0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Duodenitis	White	474	67.6	1	0.2
Gastrointestinal disorders	Duodenitis	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Duodenitis	Other	27	3.9	0	0.0
Gastrointestinal disorders	Duodenitis	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Dyspepsia	White	474	67.6	0	0.0
Gastrointestinal disorders	Dyspepsia	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Dyspepsia	Other	27	3.9	0	0.0
Gastrointestinal disorders	Dyspepsia	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Gastric ulcer	White	474	67.6	0	0.0
Gastrointestinal disorders	Gastric ulcer	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Gastric ulcer	Other	27	3.9	0	0.0
Gastrointestinal disorders	Gastric ulcer	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Gastritis	White	474	67.6	1	0.2
Gastrointestinal disorders	Gastritis	Asian	176	25.1	2	1.1
Gastrointestinal disorders	Gastritis	Other	27	3.9	0	0.0
Gastrointestinal disorders	Gastritis	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Gastrointestinal inflammation	White	474	67.6	1	0.2
Gastrointestinal disorders	Gastrointestinal inflammation	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Gastrointestinal inflammation	Other	27	3.9	0	0.0
Gastrointestinal disorders	Gastrointestinal inflammation	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Gastrooesophageal reflux disease	White	474	67.6	2	0.4
Gastrointestinal disorders	Gastrooesophageal reflux disease	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Gastrooesophageal reflux disease	Other	27	3.9	0	0.0
Gastrointestinal disorders	Gastrooesophageal reflux disease	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Haemorrhagic erosive gastritis	White	474	67.6	1	0.2
Gastrointestinal disorders	Haemorrhagic erosive gastritis	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Haemorrhagic erosive gastritis	Other	27	3.9	0	0.0
Gastrointestinal disorders	Haemorrhagic erosive gastritis	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Haemorrhoids	White	474	67.6	1	0.2
Gastrointestinal disorders	Haemorrhoids	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Haemorrhoids	Other	27	3.9	0	0.0
Gastrointestinal disorders	Haemorrhoids	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Hiatus hernia	White	474	67.6	1	0.2
Gastrointestinal disorders	Hiatus hernia	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Hiatus hernia	Other	27	3.9	0	0.0
Gastrointestinal disorders	Hiatus hernia	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Ileus	White	474	67.6	0	0.0
Gastrointestinal disorders	Ileus	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Ileus	Other	27	3.9	0	0.0
Gastrointestinal disorders	Ileus	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Inguinal hernia	White	474	67.6	1	0.2
Gastrointestinal disorders	Inguinal hernia	Asian	176	25.1	0	0.0

Gastrointestinal disorders	Inguinal hernia	Other	27	3.9	0	0.0
Gastrointestinal disorders	Inguinal hernia	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Large intestine polyp	White	474	67.6	0	0.0
Gastrointestinal disorders	Large intestine polyp	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Large intestine polyp	Other	27	3.9	0	0.0
Gastrointestinal disorders	Large intestine polyp	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Nausea	White	474	67.6	2	0.4
Gastrointestinal disorders	Nausea	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Nausea	Other	27	3.9	0	0.0
Gastrointestinal disorders	Nausea	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Pancreatitis	White	474	67.6	1	0.2
Gastrointestinal disorders	Pancreatitis	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Pancreatitis	Other	27	3.9	0	0.0
Gastrointestinal disorders	Pancreatitis	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Pancreatitis acute	White	474	67.6	0	0.0
Gastrointestinal disorders	Pancreatitis acute	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Pancreatitis acute	Other	27	3.9	0	0.0
Gastrointestinal disorders	Pancreatitis acute	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Pulpless tooth	White	474	67.6	1	0.2
Gastrointestinal disorders	Pulpless tooth	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Pulpless tooth	Other	27	3.9	0	0.0
Gastrointestinal disorders	Pulpless tooth	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Salivary gland disorder	White	474	67.6	1	0.2
Gastrointestinal disorders	Salivary gland disorder	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Salivary gland disorder	Other	27	3.9	0	0.0
Gastrointestinal disorders	Salivary gland disorder	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Toothache	White	474	67.6	1	0.2
Gastrointestinal disorders	Toothache	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Toothache	Other	27	3.9	0	0.0
Gastrointestinal disorders	Toothache	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Umbilical hernia	White	474	67.6	1	0.2
Gastrointestinal disorders	Umbilical hernia	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Umbilical hernia	Other	27	3.9	0	0.0
Gastrointestinal disorders	Umbilical hernia	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Vomiting	White	474	67.6	2	0.4
Gastrointestinal disorders	Vomiting	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Vomiting	Other	27	3.9	0	0.0
Gastrointestinal disorders	Vomiting	Unknown	24	3.4	0	0.0
General disorders and administration site conditions		White	474	67.6	22	4.6
General disorders and administration site conditions		Asian	176	25.1	5	2.8
General disorders and administration site conditions		Other	27	3.9	4	14.8
General disorders and administration site conditions		Unknown	24	3.4	1	4.2
General disorders and administration site conditions	Asthenia	White	474	67.6	7	1.5
General disorders and administration site conditions	Asthenia	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Asthenia	Other	27	3.9	0	0.0
General disorders and administration site conditions	Asthenia	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Chest pain	White	474	67.6	3	0.6
General disorders and administration site conditions	Chest pain	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Chest pain	Other	27	3.9	1	3.7
General disorders and administration site conditions	Chest pain	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Chills	White	474	67.6	0	0.0
General disorders and administration site conditions	Chills	Asian	176	25.1	1	0.6
General disorders and administration site conditions	Chills	Other	27	3.9	0	0.0
General disorders and administration site conditions	Chills	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Death	White	474	67.6	0	0.0
General disorders and administration site conditions	Death	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Death	Other	27	3.9	0	0.0
General disorders and administration site conditions	Death	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Drug intolerance	White	474	67.6	1	0.2
General disorders and administration site conditions	Drug intolerance	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Drug intolerance	Other	27	3.9	0	0.0
General disorders and administration site conditions	Drug intolerance	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Drug withdrawal syndrome	White	474	67.6	1	0.2
General disorders and administration site conditions	Drug withdrawal syndrome	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Drug withdrawal syndrome	Other	27	3.9	0	0.0
General disorders and administration site conditions	Drug withdrawal syndrome	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Fatigue	White	474	67.6	1	0.2
General disorders and administration site conditions	Fatigue	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Fatigue	Other	27	3.9	0	0.0
General disorders and administration site conditions	Fatigue	Unknown	24	3.4	1	4.2
General disorders and administration site conditions	Injection site pain	White	474	67.6	0	0.0
General disorders and administration site conditions	Injection site pain	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Injection site pain	Other	27	3.9	0	0.0
General disorders and administration site conditions	Injection site pain	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Injection site reaction	White	474	67.6	1	0.2
General disorders and administration site conditions	Injection site reaction	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Injection site reaction	Other	27	3.9	0	0.0
General disorders and administration site conditions	Injection site reaction	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Oedema peripheral	White	474	67.6	1	0.2
General disorders and administration site conditions	Oedema peripheral	Asian	176	25.1	2	1.1
General disorders and administration site conditions	Oedema peripheral	Other	27	3.9	1	3.7
General disorders and administration site conditions	Oedema peripheral	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Pain	White	474	67.6	1	0.2
General disorders and administration site conditions	Pain	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Pain	Other	27	3.9	0	0.0
General disorders and administration site conditions	Pain	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Peripheral swelling	White	474	67.6	0	0.0
General disorders and administration site conditions	Peripheral swelling	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Peripheral swelling	Other	27	3.9	1	3.7
General disorders and administration site conditions	Peripheral swelling	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Polyp	White	474	67.6	0	0.0
General disorders and administration site conditions	Polyp	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Polyp	Other	27	3.9	0	0.0
General disorders and administration site conditions	Polyp	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Pyrexia	White	474	67.6	2	0.4
General disorders and administration site conditions	Pyrexia	Asian	176	25.1	3	1.1
General disorders and administration site conditions	Pyrexia	Other	27	3.9	1	3.7
General disorders and administration site conditions	Pyrexia	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Stent-graft endoleak	White	474	67.6	0	0.0
General disorders and administration site conditions	Stent-graft endoleak	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Stent-graft endoleak	Other	27	3.9	1	3.7
General disorders and administration site conditions	Stent-graft endoleak	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Systemic inflammatory response syndrome	White	474	67.6	1	0.2
General disorders and administration site conditions	Systemic inflammatory response syndrome	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Systemic inflammatory response syndrome	Other	27	3.9	0	0.0
General disorders and administration site conditions	Systemic inflammatory response syndrome	Unknown	24	3.4	0	0.0
Hepatobiliary disorders		White	474	67.6	5	1.1
Hepatobiliary disorders		Asian	176	25.1	3	1.7
Hepatobiliary disorders		Other	27	3.9	0	0.0
Hepatobiliary disorders		Unknown	24	3.4	0	0.0

Hepatobiliary disorders	Cholecystitis	White	474	67.6	0	0.0
Hepatobiliary disorders	Cholecystitis	Asian	176	25.1	1	0.6
Hepatobiliary disorders	Cholecystitis	Other	27	3.9	0	0.0
Hepatobiliary disorders	Cholecystitis	Unknown	24	3.4	0	0.0
Hepatobiliary disorders	Cholelithiasis	White	474	67.6	3	0.4
Hepatobiliary disorders	Cholelithiasis	Asian	176	25.1	1	0.6
Hepatobiliary disorders	Cholelithiasis	Other	27	3.9	0	0.0
Hepatobiliary disorders	Cholelithiasis	Unknown	24	3.4	0	0.0
Hepatobiliary disorders	Hepatic cyst	White	474	67.6	0	0.0
Hepatobiliary disorders	Hepatic cyst	Asian	176	25.1	1	0.6
Hepatobiliary disorders	Hepatic cyst	Other	27	3.9	0	0.0
Hepatobiliary disorders	Hepatic cyst	Unknown	24	3.4	0	0.0
Hepatobiliary disorders	Hepatic steatosis	White	474	67.6	1	0.2
Hepatobiliary disorders	Hepatic steatosis	Asian	176	25.1	2	1.1
Hepatobiliary disorders	Hepatic steatosis	Other	27	3.9	0	0.0
Hepatobiliary disorders	Hepatic steatosis	Unknown	24	3.4	0	0.0
Hepatobiliary disorders	Portal hypertension	White	474	67.6	1	0.2
Hepatobiliary disorders	Portal hypertension	Asian	176	25.1	0	0.0
Hepatobiliary disorders	Portal hypertension	Other	27	3.9	0	0.0
Hepatobiliary disorders	Portal hypertension	Unknown	24	3.4	0	0.0
Immune system disorders		White	474	67.6	7	1.5
Immune system disorders		Asian	176	25.1	3	1.7
Immune system disorders		Other	27	3.9	0	0.0
Immune system disorders		Unknown	24	3.4	0	0.0
Immune system disorders	Contrast media allergy	White	474	67.6	1	0.2
Immune system disorders	Contrast media allergy	Asian	176	25.1	1	0.6
Immune system disorders	Contrast media allergy	Other	27	3.9	0	0.0
Immune system disorders	Contrast media allergy	Unknown	24	3.4	1	4.2
Immune system disorders	Contrast media reaction	White	474	67.6	1	0.2
Immune system disorders	Contrast media reaction	Asian	176	25.1	0	0.0
Immune system disorders	Contrast media reaction	Other	27	3.9	0	0.0
Immune system disorders	Contrast media reaction	Unknown	24	3.4	0	0.0
Immune system disorders	Drug hypersensitivity	White	474	67.6	1	0.2
Immune system disorders	Drug hypersensitivity	Asian	176	25.1	0	0.0
Immune system disorders	Drug hypersensitivity	Other	27	3.9	0	0.0
Immune system disorders	Drug hypersensitivity	Unknown	24	3.4	0	0.0
Immune system disorders	Food allergy	White	474	67.6	1	0.2
Immune system disorders	Food allergy	Asian	176	25.1	0	0.0
Immune system disorders	Food allergy	Other	27	3.9	0	0.0
Immune system disorders	Food allergy	Unknown	24	3.4	0	0.0
Immune system disorders	Iodine allergy	White	474	67.6	1	0.2
Immune system disorders	Iodine allergy	Asian	176	25.1	0	0.0
Immune system disorders	Iodine allergy	Other	27	3.9	0	0.0
Immune system disorders	Iodine allergy	Unknown	24	3.4	0	0.0
Immune system disorders	Seasonal allergy	White	474	67.6	0	0.0
Immune system disorders	Seasonal allergy	Asian	176	25.1	2	1.1
Immune system disorders	Seasonal allergy	Other	27	3.9	0	0.0
Immune system disorders	Seasonal allergy	Unknown	24	3.4	0	0.0
Infections and infestations		White	474	67.6	155	32.7
Infections and infestations		Asian	176	25.1	55	31.3
Infections and infestations		Other	27	3.9	8	29.6
Infections and infestations		Unknown	24	3.4	7	29.2
Infections and infestations	Adenoviral conjunctivitis	White	474	67.6	1	0.2
Infections and infestations	Adenoviral conjunctivitis	Asian	176	25.1	0	0.0
Infections and infestations	Adenoviral conjunctivitis	Other	27	3.9	0	0.0
Infections and infestations	Adenoviral conjunctivitis	Unknown	24	3.4	0	0.0
Infections and infestations	Arthritis infective	White	474	67.6	1	0.2
Infections and infestations	Arthritis infective	Asian	176	25.1	0	0.0
Infections and infestations	Arthritis infective	Other	27	3.9	0	0.0
Infections and infestations	Arthritis infective	Unknown	24	3.4	0	0.0
Infections and infestations	Bronchitis	White	474	67.6	9	1.9
Infections and infestations	Bronchitis	Asian	176	25.1	0	0.0
Infections and infestations	Bronchitis	Other	27	3.9	0	0.0
Infections and infestations	Bronchitis	Unknown	24	3.4	0	0.0
Infections and infestations	COVID-19	White	474	67.6	67	12.9
Infections and infestations	COVID-19	Asian	176	25.1	26	14.8
Infections and infestations	COVID-19	Other	27	3.9	0	0.0
Infections and infestations	COVID-19	Unknown	24	3.4	4	16.7
Infections and infestations	COVID-19 pneumonia	White	474	67.6	1	0.2
Infections and infestations	COVID-19 pneumonia	Asian	176	25.1	0	0.0
Infections and infestations	COVID-19 pneumonia	Other	27	3.9	0	0.0
Infections and infestations	COVID-19 pneumonia	Unknown	24	3.4	0	0.0
Infections and infestations	Cellulitis	White	474	67.6	6	1.3
Infections and infestations	Cellulitis	Asian	176	25.1	1	0.6
Infections and infestations	Cellulitis	Other	27	3.9	0	0.0
Infections and infestations	Cellulitis	Unknown	24	3.4	0	0.0
Infections and infestations	Chronic sinusitis	White	474	67.6	2	0.4
Infections and infestations	Chronic sinusitis	Asian	176	25.1	0	0.0
Infections and infestations	Chronic sinusitis	Other	27	3.9	0	0.0
Infections and infestations	Chronic sinusitis	Unknown	24	3.4	0	0.0
Infections and infestations	Clostridium difficile infection	White	474	67.6	1	0.2
Infections and infestations	Clostridium difficile infection	Asian	176	25.1	0	0.0
Infections and infestations	Clostridium difficile infection	Other	27	3.9	0	0.0
Infections and infestations	Clostridium difficile infection	Unknown	24	3.4	0	0.0
Infections and infestations	Conjunctivitis	White	474	67.6	1	0.2
Infections and infestations	Conjunctivitis	Asian	176	25.1	4	2.3
Infections and infestations	Conjunctivitis	Other	27	3.9	1	3.7
Infections and infestations	Conjunctivitis	Unknown	24	3.4	2	8.3
Infections and infestations	Conjunctivitis bacterial	White	474	67.6	1	0.2
Infections and infestations	Conjunctivitis bacterial	Asian	176	25.1	0	0.0
Infections and infestations	Conjunctivitis bacterial	Other	27	3.9	0	0.0
Infections and infestations	Conjunctivitis bacterial	Unknown	24	3.4	0	0.0
Infections and infestations	Conjunctivitis viral	White	474	67.6	1	0.2
Infections and infestations	Conjunctivitis viral	Asian	176	25.1	0	0.0
Infections and infestations	Conjunctivitis viral	Other	27	3.9	0	0.0
Infections and infestations	Conjunctivitis viral	Unknown	24	3.4	0	0.0
Infections and infestations	Cystitis	White	474	67.6	2	0.4
Infections and infestations	Cystitis	Asian	176	25.1	1	0.6
Infections and infestations	Cystitis	Other	27	3.9	0	0.0
Infections and infestations	Cystitis	Unknown	24	3.4	0	0.0
Infections and infestations	Device related infection	White	474	67.6	0	0.0
Infections and infestations	Device related infection	Asian	176	25.1	0	0.0
Infections and infestations	Device related infection	Other	27	3.9	0	0.0
Infections and infestations	Device related infection	Unknown	24	3.4	0	0.0
Infections and infestations	Diabetic foot infection	White	474	67.6	0	0.0
Infections and infestations	Diabetic foot infection	Asian	176	25.1	0	0.0
Infections and infestations	Diabetic foot infection	Other	27	3.9	1	3.7
Infections and infestations	Diabetic foot infection	Unknown	24	3.4	0	0.0
Infections and infestations	Ear infection	White	474	67.6	3	0.6
Infections and infestations	Ear infection	Asian	176	25.1	0	0.0

Infections and infestations	Ear infection	Other	27	3.9	0	0.0
Infections and infestations	Ear infection	Unknown	24	3.4	0	0.0
Infections and infestations	Endophthalmitis	White	474	67.6	1	0.2
Infections and infestations	Endophthalmitis	Asian	176	25.1	0	0.0
Infections and infestations	Endophthalmitis	Other	27	3.9	0	0.0
Infections and infestations	Endophthalmitis	Unknown	24	3.4	0	0.0
Infections and infestations	Enteritis infectious	White	474	67.6	1	0.2
Infections and infestations	Enteritis infectious	Asian	176	25.1	0	0.0
Infections and infestations	Enteritis infectious	Other	27	3.9	0	0.0
Infections and infestations	Enteritis infectious	Unknown	24	3.4	0	0.0
Infections and infestations	Escherichia urinary tract infection	White	474	67.6	1	0.2
Infections and infestations	Escherichia urinary tract infection	Asian	176	25.1	0	0.0
Infections and infestations	Escherichia urinary tract infection	Other	27	3.9	0	0.0
Infections and infestations	Escherichia urinary tract infection	Unknown	24	3.4	0	0.0
Infections and infestations	Eye infection	White	474	67.6	0	0.0
Infections and infestations	Eye infection	Asian	176	25.1	0	0.0
Infections and infestations	Eye infection	Other	27	3.9	1	3.7
Infections and infestations	Eye infection	Unknown	24	3.4	0	0.0
Infections and infestations	Eye infection bacterial	White	474	67.6	0	0.0
Infections and infestations	Eye infection bacterial	Asian	176	25.1	0	0.0
Infections and infestations	Eye infection bacterial	Other	27	3.9	0	0.0
Infections and infestations	Eye infection bacterial	Unknown	24	3.4	1	4.2
Infections and infestations	Folliculitis	White	474	67.6	1	0.2
Infections and infestations	Folliculitis	Asian	176	25.1	0	0.0
Infections and infestations	Folliculitis	Other	27	3.9	0	0.0
Infections and infestations	Folliculitis	Unknown	24	3.4	0	0.0
Infections and infestations	Fungal skin infection	White	474	67.6	1	0.2
Infections and infestations	Fungal skin infection	Asian	176	25.1	0	0.0
Infections and infestations	Fungal skin infection	Other	27	3.9	0	0.0
Infections and infestations	Fungal skin infection	Unknown	24	3.4	0	0.0
Infections and infestations	Gastroenteritis	White	474	67.6	1	0.2
Infections and infestations	Gastroenteritis	Asian	176	25.1	0	0.0
Infections and infestations	Gastroenteritis	Other	27	3.9	0	0.0
Infections and infestations	Gastroenteritis	Unknown	24	3.4	0	0.0
Infections and infestations	Gastroenteritis viral	White	474	67.6	3	0.6
Infections and infestations	Gastroenteritis viral	Asian	176	25.1	0	0.0
Infections and infestations	Gastroenteritis viral	Other	27	3.9	1	3.7
Infections and infestations	Gastroenteritis viral	Unknown	24	3.4	0	0.0
Infections and infestations	Gastrointestinal infection	White	474	67.6	1	0.2
Infections and infestations	Gastrointestinal infection	Asian	176	25.1	0	0.0
Infections and infestations	Gastrointestinal infection	Other	27	3.9	0	0.0
Infections and infestations	Gastrointestinal infection	Unknown	24	3.4	0	0.0
Infections and infestations	Helicobacter infection	White	474	67.6	0	0.0
Infections and infestations	Helicobacter infection	Asian	176	25.1	1	0.6
Infections and infestations	Helicobacter infection	Other	27	3.9	0	0.0
Infections and infestations	Helicobacter infection	Unknown	24	3.4	0	0.0
Infections and infestations	Herpes virus infection	White	474	67.6	0	0.0
Infections and infestations	Herpes virus infection	Asian	176	25.1	1	0.6
Infections and infestations	Herpes virus infection	Other	27	3.9	0	0.0
Infections and infestations	Herpes virus infection	Unknown	24	3.4	0	0.0
Infections and infestations	Herpes zoster	White	474	67.6	1	1.1
Infections and infestations	Herpes zoster	Asian	176	25.1	1	0.6
Infections and infestations	Herpes zoster	Other	27	3.9	0	0.0
Infections and infestations	Herpes zoster	Unknown	24	3.4	0	0.0
Infections and infestations	Hordeolum	White	474	67.6	8	1.1
Infections and infestations	Hordeolum	Asian	176	25.1	0	0.0
Infections and infestations	Hordeolum	Other	27	3.9	0	0.0
Infections and infestations	Hordeolum	Unknown	24	3.4	0	0.0
Infections and infestations	Infected bite	White	474	67.6	1	0.2
Infections and infestations	Infected bite	Asian	176	25.1	0	0.0
Infections and infestations	Infected bite	Other	27	3.9	0	0.0
Infections and infestations	Infected bite	Unknown	24	3.4	0	0.0
Infections and infestations	Influenza	White	474	67.6	17	3.6
Infections and infestations	Influenza	Asian	176	25.1	1	0.6
Infections and infestations	Influenza	Other	27	3.9	0	0.0
Infections and infestations	Influenza	Unknown	24	3.4	1	4.2
Infections and infestations	Kidney infection	White	474	67.6	0	0.2
Infections and infestations	Kidney infection	Asian	176	25.1	0	0.0
Infections and infestations	Kidney infection	Other	27	3.9	0	0.0
Infections and infestations	Kidney infection	Unknown	24	3.4	0	0.0
Infections and infestations	Laryngitis	White	474	67.6	1	0.2
Infections and infestations	Laryngitis	Asian	176	25.1	0	0.0
Infections and infestations	Laryngitis	Other	27	3.9	0	0.0
Infections and infestations	Laryngitis	Unknown	24	3.4	0	0.0
Infections and infestations	Localised infection	White	474	67.6	1	0.2
Infections and infestations	Localised infection	Asian	176	25.1	0	0.0
Infections and infestations	Localised infection	Other	27	3.9	0	0.0
Infections and infestations	Localised infection	Unknown	24	3.4	0	0.0
Infections and infestations	Lower respiratory tract infection	White	474	67.6	1	0.2
Infections and infestations	Lower respiratory tract infection	Asian	176	25.1	0	0.0
Infections and infestations	Lower respiratory tract infection	Other	27	3.9	0	0.0
Infections and infestations	Lower respiratory tract infection	Unknown	24	3.4	0	0.0
Infections and infestations	Nasopharyngitis	White	474	67.6	20	4.2
Infections and infestations	Nasopharyngitis	Asian	176	25.1	6	3.4
Infections and infestations	Nasopharyngitis	Other	27	3.9	1	3.7
Infections and infestations	Nasopharyngitis	Unknown	24	3.4	0	0.0
Infections and infestations	Necrotising fasciitis	White	474	67.6	0	0.0
Infections and infestations	Necrotising fasciitis	Asian	176	25.1	0	0.0
Infections and infestations	Necrotising fasciitis	Other	27	3.9	1	3.7
Infections and infestations	Necrotising fasciitis	Unknown	24	3.4	0	0.0
Infections and infestations	Oral herpes	White	474	67.6	1	0.2
Infections and infestations	Oral herpes	Asian	176	25.1	0	0.6
Infections and infestations	Oral herpes	Other	27	3.9	0	0.0
Infections and infestations	Oral herpes	Unknown	24	3.4	0	0.0
Infections and infestations	Otitis externa	White	474	67.6	1	0.2
Infections and infestations	Otitis externa	Asian	176	25.1	0	0.0
Infections and infestations	Otitis externa	Other	27	3.9	0	0.0
Infections and infestations	Otitis externa	Unknown	24	3.4	0	0.0
Infections and infestations	Otosalpingitis	White	474	67.6	1	0.2
Infections and infestations	Otosalpingitis	Asian	176	25.1	0	0.0
Infections and infestations	Otosalpingitis	Other	27	3.9	0	0.0
Infections and infestations	Otosalpingitis	Unknown	24	3.4	0	0.0
Infections and infestations	Perichondritis	White	474	67.6	0	0.0
Infections and infestations	Perichondritis	Asian	176	25.1	1	0.6
Infections and infestations	Perichondritis	Other	27	3.9	0	0.0
Infections and infestations	Perichondritis	Unknown	24	3.4	0	0.0
Infections and infestations	Periodontitis	White	474	67.6	0	0.0
Infections and infestations	Periodontitis	Asian	176	25.1	8	1.1
Infections and infestations	Periodontitis	Other	27	3.9	0	0.0
Infections and infestations	Periodontitis	Unknown	24	3.4	0	0.0
Infections and infestations	Pharyngitis	White	474	67.6	1	0.2
Infections and infestations	Pharyngitis	Asian	176	25.1	1	0.6

Infections and infestations	Pharyngitis	Other	27	3.9	0	0.0
Infections and infestations	Pharyngitis	Unknown	24	3.4	0	0.0
Infections and infestations	Pneumonia	White	474	67.6	7	1.5
Infections and infestations	Pneumonia	Asian	176	25.1	1	0.6
Infections and infestations	Pneumonia	Other	27	3.9	0	0.0
Infections and infestations	Pneumonia	Unknown	24	3.4	1	4.2
Infections and infestations	Pneumonia viral	White	474	67.6	2	0.4
Infections and infestations	Pneumonia viral	Asian	176	25.1	1	0.6
Infections and infestations	Pneumonia viral	Other	27	3.9	0	0.0
Infections and infestations	Pneumonia viral	Unknown	24	3.4	0	0.0
Infections and infestations	Pulpitis dental	White	474	67.6	3	0.6
Infections and infestations	Pulpitis dental	Asian	176	25.1	0	0.0
Infections and infestations	Pulpitis dental	Other	27	3.9	0	0.0
Infections and infestations	Pulpitis dental	Unknown	24	3.4	0	0.0
Infections and infestations	Respiratory syncytial virus infection	White	474	67.6	0	0.0
Infections and infestations	Respiratory syncytial virus infection	Asian	176	25.1	1	0.6
Infections and infestations	Respiratory syncytial virus infection	Other	27	3.9	0	0.0
Infections and infestations	Respiratory syncytial virus infection	Unknown	24	3.4	0	0.0
Infections and infestations	Respiratory tract infection	White	474	67.6	1	0.2
Infections and infestations	Respiratory tract infection	Asian	176	25.1	1	0.6
Infections and infestations	Respiratory tract infection	Other	27	3.9	0	0.0
Infections and infestations	Respiratory tract infection	Unknown	24	3.4	0	0.0
Infections and infestations	Respiratory tract infection viral	White	474	67.6	1	0.2
Infections and infestations	Respiratory tract infection viral	Asian	176	25.1	0	0.0
Infections and infestations	Respiratory tract infection viral	Other	27	3.9	0	0.0
Infections and infestations	Respiratory tract infection viral	Unknown	24	3.4	0	0.0
Infections and infestations	Rhinitis	White	474	67.6	0	0.0
Infections and infestations	Rhinitis	Asian	176	25.1	1	0.6
Infections and infestations	Rhinitis	Other	27	3.9	0	0.0
Infections and infestations	Rhinitis	Unknown	24	3.4	0	0.0
Infections and infestations	Sepsis	White	474	67.6	2	0.4
Infections and infestations	Sepsis	Asian	176	25.1	0	0.0
Infections and infestations	Sepsis	Other	27	3.9	0	0.0
Infections and infestations	Sepsis	Unknown	24	3.4	0	0.0
Infections and infestations	Septic arthritis staphylococcal	White	474	67.6	1	0.2
Infections and infestations	Septic arthritis staphylococcal	Asian	176	25.1	1	0.6
Infections and infestations	Septic arthritis staphylococcal	Other	27	3.9	0	0.0
Infections and infestations	Septic arthritis staphylococcal	Unknown	24	3.4	0	0.0
Infections and infestations	Sinusitis	White	474	67.6	8	1.7
Infections and infestations	Sinusitis	Asian	176	25.1	1	0.6
Infections and infestations	Sinusitis	Other	27	3.9	0	0.0
Infections and infestations	Sinusitis	Unknown	24	3.4	0	0.0
Infections and infestations	Staphylococcal infection	White	474	67.6	1	0.2
Infections and infestations	Staphylococcal infection	Asian	176	25.1	0	0.0
Infections and infestations	Staphylococcal infection	Other	27	3.9	0	0.0
Infections and infestations	Staphylococcal infection	Unknown	24	3.4	0	0.0
Infections and infestations	Suspected COVID-19	White	474	67.6	0	0.0
Infections and infestations	Suspected COVID-19	Asian	176	25.1	10	5.7
Infections and infestations	Suspected COVID-19	Other	27	3.9	0	0.0
Infections and infestations	Suspected COVID-19	Unknown	24	3.4	0	0.0
Infections and infestations	Tinea pedis	White	474	67.6	1	0.2
Infections and infestations	Tinea pedis	Asian	176	25.1	0	0.0
Infections and infestations	Tinea pedis	Other	27	3.9	0	0.0
Infections and infestations	Tinea pedis	Unknown	24	3.4	0	0.0
Infections and infestations	Tooth abscess	White	474	67.6	3	0.6
Infections and infestations	Tooth abscess	Asian	176	25.1	0	0.0
Infections and infestations	Tooth abscess	Other	27	3.9	0	0.0
Infections and infestations	Tooth abscess	Unknown	24	3.4	0	0.0
Infections and infestations	Tooth infection	White	474	67.6	2	0.4
Infections and infestations	Tooth infection	Asian	176	25.1	0	0.0
Infections and infestations	Tooth infection	Other	27	3.9	1	3.7
Infections and infestations	Tooth infection	Unknown	24	3.4	0	0.0
Infections and infestations	Upper respiratory tract infection	White	474	67.6	14	3.0
Infections and infestations	Upper respiratory tract infection	Asian	176	25.1	3	1.7
Infections and infestations	Upper respiratory tract infection	Other	27	3.9	0	0.0
Infections and infestations	Upper respiratory tract infection	Unknown	24	3.4	0	0.0
Infections and infestations	Urinary tract candidiasis	White	474	67.6	0	0.0
Infections and infestations	Urinary tract candidiasis	Asian	176	25.1	0	0.0
Infections and infestations	Urinary tract candidiasis	Other	27	3.9	0	0.0
Infections and infestations	Urinary tract candidiasis	Unknown	24	3.4	0	0.0
Infections and infestations	Urinary tract infection	White	474	67.6	13	2.7
Infections and infestations	Urinary tract infection	Asian	176	25.1	0	0.0
Infections and infestations	Urinary tract infection	Other	27	3.9	1	3.7
Infections and infestations	Urinary tract infection	Unknown	24	3.4	0	0.0
Infections and infestations	Urosepsis	White	474	67.6	1	0.2
Infections and infestations	Urosepsis	Asian	176	25.1	0	0.0
Infections and infestations	Urosepsis	Other	27	3.9	0	0.0
Infections and infestations	Urosepsis	Unknown	24	3.4	0	0.0
Infections and infestations	Viral rash	White	474	67.6	1	0.2
Infections and infestations	Viral rash	Asian	176	25.1	0	0.0
Infections and infestations	Viral rash	Other	27	3.9	0	0.0
Infections and infestations	Viral rash	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications		White	474	67.6	39	8.2
Injury, poisoning and procedural complications		Asian	176	25.1	12	6.8
Injury, poisoning and procedural complications		Other	27	3.9	1	3.7
Injury, poisoning and procedural complications		Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Accident	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Accident	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Accident	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Accident	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Arthropod bite	White	474	67.6	0	0.0
Injury, poisoning and procedural complications	Arthropod bite	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Arthropod bite	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Arthropod bite	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Arthropod sting	White	474	67.6	0	0.0
Injury, poisoning and procedural complications	Arthropod sting	Asian	176	25.1	1	0.6
Injury, poisoning and procedural complications	Arthropod sting	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Arthropod sting	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Contusion	White	474	67.6	2	0.4
Injury, poisoning and procedural complications	Contusion	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Contusion	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Contusion	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Eye contusion	White	474	67.6	2	0.4
Injury, poisoning and procedural complications	Eye contusion	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Eye contusion	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Eye contusion	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Fall	White	474	67.6	14	2.1
Injury, poisoning and procedural complications	Fall	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Fall	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Fall	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Femur fracture	White	474	67.6	2	0.4

Injury, poisoning and procedural complications	Wrist fracture	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Wrist fracture	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Wrist fracture	Unknown	24	3.4	0	0.0
Investigations		White	474	67.6	39	8.2
Investigations		Asian	176	25.1	20	11.4
Investigations		Other	27	3.9	2	7.4
Investigations		Unknown	24	3.4	1	4.2
Investigations	Alanine aminotransferase increased	White	474	67.6	0	0.0
Investigations	Alanine aminotransferase increased	Asian	176	25.1	0	0.0
Investigations	Alanine aminotransferase increased	Other	27	3.9	0	0.0
Investigations	Alanine aminotransferase increased	Unknown	24	3.4	0	0.0
Investigations	Aspartate aminotransferase increased	White	474	67.6	0	0.0
Investigations	Aspartate aminotransferase increased	Asian	176	25.1	1	0.6
Investigations	Aspartate aminotransferase increased	Other	27	3.9	0	0.0
Investigations	Aspartate aminotransferase increased	Unknown	24	3.4	0	0.0
Investigations	Blood albumin increased	White	474	67.6	0	0.0
Investigations	Blood albumin increased	Asian	176	25.1	0	0.0
Investigations	Blood albumin increased	Other	27	3.9	1	3.7
Investigations	Blood albumin increased	Unknown	24	3.4	0	0.0
Investigations	Blood bilirubin increased	White	474	67.6	0	0.0
Investigations	Blood bilirubin increased	Asian	176	25.1	1	0.6
Investigations	Blood bilirubin increased	Other	27	3.9	0	0.0
Investigations	Blood bilirubin increased	Unknown	24	3.4	0	0.0
Investigations	Blood cholesterol increased	White	474	67.6	0	0.0
Investigations	Blood cholesterol increased	Asian	176	25.1	1	0.6
Investigations	Blood cholesterol increased	Other	27	3.9	0	0.0
Investigations	Blood cholesterol increased	Unknown	24	3.4	0	0.0
Investigations	Blood creatinine increased	White	474	67.6	1	0.2
Investigations	Blood creatinine increased	Asian	176	25.1	0	0.0
Investigations	Blood creatinine increased	Other	27	3.9	0	0.0
Investigations	Blood creatinine increased	Unknown	24	3.4	0	0.0
Investigations	Blood glucose abnormal	White	474	67.6	0	0.0
Investigations	Blood glucose abnormal	Asian	176	25.1	1	0.6
Investigations	Blood glucose abnormal	Other	27	3.9	0	0.0
Investigations	Blood glucose abnormal	Unknown	24	3.4	0	0.0
Investigations	Blood glucose increased	White	474	67.6	2	0.4
Investigations	Blood glucose increased	Asian	176	25.1	1	0.6
Investigations	Blood glucose increased	Other	27	3.9	1	3.7
Investigations	Blood glucose increased	Unknown	24	3.4	0	0.0
Investigations	Blood potassium increased	White	474	67.6	0	0.0
Investigations	Blood potassium increased	Asian	176	25.1	0	0.0
Investigations	Blood potassium increased	Other	27	3.9	0	0.0
Investigations	Blood potassium increased	Unknown	24	3.4	0	0.0
Investigations	Blood pressure decreased	White	474	67.6	1	0.2
Investigations	Blood pressure decreased	Asian	176	25.1	0	0.0
Investigations	Blood pressure decreased	Other	27	3.9	0	0.0
Investigations	Blood pressure decreased	Unknown	24	3.4	0	0.0
Investigations	Blood pressure increased	White	474	67.6	1	0.2
Investigations	Blood pressure increased	Asian	176	25.1	2	1.1
Investigations	Blood pressure increased	Other	27	3.9	0	0.0
Investigations	Blood pressure increased	Unknown	24	3.4	0	0.0
Investigations	Blood testosterone decreased	White	474	67.6	1	0.2
Investigations	Blood testosterone decreased	Asian	176	25.1	0	0.0
Investigations	Blood testosterone decreased	Other	27	3.9	0	0.0
Investigations	Blood testosterone decreased	Unknown	24	3.4	0	0.0
Investigations	Blood thyroid stimulating hormone increased	White	474	67.6	1	0.2
Investigations	Blood thyroid stimulating hormone increased	Asian	176	25.1	0	0.0
Investigations	Blood thyroid stimulating hormone increased	Other	27	3.9	0	0.0
Investigations	Blood thyroid stimulating hormone increased	Unknown	24	3.4	0	0.0
Investigations	Blood triglycerides increased	White	474	67.6	0	0.0
Investigations	Blood triglycerides increased	Asian	176	25.1	0	0.0
Investigations	Blood triglycerides increased	Other	27	3.9	0	0.0
Investigations	Blood triglycerides increased	Unknown	24	3.4	0	0.0
Investigations	Blood uric acid increased	White	474	67.6	0	0.0
Investigations	Blood uric acid increased	Asian	176	25.1	1	0.6
Investigations	Blood uric acid increased	Other	27	3.9	0	0.0
Investigations	Blood uric acid increased	Unknown	24	3.4	0	0.0
Investigations	Grip strength decreased	White	474	67.6	1	0.2
Investigations	Grip strength decreased	Asian	176	25.1	0	0.0
Investigations	Grip strength decreased	Other	27	3.9	0	0.0
Investigations	Grip strength decreased	Unknown	24	3.4	0	0.0
Investigations	Haematocrit decreased	White	474	67.6	0	0.0
Investigations	Haematocrit decreased	Asian	176	25.1	0	0.0
Investigations	Haematocrit decreased	Other	27	3.9	1	3.7
Investigations	Haematocrit decreased	Unknown	24	3.4	0	0.0
Investigations	Haemoglobin decreased	White	474	67.6	0	0.0
Investigations	Haemoglobin decreased	Asian	176	25.1	0	0.0
Investigations	Haemoglobin decreased	Other	27	3.9	1	3.7
Investigations	Haemoglobin decreased	Unknown	24	3.4	0	0.0
Investigations	Heart rate irregular	White	474	67.6	1	0.2
Investigations	Heart rate irregular	Asian	176	25.1	0	0.0
Investigations	Heart rate irregular	Other	27	3.9	0	0.0
Investigations	Heart rate irregular	Unknown	24	3.4	0	0.0
Investigations	Intraocular pressure increased	White	474	67.6	4	0.8
Investigations	Intraocular pressure increased	Asian	176	25.1	11	6.3
Investigations	Intraocular pressure increased	Other	27	3.9	1	3.7
Investigations	Intraocular pressure increased	Unknown	24	3.4	1	4.2
Investigations	Liver function test increased	White	474	67.6	1	0.2
Investigations	Liver function test increased	Asian	176	25.1	0	0.0
Investigations	Liver function test increased	Other	27	3.9	0	0.0
Investigations	Liver function test increased	Unknown	24	3.4	0	0.0
Investigations	Occult blood positive	White	474	67.6	0	0.0
Investigations	Occult blood positive	Asian	176	25.1	0	0.0
Investigations	Occult blood positive	Other	27	3.9	0	0.0
Investigations	Occult blood positive	Unknown	24	3.4	0	0.0
Investigations	Optic nerve cup/disc ratio increased	White	474	67.6	0	0.0
Investigations	Optic nerve cup/disc ratio increased	Asian	176	25.1	0	0.0
Investigations	Optic nerve cup/disc ratio increased	Other	27	3.9	0	0.0
Investigations	Optic nerve cup/disc ratio increased	Unknown	24	3.4	1	4.2
Investigations	Red blood cell count decreased	White	474	67.6	0	0.0
Investigations	Red blood cell count decreased	Asian	176	25.1	0	0.0
Investigations	Red blood cell count decreased	Other	27	3.9	0	0.0
Investigations	Red blood cell count decreased	Unknown	24	3.4	0	0.0
Investigations	SARS-CoV-2 test positive	White	474	67.6	4	0.8
Investigations	SARS-CoV-2 test positive	Asian	176	25.1	0	0.0
Investigations	SARS-CoV-2 test positive	Other	27	3.9	0	0.0
Investigations	SARS-CoV-2 test positive	Unknown	24	3.4	0	0.0
Investigations	Urinary occult blood	White	474	67.6	0	0.0
Investigations	Urinary occult blood	Asian	176	25.1	1	0.6
Investigations	Urinary occult blood	Other	27	3.9	0	0.0
Investigations	Urinary occult blood	Unknown	24	3.4	0	0.0

Investigations	Weight decreased	White	474	67.6	1	0.2
Investigations	Weight decreased	Asian	176	25.1	0	0.0
Investigations	Weight decreased	Other	27	3.9	0	0.0
Investigations	Weight decreased	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders		White	474	67.6	19	4.0
Metabolism and nutrition disorders		Asian	176	25.1	11	6.3
Metabolism and nutrition disorders		Other	27	3.9	3	11.1
Metabolism and nutrition disorders		Unknown	24	3.4	1	4.2
Metabolism and nutrition disorders	Decreased appetite	White	474	67.6	0	0.0
Metabolism and nutrition disorders	Decreased appetite	Asian	176	25.1	1	0.6
Metabolism and nutrition disorders	Decreased appetite	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Decreased appetite	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Dehydration	White	474	67.6	2	0.4
Metabolism and nutrition disorders	Dehydration	Asian	176	25.1	0	0.0
Metabolism and nutrition disorders	Dehydration	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Dehydration	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus	White	474	67.6	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus	Asian	176	25.1	2	1.1
Metabolism and nutrition disorders	Diabetes mellitus	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Diabetes mellitus	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Dyslipidaemia	White	474	67.6	0	0.0
Metabolism and nutrition disorders	Dyslipidaemia	Asian	176	25.1	2	1.1
Metabolism and nutrition disorders	Dyslipidaemia	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Dyslipidaemia	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Glucose tolerance impaired	White	474	67.6	1	0.2
Metabolism and nutrition disorders	Glucose tolerance impaired	Asian	176	25.1	0	0.0
Metabolism and nutrition disorders	Glucose tolerance impaired	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Glucose tolerance impaired	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Gout	White	474	67.6	0	0.0
Metabolism and nutrition disorders	Gout	Asian	176	25.1	1	0.6
Metabolism and nutrition disorders	Gout	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Gout	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Hypercholesterolaemia	White	474	67.6	5	1.1
Metabolism and nutrition disorders	Hypercholesterolaemia	Asian	176	25.1	0	0.0
Metabolism and nutrition disorders	Hypercholesterolaemia	Other	27	3.9	0	3.7
Metabolism and nutrition disorders	Hypercholesterolaemia	Unknown	24	3.4	1	4.2
Metabolism and nutrition disorders	Hyperglycaemia	White	474	67.6	1	0.2
Metabolism and nutrition disorders	Hyperglycaemia	Asian	176	25.1	0	0.0
Metabolism and nutrition disorders	Hyperglycaemia	Other	27	3.9	1	3.7
Metabolism and nutrition disorders	Hyperglycaemia	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Hyperlipidaemia	White	474	67.6	0	0.0
Metabolism and nutrition disorders	Hyperlipidaemia	Asian	176	25.1	1	0.6
Metabolism and nutrition disorders	Hyperlipidaemia	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Hyperlipidaemia	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Hyperuricaemia	White	474	67.6	1	0.2
Metabolism and nutrition disorders	Hyperuricaemia	Asian	176	25.1	1	0.6
Metabolism and nutrition disorders	Hyperuricaemia	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Hyperuricaemia	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Hypervolaemia	White	474	67.6	0	0.0
Metabolism and nutrition disorders	Hypervolaemia	Asian	176	25.1	0	0.0
Metabolism and nutrition disorders	Hypervolaemia	Other	27	3.9	1	3.7
Metabolism and nutrition disorders	Hypervolaemia	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Hypoglycaemia	White	474	67.6	0	0.0
Metabolism and nutrition disorders	Hypoglycaemia	Asian	176	25.1	1	0.6
Metabolism and nutrition disorders	Hypoglycaemia	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Hypoglycaemia	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Hypokalaemia	White	474	67.6	1	1.1
Metabolism and nutrition disorders	Hypokalaemia	Asian	176	25.1	1	0.6
Metabolism and nutrition disorders	Hypokalaemia	Other	27	3.9	1	3.7
Metabolism and nutrition disorders	Hypokalaemia	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Hyponatremia	White	474	67.6	1	0.2
Metabolism and nutrition disorders	Hyponatremia	Asian	176	25.1	0	0.0
Metabolism and nutrition disorders	Hyponatremia	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Hyponatremia	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	White	474	67.6	5	1.1
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Asian	176	25.1	0	1.1
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Other	27	3.9	1	3.7
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Vitamin B12 deficiency	White	474	67.6	2	0.4
Metabolism and nutrition disorders	Vitamin B12 deficiency	Asian	176	25.1	0	0.0
Metabolism and nutrition disorders	Vitamin B12 deficiency	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Vitamin B12 deficiency	Unknown	24	3.4	0	0.0
Metabolism and nutrition disorders	Vitamin D deficiency	White	474	67.6	1	0.2
Metabolism and nutrition disorders	Vitamin D deficiency	Asian	176	25.1	0	0.0
Metabolism and nutrition disorders	Vitamin D deficiency	Other	27	3.9	0	0.0
Metabolism and nutrition disorders	Vitamin D deficiency	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders		White	474	67.6	40	8.4
Musculoskeletal and connective tissue disorders		Asian	176	25.1	16	9.1
Musculoskeletal and connective tissue disorders		Other	27	3.9	3	11.1
Musculoskeletal and connective tissue disorders		Unknown	24	3.4	2	8.3
Musculoskeletal and connective tissue disorders	Arthralgia	White	474	67.6	9	1.9
Musculoskeletal and connective tissue disorders	Arthralgia	Asian	176	25.1	4	2.3
Musculoskeletal and connective tissue disorders	Arthralgia	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Arthralgia	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Arthritis	White	474	67.6	0	0.0
Musculoskeletal and connective tissue disorders	Arthritis	Asian	176	25.1	2	1.1
Musculoskeletal and connective tissue disorders	Arthritis	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Arthritis	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Back pain	White	474	67.6	9	1.9
Musculoskeletal and connective tissue disorders	Back pain	Asian	176	25.1	3	1.7
Musculoskeletal and connective tissue disorders	Back pain	Other	27	3.9	0	3.7
Musculoskeletal and connective tissue disorders	Back pain	Unknown	24	3.4	1	4.2
Musculoskeletal and connective tissue disorders	Bone disorder	White	474	67.6	1	0.2
Musculoskeletal and connective tissue disorders	Bone disorder	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Bone disorder	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Bone disorder	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Bone loss	White	474	67.6	1	0.2
Musculoskeletal and connective tissue disorders	Bone loss	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Bone loss	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Bone loss	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Bursitis	White	474	67.6	0	0.4
Musculoskeletal and connective tissue disorders	Bursitis	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Bursitis	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Bursitis	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Coccydynia	White	474	67.6	1	0.2
Musculoskeletal and connective tissue disorders	Coccydynia	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Coccydynia	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Coccydynia	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Fibromyalgia	White	474	67.6	0	0.0
Musculoskeletal and connective tissue disorders	Fibromyalgia	Asian	176	25.1	1	0.6

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	Asian	176	25.1	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	White	474	67.6	1	0.2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Asian	176	25.1	1	0.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	White	474	67.6	1	0.2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Asian	176	25.1	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	White	474	67.6	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asian	176	25.1	1	0.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	White	474	67.6	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Asian	176	25.1	1	0.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	White	474	67.6	1	0.2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	Asian	176	25.1	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	White	474	67.6	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Asian	176	25.1	1	0.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	White	474	67.6	1	0.2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Asian	176	25.1	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	White	474	67.6	1	0.2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	Asian	176	25.1	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	White	474	67.6	4	0.8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Asian	176	25.1	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	White	474	67.6	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Asian	176	25.1	1	0.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Unknown	24	3.4	0	0.0
Nervous system disorders		White	474	67.6	34	7.2
Nervous system disorders		Asian	176	25.1	14	8.0
Nervous system disorders		Other	27	3.9	2	7.4
Nervous system disorders		Unknown	24	3.4	1	4.2
Nervous system disorders	Autonomic neuropathy	White	474	67.6	1	0.2
Nervous system disorders	Autonomic neuropathy	Asian	176	25.1	0	0.0
Nervous system disorders	Autonomic neuropathy	Other	27	3.9	0	0.0
Nervous system disorders	Autonomic neuropathy	Unknown	24	3.4	0	0.0
Nervous system disorders	Balance disorder	White	474	67.6	1	0.2
Nervous system disorders	Balance disorder	Asian	176	25.1	0	0.0
Nervous system disorders	Balance disorder	Other	27	3.9	0	0.0
Nervous system disorders	Balance disorder	Unknown	24	3.4	0	0.0
Nervous system disorders	Carotid arteriosclerosis	White	474	67.6	0	0.0
Nervous system disorders	Carotid arteriosclerosis	Asian	176	25.1	1	0.6
Nervous system disorders	Carotid arteriosclerosis	Other	27	3.9	0	0.0
Nervous system disorders	Carotid arteriosclerosis	Unknown	24	3.4	0	0.0
Nervous system disorders	Carpal tunnel syndrome	White	474	67.6	1	0.2
Nervous system disorders	Carpal tunnel syndrome	Asian	176	25.1	0	0.0
Nervous system disorders	Carpal tunnel syndrome	Other	27	3.9	0	0.0
Nervous system disorders	Carpal tunnel syndrome	Unknown	24	3.4	0	0.0
Nervous system disorders	Cerebral atrophy	White	474	67.6	0	0.0
Nervous system disorders	Cerebral atrophy	Asian	176	25.1	1	0.6
Nervous system disorders	Cerebral atrophy	Other	27	3.9	0	0.0
Nervous system disorders	Cerebral atrophy	Unknown	24	3.4	0	0.0
Nervous system disorders	Cerebral disorder	White	474	67.6	0	0.0
Nervous system disorders	Cerebral disorder	Asian	176	25.1	1	0.6
Nervous system disorders	Cerebral disorder	Other	27	3.9	0	0.0
Nervous system disorders	Cerebral disorder	Unknown	24	3.4	0	0.0
Nervous system disorders	Cerebral infarction	White	474	67.6	0	0.0
Nervous system disorders	Cerebral infarction	Asian	176	25.1	1	0.6
Nervous system disorders	Cerebral infarction	Other	27	3.9	0	0.0
Nervous system disorders	Cerebral infarction	Unknown	24	3.4	0	0.0
Nervous system disorders	Cerebrovascular accident	White	474	67.6	1	0.2
Nervous system disorders	Cerebrovascular accident	Asian	176	25.1	0	0.0

Nervous system disorders	Cerebrovascular accident	Other	27	3.9	0	0.0
Nervous system disorders	Cerebrovascular accident	Unknown	24	3.4	0	0.0
Nervous system disorders	Cervicobrachial syndrome	White	474	67.6	1	0.2
Nervous system disorders	Cervicobrachial syndrome	Asian	176	25.1	0	0.0
Nervous system disorders	Cervicobrachial syndrome	Other	27	3.9	0	0.0
Nervous system disorders	Cervicobrachial syndrome	Unknown	24	3.4	0	0.0
Nervous system disorders	Cognitive disorder	White	474	67.6	1	0.2
Nervous system disorders	Cognitive disorder	Asian	176	25.1	0	0.0
Nervous system disorders	Cognitive disorder	Other	27	3.9	0	0.0
Nervous system disorders	Cognitive disorder	Unknown	24	3.4	0	0.0
Nervous system disorders	Dementia Alzheimer's type	White	474	67.6	0	0.0
Nervous system disorders	Dementia Alzheimer's type	Asian	176	25.1	0	0.0
Nervous system disorders	Dementia Alzheimer's type	Other	27	3.9	2	7.4
Nervous system disorders	Dementia Alzheimer's type	Unknown	24	3.4	0	0.0
Nervous system disorders	Diabetic neuropathy	White	474	67.6	1	0.2
Nervous system disorders	Diabetic neuropathy	Asian	176	25.1	1	0.6
Nervous system disorders	Diabetic neuropathy	Other	27	3.9	0	0.0
Nervous system disorders	Diabetic neuropathy	Unknown	24	3.4	0	0.0
Nervous system disorders	Dizziness	White	474	67.6	2	0.4
Nervous system disorders	Dizziness	Asian	176	25.1	4	2.3
Nervous system disorders	Dizziness	Other	27	3.9	0	0.0
Nervous system disorders	Dizziness	Unknown	24	3.4	1	4.2
Nervous system disorders	Dysarthria	White	474	67.6	0	0.0
Nervous system disorders	Dysarthria	Asian	176	25.1	1	0.6
Nervous system disorders	Dysarthria	Other	27	3.9	0	0.0
Nervous system disorders	Dysarthria	Unknown	24	3.4	0	0.0
Nervous system disorders	Encephalopathy	White	474	67.6	1	0.2
Nervous system disorders	Encephalopathy	Asian	176	25.1	0	0.0
Nervous system disorders	Encephalopathy	Other	27	3.9	0	0.0
Nervous system disorders	Encephalopathy	Unknown	24	3.4	0	0.0
Nervous system disorders	Headache	White	474	67.6	10	2.1
Nervous system disorders	Headache	Asian	176	25.1	0	0.0
Nervous system disorders	Headache	Other	27	3.9	0	0.0
Nervous system disorders	Headache	Unknown	24	3.4	1	4.2
Nervous system disorders	Hypoesthesia	White	474	67.6	1	0.2
Nervous system disorders	Hypoesthesia	Asian	176	25.1	4	2.3
Nervous system disorders	Hypoesthesia	Other	27	3.9	0	0.0
Nervous system disorders	Hypoesthesia	Unknown	24	3.4	0	0.0
Nervous system disorders	Intercostal neuralgia	White	474	67.6	0	0.0
Nervous system disorders	Intercostal neuralgia	Asian	176	25.1	1	0.6
Nervous system disorders	Intercostal neuralgia	Other	27	3.9	0	0.0
Nervous system disorders	Intercostal neuralgia	Unknown	24	3.4	0	0.0
Nervous system disorders	Ischaemic stroke	White	474	67.6	2	0.4
Nervous system disorders	Ischaemic stroke	Asian	176	25.1	0	0.0
Nervous system disorders	Ischaemic stroke	Other	27	3.9	0	0.0
Nervous system disorders	Ischaemic stroke	Unknown	24	3.4	0	0.0
Nervous system disorders	Lacunar infarction	White	474	67.6	0	0.0
Nervous system disorders	Lacunar infarction	Asian	176	25.1	2	1.1
Nervous system disorders	Lacunar infarction	Other	27	3.9	0	0.0
Nervous system disorders	Lacunar infarction	Unknown	24	3.4	0	0.0
Nervous system disorders	Loss of consciousness	White	474	67.6	1	0.2
Nervous system disorders	Loss of consciousness	Asian	176	25.1	0	0.0
Nervous system disorders	Loss of consciousness	Other	27	3.9	0	0.0
Nervous system disorders	Loss of consciousness	Unknown	24	3.4	0	0.0
Nervous system disorders	Lumbar radiculopathy	White	474	67.6	1	0.2
Nervous system disorders	Lumbar radiculopathy	Asian	176	25.1	0	0.0
Nervous system disorders	Lumbar radiculopathy	Other	27	3.9	0	0.0
Nervous system disorders	Lumbar radiculopathy	Unknown	24	3.4	0	0.0
Nervous system disorders	Migraine	White	474	67.6	1	0.2
Nervous system disorders	Migraine	Asian	176	25.1	0	0.0
Nervous system disorders	Migraine	Other	27	3.9	0	0.0
Nervous system disorders	Migraine	Unknown	24	3.4	0	0.0
Nervous system disorders	Neuralgia	White	474	67.6	1	0.2
Nervous system disorders	Neuralgia	Asian	176	25.1	1	0.6
Nervous system disorders	Neuralgia	Other	27	3.9	0	0.0
Nervous system disorders	Neuralgia	Unknown	24	3.4	0	0.0
Nervous system disorders	Neuropathy peripheral	White	474	67.6	2	0.4
Nervous system disorders	Neuropathy peripheral	Asian	176	25.1	0	0.0
Nervous system disorders	Neuropathy peripheral	Other	27	3.9	0	0.0
Nervous system disorders	Neuropathy peripheral	Unknown	24	3.4	0	0.0
Nervous system disorders	Ophthalmic migraine	White	474	67.6	1	0.2
Nervous system disorders	Ophthalmic migraine	Asian	176	25.1	0	0.0
Nervous system disorders	Ophthalmic migraine	Other	27	3.9	0	0.0
Nervous system disorders	Ophthalmic migraine	Unknown	24	3.4	0	0.0
Nervous system disorders	Paralysis	White	474	67.6	0	0.0
Nervous system disorders	Paralysis	Asian	176	25.1	1	0.6
Nervous system disorders	Paralysis	Other	27	3.9	0	0.0
Nervous system disorders	Paralysis	Unknown	24	3.4	0	0.0
Nervous system disorders	Parkinsonism	White	474	67.6	0	0.0
Nervous system disorders	Parkinsonism	Asian	176	25.1	1	0.6
Nervous system disorders	Parkinsonism	Other	27	3.9	0	0.0
Nervous system disorders	Parkinsonism	Unknown	24	3.4	0	0.0
Nervous system disorders	Presyncope	White	474	67.6	1	0.2
Nervous system disorders	Presyncope	Asian	176	25.1	0	0.0
Nervous system disorders	Presyncope	Other	27	3.9	0	0.0
Nervous system disorders	Presyncope	Unknown	24	3.4	0	0.0
Nervous system disorders	Sciatica	White	474	67.6	2	0.4
Nervous system disorders	Sciatica	Asian	176	25.1	0	0.0
Nervous system disorders	Sciatica	Other	27	3.9	0	0.0
Nervous system disorders	Sciatica	Unknown	24	3.4	0	0.0
Nervous system disorders	Syncope	White	474	67.6	3	0.6
Nervous system disorders	Syncope	Asian	176	25.1	1	0.6
Nervous system disorders	Syncope	Other	27	3.9	0	0.0
Nervous system disorders	Syncope	Unknown	24	3.4	0	0.0
Product issues		White	474	67.6	1	0.2
Product issues		Asian	176	25.1	0	0.0
Product issues		Other	27	3.9	0	0.0
Product issues		Unknown	24	3.4	0	0.0
Product issues	Device physical property issue	White	474	67.6	1	0.2
Product issues	Device physical property issue	Asian	176	25.1	0	0.0
Product issues	Device physical property issue	Other	27	3.9	0	0.0
Product issues	Device physical property issue	Unknown	24	3.4	0	0.0
Psychiatric disorders		White	474	67.6	5	1.1
Psychiatric disorders		Asian	176	25.1	4	2.3
Psychiatric disorders		Other	27	3.9	0	0.0
Psychiatric disorders		Unknown	24	3.4	0	0.0
Psychiatric disorders	Anxiety	White	474	67.6	1	0.2
Psychiatric disorders	Anxiety	Asian	176	25.1	0	0.0
Psychiatric disorders	Anxiety	Other	27	3.9	0	0.0
Psychiatric disorders	Anxiety	Unknown	24	3.4	0	0.0

Psychiatric disorders	Attention deficit hyperactivity disorder	White	474	67.6	1	0.2
Psychiatric disorders	Attention deficit hyperactivity disorder	Asian	176	25.1	0	0.0
Psychiatric disorders	Attention deficit hyperactivity disorder	Other	27	3.9	0	0.0
Psychiatric disorders	Attention deficit hyperactivity disorder	Unknown	24	3.4	0	0.0
Psychiatric disorders	Depression	White	474	67.6	1	0.2
Psychiatric disorders	Depression	Asian	176	25.1	1	0.6
Psychiatric disorders	Depression	Other	27	3.9	0	0.0
Psychiatric disorders	Depression	Unknown	24	3.4	0	0.0
Psychiatric disorders	Generalised anxiety disorder	White	474	67.6	1	0.2
Psychiatric disorders	Generalised anxiety disorder	Asian	176	25.1	0	0.0
Psychiatric disorders	Generalised anxiety disorder	Other	27	3.9	0	0.0
Psychiatric disorders	Generalised anxiety disorder	Unknown	24	3.4	0	0.0
Psychiatric disorders	Insomnia	White	474	67.6	1	0.2
Psychiatric disorders	Insomnia	Asian	176	25.1	2	1.1
Psychiatric disorders	Insomnia	Other	27	3.9	0	0.0
Psychiatric disorders	Insomnia	Unknown	24	3.4	0	0.0
Psychiatric disorders	Sleep disorder	White	474	67.6	0	0.0
Psychiatric disorders	Sleep disorder	Asian	176	25.1	1	0.6
Psychiatric disorders	Sleep disorder	Other	27	3.9	0	0.0
Psychiatric disorders	Sleep disorder	Unknown	24	3.4	0	0.0
Renal and urinary disorders		White	474	67.6	13	2.7
Renal and urinary disorders		Asian	176	25.1	2	1.1
Renal and urinary disorders		Other	27	3.9	0	0.0
Renal and urinary disorders		Unknown	24	3.4	0	0.0
Renal and urinary disorders	Acute kidney injury	White	474	67.6	3	0.6
Renal and urinary disorders	Acute kidney injury	Asian	176	25.1	0	0.0
Renal and urinary disorders	Acute kidney injury	Other	27	3.9	0	0.0
Renal and urinary disorders	Acute kidney injury	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Cystitis interstitial	White	474	67.6	0	0.0
Renal and urinary disorders	Cystitis interstitial	Asian	176	25.1	0	0.0
Renal and urinary disorders	Cystitis interstitial	Other	27	3.9	0	0.0
Renal and urinary disorders	Cystitis interstitial	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Diabetic nephropathy	White	474	67.6	0	0.0
Renal and urinary disorders	Diabetic nephropathy	Asian	176	25.1	1	0.6
Renal and urinary disorders	Diabetic nephropathy	Other	27	3.9	0	0.0
Renal and urinary disorders	Diabetic nephropathy	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Dysuria	White	474	67.6	1	0.2
Renal and urinary disorders	Dysuria	Asian	176	25.1	0	0.0
Renal and urinary disorders	Dysuria	Other	27	3.9	0	0.0
Renal and urinary disorders	Dysuria	Unknown	24	3.4	0	0.0
Renal and urinary disorders	End stage renal disease	White	474	67.6	0	0.0
Renal and urinary disorders	End stage renal disease	Asian	176	25.1	0	0.0
Renal and urinary disorders	End stage renal disease	Other	27	3.9	0	0.0
Renal and urinary disorders	End stage renal disease	Unknown	24	3.4	1	4.2
Renal and urinary disorders	Haematuria	White	474	67.6	1	0.2
Renal and urinary disorders	Haematuria	Asian	176	25.1	0	0.0
Renal and urinary disorders	Haematuria	Other	27	3.9	0	0.0
Renal and urinary disorders	Haematuria	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Hypertonic bladder	White	474	67.6	1	0.2
Renal and urinary disorders	Hypertonic bladder	Asian	176	25.1	0	0.0
Renal and urinary disorders	Hypertonic bladder	Other	27	3.9	0	0.0
Renal and urinary disorders	Hypertonic bladder	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Nephrolithiasis	White	474	67.6	2	0.4
Renal and urinary disorders	Nephrolithiasis	Asian	176	25.1	1	0.6
Renal and urinary disorders	Nephrolithiasis	Other	27	3.9	0	0.0
Renal and urinary disorders	Nephrolithiasis	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Nephropathy	White	474	67.6	1	0.2
Renal and urinary disorders	Nephropathy	Asian	176	25.1	0	0.0
Renal and urinary disorders	Nephropathy	Other	27	3.9	0	0.0
Renal and urinary disorders	Nephropathy	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Renal failure	White	474	67.6	2	0.4
Renal and urinary disorders	Renal failure	Asian	176	25.1	0	0.0
Renal and urinary disorders	Renal failure	Other	27	3.9	0	0.0
Renal and urinary disorders	Renal failure	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Urinary retention	White	474	67.6	1	0.2
Renal and urinary disorders	Urinary retention	Asian	176	25.1	0	0.0
Renal and urinary disorders	Urinary retention	Other	27	3.9	0	0.0
Renal and urinary disorders	Urinary retention	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Urinary tract inflammation	White	474	67.6	1	0.2
Renal and urinary disorders	Urinary tract inflammation	Asian	176	25.1	0	0.0
Renal and urinary disorders	Urinary tract inflammation	Other	27	3.9	0	0.0
Renal and urinary disorders	Urinary tract inflammation	Unknown	24	3.4	0	0.0
Reproductive system and breast disorders		White	474	67.6	3	0.6
Reproductive system and breast disorders		Asian	176	25.1	2	1.1
Reproductive system and breast disorders		Other	27	3.9	1	3.7
Reproductive system and breast disorders		Unknown	24	3.4	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	White	474	67.6	2	0.4
Reproductive system and breast disorders	Benign prostatic hyperplasia	Asian	176	25.1	1	0.6
Reproductive system and breast disorders	Benign prostatic hyperplasia	Other	27	3.9	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Unknown	24	3.4	0	0.0
Reproductive system and breast disorders	Cystocele	White	474	67.6	1	0.2
Reproductive system and breast disorders	Cystocele	Asian	176	25.1	0	0.0
Reproductive system and breast disorders	Cystocele	Other	27	3.9	0	0.0
Reproductive system and breast disorders	Cystocele	Unknown	24	3.4	0	0.0
Reproductive system and breast disorders	Gynaecomastia	White	474	67.6	0	0.0
Reproductive system and breast disorders	Gynaecomastia	Asian	176	25.1	1	0.6
Reproductive system and breast disorders	Gynaecomastia	Other	27	3.9	0	0.0
Reproductive system and breast disorders	Gynaecomastia	Unknown	24	3.4	0	0.0
Reproductive system and breast disorders	Prostatitis	White	474	67.6	0	0.0
Reproductive system and breast disorders	Prostatitis	Asian	176	25.1	0	0.0
Reproductive system and breast disorders	Prostatitis	Other	27	3.9	0	0.0
Reproductive system and breast disorders	Prostatitis	Unknown	24	3.4	0	0.0
Reproductive system and breast disorders	Vaginal ulceration	White	474	67.6	0	0.0
Reproductive system and breast disorders	Vaginal ulceration	Asian	176	25.1	0	0.0
Reproductive system and breast disorders	Vaginal ulceration	Other	27	3.9	1	3.7
Reproductive system and breast disorders	Vaginal ulceration	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders		White	474	67.6	21	4.4
Respiratory, thoracic and mediastinal disorders		Asian	176	25.1	9	5.1
Respiratory, thoracic and mediastinal disorders		Other	27	3.9	1	3.7
Respiratory, thoracic and mediastinal disorders		Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	White	474	67.6	2	0.4
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Asian	176	25.1	0	0.0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Asthma	White	474	67.6	0	0.0
Respiratory, thoracic and mediastinal disorders	Asthma	Asian	176	25.1	1	0.6
Respiratory, thoracic and mediastinal disorders	Asthma	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Asthma	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	White	474	67.6	1	0.2

Skin and subcutaneous tissue disorders	Diabetic foot	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Diabetic foot	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Diabetic foot	Other	27	3.9	1	3.7
Skin and subcutaneous tissue disorders	Diabetic foot	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Eczema	White	474	67.6	0	0.0
Skin and subcutaneous tissue disorders	Eczema	Asian	176	25.1	1	0.6
Skin and subcutaneous tissue disorders	Eczema	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Eczema	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Erythema	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Erythema	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Erythema	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Erythema	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Hyperkeratosis	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Hyperkeratosis	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Hyperkeratosis	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Hyperkeratosis	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Ingrowing nail	White	474	67.6	0	0.0
Skin and subcutaneous tissue disorders	Ingrowing nail	Asian	176	25.1	1	0.6
Skin and subcutaneous tissue disorders	Ingrowing nail	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Ingrowing nail	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Nail bed bleeding	White	474	67.6	0	0.0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Asian	176	25.1	1	0.6
Skin and subcutaneous tissue disorders	Nail bed bleeding	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Nail dystrophy	White	474	67.6	0	0.0
Skin and subcutaneous tissue disorders	Nail dystrophy	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Nail dystrophy	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Nail dystrophy	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Purpura	White	474	67.6	0	0.0
Skin and subcutaneous tissue disorders	Purpura	Asian	176	25.1	0	0.6
Skin and subcutaneous tissue disorders	Purpura	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Purpura	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Rash	White	474	67.6	3	0.6
Skin and subcutaneous tissue disorders	Rash	Asian	176	25.1	1	0.6
Skin and subcutaneous tissue disorders	Rash	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Rash	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Skin lesion	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Skin lesion	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Skin lesion	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Skin lesion	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Skin ulcer	White	474	67.6	0	0.4
Skin and subcutaneous tissue disorders	Skin ulcer	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Skin ulcer	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Skin ulcer	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Toxic skin eruption	White	474	67.6	0	0.0
Skin and subcutaneous tissue disorders	Toxic skin eruption	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Toxic skin eruption	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Toxic skin eruption	Unknown	24	3.4	1	4.2
Skin and subcutaneous tissue disorders	Urticaria	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Urticaria	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Urticaria	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Urticaria	Unknown	24	3.4	0	0.0
			27	3.9	1	
Surgical and medical procedures		White	474	67.6	8	1.7
Surgical and medical procedures		Asian	176	25.1	1	0.6
Surgical and medical procedures		Other	27	3.9	0	0.0
Surgical and medical procedures		Unknown	24	3.4	1	4.2
Surgical and medical procedures	Dental implantation	White	474	67.6	2	0.4
Surgical and medical procedures	Dental implantation	Asian	176	25.1	1	0.6
Surgical and medical procedures	Dental implantation	Other	27	3.9	0	0.0
Surgical and medical procedures	Dental implantation	Unknown	24	3.4	0	0.0
Surgical and medical procedures	Large intestinal polypectomy	White	474	67.6	3	0.2
Surgical and medical procedures	Large intestinal polypectomy	Asian	176	25.1	0	0.0
Surgical and medical procedures	Large intestinal polypectomy	Other	27	3.9	0	0.0
Surgical and medical procedures	Large intestinal polypectomy	Unknown	24	3.4	0	0.0
Surgical and medical procedures	Ligament operation	White	474	67.6	1	0.2
Surgical and medical procedures	Ligament operation	Asian	176	25.1	0	0.0
Surgical and medical procedures	Ligament operation	Other	27	3.9	0	0.0
Surgical and medical procedures	Ligament operation	Unknown	24	3.4	0	0.0
Surgical and medical procedures	Neurectomy	White	474	67.6	1	0.2
Surgical and medical procedures	Neurectomy	Asian	176	25.1	0	0.0
Surgical and medical procedures	Neurectomy	Other	27	3.9	0	0.0
Surgical and medical procedures	Neurectomy	Unknown	24	3.4	0	0.0
Surgical and medical procedures	Renal transplant	White	474	67.6	0	0.0
Surgical and medical procedures	Renal transplant	Asian	176	25.1	0	0.0
Surgical and medical procedures	Renal transplant	Other	27	3.9	0	0.0
Surgical and medical procedures	Renal transplant	Unknown	24	3.4	1	4.2
Surgical and medical procedures	Toe operation	White	474	67.6	1	0.2
Surgical and medical procedures	Toe operation	Asian	176	25.1	0	0.0
Surgical and medical procedures	Toe operation	Other	27	3.9	0	0.0
Surgical and medical procedures	Toe operation	Unknown	24	3.4	0	0.0
Surgical and medical procedures	Tooth extraction	White	474	67.6	4	0.8
Surgical and medical procedures	Tooth extraction	Asian	176	25.1	0	0.0
Surgical and medical procedures	Tooth extraction	Other	27	3.9	0	0.0
Surgical and medical procedures	Tooth extraction	Unknown	24	3.4	0	0.0
Vascular disorders		White	474	67.6	31	6.5
Vascular disorders		Asian	176	25.1	6	3.4
Vascular disorders		Other	27	3.9	2	7.4
Vascular disorders		Unknown	24	3.4	0	0.0
Vascular disorders	Aortic aneurysm	White	474	67.6	1	0.2
Vascular disorders	Aortic aneurysm	Asian	176	25.1	0	0.0
Vascular disorders	Aortic aneurysm	Other	27	3.9	0	0.0
Vascular disorders	Aortic aneurysm	Unknown	24	3.4	0	0.0
Vascular disorders	Aortic dissection	White	474	67.6	1	0.2
Vascular disorders	Aortic dissection	Asian	176	25.1	0	0.0
Vascular disorders	Aortic dissection	Other	27	3.9	0	0.0
Vascular disorders	Aortic dissection	Unknown	24	3.4	0	0.0
Vascular disorders	Aortic stenosis	White	474	67.6	1	0.2
Vascular disorders	Aortic stenosis	Asian	176	25.1	0	0.0
Vascular disorders	Aortic stenosis	Other	27	3.9	0	0.0
Vascular disorders	Aortic stenosis	Unknown	24	3.4	0	0.0
Vascular disorders	Deep vein thrombosis	White	474	67.6	0	0.2
Vascular disorders	Deep vein thrombosis	Asian	176	25.1	0	0.0
Vascular disorders	Deep vein thrombosis	Other	27	3.9	0	0.0
Vascular disorders	Deep vein thrombosis	Unknown	24	3.4	0	0.0
Vascular disorders	Hematoma	White	474	67.6	1	0.2
Vascular disorders	Hematoma	Asian	176	25.1	0	0.0
Vascular disorders	Hematoma	Other	27	3.9	0	0.0
Vascular disorders	Hematoma	Unknown	24	3.4	0	0.0
Vascular disorders	Hemorrhage	White	474	67.6	0	0.0
Vascular disorders	Hemorrhage	Asian	176	25.1	1	0.6

Vascular disorders	Haemorrhage	Other	27	3.9	0	0.0
Vascular disorders	Haemorrhage	Unknown	24	3.4	0	0.0
Vascular disorders	Hypertension	White	474	67.6	18	3.8
Vascular disorders	Hypertension	Asian	176	25.1	4	2.3
Vascular disorders	Hypertension	Other	27	3.9	1	3.7
Vascular disorders	Hypertension	Unknown	24	3.4	0	0.0
Vascular disorders	Hypertensive crisis	White	474	67.6	3	0.6
Vascular disorders	Hypertensive crisis	Asian	176	25.1	0	0.0
Vascular disorders	Hypertensive crisis	Other	27	3.9	0	0.0
Vascular disorders	Hypertensive crisis	Unknown	24	3.4	0	0.0
Vascular disorders	Hypotension	White	474	67.6	3	0.6
Vascular disorders	Hypotension	Asian	176	25.1	1	0.6
Vascular disorders	Hypotension	Other	27	3.9	0	0.0
Vascular disorders	Hypotension	Unknown	24	3.4	0	0.0
Vascular disorders	Internal haemorrhage	White	474	67.6	0	0.0
Vascular disorders	Internal haemorrhage	Asian	176	25.1	1	0.6
Vascular disorders	Internal haemorrhage	Other	27	3.9	0	0.0
Vascular disorders	Internal haemorrhage	Unknown	24	3.4	0	0.0
Vascular disorders	Lymphoedema	White	474	67.6	1	0.2
Vascular disorders	Lymphoedema	Asian	176	25.1	0	0.0
Vascular disorders	Lymphoedema	Other	27	3.9	0	0.0
Vascular disorders	Lymphoedema	Unknown	24	3.4	0	0.0
Vascular disorders	Peripheral artery aneurysm	White	474	67.6	0	0.0
Vascular disorders	Peripheral artery aneurysm	Asian	176	25.1	0	0.0
Vascular disorders	Peripheral artery aneurysm	Other	27	3.9	1	3.7
Vascular disorders	Peripheral artery aneurysm	Unknown	24	3.4	0	0.0
Vascular disorders	Secondary hypertension	White	474	67.6	1	0.2
Vascular disorders	Secondary hypertension	Asian	176	25.1	0	0.0
Vascular disorders	Secondary hypertension	Other	27	3.9	0	0.0
Vascular disorders	Secondary hypertension	Unknown	24	3.4	0	0.0
Vascular disorders	Thrombosis	White	474	67.6	1	0.2
Vascular disorders	Thrombosis	Asian	176	25.1	0	0.0
Vascular disorders	Thrombosis	Other	27	3.9	0	0.0
Vascular disorders	Thrombosis	Unknown	24	3.4	0	0.0

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_se_soc_descriptive_w72.mas
Output: root/clinical_studies/R06867461/CDT30303/RR41986/data_analysis/ACK_CSR_Final/prod/output/t_se_soc_descriptive_w72_sg_AR_MR72_Sea24_28AUG2023_41986.xls
26APR2024 18:00

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Any AEs

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

Baseline RVO status

MedDRA System Organ Class	MedDRA Preferred Term	Level	Favicimab (N=701)			
			Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		CRVO	574	81,9	8	1,4
Blood and lymphatic system disorders		HRVO	121	17,3	2	1,7
Blood and lymphatic system disorders		Missing	6	0,9	0	0,0
Blood and lymphatic system disorders	Anaemia	CRVO	574	81,9	7	1,2
Blood and lymphatic system disorders	Anaemia	HRVO	121	17,3	1	0,8
Blood and lymphatic system disorders	Anaemia	Missing	6	0,9	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	CRVO	574	81,9	1	0,2
Blood and lymphatic system disorders	Deficiency anaemia	HRVO	121	17,3	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Missing	6	0,9	0	0,0
Blood and lymphatic system disorders	Iron deficiency anaemia	CRVO	574	81,9	0	0,0
Blood and lymphatic system disorders	Iron deficiency anaemia	HRVO	121	17,3	1	0,8
Blood and lymphatic system disorders	Iron deficiency anaemia	Missing	6	0,9	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	CRVO	574	81,9	1	0,2
Blood and lymphatic system disorders	Mesenteric lymphadenitis	HRVO	121	17,3	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Missing	6	0,9	0	0,0
Cardiac disorders		CRVO	574	81,9	27	4,7
Cardiac disorders		HRVO	121	17,3	2	1,7
Cardiac disorders		Missing	6	0,9	1	16,7
Cardiac disorders	Acute left ventricular failure	CRVO	574	81,9	1	0,2
Cardiac disorders	Acute left ventricular failure	HRVO	121	17,3	0	0,0
Cardiac disorders	Acute left ventricular failure	Missing	6	0,9	0	0,0
Cardiac disorders	Acute myocardial infarction	CRVO	574	81,9	2	0,3
Cardiac disorders	Acute myocardial infarction	HRVO	121	17,3	0	0,0
Cardiac disorders	Acute myocardial infarction	Missing	6	0,9	0	0,0
Cardiac disorders	Aortic valve incompetence	CRVO	574	81,9	1	0,2
Cardiac disorders	Aortic valve incompetence	HRVO	121	17,3	0	0,0
Cardiac disorders	Aortic valve incompetence	Missing	6	0,9	0	0,0
Cardiac disorders	Arrhythmia	CRVO	574	81,9	1	0,2
Cardiac disorders	Arrhythmia	HRVO	121	17,3	0	0,0
Cardiac disorders	Arrhythmia	Missing	6	0,9	0	0,0
Cardiac disorders	Atrial fibrillation	CRVO	574	81,9	7	1,2
Cardiac disorders	Atrial fibrillation	HRVO	121	17,3	2	1,7
Cardiac disorders	Atrial fibrillation	Missing	6	0,9	0	0,0
Cardiac disorders	Bradycardia	CRVO	574	81,9	1	0,2
Cardiac disorders	Bradycardia	HRVO	121	17,3	0	0,0
Cardiac disorders	Bradycardia	Missing	6	0,9	0	0,0
Cardiac disorders	Cardiac failure	CRVO	574	81,9	1	0,2
Cardiac disorders	Cardiac failure	HRVO	121	17,3	0	0,0
Cardiac disorders	Cardiac failure	Missing	6	0,9	0	0,0
Cardiac disorders	Cardiac failure congestive	CRVO	574	81,9	2	0,3
Cardiac disorders	Cardiac failure congestive	HRVO	121	17,3	0	0,0
Cardiac disorders	Cardiac failure congestive	Missing	6	0,9	0	0,0
Cardiac disorders	Cardiomegaly	CRVO	574	81,9	1	0,2
Cardiac disorders	Cardiomegaly	HRVO	121	17,3	0	0,0
Cardiac disorders	Cardiomegaly	Missing	6	0,9	0	0,0
Cardiac disorders	Coronary artery disease	CRVO	574	81,9	1	0,2
Cardiac disorders	Coronary artery disease	HRVO	121	17,3	0	0,0
Cardiac disorders	Coronary artery disease	Missing	6	0,9	0	0,0
Cardiac disorders	Coronary artery stenosis	CRVO	574	81,9	1	0,2
Cardiac disorders	Coronary artery stenosis	HRVO	121	17,3	0	0,0
Cardiac disorders	Coronary artery stenosis	Missing	6	0,9	0	0,0
Cardiac disorders	Left ventricular dysfunction	CRVO	574	81,9	2	0,3
Cardiac disorders	Left ventricular dysfunction	HRVO	121	17,3	0	0,0
Cardiac disorders	Left ventricular dysfunction	Missing	6	0,9	0	0,0
Cardiac disorders	Myocardial infarction	CRVO	574	81,9	3	0,5
Cardiac disorders	Myocardial infarction	HRVO	121	17,3	0	0,0
Cardiac disorders	Myocardial infarction	Missing	6	0,9	0	0,0
Cardiac disorders	Myocardial ischaemia	CRVO	574	81,9	1	0,2
Cardiac disorders	Myocardial ischaemia	HRVO	121	17,3	0	0,0
Cardiac disorders	Myocardial ischaemia	Missing	6	0,9	0	0,0
Cardiac disorders	Palpitations	CRVO	574	81,9	1	0,2
Cardiac disorders	Palpitations	HRVO	121	17,3	0	0,0
Cardiac disorders	Palpitations	Missing	6	0,9	0	0,0
Cardiac disorders	Pericardial effusion	CRVO	574	81,9	1	0,2
Cardiac disorders	Pericardial effusion	HRVO	121	17,3	0	0,0
Cardiac disorders	Pericardial effusion	Missing	6	0,9	0	0,0
Cardiac disorders	Sinus tachycardia	CRVO	574	81,9	1	0,2
Cardiac disorders	Sinus tachycardia	HRVO	121	17,3	0	0,0
Cardiac disorders	Sinus tachycardia	Missing	6	0,9	0	0,0

Cardiac disorders	Stress cardiomyopathy	CRVO	574	81,9	1	0,2
Cardiac disorders	Stress cardiomyopathy	HRVO	121	17,3	0	0,0
Cardiac disorders	Stress cardiomyopathy	Missing	6	0,9	0	0,0
Cardiac disorders	Supraventricular tachycardia	CRVO	574	81,9	0	0,0
Cardiac disorders	Supraventricular tachycardia	HRVO	121	17,3	0	0,0
Cardiac disorders	Supraventricular tachycardia	Missing	6	0,9	1	16,7
Cardiac disorders	Tachycardia	CRVO	574	81,9	2	0,3
Cardiac disorders	Tachycardia	HRVO	121	17,3	0	0,0
Cardiac disorders	Tachycardia	Missing	6	0,9	0	0,0
Congenital, familial and genetic disorders		CRVO	574	81,9	1	0,2
Congenital, familial and genetic disorders		HRVO	121	17,3	1	0,8
Congenital, familial and genetic disorders		Missing	6	0,9	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	CRVO	574	81,9	1	0,2
Congenital, familial and genetic disorders	Corneal dystrophy	HRVO	121	17,3	1	0,8
Congenital, familial and genetic disorders	Corneal dystrophy	Missing	6	0,9	0	0,0
Ear and labyrinth disorders		CRVO	574	81,9	3	0,5
Ear and labyrinth disorders		HRVO	121	17,3	1	0,8
Ear and labyrinth disorders		Missing	6	0,9	0	0,0
Ear and labyrinth disorders	Vertigo	CRVO	574	81,9	3	0,5
Ear and labyrinth disorders	Vertigo	HRVO	121	17,3	1	0,8
Ear and labyrinth disorders	Vertigo	Missing	6	0,9	0	0,0
Endocrine disorders		CRVO	574	81,9	8	1,4
Endocrine disorders		HRVO	121	17,3	2	1,7
Endocrine disorders		Missing	6	0,9	0	0,0
Endocrine disorders	Adrenal insufficiency	CRVO	574	81,9	1	0,2
Endocrine disorders	Adrenal insufficiency	HRVO	121	17,3	0	0,0
Endocrine disorders	Adrenal insufficiency	Missing	6	0,9	0	0,0
Endocrine disorders	Adrenal mass	CRVO	574	81,9	2	0,3
Endocrine disorders	Adrenal mass	HRVO	121	17,3	0	0,0
Endocrine disorders	Adrenal mass	Missing	6	0,9	0	0,0
Endocrine disorders	Adrenomegaly	CRVO	574	81,9	1	0,2
Endocrine disorders	Adrenomegaly	HRVO	121	17,3	0	0,0
Endocrine disorders	Adrenomegaly	Missing	6	0,9	0	0,0
Endocrine disorders	Androgen deficiency	CRVO	574	81,9	1	0,2
Endocrine disorders	Androgen deficiency	HRVO	121	17,3	0	0,0
Endocrine disorders	Androgen deficiency	Missing	6	0,9	0	0,0
Endocrine disorders	Goitre	CRVO	574	81,9	0	0,0
Endocrine disorders	Goitre	HRVO	121	17,3	1	0,8
Endocrine disorders	Goitre	Missing	6	0,9	0	0,0
Endocrine disorders	Hypothyroidism	CRVO	574	81,9	3	0,5
Endocrine disorders	Hypothyroidism	HRVO	121	17,3	1	0,8
Endocrine disorders	Hypothyroidism	Missing	6	0,9	0	0,0
Endocrine disorders	Thyroid cyst	CRVO	574	81,9	1	0,2
Endocrine disorders	Thyroid cyst	HRVO	121	17,3	0	0,0
Endocrine disorders	Thyroid cyst	Missing	6	0,9	0	0,0
Endocrine disorders	Thyroid mass	CRVO	574	81,9	1	0,2
Endocrine disorders	Thyroid mass	HRVO	121	17,3	0	0,0
Endocrine disorders	Thyroid mass	Missing	6	0,9	0	0,0
Eye disorders		CRVO	574	81,9	220	38,3
Eye disorders		HRVO	121	17,3	40	33,1
Eye disorders		Missing	6	0,9	2	33,3
Eye disorders	Age-related macular degeneration	CRVO	574	81,9	1	0,2
Eye disorders	Age-related macular degeneration	HRVO	121	17,3	0	0,0
Eye disorders	Age-related macular degeneration	Missing	6	0,9	0	0,0
Eye disorders	Anisocoria	CRVO	574	81,9	1	0,2
Eye disorders	Anisocoria	HRVO	121	17,3	0	0,0
Eye disorders	Anisocoria	Missing	6	0,9	0	0,0
Eye disorders	Asthenopia	CRVO	574	81,9	1	0,2
Eye disorders	Asthenopia	HRVO	121	17,3	1	0,8
Eye disorders	Asthenopia	Missing	6	0,9	0	0,0
Eye disorders	Blepharitis	CRVO	574	81,9	4	0,7
Eye disorders	Blepharitis	HRVO	121	17,3	1	0,8
Eye disorders	Blepharitis	Missing	6	0,9	0	0,0
Eye disorders	Borderline glaucoma	CRVO	574	81,9	1	0,2
Eye disorders	Borderline glaucoma	HRVO	121	17,3	1	0,8
Eye disorders	Borderline glaucoma	Missing	6	0,9	0	0,0
Eye disorders	Cataract	CRVO	574	81,9	27	4,7
Eye disorders	Cataract	HRVO	121	17,3	7	5,8
Eye disorders	Cataract	Missing	6	0,9	0	0,0
Eye disorders	Cataract nuclear	CRVO	574	81,9	1	0,2
Eye disorders	Cataract nuclear	HRVO	121	17,3	0	0,0
Eye disorders	Cataract nuclear	Missing	6	0,9	0	0,0
Eye disorders	Cataract subcapsular	CRVO	574	81,9	1	0,2
Eye disorders	Cataract subcapsular	HRVO	121	17,3	0	0,0
Eye disorders	Cataract subcapsular	Missing	6	0,9	0	0,0
Eye disorders	Central serous chorioretinopathy	CRVO	574	81,9	3	0,5
Eye disorders	Central serous chorioretinopathy	HRVO	121	17,3	1	0,8
Eye disorders	Central serous chorioretinopathy	Missing	6	0,9	0	0,0
Eye disorders	Chalazion	CRVO	574	81,9	4	0,7

Eye disorders	Chalazion	HRVO	121	17,3	0	0,0
Eye disorders	Chalazion	Missing	6	0,9	0	0,0
Eye disorders	Choroidal effusion	CRVO	574	81,9	1	0,2
Eye disorders	Choroidal effusion	HRVO	121	17,3	0	0,0
Eye disorders	Choroidal effusion	Missing	6	0,9	0	0,0
Eye disorders	Conjunctival haemorrhage	CRVO	574	81,9	15	2,6
Eye disorders	Conjunctival haemorrhage	HRVO	121	17,3	5	4,1
Eye disorders	Conjunctival haemorrhage	Missing	6	0,9	1	16,7
Eye disorders	Conjunctival hyperaemia	CRVO	574	81,9	2	0,3
Eye disorders	Conjunctival hyperaemia	HRVO	121	17,3	0	0,0
Eye disorders	Conjunctival hyperaemia	Missing	6	0,9	0	0,0
Eye disorders	Conjunctival telangiectasia	CRVO	574	81,9	1	0,2
Eye disorders	Conjunctival telangiectasia	HRVO	121	17,3	0	0,0
Eye disorders	Conjunctival telangiectasia	Missing	6	0,9	0	0,0
Eye disorders	Conjunctivitis allergic	CRVO	574	81,9	0	0,0
Eye disorders	Conjunctivitis allergic	HRVO	121	17,3	1	0,8
Eye disorders	Conjunctivitis allergic	Missing	6	0,9	0	0,0
Eye disorders	Corneal deposits	CRVO	574	81,9	0	0,0
Eye disorders	Corneal deposits	HRVO	121	17,3	1	0,8
Eye disorders	Corneal deposits	Missing	6	0,9	0	0,0
Eye disorders	Corneal erosion	CRVO	574	81,9	0	0,0
Eye disorders	Corneal erosion	HRVO	121	17,3	1	0,8
Eye disorders	Corneal erosion	Missing	6	0,9	0	0,0
Eye disorders	Corneal infiltrates	CRVO	574	81,9	1	0,2
Eye disorders	Corneal infiltrates	HRVO	121	17,3	0	0,0
Eye disorders	Corneal infiltrates	Missing	6	0,9	0	0,0
Eye disorders	Corneal opacity	CRVO	574	81,9	1	0,2
Eye disorders	Corneal opacity	HRVO	121	17,3	0	0,0
Eye disorders	Corneal opacity	Missing	6	0,9	0	0,0
Eye disorders	Corneal pigmentation	CRVO	574	81,9	0	0,0
Eye disorders	Corneal pigmentation	HRVO	121	17,3	1	0,8
Eye disorders	Corneal pigmentation	Missing	6	0,9	0	0,0
Eye disorders	Cystoid macular oedema	CRVO	574	81,9	26	4,5
Eye disorders	Cystoid macular oedema	HRVO	121	17,3	2	1,7
Eye disorders	Cystoid macular oedema	Missing	6	0,9	0	0,0
Eye disorders	Detachment of retinal pigment epithelium	CRVO	574	81,9	2	0,3
Eye disorders	Detachment of retinal pigment epithelium	HRVO	121	17,3	0	0,0
Eye disorders	Detachment of retinal pigment epithelium	Missing	6	0,9	0	0,0
Eye disorders	Diabetic retinal oedema	CRVO	574	81,9	1	0,2
Eye disorders	Diabetic retinal oedema	HRVO	121	17,3	0	0,0
Eye disorders	Diabetic retinal oedema	Missing	6	0,9	0	0,0
Eye disorders	Diabetic retinopathy	CRVO	574	81,9	2	0,3
Eye disorders	Diabetic retinopathy	HRVO	121	17,3	0	0,0
Eye disorders	Diabetic retinopathy	Missing	6	0,9	0	0,0
Eye disorders	Diplopia	CRVO	574	81,9	1	0,2
Eye disorders	Diplopia	HRVO	121	17,3	0	0,0
Eye disorders	Diplopia	Missing	6	0,9	0	0,0
Eye disorders	Dry age-related macular degeneration	CRVO	574	81,9	1	0,2
Eye disorders	Dry age-related macular degeneration	HRVO	121	17,3	0	0,0
Eye disorders	Dry age-related macular degeneration	Missing	6	0,9	0	0,0
Eye disorders	Dry eye	CRVO	574	81,9	11	1,9
Eye disorders	Dry eye	HRVO	121	17,3	3	2,5
Eye disorders	Dry eye	Missing	6	0,9	1	16,7
Eye disorders	Eczema eyelids	CRVO	574	81,9	0	0,0
Eye disorders	Eczema eyelids	HRVO	121	17,3	1	0,8
Eye disorders	Eczema eyelids	Missing	6	0,9	0	0,0
Eye disorders	Epi-retinal membrane	CRVO	574	81,9	16	2,8
Eye disorders	Epi-retinal membrane	HRVO	121	17,3	1	0,8
Eye disorders	Epi-retinal membrane	Missing	6	0,9	0	0,0
Eye disorders	Episcleritis	CRVO	574	81,9	1	0,2
Eye disorders	Episcleritis	HRVO	121	17,3	0	0,0
Eye disorders	Episcleritis	Missing	6	0,9	0	0,0
Eye disorders	Eye irritation	CRVO	574	81,9	1	0,2
Eye disorders	Eye irritation	HRVO	121	17,3	0	0,0
Eye disorders	Eye irritation	Missing	6	0,9	0	0,0
Eye disorders	Eye pain	CRVO	574	81,9	5	0,9
Eye disorders	Eye pain	HRVO	121	17,3	5	4,1
Eye disorders	Eye pain	Missing	6	0,9	0	0,0
Eye disorders	Eye pruritus	CRVO	574	81,9	2	0,3
Eye disorders	Eye pruritus	HRVO	121	17,3	2	1,7
Eye disorders	Eye pruritus	Missing	6	0,9	0	0,0
Eye disorders	Eyelid cyst	CRVO	574	81,9	1	0,2
Eye disorders	Eyelid cyst	HRVO	121	17,3	0	0,0
Eye disorders	Eyelid cyst	Missing	6	0,9	0	0,0
Eye disorders	Eyelid oedema	CRVO	574	81,9	1	0,2
Eye disorders	Eyelid oedema	HRVO	121	17,3	0	0,0
Eye disorders	Eyelid oedema	Missing	6	0,9	0	0,0
Eye disorders	Foreign body sensation in eyes	CRVO	574	81,9	3	0,5
Eye disorders	Foreign body sensation in eyes	HRVO	121	17,3	0	0,0
Eye disorders	Foreign body sensation in eyes	Missing	6	0,9	0	0,0
Eye disorders	Glaucoma	CRVO	574	81,9	11	1,9
Eye disorders	Glaucoma	HRVO	121	17,3	4	3,3
Eye disorders	Glaucoma	Missing	6	0,9	0	0,0

Eye disorders	Hypotony of eye	CRVO	574	81,9	1	0,2
Eye disorders	Hypotony of eye	HRVO	121	17,3	0	0,0
Eye disorders	Hypotony of eye	Missing	6	0,9	0	0,0
Eye disorders	Iridocyclitis	CRVO	574	81,9	5	0,9
Eye disorders	Iridocyclitis	HRVO	121	17,3	2	1,7
Eye disorders	Iridocyclitis	Missing	6	0,9	0	0,0
Eye disorders	Iris neovascularisation	CRVO	574	81,9	2	0,3
Eye disorders	Iris neovascularisation	HRVO	121	17,3	0	0,0
Eye disorders	Iris neovascularisation	Missing	6	0,9	0	0,0
Eye disorders	Iritis	CRVO	574	81,9	2	0,3
Eye disorders	Iritis	HRVO	121	17,3	2	1,7
Eye disorders	Iritis	Missing	6	0,9	0	0,0
Eye disorders	Keratic precipitates	CRVO	574	81,9	1	0,2
Eye disorders	Keratic precipitates	HRVO	121	17,3	0	0,0
Eye disorders	Keratic precipitates	Missing	6	0,9	0	0,0
Eye disorders	Keratitis	CRVO	574	81,9	1	0,2
Eye disorders	Keratitis	HRVO	121	17,3	1	0,8
Eye disorders	Keratitis	Missing	6	0,9	0	0,0
Eye disorders	Keratopathy	CRVO	574	81,9	1	0,2
Eye disorders	Keratopathy	HRVO	121	17,3	0	0,0
Eye disorders	Keratopathy	Missing	6	0,9	0	0,0
Eye disorders	Lacrimal disorder	CRVO	574	81,9	1	0,2
Eye disorders	Lacrimal disorder	HRVO	121	17,3	0	0,0
Eye disorders	Lacrimal disorder	Missing	6	0,9	0	0,0
Eye disorders	Lacrimation increased	CRVO	574	81,9	3	0,5
Eye disorders	Lacrimation increased	HRVO	121	17,3	2	1,7
Eye disorders	Lacrimation increased	Missing	6	0,9	0	0,0
Eye disorders	Lenticular opacities	CRVO	574	81,9	1	0,2
Eye disorders	Lenticular opacities	HRVO	121	17,3	0	0,0
Eye disorders	Lenticular opacities	Missing	6	0,9	0	0,0
Eye disorders	Macular degeneration	CRVO	574	81,9	0	0,0
Eye disorders	Macular degeneration	HRVO	121	17,3	2	1,7
Eye disorders	Macular degeneration	Missing	6	0,9	0	0,0
Eye disorders	Macular detachment	CRVO	574	81,9	1	0,2
Eye disorders	Macular detachment	HRVO	121	17,3	1	0,8
Eye disorders	Macular detachment	Missing	6	0,9	0	0,0
Eye disorders	Macular hole	CRVO	574	81,9	2	0,3
Eye disorders	Macular hole	HRVO	121	17,3	0	0,0
Eye disorders	Macular hole	Missing	6	0,9	0	0,0
Eye disorders	Macular ischaemia	CRVO	574	81,9	2	0,3
Eye disorders	Macular ischaemia	HRVO	121	17,3	0	0,0
Eye disorders	Macular ischaemia	Missing	6	0,9	0	0,0
Eye disorders	Macular oedema	CRVO	574	81,9	20	3,5
Eye disorders	Macular oedema	HRVO	121	17,3	6	5,0
Eye disorders	Macular oedema	Missing	6	0,9	0	0,0
Eye disorders	Macular scar	CRVO	574	81,9	1	0,2
Eye disorders	Macular scar	HRVO	121	17,3	0	0,0
Eye disorders	Macular scar	Missing	6	0,9	0	0,0
Eye disorders	Meibomianitis	CRVO	574	81,9	1	0,2
Eye disorders	Meibomianitis	HRVO	121	17,3	0	0,0
Eye disorders	Meibomianitis	Missing	6	0,9	0	0,0
Eye disorders	Neovascular age-related macular degeneration	CRVO	574	81,9	1	0,2
Eye disorders	Neovascular age-related macular degeneration	HRVO	121	17,3	0	0,0
Eye disorders	Neovascular age-related macular degeneration	Missing	6	0,9	0	0,0
Eye disorders	Non-infectious endophthalmitis	CRVO	574	81,9	1	0,2
Eye disorders	Non-infectious endophthalmitis	HRVO	121	17,3	0	0,0
Eye disorders	Non-infectious endophthalmitis	Missing	6	0,9	0	0,0
Eye disorders	Noninfective conjunctivitis	CRVO	574	81,9	1	0,2
Eye disorders	Noninfective conjunctivitis	HRVO	121	17,3	0	0,0
Eye disorders	Noninfective conjunctivitis	Missing	6	0,9	0	0,0
Eye disorders	Normal tension glaucoma	CRVO	574	81,9	1	0,2
Eye disorders	Normal tension glaucoma	HRVO	121	17,3	0	0,0
Eye disorders	Normal tension glaucoma	Missing	6	0,9	0	0,0
Eye disorders	Ocular hyperaemia	CRVO	574	81,9	2	0,3
Eye disorders	Ocular hyperaemia	HRVO	121	17,3	0	0,0
Eye disorders	Ocular hyperaemia	Missing	6	0,9	0	0,0
Eye disorders	Ocular hypertension	CRVO	574	81,9	10	1,7
Eye disorders	Ocular hypertension	HRVO	121	17,3	2	1,7
Eye disorders	Ocular hypertension	Missing	6	0,9	0	0,0
Eye disorders	Open angle glaucoma	CRVO	574	81,9	2	0,3
Eye disorders	Open angle glaucoma	HRVO	121	17,3	0	0,0
Eye disorders	Open angle glaucoma	Missing	6	0,9	0	0,0
Eye disorders	Optic atrophy	CRVO	574	81,9	1	0,2
Eye disorders	Optic atrophy	HRVO	121	17,3	0	0,0
Eye disorders	Optic atrophy	Missing	6	0,9	0	0,0
Eye disorders	Optic disc disorder	CRVO	574	81,9	1	0,2
Eye disorders	Optic disc disorder	HRVO	121	17,3	0	0,0
Eye disorders	Optic disc disorder	Missing	6	0,9	0	0,0
Eye disorders	Optic disc haemorrhage	CRVO	574	81,9	2	0,3
Eye disorders	Optic disc haemorrhage	HRVO	121	17,3	1	0,8
Eye disorders	Optic disc haemorrhage	Missing	6	0,9	0	0,0
Eye disorders	Optic disc vascular disorder	CRVO	574	81,9	0	0,0
Eye disorders	Optic disc vascular disorder	HRVO	121	17,3	1	0,8

Eye disorders	Optic disc vascular disorder	Missing	6	0,9	0	0,0
Eye disorders	Papilloedema	CRVO	574	81,9	2	0,3
Eye disorders	Papilloedema	HRVO	121	17,3	0	0,0
Eye disorders	Papilloedema	Missing	6	0,9	0	0,0
Eye disorders	Periorbital pain	CRVO	574	81,9	1	0,2
Eye disorders	Periorbital pain	HRVO	121	17,3	0	0,0
Eye disorders	Periorbital pain	Missing	6	0,9	0	0,0
Eye disorders	Photopsia	CRVO	574	81,9	1	0,2
Eye disorders	Photopsia	HRVO	121	17,3	1	0,8
Eye disorders	Photopsia	Missing	6	0,9	0	0,0
Eye disorders	Pinguecula	CRVO	574	81,9	1	0,2
Eye disorders	Pinguecula	HRVO	121	17,3	0	0,0
Eye disorders	Pinguecula	Missing	6	0,9	0	0,0
Eye disorders	Posterior capsule opacification	CRVO	574	81,9	5	0,9
Eye disorders	Posterior capsule opacification	HRVO	121	17,3	2	1,7
Eye disorders	Posterior capsule opacification	Missing	6	0,9	0	0,0
Eye disorders	Punctate keratitis	CRVO	574	81,9	4	0,7
Eye disorders	Punctate keratitis	HRVO	121	17,3	1	0,8
Eye disorders	Punctate keratitis	Missing	6	0,9	1	16,7
Eye disorders	Retinal aneurysm	CRVO	574	81,9	1	0,2
Eye disorders	Retinal aneurysm	HRVO	121	17,3	1	0,8
Eye disorders	Retinal aneurysm	Missing	6	0,9	0	0,0
Eye disorders	Retinal artery embolism	CRVO	574	81,9	1	0,2
Eye disorders	Retinal artery embolism	HRVO	121	17,3	0	0,0
Eye disorders	Retinal artery embolism	Missing	6	0,9	0	0,0
Eye disorders	Retinal artery occlusion	CRVO	574	81,9	4	0,7
Eye disorders	Retinal artery occlusion	HRVO	121	17,3	0	0,0
Eye disorders	Retinal artery occlusion	Missing	6	0,9	0	0,0
Eye disorders	Retinal collateral vessels	CRVO	574	81,9	3	0,5
Eye disorders	Retinal collateral vessels	HRVO	121	17,3	0	0,0
Eye disorders	Retinal collateral vessels	Missing	6	0,9	0	0,0
Eye disorders	Retinal depigmentation	CRVO	574	81,9	1	0,2
Eye disorders	Retinal depigmentation	HRVO	121	17,3	0	0,0
Eye disorders	Retinal depigmentation	Missing	6	0,9	0	0,0
Eye disorders	Retinal detachment	CRVO	574	81,9	2	0,3
Eye disorders	Retinal detachment	HRVO	121	17,3	0	0,0
Eye disorders	Retinal detachment	Missing	6	0,9	0	0,0
Eye disorders	Retinal disorder	CRVO	574	81,9	0	0,0
Eye disorders	Retinal disorder	HRVO	121	17,3	1	0,8
Eye disorders	Retinal disorder	Missing	6	0,9	0	0,0
Eye disorders	Retinal drusen	CRVO	574	81,9	1	0,2
Eye disorders	Retinal drusen	HRVO	121	17,3	0	0,0
Eye disorders	Retinal drusen	Missing	6	0,9	0	0,0
Eye disorders	Retinal exudates	CRVO	574	81,9	1	0,2
Eye disorders	Retinal exudates	HRVO	121	17,3	1	0,8
Eye disorders	Retinal exudates	Missing	6	0,9	0	0,0
Eye disorders	Retinal haemorrhage	CRVO	574	81,9	5	0,9
Eye disorders	Retinal haemorrhage	HRVO	121	17,3	2	1,7
Eye disorders	Retinal haemorrhage	Missing	6	0,9	0	0,0
Eye disorders	Retinal ischaemia	CRVO	574	81,9	2	0,3
Eye disorders	Retinal ischaemia	HRVO	121	17,3	0	0,0
Eye disorders	Retinal ischaemia	Missing	6	0,9	0	0,0
Eye disorders	Retinal neovascularisation	CRVO	574	81,9	3	0,5
Eye disorders	Retinal neovascularisation	HRVO	121	17,3	0	0,0
Eye disorders	Retinal neovascularisation	Missing	6	0,9	0	0,0
Eye disorders	Retinal tear	CRVO	574	81,9	2	0,3
Eye disorders	Retinal tear	HRVO	121	17,3	1	0,8
Eye disorders	Retinal tear	Missing	6	0,9	0	0,0
Eye disorders	Retinal vein occlusion	CRVO	574	81,9	20	3,5
Eye disorders	Retinal vein occlusion	HRVO	121	17,3	3	2,5
Eye disorders	Retinal vein occlusion	Missing	6	0,9	0	0,0
Eye disorders	Retinopathy hypertensive	CRVO	574	81,9	1	0,2
Eye disorders	Retinopathy hypertensive	HRVO	121	17,3	0	0,0
Eye disorders	Retinopathy hypertensive	Missing	6	0,9	0	0,0
Eye disorders	Subretinal fluid	CRVO	574	81,9	0	0,0
Eye disorders	Subretinal fluid	HRVO	121	17,3	1	0,8
Eye disorders	Subretinal fluid	Missing	6	0,9	0	0,0
Eye disorders	Uveitis	CRVO	574	81,9	1	0,2
Eye disorders	Uveitis	HRVO	121	17,3	0	0,0
Eye disorders	Uveitis	Missing	6	0,9	0	0,0
Eye disorders	Vision blurred	CRVO	574	81,9	3	0,5
Eye disorders	Vision blurred	HRVO	121	17,3	0	0,0
Eye disorders	Vision blurred	Missing	6	0,9	0	0,0
Eye disorders	Visual acuity reduced	CRVO	574	81,9	7	1,2
Eye disorders	Visual acuity reduced	HRVO	121	17,3	1	0,8
Eye disorders	Visual acuity reduced	Missing	6	0,9	0	0,0
Eye disorders	Visual acuity reduced transiently	CRVO	574	81,9	0	0,0
Eye disorders	Visual acuity reduced transiently	HRVO	121	17,3	1	0,8
Eye disorders	Visual acuity reduced transiently	Missing	6	0,9	0	0,0
Eye disorders	Visual field defect	CRVO	574	81,9	1	0,2
Eye disorders	Visual field defect	HRVO	121	17,3	0	0,0
Eye disorders	Visual field defect	Missing	6	0,9	0	0,0
Eye disorders	Visual impairment	CRVO	574	81,9	4	0,7

Eye disorders	Visual impairment	HRVO	121	17,3	0	0,0
Eye disorders	Visual impairment	Missing	6	0,9	0	0,0
Eye disorders	Vitreoretinal traction syndrome	CRVO	574	81,9	3	0,5
Eye disorders	Vitreoretinal traction syndrome	HRVO	121	17,3	0	0,0
Eye disorders	Vitreoretinal traction syndrome	Missing	6	0,9	0	0,0
Eye disorders	Vitreous detachment	CRVO	574	81,9	22	3,8
Eye disorders	Vitreous detachment	HRVO	121	17,3	6	5,0
Eye disorders	Vitreous detachment	Missing	6	0,9	1	16,7
Eye disorders	Vitreous floaters	CRVO	574	81,9	6	1,0
Eye disorders	Vitreous floaters	HRVO	121	17,3	4	3,3
Eye disorders	Vitreous floaters	Missing	6	0,9	0	0,0
Eye disorders	Vitreous haemorrhage	CRVO	574	81,9	4	0,7
Eye disorders	Vitreous haemorrhage	HRVO	121	17,3	0	0,0
Eye disorders	Vitreous haemorrhage	Missing	6	0,9	0	0,0
Eye disorders	Vitreous opacities	CRVO	574	81,9	1	0,2
Eye disorders	Vitreous opacities	HRVO	121	17,3	0	0,0
Eye disorders	Vitreous opacities	Missing	6	0,9	0	0,0
Eye disorders	Vitritis	CRVO	574	81,9	4	0,7
Eye disorders	Vitritis	HRVO	121	17,3	0	0,0
Eye disorders	Vitritis	Missing	6	0,9	0	0,0
Gastrointestinal disorders		CRVO	574	81,9	37	6,4
Gastrointestinal disorders		HRVO	121	17,3	5	4,1
Gastrointestinal disorders		Missing	6	0,9	0	0,0
Gastrointestinal disorders	Abdominal discomfort	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Abdominal discomfort	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Abdominal discomfort	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Abdominal pain	CRVO	574	81,9	0	0,0
Gastrointestinal disorders	Abdominal pain	HRVO	121	17,3	1	0,8
Gastrointestinal disorders	Abdominal pain	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Abdominal pain upper	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Abdominal pain upper	HRVO	121	17,3	1	0,8
Gastrointestinal disorders	Abdominal pain upper	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Barrett's oesophagus	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Chronic gastritis	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Chronic gastritis	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Chronic gastritis	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Coeliac disease	CRVO	574	81,9	0	0,0
Gastrointestinal disorders	Coeliac disease	HRVO	121	17,3	1	0,8
Gastrointestinal disorders	Coeliac disease	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Colitis	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Colitis	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Colitis	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Constipation	CRVO	574	81,9	5	0,9
Gastrointestinal disorders	Constipation	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Constipation	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Dental discomfort	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Dental discomfort	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Dental discomfort	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Diarrhoea	CRVO	574	81,9	9	1,6
Gastrointestinal disorders	Diarrhoea	HRVO	121	17,3	2	1,7
Gastrointestinal disorders	Diarrhoea	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Diverticulum intestinal	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Diverticulum intestinal	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Diverticulum intestinal	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Duodenal ulcer haemorrhage	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Duodenitis	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Duodenitis	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Duodenitis	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Dyspepsia	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Dyspepsia	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Dyspepsia	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastric ulcer	CRVO	574	81,9	0	0,0
Gastrointestinal disorders	Gastric ulcer	HRVO	121	17,3	1	0,8
Gastrointestinal disorders	Gastric ulcer	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastritis	CRVO	574	81,9	3	0,5
Gastrointestinal disorders	Gastritis	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Gastritis	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Gastrointestinal inflammation	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	CRVO	574	81,9	2	0,3
Gastrointestinal disorders	Gastrooesophageal reflux disease	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Haemorrhagic erosive gastritis	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Haemorrhagic erosive gastritis	HRVO	121	17,3	0	0,0

Gastrointestinal disorders	Haemorrhagic erosive gastritis	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Haemorrhoids	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Haemorrhoids	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Haemorrhoids	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Hiatus hernia	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Hiatus hernia	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Hiatus hernia	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Ileus	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Ileus	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Ileus	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Inguinal hernia	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Inguinal hernia	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Inguinal hernia	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Large intestine polyp	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Large intestine polyp	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Large intestine polyp	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Nausea	CRVO	574	81,9	3	0,5
Gastrointestinal disorders	Nausea	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Nausea	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Pancreatitis	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Pancreatitis	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Pancreatitis	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Pancreatitis acute	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Pancreatitis acute	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Pulpless tooth	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Pulpless tooth	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Pulpless tooth	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Salivary gland disorder	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Salivary gland disorder	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Salivary gland disorder	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Toothache	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Toothache	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Toothache	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Umbilical hernia	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Umbilical hernia	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Umbilical hernia	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Vomiting	CRVO	574	81,9	2	0,3
Gastrointestinal disorders	Vomiting	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Vomiting	Missing	6	0,9	0	0,0
General disorders and administration site conditions		CRVO	574	81,9	26	4,5
General disorders and administration site conditions		HRVO	121	17,3	6	5,0
General disorders and administration site conditions		Missing	6	0,9	0	0,0
General disorders and administration site conditions	Asthenia	CRVO	574	81,9	6	1,0
General disorders and administration site conditions	Asthenia	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Asthenia	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Chest pain	CRVO	574	81,9	3	0,5
General disorders and administration site conditions	Chest pain	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Chest pain	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Chills	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Chills	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Chills	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Death	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Death	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Death	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Drug intolerance	CRVO	574	81,9	0	0,0
General disorders and administration site conditions	Drug intolerance	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Drug intolerance	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Drug withdrawal syndrome	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Drug withdrawal syndrome	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Drug withdrawal syndrome	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Fatigue	CRVO	574	81,9	2	0,3
General disorders and administration site conditions	Fatigue	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Fatigue	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Injection site pain	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Injection site pain	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Injection site pain	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Injection site reaction	CRVO	574	81,9	0	0,0
General disorders and administration site conditions	Injection site reaction	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Injection site reaction	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Oedema peripheral	CRVO	574	81,9	4	0,7
General disorders and administration site conditions	Oedema peripheral	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Oedema peripheral	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Pain	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Pain	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Pain	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Peripheral swelling	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Peripheral swelling	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Peripheral swelling	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Polyp	CRVO	574	81,9	0	0,0
General disorders and administration site conditions	Polyp	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Polyp	Missing	6	0,9	0	0,0

General disorders and administration site conditions	Pyrexia	CRVO	574	81,9	3	0,5
General disorders and administration site conditions	Pyrexia	HRVO	121	17,3	2	1,7
General disorders and administration site conditions	Pyrexia	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Stent-graft endoleak	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Systemic inflammatory response syndrome	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	Missing	6	0,9	0	0,0
Hepatobiliary disorders		CRVO	574	81,9	8	1,4
Hepatobiliary disorders		HRVO	121	17,3	0	0,0
Hepatobiliary disorders		Missing	6	0,9	0	0,0
Hepatobiliary disorders	Cholecystitis	CRVO	574	81,9	1	0,2
Hepatobiliary disorders	Cholecystitis	HRVO	121	17,3	0	0,0
Hepatobiliary disorders	Cholecystitis	Missing	6	0,9	0	0,0
Hepatobiliary disorders	Cholelithiasis	CRVO	574	81,9	4	0,7
Hepatobiliary disorders	Cholelithiasis	HRVO	121	17,3	0	0,0
Hepatobiliary disorders	Cholelithiasis	Missing	6	0,9	0	0,0
Hepatobiliary disorders	Hepatic cyst	CRVO	574	81,9	1	0,2
Hepatobiliary disorders	Hepatic cyst	HRVO	121	17,3	0	0,0
Hepatobiliary disorders	Hepatic cyst	Missing	6	0,9	0	0,0
Hepatobiliary disorders	Hepatic steatosis	CRVO	574	81,9	3	0,5
Hepatobiliary disorders	Hepatic steatosis	HRVO	121	17,3	0	0,0
Hepatobiliary disorders	Hepatic steatosis	Missing	6	0,9	0	0,0
Hepatobiliary disorders	Portal hypertension	CRVO	574	81,9	1	0,2
Hepatobiliary disorders	Portal hypertension	HRVO	121	17,3	0	0,0
Hepatobiliary disorders	Portal hypertension	Missing	6	0,9	0	0,0
Immune system disorders		CRVO	574	81,9	10	1,7
Immune system disorders		HRVO	121	17,3	1	0,8
Immune system disorders		Missing	6	0,9	0	0,0
Immune system disorders	Contrast media allergy	CRVO	574	81,9	3	0,5
Immune system disorders	Contrast media allergy	HRVO	121	17,3	0	0,0
Immune system disorders	Contrast media allergy	Missing	6	0,9	0	0,0
Immune system disorders	Contrast media reaction	CRVO	574	81,9	0	0,0
Immune system disorders	Contrast media reaction	HRVO	121	17,3	1	0,8
Immune system disorders	Contrast media reaction	Missing	6	0,9	0	0,0
Immune system disorders	Drug hypersensitivity	CRVO	574	81,9	1	0,2
Immune system disorders	Drug hypersensitivity	HRVO	121	17,3	0	0,0
Immune system disorders	Drug hypersensitivity	Missing	6	0,9	0	0,0
Immune system disorders	Food allergy	CRVO	574	81,9	1	0,2
Immune system disorders	Food allergy	HRVO	121	17,3	0	0,0
Immune system disorders	Food allergy	Missing	6	0,9	0	0,0
Immune system disorders	Iodine allergy	CRVO	574	81,9	1	0,2
Immune system disorders	Iodine allergy	HRVO	121	17,3	0	0,0
Immune system disorders	Iodine allergy	Missing	6	0,9	0	0,0
Immune system disorders	Seasonal allergy	CRVO	574	81,9	4	0,7
Immune system disorders	Seasonal allergy	HRVO	121	17,3	0	0,0
Immune system disorders	Seasonal allergy	Missing	6	0,9	0	0,0
Infections and infestations		CRVO	574	81,9	186	32,4
Infections and infestations		HRVO	121	17,3	36	29,8
Infections and infestations		Missing	6	0,9	3	50,0
Infections and infestations	Adenoviral conjunctivitis	CRVO	574	81,9	1	0,2
Infections and infestations	Adenoviral conjunctivitis	HRVO	121	17,3	0	0,0
Infections and infestations	Adenoviral conjunctivitis	Missing	6	0,9	0	0,0
Infections and infestations	Arthritis infective	CRVO	574	81,9	1	0,2
Infections and infestations	Arthritis infective	HRVO	121	17,3	0	0,0
Infections and infestations	Arthritis infective	Missing	6	0,9	0	0,0
Infections and infestations	Bronchitis	CRVO	574	81,9	7	1,2
Infections and infestations	Bronchitis	HRVO	121	17,3	2	1,7
Infections and infestations	Bronchitis	Missing	6	0,9	0	0,0
Infections and infestations	COVID-19	CRVO	574	81,9	74	12,9
Infections and infestations	COVID-19	HRVO	121	17,3	16	13,2
Infections and infestations	COVID-19	Missing	6	0,9	1	16,7
Infections and infestations	COVID-19 pneumonia	CRVO	574	81,9	0	0,0
Infections and infestations	COVID-19 pneumonia	HRVO	121	17,3	1	0,8
Infections and infestations	COVID-19 pneumonia	Missing	6	0,9	0	0,0
Infections and infestations	Cellulitis	CRVO	574	81,9	6	1,0
Infections and infestations	Cellulitis	HRVO	121	17,3	1	0,8
Infections and infestations	Cellulitis	Missing	6	0,9	0	0,0
Infections and infestations	Chronic sinusitis	CRVO	574	81,9	1	0,2
Infections and infestations	Chronic sinusitis	HRVO	121	17,3	1	0,8
Infections and infestations	Chronic sinusitis	Missing	6	0,9	0	0,0
Infections and infestations	Clostridium difficile infection	CRVO	574	81,9	1	0,2
Infections and infestations	Clostridium difficile infection	HRVO	121	17,3	0	0,0
Infections and infestations	Clostridium difficile infection	Missing	6	0,9	0	0,0
Infections and infestations	Conjunctivitis	CRVO	574	81,9	14	2,4
Infections and infestations	Conjunctivitis	HRVO	121	17,3	0	0,0
Infections and infestations	Conjunctivitis	Missing	6	0,9	0	0,0
Infections and infestations	Conjunctivitis bacterial	CRVO	574	81,9	1	0,2
Infections and infestations	Conjunctivitis bacterial	HRVO	121	17,3	0	0,0

Infections and infestations	Conjunctivitis bacterial	Missing	6	0,9	0	0,0
Infections and infestations	Conjunctivitis viral	CRVO	574	81,9	1	0,2
Infections and infestations	Conjunctivitis viral	HRVO	121	17,3	0	0,0
Infections and infestations	Conjunctivitis viral	Missing	6	0,9	0	0,0
Infections and infestations	Cystitis	CRVO	574	81,9	3	0,5
Infections and infestations	Cystitis	HRVO	121	17,3	0	0,0
Infections and infestations	Cystitis	Missing	6	0,9	0	0,0
Infections and infestations	Device related infection	CRVO	574	81,9	1	0,2
Infections and infestations	Device related infection	HRVO	121	17,3	0	0,0
Infections and infestations	Device related infection	Missing	6	0,9	0	0,0
Infections and infestations	Diabetic foot infection	CRVO	574	81,9	1	0,2
Infections and infestations	Diabetic foot infection	HRVO	121	17,3	0	0,0
Infections and infestations	Diabetic foot infection	Missing	6	0,9	0	0,0
Infections and infestations	Ear infection	CRVO	574	81,9	3	0,5
Infections and infestations	Ear infection	HRVO	121	17,3	0	0,0
Infections and infestations	Ear infection	Missing	6	0,9	0	0,0
Infections and infestations	Endophthalmitis	CRVO	574	81,9	0	0,0
Infections and infestations	Endophthalmitis	HRVO	121	17,3	1	0,8
Infections and infestations	Endophthalmitis	Missing	6	0,9	0	0,0
Infections and infestations	Enteritis infectious	CRVO	574	81,9	1	0,2
Infections and infestations	Enteritis infectious	HRVO	121	17,3	0	0,0
Infections and infestations	Enteritis infectious	Missing	6	0,9	0	0,0
Infections and infestations	Escherichia urinary tract infection	CRVO	574	81,9	1	0,2
Infections and infestations	Escherichia urinary tract infection	HRVO	121	17,3	0	0,0
Infections and infestations	Escherichia urinary tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Eye infection	CRVO	574	81,9	0	0,0
Infections and infestations	Eye infection	HRVO	121	17,3	1	0,8
Infections and infestations	Eye infection	Missing	6	0,9	0	0,0
Infections and infestations	Eye infection bacterial	CRVO	574	81,9	0	0,0
Infections and infestations	Eye infection bacterial	HRVO	121	17,3	1	0,8
Infections and infestations	Eye infection bacterial	Missing	6	0,9	0	0,0
Infections and infestations	Folliculitis	CRVO	574	81,9	1	0,2
Infections and infestations	Folliculitis	HRVO	121	17,3	0	0,0
Infections and infestations	Folliculitis	Missing	6	0,9	0	0,0
Infections and infestations	Fungal skin infection	CRVO	574	81,9	1	0,2
Infections and infestations	Fungal skin infection	HRVO	121	17,3	0	0,0
Infections and infestations	Fungal skin infection	Missing	6	0,9	0	0,0
Infections and infestations	Gastroenteritis	CRVO	574	81,9	1	0,2
Infections and infestations	Gastroenteritis	HRVO	121	17,3	0	0,0
Infections and infestations	Gastroenteritis	Missing	6	0,9	0	0,0
Infections and infestations	Gastroenteritis viral	CRVO	574	81,9	3	0,5
Infections and infestations	Gastroenteritis viral	HRVO	121	17,3	0	0,0
Infections and infestations	Gastroenteritis viral	Missing	6	0,9	1	16,7
Infections and infestations	Gastrointestinal infection	CRVO	574	81,9	1	0,2
Infections and infestations	Gastrointestinal infection	HRVO	121	17,3	0	0,0
Infections and infestations	Gastrointestinal infection	Missing	6	0,9	0	0,0
Infections and infestations	Helicobacter infection	CRVO	574	81,9	1	0,2
Infections and infestations	Helicobacter infection	HRVO	121	17,3	0	0,0
Infections and infestations	Helicobacter infection	Missing	6	0,9	0	0,0
Infections and infestations	Herpes virus infection	CRVO	574	81,9	1	0,2
Infections and infestations	Herpes virus infection	HRVO	121	17,3	0	0,0
Infections and infestations	Herpes virus infection	Missing	6	0,9	0	0,0
Infections and infestations	Herpes zoster	CRVO	574	81,9	5	0,9
Infections and infestations	Herpes zoster	HRVO	121	17,3	1	0,8
Infections and infestations	Herpes zoster	Missing	6	0,9	0	0,0
Infections and infestations	Hordeolum	CRVO	574	81,9	3	0,5
Infections and infestations	Hordeolum	HRVO	121	17,3	1	0,8
Infections and infestations	Hordeolum	Missing	6	0,9	1	16,7
Infections and infestations	Infected bite	CRVO	574	81,9	0	0,0
Infections and infestations	Infected bite	HRVO	121	17,3	1	0,8
Infections and infestations	Infected bite	Missing	6	0,9	0	0,0
Infections and infestations	Influenza	CRVO	574	81,9	14	2,4
Infections and infestations	Influenza	HRVO	121	17,3	5	4,1
Infections and infestations	Influenza	Missing	6	0,9	0	0,0
Infections and infestations	Kidney infection	CRVO	574	81,9	1	0,2
Infections and infestations	Kidney infection	HRVO	121	17,3	0	0,0
Infections and infestations	Kidney infection	Missing	6	0,9	0	0,0
Infections and infestations	Laryngitis	CRVO	574	81,9	1	0,2
Infections and infestations	Laryngitis	HRVO	121	17,3	0	0,0
Infections and infestations	Laryngitis	Missing	6	0,9	0	0,0
Infections and infestations	Localised infection	CRVO	574	81,9	1	0,2
Infections and infestations	Localised infection	HRVO	121	17,3	0	0,0
Infections and infestations	Localised infection	Missing	6	0,9	0	0,0
Infections and infestations	Lower respiratory tract infection	CRVO	574	81,9	0	0,0
Infections and infestations	Lower respiratory tract infection	HRVO	121	17,3	1	0,8
Infections and infestations	Lower respiratory tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Nasopharyngitis	CRVO	574	81,9	25	4,4
Infections and infestations	Nasopharyngitis	HRVO	121	17,3	2	1,7
Infections and infestations	Nasopharyngitis	Missing	6	0,9	0	0,0
Infections and infestations	Necrotising fasciitis	CRVO	574	81,9	0	0,0
Infections and infestations	Necrotising fasciitis	HRVO	121	17,3	1	0,8
Infections and infestations	Necrotising fasciitis	Missing	6	0,9	0	0,0
Infections and infestations	Oral herpes	CRVO	574	81,9	1	0,2

Infections and infestations	Oral herpes	HRVO	121	17,3	1	0,8
Infections and infestations	Oral herpes	Missing	6	0,9	0	0,0
Infections and infestations	Otitis externa	CRVO	574	81,9	1	0,2
Infections and infestations	Otitis externa	HRVO	121	17,3	0	0,0
Infections and infestations	Otitis externa	Missing	6	0,9	0	0,0
Infections and infestations	Otosalpingitis	CRVO	574	81,9	1	0,2
Infections and infestations	Otosalpingitis	HRVO	121	17,3	0	0,0
Infections and infestations	Otosalpingitis	Missing	6	0,9	0	0,0
Infections and infestations	Perichondritis	CRVO	574	81,9	1	0,2
Infections and infestations	Perichondritis	HRVO	121	17,3	0	0,0
Infections and infestations	Perichondritis	Missing	6	0,9	0	0,0
Infections and infestations	Periodontitis	CRVO	574	81,9	2	0,3
Infections and infestations	Periodontitis	HRVO	121	17,3	0	0,0
Infections and infestations	Periodontitis	Missing	6	0,9	0	0,0
Infections and infestations	Pharyngitis	CRVO	574	81,9	2	0,3
Infections and infestations	Pharyngitis	HRVO	121	17,3	0	0,0
Infections and infestations	Pharyngitis	Missing	6	0,9	0	0,0
Infections and infestations	Pneumonia	CRVO	574	81,9	8	1,4
Infections and infestations	Pneumonia	HRVO	121	17,3	2	1,7
Infections and infestations	Pneumonia	Missing	6	0,9	0	0,0
Infections and infestations	Pneumonia viral	CRVO	574	81,9	3	0,5
Infections and infestations	Pneumonia viral	HRVO	121	17,3	0	0,0
Infections and infestations	Pneumonia viral	Missing	6	0,9	0	0,0
Infections and infestations	Pulpitis dental	CRVO	574	81,9	3	0,5
Infections and infestations	Pulpitis dental	HRVO	121	17,3	0	0,0
Infections and infestations	Pulpitis dental	Missing	6	0,9	0	0,0
Infections and infestations	Respiratory syncytial virus infection	CRVO	574	81,9	1	0,2
Infections and infestations	Respiratory syncytial virus infection	HRVO	121	17,3	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Missing	6	0,9	0	0,0
Infections and infestations	Respiratory tract infection	CRVO	574	81,9	2	0,3
Infections and infestations	Respiratory tract infection	HRVO	121	17,3	0	0,0
Infections and infestations	Respiratory tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Respiratory tract infection viral	CRVO	574	81,9	1	0,2
Infections and infestations	Respiratory tract infection viral	HRVO	121	17,3	0	0,0
Infections and infestations	Respiratory tract infection viral	Missing	6	0,9	0	0,0
Infections and infestations	Rhinitis	CRVO	574	81,9	1	0,2
Infections and infestations	Rhinitis	HRVO	121	17,3	0	0,0
Infections and infestations	Rhinitis	Missing	6	0,9	0	0,0
Infections and infestations	Sepsis	CRVO	574	81,9	2	0,3
Infections and infestations	Sepsis	HRVO	121	17,3	0	0,0
Infections and infestations	Sepsis	Missing	6	0,9	0	0,0
Infections and infestations	Septic arthritis staphylococcal	CRVO	574	81,9	0	0,0
Infections and infestations	Septic arthritis staphylococcal	HRVO	121	17,3	1	0,8
Infections and infestations	Septic arthritis staphylococcal	Missing	6	0,9	0	0,0
Infections and infestations	Sinusitis	CRVO	574	81,9	6	1,0
Infections and infestations	Sinusitis	HRVO	121	17,3	3	2,5
Infections and infestations	Sinusitis	Missing	6	0,9	0	0,0
Infections and infestations	Staphylococcal infection	CRVO	574	81,9	1	0,2
Infections and infestations	Staphylococcal infection	HRVO	121	17,3	0	0,0
Infections and infestations	Staphylococcal infection	Missing	6	0,9	0	0,0
Infections and infestations	Suspected COVID-19	CRVO	574	81,9	9	1,6
Infections and infestations	Suspected COVID-19	HRVO	121	17,3	1	0,8
Infections and infestations	Suspected COVID-19	Missing	6	0,9	0	0,0
Infections and infestations	Tinea pedis	CRVO	574	81,9	0	0,0
Infections and infestations	Tinea pedis	HRVO	121	17,3	1	0,8
Infections and infestations	Tinea pedis	Missing	6	0,9	0	0,0
Infections and infestations	Tooth abscess	CRVO	574	81,9	2	0,3
Infections and infestations	Tooth abscess	HRVO	121	17,3	0	0,0
Infections and infestations	Tooth abscess	Missing	6	0,9	0	0,0
Infections and infestations	Tooth infection	CRVO	574	81,9	2	0,3
Infections and infestations	Tooth infection	HRVO	121	17,3	1	0,8
Infections and infestations	Tooth infection	Missing	6	0,9	0	0,0
Infections and infestations	Upper respiratory tract infection	CRVO	574	81,9	14	2,4
Infections and infestations	Upper respiratory tract infection	HRVO	121	17,3	3	2,5
Infections and infestations	Upper respiratory tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Urinary tract candidiasis	CRVO	574	81,9	1	0,2
Infections and infestations	Urinary tract candidiasis	HRVO	121	17,3	0	0,0
Infections and infestations	Urinary tract candidiasis	Missing	6	0,9	0	0,0
Infections and infestations	Urinary tract infection	CRVO	574	81,9	10	1,7
Infections and infestations	Urinary tract infection	HRVO	121	17,3	4	3,3
Infections and infestations	Urinary tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Urosepsis	CRVO	574	81,9	1	0,2
Infections and infestations	Urosepsis	HRVO	121	17,3	0	0,0
Infections and infestations	Urosepsis	Missing	6	0,9	0	0,0
Infections and infestations	Viral rash	CRVO	574	81,9	1	0,2
Infections and infestations	Viral rash	HRVO	121	17,3	0	0,0
Infections and infestations	Viral rash	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications		CRVO	574	81,9	46	8,0
Injury, poisoning and procedural complications		HRVO	121	17,3	9	7,4
Injury, poisoning and procedural complications		Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Accident	CRVO	574	81,9	0	0,0
Injury, poisoning and procedural complications	Accident	HRVO	121	17,3	1	0,8

Injury, poisoning and procedural complications	Soft tissue injury	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Soft tissue injury	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Spinal compression fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Sunburn	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Sunburn	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Sunburn	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Thermal burn	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Thermal burn	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Thermal burn	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Tibia fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Tooth fracture	HRVO	121	17,3	1	0,8
Injury, poisoning and procedural complications	Tooth fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	CRVO	574	81,9	3	0,5
Injury, poisoning and procedural complications	Wrist fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	Missing	6	0,9	0	0,0
Investigations		CRVO	574	81,9	55	9,6
Investigations		HRVO	121	17,3	6	5,0
Investigations		Missing	6	0,9	1	16,7
Investigations	Alanine aminotransferase increased	CRVO	574	81,9	1	0,2
Investigations	Alanine aminotransferase increased	HRVO	121	17,3	0	0,0
Investigations	Alanine aminotransferase increased	Missing	6	0,9	0	0,0
Investigations	Aspartate aminotransferase increased	CRVO	574	81,9	1	0,2
Investigations	Aspartate aminotransferase increased	HRVO	121	17,3	0	0,0
Investigations	Aspartate aminotransferase increased	Missing	6	0,9	0	0,0
Investigations	Blood albumin increased	CRVO	574	81,9	1	0,2
Investigations	Blood albumin increased	HRVO	121	17,3	0	0,0
Investigations	Blood albumin increased	Missing	6	0,9	0	0,0
Investigations	Blood bilirubin increased	CRVO	574	81,9	1	0,2
Investigations	Blood bilirubin increased	HRVO	121	17,3	0	0,0
Investigations	Blood bilirubin increased	Missing	6	0,9	0	0,0
Investigations	Blood cholesterol increased	CRVO	574	81,9	2	0,3
Investigations	Blood cholesterol increased	HRVO	121	17,3	0	0,0
Investigations	Blood cholesterol increased	Missing	6	0,9	0	0,0
Investigations	Blood creatinine increased	CRVO	574	81,9	2	0,3
Investigations	Blood creatinine increased	HRVO	121	17,3	0	0,0
Investigations	Blood creatinine increased	Missing	6	0,9	0	0,0
Investigations	Blood glucose abnormal	CRVO	574	81,9	1	0,2
Investigations	Blood glucose abnormal	HRVO	121	17,3	0	0,0
Investigations	Blood glucose abnormal	Missing	6	0,9	0	0,0
Investigations	Blood glucose increased	CRVO	574	81,9	4	0,7
Investigations	Blood glucose increased	HRVO	121	17,3	0	0,0
Investigations	Blood glucose increased	Missing	6	0,9	0	0,0
Investigations	Blood potassium increased	CRVO	574	81,9	0	0,0
Investigations	Blood potassium increased	HRVO	121	17,3	1	0,8
Investigations	Blood potassium increased	Missing	6	0,9	0	0,0
Investigations	Blood pressure decreased	CRVO	574	81,9	1	0,2
Investigations	Blood pressure decreased	HRVO	121	17,3	0	0,0
Investigations	Blood pressure decreased	Missing	6	0,9	0	0,0
Investigations	Blood pressure increased	CRVO	574	81,9	3	0,5
Investigations	Blood pressure increased	HRVO	121	17,3	0	0,0
Investigations	Blood pressure increased	Missing	6	0,9	0	0,0
Investigations	Blood testosterone decreased	CRVO	574	81,9	1	0,2
Investigations	Blood testosterone decreased	HRVO	121	17,3	0	0,0
Investigations	Blood testosterone decreased	Missing	6	0,9	0	0,0
Investigations	Blood thyroid stimulating hormone increased	CRVO	574	81,9	1	0,2
Investigations	Blood thyroid stimulating hormone increased	HRVO	121	17,3	0	0,0
Investigations	Blood thyroid stimulating hormone increased	Missing	6	0,9	0	0,0
Investigations	Blood triglycerides increased	CRVO	574	81,9	0	0,0
Investigations	Blood triglycerides increased	HRVO	121	17,3	1	0,8
Investigations	Blood triglycerides increased	Missing	6	0,9	0	0,0
Investigations	Blood uric acid increased	CRVO	574	81,9	0	0,0
Investigations	Blood uric acid increased	HRVO	121	17,3	1	0,8
Investigations	Blood uric acid increased	Missing	6	0,9	0	0,0
Investigations	Grip strength decreased	CRVO	574	81,9	1	0,2
Investigations	Grip strength decreased	HRVO	121	17,3	0	0,0
Investigations	Grip strength decreased	Missing	6	0,9	0	0,0
Investigations	Haematocrit decreased	CRVO	574	81,9	1	0,2
Investigations	Haematocrit decreased	HRVO	121	17,3	0	0,0
Investigations	Haematocrit decreased	Missing	6	0,9	0	0,0
Investigations	Haemoglobin decreased	CRVO	574	81,9	1	0,2
Investigations	Haemoglobin decreased	HRVO	121	17,3	0	0,0
Investigations	Haemoglobin decreased	Missing	6	0,9	0	0,0
Investigations	Heart rate irregular	CRVO	574	81,9	1	0,2
Investigations	Heart rate irregular	HRVO	121	17,3	0	0,0
Investigations	Heart rate irregular	Missing	6	0,9	0	0,0
Investigations	Intraocular pressure increased	CRVO	574	81,9	30	5,2
Investigations	Intraocular pressure increased	HRVO	121	17,3	3	2,5

Investigations	Intraocular pressure increased	Missing	6	0,9	1	16,7
Investigations	Liver function test increased	CRVO	574	81,9	1	0,2
Investigations	Liver function test increased	HRVO	121	17,3	0	0,0
Investigations	Liver function test increased	Missing	6	0,9	0	0,0
Investigations	Occult blood positive	CRVO	574	81,9	1	0,2
Investigations	Occult blood positive	HRVO	121	17,3	0	0,0
Investigations	Occult blood positive	Missing	6	0,9	0	0,0
Investigations	Optic nerve cup/disc ratio increased	CRVO	574	81,9	1	0,2
Investigations	Optic nerve cup/disc ratio increased	HRVO	121	17,3	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Missing	6	0,9	0	0,0
Investigations	Red blood cell count decreased	CRVO	574	81,9	1	0,2
Investigations	Red blood cell count decreased	HRVO	121	17,3	0	0,0
Investigations	Red blood cell count decreased	Missing	6	0,9	0	0,0
Investigations	SARS-CoV-2 test positive	CRVO	574	81,9	4	0,7
Investigations	SARS-CoV-2 test positive	HRVO	121	17,3	0	0,0
Investigations	SARS-CoV-2 test positive	Missing	6	0,9	0	0,0
Investigations	Urinary occult blood	CRVO	574	81,9	0	0,0
Investigations	Urinary occult blood	HRVO	121	17,3	1	0,8
Investigations	Urinary occult blood	Missing	6	0,9	0	0,0
Investigations	Weight decreased	CRVO	574	81,9	1	0,2
Investigations	Weight decreased	HRVO	121	17,3	0	0,0
Investigations	Weight decreased	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders		CRVO	574	81,9	28	4,9
Metabolism and nutrition disorders		HRVO	121	17,3	6	5,0
Metabolism and nutrition disorders		Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Decreased appetite	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Decreased appetite	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Decreased appetite	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Dehydration	CRVO	574	81,9	2	0,3
Metabolism and nutrition disorders	Dehydration	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Dehydration	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	CRVO	574	81,9	2	0,3
Metabolism and nutrition disorders	Diabetes mellitus	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Diabetes mellitus	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Dyslipidaemia	CRVO	574	81,9	2	0,3
Metabolism and nutrition disorders	Dyslipidaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Dyslipidaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Glucose tolerance impaired	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Gout	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Gout	HRVO	121	17,3	1	0,8
Metabolism and nutrition disorders	Gout	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	CRVO	574	81,9	5	0,9
Metabolism and nutrition disorders	Hypercholesterolaemia	HRVO	121	17,3	2	1,7
Metabolism and nutrition disorders	Hypercholesterolaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hyperglycaemia	HRVO	121	17,3	1	0,8
Metabolism and nutrition disorders	Hyperglycaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hyperlipidaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hyperlipidaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hyperlipidaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hyperuricaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hyperuricaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hyperuricaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hypervolaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hypoglycaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	CRVO	574	81,9	7	1,2
Metabolism and nutrition disorders	Hypokalaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hyponatraemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	CRVO	574	81,9	5	0,9
Metabolism and nutrition disorders	Type 2 diabetes mellitus	HRVO	121	17,3	3	2,5
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Vitamin B12 deficiency	CRVO	574	81,9	2	0,3
Metabolism and nutrition disorders	Vitamin B12 deficiency	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Vitamin B12 deficiency	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Vitamin D deficiency	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Vitamin D deficiency	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Vitamin D deficiency	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders		CRVO	574	81,9	49	8,5
Musculoskeletal and connective tissue disorders		HRVO	121	17,3	12	9,9
Musculoskeletal and connective tissue disorders		Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	CRVO	574	81,9	11	1,9
Musculoskeletal and connective tissue disorders	Arthralgia	HRVO	121	17,3	2	1,7

Musculoskeletal and connective tissue disorders	Arthralgia	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Arthritis	CRVO	574	81,9	3	0,5
Musculoskeletal and connective tissue disorders	Arthritis	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Arthritis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	CRVO	574	81,9	11	1,9
Musculoskeletal and connective tissue disorders	Back pain	HRVO	121	17,3	3	2,5
Musculoskeletal and connective tissue disorders	Back pain	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Bone disorder	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Bone disorder	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Bone disorder	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Bone loss	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Bursitis	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Bursitis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Coccydynia	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Coccydynia	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Coccydynia	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Fibromyalgia	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Fibromyalgia	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Fibromyalgia	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Flank pain	CRVO	574	81,9	2	0,3
Musculoskeletal and connective tissue disorders	Flank pain	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Flank pain	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Joint effusion	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Joint swelling	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Joint swelling	HRVO	121	17,3	2	1,7
Musculoskeletal and connective tissue disorders	Joint swelling	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Mobility decreased	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Muscle contracture	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Muscle contracture	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Muscle contracture	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Muscular weakness	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Muscular weakness	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Muscular weakness	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Myalgia	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Myalgia	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Myalgia	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Neck pain	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Neck pain	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Neck pain	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	CRVO	574	81,9	4	0,7
Musculoskeletal and connective tissue disorders	Osteoarthritis	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Osteoarthritis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	CRVO	574	81,9	4	0,7
Musculoskeletal and connective tissue disorders	Pain in extremity	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Periarthritis	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Plantar fasciitis	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Plantar fasciitis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Polymyositis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	HRVO	121	17,3	2	1,7
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Scoliosis	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Spinal pain	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Spinal pain	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Synovial cyst	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Synovial cyst	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Synovial cyst	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	CRVO	574	81,9	0	0,0

Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Tendonitis	CRVO	574	81,9	2	0,3
Musculoskeletal and connective tissue disorders	Tendonitis	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Tendonitis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Trigger finger	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Trigger finger	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Trigger finger	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		CRVO	574	81,9	15	2,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		HRVO	121	17,3	1	0,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adrenal adenoma	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	CRVO	574	81,9	2	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	CRVO	574	81,9	2	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hair follicle tumour benign	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	CRVO	574	81,9	4	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	CRVO	574	81,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	HRVO	121	17,3	1	0,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Missing	6	0,9	0	0,0
Nervous system disorders		CRVO	574	81,9	43	7,5
Nervous system disorders		HRVO	121	17,3	8	6,6

Nervous system disorders		Missing	6	0,9	0	0,0
Nervous system disorders	Autonomic neuropathy	CRVO	574	81,9	1	0,2
Nervous system disorders	Autonomic neuropathy	HRVO	121	17,3	0	0,0
Nervous system disorders	Autonomic neuropathy	Missing	6	0,9	0	0,0
Nervous system disorders	Balance disorder	CRVO	574	81,9	1	0,2
Nervous system disorders	Balance disorder	HRVO	121	17,3	0	0,0
Nervous system disorders	Balance disorder	Missing	6	0,9	0	0,0
Nervous system disorders	Carotid arteriosclerosis	CRVO	574	81,9	1	0,2
Nervous system disorders	Carotid arteriosclerosis	HRVO	121	17,3	0	0,0
Nervous system disorders	Carotid arteriosclerosis	Missing	6	0,9	0	0,0
Nervous system disorders	Carpal tunnel syndrome	CRVO	574	81,9	1	0,2
Nervous system disorders	Carpal tunnel syndrome	HRVO	121	17,3	0	0,0
Nervous system disorders	Carpal tunnel syndrome	Missing	6	0,9	0	0,0
Nervous system disorders	Cerebral atrophy	CRVO	574	81,9	1	0,2
Nervous system disorders	Cerebral atrophy	HRVO	121	17,3	0	0,0
Nervous system disorders	Cerebral atrophy	Missing	6	0,9	0	0,0
Nervous system disorders	Cerebral disorder	CRVO	574	81,9	1	0,2
Nervous system disorders	Cerebral disorder	HRVO	121	17,3	0	0,0
Nervous system disorders	Cerebral disorder	Missing	6	0,9	0	0,0
Nervous system disorders	Cerebral infarction	CRVO	574	81,9	1	0,2
Nervous system disorders	Cerebral infarction	HRVO	121	17,3	0	0,0
Nervous system disorders	Cerebral infarction	Missing	6	0,9	0	0,0
Nervous system disorders	Cerebrovascular accident	CRVO	574	81,9	0	0,0
Nervous system disorders	Cerebrovascular accident	HRVO	121	17,3	1	0,8
Nervous system disorders	Cerebrovascular accident	Missing	6	0,9	0	0,0
Nervous system disorders	Cervicobrachial syndrome	CRVO	574	81,9	1	0,2
Nervous system disorders	Cervicobrachial syndrome	HRVO	121	17,3	0	0,0
Nervous system disorders	Cervicobrachial syndrome	Missing	6	0,9	0	0,0
Nervous system disorders	Cognitive disorder	CRVO	574	81,9	1	0,2
Nervous system disorders	Cognitive disorder	HRVO	121	17,3	0	0,0
Nervous system disorders	Cognitive disorder	Missing	6	0,9	0	0,0
Nervous system disorders	Dementia Alzheimer's type	CRVO	574	81,9	2	0,3
Nervous system disorders	Dementia Alzheimer's type	HRVO	121	17,3	0	0,0
Nervous system disorders	Dementia Alzheimer's type	Missing	6	0,9	0	0,0
Nervous system disorders	Diabetic neuropathy	CRVO	574	81,9	2	0,3
Nervous system disorders	Diabetic neuropathy	HRVO	121	17,3	0	0,0
Nervous system disorders	Diabetic neuropathy	Missing	6	0,9	0	0,0
Nervous system disorders	Dizziness	CRVO	574	81,9	6	1,0
Nervous system disorders	Dizziness	HRVO	121	17,3	1	0,8
Nervous system disorders	Dizziness	Missing	6	0,9	0	0,0
Nervous system disorders	Dysarthria	CRVO	574	81,9	1	0,2
Nervous system disorders	Dysarthria	HRVO	121	17,3	0	0,0
Nervous system disorders	Dysarthria	Missing	6	0,9	0	0,0
Nervous system disorders	Encephalopathy	CRVO	574	81,9	1	0,2
Nervous system disorders	Encephalopathy	HRVO	121	17,3	0	0,0
Nervous system disorders	Encephalopathy	Missing	6	0,9	0	0,0
Nervous system disorders	Headache	CRVO	574	81,9	7	1,2
Nervous system disorders	Headache	HRVO	121	17,3	4	3,3
Nervous system disorders	Headache	Missing	6	0,9	0	0,0
Nervous system disorders	Hypoaesthesia	CRVO	574	81,9	1	0,2
Nervous system disorders	Hypoaesthesia	HRVO	121	17,3	0	0,0
Nervous system disorders	Hypoaesthesia	Missing	6	0,9	0	0,0
Nervous system disorders	Intercostal neuralgia	CRVO	574	81,9	1	0,2
Nervous system disorders	Intercostal neuralgia	HRVO	121	17,3	0	0,0
Nervous system disorders	Intercostal neuralgia	Missing	6	0,9	0	0,0
Nervous system disorders	Ischaemic stroke	CRVO	574	81,9	1	0,2
Nervous system disorders	Ischaemic stroke	HRVO	121	17,3	1	0,8
Nervous system disorders	Ischaemic stroke	Missing	6	0,9	0	0,0
Nervous system disorders	Lacunar infarction	CRVO	574	81,9	2	0,3
Nervous system disorders	Lacunar infarction	HRVO	121	17,3	0	0,0
Nervous system disorders	Lacunar infarction	Missing	6	0,9	0	0,0
Nervous system disorders	Loss of consciousness	CRVO	574	81,9	1	0,2
Nervous system disorders	Loss of consciousness	HRVO	121	17,3	0	0,0
Nervous system disorders	Loss of consciousness	Missing	6	0,9	0	0,0
Nervous system disorders	Lumbar radiculopathy	CRVO	574	81,9	0	0,0
Nervous system disorders	Lumbar radiculopathy	HRVO	121	17,3	1	0,8
Nervous system disorders	Lumbar radiculopathy	Missing	6	0,9	0	0,0
Nervous system disorders	Migraine	CRVO	574	81,9	1	0,2
Nervous system disorders	Migraine	HRVO	121	17,3	0	0,0
Nervous system disorders	Migraine	Missing	6	0,9	0	0,0
Nervous system disorders	Neuralgia	CRVO	574	81,9	2	0,3
Nervous system disorders	Neuralgia	HRVO	121	17,3	0	0,0
Nervous system disorders	Neuralgia	Missing	6	0,9	0	0,0
Nervous system disorders	Neuropathy peripheral	CRVO	574	81,9	2	0,3
Nervous system disorders	Neuropathy peripheral	HRVO	121	17,3	0	0,0
Nervous system disorders	Neuropathy peripheral	Missing	6	0,9	0	0,0
Nervous system disorders	Ophthalmic migraine	CRVO	574	81,9	1	0,2
Nervous system disorders	Ophthalmic migraine	HRVO	121	17,3	0	0,0
Nervous system disorders	Ophthalmic migraine	Missing	6	0,9	0	0,0
Nervous system disorders	Paralysis	CRVO	574	81,9	1	0,2
Nervous system disorders	Paralysis	HRVO	121	17,3	0	0,0
Nervous system disorders	Paralysis	Missing	6	0,9	0	0,0
Nervous system disorders	Parkinsonism	CRVO	574	81,9	1	0,2

Nervous system disorders	Parkinsonism	HRVO	121	17,3	0	0,0
Nervous system disorders	Parkinsonism	Missing	6	0,9	0	0,0
Nervous system disorders	Presyncope	CRVO	574	81,9	1	0,2
Nervous system disorders	Presyncope	HRVO	121	17,3	0	0,0
Nervous system disorders	Presyncope	Missing	6	0,9	0	0,0
Nervous system disorders	Sciatica	CRVO	574	81,9	1	0,2
Nervous system disorders	Sciatica	HRVO	121	17,3	1	0,8
Nervous system disorders	Sciatica	Missing	6	0,9	0	0,0
Nervous system disorders	Syncope	CRVO	574	81,9	3	0,5
Nervous system disorders	Syncope	HRVO	121	17,3	1	0,8
Nervous system disorders	Syncope	Missing	6	0,9	0	0,0
Product issues		CRVO	574	81,9	1	0,2
Product issues		HRVO	121	17,3	0	0,0
Product issues		Missing	6	0,9	0	0,0
Product issues	Device physical property issue	CRVO	574	81,9	1	0,2
Product issues	Device physical property issue	HRVO	121	17,3	0	0,0
Product issues	Device physical property issue	Missing	6	0,9	0	0,0
Psychiatric disorders		CRVO	574	81,9	8	1,4
Psychiatric disorders		HRVO	121	17,3	1	0,8
Psychiatric disorders		Missing	6	0,9	0	0,0
Psychiatric disorders	Anxiety	CRVO	574	81,9	1	0,2
Psychiatric disorders	Anxiety	HRVO	121	17,3	0	0,0
Psychiatric disorders	Anxiety	Missing	6	0,9	0	0,0
Psychiatric disorders	Attention deficit hyperactivity disorder	CRVO	574	81,9	1	0,2
Psychiatric disorders	Attention deficit hyperactivity disorder	HRVO	121	17,3	0	0,0
Psychiatric disorders	Attention deficit hyperactivity disorder	Missing	6	0,9	0	0,0
Psychiatric disorders	Depression	CRVO	574	81,9	1	0,2
Psychiatric disorders	Depression	HRVO	121	17,3	1	0,8
Psychiatric disorders	Depression	Missing	6	0,9	0	0,0
Psychiatric disorders	Generalised anxiety disorder	CRVO	574	81,9	1	0,2
Psychiatric disorders	Generalised anxiety disorder	HRVO	121	17,3	0	0,0
Psychiatric disorders	Generalised anxiety disorder	Missing	6	0,9	0	0,0
Psychiatric disorders	Insomnia	CRVO	574	81,9	3	0,5
Psychiatric disorders	Insomnia	HRVO	121	17,3	0	0,0
Psychiatric disorders	Insomnia	Missing	6	0,9	0	0,0
Psychiatric disorders	Sleep disorder	CRVO	574	81,9	1	0,2
Psychiatric disorders	Sleep disorder	HRVO	121	17,3	0	0,0
Psychiatric disorders	Sleep disorder	Missing	6	0,9	0	0,0
Renal and urinary disorders		CRVO	574	81,9	14	2,4
Renal and urinary disorders		HRVO	121	17,3	2	1,7
Renal and urinary disorders		Missing	6	0,9	0	0,0
Renal and urinary disorders	Acute kidney injury	CRVO	574	81,9	2	0,3
Renal and urinary disorders	Acute kidney injury	HRVO	121	17,3	1	0,8
Renal and urinary disorders	Acute kidney injury	Missing	6	0,9	0	0,0
Renal and urinary disorders	Cystitis interstitial	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Cystitis interstitial	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Cystitis interstitial	Missing	6	0,9	0	0,0
Renal and urinary disorders	Diabetic nephropathy	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Diabetic nephropathy	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Missing	6	0,9	0	0,0
Renal and urinary disorders	Dysuria	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Dysuria	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Dysuria	Missing	6	0,9	0	0,0
Renal and urinary disorders	End stage renal disease	CRVO	574	81,9	1	0,2
Renal and urinary disorders	End stage renal disease	HRVO	121	17,3	0	0,0
Renal and urinary disorders	End stage renal disease	Missing	6	0,9	0	0,0
Renal and urinary disorders	Haematuria	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Haematuria	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Haematuria	Missing	6	0,9	0	0,0
Renal and urinary disorders	Hypertonic bladder	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Hypertonic bladder	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Hypertonic bladder	Missing	6	0,9	0	0,0
Renal and urinary disorders	Nephrolithiasis	CRVO	574	81,9	3	0,5
Renal and urinary disorders	Nephrolithiasis	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Nephrolithiasis	Missing	6	0,9	0	0,0
Renal and urinary disorders	Nephropathy	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Nephropathy	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Nephropathy	Missing	6	0,9	0	0,0
Renal and urinary disorders	Renal failure	CRVO	574	81,9	2	0,3
Renal and urinary disorders	Renal failure	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Renal failure	Missing	6	0,9	0	0,0
Renal and urinary disorders	Urinary retention	CRVO	574	81,9	0	0,0
Renal and urinary disorders	Urinary retention	HRVO	121	17,3	1	0,8
Renal and urinary disorders	Urinary retention	Missing	6	0,9	0	0,0
Renal and urinary disorders	Urinary tract inflammation	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Urinary tract inflammation	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Urinary tract inflammation	Missing	6	0,9	0	0,0
Reproductive system and breast disorders		CRVO	574	81,9	4	0,7
Reproductive system and breast disorders		HRVO	121	17,3	2	1,7

Reproductive system and breast disorders		Missing	6	0,9	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	CRVO	574	81,9	2	0,3
Reproductive system and breast disorders	Benign prostatic hyperplasia	HRVO	121	17,3	1	0,8
Reproductive system and breast disorders	Benign prostatic hyperplasia	Missing	6	0,9	0	0,0
Reproductive system and breast disorders	Cystocele	CRVO	574	81,9	1	0,2
Reproductive system and breast disorders	Cystocele	HRVO	121	17,3	0	0,0
Reproductive system and breast disorders	Cystocele	Missing	6	0,9	0	0,0
Reproductive system and breast disorders	Gynaecomastia	CRVO	574	81,9	1	0,2
Reproductive system and breast disorders	Gynaecomastia	HRVO	121	17,3	0	0,0
Reproductive system and breast disorders	Gynaecomastia	Missing	6	0,9	0	0,0
Reproductive system and breast disorders	Prostatitis	CRVO	574	81,9	0	0,0
Reproductive system and breast disorders	Prostatitis	HRVO	121	17,3	1	0,8
Reproductive system and breast disorders	Prostatitis	Missing	6	0,9	0	0,0
Reproductive system and breast disorders	Vaginal ulceration	CRVO	574	81,9	0	0,0
Reproductive system and breast disorders	Vaginal ulceration	HRVO	121	17,3	1	0,8
Reproductive system and breast disorders	Vaginal ulceration	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders		CRVO	574	81,9	24	4,2
Respiratory, thoracic and mediastinal disorders		HRVO	121	17,3	7	5,8
Respiratory, thoracic and mediastinal disorders		Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	CRVO	574	81,9	2	0,3
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Asthma	CRVO	574	81,9	2	0,3
Respiratory, thoracic and mediastinal disorders	Asthma	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Asthma	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Bronchiectasis	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	CRVO	574	81,9	4	0,7
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	HRVO	121	17,3	2	1,7
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Cough	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Cough	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Dry throat	CRVO	574	81,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Dry throat	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Dry throat	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Dyspnoea	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	CRVO	574	81,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Epistaxis	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Epistaxis	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	CRVO	574	81,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung opacity	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Lung opacity	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Lung opacity	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Nasal congestion	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal congestion	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Nasal polyps	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	CRVO	574	81,9	3	0,5
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural thickening	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Pleural thickening	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pleural thickening	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary calcification	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	CRVO	574	81,9	2	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Sinus disorder	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Missing	6	0,9	0	0,0

Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Tracheal diverticulum	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders		CRVO	574	81,9	13	2,3
Skin and subcutaneous tissue disorders		HRVO	121	17,3	9	7,4
Skin and subcutaneous tissue disorders		Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Androgenetic alopecia	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Dermal cyst	CRVO	574	81,9	0	0,0
Skin and subcutaneous tissue disorders	Dermal cyst	HRVO	121	17,3	1	0,8
Skin and subcutaneous tissue disorders	Dermal cyst	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Dermatitis	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis allergic	CRVO	574	81,9	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis allergic	HRVO	121	17,3	1	0,8
Skin and subcutaneous tissue disorders	Dermatitis allergic	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	CRVO	574	81,9	2	0,3
Skin and subcutaneous tissue disorders	Dermatitis contact	HRVO	121	17,3	1	0,8
Skin and subcutaneous tissue disorders	Dermatitis contact	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	CRVO	574	81,9	2	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Eczema	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Eczema	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Eczema	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Erythema	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Erythema	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Erythema	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Hyperkeratosis	CRVO	574	81,9	0	0,0
Skin and subcutaneous tissue disorders	Hyperkeratosis	HRVO	121	17,3	1	0,8
Skin and subcutaneous tissue disorders	Hyperkeratosis	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Ingrowing nail	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Ingrowing nail	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Ingrowing nail	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Nail bed bleeding	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Nail dystrophy	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Purpura	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Purpura	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Purpura	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Rash	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Rash	HRVO	121	17,3	3	2,5
Skin and subcutaneous tissue disorders	Rash	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Skin lesion	CRVO	574	81,9	0	0,0
Skin and subcutaneous tissue disorders	Skin lesion	HRVO	121	17,3	1	0,8
Skin and subcutaneous tissue disorders	Skin lesion	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Skin ulcer	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Skin ulcer	HRVO	121	17,3	1	0,8
Skin and subcutaneous tissue disorders	Skin ulcer	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Toxic skin eruption	CRVO	574	81,9	0	0,0
Skin and subcutaneous tissue disorders	Toxic skin eruption	HRVO	121	17,3	1	0,8
Skin and subcutaneous tissue disorders	Toxic skin eruption	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Urticaria	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	Missing	6	0,9	0	0,0
Surgical and medical procedures		CRVO	574	81,9	8	1,4
Surgical and medical procedures		HRVO	121	17,3	2	1,7
Surgical and medical procedures		Missing	6	0,9	0	0,0
Surgical and medical procedures	Dental implantation	CRVO	574	81,9	3	0,5
Surgical and medical procedures	Dental implantation	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Dental implantation	Missing	6	0,9	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	CRVO	574	81,9	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	HRVO	121	17,3	1	0,8
Surgical and medical procedures	Large intestinal polypectomy	Missing	6	0,9	0	0,0
Surgical and medical procedures	Ligament operation	CRVO	574	81,9	1	0,2
Surgical and medical procedures	Ligament operation	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Ligament operation	Missing	6	0,9	0	0,0
Surgical and medical procedures	Neurectomy	CRVO	574	81,9	0	0,0
Surgical and medical procedures	Neurectomy	HRVO	121	17,3	1	0,8
Surgical and medical procedures	Neurectomy	Missing	6	0,9	0	0,0

Surgical and medical procedures	Renal transplant	CRVO	574	81,9	1	0,2
Surgical and medical procedures	Renal transplant	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Renal transplant	Missing	6	0,9	0	0,0
Surgical and medical procedures	Toe operation	CRVO	574	81,9	1	0,2
Surgical and medical procedures	Toe operation	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Toe operation	Missing	6	0,9	0	0,0
Surgical and medical procedures	Tooth extraction	CRVO	574	81,9	4	0,7
Surgical and medical procedures	Tooth extraction	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Tooth extraction	Missing	6	0,9	0	0,0
Vascular disorders		CRVO	574	81,9	27	4,7
Vascular disorders		HRVO	121	17,3	12	9,9
Vascular disorders		Missing	6	0,9	0	0,0
Vascular disorders	Aortic aneurysm	CRVO	574	81,9	0	0,0
Vascular disorders	Aortic aneurysm	HRVO	121	17,3	1	0,8
Vascular disorders	Aortic aneurysm	Missing	6	0,9	0	0,0
Vascular disorders	Aortic dissection	CRVO	574	81,9	1	0,2
Vascular disorders	Aortic dissection	HRVO	121	17,3	0	0,0
Vascular disorders	Aortic dissection	Missing	6	0,9	0	0,0
Vascular disorders	Aortic stenosis	CRVO	574	81,9	0	0,0
Vascular disorders	Aortic stenosis	HRVO	121	17,3	1	0,8
Vascular disorders	Aortic stenosis	Missing	6	0,9	0	0,0
Vascular disorders	Deep vein thrombosis	CRVO	574	81,9	1	0,2
Vascular disorders	Deep vein thrombosis	HRVO	121	17,3	0	0,0
Vascular disorders	Deep vein thrombosis	Missing	6	0,9	0	0,0
Vascular disorders	Haematoma	CRVO	574	81,9	1	0,2
Vascular disorders	Haematoma	HRVO	121	17,3	0	0,0
Vascular disorders	Haematoma	Missing	6	0,9	0	0,0
Vascular disorders	Haemorrhage	CRVO	574	81,9	1	0,2
Vascular disorders	Haemorrhage	HRVO	121	17,3	0	0,0
Vascular disorders	Haemorrhage	Missing	6	0,9	0	0,0
Vascular disorders	Hypertension	CRVO	574	81,9	15	2,6
Vascular disorders	Hypertension	HRVO	121	17,3	8	6,6
Vascular disorders	Hypertension	Missing	6	0,9	0	0,0
Vascular disorders	Hypertensive crisis	CRVO	574	81,9	2	0,3
Vascular disorders	Hypertensive crisis	HRVO	121	17,3	1	0,8
Vascular disorders	Hypertensive crisis	Missing	6	0,9	0	0,0
Vascular disorders	Hypotension	CRVO	574	81,9	4	0,7
Vascular disorders	Hypotension	HRVO	121	17,3	0	0,0
Vascular disorders	Hypotension	Missing	6	0,9	0	0,0
Vascular disorders	Internal haemorrhage	CRVO	574	81,9	1	0,2
Vascular disorders	Internal haemorrhage	HRVO	121	17,3	0	0,0
Vascular disorders	Internal haemorrhage	Missing	6	0,9	0	0,0
Vascular disorders	Lymphoedema	CRVO	574	81,9	1	0,2
Vascular disorders	Lymphoedema	HRVO	121	17,3	0	0,0
Vascular disorders	Lymphoedema	Missing	6	0,9	0	0,0
Vascular disorders	Peripheral artery aneurysm	CRVO	574	81,9	1	0,2
Vascular disorders	Peripheral artery aneurysm	HRVO	121	17,3	0	0,0
Vascular disorders	Peripheral artery aneurysm	Missing	6	0,9	0	0,0
Vascular disorders	Secondary hypertension	CRVO	574	81,9	0	0,0
Vascular disorders	Secondary hypertension	HRVO	121	17,3	1	0,8
Vascular disorders	Secondary hypertension	Missing	6	0,9	0	0,0
Vascular disorders	Thrombosis	CRVO	574	81,9	1	0,2
Vascular disorders	Thrombosis	HRVO	121	17,3	0	0,0
Vascular disorders	Thrombosis	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_eg_AE_WK72_SEa24_29AUG2023_41986.xls
26APR2024 18:00

POPULATION: Safety-Evaluable Population after Week 24
 ENDPPOINT: Moderate AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Blood and lymphatic system disorders		n/a	701	100,0	5	0,7
Blood and lymphatic system disorders	Anaemia	n/a	701	100,0	5	0,7
Blood and lymphatic system disorders	Mesenteric lymphadenitis	n/a	701	100,0	1	0,1
Cardiac disorders		n/a	701	100,0	15	2,1
Cardiac disorders	Acute left ventricular failure	n/a	701	100,0	1	0,1
Cardiac disorders	Aortic valve incompetence	n/a	701	100,0	1	0,1
Cardiac disorders	Arrhythmia	n/a	701	100,0	1	0,1
Cardiac disorders	Atrial fibrillation	n/a	701	100,0	5	0,7
Cardiac disorders	Bradycardia	n/a	701	100,0	1	0,1
Cardiac disorders	Cardiomegaly	n/a	701	100,0	1	0,1
Cardiac disorders	Coronary artery stenosis	n/a	701	100,0	1	0,1
Cardiac disorders	Myocardial infarction	n/a	701	100,0	1	0,1
Cardiac disorders	Myocardial ischaemia	n/a	701	100,0	1	0,1
Cardiac disorders	Palpitations	n/a	701	100,0	1	0,1
Cardiac disorders	Sinus tachycardia	n/a	701	100,0	1	0,1
Cardiac disorders	Supraventricular tachycardia	n/a	701	100,0	1	0,1
Congenital, familial and genetic disorders		n/a	701	100,0	1	0,1
Congenital, familial and genetic disorders	Corneal dystrophy	n/a	701	100,0	1	0,1
Ear and labyrinth disorders		n/a	701	100,0	2	0,3
Ear and labyrinth disorders	Vertigo	n/a	701	100,0	2	0,3
Endocrine disorders		n/a	701	100,0	2	0,3
Endocrine disorders	Androgen deficiency	n/a	701	100,0	1	0,1
Endocrine disorders	Hypothyroidism	n/a	701	100,0	1	0,1
Eye disorders		n/a	701	100,0	92	13,1
Eye disorders	Asthenopia	n/a	701	100,0	1	0,1
Eye disorders	Blepharitis	n/a	701	100,0	1	0,1
Eye disorders	Cataract	n/a	701	100,0	10	1,4
Eye disorders	Cataract nuclear	n/a	701	100,0	1	0,1
Eye disorders	Cataract subcapsular	n/a	701	100,0	1	0,1
Eye disorders	Chalazion	n/a	701	100,0	1	0,1
Eye disorders	Choroidal effusion	n/a	701	100,0	1	0,1
Eye disorders	Conjunctival telangiectasia	n/a	701	100,0	1	0,1
Eye disorders	Cystoid macular oedema	n/a	701	100,0	11	1,6
Eye disorders	Dry eye	n/a	701	100,0	2	0,3
Eye disorders	Eczema eyelids	n/a	701	100,0	1	0,1
Eye disorders	Eye irritation	n/a	701	100,0	1	0,1
Eye disorders	Eye pain	n/a	701	100,0	6	0,9
Eye disorders	Glaucoma	n/a	701	100,0	8	1,1
Eye disorders	Iridocyclitis	n/a	701	100,0	4	0,6
Eye disorders	Iris neovascularisation	n/a	701	100,0	1	0,1
Eye disorders	Iritis	n/a	701	100,0	1	0,1

Eye disorders	Keratopathy	n/a	701	100,0	1	0,1
Eye disorders	Lacrimal disorder	n/a	701	100,0	1	0,1
Eye disorders	Lacrimation increased	n/a	701	100,0	2	0,3
Eye disorders	Lenticular opacities	n/a	701	100,0	1	0,1
Eye disorders	Macular degeneration	n/a	701	100,0	1	0,1
Eye disorders	Macular ischaemia	n/a	701	100,0	1	0,1
Eye disorders	Macular oedema	n/a	701	100,0	13	1,9
Eye disorders	Neovascular age-related macular degeneration	n/a	701	100,0	1	0,1
Eye disorders	Non-infectious endophthalmitis	n/a	701	100,0	1	0,1
Eye disorders	Noninfective conjunctivitis	n/a	701	100,0	1	0,1
Eye disorders	Ocular hypertension	n/a	701	100,0	7	1,0
Eye disorders	Open angle glaucoma	n/a	701	100,0	1	0,1
Eye disorders	Optic disc haemorrhage	n/a	701	100,0	2	0,3
Eye disorders	Papilloedema	n/a	701	100,0	1	0,1
Eye disorders	Posterior capsule opacification	n/a	701	100,0	3	0,4
Eye disorders	Punctate keratitis	n/a	701	100,0	2	0,3
Eye disorders	Retinal artery occlusion	n/a	701	100,0	2	0,3
Eye disorders	Retinal collateral vessels	n/a	701	100,0	2	0,3
Eye disorders	Retinal detachment	n/a	701	100,0	1	0,1
Eye disorders	Retinal disorder	n/a	701	100,0	1	0,1
Eye disorders	Retinal haemorrhage	n/a	701	100,0	1	0,1
Eye disorders	Retinal ischaemia	n/a	701	100,0	1	0,1
Eye disorders	Retinal vein occlusion	n/a	701	100,0	9	1,3
Eye disorders	Uveitis	n/a	701	100,0	1	0,1
Eye disorders	Vision blurred	n/a	701	100,0	1	0,1
Eye disorders	Visual acuity reduced	n/a	701	100,0	4	0,6
Eye disorders	Visual impairment	n/a	701	100,0	1	0,1
Eye disorders	Vitreoretinal traction syndrome	n/a	701	100,0	1	0,1
Eye disorders	Vitreous detachment	n/a	701	100,0	1	0,1
Eye disorders	Vitreous floaters	n/a	701	100,0	1	0,1
Eye disorders	Vitreous haemorrhage	n/a	701	100,0	1	0,1
Eye disorders	Vitritis	n/a	701	100,0	2	0,3
Gastrointestinal disorders		n/a	701	100,0	16	2,3
Gastrointestinal disorders	Abdominal pain	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Abdominal pain upper	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Barrett's oesophagus	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Coeliac disease	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Colitis	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Constipation	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Dental discomfort	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Diarrhoea	n/a	701	100,0	3	0,4
Gastrointestinal disorders	Gastric ulcer	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Gastritis	n/a	701	100,0	2	0,3
Gastrointestinal disorders	Gastrooesophageal reflux disease	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Hiatus hernia	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Ileus	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Inguinal hernia	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Large intestine polyp	n/a	701	100,0	1	0,1
General disorders and administration site conditions		n/a	701	100,0	13	1,9
General disorders and administration site conditions	Asthenia	n/a	701	100,0	4	0,6
General disorders and administration site conditions	Chest pain	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Injection site pain	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Oedema peripheral	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Pain	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Polyp	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Pyrexia	n/a	701	100,0	4	0,6
General disorders and administration site conditions	Systemic inflammatory response syndrome	n/a	701	100,0	1	0,1

Hepatobiliary disorders		n/a	701	100,0	3	0,4
Hepatobiliary disorders	Cholecystitis	n/a	701	100,0	1	0,1
Hepatobiliary disorders	Cholelithiasis	n/a	701	100,0	2	0,3
Immune system disorders		n/a	701	100,0	3	0,4
Immune system disorders	Drug hypersensitivity	n/a	701	100,0	1	0,1
Immune system disorders	Iodine allergy	n/a	701	100,0	1	0,1
Immune system disorders	Seasonal allergy	n/a	701	100,0	1	0,1
Infections and infestations		n/a	701	100,0	64	9,1
Infections and infestations	Arthritis infective	n/a	701	100,0	1	0,1
Infections and infestations	Bronchitis	n/a	701	100,0	4	0,6
Infections and infestations	COVID-19	n/a	701	100,0	19	2,7
Infections and infestations	Cellulitis	n/a	701	100,0	4	0,6
Infections and infestations	Conjunctivitis	n/a	701	100,0	3	0,4
Infections and infestations	Cystitis	n/a	701	100,0	1	0,1
Infections and infestations	Ear infection	n/a	701	100,0	1	0,1
Infections and infestations	Fungal skin infection	n/a	701	100,0	1	0,1
Infections and infestations	Helicobacter infection	n/a	701	100,0	1	0,1
Infections and infestations	Herpes zoster	n/a	701	100,0	2	0,3
Infections and infestations	Influenza	n/a	701	100,0	8	1,1
Infections and infestations	Kidney infection	n/a	701	100,0	1	0,1
Infections and infestations	Laryngitis	n/a	701	100,0	1	0,1
Infections and infestations	Nasopharyngitis	n/a	701	100,0	4	0,6
Infections and infestations	Pharyngitis	n/a	701	100,0	1	0,1
Infections and infestations	Pneumonia	n/a	701	100,0	5	0,7
Infections and infestations	Pneumonia viral	n/a	701	100,0	1	0,1
Infections and infestations	Pulpitis dental	n/a	701	100,0	2	0,3
Infections and infestations	Respiratory tract infection	n/a	701	100,0	2	0,3
Infections and infestations	Respiratory tract infection viral	n/a	701	100,0	1	0,1
Infections and infestations	Sinusitis	n/a	701	100,0	2	0,3
Infections and infestations	Staphylococcal infection	n/a	701	100,0	1	0,1
Infections and infestations	Suspected COVID-19	n/a	701	100,0	1	0,1
Infections and infestations	Tooth abscess	n/a	701	100,0	1	0,1
Infections and infestations	Upper respiratory tract infection	n/a	701	100,0	9	1,3
Infections and infestations	Urinary tract infection	n/a	701	100,0	7	1,0
Injury, poisoning and procedural complications		n/a	701	100,0	25	3,6
Injury, poisoning and procedural complications	Arthropod bite	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Fall	n/a	701	100,0	6	0,9
Injury, poisoning and procedural complications	Femur fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Fibula fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Foreign body in eye	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Hand fracture	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Hip fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Hypobarism	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Limb injury	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Lower limb fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Lumbar vertebral fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Muscle strain	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Posterior capsule rupture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Rib fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Road traffic accident	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Skin laceration	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Spinal compression fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Sunburn	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Tibia fracture	n/a	701	100,0	1	0,1

Injury, poisoning and procedural complications	Tooth fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Wrist fracture	n/a	701	100,0	2	0,3
Investigations		n/a	701	100,0	16	2,3
Investigations	Blood pressure increased	n/a	701	100,0	2	0,3
Investigations	Blood testosterone decreased	n/a	701	100,0	1	0,1
Investigations	Intraocular pressure increased	n/a	701	100,0	10	1,4
Investigations	Occult blood positive	n/a	701	100,0	1	0,1
Investigations	Optic nerve cup/disc ratio increased	n/a	701	100,0	1	0,1
Investigations	Weight decreased	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders		n/a	701	100,0	14	2,0
Metabolism and nutrition disorders	Dehydration	n/a	701	100,0	2	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Gout	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hypercholesterolaemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hyperglycaemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hypoglycaemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hypokalaemia	n/a	701	100,0	5	0,7
Metabolism and nutrition disorders	Hyponatraemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Type 2 diabetes mellitus	n/a	701	100,0	2	0,3
Musculoskeletal and connective tissue disorders		n/a	701	100,0	16	2,3
Musculoskeletal and connective tissue disorders	Arthralgia	n/a	701	100,0	2	0,3
Musculoskeletal and connective tissue disorders	Back pain	n/a	701	100,0	4	0,6
Musculoskeletal and connective tissue disorders	Bone loss	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Bursitis	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Flank pain	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Osteoarthritis	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Pain in extremity	n/a	701	100,0	2	0,3
Musculoskeletal and connective tissue disorders	Periarthritis	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Scoliosis	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	701	100,0	6	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	n/a	701	100,0	2	0,3
Nervous system disorders		n/a	701	100,0	17	2,4
Nervous system disorders	Cerebral atrophy	n/a	701	100,0	1	0,1
Nervous system disorders	Cerebral infarction	n/a	701	100,0	1	0,1
Nervous system disorders	Diabetic neuropathy	n/a	701	100,0	2	0,3
Nervous system disorders	Dizziness	n/a	701	100,0	1	0,1
Nervous system disorders	Encephalopathy	n/a	701	100,0	1	0,1
Nervous system disorders	Headache	n/a	701	100,0	2	0,3
Nervous system disorders	Ischaemic stroke	n/a	701	100,0	1	0,1
Nervous system disorders	Lacunar infarction	n/a	701	100,0	1	0,1
Nervous system disorders	Loss of consciousness	n/a	701	100,0	1	0,1
Nervous system disorders	Neuralgia	n/a	701	100,0	1	0,1
Nervous system disorders	Neuropathy peripheral	n/a	701	100,0	2	0,3
Nervous system disorders	Ophthalmic migraine	n/a	701	100,0	1	0,1
Nervous system disorders	Sciatica	n/a	701	100,0	2	0,3
Nervous system disorders	Syncope	n/a	701	100,0	2	0,3

Psychiatric disorders		n/a	701	100,0	3	0,4
Psychiatric disorders	Anxiety	n/a	701	100,0	1	0,1
Psychiatric disorders	Depression	n/a	701	100,0	1	0,1
Psychiatric disorders	Insomnia	n/a	701	100,0	1	0,1
Renal and urinary disorders		n/a	701	100,0	6	0,9
Renal and urinary disorders	Acute kidney injury	n/a	701	100,0	2	0,3
Renal and urinary disorders	Diabetic nephropathy	n/a	701	100,0	1	0,1
Renal and urinary disorders	Renal failure	n/a	701	100,0	1	0,1
Renal and urinary disorders	Urinary retention	n/a	701	100,0	1	0,1
Renal and urinary disorders	Urinary tract inflammation	n/a	701	100,0	1	0,1
Reproductive system and breast disorders		n/a	701	100,0	2	0,3
Reproductive system and breast disorders	Benign prostatic hyperplasia	n/a	701	100,0	1	0,1
Reproductive system and breast disorders	Cystocele	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders		n/a	701	100,0	12	1,7
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Asthma	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	701	100,0	5	0,7
Respiratory, thoracic and mediastinal disorders	Cough	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Nasal polyps	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Sinus disorder	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders		n/a	701	100,0	10	1,4
Skin and subcutaneous tissue disorders	Androgenetic alopecia	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Dermatitis	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Dermatitis contact	n/a	701	100,0	3	0,4
Skin and subcutaneous tissue disorders	Diabetic foot	n/a	701	100,0	2	0,3
Skin and subcutaneous tissue disorders	Erythema	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Nail bed bleeding	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Nail dystrophy	n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Urticaria	n/a	701	100,0	1	0,1
Surgical and medical procedures		n/a	701	100,0	5	0,7
Surgical and medical procedures	Dental implantation	n/a	701	100,0	2	0,3
Surgical and medical procedures	Ligament operation	n/a	701	100,0	1	0,1
Surgical and medical procedures	Toe operation	n/a	701	100,0	1	0,1
Surgical and medical procedures	Tooth extraction	n/a	701	100,0	1	0,1
Vascular disorders		n/a	701	100,0	17	2,4
Vascular disorders	Aortic stenosis	n/a	701	100,0	1	0,1
Vascular disorders	Hypertension	n/a	701	100,0	11	1,6
Vascular disorders	Hypertensive crisis	n/a	701	100,0	2	0,3
Vascular disorders	Hypotension	n/a	701	100,0	3	0,4
Vascular disorders	Thrombosis	n/a	701	100,0	1	0,1

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WM0DAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:08

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AES
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Gender

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		Male	374	53,4	2	0,5
Blood and lymphatic system disorders		Female	327	46,6	3	0,9
Blood and lymphatic system disorders	Anaemia	Male	374	53,4	2	0,5
Blood and lymphatic system disorders	Anaemia	Female	327	46,6	3	0,9
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Male	374	53,4	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Female	327	46,6	1	0,3
Cardiac disorders		Male	374	53,4	6	1,6
Cardiac disorders		Female	327	46,6	9	2,8
Cardiac disorders	Acute left ventricular failure	Male	374	53,4	0	0,0
Cardiac disorders	Acute left ventricular failure	Female	327	46,6	1	0,3
Cardiac disorders	Aortic valve incompetence	Male	374	53,4	0	0,0
Cardiac disorders	Aortic valve incompetence	Female	327	46,6	1	0,3
Cardiac disorders	Arrhythmia	Male	374	53,4	0	0,0
Cardiac disorders	Arrhythmia	Female	327	46,6	1	0,3
Cardiac disorders	Atrial fibrillation	Male	374	53,4	2	0,5
Cardiac disorders	Atrial fibrillation	Female	327	46,6	3	0,9
Cardiac disorders	Bradycardia	Male	374	53,4	1	0,3
Cardiac disorders	Bradycardia	Female	327	46,6	0	0,0
Cardiac disorders	Cardiomegaly	Male	374	53,4	0	0,0
Cardiac disorders	Cardiomegaly	Female	327	46,6	1	0,3
Cardiac disorders	Coronary artery stenosis	Male	374	53,4	0	0,0
Cardiac disorders	Coronary artery stenosis	Female	327	46,6	1	0,3
Cardiac disorders	Myocardial infarction	Male	374	53,4	1	0,3
Cardiac disorders	Myocardial infarction	Female	327	46,6	0	0,0
Cardiac disorders	Myocardial ischaemia	Male	374	53,4	1	0,3
Cardiac disorders	Myocardial ischaemia	Female	327	46,6	0	0,0
Cardiac disorders	Palpitations	Male	374	53,4	0	0,0
Cardiac disorders	Palpitations	Female	327	46,6	1	0,3
Cardiac disorders	Sinus tachycardia	Male	374	53,4	0	0,0
Cardiac disorders	Sinus tachycardia	Female	327	46,6	1	0,3
Cardiac disorders	Supraventricular tachycardia	Male	374	53,4	1	0,3
Cardiac disorders	Supraventricular tachycardia	Female	327	46,6	0	0,0
Congenital, familial and genetic disorders		Male	374	53,4	0	0,0
Congenital, familial and genetic disorders		Female	327	46,6	1	0,3
Congenital, familial and genetic disorders	Corneal dystrophy	Male	374	53,4	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	Female	327	46,6	1	0,3
Ear and labyrinth disorders		Male	374	53,4	1	0,3
Ear and labyrinth disorders		Female	327	46,6	1	0,3
Ear and labyrinth disorders	Vertigo	Male	374	53,4	1	0,3
Ear and labyrinth disorders	Vertigo	Female	327	46,6	1	0,3
Endocrine disorders		Male	374	53,4	1	0,3
Endocrine disorders		Female	327	46,6	1	0,3
Endocrine disorders	Androgen deficiency	Male	374	53,4	1	0,3
Endocrine disorders	Androgen deficiency	Female	327	46,6	0	0,0
Endocrine disorders	Hypothyroidism	Male	374	53,4	0	0,0
Endocrine disorders	Hypothyroidism	Female	327	46,6	1	0,3

Eye disorders		Male	374	53,4	45	12,0
Eye disorders		Female	327	46,6	47	14,4
Eye disorders	Asthenopia	Male	374	53,4	1	0,3
Eye disorders	Asthenopia	Female	327	46,6	0	0,0
Eye disorders	Blepharitis	Male	374	53,4	1	0,3
Eye disorders	Blepharitis	Female	327	46,6	0	0,0
Eye disorders	Cataract	Male	374	53,4	2	0,5
Eye disorders	Cataract	Female	327	46,6	8	2,4
Eye disorders	Cataract nuclear	Male	374	53,4	0	0,0
Eye disorders	Cataract nuclear	Female	327	46,6	1	0,3
Eye disorders	Cataract subcapsular	Male	374	53,4	1	0,3
Eye disorders	Cataract subcapsular	Female	327	46,6	0	0,0
Eye disorders	Chalazion	Male	374	53,4	0	0,0
Eye disorders	Chalazion	Female	327	46,6	1	0,3
Eye disorders	Choroidal effusion	Male	374	53,4	1	0,3
Eye disorders	Choroidal effusion	Female	327	46,6	0	0,0
Eye disorders	Conjunctival telangiectasia	Male	374	53,4	0	0,0
Eye disorders	Conjunctival telangiectasia	Female	327	46,6	1	0,3
Eye disorders	Cystoid macular oedema	Male	374	53,4	8	2,1
Eye disorders	Cystoid macular oedema	Female	327	46,6	3	0,9
Eye disorders	Dry eye	Male	374	53,4	2	0,5
Eye disorders	Dry eye	Female	327	46,6	0	0,0
Eye disorders	Eczeema eyelids	Male	374	53,4	0	0,0
Eye disorders	Eczeema eyelids	Female	327	46,6	1	0,3
Eye disorders	Eye irritation	Male	374	53,4	1	0,3
Eye disorders	Eye irritation	Female	327	46,6	0	0,0
Eye disorders	Eye pain	Male	374	53,4	1	0,3
Eye disorders	Eye pain	Female	327	46,6	5	1,5
Eye disorders	Glaucoma	Male	374	53,4	6	1,6
Eye disorders	Glaucoma	Female	327	46,6	2	0,6
Eye disorders	Iridocyclitis	Male	374	53,4	2	0,5
Eye disorders	Iridocyclitis	Female	327	46,6	2	0,6
Eye disorders	Iris neovascularisation	Male	374	53,4	1	0,3
Eye disorders	Iris neovascularisation	Female	327	46,6	0	0,0
Eye disorders	Iritis	Male	374	53,4	1	0,3
Eye disorders	Iritis	Female	327	46,6	0	0,0
Eye disorders	Keratopathy	Male	374	53,4	0	0,0
Eye disorders	Keratopathy	Female	327	46,6	1	0,3
Eye disorders	Lacrimal disorder	Male	374	53,4	0	0,0
Eye disorders	Lacrimal disorder	Female	327	46,6	1	0,3
Eye disorders	Lacrimation increased	Male	374	53,4	2	0,5
Eye disorders	Lacrimation increased	Female	327	46,6	0	0,0
Eye disorders	Lenticular opacities	Male	374	53,4	1	0,3
Eye disorders	Lenticular opacities	Female	327	46,6	0	0,0
Eye disorders	Macular degeneration	Male	374	53,4	1	0,3
Eye disorders	Macular degeneration	Female	327	46,6	0	0,0
Eye disorders	Macular ischaemia	Male	374	53,4	1	0,3
Eye disorders	Macular ischaemia	Female	327	46,6	0	0,0
Eye disorders	Macular oedema	Male	374	53,4	4	1,1
Eye disorders	Macular oedema	Female	327	46,6	9	2,8
Eye disorders	Neovascular age-related macular degeneration	Male	374	53,4	1	0,3
Eye disorders	Neovascular age-related macular degeneration	Female	327	46,6	0	0,0
Eye disorders	Non-infectious endophthalmitis	Male	374	53,4	0	0,0
Eye disorders	Non-infectious endophthalmitis	Female	327	46,6	1	0,3
Eye disorders	Noninfective conjunctivitis	Male	374	53,4	1	0,3
Eye disorders	Noninfective conjunctivitis	Female	327	46,6	0	0,0
Eye disorders	Ocular hypertension	Male	374	53,4	5	1,3
Eye disorders	Ocular hypertension	Female	327	46,6	2	0,6
Eye disorders	Open angle glaucoma	Male	374	53,4	1	0,3
Eye disorders	Open angle glaucoma	Female	327	46,6	0	0,0
Eye disorders	Optic disc haemorrhage	Male	374	53,4	2	0,5
Eye disorders	Optic disc haemorrhage	Female	327	46,6	0	0,0
Eye disorders	Papilloedema	Male	374	53,4	0	0,0
Eye disorders	Papilloedema	Female	327	46,6	1	0,3

Eye disorders	Posterior capsule opacification	Male	374	53,4	1	0,3
Eye disorders	Posterior capsule opacification	Female	327	46,6	2	0,6
Eye disorders	Punctate keratitis	Male	374	53,4	1	0,3
Eye disorders	Punctate keratitis	Female	327	46,6	1	0,3
Eye disorders	Retinal artery occlusion	Male	374	53,4	2	0,5
Eye disorders	Retinal artery occlusion	Female	327	46,6	0	0,0
Eye disorders	Retinal collateral vessels	Male	374	53,4	1	0,3
Eye disorders	Retinal collateral vessels	Female	327	46,6	1	0,3
Eye disorders	Retinal detachment	Male	374	53,4	1	0,3
Eye disorders	Retinal detachment	Female	327	46,6	0	0,0
Eye disorders	Retinal disorder	Male	374	53,4	1	0,3
Eye disorders	Retinal disorder	Female	327	46,6	0	0,0
Eye disorders	Retinal haemorrhage	Male	374	53,4	0	0,0
Eye disorders	Retinal haemorrhage	Female	327	46,6	1	0,3
Eye disorders	Retinal ischaemia	Male	374	53,4	1	0,3
Eye disorders	Retinal ischaemia	Female	327	46,6	0	0,0
Eye disorders	Retinal vein occlusion	Male	374	53,4	5	1,3
Eye disorders	Retinal vein occlusion	Female	327	46,6	4	1,2
Eye disorders	Uveitis	Male	374	53,4	0	0,0
Eye disorders	Uveitis	Female	327	46,6	1	0,3
Eye disorders	Vision blurred	Male	374	53,4	1	0,3
Eye disorders	Vision blurred	Female	327	46,6	0	0,0
Eye disorders	Visual acuity reduced	Male	374	53,4	3	0,8
Eye disorders	Visual acuity reduced	Female	327	46,6	1	0,3
Eye disorders	Visual impairment	Male	374	53,4	0	0,0
Eye disorders	Visual impairment	Female	327	46,6	1	0,3
Eye disorders	Vitreoretinal traction syndrome	Male	374	53,4	1	0,3
Eye disorders	Vitreoretinal traction syndrome	Female	327	46,6	0	0,0
Eye disorders	Vitreous detachment	Male	374	53,4	1	0,3
Eye disorders	Vitreous detachment	Female	327	46,6	0	0,0
Eye disorders	Vitreous floaters	Male	374	53,4	0	0,0
Eye disorders	Vitreous floaters	Female	327	46,6	1	0,3
Eye disorders	Vitreous haemorrhage	Male	374	53,4	0	0,0
Eye disorders	Vitreous haemorrhage	Female	327	46,6	1	0,3
Eye disorders	Vitritis	Male	374	53,4	1	0,3
Eye disorders	Vitritis	Female	327	46,6	1	0,3
Gastrointestinal disorders		Male	374	53,4	8	2,1
Gastrointestinal disorders		Female	327	46,6	8	2,4
Gastrointestinal disorders	Abdominal pain	Male	374	53,4	1	0,3
Gastrointestinal disorders	Abdominal pain	Female	327	46,6	0	0,0
Gastrointestinal disorders	Abdominal pain upper	Male	374	53,4	1	0,3
Gastrointestinal disorders	Abdominal pain upper	Female	327	46,6	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	Male	374	53,4	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	Female	327	46,6	1	0,3
Gastrointestinal disorders	Coeliac disease	Male	374	53,4	0	0,0
Gastrointestinal disorders	Coeliac disease	Female	327	46,6	1	0,3
Gastrointestinal disorders	Colitis	Male	374	53,4	0	0,0
Gastrointestinal disorders	Colitis	Female	327	46,6	1	0,3
Gastrointestinal disorders	Constipation	Male	374	53,4	1	0,3
Gastrointestinal disorders	Constipation	Female	327	46,6	0	0,0
Gastrointestinal disorders	Dental discomfort	Male	374	53,4	0	0,0
Gastrointestinal disorders	Dental discomfort	Female	327	46,6	1	0,3
Gastrointestinal disorders	Diarrhoea	Male	374	53,4	1	0,3
Gastrointestinal disorders	Diarrhoea	Female	327	46,6	2	0,6
Gastrointestinal disorders	Gastric ulcer	Male	374	53,4	1	0,3
Gastrointestinal disorders	Gastric ulcer	Female	327	46,6	0	0,0
Gastrointestinal disorders	Gastritis	Male	374	53,4	2	0,5
Gastrointestinal disorders	Gastritis	Female	327	46,6	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	Male	374	53,4	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	Female	327	46,6	1	0,3
Gastrointestinal disorders	Hiatus hernia	Male	374	53,4	0	0,0
Gastrointestinal disorders	Hiatus hernia	Female	327	46,6	1	0,3
Gastrointestinal disorders	Ileus	Male	374	53,4	1	0,3

Gastrointestinal disorders	Ileus	Female	327	46,6	0	0,0
Gastrointestinal disorders	Inguinal hernia	Male	374	53,4	1	0,3
Gastrointestinal disorders	Inguinal hernia	Female	327	46,6	0	0,0
Gastrointestinal disorders	Large intestine polyp	Male	374	53,4	0	0,0
Gastrointestinal disorders	Large intestine polyp	Female	327	46,6	1	0,3
General disorders and administration site conditions		Male	374	53,4	3	0,8
General disorders and administration site conditions		Female	327	46,6	10	3,1
General disorders and administration site conditions	Asthenia	Male	374	53,4	0	0,0
General disorders and administration site conditions	Asthenia	Female	327	46,6	4	1,2
General disorders and administration site conditions	Chest pain	Male	374	53,4	1	0,3
General disorders and administration site conditions	Chest pain	Female	327	46,6	0	0,0
General disorders and administration site conditions	Injection site pain	Male	374	53,4	0	0,0
General disorders and administration site conditions	Injection site pain	Female	327	46,6	1	0,3
General disorders and administration site conditions	Oedema peripheral	Male	374	53,4	0	0,0
General disorders and administration site conditions	Oedema peripheral	Female	327	46,6	1	0,3
General disorders and administration site conditions	Pain	Male	374	53,4	1	0,3
General disorders and administration site conditions	Pain	Female	327	46,6	0	0,0
General disorders and administration site conditions	Polyp	Male	374	53,4	0	0,0
General disorders and administration site conditions	Polyp	Female	327	46,6	1	0,3
General disorders and administration site conditions	Pyrexia	Male	374	53,4	2	0,5
General disorders and administration site conditions	Pyrexia	Female	327	46,6	2	0,6
General disorders and administration site conditions	Systemic inflammatory response syndrome	Male	374	53,4	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	Female	327	46,6	1	0,3
Hepatobiliary disorders		Male	374	53,4	0	0,0
Hepatobiliary disorders		Female	327	46,6	3	0,9
Hepatobiliary disorders	Cholecystitis	Male	374	53,4	0	0,0
Hepatobiliary disorders	Cholecystitis	Female	327	46,6	1	0,3
Hepatobiliary disorders	Cholelithiasis	Male	374	53,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	Female	327	46,6	2	0,6
Immune system disorders		Male	374	53,4	2	0,5
Immune system disorders		Female	327	46,6	1	0,3
Immune system disorders	Drug hypersensitivity	Male	374	53,4	0	0,0
Immune system disorders	Drug hypersensitivity	Female	327	46,6	1	0,3
Immune system disorders	Iodine allergy	Male	374	53,4	1	0,3
Immune system disorders	Iodine allergy	Female	327	46,6	0	0,0
Immune system disorders	Seasonal allergy	Male	374	53,4	1	0,3
Immune system disorders	Seasonal allergy	Female	327	46,6	0	0,0
Infections and infestations		Male	374	53,4	18	4,8
Infections and infestations		Female	327	46,6	46	14,1
Infections and infestations	Arthritis infective	Male	374	53,4	0	0,0
Infections and infestations	Arthritis infective	Female	327	46,6	1	0,3
Infections and infestations	Bronchitis	Male	374	53,4	2	0,5
Infections and infestations	Bronchitis	Female	327	46,6	2	0,6
Infections and infestations	COVID-19	Male	374	53,4	10	2,7
Infections and infestations	COVID-19	Female	327	46,6	9	2,8
Infections and infestations	Cellulitis	Male	374	53,4	1	0,3
Infections and infestations	Cellulitis	Female	327	46,6	3	0,9
Infections and infestations	Conjunctivitis	Male	374	53,4	2	0,5
Infections and infestations	Conjunctivitis	Female	327	46,6	1	0,3
Infections and infestations	Cystitis	Male	374	53,4	0	0,0
Infections and infestations	Cystitis	Female	327	46,6	1	0,3
Infections and infestations	Ear infection	Male	374	53,4	0	0,0
Infections and infestations	Ear infection	Female	327	46,6	1	0,3
Infections and infestations	Fungal skin infection	Male	374	53,4	0	0,0
Infections and infestations	Fungal skin infection	Female	327	46,6	1	0,3
Infections and infestations	Helicobacter infection	Male	374	53,4	0	0,0
Infections and infestations	Helicobacter infection	Female	327	46,6	1	0,3
Infections and infestations	Herpes zoster	Male	374	53,4	1	0,3
Infections and infestations	Herpes zoster	Female	327	46,6	1	0,3
Infections and infestations	Influenza	Male	374	53,4	1	0,3

Infections and infestations	Influenza	Female	327	46,6	7	2,1
Infections and infestations	Kidney infection	Male	374	53,4	0	0,0
Infections and infestations	Kidney infection	Female	327	46,6	1	0,3
Infections and infestations	Laryngitis	Male	374	53,4	0	0,0
Infections and infestations	Laryngitis	Female	327	46,6	1	0,3
Infections and infestations	Nasopharyngitis	Male	374	53,4	0	0,0
Infections and infestations	Nasopharyngitis	Female	327	46,6	4	1,2
Infections and infestations	Pharyngitis	Male	374	53,4	0	0,0
Infections and infestations	Pharyngitis	Female	327	46,6	1	0,3
Infections and infestations	Pneumonia	Male	374	53,4	1	0,3
Infections and infestations	Pneumonia	Female	327	46,6	4	1,2
Infections and infestations	Pneumonia viral	Male	374	53,4	1	0,3
Infections and infestations	Pneumonia viral	Female	327	46,6	0	0,0
Infections and infestations	Pulpitis dental	Male	374	53,4	0	0,0
Infections and infestations	Pulpitis dental	Female	327	46,6	2	0,6
Infections and infestations	Respiratory tract infection	Male	374	53,4	0	0,0
Infections and infestations	Respiratory tract infection	Female	327	46,6	2	0,6
Infections and infestations	Respiratory tract infection viral	Male	374	53,4	0	0,0
Infections and infestations	Respiratory tract infection viral	Female	327	46,6	1	0,3
Infections and infestations	Sinusitis	Male	374	53,4	0	0,0
Infections and infestations	Sinusitis	Female	327	46,6	2	0,6
Infections and infestations	Staphylococcal infection	Male	374	53,4	0	0,0
Infections and infestations	Staphylococcal infection	Female	327	46,6	1	0,3
Infections and infestations	Suspected COVID-19	Male	374	53,4	1	0,3
Infections and infestations	Suspected COVID-19	Female	327	46,6	0	0,0
Infections and infestations	Tooth abscess	Male	374	53,4	1	0,3
Infections and infestations	Tooth abscess	Female	327	46,6	0	0,0
Infections and infestations	Upper respiratory tract infection	Male	374	53,4	2	0,5
Infections and infestations	Upper respiratory tract infection	Female	327	46,6	7	2,1
Infections and infestations	Urinary tract infection	Male	374	53,4	1	0,3
Infections and infestations	Urinary tract infection	Female	327	46,6	6	1,8
Injury, poisoning and procedural complications		Male	374	53,4	15	4,0
Injury, poisoning and procedural complications		Female	327	46,6	10	3,1
Injury, poisoning and procedural complications	Arthropod bite	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Arthropod bite	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Fall	Male	374	53,4	3	0,8
Injury, poisoning and procedural complications	Fall	Female	327	46,6	3	0,9
Injury, poisoning and procedural complications	Femur fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Fibula fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Fibula fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Foreign body in eye	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Hand fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Hand fracture	Female	327	46,6	2	0,6
Injury, poisoning and procedural complications	Hip fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Hypobarism	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Hypobarism	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Limb injury	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Limb injury	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Lower limb fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Lower limb fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Lumbar vertebral fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Muscle strain	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Muscle strain	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Posterior capsule rupture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Rib fracture	Female	327	46,6	0	0,0

Injury, poisoning and procedural complications	Road traffic accident	Male	374	53,4	2	0,5
Injury, poisoning and procedural complications	Road traffic accident	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Skin laceration	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Spinal compression fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Sunburn	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Sunburn	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Tibia fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Tibia fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Wrist fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Wrist fracture	Female	327	46,6	1	0,3
Investigations		Male	374	53,4	6	1,6
Investigations		Female	327	46,6	10	3,1
Investigations	Blood pressure increased	Male	374	53,4	0	0,0
Investigations	Blood pressure increased	Female	327	46,6	2	0,6
Investigations	Blood testosterone decreased	Male	374	53,4	1	0,3
Investigations	Blood testosterone decreased	Female	327	46,6	0	0,0
Investigations	Intraocular pressure increased	Male	374	53,4	5	1,3
Investigations	Intraocular pressure increased	Female	327	46,6	5	1,5
Investigations	Occult blood positive	Male	374	53,4	0	0,0
Investigations	Occult blood positive	Female	327	46,6	1	0,3
Investigations	Optic nerve cup/disc ratio increased	Male	374	53,4	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Female	327	46,6	1	0,3
Investigations	Weight decreased	Male	374	53,4	0	0,0
Investigations	Weight decreased	Female	327	46,6	1	0,3
Metabolism and nutrition disorders		Male	374	53,4	8	2,1
Metabolism and nutrition disorders		Female	327	46,6	6	1,8
Metabolism and nutrition disorders	Dehydration	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Dehydration	Female	327	46,6	1	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Gout	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Gout	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Hypercholesterolaemia	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Male	374	53,4	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Female	327	46,6	1	0,3
Metabolism and nutrition disorders	Hypoglycaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Hypoglycaemia	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Male	374	53,4	2	0,5
Metabolism and nutrition disorders	Hypokalaemia	Female	327	46,6	3	0,9
Metabolism and nutrition disorders	Hyponatraemia	Male	374	53,4	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	Female	327	46,6	1	0,3
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders		Male	374	53,4	9	2,4
Musculoskeletal and connective tissue disorders		Female	327	46,6	7	2,1
Musculoskeletal and connective tissue disorders	Arthralgia	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Arthralgia	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Back pain	Male	374	53,4	2	0,5
Musculoskeletal and connective tissue disorders	Back pain	Female	327	46,6	2	0,6
Musculoskeletal and connective tissue disorders	Bone loss	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Bursitis	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Flank pain	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Flank pain	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Male	374	53,4	0	0,0

Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Osteoarthritis	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	Male	374	53,4	2	0,5
Musculoskeletal and connective tissue disorders	Pain in extremity	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Periarthritis	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Scoliosis	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Male	374	53,4	4	1,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Female	327	46,6	2	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Male	374	53,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Female	327	46,6	1	0,3
Nervous system disorders		Male	374	53,4	7	1,9
Nervous system disorders		Female	327	46,6	10	3,1
Nervous system disorders	Cerebral atrophy	Male	374	53,4	0	0,0
Nervous system disorders	Cerebral atrophy	Female	327	46,6	1	0,3
Nervous system disorders	Cerebral infarction	Male	374	53,4	1	0,3
Nervous system disorders	Cerebral infarction	Female	327	46,6	0	0,0
Nervous system disorders	Diabetic neuropathy	Male	374	53,4	1	0,3
Nervous system disorders	Diabetic neuropathy	Female	327	46,6	1	0,3
Nervous system disorders	Dizziness	Male	374	53,4	0	0,0
Nervous system disorders	Dizziness	Female	327	46,6	1	0,3
Nervous system disorders	Encephalopathy	Male	374	53,4	0	0,0
Nervous system disorders	Encephalopathy	Female	327	46,6	1	0,3
Nervous system disorders	Headache	Male	374	53,4	0	0,0
Nervous system disorders	Headache	Female	327	46,6	2	0,6
Nervous system disorders	Ischaemic stroke	Male	374	53,4	1	0,3
Nervous system disorders	Ischaemic stroke	Female	327	46,6	0	0,0
Nervous system disorders	Lacunar infarction	Male	374	53,4	0	0,0
Nervous system disorders	Lacunar infarction	Female	327	46,6	1	0,3
Nervous system disorders	Loss of consciousness	Male	374	53,4	0	0,0
Nervous system disorders	Loss of consciousness	Female	327	46,6	1	0,3
Nervous system disorders	Neuralgia	Male	374	53,4	0	0,0
Nervous system disorders	Neuralgia	Female	327	46,6	1	0,3
Nervous system disorders	Neuropathy peripheral	Male	374	53,4	1	0,3
Nervous system disorders	Neuropathy peripheral	Female	327	46,6	1	0,3
Nervous system disorders	Ophthalmic migraine	Male	374	53,4	0	0,0
Nervous system disorders	Ophthalmic migraine	Female	327	46,6	1	0,3
Nervous system disorders	Sciatica	Male	374	53,4	2	0,5
Nervous system disorders	Sciatica	Female	327	46,6	0	0,0
Nervous system disorders	Syncope	Male	374	53,4	1	0,3
Nervous system disorders	Syncope	Female	327	46,6	1	0,3
Psychiatric disorders		Male	374	53,4	1	0,3
Psychiatric disorders		Female	327	46,6	2	0,6
Psychiatric disorders	Anxiety	Male	374	53,4	1	0,3
Psychiatric disorders	Anxiety	Female	327	46,6	0	0,0

Psychiatric disorders	Depression	Male	374	53,4	0	0,0
Psychiatric disorders	Depression	Female	327	46,6	1	0,3
Psychiatric disorders	Insomnia	Male	374	53,4	0	0,0
Psychiatric disorders	Insomnia	Female	327	46,6	1	0,3
Renal and urinary disorders		Male	374	53,4	5	1,3
Renal and urinary disorders		Female	327	46,6	1	0,3
Renal and urinary disorders	Acute kidney injury	Male	374	53,4	2	0,5
Renal and urinary disorders	Acute kidney injury	Female	327	46,6	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Male	374	53,4	1	0,3
Renal and urinary disorders	Diabetic nephropathy	Female	327	46,6	0	0,0
Renal and urinary disorders	Renal failure	Male	374	53,4	1	0,3
Renal and urinary disorders	Renal failure	Female	327	46,6	0	0,0
Renal and urinary disorders	Urinary retention	Male	374	53,4	0	0,0
Renal and urinary disorders	Urinary retention	Female	327	46,6	1	0,3
Renal and urinary disorders	Urinary tract inflammation	Male	374	53,4	1	0,3
Renal and urinary disorders	Urinary tract inflammation	Female	327	46,6	0	0,0
Reproductive system and breast disorders		Male	374	53,4	1	0,3
Reproductive system and breast disorders		Female	327	46,6	1	0,3
Reproductive system and breast disorders	Benign prostatic hyperplasia	Male	374	53,4	1	0,3
Reproductive system and breast disorders	Benign prostatic hyperplasia	Female	327	46,6	0	0,0
Reproductive system and breast disorders	Cystocele	Male	374	53,4	0	0,0
Reproductive system and breast disorders	Cystocele	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders		Male	374	53,4	6	1,6
Respiratory, thoracic and mediastinal disorders		Female	327	46,6	6	1,8
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Female	327	46,6	2	0,6
Respiratory, thoracic and mediastinal disorders	Asthma	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Asthma	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Male	374	53,4	4	1,1
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Cough	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders		Male	374	53,4	3	0,8
Skin and subcutaneous tissue disorders		Female	327	46,6	7	2,1
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis contact	Male	374	53,4	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis contact	Female	327	46,6	2	0,6
Skin and subcutaneous tissue disorders	Diabetic foot	Male	374	53,4	2	0,5
Skin and subcutaneous tissue disorders	Diabetic foot	Female	327	46,6	0	0,0
Skin and subcutaneous tissue disorders	Erythema	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Erythema	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Nail bed bleeding	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Nail dystrophy	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	Female	327	46,6	1	0,3
Skin and subcutaneous tissue disorders	Urticaria	Male	374	53,4	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	Female	327	46,6	1	0,3

Surgical and medical procedures		Male	374	53,4	1	0,3
Surgical and medical procedures		Female	327	46,6	4	1,2
Surgical and medical procedures	Dental implantation	Male	374	53,4	0	0,0
Surgical and medical procedures	Dental implantation	Female	327	46,6	2	0,6
Surgical and medical procedures	Ligament operation	Male	374	53,4	1	0,3
Surgical and medical procedures	Ligament operation	Female	327	46,6	0	0,0
Surgical and medical procedures	Toe operation	Male	374	53,4	0	0,0
Surgical and medical procedures	Toe operation	Female	327	46,6	1	0,3
Surgical and medical procedures	Tooth extraction	Male	374	53,4	0	0,0
Surgical and medical procedures	Tooth extraction	Female	327	46,6	1	0,3
Vascular disorders		Male	374	53,4	11	2,9
Vascular disorders		Female	327	46,6	6	1,8
Vascular disorders	Aortic stenosis	Male	374	53,4	1	0,3
Vascular disorders	Aortic stenosis	Female	327	46,6	0	0,0
Vascular disorders	Hypertension	Male	374	53,4	8	2,1
Vascular disorders	Hypertension	Female	327	46,6	3	0,9
Vascular disorders	Hypertensive crisis	Male	374	53,4	1	0,3
Vascular disorders	Hypertensive crisis	Female	327	46,6	1	0,3
Vascular disorders	Hypotension	Male	374	53,4	2	0,5
Vascular disorders	Hypotension	Female	327	46,6	1	0,3
Vascular disorders	Thrombosis	Male	374	53,4	0	0,0
Vascular disorders	Thrombosis	Female	327	46,6	1	0,3

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WMODAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:08

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AES
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Age

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<65 years	308	43,9	1	0,3
Blood and lymphatic system disorders		>=65 years	393	56,1	4	1,0
Blood and lymphatic system disorders	Anaemia	<65 years	308	43,9	1	0,3
Blood and lymphatic system disorders	Anaemia	>=65 years	393	56,1	4	1,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	<65 years	308	43,9	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	>=65 years	393	56,1	1	0,3
Cardiac disorders		<65 years	308	43,9	4	1,3
Cardiac disorders		>=65 years	393	56,1	11	2,8
Cardiac disorders	Acute left ventricular failure	<65 years	308	43,9	0	0,0
Cardiac disorders	Acute left ventricular failure	>=65 years	393	56,1	1	0,3
Cardiac disorders	Aortic valve incompetence	<65 years	308	43,9	0	0,0
Cardiac disorders	Aortic valve incompetence	>=65 years	393	56,1	1	0,3
Cardiac disorders	Arrhythmia	<65 years	308	43,9	0	0,0
Cardiac disorders	Arrhythmia	>=65 years	393	56,1	1	0,3
Cardiac disorders	Atrial fibrillation	<65 years	308	43,9	1	0,3
Cardiac disorders	Atrial fibrillation	>=65 years	393	56,1	4	1,0
Cardiac disorders	Bradycardia	<65 years	308	43,9	0	0,0
Cardiac disorders	Bradycardia	>=65 years	393	56,1	1	0,3
Cardiac disorders	Cardiomegaly	<65 years	308	43,9	0	0,0
Cardiac disorders	Cardiomegaly	>=65 years	393	56,1	1	0,3
Cardiac disorders	Coronary artery stenosis	<65 years	308	43,9	0	0,0
Cardiac disorders	Coronary artery stenosis	>=65 years	393	56,1	1	0,3
Cardiac disorders	Myocardial infarction	<65 years	308	43,9	1	0,3
Cardiac disorders	Myocardial infarction	>=65 years	393	56,1	0	0,0
Cardiac disorders	Myocardial ischaemia	<65 years	308	43,9	1	0,3
Cardiac disorders	Myocardial ischaemia	>=65 years	393	56,1	0	0,0
Cardiac disorders	Palpitations	<65 years	308	43,9	1	0,3
Cardiac disorders	Palpitations	>=65 years	393	56,1	0	0,0
Cardiac disorders	Sinus tachycardia	<65 years	308	43,9	0	0,0
Cardiac disorders	Sinus tachycardia	>=65 years	393	56,1	1	0,3
Cardiac disorders	Supraventricular tachycardia	<65 years	308	43,9	0	0,0
Cardiac disorders	Supraventricular tachycardia	>=65 years	393	56,1	1	0,3
Congenital, familial and genetic disorders		<65 years	308	43,9	0	0,0
Congenital, familial and genetic disorders		>=65 years	393	56,1	1	0,3
Congenital, familial and genetic disorders	Corneal dystrophy	<65 years	308	43,9	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	>=65 years	393	56,1	1	0,3
Ear and labyrinth disorders		<65 years	308	43,9	0	0,0
Ear and labyrinth disorders		>=65 years	393	56,1	2	0,5
Ear and labyrinth disorders	Vertigo	<65 years	308	43,9	0	0,0
Ear and labyrinth disorders	Vertigo	>=65 years	393	56,1	2	0,5
Endocrine disorders		<65 years	308	43,9	1	0,3
Endocrine disorders		>=65 years	393	56,1	1	0,3
Endocrine disorders	Androgen deficiency	<65 years	308	43,9	1	0,3
Endocrine disorders	Androgen deficiency	>=65 years	393	56,1	0	0,0
Endocrine disorders	Hypothyroidism	<65 years	308	43,9	0	0,0
Endocrine disorders	Hypothyroidism	>=65 years	393	56,1	1	0,3

Eye disorders		<65 years	308	43,9	38	12,3
Eye disorders		>=65 years	393	56,1	54	13,7
Eye disorders	Asthenopia	<65 years	308	43,9	0	0,0
Eye disorders	Asthenopia	>=65 years	393	56,1	1	0,3
Eye disorders	Blepharitis	<65 years	308	43,9	0	0,0
Eye disorders	Blepharitis	>=65 years	393	56,1	1	0,3
Eye disorders	Cataract	<65 years	308	43,9	1	0,3
Eye disorders	Cataract	>=65 years	393	56,1	9	2,3
Eye disorders	Cataract nuclear	<65 years	308	43,9	0	0,0
Eye disorders	Cataract nuclear	>=65 years	393	56,1	1	0,3
Eye disorders	Cataract subcapsular	<65 years	308	43,9	0	0,0
Eye disorders	Cataract subcapsular	>=65 years	393	56,1	1	0,3
Eye disorders	Chalazion	<65 years	308	43,9	0	0,0
Eye disorders	Chalazion	>=65 years	393	56,1	1	0,3
Eye disorders	Choroidal effusion	<65 years	308	43,9	0	0,0
Eye disorders	Choroidal effusion	>=65 years	393	56,1	1	0,3
Eye disorders	Conjunctival telangiectasia	<65 years	308	43,9	1	0,3
Eye disorders	Conjunctival telangiectasia	>=65 years	393	56,1	0	0,0
Eye disorders	Cystoid macular oedema	<65 years	308	43,9	7	2,3
Eye disorders	Cystoid macular oedema	>=65 years	393	56,1	4	1,0
Eye disorders	Dry eye	<65 years	308	43,9	1	0,3
Eye disorders	Dry eye	>=65 years	393	56,1	1	0,3
Eye disorders	Eczema eyelids	<65 years	308	43,9	0	0,0
Eye disorders	Eczema eyelids	>=65 years	393	56,1	1	0,3
Eye disorders	Eye irritation	<65 years	308	43,9	0	0,0
Eye disorders	Eye irritation	>=65 years	393	56,1	1	0,3
Eye disorders	Eye pain	<65 years	308	43,9	4	1,3
Eye disorders	Eye pain	>=65 years	393	56,1	2	0,5
Eye disorders	Glaucoma	<65 years	308	43,9	2	0,6
Eye disorders	Glaucoma	>=65 years	393	56,1	6	1,5
Eye disorders	Iridocyclitis	<65 years	308	43,9	2	0,6
Eye disorders	Iridocyclitis	>=65 years	393	56,1	2	0,5
Eye disorders	Iris neovascularisation	<65 years	308	43,9	0	0,0
Eye disorders	Iris neovascularisation	>=65 years	393	56,1	1	0,3
Eye disorders	Iritis	<65 years	308	43,9	1	0,3
Eye disorders	Iritis	>=65 years	393	56,1	0	0,0
Eye disorders	Keratopathy	<65 years	308	43,9	0	0,0
Eye disorders	Keratopathy	>=65 years	393	56,1	1	0,3
Eye disorders	Lacrimal disorder	<65 years	308	43,9	0	0,0
Eye disorders	Lacrimal disorder	>=65 years	393	56,1	1	0,3
Eye disorders	Lacrimation increased	<65 years	308	43,9	0	0,0
Eye disorders	Lacrimation increased	>=65 years	393	56,1	2	0,5
Eye disorders	Lenticular opacities	<65 years	308	43,9	1	0,3
Eye disorders	Lenticular opacities	>=65 years	393	56,1	0	0,0
Eye disorders	Macular degeneration	<65 years	308	43,9	1	0,3
Eye disorders	Macular degeneration	>=65 years	393	56,1	0	0,0
Eye disorders	Macular ischaemia	<65 years	308	43,9	1	0,3
Eye disorders	Macular ischaemia	>=65 years	393	56,1	0	0,0
Eye disorders	Macular oedema	<65 years	308	43,9	7	2,3
Eye disorders	Macular oedema	>=65 years	393	56,1	6	1,5
Eye disorders	Neovascular age-related macular degeneration	<65 years	308	43,9	0	0,0
Eye disorders	Neovascular age-related macular degeneration	>=65 years	393	56,1	1	0,3
Eye disorders	Non-infectious endophthalmitis	<65 years	308	43,9	0	0,0
Eye disorders	Non-infectious endophthalmitis	>=65 years	393	56,1	1	0,3
Eye disorders	Noninfective conjunctivitis	<65 years	308	43,9	0	0,0
Eye disorders	Noninfective conjunctivitis	>=65 years	393	56,1	1	0,3
Eye disorders	Ocular hypertension	<65 years	308	43,9	3	1,0
Eye disorders	Ocular hypertension	>=65 years	393	56,1	4	1,0
Eye disorders	Open angle glaucoma	<65 years	308	43,9	1	0,3
Eye disorders	Open angle glaucoma	>=65 years	393	56,1	0	0,0
Eye disorders	Optic disc haemorrhage	<65 years	308	43,9	0	0,0
Eye disorders	Optic disc haemorrhage	>=65 years	393	56,1	2	0,5
Eye disorders	Papilloedema	<65 years	308	43,9	0	0,0
Eye disorders	Papilloedema	>=65 years	393	56,1	1	0,3

Eye disorders	Posterior capsule opacification	<65 years	308	43,9	0	0,0
Eye disorders	Posterior capsule opacification	>=65 years	393	56,1	3	0,8
Eye disorders	Punctate keratitis	<65 years	308	43,9	0	0,0
Eye disorders	Punctate keratitis	>=65 years	393	56,1	2	0,5
Eye disorders	Retinal artery occlusion	<65 years	308	43,9	0	0,0
Eye disorders	Retinal artery occlusion	>=65 years	393	56,1	2	0,5
Eye disorders	Retinal collateral vessels	<65 years	308	43,9	1	0,3
Eye disorders	Retinal collateral vessels	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal detachment	<65 years	308	43,9	0	0,0
Eye disorders	Retinal detachment	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal disorder	<65 years	308	43,9	0	0,0
Eye disorders	Retinal disorder	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal haemorrhage	<65 years	308	43,9	1	0,3
Eye disorders	Retinal haemorrhage	>=65 years	393	56,1	0	0,0
Eye disorders	Retinal ischaemia	<65 years	308	43,9	0	0,0
Eye disorders	Retinal ischaemia	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal vein occlusion	<65 years	308	43,9	5	1,6
Eye disorders	Retinal vein occlusion	>=65 years	393	56,1	4	1,0
Eye disorders	Uveitis	<65 years	308	43,9	1	0,3
Eye disorders	Uveitis	>=65 years	393	56,1	0	0,0
Eye disorders	Vision blurred	<65 years	308	43,9	1	0,3
Eye disorders	Vision blurred	>=65 years	393	56,1	0	0,0
Eye disorders	Visual acuity reduced	<65 years	308	43,9	1	0,3
Eye disorders	Visual acuity reduced	>=65 years	393	56,1	3	0,8
Eye disorders	Visual impairment	<65 years	308	43,9	0	0,0
Eye disorders	Visual impairment	>=65 years	393	56,1	1	0,3
Eye disorders	Vitreoretinal traction syndrome	<65 years	308	43,9	0	0,0
Eye disorders	Vitreoretinal traction syndrome	>=65 years	393	56,1	1	0,3
Eye disorders	Vitreous detachment	<65 years	308	43,9	1	0,3
Eye disorders	Vitreous detachment	>=65 years	393	56,1	0	0,0
Eye disorders	Vitreous floaters	<65 years	308	43,9	0	0,0
Eye disorders	Vitreous floaters	>=65 years	393	56,1	1	0,3
Eye disorders	Vitreous haemorrhage	<65 years	308	43,9	0	0,0
Eye disorders	Vitreous haemorrhage	>=65 years	393	56,1	1	0,3
Eye disorders	Vitritis	<65 years	308	43,9	0	0,0
Eye disorders	Vitritis	>=65 years	393	56,1	2	0,5
Gastrointestinal disorders		<65 years	308	43,9	3	1,0
Gastrointestinal disorders		>=65 years	393	56,1	13	3,3
Gastrointestinal disorders	Abdominal pain	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Abdominal pain	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Abdominal pain upper	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Abdominal pain upper	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Barrett's oesophagus	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Barrett's oesophagus	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Coeliac disease	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Coeliac disease	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Colitis	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Colitis	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Constipation	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Constipation	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Dental discomfort	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Dental discomfort	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Diarrhoea	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Diarrhoea	>=65 years	393	56,1	3	0,8
Gastrointestinal disorders	Gastric ulcer	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Gastric ulcer	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Gastritis	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Gastritis	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Gastrooesophageal reflux disease	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Hiatus hernia	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Hiatus hernia	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Ileus	<65 years	308	43,9	0	0,0

Gastrointestinal disorders	Ileus	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Inguinal hernia	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Inguinal hernia	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Large intestine polyp	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Large intestine polyp	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions		<65 years	308	43,9	3	1,0
General disorders and administration site conditions		>=65 years	393	56,1	10	2,5
General disorders and administration site conditions	Asthenia	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Asthenia	>=65 years	393	56,1	4	1,0
General disorders and administration site conditions	Chest pain	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Chest pain	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Injection site pain	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Injection site pain	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Oedema peripheral	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Oedema peripheral	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Pain	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Pain	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Polyp	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Polyp	>=65 years	393	56,1	0	0,0
General disorders and administration site conditions	Pyrexia	<65 years	308	43,9	2	0,6
General disorders and administration site conditions	Pyrexia	>=65 years	393	56,1	2	0,5
General disorders and administration site conditions	Systemic inflammatory response syndrome	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	>=65 years	393	56,1	1	0,3
Hepatobiliary disorders		<65 years	308	43,9	2	0,6
Hepatobiliary disorders		>=65 years	393	56,1	1	0,3
Hepatobiliary disorders	Cholecystitis	<65 years	308	43,9	1	0,3
Hepatobiliary disorders	Cholecystitis	>=65 years	393	56,1	0	0,0
Hepatobiliary disorders	Cholelithiasis	<65 years	308	43,9	1	0,3
Hepatobiliary disorders	Cholelithiasis	>=65 years	393	56,1	1	0,3
Immune system disorders		<65 years	308	43,9	0	0,0
Immune system disorders		>=65 years	393	56,1	3	0,8
Immune system disorders	Drug hypersensitivity	<65 years	308	43,9	0	0,0
Immune system disorders	Drug hypersensitivity	>=65 years	393	56,1	1	0,3
Immune system disorders	Iodine allergy	<65 years	308	43,9	0	0,0
Immune system disorders	Iodine allergy	>=65 years	393	56,1	1	0,3
Immune system disorders	Seasonal allergy	<65 years	308	43,9	0	0,0
Immune system disorders	Seasonal allergy	>=65 years	393	56,1	1	0,3
Infections and infestations		<65 years	308	43,9	29	9,4
Infections and infestations		>=65 years	393	56,1	35	8,9
Infections and infestations	Arthritis infective	<65 years	308	43,9	0	0,0
Infections and infestations	Arthritis infective	>=65 years	393	56,1	1	0,3
Infections and infestations	Bronchitis	<65 years	308	43,9	1	0,3
Infections and infestations	Bronchitis	>=65 years	393	56,1	3	0,8
Infections and infestations	COVID-19	<65 years	308	43,9	10	3,2
Infections and infestations	COVID-19	>=65 years	393	56,1	9	2,3
Infections and infestations	Cellulitis	<65 years	308	43,9	0	0,0
Infections and infestations	Cellulitis	>=65 years	393	56,1	4	1,0
Infections and infestations	Conjunctivitis	<65 years	308	43,9	1	0,3
Infections and infestations	Conjunctivitis	>=65 years	393	56,1	2	0,5
Infections and infestations	Cystitis	<65 years	308	43,9	0	0,0
Infections and infestations	Cystitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Ear infection	<65 years	308	43,9	0	0,0
Infections and infestations	Ear infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Fungal skin infection	<65 years	308	43,9	0	0,0
Infections and infestations	Fungal skin infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Helicobacter infection	<65 years	308	43,9	1	0,3
Infections and infestations	Helicobacter infection	>=65 years	393	56,1	0	0,0
Infections and infestations	Herpes zoster	<65 years	308	43,9	0	0,0
Infections and infestations	Herpes zoster	>=65 years	393	56,1	2	0,5
Infections and infestations	Influenza	<65 years	308	43,9	5	1,6

Infections and infestations	Influenza	>=65 years	393	56,1	3	0,8
Infections and infestations	Kidney infection	<65 years	308	43,9	1	0,3
Infections and infestations	Kidney infection	>=65 years	393	56,1	0	0,0
Infections and infestations	Laryngitis	<65 years	308	43,9	0	0,0
Infections and infestations	Laryngitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Nasopharyngitis	<65 years	308	43,9	3	1,0
Infections and infestations	Nasopharyngitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Pharyngitis	<65 years	308	43,9	0	0,0
Infections and infestations	Pharyngitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Pneumonia	<65 years	308	43,9	2	0,6
Infections and infestations	Pneumonia	>=65 years	393	56,1	3	0,8
Infections and infestations	Pneumonia viral	<65 years	308	43,9	1	0,3
Infections and infestations	Pneumonia viral	>=65 years	393	56,1	0	0,0
Infections and infestations	Pulpitis dental	<65 years	308	43,9	2	0,6
Infections and infestations	Pulpitis dental	>=65 years	393	56,1	0	0,0
Infections and infestations	Respiratory tract infection	<65 years	308	43,9	0	0,0
Infections and infestations	Respiratory tract infection	>=65 years	393	56,1	2	0,5
Infections and infestations	Respiratory tract infection viral	<65 years	308	43,9	0	0,0
Infections and infestations	Respiratory tract infection viral	>=65 years	393	56,1	1	0,3
Infections and infestations	Sinusitis	<65 years	308	43,9	1	0,3
Infections and infestations	Sinusitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Staphylococcal infection	<65 years	308	43,9	0	0,0
Infections and infestations	Staphylococcal infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Suspected COVID-19	<65 years	308	43,9	0	0,0
Infections and infestations	Suspected COVID-19	>=65 years	393	56,1	1	0,3
Infections and infestations	Tooth abscess	<65 years	308	43,9	1	0,3
Infections and infestations	Tooth abscess	>=65 years	393	56,1	0	0,0
Infections and infestations	Upper respiratory tract infection	<65 years	308	43,9	7	2,3
Infections and infestations	Upper respiratory tract infection	>=65 years	393	56,1	2	0,5
Infections and infestations	Urinary tract infection	<65 years	308	43,9	0	0,0
Infections and infestations	Urinary tract infection	>=65 years	393	56,1	7	1,8
Injury, poisoning and procedural complications		<65 years	308	43,9	9	2,9
Injury, poisoning and procedural complications		>=65 years	393	56,1	16	4,1
Injury, poisoning and procedural complications	Arthropod bite	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Arthropod bite	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Fall	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Fall	>=65 years	393	56,1	5	1,3
Injury, poisoning and procedural complications	Femur fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Fibula fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Fibula fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Foreign body in eye	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Hand fracture	<65 years	308	43,9	2	0,6
Injury, poisoning and procedural complications	Hand fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Hip fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Hip fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Hypobarism	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Hypobarism	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Limb injury	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Limb injury	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Lower limb fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Lumbar vertebral fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Muscle strain	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Muscle strain	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Posterior capsule rupture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Rib fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Rib fracture	>=65 years	393	56,1	1	0,3

Injury, poisoning and procedural complications	Road traffic accident	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Road traffic accident	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Skin laceration	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Skin laceration	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Spinal compression fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Sunburn	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Sunburn	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Tibia fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Tibia fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Wrist fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	>=65 years	393	56,1	2	0,5
Investigations		<65 years	308	43,9	8	2,6
Investigations		>=65 years	393	56,1	8	2,0
Investigations	Blood pressure increased	<65 years	308	43,9	0	0,0
Investigations	Blood pressure increased	>=65 years	393	56,1	2	0,5
Investigations	Blood testosterone decreased	<65 years	308	43,9	1	0,3
Investigations	Blood testosterone decreased	>=65 years	393	56,1	0	0,0
Investigations	Intraocular pressure increased	<65 years	308	43,9	6	1,9
Investigations	Intraocular pressure increased	>=65 years	393	56,1	4	1,0
Investigations	Occult blood positive	<65 years	308	43,9	0	0,0
Investigations	Occult blood positive	>=65 years	393	56,1	1	0,3
Investigations	Optic nerve cup/disc ratio increased	<65 years	308	43,9	1	0,3
Investigations	Optic nerve cup/disc ratio increased	>=65 years	393	56,1	0	0,0
Investigations	Weight decreased	<65 years	308	43,9	0	0,0
Investigations	Weight decreased	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders		<65 years	308	43,9	6	1,9
Metabolism and nutrition disorders		>=65 years	393	56,1	8	2,0
Metabolism and nutrition disorders	Dehydration	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Dehydration	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	>=65 years	393	56,1	0	0,0
Metabolism and nutrition disorders	Gout	<65 years	308	43,9	0	0,0
Metabolism and nutrition disorders	Gout	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Hypercholesterolaemia	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Hypercholesterolaemia	>=65 years	393	56,1	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	<65 years	308	43,9	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Hypoglycaemia	<65 years	308	43,9	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Hypokalaemia	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Hypokalaemia	>=65 years	393	56,1	4	1,0
Metabolism and nutrition disorders	Hyponatraemia	<65 years	308	43,9	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Type 2 diabetes mellitus	<65 years	308	43,9	2	0,6
Metabolism and nutrition disorders	Type 2 diabetes mellitus	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders		<65 years	308	43,9	6	1,9
Musculoskeletal and connective tissue disorders		>=65 years	393	56,1	10	2,5
Musculoskeletal and connective tissue disorders	Arthralgia	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	>=65 years	393	56,1	2	0,5
Musculoskeletal and connective tissue disorders	Back pain	<65 years	308	43,9	2	0,6
Musculoskeletal and connective tissue disorders	Back pain	>=65 years	393	56,1	2	0,5
Musculoskeletal and connective tissue disorders	Bone loss	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Bone loss	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Flank pain	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Flank pain	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	<65 years	308	43,9	0	0,0

Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Osteoarthritis	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Pain in extremity	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Pain in extremity	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Periarthritis	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Periarthritis	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Scoliosis	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	>=65 years	393	56,1	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=65 years	393	56,1	6	1,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	>=65 years	393	56,1	2	0,5
Nervous system disorders		<65 years	308	43,9	5	1,6
Nervous system disorders		>=65 years	393	56,1	12	3,1
Nervous system disorders	Cerebral atrophy	<65 years	308	43,9	0	0,0
Nervous system disorders	Cerebral atrophy	>=65 years	393	56,1	1	0,3
Nervous system disorders	Cerebral infarction	<65 years	308	43,9	1	0,3
Nervous system disorders	Cerebral infarction	>=65 years	393	56,1	0	0,0
Nervous system disorders	Diabetic neuropathy	<65 years	308	43,9	0	0,0
Nervous system disorders	Diabetic neuropathy	>=65 years	393	56,1	2	0,5
Nervous system disorders	Dizziness	<65 years	308	43,9	0	0,0
Nervous system disorders	Dizziness	>=65 years	393	56,1	1	0,3
Nervous system disorders	Encephalopathy	<65 years	308	43,9	0	0,0
Nervous system disorders	Encephalopathy	>=65 years	393	56,1	1	0,3
Nervous system disorders	Headache	<65 years	308	43,9	1	0,3
Nervous system disorders	Headache	>=65 years	393	56,1	1	0,3
Nervous system disorders	Ischaemic stroke	<65 years	308	43,9	0	0,0
Nervous system disorders	Ischaemic stroke	>=65 years	393	56,1	1	0,3
Nervous system disorders	Lacunar infarction	<65 years	308	43,9	0	0,0
Nervous system disorders	Lacunar infarction	>=65 years	393	56,1	1	0,3
Nervous system disorders	Loss of consciousness	<65 years	308	43,9	0	0,0
Nervous system disorders	Loss of consciousness	>=65 years	393	56,1	1	0,3
Nervous system disorders	Neuralgia	<65 years	308	43,9	1	0,3
Nervous system disorders	Neuralgia	>=65 years	393	56,1	0	0,0
Nervous system disorders	Neuropathy peripheral	<65 years	308	43,9	0	0,0
Nervous system disorders	Neuropathy peripheral	>=65 years	393	56,1	2	0,5
Nervous system disorders	Ophthalmic migraine	<65 years	308	43,9	1	0,3
Nervous system disorders	Ophthalmic migraine	>=65 years	393	56,1	0	0,0
Nervous system disorders	Sciatica	<65 years	308	43,9	1	0,3
Nervous system disorders	Sciatica	>=65 years	393	56,1	1	0,3
Nervous system disorders	Syncope	<65 years	308	43,9	0	0,0
Nervous system disorders	Syncope	>=65 years	393	56,1	2	0,5
Psychiatric disorders		<65 years	308	43,9	1	0,3
Psychiatric disorders		>=65 years	393	56,1	2	0,5
Psychiatric disorders	Anxiety	<65 years	308	43,9	0	0,0
Psychiatric disorders	Anxiety	>=65 years	393	56,1	1	0,3

Psychiatric disorders	Depression	<65 years	308	43,9	1	0,3
Psychiatric disorders	Depression	>=65 years	393	56,1	0	0,0
Psychiatric disorders	Insomnia	<65 years	308	43,9	0	0,0
Psychiatric disorders	Insomnia	>=65 years	393	56,1	1	0,3
Renal and urinary disorders		<65 years	308	43,9	3	1,0
Renal and urinary disorders		>=65 years	393	56,1	3	0,8
Renal and urinary disorders	Acute kidney injury	<65 years	308	43,9	1	0,3
Renal and urinary disorders	Acute kidney injury	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Diabetic nephropathy	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Diabetic nephropathy	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Renal failure	<65 years	308	43,9	1	0,3
Renal and urinary disorders	Renal failure	>=65 years	393	56,1	0	0,0
Renal and urinary disorders	Urinary retention	<65 years	308	43,9	1	0,3
Renal and urinary disorders	Urinary retention	>=65 years	393	56,1	0	0,0
Renal and urinary disorders	Urinary tract inflammation	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Urinary tract inflammation	>=65 years	393	56,1	1	0,3
Reproductive system and breast disorders		<65 years	308	43,9	1	0,3
Reproductive system and breast disorders		>=65 years	393	56,1	1	0,3
Reproductive system and breast disorders	Benign prostatic hyperplasia	<65 years	308	43,9	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	>=65 years	393	56,1	1	0,3
Reproductive system and breast disorders	Cystocele	<65 years	308	43,9	1	0,3
Reproductive system and breast disorders	Cystocele	>=65 years	393	56,1	0	0,0
Respiratory, thoracic and mediastinal disorders		<65 years	308	43,9	1	0,3
Respiratory, thoracic and mediastinal disorders		>=65 years	393	56,1	11	2,8
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	>=65 years	393	56,1	2	0,5
Respiratory, thoracic and mediastinal disorders	Asthma	<65 years	308	43,9	1	0,3
Respiratory, thoracic and mediastinal disorders	Asthma	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=65 years	393	56,1	5	1,3
Respiratory, thoracic and mediastinal disorders	Cough	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Dyspnoea	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Nasal polyps	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Sinus disorder	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders		<65 years	308	43,9	5	1,6
Skin and subcutaneous tissue disorders		>=65 years	393	56,1	5	1,3
Skin and subcutaneous tissue disorders	Androgenetic alopecia	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Dermatitis contact	<65 years	308	43,9	2	0,6
Skin and subcutaneous tissue disorders	Dermatitis contact	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	<65 years	308	43,9	1	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Erythema	<65 years	308	43,9	1	0,3
Skin and subcutaneous tissue disorders	Erythema	>=65 years	393	56,1	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	<65 years	308	43,9	1	0,3
Skin and subcutaneous tissue disorders	Nail bed bleeding	>=65 years	393	56,1	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Urticaria	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	>=65 years	393	56,1	1	0,3

Surgical and medical procedures		<65 years	308	43,9	3	1,0
Surgical and medical procedures		>=65 years	393	56,1	2	0,5
Surgical and medical procedures	Dental implantation	<65 years	308	43,9	2	0,6
Surgical and medical procedures	Dental implantation	>=65 years	393	56,1	0	0,0
Surgical and medical procedures	Ligament operation	<65 years	308	43,9	1	0,3
Surgical and medical procedures	Ligament operation	>=65 years	393	56,1	0	0,0
Surgical and medical procedures	Toe operation	<65 years	308	43,9	0	0,0
Surgical and medical procedures	Toe operation	>=65 years	393	56,1	1	0,3
Surgical and medical procedures	Tooth extraction	<65 years	308	43,9	0	0,0
Surgical and medical procedures	Tooth extraction	>=65 years	393	56,1	1	0,3
Vascular disorders		<65 years	308	43,9	4	1,3
Vascular disorders		>=65 years	393	56,1	13	3,3
Vascular disorders	Aortic stenosis	<65 years	308	43,9	0	0,0
Vascular disorders	Aortic stenosis	>=65 years	393	56,1	1	0,3
Vascular disorders	Hypertension	<65 years	308	43,9	3	1,0
Vascular disorders	Hypertension	>=65 years	393	56,1	8	2,0
Vascular disorders	Hypertensive crisis	<65 years	308	43,9	0	0,0
Vascular disorders	Hypertensive crisis	>=65 years	393	56,1	2	0,5
Vascular disorders	Hypotension	<65 years	308	43,9	1	0,3
Vascular disorders	Hypotension	>=65 years	393	56,1	2	0,5
Vascular disorders	Thrombosis	<65 years	308	43,9	0	0,0
Vascular disorders	Thrombosis	>=65 years	393	56,1	1	0,3

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WMODAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:08

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETRS letter score

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders		35 - 54 letters	206	29,4	2	1,0
Blood and lymphatic system disorders		>=55 letters	339	48,4	3	0,9
Blood and lymphatic system disorders	Anaemia	<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders	Anaemia	35 - 54 letters	206	29,4	2	1,0
Blood and lymphatic system disorders	Anaemia	>=55 letters	339	48,4	3	0,9
Blood and lymphatic system disorders	Mesenteric lymphadenitis	<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	35 - 54 letters	206	29,4	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	>=55 letters	339	48,4	1	0,3
Cardiac disorders		<=34 letters	156	22,3	2	1,3
Cardiac disorders		35 - 54 letters	206	29,4	6	2,9
Cardiac disorders		>=55 letters	339	48,4	7	2,1
Cardiac disorders	Acute left ventricular failure	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Acute left ventricular failure	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Acute left ventricular failure	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Aortic valve incompetence	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Aortic valve incompetence	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Aortic valve incompetence	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Arrhythmia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Arrhythmia	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Arrhythmia	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Atrial fibrillation	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Atrial fibrillation	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Atrial fibrillation	>=55 letters	339	48,4	4	1,2
Cardiac disorders	Bradycardia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Bradycardia	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Bradycardia	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Cardiomegaly	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Cardiomegaly	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Cardiomegaly	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Coronary artery stenosis	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Coronary artery stenosis	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Coronary artery stenosis	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Myocardial infarction	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Myocardial infarction	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Myocardial infarction	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Myocardial ischaemia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Myocardial ischaemia	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Myocardial ischaemia	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Palpitations	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Palpitations	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Palpitations	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Sinus tachycardia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Sinus tachycardia	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Sinus tachycardia	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Supraventricular tachycardia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Supraventricular tachycardia	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Supraventricular tachycardia	>=55 letters	339	48,4	1	0,3
Congenital, familial and genetic disorders		<=34 letters	156	22,3	1	0,6
Congenital, familial and genetic disorders		35 - 54 letters	206	29,4	0	0,0
Congenital, familial and genetic disorders		>=55 letters	339	48,4	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	<=34 letters	156	22,3	1	0,6
Congenital, familial and genetic disorders	Corneal dystrophy	35 - 54 letters	206	29,4	0	0,0

Congenital, familial and genetic disorders	Corneal dystrophy	>=55 letters	339	48,4	0	0,0
Ear and labyrinth disorders		<=34 letters	156	22,3	0	0,0
Ear and labyrinth disorders		35 - 54 letters	206	29,4	0	0,0
Ear and labyrinth disorders		>=55 letters	339	48,4	2	0,6
Ear and labyrinth disorders	Vertigo	<=34 letters	156	22,3	0	0,0
Ear and labyrinth disorders	Vertigo	35 - 54 letters	206	29,4	0	0,0
Ear and labyrinth disorders	Vertigo	>=55 letters	339	48,4	2	0,6
Endocrine disorders		<=34 letters	156	22,3	0	0,0
Endocrine disorders		35 - 54 letters	206	29,4	1	0,5
Endocrine disorders		>=55 letters	339	48,4	1	0,3
Endocrine disorders	Androgen deficiency	<=34 letters	156	22,3	0	0,0
Endocrine disorders	Androgen deficiency	35 - 54 letters	206	29,4	1	0,5
Endocrine disorders	Androgen deficiency	>=55 letters	339	48,4	0	0,0
Endocrine disorders	Hypothyroidism	<=34 letters	156	22,3	0	0,0
Endocrine disorders	Hypothyroidism	35 - 54 letters	206	29,4	0	0,0
Endocrine disorders	Hypothyroidism	>=55 letters	339	48,4	1	0,3
Eye disorders		<=34 letters	156	22,3	17	10,9
Eye disorders		35 - 54 letters	206	29,4	31	15,0
Eye disorders		>=55 letters	339	48,4	44	13,0
Eye disorders	Asthenopia	<=34 letters	156	22,3	0	0,0
Eye disorders	Asthenopia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Asthenopia	>=55 letters	339	48,4	0	0,0
Eye disorders	Blepharitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Blepharitis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Blepharitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Cataract	<=34 letters	156	22,3	4	2,6
Eye disorders	Cataract	35 - 54 letters	206	29,4	3	1,5
Eye disorders	Cataract	>=55 letters	339	48,4	3	0,9
Eye disorders	Cataract nuclear	<=34 letters	156	22,3	0	0,0
Eye disorders	Cataract nuclear	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Cataract nuclear	>=55 letters	339	48,4	1	0,3
Eye disorders	Cataract subcapsular	<=34 letters	156	22,3	0	0,0
Eye disorders	Cataract subcapsular	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Cataract subcapsular	>=55 letters	339	48,4	1	0,3
Eye disorders	Chalazion	<=34 letters	156	22,3	0	0,0
Eye disorders	Chalazion	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Chalazion	>=55 letters	339	48,4	0	0,0
Eye disorders	Choroidal effusion	<=34 letters	156	22,3	0	0,0
Eye disorders	Choroidal effusion	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Choroidal effusion	>=55 letters	339	48,4	0	0,0
Eye disorders	Conjunctival telangiectasia	<=34 letters	156	22,3	0	0,0
Eye disorders	Conjunctival telangiectasia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Conjunctival telangiectasia	>=55 letters	339	48,4	0	0,0
Eye disorders	Cystoid macular oedema	<=34 letters	156	22,3	1	0,6
Eye disorders	Cystoid macular oedema	35 - 54 letters	206	29,4	3	1,5
Eye disorders	Cystoid macular oedema	>=55 letters	339	48,4	7	2,1
Eye disorders	Dry eye	<=34 letters	156	22,3	1	0,6
Eye disorders	Dry eye	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Dry eye	>=55 letters	339	48,4	0	0,0
Eye disorders	Eczema eyelids	<=34 letters	156	22,3	0	0,0
Eye disorders	Eczema eyelids	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Eczema eyelids	>=55 letters	339	48,4	1	0,3
Eye disorders	Eye irritation	<=34 letters	156	22,3	0	0,0
Eye disorders	Eye irritation	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Eye irritation	>=55 letters	339	48,4	0	0,0
Eye disorders	Eye pain	<=34 letters	156	22,3	1	0,6
Eye disorders	Eye pain	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Eye pain	>=55 letters	339	48,4	4	1,2
Eye disorders	Glaucoma	<=34 letters	156	22,3	2	1,3
Eye disorders	Glaucoma	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Glaucoma	>=55 letters	339	48,4	4	1,2
Eye disorders	Iridocyclitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Iridocyclitis	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Iridocyclitis	>=55 letters	339	48,4	3	0,9
Eye disorders	Iris neovascularisation	<=34 letters	156	22,3	0	0,0

Eye disorders	Iris neovascularisation	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Iris neovascularisation	>=55 letters	339	48,4	0	0,0
Eye disorders	Iritis	<=34 letters	156	22,3	0	0,0
Eye disorders	Iritis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Iritis	>=55 letters	339	48,4	1	0,3
Eye disorders	Keratopathy	<=34 letters	156	22,3	0	0,0
Eye disorders	Keratopathy	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Keratopathy	>=55 letters	339	48,4	1	0,3
Eye disorders	Lacrimal disorder	<=34 letters	156	22,3	0	0,0
Eye disorders	Lacrimal disorder	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Lacrimal disorder	>=55 letters	339	48,4	1	0,3
Eye disorders	Lacrimation increased	<=34 letters	156	22,3	0	0,0
Eye disorders	Lacrimation increased	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Lacrimation increased	>=55 letters	339	48,4	1	0,3
Eye disorders	Lenticular opacities	<=34 letters	156	22,3	0	0,0
Eye disorders	Lenticular opacities	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Lenticular opacities	>=55 letters	339	48,4	0	0,0
Eye disorders	Macular degeneration	<=34 letters	156	22,3	1	0,6
Eye disorders	Macular degeneration	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Macular degeneration	>=55 letters	339	48,4	0	0,0
Eye disorders	Macular ischaemia	<=34 letters	156	22,3	0	0,0
Eye disorders	Macular ischaemia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Macular ischaemia	>=55 letters	339	48,4	0	0,0
Eye disorders	Macular oedema	<=34 letters	156	22,3	2	1,3
Eye disorders	Macular oedema	35 - 54 letters	206	29,4	4	1,9
Eye disorders	Macular oedema	>=55 letters	339	48,4	7	2,1
Eye disorders	Neovascular age-related macular degeneration	<=34 letters	156	22,3	0	0,0
Eye disorders	Neovascular age-related macular degeneration	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Neovascular age-related macular degeneration	>=55 letters	339	48,4	1	0,3
Eye disorders	Non-infectious endophthalmitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Non-infectious endophthalmitis	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Non-infectious endophthalmitis	>=55 letters	339	48,4	0	0,0
Eye disorders	Noninfective conjunctivitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Noninfective conjunctivitis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Noninfective conjunctivitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Ocular hypertension	<=34 letters	156	22,3	1	0,6
Eye disorders	Ocular hypertension	35 - 54 letters	206	29,4	3	1,5
Eye disorders	Ocular hypertension	>=55 letters	339	48,4	3	0,9
Eye disorders	Open angle glaucoma	<=34 letters	156	22,3	1	0,6
Eye disorders	Open angle glaucoma	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Open angle glaucoma	>=55 letters	339	48,4	0	0,0
Eye disorders	Optic disc haemorrhage	<=34 letters	156	22,3	0	0,0
Eye disorders	Optic disc haemorrhage	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Optic disc haemorrhage	>=55 letters	339	48,4	1	0,3
Eye disorders	Papilloedema	<=34 letters	156	22,3	0	0,0
Eye disorders	Papilloedema	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Papilloedema	>=55 letters	339	48,4	1	0,3
Eye disorders	Posterior capsule opacification	<=34 letters	156	22,3	0	0,0
Eye disorders	Posterior capsule opacification	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Posterior capsule opacification	>=55 letters	339	48,4	1	0,3
Eye disorders	Punctate keratitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Punctate keratitis	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Punctate keratitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal artery occlusion	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal artery occlusion	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal artery occlusion	>=55 letters	339	48,4	2	0,6
Eye disorders	Retinal collateral vessels	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal collateral vessels	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal collateral vessels	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal detachment	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal detachment	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal detachment	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal disorder	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal disorder	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal disorder	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal haemorrhage	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal haemorrhage	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal haemorrhage	>=55 letters	339	48,4	1	0,3

Eye disorders	Retinal ischaemia	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal ischaemia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Retinal ischaemia	>=55 letters	339	48,4	0	0,0
Eye disorders	Retinal vein occlusion	<=34 letters	156	22,3	4	2,6
Eye disorders	Retinal vein occlusion	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Retinal vein occlusion	>=55 letters	339	48,4	4	1,2
Eye disorders	Uveitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Uveitis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Uveitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Vision blurred	<=34 letters	156	22,3	0	0,0
Eye disorders	Vision blurred	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Vision blurred	>=55 letters	339	48,4	1	0,3
Eye disorders	Visual acuity reduced	<=34 letters	156	22,3	1	0,6
Eye disorders	Visual acuity reduced	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Visual acuity reduced	>=55 letters	339	48,4	1	0,3
Eye disorders	Visual impairment	<=34 letters	156	22,3	0	0,0
Eye disorders	Visual impairment	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Visual impairment	>=55 letters	339	48,4	1	0,3
Eye disorders	Vitreoretinal traction syndrome	<=34 letters	156	22,3	0	0,0
Eye disorders	Vitreoretinal traction syndrome	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Vitreoretinal traction syndrome	>=55 letters	339	48,4	1	0,3
Eye disorders	Vitreous detachment	<=34 letters	156	22,3	0	0,0
Eye disorders	Vitreous detachment	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Vitreous detachment	>=55 letters	339	48,4	1	0,3
Eye disorders	Vitreous floaters	<=34 letters	156	22,3	0	0,0
Eye disorders	Vitreous floaters	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Vitreous floaters	>=55 letters	339	48,4	1	0,3
Eye disorders	Vitreous haemorrhage	<=34 letters	156	22,3	0	0,0
Eye disorders	Vitreous haemorrhage	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Vitreous haemorrhage	>=55 letters	339	48,4	0	0,0
Eye disorders	Vitritis	<=34 letters	156	22,3	0	0,0
Eye disorders	Vitritis	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Vitritis	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders		<=34 letters	156	22,3	2	1,3
Gastrointestinal disorders		35 - 54 letters	206	29,4	6	2,9
Gastrointestinal disorders		>=55 letters	339	48,4	8	2,4
Gastrointestinal disorders	Abdominal pain	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Abdominal pain	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Abdominal pain	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Abdominal pain upper	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Abdominal pain upper	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Abdominal pain upper	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Barrett's oesophagus	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Coeliac disease	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Coeliac disease	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Coeliac disease	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Colitis	<=34 letters	156	22,3	1	0,6
Gastrointestinal disorders	Colitis	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Colitis	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Constipation	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Constipation	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Constipation	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Dental discomfort	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Dental discomfort	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Dental discomfort	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Diarrhoea	<=34 letters	156	22,3	2	1,3
Gastrointestinal disorders	Diarrhoea	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Diarrhoea	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Gastric ulcer	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Gastric ulcer	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Gastric ulcer	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Gastritis	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Gastritis	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Gastritis	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Gastrooesophageal reflux disease	<=34 letters	156	22,3	0	0,0

Gastrointestinal disorders	Gastroesophageal reflux disease	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Gastroesophageal reflux disease	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Hiatus hernia	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Hiatus hernia	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Hiatus hernia	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Ileus	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Ileus	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Ileus	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Inguinal hernia	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Inguinal hernia	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Inguinal hernia	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Large intestine polyp	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Large intestine polyp	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Large intestine polyp	>=55 letters	339	48,4	0	0,0
General disorders and administration site conditions		<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions		35 - 54 letters	206	29,4	5	2,4
General disorders and administration site conditions		>=55 letters	339	48,4	7	2,1
General disorders and administration site conditions	Asthenia	<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions	Asthenia	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Asthenia	>=55 letters	339	48,4	2	0,6
General disorders and administration site conditions	Chest pain	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Chest pain	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Chest pain	>=55 letters	339	48,4	0	0,0
General disorders and administration site conditions	Injection site pain	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Injection site pain	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Injection site pain	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Oedema peripheral	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Oedema peripheral	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Oedema peripheral	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Pain	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Pain	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Pain	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Polyp	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Polyp	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Polyp	>=55 letters	339	48,4	0	0,0
General disorders and administration site conditions	Pyrexia	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Pyrexia	35 - 54 letters	206	29,4	2	1,0
General disorders and administration site conditions	Pyrexia	>=55 letters	339	48,4	2	0,6
General disorders and administration site conditions	Systemic inflammatory response syndrome	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	>=55 letters	339	48,4	1	0,3
Hepatobiliary disorders		<=34 letters	156	22,3	1	0,6
Hepatobiliary disorders		35 - 54 letters	206	29,4	0	0,0
Hepatobiliary disorders		>=55 letters	339	48,4	2	0,6
Hepatobiliary disorders	Cholecystitis	<=34 letters	156	22,3	1	0,6
Hepatobiliary disorders	Cholecystitis	35 - 54 letters	206	29,4	0	0,0
Hepatobiliary disorders	Cholecystitis	>=55 letters	339	48,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	<=34 letters	156	22,3	0	0,0
Hepatobiliary disorders	Cholelithiasis	35 - 54 letters	206	29,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	>=55 letters	339	48,4	2	0,6
Immune system disorders		<=34 letters	156	22,3	1	0,6
Immune system disorders		35 - 54 letters	206	29,4	0	0,0
Immune system disorders		>=55 letters	339	48,4	2	0,6
Immune system disorders	Drug hypersensitivity	<=34 letters	156	22,3	0	0,0
Immune system disorders	Drug hypersensitivity	35 - 54 letters	206	29,4	0	0,0
Immune system disorders	Drug hypersensitivity	>=55 letters	339	48,4	1	0,3
Immune system disorders	Iodine allergy	<=34 letters	156	22,3	0	0,0
Immune system disorders	Iodine allergy	35 - 54 letters	206	29,4	0	0,0
Immune system disorders	Iodine allergy	>=55 letters	339	48,4	1	0,3
Immune system disorders	Seasonal allergy	<=34 letters	156	22,3	1	0,6
Immune system disorders	Seasonal allergy	35 - 54 letters	206	29,4	0	0,0
Immune system disorders	Seasonal allergy	>=55 letters	339	48,4	0	0,0
Infections and infestations		<=34 letters	156	22,3	19	12,2
Infections and infestations		35 - 54 letters	206	29,4	17	8,3

Infections and infestations		>=55 letters	339	48,4	28	8,3
Infections and infestations	Arthritis infective	<=34 letters	156	22,3	0	0,0
Infections and infestations	Arthritis infective	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Arthritis infective	>=55 letters	339	48,4	1	0,3
Infections and infestations	Bronchitis	<=34 letters	156	22,3	2	1,3
Infections and infestations	Bronchitis	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Bronchitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	COVID-19	<=34 letters	156	22,3	8	5,1
Infections and infestations	COVID-19	35 - 54 letters	206	29,4	4	1,9
Infections and infestations	COVID-19	>=55 letters	339	48,4	7	2,1
Infections and infestations	Cellulitis	<=34 letters	156	22,3	2	1,3
Infections and infestations	Cellulitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Cellulitis	>=55 letters	339	48,4	2	0,6
Infections and infestations	Conjunctivitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Conjunctivitis	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Conjunctivitis	>=55 letters	339	48,4	2	0,6
Infections and infestations	Cystitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Cystitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Cystitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Ear infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Ear infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Ear infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Fungal skin infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Fungal skin infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Fungal skin infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Helicobacter infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Helicobacter infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Helicobacter infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Herpes zoster	<=34 letters	156	22,3	0	0,0
Infections and infestations	Herpes zoster	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Herpes zoster	>=55 letters	339	48,4	1	0,3
Infections and infestations	Influenza	<=34 letters	156	22,3	3	1,9
Infections and infestations	Influenza	35 - 54 letters	206	29,4	3	1,5
Infections and infestations	influenza	>=55 letters	339	48,4	2	0,6
Infections and infestations	Kidney infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Kidney infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Kidney infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Laryngitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Laryngitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Laryngitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Nasopharyngitis	<=34 letters	156	22,3	1	0,6
Infections and infestations	Nasopharyngitis	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Nasopharyngitis	>=55 letters	339	48,4	2	0,6
Infections and infestations	Pharyngitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Pharyngitis	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Pharyngitis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Pneumonia	<=34 letters	156	22,3	2	1,3
Infections and infestations	Pneumonia	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Pneumonia	>=55 letters	339	48,4	2	0,6
Infections and infestations	Pneumonia viral	<=34 letters	156	22,3	1	0,6
Infections and infestations	Pneumonia viral	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Pneumonia viral	>=55 letters	339	48,4	0	0,0
Infections and infestations	Pulpitis dental	<=34 letters	156	22,3	0	0,0
Infections and infestations	Pulpitis dental	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Pulpitis dental	>=55 letters	339	48,4	2	0,6
Infections and infestations	Respiratory tract infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Respiratory tract infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Respiratory tract infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Respiratory tract infection viral	<=34 letters	156	22,3	0	0,0
Infections and infestations	Respiratory tract infection viral	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Respiratory tract infection viral	>=55 letters	339	48,4	0	0,0
Infections and infestations	Sinusitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Sinusitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Sinusitis	>=55 letters	339	48,4	2	0,6
Infections and infestations	Staphylococcal infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Staphylococcal infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Staphylococcal infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Suspected COVID-19	<=34 letters	156	22,3	0	0,0

Infections and infestations	Suspected COVID-19	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Suspected COVID-19	>=55 letters	339	48,4	1	0,3
Infections and infestations	Tooth abscess	<=34 letters	156	22,3	1	0,6
Infections and infestations	Tooth abscess	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Tooth abscess	>=55 letters	339	48,4	0	0,0
Infections and infestations	Upper respiratory tract infection	<=34 letters	156	22,3	2	1,3
Infections and infestations	Upper respiratory tract infection	35 - 54 letters	206	29,4	2	1,0
Infections and infestations	Upper respiratory tract infection	>=55 letters	339	48,4	5	1,5
Infections and infestations	Urinary tract infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Urinary tract infection	35 - 54 letters	206	29,4	3	1,5
Infections and infestations	Urinary tract infection	>=55 letters	339	48,4	3	0,9
Injury, poisoning and procedural complications		<=34 letters	156	22,3	7	4,5
Injury, poisoning and procedural complications		35 - 54 letters	206	29,4	3	1,5
Injury, poisoning and procedural complications		>=55 letters	339	48,4	15	4,4
Injury, poisoning and procedural complications	Arthropod bite	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Arthropod bite	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Arthropod bite	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Fall	<=34 letters	156	22,3	4	2,6
Injury, poisoning and procedural complications	Fall	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Fall	>=55 letters	339	48,4	2	0,6
Injury, poisoning and procedural complications	Femur fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Femur fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Fibula fracture	<=34 letters	156	22,3	1	0,6
Injury, poisoning and procedural complications	Fibula fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Fibula fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Fracture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Hand fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Hand fracture	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Hand fracture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Hip fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Hip fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Hip fracture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Hypobarism	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Hypobarism	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Hypobarism	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Limb injury	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Limb injury	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Limb injury	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Lower limb fracture	<=34 letters	156	22,3	1	0,6
Injury, poisoning and procedural complications	Lower limb fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Lumbar vertebral fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Muscle strain	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Muscle strain	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Muscle strain	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Posterior capsule rupture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Rib fracture	<=34 letters	156	22,3	1	0,6
Injury, poisoning and procedural complications	Rib fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Rib fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	>=55 letters	339	48,4	2	0,6
Injury, poisoning and procedural complications	Skin laceration	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Skin laceration	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Skin laceration	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Spinal compression fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	35 - 54 letters	206	29,4	0	0,0

Injury, poisoning and procedural complications	Spinal compression fracture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Sunburn	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Sunburn	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Sunburn	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Tibia fracture	<=34 letters	156	22,3	1	0,6
Injury, poisoning and procedural complications	Tibia fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Wrist fracture	<=34 letters	156	22,3	1	0,6
Injury, poisoning and procedural complications	Wrist fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	>=55 letters	339	48,4	1	0,3
Investigations		<=34 letters	156	22,3	1	0,6
Investigations		35 - 54 letters	206	29,4	3	1,5
Investigations		>=55 letters	339	48,4	12	3,5
Investigations	Blood pressure increased	<=34 letters	156	22,3	0	0,0
Investigations	Blood pressure increased	35 - 54 letters	206	29,4	1	0,5
Investigations	Blood pressure increased	>=55 letters	339	48,4	1	0,3
Investigations	Blood testosterone decreased	<=34 letters	156	22,3	0	0,0
Investigations	Blood testosterone decreased	35 - 54 letters	206	29,4	0	0,0
Investigations	Blood testosterone decreased	>=55 letters	339	48,4	1	0,3
Investigations	Intraocular pressure increased	<=34 letters	156	22,3	1	0,6
Investigations	Intraocular pressure increased	35 - 54 letters	206	29,4	1	0,5
Investigations	Intraocular pressure increased	>=55 letters	339	48,4	8	2,4
Investigations	Occult blood positive	<=34 letters	156	22,3	0	0,0
Investigations	Occult blood positive	35 - 54 letters	206	29,4	0	0,0
Investigations	Occult blood positive	>=55 letters	339	48,4	1	0,3
Investigations	Optic nerve cup/disc ratio increased	<=34 letters	156	22,3	0	0,0
Investigations	Optic nerve cup/disc ratio increased	35 - 54 letters	206	29,4	1	0,5
Investigations	Optic nerve cup/disc ratio increased	>=55 letters	339	48,4	0	0,0
Investigations	Weight decreased	<=34 letters	156	22,3	0	0,0
Investigations	Weight decreased	35 - 54 letters	206	29,4	0	0,0
Investigations	Weight decreased	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders		<=34 letters	156	22,3	2	1,3
Metabolism and nutrition disorders		35 - 54 letters	206	29,4	4	1,9
Metabolism and nutrition disorders		>=55 letters	339	48,4	8	2,4
Metabolism and nutrition disorders	Dehydration	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Dehydration	35 - 54 letters	206	29,4	1	0,5
Metabolism and nutrition disorders	Dehydration	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Gout	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Gout	35 - 54 letters	206	29,4	1	0,5
Metabolism and nutrition disorders	Gout	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Hypercholesterolaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	35 - 54 letters	206	29,4	1	0,5
Metabolism and nutrition disorders	Hyperglycaemia	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Hypokalaemia	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Hypokalaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	>=55 letters	339	48,4	4	1,2
Metabolism and nutrition disorders	Hyponatraemia	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	>=55 letters	339	48,4	1	0,3
Metabolism and nutrition disorders	Type 2 diabetes mellitus	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	35 - 54 letters	206	29,4	1	0,5
Metabolism and nutrition disorders	Type 2 diabetes mellitus	>=55 letters	339	48,4	1	0,3
Musculoskeletal and connective tissue disorders		<=34 letters	156	22,3	2	1,3

Musculoskeletal and connective tissue disorders		35 - 54 letters	206	29,4	5	2,4
Musculoskeletal and connective tissue disorders		>=55 letters	339	48,4	9	2,7
Musculoskeletal and connective tissue disorders	Arthralgia	<=34 letters	156	22,3	1	0,6
Musculoskeletal and connective tissue disorders	Arthralgia	35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders	Arthralgia	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	>=55 letters	339	48,4	4	1,2
Musculoskeletal and connective tissue disorders	Bone loss	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders	Bone loss	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	>=55 letters	339	48,4	1	0,3
Musculoskeletal and connective tissue disorders	Flank pain	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Flank pain	35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders	Flank pain	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	>=55 letters	339	48,4	1	0,3
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	<=34 letters	156	22,3	1	0,6
Musculoskeletal and connective tissue disorders	Osteoarthritis	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	>=55 letters	339	48,4	2	0,6
Musculoskeletal and connective tissue disorders	Periarthritis	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	>=55 letters	339	48,4	1	0,3
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	<=34 letters	156	22,3	1	0,6
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders	Scoliosis	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	>=55 letters	339	48,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=34 letters	156	22,3	3	1,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=55 letters	339	48,4	3	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	<=34 letters	156	22,3	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	<=34 letters	156	22,3	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	>=55 letters	339	48,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	>=55 letters	339	48,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	<=34 letters	156	22,3	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	>=55 letters	339	48,4	1	0,3
Nervous system disorders		<=34 letters	156	22,3	6	3,8
Nervous system disorders		35 - 54 letters	206	29,4	6	2,9
Nervous system disorders		>=55 letters	339	48,4	5	1,5
Nervous system disorders	Cerebral atrophy	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Cerebral atrophy	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Cerebral atrophy	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Cerebral infarction	<=34 letters	156	22,3	1	0,6

Nervous system disorders	Cerebral infarction	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Cerebral infarction	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Diabetic neuropathy	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Diabetic neuropathy	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Diabetic neuropathy	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Dizziness	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Dizziness	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Dizziness	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Encephalopathy	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Encephalopathy	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Encephalopathy	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Headache	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Headache	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Headache	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Ischaemic stroke	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Ischaemic stroke	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Ischaemic stroke	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Lacunar infarction	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Lacunar infarction	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Lacunar infarction	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Loss of consciousness	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Loss of consciousness	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Loss of consciousness	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Neuralgia	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Neuralgia	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Neuralgia	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Neuropathy peripheral	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Neuropathy peripheral	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Neuropathy peripheral	>=55 letters	339	48,4	2	0,6
Nervous system disorders	Ophthalmic migraine	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Ophthalmic migraine	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Ophthalmic migraine	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Sciatica	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Sciatica	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Sciatica	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Syncope	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Syncope	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Syncope	>=55 letters	339	48,4	1	0,3
Psychiatric disorders		<=34 letters	156	22,3	2	1,3
Psychiatric disorders		35 - 54 letters	206	29,4	0	0,0
Psychiatric disorders		>=55 letters	339	48,4	1	0,3
Psychiatric disorders	Anxiety	<=34 letters	156	22,3	0	0,0
Psychiatric disorders	Anxiety	35 - 54 letters	206	29,4	0	0,0
Psychiatric disorders	Anxiety	>=55 letters	339	48,4	1	0,3
Psychiatric disorders	Depression	<=34 letters	156	22,3	1	0,6
Psychiatric disorders	Depression	35 - 54 letters	206	29,4	0	0,0
Psychiatric disorders	Depression	>=55 letters	339	48,4	0	0,0
Psychiatric disorders	Insomnia	<=34 letters	156	22,3	1	0,6
Psychiatric disorders	Insomnia	35 - 54 letters	206	29,4	0	0,0
Psychiatric disorders	Insomnia	>=55 letters	339	48,4	0	0,0
Renal and urinary disorders		<=34 letters	156	22,3	0	0,0
Renal and urinary disorders		35 - 54 letters	206	29,4	2	1,0
Renal and urinary disorders		>=55 letters	339	48,4	4	1,2
Renal and urinary disorders	Acute kidney injury	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Acute kidney injury	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Acute kidney injury	>=55 letters	339	48,4	2	0,6
Renal and urinary disorders	Diabetic nephropathy	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Diabetic nephropathy	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Diabetic nephropathy	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Renal failure	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Renal failure	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Renal failure	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Urinary retention	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Urinary retention	35 - 54 letters	206	29,4	1	0,5
Renal and urinary disorders	Urinary retention	>=55 letters	339	48,4	0	0,0
Renal and urinary disorders	Urinary tract inflammation	<=34 letters	156	22,3	0	0,0

Renal and urinary disorders	Urinary tract inflammation	35 - 54 letters	206	29,4	1	0,5
Renal and urinary disorders	Urinary tract inflammation	>=55 letters	339	48,4	0	0,0
Reproductive system and breast disorders		<=34 letters	156	22,3	1	0,6
Reproductive system and breast disorders		35 - 54 letters	206	29,4	0	0,0
Reproductive system and breast disorders		>=55 letters	339	48,4	1	0,3
Reproductive system and breast disorders	Benign prostatic hyperplasia	<=34 letters	156	22,3	1	0,6
Reproductive system and breast disorders	Benign prostatic hyperplasia	35 - 54 letters	206	29,4	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	>=55 letters	339	48,4	0	0,0
Reproductive system and breast disorders	Cystocele	<=34 letters	156	22,3	0	0,0
Reproductive system and breast disorders	Cystocele	35 - 54 letters	206	29,4	0	0,0
Reproductive system and breast disorders	Cystocele	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders		<=34 letters	156	22,3	6	3,8
Respiratory, thoracic and mediastinal disorders		35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders		>=55 letters	339	48,4	5	1,5
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Asthma	<=34 letters	156	22,3	2	1,3
Respiratory, thoracic and mediastinal disorders	Asthma	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Asthma	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=55 letters	339	48,4	3	0,9
Respiratory, thoracic and mediastinal disorders	Cough	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Cough	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Dyspnoea	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders		<=34 letters	156	22,3	4	2,6
Skin and subcutaneous tissue disorders		35 - 54 letters	206	29,4	2	1,0
Skin and subcutaneous tissue disorders		>=55 letters	339	48,4	4	1,2
Skin and subcutaneous tissue disorders	Androgenetic alopecia	<=34 letters	156	22,3	1	0,6
Skin and subcutaneous tissue disorders	Androgenetic alopecia	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	35 - 54 letters	206	29,4	1	0,5
Skin and subcutaneous tissue disorders	Dermatitis	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	<=34 letters	156	22,3	3	1,9
Skin and subcutaneous tissue disorders	Dermatitis contact	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	>=55 letters	339	48,4	2	0,6
Skin and subcutaneous tissue disorders	Erythema	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Erythema	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Erythema	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Nail bed bleeding	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Nail dystrophy	<=34 letters	156	22,3	1	0,6
Skin and subcutaneous tissue disorders	Nail dystrophy	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	>=55 letters	339	48,4	0	0,0

Skin and subcutaneous tissue disorders	Urticaria	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	35 - 54 letters	206	29,4	1	0,5
Skin and subcutaneous tissue disorders	Urticaria	>=55 letters	339	48,4	0	0,0
Surgical and medical procedures		<=34 letters	156	22,3	0	0,0
Surgical and medical procedures		35 - 54 letters	206	29,4	2	1,0
Surgical and medical procedures		>=55 letters	339	48,4	3	0,9
Surgical and medical procedures	Dental implantation	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Dental implantation	35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures	Dental implantation	>=55 letters	339	48,4	2	0,6
Surgical and medical procedures	Ligament operation	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Ligament operation	35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures	Ligament operation	>=55 letters	339	48,4	1	0,3
Surgical and medical procedures	Toe operation	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Toe operation	35 - 54 letters	206	29,4	1	0,5
Surgical and medical procedures	Toe operation	>=55 letters	339	48,4	0	0,0
Surgical and medical procedures	Tooth extraction	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Tooth extraction	35 - 54 letters	206	29,4	1	0,5
Surgical and medical procedures	Tooth extraction	>=55 letters	339	48,4	0	0,0
Vascular disorders		<=34 letters	156	22,3	4	2,6
Vascular disorders		35 - 54 letters	206	29,4	3	1,5
Vascular disorders		>=55 letters	339	48,4	10	2,9
Vascular disorders	Aortic stenosis	<=34 letters	156	22,3	0	0,0
Vascular disorders	Aortic stenosis	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Aortic stenosis	>=55 letters	339	48,4	1	0,3
Vascular disorders	Hypertension	<=34 letters	156	22,3	2	1,3
Vascular disorders	Hypertension	35 - 54 letters	206	29,4	3	1,5
Vascular disorders	Hypertension	>=55 letters	339	48,4	6	1,8
Vascular disorders	Hypertensive crisis	<=34 letters	156	22,3	0	0,0
Vascular disorders	Hypertensive crisis	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Hypertensive crisis	>=55 letters	339	48,4	2	0,6
Vascular disorders	Hypotension	<=34 letters	156	22,3	1	0,6
Vascular disorders	Hypotension	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Hypotension	>=55 letters	339	48,4	2	0,6
Vascular disorders	Thrombosis	<=34 letters	156	22,3	1	0,6
Vascular disorders	Thrombosis	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Thrombosis	>=55 letters	339	48,4	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WM0DAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:08

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AES
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETDRS letter score

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders		>=24 letters	632	90,2	5	0,8
Blood and lymphatic system disorders	Anaemia	<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders	Anaemia	>=24 letters	632	90,2	5	0,8
Blood and lymphatic system disorders	Mesenteric lymphadenitis	<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	>=24 letters	632	90,2	1	0,2
Cardiac disorders		<=23 letters	69	9,8	2	2,9
Cardiac disorders		>=24 letters	632	90,2	13	2,1
Cardiac disorders	Acute left ventricular failure	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Acute left ventricular failure	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Aortic valve incompetence	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Aortic valve incompetence	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Arrhythmia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Arrhythmia	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Atrial fibrillation	<=23 letters	69	9,8	1	1,4
Cardiac disorders	Atrial fibrillation	>=24 letters	632	90,2	4	0,6
Cardiac disorders	Bradycardia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Bradycardia	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Cardiomegaly	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Cardiomegaly	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Coronary artery stenosis	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Coronary artery stenosis	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Myocardial infarction	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Myocardial infarction	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Myocardial ischaemia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Myocardial ischaemia	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Palpitations	<=23 letters	69	9,8	1	1,4
Cardiac disorders	Palpitations	>=24 letters	632	90,2	0	0,0
Cardiac disorders	Sinus tachycardia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Sinus tachycardia	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Supraventricular tachycardia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Supraventricular tachycardia	>=24 letters	632	90,2	1	0,2
Congenital, familial and genetic disorders		<=23 letters	69	9,8	0	0,0
Congenital, familial and genetic disorders		>=24 letters	632	90,2	1	0,2
Congenital, familial and genetic disorders	Corneal dystrophy	<=23 letters	69	9,8	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	>=24 letters	632	90,2	1	0,2
Ear and labyrinth disorders		<=23 letters	69	9,8	0	0,0
Ear and labyrinth disorders		>=24 letters	632	90,2	2	0,3
Ear and labyrinth disorders	Vertigo	<=23 letters	69	9,8	0	0,0
Ear and labyrinth disorders	Vertigo	>=24 letters	632	90,2	2	0,3
Endocrine disorders		<=23 letters	69	9,8	0	0,0
Endocrine disorders		>=24 letters	632	90,2	2	0,3
Endocrine disorders	Androgen deficiency	<=23 letters	69	9,8	0	0,0
Endocrine disorders	Androgen deficiency	>=24 letters	632	90,2	1	0,2
Endocrine disorders	Hypothyroidism	<=23 letters	69	9,8	0	0,0
Endocrine disorders	Hypothyroidism	>=24 letters	632	90,2	1	0,2

Eye disorders		<=23 letters	69	9,8	10	14,5
Eye disorders		>=24 letters	632	90,2	82	13,0
Eye disorders	Asthenopia	<=23 letters	69	9,8	0	0,0
Eye disorders	Asthenopia	>=24 letters	632	90,2	1	0,2
Eye disorders	Blepharitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Blepharitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Cataract	<=23 letters	69	9,8	3	4,3
Eye disorders	Cataract	>=24 letters	632	90,2	7	1,1
Eye disorders	Cataract nuclear	<=23 letters	69	9,8	0	0,0
Eye disorders	Cataract nuclear	>=24 letters	632	90,2	1	0,2
Eye disorders	Cataract subcapsular	<=23 letters	69	9,8	0	0,0
Eye disorders	Cataract subcapsular	>=24 letters	632	90,2	1	0,2
Eye disorders	Chalazion	<=23 letters	69	9,8	0	0,0
Eye disorders	Chalazion	>=24 letters	632	90,2	1	0,2
Eye disorders	Choroidal effusion	<=23 letters	69	9,8	0	0,0
Eye disorders	Choroidal effusion	>=24 letters	632	90,2	1	0,2
Eye disorders	Conjunctival telangiectasia	<=23 letters	69	9,8	0	0,0
Eye disorders	Conjunctival telangiectasia	>=24 letters	632	90,2	1	0,2
Eye disorders	Cystoid macular oedema	<=23 letters	69	9,8	1	1,4
Eye disorders	Cystoid macular oedema	>=24 letters	632	90,2	10	1,6
Eye disorders	Dry eye	<=23 letters	69	9,8	0	0,0
Eye disorders	Dry eye	>=24 letters	632	90,2	2	0,3
Eye disorders	Eczeema eyelids	<=23 letters	69	9,8	0	0,0
Eye disorders	Eczeema eyelids	>=24 letters	632	90,2	1	0,2
Eye disorders	Eye irritation	<=23 letters	69	9,8	0	0,0
Eye disorders	Eye irritation	>=24 letters	632	90,2	1	0,2
Eye disorders	Eye pain	<=23 letters	69	9,8	0	0,0
Eye disorders	Eye pain	>=24 letters	632	90,2	6	0,9
Eye disorders	Glaucoma	<=23 letters	69	9,8	1	1,4
Eye disorders	Glaucoma	>=24 letters	632	90,2	7	1,1
Eye disorders	Iridocyclitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Iridocyclitis	>=24 letters	632	90,2	4	0,6
Eye disorders	Iris neovascularisation	<=23 letters	69	9,8	0	0,0
Eye disorders	Iris neovascularisation	>=24 letters	632	90,2	1	0,2
Eye disorders	Iritis	<=23 letters	69	9,8	0	0,0
Eye disorders	Iritis	>=24 letters	632	90,2	1	0,2
Eye disorders	Keratopathy	<=23 letters	69	9,8	0	0,0
Eye disorders	Keratopathy	>=24 letters	632	90,2	1	0,2
Eye disorders	Lacrimal disorder	<=23 letters	69	9,8	0	0,0
Eye disorders	Lacrimal disorder	>=24 letters	632	90,2	1	0,2
Eye disorders	Lacrimation increased	<=23 letters	69	9,8	0	0,0
Eye disorders	Lacrimation increased	>=24 letters	632	90,2	2	0,3
Eye disorders	Lenticular opacities	<=23 letters	69	9,8	0	0,0
Eye disorders	Lenticular opacities	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular degeneration	<=23 letters	69	9,8	1	1,4
Eye disorders	Macular degeneration	>=24 letters	632	90,2	0	0,0
Eye disorders	Macular ischaemia	<=23 letters	69	9,8	0	0,0
Eye disorders	Macular ischaemia	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular oedema	<=23 letters	69	9,8	1	1,4
Eye disorders	Macular oedema	>=24 letters	632	90,2	12	1,9
Eye disorders	Neovascular age-related macular degeneration	<=23 letters	69	9,8	0	0,0
Eye disorders	Neovascular age-related macular degeneration	>=24 letters	632	90,2	1	0,2
Eye disorders	Non-infectious endophthalmitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Non-infectious endophthalmitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Noninfective conjunctivitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Noninfective conjunctivitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Ocular hypertension	<=23 letters	69	9,8	1	1,4
Eye disorders	Ocular hypertension	>=24 letters	632	90,2	6	0,9
Eye disorders	Open angle glaucoma	<=23 letters	69	9,8	1	1,4
Eye disorders	Open angle glaucoma	>=24 letters	632	90,2	0	0,0
Eye disorders	Optic disc haemorrhage	<=23 letters	69	9,8	0	0,0
Eye disorders	Optic disc haemorrhage	>=24 letters	632	90,2	2	0,3
Eye disorders	Papilloedema	<=23 letters	69	9,8	0	0,0
Eye disorders	Papilloedema	>=24 letters	632	90,2	1	0,2

Eye disorders	Posterior capsule opacification	<=23 letters	69	9,8	0	0,0
Eye disorders	Posterior capsule opacification	>=24 letters	632	90,2	3	0,5
Eye disorders	Punctate keratitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Punctate keratitis	>=24 letters	632	90,2	2	0,3
Eye disorders	Retinal artery occlusion	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal artery occlusion	>=24 letters	632	90,2	2	0,3
Eye disorders	Retinal collateral vessels	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal collateral vessels	>=24 letters	632	90,2	2	0,3
Eye disorders	Retinal detachment	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal detachment	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal disorder	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal disorder	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal haemorrhage	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal haemorrhage	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal ischaemia	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal ischaemia	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal vein occlusion	<=23 letters	69	9,8	3	4,3
Eye disorders	Retinal vein occlusion	>=24 letters	632	90,2	6	0,9
Eye disorders	Uveitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Uveitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Vision blurred	<=23 letters	69	9,8	0	0,0
Eye disorders	Vision blurred	>=24 letters	632	90,2	1	0,2
Eye disorders	Visual acuity reduced	<=23 letters	69	9,8	0	0,0
Eye disorders	Visual acuity reduced	>=24 letters	632	90,2	4	0,6
Eye disorders	Visual impairment	<=23 letters	69	9,8	0	0,0
Eye disorders	Visual impairment	>=24 letters	632	90,2	1	0,2
Eye disorders	Vitreoretinal traction syndrome	<=23 letters	69	9,8	0	0,0
Eye disorders	Vitreoretinal traction syndrome	>=24 letters	632	90,2	1	0,2
Eye disorders	Vitreous detachment	<=23 letters	69	9,8	0	0,0
Eye disorders	Vitreous detachment	>=24 letters	632	90,2	1	0,2
Eye disorders	Vitreous floaters	<=23 letters	69	9,8	0	0,0
Eye disorders	Vitreous floaters	>=24 letters	632	90,2	1	0,2
Eye disorders	Vitreous haemorrhage	<=23 letters	69	9,8	0	0,0
Eye disorders	Vitreous haemorrhage	>=24 letters	632	90,2	1	0,2
Eye disorders	Vitritis	<=23 letters	69	9,8	0	0,0
Eye disorders	Vitritis	>=24 letters	632	90,2	2	0,3
Gastrointestinal disorders		<=23 letters	69	9,8	1	1,4
Gastrointestinal disorders		>=24 letters	632	90,2	15	2,4
Gastrointestinal disorders	Abdominal pain	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Abdominal pain	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Abdominal pain upper	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Abdominal pain upper	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Barrett's oesophagus	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Coeliac disease	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Coeliac disease	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Colitis	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Colitis	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Constipation	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Constipation	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Dental discomfort	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Dental discomfort	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Diarrhoea	<=23 letters	69	9,8	1	1,4
Gastrointestinal disorders	Diarrhoea	>=24 letters	632	90,2	2	0,3
Gastrointestinal disorders	Gastric ulcer	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastric ulcer	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Gastritis	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastritis	>=24 letters	632	90,2	2	0,3
Gastrointestinal disorders	Gastrooesophageal reflux disease	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Hiatus hernia	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Hiatus hernia	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Ileus	<=23 letters	69	9,8	0	0,0

Gastrointestinal disorders	Ileus	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Inguinal hernia	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Inguinal hernia	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Large intestine polyp	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Large intestine polyp	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions		<=23 letters	69	9,8	1	1,4
General disorders and administration site conditions		>=24 letters	632	90,2	12	1,9
General disorders and administration site conditions	Asthenia	<=23 letters	69	9,8	1	1,4
General disorders and administration site conditions	Asthenia	>=24 letters	632	90,2	3	0,5
General disorders and administration site conditions	Chest pain	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Chest pain	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Injection site pain	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Injection site pain	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Oedema peripheral	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Oedema peripheral	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Pain	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Pain	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Polyp	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Polyp	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Pyrexia	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Pyrexia	>=24 letters	632	90,2	4	0,6
General disorders and administration site conditions	Systemic inflammatory response syndrome	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	>=24 letters	632	90,2	1	0,2
Hepatobiliary disorders		<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders		>=24 letters	632	90,2	3	0,5
Hepatobiliary disorders	Cholecystitis	<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders	Cholecystitis	>=24 letters	632	90,2	1	0,2
Hepatobiliary disorders	Cholelithiasis	<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders	Cholelithiasis	>=24 letters	632	90,2	2	0,3
Immune system disorders		<=23 letters	69	9,8	0	0,0
Immune system disorders		>=24 letters	632	90,2	3	0,5
Immune system disorders	Drug hypersensitivity	<=23 letters	69	9,8	0	0,0
Immune system disorders	Drug hypersensitivity	>=24 letters	632	90,2	1	0,2
Immune system disorders	Iodine allergy	<=23 letters	69	9,8	0	0,0
Immune system disorders	Iodine allergy	>=24 letters	632	90,2	1	0,2
Immune system disorders	Seasonal allergy	<=23 letters	69	9,8	0	0,0
Immune system disorders	Seasonal allergy	>=24 letters	632	90,2	1	0,2
Infections and infestations		<=23 letters	69	9,8	8	11,6
Infections and infestations		>=24 letters	632	90,2	56	8,9
Infections and infestations	Arthritis infective	<=23 letters	69	9,8	0	0,0
Infections and infestations	Arthritis infective	>=24 letters	632	90,2	1	0,2
Infections and infestations	Bronchitis	<=23 letters	69	9,8	1	1,4
Infections and infestations	Bronchitis	>=24 letters	632	90,2	3	0,5
Infections and infestations	COVID-19	<=23 letters	69	9,8	4	5,8
Infections and infestations	COVID-19	>=24 letters	632	90,2	15	2,4
Infections and infestations	Cellulitis	<=23 letters	69	9,8	1	1,4
Infections and infestations	Cellulitis	>=24 letters	632	90,2	3	0,5
Infections and infestations	Conjunctivitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Conjunctivitis	>=24 letters	632	90,2	3	0,5
Infections and infestations	Cystitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Cystitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Ear infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Ear infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Fungal skin infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Fungal skin infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Helicobacter infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Helicobacter infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Herpes zoster	<=23 letters	69	9,8	0	0,0
Infections and infestations	Herpes zoster	>=24 letters	632	90,2	2	0,3
Infections and infestations	Influenza	<=23 letters	69	9,8	2	2,9

Infections and infestations	Influenza	>=24 letters	632	90,2	6	0,9
Infections and infestations	Kidney infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Kidney infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Laryngitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Laryngitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Nasopharyngitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Nasopharyngitis	>=24 letters	632	90,2	4	0,6
Infections and infestations	Pharyngitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Pharyngitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Pneumonia	<=23 letters	69	9,8	2	2,9
Infections and infestations	Pneumonia	>=24 letters	632	90,2	3	0,5
Infections and infestations	Pneumonia viral	<=23 letters	69	9,8	1	1,4
Infections and infestations	Pneumonia viral	>=24 letters	632	90,2	0	0,0
Infections and infestations	Pulpitis dental	<=23 letters	69	9,8	0	0,0
Infections and infestations	Pulpitis dental	>=24 letters	632	90,2	2	0,3
Infections and infestations	Respiratory tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Respiratory tract infection	>=24 letters	632	90,2	2	0,3
Infections and infestations	Respiratory tract infection viral	<=23 letters	69	9,8	0	0,0
Infections and infestations	Respiratory tract infection viral	>=24 letters	632	90,2	1	0,2
Infections and infestations	Sinusitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Sinusitis	>=24 letters	632	90,2	2	0,3
Infections and infestations	Staphylococcal infection	<=23 letters	69	9,8	1	1,4
Infections and infestations	Staphylococcal infection	>=24 letters	632	90,2	0	0,0
Infections and infestations	Suspected COVID-19	<=23 letters	69	9,8	0	0,0
Infections and infestations	Suspected COVID-19	>=24 letters	632	90,2	1	0,2
Infections and infestations	Tooth abscess	<=23 letters	69	9,8	1	1,4
Infections and infestations	Tooth abscess	>=24 letters	632	90,2	0	0,0
Infections and infestations	Upper respiratory tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Upper respiratory tract infection	>=24 letters	632	90,2	9	1,4
Infections and infestations	Urinary tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Urinary tract infection	>=24 letters	632	90,2	7	1,1
Injury, poisoning and procedural complications		<=23 letters	69	9,8	3	4,3
Injury, poisoning and procedural complications		>=24 letters	632	90,2	22	3,5
Injury, poisoning and procedural complications	Arthropod bite	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Arthropod bite	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Fall	<=23 letters	69	9,8	2	2,9
Injury, poisoning and procedural complications	Fall	>=24 letters	632	90,2	4	0,6
Injury, poisoning and procedural complications	Femur fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Fibula fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Fibula fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Foreign body in eye	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Hand fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Hand fracture	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Hip fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Hip fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Hypobarism	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Hypobarism	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Limb injury	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Limb injury	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Lower limb fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Lumbar vertebral fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Muscle strain	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Muscle strain	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Posterior capsule rupture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Rib fracture	<=23 letters	69	9,8	1	1,4
Injury, poisoning and procedural complications	Rib fracture	>=24 letters	632	90,2	0	0,0

Injury, poisoning and procedural complications	Road traffic accident	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Skin laceration	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Skin laceration	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Spinal compression fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Sunburn	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Sunburn	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Tibia fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Tooth fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Wrist fracture	<=23 letters	69	9,8	1	1,4
Injury, poisoning and procedural complications	Wrist fracture	>=24 letters	632	90,2	1	0,2
Investigations		<=23 letters	69	9,8	1	1,4
Investigations		>=24 letters	632	90,2	15	2,4
Investigations	Blood pressure increased	<=23 letters	69	9,8	0	0,0
Investigations	Blood pressure increased	>=24 letters	632	90,2	2	0,3
Investigations	Blood testosterone decreased	<=23 letters	69	9,8	0	0,0
Investigations	Blood testosterone decreased	>=24 letters	632	90,2	1	0,2
Investigations	Intraocular pressure increased	<=23 letters	69	9,8	1	1,4
Investigations	Intraocular pressure increased	>=24 letters	632	90,2	9	1,4
Investigations	Occult blood positive	<=23 letters	69	9,8	0	0,0
Investigations	Occult blood positive	>=24 letters	632	90,2	1	0,2
Investigations	Optic nerve cup/disc ratio increased	<=23 letters	69	9,8	0	0,0
Investigations	Optic nerve cup/disc ratio increased	>=24 letters	632	90,2	1	0,2
Investigations	Weight decreased	<=23 letters	69	9,8	0	0,0
Investigations	Weight decreased	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders		<=23 letters	69	9,8	1	1,4
Metabolism and nutrition disorders		>=24 letters	632	90,2	13	2,1
Metabolism and nutrition disorders	Dehydration	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Dehydration	>=24 letters	632	90,2	2	0,3
Metabolism and nutrition disorders	Glucose tolerance impaired	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Gout	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Gout	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hypercholesterolaemia	<=23 letters	69	9,8	1	1,4
Metabolism and nutrition disorders	Hypercholesterolaemia	>=24 letters	632	90,2	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hypoglycaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hypokalaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	>=24 letters	632	90,2	5	0,8
Metabolism and nutrition disorders	Hyponatraemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Type 2 diabetes mellitus	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	>=24 letters	632	90,2	2	0,3
Musculoskeletal and connective tissue disorders		<=23 letters	69	9,8	1	1,4
Musculoskeletal and connective tissue disorders		>=24 letters	632	90,2	15	2,4
Musculoskeletal and connective tissue disorders	Arthralgia	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	>=24 letters	632	90,2	2	0,3
Musculoskeletal and connective tissue disorders	Back pain	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	>=24 letters	632	90,2	4	0,6
Musculoskeletal and connective tissue disorders	Bone loss	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Bursitis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Flank pain	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Flank pain	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	<=23 letters	69	9,8	0	0,0

Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Osteoarthritis	<=23 letters	69	9,8	1	1,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=24 letters	632	90,2	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	>=24 letters	632	90,2	2	0,3
Musculoskeletal and connective tissue disorders	Periarthritis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Scoliosis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=24 letters	632	90,2	6	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	>=24 letters	632	90,2	2	0,3
Nervous system disorders		<=23 letters	69	9,8	1	1,4
Nervous system disorders		>=24 letters	632	90,2	16	2,5
Nervous system disorders	Cerebral atrophy	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cerebral atrophy	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Cerebral infarction	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cerebral infarction	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Diabetic neuropathy	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Diabetic neuropathy	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Dizziness	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Dizziness	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Encephalopathy	<=23 letters	69	9,8	1	1,4
Nervous system disorders	Encephalopathy	>=24 letters	632	90,2	0	0,0
Nervous system disorders	Headache	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Headache	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Ischaemic stroke	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Ischaemic stroke	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Lacunar infarction	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Lacunar infarction	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Loss of consciousness	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Loss of consciousness	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Neuralgia	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Neuralgia	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Neuropathy peripheral	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Neuropathy peripheral	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Ophthalmic migraine	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Ophthalmic migraine	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Sciatica	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Sciatica	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Syncope	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Syncope	>=24 letters	632	90,2	2	0,3
Psychiatric disorders		<=23 letters	69	9,8	1	1,4
Psychiatric disorders		>=24 letters	632	90,2	2	0,3
Psychiatric disorders	Anxiety	<=23 letters	69	9,8	0	0,0
Psychiatric disorders	Anxiety	>=24 letters	632	90,2	1	0,2

Psychiatric disorders	Depression	<=23 letters	69	9,8	0	0,0
Psychiatric disorders	Depression	>=24 letters	632	90,2	1	0,2
Psychiatric disorders	Insomnia	<=23 letters	69	9,8	1	1,4
Psychiatric disorders	Insomnia	>=24 letters	632	90,2	0	0,0
Renal and urinary disorders		<=23 letters	69	9,8	0	0,0
Renal and urinary disorders		>=24 letters	632	90,2	6	0,9
Renal and urinary disorders	Acute kidney injury	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Acute kidney injury	>=24 letters	632	90,2	2	0,3
Renal and urinary disorders	Diabetic nephropathy	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Diabetic nephropathy	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Renal failure	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Renal failure	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Urinary retention	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Urinary retention	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Urinary tract inflammation	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Urinary tract inflammation	>=24 letters	632	90,2	1	0,2
Reproductive system and breast disorders		<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders		>=24 letters	632	90,2	2	0,3
Reproductive system and breast disorders	Benign prostatic hyperplasia	<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	>=24 letters	632	90,2	1	0,2
Reproductive system and breast disorders	Cystocele	<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders	Cystocele	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders		<=23 letters	69	9,8	4	5,8
Respiratory, thoracic and mediastinal disorders		>=24 letters	632	90,2	8	1,3
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	<=23 letters	69	9,8	1	1,4
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Asthma	<=23 letters	69	9,8	2	2,9
Respiratory, thoracic and mediastinal disorders	Asthma	>=24 letters	632	90,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<=23 letters	69	9,8	1	1,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=24 letters	632	90,2	4	0,6
Respiratory, thoracic and mediastinal disorders	Cough	<=23 letters	69	9,8	1	1,4
Respiratory, thoracic and mediastinal disorders	Cough	>=24 letters	632	90,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Nasal polyps	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Sinus disorder	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders		<=23 letters	69	9,8	2	2,9
Skin and subcutaneous tissue disorders		>=24 letters	632	90,2	8	1,3
Skin and subcutaneous tissue disorders	Androgenetic alopecia	<=23 letters	69	9,8	1	1,4
Skin and subcutaneous tissue disorders	Androgenetic alopecia	>=24 letters	632	90,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Dermatitis contact	<=23 letters	69	9,8	1	1,4
Skin and subcutaneous tissue disorders	Dermatitis contact	>=24 letters	632	90,2	2	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	>=24 letters	632	90,2	2	0,3
Skin and subcutaneous tissue disorders	Erythema	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Erythema	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Nail bed bleeding	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Nail dystrophy	<=23 letters	69	9,8	1	1,4
Skin and subcutaneous tissue disorders	Nail dystrophy	>=24 letters	632	90,2	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	>=24 letters	632	90,2	1	0,2

Surgical and medical procedures		<=23 letters	69	9,8	0	0,0
Surgical and medical procedures		>=24 letters	632	90,2	5	0,8
Surgical and medical procedures	Dental implantation	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Dental implantation	>=24 letters	632	90,2	2	0,3
Surgical and medical procedures	Ligament operation	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Ligament operation	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures	Toe operation	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Toe operation	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures	Tooth extraction	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Tooth extraction	>=24 letters	632	90,2	1	0,2
Vascular disorders		<=23 letters	69	9,8	2	2,9
Vascular disorders		>=24 letters	632	90,2	15	2,4
Vascular disorders	Aortic stenosis	<=23 letters	69	9,8	0	0,0
Vascular disorders	Aortic stenosis	>=24 letters	632	90,2	1	0,2
Vascular disorders	Hypertension	<=23 letters	69	9,8	1	1,4
Vascular disorders	Hypertension	>=24 letters	632	90,2	10	1,6
Vascular disorders	Hypertensive crisis	<=23 letters	69	9,8	0	0,0
Vascular disorders	Hypertensive crisis	>=24 letters	632	90,2	2	0,3
Vascular disorders	Hypotension	<=23 letters	69	9,8	1	1,4
Vascular disorders	Hypotension	>=24 letters	632	90,2	2	0,3
Vascular disorders	Thrombosis	<=23 letters	69	9,8	0	0,0
Vascular disorders	Thrombosis	>=24 letters	632	90,2	1	0,2

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WM0DAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:08

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Moderate AEs

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

Geographic Region

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		Europe	214	30,5	1	0,5
Blood and lymphatic system disorders		America	282	40,2	4	1,4
Blood and lymphatic system disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Blood and lymphatic system disorders	Anaemia	Europe	214	30,5	1	0,5
Blood and lymphatic system disorders	Anaemia	America	282	40,2	4	1,4
Blood and lymphatic system disorders	Anaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Europe	214	30,5	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	America	282	40,2	1	0,4
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders		Europe	214	30,5	6	2,8
Cardiac disorders		America	282	40,2	8	2,8
Cardiac disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Acute left ventricular failure	Europe	214	30,5	0	0,0
Cardiac disorders	Acute left ventricular failure	America	282	40,2	1	0,4
Cardiac disorders	Acute left ventricular failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Aortic valve incompetence	Europe	214	30,5	0	0,0
Cardiac disorders	Aortic valve incompetence	America	282	40,2	1	0,4
Cardiac disorders	Aortic valve incompetence	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Arrhythmia	Europe	214	30,5	1	0,5
Cardiac disorders	Arrhythmia	America	282	40,2	0	0,0
Cardiac disorders	Arrhythmia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Atrial fibrillation	Europe	214	30,5	1	0,5
Cardiac disorders	Atrial fibrillation	America	282	40,2	4	1,4
Cardiac disorders	Atrial fibrillation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Bradycardia	Europe	214	30,5	1	0,5
Cardiac disorders	Bradycardia	America	282	40,2	0	0,0
Cardiac disorders	Bradycardia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Cardiomegaly	Europe	214	30,5	0	0,0
Cardiac disorders	Cardiomegaly	America	282	40,2	1	0,4
Cardiac disorders	Cardiomegaly	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Coronary artery stenosis	Europe	214	30,5	1	0,5
Cardiac disorders	Coronary artery stenosis	America	282	40,2	0	0,0
Cardiac disorders	Coronary artery stenosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Myocardial infarction	Europe	214	30,5	0	0,0
Cardiac disorders	Myocardial infarction	America	282	40,2	0	0,0
Cardiac disorders	Myocardial infarction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Myocardial ischaemia	Europe	214	30,5	1	0,5
Cardiac disorders	Myocardial ischaemia	America	282	40,2	0	0,0
Cardiac disorders	Myocardial ischaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Palpitations	Europe	214	30,5	1	0,5
Cardiac disorders	Palpitations	America	282	40,2	0	0,0
Cardiac disorders	Palpitations	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Sinus tachycardia	Europe	214	30,5	0	0,0
Cardiac disorders	Sinus tachycardia	America	282	40,2	1	0,4
Cardiac disorders	Sinus tachycardia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Supraventricular tachycardia	Europe	214	30,5	0	0,0
Cardiac disorders	Supraventricular tachycardia	America	282	40,2	1	0,4
Cardiac disorders	Supraventricular tachycardia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Congenital, familial and genetic disorders		Europe	214	30,5	0	0,0
Congenital, familial and genetic disorders		America	282	40,2	1	0,4
Congenital, familial and genetic disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	Europe	214	30,5	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	America	282	40,2	1	0,4

Congenital, familial and genetic disorders	Corneal dystrophy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Ear and labyrinth disorders		Europe	214	30,5	1	0,5
Ear and labyrinth disorders		America	282	40,2	0	0,0
Ear and labyrinth disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Ear and labyrinth disorders	Vertigo	Europe	214	30,5	1	0,5
Ear and labyrinth disorders	Vertigo	America	282	40,2	0	0,0
Ear and labyrinth disorders	Vertigo	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Endocrine disorders		Europe	214	30,5	0	0,0
Endocrine disorders		America	282	40,2	2	0,7
Endocrine disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Endocrine disorders	Androgen deficiency	Europe	214	30,5	0	0,0
Endocrine disorders	Androgen deficiency	America	282	40,2	1	0,4
Endocrine disorders	Androgen deficiency	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Endocrine disorders	Hypothyroidism	Europe	214	30,5	0	0,0
Endocrine disorders	Hypothyroidism	America	282	40,2	1	0,4
Endocrine disorders	Hypothyroidism	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders		Europe	214	30,5	36	16,8
Eye disorders		America	282	40,2	36	12,8
Eye disorders		Asia Pacific (inc. Australia)	205	29,2	20	9,8
Eye disorders	Asthenopia	Europe	214	30,5	0	0,0
Eye disorders	Asthenopia	America	282	40,2	0	0,0
Eye disorders	Asthenopia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Blepharitis	Europe	214	30,5	0	0,0
Eye disorders	Blepharitis	America	282	40,2	1	0,4
Eye disorders	Blepharitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Cataract	Europe	214	30,5	3	1,4
Eye disorders	Cataract	America	282	40,2	7	2,5
Eye disorders	Cataract	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Cataract nuclear	Europe	214	30,5	1	0,5
Eye disorders	Cataract nuclear	America	282	40,2	0	0,0
Eye disorders	Cataract nuclear	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Cataract subcapsular	Europe	214	30,5	1	0,5
Eye disorders	Cataract subcapsular	America	282	40,2	0	0,0
Eye disorders	Cataract subcapsular	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Chalazion	Europe	214	30,5	0	0,0
Eye disorders	Chalazion	America	282	40,2	1	0,4
Eye disorders	Chalazion	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Choroidal effusion	Europe	214	30,5	0	0,0
Eye disorders	Choroidal effusion	America	282	40,2	1	0,4
Eye disorders	Choroidal effusion	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Conjunctival telangiectasia	Europe	214	30,5	0	0,0
Eye disorders	Conjunctival telangiectasia	America	282	40,2	0	0,0
Eye disorders	Conjunctival telangiectasia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Cystoid macular oedema	Europe	214	30,5	3	1,4
Eye disorders	Cystoid macular oedema	America	282	40,2	1	0,4
Eye disorders	Cystoid macular oedema	Asia Pacific (inc. Australia)	205	29,2	7	3,4
Eye disorders	Dry eye	Europe	214	30,5	1	0,5
Eye disorders	Dry eye	America	282	40,2	1	0,4
Eye disorders	Dry eye	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Eczema eyelids	Europe	214	30,5	1	0,5
Eye disorders	Eczema eyelids	America	282	40,2	0	0,0
Eye disorders	Eczema eyelids	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Eye irritation	Europe	214	30,5	1	0,5
Eye disorders	Eye irritation	America	282	40,2	0	0,0
Eye disorders	Eye irritation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Eye pain	Europe	214	30,5	3	1,4
Eye disorders	Eye pain	America	282	40,2	2	0,7
Eye disorders	Eye pain	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Glaucoma	Europe	214	30,5	5	2,3
Eye disorders	Glaucoma	America	282	40,2	2	0,7
Eye disorders	Glaucoma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Iridocyclitis	Europe	214	30,5	1	0,5
Eye disorders	Iridocyclitis	America	282	40,2	1	0,4
Eye disorders	Iridocyclitis	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Iris neovascularisation	Europe	214	30,5	1	0,5

Eye disorders	Iris neovascularisation	America	282	40,2	0	0,0
Eye disorders	Iris neovascularisation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Iritis	Europe	214	30,5	0	0,0
Eye disorders	Iritis	America	282	40,2	1	0,4
Eye disorders	Iritis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Keratopathy	Europe	214	30,5	1	0,5
Eye disorders	Keratopathy	America	282	40,2	0	0,0
Eye disorders	Keratopathy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Lacrimal disorder	Europe	214	30,5	0	0,0
Eye disorders	Lacrimal disorder	America	282	40,2	0	0,0
Eye disorders	Lacrimal disorder	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Lacrimation increased	Europe	214	30,5	2	0,9
Eye disorders	Lacrimation increased	America	282	40,2	0	0,0
Eye disorders	Lacrimation increased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Lenticular opacities	Europe	214	30,5	1	0,5
Eye disorders	Lenticular opacities	America	282	40,2	0	0,0
Eye disorders	Lenticular opacities	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular degeneration	Europe	214	30,5	1	0,5
Eye disorders	Macular degeneration	America	282	40,2	0	0,0
Eye disorders	Macular degeneration	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular ischaemia	Europe	214	30,5	1	0,5
Eye disorders	Macular ischaemia	America	282	40,2	0	0,0
Eye disorders	Macular ischaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular oedema	Europe	214	30,5	5	2,3
Eye disorders	Macular oedema	America	282	40,2	3	1,1
Eye disorders	Macular oedema	Asia Pacific (inc. Australia)	205	29,2	5	2,4
Eye disorders	Neovascular age-related macular degeneration	Europe	214	30,5	0	0,0
Eye disorders	Neovascular age-related macular degeneration	America	282	40,2	0	0,0
Eye disorders	Neovascular age-related macular degeneration	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Non-infectious endophthalmitis	Europe	214	30,5	0	0,0
Eye disorders	Non-infectious endophthalmitis	America	282	40,2	0	0,0
Eye disorders	Non-infectious endophthalmitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Noninfective conjunctivitis	Europe	214	30,5	0	0,0
Eye disorders	Noninfective conjunctivitis	America	282	40,2	1	0,4
Eye disorders	Noninfective conjunctivitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Ocular hypertension	Europe	214	30,5	4	1,9
Eye disorders	Ocular hypertension	America	282	40,2	2	0,7
Eye disorders	Ocular hypertension	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Open angle glaucoma	Europe	214	30,5	0	0,0
Eye disorders	Open angle glaucoma	America	282	40,2	1	0,4
Eye disorders	Open angle glaucoma	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Optic disc haemorrhage	Europe	214	30,5	0	0,0
Eye disorders	Optic disc haemorrhage	America	282	40,2	2	0,7
Eye disorders	Optic disc haemorrhage	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Papilloedema	Europe	214	30,5	0	0,0
Eye disorders	Papilloedema	America	282	40,2	0	0,0
Eye disorders	Papilloedema	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Posterior capsule opacification	Europe	214	30,5	0	0,0
Eye disorders	Posterior capsule opacification	America	282	40,2	3	1,1
Eye disorders	Posterior capsule opacification	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Punctate keratitis	Europe	214	30,5	0	0,0
Eye disorders	Punctate keratitis	America	282	40,2	2	0,7
Eye disorders	Punctate keratitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal artery occlusion	Europe	214	30,5	0	0,0
Eye disorders	Retinal artery occlusion	America	282	40,2	1	0,4
Eye disorders	Retinal artery occlusion	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Retinal collateral vessels	Europe	214	30,5	0	0,0
Eye disorders	Retinal collateral vessels	America	282	40,2	2	0,7
Eye disorders	Retinal collateral vessels	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal detachment	Europe	214	30,5	0	0,0
Eye disorders	Retinal detachment	America	282	40,2	1	0,4
Eye disorders	Retinal detachment	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal disorder	Europe	214	30,5	1	0,5
Eye disorders	Retinal disorder	America	282	40,2	0	0,0
Eye disorders	Retinal disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal haemorrhage	Europe	214	30,5	0	0,0
Eye disorders	Retinal haemorrhage	America	282	40,2	1	0,4
Eye disorders	Retinal haemorrhage	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Eye disorders	Retinal ischaemia	Europe	214	30,5	1	0,5
Eye disorders	Retinal ischaemia	America	282	40,2	0	0,0
Eye disorders	Retinal ischaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal vein occlusion	Europe	214	30,5	2	0,9
Eye disorders	Retinal vein occlusion	America	282	40,2	5	1,8
Eye disorders	Retinal vein occlusion	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Uveitis	Europe	214	30,5	1	0,5
Eye disorders	Uveitis	America	282	40,2	0	0,0
Eye disorders	Uveitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Vision blurred	Europe	214	30,5	1	0,5
Eye disorders	Vision blurred	America	282	40,2	0	0,0
Eye disorders	Vision blurred	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Visual acuity reduced	Europe	214	30,5	2	0,9
Eye disorders	Visual acuity reduced	America	282	40,2	2	0,7
Eye disorders	Visual acuity reduced	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Visual impairment	Europe	214	30,5	1	0,5
Eye disorders	Visual impairment	America	282	40,2	0	0,0
Eye disorders	Visual impairment	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Vitreoretinal traction syndrome	Europe	214	30,5	0	0,0
Eye disorders	Vitreoretinal traction syndrome	America	282	40,2	1	0,4
Eye disorders	Vitreoretinal traction syndrome	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Vitreous detachment	Europe	214	30,5	1	0,5
Eye disorders	Vitreous detachment	America	282	40,2	0	0,0
Eye disorders	Vitreous detachment	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Vitreous floaters	Europe	214	30,5	1	0,5
Eye disorders	Vitreous floaters	America	282	40,2	0	0,0
Eye disorders	Vitreous floaters	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Vitreous haemorrhage	Europe	214	30,5	1	0,5
Eye disorders	Vitreous haemorrhage	America	282	40,2	0	0,0
Eye disorders	Vitreous haemorrhage	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Vitritis	Europe	214	30,5	0	0,0
Eye disorders	Vitritis	America	282	40,2	1	0,4
Eye disorders	Vitritis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders		Europe	214	30,5	7	3,3
Gastrointestinal disorders		America	282	40,2	5	1,8
Gastrointestinal disorders		Asia Pacific (inc. Australia)	205	29,2	4	2,0
Gastrointestinal disorders	Abdominal pain	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Abdominal pain	America	282	40,2	0	0,0
Gastrointestinal disorders	Abdominal pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Abdominal pain upper	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Abdominal pain upper	America	282	40,2	0	0,0
Gastrointestinal disorders	Abdominal pain upper	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Barrett's oesophagus	America	282	40,2	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Coeliac disease	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Coeliac disease	America	282	40,2	0	0,0
Gastrointestinal disorders	Coeliac disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Colitis	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Colitis	America	282	40,2	1	0,4
Gastrointestinal disorders	Colitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Constipation	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Constipation	America	282	40,2	1	0,4
Gastrointestinal disorders	Constipation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Dental discomfort	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Dental discomfort	America	282	40,2	0	0,0
Gastrointestinal disorders	Dental discomfort	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Diarrhoea	Europe	214	30,5	2	0,9
Gastrointestinal disorders	Diarrhoea	America	282	40,2	1	0,4
Gastrointestinal disorders	Diarrhoea	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Gastric ulcer	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Gastric ulcer	America	282	40,2	0	0,0
Gastrointestinal disorders	Gastric ulcer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Gastritis	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Gastritis	America	282	40,2	1	0,4
Gastrointestinal disorders	Gastritis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Gastrooesophageal reflux disease	Europe	214	30,5	0	0,0

Gastrointestinal disorders	Gastroesophageal reflux disease	America	282	40,2	1	0,4
Gastrointestinal disorders	Gastroesophageal reflux disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Hiatus hernia	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Hiatus hernia	America	282	40,2	1	0,4
Gastrointestinal disorders	Hiatus hernia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Ileus	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Ileus	America	282	40,2	0	0,0
Gastrointestinal disorders	Ileus	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Inguinal hernia	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Inguinal hernia	America	282	40,2	0	0,0
Gastrointestinal disorders	Inguinal hernia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Large intestine polyp	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Large intestine polyp	America	282	40,2	0	0,0
Gastrointestinal disorders	Large intestine polyp	Asia Pacific (inc. Australia)	205	29,2	1	0,5
General disorders and administration site conditions		Europe	214	30,5	7	3,3
General disorders and administration site conditions		America	282	40,2	4	1,4
General disorders and administration site conditions		Asia Pacific (inc. Australia)	205	29,2	2	1,0
General disorders and administration site conditions	Asthenia	Europe	214	30,5	4	1,9
General disorders and administration site conditions	Asthenia	America	282	40,2	0	0,0
General disorders and administration site conditions	Asthenia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Chest pain	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Chest pain	America	282	40,2	0	0,0
General disorders and administration site conditions	Chest pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Injection site pain	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Injection site pain	America	282	40,2	0	0,0
General disorders and administration site conditions	Injection site pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Oedema peripheral	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Oedema peripheral	America	282	40,2	1	0,4
General disorders and administration site conditions	Oedema peripheral	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Pain	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Pain	America	282	40,2	1	0,4
General disorders and administration site conditions	Pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Polyp	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Polyp	America	282	40,2	0	0,0
General disorders and administration site conditions	Polyp	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Pyrexia	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Pyrexia	America	282	40,2	1	0,4
General disorders and administration site conditions	Pyrexia	Asia Pacific (inc. Australia)	205	29,2	2	1,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	America	282	40,2	1	0,4
General disorders and administration site conditions	Systemic inflammatory response syndrome	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Hepatobiliary disorders		Europe	214	30,5	1	0,5
Hepatobiliary disorders		America	282	40,2	1	0,4
Hepatobiliary disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Hepatobiliary disorders	Cholecystitis	Europe	214	30,5	0	0,0
Hepatobiliary disorders	Cholecystitis	America	282	40,2	0	0,0
Hepatobiliary disorders	Cholecystitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Hepatobiliary disorders	Cholelithiasis	Europe	214	30,5	1	0,5
Hepatobiliary disorders	Cholelithiasis	America	282	40,2	1	0,4
Hepatobiliary disorders	Cholelithiasis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Immune system disorders		Europe	214	30,5	1	0,5
Immune system disorders		America	282	40,2	1	0,4
Immune system disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Immune system disorders	Drug hypersensitivity	Europe	214	30,5	0	0,0
Immune system disorders	Drug hypersensitivity	America	282	40,2	0	0,0
Immune system disorders	Drug hypersensitivity	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Immune system disorders	Iodine allergy	Europe	214	30,5	1	0,5
Immune system disorders	Iodine allergy	America	282	40,2	0	0,0
Immune system disorders	Iodine allergy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Immune system disorders	Seasonal allergy	Europe	214	30,5	0	0,0
Immune system disorders	Seasonal allergy	America	282	40,2	1	0,4
Immune system disorders	Seasonal allergy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations		Europe	214	30,5	26	12,1
Infections and infestations		America	282	40,2	23	8,2

Infections and infestations		Asia Pacific (inc. Australia)	205	29,2	15	7,3
Infections and infestations	Arthritis infective	Europe	214	30,5	1	0,5
Infections and infestations	Arthritis infective	America	282	40,2	0	0,0
Infections and infestations	Arthritis infective	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Bronchitis	Europe	214	30,5	1	0,5
Infections and infestations	Bronchitis	America	282	40,2	3	1,1
Infections and infestations	Bronchitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	COVID-19	Europe	214	30,5	4	1,9
Infections and infestations	COVID-19	America	282	40,2	8	2,8
Infections and infestations	COVID-19	Asia Pacific (inc. Australia)	205	29,2	7	3,4
Infections and infestations	Cellulitis	Europe	214	30,5	1	0,5
Infections and infestations	Cellulitis	America	282	40,2	3	1,1
Infections and infestations	Cellulitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Conjunctivitis	Europe	214	30,5	1	0,5
Infections and infestations	Conjunctivitis	America	282	40,2	2	0,7
Infections and infestations	Conjunctivitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Cystitis	Europe	214	30,5	0	0,0
Infections and infestations	Cystitis	America	282	40,2	1	0,4
Infections and infestations	Cystitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Ear infection	Europe	214	30,5	1	0,5
Infections and infestations	Ear infection	America	282	40,2	0	0,0
Infections and infestations	Ear infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Fungal skin infection	Europe	214	30,5	0	0,0
Infections and infestations	Fungal skin infection	America	282	40,2	1	0,4
Infections and infestations	Fungal skin infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Helicobacter infection	Europe	214	30,5	0	0,0
Infections and infestations	Helicobacter infection	America	282	40,2	0	0,0
Infections and infestations	Helicobacter infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Herpes zoster	Europe	214	30,5	0	0,0
Infections and infestations	Herpes zoster	America	282	40,2	1	0,4
Infections and infestations	Herpes zoster	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Influenza	Europe	214	30,5	3	1,4
Infections and infestations	Influenza	America	282	40,2	3	1,1
Infections and infestations	influenza	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Infections and infestations	Kidney infection	Europe	214	30,5	0	0,0
Infections and infestations	Kidney infection	America	282	40,2	1	0,4
Infections and infestations	Kidney infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Laryngitis	Europe	214	30,5	1	0,5
Infections and infestations	Laryngitis	America	282	40,2	0	0,0
Infections and infestations	Laryngitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Nasopharyngitis	Europe	214	30,5	2	0,9
Infections and infestations	Nasopharyngitis	America	282	40,2	0	0,0
Infections and infestations	Nasopharyngitis	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Infections and infestations	Pharyngitis	Europe	214	30,5	0	0,0
Infections and infestations	Pharyngitis	America	282	40,2	0	0,0
Infections and infestations	Pharyngitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Pneumonia	Europe	214	30,5	0	0,0
Infections and infestations	Pneumonia	America	282	40,2	3	1,1
Infections and infestations	Pneumonia	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Infections and infestations	Pneumonia viral	Europe	214	30,5	0	0,0
Infections and infestations	Pneumonia viral	America	282	40,2	0	0,0
Infections and infestations	Pneumonia viral	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Pulpitis dental	Europe	214	30,5	2	0,9
Infections and infestations	Pulpitis dental	America	282	40,2	0	0,0
Infections and infestations	Pulpitis dental	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Respiratory tract infection	Europe	214	30,5	1	0,5
Infections and infestations	Respiratory tract infection	America	282	40,2	0	0,0
Infections and infestations	Respiratory tract infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Respiratory tract infection viral	Europe	214	30,5	1	0,5
Infections and infestations	Respiratory tract infection viral	America	282	40,2	0	0,0
Infections and infestations	Respiratory tract infection viral	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Sinusitis	Europe	214	30,5	1	0,5
Infections and infestations	Sinusitis	America	282	40,2	0	0,0
Infections and infestations	Sinusitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Staphylococcal infection	Europe	214	30,5	0	0,0
Infections and infestations	Staphylococcal infection	America	282	40,2	1	0,4
Infections and infestations	Staphylococcal infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Suspected COVID-19	Europe	214	30,5	0	0,0

Infections and infestations	Suspected COVID-19	America	282	40,2	0	0,0
Infections and infestations	Suspected COVID-19	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Tooth abscess	Europe	214	30,5	0	0,0
Infections and infestations	Tooth abscess	America	282	40,2	1	0,4
Infections and infestations	Tooth abscess	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Upper respiratory tract infection	Europe	214	30,5	8	3,7
Infections and infestations	Upper respiratory tract infection	America	282	40,2	0	0,0
Infections and infestations	Upper respiratory tract infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Urinary tract infection	Europe	214	30,5	1	0,5
Infections and infestations	Urinary tract infection	America	282	40,2	5	1,8
Infections and infestations	Urinary tract infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications		Europe	214	30,5	4	1,9
Injury, poisoning and procedural complications		America	282	40,2	14	5,0
Injury, poisoning and procedural complications		Asia Pacific (inc. Australia)	205	29,2	7	3,4
Injury, poisoning and procedural complications	Arthropod bite	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Arthropod bite	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Arthropod bite	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Fall	Europe	214	30,5	2	0,9
Injury, poisoning and procedural complications	Fall	America	282	40,2	3	1,1
Injury, poisoning and procedural complications	Fall	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Femur fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Femur fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Femur fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Fibula fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Fibula fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Fibula fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Foreign body in eye	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Hand fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Hand fracture	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Hand fracture	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Injury, poisoning and procedural complications	Hip fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Hip fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Hip fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Hypobarism	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Hypobarism	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Hypobarism	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Limb injury	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Limb injury	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Limb injury	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Lower limb fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Lumbar vertebral fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Muscle strain	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Muscle strain	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Muscle strain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Rib fracture	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Rib fracture	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	America	282	40,2	2	0,7
Injury, poisoning and procedural complications	Road traffic accident	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Skin laceration	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Spinal compression fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	America	282	40,2	0	0,0

Injury, poisoning and procedural complications	Spinal compression fracture	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Sunburn	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Sunburn	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Sunburn	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Tibia fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Tibia fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Tooth fracture	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	America	282	40,2	2	0,7
Injury, poisoning and procedural complications	Wrist fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations		Europe	214	30,5	7	3,3
Investigations		America	282	40,2	5	1,8
Investigations		Asia Pacific (inc. Australia)	205	29,2	4	2,0
Investigations	Blood pressure increased	Europe	214	30,5	1	0,5
Investigations	Blood pressure increased	America	282	40,2	0	0,0
Investigations	Blood pressure increased	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Investigations	Blood testosterone decreased	Europe	214	30,5	0	0,0
Investigations	Blood testosterone decreased	America	282	40,2	1	0,4
Investigations	Blood testosterone decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Intraocular pressure increased	Europe	214	30,5	4	1,9
Investigations	Intraocular pressure increased	America	282	40,2	3	1,1
Investigations	Intraocular pressure increased	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Investigations	Occult blood positive	Europe	214	30,5	0	0,0
Investigations	Occult blood positive	America	282	40,2	1	0,4
Investigations	Occult blood positive	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Europe	214	30,5	1	0,5
Investigations	Optic nerve cup/disc ratio increased	America	282	40,2	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Investigations	Weight decreased	Europe	214	30,5	1	0,5
Investigations	Weight decreased	America	282	40,2	0	0,0
Investigations	Weight decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders		Europe	214	30,5	3	1,4
Metabolism and nutrition disorders		America	282	40,2	10	3,5
Metabolism and nutrition disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Dehydration	Europe	214	30,5	1	0,5
Metabolism and nutrition disorders	Dehydration	America	282	40,2	1	0,4
Metabolism and nutrition disorders	Dehydration	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	America	282	40,2	1	0,4
Metabolism and nutrition disorders	Glucose tolerance impaired	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Gout	Europe	214	30,5	1	0,5
Metabolism and nutrition disorders	Gout	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Gout	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	America	282	40,2	1	0,4
Metabolism and nutrition disorders	Hypercholesterolaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Europe	214	30,5	1	0,5
Metabolism and nutrition disorders	Hyperglycaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Hypokalaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	America	282	40,2	5	1,8
Metabolism and nutrition disorders	Hypokalaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	America	282	40,2	1	0,4
Metabolism and nutrition disorders	Hyponatraemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	America	282	40,2	2	0,7
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders		Europe	214	30,5	6	2,8

Musculoskeletal and connective tissue disorders		America	282	40,2	7	2,5
Musculoskeletal and connective tissue disorders		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Musculoskeletal and connective tissue disorders	Arthralgia	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Arthralgia	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Arthralgia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Back pain	America	282	40,2	3	1,1
Musculoskeletal and connective tissue disorders	Back pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Bone loss	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Flank pain	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Flank pain	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Flank pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Osteoarthritis	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Osteoarthritis	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	Europe	214	30,5	2	0,9
Musculoskeletal and connective tissue disorders	Pain in extremity	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Scoliosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Europe	214	30,5	2	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		America	282	40,2	3	1,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	America	282	40,2	1	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Europe	214	30,5	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Europe	214	30,5	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	America	282	40,2	2	0,7
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders		Europe	214	30,5	5	2,3
Nervous system disorders		America	282	40,2	7	2,5
Nervous system disorders		Asia Pacific (inc. Australia)	205	29,2	5	2,4
Nervous system disorders	Cerebral atrophy	Europe	214	30,5	0	0,0
Nervous system disorders	Cerebral atrophy	America	282	40,2	0	0,0
Nervous system disorders	Cerebral atrophy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Cerebral infarction	Europe	214	30,5	0	0,0

Nervous system disorders	Cerebral infarction	America	282	40,2	0	0,0
Nervous system disorders	Cerebral infarction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Diabetic neuropathy	Europe	214	30,5	0	0,0
Nervous system disorders	Diabetic neuropathy	America	282	40,2	1	0,4
Nervous system disorders	Diabetic neuropathy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Dizziness	Europe	214	30,5	1	0,5
Nervous system disorders	Dizziness	America	282	40,2	0	0,0
Nervous system disorders	Dizziness	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Encephalopathy	Europe	214	30,5	0	0,0
Nervous system disorders	Encephalopathy	America	282	40,2	1	0,4
Nervous system disorders	Encephalopathy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Headache	Europe	214	30,5	1	0,5
Nervous system disorders	Headache	America	282	40,2	1	0,4
Nervous system disorders	Headache	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Ischaemic stroke	Europe	214	30,5	0	0,0
Nervous system disorders	Ischaemic stroke	America	282	40,2	0	0,0
Nervous system disorders	Ischaemic stroke	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Lacunar infarction	Europe	214	30,5	0	0,0
Nervous system disorders	Lacunar infarction	America	282	40,2	0	0,0
Nervous system disorders	Lacunar infarction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Loss of consciousness	Europe	214	30,5	1	0,5
Nervous system disorders	Loss of consciousness	America	282	40,2	0	0,0
Nervous system disorders	Loss of consciousness	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Neuralgia	Europe	214	30,5	0	0,0
Nervous system disorders	Neuralgia	America	282	40,2	1	0,4
Nervous system disorders	Neuralgia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Neuropathy peripheral	Europe	214	30,5	0	0,0
Nervous system disorders	Neuropathy peripheral	America	282	40,2	2	0,7
Nervous system disorders	Neuropathy peripheral	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Ophthalmic migraine	Europe	214	30,5	0	0,0
Nervous system disorders	Ophthalmic migraine	America	282	40,2	1	0,4
Nervous system disorders	Ophthalmic migraine	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Sciatica	Europe	214	30,5	2	0,9
Nervous system disorders	Sciatica	America	282	40,2	0	0,0
Nervous system disorders	Sciatica	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Syncope	Europe	214	30,5	0	0,0
Nervous system disorders	Syncope	America	282	40,2	1	0,4
Nervous system disorders	Syncope	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Psychiatric disorders		Europe	214	30,5	1	0,5
Psychiatric disorders		America	282	40,2	2	0,7
Psychiatric disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Psychiatric disorders	Anxiety	Europe	214	30,5	0	0,0
Psychiatric disorders	Anxiety	America	282	40,2	1	0,4
Psychiatric disorders	Anxiety	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Psychiatric disorders	Depression	Europe	214	30,5	1	0,5
Psychiatric disorders	Depression	America	282	40,2	0	0,0
Psychiatric disorders	Depression	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Psychiatric disorders	Insomnia	Europe	214	30,5	0	0,0
Psychiatric disorders	Insomnia	America	282	40,2	1	0,4
Psychiatric disorders	Insomnia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders		Europe	214	30,5	3	1,4
Renal and urinary disorders		America	282	40,2	2	0,7
Renal and urinary disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	Acute kidney injury	Europe	214	30,5	1	0,5
Renal and urinary disorders	Acute kidney injury	America	282	40,2	1	0,4
Renal and urinary disorders	Acute kidney injury	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Europe	214	30,5	0	0,0
Renal and urinary disorders	Diabetic nephropathy	America	282	40,2	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	Renal failure	Europe	214	30,5	1	0,5
Renal and urinary disorders	Renal failure	America	282	40,2	0	0,0
Renal and urinary disorders	Renal failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Urinary retention	Europe	214	30,5	0	0,0
Renal and urinary disorders	Urinary retention	America	282	40,2	1	0,4
Renal and urinary disorders	Urinary retention	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Urinary tract inflammation	Europe	214	30,5	1	0,5

Renal and urinary disorders	Urinary tract inflammation	America	282	40,2	0	0,0
Renal and urinary disorders	Urinary tract inflammation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Reproductive system and breast disorders		Europe	214	30,5	0	0,0
Reproductive system and breast disorders		America	282	40,2	2	0,7
Reproductive system and breast disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Europe	214	30,5	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	America	282	40,2	1	0,4
Reproductive system and breast disorders	Benign prostatic hyperplasia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Reproductive system and breast disorders	Cystocele	Europe	214	30,5	0	0,0
Reproductive system and breast disorders	Cystocele	America	282	40,2	1	0,4
Reproductive system and breast disorders	Cystocele	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders		Europe	214	30,5	6	2,8
Respiratory, thoracic and mediastinal disorders		America	282	40,2	5	1,8
Respiratory, thoracic and mediastinal disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	America	282	40,2	2	0,7
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Asthma	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Asthma	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Asthma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Europe	214	30,5	3	1,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	America	282	40,2	2	0,7
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Cough	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Dyspnoea	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders		Europe	214	30,5	4	1,9
Skin and subcutaneous tissue disorders		America	282	40,2	3	1,1
Skin and subcutaneous tissue disorders		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Androgenetic alopecia	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Skin and subcutaneous tissue disorders	Dermatitis contact	Europe	214	30,5	2	0,9
Skin and subcutaneous tissue disorders	Dermatitis contact	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Skin and subcutaneous tissue disorders	Diabetic foot	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	America	282	40,2	2	0,7
Skin and subcutaneous tissue disorders	Diabetic foot	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Erythema	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Erythema	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Erythema	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Skin and subcutaneous tissue disorders	Nail dystrophy	Europe	214	30,5	1	0,5
Skin and subcutaneous tissue disorders	Nail dystrophy	America	282	40,2	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Skin and subcutaneous tissue disorders	Urticaria	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	America	282	40,2	1	0,4
Skin and subcutaneous tissue disorders	Urticaria	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures		Europe	214	30,5	3	1,4
Surgical and medical procedures		America	282	40,2	2	0,7
Surgical and medical procedures		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Dental implantation	Europe	214	30,5	1	0,5
Surgical and medical procedures	Dental implantation	America	282	40,2	1	0,4
Surgical and medical procedures	Dental implantation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Ligament operation	Europe	214	30,5	0	0,0
Surgical and medical procedures	Ligament operation	America	282	40,2	1	0,4
Surgical and medical procedures	Ligament operation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Toe operation	Europe	214	30,5	1	0,5
Surgical and medical procedures	Toe operation	America	282	40,2	0	0,0
Surgical and medical procedures	Toe operation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Tooth extraction	Europe	214	30,5	1	0,5
Surgical and medical procedures	Tooth extraction	America	282	40,2	0	0,0
Surgical and medical procedures	Tooth extraction	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders		Europe	214	30,5	7	3,3
Vascular disorders		America	282	40,2	7	2,5
Vascular disorders		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Vascular disorders	Aortic stenosis	Europe	214	30,5	1	0,5
Vascular disorders	Aortic stenosis	America	282	40,2	0	0,0
Vascular disorders	Aortic stenosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Hypertension	Europe	214	30,5	4	1,9
Vascular disorders	Hypertension	America	282	40,2	4	1,4
Vascular disorders	Hypertension	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Vascular disorders	Hypertensive crisis	Europe	214	30,5	1	0,5
Vascular disorders	Hypertensive crisis	America	282	40,2	1	0,4
Vascular disorders	Hypertensive crisis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Hypotension	Europe	214	30,5	1	0,5
Vascular disorders	Hypotension	America	282	40,2	1	0,4
Vascular disorders	Hypotension	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Vascular disorders	Thrombosis	Europe	214	30,5	0	0,0
Vascular disorders	Thrombosis	America	282	40,2	1	0,4
Vascular disorders	Thrombosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WM0DAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:08

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Blood and lymphatic system disorders		White	474	67.6	5	1.1
Blood and lymphatic system disorders		Asian	176	25.1	0	0.0
Blood and lymphatic system disorders		Other	27	3.9	0	0.0
Blood and lymphatic system disorders		Unknown	24	3.4	0	0.0
Blood and lymphatic system disorders	Anaemia	White	474	67.6	5	1.1
Blood and lymphatic system disorders	Anaemia	Asian	176	25.1	0	0.0
Blood and lymphatic system disorders	Anaemia	Other	27	3.9	0	0.0
Blood and lymphatic system disorders	Anaemia	Unknown	24	3.4	0	0.0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	White	474	67.6	1	0.2
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Asian	176	25.1	0	0.0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Other	27	3.9	0	0.0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Unknown	24	3.4	0	0.0
Cardiac disorders		White	474	67.6	13	2.7
Cardiac disorders		Asian	176	25.1	1	0.6
Cardiac disorders		Other	27	3.9	1	3.7
Cardiac disorders		Unknown	24	3.4	0	0.0
Cardiac disorders	Acute left ventricular failure	White	474	67.6	1	0.2
Cardiac disorders	Acute left ventricular failure	Asian	176	25.1	0	0.0
Cardiac disorders	Acute left ventricular failure	Other	27	3.9	0	0.0
Cardiac disorders	Acute left ventricular failure	Unknown	24	3.4	0	0.0
Cardiac disorders	Aortic valve incompetence	White	474	67.6	1	0.2
Cardiac disorders	Aortic valve incompetence	Asian	176	25.1	0	0.0
Cardiac disorders	Aortic valve incompetence	Other	27	3.9	0	0.0
Cardiac disorders	Aortic valve incompetence	Unknown	24	3.4	0	0.0
Cardiac disorders	Arrhythmia	White	474	67.6	1	0.2
Cardiac disorders	Arrhythmia	Asian	176	25.1	0	0.0
Cardiac disorders	Arrhythmia	Other	27	3.9	0	0.0
Cardiac disorders	Arrhythmia	Unknown	24	3.4	0	0.0
Cardiac disorders	Atrial fibrillation	White	474	67.6	4	0.8
Cardiac disorders	Atrial fibrillation	Asian	176	25.1	0	0.0
Cardiac disorders	Atrial fibrillation	Other	27	3.9	1	3.7
Cardiac disorders	Atrial fibrillation	Unknown	24	3.4	0	0.0
Cardiac disorders	Bradycardia	White	474	67.6	1	0.2
Cardiac disorders	Bradycardia	Asian	176	25.1	0	0.0
Cardiac disorders	Bradycardia	Other	27	3.9	0	0.0
Cardiac disorders	Bradycardia	Unknown	24	3.4	0	0.0
Cardiac disorders	Cardiomegaly	White	474	67.6	1	0.2
Cardiac disorders	Cardiomegaly	Asian	176	25.1	0	0.0
Cardiac disorders	Cardiomegaly	Other	27	3.9	0	0.0
Cardiac disorders	Cardiomegaly	Unknown	24	3.4	0	0.0
Cardiac disorders	Coronary artery stenosis	White	474	67.6	1	0.2
Cardiac disorders	Coronary artery stenosis	Asian	176	25.1	0	0.0
Cardiac disorders	Coronary artery stenosis	Other	27	3.9	0	0.0
Cardiac disorders	Coronary artery stenosis	Unknown	24	3.4	0	0.0
Cardiac disorders	Myocardial infarction	White	474	67.6	0	0.0
Cardiac disorders	Myocardial infarction	Asian	176	25.1	1	0.6
Cardiac disorders	Myocardial infarction	Other	27	3.9	0	0.0
Cardiac disorders	Myocardial infarction	Unknown	24	3.4	0	0.0
Cardiac disorders	Myocardial ischaemia	White	474	67.6	1	0.2
Cardiac disorders	Myocardial ischaemia	Asian	176	25.1	0	0.0
Cardiac disorders	Myocardial ischaemia	Other	27	3.9	0	0.0
Cardiac disorders	Myocardial ischaemia	Unknown	24	3.4	0	0.0
Cardiac disorders	Palpitations	White	474	67.6	1	0.2
Cardiac disorders	Palpitations	Asian	176	25.1	0	0.0
Cardiac disorders	Palpitations	Other	27	3.9	0	0.0
Cardiac disorders	Palpitations	Unknown	24	3.4	0	0.0
Cardiac disorders	Sinus tachycardia	White	474	67.6	1	0.2
Cardiac disorders	Sinus tachycardia	Asian	176	25.1	0	0.0
Cardiac disorders	Sinus tachycardia	Other	27	3.9	0	0.0
Cardiac disorders	Sinus tachycardia	Unknown	24	3.4	0	0.0
Cardiac disorders	Supraventricular tachycardia	White	474	67.6	1	0.2
Cardiac disorders	Supraventricular tachycardia	Asian	176	25.1	0	0.0
Cardiac disorders	Supraventricular tachycardia	Other	27	3.9	0	0.0
Cardiac disorders	Supraventricular tachycardia	Unknown	24	3.4	0	0.0
Congenital, familial and genetic disorders		White	474	67.6	0	0.0
Congenital, familial and genetic disorders		Asian	176	25.1	0	0.0
Congenital, familial and genetic disorders		Other	27	3.9	1	3.7
Congenital, familial and genetic disorders		Unknown	24	3.4	0	0.0
Congenital, familial and genetic disorders	Corneal dystrophy	White	474	67.6	0	0.0
Congenital, familial and genetic disorders	Corneal dystrophy	Asian	176	25.1	0	0.0
Congenital, familial and genetic disorders	Corneal dystrophy	Other	27	3.9	1	3.7
Congenital, familial and genetic disorders	Corneal dystrophy	Unknown	24	3.4	0	0.0
Ear and labyrinth disorders		White	474	67.6	1	0.2
Ear and labyrinth disorders		Asian	176	25.1	1	0.6

Ear and labyrinth disorders		Other	27	3,9	0	0,0
Ear and labyrinth disorders		Unknown	24	3,4	0	0,0
Ear and labyrinth disorders	Vertigo	White	474	67,6	1	0,2
Ear and labyrinth disorders	Vertigo	Asian	176	25,1	1	0,6
Ear and labyrinth disorders	Vertigo	Other	27	3,9	0	0,0
Ear and labyrinth disorders	Vertigo	Unknown	24	3,4	0	0,0
Endocrine disorders		White	474	67,6	2	0,4
Endocrine disorders		Asian	176	25,1	0	0,0
Endocrine disorders		Other	27	3,9	0	0,0
Endocrine disorders		Unknown	24	3,4	0	0,0
Endocrine disorders	Androgen deficiency	White	474	67,6	1	0,2
Endocrine disorders	Androgen deficiency	Asian	176	25,1	0	0,0
Endocrine disorders	Androgen deficiency	Other	27	3,9	0	0,0
Endocrine disorders	Androgen deficiency	Unknown	24	3,4	0	0,0
Endocrine disorders	Hypothyroidism	White	474	67,6	1	0,2
Endocrine disorders	Hypothyroidism	Asian	176	25,1	0	0,0
Endocrine disorders	Hypothyroidism	Other	27	3,9	0	0,0
Endocrine disorders	Hypothyroidism	Unknown	24	3,4	0	0,0
Eye disorders		White	474	67,6	70	14,8
Eye disorders		Asian	176	25,1	14	8,0
Eye disorders		Other	27	3,9	5	18,5
Eye disorders		Unknown	24	3,4	3	12,5
Eye disorders	Asthenopia	White	474	67,6	0	0,0
Eye disorders	Asthenopia	Asian	176	25,1	1	0,6
Eye disorders	Asthenopia	Other	27	3,9	0	0,0
Eye disorders	Asthenopia	Unknown	24	3,4	0	0,0
Eye disorders	Blepharitis	White	474	67,6	1	0,2
Eye disorders	Blepharitis	Asian	176	25,1	0	0,0
Eye disorders	Blepharitis	Other	27	3,9	0	0,0
Eye disorders	Blepharitis	Unknown	24	3,4	0	0,0
Eye disorders	Cataract	White	474	67,6	8	1,7
Eye disorders	Cataract	Asian	176	25,1	0	0,0
Eye disorders	Cataract	Other	27	3,9	2	7,4
Eye disorders	Cataract	Unknown	24	3,4	0	0,0
Eye disorders	Cataract nuclear	White	474	67,6	1	0,2
Eye disorders	Cataract nuclear	Asian	176	25,1	0	0,0
Eye disorders	Cataract nuclear	Other	27	3,9	0	0,0
Eye disorders	Cataract nuclear	Unknown	24	3,4	0	0,0
Eye disorders	Cataract subcapsular	White	474	67,6	1	0,2
Eye disorders	Cataract subcapsular	Asian	176	25,1	0	0,0
Eye disorders	Cataract subcapsular	Other	27	3,9	0	0,0
Eye disorders	Cataract subcapsular	Unknown	24	3,4	0	0,0
Eye disorders	Chalazion	White	474	67,6	1	0,2
Eye disorders	Chalazion	Asian	176	25,1	0	0,0
Eye disorders	Chalazion	Other	27	3,9	0	0,0
Eye disorders	Chalazion	Unknown	24	3,4	0	0,0
Eye disorders	Choroidal effusion	White	474	67,6	1	0,2
Eye disorders	Choroidal effusion	Asian	176	25,1	0	0,0
Eye disorders	Choroidal effusion	Other	27	3,9	0	0,0
Eye disorders	Choroidal effusion	Unknown	24	3,4	0	0,0
Eye disorders	Conjunctival telangiectasia	White	474	67,6	0	0,0
Eye disorders	Conjunctival telangiectasia	Asian	176	25,1	1	0,6
Eye disorders	Conjunctival telangiectasia	Other	27	3,9	0	0,0
Eye disorders	Conjunctival telangiectasia	Unknown	24	3,4	0	0,0
Eye disorders	Cystoid macular oedema	White	474	67,6	7	1,5
Eye disorders	Cystoid macular oedema	Asian	176	25,1	4	2,3
Eye disorders	Cystoid macular oedema	Other	27	3,9	0	0,0
Eye disorders	Cystoid macular oedema	Unknown	24	3,4	0	0,0
Eye disorders	Dry eye	White	474	67,6	2	0,4
Eye disorders	Dry eye	Asian	176	25,1	0	0,0
Eye disorders	Dry eye	Other	27	3,9	0	0,0
Eye disorders	Dry eye	Unknown	24	3,4	0	0,0
Eye disorders	Eczema eyelids	White	474	67,6	0	0,0
Eye disorders	Eczema eyelids	Asian	176	25,1	0	0,0
Eye disorders	Eczema eyelids	Other	27	3,9	0	0,0
Eye disorders	Eczema eyelids	Unknown	24	3,4	1	4,2
Eye disorders	Eye irritation	White	474	67,6	1	0,2
Eye disorders	Eye irritation	Asian	176	25,1	0	0,0
Eye disorders	Eye irritation	Other	27	3,9	0	0,0
Eye disorders	Eye irritation	Unknown	24	3,4	0	0,0
Eye disorders	Eye pain	White	474	67,6	4	0,8
Eye disorders	Eye pain	Asian	176	25,1	1	0,6
Eye disorders	Eye pain	Other	27	3,9	1	3,7
Eye disorders	Eye pain	Unknown	24	3,4	0	0,0
Eye disorders	Glaucoma	White	474	67,6	7	1,5
Eye disorders	Glaucoma	Asian	176	25,1	1	0,6
Eye disorders	Glaucoma	Other	27	3,9	0	0,0
Eye disorders	Glaucoma	Unknown	24	3,4	0	0,0
Eye disorders	Iridocyclitis	White	474	67,6	3	0,6
Eye disorders	Iridocyclitis	Asian	176	25,1	1	0,6
Eye disorders	Iridocyclitis	Other	27	3,9	0	0,0
Eye disorders	Iridocyclitis	Unknown	24	3,4	0	0,0
Eye disorders	Iris neovascularisation	White	474	67,6	1	0,2
Eye disorders	Iris neovascularisation	Asian	176	25,1	0	0,0
Eye disorders	Iris neovascularisation	Other	27	3,9	0	0,0
Eye disorders	Iris neovascularisation	Unknown	24	3,4	0	0,0
Eye disorders	Iritis	White	474	67,6	1	0,2
Eye disorders	Iritis	Asian	176	25,1	0	0,0

Eye disorders	Iritis	Other	27	3,9	0	0,0
Eye disorders	Iritis	Unknown	24	3,4	0	0,0
Eye disorders	Keratopathy	White	474	67,6	1	0,2
Eye disorders	Keratopathy	Asian	176	25,1	0	0,0
Eye disorders	Keratopathy	Other	27	3,9	0	0,0
Eye disorders	Keratopathy	Unknown	24	3,4	0	0,0
Eye disorders	Lacrimal disorder	White	474	67,6	1	0,2
Eye disorders	Lacrimal disorder	Asian	176	25,1	0	0,0
Eye disorders	Lacrimal disorder	Other	27	3,9	0	0,0
Eye disorders	Lacrimal disorder	Unknown	24	3,4	0	0,0
Eye disorders	Lacrimation increased	White	474	67,6	2	0,4
Eye disorders	Lacrimation increased	Asian	176	25,1	0	0,0
Eye disorders	Lacrimation increased	Other	27	3,9	0	0,0
Eye disorders	Lacrimation increased	Unknown	24	3,4	0	0,0
Eye disorders	Lenticular opacities	White	474	67,6	1	0,2
Eye disorders	Lenticular opacities	Asian	176	25,1	0	0,0
Eye disorders	Lenticular opacities	Other	27	3,9	0	0,0
Eye disorders	Lenticular opacities	Unknown	24	3,4	0	0,0
Eye disorders	Macular degeneration	White	474	67,6	1	0,2
Eye disorders	Macular degeneration	Asian	176	25,1	0	0,0
Eye disorders	Macular degeneration	Other	27	3,9	0	0,0
Eye disorders	Macular degeneration	Unknown	24	3,4	0	0,0
Eye disorders	Macular ischaemia	White	474	67,6	1	0,2
Eye disorders	Macular ischaemia	Asian	176	25,1	0	0,0
Eye disorders	Macular ischaemia	Other	27	3,9	0	0,0
Eye disorders	Macular ischaemia	Unknown	24	3,4	0	0,0
Eye disorders	Macular oedema	White	474	67,6	8	1,7
Eye disorders	Macular oedema	Asian	176	25,1	4	2,2
Eye disorders	Macular oedema	Other	27	3,9	1	3,7
Eye disorders	Macular oedema	Unknown	24	3,4	0	0,0
Eye disorders	Neovascular age-related macular degeneration	White	474	67,6	1	0,2
Eye disorders	Neovascular age-related macular degeneration	Asian	176	25,1	0	0,0
Eye disorders	Neovascular age-related macular degeneration	Other	27	3,9	0	0,0
Eye disorders	Neovascular age-related macular degeneration	Unknown	24	3,4	0	0,0
Eye disorders	Non-infectious endophthalmitis	White	474	67,6	0	0,0
Eye disorders	Non-infectious endophthalmitis	Asian	176	25,1	1	0,6
Eye disorders	Non-infectious endophthalmitis	Other	27	3,9	0	0,0
Eye disorders	Non-infectious endophthalmitis	Unknown	24	3,4	0	0,0
Eye disorders	Noninfective conjunctivitis	White	474	67,6	1	0,2
Eye disorders	Noninfective conjunctivitis	Asian	176	25,1	0	0,0
Eye disorders	Noninfective conjunctivitis	Other	27	3,9	0	0,0
Eye disorders	Noninfective conjunctivitis	Unknown	24	3,4	0	0,0
Eye disorders	Ocular hypertension	White	474	67,6	4	0,8
Eye disorders	Ocular hypertension	Asian	176	25,1	1	0,6
Eye disorders	Ocular hypertension	Other	27	3,9	1	3,7
Eye disorders	Ocular hypertension	Unknown	24	3,4	1	4,2
Eye disorders	Open angle glaucoma	White	474	67,6	1	0,2
Eye disorders	Open angle glaucoma	Asian	176	25,1	0	0,0
Eye disorders	Open angle glaucoma	Other	27	3,9	0	0,0
Eye disorders	Open angle glaucoma	Unknown	24	3,4	0	0,0
Eye disorders	Optic disc haemorrhage	White	474	67,6	2	0,4
Eye disorders	Optic disc haemorrhage	Asian	176	25,1	0	0,0
Eye disorders	Optic disc haemorrhage	Other	27	3,9	0	0,0
Eye disorders	Optic disc haemorrhage	Unknown	24	3,4	0	0,0
Eye disorders	Papilloedema	White	474	67,6	1	0,2
Eye disorders	Papilloedema	Asian	176	25,1	0	0,0
Eye disorders	Papilloedema	Other	27	3,9	0	0,0
Eye disorders	Papilloedema	Unknown	24	3,4	0	0,0
Eye disorders	Posterior capsule opacification	White	474	67,6	3	0,6
Eye disorders	Posterior capsule opacification	Asian	176	25,1	0	0,0
Eye disorders	Posterior capsule opacification	Other	27	3,9	0	0,0
Eye disorders	Posterior capsule opacification	Unknown	24	3,4	0	0,0
Eye disorders	Punctate keratitis	White	474	67,6	2	0,4
Eye disorders	Punctate keratitis	Asian	176	25,1	0	0,0
Eye disorders	Punctate keratitis	Other	27	3,9	0	0,0
Eye disorders	Punctate keratitis	Unknown	24	3,4	0	0,0
Eye disorders	Retinal artery occlusion	White	474	67,6	1	0,2
Eye disorders	Retinal artery occlusion	Asian	176	25,1	1	0,6
Eye disorders	Retinal artery occlusion	Other	27	3,9	0	0,0
Eye disorders	Retinal artery occlusion	Unknown	24	3,4	0	0,0
Eye disorders	Retinal collateral vessels	White	474	67,6	2	0,4
Eye disorders	Retinal collateral vessels	Asian	176	25,1	0	0,0
Eye disorders	Retinal collateral vessels	Other	27	3,9	0	0,0
Eye disorders	Retinal collateral vessels	Unknown	24	3,4	0	0,0
Eye disorders	Retinal detachment	White	474	67,6	1	0,2
Eye disorders	Retinal detachment	Asian	176	25,1	0	0,0
Eye disorders	Retinal detachment	Other	27	3,9	0	0,0
Eye disorders	Retinal detachment	Unknown	24	3,4	0	0,0
Eye disorders	Retinal disorder	White	474	67,6	1	0,2
Eye disorders	Retinal disorder	Asian	176	25,1	0	0,0
Eye disorders	Retinal disorder	Other	27	3,9	0	0,0
Eye disorders	Retinal disorder	Unknown	24	3,4	0	0,0
Eye disorders	Retinal haemorrhage	White	474	67,6	0	0,0
Eye disorders	Retinal haemorrhage	Asian	176	25,1	1	0,6
Eye disorders	Retinal haemorrhage	Other	27	3,9	0	0,0
Eye disorders	Retinal haemorrhage	Unknown	24	3,4	0	0,0
Eye disorders	Retinal ischaemia	White	474	67,6	0	0,0
Eye disorders	Retinal ischaemia	Asian	176	25,1	0	0,0
Eye disorders	Retinal ischaemia	Other	27	3,9	0	0,0
Eye disorders	Retinal ischaemia	Unknown	24	3,4	1	4,2

Eye disorders	Retinal vein occlusion	White	474	67.6	9	1.9
Eye disorders	Retinal vein occlusion	Asian	176	25.1	0	0.0
Eye disorders	Retinal vein occlusion	Other	27	3.9	0	0.0
Eye disorders	Retinal vein occlusion	Unknown	24	3.4	0	0.0
Eye disorders	Uveitis	White	474	67.6	1	0.2
Eye disorders	Uveitis	Asian	176	25.1	0	0.0
Eye disorders	Uveitis	Other	27	3.9	0	0.0
Eye disorders	Uveitis	Unknown	24	3.4	0	0.0
Eye disorders	Vision blurred	White	474	67.6	1	0.2
Eye disorders	Vision blurred	Asian	176	25.1	0	0.0
Eye disorders	Vision blurred	Other	27	3.9	0	0.0
Eye disorders	Vision blurred	Unknown	24	3.4	0	0.0
Eye disorders	Visual acuity reduced	White	474	67.6	4	0.8
Eye disorders	Visual acuity reduced	Asian	176	25.1	0	0.0
Eye disorders	Visual acuity reduced	Other	27	3.9	0	0.0
Eye disorders	Visual acuity reduced	Unknown	24	3.4	0	0.0
Eye disorders	Visual impairment	White	474	67.6	1	0.2
Eye disorders	Visual impairment	Asian	176	25.1	0	0.0
Eye disorders	Visual impairment	Other	27	3.9	0	0.0
Eye disorders	Visual impairment	Unknown	24	3.4	0	0.0
Eye disorders	Vitreoretinal traction syndrome	White	474	67.6	1	0.2
Eye disorders	Vitreoretinal traction syndrome	Asian	176	25.1	0	0.0
Eye disorders	Vitreoretinal traction syndrome	Other	27	3.9	0	0.0
Eye disorders	Vitreoretinal traction syndrome	Unknown	24	3.4	0	0.0
Eye disorders	Vitreous detachment	White	474	67.6	1	0.2
Eye disorders	Vitreous detachment	Asian	176	25.1	0	0.0
Eye disorders	Vitreous detachment	Other	27	3.9	0	0.0
Eye disorders	Vitreous detachment	Unknown	24	3.4	0	0.0
Eye disorders	Vitreous floaters	White	474	67.6	1	0.2
Eye disorders	Vitreous floaters	Asian	176	25.1	0	0.0
Eye disorders	Vitreous floaters	Other	27	3.9	0	0.0
Eye disorders	Vitreous floaters	Unknown	24	3.4	0	0.0
Eye disorders	Vitreous haemorrhage	White	474	67.6	1	0.2
Eye disorders	Vitreous haemorrhage	Asian	176	25.1	0	0.0
Eye disorders	Vitreous haemorrhage	Other	27	3.9	0	0.0
Eye disorders	Vitreous haemorrhage	Unknown	24	3.4	0	0.0
Eye disorders	Vitritis	White	474	67.6	2	0.4
Eye disorders	Vitritis	Asian	176	25.1	0	0.0
Eye disorders	Vitritis	Other	27	3.9	0	0.0
Eye disorders	Vitritis	Unknown	24	3.4	0	0.0
Gastrointestinal disorders		White	474	67.6	12	2.5
Gastrointestinal disorders		Asian	176	25.1	4	2.3
Gastrointestinal disorders		Other	27	3.9	0	0.0
Gastrointestinal disorders		Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Abdominal pain	White	474	67.6	1	0.2
Gastrointestinal disorders	Abdominal pain	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Abdominal pain	Other	27	3.9	0	0.0
Gastrointestinal disorders	Abdominal pain	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Abdominal pain upper	White	474	67.6	1	0.2
Gastrointestinal disorders	Abdominal pain upper	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Abdominal pain upper	Other	27	3.9	0	0.0
Gastrointestinal disorders	Abdominal pain upper	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Barrett's oesophagus	White	474	67.6	1	0.2
Gastrointestinal disorders	Barrett's oesophagus	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Barrett's oesophagus	Other	27	3.9	0	0.0
Gastrointestinal disorders	Barrett's oesophagus	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Coeliac disease	White	474	67.6	1	0.2
Gastrointestinal disorders	Coeliac disease	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Coeliac disease	Other	27	3.9	0	0.0
Gastrointestinal disorders	Coeliac disease	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Colitis	White	474	67.6	1	0.2
Gastrointestinal disorders	Colitis	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Colitis	Other	27	3.9	0	0.0
Gastrointestinal disorders	Colitis	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Constipation	White	474	67.6	1	0.2
Gastrointestinal disorders	Constipation	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Constipation	Other	27	3.9	0	0.0
Gastrointestinal disorders	Constipation	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Dental discomfort	White	474	67.6	1	0.2
Gastrointestinal disorders	Dental discomfort	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Dental discomfort	Other	27	3.9	0	0.0
Gastrointestinal disorders	Dental discomfort	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Diarrhoea	White	474	67.6	3	0.6
Gastrointestinal disorders	Diarrhoea	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Diarrhoea	Other	27	3.9	0	0.0
Gastrointestinal disorders	Diarrhoea	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Gastric ulcer	White	474	67.6	0	0.0
Gastrointestinal disorders	Gastric ulcer	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Gastric ulcer	Other	27	3.9	0	0.0
Gastrointestinal disorders	Gastric ulcer	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Gastritis	White	474	67.6	1	0.2
Gastrointestinal disorders	Gastritis	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Gastritis	Other	27	3.9	0	0.0
Gastrointestinal disorders	Gastritis	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Gastroesophageal reflux disease	White	474	67.6	1	0.2
Gastrointestinal disorders	Gastroesophageal reflux disease	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Gastroesophageal reflux disease	Other	27	3.9	0	0.0
Gastrointestinal disorders	Gastroesophageal reflux disease	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Hiatus hernia	White	474	67.6	1	0.2

Gastrointestinal disorders	Hiatus hernia	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Hiatus hernia	Other	27	3.9	0	0.0
Gastrointestinal disorders	Hiatus hernia	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Ileus	White	474	67.6	0	0.0
Gastrointestinal disorders	Ileus	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Ileus	Other	27	3.9	0	0.0
Gastrointestinal disorders	Ileus	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Inguinal hernia	White	474	67.6	1	0.2
Gastrointestinal disorders	Inguinal hernia	Asian	176	25.1	0	0.0
Gastrointestinal disorders	Inguinal hernia	Other	27	3.9	0	0.0
Gastrointestinal disorders	Inguinal hernia	Unknown	24	3.4	0	0.0
Gastrointestinal disorders	Large intestine polyp	White	474	67.6	0	0.0
Gastrointestinal disorders	Large intestine polyp	Asian	176	25.1	1	0.6
Gastrointestinal disorders	Large intestine polyp	Other	27	3.9	0	0.0
Gastrointestinal disorders	Large intestine polyp	Unknown	24	3.4	0	0.0
General disorders and administration site conditions		White	474	67.6	9	1.9
General disorders and administration site conditions		Asian	176	25.1	2	1.1
General disorders and administration site conditions		Other	27	3.9	2	7.4
General disorders and administration site conditions		Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Asthenia	White	474	67.6	4	0.8
General disorders and administration site conditions	Asthenia	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Asthenia	Other	27	3.9	0	0.0
General disorders and administration site conditions	Asthenia	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Chest pain	White	474	67.6	1	0.2
General disorders and administration site conditions	Chest pain	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Chest pain	Other	27	3.9	0	0.0
General disorders and administration site conditions	Chest pain	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Injection site pain	White	474	67.6	1	0.2
General disorders and administration site conditions	Injection site pain	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Injection site pain	Other	27	3.9	0	0.0
General disorders and administration site conditions	Injection site pain	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Oedema peripheral	White	474	67.6	0	0.0
General disorders and administration site conditions	Oedema peripheral	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Oedema peripheral	Other	27	3.9	1	3.7
General disorders and administration site conditions	Oedema peripheral	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Pain	White	474	67.6	1	0.2
General disorders and administration site conditions	Pain	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Pain	Other	27	3.9	0	0.0
General disorders and administration site conditions	Pain	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Polyp	White	474	67.6	1	0.2
General disorders and administration site conditions	Polyp	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Polyp	Other	27	3.9	0	0.0
General disorders and administration site conditions	Polyp	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Pyrexia	White	474	67.6	1	0.2
General disorders and administration site conditions	Pyrexia	Asian	176	25.1	2	1.1
General disorders and administration site conditions	Pyrexia	Other	27	3.9	1	3.7
General disorders and administration site conditions	Pyrexia	Unknown	24	3.4	0	0.0
General disorders and administration site conditions	Systemic inflammatory response syndrome	White	474	67.6	1	0.2
General disorders and administration site conditions	Systemic inflammatory response syndrome	Asian	176	25.1	0	0.0
General disorders and administration site conditions	Systemic inflammatory response syndrome	Other	27	3.9	0	0.0
General disorders and administration site conditions	Systemic inflammatory response syndrome	Unknown	24	3.4	0	0.0
Hepatobiliary disorders		White	474	67.6	2	0.4
Hepatobiliary disorders		Asian	176	25.1	1	0.6
Hepatobiliary disorders		Other	27	3.9	0	0.0
Hepatobiliary disorders		Unknown	24	3.4	0	0.0
Hepatobiliary disorders	Cholecystitis	White	474	67.6	0	0.0
Hepatobiliary disorders	Cholecystitis	Asian	176	25.1	1	0.6
Hepatobiliary disorders	Cholecystitis	Other	27	3.9	0	0.0
Hepatobiliary disorders	Cholecystitis	Unknown	24	3.4	0	0.0
Hepatobiliary disorders	Cholelithiasis	White	474	67.6	2	0.4
Hepatobiliary disorders	Cholelithiasis	Asian	176	25.1	0	0.0
Hepatobiliary disorders	Cholelithiasis	Other	27	3.9	0	0.0
Hepatobiliary disorders	Cholelithiasis	Unknown	24	3.4	0	0.0
Immune system disorders		White	474	67.6	3	0.6
Immune system disorders		Asian	176	25.1	0	0.0
Immune system disorders		Other	27	3.9	0	0.0
Immune system disorders		Unknown	24	3.4	0	0.0
Immune system disorders	Drug hypersensitivity	White	474	67.6	1	0.2
Immune system disorders	Drug hypersensitivity	Asian	176	25.1	0	0.0
Immune system disorders	Drug hypersensitivity	Other	27	3.9	0	0.0
Immune system disorders	Drug hypersensitivity	Unknown	24	3.4	0	0.0
Immune system disorders	Iodine allergy	White	474	67.6	1	0.2
Immune system disorders	Iodine allergy	Asian	176	25.1	0	0.0
Immune system disorders	Iodine allergy	Other	27	3.9	0	0.0
Immune system disorders	Iodine allergy	Unknown	24	3.4	0	0.0
Immune system disorders	Seasonal allergy	White	474	67.6	1	0.2
Immune system disorders	Seasonal allergy	Asian	176	25.1	0	0.0
Immune system disorders	Seasonal allergy	Other	27	3.9	0	0.0
Immune system disorders	Seasonal allergy	Unknown	24	3.4	0	0.0
Infections and infestations		White	474	67.6	47	9.9
Infections and infestations		Asian	176	25.1	13	7.4
Infections and infestations		Other	27	3.9	3	11.1
Infections and infestations		Unknown	24	3.4	1	4.2
Infections and infestations	Arthritis infective	White	474	67.6	1	0.2
Infections and infestations	Arthritis infective	Asian	176	25.1	0	0.0
Infections and infestations	Arthritis infective	Other	27	3.9	0	0.0

Infections and infestations	Arthritis infective	Unknown	24	3,4	0	0,0
Infections and infestations	Bronchitis	White	474	67,6	4	0,8
Infections and infestations	Bronchitis	Asian	176	25,1	0	0,0
Infections and infestations	Bronchitis	Other	27	3,9	0	0,0
Infections and infestations	Bronchitis	Unknown	24	3,4	0	0,0
Infections and infestations	COVID-19	White	474	67,6	12	2,5
Infections and infestations	COVID-19	Asian	176	25,1	6	3,4
Infections and infestations	COVID-19	Other	27	3,9	0	0,0
Infections and infestations	COVID-19	Unknown	24	3,4	1	4,2
Infections and infestations	Cellulitis	White	474	67,6	4	0,8
Infections and infestations	Cellulitis	Asian	176	25,1	0	0,0
Infections and infestations	Cellulitis	Other	27	3,9	0	0,0
Infections and infestations	Cellulitis	Unknown	24	3,4	0	0,0
Infections and infestations	Conjunctivitis	White	474	67,6	1	0,2
Infections and infestations	Conjunctivitis	Asian	176	25,1	0	0,0
Infections and infestations	Conjunctivitis	Other	27	3,9	1	3,7
Infections and infestations	Conjunctivitis	Unknown	24	3,4	1	4,2
Infections and infestations	Cystitis	White	474	67,6	1	0,2
Infections and infestations	Cystitis	Asian	176	25,1	0	0,0
Infections and infestations	Cystitis	Other	27	3,9	0	0,0
Infections and infestations	Cystitis	Unknown	24	3,4	0	0,0
Infections and infestations	Ear infection	White	474	67,6	1	0,2
Infections and infestations	Ear infection	Asian	176	25,1	0	0,0
Infections and infestations	Ear infection	Other	27	3,9	0	0,0
Infections and infestations	Ear infection	Unknown	24	3,4	0	0,0
Infections and infestations	Fungal skin infection	White	474	67,6	1	0,2
Infections and infestations	Fungal skin infection	Asian	176	25,1	0	0,0
Infections and infestations	Fungal skin infection	Other	27	3,9	0	0,0
Infections and infestations	Fungal skin infection	Unknown	24	3,4	0	0,0
Infections and infestations	Helicobacter infection	White	474	67,6	0	0,0
Infections and infestations	Helicobacter infection	Asian	176	25,1	1	0,6
Infections and infestations	Helicobacter infection	Other	27	3,9	0	0,0
Infections and infestations	Helicobacter infection	Unknown	24	3,4	0	0,0
Infections and infestations	Herpes zoster	White	474	67,6	1	0,2
Infections and infestations	Herpes zoster	Asian	176	25,1	1	0,6
Infections and infestations	Herpes zoster	Other	27	3,9	0	0,0
Infections and infestations	Herpes zoster	Unknown	24	3,4	0	0,0
Infections and infestations	Influenza	White	474	67,6	7	1,5
Infections and infestations	Influenza	Asian	176	25,1	1	0,6
Infections and infestations	Influenza	Other	27	3,9	0	0,0
Infections and infestations	Influenza	Unknown	24	3,4	0	0,0
Infections and infestations	Kidney infection	White	474	67,6	1	0,2
Infections and infestations	Kidney infection	Asian	176	25,1	0	0,0
Infections and infestations	Kidney infection	Other	27	3,9	0	0,0
Infections and infestations	Kidney infection	Unknown	24	3,4	0	0,0
Infections and infestations	Laryngitis	White	474	67,6	1	0,2
Infections and infestations	Laryngitis	Asian	176	25,1	0	0,0
Infections and infestations	Laryngitis	Other	27	3,9	0	0,0
Infections and infestations	Laryngitis	Unknown	24	3,4	0	0,0
Infections and infestations	Nasopharyngitis	White	474	67,6	3	0,6
Infections and infestations	Nasopharyngitis	Asian	176	25,1	1	0,6
Infections and infestations	Nasopharyngitis	Other	27	3,9	0	0,0
Infections and infestations	Nasopharyngitis	Unknown	24	3,4	0	0,0
Infections and infestations	Pharyngitis	White	474	67,6	0	0,0
Infections and infestations	Pharyngitis	Asian	176	25,1	1	0,6
Infections and infestations	Pharyngitis	Other	27	3,9	0	0,0
Infections and infestations	Pharyngitis	Unknown	24	3,4	0	0,0
Infections and infestations	Pneumonia	White	474	67,6	3	0,6
Infections and infestations	Pneumonia	Asian	176	25,1	1	0,6
Infections and infestations	Pneumonia	Other	27	3,9	1	3,7
Infections and infestations	Pneumonia	Unknown	24	3,4	0	0,0
Infections and infestations	Pneumonia viral	White	474	67,6	0	0,0
Infections and infestations	Pneumonia viral	Asian	176	25,1	1	0,6
Infections and infestations	Pneumonia viral	Other	27	3,9	0	0,0
Infections and infestations	Pneumonia viral	Unknown	24	3,4	0	0,0
Infections and infestations	Pulpitis dental	White	474	67,6	2	0,4
Infections and infestations	Pulpitis dental	Asian	176	25,1	0	0,0
Infections and infestations	Pulpitis dental	Other	27	3,9	0	0,0
Infections and infestations	Pulpitis dental	Unknown	24	3,4	0	0,0
Infections and infestations	Respiratory tract infection	White	474	67,6	1	0,2
Infections and infestations	Respiratory tract infection	Asian	176	25,1	1	0,6
Infections and infestations	Respiratory tract infection	Other	27	3,9	0	0,0
Infections and infestations	Respiratory tract infection	Unknown	24	3,4	0	0,0
Infections and infestations	Respiratory tract infection viral	White	474	67,6	1	0,2
Infections and infestations	Respiratory tract infection viral	Asian	176	25,1	0	0,0
Infections and infestations	Respiratory tract infection viral	Other	27	3,9	0	0,0
Infections and infestations	Respiratory tract infection viral	Unknown	24	3,4	0	0,0
Infections and infestations	Sinusitis	White	474	67,6	1	0,2
Infections and infestations	Sinusitis	Asian	176	25,1	1	0,6
Infections and infestations	Sinusitis	Other	27	3,9	0	0,0
Infections and infestations	Sinusitis	Unknown	24	3,4	0	0,0
Infections and infestations	Staphylococcal infection	White	474	67,6	1	0,2
Infections and infestations	Staphylococcal infection	Asian	176	25,1	0	0,0
Infections and infestations	Staphylococcal infection	Other	27	3,9	0	0,0
Infections and infestations	Staphylococcal infection	Unknown	24	3,4	0	0,0
Infections and infestations	Suspected COVID-19	White	474	67,6	0	0,0
Infections and infestations	Suspected COVID-19	Asian	176	25,1	1	0,6
Infections and infestations	Suspected COVID-19	Other	27	3,9	0	0,0
Infections and infestations	Suspected COVID-19	Unknown	24	3,4	0	0,0
Infections and infestations	Tooth abscess	White	474	67,6	1	0,2

Infections and infestations	Tooth abscess	Asian	176	25.1	0	0.0
Infections and infestations	Tooth abscess	Other	27	3.9	0	0.0
Infections and infestations	Tooth abscess	Unknown	24	3.4	0	0.0
Infections and infestations	Upper respiratory tract infection	White	474	67.6	8	1.7
Infections and infestations	Upper respiratory tract infection	Asian	176	25.1	1	0.6
Infections and infestations	Upper respiratory tract infection	Other	27	3.9	0	0.0
Infections and infestations	Upper respiratory tract infection	Unknown	24	3.4	0	0.0
Infections and infestations	Urinary tract infection	White	474	67.6	6	1.3
Infections and infestations	Urinary tract infection	Asian	176	25.1	0	0.0
Infections and infestations	Urinary tract infection	Other	27	3.9	1	3.7
Infections and infestations	Urinary tract infection	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications		White	474	67.6	18	3.8
Injury, poisoning and procedural complications		Asian	176	25.1	5	2.8
Injury, poisoning and procedural complications		Other	27	3.9	1	3.7
Injury, poisoning and procedural complications		Unknown	24	3.4	1	4.2
Injury, poisoning and procedural complications	Arthropod bite	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Arthropod bite	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Arthropod bite	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Arthropod bite	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Fall	White	474	67.6	6	1.3
Injury, poisoning and procedural complications	Fall	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Fall	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Fall	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Femur fracture	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Femur fracture	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Femur fracture	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Femur fracture	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Fibula fracture	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Fibula fracture	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Fibula fracture	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Fibula fracture	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Foreign body in eye	White	474	67.6	0	0.0
Injury, poisoning and procedural complications	Foreign body in eye	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Foreign body in eye	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Foreign body in eye	Unknown	24	3.4	1	4.2
Injury, poisoning and procedural complications	Fracture	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Fracture	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Fracture	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Fracture	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Hand fracture	White	474	67.6	0	0.0
Injury, poisoning and procedural complications	Hand fracture	Asian	176	25.1	2	1.1
Injury, poisoning and procedural complications	Hand fracture	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Hand fracture	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Hip fracture	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Hip fracture	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Hip fracture	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Hip fracture	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Hypobarism	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Hypobarism	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Hypobarism	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Hypobarism	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Limb injury	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Limb injury	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Limb injury	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Limb injury	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Lower limb fracture	White	474	67.6	0	0.0
Injury, poisoning and procedural complications	Lower limb fracture	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Lower limb fracture	Other	27	3.9	1	3.7
Injury, poisoning and procedural complications	Lower limb fracture	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Lumbar vertebral fracture	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Muscle strain	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Muscle strain	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Muscle strain	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Muscle strain	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Posterior capsule rupture	White	474	67.6	0	0.0
Injury, poisoning and procedural complications	Posterior capsule rupture	Asian	176	25.1	1	0.6
Injury, poisoning and procedural complications	Posterior capsule rupture	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Posterior capsule rupture	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Rib fracture	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Rib fracture	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Rib fracture	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Rib fracture	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Road traffic accident	White	474	67.6	2	0.4
Injury, poisoning and procedural complications	Road traffic accident	Asian	176	25.1	0	0.0
Injury, poisoning and procedural complications	Road traffic accident	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Road traffic accident	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Skin laceration	White	474	67.6	0	0.0
Injury, poisoning and procedural complications	Skin laceration	Asian	176	25.1	1	0.6
Injury, poisoning and procedural complications	Skin laceration	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Skin laceration	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Spinal compression fracture	White	474	67.6	0	0.0
Injury, poisoning and procedural complications	Spinal compression fracture	Asian	176	25.1	1	0.6
Injury, poisoning and procedural complications	Spinal compression fracture	Other	27	3.9	0	0.0
Injury, poisoning and procedural complications	Spinal compression fracture	Unknown	24	3.4	0	0.0
Injury, poisoning and procedural complications	Sunburn	White	474	67.6	1	0.2
Injury, poisoning and procedural complications	Sunburn	Asian	176	25.1	0	0.0

Injury, poisoning and procedural complications	Sunburn	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Sunburn	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Tibia fracture	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Tooth fracture	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	White	474	67,6	2	0,4
Injury, poisoning and procedural complications	Wrist fracture	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	Unknown	24	3,4	0	0,0
Investigations		White	474	67,6	11	2,3
Investigations		Asian	176	25,1	4	2,3
Investigations		Other	27	3,9	0	0,0
Investigations		Unknown	24	3,4	1	4,2
Investigations	Blood pressure increased	White	474	67,6	1	0,2
Investigations	Blood pressure increased	Asian	176	25,1	1	0,6
Investigations	Blood pressure increased	Other	27	3,9	0	0,0
Investigations	Blood pressure increased	Unknown	24	3,4	0	0,0
Investigations	Blood testosterone decreased	White	474	67,6	1	0,2
Investigations	Blood testosterone decreased	Asian	176	25,1	0	0,0
Investigations	Blood testosterone decreased	Other	27	3,9	0	0,0
Investigations	Blood testosterone decreased	Unknown	24	3,4	0	0,0
Investigations	Intraocular pressure increased	White	474	67,6	7	1,5
Investigations	Intraocular pressure increased	Asian	176	25,1	3	1,7
Investigations	Intraocular pressure increased	Other	27	3,9	0	0,0
Investigations	Intraocular pressure increased	Unknown	24	3,4	0	0,0
Investigations	Occult blood positive	White	474	67,6	1	0,2
Investigations	Occult blood positive	Asian	176	25,1	0	0,0
Investigations	Occult blood positive	Other	27	3,9	0	0,0
Investigations	Occult blood positive	Unknown	24	3,4	0	0,0
Investigations	Optic nerve cup/disc ratio increased	White	474	67,6	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Asian	176	25,1	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Other	27	3,9	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Unknown	24	3,4	1	4,2
Investigations	Weight decreased	White	474	67,6	1	0,2
Investigations	Weight decreased	Asian	176	25,1	0	0,0
Investigations	Weight decreased	Other	27	3,9	0	0,0
Investigations	Weight decreased	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders		White	474	67,6	12	2,5
Metabolism and nutrition disorders		Asian	176	25,1	1	0,6
Metabolism and nutrition disorders		Other	27	3,9	1	3,7
Metabolism and nutrition disorders		Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Dehydration	White	474	67,6	2	0,4
Metabolism and nutrition disorders	Dehydration	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Dehydration	Other	27	3,9	0	0,0
Metabolism and nutrition disorders	Dehydration	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	White	474	67,6	1	0,2
Metabolism and nutrition disorders	Glucose tolerance impaired	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	Other	27	3,9	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Gout	White	474	67,6	1	0,2
Metabolism and nutrition disorders	Gout	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Gout	Other	27	3,9	0	0,0
Metabolism and nutrition disorders	Gout	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	White	474	67,6	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	Other	27	3,9	1	3,7
Metabolism and nutrition disorders	Hypercholesterolaemia	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	White	474	67,6	1	0,2
Metabolism and nutrition disorders	Hyperglycaemia	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Other	27	3,9	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	White	474	67,6	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	Asian	176	25,1	1	0,6
Metabolism and nutrition disorders	Hypoglycaemia	Other	27	3,9	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	White	474	67,6	5	1,1
Metabolism and nutrition disorders	Hypokalaemia	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Other	27	3,9	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	White	474	67,6	1	0,2
Metabolism and nutrition disorders	Hyponatraemia	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	Other	27	3,9	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	White	474	67,6	2	0,4
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Other	27	3,9	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders		White	474	67,6	13	2,7
Musculoskeletal and connective tissue disorders		Asian	176	25,1	2	1,1
Musculoskeletal and connective tissue disorders		Other	27	3,9	1	3,7
Musculoskeletal and connective tissue disorders		Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	White	474	67,6	2	0,4

Musculoskeletal and connective tissue disorders	Arthralgia	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Arthralgia	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Arthralgia	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Back pain	White	474	67.6	4	0.8
Musculoskeletal and connective tissue disorders	Back pain	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Back pain	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Back pain	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Bone loss	White	474	67.6	1	0.2
Musculoskeletal and connective tissue disorders	Bone loss	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Bone loss	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Bone loss	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Bursitis	White	474	67.6	1	0.2
Musculoskeletal and connective tissue disorders	Bursitis	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Bursitis	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Bursitis	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Flank pain	White	474	67.6	1	0.2
Musculoskeletal and connective tissue disorders	Flank pain	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Flank pain	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Flank pain	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	White	474	67.6	1	0.2
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	White	474	67.6	0	0.0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Asian	176	25.1	1	0.6
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Osteoarthritis	White	474	67.6	1	0.2
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Pain in extremity	White	474	67.6	2	0.4
Musculoskeletal and connective tissue disorders	Pain in extremity	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Pain in extremity	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Pain in extremity	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Periarthritis	White	474	67.6	0	0.0
Musculoskeletal and connective tissue disorders	Periarthritis	Asian	176	25.1	1	0.6
Musculoskeletal and connective tissue disorders	Periarthritis	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Periarthritis	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	White	474	67.6	1	0.2
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Scoliosis	White	474	67.6	1	0.2
Musculoskeletal and connective tissue disorders	Scoliosis	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Scoliosis	Other	27	3.9	0	0.0
Musculoskeletal and connective tissue disorders	Scoliosis	Unknown	24	3.4	0	0.0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	White	474	67.6	0	0.0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Asian	176	25.1	0	0.0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Other	27	3.9	1	3.7
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		White	474	67.6	5	1.1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asian	176	25.1	1	0.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	White	474	67.6	1	0.2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Asian	176	25.1	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	White	474	67.6	1	0.2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Asian	176	25.1	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	White	474	67.6	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Asian	176	25.1	1	0.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	White	474	67.6	1	0.2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Asian	176	25.1	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Unknown	24	3.4	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	White	474	67.6	2	0.4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Asian	176	25.1	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Other	27	3.9	0	0.0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Unknown	24	3.4	0	0.0
Nervous system disorders		White	474	67.6	13	2.7
Nervous system disorders		Asian	176	25.1	4	2.3
Nervous system disorders		Other	27	3.9	0	0.0
Nervous system disorders		Unknown	24	3.4	0	0.0
Nervous system disorders	Cerebral atrophy	White	474	67.6	0	0.0
Nervous system disorders	Cerebral atrophy	Asian	176	25.1	1	0.6
Nervous system disorders	Cerebral atrophy	Other	27	3.9	0	0.0
Nervous system disorders	Cerebral atrophy	Unknown	24	3.4	0	0.0
Nervous system disorders	Cerebral infarction	White	474	67.6	0	0.0
Nervous system disorders	Cerebral infarction	Asian	176	25.1	1	0.6
Nervous system disorders	Cerebral infarction	Other	27	3.9	0	0.0
Nervous system disorders	Cerebral infarction	Unknown	24	3.4	0	0.0
Nervous system disorders	Diabetic neuropathy	White	474	67.6	1	0.2

Nervous system disorders	Diabetic neuropathy	Asian	176	25.1	1	0.6
Nervous system disorders	Diabetic neuropathy	Other	27	3.9	0	0.0
Nervous system disorders	Diabetic neuropathy	Unknown	24	3.4	0	0.0
Nervous system disorders	Dizziness	White	474	67.6	1	0.2
Nervous system disorders	Dizziness	Asian	176	25.1	0	0.0
Nervous system disorders	Dizziness	Other	27	3.9	0	0.0
Nervous system disorders	Dizziness	Unknown	24	3.4	0	0.0
Nervous system disorders	Encephalopathy	White	474	67.6	1	0.2
Nervous system disorders	Encephalopathy	Asian	176	25.1	0	0.0
Nervous system disorders	Encephalopathy	Other	27	3.9	0	0.0
Nervous system disorders	Encephalopathy	Unknown	24	3.4	0	0.0
Nervous system disorders	Headache	White	474	67.6	2	0.4
Nervous system disorders	Headache	Asian	176	25.1	0	0.0
Nervous system disorders	Headache	Other	27	3.9	0	0.0
Nervous system disorders	Headache	Unknown	24	3.4	0	0.0
Nervous system disorders	Ischaemic stroke	White	474	67.6	1	0.2
Nervous system disorders	Ischaemic stroke	Asian	176	25.1	0	0.0
Nervous system disorders	Ischaemic stroke	Other	27	3.9	0	0.0
Nervous system disorders	Ischaemic stroke	Unknown	24	3.4	0	0.0
Nervous system disorders	Lacunar infarction	White	474	67.6	0	0.0
Nervous system disorders	Lacunar infarction	Asian	176	25.1	1	0.6
Nervous system disorders	Lacunar infarction	Other	27	3.9	0	0.0
Nervous system disorders	Lacunar infarction	Unknown	24	3.4	0	0.0
Nervous system disorders	Loss of consciousness	White	474	67.6	1	0.2
Nervous system disorders	Loss of consciousness	Asian	176	25.1	0	0.0
Nervous system disorders	Loss of consciousness	Other	27	3.9	0	0.0
Nervous system disorders	Loss of consciousness	Unknown	24	3.4	0	0.0
Nervous system disorders	Neuralgia	White	474	67.6	1	0.2
Nervous system disorders	Neuralgia	Asian	176	25.1	0	0.0
Nervous system disorders	Neuralgia	Other	27	3.9	0	0.0
Nervous system disorders	Neuralgia	Unknown	24	3.4	0	0.0
Nervous system disorders	Neuropathy peripheral	White	474	67.6	2	0.4
Nervous system disorders	Neuropathy peripheral	Asian	176	25.1	0	0.0
Nervous system disorders	Neuropathy peripheral	Other	27	3.9	0	0.0
Nervous system disorders	Neuropathy peripheral	Unknown	24	3.4	0	0.0
Nervous system disorders	Ophthalmic migraine	White	474	67.6	1	0.2
Nervous system disorders	Ophthalmic migraine	Asian	176	25.1	0	0.0
Nervous system disorders	Ophthalmic migraine	Other	27	3.9	0	0.0
Nervous system disorders	Ophthalmic migraine	Unknown	24	3.4	0	0.0
Nervous system disorders	Sciatica	White	474	67.6	2	0.4
Nervous system disorders	Sciatica	Asian	176	25.1	0	0.0
Nervous system disorders	Sciatica	Other	27	3.9	0	0.0
Nervous system disorders	Sciatica	Unknown	24	3.4	0	0.0
Nervous system disorders	Syncope	White	474	67.6	1	0.2
Nervous system disorders	Syncope	Asian	176	25.1	1	0.6
Nervous system disorders	Syncope	Other	27	3.9	0	0.0
Nervous system disorders	Syncope	Unknown	24	3.4	0	0.0
Psychiatric disorders		White	474	67.6	3	0.6
Psychiatric disorders		Asian	176	25.1	0	0.0
Psychiatric disorders		Other	27	3.9	0	0.0
Psychiatric disorders		Unknown	24	3.4	0	0.0
Psychiatric disorders	Anxiety	White	474	67.6	1	0.2
Psychiatric disorders	Anxiety	Asian	176	25.1	0	0.0
Psychiatric disorders	Anxiety	Other	27	3.9	0	0.0
Psychiatric disorders	Anxiety	Unknown	24	3.4	0	0.0
Psychiatric disorders	Depression	White	474	67.6	1	0.2
Psychiatric disorders	Depression	Asian	176	25.1	0	0.0
Psychiatric disorders	Depression	Other	27	3.9	0	0.0
Psychiatric disorders	Depression	Unknown	24	3.4	0	0.0
Psychiatric disorders	Insomnia	White	474	67.6	1	0.2
Psychiatric disorders	Insomnia	Asian	176	25.1	0	0.0
Psychiatric disorders	Insomnia	Other	27	3.9	0	0.0
Psychiatric disorders	Insomnia	Unknown	24	3.4	0	0.0
Renal and urinary disorders		White	474	67.6	5	1.1
Renal and urinary disorders		Asian	176	25.1	1	0.6
Renal and urinary disorders		Other	27	3.9	0	0.0
Renal and urinary disorders		Unknown	24	3.4	0	0.0
Renal and urinary disorders	Acute kidney injury	White	474	67.6	2	0.4
Renal and urinary disorders	Acute kidney injury	Asian	176	25.1	0	0.0
Renal and urinary disorders	Acute kidney injury	Other	27	3.9	0	0.0
Renal and urinary disorders	Acute kidney injury	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Diabetic nephropathy	White	474	67.6	0	0.0
Renal and urinary disorders	Diabetic nephropathy	Asian	176	25.1	1	0.6
Renal and urinary disorders	Diabetic nephropathy	Other	27	3.9	0	0.0
Renal and urinary disorders	Diabetic nephropathy	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Renal failure	White	474	67.6	1	0.2
Renal and urinary disorders	Renal failure	Asian	176	25.1	0	0.0
Renal and urinary disorders	Renal failure	Other	27	3.9	0	0.0
Renal and urinary disorders	Renal failure	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Urinary retention	White	474	67.6	1	0.2
Renal and urinary disorders	Urinary retention	Asian	176	25.1	0	0.0
Renal and urinary disorders	Urinary retention	Other	27	3.9	0	0.0
Renal and urinary disorders	Urinary retention	Unknown	24	3.4	0	0.0
Renal and urinary disorders	Urinary tract inflammation	White	474	67.6	1	0.2
Renal and urinary disorders	Urinary tract inflammation	Asian	176	25.1	0	0.0
Renal and urinary disorders	Urinary tract inflammation	Other	27	3.9	0	0.0
Renal and urinary disorders	Urinary tract inflammation	Unknown	24	3.4	0	0.0

Reproductive system and breast disorders		White	474	67.6	2	0.4
Reproductive system and breast disorders		Asian	176	25.1	0	0.0
Reproductive system and breast disorders		Other	27	3.9	0	0.0
Reproductive system and breast disorders		Unknown	24	3.4	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	White	474	67.6	1	0.2
Reproductive system and breast disorders	Benign prostatic hyperplasia	Asian	176	25.1	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Other	27	3.9	0	0.0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Unknown	24	3.4	0	0.0
Reproductive system and breast disorders	Cystocele	White	474	67.6	1	0.2
Reproductive system and breast disorders	Cystocele	Asian	176	25.1	0	0.0
Reproductive system and breast disorders	Cystocele	Other	27	3.9	0	0.0
Reproductive system and breast disorders	Cystocele	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders		White	474	67.6	11	2.3
Respiratory, thoracic and mediastinal disorders		Asian	176	25.1	1	0.6
Respiratory, thoracic and mediastinal disorders		Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders		Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	White	474	67.6	2	0.4
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Asian	176	25.1	0	0.0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Asthma	White	474	67.6	1	0.2
Respiratory, thoracic and mediastinal disorders	Asthma	Asian	176	25.1	1	0.6
Respiratory, thoracic and mediastinal disorders	Asthma	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Asthma	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	White	474	67.6	5	1.1
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Asian	176	25.1	0	0.0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Cough	White	474	67.6	1	0.2
Respiratory, thoracic and mediastinal disorders	Cough	Asian	176	25.1	0	0.0
Respiratory, thoracic and mediastinal disorders	Cough	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Cough	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	White	474	67.6	1	0.2
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Asian	176	25.1	0	0.0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	White	474	67.6	1	0.2
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Asian	176	25.1	0	0.0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	White	474	67.6	1	0.2
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Asian	176	25.1	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	White	474	67.6	1	0.2
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Asian	176	25.1	0	0.0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Unknown	24	3.4	0	0.0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	White	474	67.6	1	0.2
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Asian	176	25.1	0	0.0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Other	27	3.9	0	0.0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders		White	474	67.6	5	1.1
Skin and subcutaneous tissue disorders		Asian	176	25.1	4	2.3
Skin and subcutaneous tissue disorders		Other	27	3.9	1	3.7
Skin and subcutaneous tissue disorders		Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Dermatitis	White	474	67.6	0	0.0
Skin and subcutaneous tissue disorders	Dermatitis	Asian	176	25.1	1	0.6
Skin and subcutaneous tissue disorders	Dermatitis	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Dermatitis	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Dermatitis contact	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Dermatitis contact	Asian	176	25.1	2	1.1
Skin and subcutaneous tissue disorders	Dermatitis contact	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Dermatitis contact	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Diabetic foot	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Diabetic foot	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Diabetic foot	Other	27	3.9	1	3.7
Skin and subcutaneous tissue disorders	Diabetic foot	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Erythema	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Erythema	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Erythema	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Erythema	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Nail bed bleeding	White	474	67.6	0	0.0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Asian	176	25.1	1	0.6
Skin and subcutaneous tissue disorders	Nail bed bleeding	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Nail dystrophy	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Nail dystrophy	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Nail dystrophy	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Nail dystrophy	Unknown	24	3.4	0	0.0
Skin and subcutaneous tissue disorders	Urticaria	White	474	67.6	1	0.2
Skin and subcutaneous tissue disorders	Urticaria	Asian	176	25.1	0	0.0
Skin and subcutaneous tissue disorders	Urticaria	Other	27	3.9	0	0.0
Skin and subcutaneous tissue disorders	Urticaria	Unknown	24	3.4	0	0.0

Surgical and medical procedures		White	474	67.6	4	0.8
Surgical and medical procedures		Asian	176	25.1	1	0.6
Surgical and medical procedures		Other	27	3.9	0	0.0
Surgical and medical procedures		Unknown	24	3.4	0	0.0
Surgical and medical procedures	Dental implantation	White	474	67.6	1	0.2
Surgical and medical procedures	Dental implantation	Asian	176	25.1	1	0.6
Surgical and medical procedures	Dental implantation	Other	27	3.9	0	0.0
Surgical and medical procedures	Dental implantation	Unknown	24	3.4	0	0.0
Surgical and medical procedures	Ligament operation	White	474	67.6	1	0.2
Surgical and medical procedures	Ligament operation	Asian	176	25.1	0	0.0
Surgical and medical procedures	Ligament operation	Other	27	3.9	0	0.0
Surgical and medical procedures	Ligament operation	Unknown	24	3.4	0	0.0
Surgical and medical procedures	Toe operation	White	474	67.6	1	0.2
Surgical and medical procedures	Toe operation	Asian	176	25.1	0	0.0
Surgical and medical procedures	Toe operation	Other	27	3.9	0	0.0
Surgical and medical procedures	Toe operation	Unknown	24	3.4	0	0.0
Surgical and medical procedures	Tooth extraction	White	474	67.6	1	0.2
Surgical and medical procedures	Tooth extraction	Asian	176	25.1	0	0.0
Surgical and medical procedures	Tooth extraction	Other	27	3.9	0	0.0
Surgical and medical procedures	Tooth extraction	Unknown	24	3.4	0	0.0
Vascular disorders		White	474	67.6	15	3.2
Vascular disorders		Asian	176	25.1	1	0.6
Vascular disorders		Other	27	3.9	1	3.7
Vascular disorders		Unknown	24	3.4	0	0.0
Vascular disorders	Aortic stenosis	White	474	67.6	1	0.2
Vascular disorders	Aortic stenosis	Asian	176	25.1	0	0.0
Vascular disorders	Aortic stenosis	Other	27	3.9	0	0.0
Vascular disorders	Aortic stenosis	Unknown	24	3.4	0	0.0
Vascular disorders	Hypertension	White	474	67.6	9	1.9
Vascular disorders	Hypertension	Asian	176	25.1	1	0.6
Vascular disorders	Hypertension	Other	27	3.9	1	3.7
Vascular disorders	Hypertension	Unknown	24	3.4	0	0.0
Vascular disorders	Hypertensive crisis	White	474	67.6	2	0.4
Vascular disorders	Hypertensive crisis	Asian	176	25.1	0	0.0
Vascular disorders	Hypertensive crisis	Other	27	3.9	0	0.0
Vascular disorders	Hypertensive crisis	Unknown	24	3.4	0	0.0
Vascular disorders	Hypotension	White	474	67.6	2	0.4
Vascular disorders	Hypotension	Asian	176	25.1	1	0.6
Vascular disorders	Hypotension	Other	27	3.9	0	0.0
Vascular disorders	Hypotension	Unknown	24	3.4	0	0.0
Vascular disorders	Thrombosis	White	474	67.6	1	0.2
Vascular disorders	Thrombosis	Asian	176	25.1	0	0.0
Vascular disorders	Thrombosis	Other	27	3.9	0	0.0
Vascular disorders	Thrombosis	Unknown	24	3.4	0	0.0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WMODAE_WK72_SEa24_29AUG2023_41986.xls
26APR2024 18:08

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Moderate AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline RVO status

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		CRVO	574	81,9	4	0,7
Blood and lymphatic system disorders		HRVO	121	17,3	1	0,8
Blood and lymphatic system disorders		Missing	6	0,9	0	0,0
Blood and lymphatic system disorders	Anaemia	CRVO	574	81,9	4	0,7
Blood and lymphatic system disorders	Anaemia	HRVO	121	17,3	1	0,8
Blood and lymphatic system disorders	Anaemia	Missing	6	0,9	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	CRVO	574	81,9	1	0,2
Blood and lymphatic system disorders	Mesenteric lymphadenitis	HRVO	121	17,3	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Missing	6	0,9	0	0,0
Cardiac disorders		CRVO	574	81,9	13	2,3
Cardiac disorders		HRVO	121	17,3	1	0,8
Cardiac disorders		Missing	6	0,9	1	16,7
Cardiac disorders	Acute left ventricular failure	CRVO	574	81,9	1	0,2
Cardiac disorders	Acute left ventricular failure	HRVO	121	17,3	0	0,0
Cardiac disorders	Acute left ventricular failure	Missing	6	0,9	0	0,0
Cardiac disorders	Aortic valve incompetence	CRVO	574	81,9	1	0,2
Cardiac disorders	Aortic valve incompetence	HRVO	121	17,3	0	0,0
Cardiac disorders	Aortic valve incompetence	Missing	6	0,9	0	0,0
Cardiac disorders	Arrhythmia	CRVO	574	81,9	1	0,2
Cardiac disorders	Arrhythmia	HRVO	121	17,3	0	0,0
Cardiac disorders	Arrhythmia	Missing	6	0,9	0	0,0
Cardiac disorders	Atrial fibrillation	CRVO	574	81,9	4	0,7
Cardiac disorders	Atrial fibrillation	HRVO	121	17,3	1	0,8
Cardiac disorders	Atrial fibrillation	Missing	6	0,9	0	0,0
Cardiac disorders	Bradycardia	CRVO	574	81,9	1	0,2
Cardiac disorders	Bradycardia	HRVO	121	17,3	0	0,0
Cardiac disorders	Bradycardia	Missing	6	0,9	0	0,0
Cardiac disorders	Cardiomegaly	CRVO	574	81,9	1	0,2
Cardiac disorders	Cardiomegaly	HRVO	121	17,3	0	0,0
Cardiac disorders	Cardiomegaly	Missing	6	0,9	0	0,0
Cardiac disorders	Coronary artery stenosis	CRVO	574	81,9	1	0,2
Cardiac disorders	Coronary artery stenosis	HRVO	121	17,3	0	0,0
Cardiac disorders	Coronary artery stenosis	Missing	6	0,9	0	0,0
Cardiac disorders	Myocardial infarction	CRVO	574	81,9	1	0,2
Cardiac disorders	Myocardial infarction	HRVO	121	17,3	0	0,0
Cardiac disorders	Myocardial infarction	Missing	6	0,9	0	0,0
Cardiac disorders	Myocardial ischaemia	CRVO	574	81,9	1	0,2
Cardiac disorders	Myocardial ischaemia	HRVO	121	17,3	0	0,0
Cardiac disorders	Myocardial ischaemia	Missing	6	0,9	0	0,0
Cardiac disorders	Palpitations	CRVO	574	81,9	1	0,2
Cardiac disorders	Palpitations	HRVO	121	17,3	0	0,0
Cardiac disorders	Palpitations	Missing	6	0,9	0	0,0
Cardiac disorders	Sinus tachycardia	CRVO	574	81,9	1	0,2
Cardiac disorders	Sinus tachycardia	HRVO	121	17,3	0	0,0
Cardiac disorders	Sinus tachycardia	Missing	6	0,9	0	0,0
Cardiac disorders	Supraventricular tachycardia	CRVO	574	81,9	0	0,0
Cardiac disorders	Supraventricular tachycardia	HRVO	121	17,3	0	0,0
Cardiac disorders	Supraventricular tachycardia	Missing	6	0,9	1	16,7
Congenital, familial and genetic disorders		CRVO	574	81,9	1	0,2
Congenital, familial and genetic disorders		HRVO	121	17,3	0	0,0
Congenital, familial and genetic disorders		Missing	6	0,9	0	0,0
Congenital, familial and genetic disorders	Corneal dystrophy	CRVO	574	81,9	1	0,2
Congenital, familial and genetic disorders	Corneal dystrophy	HRVO	121	17,3	0	0,0

Congenital, familial and genetic disorders	Corneal dystrophy	Missing	6	0,9	0	0,0
Ear and labyrinth disorders		CRVO	574	81,9	2	0,3
Ear and labyrinth disorders		HRVO	121	17,3	0	0,0
Ear and labyrinth disorders		Missing	6	0,9	0	0,0
Ear and labyrinth disorders	Vertigo	CRVO	574	81,9	2	0,3
Ear and labyrinth disorders	Vertigo	HRVO	121	17,3	0	0,0
Ear and labyrinth disorders	Vertigo	Missing	6	0,9	0	0,0
Endocrine disorders		CRVO	574	81,9	2	0,3
Endocrine disorders		HRVO	121	17,3	0	0,0
Endocrine disorders		Missing	6	0,9	0	0,0
Endocrine disorders	Androgen deficiency	CRVO	574	81,9	1	0,2
Endocrine disorders	Androgen deficiency	HRVO	121	17,3	0	0,0
Endocrine disorders	Androgen deficiency	Missing	6	0,9	0	0,0
Endocrine disorders	Hypothyroidism	CRVO	574	81,9	1	0,2
Endocrine disorders	Hypothyroidism	HRVO	121	17,3	0	0,0
Endocrine disorders	Hypothyroidism	Missing	6	0,9	0	0,0
Eye disorders		CRVO	574	81,9	71	12,4
Eye disorders		HRVO	121	17,3	21	17,4
Eye disorders		Missing	6	0,9	0	0,0
Eye disorders	Asthenopia	CRVO	574	81,9	0	0,0
Eye disorders	Asthenopia	HRVO	121	17,3	1	0,8
Eye disorders	Asthenopia	Missing	6	0,9	0	0,0
Eye disorders	Blepharitis	CRVO	574	81,9	1	0,2
Eye disorders	Blepharitis	HRVO	121	17,3	0	0,0
Eye disorders	Blepharitis	Missing	6	0,9	0	0,0
Eye disorders	Cataract	CRVO	574	81,9	9	1,6
Eye disorders	Cataract	HRVO	121	17,3	1	0,8
Eye disorders	Cataract	Missing	6	0,9	0	0,0
Eye disorders	Cataract nuclear	CRVO	574	81,9	1	0,2
Eye disorders	Cataract nuclear	HRVO	121	17,3	0	0,0
Eye disorders	Cataract nuclear	Missing	6	0,9	0	0,0
Eye disorders	Cataract subcapsular	CRVO	574	81,9	1	0,2
Eye disorders	Cataract subcapsular	HRVO	121	17,3	0	0,0
Eye disorders	Cataract subcapsular	Missing	6	0,9	0	0,0
Eye disorders	Chalazion	CRVO	574	81,9	1	0,2
Eye disorders	Chalazion	HRVO	121	17,3	0	0,0
Eye disorders	Chalazion	Missing	6	0,9	0	0,0
Eye disorders	Choroidal effusion	CRVO	574	81,9	1	0,2
Eye disorders	Choroidal effusion	HRVO	121	17,3	0	0,0
Eye disorders	Choroidal effusion	Missing	6	0,9	0	0,0
Eye disorders	Conjunctival telangiectasia	CRVO	574	81,9	1	0,2
Eye disorders	Conjunctival telangiectasia	HRVO	121	17,3	0	0,0
Eye disorders	Conjunctival telangiectasia	Missing	6	0,9	0	0,0
Eye disorders	Cystoid macular oedema	CRVO	574	81,9	10	1,7
Eye disorders	Cystoid macular oedema	HRVO	121	17,3	1	0,8
Eye disorders	Cystoid macular oedema	Missing	6	0,9	0	0,0
Eye disorders	Dry eye	CRVO	574	81,9	1	0,2
Eye disorders	Dry eye	HRVO	121	17,3	1	0,8
Eye disorders	Dry eye	Missing	6	0,9	0	0,0
Eye disorders	Eczema eyelids	CRVO	574	81,9	0	0,0
Eye disorders	Eczema eyelids	HRVO	121	17,3	1	0,8
Eye disorders	Eczema eyelids	Missing	6	0,9	0	0,0
Eye disorders	Eye irritation	CRVO	574	81,9	1	0,2
Eye disorders	Eye irritation	HRVO	121	17,3	0	0,0
Eye disorders	Eye irritation	Missing	6	0,9	0	0,0
Eye disorders	Eye pain	CRVO	574	81,9	2	0,3
Eye disorders	Eye pain	HRVO	121	17,3	4	3,3
Eye disorders	Eye pain	Missing	6	0,9	0	0,0
Eye disorders	Glaucoma	CRVO	574	81,9	5	0,9
Eye disorders	Glaucoma	HRVO	121	17,3	3	2,5
Eye disorders	Glaucoma	Missing	6	0,9	0	0,0
Eye disorders	Iridocyclitis	CRVO	574	81,9	3	0,5
Eye disorders	Iridocyclitis	HRVO	121	17,3	1	0,8
Eye disorders	Iridocyclitis	Missing	6	0,9	0	0,0
Eye disorders	Iris neovascularisation	CRVO	574	81,9	1	0,2

Eye disorders	Iris neovascularisation	HRVO	121	17,3	0	0,0
Eye disorders	Iris neovascularisation	Missing	6	0,9	0	0,0
Eye disorders	Iritis	CRVO	574	81,9	0	0,0
Eye disorders	Iritis	HRVO	121	17,3	1	0,8
Eye disorders	Iritis	Missing	6	0,9	0	0,0
Eye disorders	Keratopathy	CRVO	574	81,9	1	0,2
Eye disorders	Keratopathy	HRVO	121	17,3	0	0,0
Eye disorders	Keratopathy	Missing	6	0,9	0	0,0
Eye disorders	Lacrimal disorder	CRVO	574	81,9	1	0,2
Eye disorders	Lacrimal disorder	HRVO	121	17,3	0	0,0
Eye disorders	Lacrimal disorder	Missing	6	0,9	0	0,0
Eye disorders	Lacrimation increased	CRVO	574	81,9	1	0,2
Eye disorders	Lacrimation increased	HRVO	121	17,3	1	0,8
Eye disorders	Lacrimation increased	Missing	6	0,9	0	0,0
Eye disorders	Lenticular opacities	CRVO	574	81,9	1	0,2
Eye disorders	Lenticular opacities	HRVO	121	17,3	0	0,0
Eye disorders	Lenticular opacities	Missing	6	0,9	0	0,0
Eye disorders	Macular degeneration	CRVO	574	81,9	0	0,0
Eye disorders	Macular degeneration	HRVO	121	17,3	1	0,8
Eye disorders	Macular degeneration	Missing	6	0,9	0	0,0
Eye disorders	Macular ischaemia	CRVO	574	81,9	1	0,2
Eye disorders	Macular ischaemia	HRVO	121	17,3	0	0,0
Eye disorders	Macular ischaemia	Missing	6	0,9	0	0,0
Eye disorders	Macular oedema	CRVO	574	81,9	9	1,6
Eye disorders	Macular oedema	HRVO	121	17,3	4	3,3
Eye disorders	Macular oedema	Missing	6	0,9	0	0,0
Eye disorders	Neovascular age-related macular degeneration	CRVO	574	81,9	1	0,2
Eye disorders	Neovascular age-related macular degeneration	HRVO	121	17,3	0	0,0
Eye disorders	Neovascular age-related macular degeneration	Missing	6	0,9	0	0,0
Eye disorders	Non-infectious endophthalmitis	CRVO	574	81,9	1	0,2
Eye disorders	Non-infectious endophthalmitis	HRVO	121	17,3	0	0,0
Eye disorders	Non-infectious endophthalmitis	Missing	6	0,9	0	0,0
Eye disorders	Noninfective conjunctivitis	CRVO	574	81,9	1	0,2
Eye disorders	Noninfective conjunctivitis	HRVO	121	17,3	0	0,0
Eye disorders	Noninfective conjunctivitis	Missing	6	0,9	0	0,0
Eye disorders	Ocular hypertension	CRVO	574	81,9	5	0,9
Eye disorders	Ocular hypertension	HRVO	121	17,3	2	1,7
Eye disorders	Ocular hypertension	Missing	6	0,9	0	0,0
Eye disorders	Open angle glaucoma	CRVO	574	81,9	1	0,2
Eye disorders	Open angle glaucoma	HRVO	121	17,3	0	0,0
Eye disorders	Open angle glaucoma	Missing	6	0,9	0	0,0
Eye disorders	Optic disc haemorrhage	CRVO	574	81,9	2	0,3
Eye disorders	Optic disc haemorrhage	HRVO	121	17,3	0	0,0
Eye disorders	Optic disc haemorrhage	Missing	6	0,9	0	0,0
Eye disorders	Papilloedema	CRVO	574	81,9	1	0,2
Eye disorders	Papilloedema	HRVO	121	17,3	0	0,0
Eye disorders	Papilloedema	Missing	6	0,9	0	0,0
Eye disorders	Posterior capsule opacification	CRVO	574	81,9	2	0,3
Eye disorders	Posterior capsule opacification	HRVO	121	17,3	1	0,8
Eye disorders	Posterior capsule opacification	Missing	6	0,9	0	0,0
Eye disorders	Punctate keratitis	CRVO	574	81,9	2	0,3
Eye disorders	Punctate keratitis	HRVO	121	17,3	0	0,0
Eye disorders	Punctate keratitis	Missing	6	0,9	0	0,0
Eye disorders	Retinal artery occlusion	CRVO	574	81,9	2	0,3
Eye disorders	Retinal artery occlusion	HRVO	121	17,3	0	0,0
Eye disorders	Retinal artery occlusion	Missing	6	0,9	0	0,0
Eye disorders	Retinal collateral vessels	CRVO	574	81,9	2	0,3
Eye disorders	Retinal collateral vessels	HRVO	121	17,3	0	0,0
Eye disorders	Retinal collateral vessels	Missing	6	0,9	0	0,0
Eye disorders	Retinal detachment	CRVO	574	81,9	1	0,2
Eye disorders	Retinal detachment	HRVO	121	17,3	0	0,0
Eye disorders	Retinal detachment	Missing	6	0,9	0	0,0
Eye disorders	Retinal disorder	CRVO	574	81,9	0	0,0
Eye disorders	Retinal disorder	HRVO	121	17,3	1	0,8
Eye disorders	Retinal disorder	Missing	6	0,9	0	0,0
Eye disorders	Retinal haemorrhage	CRVO	574	81,9	1	0,2
Eye disorders	Retinal haemorrhage	HRVO	121	17,3	0	0,0
Eye disorders	Retinal haemorrhage	Missing	6	0,9	0	0,0

Eye disorders	Retinal ischaemia	CRVO	574	81,9	1	0,2
Eye disorders	Retinal ischaemia	HRVO	121	17,3	0	0,0
Eye disorders	Retinal ischaemia	Missing	6	0,9	0	0,0
Eye disorders	Retinal vein occlusion	CRVO	574	81,9	7	1,2
Eye disorders	Retinal vein occlusion	HRVO	121	17,3	2	1,7
Eye disorders	Retinal vein occlusion	Missing	6	0,9	0	0,0
Eye disorders	Uveitis	CRVO	574	81,9	1	0,2
Eye disorders	Uveitis	HRVO	121	17,3	0	0,0
Eye disorders	Uveitis	Missing	6	0,9	0	0,0
Eye disorders	Vision blurred	CRVO	574	81,9	1	0,2
Eye disorders	Vision blurred	HRVO	121	17,3	0	0,0
Eye disorders	Vision blurred	Missing	6	0,9	0	0,0
Eye disorders	Visual acuity reduced	CRVO	574	81,9	3	0,5
Eye disorders	Visual acuity reduced	HRVO	121	17,3	1	0,8
Eye disorders	Visual acuity reduced	Missing	6	0,9	0	0,0
Eye disorders	Visual impairment	CRVO	574	81,9	1	0,2
Eye disorders	Visual impairment	HRVO	121	17,3	0	0,0
Eye disorders	Visual impairment	Missing	6	0,9	0	0,0
Eye disorders	Vitreoretinal traction syndrome	CRVO	574	81,9	1	0,2
Eye disorders	Vitreoretinal traction syndrome	HRVO	121	17,3	0	0,0
Eye disorders	Vitreoretinal traction syndrome	Missing	6	0,9	0	0,0
Eye disorders	Vitreous detachment	CRVO	574	81,9	1	0,2
Eye disorders	Vitreous detachment	HRVO	121	17,3	0	0,0
Eye disorders	Vitreous detachment	Missing	6	0,9	0	0,0
Eye disorders	Vitreous floaters	CRVO	574	81,9	1	0,2
Eye disorders	Vitreous floaters	HRVO	121	17,3	0	0,0
Eye disorders	Vitreous floaters	Missing	6	0,9	0	0,0
Eye disorders	Vitreous haemorrhage	CRVO	574	81,9	1	0,2
Eye disorders	Vitreous haemorrhage	HRVO	121	17,3	0	0,0
Eye disorders	Vitreous haemorrhage	Missing	6	0,9	0	0,0
Eye disorders	Vitritis	CRVO	574	81,9	2	0,3
Eye disorders	Vitritis	HRVO	121	17,3	0	0,0
Eye disorders	Vitritis	Missing	6	0,9	0	0,0
Gastrointestinal disorders		CRVO	574	81,9	12	2,1
Gastrointestinal disorders		HRVO	121	17,3	4	3,3
Gastrointestinal disorders		Missing	6	0,9	0	0,0
Gastrointestinal disorders	Abdominal pain	CRVO	574	81,9	0	0,0
Gastrointestinal disorders	Abdominal pain	HRVO	121	17,3	1	0,8
Gastrointestinal disorders	Abdominal pain	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Abdominal pain upper	CRVO	574	81,9	0	0,0
Gastrointestinal disorders	Abdominal pain upper	HRVO	121	17,3	1	0,8
Gastrointestinal disorders	Abdominal pain upper	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Barrett's oesophagus	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Barrett's oesophagus	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Coeliac disease	CRVO	574	81,9	0	0,0
Gastrointestinal disorders	Coeliac disease	HRVO	121	17,3	1	0,8
Gastrointestinal disorders	Coeliac disease	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Colitis	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Colitis	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Colitis	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Constipation	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Constipation	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Constipation	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Dental discomfort	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Dental discomfort	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Dental discomfort	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Diarrhoea	CRVO	574	81,9	2	0,3
Gastrointestinal disorders	Diarrhoea	HRVO	121	17,3	1	0,8
Gastrointestinal disorders	Diarrhoea	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastric ulcer	CRVO	574	81,9	0	0,0
Gastrointestinal disorders	Gastric ulcer	HRVO	121	17,3	1	0,8
Gastrointestinal disorders	Gastric ulcer	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastritis	CRVO	574	81,9	2	0,3
Gastrointestinal disorders	Gastritis	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Gastritis	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	CRVO	574	81,9	1	0,2

Gastrointestinal disorders	Gastrooesophageal reflux disease	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Gastrooesophageal reflux disease	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Hiatus hernia	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Hiatus hernia	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Hiatus hernia	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Ileus	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Ileus	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Ileus	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Inguinal hernia	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Inguinal hernia	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Inguinal hernia	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Large intestine polyp	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Large intestine polyp	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Large intestine polyp	Missing	6	0,9	0	0,0
General disorders and administration site conditions						
General disorders and administration site conditions		CRVO	574	81,9	11	1,9
General disorders and administration site conditions		HRVO	121	17,3	2	1,7
General disorders and administration site conditions		Missing	6	0,9	0	0,0
General disorders and administration site conditions	Asthenia	CRVO	574	81,9	4	0,7
General disorders and administration site conditions	Asthenia	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Asthenia	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Chest pain	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Chest pain	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Chest pain	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Injection site pain	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Injection site pain	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Injection site pain	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Oedema peripheral	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Oedema peripheral	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Oedema peripheral	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Pain	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Pain	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Pain	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Polyp	CRVO	574	81,9	0	0,0
General disorders and administration site conditions	Polyp	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Polyp	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Pyrexia	CRVO	574	81,9	2	0,3
General disorders and administration site conditions	Pyrexia	HRVO	121	17,3	2	1,7
General disorders and administration site conditions	Pyrexia	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Systemic inflammatory response syndrome	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Systemic inflammatory response syndrome	Missing	6	0,9	0	0,0
Hepatobiliary disorders		CRVO	574	81,9	3	0,5
Hepatobiliary disorders		HRVO	121	17,3	0	0,0
Hepatobiliary disorders		Missing	6	0,9	0	0,0
Hepatobiliary disorders	Cholecystitis	CRVO	574	81,9	1	0,2
Hepatobiliary disorders	Cholecystitis	HRVO	121	17,3	0	0,0
Hepatobiliary disorders	Cholecystitis	Missing	6	0,9	0	0,0
Hepatobiliary disorders	Cholelithiasis	CRVO	574	81,9	2	0,3
Hepatobiliary disorders	Cholelithiasis	HRVO	121	17,3	0	0,0
Hepatobiliary disorders	Cholelithiasis	Missing	6	0,9	0	0,0
Immune system disorders		CRVO	574	81,9	3	0,5
Immune system disorders		HRVO	121	17,3	0	0,0
Immune system disorders		Missing	6	0,9	0	0,0
Immune system disorders	Drug hypersensitivity	CRVO	574	81,9	1	0,2
Immune system disorders	Drug hypersensitivity	HRVO	121	17,3	0	0,0
Immune system disorders	Drug hypersensitivity	Missing	6	0,9	0	0,0
Immune system disorders	Iodine allergy	CRVO	574	81,9	1	0,2
Immune system disorders	Iodine allergy	HRVO	121	17,3	0	0,0
Immune system disorders	Iodine allergy	Missing	6	0,9	0	0,0
Immune system disorders	Seasonal allergy	CRVO	574	81,9	1	0,2
Immune system disorders	Seasonal allergy	HRVO	121	17,3	0	0,0
Immune system disorders	Seasonal allergy	Missing	6	0,9	0	0,0
Infections and infestations		CRVO	574	81,9	52	9,1
Infections and infestations		HRVO	121	17,3	11	9,1

Infections and infestations		Missing	6	0,9	1	16,7
Infections and infestations	Arthritis infective	CRVO	574	81,9	1	0,2
Infections and infestations	Arthritis infective	HRVO	121	17,3	0	0,0
Infections and infestations	Arthritis infective	Missing	6	0,9	0	0,0
Infections and infestations	Bronchitis	CRVO	574	81,9	2	0,3
Infections and infestations	Bronchitis	HRVO	121	17,3	2	1,7
Infections and infestations	Bronchitis	Missing	6	0,9	0	0,0
Infections and infestations	COVID-19	CRVO	574	81,9	17	3,0
Infections and infestations	COVID-19	HRVO	121	17,3	1	0,8
Infections and infestations	COVID-19	Missing	6	0,9	1	16,7
Infections and infestations	Cellulitis	CRVO	574	81,9	3	0,5
Infections and infestations	Cellulitis	HRVO	121	17,3	1	0,8
Infections and infestations	Cellulitis	Missing	6	0,9	0	0,0
Infections and infestations	Conjunctivitis	CRVO	574	81,9	3	0,5
Infections and infestations	Conjunctivitis	HRVO	121	17,3	0	0,0
Infections and infestations	Conjunctivitis	Missing	6	0,9	0	0,0
Infections and infestations	Cystitis	CRVO	574	81,9	1	0,2
Infections and infestations	Cystitis	HRVO	121	17,3	0	0,0
Infections and infestations	Cystitis	Missing	6	0,9	0	0,0
Infections and infestations	Ear infection	CRVO	574	81,9	1	0,2
Infections and infestations	Ear infection	HRVO	121	17,3	0	0,0
Infections and infestations	Ear infection	Missing	6	0,9	0	0,0
Infections and infestations	Fungal skin infection	CRVO	574	81,9	1	0,2
Infections and infestations	Fungal skin infection	HRVO	121	17,3	0	0,0
Infections and infestations	Fungal skin infection	Missing	6	0,9	0	0,0
Infections and infestations	Helicobacter infection	CRVO	574	81,9	1	0,2
Infections and infestations	Helicobacter infection	HRVO	121	17,3	0	0,0
Infections and infestations	Helicobacter infection	Missing	6	0,9	0	0,0
Infections and infestations	Herpes zoster	CRVO	574	81,9	1	0,2
Infections and infestations	Herpes zoster	HRVO	121	17,3	1	0,8
Infections and infestations	Herpes zoster	Missing	6	0,9	0	0,0
Infections and infestations	Influenza	CRVO	574	81,9	5	0,9
Infections and infestations	Influenza	HRVO	121	17,3	3	2,5
Infections and infestations	influenza	Missing	6	0,9	0	0,0
Infections and infestations	Kidney infection	CRVO	574	81,9	1	0,2
Infections and infestations	Kidney infection	HRVO	121	17,3	0	0,0
Infections and infestations	Kidney infection	Missing	6	0,9	0	0,0
Infections and infestations	Laryngitis	CRVO	574	81,9	1	0,2
Infections and infestations	Laryngitis	HRVO	121	17,3	0	0,0
Infections and infestations	Laryngitis	Missing	6	0,9	0	0,0
Infections and infestations	Nasopharyngitis	CRVO	574	81,9	4	0,7
Infections and infestations	Nasopharyngitis	HRVO	121	17,3	0	0,0
Infections and infestations	Nasopharyngitis	Missing	6	0,9	0	0,0
Infections and infestations	Pharyngitis	CRVO	574	81,9	1	0,2
Infections and infestations	Pharyngitis	HRVO	121	17,3	0	0,0
Infections and infestations	Pharyngitis	Missing	6	0,9	0	0,0
Infections and infestations	Pneumonia	CRVO	574	81,9	4	0,7
Infections and infestations	Pneumonia	HRVO	121	17,3	1	0,8
Infections and infestations	Pneumonia	Missing	6	0,9	0	0,0
Infections and infestations	Pneumonia viral	CRVO	574	81,9	1	0,2
Infections and infestations	Pneumonia viral	HRVO	121	17,3	0	0,0
Infections and infestations	Pneumonia viral	Missing	6	0,9	0	0,0
Infections and infestations	Pulpitis dental	CRVO	574	81,9	2	0,3
Infections and infestations	Pulpitis dental	HRVO	121	17,3	0	0,0
Infections and infestations	Pulpitis dental	Missing	6	0,9	0	0,0
Infections and infestations	Respiratory tract infection	CRVO	574	81,9	2	0,3
Infections and infestations	Respiratory tract infection	HRVO	121	17,3	0	0,0
Infections and infestations	Respiratory tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Respiratory tract infection viral	CRVO	574	81,9	1	0,2
Infections and infestations	Respiratory tract infection viral	HRVO	121	17,3	0	0,0
Infections and infestations	Respiratory tract infection viral	Missing	6	0,9	0	0,0
Infections and infestations	Sinusitis	CRVO	574	81,9	1	0,2
Infections and infestations	Sinusitis	HRVO	121	17,3	1	0,8
Infections and infestations	Sinusitis	Missing	6	0,9	0	0,0
Infections and infestations	Staphylococcal infection	CRVO	574	81,9	1	0,2
Infections and infestations	Staphylococcal infection	HRVO	121	17,3	0	0,0
Infections and infestations	Staphylococcal infection	Missing	6	0,9	0	0,0
Infections and infestations	Suspected COVID-19	CRVO	574	81,9	1	0,2

Infections and infestations	Suspected COVID-19	HRVO	121	17,3	0	0,0
Infections and infestations	Suspected COVID-19	Missing	6	0,9	0	0,0
Infections and infestations	Tooth abscess	CRVO	574	81,9	1	0,2
Infections and infestations	Tooth abscess	HRVO	121	17,3	0	0,0
Infections and infestations	Tooth abscess	Missing	6	0,9	0	0,0
Infections and infestations	Upper respiratory tract infection	CRVO	574	81,9	6	1,0
Infections and infestations	Upper respiratory tract infection	HRVO	121	17,3	3	2,5
Infections and infestations	Upper respiratory tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Urinary tract infection	CRVO	574	81,9	5	0,9
Infections and infestations	Urinary tract infection	HRVO	121	17,3	2	1,7
Infections and infestations	Urinary tract infection	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications		CRVO	574	81,9	23	4,0
Injury, poisoning and procedural complications		HRVO	121	17,3	2	1,7
Injury, poisoning and procedural complications		Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Arthropod bite	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Arthropod bite	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Arthropod bite	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Fall	CRVO	574	81,9	5	0,9
Injury, poisoning and procedural complications	Fall	HRVO	121	17,3	1	0,8
Injury, poisoning and procedural complications	Fall	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Femur fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Femur fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Fibula fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Fibula fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Fibula fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Foreign body in eye	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Foreign body in eye	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Hand fracture	CRVO	574	81,9	2	0,3
Injury, poisoning and procedural complications	Hand fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Hand fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Hip fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Hip fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Hypobarism	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Hypobarism	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Hypobarism	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Limb injury	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Limb injury	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Limb injury	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	CRVO	574	81,9	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	HRVO	121	17,3	1	0,8
Injury, poisoning and procedural complications	Lower limb fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Lumbar vertebral fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Lumbar vertebral fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Muscle strain	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Muscle strain	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Muscle strain	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Posterior capsule rupture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Posterior capsule rupture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Rib fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Rib fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	CRVO	574	81,9	2	0,3
Injury, poisoning and procedural complications	Road traffic accident	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Skin laceration	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Skin laceration	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Spinal compression fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Spinal compression fracture	HRVO	121	17,3	0	0,0

Injury, poisoning and procedural complications	Spinal compression fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Sunburn	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Sunburn	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Sunburn	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Tibia fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Tibia fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Tooth fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Tooth fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	CRVO	574	81,9	2	0,3
Injury, poisoning and procedural complications	Wrist fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Wrist fracture	Missing	6	0,9	0	0,0
Investigations		CRVO	574	81,9	13	2,3
Investigations		HRVO	121	17,3	2	1,7
Investigations		Missing	6	0,9	1	16,7
Investigations	Blood pressure increased	CRVO	574	81,9	2	0,3
Investigations	Blood pressure increased	HRVO	121	17,3	0	0,0
Investigations	Blood pressure increased	Missing	6	0,9	0	0,0
Investigations	Blood testosterone decreased	CRVO	574	81,9	1	0,2
Investigations	Blood testosterone decreased	HRVO	121	17,3	0	0,0
Investigations	Blood testosterone decreased	Missing	6	0,9	0	0,0
Investigations	Intraocular pressure increased	CRVO	574	81,9	7	1,2
Investigations	Intraocular pressure increased	HRVO	121	17,3	2	1,7
Investigations	Intraocular pressure increased	Missing	6	0,9	1	16,7
Investigations	Occult blood positive	CRVO	574	81,9	1	0,2
Investigations	Occult blood positive	HRVO	121	17,3	0	0,0
Investigations	Occult blood positive	Missing	6	0,9	0	0,0
Investigations	Optic nerve cup/disc ratio increased	CRVO	574	81,9	1	0,2
Investigations	Optic nerve cup/disc ratio increased	HRVO	121	17,3	0	0,0
Investigations	Optic nerve cup/disc ratio increased	Missing	6	0,9	0	0,0
Investigations	Weight decreased	CRVO	574	81,9	1	0,2
Investigations	Weight decreased	HRVO	121	17,3	0	0,0
Investigations	Weight decreased	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders		CRVO	574	81,9	11	1,9
Metabolism and nutrition disorders		HRVO	121	17,3	3	2,5
Metabolism and nutrition disorders		Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Dehydration	CRVO	574	81,9	2	0,3
Metabolism and nutrition disorders	Dehydration	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Dehydration	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Glucose tolerance impaired	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Glucose tolerance impaired	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Gout	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Gout	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Gout	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hypercholesterolaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hypercholesterolaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	CRVO	574	81,9	0	0,0
Metabolism and nutrition disorders	Hyperglycaemia	HRVO	121	17,3	1	0,8
Metabolism and nutrition disorders	Hyperglycaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hypoglycaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hypoglycaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	CRVO	574	81,9	5	0,9
Metabolism and nutrition disorders	Hypokalaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hyponatraemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hyponatraemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	CRVO	574	81,9	0	0,0
Metabolism and nutrition disorders	Type 2 diabetes mellitus	HRVO	121	17,3	2	1,7
Metabolism and nutrition disorders	Type 2 diabetes mellitus	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders		CRVO	574	81,9	11	1,9

Musculoskeletal and connective tissue disorders		HRVO	121	17,3	5	4,1
Musculoskeletal and connective tissue disorders		Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	CRVO	574	81,9	2	0,3
Musculoskeletal and connective tissue disorders	Arthralgia	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	CRVO	574	81,9	3	0,5
Musculoskeletal and connective tissue disorders	Back pain	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Back pain	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Bone loss	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Bone loss	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Bursitis	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Bursitis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Flank pain	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Flank pain	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Flank pain	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Intervertebral disc disorder	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Lumbar spinal stenosis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Osteoarthritis	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	CRVO	574	81,9	2	0,3
Musculoskeletal and connective tissue disorders	Pain in extremity	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Pain in extremity	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Periarthritis	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Periarthritis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Scoliosis	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Scoliosis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		CRVO	574	81,9	6	1,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cutaneous T-cell lymphoma	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	CRVO	574	81,9	2	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	Missing	6	0,9	0	0,0
Nervous system disorders		CRVO	574	81,9	15	2,6
Nervous system disorders		HRVO	121	17,3	2	1,7
Nervous system disorders		Missing	6	0,9	0	0,0
Nervous system disorders	Cerebral atrophy	CRVO	574	81,9	1	0,2
Nervous system disorders	Cerebral atrophy	HRVO	121	17,3	0	0,0
Nervous system disorders	Cerebral atrophy	Missing	6	0,9	0	0,0
Nervous system disorders	Cerebral infarction	CRVO	574	81,9	1	0,2

Nervous system disorders	Cerebral infarction	HRVO	121	17,3	0	0,0
Nervous system disorders	Cerebral infarction	Missing	6	0,9	0	0,0
Nervous system disorders	Diabetic neuropathy	CRVO	574	81,9	2	0,3
Nervous system disorders	Diabetic neuropathy	HRVO	121	17,3	0	0,0
Nervous system disorders	Diabetic neuropathy	Missing	6	0,9	0	0,0
Nervous system disorders	Dizziness	CRVO	574	81,9	1	0,2
Nervous system disorders	Dizziness	HRVO	121	17,3	0	0,0
Nervous system disorders	Dizziness	Missing	6	0,9	0	0,0
Nervous system disorders	Encephalopathy	CRVO	574	81,9	1	0,2
Nervous system disorders	Encephalopathy	HRVO	121	17,3	0	0,0
Nervous system disorders	Encephalopathy	Missing	6	0,9	0	0,0
Nervous system disorders	Headache	CRVO	574	81,9	0	0,0
Nervous system disorders	Headache	HRVO	121	17,3	2	1,7
Nervous system disorders	Headache	Missing	6	0,9	0	0,0
Nervous system disorders	Ischaemic stroke	CRVO	574	81,9	1	0,2
Nervous system disorders	Ischaemic stroke	HRVO	121	17,3	0	0,0
Nervous system disorders	Ischaemic stroke	Missing	6	0,9	0	0,0
Nervous system disorders	Lacunar infarction	CRVO	574	81,9	1	0,2
Nervous system disorders	Lacunar infarction	HRVO	121	17,3	0	0,0
Nervous system disorders	Lacunar infarction	Missing	6	0,9	0	0,0
Nervous system disorders	Loss of consciousness	CRVO	574	81,9	1	0,2
Nervous system disorders	Loss of consciousness	HRVO	121	17,3	0	0,0
Nervous system disorders	Loss of consciousness	Missing	6	0,9	0	0,0
Nervous system disorders	Neuralgia	CRVO	574	81,9	1	0,2
Nervous system disorders	Neuralgia	HRVO	121	17,3	0	0,0
Nervous system disorders	Neuralgia	Missing	6	0,9	0	0,0
Nervous system disorders	Neuropathy peripheral	CRVO	574	81,9	2	0,3
Nervous system disorders	Neuropathy peripheral	HRVO	121	17,3	0	0,0
Nervous system disorders	Neuropathy peripheral	Missing	6	0,9	0	0,0
Nervous system disorders	Ophthalmic migraine	CRVO	574	81,9	1	0,2
Nervous system disorders	Ophthalmic migraine	HRVO	121	17,3	0	0,0
Nervous system disorders	Ophthalmic migraine	Missing	6	0,9	0	0,0
Nervous system disorders	Sciatica	CRVO	574	81,9	1	0,2
Nervous system disorders	Sciatica	HRVO	121	17,3	1	0,8
Nervous system disorders	Sciatica	Missing	6	0,9	0	0,0
Nervous system disorders	Syncope	CRVO	574	81,9	2	0,3
Nervous system disorders	Syncope	HRVO	121	17,3	0	0,0
Nervous system disorders	Syncope	Missing	6	0,9	0	0,0
Psychiatric disorders		CRVO	574	81,9	2	0,3
Psychiatric disorders		HRVO	121	17,3	1	0,8
Psychiatric disorders		Missing	6	0,9	0	0,0
Psychiatric disorders	Anxiety	CRVO	574	81,9	1	0,2
Psychiatric disorders	Anxiety	HRVO	121	17,3	0	0,0
Psychiatric disorders	Anxiety	Missing	6	0,9	0	0,0
Psychiatric disorders	Depression	CRVO	574	81,9	0	0,0
Psychiatric disorders	Depression	HRVO	121	17,3	1	0,8
Psychiatric disorders	Depression	Missing	6	0,9	0	0,0
Psychiatric disorders	Insomnia	CRVO	574	81,9	1	0,2
Psychiatric disorders	Insomnia	HRVO	121	17,3	0	0,0
Psychiatric disorders	Insomnia	Missing	6	0,9	0	0,0
Renal and urinary disorders		CRVO	574	81,9	4	0,7
Renal and urinary disorders		HRVO	121	17,3	2	1,7
Renal and urinary disorders		Missing	6	0,9	0	0,0
Renal and urinary disorders	Acute kidney injury	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Acute kidney injury	HRVO	121	17,3	1	0,8
Renal and urinary disorders	Acute kidney injury	Missing	6	0,9	0	0,0
Renal and urinary disorders	Diabetic nephropathy	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Diabetic nephropathy	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Missing	6	0,9	0	0,0
Renal and urinary disorders	Renal failure	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Renal failure	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Renal failure	Missing	6	0,9	0	0,0
Renal and urinary disorders	Urinary retention	CRVO	574	81,9	0	0,0
Renal and urinary disorders	Urinary retention	HRVO	121	17,3	1	0,8
Renal and urinary disorders	Urinary retention	Missing	6	0,9	0	0,0
Renal and urinary disorders	Urinary tract inflammation	CRVO	574	81,9	1	0,2

Renal and urinary disorders	Urinary tract inflammation	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Urinary tract inflammation	Missing	6	0,9	0	0,0
Reproductive system and breast disorders		CRVO	574	81,9	2	0,3
Reproductive system and breast disorders		HRVO	121	17,3	0	0,0
Reproductive system and breast disorders		Missing	6	0,9	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	CRVO	574	81,9	1	0,2
Reproductive system and breast disorders	Benign prostatic hyperplasia	HRVO	121	17,3	0	0,0
Reproductive system and breast disorders	Benign prostatic hyperplasia	Missing	6	0,9	0	0,0
Reproductive system and breast disorders	Cystocele	CRVO	574	81,9	1	0,2
Reproductive system and breast disorders	Cystocele	HRVO	121	17,3	0	0,0
Reproductive system and breast disorders	Cystocele	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders		CRVO	574	81,9	11	1,9
Respiratory, thoracic and mediastinal disorders		HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders		Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	CRVO	574	81,9	2	0,3
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Asthma	CRVO	574	81,9	2	0,3
Respiratory, thoracic and mediastinal disorders	Asthma	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Asthma	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	CRVO	574	81,9	4	0,7
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Cough	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Cough	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Dyspnoea	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Nasal polyps	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Nasal polyps	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Sinus disorder	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Sinus disorder	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders		CRVO	574	81,9	9	1,6
Skin and subcutaneous tissue disorders		HRVO	121	17,3	1	0,8
Skin and subcutaneous tissue disorders		Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Androgenetic alopecia	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Androgenetic alopecia	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Dermatitis	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Dermatitis contact	CRVO	574	81,9	2	0,3
Skin and subcutaneous tissue disorders	Dermatitis contact	HRVO	121	17,3	1	0,8
Skin and subcutaneous tissue disorders	Dermatitis contact	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	CRVO	574	81,9	2	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Erythema	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Erythema	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Erythema	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Nail bed bleeding	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Nail bed bleeding	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Nail dystrophy	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Nail dystrophy	Missing	6	0,9	0	0,0

Skin and subcutaneous tissue disorders	Urticaria	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Urticaria	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Urticaria	Missing	6	0,9	0	0,0
Surgical and medical procedures		CRVO	574	81,9	5	0,9
Surgical and medical procedures		HRVO	121	17,3	0	0,0
Surgical and medical procedures		Missing	6	0,9	0	0,0
Surgical and medical procedures	Dental implantation	CRVO	574	81,9	2	0,3
Surgical and medical procedures	Dental implantation	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Dental implantation	Missing	6	0,9	0	0,0
Surgical and medical procedures	Ligament operation	CRVO	574	81,9	1	0,2
Surgical and medical procedures	Ligament operation	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Ligament operation	Missing	6	0,9	0	0,0
Surgical and medical procedures	Toe operation	CRVO	574	81,9	1	0,2
Surgical and medical procedures	Toe operation	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Toe operation	Missing	6	0,9	0	0,0
Surgical and medical procedures	Tooth extraction	CRVO	574	81,9	1	0,2
Surgical and medical procedures	Tooth extraction	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Tooth extraction	Missing	6	0,9	0	0,0
Vascular disorders		CRVO	574	81,9	12	2,1
Vascular disorders		HRVO	121	17,3	5	4,1
Vascular disorders		Missing	6	0,9	0	0,0
Vascular disorders	Aortic stenosis	CRVO	574	81,9	0	0,0
Vascular disorders	Aortic stenosis	HRVO	121	17,3	1	0,8
Vascular disorders	Aortic stenosis	Missing	6	0,9	0	0,0
Vascular disorders	Hypertension	CRVO	574	81,9	8	1,4
Vascular disorders	Hypertension	HRVO	121	17,3	3	2,5
Vascular disorders	Hypertension	Missing	6	0,9	0	0,0
Vascular disorders	Hypertensive crisis	CRVO	574	81,9	1	0,2
Vascular disorders	Hypertensive crisis	HRVO	121	17,3	1	0,8
Vascular disorders	Hypertensive crisis	Missing	6	0,9	0	0,0
Vascular disorders	Hypotension	CRVO	574	81,9	3	0,5
Vascular disorders	Hypotension	HRVO	121	17,3	0	0,0
Vascular disorders	Hypotension	Missing	6	0,9	0	0,0
Vascular disorders	Thrombosis	CRVO	574	81,9	1	0,2
Vascular disorders	Thrombosis	HRVO	121	17,3	0	0,0
Vascular disorders	Thrombosis	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WMODAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:08

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		n/a	701	100,0	1	0,1
Blood and lymphatic system disorders	Deficiency anaemia	n/a	701	100,0	1	0,1
Cardiac disorders		n/a	701	100,0	9	1,3
Cardiac disorders	Acute myocardial infarction	n/a	701	100,0	2	0,3
Cardiac disorders	Atrial fibrillation	n/a	701	100,0	3	0,4
Cardiac disorders	Cardiac failure	n/a	701	100,0	1	0,1
Cardiac disorders	Cardiac failure congestive	n/a	701	100,0	2	0,3
Cardiac disorders	Left ventricular dysfunction	n/a	701	100,0	1	0,1
Cardiac disorders	Myocardial infarction	n/a	701	100,0	2	0,3
Cardiac disorders	Stress cardiomyopathy	n/a	701	100,0	1	0,1
Eye disorders		n/a	701	100,0	21	3,0
Eye disorders	Cataract	n/a	701	100,0	1	0,1
Eye disorders	Cystoid macular oedema	n/a	701	100,0	4	0,6
Eye disorders	Epiretinal membrane	n/a	701	100,0	1	0,1
Eye disorders	Glaucoma	n/a	701	100,0	1	0,1
Eye disorders	Hypotony of eye	n/a	701	100,0	1	0,1
Eye disorders	Macular hole	n/a	701	100,0	1	0,1
Eye disorders	Macular ischaemia	n/a	701	100,0	1	0,1
Eye disorders	Macular oedema	n/a	701	100,0	3	0,4
Eye disorders	Retinal artery embolism	n/a	701	100,0	1	0,1
Eye disorders	Retinal artery occlusion	n/a	701	100,0	2	0,3
Eye disorders	Retinal detachment	n/a	701	100,0	1	0,1
Eye disorders	Retinal ischaemia	n/a	701	100,0	1	0,1
Eye disorders	Retinal vein occlusion	n/a	701	100,0	4	0,6
Gastrointestinal disorders		n/a	701	100,0	5	0,7
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Duodenal ulcer haemorrhage	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Gastrointestinal inflammation	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Pancreatitis	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Pancreatitis acute	n/a	701	100,0	1	0,1
General disorders and administration site conditions		n/a	701	100,0	6	0,9
General disorders and administration site conditions	Asthenia	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Chest pain	n/a	701	100,0	2	0,3
General disorders and administration site conditions	Death	n/a	701	100,0	2	0,3
General disorders and administration site conditions	Stent-graft endoleak	n/a	701	100,0	1	0,1
Hepatobiliary disorders		n/a	701	100,0	1	0,1
Hepatobiliary disorders	Cholelithiasis	n/a	701	100,0	1	0,1
Infections and infestations		n/a	701	100,0	21	3,0
Infections and infestations	COVID-19	n/a	701	100,0	2	0,3

Infections and infestations	COVID-19 pneumonia	n/a	701	100,0	1	0,1
Infections and infestations	Cellulitis	n/a	701	100,0	1	0,1
Infections and infestations	Clostridium difficile infection	n/a	701	100,0	1	0,1
Infections and infestations	Device related infection	n/a	701	100,0	1	0,1
Infections and infestations	Endophthalmitis	n/a	701	100,0	1	0,1
Infections and infestations	Enteritis infectious	n/a	701	100,0	1	0,1
Infections and infestations	Escherichia urinary tract infection	n/a	701	100,0	1	0,1
Infections and infestations	Influenza	n/a	701	100,0	2	0,3
Infections and infestations	Lower respiratory tract infection	n/a	701	100,0	1	0,1
Infections and infestations	Necrotising fasciitis	n/a	701	100,0	1	0,1
Infections and infestations	Pneumonia	n/a	701	100,0	4	0,6
Infections and infestations	Pneumonia viral	n/a	701	100,0	2	0,3
Infections and infestations	Respiratory syncytial virus infection	n/a	701	100,0	1	0,1
Infections and infestations	Sepsis	n/a	701	100,0	2	0,3
Infections and infestations	Tooth infection	n/a	701	100,0	1	0,1
Infections and infestations	Urinary tract candidiasis	n/a	701	100,0	1	0,1
Infections and infestations	Urosepsis	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications		n/a	701	100,0	8	1,1
Injury, poisoning and procedural complications	Accident	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Contusion	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Fall	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Femur fracture	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Ligament rupture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Lower limb fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Rib fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Shunt stenosis	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Skin laceration	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders		n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hypervolaemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hypokalaemia	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders		n/a	701	100,0	5	0,7
Musculoskeletal and connective tissue disorders	Arthralgia	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Joint effusion	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Mobility decreased	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Osteoarthritis	n/a	701	100,0	2	0,3
Musculoskeletal and connective tissue disorders	Polymyositis	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	701	100,0	2	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	n/a	701	100,0	1	0,1
Nervous system disorders		n/a	701	100,0	5	0,7
Nervous system disorders	Cerebrovascular accident	n/a	701	100,0	1	0,1
Nervous system disorders	Dysarthria	n/a	701	100,0	1	0,1
Nervous system disorders	Headache	n/a	701	100,0	1	0,1
Nervous system disorders	Hypoaesthesia	n/a	701	100,0	1	0,1
Nervous system disorders	Ischaemic stroke	n/a	701	100,0	1	0,1
Psychiatric disorders		n/a	701	100,0	1	0,1
Psychiatric disorders	Sleep disorder	n/a	701	100,0	1	0,1
Renal and urinary disorders		n/a	701	100,0	3	0,4
Renal and urinary disorders	Acute kidney injury	n/a	701	100,0	1	0,1
Renal and urinary disorders	Cystitis interstitial	n/a	701	100,0	1	0,1

Renal and urinary disorders	End stage renal disease	n/a	701	100,0	1	0,1
Renal and urinary disorders	Nephropathy	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders		n/a	701	100,0	5	0,7
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	n/a	701	100,0	1	0,1
Surgical and medical procedures		n/a	701	100,0	2	0,3
Surgical and medical procedures	Large intestinal polypectomy	n/a	701	100,0	1	0,1
Surgical and medical procedures	Renal transplant	n/a	701	100,0	1	0,1
Vascular disorders		n/a	701	100,0	4	0,6
Vascular disorders	Aortic aneurysm	n/a	701	100,0	1	0,1
Vascular disorders	Aortic dissection	n/a	701	100,0	1	0,1
Vascular disorders	Haemorrhage	n/a	701	100,0	1	0,1
Vascular disorders	Peripheral artery aneurysm	n/a	701	100,0	1	0,1

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:14

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Gender

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		Male	374	53,4	1	0,3
Blood and lymphatic system disorders		Female	327	46,6	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Male	374	53,4	1	0,3
Blood and lymphatic system disorders	Deficiency anaemia	Female	327	46,6	0	0,0
Cardiac disorders		Male	374	53,4	5	1,3
Cardiac disorders		Female	327	46,6	4	1,2
Cardiac disorders	Acute myocardial infarction	Male	374	53,4	1	0,3
Cardiac disorders	Acute myocardial infarction	Female	327	46,6	1	0,3
Cardiac disorders	Atrial fibrillation	Male	374	53,4	3	0,8
Cardiac disorders	Atrial fibrillation	Female	327	46,6	0	0,0
Cardiac disorders	Cardiac failure	Male	374	53,4	0	0,0
Cardiac disorders	Cardiac failure	Female	327	46,6	1	0,3
Cardiac disorders	Cardiac failure congestive	Male	374	53,4	1	0,3
Cardiac disorders	Cardiac failure congestive	Female	327	46,6	1	0,3
Cardiac disorders	Left ventricular dysfunction	Male	374	53,4	1	0,3
Cardiac disorders	Left ventricular dysfunction	Female	327	46,6	0	0,0
Cardiac disorders	Myocardial infarction	Male	374	53,4	1	0,3
Cardiac disorders	Myocardial infarction	Female	327	46,6	1	0,3
Cardiac disorders	Stress cardiomyopathy	Male	374	53,4	0	0,0
Cardiac disorders	Stress cardiomyopathy	Female	327	46,6	1	0,3
Eye disorders		Male	374	53,4	10	2,7
Eye disorders		Female	327	46,6	11	3,4
Eye disorders	Cataract	Male	374	53,4	0	0,0
Eye disorders	Cataract	Female	327	46,6	1	0,3
Eye disorders	Cystoid macular oedema	Male	374	53,4	3	0,8
Eye disorders	Cystoid macular oedema	Female	327	46,6	1	0,3
Eye disorders	Epiretinal membrane	Male	374	53,4	0	0,0
Eye disorders	Epiretinal membrane	Female	327	46,6	1	0,3
Eye disorders	Glaucoma	Male	374	53,4	1	0,3
Eye disorders	Glaucoma	Female	327	46,6	0	0,0
Eye disorders	Hypotony of eye	Male	374	53,4	0	0,0
Eye disorders	Hypotony of eye	Female	327	46,6	1	0,3
Eye disorders	Macular hole	Male	374	53,4	0	0,0
Eye disorders	Macular hole	Female	327	46,6	1	0,3
Eye disorders	Macular ischaemia	Male	374	53,4	1	0,3
Eye disorders	Macular ischaemia	Female	327	46,6	0	0,0
Eye disorders	Macular oedema	Male	374	53,4	0	0,0
Eye disorders	Macular oedema	Female	327	46,6	3	0,9
Eye disorders	Retinal artery embolism	Male	374	53,4	1	0,3
Eye disorders	Retinal artery embolism	Female	327	46,6	0	0,0
Eye disorders	Retinal artery occlusion	Male	374	53,4	2	0,5
Eye disorders	Retinal artery occlusion	Female	327	46,6	0	0,0
Eye disorders	Retinal detachment	Male	374	53,4	1	0,3

Eye disorders	Retinal detachment	Female	327	46,6	0	0,0
Eye disorders	Retinal ischaemia	Male	374	53,4	0	0,0
Eye disorders	Retinal ischaemia	Female	327	46,6	1	0,3
Eye disorders	Retinal vein occlusion	Male	374	53,4	2	0,5
Eye disorders	Retinal vein occlusion	Female	327	46,6	2	0,6
Gastrointestinal disorders		Male	374	53,4	4	1,1
Gastrointestinal disorders		Female	327	46,6	1	0,3
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Male	374	53,4	1	0,3
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Female	327	46,6	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Male	374	53,4	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Female	327	46,6	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Male	374	53,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Female	327	46,6	1	0,3
Gastrointestinal disorders	Pancreatitis	Male	374	53,4	1	0,3
Gastrointestinal disorders	Pancreatitis	Female	327	46,6	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Male	374	53,4	1	0,3
Gastrointestinal disorders	Pancreatitis acute	Female	327	46,6	0	0,0
General disorders and administration site conditions		Male	374	53,4	4	1,1
General disorders and administration site conditions		Female	327	46,6	2	0,6
General disorders and administration site conditions	Asthenia	Male	374	53,4	1	0,3
General disorders and administration site conditions	Asthenia	Female	327	46,6	0	0,0
General disorders and administration site conditions	Chest pain	Male	374	53,4	1	0,3
General disorders and administration site conditions	Chest pain	Female	327	46,6	1	0,3
General disorders and administration site conditions	Death	Male	374	53,4	1	0,3
General disorders and administration site conditions	Death	Female	327	46,6	1	0,3
General disorders and administration site conditions	Stent-graft endoleak	Male	374	53,4	1	0,3
General disorders and administration site conditions	Stent-graft endoleak	Female	327	46,6	0	0,0
Hepatobiliary disorders		Male	374	53,4	0	0,0
Hepatobiliary disorders		Female	327	46,6	1	0,3
Hepatobiliary disorders	Cholelithiasis	Male	374	53,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	Female	327	46,6	1	0,3
Infections and infestations		Male	374	53,4	10	2,7
Infections and infestations		Female	327	46,6	11	3,4
Infections and infestations	COVID-19	Male	374	53,4	2	0,5
Infections and infestations	COVID-19	Female	327	46,6	0	0,0
Infections and infestations	COVID-19 pneumonia	Male	374	53,4	0	0,0
Infections and infestations	COVID-19 pneumonia	Female	327	46,6	1	0,3
Infections and infestations	Cellulitis	Male	374	53,4	0	0,0
Infections and infestations	Cellulitis	Female	327	46,6	1	0,3
Infections and infestations	Clostridium difficile infection	Male	374	53,4	1	0,3
Infections and infestations	Clostridium difficile infection	Female	327	46,6	0	0,0
Infections and infestations	Device related infection	Male	374	53,4	1	0,3
Infections and infestations	Device related infection	Female	327	46,6	0	0,0
Infections and infestations	Endophthalmitis	Male	374	53,4	1	0,3
Infections and infestations	Endophthalmitis	Female	327	46,6	0	0,0
Infections and infestations	Enteritis infectious	Male	374	53,4	0	0,0
Infections and infestations	Enteritis infectious	Female	327	46,6	1	0,3
Infections and infestations	Escherichia urinary tract infection	Male	374	53,4	0	0,0
Infections and infestations	Escherichia urinary tract infection	Female	327	46,6	1	0,3
Infections and infestations	Influenza	Male	374	53,4	2	0,5
Infections and infestations	Influenza	Female	327	46,6	0	0,0
Infections and infestations	Lower respiratory tract infection	Male	374	53,4	1	0,3
Infections and infestations	Lower respiratory tract infection	Female	327	46,6	0	0,0

Infections and infestations	Necrotising fasciitis	Male	374	53,4	1	0,3
Infections and infestations	Necrotising fasciitis	Female	327	46,6	0	0,0
Infections and infestations	Pneumonia	Male	374	53,4	2	0,5
Infections and infestations	Pneumonia	Female	327	46,6	2	0,6
Infections and infestations	Pneumonia viral	Male	374	53,4	0	0,0
Infections and infestations	Pneumonia viral	Female	327	46,6	2	0,6
Infections and infestations	Respiratory syncytial virus infection	Male	374	53,4	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Female	327	46,6	1	0,3
Infections and infestations	Sepsis	Male	374	53,4	1	0,3
Infections and infestations	Sepsis	Female	327	46,6	1	0,3
Infections and infestations	Tooth infection	Male	374	53,4	0	0,0
Infections and infestations	Tooth infection	Female	327	46,6	1	0,3
Infections and infestations	Urinary tract candidiasis	Male	374	53,4	0	0,0
Infections and infestations	Urinary tract candidiasis	Female	327	46,6	1	0,3
Infections and infestations	Urosepsis	Male	374	53,4	1	0,3
Infections and infestations	Urosepsis	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications		Male	374	53,4	5	1,3
Injury, poisoning and procedural complications		Female	327	46,6	3	0,9
Injury, poisoning and procedural complications	Accident	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Accident	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Contusion	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Contusion	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Fall	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Fall	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Femur fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Ligament rupture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Ligament rupture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Rib fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Shunt stenosis	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Shunt stenosis	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Skin laceration	Female	327	46,6	0	0,0
Metabolism and nutrition disorders		Male	374	53,4	1	0,3
Metabolism and nutrition disorders		Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Hypervolaemia	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Hypokalaemia	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders		Male	374	53,4	3	0,8
Musculoskeletal and connective tissue disorders		Female	327	46,6	2	0,6
Musculoskeletal and connective tissue disorders	Arthralgia	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Arthralgia	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Osteoarthritis	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Osteoarthritis	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Polymyositis	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Female	327	46,6	1	0,3

Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Male	374	53,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Female	327	46,6	0	0,0
Nervous system disorders		Male	374	53,4	2	0,5
Nervous system disorders		Female	327	46,6	3	0,9
Nervous system disorders	Cerebrovascular accident	Male	374	53,4	0	0,0
Nervous system disorders	Cerebrovascular accident	Female	327	46,6	1	0,3
Nervous system disorders	Dysarthria	Male	374	53,4	0	0,0
Nervous system disorders	Dysarthria	Female	327	46,6	1	0,3
Nervous system disorders	Headache	Male	374	53,4	1	0,3
Nervous system disorders	Headache	Female	327	46,6	0	0,0
Nervous system disorders	Hypoaesthesia	Male	374	53,4	0	0,0
Nervous system disorders	Hypoaesthesia	Female	327	46,6	1	0,3
Nervous system disorders	Ischaemic stroke	Male	374	53,4	1	0,3
Nervous system disorders	Ischaemic stroke	Female	327	46,6	0	0,0
Psychiatric disorders		Male	374	53,4	0	0,0
Psychiatric disorders		Female	327	46,6	1	0,3
Psychiatric disorders	Sleep disorder	Male	374	53,4	0	0,0
Psychiatric disorders	Sleep disorder	Female	327	46,6	1	0,3
Renal and urinary disorders		Male	374	53,4	2	0,5
Renal and urinary disorders		Female	327	46,6	1	0,3
Renal and urinary disorders	Acute kidney injury	Male	374	53,4	0	0,0
Renal and urinary disorders	Acute kidney injury	Female	327	46,6	1	0,3
Renal and urinary disorders	Cystitis interstitial	Male	374	53,4	0	0,0
Renal and urinary disorders	Cystitis interstitial	Female	327	46,6	1	0,3
Renal and urinary disorders	End stage renal disease	Male	374	53,4	1	0,3
Renal and urinary disorders	End stage renal disease	Female	327	46,6	0	0,0
Renal and urinary disorders	Nephropathy	Male	374	53,4	1	0,3
Renal and urinary disorders	Nephropathy	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders		Male	374	53,4	3	0,8
Respiratory, thoracic and mediastinal disorders		Female	327	46,6	2	0,6
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Female	327	46,6	1	0,3
Surgical and medical procedures		Male	374	53,4	2	0,5
Surgical and medical procedures		Female	327	46,6	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	Male	374	53,4	1	0,3
Surgical and medical procedures	Large intestinal polypectomy	Female	327	46,6	0	0,0
Surgical and medical procedures	Renal transplant	Male	374	53,4	1	0,3
Surgical and medical procedures	Renal transplant	Female	327	46,6	0	0,0

Vascular disorders		Male	374	53,4	3	0,8
Vascular disorders		Female	327	46,6	1	0,3
Vascular disorders	Aortic aneurysm	Male	374	53,4	1	0,3
Vascular disorders	Aortic aneurysm	Female	327	46,6	0	0,0
Vascular disorders	Aortic dissection	Male	374	53,4	0	0,0
Vascular disorders	Aortic dissection	Female	327	46,6	1	0,3
Vascular disorders	Haemorrhage	Male	374	53,4	1	0,3
Vascular disorders	Haemorrhage	Female	327	46,6	0	0,0
Vascular disorders	Peripheral artery aneurysm	Male	374	53,4	1	0,3
Vascular disorders	Peripheral artery aneurysm	Female	327	46,6	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_29AUG2023_41986.xls
26APR2024 18:14

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Age

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<65 years	308	43,9	0	0,0
Blood and lymphatic system disorders		>=65 years	393	56,1	1	0,3
Blood and lymphatic system disorders	Deficiency anaemia	<65 years	308	43,9	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	>=65 years	393	56,1	1	0,3
Cardiac disorders		<65 years	308	43,9	2	0,6
Cardiac disorders		>=65 years	393	56,1	7	1,8
Cardiac disorders	Acute myocardial infarction	<65 years	308	43,9	0	0,0
Cardiac disorders	Acute myocardial infarction	>=65 years	393	56,1	2	0,5
Cardiac disorders	Atrial fibrillation	<65 years	308	43,9	0	0,0
Cardiac disorders	Atrial fibrillation	>=65 years	393	56,1	3	0,8
Cardiac disorders	Cardiac failure	<65 years	308	43,9	0	0,0
Cardiac disorders	Cardiac failure	>=65 years	393	56,1	1	0,3
Cardiac disorders	Cardiac failure congestive	<65 years	308	43,9	0	0,0
Cardiac disorders	Cardiac failure congestive	>=65 years	393	56,1	2	0,5
Cardiac disorders	Left ventricular dysfunction	<65 years	308	43,9	0	0,0
Cardiac disorders	Left ventricular dysfunction	>=65 years	393	56,1	1	0,3
Cardiac disorders	Myocardial infarction	<65 years	308	43,9	1	0,3
Cardiac disorders	Myocardial infarction	>=65 years	393	56,1	1	0,3
Cardiac disorders	Stress cardiomyopathy	<65 years	308	43,9	1	0,3
Cardiac disorders	Stress cardiomyopathy	>=65 years	393	56,1	0	0,0
Eye disorders		<65 years	308	43,9	6	1,9
Eye disorders		>=65 years	393	56,1	15	3,8
Eye disorders	Cataract	<65 years	308	43,9	0	0,0
Eye disorders	Cataract	>=65 years	393	56,1	1	0,3
Eye disorders	Cystoid macular oedema	<65 years	308	43,9	1	0,3
Eye disorders	Cystoid macular oedema	>=65 years	393	56,1	3	0,8
Eye disorders	Epiretinal membrane	<65 years	308	43,9	1	0,3
Eye disorders	Epiretinal membrane	>=65 years	393	56,1	0	0,0
Eye disorders	Glaucoma	<65 years	308	43,9	0	0,0
Eye disorders	Glaucoma	>=65 years	393	56,1	1	0,3
Eye disorders	Hypotony of eye	<65 years	308	43,9	1	0,3
Eye disorders	Hypotony of eye	>=65 years	393	56,1	0	0,0
Eye disorders	Macular hole	<65 years	308	43,9	0	0,0
Eye disorders	Macular hole	>=65 years	393	56,1	1	0,3
Eye disorders	Macular ischaemia	<65 years	308	43,9	0	0,0
Eye disorders	Macular ischaemia	>=65 years	393	56,1	1	0,3
Eye disorders	Macular oedema	<65 years	308	43,9	1	0,3
Eye disorders	Macular oedema	>=65 years	393	56,1	2	0,5
Eye disorders	Retinal artery embolism	<65 years	308	43,9	0	0,0
Eye disorders	Retinal artery embolism	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal artery occlusion	<65 years	308	43,9	0	0,0
Eye disorders	Retinal artery occlusion	>=65 years	393	56,1	2	0,5
Eye disorders	Retinal detachment	<65 years	308	43,9	0	0,0

Eye disorders	Retinal detachment	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal ischaemia	<65 years	308	43,9	0	0,0
Eye disorders	Retinal ischaemia	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal vein occlusion	<65 years	308	43,9	2	0,6
Eye disorders	Retinal vein occlusion	>=65 years	393	56,1	2	0,5
Gastrointestinal disorders		<65 years	308	43,9	2	0,6
Gastrointestinal disorders		>=65 years	393	56,1	3	0,8
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Pancreatitis	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Pancreatitis	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Pancreatitis acute	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Pancreatitis acute	>=65 years	393	56,1	0	0,0
General disorders and administration site conditions		<65 years	308	43,9	2	0,6
General disorders and administration site conditions		>=65 years	393	56,1	4	1,0
General disorders and administration site conditions	Asthenia	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Asthenia	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Chest pain	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Chest pain	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Death	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Death	>=65 years	393	56,1	2	0,5
General disorders and administration site conditions	Stent-graft endoleak	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Stent-graft endoleak	>=65 years	393	56,1	0	0,0
Hepatobiliary disorders		<65 years	308	43,9	0	0,0
Hepatobiliary disorders		>=65 years	393	56,1	1	0,3
Hepatobiliary disorders	Cholelithiasis	<65 years	308	43,9	0	0,0
Hepatobiliary disorders	Cholelithiasis	>=65 years	393	56,1	1	0,3
Infections and infestations		<65 years	308	43,9	2	0,6
Infections and infestations		>=65 years	393	56,1	19	4,8
Infections and infestations	COVID-19	<65 years	308	43,9	0	0,0
Infections and infestations	COVID-19	>=65 years	393	56,1	2	0,5
Infections and infestations	COVID-19 pneumonia	<65 years	308	43,9	0	0,0
Infections and infestations	COVID-19 pneumonia	>=65 years	393	56,1	1	0,3
Infections and infestations	Cellulitis	<65 years	308	43,9	0	0,0
Infections and infestations	Cellulitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Clostridium difficile infection	<65 years	308	43,9	0	0,0
Infections and infestations	Clostridium difficile infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Device related infection	<65 years	308	43,9	0	0,0
Infections and infestations	Device related infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Endophthalmitis	<65 years	308	43,9	0	0,0
Infections and infestations	Endophthalmitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Enteritis infectious	<65 years	308	43,9	0	0,0
Infections and infestations	Enteritis infectious	>=65 years	393	56,1	1	0,3
Infections and infestations	Escherichia urinary tract infection	<65 years	308	43,9	0	0,0
Infections and infestations	Escherichia urinary tract infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Influenza	<65 years	308	43,9	0	0,0
Infections and infestations	Influenza	>=65 years	393	56,1	2	0,5
Infections and infestations	Lower respiratory tract infection	<65 years	308	43,9	0	0,0
Infections and infestations	Lower respiratory tract infection	>=65 years	393	56,1	1	0,3

Infections and infestations	Necrotising fasciitis	<65 years	308	43,9	0	0,0
Infections and infestations	Necrotising fasciitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Pneumonia	<65 years	308	43,9	0	0,0
Infections and infestations	Pneumonia	>=65 years	393	56,1	4	1,0
Infections and infestations	Pneumonia viral	<65 years	308	43,9	1	0,3
Infections and infestations	Pneumonia viral	>=65 years	393	56,1	1	0,3
Infections and infestations	Respiratory syncytial virus infection	<65 years	308	43,9	0	0,0
Infections and infestations	Respiratory syncytial virus infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Sepsis	<65 years	308	43,9	0	0,0
Infections and infestations	Sepsis	>=65 years	393	56,1	2	0,5
Infections and infestations	Tooth infection	<65 years	308	43,9	1	0,3
Infections and infestations	Tooth infection	>=65 years	393	56,1	0	0,0
Infections and infestations	Urinary tract candidiasis	<65 years	308	43,9	0	0,0
Infections and infestations	Urinary tract candidiasis	>=65 years	393	56,1	1	0,3
Infections and infestations	Urosepsis	<65 years	308	43,9	0	0,0
Infections and infestations	Urosepsis	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications		<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications		>=65 years	393	56,1	7	1,8
Injury, poisoning and procedural complications	Accident	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Accident	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Contusion	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Contusion	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Fall	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Fall	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Femur fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=65 years	393	56,1	2	0,5
Injury, poisoning and procedural complications	Ligament rupture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Ligament rupture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Rib fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Rib fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Shunt stenosis	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Skin laceration	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Skin laceration	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders		<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders		>=65 years	393	56,1	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Hypervolaemia	>=65 years	393	56,1	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Hypokalaemia	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders		<65 years	308	43,9	3	1,0
Musculoskeletal and connective tissue disorders		>=65 years	393	56,1	2	0,5
Musculoskeletal and connective tissue disorders	Arthralgia	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Osteoarthritis	<65 years	308	43,9	2	0,6
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	>=65 years	393	56,1	1	0,3

Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=65 years	393	56,1	2	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	>=65 years	393	56,1	1	0,3
Nervous system disorders		<65 years	308	43,9	2	0,6
Nervous system disorders		>=65 years	393	56,1	3	0,8
Nervous system disorders	Cerebrovascular accident	<65 years	308	43,9	0	0,0
Nervous system disorders	Cerebrovascular accident	>=65 years	393	56,1	1	0,3
Nervous system disorders	Dysarthria	<65 years	308	43,9	1	0,3
Nervous system disorders	Dysarthria	>=65 years	393	56,1	0	0,0
Nervous system disorders	Headache	<65 years	308	43,9	0	0,0
Nervous system disorders	Headache	>=65 years	393	56,1	1	0,3
Nervous system disorders	Hypoaesthesia	<65 years	308	43,9	1	0,3
Nervous system disorders	Hypoaesthesia	>=65 years	393	56,1	0	0,0
Nervous system disorders	Ischaemic stroke	<65 years	308	43,9	0	0,0
Nervous system disorders	Ischaemic stroke	>=65 years	393	56,1	1	0,3
Psychiatric disorders		<65 years	308	43,9	1	0,3
Psychiatric disorders		>=65 years	393	56,1	0	0,0
Psychiatric disorders	Sleep disorder	<65 years	308	43,9	1	0,3
Psychiatric disorders	Sleep disorder	>=65 years	393	56,1	0	0,0
Renal and urinary disorders		<65 years	308	43,9	0	0,0
Renal and urinary disorders		>=65 years	393	56,1	3	0,8
Renal and urinary disorders	Acute kidney injury	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Acute kidney injury	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Cystitis interstitial	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Cystitis interstitial	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	End stage renal disease	<65 years	308	43,9	0	0,0
Renal and urinary disorders	End stage renal disease	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Nephropathy	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Nephropathy	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders		<65 years	308	43,9	2	0,6
Respiratory, thoracic and mediastinal disorders		>=65 years	393	56,1	3	0,8
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<65 years	308	43,9	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=65 years	393	56,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=65 years	393	56,1	2	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	<65 years	308	43,9	1	0,3
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	>=65 years	393	56,1	0	0,0
Surgical and medical procedures		<65 years	308	43,9	0	0,0
Surgical and medical procedures		>=65 years	393	56,1	2	0,5
Surgical and medical procedures	Large intestinal polypectomy	<65 years	308	43,9	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	>=65 years	393	56,1	1	0,3
Surgical and medical procedures	Renal transplant	<65 years	308	43,9	0	0,0
Surgical and medical procedures	Renal transplant	>=65 years	393	56,1	1	0,3

Vascular disorders		<65 years	308	43,9	1	0,3
Vascular disorders		>=65 years	393	56,1	3	0,8
Vascular disorders	Aortic aneurysm	<65 years	308	43,9	0	0,0
Vascular disorders	Aortic aneurysm	>=65 years	393	56,1	1	0,3
Vascular disorders	Aortic dissection	<65 years	308	43,9	0	0,0
Vascular disorders	Aortic dissection	>=65 years	393	56,1	1	0,3
Vascular disorders	Haemorrhage	<65 years	308	43,9	0	0,0
Vascular disorders	Haemorrhage	>=65 years	393	56,1	1	0,3
Vascular disorders	Peripheral artery aneurysm	<65 years	308	43,9	1	0,3
Vascular disorders	Peripheral artery aneurysm	>=65 years	393	56,1	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_29AUG2023_41986.xls
26APR2024 18:14

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETDRS letter score

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=701)			
			Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders		35 - 54 letters	206	29,4	0	0,0
Blood and lymphatic system disorders		>=55 letters	339	48,4	1	0,3
Blood and lymphatic system disorders	Deficiency anaemia	<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	35 - 54 letters	206	29,4	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	>=55 letters	339	48,4	1	0,3
Cardiac disorders		<=34 letters	156	22,3	1	0,6
Cardiac disorders		35 - 54 letters	206	29,4	4	1,9
Cardiac disorders		>=55 letters	339	48,4	4	1,2
Cardiac disorders	Acute myocardial infarction	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Acute myocardial infarction	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Acute myocardial infarction	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Atrial fibrillation	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Atrial fibrillation	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Atrial fibrillation	>=55 letters	339	48,4	2	0,6
Cardiac disorders	Cardiac failure	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Cardiac failure	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Cardiac failure	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Cardiac failure congestive	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Cardiac failure congestive	35 - 54 letters	206	29,4	2	1,0
Cardiac disorders	Cardiac failure congestive	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Left ventricular dysfunction	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Left ventricular dysfunction	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Left ventricular dysfunction	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Myocardial infarction	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Myocardial infarction	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Myocardial infarction	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Stress cardiomyopathy	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Stress cardiomyopathy	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Stress cardiomyopathy	>=55 letters	339	48,4	0	0,0
Eye disorders		<=34 letters	156	22,3	4	2,6
Eye disorders		35 - 54 letters	206	29,4	4	1,9
Eye disorders		>=55 letters	339	48,4	13	3,8
Eye disorders	Cataract	<=34 letters	156	22,3	0	0,0
Eye disorders	Cataract	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Cataract	>=55 letters	339	48,4	0	0,0
Eye disorders	Cystoid macular oedema	<=34 letters	156	22,3	0	0,0
Eye disorders	Cystoid macular oedema	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Cystoid macular oedema	>=55 letters	339	48,4	4	1,2
Eye disorders	Epiletinal membrane	<=34 letters	156	22,3	0	0,0
Eye disorders	Epiletinal membrane	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Epiletinal membrane	>=55 letters	339	48,4	0	0,0
Eye disorders	Glaucoma	<=34 letters	156	22,3	0	0,0
Eye disorders	Glaucoma	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Glaucoma	>=55 letters	339	48,4	1	0,3
Eye disorders	Hypotony of eye	<=34 letters	156	22,3	1	0,6
Eye disorders	Hypotony of eye	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Hypotony of eye	>=55 letters	339	48,4	0	0,0
Eye disorders	Macular hole	<=34 letters	156	22,3	0	0,0
Eye disorders	Macular hole	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Macular hole	>=55 letters	339	48,4	1	0,3
Eye disorders	Macular ischaemia	<=34 letters	156	22,3	0	0,0
Eye disorders	Macular ischaemia	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Macular ischaemia	>=55 letters	339	48,4	1	0,3
Eye disorders	Macular oedema	<=34 letters	156	22,3	0	0,0
Eye disorders	Macular oedema	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Macular oedema	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal artery embolism	<=34 letters	156	22,3	0	0,0

Eye disorders	Retinal artery embolism	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal artery embolism	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal artery occlusion	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal artery occlusion	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal artery occlusion	>=55 letters	339	48,4	2	0,6
Eye disorders	Retinal detachment	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal detachment	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal detachment	>=55 letters	339	48,4	0	0,0
Eye disorders	Retinal ischaemia	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal ischaemia	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal ischaemia	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal vein occlusion	<=34 letters	156	22,3	2	1,3
Eye disorders	Retinal vein occlusion	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal vein occlusion	>=55 letters	339	48,4	2	0,6
Gastrointestinal disorders		<=34 letters	156	22,3	1	0,6
Gastrointestinal disorders		35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders		>=55 letters	339	48,4	4	1,2
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Gastrointestinal inflammation	<=34 letters	156	22,3	1	0,6
Gastrointestinal disorders	Gastrointestinal inflammation	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Pancreatitis	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Pancreatitis	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Pancreatitis	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Pancreatitis acute	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Pancreatitis acute	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Pancreatitis acute	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions		<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions		35 - 54 letters	206	29,4	2	1,0
General disorders and administration site conditions		>=55 letters	339	48,4	3	0,9
General disorders and administration site conditions	Asthenia	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Asthenia	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Asthenia	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Chest pain	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Chest pain	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Chest pain	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Death	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Death	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Death	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Stent-graft endoleak	<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions	Stent-graft endoleak	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	>=55 letters	339	48,4	0	0,0
Hepatobiliary disorders		<=34 letters	156	22,3	0	0,0
Hepatobiliary disorders		35 - 54 letters	206	29,4	1	0,5
Hepatobiliary disorders		>=55 letters	339	48,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	<=34 letters	156	22,3	0	0,0
Hepatobiliary disorders	Cholelithiasis	35 - 54 letters	206	29,4	1	0,5
Hepatobiliary disorders	Cholelithiasis	>=55 letters	339	48,4	0	0,0
Infections and infestations		<=34 letters	156	22,3	4	2,6
Infections and infestations		35 - 54 letters	206	29,4	7	3,4
Infections and infestations		>=55 letters	339	48,4	10	2,9
Infections and infestations	COVID-19	<=34 letters	156	22,3	0	0,0
Infections and infestations	COVID-19	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	COVID-19	>=55 letters	339	48,4	2	0,6
Infections and infestations	COVID-19 pneumonia	<=34 letters	156	22,3	0	0,0
Infections and infestations	COVID-19 pneumonia	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	COVID-19 pneumonia	>=55 letters	339	48,4	0	0,0
Infections and infestations	Cellulitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Cellulitis	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Cellulitis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Clostridium difficile infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Clostridium difficile infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Clostridium difficile infection	>=55 letters	339	48,4	0	0,0

Infections and infestations	Device related infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Device related infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Device related infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Endophthalmitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Endophthalmitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Endophthalmitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Enteritis infectious	<=34 letters	156	22,3	0	0,0
Infections and infestations	Enteritis infectious	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Enteritis infectious	>=55 letters	339	48,4	1	0,3
Infections and infestations	Escherichia urinary tract infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Escherichia urinary tract infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Escherichia urinary tract infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Influenza	<=34 letters	156	22,3	0	0,0
Infections and infestations	Influenza	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Influenza	>=55 letters	339	48,4	2	0,6
Infections and infestations	Lower respiratory tract infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Lower respiratory tract infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Lower respiratory tract infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Necrotising fasciitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Necrotising fasciitis	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Necrotising fasciitis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Pneumonia	<=34 letters	156	22,3	1	0,6
Infections and infestations	Pneumonia	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Pneumonia	>=55 letters	339	48,4	3	0,9
Infections and infestations	Pneumonia viral	<=34 letters	156	22,3	0	0,0
Infections and infestations	Pneumonia viral	35 - 54 letters	206	29,4	2	1,0
Infections and infestations	Pneumonia viral	>=55 letters	339	48,4	0	0,0
Infections and infestations	Respiratory syncytial virus infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Respiratory syncytial virus infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Respiratory syncytial virus infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Sepsis	<=34 letters	156	22,3	2	1,3
Infections and infestations	Sepsis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Sepsis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Tooth infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Tooth infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Tooth infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Urinary tract candidiasis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Urinary tract candidiasis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Urinary tract candidiasis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Urosepsis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Urosepsis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Urosepsis	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications		<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications		35 - 54 letters	206	29,4	5	2,4
Injury, poisoning and procedural complications		>=55 letters	339	48,4	3	0,9
Injury, poisoning and procedural complications	Accident	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Accident	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Accident	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Contusion	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Contusion	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Contusion	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Fall	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Fall	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Fall	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Femur fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Femur fracture	35 - 54 letters	206	29,4	2	1,0
Injury, poisoning and procedural complications	Femur fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Lower limb fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Lower limb fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Rib fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Rib fracture	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Rib fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Skin laceration	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Skin laceration	35 - 54 letters	206	29,4	1	0,5

Injury, poisoning and procedural complications	Skin laceration	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders		<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders		35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders		>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Hypervolaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Hypokalaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders		<=34 letters	156	22,3	2	1,3
Musculoskeletal and connective tissue disorders		35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders		>=55 letters	339	48,4	2	0,6
Musculoskeletal and connective tissue disorders	Arthralgia	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	>=55 letters	339	48,4	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	<=34 letters	156	22,3	1	0,6
Musculoskeletal and connective tissue disorders	Joint effusion	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders	Mobility decreased	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	<=34 letters	156	22,3	1	0,6
Musculoskeletal and connective tissue disorders	Osteoarthritis	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=55 letters	339	48,4	1	0,3
Musculoskeletal and connective tissue disorders	Polymyositis	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders	Polymyositis	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		35 - 54 letters	206	29,4	2	1,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	>=55 letters	339	48,4	0	0,0
Nervous system disorders		<=34 letters	156	22,3	0	0,0
Nervous system disorders		35 - 54 letters	206	29,4	3	1,5
Nervous system disorders		>=55 letters	339	48,4	2	0,6
Nervous system disorders	Cerebrovascular accident	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Cerebrovascular accident	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Cerebrovascular accident	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Dysarthria	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Dysarthria	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Dysarthria	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Headache	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Headache	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Headache	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Hypoaesthesia	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Hypoaesthesia	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Hypoaesthesia	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Ischaemic stroke	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Ischaemic stroke	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Ischaemic stroke	>=55 letters	339	48,4	1	0,3
Psychiatric disorders		<=34 letters	156	22,3	0	0,0
Psychiatric disorders		35 - 54 letters	206	29,4	0	0,0
Psychiatric disorders		>=55 letters	339	48,4	1	0,3
Psychiatric disorders	Sleep disorder	<=34 letters	156	22,3	0	0,0
Psychiatric disorders	Sleep disorder	35 - 54 letters	206	29,4	0	0,0
Psychiatric disorders	Sleep disorder	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders		<=34 letters	156	22,3	0	0,0
Renal and urinary disorders		35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders		>=55 letters	339	48,4	3	0,9
Renal and urinary disorders	Acute kidney injury	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Acute kidney injury	35 - 54 letters	206	29,4	0	0,0

Renal and urinary disorders	Acute kidney injury	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Cystitis interstitial	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Cystitis interstitial	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Cystitis interstitial	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	End stage renal disease	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	End stage renal disease	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	End stage renal disease	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Nephropathy	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Nephropathy	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Nephropathy	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders		<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders		35 - 54 letters	206	29,4	3	1,5
Respiratory, thoracic and mediastinal disorders		>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=55 letters	339	48,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	>=55 letters	339	48,4	0	0,0
Surgical and medical procedures		<=34 letters	156	22,3	0	0,0
Surgical and medical procedures		35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures		>=55 letters	339	48,4	2	0,6
Surgical and medical procedures	Large intestinal polypectomy	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	>=55 letters	339	48,4	1	0,3
Surgical and medical procedures	Renal transplant	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Renal transplant	35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures	Renal transplant	>=55 letters	339	48,4	1	0,3
Vascular disorders		<=34 letters	156	22,3	1	0,6
Vascular disorders		35 - 54 letters	206	29,4	1	0,5
Vascular disorders		>=55 letters	339	48,4	2	0,6
Vascular disorders	Aortic aneurysm	<=34 letters	156	22,3	0	0,0
Vascular disorders	Aortic aneurysm	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Aortic aneurysm	>=55 letters	339	48,4	1	0,3
Vascular disorders	Aortic dissection	<=34 letters	156	22,3	0	0,0
Vascular disorders	Aortic dissection	35 - 54 letters	206	29,4	1	0,5
Vascular disorders	Aortic dissection	>=55 letters	339	48,4	0	0,0
Vascular disorders	Haemorrhage	<=34 letters	156	22,3	0	0,0
Vascular disorders	Haemorrhage	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Haemorrhage	>=55 letters	339	48,4	1	0,3
Vascular disorders	Peripheral artery aneurysm	<=34 letters	156	22,3	1	0,6
Vascular disorders	Peripheral artery aneurysm	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Peripheral artery aneurysm	>=55 letters	339	48,4	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_29AUG2023_41986.xls
26APR2024 18:14

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETRS letter score

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders		>=24 letters	632	90,2	1	0,2
Blood and lymphatic system disorders	Deficiency anaemia	<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	>=24 letters	632	90,2	1	0,2
Cardiac disorders		<=23 letters	69	9,8	0	0,0
Cardiac disorders		>=24 letters	632	90,2	9	1,4
Cardiac disorders	Acute myocardial infarction	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Acute myocardial infarction	>=24 letters	632	90,2	2	0,3
Cardiac disorders	Atrial fibrillation	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Atrial fibrillation	>=24 letters	632	90,2	3	0,5
Cardiac disorders	Cardiac failure	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Cardiac failure	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Cardiac failure congestive	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Cardiac failure congestive	>=24 letters	632	90,2	2	0,3
Cardiac disorders	Left ventricular dysfunction	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Left ventricular dysfunction	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Myocardial infarction	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Myocardial infarction	>=24 letters	632	90,2	2	0,3
Cardiac disorders	Stress cardiomyopathy	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Stress cardiomyopathy	>=24 letters	632	90,2	1	0,2
Eye disorders		<=23 letters	69	9,8	0	0,0
Eye disorders		>=24 letters	632	90,2	21	3,3
Eye disorders	Cataract	<=23 letters	69	9,8	0	0,0
Eye disorders	Cataract	>=24 letters	632	90,2	1	0,2
Eye disorders	Cystoid macular oedema	<=23 letters	69	9,8	0	0,0
Eye disorders	Cystoid macular oedema	>=24 letters	632	90,2	4	0,6
Eye disorders	Epiretinal membrane	<=23 letters	69	9,8	0	0,0
Eye disorders	Epiretinal membrane	>=24 letters	632	90,2	1	0,2
Eye disorders	Glaucoma	<=23 letters	69	9,8	0	0,0
Eye disorders	Glaucoma	>=24 letters	632	90,2	1	0,2
Eye disorders	Hypotony of eye	<=23 letters	69	9,8	0	0,0
Eye disorders	Hypotony of eye	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular hole	<=23 letters	69	9,8	0	0,0
Eye disorders	Macular hole	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular ischaemia	<=23 letters	69	9,8	0	0,0
Eye disorders	Macular ischaemia	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular oedema	<=23 letters	69	9,8	0	0,0
Eye disorders	Macular oedema	>=24 letters	632	90,2	3	0,5
Eye disorders	Retinal artery embolism	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal artery embolism	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal artery occlusion	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal artery occlusion	>=24 letters	632	90,2	2	0,3
Eye disorders	Retinal detachment	<=23 letters	69	9,8	0	0,0

Eye disorders	Retinal detachment	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal ischaemia	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal ischaemia	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal vein occlusion	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal vein occlusion	>=24 letters	632	90,2	4	0,6
Gastrointestinal disorders		<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders		>=24 letters	632	90,2	5	0,8
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Duodenal ulcer haemorrhage	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Gastrointestinal inflammation	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Pancreatitis	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Pancreatitis	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Pancreatitis acute	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Pancreatitis acute	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions		<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions		>=24 letters	632	90,2	6	0,9
General disorders and administration site conditions	Asthenia	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Asthenia	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Chest pain	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Chest pain	>=24 letters	632	90,2	2	0,3
General disorders and administration site conditions	Death	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Death	>=24 letters	632	90,2	2	0,3
General disorders and administration site conditions	Stent-graft endoleak	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	>=24 letters	632	90,2	1	0,2
Hepatobiliary disorders		<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders		>=24 letters	632	90,2	1	0,2
Hepatobiliary disorders	Cholelithiasis	<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders	Cholelithiasis	>=24 letters	632	90,2	1	0,2
Infections and infestations		<=23 letters	69	9,8	1	1,4
Infections and infestations		>=24 letters	632	90,2	20	3,2
Infections and infestations	COVID-19	<=23 letters	69	9,8	0	0,0
Infections and infestations	COVID-19	>=24 letters	632	90,2	2	0,3
Infections and infestations	COVID-19 pneumonia	<=23 letters	69	9,8	0	0,0
Infections and infestations	COVID-19 pneumonia	>=24 letters	632	90,2	1	0,2
Infections and infestations	Cellulitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Cellulitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Clostridium difficile infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Clostridium difficile infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Device related infection	<=23 letters	69	9,8	1	1,4
Infections and infestations	Device related infection	>=24 letters	632	90,2	0	0,0
Infections and infestations	Endophthalmitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Endophthalmitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Enteritis infectious	<=23 letters	69	9,8	0	0,0
Infections and infestations	Enteritis infectious	>=24 letters	632	90,2	1	0,2
Infections and infestations	Escherichia urinary tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Escherichia urinary tract infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Influenza	<=23 letters	69	9,8	0	0,0
Infections and infestations	Influenza	>=24 letters	632	90,2	2	0,3
Infections and infestations	Lower respiratory tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Lower respiratory tract infection	>=24 letters	632	90,2	1	0,2

Infections and infestations	Necrotising fasciitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Necrotising fasciitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Pneumonia	<=23 letters	69	9,8	0	0,0
Infections and infestations	Pneumonia	>=24 letters	632	90,2	4	0,6
Infections and infestations	Pneumonia viral	<=23 letters	69	9,8	0	0,0
Infections and infestations	Pneumonia viral	>=24 letters	632	90,2	2	0,3
Infections and infestations	Respiratory syncytial virus infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Respiratory syncytial virus infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Sepsis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Sepsis	>=24 letters	632	90,2	2	0,3
Infections and infestations	Tooth infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Tooth infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Urinary tract candidiasis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Urinary tract candidiasis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Urosepsis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Urosepsis	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications		<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications		>=24 letters	632	90,2	8	1,3
Injury, poisoning and procedural complications	Accident	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Accident	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Contusion	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Contusion	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Fall	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Fall	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Femur fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Ligament rupture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Lower limb fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Rib fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Rib fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Shunt stenosis	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Skin laceration	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Skin laceration	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders		<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders		>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hypervolaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hypokalaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders		<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders		>=24 letters	632	90,2	5	0,8
Musculoskeletal and connective tissue disorders	Arthralgia	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Joint effusion	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Mobility decreased	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Osteoarthritis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	>=24 letters	632	90,2	2	0,3
Musculoskeletal and connective tissue disorders	Polymyositis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	>=24 letters	632	90,2	1	0,2

Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=24 letters	632	90,2	2	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	>=24 letters	632	90,2	1	0,2
Nervous system disorders		<=23 letters	69	9,8	0	0,0
Nervous system disorders		>=24 letters	632	90,2	5	0,8
Nervous system disorders	Cerebrovascular accident	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cerebrovascular accident	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Dysarthria	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Dysarthria	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Headache	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Headache	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Hypoaesthesia	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Hypoaesthesia	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Ischaemic stroke	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Ischaemic stroke	>=24 letters	632	90,2	1	0,2
Psychiatric disorders		<=23 letters	69	9,8	0	0,0
Psychiatric disorders		>=24 letters	632	90,2	1	0,2
Psychiatric disorders	Sleep disorder	<=23 letters	69	9,8	0	0,0
Psychiatric disorders	Sleep disorder	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders		<=23 letters	69	9,8	0	0,0
Renal and urinary disorders		>=24 letters	632	90,2	3	0,5
Renal and urinary disorders	Acute kidney injury	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Acute kidney injury	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Cystitis interstitial	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Cystitis interstitial	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	End stage renal disease	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	End stage renal disease	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Nephropathy	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Nephropathy	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders		<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders		>=24 letters	632	90,2	5	0,8
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=24 letters	632	90,2	2	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures		<=23 letters	69	9,8	0	0,0
Surgical and medical procedures		>=24 letters	632	90,2	2	0,3
Surgical and medical procedures	Large intestinal polypectomy	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures	Renal transplant	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Renal transplant	>=24 letters	632	90,2	1	0,2

Vascular disorders		<=23 letters	69	9,8	0	0,0
Vascular disorders		>=24 letters	632	90,2	4	0,6
Vascular disorders	Aortic aneurysm	<=23 letters	69	9,8	0	0,0
Vascular disorders	Aortic aneurysm	>=24 letters	632	90,2	1	0,2
Vascular disorders	Aortic dissection	<=23 letters	69	9,8	0	0,0
Vascular disorders	Aortic dissection	>=24 letters	632	90,2	1	0,2
Vascular disorders	Haemorrhage	<=23 letters	69	9,8	0	0,0
Vascular disorders	Haemorrhage	>=24 letters	632	90,2	1	0,2
Vascular disorders	Peripheral artery aneurysm	<=23 letters	69	9,8	0	0,0
Vascular disorders	Peripheral artery aneurysm	>=24 letters	632	90,2	1	0,2

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_29AUG2023_41986.xls
26APR2024 18:14

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Geographic Region

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=701)			
			Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		Europe	214	30,5	0	0,0
Blood and lymphatic system disorders		America	282	40,2	0	0,0
Blood and lymphatic system disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Blood and lymphatic system disorders	Deficiency anaemia	Europe	214	30,5	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	America	282	40,2	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders		Europe	214	30,5	4	1,9
Cardiac disorders		America	282	40,2	2	0,7
Cardiac disorders		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Cardiac disorders	Acute myocardial infarction	Europe	214	30,5	1	0,5
Cardiac disorders	Acute myocardial infarction	America	282	40,2	0	0,0
Cardiac disorders	Acute myocardial infarction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Atrial fibrillation	Europe	214	30,5	2	0,9
Cardiac disorders	Atrial fibrillation	America	282	40,2	0	0,0
Cardiac disorders	Atrial fibrillation	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Cardiac failure	Europe	214	30,5	1	0,5
Cardiac disorders	Cardiac failure	America	282	40,2	0	0,0
Cardiac disorders	Cardiac failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Cardiac failure congestive	Europe	214	30,5	0	0,0
Cardiac disorders	Cardiac failure congestive	America	282	40,2	2	0,7
Cardiac disorders	Cardiac failure congestive	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Left ventricular dysfunction	Europe	214	30,5	1	0,5
Cardiac disorders	Left ventricular dysfunction	America	282	40,2	0	0,0
Cardiac disorders	Left ventricular dysfunction	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Myocardial infarction	Europe	214	30,5	1	0,5
Cardiac disorders	Myocardial infarction	America	282	40,2	1	0,4
Cardiac disorders	Myocardial infarction	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Stress cardiomyopathy	Europe	214	30,5	0	0,0
Cardiac disorders	Stress cardiomyopathy	America	282	40,2	0	0,0
Cardiac disorders	Stress cardiomyopathy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders		Europe	214	30,5	5	2,3
Eye disorders		America	282	40,2	8	2,8
Eye disorders		Asia Pacific (inc. Australia)	205	29,2	8	3,9
Eye disorders	Cataract	Europe	214	30,5	0	0,0
Eye disorders	Cataract	America	282	40,2	1	0,4
Eye disorders	Cataract	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Cystoid macular oedema	Europe	214	30,5	0	0,0
Eye disorders	Cystoid macular oedema	America	282	40,2	2	0,7
Eye disorders	Cystoid macular oedema	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Epi-retinal membrane	Europe	214	30,5	0	0,0
Eye disorders	Epi-retinal membrane	America	282	40,2	0	0,0
Eye disorders	Epi-retinal membrane	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Glaucoma	Europe	214	30,5	0	0,0
Eye disorders	Glaucoma	America	282	40,2	0	0,0
Eye disorders	Glaucoma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Hypotony of eye	Europe	214	30,5	0	0,0
Eye disorders	Hypotony of eye	America	282	40,2	0	0,0
Eye disorders	Hypotony of eye	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Macular hole	Europe	214	30,5	1	0,5
Eye disorders	Macular hole	America	282	40,2	0	0,0
Eye disorders	Macular hole	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular ischaemia	Europe	214	30,5	0	0,0
Eye disorders	Macular ischaemia	America	282	40,2	1	0,4
Eye disorders	Macular ischaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular oedema	Europe	214	30,5	1	0,5
Eye disorders	Macular oedema	America	282	40,2	1	0,4
Eye disorders	Macular oedema	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Retinal artery embolism	Europe	214	30,5	0	0,0

Eye disorders	Retinal artery embolism	America	282	40,2	1	0,4
Eye disorders	Retinal artery embolism	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal artery occlusion	Europe	214	30,5	0	0,0
Eye disorders	Retinal artery occlusion	America	282	40,2	1	0,4
Eye disorders	Retinal artery occlusion	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Retinal detachment	Europe	214	30,5	0	0,0
Eye disorders	Retinal detachment	America	282	40,2	0	0,0
Eye disorders	Retinal detachment	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Retinal ischaemia	Europe	214	30,5	1	0,5
Eye disorders	Retinal ischaemia	America	282	40,2	0	0,0
Eye disorders	Retinal ischaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal vein occlusion	Europe	214	30,5	2	0,9
Eye disorders	Retinal vein occlusion	America	282	40,2	2	0,7
Eye disorders	Retinal vein occlusion	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders		Europe	214	30,5	1	0,5
Gastrointestinal disorders		America	282	40,2	2	0,7
Gastrointestinal disorders		Asia Pacific (inc. Australia)	205	29,2	2	1,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	America	282	40,2	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	America	282	40,2	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Gastrointestinal inflammation	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Gastrointestinal inflammation	America	282	40,2	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Pancreatitis	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Pancreatitis	America	282	40,2	1	0,4
Gastrointestinal disorders	Pancreatitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Pancreatitis acute	America	282	40,2	1	0,4
Gastrointestinal disorders	Pancreatitis acute	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions		Europe	214	30,5	2	0,9
General disorders and administration site conditions		America	282	40,2	1	0,4
General disorders and administration site conditions		Asia Pacific (inc. Australia)	205	29,2	3	1,5
General disorders and administration site conditions	Asthenia	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Asthenia	America	282	40,2	0	0,0
General disorders and administration site conditions	Asthenia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Chest pain	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Chest pain	America	282	40,2	0	0,0
General disorders and administration site conditions	Chest pain	Asia Pacific (inc. Australia)	205	29,2	2	1,0
General disorders and administration site conditions	Death	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Death	America	282	40,2	1	0,4
General disorders and administration site conditions	Death	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	America	282	40,2	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Hepatobiliary disorders		Europe	214	30,5	0	0,0
Hepatobiliary disorders		America	282	40,2	1	0,4
Hepatobiliary disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Hepatobiliary disorders	Cholelithiasis	Europe	214	30,5	0	0,0
Hepatobiliary disorders	Cholelithiasis	America	282	40,2	1	0,4
Hepatobiliary disorders	Cholelithiasis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations		Europe	214	30,5	7	3,3
Infections and infestations		America	282	40,2	10	3,5
Infections and infestations		Asia Pacific (inc. Australia)	205	29,2	4	2,0
Infections and infestations	COVID-19	Europe	214	30,5	0	0,0
Infections and infestations	COVID-19	America	282	40,2	2	0,7
Infections and infestations	COVID-19	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	COVID-19 pneumonia	Europe	214	30,5	1	0,5
Infections and infestations	COVID-19 pneumonia	America	282	40,2	0	0,0
Infections and infestations	COVID-19 pneumonia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Cellulitis	Europe	214	30,5	1	0,5
Infections and infestations	Cellulitis	America	282	40,2	0	0,0
Infections and infestations	Cellulitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Clostridium difficile infection	Europe	214	30,5	0	0,0
Infections and infestations	Clostridium difficile infection	America	282	40,2	1	0,4
Infections and infestations	Clostridium difficile infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Infections and infestations	Device related infection	Europe	214	30,5	1	0,5
Infections and infestations	Device related infection	America	282	40,2	0	0,0
Infections and infestations	Device related infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Endophthalmitis	Europe	214	30,5	1	0,5
Infections and infestations	Endophthalmitis	America	282	40,2	0	0,0
Infections and infestations	Endophthalmitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Enteritis infectious	Europe	214	30,5	0	0,0
Infections and infestations	Enteritis infectious	America	282	40,2	1	0,4
Infections and infestations	Enteritis infectious	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Escherichia urinary tract infection	Europe	214	30,5	0	0,0
Infections and infestations	Escherichia urinary tract infection	America	282	40,2	0	0,0
Infections and infestations	Escherichia urinary tract infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Influenza	Europe	214	30,5	0	0,0
Infections and infestations	Influenza	America	282	40,2	2	0,7
Infections and infestations	Influenza	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Lower respiratory tract infection	Europe	214	30,5	1	0,5
Infections and infestations	Lower respiratory tract infection	America	282	40,2	0	0,0
Infections and infestations	Lower respiratory tract infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Necrotising fasciitis	Europe	214	30,5	0	0,0
Infections and infestations	Necrotising fasciitis	America	282	40,2	1	0,4
Infections and infestations	Necrotising fasciitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Pneumonia	Europe	214	30,5	2	0,9
Infections and infestations	Pneumonia	America	282	40,2	2	0,7
Infections and infestations	Pneumonia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Pneumonia viral	Europe	214	30,5	0	0,0
Infections and infestations	Pneumonia viral	America	282	40,2	0	0,0
Infections and infestations	Pneumonia viral	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Infections and infestations	Respiratory syncytial virus infection	Europe	214	30,5	0	0,0
Infections and infestations	Respiratory syncytial virus infection	America	282	40,2	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Sepsis	Europe	214	30,5	1	0,5
Infections and infestations	Sepsis	America	282	40,2	1	0,4
Infections and infestations	Sepsis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Tooth infection	Europe	214	30,5	0	0,0
Infections and infestations	Tooth infection	America	282	40,2	1	0,4
Infections and infestations	Tooth infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Urinary tract candidiasis	Europe	214	30,5	0	0,0
Infections and infestations	Urinary tract candidiasis	America	282	40,2	0	0,0
Infections and infestations	Urinary tract candidiasis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Urosepsis	Europe	214	30,5	0	0,0
Infections and infestations	Urosepsis	America	282	40,2	1	0,4
Infections and infestations	Urosepsis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications		Europe	214	30,5	2	0,9
Injury, poisoning and procedural complications		America	282	40,2	3	1,1
Injury, poisoning and procedural complications		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Injury, poisoning and procedural complications	Accident	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Accident	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Accident	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Contusion	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Contusion	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Contusion	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Fall	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Fall	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Fall	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Femur fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Femur fracture	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Ligament rupture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Ligament rupture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Lower limb fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Rib fracture	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Shunt stenosis	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Skin laceration	Europe	214	30,5	1	0,5
Injury, poisoning and procedural complications	Skin laceration	America	282	40,2	0	0,0

Injury, poisoning and procedural complications	Skin laceration	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders		Europe	214	30,5	0	0,0
Metabolism and nutrition disorders		America	282	40,2	0	0,0
Metabolism and nutrition disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Hypervolaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Hypokalaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders		Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders		America	282	40,2	2	0,7
Musculoskeletal and connective tissue disorders		Asia Pacific (inc. Australia)	205	29,2	2	1,0
Musculoskeletal and connective tissue disorders	Arthralgia	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Joint effusion	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Mobility decreased	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Mobility decreased	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	America	282	40,2	2	0,7
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Polymyositis	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asia Pacific (inc. Australia)	205	29,2	2	1,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders		Europe	214	30,5	1	0,5
Nervous system disorders		America	282	40,2	2	0,7
Nervous system disorders		Asia Pacific (inc. Australia)	205	29,2	2	1,0
Nervous system disorders	Cerebrovascular accident	Europe	214	30,5	0	0,0
Nervous system disorders	Cerebrovascular accident	America	282	40,2	1	0,4
Nervous system disorders	Cerebrovascular accident	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Dysarthria	Europe	214	30,5	0	0,0
Nervous system disorders	Dysarthria	America	282	40,2	0	0,0
Nervous system disorders	Dysarthria	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Headache	Europe	214	30,5	0	0,0
Nervous system disorders	Headache	America	282	40,2	1	0,4
Nervous system disorders	Headache	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Hypoaesthesia	Europe	214	30,5	0	0,0
Nervous system disorders	Hypoaesthesia	America	282	40,2	0	0,0
Nervous system disorders	Hypoaesthesia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Ischaemic stroke	Europe	214	30,5	1	0,5
Nervous system disorders	Ischaemic stroke	America	282	40,2	0	0,0
Nervous system disorders	Ischaemic stroke	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Psychiatric disorders		Europe	214	30,5	0	0,0
Psychiatric disorders		America	282	40,2	0	0,0
Psychiatric disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Psychiatric disorders	Sleep disorder	Europe	214	30,5	0	0,0
Psychiatric disorders	Sleep disorder	America	282	40,2	0	0,0
Psychiatric disorders	Sleep disorder	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders		Europe	214	30,5	0	0,0
Renal and urinary disorders		America	282	40,2	2	0,7
Renal and urinary disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	Acute kidney injury	Europe	214	30,5	0	0,0
Renal and urinary disorders	Acute kidney injury	America	282	40,2	0	0,0

Renal and urinary disorders	Acute kidney injury	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	Cystitis interstitial	Europe	214	30,5	0	0,0
Renal and urinary disorders	Cystitis interstitial	America	282	40,2	0	0,0
Renal and urinary disorders	Cystitis interstitial	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	End stage renal disease	Europe	214	30,5	0	0,0
Renal and urinary disorders	End stage renal disease	America	282	40,2	1	0,4
Renal and urinary disorders	End stage renal disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Nephropathy	Europe	214	30,5	0	0,0
Renal and urinary disorders	Nephropathy	America	282	40,2	1	0,4
Renal and urinary disorders	Nephropathy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders		Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders		America	282	40,2	3	1,1
Respiratory, thoracic and mediastinal disorders		Asia Pacific (inc. Australia)	205	29,2	2	1,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	America	282	40,2	2	0,7
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Surgical and medical procedures		Europe	214	30,5	1	0,5
Surgical and medical procedures		America	282	40,2	1	0,4
Surgical and medical procedures		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	Europe	214	30,5	1	0,5
Surgical and medical procedures	Large intestinal polypectomy	America	282	40,2	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Renal transplant	Europe	214	30,5	0	0,0
Surgical and medical procedures	Renal transplant	America	282	40,2	1	0,4
Surgical and medical procedures	Renal transplant	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders		Europe	214	30,5	0	0,0
Vascular disorders		America	282	40,2	2	0,7
Vascular disorders		Asia Pacific (inc. Australia)	205	29,2	2	1,0
Vascular disorders	Aortic aneurysm	Europe	214	30,5	0	0,0
Vascular disorders	Aortic aneurysm	America	282	40,2	1	0,4
Vascular disorders	Aortic aneurysm	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Aortic dissection	Europe	214	30,5	0	0,0
Vascular disorders	Aortic dissection	America	282	40,2	1	0,4
Vascular disorders	Aortic dissection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Haemorrhage	Europe	214	30,5	0	0,0
Vascular disorders	Haemorrhage	America	282	40,2	0	0,0
Vascular disorders	Haemorrhage	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Vascular disorders	Peripheral artery aneurysm	Europe	214	30,5	0	0,0
Vascular disorders	Peripheral artery aneurysm	America	282	40,2	0	0,0
Vascular disorders	Peripheral artery aneurysm	Asia Pacific (inc. Australia)	205	29,2	1	0,5

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:14

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Blood and lymphatic system disorders		White	474	67,6	0	0,0
Blood and lymphatic system disorders		Asian	176	25,1	1	0,6
Blood and lymphatic system disorders		Other	27	3,9	0	0,0
Blood and lymphatic system disorders		Unknown	24	3,4	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	White	474	67,6	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Asian	176	25,1	1	0,6
Blood and lymphatic system disorders	Deficiency anaemia	Other	27	3,9	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Unknown	24	3,4	0	0,0
Cardiac disorders		White	474	67,6	8	1,7
Cardiac disorders		Asian	176	25,1	1	0,6
Cardiac disorders		Other	27	3,9	0	0,0
Cardiac disorders		Unknown	24	3,4	0	0,0
Cardiac disorders	Acute myocardial infarction	White	474	67,6	2	0,4
Cardiac disorders	Acute myocardial infarction	Asian	176	25,1	0	0,0
Cardiac disorders	Acute myocardial infarction	Other	27	3,9	0	0,0
Cardiac disorders	Acute myocardial infarction	Unknown	24	3,4	0	0,0
Cardiac disorders	Atrial fibrillation	White	474	67,6	2	0,4
Cardiac disorders	Atrial fibrillation	Asian	176	25,1	1	0,6
Cardiac disorders	Atrial fibrillation	Other	27	3,9	0	0,0
Cardiac disorders	Atrial fibrillation	Unknown	24	3,4	0	0,0
Cardiac disorders	Cardiac failure	White	474	67,6	1	0,2
Cardiac disorders	Cardiac failure	Asian	176	25,1	0	0,0
Cardiac disorders	Cardiac failure	Other	27	3,9	0	0,0
Cardiac disorders	Cardiac failure	Unknown	24	3,4	0	0,0
Cardiac disorders	Cardiac failure congestive	White	474	67,6	2	0,4
Cardiac disorders	Cardiac failure congestive	Asian	176	25,1	0	0,0
Cardiac disorders	Cardiac failure congestive	Other	27	3,9	0	0,0
Cardiac disorders	Cardiac failure congestive	Unknown	24	3,4	0	0,0
Cardiac disorders	Left ventricular dysfunction	White	474	67,6	1	0,2
Cardiac disorders	Left ventricular dysfunction	Asian	176	25,1	0	0,0
Cardiac disorders	Left ventricular dysfunction	Other	27	3,9	0	0,0
Cardiac disorders	Left ventricular dysfunction	Unknown	24	3,4	0	0,0
Cardiac disorders	Myocardial infarction	White	474	67,6	2	0,4
Cardiac disorders	Myocardial infarction	Asian	176	25,1	0	0,0
Cardiac disorders	Myocardial infarction	Other	27	3,9	0	0,0
Cardiac disorders	Myocardial infarction	Unknown	24	3,4	0	0,0
Cardiac disorders	Stress cardiomyopathy	White	474	67,6	1	0,2
Cardiac disorders	Stress cardiomyopathy	Asian	176	25,1	0	0,0
Cardiac disorders	Stress cardiomyopathy	Other	27	3,9	0	0,0
Cardiac disorders	Stress cardiomyopathy	Unknown	24	3,4	0	0,0
Eye disorders		White	474	67,6	16	3,4
Eye disorders		Asian	176	25,1	3	1,7
Eye disorders		Other	27	3,9	1	3,7

Eye disorders		Unknown	24	3,4	1	4,2
Eye disorders	Cataract	White	474	67,6	1	0,2
Eye disorders	Cataract	Asian	176	25,1	0	0,0
Eye disorders	Cataract	Other	27	3,9	0	0,0
Eye disorders	Cataract	Unknown	24	3,4	0	0,0
Eye disorders	Cystoid macular oedema	White	474	67,6	3	0,6
Eye disorders	Cystoid macular oedema	Asian	176	25,1	1	0,6
Eye disorders	Cystoid macular oedema	Other	27	3,9	0	0,0
Eye disorders	Cystoid macular oedema	Unknown	24	3,4	0	0,0
Eye disorders	Epiretinal membrane	White	474	67,6	1	0,2
Eye disorders	Epiretinal membrane	Asian	176	25,1	0	0,0
Eye disorders	Epiretinal membrane	Other	27	3,9	0	0,0
Eye disorders	Epiretinal membrane	Unknown	24	3,4	0	0,0
Eye disorders	Glaucoma	White	474	67,6	0	0,0
Eye disorders	Glaucoma	Asian	176	25,1	1	0,6
Eye disorders	Glaucoma	Other	27	3,9	0	0,0
Eye disorders	Glaucoma	Unknown	24	3,4	0	0,0
Eye disorders	Hypotony of eye	White	474	67,6	1	0,2
Eye disorders	Hypotony of eye	Asian	176	25,1	0	0,0
Eye disorders	Hypotony of eye	Other	27	3,9	0	0,0
Eye disorders	Hypotony of eye	Unknown	24	3,4	0	0,0
Eye disorders	Macular hole	White	474	67,6	1	0,2
Eye disorders	Macular hole	Asian	176	25,1	0	0,0
Eye disorders	Macular hole	Other	27	3,9	0	0,0
Eye disorders	Macular hole	Unknown	24	3,4	0	0,0
Eye disorders	Macular ischaemia	White	474	67,6	1	0,2
Eye disorders	Macular ischaemia	Asian	176	25,1	0	0,0
Eye disorders	Macular ischaemia	Other	27	3,9	0	0,0
Eye disorders	Macular ischaemia	Unknown	24	3,4	0	0,0
Eye disorders	Macular oedema	White	474	67,6	2	0,4
Eye disorders	Macular oedema	Asian	176	25,1	1	0,6
Eye disorders	Macular oedema	Other	27	3,9	0	0,0
Eye disorders	Macular oedema	Unknown	24	3,4	0	0,0
Eye disorders	Retinal artery embolism	White	474	67,6	1	0,2
Eye disorders	Retinal artery embolism	Asian	176	25,1	0	0,0
Eye disorders	Retinal artery embolism	Other	27	3,9	0	0,0
Eye disorders	Retinal artery embolism	Unknown	24	3,4	0	0,0
Eye disorders	Retinal artery occlusion	White	474	67,6	1	0,2
Eye disorders	Retinal artery occlusion	Asian	176	25,1	0	0,0
Eye disorders	Retinal artery occlusion	Other	27	3,9	1	3,7
Eye disorders	Retinal artery occlusion	Unknown	24	3,4	0	0,0
Eye disorders	Retinal detachment	White	474	67,6	1	0,2
Eye disorders	Retinal detachment	Asian	176	25,1	0	0,0
Eye disorders	Retinal detachment	Other	27	3,9	0	0,0
Eye disorders	Retinal detachment	Unknown	24	3,4	0	0,0
Eye disorders	Retinal ischaemia	White	474	67,6	0	0,0
Eye disorders	Retinal ischaemia	Asian	176	25,1	0	0,0
Eye disorders	Retinal ischaemia	Other	27	3,9	0	0,0
Eye disorders	Retinal ischaemia	Unknown	24	3,4	1	4,2
Eye disorders	Retinal vein occlusion	White	474	67,6	4	0,8
Eye disorders	Retinal vein occlusion	Asian	176	25,1	0	0,0
Eye disorders	Retinal vein occlusion	Other	27	3,9	0	0,0
Eye disorders	Retinal vein occlusion	Unknown	24	3,4	0	0,0
Gastrointestinal disorders		White	474	67,6	3	0,6
Gastrointestinal disorders		Asian	176	25,1	2	1,1
Gastrointestinal disorders		Other	27	3,9	0	0,0

Gastrointestinal disorders		Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	White	474	67,6	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Asian	176	25,1	1	0,6
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Other	27	3,9	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	White	474	67,6	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Asian	176	25,1	1	0,6
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Other	27	3,9	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	White	474	67,6	1	0,2
Gastrointestinal disorders	Gastrointestinal inflammation	Asian	176	25,1	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Other	27	3,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Pancreatitis	White	474	67,6	1	0,2
Gastrointestinal disorders	Pancreatitis	Asian	176	25,1	0	0,0
Gastrointestinal disorders	Pancreatitis	Other	27	3,9	0	0,0
Gastrointestinal disorders	Pancreatitis	Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Pancreatitis acute	White	474	67,6	1	0,2
Gastrointestinal disorders	Pancreatitis acute	Asian	176	25,1	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Other	27	3,9	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Unknown	24	3,4	0	0,0
General disorders and administration site conditions		White	474	67,6	5	1,1
General disorders and administration site conditions		Asian	176	25,1	0	0,0
General disorders and administration site conditions		Other	27	3,9	1	3,7
General disorders and administration site conditions		Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Asthenia	White	474	67,6	1	0,2
General disorders and administration site conditions	Asthenia	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Asthenia	Other	27	3,9	0	0,0
General disorders and administration site conditions	Asthenia	Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Chest pain	White	474	67,6	2	0,4
General disorders and administration site conditions	Chest pain	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Chest pain	Other	27	3,9	0	0,0
General disorders and administration site conditions	Chest pain	Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Death	White	474	67,6	2	0,4
General disorders and administration site conditions	Death	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Death	Other	27	3,9	0	0,0
General disorders and administration site conditions	Death	Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	White	474	67,6	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Other	27	3,9	1	3,7
General disorders and administration site conditions	Stent-graft endoleak	Unknown	24	3,4	0	0,0
Hepatobiliary disorders		White	474	67,6	1	0,2
Hepatobiliary disorders		Asian	176	25,1	0	0,0
Hepatobiliary disorders		Other	27	3,9	0	0,0
Hepatobiliary disorders		Unknown	24	3,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	White	474	67,6	1	0,2
Hepatobiliary disorders	Cholelithiasis	Asian	176	25,1	0	0,0
Hepatobiliary disorders	Cholelithiasis	Other	27	3,9	0	0,0
Hepatobiliary disorders	Cholelithiasis	Unknown	24	3,4	0	0,0
Infections and infestations		White	474	67,6	18	3,8
Infections and infestations		Asian	176	25,1	1	0,6
Infections and infestations		Other	27	3,9	2	7,4
Infections and infestations		Unknown	24	3,4	0	0,0
Infections and infestations	COVID-19	White	474	67,6	2	0,4

Infections and infestations	COVID-19	Asian	176	25,1	0	0,0
Infections and infestations	COVID-19	Other	27	3,9	0	0,0
Infections and infestations	COVID-19	Unknown	24	3,4	0	0,0
Infections and infestations	COVID-19 pneumonia	White	474	67,6	1	0,2
Infections and infestations	COVID-19 pneumonia	Asian	176	25,1	0	0,0
Infections and infestations	COVID-19 pneumonia	Other	27	3,9	0	0,0
Infections and infestations	COVID-19 pneumonia	Unknown	24	3,4	0	0,0
Infections and infestations	Cellulitis	White	474	67,6	1	0,2
Infections and infestations	Cellulitis	Asian	176	25,1	0	0,0
Infections and infestations	Cellulitis	Other	27	3,9	0	0,0
Infections and infestations	Cellulitis	Unknown	24	3,4	0	0,0
Infections and infestations	Clostridium difficile infection	White	474	67,6	1	0,2
Infections and infestations	Clostridium difficile infection	Asian	176	25,1	0	0,0
Infections and infestations	Clostridium difficile infection	Other	27	3,9	0	0,0
Infections and infestations	Clostridium difficile infection	Unknown	24	3,4	0	0,0
Infections and infestations	Device related infection	White	474	67,6	1	0,2
Infections and infestations	Device related infection	Asian	176	25,1	0	0,0
Infections and infestations	Device related infection	Other	27	3,9	0	0,0
Infections and infestations	Device related infection	Unknown	24	3,4	0	0,0
Infections and infestations	Endophthalmitis	White	474	67,6	1	0,2
Infections and infestations	Endophthalmitis	Asian	176	25,1	0	0,0
Infections and infestations	Endophthalmitis	Other	27	3,9	0	0,0
Infections and infestations	Endophthalmitis	Unknown	24	3,4	0	0,0
Infections and infestations	Enteritis infectious	White	474	67,6	1	0,2
Infections and infestations	Enteritis infectious	Asian	176	25,1	0	0,0
Infections and infestations	Enteritis infectious	Other	27	3,9	0	0,0
Infections and infestations	Enteritis infectious	Unknown	24	3,4	0	0,0
Infections and infestations	Escherichia urinary tract infection	White	474	67,6	1	0,2
Infections and infestations	Escherichia urinary tract infection	Asian	176	25,1	0	0,0
Infections and infestations	Escherichia urinary tract infection	Other	27	3,9	0	0,0
Infections and infestations	Escherichia urinary tract infection	Unknown	24	3,4	0	0,0
Infections and infestations	Influenza	White	474	67,6	2	0,4
Infections and infestations	Influenza	Asian	176	25,1	0	0,0
Infections and infestations	Influenza	Other	27	3,9	0	0,0
Infections and infestations	Influenza	Unknown	24	3,4	0	0,0
Infections and infestations	Lower respiratory tract infection	White	474	67,6	1	0,2
Infections and infestations	Lower respiratory tract infection	Asian	176	25,1	0	0,0
Infections and infestations	Lower respiratory tract infection	Other	27	3,9	0	0,0
Infections and infestations	Lower respiratory tract infection	Unknown	24	3,4	0	0,0
Infections and infestations	Necrotising fasciitis	White	474	67,6	0	0,0
Infections and infestations	Necrotising fasciitis	Asian	176	25,1	0	0,0
Infections and infestations	Necrotising fasciitis	Other	27	3,9	1	3,7
Infections and infestations	Necrotising fasciitis	Unknown	24	3,4	0	0,0
Infections and infestations	Pneumonia	White	474	67,6	4	0,8
Infections and infestations	Pneumonia	Asian	176	25,1	0	0,0
Infections and infestations	Pneumonia	Other	27	3,9	0	0,0
Infections and infestations	Pneumonia	Unknown	24	3,4	0	0,0
Infections and infestations	Pneumonia viral	White	474	67,6	2	0,4
Infections and infestations	Pneumonia viral	Asian	176	25,1	0	0,0
Infections and infestations	Pneumonia viral	Other	27	3,9	0	0,0
Infections and infestations	Pneumonia viral	Unknown	24	3,4	0	0,0
Infections and infestations	Respiratory syncytial virus infection	White	474	67,6	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Asian	176	25,1	1	0,6
Infections and infestations	Respiratory syncytial virus infection	Other	27	3,9	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Unknown	24	3,4	0	0,0
Infections and infestations	Sepsis	White	474	67,6	2	0,4
Infections and infestations	Sepsis	Asian	176	25,1	0	0,0

Infections and infestations	Sepsis	Other	27	3,9	0	0,0
Infections and infestations	Sepsis	Unknown	24	3,4	0	0,0
Infections and infestations	Tooth infection	White	474	67,6	0	0,0
Infections and infestations	Tooth infection	Asian	176	25,1	0	0,0
Infections and infestations	Tooth infection	Other	27	3,9	1	3,7
Infections and infestations	Tooth infection	Unknown	24	3,4	0	0,0
Infections and infestations	Urinary tract candidiasis	White	474	67,6	1	0,2
Infections and infestations	Urinary tract candidiasis	Asian	176	25,1	0	0,0
Infections and infestations	Urinary tract candidiasis	Other	27	3,9	0	0,0
Infections and infestations	Urinary tract candidiasis	Unknown	24	3,4	0	0,0
Infections and infestations	Urosepsis	White	474	67,6	1	0,2
Infections and infestations	Urosepsis	Asian	176	25,1	0	0,0
Infections and infestations	Urosepsis	Other	27	3,9	0	0,0
Infections and infestations	Urosepsis	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications		White	474	67,6	6	1,3
Injury, poisoning and procedural complications		Asian	176	25,1	2	1,1
Injury, poisoning and procedural complications		Other	27	3,9	0	0,0
Injury, poisoning and procedural complications		Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Accident	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Accident	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Accident	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Accident	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Contusion	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Contusion	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Contusion	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Contusion	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Fall	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Fall	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Fall	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Fall	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Femur fracture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Femur fracture	Asian	176	25,1	1	0,6
Injury, poisoning and procedural complications	Femur fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Ligament rupture	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Lower limb fracture	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Rib fracture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Rib fracture	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	White	474	67,6	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Asian	176	25,1	1	0,6
Injury, poisoning and procedural complications	Shunt stenosis	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Skin laceration	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Skin laceration	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders		White	474	67,6	0	0,0

Metabolism and nutrition disorders		Asian	176	25,1	0	0,0
Metabolism and nutrition disorders		Other	27	3,9	1	3,7
Metabolism and nutrition disorders		Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	White	474	67,6	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Other	27	3,9	1	3,7
Metabolism and nutrition disorders	Hypervolaemia	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	White	474	67,6	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Other	27	3,9	1	3,7
Metabolism and nutrition disorders	Hypokalaemia	Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders		White	474	67,6	4	0,8
Musculoskeletal and connective tissue disorders		Asian	176	25,1	0	0,0
Musculoskeletal and connective tissue disorders		Other	27	3,9	1	3,7
Musculoskeletal and connective tissue disorders		Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	White	474	67,6	1	0,2
Musculoskeletal and connective tissue disorders	Arthralgia	Asian	176	25,1	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	Other	27	3,9	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	White	474	67,6	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Asian	176	25,1	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Other	27	3,9	1	3,7
Musculoskeletal and connective tissue disorders	Joint effusion	Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	White	474	67,6	1	0,2
Musculoskeletal and connective tissue disorders	Mobility decreased	Asian	176	25,1	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Other	27	3,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	White	474	67,6	2	0,4
Musculoskeletal and connective tissue disorders	Osteoarthritis	Asian	176	25,1	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Other	27	3,9	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	White	474	67,6	1	0,2
Musculoskeletal and connective tissue disorders	Polymyositis	Asian	176	25,1	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Other	27	3,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Unknown	24	3,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		White	474	67,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asian	176	25,1	2	1,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Other	27	3,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Unknown	24	3,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	White	474	67,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asian	176	25,1	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Other	27	3,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Unknown	24	3,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	White	474	67,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Asian	176	25,1	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Other	27	3,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Unknown	24	3,4	0	0,0
Nervous system disorders		White	474	67,6	4	0,8
Nervous system disorders		Asian	176	25,1	1	0,6
Nervous system disorders		Other	27	3,9	0	0,0
Nervous system disorders		Unknown	24	3,4	0	0,0
Nervous system disorders	Cerebrovascular accident	White	474	67,6	1	0,2
Nervous system disorders	Cerebrovascular accident	Asian	176	25,1	0	0,0
Nervous system disorders	Cerebrovascular accident	Other	27	3,9	0	0,0

Nervous system disorders	Cerebrovascular accident	Unknown	24	3,4	0	0,0
Nervous system disorders	Dysarthria	White	474	67,6	0	0,0
Nervous system disorders	Dysarthria	Asian	176	25,1	1	0,6
Nervous system disorders	Dysarthria	Other	27	3,9	0	0,0
Nervous system disorders	Dysarthria	Unknown	24	3,4	0	0,0
Nervous system disorders	Headache	White	474	67,6	1	0,2
Nervous system disorders	Headache	Asian	176	25,1	0	0,0
Nervous system disorders	Headache	Other	27	3,9	0	0,0
Nervous system disorders	Headache	Unknown	24	3,4	0	0,0
Nervous system disorders	Hypoaesthesia	White	474	67,6	1	0,2
Nervous system disorders	Hypoaesthesia	Asian	176	25,1	0	0,0
Nervous system disorders	Hypoaesthesia	Other	27	3,9	0	0,0
Nervous system disorders	Hypoaesthesia	Unknown	24	3,4	0	0,0
Nervous system disorders	Ischaemic stroke	White	474	67,6	1	0,2
Nervous system disorders	Ischaemic stroke	Asian	176	25,1	0	0,0
Nervous system disorders	Ischaemic stroke	Other	27	3,9	0	0,0
Nervous system disorders	Ischaemic stroke	Unknown	24	3,4	0	0,0
Psychiatric disorders		White	474	67,6	0	0,0
Psychiatric disorders		Asian	176	25,1	1	0,6
Psychiatric disorders		Other	27	3,9	0	0,0
Psychiatric disorders		Unknown	24	3,4	0	0,0
Psychiatric disorders	Sleep disorder	White	474	67,6	0	0,0
Psychiatric disorders	Sleep disorder	Asian	176	25,1	1	0,6
Psychiatric disorders	Sleep disorder	Other	27	3,9	0	0,0
Psychiatric disorders	Sleep disorder	Unknown	24	3,4	0	0,0
Renal and urinary disorders		White	474	67,6	2	0,4
Renal and urinary disorders		Asian	176	25,1	0	0,0
Renal and urinary disorders		Other	27	3,9	0	0,0
Renal and urinary disorders		Unknown	24	3,4	1	4,2
Renal and urinary disorders	Acute kidney injury	White	474	67,6	1	0,2
Renal and urinary disorders	Acute kidney injury	Asian	176	25,1	0	0,0
Renal and urinary disorders	Acute kidney injury	Other	27	3,9	0	0,0
Renal and urinary disorders	Acute kidney injury	Unknown	24	3,4	0	0,0
Renal and urinary disorders	Cystitis interstitial	White	474	67,6	1	0,2
Renal and urinary disorders	Cystitis interstitial	Asian	176	25,1	0	0,0
Renal and urinary disorders	Cystitis interstitial	Other	27	3,9	0	0,0
Renal and urinary disorders	Cystitis interstitial	Unknown	24	3,4	0	0,0
Renal and urinary disorders	End stage renal disease	White	474	67,6	0	0,0
Renal and urinary disorders	End stage renal disease	Asian	176	25,1	0	0,0
Renal and urinary disorders	End stage renal disease	Other	27	3,9	0	0,0
Renal and urinary disorders	End stage renal disease	Unknown	24	3,4	1	4,2
Renal and urinary disorders	Nephropathy	White	474	67,6	1	0,2
Renal and urinary disorders	Nephropathy	Asian	176	25,1	0	0,0
Renal and urinary disorders	Nephropathy	Other	27	3,9	0	0,0
Renal and urinary disorders	Nephropathy	Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders		White	474	67,6	4	0,8
Respiratory, thoracic and mediastinal disorders		Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders		Other	27	3,9	1	3,7
Respiratory, thoracic and mediastinal disorders		Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	White	474	67,6	1	0,2
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Other	27	3,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	White	474	67,6	0	0,0

Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Other	27	3,9	1	3,7
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	White	474	67,6	2	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Other	27	3,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	White	474	67,6	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Other	27	3,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	White	474	67,6	1	0,2
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Other	27	3,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Unknown	24	3,4	0	0,0
Surgical and medical procedures		White	474	67,6	1	0,2
Surgical and medical procedures		Asian	176	25,1	0	0,0
Surgical and medical procedures		Other	27	3,9	0	0,0
Surgical and medical procedures		Unknown	24	3,4	1	4,2
Surgical and medical procedures	Large intestinal polypectomy	White	474	67,6	1	0,2
Surgical and medical procedures	Large intestinal polypectomy	Asian	176	25,1	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	Other	27	3,9	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	Unknown	24	3,4	0	0,0
Surgical and medical procedures	Renal transplant	White	474	67,6	0	0,0
Surgical and medical procedures	Renal transplant	Asian	176	25,1	0	0,0
Surgical and medical procedures	Renal transplant	Other	27	3,9	0	0,0
Surgical and medical procedures	Renal transplant	Unknown	24	3,4	1	4,2
Vascular disorders		White	474	67,6	2	0,4
Vascular disorders		Asian	176	25,1	1	0,6
Vascular disorders		Other	27	3,9	1	3,7
Vascular disorders		Unknown	24	3,4	0	0,0
Vascular disorders	Aortic aneurysm	White	474	67,6	1	0,2
Vascular disorders	Aortic aneurysm	Asian	176	25,1	0	0,0
Vascular disorders	Aortic aneurysm	Other	27	3,9	0	0,0
Vascular disorders	Aortic aneurysm	Unknown	24	3,4	0	0,0
Vascular disorders	Aortic dissection	White	474	67,6	1	0,2
Vascular disorders	Aortic dissection	Asian	176	25,1	0	0,0
Vascular disorders	Aortic dissection	Other	27	3,9	0	0,0
Vascular disorders	Aortic dissection	Unknown	24	3,4	0	0,0
Vascular disorders	Haemorrhage	White	474	67,6	0	0,0
Vascular disorders	Haemorrhage	Asian	176	25,1	1	0,6
Vascular disorders	Haemorrhage	Other	27	3,9	0	0,0
Vascular disorders	Haemorrhage	Unknown	24	3,4	0	0,0
Vascular disorders	Peripheral artery aneurysm	White	474	67,6	0	0,0
Vascular disorders	Peripheral artery aneurysm	Asian	176	25,1	0	0,0
Vascular disorders	Peripheral artery aneurysm	Other	27	3,9	1	3,7
Vascular disorders	Peripheral artery aneurysm	Unknown	24	3,4	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:14

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Severe AEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline RVO status

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		CRVO	574	81,9	1	0,2
Blood and lymphatic system disorders		HRVO	121	17,3	0	0,0
Blood and lymphatic system disorders		Missing	6	0,9	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	CRVO	574	81,9	1	0,2
Blood and lymphatic system disorders	Deficiency anaemia	HRVO	121	17,3	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Missing	6	0,9	0	0,0
Cardiac disorders		CRVO	574	81,9	8	1,4
Cardiac disorders		HRVO	121	17,3	1	0,8
Cardiac disorders		Missing	6	0,9	0	0,0
Cardiac disorders	Acute myocardial infarction	CRVO	574	81,9	2	0,3
Cardiac disorders	Acute myocardial infarction	HRVO	121	17,3	0	0,0
Cardiac disorders	Acute myocardial infarction	Missing	6	0,9	0	0,0
Cardiac disorders	Atrial fibrillation	CRVO	574	81,9	2	0,3
Cardiac disorders	Atrial fibrillation	HRVO	121	17,3	1	0,8
Cardiac disorders	Atrial fibrillation	Missing	6	0,9	0	0,0
Cardiac disorders	Cardiac failure	CRVO	574	81,9	1	0,2
Cardiac disorders	Cardiac failure	HRVO	121	17,3	0	0,0
Cardiac disorders	Cardiac failure	Missing	6	0,9	0	0,0
Cardiac disorders	Cardiac failure congestive	CRVO	574	81,9	2	0,3
Cardiac disorders	Cardiac failure congestive	HRVO	121	17,3	0	0,0
Cardiac disorders	Cardiac failure congestive	Missing	6	0,9	0	0,0
Cardiac disorders	Left ventricular dysfunction	CRVO	574	81,9	1	0,2
Cardiac disorders	Left ventricular dysfunction	HRVO	121	17,3	0	0,0
Cardiac disorders	Left ventricular dysfunction	Missing	6	0,9	0	0,0
Cardiac disorders	Myocardial infarction	CRVO	574	81,9	2	0,3
Cardiac disorders	Myocardial infarction	HRVO	121	17,3	0	0,0
Cardiac disorders	Myocardial infarction	Missing	6	0,9	0	0,0
Cardiac disorders	Stress cardiomyopathy	CRVO	574	81,9	1	0,2
Cardiac disorders	Stress cardiomyopathy	HRVO	121	17,3	0	0,0
Cardiac disorders	Stress cardiomyopathy	Missing	6	0,9	0	0,0
Eye disorders		CRVO	574	81,9	21	3,7
Eye disorders		HRVO	121	17,3	0	0,0
Eye disorders		Missing	6	0,9	0	0,0
Eye disorders	Cataract	CRVO	574	81,9	1	0,2
Eye disorders	Cataract	HRVO	121	17,3	0	0,0
Eye disorders	Cataract	Missing	6	0,9	0	0,0
Eye disorders	Cystoid macular oedema	CRVO	574	81,9	4	0,7
Eye disorders	Cystoid macular oedema	HRVO	121	17,3	0	0,0
Eye disorders	Cystoid macular oedema	Missing	6	0,9	0	0,0
Eye disorders	Epiretinal membrane	CRVO	574	81,9	1	0,2
Eye disorders	Epiretinal membrane	HRVO	121	17,3	0	0,0
Eye disorders	Epiretinal membrane	Missing	6	0,9	0	0,0
Eye disorders	Glaucoma	CRVO	574	81,9	1	0,2

Eye disorders	Glaucoma	HRVO	121	17,3	0	0,0
Eye disorders	Glaucoma	Missing	6	0,9	0	0,0
Eye disorders	Hypotony of eye	CRVO	574	81,9	1	0,2
Eye disorders	Hypotony of eye	HRVO	121	17,3	0	0,0
Eye disorders	Hypotony of eye	Missing	6	0,9	0	0,0
Eye disorders	Macular hole	CRVO	574	81,9	1	0,2
Eye disorders	Macular hole	HRVO	121	17,3	0	0,0
Eye disorders	Macular hole	Missing	6	0,9	0	0,0
Eye disorders	Macular ischaemia	CRVO	574	81,9	1	0,2
Eye disorders	Macular ischaemia	HRVO	121	17,3	0	0,0
Eye disorders	Macular ischaemia	Missing	6	0,9	0	0,0
Eye disorders	Macular oedema	CRVO	574	81,9	3	0,5
Eye disorders	Macular oedema	HRVO	121	17,3	0	0,0
Eye disorders	Macular oedema	Missing	6	0,9	0	0,0
Eye disorders	Retinal artery embolism	CRVO	574	81,9	1	0,2
Eye disorders	Retinal artery embolism	HRVO	121	17,3	0	0,0
Eye disorders	Retinal artery embolism	Missing	6	0,9	0	0,0
Eye disorders	Retinal artery occlusion	CRVO	574	81,9	2	0,3
Eye disorders	Retinal artery occlusion	HRVO	121	17,3	0	0,0
Eye disorders	Retinal artery occlusion	Missing	6	0,9	0	0,0
Eye disorders	Retinal detachment	CRVO	574	81,9	1	0,2
Eye disorders	Retinal detachment	HRVO	121	17,3	0	0,0
Eye disorders	Retinal detachment	Missing	6	0,9	0	0,0
Eye disorders	Retinal ischaemia	CRVO	574	81,9	1	0,2
Eye disorders	Retinal ischaemia	HRVO	121	17,3	0	0,0
Eye disorders	Retinal ischaemia	Missing	6	0,9	0	0,0
Eye disorders	Retinal vein occlusion	CRVO	574	81,9	4	0,7
Eye disorders	Retinal vein occlusion	HRVO	121	17,3	0	0,0
Eye disorders	Retinal vein occlusion	Missing	6	0,9	0	0,0
Gastrointestinal disorders		CRVO	574	81,9	5	0,9
Gastrointestinal disorders		HRVO	121	17,3	0	0,0
Gastrointestinal disorders		Missing	6	0,9	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Duodenal ulcer haemorrhage	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Gastrointestinal inflammation	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Pancreatitis	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Pancreatitis	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Pancreatitis	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Pancreatitis acute	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Pancreatitis acute	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Missing	6	0,9	0	0,0
General disorders and administration site conditions		CRVO	574	81,9	4	0,7
General disorders and administration site conditions		HRVO	121	17,3	2	1,7
General disorders and administration site conditions		Missing	6	0,9	0	0,0
General disorders and administration site conditions	Asthenia	CRVO	574	81,9	0	0,0
General disorders and administration site conditions	Asthenia	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Asthenia	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Chest pain	CRVO	574	81,9	2	0,3
General disorders and administration site conditions	Chest pain	HRVO	121	17,3	0	0,0

General disorders and administration site conditions	Chest pain	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Death	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Death	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Death	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Stent-graft endoleak	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Missing	6	0,9	0	0,0
Hepatobiliary disorders		CRVO	574	81,9	1	0,2
Hepatobiliary disorders		HRVO	121	17,3	0	0,0
Hepatobiliary disorders		Missing	6	0,9	0	0,0
Hepatobiliary disorders	Cholelithiasis	CRVO	574	81,9	1	0,2
Hepatobiliary disorders	Cholelithiasis	HRVO	121	17,3	0	0,0
Hepatobiliary disorders	Cholelithiasis	Missing	6	0,9	0	0,0
Infections and infestations		CRVO	574	81,9	15	2,6
Infections and infestations		HRVO	121	17,3	6	5,0
Infections and infestations		Missing	6	0,9	0	0,0
Infections and infestations	COVID-19	CRVO	574	81,9	2	0,3
Infections and infestations	COVID-19	HRVO	121	17,3	0	0,0
Infections and infestations	COVID-19	Missing	6	0,9	0	0,0
Infections and infestations	COVID-19 pneumonia	CRVO	574	81,9	0	0,0
Infections and infestations	COVID-19 pneumonia	HRVO	121	17,3	1	0,8
Infections and infestations	COVID-19 pneumonia	Missing	6	0,9	0	0,0
Infections and infestations	Cellulitis	CRVO	574	81,9	1	0,2
Infections and infestations	Cellulitis	HRVO	121	17,3	0	0,0
Infections and infestations	Cellulitis	Missing	6	0,9	0	0,0
Infections and infestations	Clostridium difficile infection	CRVO	574	81,9	1	0,2
Infections and infestations	Clostridium difficile infection	HRVO	121	17,3	0	0,0
Infections and infestations	Clostridium difficile infection	Missing	6	0,9	0	0,0
Infections and infestations	Device related infection	CRVO	574	81,9	1	0,2
Infections and infestations	Device related infection	HRVO	121	17,3	0	0,0
Infections and infestations	Device related infection	Missing	6	0,9	0	0,0
Infections and infestations	Endophthalmitis	CRVO	574	81,9	0	0,0
Infections and infestations	Endophthalmitis	HRVO	121	17,3	1	0,8
Infections and infestations	Endophthalmitis	Missing	6	0,9	0	0,0
Infections and infestations	Enteritis infectious	CRVO	574	81,9	1	0,2
Infections and infestations	Enteritis infectious	HRVO	121	17,3	0	0,0
Infections and infestations	Enteritis infectious	Missing	6	0,9	0	0,0
Infections and infestations	Escherichia urinary tract infection	CRVO	574	81,9	1	0,2
Infections and infestations	Escherichia urinary tract infection	HRVO	121	17,3	0	0,0
Infections and infestations	Escherichia urinary tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Influenza	CRVO	574	81,9	1	0,2
Infections and infestations	Influenza	HRVO	121	17,3	1	0,8
Infections and infestations	Influenza	Missing	6	0,9	0	0,0
Infections and infestations	Lower respiratory tract infection	CRVO	574	81,9	0	0,0
Infections and infestations	Lower respiratory tract infection	HRVO	121	17,3	1	0,8
Infections and infestations	Lower respiratory tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Necrotising fasciitis	CRVO	574	81,9	0	0,0
Infections and infestations	Necrotising fasciitis	HRVO	121	17,3	1	0,8
Infections and infestations	Necrotising fasciitis	Missing	6	0,9	0	0,0
Infections and infestations	Pneumonia	CRVO	574	81,9	3	0,5
Infections and infestations	Pneumonia	HRVO	121	17,3	1	0,8
Infections and infestations	Pneumonia	Missing	6	0,9	0	0,0
Infections and infestations	Pneumonia viral	CRVO	574	81,9	2	0,3
Infections and infestations	Pneumonia viral	HRVO	121	17,3	0	0,0
Infections and infestations	Pneumonia viral	Missing	6	0,9	0	0,0

Infections and infestations	Respiratory syncytial virus infection	CRVO	574	81,9	1	0,2
Infections and infestations	Respiratory syncytial virus infection	HRVO	121	17,3	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Missing	6	0,9	0	0,0
Infections and infestations	Sepsis	CRVO	574	81,9	2	0,3
Infections and infestations	Sepsis	HRVO	121	17,3	0	0,0
Infections and infestations	Sepsis	Missing	6	0,9	0	0,0
Infections and infestations	Tooth infection	CRVO	574	81,9	0	0,0
Infections and infestations	Tooth infection	HRVO	121	17,3	1	0,8
Infections and infestations	Tooth infection	Missing	6	0,9	0	0,0
Infections and infestations	Urinary tract candidiasis	CRVO	574	81,9	1	0,2
Infections and infestations	Urinary tract candidiasis	HRVO	121	17,3	0	0,0
Infections and infestations	Urinary tract candidiasis	Missing	6	0,9	0	0,0
Infections and infestations	Urosepsis	CRVO	574	81,9	1	0,2
Infections and infestations	Urosepsis	HRVO	121	17,3	0	0,0
Infections and infestations	Urosepsis	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications		CRVO	574	81,9	7	1,2
Injury, poisoning and procedural complications		HRVO	121	17,3	1	0,8
Injury, poisoning and procedural complications		Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Accident	CRVO	574	81,9	0	0,0
Injury, poisoning and procedural complications	Accident	HRVO	121	17,3	1	0,8
Injury, poisoning and procedural complications	Accident	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Contusion	CRVO	574	81,9	0	0,0
Injury, poisoning and procedural complications	Contusion	HRVO	121	17,3	1	0,8
Injury, poisoning and procedural complications	Contusion	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Fall	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Fall	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Fall	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Femur fracture	CRVO	574	81,9	2	0,3
Injury, poisoning and procedural complications	Femur fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Ligament rupture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Ligament rupture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Lower limb fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Rib fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Rib fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Shunt stenosis	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Skin laceration	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Skin laceration	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Skin laceration	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders		CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders		HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders		Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hypervolaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hypokalaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Missing	6	0,9	0	0,0

Musculoskeletal and connective tissue disorders		CRVO	574	81,9	3	0,5
Musculoskeletal and connective tissue disorders		HRVO	121	17,3	2	1,7
Musculoskeletal and connective tissue disorders		Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Arthralgia	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Arthralgia	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Joint effusion	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Mobility decreased	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Osteoarthritis	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Osteoarthritis	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Osteoarthritis	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Polymyositis	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		CRVO	574	81,9	2	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Missing	6	0,9	0	0,0
Nervous system disorders		CRVO	574	81,9	3	0,5
Nervous system disorders		HRVO	121	17,3	2	1,7
Nervous system disorders		Missing	6	0,9	0	0,0
Nervous system disorders	Cerebrovascular accident	CRVO	574	81,9	0	0,0
Nervous system disorders	Cerebrovascular accident	HRVO	121	17,3	1	0,8
Nervous system disorders	Cerebrovascular accident	Missing	6	0,9	0	0,0
Nervous system disorders	Dysarthria	CRVO	574	81,9	1	0,2
Nervous system disorders	Dysarthria	HRVO	121	17,3	0	0,0
Nervous system disorders	Dysarthria	Missing	6	0,9	0	0,0
Nervous system disorders	Headache	CRVO	574	81,9	1	0,2
Nervous system disorders	Headache	HRVO	121	17,3	0	0,0
Nervous system disorders	Headache	Missing	6	0,9	0	0,0
Nervous system disorders	Hypoaesthesia	CRVO	574	81,9	1	0,2
Nervous system disorders	Hypoaesthesia	HRVO	121	17,3	0	0,0
Nervous system disorders	Hypoaesthesia	Missing	6	0,9	0	0,0
Nervous system disorders	Ischaemic stroke	CRVO	574	81,9	0	0,0
Nervous system disorders	Ischaemic stroke	HRVO	121	17,3	1	0,8
Nervous system disorders	Ischaemic stroke	Missing	6	0,9	0	0,0
Psychiatric disorders		CRVO	574	81,9	1	0,2
Psychiatric disorders		HRVO	121	17,3	0	0,0
Psychiatric disorders		Missing	6	0,9	0	0,0
Psychiatric disorders	Sleep disorder	CRVO	574	81,9	1	0,2
Psychiatric disorders	Sleep disorder	HRVO	121	17,3	0	0,0
Psychiatric disorders	Sleep disorder	Missing	6	0,9	0	0,0
Renal and urinary disorders		CRVO	574	81,9	3	0,5
Renal and urinary disorders		HRVO	121	17,3	0	0,0

Renal and urinary disorders		Missing	6	0,9	0	0,0
Renal and urinary disorders	Acute kidney injury	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Acute kidney injury	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Acute kidney injury	Missing	6	0,9	0	0,0
Renal and urinary disorders	Cystitis interstitial	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Cystitis interstitial	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Cystitis interstitial	Missing	6	0,9	0	0,0
Renal and urinary disorders	End stage renal disease	CRVO	574	81,9	1	0,2
Renal and urinary disorders	End stage renal disease	HRVO	121	17,3	0	0,0
Renal and urinary disorders	End stage renal disease	Missing	6	0,9	0	0,0
Renal and urinary disorders	Nephropathy	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Nephropathy	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Nephropathy	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders		CRVO	574	81,9	4	0,7
Respiratory, thoracic and mediastinal disorders		HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders		Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	CRVO	574	81,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	Missing	6	0,9	0	0,0
Surgical and medical procedures		CRVO	574	81,9	1	0,2
Surgical and medical procedures		HRVO	121	17,3	1	0,8
Surgical and medical procedures		Missing	6	0,9	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	CRVO	574	81,9	0	0,0
Surgical and medical procedures	Large intestinal polypectomy	HRVO	121	17,3	1	0,8
Surgical and medical procedures	Large intestinal polypectomy	Missing	6	0,9	0	0,0
Surgical and medical procedures	Renal transplant	CRVO	574	81,9	1	0,2
Surgical and medical procedures	Renal transplant	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Renal transplant	Missing	6	0,9	0	0,0
Vascular disorders		CRVO	574	81,9	3	0,5
Vascular disorders		HRVO	121	17,3	1	0,8
Vascular disorders		Missing	6	0,9	0	0,0
Vascular disorders	Aortic aneurysm	CRVO	574	81,9	0	0,0
Vascular disorders	Aortic aneurysm	HRVO	121	17,3	1	0,8
Vascular disorders	Aortic aneurysm	Missing	6	0,9	0	0,0
Vascular disorders	Aortic dissection	CRVO	574	81,9	1	0,2
Vascular disorders	Aortic dissection	HRVO	121	17,3	0	0,0
Vascular disorders	Aortic dissection	Missing	6	0,9	0	0,0
Vascular disorders	Haemorrhage	CRVO	574	81,9	1	0,2
Vascular disorders	Haemorrhage	HRVO	121	17,3	0	0,0
Vascular disorders	Haemorrhage	Missing	6	0,9	0	0,0
Vascular disorders	Peripheral artery aneurysm	CRVO	574	81,9	1	0,2
Vascular disorders	Peripheral artery aneurysm	HRVO	121	17,3	0	0,0

Vascular disorders	Peripheral artery aneurysm	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WSEVAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:14

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		n/a	701	100,0	2	0,3
Blood and lymphatic system disorders	Anaemia	n/a	701	100,0	1	0,1
Blood and lymphatic system disorders	Deficiency anaemia	n/a	701	100,0	1	0,1
Blood and lymphatic system disorders	Mesenteric lymphadenitis	n/a	701	100,0	1	0,1
Cardiac disorders		n/a	701	100,0	15	2,1
Cardiac disorders	Acute myocardial infarction	n/a	701	100,0	2	0,3
Cardiac disorders	Aortic valve incompetence	n/a	701	100,0	1	0,1
Cardiac disorders	Arrhythmia	n/a	701	100,0	1	0,1
Cardiac disorders	Atrial fibrillation	n/a	701	100,0	4	0,6
Cardiac disorders	Cardiac failure	n/a	701	100,0	1	0,1
Cardiac disorders	Cardiac failure congestive	n/a	701	100,0	2	0,3
Cardiac disorders	Coronary artery disease	n/a	701	100,0	1	0,1
Cardiac disorders	Coronary artery stenosis	n/a	701	100,0	1	0,1
Cardiac disorders	Myocardial infarction	n/a	701	100,0	3	0,4
Cardiac disorders	Stress cardiomyopathy	n/a	701	100,0	1	0,1
Eye disorders		n/a	701	100,0	39	5,6
Eye disorders	Cataract	n/a	701	100,0	1	0,1
Eye disorders	Cystoid macular oedema	n/a	701	100,0	6	0,9
Eye disorders	Epi-retinal membrane	n/a	701	100,0	1	0,1
Eye disorders	Glaucoma	n/a	701	100,0	1	0,1
Eye disorders	Iridocyclitis	n/a	701	100,0	1	0,1
Eye disorders	Iris neovascularisation	n/a	701	100,0	1	0,1
Eye disorders	Macular hole	n/a	701	100,0	2	0,3
Eye disorders	Macular ischaemia	n/a	701	100,0	1	0,1
Eye disorders	Macular oedema	n/a	701	100,0	4	0,6
Eye disorders	Posterior capsule opacification	n/a	701	100,0	1	0,1
Eye disorders	Retinal artery embolism	n/a	701	100,0	1	0,1
Eye disorders	Retinal artery occlusion	n/a	701	100,0	2	0,3
Eye disorders	Retinal detachment	n/a	701	100,0	1	0,1
Eye disorders	Retinal ischaemia	n/a	701	100,0	2	0,3
Eye disorders	Retinal neovascularisation	n/a	701	100,0	2	0,3
Eye disorders	Retinal tear	n/a	701	100,0	1	0,1
Eye disorders	Retinal vein occlusion	n/a	701	100,0	8	1,1
Eye disorders	Uveitis	n/a	701	100,0	1	0,1
Eye disorders	Visual acuity reduced	n/a	701	100,0	1	0,1
Eye disorders	Vitreous haemorrhage	n/a	701	100,0	1	0,1
Eye disorders	Vitritis	n/a	701	100,0	1	0,1
Gastrointestinal disorders		n/a	701	100,0	7	1,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Duodenal ulcer haemorrhage	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Gastric ulcer	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Gastrointestinal inflammation	n/a	701	100,0	1	0,1

Gastrointestinal disorders	Large intestine polyp	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Pancreatitis	n/a	701	100,0	1	0,1
Gastrointestinal disorders	Pancreatitis acute	n/a	701	100,0	1	0,1
General disorders and administration site conditions		n/a	701	100,0	8	1,1
General disorders and administration site conditions	Asthenia	n/a	701	100,0	3	0,4
General disorders and administration site conditions	Chest pain	n/a	701	100,0	2	0,3
General disorders and administration site conditions	Death	n/a	701	100,0	2	0,3
General disorders and administration site conditions	Stent-graft endoleak	n/a	701	100,0	1	0,1
Hepatobiliary disorders		n/a	701	100,0	2	0,3
Hepatobiliary disorders	Cholecystitis	n/a	701	100,0	1	0,1
Hepatobiliary disorders	Cholelithiasis	n/a	701	100,0	1	0,1
Infections and infestations		n/a	701	100,0	22	3,1
Infections and infestations	Bronchitis	n/a	701	100,0	1	0,1
Infections and infestations	COVID-19	n/a	701	100,0	1	0,1
Infections and infestations	COVID-19 pneumonia	n/a	701	100,0	1	0,1
Infections and infestations	Cellulitis	n/a	701	100,0	2	0,3
Infections and infestations	Clostridium difficile infection	n/a	701	100,0	1	0,1
Infections and infestations	Device related infection	n/a	701	100,0	1	0,1
Infections and infestations	Endophthalmitis	n/a	701	100,0	1	0,1
Infections and infestations	Escherichia urinary tract infection	n/a	701	100,0	1	0,1
Infections and infestations	Influenza	n/a	701	100,0	2	0,3
Infections and infestations	Kidney infection	n/a	701	100,0	1	0,1
Infections and infestations	Lower respiratory tract infection	n/a	701	100,0	1	0,1
Infections and infestations	Necrotising fasciitis	n/a	701	100,0	1	0,1
Infections and infestations	Pneumonia	n/a	701	100,0	5	0,7
Infections and infestations	Pneumonia viral	n/a	701	100,0	2	0,3
Infections and infestations	Respiratory syncytial virus infection	n/a	701	100,0	1	0,1
Infections and infestations	Sepsis	n/a	701	100,0	2	0,3
Infections and infestations	Tooth infection	n/a	701	100,0	1	0,1
Infections and infestations	Urinary tract candidiasis	n/a	701	100,0	1	0,1
Infections and infestations	Urinary tract infection	n/a	701	100,0	1	0,1
Infections and infestations	Urosepsis	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications		n/a	701	100,0	9	1,3
Injury, poisoning and procedural complications	Fall	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Femur fracture	n/a	701	100,0	2	0,3
Injury, poisoning and procedural complications	Fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Hip fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Lower limb fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Rib fracture	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Road traffic accident	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Shunt stenosis	n/a	701	100,0	1	0,1
Injury, poisoning and procedural complications	Thermal burn	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders		n/a	701	100,0	2	0,3
Metabolism and nutrition disorders	Dehydration	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hypervolaemia	n/a	701	100,0	1	0,1
Metabolism and nutrition disorders	Hypokalaemia	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders		n/a	701	100,0	3	0,4
Musculoskeletal and connective tissue disorders	Back pain	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Joint effusion	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Mobility tissue decreased	n/a	701	100,0	1	0,1
Musculoskeletal and connective tissue disorders	Polymyositis	n/a	701	100,0	1	0,1

Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	701	100,0	6	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	n/a	701	100,0	1	0,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	n/a	701	100,0	1	0,1
Nervous system disorders		n/a	701	100,0	7	1,0
Nervous system disorders	Cerebrovascular accident	n/a	701	100,0	1	0,1
Nervous system disorders	Hypoaesthesia	n/a	701	100,0	1	0,1
Nervous system disorders	Ischaemic stroke	n/a	701	100,0	2	0,3
Nervous system disorders	Presyncope	n/a	701	100,0	1	0,1
Nervous system disorders	Syncope	n/a	701	100,0	2	0,3
Renal and urinary disorders		n/a	701	100,0	6	0,9
Renal and urinary disorders	Cystitis interstitial	n/a	701	100,0	1	0,1
Renal and urinary disorders	Diabetic nephropathy	n/a	701	100,0	1	0,1
Renal and urinary disorders	End stage renal disease	n/a	701	100,0	1	0,1
Renal and urinary disorders	Nephrolithiasis	n/a	701	100,0	1	0,1
Renal and urinary disorders	Nephropathy	n/a	701	100,0	1	0,1
Renal and urinary disorders	Renal failure	n/a	701	100,0	1	0,1
Reproductive system and breast disorders		n/a	701	100,0	1	0,1
Reproductive system and breast disorders	Cystocele	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders		n/a	701	100,0	7	1,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	n/a	701	100,0	1	0,1
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	701	100,0	2	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	n/a	701	100,0	2	0,3
Skin and subcutaneous tissue disorders		n/a	701	100,0	1	0,1
Skin and subcutaneous tissue disorders	Diabetic foot	n/a	701	100,0	1	0,1
Surgical and medical procedures		n/a	701	100,0	2	0,3
Surgical and medical procedures	Ligament operation	n/a	701	100,0	1	0,1
Surgical and medical procedures	Renal transplant	n/a	701	100,0	1	0,1
Vascular disorders		n/a	701	100,0	8	1,1
Vascular disorders	Aortic aneurysm	n/a	701	100,0	1	0,1
Vascular disorders	Aortic dissection	n/a	701	100,0	1	0,1
Vascular disorders	Aortic stenosis	n/a	701	100,0	1	0,1
Vascular disorders	Haemorrhage	n/a	701	100,0	1	0,1
Vascular disorders	Hypertension	n/a	701	100,0	2	0,3
Vascular disorders	Peripheral artery aneurysm	n/a	701	100,0	1	0,1
Vascular disorders	Secondary hypertension	n/a	701	100,0	1	0,1

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:20

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Gender

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		Male	374	53,4	1	0,3
Blood and lymphatic system disorders		Female	327	46,6	1	0,3
Blood and lymphatic system disorders	Anaemia	Male	374	53,4	0	0,0
Blood and lymphatic system disorders	Anaemia	Female	327	46,6	1	0,3
Blood and lymphatic system disorders	Deficiency anaemia	Male	374	53,4	1	0,3
Blood and lymphatic system disorders	Deficiency anaemia	Female	327	46,6	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Male	374	53,4	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Female	327	46,6	1	0,3
Cardiac disorders		Male	374	53,4	8	2,1
Cardiac disorders		Female	327	46,6	7	2,1
Cardiac disorders	Acute myocardial infarction	Male	374	53,4	1	0,3
Cardiac disorders	Acute myocardial infarction	Female	327	46,6	1	0,3
Cardiac disorders	Aortic valve incompetence	Male	374	53,4	0	0,0
Cardiac disorders	Aortic valve incompetence	Female	327	46,6	1	0,3
Cardiac disorders	Arrhythmia	Male	374	53,4	0	0,0
Cardiac disorders	Arrhythmia	Female	327	46,6	1	0,3
Cardiac disorders	Atrial fibrillation	Male	374	53,4	4	1,1
Cardiac disorders	Atrial fibrillation	Female	327	46,6	0	0,0
Cardiac disorders	Cardiac failure	Male	374	53,4	0	0,0
Cardiac disorders	Cardiac failure	Female	327	46,6	1	0,3
Cardiac disorders	Cardiac failure congestive	Male	374	53,4	1	0,3
Cardiac disorders	Cardiac failure congestive	Female	327	46,6	1	0,3
Cardiac disorders	Coronary artery disease	Male	374	53,4	1	0,3
Cardiac disorders	Coronary artery disease	Female	327	46,6	0	0,0
Cardiac disorders	Coronary artery stenosis	Male	374	53,4	0	0,0
Cardiac disorders	Coronary artery stenosis	Female	327	46,6	1	0,3
Cardiac disorders	Myocardial infarction	Male	374	53,4	2	0,5
Cardiac disorders	Myocardial infarction	Female	327	46,6	1	0,3
Cardiac disorders	Stress cardiomyopathy	Male	374	53,4	0	0,0
Cardiac disorders	Stress cardiomyopathy	Female	327	46,6	1	0,3
Eye disorders		Male	374	53,4	22	5,9
Eye disorders		Female	327	46,6	17	5,2
Eye disorders	Cataract	Male	374	53,4	0	0,0
Eye disorders	Cataract	Female	327	46,6	1	0,3
Eye disorders	Cystoid macular oedema	Male	374	53,4	4	1,1
Eye disorders	Cystoid macular oedema	Female	327	46,6	2	0,6
Eye disorders	Epiretinal membrane	Male	374	53,4	0	0,0
Eye disorders	Epiretinal membrane	Female	327	46,6	1	0,3
Eye disorders	Glaucoma	Male	374	53,4	1	0,3
Eye disorders	Glaucoma	Female	327	46,6	0	0,0
Eye disorders	Iridocyclitis	Male	374	53,4	1	0,3
Eye disorders	Iridocyclitis	Female	327	46,6	0	0,0
Eye disorders	Iris neovascularisation	Male	374	53,4	1	0,3
Eye disorders	Iris neovascularisation	Female	327	46,6	0	0,0
Eye disorders	Macular hole	Male	374	53,4	1	0,3
Eye disorders	Macular hole	Female	327	46,6	1	0,3
Eye disorders	Macular ischaemia	Male	374	53,4	1	0,3
Eye disorders	Macular ischaemia	Female	327	46,6	0	0,0
Eye disorders	Macular oedema	Male	374	53,4	0	0,0

Eye disorders	Macular oedema	Female	327	46,6	4	1,2
Eye disorders	Posterior capsule opacification	Male	374	53,4	0	0,0
Eye disorders	Posterior capsule opacification	Female	327	46,6	1	0,3
Eye disorders	Retinal artery embolism	Male	374	53,4	1	0,3
Eye disorders	Retinal artery embolism	Female	327	46,6	0	0,0
Eye disorders	Retinal artery occlusion	Male	374	53,4	2	0,5
Eye disorders	Retinal artery occlusion	Female	327	46,6	0	0,0
Eye disorders	Retinal detachment	Male	374	53,4	1	0,3
Eye disorders	Retinal detachment	Female	327	46,6	0	0,0
Eye disorders	Retinal ischaemia	Male	374	53,4	1	0,3
Eye disorders	Retinal ischaemia	Female	327	46,6	1	0,3
Eye disorders	Retinal neovascularisation	Male	374	53,4	1	0,3
Eye disorders	Retinal neovascularisation	Female	327	46,6	1	0,3
Eye disorders	Retinal tear	Male	374	53,4	1	0,3
Eye disorders	Retinal tear	Female	327	46,6	0	0,0
Eye disorders	Retinal vein occlusion	Male	374	53,4	4	1,1
Eye disorders	Retinal vein occlusion	Female	327	46,6	4	1,2
Eye disorders	Uveitis	Male	374	53,4	0	0,0
Eye disorders	Uveitis	Female	327	46,6	1	0,3
Eye disorders	Visual acuity reduced	Male	374	53,4	1	0,3
Eye disorders	Visual acuity reduced	Female	327	46,6	0	0,0
Eye disorders	Vitreous haemorrhage	Male	374	53,4	1	0,3
Eye disorders	Vitreous haemorrhage	Female	327	46,6	0	0,0
Eye disorders	Vitritis	Male	374	53,4	1	0,3
Eye disorders	Vitritis	Female	327	46,6	0	0,0
Gastrointestinal disorders		Male	374	53,4	5	1,3
Gastrointestinal disorders		Female	327	46,6	2	0,6
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Male	374	53,4	1	0,3
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Female	327	46,6	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Male	374	53,4	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Female	327	46,6	0	0,0
Gastrointestinal disorders	Gastric ulcer	Male	374	53,4	1	0,3
Gastrointestinal disorders	Gastric ulcer	Female	327	46,6	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Male	374	53,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Female	327	46,6	1	0,3
Gastrointestinal disorders	Large intestine polyp	Male	374	53,4	0	0,0
Gastrointestinal disorders	Large intestine polyp	Female	327	46,6	1	0,3
Gastrointestinal disorders	Pancreatitis	Male	374	53,4	1	0,3
Gastrointestinal disorders	Pancreatitis	Female	327	46,6	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Male	374	53,4	1	0,3
Gastrointestinal disorders	Pancreatitis acute	Female	327	46,6	0	0,0
General disorders and administration site conditions		Male	374	53,4	5	1,3
General disorders and administration site conditions		Female	327	46,6	3	0,9
General disorders and administration site conditions	Asthenia	Male	374	53,4	2	0,5
General disorders and administration site conditions	Asthenia	Female	327	46,6	1	0,3
General disorders and administration site conditions	Chest pain	Male	374	53,4	1	0,3
General disorders and administration site conditions	Chest pain	Female	327	46,6	1	0,3
General disorders and administration site conditions	Death	Male	374	53,4	1	0,3
General disorders and administration site conditions	Death	Female	327	46,6	1	0,3
General disorders and administration site conditions	Stent-graft endoleak	Male	374	53,4	1	0,3
General disorders and administration site conditions	Stent-graft endoleak	Female	327	46,6	0	0,0
Hepatobiliary disorders		Male	374	53,4	0	0,0
Hepatobiliary disorders		Female	327	46,6	2	0,6
Hepatobiliary disorders	Cholecystitis	Male	374	53,4	0	0,0
Hepatobiliary disorders	Cholecystitis	Female	327	46,6	1	0,3
Hepatobiliary disorders	Cholelithiasis	Male	374	53,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	Female	327	46,6	1	0,3
Infections and infestations		Male	374	53,4	10	2,7
Infections and infestations		Female	327	46,6	12	3,7
Infections and infestations	Bronchitis	Male	374	53,4	0	0,0

Infections and infestations	Bronchitis	Female	327	46,6	1	0,3
Infections and infestations	COVID-19	Male	374	53,4	1	0,3
Infections and infestations	COVID-19	Female	327	46,6	0	0,0
Infections and infestations	COVID-19 pneumonia	Male	374	53,4	0	0,0
Infections and infestations	COVID-19 pneumonia	Female	327	46,6	1	0,3
Infections and infestations	Cellulitis	Male	374	53,4	0	0,0
Infections and infestations	Cellulitis	Female	327	46,6	2	0,6
Infections and infestations	Clostridium difficile infection	Male	374	53,4	1	0,3
Infections and infestations	Clostridium difficile infection	Female	327	46,6	0	0,0
Infections and infestations	Device related infection	Male	374	53,4	1	0,3
Infections and infestations	Device related infection	Female	327	46,6	0	0,0
Infections and infestations	Endophthalmitis	Male	374	53,4	1	0,3
Infections and infestations	Endophthalmitis	Female	327	46,6	0	0,0
Infections and infestations	Escherichia urinary tract infection	Male	374	53,4	0	0,0
Infections and infestations	Escherichia urinary tract infection	Female	327	46,6	1	0,3
Infections and infestations	Influenza	Male	374	53,4	2	0,5
Infections and infestations	Influenza	Female	327	46,6	0	0,0
Infections and infestations	Kidney infection	Male	374	53,4	0	0,0
Infections and infestations	Kidney infection	Female	327	46,6	1	0,3
Infections and infestations	Lower respiratory tract infection	Male	374	53,4	1	0,3
Infections and infestations	Lower respiratory tract infection	Female	327	46,6	0	0,0
Infections and infestations	Necrotising fasciitis	Male	374	53,4	1	0,3
Infections and infestations	Necrotising fasciitis	Female	327	46,6	0	0,0
Infections and infestations	Pneumonia	Male	374	53,4	3	0,8
Infections and infestations	Pneumonia	Female	327	46,6	2	0,6
Infections and infestations	Pneumonia viral	Male	374	53,4	0	0,0
Infections and infestations	Pneumonia viral	Female	327	46,6	2	0,6
Infections and infestations	Respiratory syncytial virus infection	Male	374	53,4	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Female	327	46,6	1	0,3
Infections and infestations	Sepsis	Male	374	53,4	1	0,3
Infections and infestations	Sepsis	Female	327	46,6	1	0,3
Infections and infestations	Tooth infection	Male	374	53,4	0	0,0
Infections and infestations	Tooth infection	Female	327	46,6	1	0,3
Infections and infestations	Urinary tract candidiasis	Male	374	53,4	0	0,0
Infections and infestations	Urinary tract candidiasis	Female	327	46,6	1	0,3
Infections and infestations	Urinary tract infection	Male	374	53,4	0	0,0
Infections and infestations	Urinary tract infection	Female	327	46,6	1	0,3
Infections and infestations	Urosepsis	Male	374	53,4	1	0,3
Infections and infestations	Urosepsis	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications		Male	374	53,4	3	0,8
Injury, poisoning and procedural complications		Female	327	46,6	6	1,8
Injury, poisoning and procedural complications	Fall	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Fall	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Femur fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Femur fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Fracture	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Fracture	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Lower limb fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Rib fracture	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Female	327	46,6	1	0,3
Injury, poisoning and procedural complications	Road traffic accident	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Road traffic accident	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Male	374	53,4	1	0,3
Injury, poisoning and procedural complications	Shunt stenosis	Female	327	46,6	0	0,0
Injury, poisoning and procedural complications	Thermal burn	Male	374	53,4	0	0,0
Injury, poisoning and procedural complications	Thermal burn	Female	327	46,6	1	0,3
Metabolism and nutrition disorders		Male	374	53,4	1	0,3
Metabolism and nutrition disorders		Female	327	46,6	1	0,3
Metabolism and nutrition disorders	Dehydration	Male	374	53,4	0	0,0

Metabolism and nutrition disorders	Dehydration	Female	327	46,6	1	0,3
Metabolism and nutrition disorders	Hypervolaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Hypervolaemia	Female	327	46,6	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Male	374	53,4	1	0,3
Metabolism and nutrition disorders	Hypokalaemia	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders		Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders		Female	327	46,6	2	0,6
Musculoskeletal and connective tissue disorders	Back pain	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	Male	374	53,4	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	Female	327	46,6	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Female	327	46,6	1	0,3
Musculoskeletal and connective tissue disorders	Polymyositis	Male	374	53,4	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Male	374	53,4	4	1,1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Female	327	46,6	2	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Male	374	53,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Female	327	46,6	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Male	374	53,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Female	327	46,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Male	374	53,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Female	327	46,6	1	0,3
Nervous system disorders		Male	374	53,4	3	0,8
Nervous system disorders		Female	327	46,6	4	1,2
Nervous system disorders	Cerebrovascular accident	Male	374	53,4	0	0,0
Nervous system disorders	Cerebrovascular accident	Female	327	46,6	1	0,3
Nervous system disorders	Hypoaesthesia	Male	374	53,4	0	0,0
Nervous system disorders	Hypoaesthesia	Female	327	46,6	1	0,3
Nervous system disorders	Ischaemic stroke	Male	374	53,4	2	0,5
Nervous system disorders	Ischaemic stroke	Female	327	46,6	0	0,0
Nervous system disorders	Presyncope	Male	374	53,4	0	0,0
Nervous system disorders	Presyncope	Female	327	46,6	1	0,3
Nervous system disorders	Syncope	Male	374	53,4	1	0,3
Nervous system disorders	Syncope	Female	327	46,6	1	0,3
Renal and urinary disorders		Male	374	53,4	4	1,1
Renal and urinary disorders		Female	327	46,6	2	0,6
Renal and urinary disorders	Cystitis interstitial	Male	374	53,4	0	0,0
Renal and urinary disorders	Cystitis interstitial	Female	327	46,6	1	0,3
Renal and urinary disorders	Diabetic nephropathy	Male	374	53,4	1	0,3
Renal and urinary disorders	Diabetic nephropathy	Female	327	46,6	0	0,0
Renal and urinary disorders	End stage renal disease	Male	374	53,4	1	0,3
Renal and urinary disorders	End stage renal disease	Female	327	46,6	0	0,0
Renal and urinary disorders	Nephrolithiasis	Male	374	53,4	0	0,0
Renal and urinary disorders	Nephrolithiasis	Female	327	46,6	1	0,3
Renal and urinary disorders	Nephropathy	Male	374	53,4	1	0,3
Renal and urinary disorders	Nephropathy	Female	327	46,6	0	0,0
Renal and urinary disorders	Renal failure	Male	374	53,4	1	0,3
Renal and urinary disorders	Renal failure	Female	327	46,6	0	0,0
Reproductive system and breast disorders		Male	374	53,4	0	0,0
Reproductive system and breast disorders		Female	327	46,6	1	0,3
Reproductive system and breast disorders	Cystocele	Male	374	53,4	0	0,0
Reproductive system and breast disorders	Cystocele	Female	327	46,6	1	0,3

Respiratory, thoracic and mediastinal disorders		Male	374	53,4	5	1,3
Respiratory, thoracic and mediastinal disorders		Female	327	46,6	2	0,6
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Male	374	53,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Male	374	53,4	2	0,5
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Female	327	46,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Male	374	53,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Female	327	46,6	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Male	374	53,4	2	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Female	327	46,6	0	0,0
Skin and subcutaneous tissue disorders		Male	374	53,4	1	0,3
Skin and subcutaneous tissue disorders		Female	327	46,6	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	Male	374	53,4	1	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	Female	327	46,6	0	0,0
Surgical and medical procedures		Male	374	53,4	2	0,5
Surgical and medical procedures		Female	327	46,6	0	0,0
Surgical and medical procedures	Ligament operation	Male	374	53,4	1	0,3
Surgical and medical procedures	Ligament operation	Female	327	46,6	0	0,0
Surgical and medical procedures	Renal transplant	Male	374	53,4	1	0,3
Surgical and medical procedures	Renal transplant	Female	327	46,6	0	0,0
Vascular disorders		Male	374	53,4	5	1,3
Vascular disorders		Female	327	46,6	3	0,9
Vascular disorders	Aortic aneurysm	Male	374	53,4	1	0,3
Vascular disorders	Aortic aneurysm	Female	327	46,6	0	0,0
Vascular disorders	Aortic dissection	Male	374	53,4	0	0,0
Vascular disorders	Aortic dissection	Female	327	46,6	1	0,3
Vascular disorders	Aortic stenosis	Male	374	53,4	1	0,3
Vascular disorders	Aortic stenosis	Female	327	46,6	0	0,0
Vascular disorders	Haemorrhage	Male	374	53,4	1	0,3
Vascular disorders	Haemorrhage	Female	327	46,6	0	0,0
Vascular disorders	Hypertension	Male	374	53,4	1	0,3
Vascular disorders	Hypertension	Female	327	46,6	1	0,3
Vascular disorders	Peripheral artery aneurysm	Male	374	53,4	1	0,3
Vascular disorders	Peripheral artery aneurysm	Female	327	46,6	0	0,0
Vascular disorders	Secondary hypertension	Male	374	53,4	0	0,0
Vascular disorders	Secondary hypertension	Female	327	46,6	1	0,3

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_Sa24_29AUG2023_41986.xls

26APR2024 18:20

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Age

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<65 years	308	43,9	0	0,0
Blood and lymphatic system disorders		>=65 years	393	56,1	2	0,5
Blood and lymphatic system disorders	Anaemia	<65 years	308	43,9	0	0,0
Blood and lymphatic system disorders	Anaemia	>=65 years	393	56,1	1	0,3
Blood and lymphatic system disorders	Deficiency anaemia	<65 years	308	43,9	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	>=65 years	393	56,1	1	0,3
Blood and lymphatic system disorders	Mesenteric lymphadenitis	<65 years	308	43,9	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	>=65 years	393	56,1	1	0,3
Cardiac disorders		<65 years	308	43,9	4	1,3
Cardiac disorders		>=65 years	393	56,1	11	2,8
Cardiac disorders	Acute myocardial infarction	<65 years	308	43,9	0	0,0
Cardiac disorders	Acute myocardial infarction	>=65 years	393	56,1	2	0,5
Cardiac disorders	Aortic valve incompetence	<65 years	308	43,9	0	0,0
Cardiac disorders	Aortic valve incompetence	>=65 years	393	56,1	1	0,3
Cardiac disorders	Arrhythmia	<65 years	308	43,9	0	0,0
Cardiac disorders	Arrhythmia	>=65 years	393	56,1	1	0,3
Cardiac disorders	Atrial fibrillation	<65 years	308	43,9	1	0,3
Cardiac disorders	Atrial fibrillation	>=65 years	393	56,1	3	0,8
Cardiac disorders	Cardiac failure	<65 years	308	43,9	0	0,0
Cardiac disorders	Cardiac failure	>=65 years	393	56,1	1	0,3
Cardiac disorders	Cardiac failure congestive	<65 years	308	43,9	0	0,0
Cardiac disorders	Cardiac failure congestive	>=65 years	393	56,1	2	0,5
Cardiac disorders	Coronary artery disease	<65 years	308	43,9	0	0,0
Cardiac disorders	Coronary artery disease	>=65 years	393	56,1	1	0,3
Cardiac disorders	Coronary artery stenosis	<65 years	308	43,9	0	0,0
Cardiac disorders	Coronary artery stenosis	>=65 years	393	56,1	1	0,3
Cardiac disorders	Myocardial infarction	<65 years	308	43,9	2	0,6
Cardiac disorders	Myocardial infarction	>=65 years	393	56,1	1	0,3
Cardiac disorders	Stress cardiomyopathy	<65 years	308	43,9	1	0,3
Cardiac disorders	Stress cardiomyopathy	>=65 years	393	56,1	0	0,0
Eye disorders		<65 years	308	43,9	18	5,8
Eye disorders		>=65 years	393	56,1	21	5,3
Eye disorders	Cataract	<65 years	308	43,9	0	0,0
Eye disorders	Cataract	>=65 years	393	56,1	1	0,3
Eye disorders	Cystoid macular oedema	<65 years	308	43,9	3	1,0
Eye disorders	Cystoid macular oedema	>=65 years	393	56,1	3	0,8
Eye disorders	Epiretinal membrane	<65 years	308	43,9	1	0,3
Eye disorders	Epiretinal membrane	>=65 years	393	56,1	0	0,0
Eye disorders	Glaucoma	<65 years	308	43,9	1	0,3
Eye disorders	Glaucoma	>=65 years	393	56,1	0	0,0
Eye disorders	Iridocyclitis	<65 years	308	43,9	1	0,3
Eye disorders	Iridocyclitis	>=65 years	393	56,1	0	0,0
Eye disorders	Iris neovascularisation	<65 years	308	43,9	0	0,0
Eye disorders	Iris neovascularisation	>=65 years	393	56,1	1	0,3
Eye disorders	Macular hole	<65 years	308	43,9	1	0,3
Eye disorders	Macular hole	>=65 years	393	56,1	1	0,3
Eye disorders	Macular ischaemia	<65 years	308	43,9	0	0,0
Eye disorders	Macular ischaemia	>=65 years	393	56,1	1	0,3
Eye disorders	Macular oedema	<65 years	308	43,9	1	0,3

Eye disorders	Macular oedema	>=65 years	393	56,1	3	0,8
Eye disorders	Posterior capsule opacification	<65 years	308	43,9	0	0,0
Eye disorders	Posterior capsule opacification	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal artery embolism	<65 years	308	43,9	0	0,0
Eye disorders	Retinal artery embolism	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal artery occlusion	<65 years	308	43,9	0	0,0
Eye disorders	Retinal artery occlusion	>=65 years	393	56,1	2	0,5
Eye disorders	Retinal detachment	<65 years	308	43,9	0	0,0
Eye disorders	Retinal detachment	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal ischaemia	<65 years	308	43,9	0	0,0
Eye disorders	Retinal ischaemia	>=65 years	393	56,1	2	0,5
Eye disorders	Retinal neovascularisation	<65 years	308	43,9	2	0,6
Eye disorders	Retinal neovascularisation	>=65 years	393	56,1	0	0,0
Eye disorders	Retinal tear	<65 years	308	43,9	1	0,3
Eye disorders	Retinal tear	>=65 years	393	56,1	0	0,0
Eye disorders	Retinal vein occlusion	<65 years	308	43,9	4	1,3
Eye disorders	Retinal vein occlusion	>=65 years	393	56,1	4	1,0
Eye disorders	Uveitis	<65 years	308	43,9	1	0,3
Eye disorders	Uveitis	>=65 years	393	56,1	0	0,0
Eye disorders	Visual acuity reduced	<65 years	308	43,9	1	0,3
Eye disorders	Visual acuity reduced	>=65 years	393	56,1	0	0,0
Eye disorders	Vitreous haemorrhage	<65 years	308	43,9	1	0,3
Eye disorders	Vitreous haemorrhage	>=65 years	393	56,1	0	0,0
Eye disorders	Vitritis	<65 years	308	43,9	0	0,0
Eye disorders	Vitritis	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders		<65 years	308	43,9	2	0,6
Gastrointestinal disorders		>=65 years	393	56,1	5	1,3
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	>=65 years	393	56,1	0	0,0
Gastrointestinal disorders	Gastric ulcer	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Gastric ulcer	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Gastrointestinal inflammation	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Large intestine polyp	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Large intestine polyp	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Pancreatitis	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Pancreatitis	>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Pancreatitis acute	<65 years	308	43,9	1	0,3
Gastrointestinal disorders	Pancreatitis acute	>=65 years	393	56,1	0	0,0
General disorders and administration site conditions		<65 years	308	43,9	2	0,6
General disorders and administration site conditions		>=65 years	393	56,1	6	1,5
General disorders and administration site conditions	Asthenia	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Asthenia	>=65 years	393	56,1	3	0,8
General disorders and administration site conditions	Chest pain	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Chest pain	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Death	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Death	>=65 years	393	56,1	2	0,5
General disorders and administration site conditions	Stent-graft endoleak	<65 years	308	43,9	1	0,3
General disorders and administration site conditions	Stent-graft endoleak	>=65 years	393	56,1	0	0,0
Hepatobiliary disorders		<65 years	308	43,9	1	0,3
Hepatobiliary disorders		>=65 years	393	56,1	1	0,3
Hepatobiliary disorders	Cholecystitis	<65 years	308	43,9	1	0,3
Hepatobiliary disorders	Cholecystitis	>=65 years	393	56,1	0	0,0
Hepatobiliary disorders	Cholelithiasis	<65 years	308	43,9	0	0,0
Hepatobiliary disorders	Cholelithiasis	>=65 years	393	56,1	1	0,3
Infections and infestations		<65 years	308	43,9	4	1,3
Infections and infestations		>=65 years	393	56,1	18	4,6
Infections and infestations	Bronchitis	<65 years	308	43,9	0	0,0

Infections and infestations	Bronchitis	>=65 years	393	56,1	1	0,3
Infections and infestations	COVID-19	<65 years	308	43,9	0	0,0
Infections and infestations	COVID-19	>=65 years	393	56,1	1	0,3
Infections and infestations	COVID-19 pneumonia	<65 years	308	43,9	0	0,0
Infections and infestations	COVID-19 pneumonia	>=65 years	393	56,1	1	0,3
Infections and infestations	Cellulitis	<65 years	308	43,9	0	0,0
Infections and infestations	Cellulitis	>=65 years	393	56,1	2	0,5
Infections and infestations	Clostridium difficile infection	<65 years	308	43,9	0	0,0
Infections and infestations	Clostridium difficile infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Device related infection	<65 years	308	43,9	0	0,0
Infections and infestations	Device related infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Endophthalmitis	<65 years	308	43,9	0	0,0
Infections and infestations	Endophthalmitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Escherichia urinary tract infection	<65 years	308	43,9	0	0,0
Infections and infestations	Escherichia urinary tract infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Influenza	<65 years	308	43,9	0	0,0
Infections and infestations	Influenza	>=65 years	393	56,1	2	0,5
Infections and infestations	Kidney infection	<65 years	308	43,9	1	0,3
Infections and infestations	Kidney infection	>=65 years	393	56,1	0	0,0
Infections and infestations	Lower respiratory tract infection	<65 years	308	43,9	0	0,0
Infections and infestations	Lower respiratory tract infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Necrotising fasciitis	<65 years	308	43,9	0	0,0
Infections and infestations	Necrotising fasciitis	>=65 years	393	56,1	1	0,3
Infections and infestations	Pneumonia	<65 years	308	43,9	1	0,3
Infections and infestations	Pneumonia	>=65 years	393	56,1	4	1,0
Infections and infestations	Pneumonia viral	<65 years	308	43,9	1	0,3
Infections and infestations	Pneumonia viral	>=65 years	393	56,1	1	0,3
Infections and infestations	Respiratory syncytial virus infection	<65 years	308	43,9	0	0,0
Infections and infestations	Respiratory syncytial virus infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Sepsis	<65 years	308	43,9	0	0,0
Infections and infestations	Sepsis	>=65 years	393	56,1	2	0,5
Infections and infestations	Tooth infection	<65 years	308	43,9	1	0,3
Infections and infestations	Tooth infection	>=65 years	393	56,1	0	0,0
Infections and infestations	Urinary tract candidiasis	<65 years	308	43,9	0	0,0
Infections and infestations	Urinary tract candidiasis	>=65 years	393	56,1	1	0,3
Infections and infestations	Urinary tract infection	<65 years	308	43,9	0	0,0
Infections and infestations	Urinary tract infection	>=65 years	393	56,1	1	0,3
Infections and infestations	Urosepsis	<65 years	308	43,9	0	0,0
Infections and infestations	Urosepsis	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications		<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications		>=65 years	393	56,1	8	2,0
Injury, poisoning and procedural complications	Fall	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Fall	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Femur fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=65 years	393	56,1	2	0,5
Injury, poisoning and procedural complications	Fracture	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Fracture	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Hip fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Hip fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Lower limb fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Rib fracture	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Rib fracture	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Road traffic accident	<65 years	308	43,9	1	0,3
Injury, poisoning and procedural complications	Road traffic accident	>=65 years	393	56,1	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	>=65 years	393	56,1	1	0,3
Injury, poisoning and procedural complications	Thermal burn	<65 years	308	43,9	0	0,0
Injury, poisoning and procedural complications	Thermal burn	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders		<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders		>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Dehydration	<65 years	308	43,9	0	0,0

Metabolism and nutrition disorders	Dehydration	>=65 years	393	56,1	1	0,3
Metabolism and nutrition disorders	Hypervolaemia	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Hypervolaemia	>=65 years	393	56,1	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	<65 years	308	43,9	1	0,3
Metabolism and nutrition disorders	Hypokalaemia	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders		<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders		>=65 years	393	56,1	2	0,5
Musculoskeletal and connective tissue disorders	Back pain	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	<65 years	308	43,9	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	>=65 years	393	56,1	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	>=65 years	393	56,1	1	0,3
Musculoskeletal and connective tissue disorders	Polymyositis	<65 years	308	43,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<65 years	308	43,9	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=65 years	393	56,1	5	1,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	<65 years	308	43,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	>=65 years	393	56,1	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	<65 years	308	43,9	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	>=65 years	393	56,1	0	0,0
Nervous system disorders		<65 years	308	43,9	1	0,3
Nervous system disorders		>=65 years	393	56,1	6	1,5
Nervous system disorders	Cerebrovascular accident	<65 years	308	43,9	0	0,0
Nervous system disorders	Cerebrovascular accident	>=65 years	393	56,1	1	0,3
Nervous system disorders	Hypoaesthesia	<65 years	308	43,9	1	0,3
Nervous system disorders	Hypoaesthesia	>=65 years	393	56,1	0	0,0
Nervous system disorders	Ischaemic stroke	<65 years	308	43,9	0	0,0
Nervous system disorders	Ischaemic stroke	>=65 years	393	56,1	2	0,5
Nervous system disorders	Presyncope	<65 years	308	43,9	0	0,0
Nervous system disorders	Presyncope	>=65 years	393	56,1	1	0,3
Nervous system disorders	Syncope	<65 years	308	43,9	0	0,0
Nervous system disorders	Syncope	>=65 years	393	56,1	2	0,5
Renal and urinary disorders		<65 years	308	43,9	2	0,6
Renal and urinary disorders		>=65 years	393	56,1	4	1,0
Renal and urinary disorders	Cystitis interstitial	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Cystitis interstitial	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Diabetic nephropathy	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Diabetic nephropathy	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	End stage renal disease	<65 years	308	43,9	0	0,0
Renal and urinary disorders	End stage renal disease	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Nephrolithiasis	<65 years	308	43,9	1	0,3
Renal and urinary disorders	Nephrolithiasis	>=65 years	393	56,1	0	0,0
Renal and urinary disorders	Nephropathy	<65 years	308	43,9	0	0,0
Renal and urinary disorders	Nephropathy	>=65 years	393	56,1	1	0,3
Renal and urinary disorders	Renal failure	<65 years	308	43,9	1	0,3
Renal and urinary disorders	Renal failure	>=65 years	393	56,1	0	0,0
Reproductive system and breast disorders		<65 years	308	43,9	1	0,3
Reproductive system and breast disorders		>=65 years	393	56,1	0	0,0
Reproductive system and breast disorders	Cystocele	<65 years	308	43,9	1	0,3
Reproductive system and breast disorders	Cystocele	>=65 years	393	56,1	0	0,0

Respiratory, thoracic and mediastinal disorders		<65 years	308	43,9	1	0,3
Respiratory, thoracic and mediastinal disorders		>=65 years	393	56,1	6	1,5
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	>=65 years	393	56,1	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=65 years	393	56,1	2	0,5
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<65 years	308	43,9	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=65 years	393	56,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=65 years	393	56,1	2	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<65 years	308	43,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=65 years	393	56,1	2	0,5
Skin and subcutaneous tissue disorders		<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders		>=65 years	393	56,1	1	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	<65 years	308	43,9	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	>=65 years	393	56,1	1	0,3
Surgical and medical procedures		<65 years	308	43,9	1	0,3
Surgical and medical procedures		>=65 years	393	56,1	1	0,3
Surgical and medical procedures	Ligament operation	<65 years	308	43,9	1	0,3
Surgical and medical procedures	Ligament operation	>=65 years	393	56,1	0	0,0
Surgical and medical procedures	Renal transplant	<65 years	308	43,9	0	0,0
Surgical and medical procedures	Renal transplant	>=65 years	393	56,1	1	0,3
Vascular disorders		<65 years	308	43,9	2	0,6
Vascular disorders		>=65 years	393	56,1	6	1,5
Vascular disorders	Aortic aneurysm	<65 years	308	43,9	0	0,0
Vascular disorders	Aortic aneurysm	>=65 years	393	56,1	1	0,3
Vascular disorders	Aortic dissection	<65 years	308	43,9	0	0,0
Vascular disorders	Aortic dissection	>=65 years	393	56,1	1	0,3
Vascular disorders	Aortic stenosis	<65 years	308	43,9	0	0,0
Vascular disorders	Aortic stenosis	>=65 years	393	56,1	1	0,3
Vascular disorders	Haemorrhage	<65 years	308	43,9	0	0,0
Vascular disorders	Haemorrhage	>=65 years	393	56,1	1	0,3
Vascular disorders	Hypertension	<65 years	308	43,9	0	0,0
Vascular disorders	Hypertension	>=65 years	393	56,1	2	0,5
Vascular disorders	Peripheral artery aneurysm	<65 years	308	43,9	1	0,3
Vascular disorders	Peripheral artery aneurysm	>=65 years	393	56,1	0	0,0
Vascular disorders	Secondary hypertension	<65 years	308	43,9	1	0,3
Vascular disorders	Secondary hypertension	>=65 years	393	56,1	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_Sa24_29AUG2023_41986.xls

26APR2024 18:20

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETRS letter score

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=701)			
			Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders		35 - 54 letters	206	29,4	0	0,0
Blood and lymphatic system disorders		>=55 letters	339	48,4	2	0,6
Blood and lymphatic system disorders	Anaemia	<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders	Anaemia	35 - 54 letters	206	29,4	0	0,0
Blood and lymphatic system disorders	Anaemia	>=55 letters	339	48,4	1	0,3
Blood and lymphatic system disorders	Deficiency anaemia	<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	35 - 54 letters	206	29,4	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	>=55 letters	339	48,4	1	0,3
Blood and lymphatic system disorders	Mesenteric lymphadenitis	<=34 letters	156	22,3	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	35 - 54 letters	206	29,4	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	>=55 letters	339	48,4	1	0,3
Cardiac disorders		<=34 letters	156	22,3	1	0,6
Cardiac disorders		35 - 54 letters	206	29,4	8	3,9
Cardiac disorders		>=55 letters	339	48,4	6	1,8
Cardiac disorders	Acute myocardial infarction	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Acute myocardial infarction	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Acute myocardial infarction	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Aortic valve incompetence	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Aortic valve incompetence	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Aortic valve incompetence	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Arrhythmia	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Arrhythmia	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Arrhythmia	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Atrial fibrillation	<=34 letters	156	22,3	1	0,6
Cardiac disorders	Atrial fibrillation	35 - 54 letters	206	29,4	0	0,0
Cardiac disorders	Atrial fibrillation	>=55 letters	339	48,4	3	0,9
Cardiac disorders	Cardiac failure	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Cardiac failure	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Cardiac failure	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Cardiac failure congestive	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Cardiac failure congestive	35 - 54 letters	206	29,4	2	1,0
Cardiac disorders	Cardiac failure congestive	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Coronary artery disease	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Coronary artery disease	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Coronary artery disease	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Coronary artery stenosis	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Coronary artery stenosis	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Coronary artery stenosis	>=55 letters	339	48,4	0	0,0
Cardiac disorders	Myocardial infarction	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Myocardial infarction	35 - 54 letters	206	29,4	2	1,0
Cardiac disorders	Myocardial infarction	>=55 letters	339	48,4	1	0,3
Cardiac disorders	Stress cardiomyopathy	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Stress cardiomyopathy	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Stress cardiomyopathy	>=55 letters	339	48,4	0	0,0
Eye disorders		<=34 letters	156	22,3	9	5,8
Eye disorders		35 - 54 letters	206	29,4	11	5,3
Eye disorders		>=55 letters	339	48,4	19	5,6
Eye disorders	Cataract	<=34 letters	156	22,3	0	0,0

Eye disorders	Cataract	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Cataract	>=55 letters	339	48,4	0	0,0
Eye disorders	Cystoid macular oedema	<=34 letters	156	22,3	1	0,6
Eye disorders	Cystoid macular oedema	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Cystoid macular oedema	>=55 letters	339	48,4	5	1,5
Eye disorders	Epiretinal membrane	<=34 letters	156	22,3	0	0,0
Eye disorders	Epiretinal membrane	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Epiretinal membrane	>=55 letters	339	48,4	0	0,0
Eye disorders	Glaucoma	<=34 letters	156	22,3	0	0,0
Eye disorders	Glaucoma	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Glaucoma	>=55 letters	339	48,4	1	0,3
Eye disorders	Iridocyclitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Iridocyclitis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Iridocyclitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Iris neovascularisation	<=34 letters	156	22,3	0	0,0
Eye disorders	Iris neovascularisation	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Iris neovascularisation	>=55 letters	339	48,4	0	0,0
Eye disorders	Macular hole	<=34 letters	156	22,3	0	0,0
Eye disorders	Macular hole	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Macular hole	>=55 letters	339	48,4	1	0,3
Eye disorders	Macular ischaemia	<=34 letters	156	22,3	0	0,0
Eye disorders	Macular ischaemia	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Macular ischaemia	>=55 letters	339	48,4	1	0,3
Eye disorders	Macular oedema	<=34 letters	156	22,3	0	0,0
Eye disorders	Macular oedema	35 - 54 letters	206	29,4	3	1,5
Eye disorders	Macular oedema	>=55 letters	339	48,4	1	0,3
Eye disorders	Posterior capsule opacification	<=34 letters	156	22,3	0	0,0
Eye disorders	Posterior capsule opacification	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Posterior capsule opacification	>=55 letters	339	48,4	0	0,0
Eye disorders	Retinal artery embolism	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal artery embolism	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal artery embolism	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal artery occlusion	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal artery occlusion	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal artery occlusion	>=55 letters	339	48,4	2	0,6
Eye disorders	Retinal detachment	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal detachment	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal detachment	>=55 letters	339	48,4	0	0,0
Eye disorders	Retinal ischaemia	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal ischaemia	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Retinal ischaemia	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal neovascularisation	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal neovascularisation	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal neovascularisation	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal tear	<=34 letters	156	22,3	1	0,6
Eye disorders	Retinal tear	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Retinal tear	>=55 letters	339	48,4	0	0,0
Eye disorders	Retinal vein occlusion	<=34 letters	156	22,3	3	1,9
Eye disorders	Retinal vein occlusion	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Retinal vein occlusion	>=55 letters	339	48,4	4	1,2
Eye disorders	Uveitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Uveitis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Uveitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Visual acuity reduced	<=34 letters	156	22,3	1	0,6
Eye disorders	Visual acuity reduced	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Visual acuity reduced	>=55 letters	339	48,4	0	0,0
Eye disorders	Vitreous haemorrhage	<=34 letters	156	22,3	1	0,6
Eye disorders	Vitreous haemorrhage	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Vitreous haemorrhage	>=55 letters	339	48,4	0	0,0
Eye disorders	Vitritis	<=34 letters	156	22,3	0	0,0
Eye disorders	Vitritis	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Vitritis	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders		<=34 letters	156	22,3	1	0,6

Gastrointestinal disorders		35 - 54 letters	206	29,4	2	1,0
Gastrointestinal disorders		>=55 letters	339	48,4	4	1,2
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Duodenal ulcer haemorrhage	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Gastric ulcer	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Gastric ulcer	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Gastric ulcer	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	<=34 letters	156	22,3	1	0,6
Gastrointestinal disorders	Gastrointestinal inflammation	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Large intestine polyp	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Large intestine polyp	35 - 54 letters	206	29,4	1	0,5
Gastrointestinal disorders	Large intestine polyp	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Pancreatitis	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Pancreatitis	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Pancreatitis	>=55 letters	339	48,4	1	0,3
Gastrointestinal disorders	Pancreatitis acute	<=34 letters	156	22,3	0	0,0
Gastrointestinal disorders	Pancreatitis acute	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Pancreatitis acute	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions		<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions		35 - 54 letters	206	29,4	3	1,5
General disorders and administration site conditions		>=55 letters	339	48,4	4	1,2
General disorders and administration site conditions	Asthenia	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Asthenia	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Asthenia	>=55 letters	339	48,4	2	0,6
General disorders and administration site conditions	Chest pain	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Chest pain	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Chest pain	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Death	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Death	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Death	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Stent-graft endoleak	<=34 letters	156	22,3	1	0,6
General disorders and administration site conditions	Stent-graft endoleak	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	>=55 letters	339	48,4	0	0,0
Hepatobiliary disorders		<=34 letters	156	22,3	1	0,6
Hepatobiliary disorders		35 - 54 letters	206	29,4	1	0,5
Hepatobiliary disorders		>=55 letters	339	48,4	0	0,0
Hepatobiliary disorders	Cholecystitis	<=34 letters	156	22,3	1	0,6
Hepatobiliary disorders	Cholecystitis	35 - 54 letters	206	29,4	0	0,0
Hepatobiliary disorders	Cholecystitis	>=55 letters	339	48,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	<=34 letters	156	22,3	0	0,0
Hepatobiliary disorders	Cholelithiasis	35 - 54 letters	206	29,4	1	0,5
Hepatobiliary disorders	Cholelithiasis	>=55 letters	339	48,4	0	0,0
Infections and infestations		<=34 letters	156	22,3	7	4,5
Infections and infestations		35 - 54 letters	206	29,4	8	3,9
Infections and infestations		>=55 letters	339	48,4	7	2,1
Infections and infestations	Bronchitis	<=34 letters	156	22,3	1	0,6
Infections and infestations	Bronchitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Bronchitis	>=55 letters	339	48,4	0	0,0
Infections and infestations	COVID-19	<=34 letters	156	22,3	0	0,0
Infections and infestations	COVID-19	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	COVID-19	>=55 letters	339	48,4	1	0,3
Infections and infestations	COVID-19 pneumonia	<=34 letters	156	22,3	0	0,0
Infections and infestations	COVID-19 pneumonia	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	COVID-19 pneumonia	>=55 letters	339	48,4	0	0,0
Infections and infestations	Cellulitis	<=34 letters	156	22,3	1	0,6
Infections and infestations	Cellulitis	35 - 54 letters	206	29,4	1	0,5

Infections and infestations	Cellulitis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Clostridium difficile infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Clostridium difficile infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Clostridium difficile infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Device related infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Device related infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Device related infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Endophthalmitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Endophthalmitis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Endophthalmitis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Escherichia urinary tract infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Escherichia urinary tract infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Escherichia urinary tract infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Influenza	<=34 letters	156	22,3	0	0,0
Infections and infestations	Influenza	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Influenza	>=55 letters	339	48,4	2	0,6
Infections and infestations	Kidney infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Kidney infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Kidney infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Lower respiratory tract infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Lower respiratory tract infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Lower respiratory tract infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Necrotising fasciitis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Necrotising fasciitis	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Necrotising fasciitis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Pneumonia	<=34 letters	156	22,3	3	1,9
Infections and infestations	Pneumonia	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Pneumonia	>=55 letters	339	48,4	2	0,6
Infections and infestations	Pneumonia viral	<=34 letters	156	22,3	0	0,0
Infections and infestations	Pneumonia viral	35 - 54 letters	206	29,4	2	1,0
Infections and infestations	Pneumonia viral	>=55 letters	339	48,4	0	0,0
Infections and infestations	Respiratory syncytial virus infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Respiratory syncytial virus infection	35 - 54 letters	206	29,4	1	0,5
Infections and infestations	Respiratory syncytial virus infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Sepsis	<=34 letters	156	22,3	2	1,3
Infections and infestations	Sepsis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Sepsis	>=55 letters	339	48,4	0	0,0
Infections and infestations	Tooth infection	<=34 letters	156	22,3	0	0,0
Infections and infestations	Tooth infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Tooth infection	>=55 letters	339	48,4	1	0,3
Infections and infestations	Urinary tract candidiasis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Urinary tract candidiasis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Urinary tract candidiasis	>=55 letters	339	48,4	1	0,3
Infections and infestations	Urinary tract infection	<=34 letters	156	22,3	1	0,6
Infections and infestations	Urinary tract infection	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Urinary tract infection	>=55 letters	339	48,4	0	0,0
Infections and infestations	Urosepsis	<=34 letters	156	22,3	0	0,0
Infections and infestations	Urosepsis	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Urosepsis	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications		<=34 letters	156	22,3	1	0,6
Injury, poisoning and procedural complications		35 - 54 letters	206	29,4	5	2,4
Injury, poisoning and procedural complications		>=55 letters	339	48,4	3	0,9
Injury, poisoning and procedural complications	Fall	<=34 letters	156	22,3	1	0,6
Injury, poisoning and procedural complications	Fall	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Fall	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Femur fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Femur fracture	35 - 54 letters	206	29,4	2	1,0
Injury, poisoning and procedural complications	Femur fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Fracture	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Fracture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Hip fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Hip fracture	35 - 54 letters	206	29,4	0	0,0

Injury, poisoning and procedural complications	Hip fracture	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Lower limb fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Lower limb fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Rib fracture	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Rib fracture	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Rib fracture	>=55 letters	339	48,4	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Shunt stenosis	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	35 - 54 letters	206	29,4	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	>=55 letters	339	48,4	1	0,3
Injury, poisoning and procedural complications	Thermal burn	<=34 letters	156	22,3	0	0,0
Injury, poisoning and procedural complications	Thermal burn	35 - 54 letters	206	29,4	1	0,5
Injury, poisoning and procedural complications	Thermal burn	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders		<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders		35 - 54 letters	206	29,4	1	0,5
Metabolism and nutrition disorders		>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Dehydration	<=34 letters	156	22,3	0	0,0
Metabolism and nutrition disorders	Dehydration	35 - 54 letters	206	29,4	1	0,5
Metabolism and nutrition disorders	Dehydration	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Hypervolaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	>=55 letters	339	48,4	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	<=34 letters	156	22,3	1	0,6
Metabolism and nutrition disorders	Hypokalaemia	35 - 54 letters	206	29,4	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders		<=34 letters	156	22,3	1	0,6
Musculoskeletal and connective tissue disorders		35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders		>=55 letters	339	48,4	1	0,3
Musculoskeletal and connective tissue disorders	Back pain	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	>=55 letters	339	48,4	1	0,3
Musculoskeletal and connective tissue disorders	Joint effusion	<=34 letters	156	22,3	1	0,6
Musculoskeletal and connective tissue disorders	Joint effusion	35 - 54 letters	206	29,4	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders	Mobility decreased	>=55 letters	339	48,4	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	<=34 letters	156	22,3	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	35 - 54 letters	206	29,4	1	0,5
Musculoskeletal and connective tissue disorders	Polymyositis	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=34 letters	156	22,3	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		35 - 54 letters	206	29,4	4	1,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=55 letters	339	48,4	1	0,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	<=34 letters	156	22,3	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	>=55 letters	339	48,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	35 - 54 letters	206	29,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	>=55 letters	339	48,4	1	0,3

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	<=34 letters	156	22,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	35 - 54 letters	206	29,4	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	>=55 letters	339	48,4	0	0,0
Nervous system disorders		<=34 letters	156	22,3	2	1,3
Nervous system disorders		35 - 54 letters	206	29,4	4	1,9
Nervous system disorders		>=55 letters	339	48,4	1	0,3
Nervous system disorders	Cerebrovascular accident	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Cerebrovascular accident	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Cerebrovascular accident	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Hypoaesthesia	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Hypoaesthesia	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Hypoaesthesia	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Ischaemic stroke	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Ischaemic stroke	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Ischaemic stroke	>=55 letters	339	48,4	1	0,3
Nervous system disorders	Presyncope	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Presyncope	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Presyncope	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Syncope	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Syncope	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Syncope	>=55 letters	339	48,4	0	0,0
Renal and urinary disorders		<=34 letters	156	22,3	0	0,0
Renal and urinary disorders		35 - 54 letters	206	29,4	1	0,5
Renal and urinary disorders		>=55 letters	339	48,4	5	1,5
Renal and urinary disorders	Cystitis interstitial	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Cystitis interstitial	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Cystitis interstitial	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Diabetic nephropathy	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Diabetic nephropathy	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Diabetic nephropathy	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	End stage renal disease	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	End stage renal disease	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	End stage renal disease	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Nephrolithiasis	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Nephrolithiasis	35 - 54 letters	206	29,4	1	0,5
Renal and urinary disorders	Nephrolithiasis	>=55 letters	339	48,4	0	0,0
Renal and urinary disorders	Nephropathy	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Nephropathy	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Nephropathy	>=55 letters	339	48,4	1	0,3
Renal and urinary disorders	Renal failure	<=34 letters	156	22,3	0	0,0
Renal and urinary disorders	Renal failure	35 - 54 letters	206	29,4	0	0,0
Renal and urinary disorders	Renal failure	>=55 letters	339	48,4	1	0,3
Reproductive system and breast disorders		<=34 letters	156	22,3	0	0,0
Reproductive system and breast disorders		35 - 54 letters	206	29,4	0	0,0
Reproductive system and breast disorders		>=55 letters	339	48,4	1	0,3
Reproductive system and breast disorders	Cystocele	<=34 letters	156	22,3	0	0,0
Reproductive system and breast disorders	Cystocele	35 - 54 letters	206	29,4	0	0,0
Reproductive system and breast disorders	Cystocele	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders		<=34 letters	156	22,3	3	1,9
Respiratory, thoracic and mediastinal disorders		35 - 54 letters	206	29,4	2	1,0
Respiratory, thoracic and mediastinal disorders		>=55 letters	339	48,4	2	0,6
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	35 - 54 letters	206	29,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=55 letters	339	48,4	0	0,0

Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<=34 letters	156	22,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=55 letters	339	48,4	1	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<=34 letters	156	22,3	1	0,6
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	35 - 54 letters	206	29,4	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=55 letters	339	48,4	0	0,0
Skin and subcutaneous tissue disorders		<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders		35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders		>=55 letters	339	48,4	1	0,3
Skin and subcutaneous tissue disorders	Diabetic foot	<=34 letters	156	22,3	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	35 - 54 letters	206	29,4	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	>=55 letters	339	48,4	1	0,3
Surgical and medical procedures		<=34 letters	156	22,3	0	0,0
Surgical and medical procedures		35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures		>=55 letters	339	48,4	2	0,6
Surgical and medical procedures	Ligament operation	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Ligament operation	35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures	Ligament operation	>=55 letters	339	48,4	1	0,3
Surgical and medical procedures	Renal transplant	<=34 letters	156	22,3	0	0,0
Surgical and medical procedures	Renal transplant	35 - 54 letters	206	29,4	0	0,0
Surgical and medical procedures	Renal transplant	>=55 letters	339	48,4	1	0,3
Vascular disorders		<=34 letters	156	22,3	2	1,3
Vascular disorders		35 - 54 letters	206	29,4	2	1,0
Vascular disorders		>=55 letters	339	48,4	4	1,2
Vascular disorders	Aortic aneurysm	<=34 letters	156	22,3	0	0,0
Vascular disorders	Aortic aneurysm	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Aortic aneurysm	>=55 letters	339	48,4	1	0,3
Vascular disorders	Aortic dissection	<=34 letters	156	22,3	0	0,0
Vascular disorders	Aortic dissection	35 - 54 letters	206	29,4	1	0,5
Vascular disorders	Aortic dissection	>=55 letters	339	48,4	0	0,0
Vascular disorders	Aortic stenosis	<=34 letters	156	22,3	0	0,0
Vascular disorders	Aortic stenosis	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Aortic stenosis	>=55 letters	339	48,4	1	0,3
Vascular disorders	Haemorrhage	<=34 letters	156	22,3	0	0,0
Vascular disorders	Haemorrhage	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Haemorrhage	>=55 letters	339	48,4	1	0,3
Vascular disorders	Hypertension	<=34 letters	156	22,3	1	0,6
Vascular disorders	Hypertension	35 - 54 letters	206	29,4	1	0,5
Vascular disorders	Hypertension	>=55 letters	339	48,4	0	0,0
Vascular disorders	Peripheral artery aneurysm	<=34 letters	156	22,3	1	0,6
Vascular disorders	Peripheral artery aneurysm	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Peripheral artery aneurysm	>=55 letters	339	48,4	0	0,0
Vascular disorders	Secondary hypertension	<=34 letters	156	22,3	0	0,0
Vascular disorders	Secondary hypertension	35 - 54 letters	206	29,4	0	0,0
Vascular disorders	Secondary hypertension	>=55 letters	339	48,4	1	0,3

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:20

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETDRS letter score

MedDRA System Organ Class	MedDRA Preferred Term	Level	Faricimab (N=701)			
			Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders		>=24 letters	632	90,2	2	0,3
Blood and lymphatic system disorders	Anaemia	<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders	Anaemia	>=24 letters	632	90,2	1	0,2
Blood and lymphatic system disorders	Deficiency anaemia	<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	>=24 letters	632	90,2	1	0,2
Blood and lymphatic system disorders	Mesenteric lymphadenitis	<=23 letters	69	9,8	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	>=24 letters	632	90,2	1	0,2
Cardiac disorders		<=23 letters	69	9,8	0	0,0
Cardiac disorders		>=24 letters	632	90,2	15	2,4
Cardiac disorders	Acute myocardial infarction	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Acute myocardial infarction	>=24 letters	632	90,2	2	0,3
Cardiac disorders	Aortic valve incompetence	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Aortic valve incompetence	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Arrhythmia	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Arrhythmia	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Atrial fibrillation	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Atrial fibrillation	>=24 letters	632	90,2	4	0,6
Cardiac disorders	Cardiac failure	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Cardiac failure	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Cardiac failure congestive	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Cardiac failure congestive	>=24 letters	632	90,2	2	0,3
Cardiac disorders	Coronary artery disease	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Coronary artery disease	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Coronary artery stenosis	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Coronary artery stenosis	>=24 letters	632	90,2	1	0,2
Cardiac disorders	Myocardial infarction	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Myocardial infarction	>=24 letters	632	90,2	3	0,5
Cardiac disorders	Stress cardiomyopathy	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Stress cardiomyopathy	>=24 letters	632	90,2	1	0,2
Eye disorders		<=23 letters	69	9,8	3	4,3
Eye disorders		>=24 letters	632	90,2	36	5,7
Eye disorders	Cataract	<=23 letters	69	9,8	0	0,0
Eye disorders	Cataract	>=24 letters	632	90,2	1	0,2
Eye disorders	Cystoid macular oedema	<=23 letters	69	9,8	0	0,0
Eye disorders	Cystoid macular oedema	>=24 letters	632	90,2	6	0,9
Eye disorders	Epiretinal membrane	<=23 letters	69	9,8	0	0,0
Eye disorders	Epiretinal membrane	>=24 letters	632	90,2	1	0,2
Eye disorders	Glaucoma	<=23 letters	69	9,8	0	0,0
Eye disorders	Glaucoma	>=24 letters	632	90,2	1	0,2
Eye disorders	Iridocyclitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Iridocyclitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Iris neovascularisation	<=23 letters	69	9,8	0	0,0
Eye disorders	Iris neovascularisation	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular hole	<=23 letters	69	9,8	0	0,0
Eye disorders	Macular hole	>=24 letters	632	90,2	2	0,3
Eye disorders	Macular ischaemia	<=23 letters	69	9,8	0	0,0
Eye disorders	Macular ischaemia	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular oedema	<=23 letters	69	9,8	0	0,0

Eye disorders	Macular oedema	>=24 letters	632	90,2	4	0,6
Eye disorders	Posterior capsule opacification	<=23 letters	69	9,8	0	0,0
Eye disorders	Posterior capsule opacification	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal artery embolism	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal artery embolism	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal artery occlusion	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal artery occlusion	>=24 letters	632	90,2	2	0,3
Eye disorders	Retinal detachment	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal detachment	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal ischaemia	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal ischaemia	>=24 letters	632	90,2	2	0,3
Eye disorders	Retinal neovascularisation	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal neovascularisation	>=24 letters	632	90,2	2	0,3
Eye disorders	Retinal tear	<=23 letters	69	9,8	1	1,4
Eye disorders	Retinal tear	>=24 letters	632	90,2	0	0,0
Eye disorders	Retinal vein occlusion	<=23 letters	69	9,8	1	1,4
Eye disorders	Retinal vein occlusion	>=24 letters	632	90,2	7	1,1
Eye disorders	Uveitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Uveitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Visual acuity reduced	<=23 letters	69	9,8	0	0,0
Eye disorders	Visual acuity reduced	>=24 letters	632	90,2	1	0,2
Eye disorders	Vitreous haemorrhage	<=23 letters	69	9,8	1	1,4
Eye disorders	Vitreous haemorrhage	>=24 letters	632	90,2	0	0,0
Eye disorders	Vitritis	<=23 letters	69	9,8	0	0,0
Eye disorders	Vitritis	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders		<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders		>=24 letters	632	90,2	7	1,1
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Duodenal ulcer haemorrhage	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Gastric ulcer	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastric ulcer	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Gastrointestinal inflammation	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Large intestine polyp	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Large intestine polyp	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Pancreatitis	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Pancreatitis	>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Pancreatitis acute	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Pancreatitis acute	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions		<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions		>=24 letters	632	90,2	8	1,3
General disorders and administration site conditions	Asthenia	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Asthenia	>=24 letters	632	90,2	3	0,5
General disorders and administration site conditions	Chest pain	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Chest pain	>=24 letters	632	90,2	2	0,3
General disorders and administration site conditions	Death	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Death	>=24 letters	632	90,2	2	0,3
General disorders and administration site conditions	Stent-graft endoleak	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	>=24 letters	632	90,2	1	0,2
Hepatobiliary disorders		<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders		>=24 letters	632	90,2	2	0,3
Hepatobiliary disorders	Cholecystitis	<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders	Cholecystitis	>=24 letters	632	90,2	1	0,2
Hepatobiliary disorders	Cholelithiasis	<=23 letters	69	9,8	0	0,0
Hepatobiliary disorders	Cholelithiasis	>=24 letters	632	90,2	1	0,2
Infections and infestations		<=23 letters	69	9,8	3	4,3
Infections and infestations		>=24 letters	632	90,2	19	3,0
Infections and infestations	Bronchitis	<=23 letters	69	9,8	1	1,4

Infections and infestations	Bronchitis	>=24 letters	632	90,2	0	0,0
Infections and infestations	COVID-19	<=23 letters	69	9,8	0	0,0
Infections and infestations	COVID-19	>=24 letters	632	90,2	1	0,2
Infections and infestations	COVID-19 pneumonia	<=23 letters	69	9,8	0	0,0
Infections and infestations	COVID-19 pneumonia	>=24 letters	632	90,2	1	0,2
Infections and infestations	Cellulitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Cellulitis	>=24 letters	632	90,2	2	0,3
Infections and infestations	Clostridium difficile infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Clostridium difficile infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Device related infection	<=23 letters	69	9,8	1	1,4
Infections and infestations	Device related infection	>=24 letters	632	90,2	0	0,0
Infections and infestations	Endophthalmitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Endophthalmitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Escherichia urinary tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Escherichia urinary tract infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Influenza	<=23 letters	69	9,8	0	0,0
Infections and infestations	Influenza	>=24 letters	632	90,2	2	0,3
Infections and infestations	Kidney infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Kidney infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Lower respiratory tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Lower respiratory tract infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Necrotising fasciitis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Necrotising fasciitis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Pneumonia	<=23 letters	69	9,8	2	2,9
Infections and infestations	Pneumonia	>=24 letters	632	90,2	3	0,5
Infections and infestations	Pneumonia viral	<=23 letters	69	9,8	0	0,0
Infections and infestations	Pneumonia viral	>=24 letters	632	90,2	2	0,3
Infections and infestations	Respiratory syncytial virus infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Respiratory syncytial virus infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Sepsis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Sepsis	>=24 letters	632	90,2	2	0,3
Infections and infestations	Tooth infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Tooth infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Urinary tract candidiasis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Urinary tract candidiasis	>=24 letters	632	90,2	1	0,2
Infections and infestations	Urinary tract infection	<=23 letters	69	9,8	0	0,0
Infections and infestations	Urinary tract infection	>=24 letters	632	90,2	1	0,2
Infections and infestations	Urosepsis	<=23 letters	69	9,8	0	0,0
Infections and infestations	Urosepsis	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications		<=23 letters	69	9,8	1	1,4
Injury, poisoning and procedural complications		>=24 letters	632	90,2	8	1,3
Injury, poisoning and procedural complications	Fall	<=23 letters	69	9,8	1	1,4
Injury, poisoning and procedural complications	Fall	>=24 letters	632	90,2	0	0,0
Injury, poisoning and procedural complications	Femur fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Femur fracture	>=24 letters	632	90,2	2	0,3
Injury, poisoning and procedural complications	Fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Hip fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Hip fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Lower limb fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Rib fracture	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Rib fracture	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Road traffic accident	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Shunt stenosis	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	>=24 letters	632	90,2	1	0,2
Injury, poisoning and procedural complications	Thermal burn	<=23 letters	69	9,8	0	0,0
Injury, poisoning and procedural complications	Thermal burn	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders		<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders		>=24 letters	632	90,2	2	0,3
Metabolism and nutrition disorders	Dehydration	<=23 letters	69	9,8	0	0,0

Metabolism and nutrition disorders	Dehydration	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hypervolaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	>=24 letters	632	90,2	1	0,2
Metabolism and nutrition disorders	Hypokalaemia	<=23 letters	69	9,8	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders		<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders		>=24 letters	632	90,2	3	0,5
Musculoskeletal and connective tissue disorders	Back pain	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Joint effusion	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Mobility decreased	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	>=24 letters	632	90,2	1	0,2
Musculoskeletal and connective tissue disorders	Polymyositis	<=23 letters	69	9,8	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		>=24 letters	632	90,2	6	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	>=24 letters	632	90,2	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	<=23 letters	69	9,8	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	>=24 letters	632	90,2	1	0,2
Nervous system disorders		<=23 letters	69	9,8	1	1,4
Nervous system disorders		>=24 letters	632	90,2	6	0,9
Nervous system disorders	Cerebrovascular accident	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cerebrovascular accident	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Hypoaesthesia	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Hypoaesthesia	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Ischaemic stroke	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Ischaemic stroke	>=24 letters	632	90,2	2	0,3
Nervous system disorders	Presyncope	<=23 letters	69	9,8	1	1,4
Nervous system disorders	Presyncope	>=24 letters	632	90,2	0	0,0
Nervous system disorders	Syncope	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Syncope	>=24 letters	632	90,2	2	0,3
Renal and urinary disorders		<=23 letters	69	9,8	0	0,0
Renal and urinary disorders		>=24 letters	632	90,2	6	0,9
Renal and urinary disorders	Cystitis interstitial	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Cystitis interstitial	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Diabetic nephropathy	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Diabetic nephropathy	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	End stage renal disease	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	End stage renal disease	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Nephrolithiasis	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Nephrolithiasis	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Nephropathy	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Nephropathy	>=24 letters	632	90,2	1	0,2
Renal and urinary disorders	Renal failure	<=23 letters	69	9,8	0	0,0
Renal and urinary disorders	Renal failure	>=24 letters	632	90,2	1	0,2
Reproductive system and breast disorders		<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders		>=24 letters	632	90,2	1	0,2
Reproductive system and breast disorders	Cystocele	<=23 letters	69	9,8	0	0,0
Reproductive system and breast disorders	Cystocele	>=24 letters	632	90,2	1	0,2

Respiratory, thoracic and mediastinal disorders		<=23 letters	69	9,8	1	1,4
Respiratory, thoracic and mediastinal disorders		>=24 letters	632	90,2	6	0,9
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	<=23 letters	69	9,8	1	1,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	>=24 letters	632	90,2	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	>=24 letters	632	90,2	2	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	<=23 letters	69	9,8	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	>=24 letters	632	90,2	2	0,3
Skin and subcutaneous tissue disorders		<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders		>=24 letters	632	90,2	1	0,2
Skin and subcutaneous tissue disorders	Diabetic foot	<=23 letters	69	9,8	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures		<=23 letters	69	9,8	0	0,0
Surgical and medical procedures		>=24 letters	632	90,2	2	0,3
Surgical and medical procedures	Ligament operation	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Ligament operation	>=24 letters	632	90,2	1	0,2
Surgical and medical procedures	Renal transplant	<=23 letters	69	9,8	0	0,0
Surgical and medical procedures	Renal transplant	>=24 letters	632	90,2	1	0,2
Vascular disorders		<=23 letters	69	9,8	0	0,0
Vascular disorders		>=24 letters	632	90,2	8	1,3
Vascular disorders	Aortic aneurysm	<=23 letters	69	9,8	0	0,0
Vascular disorders	Aortic aneurysm	>=24 letters	632	90,2	1	0,2
Vascular disorders	Aortic dissection	<=23 letters	69	9,8	0	0,0
Vascular disorders	Aortic dissection	>=24 letters	632	90,2	1	0,2
Vascular disorders	Aortic stenosis	<=23 letters	69	9,8	0	0,0
Vascular disorders	Aortic stenosis	>=24 letters	632	90,2	1	0,2
Vascular disorders	Haemorrhage	<=23 letters	69	9,8	0	0,0
Vascular disorders	Haemorrhage	>=24 letters	632	90,2	1	0,2
Vascular disorders	Hypertension	<=23 letters	69	9,8	0	0,0
Vascular disorders	Hypertension	>=24 letters	632	90,2	2	0,3
Vascular disorders	Peripheral artery aneurysm	<=23 letters	69	9,8	0	0,0
Vascular disorders	Peripheral artery aneurysm	>=24 letters	632	90,2	1	0,2
Vascular disorders	Secondary hypertension	<=23 letters	69	9,8	0	0,0
Vascular disorders	Secondary hypertension	>=24 letters	632	90,2	1	0,2

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_Sa24_29AUG2023_41986.xls

26APR2024 18:20

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Geographic Region

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		Europe	214	30,5	0	0,0
Blood and lymphatic system disorders		America	282	40,2	1	0,4
Blood and lymphatic system disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Blood and lymphatic system disorders	Anaemia	Europe	214	30,5	0	0,0
Blood and lymphatic system disorders	Anaemia	America	282	40,2	1	0,4
Blood and lymphatic system disorders	Anaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Europe	214	30,5	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	America	282	40,2	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Europe	214	30,5	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	America	282	40,2	1	0,4
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders		Europe	214	30,5	7	3,3
Cardiac disorders		America	282	40,2	4	1,4
Cardiac disorders		Asia Pacific (inc. Australia)	205	29,2	4	2,0
Cardiac disorders	Acute myocardial infarction	Europe	214	30,5	1	0,5
Cardiac disorders	Acute myocardial infarction	America	282	40,2	0	0,0
Cardiac disorders	Acute myocardial infarction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Aortic valve incompetence	Europe	214	30,5	0	0,0
Cardiac disorders	Aortic valve incompetence	America	282	40,2	1	0,4
Cardiac disorders	Aortic valve incompetence	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Arrhythmia	Europe	214	30,5	1	0,5
Cardiac disorders	Arrhythmia	America	282	40,2	0	0,0
Cardiac disorders	Arrhythmia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Atrial fibrillation	Europe	214	30,5	2	0,9
Cardiac disorders	Atrial fibrillation	America	282	40,2	1	0,4
Cardiac disorders	Atrial fibrillation	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Cardiac failure	Europe	214	30,5	1	0,5
Cardiac disorders	Cardiac failure	America	282	40,2	0	0,0
Cardiac disorders	Cardiac failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Cardiac failure congestive	Europe	214	30,5	0	0,0
Cardiac disorders	Cardiac failure congestive	America	282	40,2	2	0,7
Cardiac disorders	Cardiac failure congestive	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Coronary artery disease	Europe	214	30,5	1	0,5
Cardiac disorders	Coronary artery disease	America	282	40,2	0	0,0
Cardiac disorders	Coronary artery disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Coronary artery stenosis	Europe	214	30,5	1	0,5
Cardiac disorders	Coronary artery stenosis	America	282	40,2	0	0,0
Cardiac disorders	Coronary artery stenosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Myocardial infarction	Europe	214	30,5	1	0,5
Cardiac disorders	Myocardial infarction	America	282	40,2	1	0,4
Cardiac disorders	Myocardial infarction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Cardiac disorders	Stress cardiomyopathy	Europe	214	30,5	0	0,0
Cardiac disorders	Stress cardiomyopathy	America	282	40,2	0	0,0
Cardiac disorders	Stress cardiomyopathy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders		Europe	214	30,5	9	4,2
Eye disorders		America	282	40,2	15	5,3
Eye disorders		Asia Pacific (inc. Australia)	205	29,2	15	7,3
Eye disorders	Cataract	Europe	214	30,5	0	0,0

Eye disorders	Cataract	America	282	40,2	1	0,4
Eye disorders	Cataract	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Cystoid macular oedema	Europe	214	30,5	0	0,0
Eye disorders	Cystoid macular oedema	America	282	40,2	2	0,7
Eye disorders	Cystoid macular oedema	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Eye disorders	Epiretinal membrane	Europe	214	30,5	0	0,0
Eye disorders	Epiretinal membrane	America	282	40,2	0	0,0
Eye disorders	Epiretinal membrane	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Glaucoma	Europe	214	30,5	1	0,5
Eye disorders	Glaucoma	America	282	40,2	0	0,0
Eye disorders	Glaucoma	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Iridocyclitis	Europe	214	30,5	0	0,0
Eye disorders	Iridocyclitis	America	282	40,2	1	0,4
Eye disorders	Iridocyclitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Iris neovascularisation	Europe	214	30,5	1	0,5
Eye disorders	Iris neovascularisation	America	282	40,2	0	0,0
Eye disorders	Iris neovascularisation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular hole	Europe	214	30,5	1	0,5
Eye disorders	Macular hole	America	282	40,2	1	0,4
Eye disorders	Macular hole	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular ischaemia	Europe	214	30,5	0	0,0
Eye disorders	Macular ischaemia	America	282	40,2	1	0,4
Eye disorders	Macular ischaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Macular oedema	Europe	214	30,5	1	0,5
Eye disorders	Macular oedema	America	282	40,2	1	0,4
Eye disorders	Macular oedema	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Posterior capsule opacification	Europe	214	30,5	0	0,0
Eye disorders	Posterior capsule opacification	America	282	40,2	1	0,4
Eye disorders	Posterior capsule opacification	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal artery embolism	Europe	214	30,5	0	0,0
Eye disorders	Retinal artery embolism	America	282	40,2	1	0,4
Eye disorders	Retinal artery embolism	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal artery occlusion	Europe	214	30,5	0	0,0
Eye disorders	Retinal artery occlusion	America	282	40,2	1	0,4
Eye disorders	Retinal artery occlusion	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Retinal detachment	Europe	214	30,5	0	0,0
Eye disorders	Retinal detachment	America	282	40,2	0	0,0
Eye disorders	Retinal detachment	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Retinal ischaemia	Europe	214	30,5	2	0,9
Eye disorders	Retinal ischaemia	America	282	40,2	0	0,0
Eye disorders	Retinal ischaemia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal neovascularisation	Europe	214	30,5	0	0,0
Eye disorders	Retinal neovascularisation	America	282	40,2	0	0,0
Eye disorders	Retinal neovascularisation	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Retinal tear	Europe	214	30,5	0	0,0
Eye disorders	Retinal tear	America	282	40,2	1	0,4
Eye disorders	Retinal tear	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal vein occlusion	Europe	214	30,5	1	0,5
Eye disorders	Retinal vein occlusion	America	282	40,2	4	1,4
Eye disorders	Retinal vein occlusion	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Eye disorders	Uveitis	Europe	214	30,5	1	0,5
Eye disorders	Uveitis	America	282	40,2	0	0,0
Eye disorders	Uveitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Visual acuity reduced	Europe	214	30,5	1	0,5
Eye disorders	Visual acuity reduced	America	282	40,2	0	0,0
Eye disorders	Visual acuity reduced	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Vitreous haemorrhage	Europe	214	30,5	0	0,0
Eye disorders	Vitreous haemorrhage	America	282	40,2	1	0,4
Eye disorders	Vitreous haemorrhage	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Vitritis	Europe	214	30,5	0	0,0
Eye disorders	Vitritis	America	282	40,2	0	0,0
Eye disorders	Vitritis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders		Europe	214	30,5	1	0,5

Gastrointestinal disorders		America	282	40,2	2	0,7
Gastrointestinal disorders		Asia Pacific (inc. Australia)	205	29,2	4	2,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	America	282	40,2	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	America	282	40,2	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Gastric ulcer	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Gastric ulcer	America	282	40,2	0	0,0
Gastrointestinal disorders	Gastric ulcer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Gastrointestinal inflammation	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Gastrointestinal inflammation	America	282	40,2	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Large intestine polyp	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Large intestine polyp	America	282	40,2	0	0,0
Gastrointestinal disorders	Large intestine polyp	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders	Pancreatitis	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Pancreatitis	America	282	40,2	1	0,4
Gastrointestinal disorders	Pancreatitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Europe	214	30,5	0	0,0
Gastrointestinal disorders	Pancreatitis acute	America	282	40,2	1	0,4
Gastrointestinal disorders	Pancreatitis acute	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions		Europe	214	30,5	3	1,4
General disorders and administration site conditions		America	282	40,2	2	0,7
General disorders and administration site conditions		Asia Pacific (inc. Australia)	205	29,2	3	1,5
General disorders and administration site conditions	Asthenia	Europe	214	30,5	2	0,9
General disorders and administration site conditions	Asthenia	America	282	40,2	1	0,4
General disorders and administration site conditions	Asthenia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Chest pain	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Chest pain	America	282	40,2	0	0,0
General disorders and administration site conditions	Chest pain	Asia Pacific (inc. Australia)	205	29,2	2	1,0
General disorders and administration site conditions	Death	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Death	America	282	40,2	1	0,4
General disorders and administration site conditions	Death	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Europe	214	30,5	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	America	282	40,2	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Hepatobiliary disorders		Europe	214	30,5	0	0,0
Hepatobiliary disorders		America	282	40,2	1	0,4
Hepatobiliary disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Hepatobiliary disorders	Cholecystitis	Europe	214	30,5	0	0,0
Hepatobiliary disorders	Cholecystitis	America	282	40,2	0	0,0
Hepatobiliary disorders	Cholecystitis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Hepatobiliary disorders	Cholelithiasis	Europe	214	30,5	0	0,0
Hepatobiliary disorders	Cholelithiasis	America	282	40,2	1	0,4
Hepatobiliary disorders	Cholelithiasis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations		Europe	214	30,5	7	3,3
Infections and infestations		America	282	40,2	10	3,5
Infections and infestations		Asia Pacific (inc. Australia)	205	29,2	5	2,4
Infections and infestations	Bronchitis	Europe	214	30,5	0	0,0
Infections and infestations	Bronchitis	America	282	40,2	1	0,4
Infections and infestations	Bronchitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	COVID-19	Europe	214	30,5	0	0,0
Infections and infestations	COVID-19	America	282	40,2	1	0,4
Infections and infestations	COVID-19	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	COVID-19 pneumonia	Europe	214	30,5	1	0,5
Infections and infestations	COVID-19 pneumonia	America	282	40,2	0	0,0
Infections and infestations	COVID-19 pneumonia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Cellulitis	Europe	214	30,5	1	0,5
Infections and infestations	Cellulitis	America	282	40,2	1	0,4

Infections and infestations	Cellulitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Clostridium difficile infection	Europe	214	30,5	0	0,0
Infections and infestations	Clostridium difficile infection	America	282	40,2	1	0,4
Infections and infestations	Clostridium difficile infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Device related infection	Europe	214	30,5	1	0,5
Infections and infestations	Device related infection	America	282	40,2	0	0,0
Infections and infestations	Device related infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Endophthalmitis	Europe	214	30,5	1	0,5
Infections and infestations	Endophthalmitis	America	282	40,2	0	0,0
Infections and infestations	Endophthalmitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Escherichia urinary tract infection	Europe	214	30,5	0	0,0
Infections and infestations	Escherichia urinary tract infection	America	282	40,2	0	0,0
Infections and infestations	Escherichia urinary tract infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Influenza	Europe	214	30,5	0	0,0
Infections and infestations	Influenza	America	282	40,2	2	0,7
Infections and infestations	Influenza	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Kidney infection	Europe	214	30,5	0	0,0
Infections and infestations	Kidney infection	America	282	40,2	1	0,4
Infections and infestations	Kidney infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Lower respiratory tract infection	Europe	214	30,5	1	0,5
Infections and infestations	Lower respiratory tract infection	America	282	40,2	0	0,0
Infections and infestations	Lower respiratory tract infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Necrotising fasciitis	Europe	214	30,5	0	0,0
Infections and infestations	Necrotising fasciitis	America	282	40,2	1	0,4
Infections and infestations	Necrotising fasciitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Pneumonia	Europe	214	30,5	2	0,9
Infections and infestations	Pneumonia	America	282	40,2	2	0,7
Infections and infestations	Pneumonia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Pneumonia viral	Europe	214	30,5	0	0,0
Infections and infestations	Pneumonia viral	America	282	40,2	0	0,0
Infections and infestations	Pneumonia viral	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Infections and infestations	Respiratory syncytial virus infection	Europe	214	30,5	0	0,0
Infections and infestations	Respiratory syncytial virus infection	America	282	40,2	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Sepsis	Europe	214	30,5	1	0,5
Infections and infestations	Sepsis	America	282	40,2	1	0,4
Infections and infestations	Sepsis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Tooth infection	Europe	214	30,5	0	0,0
Infections and infestations	Tooth infection	America	282	40,2	1	0,4
Infections and infestations	Tooth infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Urinary tract candidiasis	Europe	214	30,5	0	0,0
Infections and infestations	Urinary tract candidiasis	America	282	40,2	0	0,0
Infections and infestations	Urinary tract candidiasis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Infections and infestations	Urinary tract infection	Europe	214	30,5	0	0,0
Infections and infestations	Urinary tract infection	America	282	40,2	1	0,4
Infections and infestations	Urinary tract infection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Urosepsis	Europe	214	30,5	0	0,0
Infections and infestations	Urosepsis	America	282	40,2	1	0,4
Infections and infestations	Urosepsis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications		Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications		America	282	40,2	5	1,8
Injury, poisoning and procedural complications		Asia Pacific (inc. Australia)	205	29,2	4	2,0
Injury, poisoning and procedural complications	Fall	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Fall	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Fall	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Femur fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Femur fracture	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Hip fracture	America	282	40,2	1	0,4

Injury, poisoning and procedural complications	Hip fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Lower limb fracture	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Rib fracture	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Road traffic accident	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	America	282	40,2	1	0,4
Injury, poisoning and procedural complications	Road traffic accident	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Injury, poisoning and procedural complications	Thermal burn	Europe	214	30,5	0	0,0
Injury, poisoning and procedural complications	Thermal burn	America	282	40,2	0	0,0
Injury, poisoning and procedural complications	Thermal burn	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders		Europe	214	30,5	1	0,5
Metabolism and nutrition disorders		America	282	40,2	0	0,0
Metabolism and nutrition disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Dehydration	Europe	214	30,5	1	0,5
Metabolism and nutrition disorders	Dehydration	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Dehydration	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Metabolism and nutrition disorders	Hypokalaemia	Europe	214	30,5	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	America	282	40,2	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders		Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders		America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Back pain	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	America	282	40,2	1	0,4
Musculoskeletal and connective tissue disorders	Back pain	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Europe	214	30,5	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Musculoskeletal and connective tissue disorders	Mobility decreased	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Mobility decreased	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Europe	214	30,5	1	0,5
Musculoskeletal and connective tissue disorders	Polymyositis	America	282	40,2	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Europe	214	30,5	2	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asia Pacific (inc. Australia)	205	29,2	4	2,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Europe	214	30,5	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Europe	214	30,5	1	0,5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Europe	214	30,5	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	America	282	40,2	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders		Europe	214	30,5	2	0,9
Nervous system disorders		America	282	40,2	2	0,7
Nervous system disorders		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Nervous system disorders	Cerebrovascular accident	Europe	214	30,5	0	0,0
Nervous system disorders	Cerebrovascular accident	America	282	40,2	1	0,4
Nervous system disorders	Cerebrovascular accident	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Hypoaesthesia	Europe	214	30,5	0	0,0
Nervous system disorders	Hypoaesthesia	America	282	40,2	0	0,0
Nervous system disorders	Hypoaesthesia	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Ischaemic stroke	Europe	214	30,5	1	0,5
Nervous system disorders	Ischaemic stroke	America	282	40,2	0	0,0
Nervous system disorders	Ischaemic stroke	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Presyncope	Europe	214	30,5	1	0,5
Nervous system disorders	Presyncope	America	282	40,2	0	0,0
Nervous system disorders	Presyncope	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders	Syncope	Europe	214	30,5	0	0,0
Nervous system disorders	Syncope	America	282	40,2	1	0,4
Nervous system disorders	Syncope	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders		Europe	214	30,5	1	0,5
Renal and urinary disorders		America	282	40,2	3	1,1
Renal and urinary disorders		Asia Pacific (inc. Australia)	205	29,2	2	1,0
Renal and urinary disorders	Cystitis interstitial	Europe	214	30,5	0	0,0
Renal and urinary disorders	Cystitis interstitial	America	282	40,2	0	0,0
Renal and urinary disorders	Cystitis interstitial	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	Diabetic nephropathy	Europe	214	30,5	0	0,0
Renal and urinary disorders	Diabetic nephropathy	America	282	40,2	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Renal and urinary disorders	End stage renal disease	Europe	214	30,5	0	0,0
Renal and urinary disorders	End stage renal disease	America	282	40,2	1	0,4
Renal and urinary disorders	End stage renal disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Nephrolithiasis	Europe	214	30,5	0	0,0
Renal and urinary disorders	Nephrolithiasis	America	282	40,2	1	0,4
Renal and urinary disorders	Nephrolithiasis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Nephropathy	Europe	214	30,5	0	0,0
Renal and urinary disorders	Nephropathy	America	282	40,2	1	0,4
Renal and urinary disorders	Nephropathy	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Renal and urinary disorders	Renal failure	Europe	214	30,5	1	0,5
Renal and urinary disorders	Renal failure	America	282	40,2	0	0,0
Renal and urinary disorders	Renal failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Reproductive system and breast disorders		Europe	214	30,5	0	0,0
Reproductive system and breast disorders		America	282	40,2	1	0,4
Reproductive system and breast disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Reproductive system and breast disorders	Cystocele	Europe	214	30,5	0	0,0
Reproductive system and breast disorders	Cystocele	America	282	40,2	1	0,4
Reproductive system and breast disorders	Cystocele	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders		Europe	214	30,5	2	0,9
Respiratory, thoracic and mediastinal disorders		America	282	40,2	4	1,4
Respiratory, thoracic and mediastinal disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	America	282	40,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Asia Pacific (inc. Australia)	205	29,2	1	0,5

Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Europe	214	30,5	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	America	282	40,2	2	0,7
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Europe	214	30,5	1	0,5
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	America	282	40,2	1	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders		Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders		America	282	40,2	1	0,4
Skin and subcutaneous tissue disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	Europe	214	30,5	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	America	282	40,2	1	0,4
Skin and subcutaneous tissue disorders	Diabetic foot	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures		Europe	214	30,5	0	0,0
Surgical and medical procedures		America	282	40,2	2	0,7
Surgical and medical procedures		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Ligament operation	Europe	214	30,5	0	0,0
Surgical and medical procedures	Ligament operation	America	282	40,2	1	0,4
Surgical and medical procedures	Ligament operation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Surgical and medical procedures	Renal transplant	Europe	214	30,5	0	0,0
Surgical and medical procedures	Renal transplant	America	282	40,2	1	0,4
Surgical and medical procedures	Renal transplant	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders		Europe	214	30,5	3	1,4
Vascular disorders		America	282	40,2	2	0,7
Vascular disorders		Asia Pacific (inc. Australia)	205	29,2	3	1,5
Vascular disorders	Aortic aneurysm	Europe	214	30,5	0	0,0
Vascular disorders	Aortic aneurysm	America	282	40,2	1	0,4
Vascular disorders	Aortic aneurysm	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Aortic dissection	Europe	214	30,5	0	0,0
Vascular disorders	Aortic dissection	America	282	40,2	1	0,4
Vascular disorders	Aortic dissection	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Aortic stenosis	Europe	214	30,5	1	0,5
Vascular disorders	Aortic stenosis	America	282	40,2	0	0,0
Vascular disorders	Aortic stenosis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Haemorrhage	Europe	214	30,5	0	0,0
Vascular disorders	Haemorrhage	America	282	40,2	0	0,0
Vascular disorders	Haemorrhage	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Vascular disorders	Hypertension	Europe	214	30,5	1	0,5
Vascular disorders	Hypertension	America	282	40,2	0	0,0
Vascular disorders	Hypertension	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Vascular disorders	Peripheral artery aneurysm	Europe	214	30,5	0	0,0
Vascular disorders	Peripheral artery aneurysm	America	282	40,2	0	0,0
Vascular disorders	Peripheral artery aneurysm	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Vascular disorders	Secondary hypertension	Europe	214	30,5	1	0,5
Vascular disorders	Secondary hypertension	America	282	40,2	0	0,0
Vascular disorders	Secondary hypertension	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:20

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		White	474	67,6	1	0,2
Blood and lymphatic system disorders		Asian	176	25,1	1	0,6
Blood and lymphatic system disorders		Other	27	3,9	0	0,0
Blood and lymphatic system disorders		Unknown	24	3,4	0	0,0
Blood and lymphatic system disorders	Anaemia	White	474	67,6	1	0,2
Blood and lymphatic system disorders	Anaemia	Asian	176	25,1	0	0,0
Blood and lymphatic system disorders	Anaemia	Other	27	3,9	0	0,0
Blood and lymphatic system disorders	Anaemia	Unknown	24	3,4	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	White	474	67,6	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Asian	176	25,1	1	0,6
Blood and lymphatic system disorders	Deficiency anaemia	Other	27	3,9	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Unknown	24	3,4	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	White	474	67,6	1	0,2
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Asian	176	25,1	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Other	27	3,9	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Unknown	24	3,4	0	0,0
Cardiac disorders		White	474	67,6	13	2,7
Cardiac disorders		Asian	176	25,1	2	1,1
Cardiac disorders		Other	27	3,9	0	0,0
Cardiac disorders		Unknown	24	3,4	0	0,0
Cardiac disorders	Acute myocardial infarction	White	474	67,6	2	0,4
Cardiac disorders	Acute myocardial infarction	Asian	176	25,1	0	0,0
Cardiac disorders	Acute myocardial infarction	Other	27	3,9	0	0,0
Cardiac disorders	Acute myocardial infarction	Unknown	24	3,4	0	0,0
Cardiac disorders	Aortic valve incompetence	White	474	67,6	1	0,2
Cardiac disorders	Aortic valve incompetence	Asian	176	25,1	0	0,0
Cardiac disorders	Aortic valve incompetence	Other	27	3,9	0	0,0
Cardiac disorders	Aortic valve incompetence	Unknown	24	3,4	0	0,0
Cardiac disorders	Arrhythmia	White	474	67,6	1	0,2
Cardiac disorders	Arrhythmia	Asian	176	25,1	0	0,0
Cardiac disorders	Arrhythmia	Other	27	3,9	0	0,0
Cardiac disorders	Arrhythmia	Unknown	24	3,4	0	0,0
Cardiac disorders	Atrial fibrillation	White	474	67,6	3	0,6
Cardiac disorders	Atrial fibrillation	Asian	176	25,1	1	0,6
Cardiac disorders	Atrial fibrillation	Other	27	3,9	0	0,0
Cardiac disorders	Atrial fibrillation	Unknown	24	3,4	0	0,0
Cardiac disorders	Cardiac failure	White	474	67,6	1	0,2
Cardiac disorders	Cardiac failure	Asian	176	25,1	0	0,0
Cardiac disorders	Cardiac failure	Other	27	3,9	0	0,0
Cardiac disorders	Cardiac failure	Unknown	24	3,4	0	0,0
Cardiac disorders	Cardiac failure congestive	White	474	67,6	2	0,4
Cardiac disorders	Cardiac failure congestive	Asian	176	25,1	0	0,0
Cardiac disorders	Cardiac failure congestive	Other	27	3,9	0	0,0
Cardiac disorders	Cardiac failure congestive	Unknown	24	3,4	0	0,0
Cardiac disorders	Coronary artery disease	White	474	67,6	1	0,2
Cardiac disorders	Coronary artery disease	Asian	176	25,1	0	0,0
Cardiac disorders	Coronary artery disease	Other	27	3,9	0	0,0
Cardiac disorders	Coronary artery disease	Unknown	24	3,4	0	0,0
Cardiac disorders	Coronary artery stenosis	White	474	67,6	1	0,2
Cardiac disorders	Coronary artery stenosis	Asian	176	25,1	0	0,0

Cardiac disorders	Coronary artery stenosis	Other	27	3,9	0	0,0
Cardiac disorders	Coronary artery stenosis	Unknown	24	3,4	0	0,0
Cardiac disorders	Myocardial infarction	White	474	67,6	2	0,4
Cardiac disorders	Myocardial infarction	Asian	176	25,1	1	0,6
Cardiac disorders	Myocardial infarction	Other	27	3,9	0	0,0
Cardiac disorders	Myocardial infarction	Unknown	24	3,4	0	0,0
Cardiac disorders	Stress cardiomyopathy	White	474	67,6	1	0,2
Cardiac disorders	Stress cardiomyopathy	Asian	176	25,1	0	0,0
Cardiac disorders	Stress cardiomyopathy	Other	27	3,9	0	0,0
Cardiac disorders	Stress cardiomyopathy	Unknown	24	3,4	0	0,0
Eye disorders		White	474	67,6	29	6,1
Eye disorders		Asian	176	25,1	7	4,0
Eye disorders		Other	27	3,9	1	3,7
Eye disorders		Unknown	24	3,4	2	8,3
Eye disorders	Cataract	White	474	67,6	1	0,2
Eye disorders	Cataract	Asian	176	25,1	0	0,0
Eye disorders	Cataract	Other	27	3,9	0	0,0
Eye disorders	Cataract	Unknown	24	3,4	0	0,0
Eye disorders	Cystoid macular oedema	White	474	67,6	4	0,8
Eye disorders	Cystoid macular oedema	Asian	176	25,1	2	1,1
Eye disorders	Cystoid macular oedema	Other	27	3,9	0	0,0
Eye disorders	Cystoid macular oedema	Unknown	24	3,4	0	0,0
Eye disorders	Epiretinal membrane	White	474	67,6	1	0,2
Eye disorders	Epiretinal membrane	Asian	176	25,1	0	0,0
Eye disorders	Epiretinal membrane	Other	27	3,9	0	0,0
Eye disorders	Epiretinal membrane	Unknown	24	3,4	0	0,0
Eye disorders	Glaucoma	White	474	67,6	1	0,2
Eye disorders	Glaucoma	Asian	176	25,1	0	0,0
Eye disorders	Glaucoma	Other	27	3,9	0	0,0
Eye disorders	Glaucoma	Unknown	24	3,4	0	0,0
Eye disorders	Iridocyclitis	White	474	67,6	1	0,2
Eye disorders	Iridocyclitis	Asian	176	25,1	0	0,0
Eye disorders	Iridocyclitis	Other	27	3,9	0	0,0
Eye disorders	Iridocyclitis	Unknown	24	3,4	0	0,0
Eye disorders	Iris neovascularisation	White	474	67,6	1	0,2
Eye disorders	Iris neovascularisation	Asian	176	25,1	0	0,0
Eye disorders	Iris neovascularisation	Other	27	3,9	0	0,0
Eye disorders	Iris neovascularisation	Unknown	24	3,4	0	0,0
Eye disorders	Macular hole	White	474	67,6	2	0,4
Eye disorders	Macular hole	Asian	176	25,1	0	0,0
Eye disorders	Macular hole	Other	27	3,9	0	0,0
Eye disorders	Macular hole	Unknown	24	3,4	0	0,0
Eye disorders	Macular ischaemia	White	474	67,6	1	0,2
Eye disorders	Macular ischaemia	Asian	176	25,1	0	0,0
Eye disorders	Macular ischaemia	Other	27	3,9	0	0,0
Eye disorders	Macular ischaemia	Unknown	24	3,4	0	0,0
Eye disorders	Macular oedema	White	474	67,6	2	0,4
Eye disorders	Macular oedema	Asian	176	25,1	2	1,1
Eye disorders	Macular oedema	Other	27	3,9	0	0,0
Eye disorders	Macular oedema	Unknown	24	3,4	0	0,0
Eye disorders	Posterior capsule opacification	White	474	67,6	1	0,2
Eye disorders	Posterior capsule opacification	Asian	176	25,1	0	0,0
Eye disorders	Posterior capsule opacification	Other	27	3,9	0	0,0
Eye disorders	Posterior capsule opacification	Unknown	24	3,4	0	0,0
Eye disorders	Retinal artery embolism	White	474	67,6	1	0,2
Eye disorders	Retinal artery embolism	Asian	176	25,1	0	0,0
Eye disorders	Retinal artery embolism	Other	27	3,9	0	0,0
Eye disorders	Retinal artery embolism	Unknown	24	3,4	0	0,0
Eye disorders	Retinal artery occlusion	White	474	67,6	1	0,2
Eye disorders	Retinal artery occlusion	Asian	176	25,1	0	0,0
Eye disorders	Retinal artery occlusion	Other	27	3,9	1	3,7
Eye disorders	Retinal artery occlusion	Unknown	24	3,4	0	0,0
Eye disorders	Retinal detachment	White	474	67,6	1	0,2

Eye disorders	Retinal detachment	Asian	176	25,1	0	0,0
Eye disorders	Retinal detachment	Other	27	3,9	0	0,0
Eye disorders	Retinal detachment	Unknown	24	3,4	0	0,0
Eye disorders	Retinal ischaemia	White	474	67,6	0	0,0
Eye disorders	Retinal ischaemia	Asian	176	25,1	0	0,0
Eye disorders	Retinal ischaemia	Other	27	3,9	0	0,0
Eye disorders	Retinal ischaemia	Unknown	24	3,4	2	8,3
Eye disorders	Retinal neovascularisation	White	474	67,6	0	0,0
Eye disorders	Retinal neovascularisation	Asian	176	25,1	2	1,1
Eye disorders	Retinal neovascularisation	Other	27	3,9	0	0,0
Eye disorders	Retinal neovascularisation	Unknown	24	3,4	0	0,0
Eye disorders	Retinal tear	White	474	67,6	1	0,2
Eye disorders	Retinal tear	Asian	176	25,1	0	0,0
Eye disorders	Retinal tear	Other	27	3,9	0	0,0
Eye disorders	Retinal tear	Unknown	24	3,4	0	0,0
Eye disorders	Retinal vein occlusion	White	474	67,6	7	1,5
Eye disorders	Retinal vein occlusion	Asian	176	25,1	1	0,6
Eye disorders	Retinal vein occlusion	Other	27	3,9	0	0,0
Eye disorders	Retinal vein occlusion	Unknown	24	3,4	0	0,0
Eye disorders	Uveitis	White	474	67,6	1	0,2
Eye disorders	Uveitis	Asian	176	25,1	0	0,0
Eye disorders	Uveitis	Other	27	3,9	0	0,0
Eye disorders	Uveitis	Unknown	24	3,4	0	0,0
Eye disorders	Visual acuity reduced	White	474	67,6	1	0,2
Eye disorders	Visual acuity reduced	Asian	176	25,1	0	0,0
Eye disorders	Visual acuity reduced	Other	27	3,9	0	0,0
Eye disorders	Visual acuity reduced	Unknown	24	3,4	0	0,0
Eye disorders	Vitreous haemorrhage	White	474	67,6	1	0,2
Eye disorders	Vitreous haemorrhage	Asian	176	25,1	0	0,0
Eye disorders	Vitreous haemorrhage	Other	27	3,9	0	0,0
Eye disorders	Vitreous haemorrhage	Unknown	24	3,4	0	0,0
Eye disorders	Vitritis	White	474	67,6	1	0,2
Eye disorders	Vitritis	Asian	176	25,1	0	0,0
Eye disorders	Vitritis	Other	27	3,9	0	0,0
Eye disorders	Vitritis	Unknown	24	3,4	0	0,0
Gastrointestinal disorders		White	474	67,6	3	0,6
Gastrointestinal disorders		Asian	176	25,1	4	2,3
Gastrointestinal disorders		Other	27	3,9	0	0,0
Gastrointestinal disorders		Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	White	474	67,6	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Asian	176	25,1	1	0,6
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Other	27	3,9	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	White	474	67,6	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Asian	176	25,1	1	0,6
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Other	27	3,9	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Gastric ulcer	White	474	67,6	0	0,0
Gastrointestinal disorders	Gastric ulcer	Asian	176	25,1	1	0,6
Gastrointestinal disorders	Gastric ulcer	Other	27	3,9	0	0,0
Gastrointestinal disorders	Gastric ulcer	Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	White	474	67,6	1	0,2
Gastrointestinal disorders	Gastrointestinal inflammation	Asian	176	25,1	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Other	27	3,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Large intestine polyp	White	474	67,6	0	0,0
Gastrointestinal disorders	Large intestine polyp	Asian	176	25,1	1	0,6
Gastrointestinal disorders	Large intestine polyp	Other	27	3,9	0	0,0
Gastrointestinal disorders	Large intestine polyp	Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Pancreatitis	White	474	67,6	1	0,2
Gastrointestinal disorders	Pancreatitis	Asian	176	25,1	0	0,0
Gastrointestinal disorders	Pancreatitis	Other	27	3,9	0	0,0
Gastrointestinal disorders	Pancreatitis	Unknown	24	3,4	0	0,0

Gastrointestinal disorders	Pancreatitis acute	White	474	67,6	1	0,2
Gastrointestinal disorders	Pancreatitis acute	Asian	176	25,1	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Other	27	3,9	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Unknown	24	3,4	0	0,0
General disorders and administration site conditions		White	474	67,6	7	1,5
General disorders and administration site conditions		Asian	176	25,1	0	0,0
General disorders and administration site conditions		Other	27	3,9	1	3,7
General disorders and administration site conditions		Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Asthenia	White	474	67,6	3	0,6
General disorders and administration site conditions	Asthenia	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Asthenia	Other	27	3,9	0	0,0
General disorders and administration site conditions	Asthenia	Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Chest pain	White	474	67,6	2	0,4
General disorders and administration site conditions	Chest pain	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Chest pain	Other	27	3,9	0	0,0
General disorders and administration site conditions	Chest pain	Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Death	White	474	67,6	2	0,4
General disorders and administration site conditions	Death	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Death	Other	27	3,9	0	0,0
General disorders and administration site conditions	Death	Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	White	474	67,6	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Other	27	3,9	1	3,7
General disorders and administration site conditions	Stent-graft endoleak	Unknown	24	3,4	0	0,0
Hepatobiliary disorders		White	474	67,6	1	0,2
Hepatobiliary disorders		Asian	176	25,1	1	0,6
Hepatobiliary disorders		Other	27	3,9	0	0,0
Hepatobiliary disorders		Unknown	24	3,4	0	0,0
Hepatobiliary disorders	Cholecystitis	White	474	67,6	0	0,0
Hepatobiliary disorders	Cholecystitis	Asian	176	25,1	1	0,6
Hepatobiliary disorders	Cholecystitis	Other	27	3,9	0	0,0
Hepatobiliary disorders	Cholecystitis	Unknown	24	3,4	0	0,0
Hepatobiliary disorders	Cholelithiasis	White	474	67,6	1	0,2
Hepatobiliary disorders	Cholelithiasis	Asian	176	25,1	0	0,0
Hepatobiliary disorders	Cholelithiasis	Other	27	3,9	0	0,0
Hepatobiliary disorders	Cholelithiasis	Unknown	24	3,4	0	0,0
Infections and infestations		White	474	67,6	17	3,6
Infections and infestations		Asian	176	25,1	2	1,1
Infections and infestations		Other	27	3,9	3	11,1
Infections and infestations		Unknown	24	3,4	0	0,0
Infections and infestations	Bronchitis	White	474	67,6	1	0,2
Infections and infestations	Bronchitis	Asian	176	25,1	0	0,0
Infections and infestations	Bronchitis	Other	27	3,9	0	0,0
Infections and infestations	Bronchitis	Unknown	24	3,4	0	0,0
Infections and infestations	COVID-19	White	474	67,6	1	0,2
Infections and infestations	COVID-19	Asian	176	25,1	0	0,0
Infections and infestations	COVID-19	Other	27	3,9	0	0,0
Infections and infestations	COVID-19	Unknown	24	3,4	0	0,0
Infections and infestations	COVID-19 pneumonia	White	474	67,6	1	0,2
Infections and infestations	COVID-19 pneumonia	Asian	176	25,1	0	0,0
Infections and infestations	COVID-19 pneumonia	Other	27	3,9	0	0,0
Infections and infestations	COVID-19 pneumonia	Unknown	24	3,4	0	0,0
Infections and infestations	Cellulitis	White	474	67,6	2	0,4
Infections and infestations	Cellulitis	Asian	176	25,1	0	0,0
Infections and infestations	Cellulitis	Other	27	3,9	0	0,0
Infections and infestations	Cellulitis	Unknown	24	3,4	0	0,0
Infections and infestations	Clostridium difficile infection	White	474	67,6	1	0,2
Infections and infestations	Clostridium difficile infection	Asian	176	25,1	0	0,0
Infections and infestations	Clostridium difficile infection	Other	27	3,9	0	0,0
Infections and infestations	Clostridium difficile infection	Unknown	24	3,4	0	0,0
Infections and infestations	Device related infection	White	474	67,6	1	0,2

Infections and infestations	Device related infection	Asian	176	25,1	0	0,0
Infections and infestations	Device related infection	Other	27	3,9	0	0,0
Infections and infestations	Device related infection	Unknown	24	3,4	0	0,0
Infections and infestations	Endophthalmitis	White	474	67,6	1	0,2
Infections and infestations	Endophthalmitis	Asian	176	25,1	0	0,0
Infections and infestations	Endophthalmitis	Other	27	3,9	0	0,0
Infections and infestations	Endophthalmitis	Unknown	24	3,4	0	0,0
Infections and infestations	Escherichia urinary tract infection	White	474	67,6	1	0,2
Infections and infestations	Escherichia urinary tract infection	Asian	176	25,1	0	0,0
Infections and infestations	Escherichia urinary tract infection	Other	27	3,9	0	0,0
Infections and infestations	Escherichia urinary tract infection	Unknown	24	3,4	0	0,0
Infections and infestations	Influenza	White	474	67,6	2	0,4
Infections and infestations	Influenza	Asian	176	25,1	0	0,0
Infections and infestations	Influenza	Other	27	3,9	0	0,0
Infections and infestations	Influenza	Unknown	24	3,4	0	0,0
Infections and infestations	Kidney infection	White	474	67,6	1	0,2
Infections and infestations	Kidney infection	Asian	176	25,1	0	0,0
Infections and infestations	Kidney infection	Other	27	3,9	0	0,0
Infections and infestations	Kidney infection	Unknown	24	3,4	0	0,0
Infections and infestations	Lower respiratory tract infection	White	474	67,6	1	0,2
Infections and infestations	Lower respiratory tract infection	Asian	176	25,1	0	0,0
Infections and infestations	Lower respiratory tract infection	Other	27	3,9	0	0,0
Infections and infestations	Lower respiratory tract infection	Unknown	24	3,4	0	0,0
Infections and infestations	Necrotising fasciitis	White	474	67,6	0	0,0
Infections and infestations	Necrotising fasciitis	Asian	176	25,1	0	0,0
Infections and infestations	Necrotising fasciitis	Other	27	3,9	1	3,7
Infections and infestations	Necrotising fasciitis	Unknown	24	3,4	0	0,0
Infections and infestations	Pneumonia	White	474	67,6	4	0,8
Infections and infestations	Pneumonia	Asian	176	25,1	1	0,6
Infections and infestations	Pneumonia	Other	27	3,9	0	0,0
Infections and infestations	Pneumonia	Unknown	24	3,4	0	0,0
Infections and infestations	Pneumonia viral	White	474	67,6	2	0,4
Infections and infestations	Pneumonia viral	Asian	176	25,1	0	0,0
Infections and infestations	Pneumonia viral	Other	27	3,9	0	0,0
Infections and infestations	Pneumonia viral	Unknown	24	3,4	0	0,0
Infections and infestations	Respiratory syncytial virus infection	White	474	67,6	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Asian	176	25,1	1	0,6
Infections and infestations	Respiratory syncytial virus infection	Other	27	3,9	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Unknown	24	3,4	0	0,0
Infections and infestations	Sepsis	White	474	67,6	2	0,4
Infections and infestations	Sepsis	Asian	176	25,1	0	0,0
Infections and infestations	Sepsis	Other	27	3,9	0	0,0
Infections and infestations	Sepsis	Unknown	24	3,4	0	0,0
Infections and infestations	Tooth infection	White	474	67,6	0	0,0
Infections and infestations	Tooth infection	Asian	176	25,1	0	0,0
Infections and infestations	Tooth infection	Other	27	3,9	1	3,7
Infections and infestations	Tooth infection	Unknown	24	3,4	0	0,0
Infections and infestations	Urinary tract candidiasis	White	474	67,6	1	0,2
Infections and infestations	Urinary tract candidiasis	Asian	176	25,1	0	0,0
Infections and infestations	Urinary tract candidiasis	Other	27	3,9	0	0,0
Infections and infestations	Urinary tract candidiasis	Unknown	24	3,4	0	0,0
Infections and infestations	Urinary tract infection	White	474	67,6	0	0,0
Infections and infestations	Urinary tract infection	Asian	176	25,1	0	0,0
Infections and infestations	Urinary tract infection	Other	27	3,9	1	3,7
Infections and infestations	Urinary tract infection	Unknown	24	3,4	0	0,0
Infections and infestations	Urosepsis	White	474	67,6	1	0,2
Infections and infestations	Urosepsis	Asian	176	25,1	0	0,0
Infections and infestations	Urosepsis	Other	27	3,9	0	0,0
Infections and infestations	Urosepsis	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications		White	474	67,6	6	1,3
Injury, poisoning and procedural complications		Asian	176	25,1	3	1,7
Injury, poisoning and procedural complications		Other	27	3,9	0	0,0
Injury, poisoning and procedural complications		Unknown	24	3,4	0	0,0

Injury, poisoning and procedural complications	Fall	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Fall	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Fall	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Fall	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Femur fracture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Femur fracture	Asian	176	25,1	1	0,6
Injury, poisoning and procedural complications	Femur fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Fracture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Fracture	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Fracture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Hip fracture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Hip fracture	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Lower limb fracture	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Rib fracture	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Rib fracture	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	White	474	67,6	1	0,2
Injury, poisoning and procedural complications	Road traffic accident	Asian	176	25,1	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	White	474	67,6	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Asian	176	25,1	1	0,6
Injury, poisoning and procedural complications	Shunt stenosis	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Unknown	24	3,4	0	0,0
Injury, poisoning and procedural complications	Thermal burn	White	474	67,6	0	0,0
Injury, poisoning and procedural complications	Thermal burn	Asian	176	25,1	1	0,6
Injury, poisoning and procedural complications	Thermal burn	Other	27	3,9	0	0,0
Injury, poisoning and procedural complications	Thermal burn	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders		White	474	67,6	1	0,2
Metabolism and nutrition disorders		Asian	176	25,1	0	0,0
Metabolism and nutrition disorders		Other	27	3,9	1	3,7
Metabolism and nutrition disorders		Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Dehydration	White	474	67,6	1	0,2
Metabolism and nutrition disorders	Dehydration	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Dehydration	Other	27	3,9	0	0,0
Metabolism and nutrition disorders	Dehydration	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	White	474	67,6	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Other	27	3,9	1	3,7
Metabolism and nutrition disorders	Hypervolaemia	Unknown	24	3,4	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	White	474	67,6	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Asian	176	25,1	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Other	27	3,9	1	3,7
Metabolism and nutrition disorders	Hypokalaemia	Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders		White	474	67,6	2	0,4
Musculoskeletal and connective tissue disorders		Asian	176	25,1	0	0,0
Musculoskeletal and connective tissue disorders		Other	27	3,9	1	3,7
Musculoskeletal and connective tissue disorders		Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	White	474	67,6	1	0,2
Musculoskeletal and connective tissue disorders	Back pain	Asian	176	25,1	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	Other	27	3,9	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	White	474	67,6	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Asian	176	25,1	0	0,0

Musculoskeletal and connective tissue disorders	Joint effusion	Other	27	3,9	1	3,7
Musculoskeletal and connective tissue disorders	Joint effusion	Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	White	474	67,6	1	0,2
Musculoskeletal and connective tissue disorders	Mobility decreased	Asian	176	25,1	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Other	27	3,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	Unknown	24	3,4	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	White	474	67,6	1	0,2
Musculoskeletal and connective tissue disorders	Polymyositis	Asian	176	25,1	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Other	27	3,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	Unknown	24	3,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		White	474	67,6	2	0,4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Asian	176	25,1	4	2,3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Other	27	3,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Unknown	24	3,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	White	474	67,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Asian	176	25,1	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Other	27	3,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Unknown	24	3,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	White	474	67,6	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Asian	176	25,1	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Other	27	3,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Unknown	24	3,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	White	474	67,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Asian	176	25,1	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Other	27	3,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Unknown	24	3,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	White	474	67,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Asian	176	25,1	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Other	27	3,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Unknown	24	3,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	White	474	67,6	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Asian	176	25,1	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Other	27	3,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Unknown	24	3,4	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	White	474	67,6	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Asian	176	25,1	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Other	27	3,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Unknown	24	3,4	0	0,0
Nervous system disorders		White	474	67,6	6	1,3
Nervous system disorders		Asian	176	25,1	1	0,6
Nervous system disorders		Other	27	3,9	0	0,0
Nervous system disorders		Unknown	24	3,4	0	0,0
Nervous system disorders	Cerebrovascular accident	White	474	67,6	1	0,2
Nervous system disorders	Cerebrovascular accident	Asian	176	25,1	0	0,0
Nervous system disorders	Cerebrovascular accident	Other	27	3,9	0	0,0
Nervous system disorders	Cerebrovascular accident	Unknown	24	3,4	0	0,0
Nervous system disorders	Hypoaesthesia	White	474	67,6	1	0,2
Nervous system disorders	Hypoaesthesia	Asian	176	25,1	0	0,0
Nervous system disorders	Hypoaesthesia	Other	27	3,9	0	0,0
Nervous system disorders	Hypoaesthesia	Unknown	24	3,4	0	0,0
Nervous system disorders	Ischaemic stroke	White	474	67,6	2	0,4
Nervous system disorders	Ischaemic stroke	Asian	176	25,1	0	0,0
Nervous system disorders	Ischaemic stroke	Other	27	3,9	0	0,0
Nervous system disorders	Ischaemic stroke	Unknown	24	3,4	0	0,0
Nervous system disorders	Presyncope	White	474	67,6	1	0,2
Nervous system disorders	Presyncope	Asian	176	25,1	0	0,0
Nervous system disorders	Presyncope	Other	27	3,9	0	0,0
Nervous system disorders	Presyncope	Unknown	24	3,4	0	0,0
Nervous system disorders	Syncope	White	474	67,6	1	0,2
Nervous system disorders	Syncope	Asian	176	25,1	1	0,6
Nervous system disorders	Syncope	Other	27	3,9	0	0,0
Nervous system disorders	Syncope	Unknown	24	3,4	0	0,0

Renal and urinary disorders		White	474	67,6	4	0,8
Renal and urinary disorders		Asian	176	25,1	1	0,6
Renal and urinary disorders		Other	27	3,9	0	0,0
Renal and urinary disorders		Unknown	24	3,4	1	4,2
Renal and urinary disorders	Cystitis interstitial	White	474	67,6	1	0,2
Renal and urinary disorders	Cystitis interstitial	Asian	176	25,1	0	0,0
Renal and urinary disorders	Cystitis interstitial	Other	27	3,9	0	0,0
Renal and urinary disorders	Cystitis interstitial	Unknown	24	3,4	0	0,0
Renal and urinary disorders	Diabetic nephropathy	White	474	67,6	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Asian	176	25,1	1	0,6
Renal and urinary disorders	Diabetic nephropathy	Other	27	3,9	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Unknown	24	3,4	0	0,0
Renal and urinary disorders	End stage renal disease	White	474	67,6	0	0,0
Renal and urinary disorders	End stage renal disease	Asian	176	25,1	0	0,0
Renal and urinary disorders	End stage renal disease	Other	27	3,9	0	0,0
Renal and urinary disorders	End stage renal disease	Unknown	24	3,4	1	4,2
Renal and urinary disorders	Nephrolithiasis	White	474	67,6	1	0,2
Renal and urinary disorders	Nephrolithiasis	Asian	176	25,1	0	0,0
Renal and urinary disorders	Nephrolithiasis	Other	27	3,9	0	0,0
Renal and urinary disorders	Nephrolithiasis	Unknown	24	3,4	0	0,0
Renal and urinary disorders	Nephropathy	White	474	67,6	1	0,2
Renal and urinary disorders	Nephropathy	Asian	176	25,1	0	0,0
Renal and urinary disorders	Nephropathy	Other	27	3,9	0	0,0
Renal and urinary disorders	Nephropathy	Unknown	24	3,4	0	0,0
Renal and urinary disorders	Renal failure	White	474	67,6	1	0,2
Renal and urinary disorders	Renal failure	Asian	176	25,1	0	0,0
Renal and urinary disorders	Renal failure	Other	27	3,9	0	0,0
Renal and urinary disorders	Renal failure	Unknown	24	3,4	0	0,0
Reproductive system and breast disorders		White	474	67,6	1	0,2
Reproductive system and breast disorders		Asian	176	25,1	0	0,0
Reproductive system and breast disorders		Other	27	3,9	0	0,0
Reproductive system and breast disorders		Unknown	24	3,4	0	0,0
Reproductive system and breast disorders	Cystocele	White	474	67,6	1	0,2
Reproductive system and breast disorders	Cystocele	Asian	176	25,1	0	0,0
Reproductive system and breast disorders	Cystocele	Other	27	3,9	0	0,0
Reproductive system and breast disorders	Cystocele	Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders		White	474	67,6	6	1,3
Respiratory, thoracic and mediastinal disorders		Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders		Other	27	3,9	1	3,7
Respiratory, thoracic and mediastinal disorders		Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	White	474	67,6	1	0,2
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Other	27	3,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	White	474	67,6	2	0,4
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Other	27	3,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	White	474	67,6	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Other	27	3,9	1	3,7
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	White	474	67,6	2	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Other	27	3,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Unknown	24	3,4	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	White	474	67,6	2	0,4
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Asian	176	25,1	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Other	27	3,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Unknown	24	3,4	0	0,0

Skin and subcutaneous tissue disorders		White	474	67,6	1	0,2
Skin and subcutaneous tissue disorders		Asian	176	25,1	0	0,0
Skin and subcutaneous tissue disorders		Other	27	3,9	0	0,0
Skin and subcutaneous tissue disorders		Unknown	24	3,4	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	White	474	67,6	1	0,2
Skin and subcutaneous tissue disorders	Diabetic foot	Asian	176	25,1	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	Other	27	3,9	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	Unknown	24	3,4	0	0,0
Surgical and medical procedures		White	474	67,6	1	0,2
Surgical and medical procedures		Asian	176	25,1	0	0,0
Surgical and medical procedures		Other	27	3,9	0	0,0
Surgical and medical procedures		Unknown	24	3,4	1	4,2
Surgical and medical procedures	Ligament operation	White	474	67,6	1	0,2
Surgical and medical procedures	Ligament operation	Asian	176	25,1	0	0,0
Surgical and medical procedures	Ligament operation	Other	27	3,9	0	0,0
Surgical and medical procedures	Ligament operation	Unknown	24	3,4	0	0,0
Surgical and medical procedures	Renal transplant	White	474	67,6	0	0,0
Surgical and medical procedures	Renal transplant	Asian	176	25,1	0	0,0
Surgical and medical procedures	Renal transplant	Other	27	3,9	0	0,0
Surgical and medical procedures	Renal transplant	Unknown	24	3,4	1	4,2
Vascular disorders		White	474	67,6	5	1,1
Vascular disorders		Asian	176	25,1	2	1,1
Vascular disorders		Other	27	3,9	1	3,7
Vascular disorders		Unknown	24	3,4	0	0,0
Vascular disorders	Aortic aneurysm	White	474	67,6	1	0,2
Vascular disorders	Aortic aneurysm	Asian	176	25,1	0	0,0
Vascular disorders	Aortic aneurysm	Other	27	3,9	0	0,0
Vascular disorders	Aortic aneurysm	Unknown	24	3,4	0	0,0
Vascular disorders	Aortic dissection	White	474	67,6	1	0,2
Vascular disorders	Aortic dissection	Asian	176	25,1	0	0,0
Vascular disorders	Aortic dissection	Other	27	3,9	0	0,0
Vascular disorders	Aortic dissection	Unknown	24	3,4	0	0,0
Vascular disorders	Aortic stenosis	White	474	67,6	1	0,2
Vascular disorders	Aortic stenosis	Asian	176	25,1	0	0,0
Vascular disorders	Aortic stenosis	Other	27	3,9	0	0,0
Vascular disorders	Aortic stenosis	Unknown	24	3,4	0	0,0
Vascular disorders	Haemorrhage	White	474	67,6	0	0,0
Vascular disorders	Haemorrhage	Asian	176	25,1	1	0,6
Vascular disorders	Haemorrhage	Other	27	3,9	0	0,0
Vascular disorders	Haemorrhage	Unknown	24	3,4	0	0,0
Vascular disorders	Hypertension	White	474	67,6	1	0,2
Vascular disorders	Hypertension	Asian	176	25,1	1	0,6
Vascular disorders	Hypertension	Other	27	3,9	0	0,0
Vascular disorders	Hypertension	Unknown	24	3,4	0	0,0
Vascular disorders	Peripheral artery aneurysm	White	474	67,6	0	0,0
Vascular disorders	Peripheral artery aneurysm	Asian	176	25,1	0	0,0
Vascular disorders	Peripheral artery aneurysm	Other	27	3,9	1	3,7
Vascular disorders	Peripheral artery aneurysm	Unknown	24	3,4	0	0,0
Vascular disorders	Secondary hypertension	White	474	67,6	1	0,2
Vascular disorders	Secondary hypertension	Asian	176	25,1	0	0,0
Vascular disorders	Secondary hypertension	Other	27	3,9	0	0,0
Vascular disorders	Secondary hypertension	Unknown	24	3,4	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_Sa24_29AUG2023_41986.xls

26APR2024 18:20

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Any SAEs
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline RVO status

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Blood and lymphatic system disorders		CRVO	574	81,9	2	0,3
Blood and lymphatic system disorders		HRVO	121	17,3	0	0,0
Blood and lymphatic system disorders		Missing	6	0,9	0	0,0
Blood and lymphatic system disorders	Anaemia	CRVO	574	81,9	1	0,2
Blood and lymphatic system disorders	Anaemia	HRVO	121	17,3	0	0,0
Blood and lymphatic system disorders	Anaemia	Missing	6	0,9	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	CRVO	574	81,9	1	0,2
Blood and lymphatic system disorders	Deficiency anaemia	HRVO	121	17,3	0	0,0
Blood and lymphatic system disorders	Deficiency anaemia	Missing	6	0,9	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	CRVO	574	81,9	1	0,2
Blood and lymphatic system disorders	Mesenteric lymphadenitis	HRVO	121	17,3	0	0,0
Blood and lymphatic system disorders	Mesenteric lymphadenitis	Missing	6	0,9	0	0,0
Cardiac disorders		CRVO	574	81,9	14	2,4
Cardiac disorders		HRVO	121	17,3	1	0,8
Cardiac disorders		Missing	6	0,9	0	0,0
Cardiac disorders	Acute myocardial infarction	CRVO	574	81,9	2	0,3
Cardiac disorders	Acute myocardial infarction	HRVO	121	17,3	0	0,0
Cardiac disorders	Acute myocardial infarction	Missing	6	0,9	0	0,0
Cardiac disorders	Aortic valve incompetence	CRVO	574	81,9	1	0,2
Cardiac disorders	Aortic valve incompetence	HRVO	121	17,3	0	0,0
Cardiac disorders	Aortic valve incompetence	Missing	6	0,9	0	0,0
Cardiac disorders	Arrhythmia	CRVO	574	81,9	1	0,2
Cardiac disorders	Arrhythmia	HRVO	121	17,3	0	0,0
Cardiac disorders	Arrhythmia	Missing	6	0,9	0	0,0
Cardiac disorders	Atrial fibrillation	CRVO	574	81,9	3	0,5
Cardiac disorders	Atrial fibrillation	HRVO	121	17,3	1	0,8
Cardiac disorders	Atrial fibrillation	Missing	6	0,9	0	0,0
Cardiac disorders	Cardiac failure	CRVO	574	81,9	1	0,2
Cardiac disorders	Cardiac failure	HRVO	121	17,3	0	0,0
Cardiac disorders	Cardiac failure	Missing	6	0,9	0	0,0
Cardiac disorders	Cardiac failure congestive	CRVO	574	81,9	2	0,3
Cardiac disorders	Cardiac failure congestive	HRVO	121	17,3	0	0,0
Cardiac disorders	Cardiac failure congestive	Missing	6	0,9	0	0,0
Cardiac disorders	Coronary artery disease	CRVO	574	81,9	1	0,2
Cardiac disorders	Coronary artery disease	HRVO	121	17,3	0	0,0
Cardiac disorders	Coronary artery disease	Missing	6	0,9	0	0,0
Cardiac disorders	Coronary artery stenosis	CRVO	574	81,9	1	0,2
Cardiac disorders	Coronary artery stenosis	HRVO	121	17,3	0	0,0
Cardiac disorders	Coronary artery stenosis	Missing	6	0,9	0	0,0
Cardiac disorders	Myocardial infarction	CRVO	574	81,9	3	0,5
Cardiac disorders	Myocardial infarction	HRVO	121	17,3	0	0,0
Cardiac disorders	Myocardial infarction	Missing	6	0,9	0	0,0
Cardiac disorders	Stress cardiomyopathy	CRVO	574	81,9	1	0,2
Cardiac disorders	Stress cardiomyopathy	HRVO	121	17,3	0	0,0

Cardiac disorders	Stress cardiomyopathy	Missing	6	0,9	0	0,0
Eye disorders		CRVO	574	81,9	34	5,9
Eye disorders		HRVO	121	17,3	5	4,1
Eye disorders		Missing	6	0,9	0	0,0
Eye disorders	Cataract	CRVO	574	81,9	1	0,2
Eye disorders	Cataract	HRVO	121	17,3	0	0,0
Eye disorders	Cataract	Missing	6	0,9	0	0,0
Eye disorders	Cystoid macular oedema	CRVO	574	81,9	6	1,0
Eye disorders	Cystoid macular oedema	HRVO	121	17,3	0	0,0
Eye disorders	Cystoid macular oedema	Missing	6	0,9	0	0,0
Eye disorders	Epiretinal membrane	CRVO	574	81,9	1	0,2
Eye disorders	Epiretinal membrane	HRVO	121	17,3	0	0,0
Eye disorders	Epiretinal membrane	Missing	6	0,9	0	0,0
Eye disorders	Glaucoma	CRVO	574	81,9	0	0,0
Eye disorders	Glaucoma	HRVO	121	17,3	1	0,8
Eye disorders	Glaucoma	Missing	6	0,9	0	0,0
Eye disorders	Iridocyclitis	CRVO	574	81,9	0	0,0
Eye disorders	Iridocyclitis	HRVO	121	17,3	1	0,8
Eye disorders	Iridocyclitis	Missing	6	0,9	0	0,0
Eye disorders	Iris neovascularisation	CRVO	574	81,9	1	0,2
Eye disorders	Iris neovascularisation	HRVO	121	17,3	0	0,0
Eye disorders	Iris neovascularisation	Missing	6	0,9	0	0,0
Eye disorders	Macular hole	CRVO	574	81,9	2	0,3
Eye disorders	Macular hole	HRVO	121	17,3	0	0,0
Eye disorders	Macular hole	Missing	6	0,9	0	0,0
Eye disorders	Macular ischaemia	CRVO	574	81,9	1	0,2
Eye disorders	Macular ischaemia	HRVO	121	17,3	0	0,0
Eye disorders	Macular ischaemia	Missing	6	0,9	0	0,0
Eye disorders	Macular oedema	CRVO	574	81,9	4	0,7
Eye disorders	Macular oedema	HRVO	121	17,3	0	0,0
Eye disorders	Macular oedema	Missing	6	0,9	0	0,0
Eye disorders	Posterior capsule opacification	CRVO	574	81,9	0	0,0
Eye disorders	Posterior capsule opacification	HRVO	121	17,3	1	0,8
Eye disorders	Posterior capsule opacification	Missing	6	0,9	0	0,0
Eye disorders	Retinal artery embolism	CRVO	574	81,9	1	0,2
Eye disorders	Retinal artery embolism	HRVO	121	17,3	0	0,0
Eye disorders	Retinal artery embolism	Missing	6	0,9	0	0,0
Eye disorders	Retinal artery occlusion	CRVO	574	81,9	2	0,3
Eye disorders	Retinal artery occlusion	HRVO	121	17,3	0	0,0
Eye disorders	Retinal artery occlusion	Missing	6	0,9	0	0,0
Eye disorders	Retinal detachment	CRVO	574	81,9	1	0,2
Eye disorders	Retinal detachment	HRVO	121	17,3	0	0,0
Eye disorders	Retinal detachment	Missing	6	0,9	0	0,0
Eye disorders	Retinal ischaemia	CRVO	574	81,9	2	0,3
Eye disorders	Retinal ischaemia	HRVO	121	17,3	0	0,0
Eye disorders	Retinal ischaemia	Missing	6	0,9	0	0,0
Eye disorders	Retinal neovascularisation	CRVO	574	81,9	2	0,3
Eye disorders	Retinal neovascularisation	HRVO	121	17,3	0	0,0
Eye disorders	Retinal neovascularisation	Missing	6	0,9	0	0,0
Eye disorders	Retinal tear	CRVO	574	81,9	1	0,2
Eye disorders	Retinal tear	HRVO	121	17,3	0	0,0
Eye disorders	Retinal tear	Missing	6	0,9	0	0,0
Eye disorders	Retinal vein occlusion	CRVO	574	81,9	6	1,0
Eye disorders	Retinal vein occlusion	HRVO	121	17,3	2	1,7
Eye disorders	Retinal vein occlusion	Missing	6	0,9	0	0,0
Eye disorders	Uveitis	CRVO	574	81,9	1	0,2

Eye disorders	Uveitis	HRVO	121	17,3	0	0,0
Eye disorders	Uveitis	Missing	6	0,9	0	0,0
Eye disorders	Visual acuity reduced	CRVO	574	81,9	1	0,2
Eye disorders	Visual acuity reduced	HRVO	121	17,3	0	0,0
Eye disorders	Visual acuity reduced	Missing	6	0,9	0	0,0
Eye disorders	Vitreous haemorrhage	CRVO	574	81,9	1	0,2
Eye disorders	Vitreous haemorrhage	HRVO	121	17,3	0	0,0
Eye disorders	Vitreous haemorrhage	Missing	6	0,9	0	0,0
Eye disorders	Vitritis	CRVO	574	81,9	1	0,2
Eye disorders	Vitritis	HRVO	121	17,3	0	0,0
Eye disorders	Vitritis	Missing	6	0,9	0	0,0
Gastrointestinal disorders		CRVO	574	81,9	6	1,0
Gastrointestinal disorders		HRVO	121	17,3	1	0,8
Gastrointestinal disorders		Missing	6	0,9	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Diverticulum intestinal haemorrhagic	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Duodenal ulcer haemorrhage	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Duodenal ulcer haemorrhage	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastric ulcer	CRVO	574	81,9	0	0,0
Gastrointestinal disorders	Gastric ulcer	HRVO	121	17,3	1	0,8
Gastrointestinal disorders	Gastric ulcer	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Gastrointestinal inflammation	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Large intestine polyp	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Large intestine polyp	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Large intestine polyp	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Pancreatitis	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Pancreatitis	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Pancreatitis	Missing	6	0,9	0	0,0
Gastrointestinal disorders	Pancreatitis acute	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Pancreatitis acute	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Pancreatitis acute	Missing	6	0,9	0	0,0
General disorders and administration site conditions		CRVO	574	81,9	6	1,0
General disorders and administration site conditions		HRVO	121	17,3	2	1,7
General disorders and administration site conditions		Missing	6	0,9	0	0,0
General disorders and administration site conditions	Asthenia	CRVO	574	81,9	2	0,3
General disorders and administration site conditions	Asthenia	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Asthenia	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Chest pain	CRVO	574	81,9	2	0,3
General disorders and administration site conditions	Chest pain	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Chest pain	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Death	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Death	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Death	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Stent-graft endoleak	HRVO	121	17,3	0	0,0
General disorders and administration site conditions	Stent-graft endoleak	Missing	6	0,9	0	0,0
Hepatobiliary disorders		CRVO	574	81,9	2	0,3
Hepatobiliary disorders		HRVO	121	17,3	0	0,0
Hepatobiliary disorders		Missing	6	0,9	0	0,0
Hepatobiliary disorders	Cholecystitis	CRVO	574	81,9	1	0,2

Hepatobiliary disorders	Cholecystitis	HRVO	121	17,3	0	0,0
Hepatobiliary disorders	Cholecystitis	Missing	6	0,9	0	0,0
Hepatobiliary disorders	Cholelithiasis	CRVO	574	81,9	1	0,2
Hepatobiliary disorders	Cholelithiasis	HRVO	121	17,3	0	0,0
Hepatobiliary disorders	Cholelithiasis	Missing	6	0,9	0	0,0
Infections and infestations		CRVO	574	81,9	16	2,8
Infections and infestations		HRVO	121	17,3	6	5,0
Infections and infestations		Missing	6	0,9	0	0,0
Infections and infestations	Bronchitis	CRVO	574	81,9	1	0,2
Infections and infestations	Bronchitis	HRVO	121	17,3	0	0,0
Infections and infestations	Bronchitis	Missing	6	0,9	0	0,0
Infections and infestations	COVID-19	CRVO	574	81,9	1	0,2
Infections and infestations	COVID-19	HRVO	121	17,3	0	0,0
Infections and infestations	COVID-19	Missing	6	0,9	0	0,0
Infections and infestations	COVID-19 pneumonia	CRVO	574	81,9	0	0,0
Infections and infestations	COVID-19 pneumonia	HRVO	121	17,3	1	0,8
Infections and infestations	COVID-19 pneumonia	Missing	6	0,9	0	0,0
Infections and infestations	Cellulitis	CRVO	574	81,9	2	0,3
Infections and infestations	Cellulitis	HRVO	121	17,3	0	0,0
Infections and infestations	Cellulitis	Missing	6	0,9	0	0,0
Infections and infestations	Clostridium difficile infection	CRVO	574	81,9	1	0,2
Infections and infestations	Clostridium difficile infection	HRVO	121	17,3	0	0,0
Infections and infestations	Clostridium difficile infection	Missing	6	0,9	0	0,0
Infections and infestations	Device related infection	CRVO	574	81,9	1	0,2
Infections and infestations	Device related infection	HRVO	121	17,3	0	0,0
Infections and infestations	Device related infection	Missing	6	0,9	0	0,0
Infections and infestations	Endophthalmitis	CRVO	574	81,9	0	0,0
Infections and infestations	Endophthalmitis	HRVO	121	17,3	1	0,8
Infections and infestations	Endophthalmitis	Missing	6	0,9	0	0,0
Infections and infestations	Escherichia urinary tract infection	CRVO	574	81,9	1	0,2
Infections and infestations	Escherichia urinary tract infection	HRVO	121	17,3	0	0,0
Infections and infestations	Escherichia urinary tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Influenza	CRVO	574	81,9	1	0,2
Infections and infestations	Influenza	HRVO	121	17,3	1	0,8
Infections and infestations	Influenza	Missing	6	0,9	0	0,0
Infections and infestations	Kidney infection	CRVO	574	81,9	1	0,2
Infections and infestations	Kidney infection	HRVO	121	17,3	0	0,0
Infections and infestations	Kidney infection	Missing	6	0,9	0	0,0
Infections and infestations	Lower respiratory tract infection	CRVO	574	81,9	0	0,0
Infections and infestations	Lower respiratory tract infection	HRVO	121	17,3	1	0,8
Infections and infestations	Lower respiratory tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Necrotising fasciitis	CRVO	574	81,9	0	0,0
Infections and infestations	Necrotising fasciitis	HRVO	121	17,3	1	0,8
Infections and infestations	Necrotising fasciitis	Missing	6	0,9	0	0,0
Infections and infestations	Pneumonia	CRVO	574	81,9	4	0,7
Infections and infestations	Pneumonia	HRVO	121	17,3	1	0,8
Infections and infestations	Pneumonia	Missing	6	0,9	0	0,0
Infections and infestations	Pneumonia viral	CRVO	574	81,9	2	0,3
Infections and infestations	Pneumonia viral	HRVO	121	17,3	0	0,0
Infections and infestations	Pneumonia viral	Missing	6	0,9	0	0,0
Infections and infestations	Respiratory syncytial virus infection	CRVO	574	81,9	1	0,2
Infections and infestations	Respiratory syncytial virus infection	HRVO	121	17,3	0	0,0
Infections and infestations	Respiratory syncytial virus infection	Missing	6	0,9	0	0,0
Infections and infestations	Sepsis	CRVO	574	81,9	2	0,3
Infections and infestations	Sepsis	HRVO	121	17,3	0	0,0
Infections and infestations	Sepsis	Missing	6	0,9	0	0,0

Infections and infestations	Tooth infection	CRVO	574	81,9	0	0,0
Infections and infestations	Tooth infection	HRVO	121	17,3	1	0,8
Infections and infestations	Tooth infection	Missing	6	0,9	0	0,0
Infections and infestations	Urinary tract candidiasis	CRVO	574	81,9	1	0,2
Infections and infestations	Urinary tract candidiasis	HRVO	121	17,3	0	0,0
Infections and infestations	Urinary tract candidiasis	Missing	6	0,9	0	0,0
Infections and infestations	Urinary tract infection	CRVO	574	81,9	1	0,2
Infections and infestations	Urinary tract infection	HRVO	121	17,3	0	0,0
Infections and infestations	Urinary tract infection	Missing	6	0,9	0	0,0
Infections and infestations	Urosepsis	CRVO	574	81,9	1	0,2
Infections and infestations	Urosepsis	HRVO	121	17,3	0	0,0
Infections and infestations	Urosepsis	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications		CRVO	574	81,9	9	1,6
Injury, poisoning and procedural complications		HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications		Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Fall	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Fall	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Fall	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Femur fracture	CRVO	574	81,9	2	0,3
Injury, poisoning and procedural complications	Femur fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Femur fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Hip fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Hip fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Hip fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Lower limb fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Lower limb fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Rib fracture	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Rib fracture	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Rib fracture	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Road traffic accident	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Road traffic accident	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Shunt stenosis	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Shunt stenosis	Missing	6	0,9	0	0,0
Injury, poisoning and procedural complications	Thermal burn	CRVO	574	81,9	1	0,2
Injury, poisoning and procedural complications	Thermal burn	HRVO	121	17,3	0	0,0
Injury, poisoning and procedural complications	Thermal burn	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders		CRVO	574	81,9	2	0,3
Metabolism and nutrition disorders		HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders		Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Dehydration	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Dehydration	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Dehydration	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hypervolaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hypervolaemia	Missing	6	0,9	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	CRVO	574	81,9	1	0,2
Metabolism and nutrition disorders	Hypokalaemia	HRVO	121	17,3	0	0,0
Metabolism and nutrition disorders	Hypokalaemia	Missing	6	0,9	0	0,0

Musculoskeletal and connective tissue disorders		CRVO	574	81,9	2	0,3
Musculoskeletal and connective tissue disorders		HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders		Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Back pain	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Back pain	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	CRVO	574	81,9	1	0,2
Musculoskeletal and connective tissue disorders	Joint effusion	HRVO	121	17,3	0	0,0
Musculoskeletal and connective tissue disorders	Joint effusion	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Mobility decreased	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Mobility decreased	Missing	6	0,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	CRVO	574	81,9	0	0,0
Musculoskeletal and connective tissue disorders	Polymyositis	HRVO	121	17,3	1	0,8
Musculoskeletal and connective tissue disorders	Polymyositis	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		CRVO	574	81,9	5	0,9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		HRVO	121	17,3	1	0,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Bladder cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary thyroid cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	CRVO	574	81,9	1	0,2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	HRVO	121	17,3	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	Missing	6	0,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	CRVO	574	81,9	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	HRVO	121	17,3	1	0,8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Thyroid cancer	Missing	6	0,9	0	0,0
Nervous system disorders		CRVO	574	81,9	5	0,9
Nervous system disorders		HRVO	121	17,3	2	1,7
Nervous system disorders		Missing	6	0,9	0	0,0
Nervous system disorders	Cerebrovascular accident	CRVO	574	81,9	0	0,0
Nervous system disorders	Cerebrovascular accident	HRVO	121	17,3	1	0,8
Nervous system disorders	Cerebrovascular accident	Missing	6	0,9	0	0,0
Nervous system disorders	Hypoaesthesia	CRVO	574	81,9	1	0,2
Nervous system disorders	Hypoaesthesia	HRVO	121	17,3	0	0,0
Nervous system disorders	Hypoaesthesia	Missing	6	0,9	0	0,0
Nervous system disorders	Ischaemic stroke	CRVO	574	81,9	1	0,2
Nervous system disorders	Ischaemic stroke	HRVO	121	17,3	1	0,8
Nervous system disorders	Ischaemic stroke	Missing	6	0,9	0	0,0
Nervous system disorders	Presyncope	CRVO	574	81,9	1	0,2
Nervous system disorders	Presyncope	HRVO	121	17,3	0	0,0
Nervous system disorders	Presyncope	Missing	6	0,9	0	0,0
Nervous system disorders	Syncope	CRVO	574	81,9	2	0,3
Nervous system disorders	Syncope	HRVO	121	17,3	0	0,0
Nervous system disorders	Syncope	Missing	6	0,9	0	0,0

Renal and urinary disorders		CRVO	574	81,9	6	1,0
Renal and urinary disorders		HRVO	121	17,3	0	0,0
Renal and urinary disorders		Missing	6	0,9	0	0,0
Renal and urinary disorders	Cystitis interstitial	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Cystitis interstitial	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Cystitis interstitial	Missing	6	0,9	0	0,0
Renal and urinary disorders	Diabetic nephropathy	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Diabetic nephropathy	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Diabetic nephropathy	Missing	6	0,9	0	0,0
Renal and urinary disorders	End stage renal disease	CRVO	574	81,9	1	0,2
Renal and urinary disorders	End stage renal disease	HRVO	121	17,3	0	0,0
Renal and urinary disorders	End stage renal disease	Missing	6	0,9	0	0,0
Renal and urinary disorders	Nephrolithiasis	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Nephrolithiasis	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Nephrolithiasis	Missing	6	0,9	0	0,0
Renal and urinary disorders	Nephropathy	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Nephropathy	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Nephropathy	Missing	6	0,9	0	0,0
Renal and urinary disorders	Renal failure	CRVO	574	81,9	1	0,2
Renal and urinary disorders	Renal failure	HRVO	121	17,3	0	0,0
Renal and urinary disorders	Renal failure	Missing	6	0,9	0	0,0
Reproductive system and breast disorders		CRVO	574	81,9	1	0,2
Reproductive system and breast disorders		HRVO	121	17,3	0	0,0
Reproductive system and breast disorders		Missing	6	0,9	0	0,0
Reproductive system and breast disorders	Cystocele	CRVO	574	81,9	1	0,2
Reproductive system and breast disorders	Cystocele	HRVO	121	17,3	0	0,0
Reproductive system and breast disorders	Cystocele	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders		CRVO	574	81,9	6	1,0
Respiratory, thoracic and mediastinal disorders		HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders		Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Obstructive sleep apnoea syndrome	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	CRVO	574	81,9	1	0,2
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	HRVO	121	17,3	1	0,8
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Missing	6	0,9	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	CRVO	574	81,9	2	0,3
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	HRVO	121	17,3	0	0,0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders		CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders		HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders		Missing	6	0,9	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	CRVO	574	81,9	1	0,2
Skin and subcutaneous tissue disorders	Diabetic foot	HRVO	121	17,3	0	0,0
Skin and subcutaneous tissue disorders	Diabetic foot	Missing	6	0,9	0	0,0
Surgical and medical procedures		CRVO	574	81,9	2	0,3
Surgical and medical procedures		HRVO	121	17,3	0	0,0

Surgical and medical procedures		Missing	6	0,9	0	0,0
Surgical and medical procedures	Ligament operation	CRVO	574	81,9	1	0,2
Surgical and medical procedures	Ligament operation	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Ligament operation	Missing	6	0,9	0	0,0
Surgical and medical procedures	Renal transplant	CRVO	574	81,9	1	0,2
Surgical and medical procedures	Renal transplant	HRVO	121	17,3	0	0,0
Surgical and medical procedures	Renal transplant	Missing	6	0,9	0	0,0
Vascular disorders		CRVO	574	81,9	4	0,7
Vascular disorders		HRVO	121	17,3	4	3,3
Vascular disorders		Missing	6	0,9	0	0,0
Vascular disorders	Aortic aneurysm	CRVO	574	81,9	0	0,0
Vascular disorders	Aortic aneurysm	HRVO	121	17,3	1	0,8
Vascular disorders	Aortic aneurysm	Missing	6	0,9	0	0,0
Vascular disorders	Aortic dissection	CRVO	574	81,9	1	0,2
Vascular disorders	Aortic dissection	HRVO	121	17,3	0	0,0
Vascular disorders	Aortic dissection	Missing	6	0,9	0	0,0
Vascular disorders	Aortic stenosis	CRVO	574	81,9	0	0,0
Vascular disorders	Aortic stenosis	HRVO	121	17,3	1	0,8
Vascular disorders	Aortic stenosis	Missing	6	0,9	0	0,0
Vascular disorders	Haemorrhage	CRVO	574	81,9	1	0,2
Vascular disorders	Haemorrhage	HRVO	121	17,3	0	0,0
Vascular disorders	Haemorrhage	Missing	6	0,9	0	0,0
Vascular disorders	Hypertension	CRVO	574	81,9	1	0,2
Vascular disorders	Hypertension	HRVO	121	17,3	1	0,8
Vascular disorders	Hypertension	Missing	6	0,9	0	0,0
Vascular disorders	Peripheral artery aneurysm	CRVO	574	81,9	1	0,2
Vascular disorders	Peripheral artery aneurysm	HRVO	121	17,3	0	0,0
Vascular disorders	Peripheral artery aneurysm	Missing	6	0,9	0	0,0
Vascular disorders	Secondary hypertension	CRVO	574	81,9	0	0,0
Vascular disorders	Secondary hypertension	HRVO	121	17,3	1	0,8
Vascular disorders	Secondary hypertension	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_SAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:20

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Eye disorders		n/a	701	100,0	8	1,1
Eye disorders	Cystoid macular oedema	n/a	701	100,0	2	0,3
Eye disorders	Glaucoma	n/a	701	100,0	1	0,1
Eye disorders	Macular hole	n/a	701	100,0	1	0,1
Eye disorders	Retinal vein occlusion	n/a	701	100,0	1	0,1
Eye disorders	Uveitis	n/a	701	100,0	1	0,1
Eye disorders	Vitritis	n/a	701	100,0	2	0,3
Gastrointestinal disorders		n/a	701	100,0	1	0,1
Gastrointestinal disorders	Gastrointestinal inflammation	n/a	701	100,0	1	0,1
General disorders and administration site conditions		n/a	701	100,0	3	0,4
General disorders and administration site conditions	Asthenia	n/a	701	100,0	1	0,1
General disorders and administration site conditions	Death	n/a	701	100,0	2	0,3
Infections and infestations		n/a	701	100,0	1	0,1
Infections and infestations	Pneumonia	n/a	701	100,0	1	0,1
Nervous system disorders		n/a	701	100,0	2	0,3
Nervous system disorders	Cerebral infarction	n/a	701	100,0	1	0,1
Nervous system disorders	Cerebrovascular accident	n/a	701	100,0	1	0,1

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 18:23

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Gender

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Eye disorders		Male	374	53,4	3	0,8
Eye disorders		Female	327	46,6	5	1,5
Eye disorders	Cystoid macular oedema	Male	374	53,4	1	0,3
Eye disorders	Cystoid macular oedema	Female	327	46,6	1	0,3
Eye disorders	Glaucoma	Male	374	53,4	1	0,3
Eye disorders	Glaucoma	Female	327	46,6	0	0,0
Eye disorders	Macular hole	Male	374	53,4	0	0,0
Eye disorders	Macular hole	Female	327	46,6	1	0,3
Eye disorders	Retinal vein occlusion	Male	374	53,4	0	0,0
Eye disorders	Retinal vein occlusion	Female	327	46,6	1	0,3
Eye disorders	Uveitis	Male	374	53,4	0	0,0
Eye disorders	Uveitis	Female	327	46,6	1	0,3
Eye disorders	Vitritis	Male	374	53,4	1	0,3
Eye disorders	Vitritis	Female	327	46,6	1	0,3
Gastrointestinal disorders		Male	374	53,4	0	0,0
Gastrointestinal disorders		Female	327	46,6	1	0,3
Gastrointestinal disorders	Gastrointestinal inflammation	Male	374	53,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Female	327	46,6	1	0,3
General disorders and administration site conditions		Male	374	53,4	2	0,5
General disorders and administration site conditions		Female	327	46,6	1	0,3
General disorders and administration site conditions	Asthenia	Male	374	53,4	1	0,3
General disorders and administration site conditions	Asthenia	Female	327	46,6	0	0,0
General disorders and administration site conditions	Death	Male	374	53,4	1	0,3
General disorders and administration site conditions	Death	Female	327	46,6	1	0,3
Infections and infestations		Male	374	53,4	0	0,0
Infections and infestations		Female	327	46,6	1	0,3
Infections and infestations	Pneumonia	Male	374	53,4	0	0,0
Infections and infestations	Pneumonia	Female	327	46,6	1	0,3
Nervous system disorders		Male	374	53,4	1	0,3
Nervous system disorders		Female	327	46,6	1	0,3
Nervous system disorders	Cerebral infarction	Male	374	53,4	1	0,3
Nervous system disorders	Cerebral infarction	Female	327	46,6	0	0,0
Nervous system disorders	Cerebrovascular accident	Male	374	53,4	0	0,0
Nervous system disorders	Cerebrovascular accident	Female	327	46,6	1	0,3

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Age

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Eye disorders		<65 years	308	43,9	1	0,3
Eye disorders		>=65 years	393	56,1	7	1,8
Eye disorders	Cystoid macular oedema	<65 years	308	43,9	0	0,0
Eye disorders	Cystoid macular oedema	>=65 years	393	56,1	2	0,5
Eye disorders	Glaucoma	<65 years	308	43,9	0	0,0
Eye disorders	Glaucoma	>=65 years	393	56,1	1	0,3
Eye disorders	Macular hole	<65 years	308	43,9	0	0,0
Eye disorders	Macular hole	>=65 years	393	56,1	1	0,3
Eye disorders	Retinal vein occlusion	<65 years	308	43,9	0	0,0
Eye disorders	Retinal vein occlusion	>=65 years	393	56,1	1	0,3
Eye disorders	Uveitis	<65 years	308	43,9	1	0,3
Eye disorders	Uveitis	>=65 years	393	56,1	0	0,0
Eye disorders	Vitritis	<65 years	308	43,9	0	0,0
Eye disorders	Vitritis	>=65 years	393	56,1	2	0,5
Gastrointestinal disorders		<65 years	308	43,9	0	0,0
Gastrointestinal disorders		>=65 years	393	56,1	1	0,3
Gastrointestinal disorders	Gastrointestinal inflammation	<65 years	308	43,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions		<65 years	308	43,9	0	0,0
General disorders and administration site conditions		>=65 years	393	56,1	3	0,8
General disorders and administration site conditions	Asthenia	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Asthenia	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions	Death	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Death	>=65 years	393	56,1	2	0,5
Infections and infestations		<65 years	308	43,9	0	0,0
Infections and infestations		>=65 years	393	56,1	1	0,3
Infections and infestations	Pneumonia	<65 years	308	43,9	0	0,0
Infections and infestations	Pneumonia	>=65 years	393	56,1	1	0,3
Nervous system disorders		<65 years	308	43,9	1	0,3
Nervous system disorders		>=65 years	393	56,1	1	0,3
Nervous system disorders	Cerebral infarction	<65 years	308	43,9	1	0,3
Nervous system disorders	Cerebral infarction	>=65 years	393	56,1	0	0,0
Nervous system disorders	Cerebrovascular accident	<65 years	308	43,9	0	0,0
Nervous system disorders	Cerebrovascular accident	>=65 years	393	56,1	1	0,3

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETDRS letter score

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Eye disorders		<=34 letters	156	22,3	0	0,0
Eye disorders		35 - 54 letters	206	29,4	3	1,5
Eye disorders		>=55 letters	339	48,4	5	1,5
Eye disorders	Cystoid macular oedema	<=34 letters	156	22,3	0	0,0
Eye disorders	Cystoid macular oedema	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Cystoid macular oedema	>=55 letters	339	48,4	2	0,6
Eye disorders	Glaucoma	<=34 letters	156	22,3	0	0,0
Eye disorders	Glaucoma	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Glaucoma	>=55 letters	339	48,4	1	0,3
Eye disorders	Macular hole	<=34 letters	156	22,3	0	0,0
Eye disorders	Macular hole	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Macular hole	>=55 letters	339	48,4	1	0,3
Eye disorders	Retinal vein occlusion	<=34 letters	156	22,3	0	0,0
Eye disorders	Retinal vein occlusion	35 - 54 letters	206	29,4	1	0,5
Eye disorders	Retinal vein occlusion	>=55 letters	339	48,4	0	0,0
Eye disorders	Uveitis	<=34 letters	156	22,3	0	0,0
Eye disorders	Uveitis	35 - 54 letters	206	29,4	0	0,0
Eye disorders	Uveitis	>=55 letters	339	48,4	1	0,3
Eye disorders	Vitritis	<=34 letters	156	22,3	0	0,0
Eye disorders	Vitritis	35 - 54 letters	206	29,4	2	1,0
Eye disorders	Vitritis	>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders		<=34 letters	156	22,3	1	0,6
Gastrointestinal disorders		35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders		>=55 letters	339	48,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	<=34 letters	156	22,3	1	0,6
Gastrointestinal disorders	Gastrointestinal inflammation	35 - 54 letters	206	29,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=55 letters	339	48,4	0	0,0
General disorders and administration site conditions		<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions		35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions		>=55 letters	339	48,4	2	0,6
General disorders and administration site conditions	Asthenia	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Asthenia	35 - 54 letters	206	29,4	0	0,0
General disorders and administration site conditions	Asthenia	>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Death	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Death	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Death	>=55 letters	339	48,4	1	0,3

Infections and infestations		<=34 letters	156	22,3	1	0,6
Infections and infestations		35 - 54 letters	206	29,4	0	0,0
Infections and infestations		>=55 letters	339	48,4	0	0,0
Infections and infestations	Pneumonia	<=34 letters	156	22,3	1	0,6
Infections and infestations	Pneumonia	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	Pneumonia	>=55 letters	339	48,4	0	0,0
Nervous system disorders		<=34 letters	156	22,3	1	0,6
Nervous system disorders		35 - 54 letters	206	29,4	1	0,5
Nervous system disorders		>=55 letters	339	48,4	0	0,0
Nervous system disorders	Cerebral infarction	<=34 letters	156	22,3	1	0,6
Nervous system disorders	Cerebral infarction	35 - 54 letters	206	29,4	0	0,0
Nervous system disorders	Cerebral infarction	>=55 letters	339	48,4	0	0,0
Nervous system disorders	Cerebrovascular accident	<=34 letters	156	22,3	0	0,0
Nervous system disorders	Cerebrovascular accident	35 - 54 letters	206	29,4	1	0,5
Nervous system disorders	Cerebrovascular accident	>=55 letters	339	48,4	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:23

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETDRS letter score

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Eye disorders		<=23 letters	69	9,8	0	0,0
Eye disorders		>=24 letters	632	90,2	8	1,3
Eye disorders	Cystoid macular oedema	<=23 letters	69	9,8	0	0,0
Eye disorders	Cystoid macular oedema	>=24 letters	632	90,2	2	0,3
Eye disorders	Glaucoma	<=23 letters	69	9,8	0	0,0
Eye disorders	Glaucoma	>=24 letters	632	90,2	1	0,2
Eye disorders	Macular hole	<=23 letters	69	9,8	0	0,0
Eye disorders	Macular hole	>=24 letters	632	90,2	1	0,2
Eye disorders	Retinal vein occlusion	<=23 letters	69	9,8	0	0,0
Eye disorders	Retinal vein occlusion	>=24 letters	632	90,2	1	0,2
Eye disorders	Uveitis	<=23 letters	69	9,8	0	0,0
Eye disorders	Uveitis	>=24 letters	632	90,2	1	0,2
Eye disorders	Vitritis	<=23 letters	69	9,8	0	0,0
Eye disorders	Vitritis	>=24 letters	632	90,2	2	0,3
Gastrointestinal disorders		<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders		>=24 letters	632	90,2	1	0,2
Gastrointestinal disorders	Gastrointestinal inflammation	<=23 letters	69	9,8	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions		<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions		>=24 letters	632	90,2	3	0,5
General disorders and administration site conditions	Asthenia	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Asthenia	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions	Death	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Death	>=24 letters	632	90,2	2	0,3
Infections and infestations		<=23 letters	69	9,8	0	0,0
Infections and infestations		>=24 letters	632	90,2	1	0,2
Infections and infestations	Pneumonia	<=23 letters	69	9,8	0	0,0
Infections and infestations	Pneumonia	>=24 letters	632	90,2	1	0,2
Nervous system disorders		<=23 letters	69	9,8	0	0,0
Nervous system disorders		>=24 letters	632	90,2	2	0,3
Nervous system disorders	Cerebral infarction	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cerebral infarction	>=24 letters	632	90,2	1	0,2
Nervous system disorders	Cerebrovascular accident	<=23 letters	69	9,8	0	0,0
Nervous system disorders	Cerebrovascular accident	>=24 letters	632	90,2	1	0,2

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Geographic Region

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Eye disorders		Europe	214	30,5	2	0,9
Eye disorders		America	282	40,2	1	0,4
Eye disorders		Asia Pacific (inc. Australia)	205	29,2	5	2,4
Eye disorders	Cystoid macular oedema	Europe	214	30,5	0	0,0
Eye disorders	Cystoid macular oedema	America	282	40,2	0	0,0
Eye disorders	Cystoid macular oedema	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Eye disorders	Glaucoma	Europe	214	30,5	0	0,0
Eye disorders	Glaucoma	America	282	40,2	0	0,0
Eye disorders	Glaucoma	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Macular hole	Europe	214	30,5	1	0,5
Eye disorders	Macular hole	America	282	40,2	0	0,0
Eye disorders	Macular hole	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Retinal vein occlusion	Europe	214	30,5	0	0,0
Eye disorders	Retinal vein occlusion	America	282	40,2	0	0,0
Eye disorders	Retinal vein occlusion	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Eye disorders	Uveitis	Europe	214	30,5	1	0,5
Eye disorders	Uveitis	America	282	40,2	0	0,0
Eye disorders	Uveitis	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Eye disorders	Vitritis	Europe	214	30,5	0	0,0
Eye disorders	Vitritis	America	282	40,2	1	0,4
Eye disorders	Vitritis	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Gastrointestinal disorders		Europe	214	30,5	1	0,5
Gastrointestinal disorders		America	282	40,2	0	0,0
Gastrointestinal disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Europe	214	30,5	1	0,5
Gastrointestinal disorders	Gastrointestinal inflammation	America	282	40,2	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions		Europe	214	30,5	2	0,9
General disorders and administration site conditions		America	282	40,2	1	0,4
General disorders and administration site conditions		Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Asthenia	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Asthenia	America	282	40,2	0	0,0
General disorders and administration site conditions	Asthenia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Death	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Death	America	282	40,2	1	0,4
General disorders and administration site conditions	Death	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Infections and infestations		Europe	214	30,5	1	0,5
Infections and infestations		America	282	40,2	0	0,0
Infections and infestations		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	Pneumonia	Europe	214	30,5	1	0,5
Infections and infestations	Pneumonia	America	282	40,2	0	0,0
Infections and infestations	Pneumonia	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Nervous system disorders		Europe	214	30,5	0	0,0
Nervous system disorders		America	282	40,2	1	0,4
Nervous system disorders		Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Cerebral infarction	Europe	214	30,5	0	0,0
Nervous system disorders	Cerebral infarction	America	282	40,2	0	0,0
Nervous system disorders	Cerebral infarction	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Nervous system disorders	Cerebrovascular accident	Europe	214	30,5	0	0,0
Nervous system disorders	Cerebrovascular accident	America	282	40,2	1	0,4
Nervous system disorders	Cerebrovascular accident	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:23

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity

			Faricimab (N=701)			
MedDRA System Organ Class	MedDRA Preferred Term	Level	Patients		Patients with Event	
			n	%	n	%
Eye disorders		White	474	67,6	6	1,3
Eye disorders		Asian	176	25,1	2	1,1
Eye disorders		Other	27	3,9	0	0,0
Eye disorders		Unknown	24	3,4	0	0,0
Eye disorders	Cystoid macular oedema	White	474	67,6	2	0,4
Eye disorders	Cystoid macular oedema	Asian	176	25,1	0	0,0
Eye disorders	Cystoid macular oedema	Other	27	3,9	0	0,0
Eye disorders	Cystoid macular oedema	Unknown	24	3,4	0	0,0
Eye disorders	Glaucoma	White	474	67,6	0	0,0
Eye disorders	Glaucoma	Asian	176	25,1	1	0,6
Eye disorders	Glaucoma	Other	27	3,9	0	0,0
Eye disorders	Glaucoma	Unknown	24	3,4	0	0,0
Eye disorders	Macular hole	White	474	67,6	1	0,2
Eye disorders	Macular hole	Asian	176	25,1	0	0,0
Eye disorders	Macular hole	Other	27	3,9	0	0,0
Eye disorders	Macular hole	Unknown	24	3,4	0	0,0
Eye disorders	Retinal vein occlusion	White	474	67,6	0	0,0
Eye disorders	Retinal vein occlusion	Asian	176	25,1	1	0,6
Eye disorders	Retinal vein occlusion	Other	27	3,9	0	0,0
Eye disorders	Retinal vein occlusion	Unknown	24	3,4	0	0,0
Eye disorders	Uveitis	White	474	67,6	1	0,2
Eye disorders	Uveitis	Asian	176	25,1	0	0,0
Eye disorders	Uveitis	Other	27	3,9	0	0,0
Eye disorders	Uveitis	Unknown	24	3,4	0	0,0
Eye disorders	Vitritis	White	474	67,6	2	0,4
Eye disorders	Vitritis	Asian	176	25,1	0	0,0
Eye disorders	Vitritis	Other	27	3,9	0	0,0
Eye disorders	Vitritis	Unknown	24	3,4	0	0,0
Gastrointestinal disorders		White	474	67,6	1	0,2
Gastrointestinal disorders		Asian	176	25,1	0	0,0
Gastrointestinal disorders		Other	27	3,9	0	0,0
Gastrointestinal disorders		Unknown	24	3,4	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	White	474	67,6	1	0,2
Gastrointestinal disorders	Gastrointestinal inflammation	Asian	176	25,1	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Other	27	3,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Unknown	24	3,4	0	0,0

General disorders and administration site conditions		White	474	67,6	3	0,6
General disorders and administration site conditions		Asian	176	25,1	0	0,0
General disorders and administration site conditions		Other	27	3,9	0	0,0
General disorders and administration site conditions		Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Asthenia	White	474	67,6	1	0,2
General disorders and administration site conditions	Asthenia	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Asthenia	Other	27	3,9	0	0,0
General disorders and administration site conditions	Asthenia	Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Death	White	474	67,6	2	0,4
General disorders and administration site conditions	Death	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Death	Other	27	3,9	0	0,0
General disorders and administration site conditions	Death	Unknown	24	3,4	0	0,0
Infections and infestations		White	474	67,6	1	0,2
Infections and infestations		Asian	176	25,1	0	0,0
Infections and infestations		Other	27	3,9	0	0,0
Infections and infestations		Unknown	24	3,4	0	0,0
Infections and infestations	Pneumonia	White	474	67,6	1	0,2
Infections and infestations	Pneumonia	Asian	176	25,1	0	0,0
Infections and infestations	Pneumonia	Other	27	3,9	0	0,0
Infections and infestations	Pneumonia	Unknown	24	3,4	0	0,0
Nervous system disorders		White	474	67,6	1	0,2
Nervous system disorders		Asian	176	25,1	1	0,6
Nervous system disorders		Other	27	3,9	0	0,0
Nervous system disorders		Unknown	24	3,4	0	0,0
Nervous system disorders	Cerebral infarction	White	474	67,6	0	0,0
Nervous system disorders	Cerebral infarction	Asian	176	25,1	1	0,6
Nervous system disorders	Cerebral infarction	Other	27	3,9	0	0,0
Nervous system disorders	Cerebral infarction	Unknown	24	3,4	0	0,0
Nervous system disorders	Cerebrovascular accident	White	474	67,6	1	0,2
Nervous system disorders	Cerebrovascular accident	Asian	176	25,1	0	0,0
Nervous system disorders	Cerebrovascular accident	Other	27	3,9	0	0,0
Nervous system disorders	Cerebrovascular accident	Unknown	24	3,4	0	0,0

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:23

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Study Treatment Discontinuation
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline RVO status

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Eye disorders		CRVO	574	81,9	7	1,2
Eye disorders		HRVO	121	17,3	1	0,8
Eye disorders		Missing	6	0,9	0	0,0
Eye disorders	Cystoid macular oedema	CRVO	574	81,9	1	0,2
Eye disorders	Cystoid macular oedema	HRVO	121	17,3	1	0,8
Eye disorders	Cystoid macular oedema	Missing	6	0,9	0	0,0
Eye disorders	Glaucoma	CRVO	574	81,9	1	0,2
Eye disorders	Glaucoma	HRVO	121	17,3	0	0,0
Eye disorders	Glaucoma	Missing	6	0,9	0	0,0
Eye disorders	Macular hole	CRVO	574	81,9	1	0,2
Eye disorders	Macular hole	HRVO	121	17,3	0	0,0
Eye disorders	Macular hole	Missing	6	0,9	0	0,0
Eye disorders	Retinal vein occlusion	CRVO	574	81,9	1	0,2
Eye disorders	Retinal vein occlusion	HRVO	121	17,3	0	0,0
Eye disorders	Retinal vein occlusion	Missing	6	0,9	0	0,0
Eye disorders	Uveitis	CRVO	574	81,9	1	0,2
Eye disorders	Uveitis	HRVO	121	17,3	0	0,0
Eye disorders	Uveitis	Missing	6	0,9	0	0,0
Eye disorders	Vitritis	CRVO	574	81,9	2	0,3
Eye disorders	Vitritis	HRVO	121	17,3	0	0,0
Eye disorders	Vitritis	Missing	6	0,9	0	0,0
Gastrointestinal disorders		CRVO	574	81,9	1	0,2
Gastrointestinal disorders		HRVO	121	17,3	0	0,0
Gastrointestinal disorders		Missing	6	0,9	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	CRVO	574	81,9	1	0,2
Gastrointestinal disorders	Gastrointestinal inflammation	HRVO	121	17,3	0	0,0
Gastrointestinal disorders	Gastrointestinal inflammation	Missing	6	0,9	0	0,0
General disorders and administration site conditions		CRVO	574	81,9	1	0,2
General disorders and administration site conditions		HRVO	121	17,3	2	1,7
General disorders and administration site conditions		Missing	6	0,9	0	0,0
General disorders and administration site conditions	Asthenia	CRVO	574	81,9	0	0,0
General disorders and administration site conditions	Asthenia	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Asthenia	Missing	6	0,9	0	0,0
General disorders and administration site conditions	Death	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Death	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Death	Missing	6	0,9	0	0,0

Infections and infestations		CRVO	574	81,9	1	0,2
Infections and infestations		HRVO	121	17,3	0	0,0
Infections and infestations		Missing	6	0,9	0	0,0
Infections and infestations	Pneumonia	CRVO	574	81,9	1	0,2
Infections and infestations	Pneumonia	HRVO	121	17,3	0	0,0
Infections and infestations	Pneumonia	Missing	6	0,9	0	0,0
Nervous system disorders		CRVO	574	81,9	1	0,2
Nervous system disorders		HRVO	121	17,3	1	0,8
Nervous system disorders		Missing	6	0,9	0	0,0
Nervous system disorders	Cerebral infarction	CRVO	574	81,9	1	0,2
Nervous system disorders	Cerebral infarction	HRVO	121	17,3	0	0,0
Nervous system disorders	Cerebral infarction	Missing	6	0,9	0	0,0
Nervous system disorders	Cerebrovascular accident	CRVO	574	81,9	0	0,0
Nervous system disorders	Cerebrovascular accident	HRVO	121	17,3	1	0,8
Nervous system disorders	Cerebrovascular accident	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_WDSTAE_WK72_SEa24_29AUG2023_41986.xls

26APR2024 18:23

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

All

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		n/a	701	100,0	1	0,1
Cardiac disorders	Cardiac failure	n/a	701	100,0	1	0,1
General disorders and administration site conditions		n/a	701	100,0	2	0,3
General disorders and administration site conditions	Death	n/a	701	100,0	2	0,3
Infections and infestations		n/a	701	100,0	1	0,1
Infections and infestations	COVID-19	n/a	701	100,0	1	0,1
Vascular disorders		n/a	701	100,0	1	0,1
Vascular disorders	Aortic dissection	n/a	701	100,0	1	0,1

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 18:17

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Gender

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		Male	374	53,4	0	0,0
Cardiac disorders		Female	327	46,6	1	0,3
Cardiac disorders	Cardiac failure	Male	374	53,4	0	0,0
Cardiac disorders	Cardiac failure	Female	327	46,6	1	0,3
General disorders and administration site conditions		Male	374	53,4	1	0,3
General disorders and administration site conditions		Female	327	46,6	1	0,3
General disorders and administration site conditions	Death	Male	374	53,4	1	0,3
General disorders and administration site conditions	Death	Female	327	46,6	1	0,3
Infections and infestations		Male	374	53,4	1	0,3
Infections and infestations		Female	327	46,6	0	0,0
Infections and infestations	COVID-19	Male	374	53,4	1	0,3
Infections and infestations	COVID-19	Female	327	46,6	0	0,0
Vascular disorders		Male	374	53,4	0	0,0
Vascular disorders		Female	327	46,6	1	0,3
Vascular disorders	Aortic dissection	Male	374	53,4	0	0,0
Vascular disorders	Aortic dissection	Female	327	46,6	1	0,3

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 18:17

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Age

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		<65 years	308	43,9	0	0,0
Cardiac disorders		>=65 years	393	56,1	1	0,3
Cardiac disorders	Cardiac failure	<65 years	308	43,9	0	0,0
Cardiac disorders	Cardiac failure	>=65 years	393	56,1	1	0,3
General disorders and administration site conditions		<65 years	308	43,9	0	0,0
General disorders and administration site conditions		>=65 years	393	56,1	2	0,5
General disorders and administration site conditions	Death	<65 years	308	43,9	0	0,0
General disorders and administration site conditions	Death	>=65 years	393	56,1	2	0,5
Infections and infestations		<65 years	308	43,9	0	0,0
Infections and infestations		>=65 years	393	56,1	1	0,3
Infections and infestations	COVID-19	<65 years	308	43,9	0	0,0
Infections and infestations	COVID-19	>=65 years	393	56,1	1	0,3
Vascular disorders		<65 years	308	43,9	0	0,0
Vascular disorders		>=65 years	393	56,1	1	0,3
Vascular disorders	Aortic dissection	<65 years	308	43,9	0	0,0
Vascular disorders	Aortic dissection	>=65 years	393	56,1	1	0,3

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 18:17

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETDRS letter score

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		<=34 letters	156	22,3	0	0,0
Cardiac disorders		35 - 54 letters	206	29,4	1	0,5
Cardiac disorders		>=55 letters	339	48,4	0	0,0
Cardiac disorders	Cardiac failure	<=34 letters	156	22,3	0	0,0
Cardiac disorders	Cardiac failure	35 - 54 letters	206	29,4	1	0,5
Cardiac disorders	Cardiac failure	>=55 letters	339	48,4	0	0,0
General disorders and administration site conditions		<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions		35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions		>=55 letters	339	48,4	1	0,3
General disorders and administration site conditions	Death	<=34 letters	156	22,3	0	0,0
General disorders and administration site conditions	Death	35 - 54 letters	206	29,4	1	0,5
General disorders and administration site conditions	Death	>=55 letters	339	48,4	1	0,3
Infections and infestations		<=34 letters	156	22,3	0	0,0
Infections and infestations		35 - 54 letters	206	29,4	0	0,0
Infections and infestations		>=55 letters	339	48,4	1	0,3
Infections and infestations	COVID-19	<=34 letters	156	22,3	0	0,0
Infections and infestations	COVID-19	35 - 54 letters	206	29,4	0	0,0
Infections and infestations	COVID-19	>=55 letters	339	48,4	1	0,3
Vascular disorders		<=34 letters	156	22,3	0	0,0
Vascular disorders		35 - 54 letters	206	29,4	1	0,5
Vascular disorders		>=55 letters	339	48,4	0	0,0
Vascular disorders	Aortic dissection	<=34 letters	156	22,3	0	0,0
Vascular disorders	Aortic dissection	35 - 54 letters	206	29,4	1	0,5
Vascular disorders	Aortic dissection	>=55 letters	339	48,4	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 18:17

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline BCVA ETDRS letter score

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		<=23 letters	69	9,8	0	0,0
Cardiac disorders		>=24 letters	632	90,2	1	0,2
Cardiac disorders	Cardiac failure	<=23 letters	69	9,8	0	0,0
Cardiac disorders	Cardiac failure	>=24 letters	632	90,2	1	0,2
General disorders and administration site conditions		<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions		>=24 letters	632	90,2	2	0,3
General disorders and administration site conditions	Death	<=23 letters	69	9,8	0	0,0
General disorders and administration site conditions	Death	>=24 letters	632	90,2	2	0,3
Infections and infestations		<=23 letters	69	9,8	0	0,0
Infections and infestations		>=24 letters	632	90,2	1	0,2
Infections and infestations	COVID-19	<=23 letters	69	9,8	0	0,0
Infections and infestations	COVID-19	>=24 letters	632	90,2	1	0,2
Vascular disorders		<=23 letters	69	9,8	0	0,0
Vascular disorders		>=24 letters	632	90,2	1	0,2
Vascular disorders	Aortic dissection	<=23 letters	69	9,8	0	0,0
Vascular disorders	Aortic dissection	>=24 letters	632	90,2	1	0,2

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 18:17

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Geographic Region

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		Europe	214	30,5	1	0,5
Cardiac disorders		America	282	40,2	0	0,0
Cardiac disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Cardiac disorders	Cardiac failure	Europe	214	30,5	1	0,5
Cardiac disorders	Cardiac failure	America	282	40,2	0	0,0
Cardiac disorders	Cardiac failure	Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions		Europe	214	30,5	1	0,5
General disorders and administration site conditions		America	282	40,2	1	0,4
General disorders and administration site conditions		Asia Pacific (inc. Australia)	205	29,2	0	0,0
General disorders and administration site conditions	Death	Europe	214	30,5	1	0,5
General disorders and administration site conditions	Death	America	282	40,2	1	0,4
General disorders and administration site conditions	Death	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations		Europe	214	30,5	0	0,0
Infections and infestations		America	282	40,2	1	0,4
Infections and infestations		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Infections and infestations	COVID-19	Europe	214	30,5	0	0,0
Infections and infestations	COVID-19	America	282	40,2	1	0,4
Infections and infestations	COVID-19	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders		Europe	214	30,5	0	0,0
Vascular disorders		America	282	40,2	1	0,4
Vascular disorders		Asia Pacific (inc. Australia)	205	29,2	0	0,0
Vascular disorders	Aortic dissection	Europe	214	30,5	0	0,0
Vascular disorders	Aortic dissection	America	282	40,2	1	0,4
Vascular disorders	Aortic dissection	Asia Pacific (inc. Australia)	205	29,2	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 18:17

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Race/ethnicity

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		White	474	67,6	1	0,2
Cardiac disorders		Asian	176	25,1	0	0,0
Cardiac disorders		Other	27	3,9	0	0,0
Cardiac disorders		Unknown	24	3,4	0	0,0
Cardiac disorders	Cardiac failure	White	474	67,6	1	0,2
Cardiac disorders	Cardiac failure	Asian	176	25,1	0	0,0
Cardiac disorders	Cardiac failure	Other	27	3,9	0	0,0
Cardiac disorders	Cardiac failure	Unknown	24	3,4	0	0,0
General disorders and administration site conditions		White	474	67,6	2	0,4
General disorders and administration site conditions		Asian	176	25,1	0	0,0
General disorders and administration site conditions		Other	27	3,9	0	0,0
General disorders and administration site conditions		Unknown	24	3,4	0	0,0
General disorders and administration site conditions	Death	White	474	67,6	2	0,4
General disorders and administration site conditions	Death	Asian	176	25,1	0	0,0
General disorders and administration site conditions	Death	Other	27	3,9	0	0,0
General disorders and administration site conditions	Death	Unknown	24	3,4	0	0,0
Infections and infestations		White	474	67,6	1	0,2
Infections and infestations		Asian	176	25,1	0	0,0
Infections and infestations		Other	27	3,9	0	0,0
Infections and infestations		Unknown	24	3,4	0	0,0
Infections and infestations	COVID-19	White	474	67,6	1	0,2
Infections and infestations	COVID-19	Asian	176	25,1	0	0,0
Infections and infestations	COVID-19	Other	27	3,9	0	0,0
Infections and infestations	COVID-19	Unknown	24	3,4	0	0,0
Vascular disorders		White	474	67,6	1	0,2
Vascular disorders		Asian	176	25,1	0	0,0
Vascular disorders		Other	27	3,9	0	0,0
Vascular disorders		Unknown	24	3,4	0	0,0
Vascular disorders	Aortic dissection	White	474	67,6	1	0,2
Vascular disorders	Aortic dissection	Asian	176	25,1	0	0,0
Vascular disorders	Aortic dissection	Other	27	3,9	0	0,0
Vascular disorders	Aortic dissection	Unknown	24	3,4	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 18:17

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: AEs leading to Death
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

Baseline RVO status

			Faricimab (N=701)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Cardiac disorders		CRVO	574	81,9	1	0,2
Cardiac disorders		HRVO	121	17,3	0	0,0
Cardiac disorders		Missing	6	0,9	0	0,0
Cardiac disorders	Cardiac failure	CRVO	574	81,9	1	0,2
Cardiac disorders	Cardiac failure	HRVO	121	17,3	0	0,0
Cardiac disorders	Cardiac failure	Missing	6	0,9	0	0,0
General disorders and administration site conditions		CRVO	574	81,9	1	0,2
General disorders and administration site conditions		HRVO	121	17,3	1	0,8
General disorders and administration site conditions		Missing	6	0,9	0	0,0
General disorders and administration site conditions	Death	CRVO	574	81,9	1	0,2
General disorders and administration site conditions	Death	HRVO	121	17,3	1	0,8
General disorders and administration site conditions	Death	Missing	6	0,9	0	0,0
Infections and infestations		CRVO	574	81,9	1	0,2
Infections and infestations		HRVO	121	17,3	0	0,0
Infections and infestations		Missing	6	0,9	0	0,0
Infections and infestations	COVID-19	CRVO	574	81,9	1	0,2
Infections and infestations	COVID-19	HRVO	121	17,3	0	0,0
Infections and infestations	COVID-19	Missing	6	0,9	0	0,0
Vascular disorders		CRVO	574	81,9	1	0,2
Vascular disorders		HRVO	121	17,3	0	0,0
Vascular disorders		Missing	6	0,9	0	0,0
Vascular disorders	Aortic dissection	CRVO	574	81,9	1	0,2
Vascular disorders	Aortic dissection	HRVO	121	17,3	0	0,0
Vascular disorders	Aortic dissection	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ae_soc_descriptive_w72.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_soc_descriptive_w72_sg_DTHAE_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 18:17

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Intraocular Inflammation Events (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	5	0,9
Gender	Male	264	49,2	0	0,0
	Female	273	50,8	5	1,8
Age	<65 years	270	50,3	2	0,7
	>=65 years	267	49,7	3	1,1
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	2	1,1
	>=55 letters	361	67,2	3	0,8
Geographic Region	Europe	147	27,4	3	2,0
	America	197	36,7	1	0,5
	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Race/ethnicity	White	332	61,8	3	0,9
	Asian	180	33,5	2	1,1
	Other	17	3,2	0	0,0
	Unknown	8	1,5	0	0,0

The observed Intraocular Inflammation Events are Iridocyclitis, Iritis and Vitritis.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7a_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:34

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Retinal Vascular Occlusive Disease (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	20	3,7
Gender	Male	264	49,2	11	4,2
	Female	273	50,8	9	3,3
Age	<65 years	270	50,3	10	3,7
	>=65 years	267	49,7	10	3,7
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	8	4,5
	>=55 letters	361	67,2	12	3,3
Geographic Region	Europe	147	27,4	6	4,1
	America	197	36,7	10	5,1
	Asia Pacific (inc. Australia)	193	35,9	4	2,1
Race/ethnicity	White	332	61,8	15	4,5
	Asian	180	33,5	4	2,2
	Other	17	3,2	1	5,9
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8a_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:37

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: PT: Endophthalmitis (Study Eye)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10a_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:13

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Intraocular Inflammation Events (Fellow Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	1	0,2
Gender	Male	264	49,2	0	0,0
	Female	273	50,8	1	0,4
Age	<65 years	270	50,3	0	0,0
	>=65 years	267	49,7	1	0,4
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	1	0,6
	>=55 letters	361	67,2	0	0,0
Geographic Region	Europe	147	27,4	0	0,0
	America	197	36,7	0	0,0
	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Race/ethnicity	White	332	61,8	0	0,0
	Asian	180	33,5	1	0,6
	Other	17	3,2	0	0,0
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7b_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:36

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Retinal Vascular Occlusive Disease (Fellow Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	5	0,9
Gender	Male	264	49,2	3	1,1
	Female	273	50,8	2	0,7
Age	<65 years	270	50,3	2	0,7
	>=65 years	267	49,7	3	1,1
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	1	0,6
	>=55 letters	361	67,2	4	1,1
Geographic Region	Europe	147	27,4	1	0,7
	America	197	36,7	3	1,5
	Asia Pacific (inc. Australia)	193	35,9	1	0,5
Race/ethnicity	White	332	61,8	2	0,6
	Asian	180	33,5	2	1,1
	Other	17	3,2	1	5,9
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8b_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:38

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: PT: Endophthalmitis (Fellow Eye)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10b_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:14

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Intraocular Inflammation Events (Study Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7aSEV_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:10

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Retinal Vascular Occlusive Disease (Study Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8aSEV_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:12

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: PT: Endophthalmitis (Study Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10aSEV_WK72_SEa24_30AUG2023_41984
03JUL2024 15:13

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Intraocular Inflammation Events (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7bSEV_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:10

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Retinal Vascular Occlusive Disease (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8bSEV_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:12

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: PT: Endophthalmitis (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10bSEV_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:14

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Intraocular Inflammation Events (Study Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7aSER_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:09

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Retinal Vascular Occlusive Disease (Study Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8aSER_WK72_SEa24_30AUG2023_41984.:
03JUL2024 15:11

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: PT: Endophthalmitis (Study Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10aSER_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:13

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Intraocular Inflammation Events (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7bSER_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:10

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Retinal Vascular Occlusive Disease (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8bSER_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:12

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: PT: Endophthalmitis (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10bSER_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:14

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice

MODEL: Unstratified Analysis

STUDY: GR41984

Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI1_WK72_SEa24_30AUG2023_41984.xls

03JUL2024 14:58

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2a_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 14:59

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2b_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:04

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of >= 30 letters in VA Score lasting more than 1 hour (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	2	0,4
Gender	Male	264	49,2	1	0,4
	Female	273	50,8	1	0,4
Age	<65 years	270	50,3	0	0,0
	>=65 years	267	49,7	2	0,7
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	1	0,6
	>=55 letters	361	67,2	1	0,3
Geographic Region	Europe	147	27,4	0	0,0
	America	197	36,7	2	1,0
	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Race/ethnicity	White	332	61,8	1	0,3
	Asian	180	33,5	0	0,0
	Other	17	3,2	1	5,9
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3a_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:21

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of >= 30 letters in VA Score lasting more than 1 hour (Fellow Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	1	0,2
Gender	Male	264	49,2	0	0,0
	Female	273	50,8	1	0,4
Age	<65 years	270	50,3	0	0,0
	>=65 years	267	49,7	1	0,4
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	0	0,0
	>=55 letters	361	67,2	1	0,3
Geographic Region	Europe	147	27,4	1	0,7
	America	197	36,7	0	0,0
	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Race/ethnicity	White	332	61,8	1	0,3
	Asian	180	33,5	0	0,0
	Other	17	3,2	0	0,0
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3b_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:27

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4a_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:01

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4b_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:06

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Associated with severe intraocular inflammation (Study Eye)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5a_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:03

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5b_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:07

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Antiplatelet Trialists Collaboration (APTC) event
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	10	1,9
Gender	Male	264	49,2	4	1,5
	Female	273	50,8	6	2,2
Age	<65 years	270	50,3	3	1,1
	>=65 years	267	49,7	7	2,6
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	3	1,7
	>=55 letters	361	67,2	7	1,9
Geographic Region	Europe	147	27,4	2	1,4
	America	197	36,7	5	2,5
	Asia Pacific (inc. Australia)	193	35,9	3	1,6
Race/ethnicity	White	332	61,8	6	1,8
	Asian	180	33,5	3	1,7
	Other	17	3,2	0	0,0
	Unknown	8	1,5	1	12,5

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI6_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:32

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice (Severe)

MODEL: Unstratified Analysis

STUDY: GR41984

Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI1SEV_WK72_SEa24_30AUG2023_41984.xls

03JUL2024 14:59

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2aSEV_WK72_SEa24_30AUG2023_41984.:
03JUL2024 15:01

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2bSEV_WK72_SEa24_30AUG2023_41984.:
03JUL2024 15:05

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of >= 30 letters in VA Score lasting more than 1 hour (Study Eye, Severe)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	1	0,2
Gender	Male	264	49,2	1	0,4
	Female	273	50,8	0	0,0
Age	<65 years	270	50,3	0	0,0
	>=65 years	267	49,7	1	0,4
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	1	0,6
	>=55 letters	361	67,2	0	0,0
Geographic Region	Europe	147	27,4	0	0,0
	America	197	36,7	1	0,5
	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Race/ethnicity	White	332	61,8	0	0,0
	Asian	180	33,5	0	0,0
	Other	17	3,2	1	5,9
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3aSEV_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 16:10

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of >= 30 letters in VA Score lasting more than 1 hour (Fellow Eye, Severe)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	1	0,2
Gender	Male	264	49,2	0	0,0
	Female	273	50,8	1	0,4
Age	<65 years	270	50,3	0	0,0
	>=65 years	267	49,7	1	0,4
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	0	0,0
	>=55 letters	361	67,2	1	0,3
Geographic Region	Europe	147	27,4	1	0,7
	America	197	36,7	0	0,0
	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Race/ethnicity	White	332	61,8	1	0,3
	Asian	180	33,5	0	0,0
	Other	17	3,2	0	0,0
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3bSEV_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 16:16

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4aSEV_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:02

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4bSEV_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:07

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Associated with severe intraocular inflammation (Study Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5aSEV_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:04

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5bSEV_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:08

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Antiplatelet Trialists Collaboration (APTC) event (Severe)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	8	1,5
Gender	Male	264	49,2	4	1,5
	Female	273	50,8	4	1,5
Age	<65 years	270	50,3	3	1,1
	>=65 years	267	49,7	5	1,9
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	2	1,1
	>=55 letters	361	67,2	6	1,7
Geographic Region	Europe	147	27,4	1	0,7
	America	197	36,7	4	2,0
	Asia Pacific (inc. Australia)	193	35,9	3	1,6
Race/ethnicity	White	332	61,8	5	1,5
	Asian	180	33,5	3	1,7
	Other	17	3,2	0	0,0
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI6SEV_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 16:21

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice (Serious)

MODEL: Unstratified Analysis

STUDY: GR41984

Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI1SER_WK72_SEa24_30AUG2023_41984.xls

03JUL2024 14:59

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2aSER_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:00

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2bSER_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:05

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of >= 30 letters in VA Score lasting more than 1 hour (Study Eye, Serious)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	2	0,4
Gender	Male	264	49,2	1	0,4
	Female	273	50,8	1	0,4
Age	<65 years	270	50,3	0	0,0
	>=65 years	267	49,7	2	0,7
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	1	0,6
	>=55 letters	361	67,2	1	0,3
Geographic Region	Europe	147	27,4	0	0,0
	America	197	36,7	2	1,0
	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Race/ethnicity	White	332	61,8	1	0,3
	Asian	180	33,5	0	0,0
	Other	17	3,2	1	5,9
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3aSER_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:47

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of >= 30 letters in VA Score lasting more than 1 hour (Fellow Eye, Serious)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	1	0,2
Gender	Male	264	49,2	0	0,0
	Female	273	50,8	1	0,4
Age	<65 years	270	50,3	0	0,0
	>=65 years	267	49,7	1	0,4
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	0	0,0
	>=55 letters	361	67,2	1	0,3
Geographic Region	Europe	147	27,4	1	0,7
	America	197	36,7	0	0,0
	Asia Pacific (inc. Australia)	193	35,9	0	0,0
Race/ethnicity	White	332	61,8	1	0,3
	Asian	180	33,5	0	0,0
	Other	17	3,2	0	0,0
	Unknown	8	1,5	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3bSER_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:53

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4aSER_WK72_SEa24_30AUG2023_41984.:
03JUL2024 15:02

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4bSER_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:06

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Associated with severe intraocular inflammation (Study Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5aSER_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:03

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41984
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5bSER_WK72_SEa24_30AUG2023_41984.xls
03JUL2024 15:08

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Antiplatelet Trialists Collaboration (APTC) event (Serious)
 MODEL: Unstratified Analysis
 STUDY: GR41984
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=537)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	537	100,0	10	1,9
Gender	Male	264	49,2	4	1,5
	Female	273	50,8	6	2,2
Age	<65 years	270	50,3	3	1,1
	>=65 years	267	49,7	7	2,6
Baseline BCVA ETDRS letter score	<=54 letters	176	32,8	3	1,7
	>=55 letters	361	67,2	7	1,9
Geographic Region	Europe	147	27,4	2	1,4
	America	197	36,7	5	2,5
	Asia Pacific (inc. Australia)	193	35,9	3	1,6
Race/ethnicity	White	332	61,8	6	1,8
	Asian	180	33,5	3	1,7
	Other	17	3,2	0	0,0
	Unknown	8	1,5	1	12,5

Program: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI6SER_WK72_SEa24_30AUG2023_41984.xls
 26APR2024 15:57

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Intraocular Inflammation Events (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	15	2,1
Gender	Male	374	53,4	9	2,4
	Female	327	46,6	6	1,8
Age	<65 years	308	43,9	7	2,3
	>=65 years	393	56,1	8	2,0
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	3	1,9
	35 - 54 letters	206	29,4	6	2,9
	>=55 letters	339	48,4	6	1,8
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	15	2,4
Geographic Region	Europe	214	30,5	8	3,7
	America	282	40,2	3	1,1
	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Race/ethnicity	White	474	67,6	13	2,7
	Asian	176	25,1	2	1,1
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	12	2,1
	HRVO	121	17,3	3	2,5
	Missing	6	0,9	0	0,0

The observed Intraocular Inflammation Events are Uveitis, Vitritis, Iridocyclitis, Iritis, Non-infectious endophthalmitis and Keratic precipitates.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7a_WK72_SEa24_29AUG2023_41986.xls
 06MAY2024 15:39

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Retinal Vascular Occlusive Disease (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	23	3,3
Gender	Male	374	53,4	13	3,5
	Female	327	46,6	10	3,1
Age	<65 years	308	43,9	8	2,6
	>=65 years	393	56,1	15	3,8
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	9	5,8
	35 - 54 letters	206	29,4	2	1,0
	>=55 letters	339	48,4	12	3,5
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	3	4,3
	>=24 letters	632	90,2	20	3,2
Geographic Region	Europe	214	30,5	6	2,8
	America	282	40,2	10	3,5
	Asia Pacific (inc. Australia)	205	29,2	7	3,4
Race/ethnicity	White	474	67,6	18	3,8
	Asian	176	25,1	3	1,7
	Other	27	3,9	2	7,4
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	21	3,7
	HRVO	121	17,3	2	1,7
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8a_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:52

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: PT: Endophthalmitis (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	1	0,1
Gender	Male	374	53,4	1	0,3
	Female	327	46,6	0	0,0
Age	<65 years	308	43,9	0	0,0
	>=65 years	393	56,1	1	0,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	0	0,0
	>=55 letters	339	48,4	1	0,3
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	1	0,2
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	0	0,0
	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Race/ethnicity	White	474	67,6	1	0,2
	Asian	176	25,1	0	0,0
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	0	0,0
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10a_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:55

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Intraocular Inflammation Events (Fellow Eye)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7b_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:07

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Retinal Vascular Occlusive Disease (Fellow Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	4	0,6
Gender	Male	374	53,4	2	0,5
	Female	327	46,6	2	0,6
Age	<65 years	308	43,9	0	0,0
	>=65 years	393	56,1	4	1,0
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	2	1,0
	>=55 letters	339	48,4	2	0,6
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	4	0,6
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	3	1,1
	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Race/ethnicity	White	474	67,6	4	0,8
	Asian	176	25,1	0	0,0
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	3	0,5
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8b_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:53

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: PT: Endophthalmitis (Fellow Eye)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10b_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:10

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Intraocular Inflammation Events (Study Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7aSEV_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:07

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Retinal Vascular Occlusive Disease (Study Eye, Severe)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	7	1,0
Gender	Male	374	53,4	5	1,3
	Female	327	46,6	2	0,6
Age	<65 years	308	43,9	2	0,6
	>=65 years	393	56,1	5	1,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	2	1,3
	35 - 54 letters	206	29,4	0	0,0
	>=55 letters	339	48,4	5	1,5
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	7	1,1
Geographic Region	Europe	214	30,5	2	0,9
	America	282	40,2	4	1,4
	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Race/ethnicity	White	474	67,6	6	1,3
	Asian	176	25,1	0	0,0
	Other	27	3,9	1	3,7
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	7	1,2
	HRVO	121	17,3	0	0,0
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8aSEV_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:38

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: PT: Endophthalmitis (Study Eye, Severe)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	1	0,1
Gender	Male	374	53,4	1	0,3
	Female	327	46,6	0	0,0
Age	<65 years	308	43,9	0	0,0
	>=65 years	393	56,1	1	0,3
Baseline BCVA ETRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	0	0,0
	>=55 letters	339	48,4	1	0,3
Baseline BCVA ETRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	1	0,2
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	0	0,0
	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Race/ethnicity	White	474	67,6	1	0,2
	Asian	176	25,1	0	0,0
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	0	0,0
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10aSEV_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:41

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Intraocular Inflammation Events (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7bSEV_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:08

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Retinal Vascular Occlusive Disease (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8bSEV_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:09

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: PT: Endophthalmitis (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10bSEV_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:11

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Intraocular Inflammation Events (Study Eye, Serious)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	3	0,4
Gender	Male	374	53,4	2	0,5
	Female	327	46,6	1	0,3
Age	<65 years	308	43,9	2	0,6
	>=65 years	393	56,1	1	0,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	1	0,5
	>=55 letters	339	48,4	2	0,6
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	3	0,5
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	1	0,4
	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Race/ethnicity	White	474	67,6	3	0,6
	Asian	176	25,1	0	0,0
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	2	0,3
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

The observed Intraocular Inflammation Events are Uveitis, Vitritis and Iridocyclitis.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7aSER_WK72_SEa24_29AUG2023_41986.xls
 06MAY2024 15:33

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Retinal Vascular Occlusive Disease (Study Eye, Serious)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	11	1,6
Gender	Male	374	53,4	7	1,9
	Female	327	46,6	4	1,2
Age	<65 years	308	43,9	4	1,3
	>=65 years	393	56,1	7	1,8
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	3	1,9
	35 - 54 letters	206	29,4	1	0,5
	>=55 letters	339	48,4	7	2,1
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	1	1,4
	>=24 letters	632	90,2	10	1,6
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	6	2,1
	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Race/ethnicity	White	474	67,6	9	1,9
	Asian	176	25,1	1	0,6
	Other	27	3,9	1	3,7
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	9	1,6
	HRVO	121	17,3	2	1,7
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8aSER_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:16

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: PT: Endophthalmitis (Study Eye, Serious)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	1	0,1
Gender	Male	374	53,4	1	0,3
	Female	327	46,6	0	0,0
Age	<65 years	308	43,9	0	0,0
	>=65 years	393	56,1	1	0,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	0	0,0
	>=55 letters	339	48,4	1	0,3
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	1	0,2
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	0	0,0
	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Race/ethnicity	White	474	67,6	1	0,2
	Asian	176	25,1	0	0,0
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	0	0,0
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10aSER_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:20

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Intraocular Inflammation Events (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI7bSER_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:08

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Retinal Vascular Occlusive Disease (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI8bSER_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:09

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: PT: Endophthalmitis (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI10bSER_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:10

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI1_WK72_SEa24_29AUG2023_41986.xls

03JUL2024 14:59

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2a_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:01

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2b_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:02

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of >= 30 letters in VA Score lasting more than 1 hour (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	23	3,3
Gender	Male	374	53,4	12	3,2
	Female	327	46,6	11	3,4
Age	<65 years	308	43,9	9	2,9
	>=65 years	393	56,1	14	3,6
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	5	3,2
	35 - 54 letters	206	29,4	4	1,9
	>=55 letters	339	48,4	14	4,1
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	1	1,4
	>=24 letters	632	90,2	22	3,5
Geographic Region	Europe	214	30,5	4	1,9
	America	282	40,2	11	3,9
	Asia Pacific (inc. Australia)	205	29,2	8	3,9
Race/ethnicity	White	474	67,6	18	3,8
	Asian	176	25,1	3	1,7
	Other	27	3,9	1	3,7
	Unknown	24	3,4	1	4,2
Baseline RVO status	CRVO	574	81,9	20	3,5
	HRVO	121	17,3	3	2,5
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3a_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:36

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of >= 30 letters in VA Score lasting more than 1 hour (Fellow Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	1	0,1
Gender	Male	374	53,4	0	0,0
	Female	327	46,6	1	0,3
Age	<65 years	308	43,9	0	0,0
	>=65 years	393	56,1	1	0,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	1	0,5
	>=55 letters	339	48,4	0	0,0
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	1	0,2
Geographic Region	Europe	214	30,5	0	0,0
	America	282	40,2	0	0,0
	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Race/ethnicity	White	474	67,6	0	0,0
	Asian	176	25,1	1	0,6
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	1	0,2
	HRVO	121	17,3	0	0,0
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3b_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:42

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	7	1,0
Gender	Male	374	53,4	5	1,3
	Female	327	46,6	2	0,6
Age	<65 years	308	43,9	4	1,3
	>=65 years	393	56,1	3	0,8
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	3	1,9
	35 - 54 letters	206	29,4	3	1,5
	>=55 letters	339	48,4	1	0,3
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	1	1,4
	>=24 letters	632	90,2	6	0,9
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	2	0,7
	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Race/ethnicity	White	474	67,6	6	1,3
	Asian	176	25,1	1	0,6
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	7	1,2
	HRVO	121	17,3	0	0,0
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4a_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:38

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4b_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:04

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Associated with severe intraocular inflammation (Study Eye)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	1	0,1
Gender	Male	374	53,4	1	0,3
	Female	327	46,6	0	0,0
Age	<65 years	308	43,9	0	0,0
	>=65 years	393	56,1	1	0,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	0	0,0
	>=55 letters	339	48,4	1	0,3
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	1	0,2
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	0	0,0
	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Race/ethnicity	White	474	67,6	1	0,2
	Asian	176	25,1	0	0,0
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	0	0,0
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5a_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:39

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5b_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:05

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Antiplatelet Trialists Collaboration (APTC) event
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	14	2,0
Gender	Male	374	53,4	9	2,4
	Female	327	46,6	5	1,5
Age	<65 years	308	43,9	2	0,6
	>=65 years	393	56,1	12	3,1
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	1	0,6
	35 - 54 letters	206	29,4	5	2,4
	>=55 letters	339	48,4	8	2,4
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	14	2,2
Geographic Region	Europe	214	30,5	4	1,9
	America	282	40,2	5	1,8
	Asia Pacific (inc. Australia)	205	29,2	5	2,4
Race/ethnicity	White	474	67,6	12	2,5
	Asian	176	25,1	1	0,6
	Other	27	3,9	1	3,7
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	13	2,3
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI6_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 15:47

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice (Severe)

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI1SEV_WK72_SEa24_29AUG2023_41986.xls

03JUL2024 15:00

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2aSEV_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:02

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2bSEV_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:03

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of ≥ 30 letters in VA Score lasting more than 1 hour (Study Eye, Severe)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	14	2,0
Gender	Male	374	53,4	7	1,9
	Female	327	46,6	7	2,1
Age	<65 years	308	43,9	3	1,0
	≥ 65 years	393	56,1	11	2,8
Baseline BCVA ETDRS letter score	≤ 34 letters	156	22,3	1	0,6
	35 - 54 letters	206	29,4	3	1,5
	> 55 letters	339	48,4	10	2,9
Baseline BCVA ETDRS letter score	≤ 23 letters	69	9,8	0	0,0
	≥ 24 letters	632	90,2	14	2,2
Geographic Region	Europe	214	30,5	2	0,9
	America	282	40,2	8	2,8
	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Race/ethnicity	White	474	67,6	10	2,1
	Asian	176	25,1	2	1,1
	Other	27	3,9	1	3,7
	Unknown	24	3,4	1	4,2
Baseline RVO status	CRVO	574	81,9	14	2,4
	HRVO	121	17,3	0	0,0
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3aSEV_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:25

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Causes a decrease of ≥ 30 letters in VA Score lasting more than 1 hour (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3bSEV_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:03

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye, Severe)

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	3	0,4
Gender	Male	374	53,4	1	0,3
	Female	327	46,6	2	0,6
Age	<65 years	308	43,9	1	0,3
	>=65 years	393	56,1	2	0,5
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	1	0,6
	35 - 54 letters	206	29,4	1	0,5
	>=55 letters	339	48,4	1	0,3
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	3	0,5
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	0	0,0
	Asia Pacific (inc. Australia)	205	29,2	2	1,0
Race/ethnicity	White	474	67,6	3	0,6
	Asian	176	25,1	0	0,0
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	3	0,5
	HRVO	121	17,3	0	0,0
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4aSEV_WK72_SEa24_29AUG2023_41986.xls

26APR2024 16:26

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4bSEV_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:05

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Associated with severe intraocular inflammation (Study Eye, Severe)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	1	0,1
Gender	Male	374	53,4	1	0,3
	Female	327	46,6	0	0,0
Age	<65 years	308	43,9	0	0,0
	>=65 years	393	56,1	1	0,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	0	0,0
	>=55 letters	339	48,4	1	0,3
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	1	0,2
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	0	0,0
	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Race/ethnicity	White	474	67,6	1	0,2
	Asian	176	25,1	0	0,0
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	0	0,0
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5aSEV_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:28

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye, Severe)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5bSEV_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:06

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Antiplatelet Trialists Collaboration (APTC) event (Severe)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	11	1,6
Gender	Male	374	53,4	6	1,6
	Female	327	46,6	5	1,5
Age	<65 years	308	43,9	2	0,6
	>=65 years	393	56,1	9	2,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	1	0,6
	35 - 54 letters	206	29,4	4	1,9
	>=55 letters	339	48,4	6	1,8
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	11	1,7
Geographic Region	Europe	214	30,5	4	1,9
	America	282	40,2	4	1,4
	Asia Pacific (inc. Australia)	205	29,2	3	1,5
Race/ethnicity	White	474	67,6	10	2,1
	Asian	176	25,1	0	0,0
	Other	27	3,9	1	3,7
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	10	1,7
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI6SEV_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:34

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice (Serious)

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI1SER_WK72_SEa24_29AUG2023_41986.xls

03JUL2024 15:00

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Study Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2aSER_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:01

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Suspected transmission of an infectious agent by the study drug (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI2bSER_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:03

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of >= 30 letters in VA Score lasting more than 1 hour (Study Eye, Serious)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	23	3,3
Gender	Male	374	53,4	12	3,2
	Female	327	46,6	11	3,4
Age	<65 years	308	43,9	9	2,9
	>=65 years	393	56,1	14	3,6
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	5	3,2
	35 - 54 letters	206	29,4	4	1,9
	>=55 letters	339	48,4	14	4,1
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	1	1,4
	>=24 letters	632	90,2	22	3,5
Geographic Region	Europe	214	30,5	4	1,9
	America	282	40,2	11	3,9
	Asia Pacific (inc. Australia)	205	29,2	8	3,9
Race/ethnicity	White	474	67,6	18	3,8
	Asian	176	25,1	3	1,7
	Other	27	3,9	1	3,7
	Unknown	24	3,4	1	4,2
Baseline RVO status	CRVO	574	81,9	20	3,5
	HRVO	121	17,3	3	2,5
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3aSER_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:01

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Causes a decrease of ≥ 30 letters in VA Score lasting more than 1 hour (Fellow Eye, Serious)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	1	0,1
Gender	Male	374	53,4	0	0,0
	Female	327	46,6	1	0,3
Age	<65 years	308	43,9	0	0,0
	≥ 65 years	393	56,1	1	0,3
Baseline BCVA ETDRS letter score	≤ 34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	1	0,5
	≥ 55 letters	339	48,4	0	0,0
Baseline BCVA ETDRS letter score	≤ 23 letters	69	9,8	0	0,0
	≥ 24 letters	632	90,2	1	0,2
Geographic Region	Europe	214	30,5	0	0,0
	America	282	40,2	0	0,0
	Asia Pacific (inc. Australia)	205	29,2	1	0,5
Race/ethnicity	White	474	67,6	0	0,0
	Asian	176	25,1	1	0,6
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	1	0,2
	HRVO	121	17,3	0	0,0
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI3bSER_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:07

POPULATION: Safety-Evaluable Population after Week 24

ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Study Eye, Serious)

MODEL: Unstratified Analysis

STUDY: GR41986

Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	7	1,0
Gender	Male	374	53,4	5	1,3
	Female	327	46,6	2	0,6
Age	<65 years	308	43,9	4	1,3
	>=65 years	393	56,1	3	0,8
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	3	1,9
	35 - 54 letters	206	29,4	3	1,5
	>=55 letters	339	48,4	1	0,3
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	1	1,4
	>=24 letters	632	90,2	6	0,9
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	2	0,7
	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Race/ethnicity	White	474	67,6	6	1,3
	Asian	176	25,1	1	0,6
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	7	1,2
	HRVO	121	17,3	0	0,0
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4aSER_WK72_SEa24_29AUG2023_41986.xls

26APR2024 16:02

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Requires surgical or medical intervention to prevent permanent loss of sight (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI4bSER_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:05

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Associated with severe intraocular inflammation (Study Eye, Serious)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	1	0,1
Gender	Male	374	53,4	1	0,3
	Female	327	46,6	0	0,0
Age	<65 years	308	43,9	0	0,0
	>=65 years	393	56,1	1	0,3
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	0	0,0
	35 - 54 letters	206	29,4	0	0,0
	>=55 letters	339	48,4	1	0,3
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	1	0,2
Geographic Region	Europe	214	30,5	1	0,5
	America	282	40,2	0	0,0
	Asia Pacific (inc. Australia)	205	29,2	0	0,0
Race/ethnicity	White	474	67,6	1	0,2
	Asian	176	25,1	0	0,0
	Other	27	3,9	0	0,0
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	0	0,0
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5aSER_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:04

POPULATION: Safety-Evaluable Population after Week 24
ENDPOINT: Associated with severe intraocular inflammation (Fellow Eye, Serious)
MODEL: Unstratified Analysis
STUDY: GR41986
Descriptive Analysis (Safety) after Week 24

Null Report: No observations met the reporting criteria for inclusion in this output.

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI5bSER_WK72_SEa24_29AUG2023_41986.xls
03JUL2024 15:06

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: Antiplatelet Trialists Collaboration (APTC) event (Serious)
 MODEL: Unstratified Analysis
 STUDY: GR41986
 Descriptive Analysis (Safety) after Week 24

		Faricimab (N=701)			
		Patients		Patients with Event	
Name	Level	n	%	n	%
All	n/a	701	100,0	12	1,7
Gender	Male	374	53,4	7	1,9
	Female	327	46,6	5	1,5
Age	<65 years	308	43,9	2	0,6
	>=65 years	393	56,1	10	2,5
Baseline BCVA ETDRS letter score	<=34 letters	156	22,3	1	0,6
	35 - 54 letters	206	29,4	5	2,4
	>=55 letters	339	48,4	6	1,8
Baseline BCVA ETDRS letter score	<=23 letters	69	9,8	0	0,0
	>=24 letters	632	90,2	12	1,9
Geographic Region	Europe	214	30,5	4	1,9
	America	282	40,2	4	1,4
	Asia Pacific (inc. Australia)	205	29,2	4	2,0
Race/ethnicity	White	474	67,6	11	2,3
	Asian	176	25,1	0	0,0
	Other	27	3,9	1	3,7
	Unknown	24	3,4	0	0,0
Baseline RVO status	CRVO	574	81,9	11	1,9
	HRVO	121	17,3	1	0,8
	Missing	6	0,9	0	0,0

Program: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/program/t_ae_raw_descriptive.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ae_raw_descriptive_sg_AESI6SER_WK72_SEa24_29AUG2023_41986.xls
 26APR2024 16:12

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients on a Q4W Treatment Interval by Visit at Week 24 up to Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

			Faricimab (N=544)			
			Patients		Patients with Event	
Name	Visit	Level	n	%	n	%
All	Week 24	n/a	541	99,4	34	6,3
	Week 28	n/a	537	98,7	80	14,9
	Week 32	n/a	534	98,2	90	16,9
	Week 36	n/a	529	97,2	101	19,1
	Week 40	n/a	524	96,3	106	20,2
	Week 44	n/a	517	95,0	99	19,1
	Week 48	n/a	514	94,5	105	20,4
	Week 52	n/a	512	94,1	106	20,7
	Week 56	n/a	506	93,0	121	23,9
	Week 60	n/a	499	91,7	115	23,0
	Week 64	n/a	495	91,0	115	23,2
	Week 68	n/a	492	90,4	117	23,8

Only patients who have not discontinued the study at Week x are used for analysis.
 Treatment interval at Week x is defined as the treatment interval decision followed at that visit.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_visit_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_visit_a24_Q4W_W2472_ITa24_30AUG2023_41984.xls
 26APR2024 15:24

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients on a Q8W Treatment Interval by Visit at Week 24 up to Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

			Faricimab (N=544)			
			Patients		Patients with Event	
Name	Visit	Level	n	%	n	%
All	Week 24	n/a	541	99,4	507	93,7
	Week 28	n/a	537	98,7	101	18,8
	Week 32	n/a	534	98,2	67	12,5
	Week 36	n/a	529	97,2	33	6,2
	Week 40	n/a	524	96,3	76	14,5
	Week 44	n/a	517	95,0	77	14,9
	Week 48	n/a	514	94,5	76	14,8
	Week 52	n/a	512	94,1	81	15,8
	Week 56	n/a	506	93,0	77	15,2
	Week 60	n/a	499	91,7	83	16,6
	Week 64	n/a	495	91,0	83	16,8
	Week 68	n/a	492	90,4	77	15,7

Only patients who have not discontinued the study at Week x are used for analysis.
 Treatment interval at Week x is defined as the treatment interval decision followed at that visit.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_visit_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_visit_a24_Q8W_W2472_ITa24_30AUG2023_41984.xls
 26APR2024 15:26

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients on a Q12W Treatment Interval by Visit at Week 24 up to Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

			Faricimab (N=544)			
			Patients		Patients with Event	
Name	Visit	Level	n	%	n	%
All	Week 24	n/a	541	99,4	0	0,0
	Week 28	n/a	537	98,7	356	66,3
	Week 32	n/a	534	98,2	377	70,6
	Week 36	n/a	529	97,2	395	74,7
	Week 40	n/a	524	96,3	99	18,9
	Week 44	n/a	517	95,0	82	15,9
	Week 48	n/a	514	94,5	63	12,3
	Week 52	n/a	512	94,1	30	5,9
	Week 56	n/a	506	93,0	56	11,1
	Week 60	n/a	499	91,7	56	11,2
	Week 64	n/a	495	91,0	48	9,7
	Week 68	n/a	492	90,4	52	10,6

Only patients who have not discontinued the study at Week x are used for analysis.
 Treatment interval at Week x is defined as the treatment interval decision followed at that visit.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_visit_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_visit_a24_Q12W_W2472_ITa24_30AUG2023_41984.xls
 26APR2024 15:28

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients on a Q16W Treatment Interval by Visit at Week 24 up to Week 72
 MODEL: descriptive
 STUDY: GR41984
 Dichotomous Analysis (Efficacy)

			Faricimab (N=544)			
			Patients		Patients with Event	
Name	Visit	Level	n	%	n	%
All	Week 24	n/a	541	99,4	0	0,0
	Week 28	n/a	537	98,7	0	0,0
	Week 32	n/a	534	98,2	0	0,0
	Week 36	n/a	529	97,2	0	0,0
	Week 40	n/a	524	96,3	243	46,4
	Week 44	n/a	517	95,0	259	50,1
	Week 48	n/a	514	94,5	270	52,5
	Week 52	n/a	512	94,1	295	57,6
	Week 56	n/a	506	93,0	252	49,8
	Week 60	n/a	499	91,7	245	49,1
	Week 64	n/a	495	91,0	249	50,3
	Week 68	n/a	492	90,4	246	50,0

Only patients who have not discontinued the study at Week x are used for analysis.
 Treatment interval at Week x is defined as the treatment interval decision followed at that visit.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_visit_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_visit_a24_Q16W_W2472_ITa24_30AUG2023_41984.xls
 26APR2024 15:30

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients on a Q4W Treatment Interval by Visit at Week 24 up to Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

			Faricimab (N=711)			
			Patients		Patients with Event	
Name	Visit	Level	n	%	n	%
All	Week 24	n/a	706	99,3	60	8,5
	Week 28	n/a	699	98,3	150	21,5
	Week 32	n/a	696	97,9	160	23,0
	Week 36	n/a	692	97,3	168	24,3
	Week 40	n/a	687	96,6	203	29,5
	Week 44	n/a	680	95,6	188	27,6
	Week 48	n/a	675	94,9	192	28,4
	Week 52	n/a	669	94,1	204	30,5
	Week 56	n/a	667	93,8	236	35,4
	Week 60	n/a	663	93,2	219	33,0
	Week 64	n/a	656	92,3	213	32,5
	Week 68	n/a	645	90,7	216	33,5

Only patients who have not discontinued the study at Week x are used for analysis.
 Treatment interval at Week x is defined as the treatment interval decision followed at that visit.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_visit_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_visit_a24_Q4W_W2472_ITa24_29AUG2023_41986.xls
 26APR2024 15:35

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients on a Q8W Treatment Interval by Visit at Week 24 up to Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

			Faricimab (N=711)			
			Patients		Patients with Event	
Name	Visit	Level	n	%	n	%
All	Week 24	n/a	706	99,3	646	91,5
	Week 28	n/a	699	98,3	112	16,0
	Week 32	n/a	696	97,9	74	10,6
	Week 36	n/a	692	97,3	32	4,6
	Week 40	n/a	687	96,6	101	14,7
	Week 44	n/a	680	95,6	122	17,9
	Week 48	n/a	675	94,9	123	18,2
	Week 52	n/a	669	94,1	113	16,9
	Week 56	n/a	667	93,8	114	17,1
	Week 60	n/a	663	93,2	133	20,1
	Week 64	n/a	656	92,3	138	21,0
	Week 68	n/a	645	90,7	121	18,8

Only patients who have not discontinued the study at Week x are used for analysis.
 Treatment interval at Week x is defined as the treatment interval decision followed at that visit.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_visit_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_visit_a24_Q8W_W2472_ITa24_29AUG2023_41986.xls
 26APR2024 15:37

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients on a Q12W Treatment Interval by Visit at Week 24 up to Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

			Faricimab (N=711)			
			Patients		Patients with Event	
Name	Visit	Level	n	%	n	%
All	Week 24	n/a	706	99,3	0	0,0
	Week 28	n/a	699	98,3	437	62,5
	Week 32	n/a	696	97,9	462	66,4
	Week 36	n/a	692	97,3	492	71,1
	Week 40	n/a	687	96,6	116	16,9
	Week 44	n/a	680	95,6	83	12,2
	Week 48	n/a	675	94,9	59	8,7
	Week 52	n/a	669	94,1	35	5,2
	Week 56	n/a	667	93,8	65	9,7
	Week 60	n/a	663	93,2	63	9,5
	Week 64	n/a	656	92,3	58	8,8
	Week 68	n/a	645	90,7	63	9,8

Only patients who have not discontinued the study at Week x are used for analysis.
 Treatment interval at Week x is defined as the treatment interval decision followed at that visit.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_visit_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_visit_a24_Q12W_W2472_ITa24_29AUG2023_41986.xls
 26APR2024 15:38

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Proportion of Patients on a Q16W Treatment Interval by Visit at Week 24 up to Week 72
 MODEL: descriptive
 STUDY: GR41986
 Dichotomous Analysis (Efficacy)

			Faricimab (N=711)			
			Patients		Patients with Event	
Name	Visit	Level	n	%	n	%
All	Week 24	n/a	706	99,3	0	0,0
	Week 28	n/a	699	98,3	0	0,0
	Week 32	n/a	696	97,9	0	0,0
	Week 36	n/a	692	97,3	0	0,0
	Week 40	n/a	687	96,6	267	38,9
	Week 44	n/a	680	95,6	287	42,2
	Week 48	n/a	675	94,9	301	44,6
	Week 52	n/a	669	94,1	317	47,4
	Week 56	n/a	667	93,8	252	37,8
	Week 60	n/a	663	93,2	248	37,4
	Week 64	n/a	656	92,3	247	37,7
	Week 68	n/a	645	90,7	245	38,0

Only patients who have not discontinued the study at Week x are used for analysis.
 Treatment interval at Week x is defined as the treatment interval decision followed at that visit.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_eff_resp_visit_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_eff_resp_visit_a24_Q16W_W2472_ITa24_29AUG2023_41986.xls
 26APR2024 15:40

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2

ENDPOINT: --

MODEL: descriptive

STUDY: GR41984

Times in which patient reported outcomes were collected

	Faricimab (N=544)
PRO (NEI VFQ-25) (weeks)	
n	544
Median	72,29

Times were calculated as:

PRO (NEI VFQ-25): Last Date of answered questionnaire - Randomization Date + 1.

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_fu_a24.sas

Output: root/clinical_studies/R06867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_fu_a24_ITa24_30AUG2023_41984.xls

26APR2024 15:06

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: --
 MODEL: descriptive
 STUDY: GR41984
 Duration of Exposure to Treatment after Week 24

	Faricimab (N=537)
Treatment duration (weeks)	
n	532
Mean (SD)	40.0 (8.01)
Median	41,1
Min-max	0 - 46
Number of study drug administrations	
n	530
Mean (SD)	4.8 (2.72)
Median	4
Min-max	1 - 12
Dose interruption	
Number of doses interrupted	51
At least one interrupted dose	32 (6.0%)
Intraocular inflammation	0
BCVA decrease	2 (0.4%)
Elevated intraocular pressure	1 (0.2%)
Rhegmatogenous retinal break	1 (0.2%)
Rhegmatogenous retinal detachment or macular hole	0
Active or suspected infection	2 (0.4%)
Cataract surgery in the study eye	3 (0.6%)
Vitrectomy	1 (0.2%)
Intraocular surgery in study eye	1 (0.2%)
On-study prohibited medications	0
Other	26 (4.8%)
Interruptions per patient	
n	32
1	25 (4.7%)
2	3 (0.6%)
3	1 (0.2%)
4	1 (0.2%)
5	1 (0.2%)
6	0
7	0
8	1 (0.2%)

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ex_a24.sas
 Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ex_a24_SEa24_30AUG2023_41984.xls
 26APR2024 15:04

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2

ENDPOINT: Disposition of Patients after Week 24

MODEL: descriptive

STUDY: GR41984

	Faricimab (N=544)
Discontinued Study	55 (10.1%)
Adverse event	4 (0.7%)
Death	3 (0.6%)
Lost to follow-up	13 (2.4%)
Non-compliance with study drug	3 (0.6%)
Physician decision	4 (0.7%)
Withdrawal by subject	24 (4.4%)
Other	4 (0.7%)
Discontinued Treatment	54 (9.9%)
Adverse event	4 (0.7%)
Death	3 (0.6%)
Lack of efficacy	2 (0.4%)
Lost to follow-up	14 (2.6%)
Non-compliance with study drug	3 (0.6%)
Physician decision	4 (0.7%)
Withdrawal by subject	23 (4.2%)
Other	1 (0.2%)

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ds_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_ds_a24_ITa24_30AUG2023_41984.xls

26APR2024 15:06

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2

ENDPOINT: --

MODEL: descriptive

STUDY: GR41984

Concomitant Non-Ocular Medications by Medication Class and Preferred Name after Week 24

ATC Class Level 2 Other Treatment	Faricimab (N=544)
Total number of patients with at least one treatment	323 (59.4%)
Total number of treatments	1444
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	
Total number of patients with at least one treatment	46 (8.5%)
Total number of treatments	57
AMLODIPINE BESILATE/INDAPAMIDE/PERINDOPRIL ARGININE	1 (0.2%)
AMLODIPINE BESILATE/PERINDOPRIL ARGININE	1 (0.2%)
AZILSARTAN	2 (0.4%)
CANDESARTAN	2 (0.4%)
CANDESARTAN CILEXETIL	2 (0.4%)
CAPTOPRIL	5 (0.9%)
ENALAPRIL	1 (0.2%)
HYDROCHLOROTHIAZIDE/IRBESARTAN	2 (0.4%)
HYDROCHLOROTHIAZIDE/LISINAPRIL	1 (0.2%)
HYDROCHLOROTHIAZIDE/VALSARTAN	2 (0.4%)
LISINAPRIL	8 (1.5%)
LISINAPRIL DIHYDRATE	1 (0.2%)
LOSARTAN	4 (0.7%)
LOSARTAN POTASSIUM	3 (0.6%)
OLMESARTAN	2 (0.4%)
OLMESARTAN MEDOXOMIL	2 (0.4%)
PERINDOPRIL ARGININE	1 (0.2%)
RAMIPRIL	6 (1.1%)
TELMISARTAN	3 (0.6%)
VALSARTAN	5 (0.9%)
ALL OTHER NON-THERAPEUTIC PRODUCTS	
Total number of patients with at least one treatment	16 (2.9%)
Total number of treatments	25
ALL OTHER NON-THERAPEUTIC PRODUCTS	1 (0.2%)
ASCORBIC ACID	5 (0.9%)
GLUCOSE	3 (0.6%)
SODIUM CHLORIDE	9 (1.7%)
ALL OTHER THERAPEUTIC PRODUCTS	
Total number of patients with at least one treatment	29 (5.3%)
Total number of treatments	36
ACETYLCYSTEINE	4 (0.7%)
ALL OTHER THERAPEUTIC PRODUCTS	5 (0.9%)
ASCORBIC ACID	5 (0.9%)
ASTRAGALUS PROPINQUUS	1 (0.2%)
ATROPINE SULFATE	1 (0.2%)
CHONDROITIN SULFATE SODIUM	1 (0.2%)
CYANOCOBALAMIN/PYRIDOXINE HYDROCHLORIDE/THIAMINE HYDROCHLORIDE	2 (0.4%)
DIPENTEN	1 (0.2%)
HYDROXOCOBALAMIN	1 (0.2%)
IRON	2 (0.4%)
LACTOBACILLUS RHAMNOSUS	1 (0.2%)
STERIODS	3 (0.6%)
SUCROFERRIC OXYHYDROXIDE	1 (0.2%)
SUGAMMADEX SODIUM	1 (0.2%)
VITAMIN B12 NOS	2 (0.4%)
ANABOLIC AGENTS FOR SYSTEMIC USE	
Total number of patients with at least one treatment	6 (1.1%)
Total number of treatments	8
COBAMAMIDE	3 (0.6%)
STERIODS	3 (0.6%)
ANALGESICS	
Total number of patients with at least one treatment	101 (18.6%)
Total number of treatments	155
ACETYLSALICYLIC ACID	15 (2.8%)
ACETYLSALICYLIC ACID/PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.2%)
AMITRIPTYLINE	1 (0.2%)
AMITRIPTYLINE HYDROCHLORIDE	1 (0.2%)

ARCTIUM LAPPA FRUIT;ASCORBIC ACID;CHLORPHENAMINE MALEATE;FORSYTHIA SUSPENS A FRUIT;GLYCINE MAX FERMENTED SEED;GLYCYRRHIZA URALENSIS ROOT WITH RHIZOME/LONICERA JAPONICA FLOWER BUD;LOPHATHERUM GRACILE HERB;MENTHA CANADENSIS OIL;NEPETA TENUIFOLIA HERB;PARACETAMOL;PHRAGMITES AUSTRALIS SUBSP. AUSTRALIS RHIZOME;PLATYCODON GRANDIFLORUS ROOT	1 (0.2%)
ARTEMISIA ARGYI	1 (0.2%)
ASCORBIC ACID;CAFFEINE;CHLORPHENAMINE MALEATE;PARACETAMOL	1 (0.2%)
ASCORBIC ACID;CAFFEINE;PARACETAMOL;PHENYLEPHRINE HYDROCHLORIDE;TERPIN	1 (0.2%)
ASCORBIC ACID;CHLORPHENAMINE MALEATE;PARACETAMOL	1 (0.2%)
ASCORBIC ACID;CODEINE PHOSPHATE;PARACETAMOL	1 (0.2%)
ASCORBIC ACID;PARACETAMOL;PHENIRAMINE MALEATE	2 (0.4%)
ASCORBIC ACID;PARACETAMOL;PHENIRAMINE MALEATE;PHENYLEPHRINE HYDROCHLORIDE	1 (0.2%)
BIDENS BITERNATA;CAFFEINE;CHLORPHENAMINE MALEATE;CHRYSANTHEMUM INDICUM FLOWER;ILEX ASPRELLA ROOT;MELICOCPE PTELEIFOLIA;MENTHA CANADENSIS OIL;PARACETAMOL	1 (0.2%)
BUPRENORPHINE	1 (0.2%)
CAFFEINE;CHLORPHENAMINE MALEATE;COW BEZOAR;PARACETAMOL	2 (0.4%)
CAFFEINE;CODEINE PHOSPHATE;PARACETAMOL	1 (0.2%)
CAFFEINE;DIHYDROCODEINE BITARTRATE;PARACETAMOL	1 (0.2%)
CAFFEINE;PARACETAMOL;PROMETHAZINE METHYLENE DISALICYLATE;SALICYLAMIDE	1 (0.2%)
CHLORPHENAMINE MALEATE;DEXTROMETHORPHAN HYDROBROMIDE;PARACETAMOL;PSEUDOEPHEDRINE HYDROCHLORIDE	2 (0.4%)
CHLORPHENAMINE MALEATE;PARACETAMOL	1 (0.2%)
CHLORPHENAMINE MALEATE;PARACETAMOL;PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.2%)
CLONIDINE	1 (0.2%)
CODEINE PHOSPHATE	1 (0.2%)
CODEINE PHOSPHATE HEMIHYDRATE;PARACETAMOL	1 (0.2%)
CODEINE PHOSPHATE;PARACETAMOL	1 (0.2%)
CODEINE;PARACETAMOL	2 (0.4%)
CORTICOSTEROID NOS	1 (0.2%)
DIHYDROCODEINE BITARTRATE	1 (0.2%)
DULOXETINE	1 (0.2%)
DULOXETINE HYDROCHLORIDE	1 (0.2%)
FENTANYL	3 (0.6%)
FORSYTHIA SUSPENS A FRUIT;LONICERA JAPONICA FLOWER BUD;SCUTELLARIA BAICALENSIS ROOT	1 (0.2%)
GABAPENTIN	1 (0.2%)
GASTRODIA ELATA	1 (0.2%)
HYDROCODONE BITARTRATE;PARACETAMOL	1 (0.2%)
METAMIZOLE SODIUM	7 (1.3%)
METOPROLOL	4 (0.7%)
METOPROLOL SUCCINATE	2 (0.4%)
METOPROLOL TARTRATE	1 (0.2%)
MORPHINE	1 (0.2%)
NALOXONE HYDROCHLORIDE;OXYCODONE HYDROCHLORIDE	1 (0.2%)
OXYCODONE	2 (0.4%)
OXYCODONE HYDROCHLORIDE	1 (0.2%)
PARACETAMOL	47 (8.6%)
PARACETAMOL;TRAMADOL HYDROCHLORIDE	8 (1.5%)
PREGABALIN	5 (0.9%)
PROPRANLOL	1 (0.2%)
TIMOLOL	1 (0.2%)
TRAMADOL	1 (0.2%)
TRAMADOL HYDROCHLORIDE	1 (0.2%)
ANESTHETICS	
Total number of patients with at least one treatment	11 (2.0%)
Total number of treatments	18
ANESTHETICS, LOCAL	2 (0.4%)
ARTICAIN E HYDROCHLORIDE;EPINEPHRINE	1 (0.2%)
BUPIVACAINE	1 (0.2%)
BUPIVACAINE HYDROCHLORIDE	1 (0.2%)
EPINEPHRINE;LIDOCAINE	1 (0.2%)
FENTANYL	3 (0.6%)
LIDOCAINE	2 (0.4%)
LIDOCAINE HYDROCHLORIDE	1 (0.2%)
PROPOFOL	2 (0.4%)
REMIFENTANIL	1 (0.2%)
ROPIVACAINE HYDROCHLORIDE	1 (0.2%)
SEVOFLURANE	1 (0.2%)
ANTI-ACNE PREPARATIONS	
Total number of patients with at least one treatment	46 (8.5%)
Total number of treatments	60
AZITHROMYCIN	11 (2.0%)
CHLORAMPHENICOL	1 (0.2%)
CHLORHEXIDINE GLUCONATE	2 (0.4%)
CLINDAMYCIN	1 (0.2%)
DOXYCYCLINE	7 (1.3%)
IBUPROFEN	28 (5.1%)
NICOTINAMIDE	1 (0.2%)
ANTI-PARKINSON DRUGS	
Total number of patients with at least one treatment	1 (0.2%)

Total number of treatments	1
DIPHENHYDRAMINE HYDROCHLORIDE	1 (0.2%)
ANTIEMETIC PREPARATIONS	
Total number of patients with at least one treatment	20 (3.7%)
Total number of treatments	26
COBAMAMIDE	3 (0.6%)
CYANOCOBALAMIN	1 (0.2%)
CYANOCOBALAMIN;PYRIDOXINE HYDROCHLORIDE;THIAMINE HYDROCHLORIDE	2 (0.4%)
DOXYLAMINE SUCCINATE;FOLIC ACID;PYRIDOXINE HYDROCHLORIDE	1 (0.2%)
FERROUS FUMARATE	1 (0.2%)
FOLIC ACID	5 (0.9%)
HYDROXOCOBALAMIN	1 (0.2%)
IRON	2 (0.4%)
MECOBALAMIN	5 (0.9%)
VITAMIN B NOS	2 (0.4%)
VITAMIN B12 NOS	2 (0.4%)
ANTIBACTERIALS FOR SYSTEMIC USE	
Total number of patients with at least one treatment	81 (14.9%)
Total number of treatments	127
AMOXICILLIN	13 (2.4%)
AMOXICILLIN TRIHYDRATE	2 (0.4%)
AMOXICILLIN TRIHYDRATE;CLAVULANATE POTASSIUM	3 (0.6%)
AMOXICILLIN;CLAVULANATE POTASSIUM	5 (0.9%)
AMOXICILLIN;CLAVULANIC ACID	1 (0.2%)
AMPICILLIN	1 (0.2%)
ANGELICA SINENSIS	1 (0.2%)
ANTIBIOTICS	3 (0.6%)
ARTEMISIA ARGYI	1 (0.2%)
AZITHROMYCIN	11 (2.0%)
AZITHROMYCIN DIHYDRATE	1 (0.2%)
CEFACLOR	3 (0.6%)
CEFADROXIL MONOHYDRATE	1 (0.2%)
CEFALEXIN	3 (0.6%)
CEFAZOLIN	1 (0.2%)
CEFAZOLIN SODIUM	1 (0.2%)
CEFDINIR	2 (0.4%)
CEFDITOREN PIVOXIL	1 (0.2%)
CEFIXIME	2 (0.4%)
CEFIXIME TRIHYDRATE	1 (0.2%)
CEFPODOXIME PROXETIL	1 (0.2%)
CEFTRIAKONE	1 (0.2%)
CEFTRIAKONE SODIUM	4 (0.7%)
CEFUROXIME	4 (0.7%)
CHLORAMPHENICOL	1 (0.2%)
CIPROFLOXACIN	3 (0.6%)
CLARITHROMYCIN	2 (0.4%)
CLINDAMYCIN	1 (0.2%)
COW BEZOAR;METRONIDAZOLE	1 (0.2%)
DOXYCYCLINE	7 (1.3%)
DOXYCYCLINE HYCLATE	2 (0.4%)
DOXYCYCLINE HYDROCHLORIDE	1 (0.2%)
FLUCLOXACILLIN	1 (0.2%)
FOSFOMYCIN	1 (0.2%)
FURAZIDIN	1 (0.2%)
GENTAMICIN SULFATE	1 (0.2%)
LEVOFLOXACIN	9 (1.7%)
MEROPENEM	1 (0.2%)
METRONIDAZOLE	3 (0.6%)
NORFLOXACIN	2 (0.4%)
OFLOXACIN	2 (0.4%)
ROXITHROMYCIN	2 (0.4%)
SALVIA MILTIORRHIZA	2 (0.4%)
SULFAMETHOXAZOLE	1 (0.2%)
SULFAMETHOXAZOLE;TRIMETHOPRIM	2 (0.4%)
TRIMETHOPRIM	1 (0.2%)
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE	
Total number of patients with at least one treatment	36 (6.6%)
Total number of treatments	46
ACICLOVIR	5 (0.9%)
ANTIBIOTICS	3 (0.6%)
CHLORAMPHENICOL	1 (0.2%)
CIPROFLOXACIN	3 (0.6%)
CLARITHROMYCIN	2 (0.4%)
DOXYCYCLINE	7 (1.3%)
DOXYCYCLINE HYDROCHLORIDE	1 (0.2%)
GENTAMICIN SULFATE	1 (0.2%)
LEVOFLOXACIN	9 (1.7%)
METRONIDAZOLE	3 (0.6%)
NORFLOXACIN	2 (0.4%)
OFLOXACIN	2 (0.4%)

RIFAXIMIN	1 (0.2%)
VIDARABINE	1 (0.2%)
ANTI-DIARRHEALS, INTESTINAL ANTI-INFLAMMATORY/ANTI-INFECTION AGENTS	
Total number of patients with at least one treatment	35 (6.4%)
Total number of treatments	48
ALISMA PLANTAGO-AQUATICA SUBSP. ORIENTALE TUBER;ATRACTYLODES SPP. RHIZOME;CINNAMOMUM CASSIA BARK;POLYPORUS UMBELLATUS SCLEROTIUM;FORIA COCOS SCLEROTIUM	1 (0.2%)
ANTIBIOTICS	3 (0.6%)
BACILLUS LICHENIFORMIS	1 (0.2%)
BACILLUS SUBTILIS;ENTEROCOCCUS FAECIUM	1 (0.2%)
BERBERINE	1 (0.2%)
BERBERINE HYDROCHLORIDE;RHEUM SPP. ROOT WITH RHIZOME;SCUTELLARIA BAICALENSIS ROOT	1 (0.2%)
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.2%)
BIFIDOBACTERIUM ANIMALIS;LACTOBACILLUS ACIDOPHILUS;LACTOBACILLUS BULGARICUS	1 (0.2%)
BIFIDOBACTERIUM LONGUM;ENTEROCOCCUS FAECALIS;LACTOBACILLUS ACIDOPHILUS	1 (0.2%)
BIFIDOBACTERIUM NOS;LACTOBACILLUS NOS	1 (0.2%)
BUDESONIDE	2 (0.4%)
CITRUS AURANTIUM PHEL.;CREOSOTE;GLYCYRRHIZA SPP. ROOT;PHELLODENDRON SPP. BARK;UNCARIA GAMBIR LEAF WITH TWIG	1 (0.2%)
CORTICOSTEROID NOS	1 (0.2%)
ENTEROCOCCUS FAECALIS	1 (0.2%)
HYDROCORTISONE	1 (0.2%)
HYDROCORTISONE SODIUM SUCCINATE	1 (0.2%)
LACTIPLANTIBACILLUS PLANTARUM	1 (0.2%)
LACTOBACILLUS RHAMNOSUS	1 (0.2%)
LOPERAMIDE HYDROCHLORIDE	3 (0.6%)
MACROGOL 4000;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE;SODIUM SULFATE	1 (0.2%)
MICONAZOLE NITRATE	1 (0.2%)
NYSTATIN	1 (0.2%)
PREDNISOLONE	2 (0.4%)
PREDNISONE	10 (1.8%)
PROBIOTICS NOS	1 (0.2%)
RIFAXIMIN	1 (0.2%)
SULFASALAZINE	1 (0.2%)
ANTIEMETICS AND ANTINAUSEANTS	
Total number of patients with at least one treatment	26 (4.8%)
Total number of treatments	47
ALISMA PLANTAGO-AQUATICA SUBSP. ORIENTALE TUBER;ATRACTYLODES SPP. RHIZOME;CINNAMOMUM CASSIA BARK;POLYPORUS UMBELLATUS SCLEROTIUM;FORIA COCOS SCLEROTIUM	1 (0.2%)
APREPITANT	1 (0.2%)
CYANOCOBALAMIN;PYRIDOXINE HYDROCHLORIDE;THIAMINE HYDROCHLORIDE	2 (0.4%)
DIMENHYDRINATE	2 (0.4%)
DIPHENHYDRAMINE HYDROCHLORIDE	1 (0.2%)
DOMPERIDONE	1 (0.2%)
DOXYLAMINE SUCCINATE;FOLIC ACID;PYRIDOXINE HYDROCHLORIDE	1 (0.2%)
DROPERIDOL	1 (0.2%)
HYDROXYZINE	3 (0.6%)
MECLOZINE	1 (0.2%)
METOCLOPRAMIDE	5 (0.9%)
METOCLOPRAMIDE HYDROCHLORIDE	9 (1.7%)
ONDANSETRON	1 (0.2%)
ONDANSETRON HYDROCHLORIDE	1 (0.2%)
ONDANSETRON HYDROCHLORIDE DIHYDRATE	1 (0.2%)
PALONOSETRON HYDROCHLORIDE	1 (0.2%)
PROMETHAZINE	1 (0.2%)
ANTI-EPILEPTICS	
Total number of patients with at least one treatment	17 (3.1%)
Total number of treatments	17
ACETAZOLAMIDE	2 (0.4%)
CLONAZEPAM	2 (0.4%)
DIAZEPAM	2 (0.4%)
GABAPENTIN	1 (0.2%)
GASTRODIA ELATA	1 (0.2%)
LEVETIRACETAM	1 (0.2%)
MAGNESIUM SULFATE	1 (0.2%)
MIDAZOLAM	1 (0.2%)
MIDAZOLAM HYDROCHLORIDE	1 (0.2%)
PREGABALIN	5 (0.9%)
ANTI-FUNGALS FOR DERMATOLOGICAL USE	
Total number of patients with at least one treatment	12 (2.2%)
Total number of treatments	14
ANTIBIOTICS	3 (0.6%)
CLOTRIMAZOLE	1 (0.2%)
EFINACONAZOLE	1 (0.2%)
FLUCONAZOLE	1 (0.2%)
KETOCONAZOLE	1 (0.2%)

MICONAZOLE NITRATE	1 (0.2%)
NYSTATIN	1 (0.2%)
SEPTACONAZOLE NITRATE	2 (0.4%)
SULCONAZOLE	1 (0.2%)
TERBINAFINE	2 (0.4%)
ANTIGOUT PREPARATIONS	
Total number of patients with at least one treatment	5 (0.9%)
Total number of treatments	8
ALLOPURINOL	1 (0.2%)
COLCHICINE	4 (0.7%)
DOCOSAHEXAENOIC ACID;EICOSAPENTAENOIC ACID	1 (0.2%)
ANTIHEMORRHAGICS	
Total number of patients with at least one treatment	8 (1.5%)
Total number of treatments	9
ANGELICA SINENSIS;CHRYSANTHEMUM X MORIFOLIUM FLOWER;CRATAEGUS PINNATIFIDA;CURCUMA SPP. ROOT TUBER;ECLIPTA PROSTRATA;EQUISETUM HYEMALE;GENTIANA SCABRA;LEONURUS JAPONICUS RIPE FRUIT;LIGUSTICUM CHUANXIONG;LIGUSTRUM LUCIDUM RIPE FRUIT;PAEONIA OFFICINALIS SUBSP. OFFICINALIS ROOT;PAEONIA X SUFRUTICOSA BARK;PLANTAGO ASIATICA SEED;PRUNELLA VULGARIS;REHMANNIA GLUTINOSA;	1 (0.2%)
CARBAZOCROME SODIUM SULFONATE	2 (0.4%)
ETAMSILATE	1 (0.2%)
GELATIN	1 (0.2%)
MENAQUINONE	1 (0.2%)
TRANEXAMIC ACID	3 (0.6%)
ANTI-HISTAMINES FOR SYSTEMIC USE	
Total number of patients with at least one treatment	33 (6.1%)
Total number of treatments	51
BEPOTASTINE BESILATE	1 (0.2%)
CETIRIZINE	3 (0.6%)
CETIRIZINE HYDROCHLORIDE	1 (0.2%)
CHLOROPYRAMINE HYDROCHLORIDE	1 (0.2%)
CHLORPHENAMINE MALEATE	7 (1.3%)
DIMENHYDRINATE	2 (0.4%)
DIPHENHYDRAMINE HYDROCHLORIDE	1 (0.2%)
DOXYLAMINE SUCCINATE;FOLIC ACID;PYRIDOXINE HYDROCHLORIDE	1 (0.2%)
FEXOFENADINE HYDROCHLORIDE	3 (0.6%)
HYDROXYZINE	3 (0.6%)
LEVOCETIRIZINE DIHYDROCHLORIDE	1 (0.2%)
LORATADINE	7 (1.3%)
MECLOZINE	1 (0.2%)
MEQUITAZINE	1 (0.2%)
PROMETHAZINE	1 (0.2%)
ANTI-HYPERTENSIVES	
Total number of patients with at least one treatment	9 (1.7%)
Total number of treatments	9
CLONIDINE	1 (0.2%)
DOXAZOSIN MESILATE	2 (0.4%)
MAGNESIUM SULFATE	1 (0.2%)
METHYLDOPA	1 (0.2%)
SILDENAFIL CITRATE	1 (0.2%)
TADALAFIL	2 (0.4%)
TERAZOSIN HYDROCHLORIDE	1 (0.2%)
ANTI-INFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	
Total number of patients with at least one treatment	86 (15.8%)
Total number of treatments	124
ACEMETACIN	1 (0.2%)
ALISMA PLANTAGO-AQUATICA SUBSP. ORIENTALE TUBER;CORYDALIS YANUSUO TUBER;CYATHULA OFFICINALIS ROOT;GENTIANA SPP. ROOT;PAEONIA SPP. ROOT;PHELLODENDRON CHINENSE BARK;PLANTAGO SPP. SEED;SMILAX GLABRA RHIZOME	1 (0.2%)
ANGELICA SINENSIS	1 (0.2%)
BENZDAMINE	1 (0.2%)
BENZDAMINE HYDROCHLORIDE	1 (0.2%)
CELECOXIB	5 (0.9%)
CHONDROITIN SULFATE SODIUM	1 (0.2%)
CHONDROITIN SULFATE SODIUM;GLUCOSAMINE HYDROCHLORIDE	1 (0.2%)
CHONDROITIN SULFATE;GLUCOSAMINE	1 (0.2%)
CORYDALIS BUNGEANA HERB;ISATIS TINCTORIA ROOT;SCUTELLARIA BAICALENSIS ROOT;TARAXACUM MONGOLICUM HERB	1 (0.2%)
CORYDALIS DECUMBENS TUBER	1 (0.2%)
CURCUMA LONGA	1 (0.2%)
DEXIBUPROFEN	1 (0.2%)
DEKXETOPROFEN TROMETAMOL	3 (0.6%)
DICLOFENAC	6 (1.1%)
DICLOFENAC POTASSIUM	1 (0.2%)
DICLOFENAC SODIUM	6 (1.1%)
ESOMEPRAZOLE MAGNESIUM;NAPROXEN	1 (0.2%)
ESOMEPRAZOLE STRONTIUM;NAPROXEN	1 (0.2%)
ETOFENAMATE	1 (0.2%)

ETORICOXIB	1 (0.2%)
FENOPROFEN	1 (0.2%)
FLURBIPROFEN	1 (0.2%)
FORSYTHIA SUSPENSIA FRUIT;LONICERA JAPONICA FLOWER BUD;SCUTELLARIA BAICALENSIS ROOT	1 (0.2%)
GLUCOSAMINE	1 (0.2%)
GLUCOSAMINE SULFATE	1 (0.2%)
GLYCYRRHIZA SPP. ROOT;PAEONIA LACTIFLORA ROOT	1 (0.2%)
IBUPROFEN	28 (5.1%)
IBUPROFEN;PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.2%)
INDOMETACIN	1 (0.2%)
KETOPROFEN	3 (0.6%)
LOXOPROFEN	1 (0.2%)
LOXOPROFEN SODIUM	9 (1.7%)
LOXOPROFEN SODIUM DIHYDRATE	2 (0.4%)
MELOXICAM	5 (0.9%)
MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER	1 (0.2%)
NABUMETONE	1 (0.2%)
NAPROXEN	5 (0.9%)
NAPROXEN SODIUM	2 (0.4%)
NIMESULIDE	2 (0.4%)
PIROXICAM BETADEX	1 (0.2%)
SULFASALAZINE	1 (0.2%)
ZALTOPROFEN	1 (0.2%)
ANTIMYCOBACTERIALS	
Total number of patients with at least one treatment	3 (0.6%)
Total number of treatments	3
ANTIBIOTICS	3 (0.6%)
ANTIMYCOTICS FOR SYSTEMIC USE	
Total number of patients with at least one treatment	8 (1.5%)
Total number of treatments	8
ANTIBIOTICS	3 (0.6%)
FLUCONAZOLE	1 (0.2%)
ITRACONAZOLE	1 (0.2%)
KETOCONAZOLE	1 (0.2%)
MICONAZOLE NITRATE	1 (0.2%)
NYSTATIN	1 (0.2%)
ANTINEOPLASTIC AGENTS	
Total number of patients with at least one treatment	9 (1.7%)
Total number of treatments	16
CARBOPLATIN	1 (0.2%)
CELECOXIB	5 (0.9%)
DOCETAXEL	1 (0.2%)
FLUOROURACIL	1 (0.2%)
IRINOTECAN	1 (0.2%)
METHOTREXATE	1 (0.2%)
OXALIPLATIN	1 (0.2%)
PEMBROLIZUMAB	1 (0.2%)
PEMETREXED DISODIUM HEPTAHYDRATE	1 (0.2%)
PROPRANOLOL	1 (0.2%)
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS	
Total number of patients with at least one treatment	4 (0.7%)
Total number of treatments	5
LIRAGLUTIDE	1 (0.2%)
SEMAGLUTIDE	3 (0.6%)
ANTIPROTOZOALS	
Total number of patients with at least one treatment	7 (1.3%)
Total number of treatments	7
CLOTIMAZOLE	1 (0.2%)
METRONIDAZOLE	3 (0.6%)
MICONAZOLE NITRATE	1 (0.2%)
OFLOXACIN	2 (0.4%)
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	
Total number of patients with at least one treatment	34 (6.3%)
Total number of treatments	51
ANESTHETICS, LOCAL	2 (0.4%)
BEPOTASTINE BESILATE	1 (0.2%)
CALAMINE	1 (0.2%)
CETIRIZINE	3 (0.6%)
CETIRIZINE HYDROCHLORIDE	1 (0.2%)
CHLOROPYRAMINE HYDROCHLORIDE	1 (0.2%)
CHLORPHENAMINE MALEATE	7 (1.3%)
DIPHENHYDRAMINE HYDROCHLORIDE	1 (0.2%)
FEXOFENADINE HYDROCHLORIDE	3 (0.6%)
HYDROXYZINE	3 (0.6%)
LEVOCETIRIZINE DIHYDROCHLORIDE	1 (0.2%)
LIDOCAINE	2 (0.4%)

LIDOCAINE HYDROCHLORIDE	1 (0.2%)
LORATADINE	7 (1.3%)
PROMETHAZINE	1 (0.2%)
ANTIPSORIATICS	
Total number of patients with at least one treatment	2 (0.4%)
Total number of treatments	2
ANGELICA SINENSIS	1 (0.2%)
CALCITRIOL	1 (0.2%)
ANTISEPTICS AND DISINFECTANTS	
Total number of patients with at least one treatment	5 (0.9%)
Total number of treatments	5
CHLORHEXIDINE GLUCONATE	2 (0.4%)
DEQUALINIUM CHLORIDE	1 (0.2%)
ISOPROPANOL	1 (0.2%)
OCTENIDINE HYDROCHLORIDE	1 (0.2%)
ANTIITHROMBOTIC AGENTS	
Total number of patients with at least one treatment	41 (7.5%)
Total number of treatments	54
ACETYLSALICYLIC ACID	15 (2.8%)
ALTEPLASE	1 (0.2%)
APIXABAN	4 (0.7%)
CLOPIDOGREL	2 (0.4%)
CLOPIDOGREL BISULFATE	6 (1.1%)
ENOXAPARIN	2 (0.4%)
ENOXAPARIN SODIUM	7 (1.3%)
FONDAPARINUX SODIUM	1 (0.2%)
HEPARIN	2 (0.4%)
LOW MOLECULAR WEIGHT HEPARIN	1 (0.2%)
MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER	1 (0.2%)
PHENPROCOUMON	1 (0.2%)
PRASUGREL	1 (0.2%)
RIVAROXABAN	3 (0.6%)
STREPTODORNASE/STREPTOKINASE	1 (0.2%)
SULODEXIDE	2 (0.4%)
TICAGRELOR	2 (0.4%)
WARFARIN	1 (0.2%)
ANTIVIRALS FOR SYSTEMIC USE	
Total number of patients with at least one treatment	25 (4.6%)
Total number of treatments	29
ACICLOVIR	5 (0.9%)
CALCIUM SULFATE DIHYDRATE;DRYOPTERIS CRASSIRHIZOMA RHIZOME;EPHEDRA SPP. HERB;FORSYTHIA SUSPENSIA;GLYCYRRHIZA SPP. ROOT WITH RHIZOME;HOULTUYNIA CORDATA HERB;ISATIS TINCTORIA ROOT;LONICERA JAPONICA FLOWER;MENTHOL;POGOSTEMON CABLIN HERB;PRUNUS SPP. SEED;RHEUM SPP. ROOT WITH RHIZOME;RHODIOLA CREMULATA ROOT WITH RHIZOME	5 (0.9%)
INOSINE PRANOBEX	1 (0.2%)
INOSINE PRANOBEX;ZINC GLUCONATE	1 (0.2%)
MOLNUPIRAVIR	5 (0.9%)
NIRMATRELVIR;RITONAVIR	4 (0.7%)
OSELTAMIVIR PHOSPHATE	2 (0.4%)
OTHER ANTIVIRALS	1 (0.2%)
UMIFENOVIR	1 (0.2%)
VALACICLOVIR	1 (0.2%)
VIDARABINE	1 (0.2%)
BETA BLOCKING AGENTS	
Total number of patients with at least one treatment	20 (3.7%)
Total number of treatments	22
BISOPROLOL	3 (0.6%)
BISOPROLOL FUMARATE	2 (0.4%)
CARVEDILOL	5 (0.9%)
METOPROLOL	4 (0.7%)
METOPROLOL SUCCINATE	2 (0.4%)
METOPROLOL TARTRATE	1 (0.2%)
NEBIVOLOL HYDROCHLORIDE	2 (0.4%)
PROPRANOLOL	1 (0.2%)
TIMOLOL	1 (0.2%)
BILE AND LIVER THERAPY	
Total number of patients with at least one treatment	14 (2.6%)
Total number of treatments	16
ACETYLCYSTEINE	4 (0.7%)
CURCUMA LONGA	1 (0.2%)
DIMETHYL 4,4'-BIPHENYLDICARBOXYLATE;URSODEOXYCHOLIC ACID	1 (0.2%)
DL-METHIONINE;GLYCINE;GLYCYRRHIZIC ACID, AMMONIUM SALT	1 (0.2%)
GASTRODIA ELATA	1 (0.2%)
LACTULOSE	2 (0.4%)
PHOSPHOLIPIDS	1 (0.2%)
PINENE	1 (0.2%)
RIFAXIMIN	1 (0.2%)

SILYBUM MARIANUM	2 (0.4%)
URSODEOXYCHOLIC ACID	1 (0.2%)
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS	
Total number of patients with at least one treatment	27 (5.0%)
Total number of treatments	43
BLOOD, WHOLE	
CALCIUM CHLORIDE DIHYDRATE;MAGNESIUM CHLORIDE HEXAHYDRATE;POTASSIUM CHLORIDE;SODIUM ACETATE TRIHYDRATE;SODIUM CHLORIDE;SODIUM CITRATE DIHYDRATE	1 (0.2%)
CALCIUM CHLORIDE DIHYDRATE;MAGNESIUM CHLORIDE HEXAHYDRATE;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE;SODIUM CITRATE DIHYDRATE	1 (0.2%)
CALCIUM CHLORIDE DIHYDRATE;POTASSIUM CHLORIDE;SODIUM CHLORIDE;SODIUM LACTATE	2 (0.4%)
CALCIUM GLUCONATE MONOHYDRATE;GLUCOSE;MAGNESIUM CHLORIDE HEXAHYDRATE;POTASSIUM CHLORIDE;SODIUM ACETATE;SODIUM CHLORIDE;SODIUM CITRATE DIHYDRATE	
CARBOHYDRATES NOS;POTASSIUM CHLORIDE;SODIUM CHLORIDE;SODIUM LACTATE	1 (0.2%)
CHLORHEXIDINE GLUCONATE	2 (0.4%)
DEXTRAN	1 (0.2%)
ELECTROLYTES NOS	1 (0.2%)
GELATIN	1 (0.2%)
GLUCOSE	3 (0.6%)
GLYCEROL	1 (0.2%)
I.V. SOLUTIONS	1 (0.2%)
MAGNESIUM SULFATE	1 (0.2%)
MANNITOL	2 (0.4%)
PHOSPHOLIPIDS	1 (0.2%)
POTASSIUM	1 (0.2%)
POTASSIUM CHLORIDE	3 (0.6%)
SODIUM CHLORIDE	9 (1.7%)
VITAMINS NOS	3 (0.6%)
CALCIUM CHANNEL BLOCKERS	
Total number of patients with at least one treatment	22 (4.0%)
Total number of treatments	27
AMLODIPINE	8 (1.5%)
AMLODIPINE BESILATE	5 (0.9%)
AZELNIDIPINE	1 (0.2%)
BENIDIPINE	1 (0.2%)
DILTIAZEM	1 (0.2%)
LERCANIDIPINE	1 (0.2%)
LERCANIDIPINE HYDROCHLORIDE	2 (0.4%)
NIFEDIPINE	4 (0.7%)
CARDIAC THERAPY	
Total number of patients with at least one treatment	46 (8.5%)
Total number of treatments	55
AMIODARONE	1 (0.2%)
AMIODARONE HYDROCHLORIDE	1 (0.2%)
ATROPINE SULFATE	1 (0.2%)
EMPAGLIFLOZIN	1 (0.2%)
EPHEDRINE HYDROCHLORIDE	1 (0.2%)
GLYCERYL TRINITRATE	3 (0.6%)
IBUPROFEN	28 (5.1%)
INDOMETACIN	1 (0.2%)
IPRATROPIUM BROMIDE	2 (0.4%)
LIDOCAINE	2 (0.4%)
LIDOCAINE HYDROCHLORIDE	1 (0.2%)
NICOTINAMIDE	1 (0.2%)
OTHER CARDIAC PREPARATIONS	1 (0.2%)
PHENYLEPHRINE HYDROCHLORIDE	1 (0.2%)
PROPAPENONE HYDROCHLORIDE	1 (0.2%)
SALVIA MILTIORRHIZA	2 (0.4%)
SODIUM ALGINATE	1 (0.2%)
UBIDECARENONE	1 (0.2%)
CONTRAST MEDIA	
Total number of patients with at least one treatment	2 (0.4%)
Total number of treatments	2
IOHEXOL	1 (0.2%)
IOPAMIDOL	1 (0.2%)
CORTICOSTEROIDS FOR SYSTEMIC USE	
Total number of patients with at least one treatment	33 (6.1%)
Total number of treatments	47
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.2%)
BETAMETHASONE DIPROPIONATE;BETAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
CORTICOSTEROID NOS	1 (0.2%)
CORTISONE	2 (0.4%)
DEXAMETHASONE	6 (1.1%)
DEXAMETHASONE ACETATE;DEXMETHASONE SODIUM PHOSPHATE	1 (0.2%)
DEXAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
HYDROCORTISONE	1 (0.2%)
HYDROCORTISONE SODIUM SUCCINATE	1 (0.2%)
KETOCONAZOLE	1 (0.2%)

METHYLPREDNISOLONE	2 (0.4%)
METHYLPREDNISOLONE SODIUM SUCCINATE	1 (0.2%)
PREDNISOLONE	2 (0.4%)
PREDNISON	10 (1.8%)
STEROIDS	3 (0.6%)
TRIAMCINOLONE	3 (0.6%)
TRIAMCINOLONE ACETONIDE	1 (0.2%)
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	
Total number of patients with at least one treatment	32 (5.9%)
Total number of treatments	52
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.2%)
BETAMETHASONE DIPROPIONATE;BETAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
BUDESONIDE	2 (0.4%)
CORTICOSTEROID NOS	1 (0.2%)
DEXAMETHASONE	6 (1.1%)
DEXAMETHASONE ACETATE;DEXAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
DEXAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
FLUDROCORTISONE ACETATE;GRAMICIDIN;NEOMYCIN SULFATE	1 (0.2%)
FLUOCINOLONE ACETONIDE	1 (0.2%)
FLUOCINONIDE	1 (0.2%)
FLUTICASONE PROPIONATE	3 (0.6%)
HYDROCORTISONE	1 (0.2%)
HYDROCORTISONE SODIUM SUCCINATE	1 (0.2%)
METHYLPREDNISOLONE	2 (0.4%)
METHYLPREDNISOLONE SODIUM SUCCINATE	1 (0.2%)
PREDNISOLONE	2 (0.4%)
PREDNISON	10 (1.8%)
STEROIDS	3 (0.6%)
TRIAMCINOLONE	3 (0.6%)
TRIAMCINOLONE ACETONIDE	1 (0.2%)
COUGH AND COLD PREPARATIONS	
Total number of patients with at least one treatment	50 (9.2%)
Total number of treatments	72
ACETYLCYSTEINE	4 (0.7%)
AMBROXOL HYDROCHLORIDE	3 (0.6%)
AMMONIUM CHLORIDE;CHLORPHENAMINE MALEATE;DXTROMETHORPHAN HYDROBROMIDE;METHYLEPHEDRINE HYDROCHLORIDE-DL	1 (0.2%)
AMMONIUM CHLORIDE;CHLORPHENAMINE MALEATE;DIHYDROCODEINE BITARTRATE;METHYLEPHEDRINE HYDROCHLORIDE-DL;PELARGONIUM SIDOIDES	1 (0.2%)
ASARUM SPP. ROOT;CINNAMOMUM CASSIA BARK;EPHEDRA SPP. HERB;GLYCYRRHIZA SPP. ROOT;PAEONIA LACTIFLORA ROOT;PINELLIA TERNATA TUBER;SCHISANDRA CHINENSIS FRUIT;ZINGIBER OFFICINALE RHIZOME	1 (0.2%)
ASTER AGERATOIDES WHOLE PLANT;FIRMIANA SIMPLEX ROOT;KITAGAWIA PRAERUPTORA ROOT;METAGENTIANA RHODANTHA WHOLE PLANT;SCLEROMITRION DIFFUSUM WHOLE PLANT;SCUTELLARIA BAICALENSIS ROOT;STEMONA SPP. ROOT TUBER	1 (0.2%)
BENZONATATE	3 (0.6%)
BORNEOL;CAFFEINE;GLYCYRRHIZA SPP. ROOT WITH RHIZOME;PLATYCODON GRANDIFLORUS ROOT;POLYGALA SPP. ROOT;PRINUS SPP. SEED;RHUS SPP. GALLS	1 (0.2%)
BROMHEXINE	1 (0.2%)
BROMHEXINE HYDROCHLORIDE	2 (0.4%)
BROMPHENIRAMINE;DXTROMETHORPHAN;PSEUDOEPHEDRINE	1 (0.2%)
BUTAMIRATE CITRATE;GUAIFENESIN	1 (0.2%)
CALCIUM SULFATE;PLATYCODON GRANDIFLORUS ROOT	1 (0.2%)
CAMPHOR;GLYCYRRHIZA SPP. ROOT WITH RHIZOME;ILLICIIUM VERUM OIL;PAPAVER SOMNIFERUM LATEX;SODIUM BENZOATE	2 (0.4%)
CARBOCISTEINE	3 (0.6%)
CHLORPHENAMINE MALEATE;PARACETAMOL;PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.2%)
CINNAMOMUM CASSIA;EPHEDRA SPP. ;GLYCYRRHIZA SPP. ;PAEONIA LACTIFLORA;PUERARIA MONTANA VAR. LOBATA;ZINGIBER OFFICINALE;ZIZIPHUS JUJUBA	1 (0.2%)
CODEINE PHOSPHATE	1 (0.2%)
CODEINE PHOSPHATE;EPHEDRINE HYDROCHLORIDE;PROMETHAZINE HYDROCHLORIDE	1 (0.2%)
COUGH AND COLD PREPARATIONS	2 (0.4%)
DXTROMETHORPHAN HYDROBROMIDE;GUAIFENESIN	1 (0.2%)
DXTROMETHORPHAN;GUAIFENESIN	1 (0.2%)
DIHYDROCODEINE BITARTRATE	1 (0.2%)
ELECTROLYTES NOS	1 (0.2%)
ERDOSTEINE	4 (0.7%)
FORSYTHIA SUSPENSIA FRUIT;LONICERA JAPONICA FLOWER BUD;SCUTELLARIA BAICALENSIS ROOT	1 (0.2%)
GENTIANA LUTEA ROOT;PRIMULA SPP. FLOWER;RUMEX SPP. HERB;SAMBUCUS NIGRA FLOWER;VERBENA OFFICINALIS HERB	1 (0.2%)
GLYCEROL	1 (0.2%)
GLYCYRRHIZA GLABRA EXTRACT;PAPAVER SOMNIFERUM	1 (0.2%)
GLYCYRRHIZA GLABRA EXTRACT;PAPAVER SOMNIFERUM;PIMPINELLA ANISUM OIL	1 (0.2%)
GLYCYRRHIZA GLABRA;MENTHOL;PHYLLANTHUS EMBLICA;ZINGIBER OFFICINALE	1 (0.2%)
GLYCYRRHIZA SPP. ROOT;OPHIOPOGON JAPONICUS TUBER;ORYZA SATIVA FRUIT;PANAX GINSENG ROOT;PINELLIA TERNATA TUBER;ZIZIPHUS JUJUBA FRUIT	1 (0.2%)
GLYCYRRHIZA URALENSIS	1 (0.2%)
GUAIFENESIN	1 (0.2%)
L-CARBOCISTEINE	1 (0.2%)
MANNITOL	2 (0.4%)
OTHER COUGH SUPPRESSANTS	2 (0.4%)
OTHER COUGH SUPPRESSANTS AND EXPECTORANTS	2 (0.4%)

SODIUM CHLORIDE	9 (1.7%)
STREPTODORNASE;STREPTOKINASE	1 (0.2%)
DIAGNOSTIC AGENTS	
Total number of patients with at least one treatment	10 (1.8%)
Total number of treatments	11
FOLIC ACID	5 (0.9%)
GLUCOSE	3 (0.6%)
MAGNESIUM SULFATE	1 (0.2%)
MANNITOL	2 (0.4%)
DIAGNOSTIC RADIOPHARMACEUTICALS	
Total number of patients with at least one treatment	1 (0.2%)
Total number of treatments	1
TECHNETIUM TC 99M TETROFOSMIN	1 (0.2%)
DIGESTIVES, INCL. ENZYMES	
Total number of patients with at least one treatment	6 (1.1%)
Total number of treatments	6
ASPERGILLUS ORYZAE ENZYME;PANCREATIN	1 (0.2%)
ATRACTYLODES MACROCEPHALA	1 (0.2%)
PANCREATIN	2 (0.4%)
SILYBUM MARIANUM	2 (0.4%)
DIURETICS	
Total number of patients with at least one treatment	21 (3.9%)
Total number of treatments	28
ACETAZOLAMIDE	2 (0.4%)
ALISMA PLANTAGO-AQUATICA SUBSP. ORIENTALE TUBER;ATRACTYLODES SPP. RHIZOME;CINNAMOMUM CASSIA BARK;POLYPORUS UMBELLATUS SCLEROTIUM;FORIA COCOS SCLEROTIUM	1 (0.2%)
ASTRAGALUS PROPINQUUS	1 (0.2%)
ATRACTYLODES MACROCEPHALA	1 (0.2%)
BUMETANIDE	1 (0.2%)
EPLERENONE	1 (0.2%)
FUROSEMIDE	6 (1.1%)
HYDROCHLOROTHIAZIDE	3 (0.6%)
INDAPAMIDE	3 (0.6%)
SPIRONOLACTONE	3 (0.6%)
TORASEMIDE	3 (0.6%)
DRUGS FOR ACID RELATED DISORDERS	
Total number of patients with at least one treatment	37 (6.8%)
Total number of treatments	54
ALMAGATE	1 (0.2%)
ARTEMISIA ARGYI	1 (0.2%)
ARTEMISIA SPP. HERB	1 (0.2%)
BISMUTH ALUMINATE;FOENICULUM VULGARE FRUIT;FRANGULA ALNUS BARK;GLYCYRRHIZA SPP. ROOT WITH RHIZOME;MAGNESIUM BICARBONATE;SODIUM BICARBONATE	1 (0.2%)
DEXLANSOPRAZOLE	1 (0.2%)
ESOMEPRAZOLE	2 (0.4%)
ESOMEPRAZOLE MAGNESIUM	1 (0.2%)
ESOMEPRAZOLE MAGNESIUM;SODIUM BICARBONATE	1 (0.2%)
FAMOTIDINE	4 (0.7%)
LAFUTIDINE	1 (0.2%)
LANSOPRAZOLE	1 (0.2%)
MAGNESIUM HYDROXIDE	1 (0.2%)
MAGNESIUM OXIDE	1 (0.2%)
OMEPRAZOLE	7 (1.3%)
PANTOPRAZOLE	7 (1.3%)
PANTOPRAZOLE SODIUM SESQUIHYDRATE	4 (0.7%)
RABEPRAZOLE SODIUM	3 (0.6%)
REBAMIPIDE	4 (0.7%)
SODIUM ALGINATE	1 (0.2%)
SODIUM GUALENATE HYDRATE	1 (0.2%)
SOFALCONE	1 (0.2%)
TEPRENONE	1 (0.2%)
VITAMIN U	1 (0.2%)
VONOPRAZAN FUMARATE	2 (0.4%)
DRUGS FOR CONSTIPATION	
Total number of patients with at least one treatment	24 (4.4%)
Total number of treatments	37
ANGELICA SINENSIS	1 (0.2%)
BACILLUS SUBTILIS;ENTEROCOCCUS FAECIUM	1 (0.2%)
BULK-FORMING LAXATIVES	1 (0.2%)
DOCUSATE SODIUM	1 (0.2%)
DOCUSATE SODIUM;SENNOSIDE A+B	1 (0.2%)
ELECTROLYTES NOS;MACROGOL	1 (0.2%)
GLYCEROL	1 (0.2%)
LACTULOSE	2 (0.4%)
MACROGOL 4000;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE;SODIUM SULFATE	1 (0.2%)
MAGNESIUM HYDROXIDE	1 (0.2%)

MAGNESIUM OXIDE	1 (0.2%)
MAGNESIUM SULFATE	1 (0.2%)
MANNITOL	2 (0.4%)
OSMOTICALLY ACTING LAXATIVES	1 (0.2%)
PLANTAGO OVATA; SENNA ALEXANDRINA	1 (0.2%)
PROBIOTICS NOS	1 (0.2%)
SENNOSIDE A+B	1 (0.2%)
SODIUM CHLORIDE	9 (1.7%)
SODIUM CITRATE;SODIUM LAURYL SULFOACETATE;SORBITOL	1 (0.2%)
SODIUM PHOSPHATE MONOBASIC	1 (0.2%)
SODIUM PICOSULFATE	1 (0.2%)
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	
Total number of patients with at least one treatment	23 (4.2%)
Total number of treatments	37
ATROPINE SULFATE	1 (0.2%)
CITRUS MEDICA FRUIT;CITRUS SPP. FRUIT;CONCHA ARCAE;COPTIS CHINENSIS RHIZOME;CORDYLIS YANHUSUO TUBER;CYPERUS ROTUNDUS RHIZOME;LITSEA CUBEBA FRUIT;MELIA AZEDARACH;RHEUM SPP. ROOT WITH RHIZOME;SEPIAE ENDOCONCHA;TETRADIIUM RUTICARPUM FRUIT	1 (0.2%)
CURCUMA LONGA	1 (0.2%)
DICYCLOVERINE HYDROCHLORIDE	1 (0.2%)
DOMPERIDONE	1 (0.2%)
GASTRODIA ELATA	1 (0.2%)
GLYCYRRHIZA URALENSIS	1 (0.2%)
HYOSCYAMINE SULFATE	1 (0.2%)
ITOPRIDE HYDROCHLORIDE	1 (0.2%)
MEBEVERINE HYDROCHLORIDE	1 (0.2%)
METOCLOPRAMIDE	5 (0.9%)
METOCLOPRAMIDE HYDROCHLORIDE	9 (1.7%)
MOSAPRIDE CITRATE	2 (0.4%)
SODIUM BUTYRATE	1 (0.2%)
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	
Total number of patients with at least one treatment	26 (4.8%)
Total number of treatments	36
AMBROXOL ACEFVLLINATE	1 (0.2%)
ARTEMISIA ARGYI	1 (0.2%)
ASARUM SPP. ROOT;CINNAMOMUM CASSIA BARK;EPHEDRA SPP. HERB;GLYCYRRHIZA SPP. ROOT;PAEONIA LACTIFLORA ROOT;PINELLIA TERNATA TUBER;SCHISANDRA CHINENSIS FRUIT;ZINGIBER OFFICINALE RHIZOME	1 (0.2%)
BECLOMETASONE DIPROPIONATE;FORMOTEROL FUMARATE;GLYCOPYRFRONIUM BROMIDE	1 (0.2%)
BUDESONIDE	2 (0.4%)
CORTICOSTEROID NOS	1 (0.2%)
DEXAMETHASONE	6 (1.1%)
DEXAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
EPHEDRINE HYDROCHLORIDE	1 (0.2%)
FLUTICASONE PROPIONATE	3 (0.6%)
FLUTICASONE PROPIONATE;SALMETEROL XINAFOATE	2 (0.4%)
FLUTICASONE;VILANTEROL	1 (0.2%)
GLYCYRRHIZA SPP. ROOT;OPHIOPOGON JAPONICUS TUBER;ORYZA SATIVA FRUIT;PANAX GINSENG ROOT;PINELLIA TERNATA TUBER;ZIZIPHUS JUJUBA FRUIT	1 (0.2%)
IPRATROPIUM BROMIDE	2 (0.4%)
MEPIPHYLLINE	1 (0.2%)
MONTELUKAST SODIUM	1 (0.2%)
SALBUTAMOL	1 (0.2%)
THEOPHYLLINE	1 (0.2%)
TRIAMCINOLONE	3 (0.6%)
TRIAMCINOLONE ACETONIDE	1 (0.2%)
DRUGS FOR TREATMENT OF BONE DISEASES	
Total number of patients with at least one treatment	3 (0.6%)
Total number of treatments	3
ALENDRONIC ACID	1 (0.2%)
DENOSUMAB	1 (0.2%)
IBANDRONATE SODIUM	1 (0.2%)
DRUGS USED IN DIABETES	
Total number of patients with at least one treatment	21 (3.9%)
Total number of treatments	26
DAPAGLIFLOZIN	2 (0.4%)
DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE	2 (0.4%)
EMPAGLIFLOZIN	1 (0.2%)
EMPAGLIFLOZIN;LINAGLIPTIN	1 (0.2%)
GLICLAZIDE	2 (0.4%)
INSULIN ASPART BIOSIMILAR 1	1 (0.2%)
INSULIN DEGLUDEC	1 (0.2%)
INSULIN GLARGINE	1 (0.2%)
INSULIN HUMAN	1 (0.2%)
LIRAGLUTIDE	1 (0.2%)
METFORMIN	2 (0.4%)
METFORMIN HYDROCHLORIDE	4 (0.7%)
SEMAGLUTIDE	3 (0.6%)
SITAGLIPTIN	1 (0.2%)

SITAGLIPTIN PHOSPHATE	1 (0.2%)
TIRZEPATIDE	1 (0.2%)
EMOLLIENTS AND PROTECTIVES	
Total number of patients with at least one treatment	5 (0.9%)
Total number of treatments	5
GLYCEROL	1 (0.2%)
MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER	1 (0.2%)
OTHER EMOLLIENTS AND PROTECTIVES	1 (0.2%)
THIOCTIC ACID	1 (0.2%)
VITAMIN E NOS	1 (0.2%)
ENDOCRINE THERAPY	
Total number of patients with at least one treatment	6 (1.1%)
Total number of treatments	10
ANASTROZOLE	1 (0.2%)
ESTRADIOL	3 (0.6%)
ESTROGENS CONJUGATED	1 (0.2%)
LEUPRORELIN ACETATE	1 (0.2%)
RELUGOLIX	1 (0.2%)
GENERAL NUTRIENTS	
Total number of patients with at least one treatment	4 (0.7%)
Total number of treatments	4
DOCOSAHEXAENOIC ACID;EICOSAPENTAENOIC ACID	1 (0.2%)
GLUCOSE	3 (0.6%)
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS	
Total number of patients with at least one treatment	36 (6.6%)
Total number of treatments	38
ANTIBIOTICS	3 (0.6%)
ASCORBIC ACID	5 (0.9%)
BERBERINE	1 (0.2%)
CHLORAMPHENICOL	1 (0.2%)
CHLORHEXIDINE GLUCONATE	2 (0.4%)
CIPROFLOXACIN	3 (0.6%)
CLINDAMYCIN	1 (0.2%)
CLOTRIMAZOLE	1 (0.2%)
DEQUALINIUM CHLORIDE	1 (0.2%)
ENTEROCOCCUS FAECALIS	1 (0.2%)
KETOCONAZOLE	1 (0.2%)
LACTIPLANTIBACILLUS PLANTARUM	1 (0.2%)
LACTOBACILLUS RHAMNOSUS	1 (0.2%)
METRONIDAZOLE	3 (0.6%)
MICONAZOLE NITRATE	1 (0.2%)
NORFLOXACIN	2 (0.4%)
NYSTATIN	1 (0.2%)
OFLOXACIN	2 (0.4%)
POTASSIUM	1 (0.2%)
SERTACONAZOLE NITRATE	2 (0.4%)
TERBINAFINE	2 (0.4%)
HOMEOPATHIC PREPARATION	
Total number of patients with at least one treatment	25 (4.6%)
Total number of treatments	34
ASCORBIC ACID	5 (0.9%)
CORTISONE	2 (0.4%)
CYANOCOBALAMIN	1 (0.2%)
IRON	2 (0.4%)
POTASSIUM	1 (0.2%)
POTASSIUM CHLORIDE	3 (0.6%)
SILYBUM MARIANUM	2 (0.4%)
SODIUM CHLORIDE	9 (1.7%)
UBIDECARENONE	1 (0.2%)
IMMUNOSTIMULANTS	
Total number of patients with at least one treatment	2 (0.4%)
Total number of treatments	2
ASTRAGALUS PROPINQUUS	1 (0.2%)
THYMOSTIMULIN	1 (0.2%)
IMMUNOSUPPRESSANTS	
Total number of patients with at least one treatment	7 (1.3%)
Total number of treatments	10
COLCHICINE	4 (0.7%)
GOLIMUMAB	1 (0.2%)
IGURATIMOD	1 (0.2%)
INFLIXIMAB	1 (0.2%)
METHOTREXATE	1 (0.2%)
LIPID MODIFYING AGENTS	
Total number of patients with at least one treatment	35 (6.4%)
Total number of treatments	38

ATORVASTATIN	6 (1.1%)
ATORVASTATIN CALCIUM	5 (0.9%)
ATORVASTATIN CALCIUM;EZETIMIBE	2 (0.4%)
BERBERINE	1 (0.2%)
CHONDROITIN SULFATE SODIUM	1 (0.2%)
CURCUMA LONGA	1 (0.2%)
DOCOSAHEXAENOIC ACID;EICOSAPENTAENOIC ACID	1 (0.2%)
EZETIMIBE	2 (0.4%)
LACTIPLANTIBACILLUS PLANTARUM	1 (0.2%)
NICOTINIC ACID	1 (0.2%)
PHOSPHOLIPIDS	1 (0.2%)
PRAVASTATIN	1 (0.2%)
ROSUVASTATIN	8 (1.5%)
ROSUVASTATIN CALCIUM	7 (1.3%)
MEDICATED DRESSINGS	
Total number of patients with at least one treatment	12 (2.2%)
Total number of treatments	18
CHLORHEXIDINE GLUCONATE	2 (0.4%)
SODIUM ALGINATE	1 (0.2%)
SODIUM CHLORIDE	9 (1.7%)
MINERAL SUPPLEMENTS	
Total number of patients with at least one treatment	21 (3.9%)
Total number of treatments	29
CALCIUM	1 (0.2%)
CALCIUM PHOSPHATE;COLECALCIFEROL	1 (0.2%)
CALCIUM;COLECALCIFEROL	1 (0.2%)
CALCIUM;COLECALCIFEROL;MENAQUINONE	1 (0.2%)
MAGNESIUM	1 (0.2%)
MAGNESIUM ASPARTATE	1 (0.2%)
MAGNESIUM HYDROXIDE	1 (0.2%)
MAGNESIUM OXIDE	1 (0.2%)
MAGNESIUM SULFATE	1 (0.2%)
POTASSIUM	1 (0.2%)
POTASSIUM CHLORIDE	3 (0.6%)
SODIUM CHLORIDE	9 (1.7%)
SODIUM PHOSPHATE MONOBASIC	1 (0.2%)
MUSCLE RELAXANTS	
Total number of patients with at least one treatment	13 (2.4%)
Total number of treatments	18
BACLOFEN	1 (0.2%)
CHLORZOXAZONE	1 (0.2%)
CYCLOBENZAPRINE	2 (0.4%)
CYCLOBENZAPRINE HYDROCHLORIDE	1 (0.2%)
DIAZEPAM	2 (0.4%)
DICLOFENAC SODIUM;ORPHENADRINE CITRATE	1 (0.2%)
EPERISONE	1 (0.2%)
EPERISONE HYDROCHLORIDE	1 (0.2%)
MEPHENOXALONE	1 (0.2%)
PRIDINOL MESILATE	1 (0.2%)
ROCURONIUM BROMIDE	1 (0.2%)
THIOCOLCHICOSIDE	1 (0.2%)
TIZANIDINE HYDROCHLORIDE	2 (0.4%)
TOLPERISONE HYDROCHLORIDE	1 (0.2%)
N/A	
Total number of patients with at least one treatment	1 (0.2%)
Total number of treatments	1
PINENE	1 (0.2%)
NASAL PREPARATIONS	
Total number of patients with at least one treatment	36 (6.6%)
Total number of treatments	52
ACETYLCYSTEINE	4 (0.7%)
AZELASTINE HYDROCHLORIDE;FLUTICASONE PROPIONATE	1 (0.2%)
BUDESONIDE	2 (0.4%)
CORTICOSTEROID NOS	1 (0.2%)
DEXAMETHASONE	6 (1.1%)
DEXAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
EBASTINE;PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.2%)
EPHEDRINE HYDROCHLORIDE	1 (0.2%)
FLUTICASONE PROPIONATE	3 (0.6%)
HYALURONATE SODIUM	1 (0.2%)
IBUPROFEN;PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.2%)
IPRATROPIUM BROMIDE	2 (0.4%)
LORATADINE;PSEUDOEPHEDRINE SULFATE	1 (0.2%)
OXYMETAZOLINE HYDROCHLORIDE	1 (0.2%)
PHENYLEPHRINE HYDROCHLORIDE	1 (0.2%)
PREDNISOLONE	2 (0.4%)
SODIUM CHLORIDE	9 (1.7%)
TRIAMCINOLONE	3 (0.6%)

TRIAMCINOLONE ACETONIDE	1 (0.2%)
OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	
Total number of patients with at least one treatment	33 (6.1%)
Total number of treatments	41
CHLORAMPHENICOL	1 (0.2%)
CHLORHEXIDINE GLUCONATE	2 (0.4%)
CIPROFLOXACIN	3 (0.6%)
CIPROFLOXACIN;DEXAMETHASONE	1 (0.2%)
CORTICOSTEROID NOS	1 (0.2%)
DEXAMETHASONE	6 (1.1%)
DEXAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
FLUDROCORTISONE ACETATE;GRAMICIDIN;NEOMYCIN SULFATE	1 (0.2%)
GENTAMICIN SULFATE	1 (0.2%)
LEVOFLOXACIN	9 (1.7%)
NORFLOXACIN	2 (0.4%)
OFLOXACIN	2 (0.4%)
PREDNISOLONE	2 (0.4%)
STEROIDS	3 (0.6%)
OPHTHALMOLOGICALS	
Total number of patients with at least one treatment	112 (20.6%)
Total number of treatments	214
ACETAZOLAMIDE	2 (0.4%)
ACETYLCHOLINE CHLORIDE	1 (0.2%)
ACETYLCYSTEINE	4 (0.7%)
ACICLOVIR	5 (0.9%)
ALTEPLASE	1 (0.2%)
AMPICILLIN	1 (0.2%)
ANESTHETICS, LOCAL	2 (0.4%)
ANTIBIOTICS	3 (0.6%)
ASCORBIC ACID	5 (0.9%)
ATROPINE SULFATE	1 (0.2%)
AZITHROMYCIN	11 (2.0%)
AZITHROMYCIN DIHYDRATE	1 (0.2%)
BEPOTASTINE BESILATE	1 (0.2%)
BRIMONIDINE TARTRATE	1 (0.2%)
BUPIVACAINE	1 (0.2%)
BUPIVACAINE HYDROCHLORIDE	1 (0.2%)
CALCIUM CHLORIDE DIHYDRATE;MAGNESIUM CHLORIDE HEXAHYDRATE;POTASSIUM CHLORIDE;SODIUM ACETATE TRIHYDRATE;SODIUM CHLORIDE;SODIUM CITRATE DIHYDRATE	1 (0.2%)
CEFUROXIME	4 (0.7%)
CETIRIZINE	3 (0.6%)
CETIRIZINE HYDROCHLORIDE	1 (0.2%)
CHLORAMPHENICOL	1 (0.2%)
CHLORHEXIDINE GLUCONATE	2 (0.4%)
CHONDROITIN SULFATE SODIUM	1 (0.2%)
CIPROFLOXACIN	3 (0.6%)
CIPROFLOXACIN;DEXAMETHASONE	1 (0.2%)
CLONIDINE	1 (0.2%)
CLOTRIMAZOLE	1 (0.2%)
CORTICOSTEROID NOS	1 (0.2%)
CORTISONE	2 (0.4%)
CYANOCOBALAMIN	1 (0.2%)
DEXAMETHASONE	6 (1.1%)
DEXAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
DEXTRAN	1 (0.2%)
DICLOFENAC	6 (1.1%)
DICLOFENAC SODIUM	6 (1.1%)
EPHEDRINE HYDROCHLORIDE	1 (0.2%)
FLUCONAZOLE	1 (0.2%)
FLUDROCORTISONE ACETATE;GRAMICIDIN;NEOMYCIN SULFATE	1 (0.2%)
FLUOCINOLONE ACETONIDE	1 (0.2%)
FLURBIPROFEN	1 (0.2%)
FORSYTHIA SUSPENSIA FRUIT;LONICERA JAPONICA FLOWER BUD;SCUTELLARIA BAICALENSIS ROOT	1 (0.2%)
GENTAMICIN SULFATE	1 (0.2%)
GLYCEROL	1 (0.2%)
HEPARIN	2 (0.4%)
HYALURONATE SODIUM	1 (0.2%)
HYDROCORTISONE	1 (0.2%)
HYDROCORTISONE SODIUM SUCCINATE	1 (0.2%)
HYLAN G-F 20	1 (0.2%)
INDOMETACIN	1 (0.2%)
LEVOFLOXACIN	9 (1.7%)
LIDOCAINE	2 (0.4%)
LIDOCAINE HYDROCHLORIDE	1 (0.2%)
MELoxicAM	5 (0.9%)
METHYLPREDNISOLONE	2 (0.4%)
METHYLPREDNISOLONE SODIUM SUCCINATE	1 (0.2%)
MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER	1 (0.2%)
NAPROXEN	5 (0.9%)
NAPROXEN SODIUM	2 (0.4%)
NORFLOXACIN	2 (0.4%)

OFLOXACIN	2 (0.4%)
OXYMETAZOLINE HYDROCHLORIDE	1 (0.2%)
PANCREATIN	2 (0.4%)
PHENYLEPHRINE HYDROCHLORIDE	1 (0.2%)
PIROXICAM BETADEX	1 (0.2%)
POTASSIUM	1 (0.2%)
POTASSIUM CHLORIDE	3 (0.6%)
PREDNISOLONE	2 (0.4%)
PREDNISON	10 (1.8%)
REBAMIPIDE	4 (0.7%)
SODIUM CHLORIDE	9 (1.7%)
SODIUM GUALENATE HYDRATE	1 (0.2%)
STEROIDS	3 (0.6%)
SULFAMETHOXAZOLE	1 (0.2%)
TIMOLOL	1 (0.2%)
TRIAMCINOLONE	3 (0.6%)
TRIAMCINOLONE ACETONIDE	1 (0.2%)
TROXERUTIN	1 (0.2%)
UBIDECARENONE	1 (0.2%)
VIDARABINE	1 (0.2%)
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	
Total number of patients with at least one treatment	7 (1.3%)
Total number of treatments	7
ACETYLCYSTEINE	4 (0.7%)
PROBIOTICS NOS	1 (0.2%)
THIOCTIC ACID	1 (0.2%)
UBIDECARENONE	1 (0.2%)
OTHER DERMATOLOGICAL PREPARATIONS	
Total number of patients with at least one treatment	63 (11.6%)
Total number of treatments	93
ANGELICA SINENSIS	1 (0.2%)
ASCORBIC ACID	5 (0.9%)
BRIMONIDINE TARTRATE	1 (0.2%)
CINNAMOMUM CASSIA;EPHEDRA SPP.;GLYCYRRHIZA SPP.;PAEONIA LACTIFLORA;PUERARIA MONTANA VAR. LOBATA;ZINGIBER OFFICINALE;ZIZIPHUS JUJUBA	1 (0.2%)
DICLOFENAC	6 (1.1%)
DICLOFENAC SODIUM	6 (1.1%)
DL-METHIONINE;GLYCINE;GLYCYRRHIZIC ACID, AMMONIUM SALT	1 (0.2%)
DUTASTERIDE	1 (0.2%)
ESTRADIOL	3 (0.6%)
FINASTERIDE	1 (0.2%)
HYALURONATE SODIUM	1 (0.2%)
IBUPROFEN	28 (5.1%)
MAGNESIUM SULFATE	1 (0.2%)
OXYMETAZOLINE HYDROCHLORIDE	1 (0.2%)
PYRIDOXINE HYDROCHLORIDE	8 (1.5%)
TRANEXAMIC ACID	3 (0.6%)
UBIDECARENONE	1 (0.2%)
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	
Total number of patients with at least one treatment	4 (0.7%)
Total number of treatments	4
GELATIN	1 (0.2%)
HYALURONATE SODIUM	1 (0.2%)
HYLAN G-F 20	1 (0.2%)
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	1 (0.2%)
OTHER GYNECOLOGICALS	
Total number of patients with at least one treatment	45 (8.3%)
Total number of treatments	60
ANGELICA SINENSIS	1 (0.2%)
ARTEMISIA ARGYI	1 (0.2%)
BENZDYAMINE	1 (0.2%)
BENZDYAMINE HYDROCHLORIDE	1 (0.2%)
CLONIDINE	1 (0.2%)
GLYCEROL	1 (0.2%)
HYALURONATE SODIUM	1 (0.2%)
IBUPROFEN	28 (5.1%)
METHOTREXATE	1 (0.2%)
NAPROXEN	5 (0.9%)
NAPROXEN SODIUM	2 (0.4%)
NIFEDIPINE	4 (0.7%)
PAROXETINE HYDROCHLORIDE	1 (0.2%)
PROGESTERONE	2 (0.4%)
SALBUTAMOL	1 (0.2%)
SALVIA MILTIORRHIZA	2 (0.4%)
STREPTODORNASE;STREPTOKINASE	1 (0.2%)
OTHER HEMATOLOGICAL AGENTS	
Total number of patients with at least one treatment	2 (0.4%)
Total number of treatments	2

BROMELAINS:PAPAIN;RUTOSIDE	1 (0.2%)
STREPTODORNASE;STREPTOKINASE	1 (0.2%)
OTHER NERVOUS SYSTEM DRUGS	
Total number of patients with at least one treatment	29 (5.3%)
Total number of treatments	42
ACETYLCHOLINE CHLORIDE	1 (0.2%)
BACLOFEN	1 (0.2%)
BETAHISTINE	1 (0.2%)
BETAHISTINE HYDROCHLORIDE	1 (0.2%)
BUPRENORPHINE	1 (0.2%)
BUTYLPHTHALIDE	2 (0.4%)
CHOLINE ALFOSCEBRATE	1 (0.2%)
CINNARIZINE;DIMENHYDRINATE	1 (0.2%)
CLONIDINE	1 (0.2%)
COBAMAMIDE	3 (0.6%)
CYANOCOBALAMIN	1 (0.2%)
CYANOCOBALAMIN;PYRIDOXINE HYDROCHLORIDE;THIAMINE HYDROCHLORIDE	2 (0.4%)
DIMENHYDRINATE	2 (0.4%)
EDARAVONE	1 (0.2%)
GABAPENTIN	1 (0.2%)
GANGLIOSIDE : GM1;HYPOXANTHINE;POLYPEPTIDE NOS	1 (0.2%)
GASTRODIA ELATA	1 (0.2%)
GINKGO BILOBA EXTRACT	2 (0.4%)
HYDROXOCOBALAMIN	1 (0.2%)
MECLOZINE	1 (0.2%)
MECOBALAMIN	5 (0.9%)
METHYLETHYLPIRIDINOL SUCCINATE	1 (0.2%)
NALOXONE HYDROCHLORIDE;OXYCODONE HYDROCHLORIDE	1 (0.2%)
OXYBATE CALCIUM;OXYBATE MAGNESIUM;OXYBATE POTASSIUM;OXYBATE SODIUM	1 (0.2%)
PHOSPHOLIPIDS	1 (0.2%)
PROPRANOLOL	1 (0.2%)
THIOCTIC ACID	1 (0.2%)
VITAMIN B12 NOS	2 (0.4%)
OTHER RESPIRATORY SYSTEM PRODUCTS	
Total number of patients with at least one treatment	9 (1.7%)
Total number of treatments	9
ACETAZOLAMIDE	2 (0.4%)
AMBROXOL HYDROCHLORIDE	3 (0.6%)
ASARUM SPP. ROOT;CINNAMOMUM CASSIA BARK;EPHEDRA SPP. HERB;GLYCYRRHIZA SPP. ROOT;PAEONIA LACTIFLORA ROOT;PINELLIA TERNATA TUBER;SCHISANDRA CHINENSIS FRUIT;ZINGIBER OFFICINALE RHIZOME	1 (0.2%)
GLYCYRRHIZA SPP. ROOT;OPHIPOGON JAPONICUS TUBER;ORYZA SATIVA FRUIT;PANAX GINSENG ROOT;PINELLIA TERNATA TUBER;ZIZIPHUS JUJUBA FRUIT	1 (0.2%)
OTHER RESPIRATORY SYSTEM PRODUCTS	1 (0.2%)
PHOSPHOLIPIDS	1 (0.2%)
OTOLOGICALS	
Total number of patients with at least one treatment	49 (9.0%)
Total number of treatments	66
ANESTHETICS, LOCAL	2 (0.4%)
CHLORAMPHENICOL	1 (0.2%)
CHLORHEXIDINE GLUCONATE	2 (0.4%)
CIPROFLOXACIN	3 (0.6%)
CIPROFLOXACIN;DEXAMETHASONE	1 (0.2%)
CLOTRIMAZOLE	1 (0.2%)
CORTICOSTEROID NOS	1 (0.2%)
DEXAMETHASONE	6 (1.1%)
DEXAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
DOCUSATE SODIUM	1 (0.2%)
FLUOCINOLONE ACETONIDE	1 (0.2%)
FOSFOMYCIN	1 (0.2%)
GENTAMICIN SULFATE	1 (0.2%)
GLYCEROL	1 (0.2%)
HYDROCORTISONE	1 (0.2%)
HYDROCORTISONE SODIUM SUCCINATE	1 (0.2%)
LEVOFLOXACIN	9 (1.7%)
LIDOCAINE	2 (0.4%)
LIDOCAINE HYDROCHLORIDE	1 (0.2%)
MICONAZOLE NITRATE	1 (0.2%)
OFLOXACIN	2 (0.4%)
PREDNISOLONE	2 (0.4%)
SODIUM CHLORIDE	9 (1.7%)
STEROIDS	3 (0.6%)
PERIPHERAL VASODILATORS	
Total number of patients with at least one treatment	6 (1.1%)
Total number of treatments	10
BETAHISTINE	1 (0.2%)
BETAHISTINE HYDROCHLORIDE	1 (0.2%)
GASTRODIA ELATA	1 (0.2%)
GINKGO BILOBA EXTRACT	2 (0.4%)
KALLIDINOGENASE	1 (0.2%)

METHYLETHYLPIRIDINOL SUCCINATE	1 (0.2%)
NAFTIDROFURYL OXALATE	1 (0.2%)
NICOTINIC ACID	1 (0.2%)
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	
Total number of patients with at least one treatment	1 (0.2%)
Total number of treatments	3
LEUPRORELIN ACETATE	1 (0.2%)
RELUGOLIX	1 (0.2%)
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS	
Total number of patients with at least one treatment	12 (2.2%)
Total number of treatments	18
HYALURONATE SODIUM	1 (0.2%)
HYLAN G-F 20	1 (0.2%)
SODIUM CHLORIDE	9 (1.7%)
STREPTODORNASE/STREPTOKINASE	1 (0.2%)
PSYCHOANALEPTICS	
Total number of patients with at least one treatment	21 (3.9%)
Total number of treatments	27
AMITRIPTYLINE	1 (0.2%)
AMITRIPTYLINE HYDROCHLORIDE	1 (0.2%)
ATRACYLODES MACROCEPHALA	1 (0.2%)
CITICOLINE SODIUM	2 (0.4%)
CLONIDINE	1 (0.2%)
DULOXETINE	1 (0.2%)
DULOXETINE HYDROCHLORIDE	1 (0.2%)
ESCITALOPRAM	1 (0.2%)
FLUPENTIXOL DIHYDROCHLORIDE/MELITRACEN HYDROCHLORIDE	1 (0.2%)
GINKGO BILOBA EXTRACT	2 (0.4%)
INOSINE/NICOTINAMIDE/RIBOFLAVIN/SUCCINIC ACID	1 (0.2%)
MEMANTINE	1 (0.2%)
MEMANTINE HYDROCHLORIDE	1 (0.2%)
METHYLETHYLPIRIDINOL SUCCINATE	1 (0.2%)
OPIPRAMOL HYDROCHLORIDE	1 (0.2%)
PAROXETINE HYDROCHLORIDE	1 (0.2%)
PIRACETAM	2 (0.4%)
SERTRALINE	1 (0.2%)
SERTRALINE HYDROCHLORIDE	1 (0.2%)
TRAZODONE	1 (0.2%)
TRAZODONE HYDROCHLORIDE	2 (0.4%)
VINPOCETINE	1 (0.2%)
PSYCHOLEPTICS	
Total number of patients with at least one treatment	31 (5.7%)
Total number of treatments	36
ALPRAZOLAM	2 (0.4%)
AMITRIPTYLINE	1 (0.2%)
AMITRIPTYLINE HYDROCHLORIDE	1 (0.2%)
CLONAZEPAM	2 (0.4%)
DIAZEPAM	2 (0.4%)
DIPHENHYDRAMINE HYDROCHLORIDE	1 (0.2%)
DROPERIDOL	1 (0.2%)
DULOXETINE	1 (0.2%)
DULOXETINE HYDROCHLORIDE	1 (0.2%)
ESCITALOPRAM	1 (0.2%)
GAMMA-AMINOBUTYRIC ACID/MAGNESIUM OXIDE/MATRICARIA CHAMOMILLA/MELATONIN/PASSIFLORA INCARNATA/TRYPTOPHAN/VALERIANA OFFICINALIS ROOT EXTRACT/WITHANIA SOMNIFERA EXTRACT	1 (0.2%)
GASTRODIA ELATA	1 (0.2%)
HYDROXYZINE	3 (0.6%)
LEMBorexant	1 (0.2%)
LEVOMEPRAMAZINE HYDROCHLORIDE	1 (0.2%)
MELATONIN	2 (0.4%)
MEPHENOxALONE	1 (0.2%)
MIDAZOLAM	1 (0.2%)
MIDAZOLAM HYDROCHLORIDE	1 (0.2%)
PAROXETINE HYDROCHLORIDE	1 (0.2%)
PREGABALIN	5 (0.9%)
PROMETHAZINE	1 (0.2%)
PROPRANOLOL	1 (0.2%)
SERTRALINE	1 (0.2%)
SERTRALINE HYDROCHLORIDE	1 (0.2%)
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	
Total number of patients with at least one treatment	4 (0.7%)
Total number of treatments	10
ESTRADIOL	3 (0.6%)
ESTROGENS CONJUGATED	1 (0.2%)
PROGESTERONE	2 (0.4%)
TESTOSTERONE	2 (0.4%)

STOMATOLOGICAL PREPARATIONS	
Total number of patients with at least one treatment	79 (14.5%)
Total number of treatments	115
ACETYLSALICYLIC ACID	15 (2.8%)
ANESTHETICS, LOCAL	2 (0.4%)
BENZYDAMINE	1 (0.2%)
BENZYDAMINE HYDROCHLORIDE	1 (0.2%)
CHLORAMPHENICOL	1 (0.2%)
CHLORHEXIDINE GLUCONATE	2 (0.4%)
CLOTTRIMAZOLE	1 (0.2%)
CORTICOSTEROID NOS	1 (0.2%)
CURCUMA LONGA	1 (0.2%)
DEXAMETHASONE	6 (1.1%)
DEXAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
DICLOFENAC	6 (1.1%)
DICLOFENAC SODIUM	6 (1.1%)
DOXYCYCLINE	7 (1.3%)
DOXYCYCLINE HYCLATE	2 (0.4%)
DOXYCYCLINE HYDROCHLORIDE	1 (0.2%)
ELECTROLYTES NOS	1 (0.2%)
FLURBIPROFEN	1 (0.2%)
GLYCEROL	1 (0.2%)
GLYCYRRHIZA SPP. ROOT/PLATYCODON GRANDIFLORUS ROOT	1 (0.2%)
HYALURONATE SODIUM	1 (0.2%)
HYDROCORTISONE	1 (0.2%)
HYDROCORTISONE SODIUM SUCCINATE	1 (0.2%)
KETOPROFEN	3 (0.6%)
LIDOCAINE	2 (0.4%)
LIDOCAINE HYDROCHLORIDE	1 (0.2%)
METRONIDAZOLE	3 (0.6%)
MICONAZOLE NITRATE	1 (0.2%)
NAPROXEN	5 (0.9%)
NIMESULIDE	2 (0.4%)
NYSTATIN	1 (0.2%)
OCTENIDINE HYDROCHLORIDE	1 (0.2%)
POTASSIUM	1 (0.2%)
PREDNISOLONE	2 (0.4%)
SODIUM CHLORIDE	9 (1.7%)
SODIUM GUALENATE HYDRATE	1 (0.2%)
TRANEXAMIC ACID	3 (0.6%)
TRIAMCINOLONE	3 (0.6%)
TRIAMCINOLONE ACETONIDE	1 (0.2%)
THROAT PREPARATIONS	
Total number of patients with at least one treatment	62 (11.4%)
Total number of treatments	77
AMBROXOL HYDROCHLORIDE	3 (0.6%)
ANESTHETICS, LOCAL	2 (0.4%)
ANTIBIOTICS	3 (0.6%)
BENZOCAINE/HEXYLRESORCINOL/TYROTHRICIN	1 (0.2%)
BENZYDAMINE	1 (0.2%)
BENZYDAMINE HYDROCHLORIDE	1 (0.2%)
CHLORHEXIDINE GLUCONATE	2 (0.4%)
DEQUALINIUM CHLORIDE	1 (0.2%)
DICLOFENAC	6 (1.1%)
DICLOFENAC SODIUM	6 (1.1%)
FLURBIPROFEN	1 (0.2%)
HEXYLRESORCINOL	1 (0.2%)
IBUPROFEN	28 (5.1%)
KETOPROFEN	3 (0.6%)
LIDOCAINE	2 (0.4%)
LIDOCAINE HYDROCHLORIDE	1 (0.2%)
OCTENIDINE HYDROCHLORIDE	1 (0.2%)
SODIUM GUALENATE HYDRATE	1 (0.2%)
TRANEXAMIC ACID	3 (0.6%)
THYROID THERAPY	
Total number of patients with at least one treatment	6 (1.1%)
Total number of treatments	6
LEVOTHYROXINE	4 (0.7%)
PROPRANOLOL	1 (0.2%)
THYROID THERAPY	1 (0.2%)
TONICS	
Total number of patients with at least one treatment	2 (0.4%)
Total number of treatments	5
ASTRAGALUS PROPINQUUS	1 (0.2%)
ATRACYLLODES MACROCEPHALA	1 (0.2%)
CURCUMA LONGA	1 (0.2%)
GASTRODIA ELATA	1 (0.2%)
GLYCYRRHIZA URALENSIS	1 (0.2%)
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	

Total number of patients with at least one treatment	90 (16.5%)
Total number of treatments	127
ACETYLSALICYLIC ACID	15 (2.8%)
BENZYLAMINE	1 (0.2%)
BENZYLAMINE HYDROCHLORIDE	1 (0.2%)
CHONDROITIN SULFATE SODIUM	1 (0.2%)
CHONDROITIN SULFATE SODIUM:GLUCOSAMINE HYDROCHLORIDE	1 (0.2%)
CHONDROITIN SULFATE:GLUCOSAMINE	1 (0.2%)
CINEOLE;MELALEUCA LEUCADENDRA OIL;MENTHOL;METHYL SALICYLATE	1 (0.2%)
DEXIBUPROFEN	1 (0.2%)
DEKETOPROFEN TROMETAMOL	3 (0.6%)
DICLOFENAC	6 (1.1%)
DICLOFENAC POTASSIUM	1 (0.2%)
DICLOFENAC SODIUM	6 (1.1%)
ESFLURBIPROFEN;MENTHA SPP. OIL	1 (0.2%)
ETOFENAMATE	1 (0.2%)
FELBINAC	1 (0.2%)
FLURBIPROFEN	1 (0.2%)
FOLIC ACID	5 (0.9%)
GLUCOSAMINE	1 (0.2%)
GLUCOSAMINE SULFATE	1 (0.2%)
GLYCOL SALICYLATE;TOCOPHERYL ACETATE	1 (0.2%)
IBUPROFEN	28 (5.1%)
INDOMETACIN	1 (0.2%)
KETOPROFEN	3 (0.6%)
LOXOPROFEN	1 (0.2%)
LOXOPROFEN SODIUM	9 (1.7%)
LOXOPROFEN SODIUM DIHYDRATE	2 (0.4%)
MELOXICAM	5 (0.9%)
MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER	1 (0.2%)
NAPROXEN	5 (0.9%)
NAPROXEN SODIUM	2 (0.4%)
NIMESULIDE	2 (0.4%)
PHOSPHOLIPIDS	1 (0.2%)
PIROXICAM BETADEX	1 (0.2%)
TOLPERISONE HYDROCHLORIDE	1 (0.2%)
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	
Total number of patients with at least one treatment	34 (6.3%)
Total number of treatments	58
ACONITUM SPP., PROCESSED ROOT	1 (0.2%)
ALISMA PLANTAGO-AQUATICA SUBSP. ORIENTALE TUBER;ATRACYLODES SPP. RHIZOME;CINNAMOMUM CASSIA BARK;POLYPORUS UMBELLATUS SCLEROTIUM;PORIA COCOS SCLEROTIUM	1 (0.2%)
ALISMA PLANTAGO-AQUATICA SUBSP. ORIENTALE TUBER;CORYDALIS YANHUSUO TUBER;CYATHULA OFFICINALIS ROOT;GENTIANA SPP. ROOT;PAEONIA SPP. ROOT;PHELLODENDRON CHINENSE BARK;PLANTAGO SPP. SEED;SMILAX GLABRA RHIZOME	1 (0.2%)
ANGELICA SINENSIS	1 (0.2%)
ANGELICA SINENSIS;CHRYSANTHEMUM X MORIFOLIUM FLOWER;CRATAEGUS PINNATIFIDA;CURCUMA SPP. ROOT TUBER;ECLIPTA PROSTRATA;EQUISETUM HYEMALE;GENTIANA SCABRA;LEONURUS JAPONICUS RIPE FRUIT;LIGUSTICUM CHUANXIONG;LIGUSTRUM LUCIDUM RIPE FRUIT;PAEONIA OFFICINALIS SUBSP. OFFICINALIS ROOT;PAEONIA X SUFRUTICOSA BARK;PLANTAGO ASIATICA SEED;PRUNELLA VULGARIS;REHMANNIA GLUTINOSA	1 (0.2%)
ARCTIUM LAPPА FRUIT;ASCORBIC ACID;CHLORPHENAMINE MALEATE;FORSYTHIA SUSPENSА FRUIT;GLYCINE MAX FERMENTED SEED;GLYCYRRHIZA URALENSIS ROOT WITH RHIZOME;LONICERA JAPONICA FLOWER BUD;LOPHATHERUM GRACILE HERB;MENTHA CANADENSIS OIL;NEPETA TENUIFOLIA HERB;PARACETAMOL;PHRAGMITES AUSTRALIS SUBSP. AUSTRALIS RHIZOME;PLATYCODON GRANDIFLORUS ROOT	1 (0.2%)
ARTEMISIA ARGYI	1 (0.2%)
ARTEMISIA SPP. HERB	1 (0.2%)
ASARUM SPP. ROOT;CINNAMOMUM CASSIA BARK;EPHEDRA SPP. HERB;GLYCYRRHIZA SPP. ROOT;PAEONIA LACTIFLORA ROOT;PINELLIA TERNATA TUBER;SCHISANDRA CHINENSIS FRUIT;ZINGIBER OFFICINALE RHIZOME	1 (0.2%)
ASTER AGERATOIDES WHOLE PLANT;FIRMIANA SIMPLEX ROOT;KITAGAWIA PRAERUPTORA ROOT;METAGENTIANA RHODANTHA WHOLE PLANT;SCLEROMITRION DIFFUSUM WHOLE PLANT;SCUTELLARIA BAICALENSIS ROOT;STEMONA SPP. ROOT TUBER	1 (0.2%)
ASTRAGALUS PROPINQUUS	1 (0.2%)
ATRACYLODES MACROCEPHALA	1 (0.2%)
BERBERINE HYDROCHLORIDE;RHEUM SPP. ROOT WITH RHIZOME;SCUTELLARIA BAICALENSIS ROOT	1 (0.2%)
BIDENS BITERNATA;CAFFEINE;CHLORPHENAMINE MALEATE;CHRYSANTHEMUM INDICUM FLOWER;ILEX ASPRELLA ROOT;MELICOCPE PTELEIFOLIA;MENTHA CANADENSIS OIL;PARACETAMOL	1 (0.2%)
BORNEOL;CAFFEINE;GLYCYRRHIZA SPP. ROOT WITH RHIZOME;PLATYCODON GRANDIFLORUS ROOT;POLYGALA SPP. ROOT;PRUNUS SPP. SEED;RHUS SPP. GALLS	1 (0.2%)
CALCIUM SULFATE DIHYDRATE;DRYOPTERIS CRASSIRHIZOMA RHIZOME;EPHEDRA SPP. HERB;FORSYTHIA SUSPENSА;GLYCYRRHIZA SPP. ROOT WITH RHIZOME;HOOTUYINIA CORDATA HERB;ISATIS TINCTORIA ROOT;LONICERA JAPONICA FLOWER;MENTHOL;POCOSTEMUM CASLIN HERB;PRUNUS SPP. SEED;RHEUM SPP. ROOT WITH RHIZOME;RHODIOLA CRENULATA ROOT WITH RHIZOME	5 (0.9%)
CAMPHOR;GLYCYRRHIZA SPP. ROOT WITH RHIZOME;ILLICIUM VERUM OIL;PAPAVER SOMNIFERUM LATEX;SODIUM BENZOATE	2 (0.4%)
CHICKEN	1 (0.2%)
CHICKEN'S GIZZARD-MEMBRANE	1 (0.2%)
CINNAMOMUM CASSIA;EPHEDRA SPP. ;GLYCYRRHIZA SPP.;PAEONIA LACTIFLORA;PUERARIA MONTANA VAR. LOBATA;ZINGIBER OFFICINALE;ZIZIPHUS JUJUBA	1 (0.2%)

CITRUS MEDICA FRUIT;CITRUS SPP. FRUIT;CONCHA ARCAE;COPTIS CHINENSIS RHIZOME;CORYDALIS YANHUSUO TUBER;CYPERUS ROTUNDUS RHIZOME;LITSEA CUBEBA FRUIT;MELIA AZEDARACH;RHEUM SPP. ROOT WITH RHIZOME;SEPIAE ENDOCONCHA;TETRADIMUM RUTICARPUM FRUIT	1 (0.2%)
CORYDALIS BUNGEANA HERB;ISATIS TINCTORIA ROOT;SCUTELLARIA BAICALENSIS ROOT;TARAXACUM MONGOLICUM HERB	1 (0.2%)
CORYDALIS DECUMBENS TUBER	1 (0.2%)
CURCUMA LONGA	1 (0.2%)
FORSYTHIA SUSPENSIA FRUIT;LONICERA JAPONICA FLOWER BUD;SCUTELLARIA BAICALENSIS ROOT	1 (0.2%)
GASTRODIA ELATA	1 (0.2%)
GENTIANA LUTEA ROOT;PRIMULA SPP. FLOWER;RUMEX SPP. HERB;SAMBUCUS NIGRA FLOWER;VERBENA OFFICINALIS HERB	1 (0.2%)
GINKGO BILOBA EXTRACT	2 (0.4%)
GLYCYRRHIZA GLABRA EXTRACT;PAPAVER SOMNIFERUM	1 (0.2%)
GLYCYRRHIZA GLABRA EXTRACT;PAPAVER SOMNIFERUM;PIMPINELLA ANISUM OIL	1 (0.2%)
GLYCYRRHIZA SPP. ROOT;OPHIOPOGON JAPONICUS TUBER;ORYZA SATIVA FRUIT;PANAX GINSENG ROOT;PINELLIA TERNATA TUBER;ZIZIPHUS JILIBA FRUIT	1 (0.2%)
GLYCYRRHIZA SPP. ROOT;PAEONIA LACTIFLORA ROOT	1 (0.2%)
GLYCYRRHIZA SPP. ROOT;PLATYCODON GRANDIFLORUS ROOT	1 (0.2%)
GLYCYRRHIZA URALENSIS	1 (0.2%)
HIBISCUS SPP.	1 (0.2%)
ISATIS SPP.	1 (0.2%)
LOTUS CORNICULATUS	1 (0.2%)
PLANTAGO OVATA;SENNA ALEXANDRINA	1 (0.2%)
SALVIA MILTIORRHIZA	2 (0.4%)
SILYBUM MARIANUM	2 (0.4%)
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	6 (1.1%)
VITIS VINIFERA SEED	1 (0.2%)
UROLOGICALS	
Total number of patients with at least one treatment	23 (4.2%)
Total number of treatments	29
AMITRIPTYLINE	1 (0.2%)
AMITRIPTYLINE HYDROCHLORIDE	1 (0.2%)
BUDESONIDE	2 (0.4%)
CHONDROITIN SULFATE SODIUM	1 (0.2%)
DOXAZOSIN MESILATE	2 (0.4%)
DULOXETINE	1 (0.2%)
DULOXETINE HYDROCHLORIDE	1 (0.2%)
DUTASTERIDE	1 (0.2%)
FINASTERIDE	1 (0.2%)
GASTRODIA ELATA	1 (0.2%)
HYALURONATE SODIUM	1 (0.2%)
LIDOCAINE	2 (0.4%)
LIDOCAINE HYDROCHLORIDE	1 (0.2%)
MAGNESIUM HYDROXIDE	1 (0.2%)
MIRABEGRON	2 (0.4%)
OTHER DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	1 (0.2%)
SILDENAFIL CITRATE	1 (0.2%)
TADALAFIL	2 (0.4%)
TAMSULOSIN	2 (0.4%)
TAMSULOSIN HYDROCHLORIDE	3 (0.6%)
TERAZOSIN HYDROCHLORIDE	1 (0.2%)
VACCINES	
Total number of patients with at least one treatment	111 (20.4%)
Total number of treatments	156
COVID-19 VACCINE	14 (2.6%)
COVID-19 VACCINE INACT	1 (0.2%)
COVID-19 VACCINE INACT (VERO)	3 (0.6%)
COVID-19 VACCINE INACT (VERO) CZ02	1 (0.2%)
COVID-19 VACCINE NRVV AD (CHAD0X1 NCOV-19)	3 (0.6%)
COVID-19 VACCINE NRVV AD26 (GAM-COVID-VAC);COVID-19 VACCINE NRVV AD5 (GAM-COVID-VAC)	2 (0.4%)
COVID-19 VACCINE NRVV AD26 (JINI 78436735)	2 (0.4%)
DIPHThERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR 3-COMPONENT;POLIO VACCINE INACT 3V (VERO);TETANUS VACCINE TOXOID	1 (0.2%)
ELASOMERAN	32 (5.9%)
HEPATITIS B VACCINE	1 (0.2%)
HEPATITIS B VACCINE RHBSAG (YEAST)	1 (0.2%)
INFLUENZA VACCINE	27 (5.0%)
INFLUENZA VACCINE INACT SAG 4V	1 (0.2%)
INFLUENZA VACCINE INACT SPLIT 4V	2 (0.4%)
PNEUMOCOCCAL VACCINE	2 (0.4%)
PNEUMOCOCCAL VACCINE POLYSACCH	1 (0.2%)
TOZINAMERAN	41 (7.5%)
VARICELLA ZOSTER VACCINE	1 (0.2%)
VARICELLA ZOSTER VACCINE RGE (CHO)	2 (0.4%)
VASOPROTECTIVES	
Total number of patients with at least one treatment	44 (8.1%)
Total number of treatments	53
ANESTHETICS, LOCAL	2 (0.4%)
ANGELICA SINENSIS	1 (0.2%)

ANTIBIOTICS	3 (0.6%)
ASCORBIC ACID;RUTOSIDE	1 (0.2%)
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.2%)
CINCHOCaine HYDROCHLORIDE;ESCLUSIDE;HYDROCORTISONE;NEOMYCIN SULFATE	1 (0.2%)
CORTICOSTEROID NOS	1 (0.2%)
DEXAMETHASONE	6 (1.1%)
DEXAMETHASONE SODIUM PHOSPHATE	1 (0.2%)
DILTIAZEM	1 (0.2%)
DIOSMIN	3 (0.6%)
FLUOCINOLONE ACETONIDE	1 (0.2%)
FLUOCINONIDE	1 (0.2%)
GLYCERYL TRINITRATE	3 (0.6%)
HEPARIN	2 (0.4%)
HYALURONATE SODIUM	1 (0.2%)
HYDROCORTISONE	1 (0.2%)
HYDROCORTISONE SODIUM SUCCINATE	1 (0.2%)
LIDOCAINE	2 (0.4%)
LIDOCAINE HYDROCHLORIDE	1 (0.2%)
MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER	1 (0.2%)
NIFEDIPINE	4 (0.7%)
PHENYLEPHRINE HYDROCHLORIDE	1 (0.2%)
PREDNISOLONE	2 (0.4%)
SODIUM ALGINATE	1 (0.2%)
STREPTODORNASE;STREPTOKINASE	1 (0.2%)
TRIAMCINOLONE	3 (0.6%)
TRIAMCINOLONE ACETONIDE	1 (0.2%)
TROXERUTIN	1 (0.2%)
VITIS VINIFERA SEED	1 (0.2%)
VITAMINS	
Total number of patients with at least one treatment	32 (5.9%)
Total number of treatments	50
ALFACALCIDOL	2 (0.4%)
ASCORBIC ACID	5 (0.9%)
ASCORBIC ACID;BIOFLAVONOIDS NOS;RUTOSIDE;SODIUM SELENITE;ZINC GLUCONATE	1 (0.2%)
ASCORBIC ACID;VITAMIN B COMPLEX	1 (0.2%)
CALCITRIOL	1 (0.2%)
COLECALCIFEROL	3 (0.6%)
COLECALCIFEROL;MENAQUINONE-7	1 (0.2%)
CYANOCOBALAMIN;LIDOCAINE HYDROCHLORIDE;PYRIDOXINE HYDROCHLORIDE;THIAMINE HYDROCHLORIDE	1 (0.2%)
CYANOCOBALAMIN;PYRIDOXINE HYDROCHLORIDE;THIAMINE HYDROCHLORIDE	2 (0.4%)
ERGOCALCIFEROL	1 (0.2%)
NICOTINAMIDE	1 (0.2%)
NICOTINIC ACID	1 (0.2%)
PYRIDOXINE HYDROCHLORIDE	8 (1.5%)
VITAMIN B NOS	2 (0.4%)
VITAMIN D NOS	4 (0.7%)
VITAMIN E NOS	1 (0.2%)
VITAMINS NOS	3 (0.6%)

Treatments are coded using the WHO Drug Global B3 Format dictionary Version September 1, 2020. Treatments can appear under multiple classes. Multiple uses of a specific medication for a patient were counted once in the frequency for the medication. Likewise, multiple uses within a specific medication class for a patient were counted once in the frequency for the medication class. For frequency counts in the "total number of treatments", multiple uses of the same treatment for a patient were counted separately.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_cm.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41984/data_analysis/ACE_CSR_Final/prod/output/t_cm_CONC_NOCUL_A24_ITa24_30AUG2023_41984.xls
26APR2024 15:07

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
ENDPOINT: --
MODEL: descriptive
STUDY: GR41986
Times in which patient reported outcomes were collected

	Faricimab (N=711)
PRO (NEI VFQ-25) (weeks)	
n	711
Median	72,43

Times were calculated as:

PRO (NEI VFQ-25): Last Date of answered questionnaire - Randomization Date + 1.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_fu_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_fu_a24_ITa24_29AUG2023_41986.xls

26APR2024 15:20

POPULATION: Safety-Evaluable Population after Week 24
 ENDPOINT: --
 MODEL: descriptive
 STUDY: GR41986
 Duration of Exposure to Treatment after Week 24

	Faricimab (N=701)
Treatment duration (weeks)	
n	696
Mean (SD)	40.5 (7.15)
Median	42,1
Min-max	0 - 46
Number of study drug administrations	
n	695
Mean (SD)	5.5 (2.98)
Median	5
Min-max	1 - 12
Dose interruption	
Number of doses interrupted	108
At least one interrupted dose	72 (10.3%)
Intraocular inflammation	11 (1.6%)
BCVA decrease	2 (0.3%)
Elevated intraocular pressure	4 (0.6%)
Rhegmatogenous retinal break	0
Rhegmatogenous retinal detachment or macular hole	2 (0.3%)
Active or suspected infection	6 (0.9%)
Cataract surgery in the study eye	6 (0.9%)
Vitrectomy	1 (0.1%)
Intraocular surgery in study eye	2 (0.3%)
On-study prohibited medications	1 (0.1%)
Other	51 (7.3%)
Interruptions per patient	
n	72
1	54 (7.7%)
2	10 (1.4%)
3	3 (0.4%)
4	2 (0.3%)
5	1 (0.1%)
6	2 (0.3%)
7	0
8	0
9	0
10	0

Program: root/clinical_studies/R06867461/CDT30303/share/ACE_data_analysis/prod/program/t_ex_a24.sas
 Output: root/clinical_studies/R06867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ex_a24_SEa24_29AUG2023_41986.xls
 26APR2024 15:18

POPULATION: Intent-To-Treat Population, Patients entering Study Part 2
 ENDPOINT: Disposition of Patients after Week 24
 MODEL: descriptive
 STUDY: GR41986

	Faricimab (N=711)
Discontinued Study	55 (7.7%)
Adverse event	10 (1.4%)
Death	5 (0.7%)
Lost to follow-up	12 (1.7%)
Non-compliance with study drug	1 (0.1%)
Physician decision	4 (0.6%)
Withdrawal by subject	20 (2.8%)
Other	3 (0.4%)
Discontinued Treatment	63 (8.9%)
Adverse event	16 (2.3%)
Death	4 (0.6%)
Lost to follow-up	12 (1.7%)
Non-compliance with study drug	2 (0.3%)
Physician decision	7 (1.0%)
Withdrawal by subject	20 (2.8%)
Other	2 (0.3%)

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_ds_a24.sas

Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_ds_a24_ITa24_29AUG2023_41986.xls
 26APR2024 15:21

CAFFEINE/CHLORPHENAMINE MALEATE/COM BEZOAR/PARACETAMOL	1 (0.1%)
CAFFEINE/CHLORPHENAMINE MALEATE/DIHYDROCODEINE PHOSPHATE/GUAFENESIN/METHYLEPHEDRINE	1 (0.1%)
HYDROCHLORIDE-DL-PARACETAMOL/RIBOFLAVIN	1 (0.1%)
CAFFEINE/PARACETAMOL/PROXETAZINE METHYLENE DINALCYLATE/SALICYLAMIDE	1 (0.1%)
CANABIDIOL	1 (0.1%)
CLONIDINE	1 (0.1%)
CODEINE PHOSPHATE	1 (0.1%)
CODEINE PHOSPHATE/IBUPROFEN	1 (0.1%)
CODEINE PHOSPHATE/PARACETAMOL	5 (0.7%)
CODEINE/PARACETAMOL	2 (0.3%)
DEKETOPIROFEN TRIMETAMOL/TRAMADOL HYDROCHLORIDE	1 (0.1%)
DEXTROMETHORPHAN HYDROBROMIDE/DOXYLAMINE SUCCINATE/EFEDRINE SULFATE/ETHANOL/PARACETAMOL	1 (0.1%)
DEXTROMETHORPHAN HYDROBROMIDE/PARACETAMOL/PSEUDOEPHEDRINE HYDROCHLORIDE	2 (0.3%)
DIHYDROCODEINE PHOSPHATE	1 (0.1%)
DULOXETINE	1 (0.1%)
PENTANYL	5 (0.7%)
FLORAZEPINE DIHYDROCHLORIDE	1 (0.1%)
FORSYTHIA SUSPENSIO FRUIT/LONGICERA JAPONICA FLOWER RHIZ/SCUTELLARIA BAICALENSIS ROOT	1 (0.1%)
GABAPENTIN	5 (0.7%)
GUAFENESIN/PARACETAMOL/PHENYLEPHRINE HYDROCHLORIDE	1 (0.1%)
HIPPOPHOSPHAMIDES	1 (0.1%)
HYDROCODONE	1 (0.1%)
HYDROCODONE BITARTRATE/PARACETAMOL	1 (0.1%)
HYDROCODONE/PARACETAMOL	3 (0.4%)
HYDROXYPHENE	1 (0.1%)
MENTHOL	1 (0.1%)
METAMIZOLE	3 (0.4%)
METAMIZOLE MAGNESIUM	1 (0.1%)
METAMIZOLE SODIUM	4 (0.6%)
METOPROLOL	3 (0.4%)
METOPROLOL SUCCINATE	2 (0.3%)
METOPROLOL TARTRATE	2 (0.3%)
MIDOBALAN MESILATE	1 (0.1%)
MORPHINE	4 (0.6%)
MORPHINE SULFATE	1 (0.1%)
NAMAPHTHAN HYDROCHLORIDE	1 (0.1%)
OXYCODONE	8 (1.1%)
OXYCODONE HYDROCHLORIDE	1 (0.1%)
OXYCODONE HYDROCHLORIDE/PARACETAMOL	1 (0.1%)
PARACETAMOL	75 (10.5%)
PARACETAMOL/TRAMADOL HYDROCHLORIDE	6 (0.8%)
PREGABALIN	10 (1.4%)
PROPRANOLOL	2 (0.3%)
PROPRANOLOL HYDROCHLORIDE	1 (0.1%)
SAPONINIKOVIA DIVARICATA	1 (0.1%)
SUFENTANIL CITRATE	1 (0.1%)
SUMATRIPTAN	1 (0.1%)
TAMOXIFEN HYDROCHLORIDE	2 (0.3%)
TIMETAL	1 (0.1%)
TOPIRAMATE	2 (0.3%)
TRAMADOL	4 (0.6%)
ANESTHETICS	
Total number of patients with at least one treatment	19 (2.7%)
Total number of treatments	49
ANESTHETICS, LOCAL	2 (0.3%)
ARTICAINNE HYDROCHLORIDE/EPINEPHRINE BITARTRATE	1 (0.1%)
BUPIVACAINE	1 (0.1%)
BUPIVACAINE HYDROCHLORIDE	1 (0.1%)
DYCLONINE HYDROCHLORIDE	2 (0.3%)
ETOMIDATE	1 (0.1%)
PENTANYL	5 (0.7%)
ETAMIBNE HYDROCHLORIDE	1 (0.1%)
LIDOCaine	8 (1.1%)
LIDOCaine HYDROCHLORIDE	2 (0.3%)
PROPOL	4 (0.6%)
REMIFENTANIL HYDROCHLORIDE	1 (0.1%)
ROPIVACAINE	1 (0.1%)
SEVOPROXANE	1 (0.1%)
SUFENTANIL CITRATE	1 (0.1%)
ANTI-ACNE PREPARATIONS	
Total number of patients with at least one treatment	70 (9.8%)
Total number of treatments	85
ADAPALENE	1 (0.1%)
AZITHROMYCIN	18 (2.5%)
BENZOYL PEROXIDE	1 (0.1%)
CLINDAMYCIN	4 (0.6%)
CLINDAMYCIN PHOSPHATE	1 (0.1%)
DIMETICONE	1 (0.1%)
DOXYCYCLINE	10 (1.4%)
DOXYCYCLINE MONOHYDRATE	1 (0.1%)
ERYTHROMYCIN	2 (0.3%)
ERYTHROMYCIN	37 (5.2%)
ERYTHROMYCIN PIVOXIL	1 (0.1%)
ZINC	1 (0.1%)
ANTI-PARKINSON DRUGS	
Total number of patients with at least one treatment	5 (0.7%)
Total number of treatments	6
ANISODAMINE	1 (0.1%)
BENSERAZIDE HYDROCHLORIDE/LEVODOPA	1 (0.1%)
DIPHENHYDRAMINE	1 (0.1%)
DIPHENHYDRAMINE HYDROCHLORIDE	1 (0.1%)
PRAMIPEXOLE DIHYDROCHLORIDE	1 (0.1%)
ANTI-ANEMIC PREPARATIONS	
Total number of patients with at least one treatment	28 (3.9%)
Total number of treatments	54
CORAMIDE	1 (0.1%)
CYANOCOBALAMIN	4 (0.6%)
CYANOCOBALAMIN/FERROUS FUMARATE/FOLIC ACID/NICOTINAMIDE/RIBOFLAVIN/THIAMINE MONONITRATE	1 (0.1%)
DABERFOTIN ALFA	1 (0.1%)
ERYTHROPOIETIN	1 (0.1%)
FERRIC CARBOXYMALTOSE	1 (0.1%)
FERRIC CITRATE	1 (0.1%)
FERRIC HYDROXIDE POLYMALTOSE COMPLEX	1 (0.1%)
FERRIC PHOSPHOSULFATE	1 (0.1%)
FERRIC SODIUM GLUCONATE COMPLEX	1 (0.1%)
FERROUS FUMARATE	1 (0.1%)
FERROUS SODIUM CITRATE	1 (0.1%)

FERROUS SULFATE	5 (0.74)
FERROUS SULFATE EXSICCATED/SODIUM ASCORBATE	1 (0.14)
FOLIC ACID	3 (0.44)
FOLIC ACID/IRON/VITAMINS NOS	1 (0.14)
IRON	2 (0.28)
MECOBALAMIN	2 (0.28)
PANAX NOTOGINSENG	1 (0.14)
SACCHARATED IRON OXIDE	2 (0.28)
VITAMIN B NOS	3 (0.44)
VITAMIN B12 NOS	1 (0.14)
ANTIBACTERIALS FOR SYSTEMIC USE	
Total number of patients with at least one treatment	127 (17.94)
Total number of treatments	222
ALLIUM SATIVUM	1 (0.14)
AMIKACIN	1 (0.14)
AMOXICILLIN	20 (2.84)
AMOXICILLIN TRIHYDRATE	1 (0.14)
AMOXICILLIN TRIHYDRATE/CLAVULANATE POTASSIUM	5 (0.74)
AMOXICILLIN/CLAVULANATE POTASSIUM	15 (2.14)
AMOXICILLIN/CLAVULANIC ACID	1 (0.14)
AMPICILLIN	1 (0.14)
ANTIBIOTICS	2 (0.28)
AZITHROMYCIN	18 (2.54)
AZTREHAM	1 (0.14)
BACITRACIN	1 (0.14)
BENHYLPENICILLIN SODIUM	1 (0.14)
CEFALEXIN	14 (2.04)
CEFAZOLIN	3 (0.44)
CEFAZOLIN SODIUM	2 (0.28)
CEDAZEM PIVOXIL HYDROCHLORIDE	1 (0.14)
CEFDINIR	3 (0.44)
CEFDINIR	2 (0.28)
CEFIXIME	2 (0.28)
CEFTIOXIME SODIUM/BICTACTAM SODIUM	1 (0.14)
CEFTIOXIME PROXETIL	2 (0.28)
CEFRADINE	1 (0.14)
CEFTRIAXONE	2 (0.28)
CEFTRIAXONE SODIUM	4 (0.64)
CEFUROXIME	3 (0.44)
CEFUROXIME AXETIL	1 (0.14)
CEFUROXIME SODIUM	1 (0.14)
CIPROFLOXACIN	9 (1.34)
CIPROFLOXACIN HYDROCHLORIDE	2 (0.28)
CLARITHROMYCIN	6 (0.84)
CLAVULANIC ACID	1 (0.14)
CLINDAMYCIN	4 (0.64)
CLINDAMYCIN PHOSPHATE	1 (0.14)
DALBAVANCIN HYDROCHLORIDE	1 (0.14)
DOXYCYCLINE	10 (1.44)
DOXYCYCLINE HYCLATE	2 (0.28)
DOXYCYCLINE MONOHYDRATE	1 (0.14)
ERYTHROMYCIN	2 (0.28)
FLUCLOXACILIN	4 (0.64)
FUSIDIC ACID	1 (0.14)
FUSIDATE SODIUM	1 (0.14)
GENTAMICIN	1 (0.14)
LEVOFLOXACIN	6 (0.84)
LEVOFLOXACIN HEMIHYDRATE	1 (0.14)
LEVOFLOXACIN HYDROCHLORIDE	1 (0.14)
METRONIDAZOLE	6 (0.84)
METRONIDAZOLE/SODIUM CHLORIDE	1 (0.14)
MOXIFLOXACIN	1 (0.14)
NEOMYCIN	1 (0.14)
NEBELA SATIVA SEED OIL	1 (0.14)
NITROFURANTOIN	4 (0.64)
PIPERACILLIN SODIUM/TAZOBACTAM SODIUM	4 (0.64)
PRULIFLOXACIN	1 (0.14)
RIFAMPICIN	1 (0.14)
ROXITHROMYCIN	4 (0.64)
SALVA MELIORSINIZA	1 (0.14)
SULFAMETHIZOLE/TRIMETHOPRIM	1 (0.14)
SULFAMETHOXAZOLE	1 (0.14)
SULFAMETHOXAZOLE/TRIMETHOPRIM	3 (0.44)
TELCOPOLANIN	1 (0.14)
TETRACYCLINE	1 (0.14)
TOBRAMYCIN	1 (0.14)
TRIMETHOPRIM	2 (0.28)
VANCOMYCIN	3 (0.44)
VANCOMYCIN HYDROCHLORIDE	1 (0.14)
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE	
Total number of patients with at least one treatment	54 (7.64)
Total number of treatments	73
ACICLOVIR	4 (0.64)
AMIKACIN	1 (0.14)
ANTIBIOTICS	2 (0.28)
BACITRACIN	1 (0.14)
BACITRACIN/LIDOCAINE HYDROCHLORIDE/NEOMYCIN SULFATE/POLYMYXIN B SULFATE	1 (0.14)
BBEZOYL PEROXIDE	1 (0.14)
CIPROFLOXACIN	9 (1.34)
CIPROFLOXACIN HYDROCHLORIDE	2 (0.28)
CLARITHROMYCIN	6 (0.84)
DOXYCYCLINE	10 (1.44)
ERYTHROMYCIN	2 (0.28)
FUSIDATE SODIUM	1 (0.14)
GENTAMICIN	1 (0.14)
INTERFERON ALFA-2B	1 (0.14)
LEVOFLOXACIN	6 (0.84)
LEVOFLOXACIN HYDROCHLORIDE	1 (0.14)
LYSIZIME CHLORIDE	1 (0.14)
METRONIDAZOLE	6 (0.84)
MOXIFLOXACIN	1 (0.14)
MUPIROCIN	1 (0.14)
NEOMYCIN	1 (0.14)
RIBAVIRIN	1 (0.14)
RIFAMPICIN	1 (0.14)
RIFAXIMIN	1 (0.14)
SULFADIAZINE SILVER	2 (0.28)
TETRACYCLINE	1 (0.14)

ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	
Total number of patients with at least one treatment	45 (6.34)
Total number of treatments	66
ANTIBIOTICS	
ATROPINE SULFATE/DIPHENOXYLATE HYDROCHLORIDE	2 (0.34)
BACILLUS LICHENIFORMIS	1 (0.14)
BACITRACIN	1 (0.14)
BETAMETHASONE	2 (0.34)
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.14)
BETAMETHASONE VALERATE	1 (0.14)
BIFIDOBACTERIUM ANIMALIS/LACTOBACILLUS ACIDOPHILUS/LACTOBACILLUS BULGARICUS	1 (0.14)
BIFIDOBACTERIUM LORUM/ENTEROCOCCUS FAECALIS/LACTOBACILLUS ACIDOPHILUS	1 (0.14)
BIFIDOBACTERIUM NIS/LACTOBACILLUS NIS	1 (0.14)
BISMUTH SUBSALICYLATE	1 (0.14)
BISMUTH	1 (0.14)
CALCIUM CHLORIDE DIHYDRATE/GLUCOSE MONOHYDRATE/MAGNESIUM CHLORIDE HEXAHYDRATE/POTASSIUM CHLORIDE/SODIUM CHLORIDE/SODIUM LACTATE	1 (0.14)
ENTEROCOCCUS FAECALIS	1 (0.14)
FURAZOLIDONE	1 (0.14)
GLUCOSE/POTASSIUM CHLORIDE/SODIUM CHLORIDE	2 (0.34)
HYDROCORTISONE	2 (0.34)
HYDROCORTISONE BUTYRATE	1 (0.14)
HYDROCORTISONE SODIUM PHOSPHATE	1 (0.14)
LACTOBACILLUS ACIDOPHILUS	1 (0.14)
LOBESAMIDE HYDROCHLORIDE	4 (0.63)
METHYL	1 (0.14)
METHYLURACIL	1 (0.14)
NEOMYCIN	1 (0.14)
NYSTATIN	1 (0.14)
PLANTAGO OVATA	1 (0.14)
PRENIBIOLONE	3 (0.44)
PRENIBIOLONE	14 (2.04)
PROBIOTICS NOS	2 (0.34)
RIFAXIMIN	1 (0.14)
SACCHAROMYCES BOULARDII	2 (0.34)
SILVER	1 (0.14)
VANCOMYCIN	3 (0.44)
VANCOMYCIN HYDROCHLORIDE	1 (0.14)
ANTIDEMETICS AND ANTIEMETICANTS	
Total number of patients with at least one treatment	30 (4.24)
Total number of treatments	48
CHLORFRAZEMINE	1 (0.14)
CYCLOZIMINE	1 (0.14)
DIPRENICAL HYDROCHLORIDE	1 (0.14)
DIPRENHYDRAMINE	1 (0.14)
DIPRENHYDRAMINE HYDROCHLORIDE	1 (0.14)
DOMPERIDONE	5 (0.74)
HYDROXYZINE	3 (0.44)
HYDROXINE HYDROBROMIDE	1 (0.14)
LEVOSULPRIDE	1 (0.14)
METOCLOPRAMIDE	2 (0.34)
METOCLOPRAMIDE DIHYDROCHLORIDE	1 (0.14)
METOCLOPRAMIDE HYDROCHLORIDE	6 (0.84)
ONDANSETRON	10 (1.44)
ANTI-EPILEPTICS	
Total number of patients with at least one treatment	37 (5.24)
Total number of treatments	59
ACTEALAMIDE	10 (1.44)
CANNABIDIOL	1 (0.14)
CLONAZEPAM	1 (0.14)
GABAPENTIN	5 (0.74)
LORAZEPAM	1 (0.14)
MAGNESIUM SULFATE	2 (0.34)
MIDAZOLAM	5 (0.74)
PREDBALIN	10 (1.44)
TOPIRAMATE	2 (0.34)
ANTI-FUNGALS FOR DERMATOLOGICAL USE	
Total number of patients with at least one treatment	8 (1.14)
Total number of treatments	10
ANTIFUNGALS	
BIFONAZOLE	2 (0.34)
BIFONAZOLE	1 (0.14)
CLOTRIMAZOLE	1 (0.14)
FLUCONAZOLE	1 (0.14)
NYSTATIN	1 (0.14)
TERBINAFINE	1 (0.14)
TERBINAFINE HYDROCHLORIDE	1 (0.14)
UREA	2 (0.34)
ANTIGOUT PREPARATIONS	
Total number of patients with at least one treatment	5 (0.74)
Total number of treatments	6
ALLOPURINOL	1 (0.14)
COLCHICINE	2 (0.34)
DOCOSAHENAENOIC ACID/EICOSAPENTAENOIC ACID	1 (0.14)
FERROXYSTAT	2 (0.34)
ANTI-THROMBOTICS	
Total number of patients with at least one treatment	9 (1.34)
Total number of treatments	12
AMINO ACIDS NOS	1 (0.14)
ANEMICA SINENSIS/CHRYSANTHEMUM X MORIFOLIUM FLOWER/CRATAEGUS PINNATIFIDA/CURCUMA SPP. ROOT TUBER/ICLIPITA FROSTYATA/EQUISETUM HYEMALIS/GEFFIANA SCABRA/LORONISUS JAPONICUS RIPE FRUIT/LIGUSTICUM CHUANXIONG/LIGUSTICUM LACTIDUM RIPE FRUIT/PARONIA OFFICINALIS SUBSP. OFFICINALIS ROOT/PARONIA X SUFFRUTICOSA BARK/PLANTAGO ASIATICA SEED/PRINELLA VILGANS/REHMANNIA GLUTINOSA	2 (0.34)
BASIC FIBROBLAST GROWTH FACTOR	1 (0.14)
EPINEPHRINE	1 (0.14)
GELATIN	1 (0.14)
LYSOZYME CHLORIDE	1 (0.14)
NAFAMOSTAT MESILATE	1 (0.14)
PANAX NOTOGINSENG	1 (0.14)
TRANSAMIC ACID	2 (0.34)
ANTI-HISTAMINES FOR SYSTEMIC USE	
Total number of patients with at least one treatment	36 (5.14)
Total number of treatments	60
BENOTASTINE MESILATE	1 (0.14)
BILASTINE	2 (0.34)
CETIRIZINE	2 (0.34)
CETIRIZINE HYDROCHLORIDE	4 (0.63)

CHLORPHENIRAMINE MALEATE	6 (0.84)
CYCLIZINE	1 (0.14)
DESLORATADINE	1 (0.14)
DESMETHYLPHENIRAMINE MALEATE	1 (0.14)
DIPHENHYDRAMINE	1 (0.14)
DIPHENHYDRAMINE HYDROCHLORIDE	1 (0.14)
EBASTINE	1 (0.14)
FEKOPENADINE	1 (0.14)
FEKOPENADINE HYDROCHLORIDE	5 (0.74)
HYDROXIZINE	3 (0.44)
LEVOCETIRIZINE DIHYDROCHLORIDE	2 (0.34)
LORATADINE	5 (0.74)
OLOPATADINE HYDROCHLORIDE	2 (0.34)
ANTIHYPERTENSIVES	
Total number of patients with at least one treatment	12 (1.74)
Total number of treatments	15
CLONIDINE	1 (0.14)
DOXAZOSIN	1 (0.14)
DOXAZOSIN MESILATE	1 (0.14)
HYDRALAZINE	2 (0.34)
HYDRALAZINE HYDROCHLORIDE	1 (0.14)
MAGNESIUM SULFATE	2 (0.34)
METHYLDOPA	1 (0.14)
MORFININE	1 (0.14)
NAFTOPIDIL	1 (0.14)
TADALAFIL	1 (0.14)
URAPIDIL	1 (0.14)
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	
Total number of patients with at least one treatment	95 (13.44)
Total number of treatments	141
ACICLOVIR	2 (0.34)
ACONITUM RIZNEZOFFII ROOT TUBER/ANGELICA BISERRATA ROOT/CANTHARIS TINCTORIUS FLOWER/CLMATUS CHINENSIS ROOT WITH RAIZOME/DIPRACIS INERMIS ROOT/GERANIUM SPP. HERB/VISCUM COLUBRATUM LEAF WITH STEM	1 (0.14)
BENZYLAMINE HYDROCHLORIDE	1 (0.14)
CHELEDOXIN	6 (0.84)
CHEMBUOTIN SULFATE SODIUM	1 (0.14)
CHEMBUOTIN SULFATE/GLUCOSAMINE HYDROCHLORIDE	1 (0.14)
CINNAMOMUM CASSIA BARK/EPHEDRA SPP. HERB/GLYCYRRHIZA SPP. ROOT/PRENNIS SPP. SEED CLMATUS SPP. EXTRACT/PRINELLA VULGARIS EXTRACT/TRICHOSANTHES KIRILOWII EXTRACT	1 (0.14)
DEKIBUPROFEN	3 (0.44)
DEKETOPROFEN	1 (0.14)
DEKETOPROFEN TROMETAMOL	1 (0.14)
DICLOFENAC	11 (1.54)
DICLOFENAC SODIUM	9 (1.34)
ESOMEPRAZOLE STRONTIUM/NAPROXEN	1 (0.14)
ETOFENAMATE	1 (0.14)
ETORICOXIB	2 (0.34)
FLURBIPROFEN	3 (0.44)
FORSYTHIA SUSPENSUS FRUIT/LONICERA JAPONICA FLOWER BUD/SCUTELLARIA BAICALENSIS ROOT GLYCYRRHIZA SPP. ROOT/PARONIA LACTIFLORA ROOT	1 (0.14)
GLUCALILERE	1 (0.14)
IBUPROFEN	1 (0.14)
IBUPROFEN	37 (5.24)
IBUPROFEN PICOLOL	1 (0.14)
IBUPROXIB	1 (0.14)
INDOMETACIN	1 (0.14)
KETOPROFEN	4 (0.64)
KETOROLAC	4 (0.64)
KETOROLAC TROMETHAMINE	1 (0.14)
KRILL OIL	1 (0.14)
LOXAPROFEN SODIUM	9 (1.34)
LOXAPROFEN SODIUM DIHYDRATE	1 (0.14)
MEFENAMIC ACID	1 (0.14)
MELOXICAM	2 (0.34)
NABUMETONE	1 (0.14)
NAPROXEN	2 (0.34)
NAPROXEN SODIUM	3 (0.44)
NIMESULIDE	2 (0.34)
OTHER ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION WITH OTHER DRUGS	1 (0.14)
PELLIBUPROFEN	1 (0.14)
PIROXICAM BETADEX	1 (0.14)
PRANIPROFEN	1 (0.14)
TIZANIDINE HYDROCHLORIDE	1 (0.14)
VIGLA ODORATA	1 (0.14)
ANTIMYCOBACTERIALS	
Total number of patients with at least one treatment	3 (0.44)
Total number of treatments	3
ANTIBIOTICS	2 (0.34)
RIFAMPICIN	1 (0.14)
ANTIMYCOTIC FOR SYSTEMIC USE	
Total number of patients with at least one treatment	3 (0.44)
Total number of treatments	4
ANTIBIOTICS	2 (0.34)
FLUCONAZOLE	1 (0.14)
MYSTATIN	1 (0.14)
ANTINEOPLASTIC AGENTS	
Total number of patients with at least one treatment	10 (1.44)
Total number of treatments	11
CHELEDOXIN	6 (0.84)
METHOPRESTAT	1 (0.14)
PROPRANOLOL	2 (0.34)
PROPRANOLOL HYDROCHLORIDE	1 (0.14)
VIGLA ODORATA	1 (0.14)
ANTIONEMITY PREPARATIONS EXCL. DIET PRODUCTS	
Total number of patients with at least one treatment	5 (0.74)
Total number of treatments	5
ASPETAMINE ASPARTATE/AMPHETAMINE SULFATE/DEKAMPETAMINE SACCHARATE/DEKAMPETAMINE SULFATE	1 (0.14)
LISINAPRIL	1 (0.14)
PLANTAGO OYATA	1 (0.14)
SEMGALITIE	2 (0.34)
ANTIPROTOZOALS	
Total number of patients with at least one treatment	6 (0.84)
Total number of treatments	10
CLOTRIMAZOLE	1 (0.14)

METRONIDAZOLE	6 (0.84)
ANTIPYRITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	
Total number of patients with at least one treatment	45 (6.34)
Total number of treatments	75
ANESTHETICS, LOCAL	2 (0.34)
BEFOTASTINE BESILATE	1 (0.14)
BILASTINE	2 (0.34)
CETIRIZINE	2 (0.34)
CETIRIZINE HYDROCHLORIDE	4 (0.64)
CHLORPHENIRAMINE MALEATE	6 (0.84)
CROTAMITOL	1 (0.14)
DESLOKATADINE	1 (0.14)
DEXCLOPHENIRAMINE MALEATE	1 (0.14)
DIPHENHYDRAMINE	1 (0.14)
DIPHENHYDRAMINE HYDROCHLORIDE	1 (0.14)
EBASTINE	1 (0.14)
FEKOPENADINE	1 (0.14)
FEKOPENADINE HYDROCHLORIDE	5 (0.74)
HYDROXIZINE	3 (0.44)
LEVOCETIRIZINE DIHYDROCHLORIDE	2 (0.34)
LIDOCAINE	8 (1.14)
LIDOCAINE HYDROCHLORIDE	2 (0.34)
LEBATADINE	5 (0.74)
MENTHOL	1 (0.14)
OLGAPATADINE HYDROCHLORIDE	2 (0.34)
ANTIPYRITICS	
Total number of patients with at least one treatment	2 (0.34)
Total number of treatments	2
CALCITRIOL	1 (0.14)
TAPINAROP	1 (0.14)
ANTISEPTICS AND DISINFECTANTS	
Total number of patients with at least one treatment	7 (1.04)
Total number of treatments	10
CAMMELLOSE SODIUM/SILVER	1 (0.14)
CETYLPIPRIDINIUM CHLORIDE	1 (0.14)
DEQUALINIUM CHLORIDE	1 (0.14)
ETHANOL	2 (0.34)
POLYDINE IODINE	2 (0.34)
SILVER	1 (0.14)
ANTITHROMBOTIC AGENTS	
Total number of patients with at least one treatment	53 (7.54)
Total number of treatments	86
ACETYLSALICYLIC ACID	19 (2.74)
APEXABAN	15 (2.14)
CERTOPARIN SODIUM	1 (0.14)
CLOPIDOGREL	2 (0.34)
CLOPIDOGREL BISULFATE	5 (0.74)
DABIGATRAN ETEXILATE MESLATE	1 (0.14)
DALTEPARIN SODIUM	2 (0.34)
EDOXABAN	1 (0.14)
EDOXABAN TOSILATE	1 (0.14)
ENOXAPARIN	6 (0.84)
ENOXAPARIN SODIUM	6 (0.84)
HEPARIN	2 (0.34)
HEPARIN SODIUM	3 (0.44)
HEPARINOID	1 (0.14)
HEPARINAT MESLATE	1 (0.14)
PARNAPARIN SODIUM	1 (0.14)
RIVAROXABAN	3 (0.44)
STREPTODORNASE/STREPTOKINASE	1 (0.14)
TICAGRELOR	2 (0.34)
WARFARIN	1 (0.14)
WARFARIN POTASSIUM	1 (0.14)
WARFARIN SODIUM	1 (0.14)
ANTIVIRALS FOR SYSTEMIC USE	
Total number of patients with at least one treatment	32 (4.54)
Total number of treatments	38
ACICLOVIR	4 (0.64)
ADVUDINE	1 (0.14)
CALCIUM SULFATE DIHYDRATE/DRYOPTERIS CRASSIRHIZOMA RHIZOME/EPHEDRA SPP. HERB./PORSYTHIA SUSPENSIS/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/HOUTTUNIA OBOVATA HERB./ISATIS TINCTORIA ROOT/LONICERA JAPONICA FLOWER/MINTHOL/PODOSTEMON CABLIN HERB./PRUNUS SPP. SEED/RHEUM SPP. ROOT WITH RHIZOME/RHODIOLA CRANULATA ROOT WITH RHIZOME	3 (0.44)
EMTICITABINE/ELIPREVIRINE HYDROCHLORIDE/TENOFOVIR ALAFENAMIDE FUMARATE	1 (0.14)
HIPPURIC ACID	1 (0.14)
INSULINE FRANOEX	1 (0.14)
INSULINE FRANOEX/ZINC GLUCONATE	1 (0.14)
LAMIVUDINE OCTANATE	1 (0.14)
LYSINE CHLORIDE	1 (0.14)
MOLNUPREVIR	4 (0.64)
NIRMAVIR/RYTOXAVIR	9 (1.34)
OSELTAMIVIR	2 (0.34)
OSELTAMIVIR PHOSPHATE	1 (0.14)
OTHER ANTIVIRALS	1 (0.14)
REMSDESIVIR	1 (0.14)
RIBAVIRIN	1 (0.14)
VALACICLOVIR	1 (0.14)
VALGANCICLOVIR	1 (0.14)
APPETITE STIMULANTS	
Total number of patients with at least one treatment	1 (0.14)
Total number of treatments	2
CARNITINE HYDROCHLORIDE/CYANOCOBALAMIN/CYPROHEPTADINE OKOTATE/LYSINE HYDROCHLORIDE	1 (0.14)
MEGESTROL ACETATE	1 (0.14)
BETA BLOCKING AGENTS	
Total number of patients with at least one treatment	30 (4.24)
Total number of treatments	35
ATENOLOL	1 (0.14)
BISOPROLOL	4 (0.64)
BISOPROLOL FUMARATE	5 (0.74)
CARVEDILOL	6 (0.84)
LABETALOL	2 (0.34)
METOPROLOL	3 (0.44)
METOPROLOL SUCCINATE	2 (0.34)
METOPROLOL TARTRATE	2 (0.34)
NEBIVOLOL	1 (0.14)

NERIVOLOL HYDROCHLORIDE	1 (0.1%)
PROPRANOLOL	2 (0.3%)
PROPRANOLOL HYDROCHLORIDE	1 (0.1%)
ROPALOL	1 (0.1%)
TIMOLOL	1 (0.1%)
BILE AND LIVER THERAPY	
Total number of patients with at least one treatment	16 (2.3%)
Total number of treatments	28
ACTIVATED CHARCOAL	5 (0.7%)
AMORACIA RUSTICANA/CHARCOAL, ACTIVATED/DEHYDROCHOLIC ACID/MENHA X PIPERITA OIL	1 (0.1%)
BICUCYLL	1 (0.1%)
BORNEOL/CAMPHENE/CINOLE/MENTHOL/MENTHONE/OLEA EUROPAEA/PINENE	1 (0.1%)
DIAMMONIUM GLYCYRRHIZINATE	1 (0.1%)
DE-MEINONINE/GLYCINIUM GLYCYRRHIZIC ACID, AMMONIUM SALT	1 (0.1%)
DROFAPERINE HYDROCHLORIDE	1 (0.1%)
GLUTATHIONE	1 (0.1%)
GLYCYRRHIZA GLABRA	2 (0.3%)
HIPPOPHAE RHAMNOIDES	1 (0.1%)
HYDROXYMONE	1 (0.1%)
LACTULOSE	2 (0.3%)
RIFAXIMIN	1 (0.1%)
URSODEOXYCHOLIC ACID	1 (0.1%)
VIOLA ODORATA	1 (0.1%)
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS	
Total number of patients with at least one treatment	41 (5.8%)
Total number of treatments	123
ALANYL GLUTAMINE	1 (0.1%)
ALBUMIN HUMAN	1 (0.1%)
AMINO ACIDS NOS	1 (0.1%)
BLOOD, CALF, DEPROT., LOW PORTION	1 (0.1%)
CALCIUM CHLORIDE DIHYDRATE/GLUCOSE MONOHYDRATE/MAGNESIUM CHLORIDE HEXAHYDRATE/POTASSIUM CHLORIDE/SODIUM CHLORIDE/SODIUM LACTATE	1 (0.1%)
CALCIUM CHLORIDE DIHYDRATE/GLUCOSE/MAGNESIUM CHLORIDE HEXAHYDRATE/POTASSIUM CHLORIDE/SODIUM ACETATE/SODIUM BICARBONATE/SODIUM CHLORIDE	1 (0.1%)
CALCIUM CHLORIDE DIHYDRATE/MALTOSE/POTASSIUM CHLORIDE/SODIUM CHLORIDE/SODIUM LACTATE	1 (0.1%)
CALCIUM CHLORIDE DIHYDRATE/POTASSIUM CHLORIDE/SODIUM CHLORIDE/SODIUM LACTATE	1 (0.1%)
CALCIUM CHLORIDE/DIHYDRATE/POTASSIUM CHLORIDE/SODIUM ACETATE/SODIUM CHLORIDE	1 (0.1%)
CALCIUM CHLORIDE/MAGNESIUM CHLORIDE/MALIC ACID/POTASSIUM CHLORIDE/SODIUM ACETATE/SODIUM CHLORIDE	1 (0.1%)
CALCIUM CHLORIDE/MAGNESIUM CHLORIDE/POTASSIUM CHLORIDE/SODIUM ACETATE/SODIUM CHLORIDE	1 (0.1%)
CALCIUM CHLORIDE/MAGNESIUM CHLORIDE/POTASSIUM CHLORIDE/SODIUM ACETATE/SODIUM CHLORIDE/SODIUM CHLORIDE	1 (0.1%)
CALCIUM CHLORIDE/MAGNESIUM CHLORIDE/POTASSIUM CHLORIDE/SODIUM ACETATE/SODIUM CHLORIDE/SODIUM CHLORIDE/SODIUM CITRATE	1 (0.1%)
CALCIUM CHLORIDE/POTASSIUM CHLORIDE/SODIUM CHLORIDE	1 (0.1%)
CALCIUM CHLORIDE/POTASSIUM CHLORIDE/SODIUM CHLORIDE/SODIUM LACTATE	1 (0.1%)
CALCIUM CHLORIDE/POTASSIUM CHLORIDE/SODIUM LACTATE	2 (0.3%)
CETILPREDINUM CHLORIDE	1 (0.1%)
ELECTROLYTES NOS	2 (0.3%)
FUCTOSE GLYCEROL	2 (0.3%)
GELATIN	1 (0.1%)
GLUCOSE	1 (0.1%)
GLUCOSE/POTASSIUM CHLORIDE/SODIUM CHLORIDE	2 (0.3%)
GLUCOSE/SODIUM CHLORIDE/SODIUM LACTATE	1 (0.1%)
GLUCEROL	1 (0.1%)
MAGNESIUM SULFATE	2 (0.3%)
MANNITOL	3 (0.4%)
MEGACYLIN	1 (0.1%)
HYPERBARS NOS	1 (0.1%)
POTASSIUM ASPARTATE	1 (0.1%)
POTASSIUM CHLORIDE	17 (2.4%)
POTASSIUM PHOSPHATE DIBASIC/POTASSIUM PHOSPHATE MONOBASIC	1 (0.1%)
POTASSIUM PHOSPHATE MONOBASIC	1 (0.1%)
RED BLOOD CELLS, CONCENTRATED	1 (0.1%)
RED BLOOD CELLS, LEUCOCYTES DEPLETED	1 (0.1%)
SODIUM BICARBONATE	1 (0.1%)
SODIUM CHLORIDE	16 (2.3%)
SODIUM PHOSPHATE	1 (0.1%)
UREA	2 (0.3%)
VITAMINS NOS	1 (0.1%)
ZINC	1 (0.1%)
CALCIUM CHANNEL BLOCKERS	
Total number of patients with at least one treatment	24 (3.4%)
Total number of treatments	28
AMLODIPINE	10 (1.4%)
AMLODIPINE BESILATE	4 (0.6%)
AZELINIDIPINE	1 (0.1%)
DILTIAZEM	2 (0.3%)
DILTIAZEM HYDROCHLORIDE	1 (0.1%)
LESCANIDIPINE	1 (0.1%)
LESCANIDIPINE HYDROCHLORIDE	2 (0.3%)
LEVAMLODIPINE BESILATE	1 (0.1%)
NICARDIPINE HYDROCHLORIDE	2 (0.3%)
NIFEDIPINE	2 (0.3%)
NITRENDIPINE	1 (0.1%)
CARDIAC THERAPY	
Total number of patients with at least one treatment	70 (9.8%)
Total number of treatments	109
ATENOLOL	1 (0.1%)
AMIODARONE	5 (0.7%)
AMIODARONE HYDROCHLORIDE	1 (0.1%)
ANGELICA SINENSIS ROOT/BOMBYX MORI/BUNGARUS MULTICINCTUS/CARTHAGUS TINCTORIUS	
FLORIDI/CENTIPEDA/CARABOLUS/LABRARIA FRUIT/CLERMATEI SPP. ROOT WITH RHIZOME/CYATHULA OFFICINALIS ROOT/EUPOLYPHAGA SINENSIS/LEONURUS JAPONICUS FRUIT/LIGUSTICUM CHIANLIONG	
RHIZOME/LCINICERA JAPONICA STEM/LYCOPODIUM JAPONICUM WHOLE PLANT/MESOBUTHUS MANTENSI//PHERETIMA SPP./PURNUS SPP. SEED	1 (0.1%)
ATRACTYLODES LANCEA RHIZOME/CINNAMOMUM CASSIA BARK/GLYCYRRHIZA SPP. ROOT/PORIA COCOS SCLEROTIUM	1 (0.1%)
ATROPINE SULFATE	1 (0.1%)
BORNEOL/ROSMELLEIA SACRA BUSH/CENTIPEDA/CICADA SLIQUID/DALBERGIA GOROKPESA/EUPOLYPHAGA STELEOPHAGA/LEUCI/MESOBUTHUS MANTENSI/PACHIA SPP. ROOT/PANAX GINSENG ROOT/SANTALUM ALBUM	
HEARTWOOD/ZIZIPHUS JUTURA SEED	1 (0.1%)
DIGOXIN	4 (0.6%)
DROBNARONE HYDROCHLORIDE	1 (0.1%)
EMOXIPLOXIN	7 (1.0%)
EPINEPHRINE	1 (0.1%)
EPINEPHRINE	1 (0.1%)
ETHANOL	1 (0.1%)
FLUCANIDE	1 (0.1%)
GLUCERYL TRINITRATE	2 (0.3%)

HIPPOPHAE RHAMNOIDES	1 (0.1%)
IBUPROFEN	37 (5.2%)
IBUPROFEN PICOLOL	1 (0.1%)
INDOMETACIN	1 (0.1%)
IPRATROPIUM BROMIDE	3 (0.4%)
LIDOCAINE	8 (1.1%)
LIDOCAINE HYDROCHLORIDE	2 (0.3%)
MAGNESIUM ASPARTATE/POTASSIUM ASPARTATE	1 (0.1%)
PANAX NOTOGINSENG	1 (0.1%)
PANAX NOTOGINSENG ROOT TOTAL SAPONIN EXTRACT	1 (0.1%)
PHENYLEPHRINE	1 (0.1%)
PROPAPFENONE HYDROCHLORIDE	2 (0.3%)
SALVIA MILTIORRHIZA	1 (0.1%)
TAMSIKINONE TIA SODIUM SULFONATE	1 (0.1%)
CONTRAST MEDIA	
Total number of patients with at least one treatment	4 (0.6%)
Total number of treatments	8
IOBERGOL	1 (0.1%)
IOBERGOL	2 (0.3%)
IOPANICOL	1 (0.1%)
IOPRONIDE	1 (0.1%)
CORTICOSTEROIDS FOR SYSTEMIC USE	
Total number of patients with at least one treatment	45 (6.3%)
Total number of treatments	69
BETAMETHASONE	2 (0.3%)
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.1%)
BETAMETHASONE DIPROPIONATE/BETAMETHASONE SODIUM PHOSPHATE	1 (0.1%)
BETAMETHASONE VALERATE	1 (0.1%)
BETAMETHASONE/DEXCHLORPHENIRAMINE MALEATE	1 (0.1%)
CORTISONE	1 (0.1%)
DEKAMETHASONE	5 (0.7%)
DEKAMETHASONE DIPROPIONATE	1 (0.1%)
DEKAMETHASONE PHOSPHATE	1 (0.1%)
DEKAMETHASONE SODIUM PHOSPHATE	4 (0.6%)
HYDROCORTISONE	2 (0.3%)
HYDROCORTISONE BUTYRATE	1 (0.1%)
HYDROCORTISONE SODIUM PHOSPHATE	1 (0.1%)
METHYLPREDNISOLONE	8 (1.1%)
METHYLPREDNISOLONE SODIUM SUCCINATE	1 (0.1%)
PREDNISOLONE	3 (0.4%)
PREDNISOLONE VALERATE	1 (0.1%)
PREDNISONE	14 (2.0%)
TRIAMCINOLONE	3 (0.4%)
TRIAMCINOLONE ACETONIDE	2 (0.3%)
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	
Total number of patients with at least one treatment	56 (7.9%)
Total number of treatments	84
BETAMETHASONE	2 (0.3%)
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.1%)
BETAMETHASONE DIPROPIONATE/BETAMETHASONE SODIUM PHOSPHATE	1 (0.1%)
BETAMETHASONE VALERATE	1 (0.1%)
BETAMETHASONE VALERATE/GENTAMICIN SULFATE	1 (0.1%)
BUDERSONIDE	1 (0.1%)
CIPROFLOXACIN/FLUCINOLONE ACETONIDE	1 (0.1%)
CLOBETASOL	1 (0.1%)
CLOBETASOL PROPIONATE	2 (0.3%)
DEKAMETHASONE	5 (0.7%)
DEKAMETHASONE DIPROPIONATE	1 (0.1%)
DEKAMETHASONE SODIUM PHOSPHATE	4 (0.6%)
DEKAMETHASONE/GENTAMICIN SULFATE	1 (0.1%)
FLUCINOLONE ACETONIDE	1 (0.1%)
FLUTICASON PROPIONATE	4 (0.6%)
HYDROCORTISONE	2 (0.3%)
HYDROCORTISONE BUTYRATE	1 (0.1%)
HYDROCORTISONE SODIUM PHOSPHATE	1 (0.1%)
HYDROCORTISONE/OXYTETRACYCLINE HYDROCHLORIDE	1 (0.1%)
METHYLPREDNISOLONE	8 (1.1%)
METHYLPREDNISOLONE SODIUM SUCCINATE	1 (0.1%)
MOMETASONE FUROATE	4 (0.6%)
PREDNISOLONE	3 (0.4%)
PREDNISOLONE VALERATE	1 (0.1%)
PREDNISONE	14 (2.0%)
TRIAMCINOLONE	3 (0.4%)
TRIAMCINOLONE ACETONIDE	2 (0.3%)
COUGH AND COLD PREPARATIONS	
Total number of patients with at least one treatment	65 (9.1%)
Total number of treatments	126
ACETYLCESTEINE	5 (0.7%)
ACRIS CALAMIS VAR. ANGUSTATUS RHIZOME/ANGELICA DAHRICA ROOT/ANGELICA SINENSIS ROOT/CINNAMOMUM CASSIA TWIG/EPHEDRA SPP. STEM/LIGUSTICUM CHUANJIONG RHIZOME/MENTHA CANADENSIS HERB/MENTHA TENUIFOLIA HERB/NOTOPTERYDIUM SPP. ROOT WITH RHIZOME/PLATYCODON GRANDIFLORUS ROOT/PRUNUS SPP. SEED/PUERARIA MONTANA VAR. LOBATA ROOT/SAPOSHNIKOVIA DIVARICATA ROOT/SCUTELLARIA BAICALENSIS ROOT	1 (0.1%)
AMERDOL	1 (0.1%)
AMERDOL HYDROCHLORIDE	3 (0.4%)
AMMONIUM BICARBONATE/CEPHALIS SPP. TINCTURE	1 (0.1%)
AMMONIUM CHLORIDE/CHLORPHENAMINE MALEATE/DIHYDROCODEINE BITARTRATE/METHYLEPHEDRINE HYDROCHLORIDE-DL	1 (0.1%)
AMMONIUM CHLORIDE/CHLORPHENAMINE MALEATE/DIHYDROCODEINE BITARTRATE/METHYLEPHEDRINE HYDROCHLORIDE-DL/PELARGONIUM SIDOIDES	1 (0.1%)
AMMONIUM CHLORIDE/DIPHENHYDRAMINE HYDROCHLORIDE/SODIUM CITRATE	1 (0.1%)
ANEMARRHENA ASPHODELOIDES RHIZOME/ARISTOLOCHIA DEBILIS FRUIT/ASPARGUS COCHINCHINENSIS ROOT/TUBER/BECKLEIA OFFICINALIS FLOWER/BID/CALCIUM SULFATE DIHYDRATE/CITRUS AURANTIUM FRUIT PEEL/CITRUS AURANTIUM UNRIPE FRUIT/DESCURAINIA SOPHIA SEED/DOLOMIARA COTUS/FRITILLARIA SPP. BULB/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/KITAGAWIA FRAGRIFLORA/MEKES ALBA LEAF/OPHIOPOGON JAPONICUS ROOT TUBER	1 (0.1%)
ARCTIUM LAPPA FRUIT/ARCTICHA SUSPENSIA FRUIT/GLYCINE MAX FERMENTED SEED/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/LONICERA JAPONICA FLOWER/LOPHATHERUM GRACILE LEAF WITH STEM/MENTHA CANADENSIS HERB/MENTHA TENUIFOLIA HERB/PHRAGMITES AUSTRALIS SUBSP. AUSTRALIS RHIZOME/PLATYCODON GRANDIFLORUS ROOT	1 (0.1%)
ASTER AGERATOIDES WHOLE PLANT/FEMIANA SIMPLEX ROOT/KITAGAWIA FRAGRIFLORA ROOT/METAGENTIANA RHODANTHA WHOLE PLANT/SCLEROMITRION DIFFUSUM WHOLE PLANT/SCUTELLARIA BAICALENSIS ROOT/STEMONA SPP. ROOT TUBER	1 (0.1%)
BENZOATE	1 (0.1%)
BENZONIN/CHLORPHENAMINE MALEATE	1 (0.1%)
CAMPHOR/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/ILLICITUM VERUM OIL/PAPAVER SOMNIFERUM	1 (0.1%)
LATREX/SODIUM BENZOATE	1 (0.1%)
CARBOCISTEINE	8 (1.1%)
CHLORPHENAMINE MALEATE/DEXTROMETHORFAN HYDROBROMIDE/PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.1%)

CHLORPHENIRAMINE MALEATE/DIHYDROCODEINE BITARTRATE/GUAFENESIN/METHYLEPHEDRINE HYDROCHLORIDE	
DL	2 (0.38)
CHLORPHENIRAMINE MALEATE/DIHYDROCODEINE PHOSPHATE/METHYLEPHEDRINE HYDROCHLORIDE-DL	3 (0.48)
CINNAMOMUM CASSIA BARK/EPHEDRA SPP. HERB/GLUCYRRHIZA SPP. ROOT/PANONIA LACTIFLORA	
ROOT/PUEBARIA MONTANA VAR. LOBATA ROOT/ZINGIBER OFFICINALE RHIZOME/ZIZIPHUS JUTURNA FRUIT	1 (0.14)
CINNAMOMUM CASSIA BARK/EPHEDRA SPP. HERB/GLUCYRRHIZA SPP. ROOT/PERUVA SPP. SEED	1 (0.14)
CINNAMOMUM CASSIA STEM/EPHEDRA SPP. STEM/GLUCYRRHIZA SPP. ROOT WITH RHIZOME/PANONIA LACTIFLORA ROOT/PUEBARIA MONTANA VAR. LOBATA ROOT/ZINGIBER OFFICINALE RHIZOME/ZIZIPHUS JUTURNA FRUIT	1 (0.14)
CODEINE HYDROCHLORIDE/SULFOGALICOL	1 (0.14)
CODEINE PHOSPHATE	1 (0.14)
CODEINE PHOSPHATE/GUAFENESIN	1 (0.14)
CODEINE PHOSPHATE/SULFOGALICOL	1 (0.14)
CODEINE/GUAFENESIN	1 (0.14)
CODEN AND COLD PREPARATIONS	1 (0.14)
DEXTROMETHORPHAN	1 (0.14)
DEXTROMETHORPHAN HYDROBROMIDE	1 (0.14)
DEXTROMETHORPHAN HYDROBROMIDE/GUAFENESIN	2 (0.38)
DEXTROMETHORPHAN HYDROBROMIDE/LYSOZYME HYDROCHLORIDE/POTASSIUM CRESOLSULFONATE	1 (0.14)
DEXTROMETHORPHAN HYDROBROMIDE/METHYLEPHEDRINE HYDROCHLORIDE-DL/POTASSIUM CRESOLSULFONATE	1 (0.14)
ERMIA MARITIMA BULB/GUAFENESIN/PHOLCODINE/POLYGALA SPP. ROOT/PSEUDOPHEPERINE HYDROCHLORIDE/TRIPROLDINE HYDROCHLORIDE	1 (0.14)
ELECTROLYTES NOS	2 (0.38)
EGDOSTRINE	2 (0.38)
FERRYTHIA SUSPENSIA FRUIT/LONICERA JAPONICA FLOWER BUD/SCUTELLARIA BAICALENSIS ROOT	1 (0.14)
GLYCEROL	1 (0.14)
GLUCYRRHIZA GLABRA	2 (0.38)
GUAFENESIN	3 (0.48)
HERBAL COUGH AND COLD REMEDIES, OTHER	1 (0.14)
HIPPURIC ACID	1 (0.14)
HYDROCODONE	1 (0.14)
LEVODOPROPYLIZINE	2 (0.38)
LYSOZYME CHLORIDE	1 (0.14)
MANNITOL	3 (0.48)
MENTHOL	1 (0.14)
OTHER COLD PREPARATIONS	1 (0.14)
OTHER COUGH SUPPRESSANTS AND EXPECTORANTS	1 (0.14)
PANONIA LACTIFLORA/PLANTAGO SPP. HERB/PLATYCODON GRANDIFLORUS	1 (0.14)
PELAGONICUM RHIZOMES	2 (0.38)
SAPONINICACIA DIVARICATA	1 (0.14)
SODIUM CHLORIDE	16 (2.38)
STREPTODORNASE/STREPTOKINASE	1 (0.14)
VIOLA ODORATA	1 (0.14)
ZINC	1 (0.14)
DIAGNOSTIC AGENTS	
Total number of patients with at least one treatment	8 (1.14)
Total number of treatments	8
FOLIC ACID	3 (0.48)
GLUCOSE	1 (0.14)
INDIGO CARBINE	1 (0.14)
MAGNESIUM SULFATE	2 (0.38)
MANNITOL	3 (0.48)
DIAGNOSTIC RADIOPHARMACEUTICALS	
Total number of patients with at least one treatment	1 (0.14)
Total number of treatments	1
THALLIUM (201TL) CHLORIDE	1 (0.14)
DIGESTIVES, INCL. ENZYMES	
Total number of patients with at least one treatment	4 (0.64)
Total number of treatments	5
ALPHA-AMYLASE SWINE	
ALPHA-AMYLASE/CELLULASE/PANCRELIPASE/PAPAIN/PEPSIN/TRYPsin/URSODEOXYCHOLIC ACID	1 (0.14)
BROMELAINS	1 (0.14)
ENZYMES NOS	1 (0.14)
HIPPURIC ACID	1 (0.14)
DIURETICS	
Total number of patients with at least one treatment	36 (5.14)
Total number of treatments	57
ACETAZOLAMIDE	10 (1.48)
BEMETANIDE	1 (0.14)
EFDESIONE	3 (0.48)
FUROSEMIDE	12 (1.78)
FUROSEMIDE SODIUM	1 (0.14)
HYDROCHLOROTHIAZIDE	5 (0.78)
INAPAMIDE	1 (0.14)
SPARNOLOLACTONE	2 (0.38)
TYRASEMIDE	1 (0.14)
VIOLA ODORATA	1 (0.14)
DRUGS FOR ACID RELATED DISORDERS	
Total number of patients with at least one treatment	55 (7.78)
Total number of treatments	84
ALDOLAM/BICODIESTASE 2000/CALCIUM CARBONATE/CINNAMOMUM VERUM/GINSENG NOS/GLUCYRRHIZA GLABRA/LEVOLUTAMIDE/LIPASE/MAGNESIUM CARBONATE/PROZYME 6/SCOPOLIA CARNIOLICA EXTRACT/SIMULANATE/SODIUM BICARBONATE	1 (0.14)
ALMAGAT	1 (0.14)
ALUMINIUM HYDROXIDE/ALUMINIUM PHOSPHATE/CYANOPIS TETRAACOLORA OSM/MAGNESIUM HYDROXIDE	1 (0.14)
ALUMINIUM HYDROXIDE/MAGNESIUM HYDROXIDE/SIMETICONE	1 (0.14)
ARTEMISIA SPP. HERB	1 (0.14)
BISMUTH PECTIN	1 (0.14)
BISMUTH SUBSALICYLATE	1 (0.14)
CALCIUM CARBONATE	3 (0.48)
ESMOPEZOLE	1 (0.14)
ESMOPEZOLE MAGNESIUM	2 (0.38)
FAMOTIDINE	2 (0.38)
GLUCYRRHIZA GLABRA	2 (0.38)
HIPPURIC ACID	1 (0.14)
LAPUTIDINE	2 (0.38)
LANSOPRAZOLE	5 (0.78)
LEVOLUTAMIDE/SODIUM GUALLENATE	1 (0.14)
MAGNESIUM CARBONATE	1 (0.14)
MAGNESIUM OXIDE	3 (0.48)
OMEPRazole	10 (1.48)
PANTOPRAZOLE	13 (1.88)
PANTOPRAZOLE SODIUM SEQUIHYDRATE	3 (0.48)
RABEPRazole SODIUM	3 (0.48)
RANITIDINE	1 (0.14)
REBAMIPIDE	8 (1.14)

SODIUM BICARBONATE	1 (0.14)
SODIUM GUALANATE HYDRATE	1 (0.14)
SUCRALFATE	2 (0.34)
SULFINIRAM	1 (0.14)
TROPICAZAN	1 (0.14)
TRIPOTASSIUM DICITRATOBISSMUTHATE	1 (0.14)
DRUGS FOR CONSTIPATION	
Total number of patients with at least one treatment	38 (5.34)
Total number of treatments	81
ASCORBIC ACID/MACROGOL 3350/POTASSIUM CHLORIDE/SODIUM ASCORBATE/SODIUM CHLORIDE/SODIUM SULFATE	1 (0.14)
BISACODYL	1 (0.14)
CANNABIS SATIVA FRUIT/CITRUS SPP. UNRIPE FRUIT/MAGNOLIA SPP. BARK/PANONIA LACTIFLORA ROOT/PRUNUS SPP. SEED/RHEUM SPP. RHIZOME	1 (0.14)
DOCUSATE SODIUM	4 (0.64)
FRICTOSE/GLYCEROL	2 (0.34)
GLYCEROL	1 (0.14)
GLYCERYLSEDATE SPP. ROOT/RHEUM SPP. RHIZOME	1 (0.14)
LACTULOSE	2 (0.34)
MACROGOL 3350	1 (0.14)
MACROGOL 3350/POTASSIUM CHLORIDE/SODIUM BICARBONATE/SODIUM CHLORIDE	1 (0.14)
MAGNESIUM CARBONATE	1 (0.14)
MAGNESIUM OXIDE	3 (0.44)
MAGNESIUM SULFATE	2 (0.34)
MANNITOL	3 (0.44)
NALOXONE	2 (0.34)
PANAX GINSENG ROOT/ZANTHOXYLUM PIPERITUM PERICARP/ZINGIBER OFFICINALE PROCESSED RHIZOME	1 (0.14)
PLANTAGO OVATA	1 (0.14)
POTASSIUM PHOSPHATE DIBASIC/POTASSIUM PHOSPHATE MONOBASIC	1 (0.14)
PRUCLOPRIDE	2 (0.34)
SENA SPP.	1 (0.14)
SENNOSIDE A+B	2 (0.34)
SODIUM CHLORIDE	16 (2.34)
SODIUM PHOSPHATE	1 (0.14)
SODIUM PICO SULFATE	1 (0.14)
VIOLA ODORATA	1 (0.14)
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	
Total number of patients with at least one treatment	29 (4.14)
Total number of treatments	82
ALLIUM PLANTAGO-AQUATICA SUBSP. ORIENTALE RHIZOME/ANNONACOIDES ALTAICA RHIZOME/ANHELICA SINENSIS ROOT/ARTEMISIA SPP. HERB/ATRACYLODES MACROCEPHALA RHIZOME/CHICKEN'S GIZZARD-MEMBRANE/CRYDALIS YAMUSUO TUBER/DENDROBIUM NOBILE STEM/LIGUSTICUM CHUANXIONG RHIZOME/LILLIUM SPP. BULB/LINDERA AGRREGATA ROOT TUBER/OPHIOPOGON JAPONICUS ROOT TUBER/PANONIA LACTIFLORA ROOT	1 (0.14)
ANHELICA ARCHANGELICA ROOT/CARUM CARVI FRUIT/CHLIDONIUM MAJUS HERB/GLYCERYLSEDATE GLABRA ROOT/IBERIS AMARA/MATRICARIA CHAMOMILLA FLOWER/HELISSA OFFICINALIS LEAF/MENTHA X PIPERITA LEAF/WILLOW MAELAHUM FRUIT	1 (0.14)
ANTISERAMINE	1 (0.14)
ATROPINE SULFATE	1 (0.14)
DIMETICONE	1 (0.14)
DOMPERIDONE	5 (0.74)
EMETANSELINE HYDROCHLORIDE	1 (0.14)
GASTROLYN SLATA, THER.	1 (0.14)
GLYCERYLSEDATE GLABRA	2 (0.34)
HYOSCINE BUTYLBROMIDE	1 (0.14)
HYOSCINE HYDROBROMIDE	1 (0.14)
TYMPHINE	1 (0.14)
TYMPHINE HYDROCHLORIDE	1 (0.14)
LEVOSULPRIDE	1 (0.14)
MERBEVERINE HYDROCHLORIDE	1 (0.14)
METOCLOPRAMIDE	2 (0.34)
METOCLOPRAMIDE DIHYDROCHLORIDE	1 (0.14)
METOCLOPRAMIDE HYDROCHLORIDE	6 (0.84)
MOSAPRIDE CITRATE	1 (0.14)
NIGELLA SATIVA SEED OIL	1 (0.14)
SIMETICONE	1 (0.14)
TROSPIDIUM CHLORIDE	1 (0.14)
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	
Total number of patients with at least one treatment	37 (5.24)
Total number of treatments	59
BETAMETHASONE	2 (0.34)
BETAMETHASONE VALERATE	1 (0.14)
BUDESONIDE	1 (0.14)
BUDESONIDE/FORMOTEROL FUMARATE	3 (0.44)
CINNAMOMUM CASSIA BARK/EPHEDRA SPP. HERB/GLYCERYLSEDATE SPP. ROOT/PRUNUS SPP. SEED	1 (0.14)
DEKAMETHASONE	5 (0.74)
DEKAMETHASONE SODIUM PHOSPHATE	4 (0.64)
DIPROPHYLLINE	1 (0.14)
EPHEDRINE	1 (0.14)
EPINEPHRINE	1 (0.14)
FENOTEROL HYDROBROMIDE/IPRATROPIUM BROMIDE	1 (0.14)
FLUTICASONE FUORATE/UMECILDINIUM BROMIDE/VILANTEROL TRIPERENATE	1 (0.14)
FLUTICASONE FUORATE/VILANTEROL TRIPERENATE	1 (0.14)
FLUTICASONE PROPIONATE	4 (0.64)
FLUTICASONE PROPIONATE/SALMETEROL XINAFOATE	1 (0.14)
GLUCOPYRCONIUM BROMIDE/INDACATEROL MALEATE	1 (0.14)
IPRATROPIUM BROMIDE	3 (0.44)
IPRATROPIUM/SALBUTAMOL	1 (0.14)
METHYLPHEDRINE HYDROCHLORIDE-DL	1 (0.14)
MOMETASONE FUORATE	4 (0.64)
MONTelukAST SODIUM	2 (0.34)
PELANONITUM BIODIDES	2 (0.34)
SALBUTAMOL	3 (0.44)
TIOTROPIUM BROMIDE MONOHYDRATE	1 (0.14)
TRIAMCINOLONE	3 (0.44)
TRIAMCINOLONE ACETONIDE	2 (0.34)
UMECILDINIUM/VILANTEROL	1 (0.14)
VIOLA ODORATA	1 (0.14)
DRUGS FOR TREATMENT OF BONE DISEASES	
Total number of patients with at least one treatment	5 (0.74)
Total number of treatments	5
ALENDRONATE SODIUM	1 (0.14)
ALENDRONIC ACID	1 (0.14)
ANHELICA SINENSIS ROOT/BOSELLIA SACKA BARK RESIN/CALAMUS DRACO FRUIT RESIN/COMMIPHORA MYRRHA RESIN/RYNARIA ROOSII RHIZOME/EUPOLYPHAGA SINENSIS/PYRITE/RHEUM SPP. ROOT WITH RHIZOME/SODIUM BOPATE DECAHYDRATE	1 (0.14)
ZOLEDRONIC ACID	2 (0.34)
DRUGS USED IN DIABETES	

Total number of patients with at least one treatment	37 (5.24)
Total number of treatments	53
DAPAGLIFLOZIN	2 (0.34)
DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE	5 (0.74)
DILAGLITIDE	2 (0.34)
EMPAFLIFLOZIN	7 (1.04)
EPALRESTAT	1 (0.14)
GLICLAXIDE	1 (0.14)
GLIMEPIRIDE	2 (0.34)
GLIPIFIDE	1 (0.14)
INSULIN	3 (0.44)
INSULIN ASPART	2 (0.34)
INSULIN DETEMIR	1 (0.14)
INSULIN GLARGINE	2 (0.34)
INSULIN HUMAN	1 (0.14)
INSULIN HUMAN INJECTION, ISOPHANE	1 (0.14)
INSULIN LISPRO	1 (0.14)
LINAHLIPTIN	1 (0.14)
LIPAGLITIDE	1 (0.14)
METFORMIN	4 (0.64)
METFORMIN HYDROCHLORIDE	3 (0.44)
METFORMIN HYDROCHLORIDE/VILLAGLIPTIN	2 (0.34)
MIGLITOL	2 (0.34)
REPAGLINIDE	2 (0.34)
SEMAGLITIDE	2 (0.34)
VOGLIBOSE	1 (0.14)
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS	
Total number of patients with at least one treatment	4 (0.64)
Total number of treatments	10
CHRYMANTON	1 (0.14)
DIMETICONE	1 (0.14)
PELAGONUM SIDOIDES	2 (0.34)
EMULSIFIERS AND PROTECTIVES	
Total number of patients with at least one treatment	10 (1.44)
Total number of treatments	30
DIMETICONE	1 (0.14)
EMULSIFYING WAX/PARAFFIN, LIQUID/WHITE SOFT PARAFFIN	1 (0.14)
GLYCEROL	1 (0.14)
HEXARACHID	1 (0.14)
HIPPOPHAE RHAMNOIDES	1 (0.14)
OTHER EMULSIFIERS AND PROTECTIVES	1 (0.14)
PRINUS AMMIRACIA	1 (0.14)
UREA	2 (0.34)
VIOLA ODORATA	1 (0.14)
VITAMIN E NOS	1 (0.14)
WHITE SOFT PARAFFIN	1 (0.14)
ZINC	1 (0.14)
ZINC OXIDE	2 (0.34)
ENDOCRINE THERAPY	
Total number of patients with at least one treatment	2 (0.34)
Total number of treatments	2
LETROZOLE	1 (0.14)
MEDROXYL ACETATE	1 (0.14)
GENERAL NUTRIENTS	
Total number of patients with at least one treatment	6 (0.84)
Total number of treatments	16
(R)-3-METHYL-2-OXOVALERIANIC ACID CALCIUM (RS)-3-METHYL-2-OXOBUTYRIC ACID CALCIUM/CALCIUM	
(R)-4-METHYL-2-OXOVALERIANAT/CALCIUM 2-OXO-3-PHENYLPROPIONATE/DESMININOL	
CALCIUM HISTIDINE/LYSINE ACETATE/THREONINE/TRYPHOPHAN/TYROSINE	1 (0.14)
ALANYL GLUTAMINE	1 (0.14)
AMINO ACIDS NOS	1 (0.14)
CARBOHYDRATES NOS/ELECTROLYTES NOS/LIPIDS NOS/PROTEINS NOS/VITAMINS NOS	1 (0.14)
DOCOSAHENAIC ACID/EICOSAPENTAENOIC ACID	1 (0.14)
GLUCOSE	1 (0.14)
NUTRIENTS NOS	1 (0.14)
POTASSIUM ASPARTATE	1 (0.14)
GYNCOLOGICAL ANTIINFECTIVES AND ANTISEPTICS	
Total number of patients with at least one treatment	36 (5.14)
Total number of treatments	66
ANTIBIOTICS	2 (0.34)
ASCORBIC ACID	8 (1.14)
CIPROFLOXACIN	9 (1.34)
CIPROFLOXACIN HYDROCHLORIDE	2 (0.34)
CLINDAMYCIN	4 (0.64)
CLINDAMYCIN PHOSPHATE	1 (0.14)
CLOTRIMAZOLE	1 (0.14)
DEQUALINIUM CHLORIDE	1 (0.14)
ENTEROCOCCUS FACCALIS	1 (0.14)
FURAZOLIDONE	1 (0.14)
LACTOBACILLUS ACIDOPHILUS	1 (0.14)
METRONIDAZOLE	6 (0.84)
MYSTATIN	1 (0.14)
POVIDONE-IODINE	2 (0.34)
SILVER	1 (0.14)
TERBINAFINE	1 (0.14)
TERBINAFINE HYDROCHLORIDE	1 (0.14)
HOMOEOPATHIC PREPARATION	
Total number of patients with at least one treatment	43 (6.04)
Total number of treatments	92
ASCORBIC ACID	8 (1.14)
CALCIUM CARBONATE	3 (0.44)
CORTISONE	1 (0.14)
CYANOCOBALAMIN	4 (0.64)
EPINEPHRINE	1 (0.14)
HOMOEOPATHICS NOS	2 (0.34)
IRON	2 (0.34)
PELAGONUM SIDOIDES	2 (0.34)
PHOSPHORUS	1 (0.14)
POTASSIUM CHLORIDE	17 (2.44)
RIBOFLAVIN	1 (0.14)
SILVER	1 (0.14)
SODIUM CHLORIDE	16 (2.34)
SODIUM PHOSPHATE	1 (0.14)
UREA	2 (0.34)
ZINC	1 (0.14)

IMMUNOSTIMULANTS	
Total number of patients with at least one treatment	4 (0.64)
Total number of treatments	7
ALISMA PLANTAGO-AQUATICA SUBSP. ORIENTALE RHIZOME/ANGELICA SINENSIS ROOT/ASARUM SPP. ROOT WITH RHIZOME/ASTRAGALUS SPP. ROOT/CUSCUTA SPP. SEED/DEER HORN/GASTRODIA ELATA TUBER/LYCIUM BAMBAMUM FRUIT/PANAX GINSENG ROOT/REHMANNIA GLUTINOSA ROOT TUBER/SENNA SPP. SEED	1 (0.14)
ASTRAGALUS MEMBRILLICUS ROOT/COCOSOPSIS PILOBLA ROOT	1 (0.14)
GLUTATHIONE	1 (0.14)
INTERFERON ALFA-2B	1 (0.14)
METHYLURACIL	1 (0.14)
SILVER	1 (0.14)
IMMUNOSUPPRESSANTS	
Total number of patients with at least one treatment	5 (0.78)
Total number of treatments	6
AZATHIOPRINE	1 (0.14)
CYCLOSPORINE	2 (0.38)
METHOTREXATE	1 (0.14)
MYCOPHENOLIC ACID	1 (0.14)
TACROLIMUS	1 (0.14)
INVESTIGATIONAL DRUG	
Total number of patients with at least one treatment	1 (0.14)
Total number of treatments	1
AVUDINE	1 (0.14)
LIPID MODIFYING AGENTS	
Total number of patients with at least one treatment	35 (4.94)
Total number of treatments	39
ALLIUM SATIVUM	1 (0.14)
AMEZDIPINE BESILATE/ATORVASTATIN CALCIUM	1 (0.14)
ATORVASTATIN	5 (0.78)
ATORVASTATIN CALCIUM	5 (0.78)
BEZAFIBRATE	1 (0.14)
CHEMBROITIN SULFATE SODIUM	1 (0.14)
DOCOSAHENNAIC ACID/EICOSAPENTAENOIC ACID	1 (0.14)
EZETIMIBE	4 (0.64)
EZETIMIBE/ROSUVASTATIN CALCIUM	1 (0.14)
GANOLENIC ACID	1 (0.14)
KRILL OIL	1 (0.14)
LOVASTATIN	1 (0.14)
PITAVASTATIN CALCIUM	2 (0.38)
PRAVASTATIN	1 (0.14)
PFELICARBATE	1 (0.14)
ROSUVASTATIN	6 (0.88)
ROSUVASTATIN CALCIUM	5 (0.78)
SIMVASTATIN	1 (0.14)
MEDICATED DRESSINGS	
Total number of patients with at least one treatment	25 (3.58)
Total number of treatments	42
CARAMELLOSE SODIUM/SILVER	1 (0.14)
CEFTIPIRIMIDINIUM CHLORIDE	1 (0.14)
PHENOLIC SODIUM	1 (0.14)
IODOPHOR	1 (0.14)
POVIDONE-IODINE	2 (0.38)
SILVER	1 (0.14)
SODIUM CHLORIDE	16 (2.38)
ZINC	1 (0.14)
ZINC OXIDE	2 (0.38)
MINERAL SUPPLEMENTS	
Total number of patients with at least one treatment	43 (6.04)
Total number of treatments	82
ASCORBIC ACID/POTASSIUM BICARBONATE	1 (0.14)
CALCIUM	3 (0.44)
CALCIUM CARBONATE	3 (0.44)
CALCIUM CARBONATE/DICALCIPEROL	1 (0.14)
CALCIUM/DICALCIPEROL	1 (0.14)
CALCIUM/MAGNESIUM CHLORIDE	1 (0.14)
MAGNESIUM	3 (0.44)
MAGNESIUM ASPARTATE	1 (0.14)
MAGNESIUM ASPARTATE/POTASSIUM ASPARTATE	1 (0.14)
MAGNESIUM CARBONATE	1 (0.14)
MAGNESIUM OXIDE	3 (0.44)
MAGNESIUM SULFATE	2 (0.38)
MAGNESIUM/PYRIDOXINE HYDROCHLORIDE	1 (0.14)
POTASSIUM ASPARTATE	1 (0.14)
POTASSIUM CHLORIDE	17 (2.44)
POTASSIUM GLUCONATE	1 (0.14)
POTASSIUM PHOSPHATE DIBASIC/POTASSIUM PHOSPHATE MONOBASIC	1 (0.14)
POTASSIUM PHOSPHATE MONOBASIC	1 (0.14)
SODIUM CHLORIDE	16 (2.38)
SODIUM PHOSPHATE	1 (0.14)
ZINC	1 (0.14)
ZINC OXIDE	2 (0.38)
MUSCLE RELAXANTS	
Total number of patients with at least one treatment	15 (2.14)
Total number of treatments	16
BACLOFEN	2 (0.38)
CISATRACTURIUM BESILATE	1 (0.14)
CYCLOBENZAPRINE	2 (0.38)
EPERIIONE HYDROCHLORIDE	2 (0.38)
METHYDOLONE	1 (0.14)
METHOCARBAMOL	2 (0.38)
ORPHENADRINE CITRATE/PARACETAMOL	1 (0.14)
ROCURONIUM	1 (0.14)
TIZANIDINE	1 (0.14)
TIZANIDINE HYDROCHLORIDE	2 (0.38)
N/A	
Total number of patients with at least one treatment	1 (0.14)
Total number of treatments	1
ALLIUM SATIVUM	1 (0.14)
NASAL PREPARATIONS	
Total number of patients with at least one treatment	56 (7.94)
Total number of treatments	94
ACETYLCHOLINE	5 (0.78)
ATROPA BELLADONNA EXTRACT/CAFFEINE/CARBINOXAMINE MALEATE/PSEUDOEPHEDRINE HYDROCHLORIDE	1 (0.14)

BETAMETHASONE	2 (0.34)
BETAMETHASONE VALERATE	1 (0.14)
BIBERONIDE	1 (0.14)
CALCIUM CHLORIDE/POTASSIUM CHLORIDE/SODIUM CHLORIDE	1 (0.14)
DEKAMETHASONE	5 (0.74)
DEKAMETHASONE DIPROPIONATE	1 (0.14)
DEKAMETHASONE SODIUM PHOSPHATE	4 (0.64)
DEKSPANTHENOL/RETINOL	1 (0.14)
EPHEDRINE	1 (0.14)
EPINEPHRINE	1 (0.14)
ETHANOL	1 (0.14)
FLUTICASONE PROPIONATE	4 (0.64)
IPRATROPIUM BROMIDE	3 (0.44)
METHYL	1 (0.14)
MENTHOL	1 (0.14)
MENTHOL PURGATE	4 (0.64)
MIPROCCIN	1 (0.14)
OLGAPTADINE HYDROCHLORIDE	2 (0.34)
PHENYLEPHRINE	1 (0.14)
POVIDONE-IODINE	2 (0.34)
PRENISOLONE	3 (0.44)
PRENISOBERINE HYDROCHLORIDE	1 (0.14)
RIBAVIRIN	1 (0.14)
SILVER	1 (0.14)
SODIUM BICARBONATE	1 (0.14)
SODIUM CHLORIDE	16 (2.34)
TRIANCINOLONE	3 (0.44)
TRIANCINOLONE ACETONIDE	2 (0.34)
XYLOMETAZOLINE HYDROCHLORIDE	1 (0.14)
ZINC	1 (0.14)
OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	
Total number of patients with at least one treatment	35 (4.94)
Total number of treatments	40
BETAMETHASONE	2 (0.34)
BETAMETHASONE VALERATE/GENTAMICIN SULFATE	1 (0.14)
CIPROFLOXACIN	9 (1.34)
CIPROFLOXACIN HYDROCHLORIDE	2 (0.34)
DEKAMETHASONE	5 (0.74)
DEKAMETHASONE DIPROPIONATE	1 (0.14)
DEKAMETHASONE SODIUM PHOSPHATE	4 (0.64)
DEKAMETHASONE/GENTAMICIN SULFATE	1 (0.14)
DEKAMETHASONE/NEOMYCIN SULFATE/POLYMYXIN B SULFATE	1 (0.14)
GENTAMICIN	1 (0.14)
HYDROCORTISONE/OXYTETRACYCLINE HYDROCHLORIDE	1 (0.14)
LEVOPLOXACIN	6 (0.84)
LEVOPLOXACIN HEMIHYDRATE	1 (0.14)
NEOMYCIN	1 (0.14)
PRENISOLONE	3 (0.44)
PRENISOLONE VALEROACETATE	1 (0.14)
TETRACYCLINE	1 (0.14)
OPHTHALMOLOGICALS	
Total number of patients with at least one treatment	148 (20.84)
Total number of treatments	419
ACETAZOLAMIDE	10 (1.44)
ACETYLTYROSINE	5 (0.74)
ACICLOVIR	4 (0.64)
ADRENOLINE	1 (0.14)
ALBUMIN HUMAN	1 (0.14)
AMERACIN	1 (0.14)
AMIBO ACID MS	1 (0.14)
AMPCILLIN	1 (0.14)
ANESTHETICS, LOCAL	2 (0.34)
ANISCOMAMINE	1 (0.14)
ANTIBIOTICS	2 (0.34)
ARBOVIC ACID	8 (1.14)
ATROPINE SULFATE	1 (0.14)
AZITHROMYCIN	18 (2.54)
BACITRACIN	1 (0.14)
BENZYLPERICILLIN SODIUM	1 (0.14)
BEPTASTINE BESILATE	1 (0.14)
BETAMETHASONE	2 (0.34)
BETAMETHASONE VALERATE	1 (0.14)
BETAMETHASONE VALERATE/GENTAMICIN SULFATE	1 (0.14)
BILASTINE	2 (0.34)
BLOOD, CALF, DEFROT., LAMN PORTION	1 (0.14)
BROMOXIPRINE	1 (0.14)
BUPIVACAINE	1 (0.14)
BUPIVACAINE HYDROCHLORIDE	1 (0.14)
CALCIUM CHLORIDE/MAGNESIUM CHLORIDE/POTASSIUM CHLORIDE/SODIUM ACETATE/SODIUM CHLORIDE/SODIUM CITRATE	1 (0.14)
CEFUROXIME	3 (0.44)
CEFUROXIME SODIUM	1 (0.14)
CETIRIZINE	2 (0.34)
CETIRIZINE HYDROCHLORIDE	4 (0.64)
CETILPREDINOLUM CHLORIDE	1 (0.14)
CHEMOTOXIN SULFATE SODIUM	1 (0.14)
CIPROFLOXACIN	9 (1.34)
CIPROFLOXACIN HYDROCHLORIDE	2 (0.34)
CLARIDINE	1 (0.14)
CLOTHRALGOL	1 (0.14)
COXYSONE	1 (0.14)
CYANOCOBALAMIN	4 (0.64)
DEKAMETHASONE	5 (0.74)
DEKAMETHASONE DIPROPIONATE	1 (0.14)
DEKAMETHASONE PHOSPHATE	1 (0.14)
DEKAMETHASONE SODIUM PHOSPHATE	4 (0.64)
DEKAMETHASONE/GENTAMICIN SULFATE	1 (0.14)
DEKAMETHASONE/NEOMYCIN SULFATE/POLYMYXIN B SULFATE	1 (0.14)
DEKSPANTHENOL/RETINOL	1 (0.14)
DICLOFENAC	11 (1.54)
DICLOFENAC SODIUM	9 (1.34)
DIMETICONE	1 (0.14)
EPHEDRINE	1 (0.14)
EPINEPHRINE	1 (0.14)
ERYTHROMYCIN	2 (0.34)
FLUCONAZOLE	1 (0.14)
FLUCONAZOLE ACETONIDE	1 (0.14)
FLURBIPROFEN	3 (0.44)
FORSYTHIA SUSPENSIA FRUIT/LONICERA JAPONICA FLOWER BUD/SCUTELLARIA BAICALENSIS ROOT	1 (0.14)
FUSIDATE SODIUM	1 (0.14)
GENTAMICIN	1 (0.14)

GLUCOSE/POTASSIUM CHLORIDE/SODIUM CHLORIDE	2 (0.34)
GLUTATHIONE	1 (0.14)
GLYCEROL	1 (0.14)
GUARANTHENE	1 (0.14)
HEPARIN	2 (0.34)
HEPARIN SODIUM	3 (0.44)
HEPARINOID	1 (0.14)
HIPPURIC ACID	1 (0.14)
HYALURONIC ACID	1 (0.14)
HYDROCORTISONE	2 (0.34)
HYDROCORTISONE SODIUM PHOSPHATE	1 (0.14)
HYDROCORTISONE/OXYTETRACYCLINE HYDROCHLORIDE	1 (0.14)
HYOSCINE HYDROBROMIDE	1 (0.14)
INDOMETACIN	1 (0.14)
INTERFERON ALPHA-2B	1 (0.14)
KETOROLAC	4 (0.64)
KETOROLAC TROMETHAMINE	1 (0.14)
LEVOPROXETIN	6 (0.84)
LEVOPROXETIN HEMIHYDRATE	1 (0.14)
LEVOPROXETIN HYDROCHLORIDE	1 (0.14)
LIDOCAINE	8 (1.14)
LIDOCAINE HYDROCHLORIDE	2 (0.34)
MELGICICAM	2 (0.34)
METHYLPREDNISOLONE	8 (1.14)
METHYLPREDNISOLONE SODIUM SUCCINATE	1 (0.14)
MORPHOLINE	1 (0.14)
IBUPROFEN	2 (0.34)
IBUPROFEN SODIUM	3 (0.44)
IBUPROFEN	1 (0.14)
IBUPROFEN METILSULFATE	1 (0.14)
IGLOPATADINE HYDROCHLORIDE	2 (0.34)
OTHER ANTIALLERGICS	1 (0.14)
OTHER OPHTHALMOLOGICALS	2 (0.34)
IBUPROFEN	1 (0.14)
IBUPROFEN	1 (0.14)
POTASSIUM CHLORIDE	17 (2.44)
POTASSIUM PHOSPHATE DIBASIC/POTASSIUM PHOSPHATE MONOBASIC	1 (0.14)
POVIDONE-IODINE	2 (0.34)
FRANCOFROPIN	1 (0.14)
PRENIZOLONE	3 (0.44)
PRENIZOLONE VALEROACETATE	1 (0.14)
PRENIZOLONE	14 (2.04)
REBAMIPIDE	8 (1.14)
RIBAVIRIN	1 (0.14)
RIBOPFLAVIN	1 (0.14)
RIFAMPICIN	1 (0.14)
SILVER	1 (0.14)
SODIUM CHLORIDE	16 (2.34)
SODIUM CHLORIDE HYDRATE	1 (0.14)
SODIUM PHOSPHATE	1 (0.14)
SULFACILAMINE SILVER	2 (0.34)
SULFAMETHOXAZOLE	1 (0.14)
TACROLIMUS	1 (0.14)
TETRACYCLINE	1 (0.14)
TIMOLOL	1 (0.14)
TRIMASTICIN	1 (0.14)
TRIAMCINOLONE	3 (0.44)
TRIAMCINOLONE ACETONIDE	2 (0.34)
TRIMASTICIN	1 (0.14)
TRIMASTICIN	3 (0.44)
VANCOMICIN HYDROCHLORIDE	1 (0.14)
XYLOMETAZOLINE HYDROCHLORIDE	1 (0.14)
ZINC	1 (0.14)
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	
Total number of patients with at least one treatment	18 (2.54)
Total number of treatments	20
ACETYLCHOLINE	5 (0.74)
ALANYL GLUTAMINE	1 (0.14)
AMINO ACIDS NOS	1 (0.14)
CLONITRILUM BUTYRICUM	3 (0.44)
ESOPHAGITIS NOS	1 (0.14)
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	1 (0.14)
PROPRIOPIRUS	1 (0.14)
PROBIOTICS NOS	2 (0.34)
SODIUM BICARBONATE	1 (0.14)
SUCRALFATE	2 (0.34)
ZINC	1 (0.14)
OTHER DERMATOLOGICAL PREPARATIONS	
Total number of patients with at least one treatment	81 (11.44)
Total number of treatments	108
ARBIBIA SPP. STEM/ANGELICA SINENSIS ROOT/ATRACYLODES SPP. RHIZOME/CALCIUM SULFATE	
DIHYDRATE/CICADA SLOUGH/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/LINUM USITATISSIMUM SEED/LYCIIUM	
CHINENSIS ROOT BARK/HEPETA TENUIFOLIA HERB/REHMANNIA GLUTINOSA ROOT TUBER/SAPONARIA	
DIHYDRATE	1 (0.14)
ASCORBIC ACID	8 (1.14)
BRIMONIDINE	1 (0.14)
CALCIUM CHLORIDE/POTASSIUM CHLORIDE/SODIUM CHLORIDE	1 (0.14)
CINNAMOMUM CASSIA BARK/EPHEDRA SPP. HERB/GLYCYRRHIZA SPP. ROOT/PAONIA LACTIFLORA	
ROOT/PURARIA MONTANA VAR. LOBATA ROOT/ZINGIBER OFFICINALE RHIZOME/ZIZIPHUS JUJUBA FRUIT	1 (0.14)
CINNAMOMUM CASSIA TWIG/EPHEDRA SPP. STEM/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/PAONIA	
LACTIFLORA ROOT/PURARIA MONTANA VAR. LOBATA ROOT/ZINGIBER OFFICINALE RHIZOME/ZIZIPHUS	
JUJUBA FRUIT	1 (0.14)
DICLOFENAC	11 (1.54)
DICLOFENAC SODIUM	9 (1.34)
DL-METHYLTHIONE/GLYCINE/GLYCYRRHIZIC ACID, AMMONIUM SALT	1 (0.14)
DIFENHYDRAMINE	1 (0.14)
FINAESTERIDE	3 (0.44)
GAMOLANIC ACID	1 (0.14)
GUAIACOL	1 (0.14)
IBUPROFEN	37 (5.24)
IBUPROFEN PYCNOLOL	1 (0.14)
MAGNESIUM SULFATE	2 (0.34)
OTHER DERMATOLOGICALS	1 (0.14)
OXYGEN	1 (0.14)
POVIDONE-IODINE	2 (0.34)
PRILIDINE HYDROCHLORIDE	4 (0.64)
SODIUM BICARBONATE	1 (0.14)
SUCRALFATE	2 (0.34)
TACROLIMUS	1 (0.14)
TRANEZAMIC ACID	2 (0.34)

OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	
Total number of patients with at least one treatment	5 (0.7%)
Total number of treatments	5
BROMELAIN	1 (0.1%)
ENZYMES NOS	1 (0.1%)
GELATIN	1 (0.1%)
SERAPROPTASE	2 (0.3%)
OTHER GYNECOLOGICALS	
Total number of patients with at least one treatment	58 (8.2%)
Total number of treatments	73
BENZYLDAMINE HYDROCHLORIDE	1 (0.1%)
CINNAMOMUM CASSIA BARK/PARONIA LACTIFLORA ROOT/PARONIA X SUFFRUTICOSA ROOT BARK/PORIA	1 (0.1%)
COCOS SCLEROTIUM/PHUNIS SPP. SEED	1 (0.1%)
CLONIDINE	1 (0.1%)
DROTAVERINE HYDROCHLORIDE	1 (0.1%)
GLYCEROL	1 (0.1%)
IBUPROFEN	37 (5.2%)
IBUPROFEN PICOLOL	1 (0.1%)
INTERFERON ALFA-2B	1 (0.1%)
METHOTREXATE	1 (0.1%)
NAFROLEN	2 (0.3%)
NAFROLEN SODIUM	3 (0.4%)
NIFEDIPINE	2 (0.3%)
PAROXETINE HYDROCHLORIDE	1 (0.1%)
SALBUTAMOL	3 (0.4%)
SALVIA MILTERRHIZA	1 (0.1%)
SODIUM BICARBONATE	1 (0.1%)
STREPTODORNASE/STREPTOKINASE	1 (0.1%)
OTHER HEMATOLOGICAL AGENTS	
Total number of patients with at least one treatment	4 (0.6%)
Total number of treatments	5
BROMELAIN	1 (0.1%)
ENZYMES NOS	1 (0.1%)
HYALURONIDASE	1 (0.1%)
STREPTODORNASE/STREPTOKINASE	1 (0.1%)
OTHER NERVOUS SYSTEM DRUGS	
Total number of patients with at least one treatment	31 (4.4%)
Total number of treatments	44
ACETYLCHOLINE	1 (0.1%)
ATRACTYLIDES LANCIA RHIZOME/CINNAMOMUM CASSIA BARK/GLYCYRRHIZA SPP. ROOT/PORIA COCOS	1 (0.1%)
SCLEROTIUM	1 (0.1%)
BACLOFEN	2 (0.3%)
BETAHISTINE HYDROCHLORIDE	1 (0.1%)
BETAHISTINE MESILATE	2 (0.3%)
CLONIDINE	1 (0.1%)
COBAMAMIDE	1 (0.1%)
CONCHA MARGARITIFERA/PINUS MASSONIANA LEAF/PUERARIA MONTANA VAR. LOBATA ROOT	1 (0.1%)
CYANOCOBALAMIN	4 (0.6%)
DIFLOMINE BROMIDE	1 (0.1%)
FLANRANILINE DIHYDROCHLORIDE	1 (0.1%)
GABAPENTIN	5 (0.7%)
GASTRODIA ELATA TUBER	1 (0.1%)
GINKGO BILOBA LEAF EXTRACT	3 (0.4%)
MECOBALAMIN	2 (0.3%)
HALOKSINE	2 (0.3%)
NEOSTIGMINE METHYL SULFATE	1 (0.1%)
NICOTINE	1 (0.1%)
PROPRANOLOL	2 (0.3%)
PROPRANOLOL HYDROCHLORIDE	1 (0.1%)
VITAMIN B12 NOS	1 (0.1%)
OTHER RESPIRATORY SYSTEM PRODUCTS	
Total number of patients with at least one treatment	18 (2.5%)
Total number of treatments	41
ACETAZOLAMIDE	10 (1.4%)
AMBROXOL	1 (0.1%)
AMBROXOL HYDROCHLORIDE	3 (0.4%)
DIMETICONE	1 (0.1%)
PELLARONIUM SIDOIDES	2 (0.3%)
VICLA ODOBATA	1 (0.1%)
OTOLOGICALS	
Total number of patients with at least one treatment	65 (9.1%)
Total number of treatments	120
ANESTHETICS, LOCAL	2 (0.3%)
BETAMETHASONE	2 (0.3%)
BETAMETHASONE VALERATE	1 (0.1%)
CIPROFLOXACIN	9 (1.3%)
CIPROFLOXACIN HYDROCHLORIDE	2 (0.3%)
CIPROFLOXACIN/FLUCONAZOLE ACETONIDE	1 (0.1%)
CLARITHROMICIN	1 (0.1%)
DEKAMETHASONE	5 (0.7%)
DEKAMETHASONE DIPHOSPHONATE	1 (0.1%)
DEKAMETHASONE SODIUM PHOSPHATE	4 (0.6%)
DEKAMETHASONE/NEOMYCIN SULFATE/POLYMYXIN B SULFATE	1 (0.1%)
DOCUSATE SODIUM	4 (0.6%)
FLUCONAZOLE ACETONIDE	1 (0.1%)
POSEFMYCIN	1 (0.1%)
GENTAMICIN	1 (0.1%)
GLYCEROL	1 (0.1%)
HYDROCORTISONE	2 (0.3%)
HYDROCORTISONE SODIUM PHOSPHATE	1 (0.1%)
HYDROCORTISONE/OXYTETRACYCLINE HYDROCHLORIDE	1 (0.1%)
LEVOPLOXACIN	6 (0.8%)
LEVOPLOXACIN HEMIHYDRATE	1 (0.1%)
LEVOPLOXACIN HYDROCHLORIDE	1 (0.1%)
LIDOCAINE	8 (1.1%)
LIDOCAINE HYDROCHLORIDE	2 (0.3%)
NEOMYCIN	1 (0.1%)
PRENIZOLONE	3 (0.4%)
PRENIZOLONE VALEROACETATE	1 (0.1%)
SILVER	1 (0.1%)
SODIUM BICARBONATE	1 (0.1%)
SODIUM CHLORIDE	16 (2.3%)
TETRACYCLINE	1 (0.1%)
PANCREATIC ENZYMES	
Total number of patients with at least one treatment	1 (0.1%)
Total number of treatments	3

GLUCAGON	1 (0.14)
PERIPHERAL VASODILATORS	
Total number of patients with at least one treatment	7 (1.04)
Total number of treatments	10
BETAHISTINE HYDROCHLORIDE	1 (0.14)
ENZYMES NOS	1 (0.14)
FLANAZINE DIHYDROCHLORIDE	1 (0.14)
GINSGO BILBOA LEAF EXTRACT	3 (0.44)
KALLIKREINASE	1 (0.14)
PENTOXIFYLLINE	1 (0.14)
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	
Total number of patients with at least one treatment	1 (0.14)
Total number of treatments	1
TETRACOSACTIDE	1 (0.14)
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS	
Total number of patients with at least one treatment	22 (3.14)
Total number of treatments	46
AMBER (POSSILIZED TREE RESIN)/BORNEOL/CALAMINE/COW BEOAR/MUSK/PEARL/SODIUM BORATE	1 (0.14)
BROMELAINS	1 (0.14)
CARBELLULOSE/PECTIN	1 (0.14)
DIMETICONE	1 (0.14)
HYPHOSIAN RHAMNOIDES	1 (0.14)
HYPOCHLOROUS ACID/SODIUM CHLORIDE/SODIUM HYPOCHLORITE/SUPER OXIDISED WATER	1 (0.14)
METHYLURACIL	1 (0.14)
SODIUM CHLORIDE	16 (2.34)
STREPTODORNASE/STREPTOKINASE	1 (0.14)
PSYCHONALEPTICS	
Total number of patients with at least one treatment	26 (3.74)
Total number of treatments	32
AMFETAMINE ASPARTATE/AMFETAMINE SULFATE/DEXAMPETAMINE SACCHARATE/DEXAMPETAMINE SULFATE	1 (0.14)
AMITRIPTYLINE	1 (0.14)
CITICOLINE SODIUM	2 (0.34)
CLONIDINE	1 (0.14)
DEXAMPETAMINE SULFATE	1 (0.14)
DEMETHYLRHENDATE	1 (0.14)
DOBNEPEZIL	2 (0.34)
DOBNEPEZIL HYDROCHLORIDE	1 (0.14)
DULOXTINE	1 (0.14)
ENZYMES NOS	1 (0.14)
ESITALOPRAM	1 (0.14)
ESITALOPRAM OXALATE	1 (0.14)
FLIPENTIZOL DIHYDROCHLORIDE/MELITRACEN HYDROCHLORIDE	1 (0.14)
GINSGO BILBOA LEAF EXTRACT	3 (0.44)
NEKTRIPTYLINE	3 (0.44)
OTHER PSYCHOSTIMULANTS AND NEOTROPICS	1 (0.14)
PANAX GINSENS TOTAL GINSENSOIDE EXTRACT	1 (0.14)
PAROXETINE HYDROCHLORIDE	1 (0.14)
RIVASTIGMINE HYDROCHLORIDE TARTRATE	1 (0.14)
SEKTRALINE	2 (0.34)
SEKTRALINE HYDROCHLORIDE	1 (0.14)
TRAZODONE HYDROCHLORIDE	2 (0.34)
VIMOCETINE	1 (0.14)
PSYCHOLEPTICS	
Total number of patients with at least one treatment	40 (5.64)
Total number of treatments	52
ALPRAZOLAM	3 (0.44)
AMITRIPTYLINE	1 (0.14)
ATRACTYLODES LANCRA RHIZOME/CINNAMOMUM CASSIA BARK/GLYCYRRHIZA SP. ROOT/PORIA COCOS	1 (0.14)
SCHEZINUM	1 (0.14)
BROTIZOLAM	1 (0.14)
CANNABIDIOL	1 (0.14)
CHLORFRAMAZINE	1 (0.14)
CLONAZEPAM	1 (0.14)
DESMETOPIMILINE HYDROCHLORIDE	1 (0.14)
DIPHERHYDRAMINE	1 (0.14)
DIPHERHYDRAMINE HYDROCHLORIDE	1 (0.14)
DULOXTINE	1 (0.14)
ESITALOPRAM	1 (0.14)
ESITALOPRAM OXALATE	1 (0.14)
ETHYL LOFLAZEPATE	1 (0.14)
HALOPERIDOL	1 (0.14)
HYDROXYZINE	3 (0.44)
HYOSCINE HYDROBROMIDE	1 (0.14)
LEVOSULPRIDE	1 (0.14)
LOXAZEPAM	1 (0.14)
MELATORIN	2 (0.34)
MEPHENOXALONE	1 (0.14)
MIBAZOLAM	5 (0.74)
PANAX NOTOGINSENSO	1 (0.14)
PAROXETINE HYDROCHLORIDE	1 (0.14)
PREGABALIN	10 (1.44)
PROPRANOLOL	2 (0.34)
PROPRANOLOL HYDROCHLORIDE	1 (0.14)
QUAZEPAM	1 (0.14)
SEKTRALINE	2 (0.34)
SEKTRALINE HYDROCHLORIDE	1 (0.14)
SULPIRIDE	1 (0.14)
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	
Total number of patients with at least one treatment	5 (0.74)
Total number of treatments	5
DYDROGESTERONE/ESTRADIOL	1 (0.14)
MEKROSTROL ACETATE	1 (0.14)
PRASTERONE/TESTOSTERONE	1 (0.14)
TESTOSTERONE	1 (0.14)
TESTOSTERONE ENANTHATE	1 (0.14)
STYMATOLOGICAL PREPARATIONS	
Total number of patients with at least one treatment	98 (13.84)
Total number of treatments	213
ACETYSALICYLIC ACID	19 (2.74)
ANESTHETICS, LOCAL	2 (0.34)
BENZYLAMINE HYDROCHLORIDE	1 (0.14)
BETAMETHASONE	2 (0.34)
CARBELLULOSE/PECTIN	1 (0.14)
CETYLVPRIDINIUM CHLORIDE	1 (0.14)
CLOBETASOL	1 (0.14)

CLOBETASOL PROPIONATE	2 (0.34)
CLOTRIMAZOLE	1 (0.14)
DEXAMETHASONE	5 (0.74)
DEXAMETHASONE DIPROPIONATE	1 (0.14)
DEXAMETHASONE SODIUM PHOSPHATE	4 (0.64)
DICLOFENAC	11 (1.54)
DICLOFENAC SODIUM	9 (1.34)
DIMETYLONE	1 (0.14)
DOXYCYCLINE	10 (1.44)
DOXYCYCLINE HYCLATE	2 (0.34)
DOXYCYCLINE MONOHYDRATE	1 (0.14)
ELECTROLYTES NOS	2 (0.34)
EPINEPHRINE	1 (0.14)
FLURBIPROFEN	3 (0.44)
GLUCEROL	1 (0.14)
HYDROCORTISONE	2 (0.34)
KETOPROFEN	4 (0.64)
LIDOCAINE	8 (1.14)
LIDOCAINE HYDROCHLORIDE	2 (0.34)
METRONIDAZOLE	6 (0.84)
NEFROFEN	2 (0.34)
NEOMYCIN	1 (0.14)
NIMESULIDE	2 (0.34)
HYFATIN	1 (0.14)
OXIDEN	1 (0.14)
POVIDONE-IODINE	2 (0.34)
PRENISOLONE	3 (0.44)
SODIUM BICARBONATE	1 (0.14)
SODIUM CHLORIDE	16 (2.34)
SODIUM GUANINATE HYDRATE	1 (0.14)
SUCRALFATE	2 (0.34)
TETRACYCLINE	1 (0.14)
TRANEXAMIC ACID	2 (0.34)
TRAMANTOLINE	3 (0.44)
TRAMANTOLINE ACETONIDE	2 (0.34)
VIOLA ODRATA	1 (0.14)
ZINC	1 (0.14)
THROAT PREPARATIONS	
Total number of patients with at least one treatment	80 (11.24)
Total number of treatments	128
AMBROXOL	1 (0.14)
AMBROXOL HYDROCHLORIDE	3 (0.44)
AMYLMETACRESOL/DICHLOROBENZYL ALCOHOL	1 (0.14)
ANESTHETICS, LOCAL	2 (0.34)
ANTIBIOTICS	2 (0.34)
BACTRACIN	1 (0.14)
BENZYLAMINE HYDROCHLORIDE	1 (0.14)
CETYLALYLDIUM CHLORIDE	1 (0.14)
DEQUALINUM CHLORIDE	1 (0.14)
DICLOFENAC	11 (1.54)
DICLOFENAC SODIUM	9 (1.34)
DYCLONINE HYDROCHLORIDE	2 (0.34)
FLURBIPROFEN	3 (0.44)
HEXYLESORBINOL	1 (0.14)
IBUPROFEN	37 (5.24)
KETOPROFEN	4 (0.64)
LIDOCAINE	8 (1.14)
LIDOCAINE HYDROCHLORIDE	2 (0.34)
NEOMYCIN	1 (0.14)
OTHER THROAT PREPARATIONS	1 (0.14)
POVIDONE-IODINE	2 (0.34)
SILVER	1 (0.14)
SODIUM GUANINATE HYDRATE	1 (0.14)
TETRACYCLINE	1 (0.14)
TRANEXAMIC ACID	2 (0.34)
VIOLA ODRATA	1 (0.14)
THYROID THERAPY	
Total number of patients with at least one treatment	10 (1.44)
Total number of treatments	12
LEVOTHYROXINE	1 (0.14)
LEVOTHYROXINE SODIUM	5 (0.74)
LEVOTHYROXINE/LIOTHYRONINE	1 (0.14)
PROPRANOLOL	2 (0.34)
PROPRANOLOL HYDROCHLORIDE	1 (0.14)
TONICS	
Total number of patients with at least one treatment	6 (0.84)
Total number of treatments	7
ALLIUM SATIVUM	1 (0.14)
ASTRAGALUS MONDELICUS ROOT/ATRACTYLODES MACROCEPHALA RHIZOME/SAPOSHNIKOVIA DIVARICATA	1 (0.14)
ROOT	1 (0.14)
DIETARY SUPPLEMENT	2 (0.34)
HIPPOPHAE RHAMNOIDES	1 (0.14)
SILVER	1 (0.14)
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	
Total number of patients with at least one treatment	104 (14.64)
Total number of treatments	145
ACETILSALICYLIC ACID	2 (0.34)
ACETYL SALICYLIC ACID	19 (2.74)
ACORUS CALAMIS VAR. ARGUSTATUS RHIZOME/ACTAEA SPP. RHIZOME/ANGELICA DARRICA ROOT/ANGELICA SINENSIS ROOT/ARISAEMA SPP. TUBER/ATROPA BELLA-DONNA/BEAR BILE/BORSNIGOL/BOSWELLIA SPP. RESIN/CALAMIS DRACA FRUIT RESIN/CAMPHOR/CAMPHORUS TRINCTORIUS FLOWER/CEBITUM BAROMETZ RHIZOME/COMMIPHORA MYRHA RESIN/ETPOLYFAGA SINENSIS/LIGUSTICUM CHUANXITONG RHIZOME/MENTHOL/METHYL SALICYLATE/MUSK/	1 (0.14)
BENZYLAMINE HYDROCHLORIDE	1 (0.14)
CAMPHER/CHENROITIN SULFATE/GLUCOSAMINE	1 (0.14)
CHENROITIN SULFATE SODIUM	1 (0.14)
CHENROITIN SULFATE/GLUCOSAMINE HYDROCHLORIDE	1 (0.14)
DEKIBUPROFEN	3 (0.44)
DEKOKETOPROFEN	1 (0.14)
DEKOKETOPROFEN TRIMETANOL	1 (0.14)
DICLOFENAC	11 (1.54)
DICLOFENAC SODIUM	9 (1.34)
ETOFENAMATE	1 (0.14)
FELBINAC	1 (0.14)
FLURBIPROFEN	3 (0.44)
FOLIC ACID	3 (0.44)
HEPARINOID	1 (0.14)
IBUPROFEN	37 (5.24)
IBUPROFEN PICOLOL	1 (0.14)

INDOMETACIN	1 (0.14)
KETOPROFEN	4 (0.64)
KETOROLAC	4 (0.64)
KETOROLAC TRIMETHAMINE	1 (0.14)
LOXOPROFEN SODIUM	9 (1.34)
LOXOPROFEN SODIUM DIHYDRATE	1 (0.14)
MELXICAM	2 (0.34)
MENTHOL	1 (0.14)
NAPROXEN	2 (0.34)
NAPROXEN SODIUM	3 (0.44)
NIMESULIDE	2 (0.34)
PIROXICAM BETADEX	1 (0.14)
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	
Total number of patients with at least one treatment	43 (6.04)
Total number of treatments	89
ACONITUM CARMICHAELI ROOT/ANEMARRHENA ASPHOGELOIDES RHIZOME/GLYCYRRHIZA URALENSIS ROOT WITH RHIZOME/LEONURUS JAPONICUS HERB/PAONIA X SUFFRUTICOSA ROOT BARK/PELAGONIDION	
AMERENSIS BARK/PLANTAGO ASIATICA SEED/POLYPODUM AYUJICLARE HERB/RHEUM PALMATUM ROOT WITH RHIZOME	1 (0.14)
ACONITUM KUSNEZOFFII ROOT TUBER/ANGELICA BISERRATA ROOT/CARTHAMUS TINCTORIUS FLOWER/CLIMATIS CHINESE ROOT WITH RHIZOME/DIPSACUS INERMIS ROOT/GERANIUM SPP. HERB/LYCUM COLLODATUM LEAF WITH STEM	1 (0.14)
ACORUS CALAMUS VAR. ANGIUSTATUS RHIZOME/ACTAEA SPP. RHIZOME/ANGELICA DAURICA ROOT/ANGELICA SINENSIS ROOT/ARISAEMA SPP. TUBER/ATROPA BELLADONNA BEAR BILE/BOMBOL/BOSWELLIA SPP. RESIN/CALAMIS DRACO FRUIT RESIN/CAMPHOR/CARTHAMUS TINCTORIUS FLOWER/CISTOTIUM BAROMETZ RHIZOME/COMMIPHORA MYRHA RESIN/EDULPHRAGA SINENSIS/LIGUSTICUM CHUANXIONG RHIZOME/MENTHOL/METHYL SALICYLATE/MUSK	1 (0.14)
ACORUS CALAMUS VAR. ANGIUSTATUS RHIZOME/ANGELICA DAURICA ROOT/ANGELICA SINENSIS ROOT/CINNAMOMUM CASSIA TWIG/EPHEDRA SPP. STEM/LIGUSTICUM CHUANXIONG RHIZOME/MENTHA CANADENSIS HERB/NEPETA TENUIFOLIA SPIKE/NOTOPTERYGIUM SPP. ROOT WITH RHIZOME/PLATYCODON GRANDIFLORUS ROOT/PRUNUS SPP. SEED/PUEBARIA MONTANA VAR. LOBATA ROOT/SAPOSNIKOVIA DIVARICATA ROOT/SCUTELLARIA BAICALENSIS ROOT	1 (0.14)
AKERHIA SPP. STEM/ANGELICA SINENSIS ROOT/ATRACTYLODES SPP. RHIZOME/CALCIUM SULFATE DIHYDRATE/CICADA SLOUGH/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/LINUM USITATISSIMUM SEED/LYCIUM CHINESE ROOT BARK/NEPETA TENUIFOLIA HERB/REHMANNIA GLUTINOSA ROOT TUBER/SAPOSNIKOVIA DIVARICATA ROOT	1 (0.14)
ALISMA PLANTAGO-AQUATICA SUBSP. ORIENTALE RHIZOME/ANEMOZOIDES ALTAICA RHIZOME/ANGELICA SINENSIS ROOT/ARTEMISIA SPP. HERB/ATRACTYLODES MACROCEPHALA RHIZOME/CHICKEN'S GIZZARD-MEMBRANE/CORYDALIS YANSHUO TUBER/DENROBIDM NOBILIS STEM/LIGUSTICUM CHUANXIONG RHIZOME/LILIIUM SPP. BULB/LIBERIA AGRICATA ROOT TUBER/OPHIOPOGON JAPONICUS ROOT TUBER/PAONIA LACTIFLORA ROOT	1 (0.14)
ALISMA PLANTAGO-AQUATICA SUBSP. ORIENTALE RHIZOME/ANGELICA SINENSIS ROOT/ASARUM SPP. ROOT WITH RHIZOME/ASTRAGALUS SPP. ROOT/CUSCUTA SPP. SEED/DEER HORN/GASTRODIA ELATA TUBER/LYCIUM BARBARUM FRUIT/PANAX GINSENG ROOT/REHMANNIA GLUTINOSA ROOT TUBER/SENA SPP. SEED	1 (0.14)
ALLIUM SATIVUM	1 (0.14)
AMBER (POSSIBLY TREE RESIN)/BORNEOL/CALAMINUM COM BEZOM/MUSK/PEARL/SODIUM BORATE	1 (0.14)
ANEMARRHENA ASPHOGELOIDES RHIZOME/ARISTOLOCIA DEBILIS FRUIT/ASPMARUS COCCINIDENSIS ROOT TUBER/BUDOLEIA OFFICINALIS FLOWER BUD/CALCIUM SULFATE DIHYDRATE/CITRUS AURANTIUM FRUIT PEEL/CITRUS AURANTIUM UNRIPE FRUIT/DESCURAINIA SOPHIA SEED/DOLMIGAEA CUSTOS FRUIT/LALLIA SPP. BULB/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/KITAGAWIA FRAXIFLORA/MORUS ALBA LEAF/OPHIOPOGON JAPONICUS ROOT TUBER	1 (0.14)
ANGELICA ARCHANGELICA ROOT/CARUM CARVI FRUIT/CHELIDONIUM MAJUS HERB/GLYCYRRHIZA GLABRA ROOT/HERIS AMARA/MATHICARIA CHAMOMILLA FLOWER/MELISSA OFFICINALIS LEAF/MENTHA X PIPERITA LEAF/SILIBEN MARIANUM FRUIT	1 (0.14)
ANGELICA SINENSIS ROOT/BOMBYX MORI/BUNNABUS MULTICINCTUS/CARTHAMUS TINCTORIUS FLOWER/CENTIFEDE/CHARAMELES LAGENARIA FRUIT/CLIMATIS SPP. ROOT WITH RHIZOME/CYATHEA OFFICINALIS ROOT/EDULPHRAGA SINENSIS/LEONURUS JAPONICUS FRUIT/LIGUSTICUM CHUANXIONG RHIZOME/LONICERA JAPONICA STEM/LYCOPODIUM JAPONICUM WHOLE PLANT/MASTURINSI MARTENSII/PHESETIMA SPP./PRUNUS SPP. SEED	1 (0.14)
ANGELICA SINENSIS ROOT/BOSWELLIA SACRA BARK RESIN/CALAMIS DRACO FRUIT RESIN/COMMIPHORA MYRHA RESIN/DESMIDA ROOT'S RHIZOME/EDULPHRAGA SINENSIS/PIRITE/RHEUM SPP. ROOT WITH RHIZOME/SODIUM BORATE DECAHYDRATE	1 (0.14)
ANGELICA SINENSIS/CHRYSANTHEMUM X MORIFOLIUM FLOWER/CRATAEGUS PINNATIFIDA/CURCUMA SPP. ROOT TUBER/SCILLA FRONSTRATA/EQUISETUM HYEMALE/GEFFIANA SCABRA/LEONURUS JAPONICUS RIPE FRUIT/LIGUSTICUM CHUANXIONG/LIGUSTICUM LUTICUM WITH FRUIT/PAONIA OFFICINALIS SUBSP. OFFICINALIS ROOT/PAONIA X SUFFRUTICOSA BARK/PLANTAGO ASIATICA SEED/PRINELLA VULGARIS/REHMANNIA GLUTINOSA	2 (0.34)
ANGELICA SPP.	1 (0.14)
ARCTIUM LAPPA FRUIT/ASCORBIC ACID/CHLORPHENAMINE MALEATE/FORSYTHIA SUSPENSIA FRUIT/GLYCINE MAX FERMENTED SEED/GLYCYRRHIZA URALENSIS ROOT WITH RHIZOME/LONICERA JAPONICA FLOWER BUD/LOPHATHERUM GRACILE HERB/MENTHA CANADENSIS OIL/NEPETA TENUIFOLIA HERB/PARACETAMOL/PYRAMITES AUSTRALIS SUBSP. AUSTRALIS RHIZOME/PLATYCODON GRANDIFLORUS ROOT	1 (0.14)
ARCTIUM LAPPA FRUIT/FORSYTHIA SUSPENSIA FRUIT/GLYCINE MAX FERMENTED SEED/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/LONICERA JAPONICA FLOWER/LOPHATHERUM GRACILE LEAF WITH STEM/MENTHA CANADENSIS HERB/NEPETA TENUIFOLIA HERB/PYRAMITES AUSTRALIS SUBSP. AUSTRALIS RHIZOME/PLATYCODON GRANDIFLORUS ROOT	1 (0.14)
ARTEMISIA SPP. HERB	1 (0.14)
ARTEMISIA SPP. HERB EXTRACT	1 (0.14)
ASTER AGERATOIDES WHOLE PLANT/PIEMIANA SIMPLEX ROOT/KITAGAWIA FRAXIFLORA ROOT/METABENTIANA RHODANTHA WHOLE PLANT/SCLEROMITRIUM DIFFUSUM WHOLE PLANT/SCUTELLARIA BAICALENSIS ROOT/STEMONA SPP. ROOT TUBER	1 (0.14)
ASTRAGALUS MONSOLICUS ROOT/ATRACTYLODES MACROCEPHALA RHIZOME/SAPOSNIKOVIA DIVARICATA ROOT	1 (0.14)
ASTRAGALUS MONSOLICUS ROOT/COCODOPSIS PILGOSIA ROOT	1 (0.14)
ATRACTYLODES LANCEA RHIZOME/CINNAMOMUM CASSIA BARK/GLYCYRRHIZA SPP. ROOT/PORIA COCOS SCLEROTIUM	1 (0.14)
ATRACTYLODES SPP.	1 (0.14)
BIDENS BITERNATA/CAFFEINE/CHLORPHENAMINE MALEATE/CHRYSANTHEMUM INDICUM FLOWER/ILEX ASPERILLA ROOT/MELICOCPE PTERISIFOLIA/MENTHA CANADENSIS OIL/PARACETAMOL	2 (0.34)
BORNEOL/BOSWELLIA SACRA RESIN/CENTIFEDE/CICADA SLOUGH/DALBERGIA COORFEREA/HUPOLYPHAGA STELEOPHAGA/LEUCO/MEGASTURINSI/PAONIA SPP. ROOT/PANAX GINSENG ROOT/SANTALUM ALBUM SHANTWOOD/ZIZIPHUS JUTUBA SEED	1 (0.14)
CALCIUM SULFATE DIHYDRATE/CHOPSTERIS CRASSIRHIZOMA RHIZOME/EPHEDRA SPP. HERB/FORSYTHIA SUSPENSIA/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/HOUTTUNYA CORDATA HERB/ISATIS TINCTORIA ROOT/LONICERA JAPONICA FLOWER/MENTHOL/POGOSTEMON CABLIN HERB/PRUNUS SPP. SEED/RHEUM SPP. ROOT WITH RHIZOME/RHODIOLA CREMULATA ROOT WITH RHIZOME	3 (0.44)
CAMPHER/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/ILLICIUM VERUM OIL/PAPAYER SOMNIFERUM LATEX/SODIUM BENZOATE	1 (0.14)
CANNABIS SATIVA FRUIT/CITRUS SPP. UNRIPE FRUIT/MAGNELIA SPP. BARK/PAONIA LACTIFLORA ROOT/PRUNUS SPP. SEED/RHEUM SPP. RHIZOME	1 (0.14)
CHAMOMELIS SPP.	1 (0.14)
CINNAMOMUM CASSIA BARK/EPHEDRA SPP. HERB/GLYCYRRHIZA SPP. ROOT/PAONIA LACTIFLORA ROOT/PUEBARIA MONTANA VAR. LOBATA ROOT/ZINGIBER OFFICINALE RHIZOME/ZIZIPHUS JUTUBA FRUIT	1 (0.14)
CINNAMOMUM CASSIA BARK/EPHEDRA SPP. HERB/GLYCYRRHIZA SPP. ROOT/PRUNUS SPP. SEED	1 (0.14)
CINNAMOMUM CASSIA BARK/PAONIA LACTIFLORA ROOT/PAONIA X SUFFRUTICOSA ROOT BARK/PORIA COCOS SCLEROTIUM/PRUNUS SPP. SEED	1 (0.14)
CINNAMOMUM CASSIA TWIG/EPHEDRA SPP. STEM/GLYCYRRHIZA SPP. ROOT WITH RHIZOME/PAONIA LACTIFLORA ROOT/PUEBARIA MONTANA VAR. LOBATA ROOT/ZINGIBER OFFICINALE RHIZOME/ZIZIPHUS JUTUBA FRUIT	1 (0.14)
CLIMATIS SPP. EXTRACT/PRINELLA VULGARIS EXTRACT/TRICHOSANTHES KIRILONI EXTRACT	1 (0.14)
CYRCHA MARGARITIFERA/FINES MASSONIANA LEAF/PUEBARIA MONTANA VAR. LOBATA ROOT	1 (0.14)
DIPSACUS SPP.	1 (0.14)
ENZYMES HERB/HERBAL TEA	1 (0.14)
FORSYTHIA SUSPENSIA FRUIT/LONICERA JAPONICA FLOWER BUD/SCUTELLARIA BAICALENSIS ROOT	1 (0.14)
GASTRODIA ELATA TUBER	1 (0.14)
GINKGO BILoba LEAF EXTRACT	3 (0.44)

GLYCYPHIZA GLABRA	2 (0.34)
GLYCYPHIZA SPP. ROOT/PARONIA LACTIFLORA ROOT	1 (0.14)
GLYCYPHIZA SPP. ROOT/RHEUM SPP. RHIZOME	1 (0.14)
HERBAL CURE AND COLD REMEDIES, OTHER	1 (0.14)
HELIOSIS SPP.	1 (0.14)
HIPPOPHAE RHAMNOIDES	1 (0.14)
ISATIS SPP.	1 (0.14)
KRILL OIL	1 (0.14)
MOELLA SATIVA SEED OIL	1 (0.14)
PARONIA LACTIFLORA/PLANTAGO SPP. HERB/PLATYCODON GRANDIFLORUS	1 (0.14)
PANAX GINSENG ROOT/ANTHROXYLUM PIPERITUM PERICARP/ZINGIBER OFFICINALE PROCESSED RHIZOME	1 (0.14)
PANAX GINSENG TOTAL GINSENGSIDE EXTRACT	1 (0.14)
PANAX NOTOGINSENG	1 (0.14)
PANAX NOTOGINSENG ROOT TOTAL SAPONIN EXTRACT	1 (0.14)
PELAGONIMUM SIDOIDES	2 (0.34)
PLANTAGO OVATA	1 (0.14)
PRUNUS APERNIACA	1 (0.14)
PRUNUS SPP. BARK	1 (0.14)
SALVIA MILTIORSHIZA	1 (0.14)
SAPOSHNIKOVIA DIVARICATA	1 (0.14)
SERRA SPP.	1 (0.14)
SERENA REPENS	1 (0.14)
SERENA REPENS EXTRACT	1 (0.14)
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	4 (0.64)
VIGLA ODOBATA	1 (0.14)
UROLOGICALS	
Total number of patients with at least one treatment	36 (5.14)
Total number of treatments	62
ALFUZOSIN	1 (0.14)
ALFUZOSIN HYDROCHLORIDE	1 (0.14)
AMTRIPTYLINE	1 (0.14)
BIBESONID	1 (0.14)
CHEMOKITIN SULFATE SODIUM	1 (0.14)
CINNAMOMUM CASSIA BARK/PARONIA LACTIFLORA ROOT/PARONIA X SUPFRUTICOSA ROOT BARK/PORIA	
COCOS SCLEROTIUM/PRUNUS SPP. SEED	1 (0.14)
DOXAZOSIN	1 (0.14)
DOXAZOSIN MESILATE	1 (0.14)
DROTAVERINE HYDROCHLORIDE	1 (0.14)
DULOXYTINE	1 (0.14)
DUTASTERIDE	1 (0.14)
DUTASTERIDE/TAMBULOSIN HYDROCHLORIDE	1 (0.14)
ESCHERICHIA COLI	1 (0.14)
FINASTERIDE	3 (0.44)
LIDOCAINE	8 (1.14)
LIDOCAINE HYDROCHLORIDE	2 (0.34)
MIBABERGON	3 (0.44)
MARTOFIDIL	1 (0.14)
OXERTYMIN	1 (0.14)
PHENAZOPYRIDINE	1 (0.14)
POTASSIUM PHOSPHATE MONOBASIC	1 (0.14)
SERENA REPENS	1 (0.14)
SERENA REPENS EXTRACT	1 (0.14)
SEDLIN DICARBONATE	1 (0.14)
SOLIFENACIN SUCCINATE	1 (0.14)
TADALAFIL	1 (0.14)
TAMBULOSIN	4 (0.64)
TROSPIDUM CHLORIDE	1 (0.14)
VIGLA ODOBATA	1 (0.14)
VACCINES	
Total number of patients with at least one treatment	147 (20.74)
Total number of treatments	230
COVID-19 VACCINE	18 (2.54)
COVID-19 VACCINE INACT (VERO)	2 (0.34)
COVID-19 VACCINE INACT (VERO) CZ02	3 (0.44)
COVID-19 VACCINE NRVV AD (CHADOXI NCOV-19)	7 (1.04)
COVID-19 VACCINE NRVV AD26 (GAM-COVID-VAC)/COVID-19 VACCINE NRVV AD5 (GAM-COVID-VAC)	1 (0.14)
COVID-19 VACCINE NRVV AD26 (JNJ 78436735)	1 (0.14)
COVID-19 VACCINE PROT. SUBUNIT (MVC-COV1901)	1 (0.14)
COVID-19 VACCINE PROT. SUBUNIT (NVX COV 2373)	2 (0.34)
DIPHTHERIA VACCINE TOKOID/TETANUS VACCINE TOKOID	1 (0.14)
ELASMERAN	34 (4.84)
HPV VACCINE VLP B11 2V (BACILOVIRUS)	1 (0.14)
INFLUENZA VACCINE	38 (5.34)
INFLUENZA VACCINE INACT	1 (0.14)
INFLUENZA VACCINE INACT SPLIT 3V	2 (0.34)
INFLUENZA VACCINE INACT SPLIT 4V	3 (0.44)
PNEUMOCOCCAL VACCINE	1 (0.14)
PNEUMOCOCCAL VACCINE CONJ 7V (CRM197)	1 (0.14)
PNEUMOCOCCAL VACCINE POLYSACCH 23V	3 (0.44)
SMALLPOX VACCINE LIVE (MVA-BN)	1 (0.14)
TETANUS VACCINE	1 (0.14)
TETANUS VACCINE TOKOID	1 (0.14)
TICK-BORNE ENCEPHALITIS VACCINE INACT (NEUV)	1 (0.14)
TOZINAMERAN	75 (10.54)
VARICELLA ZOSTER VACCINE	1 (0.14)
VARICELLA ZOSTER VACCINE R08 (CHO)	1 (0.14)
VASOPROTECTIVES	
Total number of patients with at least one treatment	51 (7.24)
Total number of treatments	89
ANISE (FOSSILIZED TREE RESIN)/BORNEOL/CALAMINE/COV BEZDAR/MUSK/PEARL/SODIUM BORATE	1 (0.14)
ANESTHETICS, LOCAL	2 (0.34)
ANISODAMINE	1 (0.14)
ANTIBIOTICS	2 (0.34)
ASCORBIC ACID/ASCORBATE	3 (0.44)
BETAMETHASONE	2 (0.34)
BETAMETHASONE BUTYRATE PROPIONATE	1 (0.14)
BETAMETHASONE VALERATE	1 (0.14)
CALCIUM DOBESILATE	1 (0.14)
CINNAMOMUM CASSIA BARK/PARONIA LACTIFLORA ROOT/PARONIA X SUPFRUTICOSA ROOT BARK/PORIA	
COCOS SCLEROTIUM/PRUNUS SPP. SEED	1 (0.14)
DEKAMETHASONE	5 (0.74)
DEKAMETHASONE DIPROPIONATE	1 (0.14)
DEKAMETHASONE SODIUM PHOSPHATE	4 (0.64)
DILTIAZEM	2 (0.34)
DILTIAZEM HYDROCHLORIDE	1 (0.14)
DIOGININ	1 (0.14)
ESCHERICHIA COLI	1 (0.14)
FLUOCINOLONE ACETONIDE	1 (0.14)

GLYCERYL TRINITRATE	2 (0.38)
HEPARIN	2 (0.38)
HEPARIN SODIUM	3 (0.48)
HEPARINOID	1 (0.14)
HYPOPHOSPHATE RHAMNOSIDES	1 (0.14)
HYDROCORTISONE	2 (0.38)
HYDROCORTISONE SODIUM PHOSPHATE	1 (0.14)
LIDOCAINE	8 (1.14)
LIDOCAINE HYDROCHLORIDE	2 (0.38)
MARTAFONE	1 (0.14)
NIFEDIPINE	2 (0.38)
PHENYLEPHRINE	1 (0.14)
PRENIZOLONE	3 (0.48)
PRENIZOLONE VALERATE	1 (0.14)
STREPTODORNASE/STREPTOKINASE	1 (0.14)
TRIAMCINOLONE	3 (0.48)
TRIAMCINOLONE ACETONIDE	2 (0.38)
TROXERUTIN	1 (0.14)
ZINC	1 (0.14)
VITAMINS	
Total number of patients with at least one treatment	29 (4.14)
Total number of treatments	45
ASCORBIC ACID	8 (1.14)
ASCORBIC ACID/BIOFLAVONOIDS NOS/RUTOSIDE/SODIUM SELENITE/ZINC GLUCONATE	1 (0.14)
BENFOTIAMINE	2 (0.38)
BENFOTIAMINE/CYANOCOBALAMIN/PYRIDOXINE HYDROCHLORIDE	1 (0.14)
BIGITIN/CALCIUM PANTOTHENATE/CYSTINE/MAGNESIUM FIDOLATE/METHIONINE/PYRIDOXINE	1 (0.14)
CALCIOTRIOL	1 (0.14)
CALCIOTRIPEL	1 (0.14)
POLIC ACID/IRON/VITAMINS NOS	1 (0.14)
HYDROXYCOBALAMIN ACETATE/PYRIDOXINE HYDROCHLORIDE/THIAMINE DISULFIDE	1 (0.14)
MAGNESIUM/PYRIDOXINE HYDROCHLORIDE	1 (0.14)
PYRIDOXINE HYDROCHLORIDE	4 (0.64)
PYRIDOXINE HYDROCHLORIDE/THIAMINE MONONITRATE/VITAMIN B12 NOS	1 (0.14)
RIBOPHAVIN	1 (0.14)
THIAMINE	2 (0.38)
THIAMINE HYDROCHLORIDE	1 (0.14)
VITAMIN B COMPLEX	2 (0.38)
VITAMIN B NOS	3 (0.48)
VITAMIN D NOS	4 (0.64)
VITAMIN E NOS	1 (0.14)
VITAMINS NOS	1 (0.14)

Treatments are coded using the WHO Drug Global B3 Format dictionary Version September 1, 2020. Treatments can appear under multiple classes. Multiple uses of a specific medication for a patient were counted once in the frequency for the medication. Likewise, multiple uses within a specific medication class for a patient were counted once in the frequency for the medication class. For frequency counts in the "total number of treatments", multiple uses of the same treatment for a patient were counted separately.

Program: root/clinical_studies/RO6867461/CDT30303/share/ACE_data_analysis/prod/program/t_cm.sas
Output: root/clinical_studies/RO6867461/CDT30303/GR41986/data_analysis/ACE_CSR_Final/prod/output/t_cm_CDCNOCUL_A24_Ita24_29AUG2023_41986.xls
26APR2024 15:21